<SEC-DOCUMENT>0001022079-23-000018.txt : 20230221
<SEC-HEADER>0001022079-23-000018.hdr.sgml : 20230221
<ACCEPTANCE-DATETIME>20230221164748
ACCESSION NUMBER:		0001022079-23-000018
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		117
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230221
DATE AS OF CHANGE:		20230221

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			QUEST DIAGNOSTICS INC
		CENTRAL INDEX KEY:			0001022079
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				161387862
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12215
		FILM NUMBER:		23648928

	BUSINESS ADDRESS:	
		STREET 1:		500 PLAZA DRIVE
		CITY:			SECAUCUS
		STATE:			NJ
		ZIP:			07094
		BUSINESS PHONE:		9735202700

	MAIL ADDRESS:	
		STREET 1:		500 PLAZA DRIVE
		CITY:			SECAUCUS
		STATE:			NJ
		ZIP:			07094

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CORNING CLINICAL LABORATORIES INC
		DATE OF NAME CHANGE:	19960903
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>dgx-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:069b4a79-e86e-41e0-954a-e49896ade77c,g:4f5772c6-ef68-44f6-b836-f5065845bef2,d:e970e5750d9e4558bbcb5cb0dc8ea0a5--><html xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dgx="http://questdiagnostics.com/20221231" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>dgx-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV80L2ZyYWc6YWY1ZjAyODE4MjgzNDgyM2E5MWU2MTExMzI3YjMxODgvdGFibGU6MmQ1MjgyZjI0ZDQ4NGYwNGIyMTM5YWRmMzM1MzU1ZTEvdGFibGVyYW5nZToyZDUyODJmMjRkNDg0ZjA0YjIxMzlhZGYzMzUzNTVlMV8yLTEtMS0xLTc4MjE1_91585d3e-54db-4841-abc3-210c9ad43b0e">0001022079</ix:nonNumeric><ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV80L2ZyYWc6YWY1ZjAyODE4MjgzNDgyM2E5MWU2MTExMzI3YjMxODgvdGFibGU6MmQ1MjgyZjI0ZDQ4NGYwNGIyMTM5YWRmMzM1MzU1ZTEvdGFibGVyYW5nZToyZDUyODJmMjRkNDg0ZjA0YjIxMzlhZGYzMzUzNTVlMV80LTEtMS0xLTc4MjE1_f4be097a-db01-4239-bf65-ba40cede5c3a">2022</ix:nonNumeric><ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV80L2ZyYWc6YWY1ZjAyODE4MjgzNDgyM2E5MWU2MTExMzI3YjMxODgvdGFibGU6MmQ1MjgyZjI0ZDQ4NGYwNGIyMTM5YWRmMzM1MzU1ZTEvdGFibGVyYW5nZToyZDUyODJmMjRkNDg0ZjA0YjIxMzlhZGYzMzUzNTVlMV81LTEtMS0xLTc4MjE1_7cb635d1-1f4f-4d64-a84e-43fc29c85113">FY</ix:nonNumeric><ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV80L2ZyYWc6YWY1ZjAyODE4MjgzNDgyM2E5MWU2MTExMzI3YjMxODgvdGFibGU6MmQ1MjgyZjI0ZDQ4NGYwNGIyMTM5YWRmMzM1MzU1ZTEvdGFibGVyYW5nZToyZDUyODJmMjRkNDg0ZjA0YjIxMzlhZGYzMzUzNTVlMV82LTEtMS0xLTc4MjE1_9dd7a89c-4481-47b8-94f6-4686d30e7ff9">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i47d0ec07fa9b492b8d1144a50f6eb621_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzE1MDA1_cf798870-e9ec-4915-8333-6fffdab241e2">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="i2d8ec938f1c4401ea9c7bd969cee4119_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzE1MjE1_15232aa9-a205-41d3-834e-46d37c844c97">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="i4a8532c66ad64ac990f07caabad868b2_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzE5MDc3_e109cd52-340f-452f-8421-53cd708ea892">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="i97cb2aca70ed4416839a2cd2c733918e_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODEvZnJhZzoxZjJiYjBkMDExZWQ0ZjA4YWM5MmI5Y2FlOWJlNzY5ZS90YWJsZTpkZGFhYmJjNjQ2MTU0M2ZjYTlhOWY3OWU2YTcwOWUzMy90YWJsZXJhbmdlOmRkYWFiYmM2NDYxNTQzZmNhOWE5Zjc5ZTZhNzA5ZTMzXzEtMS0xLTEtNzgyMTU_37b4c223-e872-4eb6-a8c3-d223241460ff">31.5</ix:nonNumeric><ix:nonNumeric contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NDc_562c010d-bbaa-4f52-a8ac-de2660c01cb7">http://fasb.org/us-gaap/2022#OperatingLeaseRightOfUseAsset</ix:nonNumeric><ix:nonNumeric contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NDc_da6e8994-01f0-4a9a-83e2-083574a1b91f">http://fasb.org/us-gaap/2022#OperatingLeaseRightOfUseAsset</ix:nonNumeric><ix:nonNumeric contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTQ_323fe1c8-01d7-47a9-afae-473da3defda0">http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTQ_4bd99473-36cb-4abf-841b-9d98e467569f">http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" name="us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTU_6f606824-b677-4250-a7ed-24f9f3915ac5">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" name="us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTU_8ee62599-1731-4db2-b098-6e0dac4293f9">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzEyLTItMS0xLTc4MjE1_1c2a9643-64b7-48eb-992f-a3efa9e86f06">http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligations</ix:nonNumeric><ix:nonNumeric contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzEyLTItMS0xLTc4MjE1_5bf1d7b4-f29c-4002-9627-e2075dfadeb9">http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligations</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="dgx-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1477f11899e948a2a39ffb87d82e1e57_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i39a01f81398e4a8bb499e63010bd00dc_I20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i2255f9500efa4f9fbb33148f349cbf15_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f31e868418c42c5abbd3bb28b8a4277_D20230202-20230202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-02</xbrli:startDate><xbrli:endDate>2023-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb3e78d19c4a46b8a67dec2f47339bab_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">dgx:CommercialPaperAndTermSecuredOvernightFinancingRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i56456ee32fec497ca7d092cc9d8721eb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">dgx:CommercialPaperAndTermSecuredOvernightFinancingRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec0fa8127aa846ccb173e5c0dac001e5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dgx:SeniorunsecuredrevolvingcreditfacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddbc623b9422462099ee73f0b8dd8181_I20221021"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i872b3ea2e369403f8c0129ff07e0b538_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1240b052d8214432b601d5bcbb753f11_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60096e15242147fba12636c6498e0696_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide8bb1978e06466ca724c39081cca9e9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i288558364eaf483197b8585096922212_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i472db09b826445d8914756bb3c893218_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cb753814e7c442992f309372e45e63f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9986f08efdbe402bbac2c867d4d5b49a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a99166a414743a488765966d2720acc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10198ce773244072a76824474330a1cf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c187eb3582c4c4a85507116a2a9051a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65ea28f7aede4d8cb4a1add480265c52_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35ba9cb930d94eb9a0e61b9e0381a8d8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2998701e47ab4c2da75bc84322736ac6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1339fcf6a344dd38e3445336c362756_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3df6ca3ffce342b4877024296cfa0551_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib876f54cbcd740bbaa56a7f098ffd2ac_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic144ab8f0cf34804be4018d616f6d4ac_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb272b75d2c44e3689c068a802c47179_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb2b0c92f23149e9923b4ac5d5a66fc9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b1b2d14ccd04831986cecdccfec9b2d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b667d9c2eff4eebb2ac4e52f720ef07_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i095b5e9afd734c41af3e81c20d90f712_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf09d963d3644445a1026aa035d87436_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bf24e1056814b529c1aaa4c1d657c4a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4718e0f26e04ae097941f11f8d84f52_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf9d22d584794a70962f2aa7e63d53ed_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46c3bce145ea4fa5aa062add4078cdfe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide97930b20624098ba7878ad5bcd0d94_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3c04cff9ac445b78c60050390c6354a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a13b74a4feb49a384914744e3913d6d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fa9e0c121174bc7b51c26277e515b9b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cc12e58d5654ed5b8115cae8aed17f6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie63ea040842e454a8a302897c8462f6f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7dd85f38ce14e469eb57e11ba9cfd32_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e6f2503a5bd421392c0a3810d1d34b3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08ee5ae92da64f5088e4f441aadc7efd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7840e393be1c4cfaafc766cd6a649f57_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87e8a4e1a2e74540b572c7f19b5a4c4d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1e66f8b2302475fb1c8bca2f57488d3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4abbc656bb9d4006bae9f455034d8851_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4848abb5a7147028c83ac30e5fcf981_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3448ddb537854f44a9c15ae5f60d4048_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fcf55e48b7c44a8aa6c6dce683057f7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedbe1fc06b5345c38cc97c62d3b664a3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dgx:SubstantialOwnershipInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b416adaeaac49cfb869af6c8e627c39_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dgx:SubstantialOwnershipInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib62f2d7bef64474dbe05584de6966e18_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:GovernmentPayersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i316b4c39b6be48408e5109495bc92124_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:GovernmentPayersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27098106112f421c94055f0cdae93371_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:GovernmentPayersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba76f6181ce848fcbd7af0ece345152c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:GovernmentPayersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81be56c5955845f49525165bab74c70f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:PatientMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i915edbec2fea42159bcc1ba9f3179a51_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:PatientMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47d0ec07fa9b492b8d1144a50f6eb621_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dgx:LaboratoryEquipmentAndFurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05ea7f33f7e549de90d8144e632a0571_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dgx:LaboratoryEquipmentAndFurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d8ec938f1c4401ea9c7bd969cee4119_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa192df489ca4b7eb7ca0059b95703b2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a8532c66ad64ac990f07caabad868b2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c9530356f3242cdb77f114a2aa32961_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97cb2aca70ed4416839a2cd2c733918e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73714e6410064c5eac002e398216cb2c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9ea9ce1f68f4cde8b57ba97522e9899_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbf8633ce3e245ac94d164f390ff90af_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d71e5c8af24471ca79d701791aa2094_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:HealthcareInsurersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d2e4bb54e5b41c9be7d8748b8f55367_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:HealthcareInsurersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic16acd3f5abe4057b2ded728e43030c9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:GovernmentPayersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa2bee4df39349539bed4c4b3462277a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:ClientPayersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94893ea869b54dd78d6d051a6bad548d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:ClientPayersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf5f880be7d24d7a8c69fe4843654a88_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:PatientMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib881549de5d14c42a72abbd13bb6179b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:PatientMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25375b7fc67348ac91275e0d3f7a1f4b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:PatientMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f428209a39d4b7b8a174be53283b875_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:DSBusinessesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fd62e07b13c458892bd229457bbe1b5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:DSBusinessesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01555413d91d42e3b436c505bbc70a67_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:HealthcareInsurersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:FeeforserviceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82dfa27313e34853973b9607939068a5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:HealthcareInsurersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:FeeforserviceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i391fa00d0a7e46b0bc4a34ff6434ba24_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:HealthcareInsurersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:FeeforserviceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd41f50ca74e49ffadac56ef4c8022aa_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:HealthcareInsurersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:CapitatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0be3de26f2574a208f21fd35944e0cad_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:HealthcareInsurersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:CapitatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ee750c8e58548218454f6b303208917_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:HealthcareInsurersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:CapitatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a3f190b89e94247905769314473af12_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:HealthcareInsurersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i509d8b446ac14984bc658ece06fea971_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:HealthcareInsurersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18a0eea57b5d4a778b3c4fc7048a92d0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:HealthcareInsurersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99d6e0655d0f4b178b998f09b7ac1aa5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:ClientPayersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if95a07a0521045d7aa3fd6eca9554b97_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:ClientPayersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i397e6f4394d44cd0bbe7d033eb4fb637_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:ClientPayersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcdd11aeccf94ec496587c6ccc6a4281_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:PatientMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f3ad29ae1e34df5b6995f7ffaeaa6cf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:PatientMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74ad488f1dfb40baa83701a002b6d98f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i680bf76bfe8647638c33f242f0ef1980_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic662fc7ebbb744a885416e3447893d64_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0468d2fc9ab47638da16013b1893683_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:DSBusinessesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd3a7338f2d040dda1e6639ac9f7d70f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:DSBusinessesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic76d3eea03004ba5aed3d7cc7917604b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:DSBusinessesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6826b0f73ee4f00ab77a97be130c154_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:HealthcareInsurersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic12c618fa4d74532b772090eef552ce5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:HealthcareInsurersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34f778b2b04c48679029b462c5367cb2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:GovernmentPayersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibaf0eafb0e0a4b05aa543fafe1dafb0a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:ClientPayersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e02c394b9084450982de162d83141b3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:ClientPayersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a770caf14c1492f8e3fbcaf507b29ae_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i762548338af343bcbc7df9361e2ba54e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia340b53589ac4a729154593b434a8b5b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:DSBusinessesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69908b0e9ded44c68e9a26989fdf9843_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:DSBusinessesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2188840dc2a3430ebc240517ab668786_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">dgx:InvigorateProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac2da26b5ef14b8f8e69ce008fd54d9b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">dgx:InvigorateProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f2e4d03479a4236a60beb9b0835a79f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">dgx:InvigorateProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2dc2704459f476aa2a7a5bdd5d24a31_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">dgx:InvigorateProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c94d4fa6b2c4f048fbd732ba22d94f5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">dgx:InvigorateProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c9c73f96c044bfe81dabb5b4fad4570_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">dgx:InvigorateProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i390853c339b546a497c9c3581d6c33ec_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">dgx:InvigorateProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dfd2596231f42d583a3e66c7908bd62_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">dgx:InvigorateProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17932ddd3fbd4fa39599486002e2399c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">dgx:InvigorateProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7641ac8ab06549359c0d7224c74f7f8b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">dgx:InvigorateProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d8eee27a6fd4fbe801850524c5786c5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebd99150341c4b0c873203afdafdd710_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i475d92c712f048aa906901cd998f7a38_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib738456c29b743669e686681cc7a5304_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6084444236f40aca1b0c8796c27af45_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50168a95b652435bb092f9dfbde9c76a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic24828d839184f6fa08a929719d4b23f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57fc38f4b96048cbb2a8e0410884049d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74144fa02d0949e18fcfdec627d2b59e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fe6929b64864257bf0e3c4054d32428_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3022bb32f9b457dac0b1400e74fad49_D20220201-20220201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:PackHealthLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc2a90ebfed1402e9780a6ef5de70976_I20220201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:PackHealthLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a5b8ece9a5340aa9b88329c3be13301_D20220201-20220201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:PackHealthLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48a2f820f01a423fa5d8fb263ceee2c0_D20210601-20210601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:MercyHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c718b40c7aa46b79dd5ad4b49064a03_I20210601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:MercyHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e9e75dc29624f80957117764e6a8712_I20210601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:MercyHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib254cb5566f04ccb957b18919eed9f8d_D20210601-20210601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:MercyHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b56aef5907945b3abd0ec2ca54428c0_D20211213-20211213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:LabtechDiagnosticsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-13</xbrli:startDate><xbrli:endDate>2021-12-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52f75c68a74542ba8c151adcd5b7c6c1_I20211213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:LabtechDiagnosticsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8ace4c429434da1b559d5ea5059ac8a_I20211213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:LabtechDiagnosticsLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16f34a8359cd44c7a2ed3560a9171968_D20211213-20211213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:LabtechDiagnosticsLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-13</xbrli:startDate><xbrli:endDate>2021-12-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7198b30a0f3543f8b7624f5a08626715_D20200121-20200121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:BlueprintGeneticsOyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-21</xbrli:startDate><xbrli:endDate>2020-01-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c6b2d78cc5544cea4ff096768c26e2f_I20200121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:BlueprintGeneticsOyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0752516755c42d4b6bd8c225ce45827_D20200121-20200121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:BlueprintGeneticsOyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-21</xbrli:startDate><xbrli:endDate>2020-01-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffd12e5591e7425f9d86856d3c9e755a_D20200121-20200121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:BlueprintGeneticsOyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-21</xbrli:startDate><xbrli:endDate>2020-01-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbfa5abb43c94c9b95f08bbd21c21a95_D20200406-20200406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:MemorialHermannMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-06</xbrli:startDate><xbrli:endDate>2020-04-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97014f982e65418d980efc0a485ac0d0_I20200406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:MemorialHermannMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0b5a278261f4aeaa3c8450f4ab8f98b_I20200406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:MemorialHermannMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc562163c50f4774ba7552b47b943aa8_D20200406-20200406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:MemorialHermannMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-06</xbrli:startDate><xbrli:endDate>2020-04-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i318abc26c57d45e199c441d6a27fb59b_I20200801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:MidAmericaClinicalLaboratoriesLLCMACLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e330046544a4466b899b21db4a44981_D20200801-20200801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:MidAmericaClinicalLaboratoriesLLCMACLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4132aab88954f808a22077ce48c7778_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:MidAmericaClinicalLaboratoriesLLCMACLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if02f69bfea444e448def3a82a65cb96b_D20200731-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:MidAmericaClinicalLaboratoriesLLCMACLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-31</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56f4083aa1ed47fbbfc4bd4e9a05cc0f_D20200801-20200801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">dgx:OtherIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:MidAmericaClinicalLaboratoriesLLCMACLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd44c8b9d5c649278afdc75ade9c679b_I20200801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:MidAmericaClinicalLaboratoriesLLCMACLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6cc04f23f064d64bc9599f898569338_D20200801-20200801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:MidAmericaClinicalLaboratoriesLLCMACLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c20173d8dc64ebdb79161256ab69f0d_I20210401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dgx:Q2SolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5953c712e4234176ac0378246142fc74_D20210401-20210401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dgx:Q2SolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a3a680061ef49fcac90a1aabb89821b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dgx:Q2SolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcd7cd9e61214881b085d41e21b23992_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dgx:ForeignCurrencyTranslationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dgx:Q2SolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i309534767ce0403ba44362e2a393aa76_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dgx:Q2SolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a46256065f64a1f83735b542ac8cd05_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifacb18823a32464e8277a40cd0e40141_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i939ef35c1b364fccb6c395109ba883a8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i806fc0b55bb0418c955d42a8e1e2a9d5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec46d6b614174b4a84f77d9cff2de05f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e74f4a4c6c44d98bda7c8be9f02a6b2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i454f20bc7ea343f5a803483a6773d323_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08e7768575cf494bab1f563baab11bdc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec1e53779a1a46e382c71420c86a8e65_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:PackHealthAndLabtechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia070c0d807ae41f189d8789aa235216b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:PackHealthAndLabtechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">dgx:MeasurementInputComparableCompanyRevenueVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23329615d047484080f7bc81509ea79e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:PackHealthAndLabtechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i435823dcec83485dbadc7a18b519986a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:PackHealthAndLabtechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2740945331a4803b48ca4d039b3724f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">dgx:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd12294595f84e56a311bfb11080c96c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">dgx:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1029a7e4535b4243bba665741dbd11de_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">dgx:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38a23e14d23244c8a2e550a645bbdcd1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">dgx:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i341269c4649443fbbe35b79f45362759_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">dgx:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia809ec8fd18c4ad48fc0dd81f2cdd760_I20150701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">dgx:UMassJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1880b74088be4b518518151d49b3c3d9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71e02c56049a42c4a6be7ec8bf9a657b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3f1c4f0d1ab416eb53e5a18510fd0dd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i585fd94209a4454c885f38e54a3ac3d2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if150c31900d447178580723791094470_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d1d68fb080a45eaa9d48446425aaa2a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cc8a896b5014eec950deeb2b23e329e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationTypeAxis">dgx:LeaseTypeChangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8c3207c09bd46528b441166ed00ce51_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a0fe7e6792a43c6948edd202dfa3610_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67120ecad309432da683bc8101a2349a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16c4c9b2568544898fd08b624fe50b66_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98ddc5b3f9b247d7aff2886d77af5203_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dgx:LaboratoryEquipmentFurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3b24be39ce649f0b555d02d17abd4b5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dgx:LaboratoryEquipmentFurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i556301e56725415db5e0e99af8881ab2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2941ae72a36c43deb9d71ecae5604733_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cd92532b444421cbbef1840ffb1e964_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26ad136d73174bb492bfb4eb3f70e8ac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie438daf2fc794813a4a9dc699c36d20a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5cf2176ed3c4e77a2914da13e51e940_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie457eb795c6c447ab93368b3aed4f823_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9f9ea06f7194197817bb2efd0215f53_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c904f919f5841dab0cc8a467bfece73_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5d6933739c34b618deb542c4712132c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91553244d95f431f99ff6af124bfc732_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb82f3cff9fb4367b9527abfc041ea6d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfe0b2f1d56541548f5ba20eedeeffdf_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb995e58236640a2bebf429f0ef15cf6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icae1953df1b64580906887b236811607_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i309a355e12ca4ac8aebec7a6a293b7f1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34d5911f3c604626be8defe10191d842_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73c028f5ff27446fa49dcddeadcef5ff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if532e9c222b34f83ac093a3483e120ea_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">dgx:TotalAmortizingIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdf0044ebfdf413bac60a2d162bc3800_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">dgx:TotalAmortizingIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia02c4586208e4e3ba284b0ed0d180568_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">dgx:TotalAmortizingIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12811850249e482399304d53d433f814_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16c67c4eb43e4026aebad131b1687d4c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i607e1bfaecc64044abfb3030ef16268d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:UnclassifiedIndefinitelivedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e42f87022b0417485ee3c3cae380452_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:UnclassifiedIndefinitelivedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73f9034273a34d5687d848b3ebe178b2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dgx:FourpointtwofivepercentSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafc4f10dcb30465792e3db376f9db383_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dgx:FourpointtwofivepercentSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36d2de3414984080b11b7ed1f9472589_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dgx:ThreePointFiveZeroPercentSeniorNotesdueMarch2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35159921eda04fbdb92fa45ac28509d5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dgx:ThreePointFiveZeroPercentSeniorNotesdueMarch2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i744959a3bc17412a9e5af1fd1d359295_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dgx:ThreePointFourFivePercentSeniorNotesdueJune2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d5ca1c0cd5d40019d0db21e80203f2c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dgx:ThreePointFourFivePercentSeniorNotesdueJune2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e6f9e7f0256442db64c6fa43a0ced20_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dgx:FourPointTwoZeroPercentSeniorNotesdueJune2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3b4fa91393e4b0e8d2f092086ab0bdf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dgx:FourPointTwoZeroPercentSeniorNotesdueJune2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e13bac0fccd4f16898a65173f8a921b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dgx:TwoPointNineFivePercentSeniorNotesdueJune2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1c4a18ddf92439da82f42ca78db7257_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dgx:TwoPointNineFivePercentSeniorNotesdueJune2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bb1349879f5435fa9e912e4cf525b01_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dgx:TwoPointEightZeroPercentSeniorNotesDueJune2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42e6dc0040114c70b13940e177bb3b1f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dgx:TwoPointEightZeroPercentSeniorNotesDueJune2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae49dd1a44e743bdb49b617b9cfbaed7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dgx:SixPointNineFivePercentSeniorNotesDue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b3b2a9d05bf465db9db7f32f4c7f461_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dgx:SixPointNineFivePercentSeniorNotesDue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2eb4e252832c4cd59e4e6274194a0627_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dgx:FivePointSevenFivePercentSeniorNotesDue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c8de336b3a044bfa41bbd2480192421_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dgx:FivePointSevenFivePercentSeniorNotesDue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifaf7d8fd470f4603bcbefc2804dc479c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dgx:FourPointSevenZeroPercentSeniorNotesdueMarch2045Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04b933ae20f7405ea1d07a3a04b5d06a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dgx:FourPointSevenZeroPercentSeniorNotesdueMarch2045Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e9c816b535f468b832f1fb4f7578811_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dgx:FinanceLeaseObligationsandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f456f42e2b64e4cb74fbc8ba3ba7668_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dgx:FinanceLeaseObligationsandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3e292d5aced49a991453002828a13bf_D20221001-20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2473c6e1cff643f4807fa97482f2514c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ee94c3ad75540f2895fbc6c74806807_I20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3f22fe062a74e759fbf551f8c1b5809_I20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">dgx:LoanCommitmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia223c678f59d4b39a7af63150694192c_I20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03277559f860449c9b5e26471a9ae119_D20221001-20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">dgx:CommercialPaperAndTermSecuredOvernightFinancingRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71d143709b514b99a2a4f28f2a601632_D20221001-20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">dgx:CommercialPaperAndTermSecuredOvernightFinancingRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf24b8c7cb904d33aca6b6f9275180b7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e3820f04333496f8fc57291a5c51523_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied9b303df1ae4f6daa7db9f2e1d5d9f0_I20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dgx:SeniorunsecuredrevolvingcreditfacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba1e578b1a6c4c79882ebb5fa88eae23_I20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dgx:SeniorunsecuredrevolvingcreditfacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if73e958db14b401a8087839f76ce387c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dgx:SeniorunsecuredrevolvingcreditfacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if79143d725024a98b36d4ee85edf5cee_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dgx:SeniorunsecuredrevolvingcreditfacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i723c452601804300bcd7029176377b7a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b93c42f53bc4c24b90b5c3989b66730_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04612297cd0342579339c26a21934632_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60fd27e051b74dd08de8773691041dd4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fe1409e54674ca0be0e82d1932f97ca_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f4546cb1b9c4a1693b7d8224d2b29b1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb6d00d91a6d489898ca322307bd7551_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7a65c0363624e68becc030a94a0ab77_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c59c3612c6041ba80e0a3204b427ce3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78646261649e4ab5b1d6101a7499cb08_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dgx:OtherEquityComponentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78b2c70c8a144740bff9b6549c2df838_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i339059f763014b84a165529202925717_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35e31e8eeed44389aab551248c319740_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8a22be73b2240fe97a3e930cdf33583_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dgx:OtherEquityComponentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1a47bc1d3184e49a881195d814db2bc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e971db364844d9d9d8d92ab27c1ed37_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90b395d6ce534de0bc8b53e2fca569ff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafd3f192541f4ebabada939564433870_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dgx:OtherEquityComponentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06cf1391d00e4b208aa2ec8b206f2b32_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1a523db0fd148b6b27ba256f8d6079a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i580c408beba54cb7a6726b2b9bdd3f50_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c1a794ae52b4383b4bd9c5a8df17404_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dgx:OtherEquityComponentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ebd65fb3e6947f2a405a8aeaf512a19_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7541d2de1e4457b8836169fd42ffe28_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0788f175bb734eec93e8a4d7abcbb8e0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38b5a632e224465fb4d85fbc4eff5dd8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dgx:OtherEquityComponentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66bf6627917044748f98d7c18e1307e2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i109b68d4a89d48ec97b242717a341fdf_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i933dedd678a149a484d0a02f4c2d33e0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a52a88c88684f908d9a67c0b1361c4e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dgx:OtherEquityComponentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71a45e6a745e4ddf8252c87f04dd758e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1423840c822742dc9fdf987c08a9badf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4cc611bd437409a9457b4e8ca870211_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i920e105da0ab40dcba086a031fe03430_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dgx:OtherEquityComponentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e808f2e2e6543d1a2b3a31c4bb749dc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia40f541edc5a4e009d95c57cd1bcb927_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie092f7c613574f36ac6303f206cea249_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f7bde7107be4688966df19bafdeea10_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib70de56c8cc94b818521ce47775ed911_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bb911fffd174a0aa2ac5f0facc0999e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic46672a2c9fc4d0e990f241632df20c6_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib82daccc7a0640b288f5167661d2539c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida73f1775008469a8c0cf852ee5a1c29_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id98e1b95cd5d4adf98b2c4cb2f733c61_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i145904e8a701484d92f0e52d1adeca1f_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8aae4e22f3264196b0bfa35291c77a16_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62fbbac4e0dc4fa697878a348ac0758e_I20230202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia76a036d7fa340e7b4834c31bf563b49_D20230101-20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4d8aae1ad91426ab8c1e84816ea8730_D20220201-20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic235750c5b474440bd8465c5df75988a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">dgx:AcceleratedShareRepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47113d1bbe9f4fea9bec3bbe1f7f5d91_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">dgx:AcceleratedShareRepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73f261b4c48d49e994b979548d66b542_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dgx:EmployeeLongTermIncentivePlanEltipMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idca3214cc24d4df2accb5f1aee19ee63_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dgx:EmployeeLongTermIncentivePlanEltipMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ad2a8b3713f4742b9996055520adc29_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dgx:RestatedDirectorLongTermIncentivePlanDltipMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic372c83c8186472099c6d4d6461f9670_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dgx:RestatedDirectorLongTermIncentivePlanDltipMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e67e2f9ed6e486593285a490abea14a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dgx:RestatedDirectorLongTermIncentivePlanDltipMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a2a79f2f8da4bf5859f277ed9314d52_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dgx:RestatedDirectorLongTermIncentivePlanDltipMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7fd18a6db5a4c6bb7e209edcc7ba998_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecaf266ba15d4c5da2f6be8c3e8e76bd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c80ac26791d4a08826451cfe6ab22a4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4c31ce97f0b4d679967210dea5d4ce8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50195984ca72444b94471a4f11e6b415_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0800ecbb791747f4ad71925d6e8c45e7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dgx:PerformanceShareUnitsWithMarketBasedRelativeTSRGoalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94c763d3175548ab80e291e8d327ea98_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dgx:PerformanceShareUnitsWithMarketBasedRelativeTSRGoalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i066c181da1cc4104bc13332037ebc51c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dgx:PerformanceShareUnitsWithMarketBasedRelativeTSRGoalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3870621ff0c4e94a8c0db30f0a94950_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dgx:StockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a773294c9f247f4b61dc287d74d2f4a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dgx:StockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f2ed080770b4b799d26a7b0773c6afa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dgx:StockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i532fc9e0076b4da684698168d99ecf57_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dgx:StockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0859d2d438a749bd85c7c9580402ecc9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dgx:StockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3510a40b3f92452ca5683687a18ac5b5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dgx:StockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i173f1992d3144e31a2d74876e89770d5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dgx:StockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cf6871cc3fb4fc7964b07d9e8dd6df6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d352bd28a45443e80612ac16c512e54_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i061fddd15a744d87ae3c69a6d735a09b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bef679f049f4a7589e81ff16e6faf39_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3984e240129249f2b9f78c9c4f3a1818_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">dgx:SupplementalDeferredCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bf42c10d101437f98e7eac589472f72_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">dgx:SupplementalDeferredCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70242db0befe4ca299c35c570e02ae70_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">dgx:SupplementalDeferredCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id56d32d3a5174c0f9f67b3b882cf8826_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">dgx:SupplementalDeferredCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf5e6c8d02cb4230b46883164090ae6c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">dgx:SdcpIiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd8f2aef04fc44bc86451fb4062847cc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">dgx:SdcpIiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1765ce7329f47f2a55b699f67f431bf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">dgx:SdcpIiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b69605427b24c3290b808836c99ad60_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">dgx:SdcpIiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie85140ba27db46a5a05080eae640b00a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb34a0a60bd547a58f8634a55d3ea6e9_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i665754908631467fb2b6eca930750884_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5336086104449ec9ccb20ce787e8fa9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib687289786894660a55bf2477787ca9e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4aca837d0034736866ba4562ecf3fff_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ea9a777ccce400dadb97bbedd6fb6f4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i810fd9c44b7c42e0aef7f96144b246dd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie440446d54134ae79c1720e049889ebd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:RoutineclinicaltestingservicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd0d2af9458945a7ab9a6eb6470b7961_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:RoutineclinicaltestingservicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b73fe03ff7442f4bd575024a507e151_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:RoutineclinicaltestingservicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i641939e760e747a197a3088d7c7a54e4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:COVID19TestingServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89453a368ad04b51b87732034e68487c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:COVID19TestingServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c23351df28247d08a300337a2d833f5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:COVID19TestingServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3eee41bc2ea54b62a9ae3435b8b4aaa4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:GenebasedandesoterictestingservicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57003099795448e795abfddd003aa4e2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:GenebasedandesoterictestingservicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7aec35972bb74cfb959afd84e8d0cffb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:GenebasedandesoterictestingservicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i726866d00c5c49f1bfa820096ee409a8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:AnatomicpathologytestingservicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12a2b45922a846d39e944bbd98829c1c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:AnatomicpathologytestingservicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i258b629fbed9441ea0961341779923f0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:AnatomicpathologytestingservicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i862341280d314ae3b1668f3553ff24f3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:AllotherservicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba77f4a14ac549e4ad21be96084cdd06_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:AllotherservicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d5572f43c3845b0af34754ce6041d2b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:AllotherservicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_1"></div><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGV4dHJlZ2lvbjpmNDI4MzBjYWUyYTc0NTQzOWYyOTc2YjkzOWEyOGE0ZF8zMTMy_c5cf6507-eb8f-42f2-a811-ae34dd81d848">10-K</ix:nonNumeric> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">           </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGV4dHJlZ2lvbjpmNDI4MzBjYWUyYTc0NTQzOWYyOTc2YjkzOWEyOGE0ZF8zMTMz_90e87ded-471f-4ad6-bb35-89f8b0f72cfa">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">  ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the Fiscal Year Ended <ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGV4dHJlZ2lvbjpmNDI4MzBjYWUyYTc0NTQzOWYyOTc2YjkzOWEyOGE0ZF8yMTM_7fd8955e-88b1-49ad-8728-f5253fdaded5"><ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGV4dHJlZ2lvbjpmNDI4MzBjYWUyYTc0NTQzOWYyOTc2YjkzOWEyOGE0ZF8yMTM_b17903c8-ce99-4874-a9b9-3d18daec9147">December 31</ix:nonNumeric>, 2022</ix:nonNumeric> </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Or</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">           </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGV4dHJlZ2lvbjpmNDI4MzBjYWUyYTc0NTQzOWYyOTc2YjkzOWEyOGE0ZF8zMTI4_097a5f81-1fdd-4617-88a4-51f4543ab614">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from __________ to __________</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGV4dHJlZ2lvbjpmNDI4MzBjYWUyYTc0NTQzOWYyOTc2YjkzOWEyOGE0ZF8zMTM0_b3906759-1f08-49f6-ad4a-b2648aad4d86">001-12215</ix:nonNumeric> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGV4dHJlZ2lvbjpmNDI4MzBjYWUyYTc0NTQzOWYyOTc2YjkzOWEyOGE0ZF8zMTI5_4400ffb2-149e-4682-a878-6d5283880aa8">Quest Diagnostics Inc</ix:nonNumeric>orporated</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:18.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.908%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGFibGU6ZjJkNjA4NjJhYWExNDkwZmE4ZDE2N2QyZmU5YWIwMTcvdGFibGVyYW5nZTpmMmQ2MDg2MmFhYTE0OTBmYThkMTY3ZDJmZTlhYjAxN18wLTAtMS0xLTc4MjE1_1d2b8469-99d2-4736-81e2-d09cd9a61985">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGFibGU6ZjJkNjA4NjJhYWExNDkwZmE4ZDE2N2QyZmU5YWIwMTcvdGFibGVyYW5nZTpmMmQ2MDg2MmFhYTE0OTBmYThkMTY3ZDJmZTlhYjAxN18wLTUtMS0xLTc4MjE1_555f75bb-7579-47c5-a6c2-085526a43558">16-1387862</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(State of Incorporation)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(I.R.S. Employer Identification Number)</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGFibGU6ZjJkNjA4NjJhYWExNDkwZmE4ZDE2N2QyZmU5YWIwMTcvdGFibGVyYW5nZTpmMmQ2MDg2MmFhYTE0OTBmYThkMTY3ZDJmZTlhYjAxN18yLTAtMS0xLTc4MjE1_a31569f3-812b-4e42-ab31-0418a3d06519">500 Plaza Drive</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGFibGU6ZjJkNjA4NjJhYWExNDkwZmE4ZDE2N2QyZmU5YWIwMTcvdGFibGVyYW5nZTpmMmQ2MDg2MmFhYTE0OTBmYThkMTY3ZDJmZTlhYjAxN18zLTAtMS0xLTc4MjE1_16e998d1-b669-4246-a99f-3ceb47d70a80">Secaucus,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGFibGU6ZjJkNjA4NjJhYWExNDkwZmE4ZDE2N2QyZmU5YWIwMTcvdGFibGVyYW5nZTpmMmQ2MDg2MmFhYTE0OTBmYThkMTY3ZDJmZTlhYjAxN18zLTEtMS0xLTc4MjE1_7563b9b1-6d81-4460-b5bc-4612295d4c40">NJ</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGFibGU6ZjJkNjA4NjJhYWExNDkwZmE4ZDE2N2QyZmU5YWIwMTcvdGFibGVyYW5nZTpmMmQ2MDg2MmFhYTE0OTBmYThkMTY3ZDJmZTlhYjAxN18zLTItMS0xLTc4MjE1_13c7e0ad-a2bc-4596-88f1-a5384a3593de">07094</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGFibGU6ZjJkNjA4NjJhYWExNDkwZmE4ZDE2N2QyZmU5YWIwMTcvdGFibGVyYW5nZTpmMmQ2MDg2MmFhYTE0OTBmYThkMTY3ZDJmZTlhYjAxN180LTAtMS0xLTc4MjE1_ba3bb5ca-6983-4f57-b65c-bcb7a446c6df">(973)</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGFibGU6ZjJkNjA4NjJhYWExNDkwZmE4ZDE2N2QyZmU5YWIwMTcvdGFibGVyYW5nZTpmMmQ2MDg2MmFhYTE0OTBmYThkMTY3ZDJmZTlhYjAxN180LTEtMS0xLTc4MjE1_cb5c9ff5-3fdf-481c-a9a9-9ba6ed11e9fd">520-2700</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Title of Each Class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGFibGU6ZDg0Y2RjY2RhMTU2NDFhY2I5NjE4ZmI2MmIxNDhhZWYvdGFibGVyYW5nZTpkODRjZGNjZGExNTY0MWFjYjk2MThmYjYyYjE0OGFlZl8yLTAtMS0xLTc4MjE1_1001dc50-d053-4648-b453-6d38d5e9745f">Common Stock, $.01 par value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGFibGU6ZDg0Y2RjY2RhMTU2NDFhY2I5NjE4ZmI2MmIxNDhhZWYvdGFibGVyYW5nZTpkODRjZGNjZGExNTY0MWFjYjk2MThmYjYyYjE0OGFlZl8yLTEtMS0xLTc4MjE1_59879241-71aa-4ef8-8e46-c33df4c494c4">DGX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGFibGU6ZDg0Y2RjY2RhMTU2NDFhY2I5NjE4ZmI2MmIxNDhhZWYvdGFibGVyYW5nZTpkODRjZGNjZGExNTY0MWFjYjk2MThmYjYyYjE0OGFlZl8yLTItMS0xLTc4MjE1_a85e2454-777b-480a-885f-b64c43e7a8fa">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:49.734%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.066%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities registered pursuant to Section 12(g) of the Act:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">None</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGV4dHJlZ2lvbjpmNDI4MzBjYWUyYTc0NTQzOWYyOTc2YjkzOWEyOGE0ZF8zMTMw_d7980b85-930f-4222-b199-74da75ed9a12">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;X&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Yes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGV4dHJlZ2lvbjpmNDI4MzBjYWUyYTc0NTQzOWYyOTc2YjkzOWEyOGE0ZF8zMTMx_60893030-becd-4488-b00a-9def618df16e">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;X&#160;&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGV4dHJlZ2lvbjpmNDI4MzBjYWUyYTc0NTQzOWYyOTc2YjkzOWEyOGE0ZF8zMTM1_840d73d1-c653-4260-b09e-3e32c6de7dd3">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;X&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGV4dHJlZ2lvbjpmNDI4MzBjYWUyYTc0NTQzOWYyOTc2YjkzOWEyOGE0ZF8zMTM2_ad83f22f-53cc-4a5a-846a-a68b95f78899">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;X&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.859%"><tr><td style="width:1.0%"></td><td style="width:42.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGFibGU6Y2Y5YTU2Y2E1ZmI0NDYzYzk5NDlkNzI1Y2VhMzUyZGQvdGFibGVyYW5nZTpjZjlhNTZjYTVmYjQ0NjNjOTk0OWQ3MjVjZWEzNTJkZF8wLTAtMS0xLTc4MjE1_d2664f5a-70b8-4aa2-9ec3-8a36fb2a840d">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGFibGU6Y2Y5YTU2Y2E1ZmI0NDYzYzk5NDlkNzI1Y2VhMzUyZGQvdGFibGVyYW5nZTpjZjlhNTZjYTVmYjQ0NjNjOTk0OWQ3MjVjZWEzNTJkZF8xLTMtMS0xLTc4MjE1_e12f43e4-d81c-4604-894f-27cbe49e33c5">&#9744;</ix:nonNumeric></span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGFibGU6Y2Y5YTU2Y2E1ZmI0NDYzYzk5NDlkNzI1Y2VhMzUyZGQvdGFibGVyYW5nZTpjZjlhNTZjYTVmYjQ0NjNjOTk0OWQ3MjVjZWEzNTJkZF8yLTMtMS0xLTc4MjE1_aa22cb16-b670-497e-a768-9565fbddeb96">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  [&#9744; ]</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  [<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGV4dHJlZ2lvbjpmNDI4MzBjYWUyYTc0NTQzOWYyOTc2YjkzOWEyOGE0ZF8zMTM3_150a2cde-6597-4316-9b1a-b7fd8bf46fe5">&#9746;</ix:nonNumeric>]</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. [&#9744;]</span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).  [&#9744;]</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes <ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGV4dHJlZ2lvbjpmNDI4MzBjYWUyYTc0NTQzOWYyOTc2YjkzOWEyOGE0ZF8zMTM4_7337230f-cf48-49c5-b47b-ea9f153f5403">&#9744;</ix:nonNumeric>    No </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;X&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2022, the aggregate market value of the approximately 116&#160;million shares of voting and non-voting common equity held by non-affiliates of the registrant was approximately $<ix:nonFraction unitRef="usd" contextRef="i1477f11899e948a2a39ffb87d82e1e57_I20220630" decimals="-8" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGV4dHJlZ2lvbjpmNDI4MzBjYWUyYTc0NTQzOWYyOTc2YjkzOWEyOGE0ZF8yNzUx_b726cc5a-fb75-4788-b884-ab5c0d730f16">15.4</ix:nonFraction> billion, based on the closing price on such date of the registrant's Common Stock on the New York Stock Exchange.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of January&#160;31, 2023, there were outstanding <ix:nonFraction unitRef="shares" contextRef="i39a01f81398e4a8bb499e63010bd00dc_I20230131" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGV4dHJlZ2lvbjpmNDI4MzBjYWUyYTc0NTQzOWYyOTc2YjkzOWEyOGE0ZF8yODkz_7d91676a-35cb-40e4-b751-02ef480dad8a">111,323,003</ix:nonFraction> shares of the registrant&#8217;s common stock, $.01 par value.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"><tr><td style="width:1.0%"></td><td style="width:78.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.366%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Documents Incorporated by Reference</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Part of Form 10-K into</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">which incorporated</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGFibGU6OGEwMjA2ZWViMmM2NDc4MWJhOWQxNTEzOTk0MzE0YTYvdGFibGVyYW5nZTo4YTAyMDZlZWIyYzY0NzgxYmE5ZDE1MTM5OTQzMTRhNl8yLTAtMS0xLTc4MjE1_787fdce9-0494-4a9b-ac7b-6e01fd253869" escape="true">Portions of the registrant's Proxy Statement to be filed by April&#160;30, 2023</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Part III</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Such Proxy Statement, except for the portions thereof which have been specifically incorporated by reference, shall not be deemed &#8220;filed&#8221; as part of this report on Form 10-K.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_7"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> TABLE OF CONTENTS</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"></td><td style="width:10.764%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:73.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.922%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">&#160;Item</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_13">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_13">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_16">Introduction</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_13">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_19">Our Strategy</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_22">Our Strengths</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_22">8</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_25">Business Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_25">12</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_28">The Clinical Testing Industry</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_28">14</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_31">General</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_31">23</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_34">Regulation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_34">27</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_37">Available Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_37">29</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_40">Information about Our Executive Officers</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_40">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_43">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_43">32</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_58">Cautionary Factors That May Affect Future Results</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_58">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_61">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_61">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_64">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_64">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_67">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_67">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_70">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_70">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_76">Market for Registrant's Common Stock, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_76">45</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_79">Reserved</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_79">46</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_82">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_82">46</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_85">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_85">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_88">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_88">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_91">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_91">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_94">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_94">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_97">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_97">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_100">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_100">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_106">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_106">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_109">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_109">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_112">Security Ownership of Certain Beneficial Owners and Management and Related Stockholders' Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_112">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_115">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_115">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_118">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_118">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_124">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_124">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_127">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_127">55</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_133">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_133">58</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_148">Report of Management on Internal Control Over Financial Reporting</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_148">74</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_151">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F- <a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_151">1</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_154">Consolidated Financial Statements and Related Notes</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F- <a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_154">3</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_13"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The discussion in Item 1 below includes several defined terms:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ACO - Accountable Care Organization</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CAP - The College of American Pathologists</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CDC - Centers for Disease Controls and Prevention </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CLIA - Clinical Laboratory Improvement Act</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS - Centers for Medicare and Medicaid Services</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA - U.S. Food and Drug Administration</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FQHC - Federally Qualified Health Center</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HHS - U. S. Department of Health and Human Services</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IDN - Independent Delivery Network (including hospitals and hospital health systems)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPA - Independent Physician Association</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LDT - Laboratory-Developed Test</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PAMA - The Protecting Access to Medicare Act of 2014</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The discussion also includes several tables, indexed in the following guide. </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:81.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="background-color:#828282;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Guide to Tables</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services Portfolio </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Table 1</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #828282;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approaches to Accelerate Growth</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Table 2</span></td><td colspan="3" style="background-color:#dbdbdb;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Key Professional Laboratory Services Offerings</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Table 3</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer-Centric Initiatives</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Table 4</span></td><td colspan="3" style="background-color:#dbdbdb;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer-Initiated Testing</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Table 5</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Major Themes to Drive Operational Excellence</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Table 6</span></td><td colspan="3" style="background-color:#dbdbdb;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our Strengths </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Table 7</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets and Capabilities</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Table 8</span></td><td colspan="3" style="background-color:#dbdbdb;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Franchises</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Table 9</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Net Revenues</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Table 10</span></td><td colspan="3" style="background-color:#dbdbdb;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Key Trends</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Table 11</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="background-color:#dbdbdb;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Helping to Achieve the Triple Aim of Healthcare </span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Table 12</span></td><td colspan="3" style="background-color:#dbdbdb;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customers</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Table 13</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential Factors Considered When Selecting a Diagnostics Information Services Provider</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Table 14</span></td><td colspan="3" style="background-color:#dbdbdb;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Medicare and Medicaid Revenues as % of Consolidated Net Revenues </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Table 15</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Key Regulatory Schemes</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Table 16</span></td><td colspan="3" style="background-color:#dbdbdb;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Information Available at Our Corporate Governance Webpage</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Table 17</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Information Available at Our Corporate Responsibility Webpage</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Table 18</span></td><td colspan="3" style="background-color:#dbdbdb;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Officers</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Table 19</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item 1. Business</span></div><div><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTRODUCTION</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Quest Diagnostics Incorporated is the world's leading provider of diagnostic information services.  We play a crucial role in the healthcare ecosystem, empowering people to take action to improve health outcomes.  Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management.  In the right hands and with the right context, our diagnostic insights can inspire actions that transform lives.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Quest Diagnostics was incorporated in Delaware in 1990; its predecessor companies date back to 1967.  We conduct business through our headquarters in Secaucus, New Jersey, and our laboratories, patient service centers, offices and other facilities around the United States and in selected locations outside the United States.  Unless the context otherwise requires, the terms &#8220;Quest Diagnostics,&#8221; the &#8220;Company,&#8221; &#8220;we&#8221; and &#8220;our&#8221; mean Quest Diagnostics Incorporated and its consolidated subsidiaries.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The patients we serve comprise approximately one-third of the adult population of the United States annually, and approximately one-half of the adult population in the United States over a three-year period.  We estimate that annually we serve approximately half of the physicians and half of the hospitals in the United States. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During 2022, we generated net revenues of $9.9 billion.  Additional financial information concerning Quest Diagnostics for each of the years ended December&#160;31, 2022, 2021 and 2020 is included in the consolidated financial statements and notes thereto in &#8220;Financial Statements and Supplementary Data&#8221; in Part II, Item 8.</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our vision, aspirational goals and values are set forth below.&#160;&#160;&#160;&#160;</span></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><span><br/></span></div><div style="text-align:center"><img src="dgx-20221231_g1.jpg" alt="dgx-20221231_g1.jpg" style="height:476px;margin-bottom:5pt;vertical-align:text-bottom;width:277px"/></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We believe that our vision, aspirational goals and strategy align very well with, and our strong value proposition supports, the triple aim of healthcare: improving medical quality and the patient experience while reducing the cost of care.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Quest Diagnostics was at the forefront of the response to the COVID-19 pandemic, playing a pivotal role to broaden access to laboratory insights to help people lead healthier and safer lives.  We provided both molecular diagnostic and antibody serology tests to aid in the diagnosis of COVID-19 and the detection of immune response to the virus, and have performed approximately 77 million of these tests.  We built up and maintained the testing capacity to handle surges in COVID-19 testing demands, including using our national courier, air fleet and logistics network to balance volume across approximately two dozen COVID-19 testing laboratories, and also through our laboratory referral partner program. We worked with federal, state and local governments, healthcare organizations, payers, suppliers, retailers, trade associations and other laboratories in the effort to bring as much COVID-19 testing as possible to the American people.  We also provided data on COVID-19 testing that we conducted to federal, state and local public health authorities, including the CDC, and participated in studies with government and private institutions, aiding COVID-19 public health response and research.  All of our employees, including our dedicated laboratory professionals, phlebotomists, air fleet team, and couriers took tremendous pride in the role we played and worked tirelessly to help patients and communities access quality COVID-19 testing.  As the impact of COVID-19 moderates, we remain active in the continued response to COVID-19, including supporting ongoing testing needs and public health response. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We also saw how underserved communities were disproportionately impacted by COVID-19, and with the Quest Diagnostics Foundation, we launched Quest for Health Equity, an initiative to reduce health disparities in underserved communities in the U.S.  This initiative is providing a combination of testing services, education programs, alliances and financial support to efforts to address health disparities.  Since its inception, we have committed approximately $30 million to  approximately 65 programs launched across the U.S. and Puerto Rico, including supporting COVID-19 testing and vaccination events, wellness events, educating young students on healthy nutrition choices and expanding research and mentorship opportunities for Black and Hispanic scholars.  Numerous Quest for Health Equity undertakings demonstrate our commitment to FQHCs and the people they serve, including by providing free lab testing services.      </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our approach to fighting the COVID-19 pandemic was rooted in our vision of empowering better health through diagnostic insights.  We believe that the challenges we faced from the COVID-19 pandemic brought us together, made us a stronger company and will help us capture the substantial opportunities in front of us.  </span></div><div><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUR STRATEGY </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have a two-point business strategy, reviewed by our Board of Directors, to achieve our vision and our goals.</span></div><div><span><br/></span></div><div style="text-align:center"><img src="dgx-20221231_g2.jpg" alt="dgx-20221231_g2.jpg" style="height:261px;margin-bottom:5pt;vertical-align:text-bottom;width:440px"/></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accelerate Growth</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our strategy to accelerate revenue growth is based on the Company&#8217;s portfolio of services.</span></div><div style="text-align:center"><span><br/></span></div></td></tr><tr><td colspan="12" style="background-color:#606060;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Services Portfolio (Table 1)</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Activity</span></td><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #acacac;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Key Characteristics</span></td><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #acacac;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">At A Glance</span></td><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #acacac;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Quest Value Proposition</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General Diagnostics</span></td><td colspan="3" style="border-left:1pt solid #acacac;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Testing services generating strong cash flows and steady growth </span></td><td colspan="3" style="border-left:1pt solid #acacac;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; Routine and non-routine testing services</span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; Largest revenue stream</span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; Essential portion of healthcare delivery</span></div></td><td colspan="3" style="border-left:1pt solid #acacac;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; Scale<br/>&#8226; Operational excellence<br/>&#8226; Access and convenience<br/></span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced Diagnostics</span></td><td colspan="3" style="border-left:1pt solid #acacac;border-top:1pt solid #d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Testing services targeting faster growth through innovation testing model</span></td><td colspan="3" style="border-left:1pt solid #acacac;border-top:1pt solid #d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; Genetic and advanced molecular testing services </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; An important part of precision medicine</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; Innovation-based competitors</span></div></td><td colspan="3" style="border-left:1pt solid #acacac;border-right:1pt solid #000000;border-top:1pt solid #d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; Rich clinical, scientific and medical innovation expertise<br/>&#8226; Quality and reliability of new assays<br/>&#8226; Ability to manage potential new regulatory requirements</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostic Services</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #acacac;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and data-related healthcare opportunities targeting faster growth</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #acacac;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; Enables partners to deliver healthcare more efficiently (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">e.g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, risk assessment; Professional Laboratory Services; Employer Population Health)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; Services to support population health (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">e.g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, data analytics; extended care services)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #acacac;border-right:1pt solid #000000;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; Extensive diagnostic capability<br/>&#8226; Large and growing database and analytics expertise<br/>&#8226; Partnerships with industry leaders across healthcare landscape</span></td></tr></table></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have identified the following five approaches to accelerate growth.</span></div></td></tr><tr><td colspan="3" style="background-color:#606060;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Approaches to Accelerate Growth (Table 2)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1. Delivering annual revenue growth of more than 2% through accretive, strategic acquisitions</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Plus organic growth through:</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2. Capitalizing on increased health plan access </span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3. Increasing share with IDNs </span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4. Growing Advanced Diagnostics  </span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5. Building consumer-initiated testing</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;1. Growing through acquisitions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  We endeavor to grow revenue each year by more than 2% through accretive, strategic acquisitions (our target has been based on our revenues excluding the revenues from our COVID-19 testing).  Acquisition opportunities may include IDN outreach businesses, regional laboratory consolidation and businesses that will provide us with new capabilities.  Our approach to acquisitions, and the key acquisitions we consummated during 2022, are discussed below under the heading </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Deliver disciplined capital deployment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;2. Capitalizing on increased health plan access.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  We are focused on opportunities to partner with health plans.  We strengthen our relationships with health plans and increase the volume of our services for their members by focusing on driving value and providing strong value propositions for members and clinicians. This includes working with payers to reduce the cost of care, improve the customer experience and drive better outcomes for populations.  For example, we strive to build information platforms to help health plans manage utilization and population health, keep laboratory testing in network and provide an alternative to high-cost labs.  We also offer extended care services to help close gaps in care designed to be attractive to payers.  In 2022, we augmented our extended care offering by acquiring Pack Health, a patient engagement company that helps individuals adopt healthier behaviors to improve outcomes.  We expanded the plans with which we have a value-based </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contracting relationship, fostering better alignment with the health plans.  We also renewed our longstanding strategic relationship with Blue Cross and Blue Shield of Florida, Inc.   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;3.  Increasing share with IDNs.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the growing market challenges faced by IDNs, including continued consolidation, price transparency, cost and utilization pressure, evolving healthcare payment models, capital needs, changing technology and limited resources, provide us with an opportunity to partner with them more effectively as they consider their laboratory testing strategy and drive demand for our expertise.  We have deployed a dedicated team to strengthen our relationships with IDNs, including with respect to their reference testing.  We target three specific opportunities: reference testing, outreach testing and lab management.  We provide reference testing for approximately half of the hospitals in the U.S. and are a leading provider of this testing in the country.  Our industry-leading Professional Laboratory Services, highlighted in Table 3, provides a suite of solutions to help IDNs build and execute their laboratory strategy, improve quality, reduce the cost of care and focus on core competencies.  We purchase outreach testing businesses from IDNs that decide to exit that business.  In 2022, we continued to work with IDNs to help them execute their lab strategy, started providing laboratory management services to Lee Health, a community-owned health system in Southwest Florida, and entered an agreement to provide lab management services to Northern Light Health, a large integrated healthcare system in Maine. In addition, as discussed below under the heading </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Deliver disciplined capital deployment,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> we acquired the outreach testing business of Summa Health, a large integrated healthcare system in Northeastern Ohio, and agreed to acquire select assets of Northern Light Health's outreach testing business.  We also were awarded a group purchasing agreement for our laboratory stewardship solution, including Quest Lab Stewardship</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Enterprise powered by hc1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,  with Premier Inc., a leading healthcare improvement company uniting an alliance of hospitals, health systems and providers.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#606060;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Professional Laboratory Services Offerings (Table 3)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab management outsourcing</span></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced data solutions</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Test menu optimization and spend consolidation</span></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reference testing, including advanced diagnostics</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supply chain management and purchasing</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blood utilization management</span></td></tr></table></div><div style="padding-left:54pt;text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Growing Advanced Diagnostics.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  We are a leading provider of Advanced Diagnostics, with an array of offerings across the spectrum.  We aim to accelerate the growth of our Advanced Diagnostics offerings to a growth rate of at least 8% per year.  We have been investing in our Advanced Diagnostics offerings, including to enhance our innovation capabilities and to strengthen our service offering and sales force, to make our Advanced Diagnostics offerings more attractive and accessible to IDNs and clinicians.  In addition, we have invested in reducing the cost of next-generation sequencing and combining that with the power of our Blueprint Genetics</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> data analytics capabilities.  We are seeking to apply the capabilities gained by these efforts to other areas where we can make a meaningful difference in health care, including consumer genetics and offerings to pharmaceutical companies, IDNs and health plans.  In 2022, we invested in our bioinformatics capabilities and our women's health sales force, and to accelerate growth in oncology, hematology, and pharma services.  We introduced the Solid Tumor Expanded Panel to help oncologists with therapy selection and Quest AD Detect, a blood test to aid in the early assessment of Alzheimer's disease.  During 2022, we saw strong growth in prenatal genetic testing and pharma services.   </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">               </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Building consumer-initiated testing.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  For many years, we have been focused on the consumer, and have taken strong steps to be recognized as the consumer-friendly provider of choice of diagnostic information services.  Our strong consumer focus is highlighted in Table 4.  We will continue to focus on improving the consumer experience, including through improved digitization and other enhancements of our operations.  For example, our "Schedule at Check In" capability, which encourages patients to make appointments, allowing us to better manage demand and phlebotomy productivity while enhancing the patient experience, is now deployed at approximately 85% of our patient service centers. We have increased to approximately 80%   the number of our patients coming to a patient service center who have appointments, and reduced average wait times in the centers.  We also are sending more messages to patients via SMS text, increasing the speed and utility of information flow to patients and patient satisfaction.  In addition, we are building the patient payment process into the digital customer experience, improving the patient experience, helping our patient concession rate, and reducing demands on phlebotomists.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increasing consumer expectations inform our design for our consumer experience. </span></td></tr><tr><td colspan="6" style="background-color:#606060;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consumer-Centric Initiatives (Table 4)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Connectivity and access to information</span></td><td colspan="3" style="border-left:1pt solid #acacac;border-right:1pt solid #000000;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; &gt;27.5 million registered users in our MyQuest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> health portal and mobile connectivity solution, up over 6 million from a year ago.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;  Quest lab results available for Android users through the CommonHealth app.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; MyQuest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> supports Health Records using the Apple Health app.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; Using MyQuest,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">consumers can manage healthcare for a group of individuals. </span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reminders</span></td><td colspan="3" style="border-left:1pt solid #acacac;border-right:1pt solid #000000;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; Consumers whose physicians have ordered a test for them electronically can receive email reminders to complete the test.<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; Consumers who have made appointments can receive appointment reminders via text messaging.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enhanced experience</span></td><td colspan="3" style="border-left:1pt solid #acacac;border-right:1pt solid #000000;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; Electronic check-in at patient service centers.<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; Improved on-line pre-registration and appointment scheduling.<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; Real-time payment determination.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convenient access </span></td><td colspan="3" style="border-left:1pt solid #acacac;border-right:1pt solid #000000;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; Partnerships with Walmart and Safeway to expand convenient access to testing services at select Walmart and Safeway locations across the United States (approximately 200 locations at year end).</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Self-collection technology</span></td><td colspan="3" style="border-left:1pt solid #acacac;border-right:1pt solid #000000;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; Proprietary, consumer-friendly self-collection technology offered  </span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Satisfaction</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #acacac;border-right:1pt solid #000000;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; We are measuring consumer satisfaction.</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In 2018, we launched our consumer-initiated testing offering that permits consumers to request their own lab tests, to allow consumers to take control of, and to better understand, their own health through access to personal diagnostic information.  In an evolving healthcare environment, consumers are increasingly engaged in their health care and want control, a dynamic experience and convenience.  Our QuestHealth</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> offering reflects our belief that by building on the foundation of our strong consumer focus we can capture growing opportunities in consumer-initiated testing and demand for expanded access to basic health care services.  In 2022, we continued to invest in our offering, launching an enhanced digital platform with a more powerful and consumer-friendly user experience designed to better acquire, convert and retain more customers.  We collaborated with Walmart, to make consumer-initiated testing available through Walmart.com, and with eMed</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to launch a COVID-19 rapid antigen test with observed collection, helping individuals meet travel and other observed collection and test report requirements.     </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We are focusing on consumer interest to experience health care in a different way <br/>and empowering consumers to make important decisions about their health </span></td></tr><tr><td colspan="6" style="background-color:#606060;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consumer-Initiated Testing (Table 5)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer-initiated testing </span></td><td colspan="3" style="border-left:1pt solid #b6b6b6;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; Consumers can choose from approximately 60 different test purchase options focused on consumer interests, such as general health, men's and women's health, digestive health, heart health, infectious disease, sexually transmitted infection, COVID-19, and Lyme disease.  </span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b6b6b6;border-left:1pt solid #000000;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expanded offerings</span></td><td colspan="3" style="border-bottom:1pt solid #b6b6b6;border-left:1pt solid #b6b6b6;border-right:1pt solid #000000;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;  In 2022, we expanded our offerings to include, among others, new respiratory, thyroid, kidney and fitness tests.</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic healthcare services</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #b6b6b6;border-right:1pt solid #000000;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;  Comprehensive consumer health profile available, through tests and biometric measurements that provide a personalized health quotient score that can be used to track health progress over time.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Self-collection technology</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #acacac;border-right:1pt solid #000000;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; Proprietary, consumer-friendly self-collection technology offered to consumers at home.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:top"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convenient online access </span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #acacac;border-right:1pt solid #000000;border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; In addition to access through QuestHealth.com, access to services through Walmart.com.</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convenient physical access</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #acacac;border-right:1pt solid #000000;border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; Access to services in our patient service centers and in select Walmart stores.</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Drive operational excellence</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.274%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We strive to enhance operational excellence and improve our quality and efficiency across every portion of our value chain and operations, from the time that we interact with a potential customer until the time we receive payment.</span></td></tr><tr><td colspan="6" style="background-color:#606060;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Major Themes to Drive Operational Excellence (Table 6)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduce denials and patient concessions </span></td><td colspan="3" style="border-left:1pt solid #acacac;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Standardize, automate and optimize</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #acacac;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Digitize the customer experience</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #acacac;border-right:1pt solid #000000;border-top:1pt solid #acacac;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Select and retain talent</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Improving our operations will yield many benefits, including: enhancing customer experience; improving our quality and competitiveness; strengthening our foundation for growth; and increasing employee engagement and shareholder value.  We are building a superior experience, at lower cost, for all of our customers, including consumers, health plans, IDNs and clinicians.  We endeavor to improve our processes and effectiveness at the same time.  We are guided by a service dashboard that focuses throughout our operations on quality for consumers, healthcare providers and employees, including medical quality, on-time delivery, competitive costs and employee safety. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;During 2022, we made strong progress on our improvement initiatives.  We are working to further enhance end-to-end specimen tracking.  We concluded consolidation of our urinalysis testing onto a new highly automated platform.  We implemented new semi-automated technology in parasitology and are expanding use of a highly automated microbiology platform that makes use of artificial intelligence to assist with sample analysis.  We also made significant progress transferring immunoassay tests to a more automated platform, and expect to finish this project in 2023.  We increased customer adoption of our digital self-service channels, reducing demand in our call centers.  We implemented several initiatives to improve talent retention, including capability-building programs, and launched plans for a new daily management system for our frontline employees.  In addition, we continue to drive to take advantage of robotic process automation and artificial intelligence technologies to drive productivity gains.      </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our cost excellence program, Invigorate, includes structured plans to drive savings and improve productivity across the value chain, including in such areas as revenue services, information technology and procurement.  We currently aim annually to achieve savings and productivity improvements of 3% of our costs.  In 2022, we approached our goal. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7 </span></div></div></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUR STRENGTHS</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We offer high value diagnostic information services and diagnostic solutions that are attractive to our customers.  </span></td></tr><tr><td colspan="6" style="background-color:#606060;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Our Strengths (Table 7)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality </span></td><td colspan="3" style="border-left:1pt solid #acacac;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strong Operating Principles</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #acacac;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets and Capabilities to Deliver Value </span></td><td colspan="3" style="border-left:1pt solid #acacac;border-right:1pt solid #000000;border-top:1pt solid #acacac;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health Information Technology Solutions and <br/>Information Assets</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #acacac;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Innovation</span></td><td colspan="3" style="border-left:1pt solid #acacac;border-right:1pt solid #000000;border-top:1pt solid #acacac;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical and Scientific Expertise</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #acacac;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #acacac;border-right:1pt solid #000000;border-top:1pt solid #acacac;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer Focus</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quality</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our goal is to provide every patient with services and products of superior quality.  We strive to accomplish that through commitment, leadership, and establishing rigorous processes that we measure and continually seek to improve, and by using the Quest Management System, which provides best-in-class business performance tools to create and implement effective and sustainable quality processes.  Our Quality Program includes policies and procedures to document, measure and monitor the effectiveness of our laboratory operations in providing and improving quality and meeting applicable regulatory requirements.  The Quality Program is designed so that the quality of laboratory services is monitored objectively and evaluated systematically to deliver superior quality care, identify opportunities to improve patient care and resolve identified problems.  To help achieve our goal of becoming recognized as the undisputed quality leader in the diagnostics information services industry, we have implemented our Quality System Framework, which serves as a reference guide for our employees and describes our Quality System Elements, which provide the structure for each laboratory to achieve and maintain quality processes.   We also have a robust Supplier Quality Program designed to ensure we have a high-quality supplier network and to raise the bar of quality expectations across that network.  Being chosen by UnitedHealthcare as a participant in the UnitedHealthcare Preferred Lab Network reflects the strength of our quality.  For additional information about our commitment to quality, see "General - Quality Assurance" on page 25.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Strong operating principles</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have a foundation of three strong operating principles: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strengthen organizational capabilities; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">remain focused on diagnostic information services; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">deliver disciplined capital deployment.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Strengthen organizational capabilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  We continuously strive to strengthen our organizational capabilities to support our two-point strategy, enable growth and productivity, better focus on our customers, speed decision-making and empower employees.  Highlights include:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Align for Growth, Execution and Efficiency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Our organization is designed to align around growth opportunities, coordinate business units for seamless execution and leverage our company-wide infrastructure to gain more capability, value and efficiency. We relied on this organizational design to allow us to develop a coordinated and sustained strategy to respond to the unprecedented challenges we face responding to the COVID-19 pandemic.  The value creation side of our business includes product and commercial marketing and is organized by clinical franchise and focuses on customer solutions for the marketplace, including new test development and diagnostic insights.  The value delivery side includes sales, laboratory operations, field operations, logistics and client services.   </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Quest Management System</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  This system provides a foundation for day-to-day management, and includes best-in-class business performance tools to help develop new capabilities to improve our Company.  The system enables us to run the Company with a common language, approach and philosophy, and supports our efforts to maintain a high-performance culture, with employees focused on behaviors to foster our agility, transparency, customer focus, collaboration and performance orientation.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div style="padding-left:54pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remain focused on diagnostic information services.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We maintain a sharp focus on providing diagnostic information services.   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deliver disciplined capital deployment.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our disciplined capital deployment framework includes investment in our business, dividends and share repurchases.  The framework is grounded in maintaining an investment grade credit rating.  We expect to return a majority of our free cash flow to investors through a combination of dividends and share repurchases.  Consistent with that expectation, in February 2023 we announced that we increased our quarterly common stock cash dividend by approximately 7.6%, from $0.66 per common share to $0.71 per common share.  This represents our twelfth increase in the dividend since 2011.  For many years, we have maintained a common stock repurchase program.  Since the beginning of 2013, we have returned approximately $7.1 billion to stockholders through repurchases of our common stock.  Our share repurchases, dividends and capital expenditures in each of the last three years are presented in our consolidated financial statements (Part II, Item&#160;8 of this Report).  </span></div><div style="padding-left:54pt;text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company's strategy includes generating growth through value-creating, strategically-aligned acquisitions using disciplined investment criteria.  We screen potential acquisitions using guidelines that assess strategic fit and financial considerations, including value creation, return on invested capital and impact on our earnings.  In 2022, we consummated the acquisition of Pack Health, a patient engagement company that helps individuals adopt healthier behaviors to improve outcomes, and the outreach testing business of Summa Health, a large integrated healthcare system in Northeastern Ohio.  We also agreed to acquire select assets of the outreach testing business of Northern Light Health, a large integrated healthcare system in Maine.  Our significant acquisitions in each of the last three years are further discussed in Note 6 to the audited consolidated financial statements (Part II, Item&#160;8 of this Report).</span></div><div style="padding-left:54pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We will continue to invest in our business in a disciplined manner, including focusing on enhancing our solid foundation of strategic assets and capabilities, accelerating growth and driving operational excellence.  Our near-term investments in growth are likely to focus on the approaches to accelerate growth set forth in table 2 above.  Our near-term investments to drive operational excellence are likely to focus on improving the customer experience and gaining efficiency, systems standardization, and digital enablement of our processes. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets and capabilities to deliver value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:15.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We use our unmatched size, scale and capabilities to deliver a very attractive value proposition to our customers.</span></td></tr><tr><td colspan="6" style="background-color:#606060;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets and Capabilities (Table 8)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Connectivity </span></td><td colspan="3" style="border-left:1pt solid #d8d8d8;border-right:1pt solid #ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Provide healthcare connectivity solutions to &gt;475,000 clinician and IDN accounts and interface with nearly 850 electronic health records systems</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Data  </span></td><td colspan="3" style="border-left:1pt solid #d8d8d8;border-right:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   The largest private database of de-identifiable laboratory test results: &gt;60 billion patient data points </span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Logistics  </span></td><td colspan="3" style="border-left:1pt solid #d8d8d8;border-right:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Strong logistics capabilities </span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    make &gt;76,000 stops daily</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    approximately 4,000 courier vehicles</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   &gt;20 aircraft serving the U.S.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Medical and Scientific Staff </span></div></td><td colspan="3" style="border-left:1pt solid #d8d8d8;border-right:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    One of the largest medical and scientific staffs in the industry to provide interpretive consultation </span></div><div style="padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Approximately 600 M.D.s and Ph.D.s, many of whom are recognized leaders in their field </span></div><div style="padding-left:13.5pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Genetic counselors</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Healthcare Professionals  </span></div></td><td colspan="3" style="border-left:1pt solid #d8d8d8;border-right:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   Approximately 23,000 phlebotomists, paramedics, nurses and other health and wellness professionals</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Consumer Access </span></div></td><td colspan="3" style="border-left:1pt solid #d8d8d8;border-right:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Approximately 7,300 patient access points, including phlebotomists in physician offices and the most extensive patient service center network in the U.S. with approximately 2,100 locations </span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Health Plan Participation</span></div></td><td colspan="3" style="border-left:1pt solid #d8d8d8;border-right:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Access to approximately 90% of U.S. insured lives</span></div><div style="padding-left:9pt;text-indent:-13.5pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Processing Volume</span></div></td><td colspan="3" style="border-left:1pt solid #d8d8d8;border-right:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Processed approximately 208 million test requisitions in 2022, including approximately 15 million COVID-19 molecular test requisitions</span></div><div style="padding-left:9pt;text-indent:-13.5pt"><span><br/></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:15.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Range of Testing  </span></div></td><td colspan="3" style="border-left:1pt solid #d8d8d8;border-right:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Industry-leading test menu across clinical sub-specialty areas and diagnostic technologies </span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Patents</span></div></td><td colspan="3" style="border-left:1pt solid #d8d8d8;border-right:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Own or control approximately 1,100 issued and over 450 pending patents worldwide in 2022</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Innovation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We are a leading innovator in diagnostic information services.  We develop and introduce new tests, including many with a focus on personalized and targeted medicine, and new services.  Our capabilities include discovery, technology development and clinical validation of diagnostic tests.  We also partner with other developers of new technologies, services and tests to transfer their innovations to the marketplace, using our in-house expertise (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, strength in assay development and commercialization of testing services).  These developers include large commercial manufacturers, the academic community, pharmaceutical and biotechnology firms, emerging medical technology companies and others that develop and commercialize novel diagnostics, pharmaceutical and device technologies.  We maintain relationships with advisers and consultants who are leaders in key fields of science and medicine.  As the industry leader with the largest and broadest U.S. network, we believe we are the distribution channel of choice for developers of new solutions.       </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:45.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.126%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our clinical franchises enable us to perform like a boutique while maintaining our scale advantages, and work with our research and development and commercial organizations to identify/deliver new and improved solutions.</span></td></tr><tr><td colspan="6" style="background-color:#606060;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Franchises (Table 9)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular, Metabolic and Endocrinology</span></td><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer Diagnostics</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Diseases and Immunology</span></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drug Monitoring and Toxicology</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neurology</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Women&#8217;s and Reproductive Health</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek innovations and solutions that help healthcare providers, IDNs, health plans and other healthcare market participants care for their patients through better testing for predisposition, screening, monitoring, diagnosis, prognosis and treatment choices, and that deliver high clinical value to the medical community and reduce the overall cost of healthcare.  Starting with a clinical focus on a specific disease state or clinical problem, we take advantage of advanced technology for more precise, comprehensive and actionable information.  We seek to develop innovations and solutions that help to determine a patient's genotype or gene expression profile relative to a particular disease and its potential therapies, because they can help healthcare providers to determine a patient's susceptibility to disease or to tailor medical care to an individual's needs.  This would include determining if a medication might be an optimum choice for a particular person, or tailoring the right dosage once the proper medicine is prescribed.  We endeavor to improve test processes, including through increased automation.  In addition, we aim to develop holistic solutions responsive to challenges that healthcare providers and patients face, by developing solutions of tests, information and services focused on specific clinical challenges, and taking advantage of the latest healthcare data capabilities.  We also look for innovations and solutions that are less invasive than currently available options, and to increase the choices that healthcare providers and patients have for the collection of diagnostic specimens.  We seek innovation in the ways we bring solutions to customers, and in the customer experience, including enhanced services and end-to-end solutions for convenience and support. We make innovative solutions available to community physicians through our connectivity solutions, operational footprint and by making complex results actionable.  We plan to expand our innovative solutions through research and development, as well as partnerships with academic institutions, other technology and healthcare leaders and public health agencies.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the COVID-19 pandemic, we secured numerous Emergency Use Authorizations from the FDA related to molecular diagnostic COVID-19 testing and, with government and private sector partners, developed and built "pop-up" COVID-19 testing sites that offered a new, efficient model for consumer access to testing.  In 2022, we innovated with the CDC Increasing Community Access to Testing for COVID-19 program to increase access to $0 out-of-pocket COVID-19 testing in underserved communities using a combination of our capabilities including our strong COVID-19 molecular testing, our on-line capabilities and our patient service centers. We secured the first Emergency Use Authorization from the FDA during the Mpox (formerly known as Monkeypox) public emergency for an LDT to aid in the detection of Mpox.  We also launched a new obstetrics test panel that included hepatitis C screening.  These initiatives, along with other developments highlighted below under the headings "Collaboration," "Medical and Scientific Expertise," and "Healthcare Information Technology Solutions and Information Assets," demonstrate our agility and strength in innovation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We believe that strategic relationships, including with healthcare providers, public health authorities, consumer-focused entities and others, can position us for growth at the center of healthcare and that healthcare companies that can partner effectively with others will be successful in the long term.  We collaborate with partners that can help us to achieve our vision of empowering better health through diagnostic insights and have relationships across the spectrum of healthcare, including with world class healthcare and consumer-focused leaders, to foster important advances in healthcare, including in precision medicine and healthcare delivery.  We plan to continue to pursue strategic relationships to help accelerate growth and drive operational excellence.  In 2022, we collaborated with IRIS (Intelligent Retinal Imaging Systems) to offer diabetic retinopathy screening services in our patient service centers, with Walmart to make consumer-initiated testing available through Walmart.com, and with eMed</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to launch a COVID-19 rapid antigen test with observed collection, to help individuals meet travel and other observed collection and test report requirements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medical and Scientific Expertise</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;We have strong medical and scientific expertise and aspire to be a trusted authority in diagnostic medicine, provide insights and tools to support public and personal health, lead and facilitate scientific discussion and inspire innovation.  Our medical and scientific experts regularly provide presentations, symposia and webinars regarding diagnostic testing and participate on scientific committees determining guidelines for diagnostic usage.  They also publish research that demonstrates the clinical value and importance of diagnostic testing, including in connection with our research and development efforts, in peer-reviewed journals, textbooks and other publications.  For over 30 years, the Company has published the Quest Diagnostics Drug Testing Index,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">a series of reports on national workplace drug positivity trends based on the Company's employer workplace drug testing data, that is widely cited by employers, the federal government and the media to help identify and quantify drug abuse among the nation's workforce.  The Company also publishes Quest Diagnostics Health Trends,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> a series of scientific reports that provide insights into health topics, based on analysis of objective clinical laboratory data, to empower better patient care, population health management and public health policy.  Our role at the forefront of the response to the COVID-19 pandemic demonstrated this strength, as we secured numerous Emergency Use Authorizations from the FDA for innovations in connection with COVID-19 testing and specimen collection (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">e.g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">,  unobserved nasal specimen self-collection; combined COVID-19 and influenza virus tests; COVID-19 at-home specimen collection by consumers).  In 2022, we published more Health Trends</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> reports on consequences of COVID-19, along with other reports on, for example, screening pregnant women for hepatitis C, and hepatitis B and tuberculosis co-infection.  We also published studies regarding diabetes cost reductions achieved for participants in employer-sponsored health programs, perspectives on the future of Alzheimer's Disease treatment and the potential importance of employee health to addressing the "Great Resignation."  In addition, we employed our comprehensive menu of COVID-19 test and data analytics to support CDC population health research, helping to identify SAR-COV-2 seroprevalence on a multistate basis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Health Information Technology Solutions and Information Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have a history of providing leading information technology for diagnostic information services, including for patients, clinicians and healthcare organizations.   We were the first national diagnostic information services provider to offer online patient appointment scheduling and a patient connectivity solution.  Our MyQuest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patient healthcare portal, with more than 27.5 million registered users at year-end 2022, enables patients to manage healthcare and medical information for themselves and a circle of others and, among other things, use their smartphone or computer to order a test, find a Quest Diagnostics location, schedule appointments, receive appointment reminders, assess whether their health plan is in-network and receive and archive their test results.  We are expanding our use of digital and other technology tools to improve our customer experience for patients and providers.  We also were a founding member of the Synaptic Healthcare Alliance, which is working to create a platform, powered by blockchain technology, that enables a culture of innovation, removes friction and solves shared challenges impacting constituents across healthcare today.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We also have significant information assets and offer a robust portfolio of powerful analytics that inspire action and deliver value to an array of customers.  We offer an array of Quanum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> solutions based on data insights, including retrospective analytics solutions for healthcare professionals and practices, health plans, IDNs, pharmaceutical companies and public health organizations.  We believe that solutions can tap the potential of large amounts of clinical information to: enhance the customer experience; deliver more precise, comprehensive solutions and actionable information; provide increased and interactive insights and analytics; foster greater adherence to clinical and reimbursement guidelines; and advance the development of precision medicine.  We believe that the breadth and depth of our data, combined with our powerful analytics capabilities, enables us to take advantage of important data-based opportunities in diagnostics, and provides us a competitive advantage.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Customer Focus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our brand idea -- Action from Insight</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-- reflects our commitment to a superior customer experience.  The customer is at the center of everything we do; we strive to give them reason to put their trust in us.&#160; We use customer insights in developing our approach, listening to the voice of customers to identify and implement solutions and processes that will result in a superior customer experience.&#160; We also maintain our Everyday Excellence program, which includes guiding principles to support a superior customer experience, inspiring our employees to be their best every day, with every person and with every customer interaction. </span></div><div><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_25"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BUSINESS OPERATIONS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company is made up of two businesses:  Diagnostic Information Services and Diagnostic Solutions.  Our Diagnostic Information Services business develops and delivers diagnostic information services, providing insights that empower and enable a broad range of customers, including those discussed in table 13.  Our Diagnostic Solutions group includes our risk assessment services business, which offers solutions for insurers, and our healthcare information technology businesses, which offers solutions for healthcare providers.  Our services primarily are provided under the Quest Diagnostics brand, but we also provide services under other brands, including AmeriPath,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Dermpath Diagnostics,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ExamOne,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Quanum.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We are the leading provider in the United States, where we conduct substantially all of our business, of clinical laboratory and anatomic pathology testing, and related services.  We see opportunities to bring our experience and expertise in diagnostic information services to markets outside the United States, including leveraging existing facilities to serve new markets.  We have laboratory facilities in Finland, Mexico and Puerto Rico.  We are a founding member, with other leading diagnostic laboratories outside the United States, of the Global Diagnostics Network,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a strategic working group of diagnostic laboratories committed to unleashing and sharing local innovation to increase global access to diagnostic science, information and services and generating enhanced diagnostic insights to improve the delivery of global healthcare.  The Company and fellow members of the Network are focused on response to the COVID-19 pandemic and preparedness for future global infectious diseases. </span></div><div style="text-align:center"><img src="dgx-20221231_g3.jpg" alt="dgx-20221231_g3.jpg" style="height:236px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Diagnostic Information Services&#160;&#160;&#160;&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Background - clinical testing.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   Clinical testing is an essential element in the delivery of healthcare services.  Clinical testing is used for predisposition, screening, monitoring, diagnosis, prognosis and treatment choices of diseases and other medical conditions.  Clinical testing is generally categorized as clinical laboratory testing and anatomic pathology services.   Anatomic pathology involves the diagnosis of cancer and other diseases and medical conditions through examination of tissue and cell samples taken from patients. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Clinical laboratory testing, which can be characterized as routine, non-routine or advanced, generally is performed on whole blood, serum, plasma and other body fluids, such as urine, and specimens such as microbiology samples.  Clinical laboratory tests which can be performed by most clinical laboratories are considered routine.  Routine testing measures various important bodily health parameters such as the functions of the kidney, heart, liver, thyroid and other organs.  Commonly ordered routine tests include blood chemistries, urinalysis, allergy tests and complete blood cell counts.  Non-routine tests may </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">require professional &#8220;hands-on&#8221; attention from highly-skilled technical personnel, generally require more sophisticated data analysis, technology, equipment or materials, may be performed less frequently than routine tests and may be reimbursed at higher levels than routine tests.  It may not be practical, from a cost-effectiveness or infrastructure perspective, for many IDNs, ACOs, commercial laboratories or physician office laboratories to develop and perform a broad menu of non-routine tests, or to perform low-volume non-routine testing in-house.  Such tests generally are outsourced to a clinical testing laboratory which can perform these non-routine tests.  Some non-routine tests are advanced.  Advanced tests include procedures in the areas of molecular diagnostics (including next-generation sequencing), oncology, neurology, companion diagnostics and non-invasive pre-natal and other germline genetic testing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our services. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the world's leading provider of diagnostic information services.  We provide information and insights based on an industry-leading menu of routine, non-routine and advanced clinical testing and anatomic pathology testing, and other diagnostic information services.  We have strong testing capabilities, including services for the predisposition, diagnosis, treatment and monitoring of cancers and other diseases, and offer advanced tests in many fields, including endocrinology, immunology, neurology and oncology.  Increasingly, we are focused on providing solutions and insights to our customers, based on the testing that we perform, the data that we gather and our extensive medical, information and connectivity assets.  We believe that offering services, solutions and insights based on a full range of tests, information assets and other capabilities strengthens our market offering, market position and reputation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We offer the broadest access in the United States to clinical testing.  We maintain a nationwide network of laboratories, including advanced laboratories as well as rapid response laboratories (smaller facilities where we can quickly perform an abbreviated menu of routine tests for customers that require rapid turnaround times).  We operate 24 hours a day, 365 days a year.  Our nationwide network also includes patient service centers, phlebotomists in physician offices, and our connectivity resources, including call centers and mobile paramedics, nurses and other health and wellness professionals.  Our large in-house staff of medical and scientific experts, including medical directors, scientific directors, genetic counselors and board-certified geneticists, provide medical and scientific consultation to healthcare providers and patients regarding our tests and test results, and help them best utilize our services to improve outcomes and enhance satisfaction.   We also provide testing (including anatomic pathology) services and medical director services at IDN laboratories.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;  We are a leading provider of diagnostic information services for infectious disease, such as COVID-19 (including molecular diagnostic and serology antibody offerings), tuberculosis (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our T.SPOT.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TB</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Quantiferon offerings) and tick-borne disease (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our Accutix</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> offering).  We strive to be the first to provide diagnostic solutions for emerging infectious diseases (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., our offerings for Zika, West Nile Virus, SARS and Influenza A H1N1).  We have leading positions in drug monitoring and toxicology, in neurology diagnostics, in advanced cardiovascular diagnostic information services (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., our CardioIQ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Cleveland HeartLab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">offerings through our Cardiometabolic Center of Excellence</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), and in cancer diagnostics (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., our QuestVantage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">offerings).  We are the largest workplace drug testing provider, testing urine, hair, and oral fluid specimens, and are certified by HHS to perform drug testing using electronic custody and control forms for federally-mandated, safety-sensitive workers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;  We are a leading provider of employer population health services, including biometric screenings, flu shots and related preventative services that leverage clinical data to improve population health outcomes and reduce healthcare spend.  Our solutions enable employers to leverage screening insights to identify chronic disease risks, connect employees to needed in-network care, and empower better health.  Our offerings include connecting participants to the right care at the right time, such as (i) a program designed to prevent diabetes and other chronic conditions, (ii) a program that enables participants to engage with a board-certified physician about their results and to be guided about actions based on those results,  (iii) a mental health assessment program that links participants to virtual support and (iv) a program to facilitate virtual telehealth access to clinical services for participants and adult dependents, with emphasis on reducing risks related to preventable chronic diseases.  These services are sold directly to employers and by health plan resellers. In response to the COVID-19 pandemic, we developed and offered COVID-19 return to work services, to assist organizations developing plans for safer workplaces. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;  We offer Quanum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">health information technology solutions, including our products and national healthcare provider network, to help healthcare organizations and clinicians empower better health by leveraging the power of our significant information assets, including many years of test result data, and our technology prowess, including our history of providing leading information technology for diagnostic information services.  Our portfolio of offerings is designed to address analytic, clinical and financial needs.  The solutions help healthcare organizations and clinicians analyze and put in context data, and enable them to connect across the healthcare system and engage with their stakeholders.  They can enter, share and access clinical information without costly information technology implementation or significant workflow disruption.  &#160;&#160;&#160;&#160;</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;  We offer population health solutions to clinicians, health plans, and IDNs.  Our services build on the power of our information assets and data capabilities and help our customers deliver better care to their patient populations by identifying gaps in care in a population, providing clinical solutions to close the gaps and fostering consumer engagement with a solution.  For example, Quest Lab Stewardship</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> employs machine learning to help clinicians optimize medically-appropriate laboratory test utilization.  Our extended care services (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., bone density examinations; home collection kits for lab testing) help deliver better care to patient populations by identifying and filling gaps in care for patient populations and by enabling delivery of the most effective healthcare to the right populations and individuals.  These services leverage the power of our assets (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our extensive clinical data and data analytics services) and capabilities (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., call centers, patient service centers, mobile workforce) and focus on extending the reach of clinician offices beyond their traditional four walls to assess the health of their populations, and doing so when it is convenient for consumers.  Once gaps are identified, we engage patients in our retail sites, in home or by telephone, including through our call centers and our mobile capabilities, including highly trained healthcare professionals.  In 2022, we enhanced our extended care offering by acquiring Pack Health, which offers patient engagement services that help individuals adopt healthier behaviors to improve outcomes.  We also enhanced our diabetic retinopathy screening offering, collaborating with IRIS (Intelligent Retinal Imaging Systems) to offer retinal imaging services in our patient service centers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We offer services to pharmaceutical companies.  We offer clinical trials testing and have expertise in developing laboratory tests for FDA submission as companion diagnostics and laboratory developed tests for complementary diagnostics, and offer an array of assets and services to support the development of companion diagnostics, including our robust data set and patient services network. We also offer Quest Clinical Trials Connect</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to help accelerate clinical trials (and thus the speed of drugs to market) through better patient recruitment, involvement and management, and improved physician outreach.  In 2022, we also began to offer Pack Health's patient engagement services to our pharma clients.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We also offer sports teams, including at the professional and collegiate levels, performance tools, based on biomarker testing, designed to optimize high-level athletic performance through actionable insights.  This service provides the context for athletes to consider performance variables holistically, including nutritional education and intervention, maximum fitness, injury assessment and training load monitoring as well as sophisticated biometric analysis.  During the COVID-19 pandemic, we also expanded our test offerings for athletes to include COVID-19 testing, to foster the country's return to athletic fields.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Diagnostic Solutions </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Assessment Services.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  ExamOne</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is the largest provider of risk assessment services to the life insurance industry in North America.  Our risk assessment services comprise underwriting support services, including data gathering, paramedical examinations and clinical laboratory testing and analytics, designed to assist life insurance companies objectively to evaluate the mortality risks of applicants.  Most specimen collections and paramedical examinations are performed by our network of paramedical examiners at the applicant's home or workplace, but they also are offered at hundreds of Company patient service centers and many additional locations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healthcare Information Technology. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We offer healthcare organizations and clinicians robust health information technology solutions.  Our healthcare information technology offerings, including Quanum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Practice Solutions, our Electronic Health Record, Practice Management and Revenue Cycle Management Solutions for healthcare providers, and our award-winning Quanum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Enterprise Content Solutions for IDNs, connect data to decision-making and help clinicians advance clinical and operational strategies.  Healthcare organizations use Quanum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Enterprise Content Solutions at approximately 675 sites in North America.  Our Quanum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Electronic Health Record is a cloud-based, mobile-accessible offering that enables clinicians to generate a complete record of a clinical patient encounter, automates and streamlines the clinician's workflow, provides clinical decision support tools, captures patient encounter notes and lab and radiology results and enables secure communication with patients and other clinicians.</span></div><div><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_28"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE CLINICAL TESTING INDUSTRY</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key Trends</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The healthcare system in the United States is evolving.   We expect that the evolution of the healthcare industry, including impacts of the COVID-19 pandemic, which include the increased adoption of telemedicine, will continue, and that industry change is likely to be extensive.  There are a number of key trends that we expect will continue to have a significant impact on the diagnostic information services business in the United States and on our business.  These trends, discussed in the table below, present both opportunities and risks.  We believe that several of the trends, including consolidation, price transparency and consumerization, are favorable to our business.  </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Because diagnostic information services is an essential healthcare service and because of the key trends discussed below, we believe that the industry will continue to grow over the long term.  In addition, we believe that the clinical testing market continued with fundamental changes in 2022.  First, we believe that PAMA-driven reimbursement pressure is a catalyst for structural change in the market.  Second, we believe that there is an increased focus among our customers, including health plans, ACOs and government programs, on driving value in connection with laboratory testing services.  Third, we believe that ongoing consumerization in healthcare, with increased cost being borne by consumers, is changing consumption of healthcare services.  We believe that these changing market fundamentals will benefit lower-cost, high-value providers like Quest and that we are well positioned to grow from the changing market conditions and benefit from the long-term growth expected in the industry.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#606060;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Trends (Table 11)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">PAMA-driven reimbursement pressure</span></td><td colspan="3" style="border-left:1pt solid #acacac;border-right:1pt solid #ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to PAMA, reimbursement rates for many clinical laboratory tests provided under Medicare were reduced during 2018 - 2020.  PAMA calls for further revision of the Medicare Clinical Laboratory Fee Schedule for years after 2020, based on future surveys of market rates; reimbursement rate reduction from 2024-26 is capped by PAMA at 15% annually. <br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PAMA's next data collection and reporting period have been delayed, most recently by federal legislation adopted in December 2022, which further delayed the reimbursement rate reductions and reporting requirements until January 1, 2024.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Health plans driving value in lab spending</span></td><td colspan="3" style="border-left:1pt solid #acacac;border-right:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IDNs, which provide outreach testing and may encourage clinicians to send their outreach testing volume to the IDN's laboratory, historically were able to negotiate higher reimbursement rates with health plans than commercial clinical laboratories for comparable services.   In addition, health plans generally reimburse non-participating laboratory testing providers at higher out-of-network rates.  We are finding increased interest among health plans in driving better value in spending for laboratory testing.  Health plans increasingly are taking steps to encourage the movement of testing volume to high value, lower cost providers like our Company, including by identifying preferred provider partners, plan design changes (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">e.g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">., zero-dollar out-of-pocket costs for members using preferred providers) and better aligning reimbursement rates for IDN-based providers and independent commercial laboratories.  The UnitedHealthcare Preferred Lab Network, which chose us to participate, is an example of a health plan taking these steps. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health plans also are increasingly adopting policies, practices and procedures based on requirements imposed by government payers such as Medicare and Medicaid in order to influence the utilization and reimbursement of testing services.  These policies, practices and procedures are subject to change without notice.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Consumerization</span></td><td colspan="3" style="border-left:1pt solid #acacac;border-right:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumers are our customers.  Increasingly, consumers are engaged and interested in, and empowered to manage and take direct responsibility for, their own healthcare.  As a result, they are becoming more sophisticated in their understanding of their healthcare needs and their expectations of healthcare providers.  Some consumers are interested in selecting their own diagnostics tests, rather than relying upon a healthcare professional to select the tests.  In addition, consumers often are bearing increased financial responsibility for their healthcare (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">e.g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">., high deductible health plans; rising deductibles).  In our experience, consumers are more focused on transparency, ease of doing business and understanding diagnostics information services than they have been in the past.  Consumers increasingly are demanding convenience and a superior and personalized experience relevant to their needs.  During the COVID-19 pandemic, we saw consumers increase their use of telemedicine capabilities, increase their responsibility for their own healthcare (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">e.g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, increased consumer-initiated testing; increased specimen self-collection) and increase their openness to new delivery channels (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">e.g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">., retail; convenient "pop-up" test centers).  In addition, consumers are seeking prompt, direct access to their test results.  Increasingly, consumers are motivated to find high quality service providers with strong digital experience delivery engines, accessible customer service and lower prices, like our Company.  Our consumer-initiated testing offering is part of our response to this trend.  </span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #acacac;border-left:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Prevention and wellness</span></td><td colspan="3" style="border-bottom:1pt solid #acacac;border-left:1pt solid #acacac;border-right:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We believe that the value of detection, prevention, wellness and personalized care is well recognized. Government agencies and other customers discussed in table 13 increasingly focus on helping the healthy stay healthy, detecting symptoms among those at risk and providing preventive insight and care that helps avoid or reduce the negative impacts of a disease. </span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Medical innovation</span></td><td colspan="3" style="border-left:1pt solid #acacac;border-right:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical developments are creating new opportunities and new challenges and disrupting the healthcare environment. For example, during the COVID-19 pandemic, telemedicine practices became more commonly used and digital pathology is an emerging technology that may change the practice of pathology.  Information technology that includes self-learning or "artificial intelligence" features is growing and impacting healthcare.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing advances in genomics and proteomics are expected to give rise to new, more sophisticated and specialized diagnostic tests. These advances also are spurring interest in and demand for precision medicine, which relies on diagnostic and prognostic testing and in which data information services and strategies are used to deliver the most effective healthcare to the right populations and individuals. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacogenomic testing increasingly is used as a parameter to help speed drug approval processes and to better focus therapy based on patient and tumor-specific genetic markers. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Demand also is growing toward comprehensive care management solutions that serve patients, payers and healthcare providers by improving clinical decision support and access to patient data, and by increasing patient participation in care management and population health management.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Innovation also includes making healthcare services, including laboratory testing services, more convenient for populations and consumers to access, including at home (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">e.g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">., telehealth) or in retail settings.</span></div><div><span><br/></span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #acacac;border-left:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Healthcare industry evolution; focus on value</span></td><td colspan="3" style="border-bottom:1pt solid #acacac;border-left:1pt solid #acacac;border-right:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customers discussed in table 13 and other healthcare system participants have been consolidating, converging and diversifying. For example, a number of IDNs are considering establishing or have established health insurance plans, and health insurance providers are considering providing or are providing healthcare services.   In recent years, a leading provider of retail medical clinics and pharmacy benefits management services has acquired a leading health insurance provider, a leading health insurance provider has acquired a leading pharmacy benefits manager, leading providers of retail pharmacy services have acquired, or agreed to acquire, significant ownership stakes in physician practices, and the corporate parent of a leading health insurance company provides a wide array of healthcare services through its non-insurance company subsidiaries and is collaborating with the nation's largest retailer.   Health plans are entering agreements with other providers of healthcare services, including laboratory testing services providers, to partner on value-based approaches to delivering healthcare to populations.  </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidation is increasing pricing transparency and bargaining power, and may encourage internalization of clinical testing.  </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Physicians frequently now are employed by IDNs, ACOs or large group practices integrated with IDNs, instead of organizing physician-owned practices, which is impacting the dynamics for whether clinical testing is performed in or outside of an IDN.  Physicians and other clinicians also increasingly are being employed by health plans, large retailers or their affiliates.  </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-based reimbursement and demand for convenience and greater availability are contributing to changes in the healthcare system.  ACOs  and patient-centered medical homes have grown as a means to deliver patient care.  </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CMS has refreshed its strategy to reinvigorate the national push toward value-based care for Medicare and Medicaid beneficiaries, and set goals for value-based reimbursement to be achieved.   CMS has stated that the Medicare Sharing Savings Program for ACOs is a critical component of CMS' vision to advance health equity, drive high-quality, person-centered care and promote affordability and sustainability of the Medicare program.   CMS sponsors two additional programs for ACOs, has stated that its goal is for all people in traditional Medicare to be in an ACO by 2030, and is adopting policies to drive growth in ACO participation.  </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes also are taking place in the way that some healthcare services are purchased and delivered in the United States.  IDNs are under significant pressure, and IDNs and large retailers are evolving.  Healthcare services increasingly are being provided by non-traditional providers (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">e.g.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, physician assistants), in non-traditional venues (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">e.g</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">., retail medical clinics, urgent care centers) and using new technologies (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">e.g.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, telemedicine, digital pathology).  </span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Pricing transparency</span></td><td colspan="3" style="border-left:1pt solid #acacac;border-right:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">There has been a trend toward greater pricing transparency in healthcare, including in the laboratory testing marketplace.  Several states have taken action to foster greater pricing transparency in healthcare.  For example, Massachusetts launched a website to help consumers understand the wide variation in healthcare costs.  Federal laws require health care providers to provide good faith estimates of costs to self-pay patients, and provide rights and protections for consumers against surprise billing or balance billing.  In addition, the federal government has adopted new legislation and issued new regulations designed to increase transparency regarding pricing and quality in healthcare, including requiring providers, group health plans and insurers to disclose cost information to consumers in advance of care being provided.<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increased price transparency, combined with increased patient financial responsibility for medical care, is enhancing purchasing sophistication and fostering changes in behavior in the healthcare marketplace.  We believe that increased price transparency should benefit lower cost, high value providers like our Company.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Competition</span></td><td colspan="3" style="border-left:1pt solid #acacac;border-right:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The diagnostic information services industry remains fragmented, is highly competitive and is subject to new competition. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Competition is emerging from new technologies (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">e.g</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">., digital pathology) and growing from non-traditional competitors (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">e.g</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">., a government agency or an employer establishing its own clinical laboratory for testing; providers of consumer-initiated testing).  Increased IDN acquisitions of physician practices may enhance clinician ties to IDN-affiliated laboratories and may strengthen their competitive position.  However, in light of other trends, including continued reimbursement pressure, IDNs may change their approach to providing clinical testing services. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New industry entrants with extensive resources may make acquisitions or expand into our traditional areas of operations.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Healthcare utilization<br/></span></td><td colspan="3" style="border-left:1pt solid #acacac;border-right:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare utilization in the United States has fluctuated based on a number of factors.  These factors include, without limitation, the economy, healthcare benefits design, patients delaying medical care (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">e.g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">., due to the COVID-19 pandemic), and increased consumer financial responsibility for, interest in and control of their healthcare.  </span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Reimbursement pressure; affordability</span></td><td colspan="3" style="border-left:1pt solid #acacac;border-right:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">There is a strong focus in the United States on controlling the overall cost of healthcare. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare market participants, including governments, are focused on controlling costs. Examples of cost control approaches include reducing reimbursement for healthcare services, changing reimbursement methodology for healthcare services (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">e.g</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">., shift from fee for service to capitation), changing medical coverage policies (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">e.g</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">., healthcare benefits design), denying coverage for services, requiring preauthorization of laboratory testing, requiring co-pays, introducing laboratory spend management utilities and payment and patient care innovations such as ACOs and patient-centered medical homes. There is increased market activity regarding alternative payment models, including bundled payment models. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Health Transformation Alliance, initially a group of over 50 major U.S. companies, was formed to improve and reform the healthcare system in the United States.  The rising cost of healthcare in the United States was a key driver for the formation of this alliance. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">While pressure to control healthcare costs poses a risk to our Company, it also creates opportunities, such as an opportunity for increased proper utilization of testing as an efficient means to manage the total cost of healthcare.  We believe that it also creates greater opportunities for consolidation and gaining share for high value, lower-cost providers, like our Company, as compared to other providers.</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #acacac;border-left:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Legislative, regulatory and policy environment</span></td><td colspan="3" style="border-bottom:1pt solid #acacac;border-left:1pt solid #acacac;border-right:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government oversight of and attention to the healthcare industry in the United States is significant and increasing; healthcare payment reform and cost transparency are significant issues.  </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The FDA and HHS have expressed views regarding the regulation of LDTs.  Legislation introduced in recent sessions of Congress that would authorize the FDA to regulate LDTs has not become law.  If legislation that authorizes the FDA to regulate LDTs were to become law, it could have a significant impact on the clinical laboratory testing industry, including regulating LDTs in new ways, while creating avenues of opportunity and competition regarding clinical laboratory testing.  New competitors may enter the industry, and competition may come in new forms.    </span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Use of healthcare data; technology </span></td><td colspan="3" style="border-left:1pt solid #acacac;border-right:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The increased availability of healthcare data, including data made available as a result of next generation DNA sequencing, and the increased ability to effectively analyze that data at population and patient levels, is impacting healthcare practices.  It is anticipated that the increased use of data in healthcare, coupled with mobile healthcare IT solutions for doctors and patients, will help to improve patient outcomes and reduce overall healthcare costs.  We provide automated next generation genetic sequencing, which will enable genetic screening faster and at lower cost.<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Use of healthcare data, including integrated diagnostic and decision support solutions, predictive analytics, and healthcare information technology, is spurring advances in precision medicine, including medical decision making and value, for populations and individuals.  The increased focus on data and its use is increasing focus on maintaining the privacy of patient data.<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">There is a need for technology solutions to harness these opportunities.  In addition, new technology, social media and mobile technology are changing the way that healthcare markets interact with each other, and the expectations that they have about how services are provided, what services are provided, and other capabilities of healthcare market participants.  These developments are creating new opportunities and new challenges and disrupting the healthcare environment. For example, during the COVID-19 pandemic, telemedicine practices became more commonly used and digital pathology is an emerging technology that may change the practice of pathology.  Information technology that includes self-learning or "artificial intelligence" features is growing and impacting the healthcare industry. <br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare market participants, including many of our customers discussed in table 13, are striving to leverage interoperability and healthcare data analysis to positively influence the health of patient populations while maintaining patient privacy.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chronic diseases and conditions; gaps in care</span></td><td colspan="3" style="border-left:1pt solid #acacac;border-right:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We believe that the cost and challenges of identifying, treating and controlling chronic diseases and conditions such as diabetes and heart disease are now well recognized.    <br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As a result of multiple factors, including increased focus on population health management and pressure to reduce the systemic costs associated with such diseases and conditions, there is increased focus on better identifying and attempting to reduce or eliminate the gaps in care historically associated with these diseases and conditions.  Healthcare market participants are developing new approaches for this purpose.  <br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As a result of the COVID-19 pandemic, there has been an increase in delays in diagnosis and treatment of chronic diseases and conditions, particularly in underserved communities, increasing potential gaps in care.  The COVID-19 pandemic called attention to gaps in care of these conditions in underserved populations; we believe that there also is increased focus on reducing or eliminating these gaps in care. </span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #acacac;border-left:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Healthcare services delivery </span></td><td colspan="3" style="border-bottom:1pt solid #acacac;border-left:1pt solid #acacac;border-right:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare delivery is moving out of hospitals, clinician offices and other traditional locations in which it had been provided.  Care is increasingly being provided in new settings, such as outpatient, retail, consumer-focused and home settings.  In response to the COVID-19 pandemic, telemedicine practices became more commonly used.  This dynamic offers new opportunities and challenges for healthcare providers and reflects not only efforts to take advantage of new technologies, but also the trends of consumerization and affordability, each of which are discussed above in this table.</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Value of Diagnostic Information Services</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In view of the key trends discussed in table 11, healthcare providers, consumers and payers increasingly recognize the value of diagnostic information services as a means to help achieve the triple aim of healthcare: improving medical quality and the patient experience while reducing the cost of care.  The CDC states that 70% of today's medical decisions depend on laboratory test results.  Table 12 highlights how diagnostic information services contribute to improving medical quality and the patient experience while reducing healthcare costs. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#606060;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Helping to Achieve the Triple Aim of Healthcare  (Table 12)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; Detect the symptoms of disease earlier (by identifying patients at risk for disease before they require urgent care, hospital treatment or expensive therapies)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; Aid in the choice of therapeutic regimen (by helping clinicians to target the right medicines for the right patients at the right time)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; Identifying treatment-related side effects</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; Monitor patient compliance </span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; Evaluate treatment results (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">e.g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">., assessing early the efficacy of a therapy, enabling changes or discontinuation of ineffective therapies)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; Enabling population health management by identifying gaps in care and delivery of targeted solutions to individuals who need care</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; Identifying and proactively managing individuals at risk for diseases, to decrease progression and associated costs and morbidity</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; Help individuals obtain and interpret appropriate advice and referrals into needed care</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We provide diagnostic information services to a broad range of customers, including those discussed in table 13.  As discussed in table 11 above, customers are consolidating, converging and diversifying.  In many cases, the customer that orders our services is not responsible for paying for these services. Depending on the billing arrangement and applicable law, the payer may be the patient or a third party, such as a health plan, Medicare or a Medicaid program.  Increasingly, patients are bearing greater responsibility for some portion of the payment for the services we provide to them, even if a third party is primarily responsible for payment.  In addition, consumers are more frequently taking advantage of offerings like the Company's QuestHealth</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">offering, and requesting and paying for tests themselves.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:18.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#606060;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Customers (Table 13)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #acacac;border-left:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Clinicians</span></td><td colspan="3" style="border-bottom:1pt solid #acacac;border-left:1pt solid #acacac;border-right:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinicians (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">e.g</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">., primary care physicians, specialists and physician assistants) requiring diagnostic information services for patients are the primary referral source for our services when patients choose their diagnostic information services provider. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In recent years, there has been a marked increase in the number of physician practices owned by IDNs.  There also has been a notable increase in some branches of medicine of the establishment of very large "rolled-up" physician practice groups.  IDNs that own physician practices may encourage or require the practices to refer outreach testing to the IDN's affiliated laboratory.  Large specialty physician groups may encourage their members to refer testing to other members of the group or to a lab owned by the large physician group.  In each case, referrals to independent diagnostic services providers may be reduced.</span></div><div style="padding-left:18pt"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinicians determine which laboratory to recommend or use based on a variety of factors, including those set forth in table 14.</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:18.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Health plans including managed care organizations and other health insurance providers</span></td><td colspan="3" style="border-left:1pt solid #acacac;border-right:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">These customers typically reimburse us as a contracted (or out-of-network) provider for services rendered to their members.  In certain locations, health plans may delegate to IPAs or other alternative delivery systems (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">e.g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">., physician IDN organizations, ACOs, patient-centered medical homes) the ability to negotiate for diagnostic information services on behalf of certain members.  Increasingly, these customers are interested in value-based arrangements.</span></div><div style="padding-left:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health plans and IPAs often require that diagnostic information services providers accept discounted fee structures or assume all or a portion of the financial risk associated with providing such services through capitated payment arrangements. Under capitated payment arrangements, we provide services at a predetermined monthly reimbursement rate for each covered member, generally regardless of the number or cost of services provided by us.  Under some capitated programs, we may provide certain services on a negotiated fee-for-service basis.  Reimbursement under programs that do not provide for capitated payments is typically negotiated on a fee-for-service basis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement from our five largest health plans totaled approximately 20%, and no one health plan accounted for 10%, of our consolidated net revenues in 2022.  Health plans typically negotiate directly or indirectly with a number of diagnostic information services providers, and represent approximately one-half of our total clinical testing volume and approximately 45% of our net revenues from diagnostic information services.  There has been a trend of consolidation among health plans.  Some health plans also have narrowed their provider networks.  In addition, some health plans have established "preferred provider" networks within their broader networks (e.g., UnitedHealthcare's Preferred Lab Network), in effect distinguishing among contracted providers.   </span></div><div style="padding-left:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We are also sometimes a member of a &#8220;complementary network.&#8221; A complementary network generally is a set of contractual arrangements that a third party maintains with various providers that provide discounted fees for the benefit of its customers. A member of a health plan may choose to access a non-contracted provider that is a member of a complementary network; if so, the provider will be reimbursed at a rate negotiated by the complementary network.</span></div><div style="padding-left:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We offer to health plans services and programs that leverage our Company's expertise and resources, including our superior patient access, extensive test menu, medical staff, data, information technology solutions, and wellness and population health management capabilities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the last few years, our Company has had access to a very high percentage of the insured lives in the U.S., including very strong access in key high-population states.  We believe that this strong access increases our attractiveness to other customer groups, including clinicians, patients and employers.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">IDNs</span></td><td colspan="3" style="border-bottom:1pt solid #acacac;border-left:1pt solid #acacac;border-right:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We believe that we are an industry leader in servicing hospitals.  We provide services to IDNs throughout the United States, including advanced testing services, in some cases managing or serving as the medical directors of their laboratories (including through our industry-leading Professional Lab Services offering discussed in table 3 above).  IDNs generally maintain an on-site laboratory to perform the significant majority of clinical testing for their patients (inpatients and outpatients) and refer certain testing to outside service providers, which typically charge the IDNs on a negotiated fee-for-service basis. Fee schedules for IDN reference testing services often are negotiated on behalf of IDNs by group purchasing organizations. <br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We also have joint venture arrangements with leading IDNs.  These joint venture arrangements, which provide diagnostic information services for affiliated IDNs as well as for unaffiliated clinicians and other local healthcare providers, serve as our principal facilities in their service areas.  Typically, we have either a majority ownership interest in, or day-to-day management responsibilities for, our joint venture relationships. <br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In light of continued pressure to reduce systemic healthcare costs, IDNs may change their approach to providing clinical testing services, including by insourcing tests, seeking ways to improve profitability or to better utilize their laboratory capacity.  We believe that our combination of services positions us to be an attractive partner for IDNs, offering a full range of strategic relationships.</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:18.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;ACOs  </span></td><td colspan="3" style="border-left:1pt solid #acacac;border-right:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">An ACO is a network of providers and facilities that share financial risk in providing or arranging for the provision of healthcare.  ACO members collaborate to provide coordinated, high-quality care to their patients; ACOs may manage the health of a population group, exercise operational and financial control over providers across the continuum of care, and function as a payer.  Increasingly, ACOs are focusing on driving improvement in healthcare through value-based services arrangements, and to influence reimbursement for healthcare delivery.  For example, ACOs may be encouraged to consider exclusive arrangements with healthcare providers, or to limit service providers.  The Medicare Sharing Savings Program for ACOs is a critical component of CMS' vision to advance health equity, drive high-quality, person-centered care and promote affordability and sustainability of the Medicare program.  CMS sponsors two additional programs for ACOs, has stated that its goal is for all people in traditional Medicare to be in an ACO by 2030, and is adopting policies to drive growth in ACO participation.   </span></div><div style="padding-left:18pt"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We believe that our experience with value-based arrangements with other payers positions us as a strong partner for ACOs.  In addition, we believe that our extended care experience and population health capabilities are attractive to ACOs, and that our Quest for Health Equity initiative underscores our commitment to health equity important to ACOs.  </span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Employers</span></td><td colspan="3" style="border-left:1pt solid #acacac;border-right:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employers use tests for drugs of abuse to determine an individual's employability and &#8220;fitness for duty.&#8221;  Companies with high levels of employee hiring, safety conscious environments or regulatory testing requirements provide the highest volumes of testing. Factors such as the general economy, the job market and changes in the legal environment (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">e.g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">., marijuana legalization or decriminalization) can impact the utilization of drugs-of-abuse testing. Some employers retain third party administrators to handle such testing and related services; we support the needs of third party administrators as well as employers who retain us directly.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employers also are investing in population health services.  We meet their needs by providing nationwide access to our customizable services (discussed above at page 13), directly and through health plan and health improvement providers.  These services help employers, employees and others manage healthcare costs, capitalize on trends in personalized health and improve health outcomes. </span></div><div style="padding-left:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We seek to grow our employer business through offering new and innovative programs to help them with their goals of (1) maintaining a safe and productive workplace, (2) improving healthcare for employees and (3) lowering healthcare costs for employees and employers. </span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Consumers </span></td><td colspan="3" style="border-left:1pt solid #acacac;border-right:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We are well positioned to provide information and insights to individual consumers to help empower them take actions to improve their healthcare.  The changing expectations of individual consumers about their healthcare and their healthcare transactions are influencing our services and the way we provide them.  See the discussions of our consumer strategy at page 5 and consumerization above in table 11.  </span></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">FQHCs</span></td><td colspan="3" style="border-left:1pt solid #acacac;border-right:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FQHCs are non-profit, community-directed organizations that offer care to medically underserved patients; FQHCs are the largest primary care system in the United States today.  Their patients are mostly low income, members of racial and ethnic minority groups, and are uninsured or publicly insured.  <br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We offer an array of services that we believe are attractive to FQHCs as they pursue better outcomes for their patients and maintain financial stability for their organizations.  Our services include our financial assistance programs, customized billing solutions that help to assist patients who struggle to afford testing, home-based collection options and our extensive patient service center network.  We offer solutions for optimizing test utilization, simplifying lab-related tasks, and reducing inefficiencies and duplicative efforts can help FQHCs keep costs in line, and technology solutions that can help them to meet quality reporting requirements and achieve quality measures through benchmarking and identifying areas for improvement.  We also offer a tiered, flexible approach to gaps-in-care programs that helps complement FQHC efforts to emphasize preventive care.  <br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our Quest for Health Equity initiative also demonstrates our commitment to FQHCs and the people they serve; many of these initiatives support FQHCs, including by providing free lab testing services.</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #acacac;border-left:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Emerging Retail Healthcare Providers</span></td><td colspan="3" style="border-bottom:1pt solid #acacac;border-left:1pt solid #acacac;border-right:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In recent years, retail providers of healthcare services have emerged and are growing as customers.  These providers include "big-box" retailers, pharmacy chains, supermarkets, urgent care centers and Internet-based service providers.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We are taking advantage of opportunities to work with these providers, not only to offer new access partners (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">e.g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">., CVS and Rite-Aid retail locations) and new access points for our services (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">e.g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">., our collaboration with Safeway), but also to grow our business by expanding our service offerings (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">e.g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">., our collaboration with Walmart).  See the discussion of our consumer strategy at page 5</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:18.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;Government Agencies</span></td><td colspan="3" style="border-left:1pt solid #acacac;border-right:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We provide services on a fee-for-service basis to federal, state and local governmental agencies.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Historically, most Medicare and Medicaid beneficiaries were covered under the traditional Medicare and Medicaid programs administered by the federal government.  Over the last several years, the federal government has expanded its contracts with private health insurance plans for Medicare beneficiaries and has encouraged such beneficiaries to switch from the traditional programs to the private programs, called &#8220;Medicare Advantage&#8221; programs.  There has been growth of health insurance providers offering Medicare Advantage programs and of beneficiary enrollment in these programs.  States also have mandated that Medicaid beneficiaries enroll in private managed care arrangements.  We provide additional services to and in conjunction with government agencies across the United States in connection with the COVID-19 pandemic </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">see</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">e.g</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">., the discussion at page </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> above regarding our collaboration with CDC). </span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Pharmaceutical companies</span></td><td colspan="3" style="border-left:1pt solid #acacac;border-right:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We offer clinical trials testing and have expertise with laboratory developed tests for companion and complem</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">entary diagnostics, and offer an array of assets and services to support the development of companion diagnostics, including our robust data set and patient services network.  We also offer data services solutions, leveraging our data, analytics and expertise, to help therapy developers understand markets and patient and disease journeys, and plan commercial activity.  In addition, we offer Quest Clinical Trials Connect</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> to help accelerate clinical trials (and thus the speed of drugs to market) through better patient recruitment, involvement and management, and improved physician outreach.  We also offer Pack Health's patient engagement services.</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #acacac;border-left:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Laboratories</span></td><td colspan="3" style="border-bottom:1pt solid #acacac;border-left:1pt solid #acacac;border-right:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We provide services on a fee-for-service basis to other commercial clinical laboratories.</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> While there has been consolidation in the diagnostic information services industry in recent years, our industry remains fragmented and highly competitive.  We primarily compete with three types of clinical testing providers: commercial clinical laboratories, IDN-affiliated laboratories and physician-office laboratories.  Our largest commercial clinical laboratory competitor is Laboratory Corporation of America Holdings, Inc.  In addition, we compete with many smaller regional and local commercial clinical laboratories, specialized advanced laboratories and providers of consumer-initiated testing.  In anatomic pathology, we compete with anatomic pathology practices, including those in academic institutions and large physician group practices, and providers of emerging digital pathology solutions.  There also has been a trend among  physician practices to establish their own histology laboratory capabilities and/or bring pathologists into their practices, thereby reducing referrals from these practices and increasing the competitive position of these practices.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.640%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.673%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare providers consider a number of factors when selecting a diagnostic information services provider.</span></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#606060;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Potential Factors Considered When Selecting a Diagnostic Information Services Provider (Table 14)</span></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;    Service capability and quality</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;    Reputation in the medical community</span></div></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;    Accuracy, timeliness and consistency in reporting test results</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;    Healthcare information technology solutions, including connectivity options</span></div></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;    Access to medical/scientific thought leaders for consultation</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;    Patient access, including the number, convenience and geographic coverage of patient service centers</span></div></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;    Patient insurance coverage and experience</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;    Ability to develop new and useful tests and services</span></div></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;    Number and type of tests performed</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;    Qualifications of its staff</span></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;    Pricing and overall value</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;    Provider office workflow </span></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;    Real time payment determination</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;    Capabilities to support population health initiatives </span></td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td></tr></table></div><div style="padding-left:54pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We believe that providing the most attractive service offering in the industry, including the most comprehensive test menu, innovative test offerings, a positive customer experience, a staff including medical and scientific experts, strong quality, leading access and distribution, and data-powered integrated information technology solutions provide us with a competitive advantage.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We believe that large diagnostic information services providers have a competitive advantage due to their large networks and lower cost structures.  These advantages should enable larger providers to serve customers more effectively.  In addition, we believe that consolidation in the diagnostic information services industry will continue.  However, a significant portion of clinical testing is likely to continue to be performed by IDNs, which generally have affiliations with community clinicians and may have more, or more convenient, locations in a market.  As a result, we compete against IDN-affiliated laboratories primarily on the basis of service capability, quality and pricing.  In addition, market activity may increase the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">competitive environment.  For example, IDN ownership of physician practices may enhance the ties of the clinicians to IDN-affiliated laboratories, enhancing the competitive position of IDN-affiliated laboratories.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The diagnostic information services industry is faced with changing technology, new product introductions and new service offerings. Competitors may compete using advanced technology, including technology that enables more convenient or cost-effective testing.  Digital pathology, still in an emerging state, is an example of this.  Competitors also may compete on the basis of new service offerings.  Competitors also may offer testing to be performed outside of a commercial clinical laboratory, such as (1) point-of-care testing that can be performed by physicians in their offices; (2) testing that can be performed by IDNs in their own laboratories; and (3) home testing that can be carried out without requiring the services of outside providers. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The risk assessment and healthcare information technology industries are highly competitive.  We have many competitors, some of which have much more extensive experience in these industries and some of which have greater resources.  We compete in the risk assessment business by seeking to provide a wider array of quality, integrated services than our competitors, faster services completion and a superior applicant experience.  We compete in the healthcare information technology industry by offering solutions that foster better patient care and improve performance for healthcare providers, particularly smaller and medium sized physician practices.</span></div><div><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_31"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GENERAL </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Management.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Creating an inspiring workplace is one of our three corporate goals, and this goal drives our approach to human capital management.  Effectively managing our human capital resources is a priority with key components that include culture, safety and well-being programs, employee engagement, and attracting, training, development and succession planning.  Our Board of Directors actively engages in oversight of our human capital management, including by receiving management reports on key areas, strategies and initiatives.  Additional information about our human capital management strategies and initiatives is available in our annual corporate responsibility report. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of December 31, 2022, we have approximately 49,000 employees, of whom approximately 40,000 are full-time and the remainder are part-time or on-call.   Our employee population is more diverse than the U.S. workforce, taken as a whole.  Approximately 72% of our employees globally identify as women; approximately 50% of our U.S. employees identify as people of color.  A majority of our employees work directly with our customers or in our laboratories.  Fewer than 1% of our employees are represented by a union.  We believe that our overall relations with our employees are good.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Culture</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  We strive to foster a strong culture, built on our Code of Ethics, which reinforces our commitment to integrity and aligns with our vision, values, goals and brand.  Our Quest Management System, discussed above at page 8, supports our effort to maintain a focus on high performance.  We also focus on building and maintaining a collaborative, diverse and inclusive culture in which all employees are empowered to raise and discuss difficult issues and valued for their strengths, experience and unique perspectives (our focus on diversity and inclusion is discussed further below).  We encourage our employees to actively participate in their communities, and support their participation, including offering incentives for participation.  Our Everyday Excellence program includes guiding principles for our entire organization to support a superior customer experience and inspire employees to be their best every day, with every person and with every customer interaction; the program is integrated into performance assessments and frontline employee behavioral standards.  Our Recognition Quest Program reinforces our commitment to recognize above and beyond contributions and to demonstrating how much we value, care for and appreciate one another by regularly celebrating and rewarding one another as we work together.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Safety and Well-Being</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The health and safety of our employees is of paramount concern.  We use a systematic, risk-based approach to develop tailored incident prevention and response programs designed to keep our employees safe in each of our diverse functional areas, and use data insights and a detailed audit program to foster the effectiveness of our programs. We have a comprehensive curriculum of annual safety training, as well as training for new employees.  During the COVID-19 pandemic, our cross-functional Safely Working Together Steering Committee designed and implemented tactics, techniques and procedures to enable our colleagues to continue to work safely.  As part of our comprehensive and competitive compensation and benefits program, we also offer innovative initiatives to support the well-being of our employees and their families through our HealthyQuest program.  The cornerstone of HealthyQuest is our Blueprint for Wellness program, which empowers our employees and their dependents with health insights based on lab and biometric data and invites them each year to take the initiative to improve their physical and mental health.  We also offer other programs designed to engage employees in managing their health, including access to medical expertise and support programs tailored to their individual needs, helping them to adopt healthier behaviors and access better care at lower costs.  These include customized programs for conditions such as type 2 diabetes management, chronic kidney disease, cardiovascular disease, specialty drugs, and zero-cost lab testing, and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">special support for orthopedic surgery and for cancer and other serious diagnoses.  In 2022, we enhanced our mental health offering for employees.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inclusion and Diversity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  We understand the need to create an environment where employees can bring their whole selves to work, and our Everyday Equity philosophy embodies our commitment to promote inclusion and embrace diversity by consistently inviting new perspectives and exploring new experiences.  We aim to harness the unique mix of capabilities, talents, cultures, beliefs and experience of our employees and create a workforce that is demographically diverse at all levels of the organization.  Through our CTC Framework (focusing on Culture, Talent and Community), we prioritize diversity across the entire talent lifecycle, with the goals of supporting employees throughout their careers at Quest, ensuring transparency and identifying opportunities for action.  In 2022, we continued to focus on inclusion and diversity through additional training for leaders and other employees.  We also continued, with the Quest Diagnostics Foundation, Quest for Health Equity, our initiative to help reduce health disparities in underserved communities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engagement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Since 1997, we have sought to foster the engagement and enablement of our employees, and have regularly surveyed our employees to assess their engagement.  Employee engagement has been a metric in the annual incentive plan for our executive officers since 2013.  Since 2020, our strategy for gathering employee feedback utilizes more frequent employee surveys.  This approach is designed to build an agile culture, based on continuous feedback that fuels ongoing conversations about priorities, performance, opportunities and growth, to result in a higher performing organization and committed employees.  In addition, we hold regular meetings among hundreds of company leaders to foster increased communication across the company regarding topics of concern to employees.      </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Attracting, Training, Development and Succession Planning</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  We have a strong program designed to attract a diverse, qualified work force that will assist us to achieve our business goals.  For example, we are partnering with universities to help build our pipeline of expertise in medical technology, cytology and histology, and we have teamed up with a third-party  phlebotomy training program to train and certify phlebotomist candidates who can join our ranks upon graduation.  We provide training on a wide array of topics to our employees through live and online formats, including opportunities that can be accessed through their mobile devices.  We also offer a number of development opportunities for our employees, such as mentoring and education programs, including a higher education tuition assistance program.  In addition, we provide leadership training opportunities for employees at all levels, including a manager essentials curriculum, our Leading Quest Supervisor and Manager Core Program, coaching programs and trainings to strengthen critical leadership skills.  We also deliver a number of programs tailored to specific functions to drive a high-performance culture and sharpen the capabilities needed to lead our organization (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">e.g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">., our Commercial, Finance, Pathology, R&amp;D, and Product Management Leadership Programs).  We have a robust talent assessment and succession planning process to promote business continuity, including at the most senior levels; this planning is linked to our engagement and inclusion and diversity initiatives, to foster those efforts. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Sales and Marketing.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Our Diagnostic Information Services business has a unified commercial organization focused on the sale of most of our services.  It coordinates closely with our clinical franchises (discussed above under the heading I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">nnovation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and marketing organization.  The commercial organization is centrally led, and is organized regionally, in conjunction with our operations organization, to focus on local customer needs and to ensure aligned delivery for our customers.  Our commercial organization employs world-class processes and tools and strong management discipline.  We provide industry-leading training and development, focus on opportunities with IDNs and specialty physicians, and foster a customer-focused, performance-driven culture.   We also maintain distinct sales and marketing organizations for our offerings in Diagnostic Solutions and our employer drugs-of-abuse testing services. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Information Technology.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We use information systems extensively in virtually all aspects of our business, including clinical testing, test ordering and reporting, billing, customer service, logistics and management of data.  We endeavor to establish systems that create value and efficiencies for our Company and customers.  The successful delivery of our services depends, in part, on the continued and uninterrupted performance of our information technology systems.  We take precautionary measures to prevent problems that could affect our information technology systems.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Some of our historic growth has come through acquisitions and, as a result, we continue to use multiple information systems.  We have made significant progress implementing common systems in our regional laboratories, and we continue to standardize laboratory information and billing systems across our operations.  We expect that our standardization efforts will take several more years to complete, and will result in significantly more centralized systems, improved operating efficiency, more positive customer experiences and enhanced control over our operational environment.  Even after we complete our efforts to standardize our legacy systems, we will need to focus on standardizing systems in connection with future business acquisitions.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Quality Assurance.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  As discussed further under the heading </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Quality </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on page 8, our goal is to provide every patient with services and products of superior quality, and to meet that goal we employ the Quest Management System.  Employing root cause analysis, process improvements and rigorous tracking and measuring, we continuously seek to enhance quality, reduce defects, further increase the efficacy and efficiency of our operations and processes, eliminate waste and help standardize operations across our Company.&#160; </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In our laboratory operations, our quality assurance efforts focus on pre-analytic, analytic and post-analytic processes, including positive patient identification of specimens, appropriate specimen transport, analysis and report accuracy, reference interval establishment and review, statistical process control and personnel training for our laboratories and patient service centers.  As part of our quality assurance program, we utilize internal proficiency testing, comprehensive quality control and rigorous process audits.  We have introduced comprehensive and digitized data analytics software that implements advanced automated quality control procedures, offering both real-time and post-analytic analysis of data at the laboratory and corporate level.  We monitor test results to identify trends, biases, instrument failures and population shifts through digitization and data analytics.  We also focus on the licensing, credentialing, training and competence of our professional and technical staff.  For example, our cytotechnologists and pathologists participate in an internal peer-review evaluation and one or more external individual proficiency testing programs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have accreditation or licenses for our clinical laboratory operations from various regulatory agencies or accrediting organizations, such as CMS, CAP and certain states.  All of our laboratories participate in external quality surveillance programs, including proficiency testing programs administered by CAP and several state agencies. CAP is an independent, nongovernmental organization of board-certified pathologists approved by CMS to inspect clinical laboratories to determine compliance with the standards required by CLIA.  CAP offers an accreditation program to which clinical laboratories may voluntarily subscribe. All of our major laboratories, including our laboratories outside the U.S., and a number of our rapid response laboratories, are accredited by CAP.  Accreditation includes on-site inspections and participation in the CAP (or equivalent) proficiency testing program.  In addition, some of our laboratories also have International Organization for Standardization (ISO) certification for their quality management systems. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;We maintain a robust Supplier Quality Program designed to ensure a high quality supplier network and to raise the bar of quality expectation across that network.  We expect suppliers to provide the highest quality products and services and to embrace an ethic of transparent quality collaboration.  In our program, we aim to ensure and improve the quality of purchased products and services.  Our suppliers are expected to operate under quality management principles that meet industry standards, strive for zero defect manufacturing, use statistical analysis to reduce variation and meet applicable regulatory standards.  In choosing suppliers, we evaluate their quality systems and quality performance metrics. Our supplier qualification process is risk-based, with assessments and on-site audits based on risk tiers. Contracts with our suppliers include specific quality, compliance, and change management provisions as appropriate. We use supplier quality engineers who are trained to audit on ISO standards and FDA regulations applicable to suppliers&#8217; processes, and a procurement engineering team to assist with qualification and validation of new supplies and products. We actively manage supplier performance, utilizing a problem reporting and resolution process designed to drive to root cause and corrective actions. We maintain a continuous improvement dialogue with our suppliers, and with operationally critical suppliers deliver a supplier scorecard that supports continuous improvement. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;We also maintain quality assurance programs for IDN laboratories that we manage, and for our services offerings outside laboratories. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Intellectual Property Rights.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  We own significant intellectual property, including patents, patent applications, technology, trade secrets, know-how, copyrights and trademarks in the United States and other countries.  From time to time, we also license patents, patent applications, technology, trade secrets, know-how, copyrights or trademarks owned by others; we also may license our intellectual property to others. In the aggregate, our intellectual property assets and licenses are of material importance to our business.  We believe, however, that no single intellectual property asset is material to our business as a whole.  Our approach is to manage our intellectual property assets, to safeguard them and to maximize their value to our enterprise.  We actively defend our important intellectual property assets and pursue protection of our products, processes and other intellectual property where possible.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Enterprise Risk Management Program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  We maintain an enterprise risk management program designed to promote a culture of risk awareness throughout the Company's key business, operations and support functions.  Our program, which is integrated with the Company&#8217;s governance, performance management and internal control frameworks, entails a formal continuous process that identifies, assesses, mitigates and manages the risks from both internal and external conditions that could significantly impact the Company and influence its business strategy and performance, including environmental, social and governance issues.  The program is designed based on the most recent framework issued by the Committee of Sponsoring Organizations of the Treadway Commission, and we benchmark it against best practices.  We focus on the following risk types:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Operational risk - risks arising from systems, processes, people and external events that affect the Company&#8217;s operational objectives or fundamental reason for its existence, including: product life-cycle and execution; service quality and performance; information management and data protection and security, including cybersecurity; supply chain and business disruption; and other risks, including human capital, reputation and environmental.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Financial risk - risks arising from the Company&#8217;s ability to meet its financial obligations pursuant to its strategic and operational objectives, including exposure to broad market and more specific industry risk that could impact liquidity, interest rate, credit, pricing and reimbursement, and also to internal and external financial reporting.   </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Legal and compliance risk - risks arising from the regulatory and enforcement environment, legal proceedings and adherence to ethics and compliance policies and procedures.   </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Strategic risk - risks that will impede the Company&#8217;s plan to achieve its mission and vision and apply its core values, including changes in the broad market and Company's industry, business development and restructuring activities, competitive threats and practices, technology and product innovation, and public policy.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As part of our program, we routinely assess our enterprise level risks, emerging risks, overall Company-level risk tolerance and the effectiveness of risk management, and monitor the progress of and resources applied to risk mitigation; our Board of Directors actively oversees our program.  Our primary risk factors are discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> beginning on page </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_43">32</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Billing; Government Reimbursement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We generally bill for diagnostic information services on a fee-for-service basis under one of two types of fee schedules; fees may be negotiated or discounted.  The types of fee schedules are:</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;Client&#8221; fees charged to physicians, IDNs and institutions for which services are performed on a wholesale basis and which are billed on a monthly basis.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;Patient&#8221; fees charged to individual patients and certain third-party payers on a claim-by-claim basis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Billing for diagnostic information services is very complicated.  Our customers, discussed in table 13, have different billing requirements. Some billing arrangements require us to bill multiple payers, and there are several other factors that complicate billing (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., disparity in coverage and information requirements among payers; incomplete or inaccurate billing information provided by ordering clinicians; and lack of access to patients before testing).  We maintain compliance policies and procedures for our billing practices, and we audit our practices for compliance with applicable laws and regulations and internal policies and procedures. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With regard to the clinical testing services performed on behalf of Medicare beneficiaries, we generally must bill Medicare directly and must accept the Medicare carrier's fee schedule amount for covered services as payment in full.  In addition, state Medicaid programs are prohibited from paying more (and in most instances, pay significantly less) than Medicare.  Currently, Medicare does not require the beneficiary to pay a co-payment for diagnostic testing services reimbursed under the Clinical Laboratory Fee Schedule, but generally does require a patient deductible and co-insurance for anatomic pathology services. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Part B of the Medicare program contains fee schedule payment methodologies for clinical testing services performed for covered patients, including a national ceiling on the amount that carriers could pay under their local Medicare clinical testing fee schedules.  Historically, the Medicare Clinical Laboratory Fee Schedule and the Medicare Physician Fee Schedule established under that program have been subject to change, including each year.  Pursuant to PAMA, reimbursement rates for many clinical laboratory tests provided under Medicare were reduced from 2018 - 2020.  PAMA calls for further revision of the Medicare Clinical Laboratory Fee Schedule for years after 2020, based on future surveys of market rates; reimbursement reduction from 2024-26 is capped by PAMA at 15% annually.  PAMA's next data collection and reporting period have been delayed, most recently by federal legislation adopted in December 2022, which further delayed the reimbursement rate reductions and reporting requirements until January 1, 2024. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div style="text-align:center"><img src="dgx-20221231_g4.jpg" alt="dgx-20221231_g4.jpg" style="height:273px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our net revenues reimbursed under Medicare and Medicaid in 2022 were lower as a percentage of our consolidated net revenues than in recent years (excluding 2021 and 2020, when we also experienced significant COVID-19 testing).  Excluding revenues attributable to COVID-19 testing, approximately 12% of our net revenues were reimbursed under Medicare and Medicaid in 2022, compared to approximately 15% in 2019.</span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_34"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGULATION </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:18.810%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We are subject to extensive and frequently changing laws and regulations in the United States (at both the federal and state levels) and other jurisdictions in which we conduct business, and to government inspections and audits. </span></div><div style="text-align:center"><span><br/></span></div></td></tr><tr><td colspan="6" style="background-color:#606060;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Regulatory Schemes (Table 16)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">CLIA and State Clinical Laboratory Licensing</span></td><td colspan="3" style="border-left:1pt solid #acacac;border-right:1pt solid #ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CLIA regulates the operations of virtually all clinical laboratories, requiring that they be certified by the federal government and that they comply with various technical, operational, personnel and quality requirements intended to ensure that the services provided are accurate, reliable and timely.  </span></div><div style="padding-left:18pt"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State laws may require additional personnel qualifications or licenses, quality control, record maintenance, proficiency testing or detailed review of our scientific method validations and technical procedures for certain tests. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Violations of these laws and regulations may result in monetary fines, criminal and civil penalties and/or suspension or exclusion from participation in Medicare, Medicaid and other federal or state healthcare programs.</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #acacac;border-left:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Medicare and Medicaid; Fraud and Abuse</span></td><td colspan="3" style="border-bottom:1pt solid #acacac;border-left:1pt solid #acacac;border-right:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostic testing services provided under Medicare and Medicaid programs are subject to complex, evolving, stringent and frequently ambiguous federal and state laws and regulations, including those relating to billing, coverage and reimbursement.  <br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-kickback laws and regulations prohibit making payments or furnishing other benefits to influence the referral of tests billed to Medicare, Medicaid or certain other federal or state healthcare programs.  <br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, federal and state anti-self-referral laws generally prohibit Medicare and Medicaid payments for clinical tests referred by physicians who have an ownership or investment interest in, or a compensation arrangement with, the testing laboratory, unless specific exceptions are met.<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Some states have similar laws that are not limited in applicability to only Medicare and Medicaid referrals and could also affect tests that are paid for by health plans and other non-governmental payers. <br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Violations of these laws and regulations may result in monetary fines, criminal and civil penalties and/or suspension or exclusion from participation in Medicare, Medicaid and other federal or state healthcare programs. </span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:18.810%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">FDA</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #acacac;border-right:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The FDA has regulatory responsibility over, among other areas, instruments, software, test kits, reagents and other devices used by clinical laboratories to perform diagnostic testing in the United States.  The FDA also regulates drugs-of-abuse testing for employers and insurers, testing for blood bank purposes and testing of donors of human cells for purposes such as in vitro fertilization. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A number of advanced tests we develop internally are offered as LDTs. The FDA has claimed regulatory authority over all LDTs, but has stated that it exercised enforcement discretion with regard to most LDTs performed by high complexity CLIA-certified laboratories.  </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to the 21st Century Cures Act, the FDA issued final guidance regarding its position on the regulation of clinical decision software, which may be used in connection with LDTs. The guidance attempts to address uncertainty regarding whether FDA approval of certain software is required.  It has been used by the FDA, in part, to assert authority over the annotation software aspects of pharmacogenetic testing services.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The FDA and HHS have expressed views regarding the regulation of LDTs.  Legislation introduced in recent sessions of Congress that would authorize the FDA to regulate LDTs has not become law.  If legislation that authorizes the FDA to regulate LDTs were to become law, it could have a significant impact on the clinical laboratory testing industry, including regulating LDTs in new ways, while creating avenues of opportunity and competition regarding clinical laboratory testing.  New competitors may enter the industry, and competition may come in new forms.   </span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Environmental, Health and Safety</span></td><td colspan="3" style="border-left:1pt solid #acacac;border-right:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We are subject to laws and regulations related to the protection of the environment, the health and safety of employees and the handling, transportation and disposal of medical specimens, infectious and hazardous waste and radioactive materials. </span></div><div style="padding-left:18pt"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For example, the U.S. Occupational Safety and Health Administration has established extensive requirements relating specifically to workplace safety for healthcare employers in the U.S.  This includes requirements to develop and implement multi-faceted programs to protect workers from exposure to blood-borne pathogens, including preventing or minimizing any exposure through needle stick injuries. </span></div><div style="padding-left:18pt"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For purposes of transportation, some biological materials and laboratory supplies are classified as hazardous materials and are subject to regulation by one or more of the following agencies: the U.S. Department of Transportation, the U.S. Public Health Service, the U.S. Postal Service and the International Air Transport Association. </span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Physicians</span></td><td colspan="3" style="border-left:1pt solid #acacac;border-right:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our pathologists are required to hold a valid license to practice medicine in the jurisdiction in which they practice.  The manner in which licensed physicians can be organized to perform medical services may be governed by the laws of the jurisdictions in which medical services are provided and by the medical boards or other entities authorized by these jurisdictions to oversee the practice of medicine.  Several jurisdictions in which our businesses are located prohibit business corporations from engaging in the practice of medicine.  In these jurisdictions, anatomic pathology services are delivered through physician-owned entities that employ the practicing pathologists.  </span></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Privacy and Security of Health and Personal Information</span></td><td colspan="3" style="border-left:1pt solid #acacac;border-right:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We are subject to laws and regulations regarding protecting the security and privacy of certain healthcare and personal information, including: (a) the federal Health Insurance Portability and Accountability Act and the regulations thereunder, which establish (i) a complex regulatory framework including requirements for safeguarding protected health information and (ii) comprehensive federal standards regarding the uses and disclosures of protected health information; (b) state laws (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">e.g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">., California) and similar laws in other states; and (c) laws outside the U.S., including the European Union's General Data Protection Regulation and similar laws in other jurisdictions.  We may be subject to penalties for non-compliance and may be required to notify individuals or state, federal or county governments if we discover certain breaches of personal information or protected health information.  </span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #acacac;border-left:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Drug Testing; Controlled Substances</span></td><td colspan="3" style="border-bottom:1pt solid #acacac;border-left:1pt solid #acacac;border-right:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All U.S. laboratories that perform drug testing for certain public sector employees and employees of certain federally regulated businesses are required to be certified as meeting the detailed performance and quality standards of the Substance Abuse and Mental Health Services Administration. </span></div><div style="padding-left:18pt"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To obtain access to controlled substances used to perform drugs-of-abuse testing in the United States, laboratories must be licensed by the Drug Enforcement Administration. </span></div></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compliance.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We strive to conduct our business in compliance with all applicable laws and regulations.  We license and maintain appropriate accreditations for all of our laboratories and, where applicable, patient service centers, as required by federal and state agencies.  We have a long-standing and well-established compliance program.  The Quality and Compliance Committee of our Board of Directors oversees, and receives periodic management reports regarding, our compliance program.  Our program includes detailed policies and procedures and training programs intended to ensure the implementation and observance of all applicable laws and regulations (including regarding billing and reimbursement, and privacy of protected health information and personally identifiable information) and Company policies.  Further, we conduct in-depth reviews of procedures and facilities to assure regulatory compliance throughout our operations.  We conduct annual training of our employees on these compliance policies and procedures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As an integral part of our billing compliance program, we investigate reported or suspected failures to comply with Medicare or Medicaid reimbursement requirements.  As a result of these efforts, we have periodically identified and reported overpayments, refunded the payers for overpayments and taken appropriate corrective action. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_37"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AVAILABLE INFORMATION</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Securities and Exchange Commission (the &#8220;SEC&#8221;) maintains an internet site, www.sec.gov, that contains annual, quarterly and current reports, proxy and information statements and other information that issuers file electronically with the SEC.  We file reports, proxy statements and other information with the SEC; they are publicly available at the SEC's internet site.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our internet address is www.QuestDiagnostics.com.  The information on or accessible through our website is not part of and is not incorporated by reference into this Report.  We make available free of charge, on or through our Investor Relations webpage (www.QuestDiagnostics.com/investor), our proxy statements, Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and any amendments to those reports filed or furnished pursuant to the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), as soon as reasonably practical after such material is filed with, or furnished to, the SEC.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"></td><td style="width:57.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.410%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">www.QuestDiagnostics.com/investor provides information about our corporate governance.</span></td></tr><tr><td colspan="6" style="background-color:#606060;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Information Available at Our Corporate Governance Webpage (Table 17)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Directors</span></div></td><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Governance Guidelines</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of the committees of our Board of Directors</span></div></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Code of Ethics</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior management</span></div></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of Incorporation</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charters for the committees of our Board of Directors</span></div></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bylaws</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Information about our corporate political contributions </span></div></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Values </span></div></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statements of beneficial ownership of our equity securities filed by our directors, officers and others under Section 16 of the Exchange Act</span></div></td></tr></table></div><div style="text-align:center;text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We also maintain a Corporate Responsibility webpage that provides information about our corporate responsibility program, including our focus on environmental, social and governance issues and our annual Corporate Responsibility Report.</span></div><div><span><br/></span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"></td><td style="width:57.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.410%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">www.QuestDiagnostics.com/our-company/corporate-responsibility provides information about our corporate responsibility program.</span></td></tr><tr><td colspan="6" style="background-color:#606060;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Information Available at Our Corporate Responsibility Webpage (Table 18)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Responsibility Reports</span></div></td><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quest for Health Equity</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Information about our corporate political contributions</span></div></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quest Diagnostics Foundation </span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Environmental, social and governance resources</span></div></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sustainability</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Governance, ethics and values</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Community giving </span></div></td></tr></table></div><div style="text-align:center;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29 </span></div></div></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_40"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INFORMATION ABOUT OUR EXECUTIVE OFFICERS </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.964%"><tr><td style="width:1.0%"></td><td style="width:32.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.397%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#606060;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Executive Officers (Table 19)</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;border-left:1pt solid #acacac;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name, Age, Title</span></td><td colspan="3" style="background-color:#dddddd;border-left:1pt solid #acacac;border-right:1pt solid #acacac;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Background</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">James E. Davis (60) <br/>Chief Executive Officer and President</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #acacac;border-right:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On November 1, 2022, Mr. Davis became Chief Executive Officer and President, having served as CEO-Elect since February 3, 2022.  In January 2017, he became Executive Vice President, General Diagnostics; previously Mr. Davis was Senior Vice President and Group Executive - Regional Businesses.  In January 2015, he assumed responsibility for the general management of the Company's regional Diagnostic Information Services business.  Mr. Davis was responsible for our products business from February 2014 until 2016.  From February 2014 to January 2015, he was responsible for operations for the Company's Diagnostic Information Services business. &#160;Mr. Davis joined Quest Diagnostics in April 2013 as Senior Vice President, Diagnostics Solutions, with responsibility for the healthcare information technology, risk assessment, clinical trials, diagnostic products and employer solutions businesses.&#160;<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior to joining Quest Diagnostics, from March 2012 to April 2013, Mr. Davis served as Lead Director, and then as Chief Executive Officer, of InSightec, Inc., a medical device company that designs and develops ultrasound ablation devices that are guided by magnetic resonance imaging systems.  <br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Previously, Mr. Davis held a number of senior positions in General Electric&#8217;s healthcare business, including from 2007 to 2012 as Vice President and General Manager of GE Healthcare&#8217;s magnetic resonance imaging business.  Prior to joining GE Healthcare, Mr. Davis held leadership positions in GE&#8217;s aviation business and led the development of strategic and operational improvement initiatives for clients of McKinsey &amp; Company, Inc. </span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #acacac;border-left:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Mark E. Delaney (55)<br/>Senior Vice President and Chief Commercial Officer </span></td><td colspan="3" style="border-bottom:1pt solid #acacac;border-left:1pt solid #acacac;border-right:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mr. Delaney joined the Company in March 2022 and is responsible for all sales operations.  From 2017 until Hill-Rom Holdings Inc. was acquired by Baxter Healthcare in 2021, Mr. Delaney served as Vice President of Sales and Marketing at Hill-Rom, a manufacturer and provider of medical technologies and related services for the healthcare industry; after the acquisition by Baxter Mr. Delaney became Vice President and General Manager at Baxter until he joined Quest Diagnostics.      <br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Previously, Mr. Delaney served in a number of senior sales and marketing leadership roles at General Electric's healthcare business, most recently as Senior Vice President and Zone Manager, where he had regional responsibility for sales of imaging, patient monitoring, information technology and services.  </span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.964%"><tr><td style="width:1.0%"></td><td style="width:32.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.397%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Catherine T. Doherty (60) <br/>Senior Vice President, Regional Businesses </span></td><td colspan="3" style="border-left:1pt solid #acacac;border-right:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Since March 2022, Ms. Doherty has been responsible for the general management of the Company's regional Diagnostic Information Services business, the commercial organization, marketing and consumer-initiated testing.  She also is responsible for driving operational excellence, including the Company's quality and efficiency initiatives.  Ms. Doherty is the Executive Sponsor of the Company's Women in Leadership Employee Business Network.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">From January 2013 to March 2022, Ms. Doherty was Senior Vice President and Group Executive - Clinical Franchise Solutions and Marketing.  In this role, she was responsible for overseeing the development of clinical franchise solutions in the areas of general health and wellness, cardiovascular, metabolic and endocrinology, infectious disease and immunology, and prescription drug monitoring and toxicology, as well as enterprise-wide marketing, consumer-initiated testing, the employer solutions and risk assessment businesses, and beginning in February 2020, our sports diagnostics franchise.   She also was responsible for clinical franchise solutions in the areas of neurology and women's health from January 2013 to January 2017 and for the healthcare information technology business from February 2014 to January 2017.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior to January 2013, Ms. Doherty held a variety of positions of increasing responsibility since joining the Company in 1990, including Senior Vice President, Physician Services; Vice President, Hospital Services; Vice President, Office of the Chairman; Vice President, Finance and Administration for the Hospital business; Vice President, Communications and Investor Relations; and Chief Accounting Officer.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Mark A. Gardner (57), Senior Vice President, Molecular Genomics and Oncology</span></td><td colspan="3" style="border-left:1pt solid #acacac;border-right:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mr. Gardner joined the Company in October 2022 in his current role.  He is responsible for oncology, pathology, specialty genetics, and research and development.  Mr. Gardner joined Quest from Corza Medical, a provider of surgical technologies and tools, where he served since 2019 as Executive Partner, Senior Vice President and General manager of European Commercial Operations and Biosurgery Products.  Prior to that, Mr.Gardner served as Chief Executive Officer of OmniSeq Corporation, a molecular diagnostics company, from 2016 to 2019 and in Vice President and General Manager positions at Thermo Fisher Scientific Inc. from 2003 to 2016, including roles with Life Technologies and Invitrogen.  He began his career as a consultant with McKinsey and Company, Inc.</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #acacac;border-left:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Karthik Kuppusamy (53)<br/>Senior Vice President, Clinical Solutions</span></td><td colspan="3" style="border-bottom:1pt solid #acacac;border-left:1pt solid #acacac;border-right:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mr. Kuppusamy assumed his current role in August 2022.  He is responsible for the Company's clinical franchises other than oncology, as well as the Company's pharmaceutical services, genomic services, medical affairs, medical quality and global markets activities. Mr. Kuppusamy serves as co-chair of the Company's Inclusion and Diversity Council.  Previously, Mr. Kuppusamy was Vice President and General Manager of the Company's Diagnostics Information Services business in its North Region since from 2018 and General Manager of the Neurology Franchise and Consumer Genetics from 2014 to 2017.  He joined the Company in 2014 from General Electric's healthcare business where he held general manager roles in product development, research and development, sales and marketing in the Diagnostics Imaging Division.</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.964%"><tr><td style="width:1.0%"></td><td style="width:32.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.397%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Patrick Plewman (56)<br/>Senior Vice President, Diagnostics Services</span></td><td colspan="3" style="border-left:1pt solid #acacac;border-right:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mr. Plewman assumed his current role in April 2022.  He is responsible for a portfolio of data driven analytics and services offerings, including Employer Population Health, Healthcare Analytic Solutions, Pack Health, Risk Assessment (ExamOne) and Employer Solutions.  Since joining the Company in 2013, Mr. Plewman was Vice President and General Manager of the Company's Diagnostic Information Services Business in its West Region since 2018 and previously served as General Manager of the Company's Cardiovascular, Metabolic and Endocrinology Franchise, General Manager of the Company's Infectious Disease and Immunology Franchise and General Manager of the General Health and Wellness franchise.  <br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior to joining the Company, Mr. Plewman served as Co-Founder, President and Chief Executive Officer of diaDexus, Inc. Previously, Mr. Plewman held various positions of increasing responsibility at SmithKline Beecham Inc. </span></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Michael E. Prevoznik (61) <br/>Senior Vice President and General Counsel</span></td><td colspan="3" style="border-left:1pt solid #acacac;border-right:1pt solid #ffffff;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mr. Prevoznik joined the Company as Vice President and General Counsel in August 1999.  In 2003, he assumed responsibility for governmental affairs.  Mr. Prevoznik also is the Executive Co-Sponsor of the Company's Quest For Health Equity Initiative.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">From 1999 until April 2009, Mr. Prevoznik also had responsibility for the Company's Compliance Department.  In addition, from April 2011 to January 2017, he had management responsibility for the Company's diagnostic information services activities outside the U.S., and from April 2011 to January 2013, he had management responsibility for the Company's clinical trials business.  </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior to joining the Company, Mr. Prevoznik served in positions of increasing responsibility within the compliance organization at SmithKline Beecham, most recently as Vice President, Compliance, with responsibility for coordinating all SmithKline Beecham compliance activities worldwide.</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #acacac;border-left:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Sam A. Samad (53)<br/>Executive Vice President and Chief Financial Officer</span></td><td colspan="3" style="border-bottom:1pt solid #acacac;border-left:1pt solid #acacac;border-right:1pt solid #ffffff;border-top:1pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mr. Samad joined the Company in his current role in July 2022.  He is responsible for the Company's finance, accounting, investor relations, internal audit and treasury activities.  Prior to joining the Company, Mr. Samad served as Chief Financial Officer of Illumina, Inc., a global leader in DNA sequencing and array-based technologies, since 2017.  Prior to joining Illumina, Mr. Samad held several senior leadership positions at Cardinal Health, including Senior Vice President and Treasurer, with operational and financial responsibility for Cardinal Health's China business, and before that in sales and finance roles at Eli Lilly and Company, both domestically and internationally.    </span></td></tr></table></div><div><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_43"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item 1A. Risk Factors </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;You should carefully consider all of the information set forth in this Report, including the following risk factors, before deciding to invest in any of our securities.  The risks below are not the only ones that we face. Additional risks not presently known to us, or that we presently deem immaterial, may also negatively impact us.  Our business, consolidated financial condition, revenues, results of operations, profitability, reputation or cash flows, or the price of our common stock, could be materially impacted by any of these factors.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This Report also includes forward-looking statements that involve risks or uncertainties.  Our results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the risks we face described below and elsewhere.  See &#8220;Cautionary Factors that May Affect Future Results&#8221; on page </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_58">42</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></td></tr></table></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_46"></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO OUR BUSINESS</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The U.S. healthcare system is evolving and medical laboratory testing market fundamentals are changing, and our business could be adversely impacted if we fail to adapt.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The U.S. healthcare system continues to evolve.  Significant change is taking place in the healthcare system, including as discussed above under the heading The Clinical Testing Industry, beginning on page 14.  For example, value-based reimbursement is increasing (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, UnitedHealthcare's Preferred Lab Network); CMS has set goals for value-based reimbursement to be achieved by 2030.  Patients are encouraged to take increased interest in and responsibility for, and often are bearing increased responsibility for payment for, their healthcare.  Healthcare industry participants are evolving and consolidating.  Healthcare services increasingly are being provided by non-traditional providers (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., physician assistants), in non-traditional venues (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., retail medical clinics, urgent care centers) and using new technologies (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., telemedicine, digital pathology).  Utilization of the healthcare system is being influenced by several factors and may result in a decline in the demand for diagnostic information services.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In addition, we believe that clinical testing market fundamentals are changing.  We believe that PAMA-driven reimbursement pressure remains a catalyst for structural change in the market.  We also believe that health plans and consumers increasingly are focusing on driving better value in laboratory testing services.  We expect that the evolution of the healthcare industry will continue, and that industry change is likely to be extensive. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The clinical testing business is highly competitive, and if we fail to provide an appropriately priced level of service or otherwise fail to compete effectively it could have a material adverse effect on our revenues and profitability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The clinical testing business remains a fragmented and highly competitive industry.  We primarily compete with three types of clinical testing providers: other commercial clinical laboratories, IDN-affiliated laboratories and physician-office laboratories. We also compete with other providers, including anatomic pathology practices, large physician group practices and providers of consumer-initiated testing. IDNs generally maintain on-site laboratories to perform testing on their patients (inpatient or outpatient). In addition, many IDNs compete with commercial clinical laboratories for outreach (non-IDN patients) testing.  IDNs may seek to leverage their relationships with community clinicians and encourage the clinicians to send their outreach testing to the IDN's laboratory.  As a result of this affiliation between IDNs and community clinicians, we compete against IDN-affiliated laboratories primarily based on quality and scope of service as well as pricing. In addition, IDNs that own physician practices may encourage or require the practices to refer testing to the IDN's laboratory. In recent years, there has been a trend of IDNs acquiring physician practices, increasing the percentage of physician practices owned by IDNs.  Increased IDN ownership of physician practices may enhance clinician ties to IDN-affiliated laboratories and may strengthen their competitive position.  The formation of ACOs and their approach to contracts with healthcare providers also may increase competition to provide diagnostic information services.  In addition, new players have recently started to provide clinical lab testing services (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., employers; government agencies).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The diagnostic information services industry also is faced with changing technology and new product introductions. Competitors may compete using advanced technology, including technology that enables more convenient or cost-effective testing.  Digital pathology, still in an emerging state, is an example of this.  Competitors also may compete on the basis of new service offerings.  Competitors also may offer testing to be performed outside of a commercial clinical laboratory, such as (1) point-of-care testing that can be performed by physicians in their offices; (2) advanced testing that can be performed by IDNs in their own laboratories; and (3) home testing that can be carried out without requiring the services of outside providers. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government payers, such as Medicare and Medicaid, have taken steps to reduce the utilization and reimbursement of healthcare services, including clinical testing services.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We face efforts by government payers to reduce utilization of and reimbursement for diagnostic information services.   One example of this is increased use of prior authorization requirements.  We expect efforts to reduce reimbursements, to impose more stringent cost controls and to reduce utilization of clinical test services will continue.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pursuant to PAMA, reimbursement rates for many clinical laboratory tests provided under Medicare were reduced from 2018 - 2020.  PAMA calls for further revision of the Medicare Clinical Laboratory Fee Schedule for years after 2020, based on future surveys of market rates; reimbursement rate reduction from 2024-26 is capped by PAMA at 15% annually.  PAMA's next data collection and reporting period have been delayed, most recently by federal legislation adopted in December 2022, which further delayed the reimbursement rate reductions and reporting requirements until January 1, 2024.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In addition, CMS has adopted policies limiting or excluding coverage for clinical tests that we perform. We also provide physician services that are reimbursed by Medicare under a physician fee schedule, which is subject to adjustment on an annual basis.  Medicaid reimbursement varies by state and is subject to administrative and billing requirements and budget pressures.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In addition, over the last several years, the federal government has expanded its contracts with private health insurance plans for Medicare beneficiaries, called &#8220;Medicare Advantage&#8221; programs, and has encouraged such beneficiaries to switch from the traditional programs to the private programs.  There has been growth of health insurance plans offering Medicare Advantage programs, and of beneficiary enrollment in these programs.  States have mandated that Medicaid beneficiaries enroll in private managed care arrangements.  In addition, state budget pressures have encouraged states to consider several courses of action that may impact our business, such as delaying payments, reducing reimbursement, restricting coverage eligibility, denying claims and service coverage restrictions.  Further, CMS has set goals for value-based reimbursement to be achieved by 2030.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Reimbursement for Medicare services also is subject to annual reduction under the Budget Control Act of 2011, and the Statutory Pay-As-You-Go Act of 2010.       </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;From time to time, the federal government has considered whether competitive bidding could be used to provide clinical testing services for Medicare beneficiaries while maintaining quality and access to care.  Congress periodically considers cost-saving initiatives.  These initiatives have included coinsurance for clinical testing services, co-payments for clinical testing and further laboratory physician fee schedule reductions.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Other steps taken to reduce utilization and reimbursement include requirements to obtain diagnosis codes to obtain  payment, increased documentation requirements, limiting the allowable number of tests or ordering frequency, expanded prior authorization programs and otherwise increasing payment denials.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Steps to reduce utilization and reimbursement also discourage innovation and access to innovative solutions that we may offer.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Health plans and other third parties have taken steps to reduce the utilization and reimbursement of health services, including clinical testing services. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We face efforts by non-governmental third-party payers, including health plans, to reduce utilization of and reimbursement for clinical testing services. Examples include increased use of prior authorization requirements and increased denial of coverage for services. There is increased market activity regarding alternative payment models, including bundled payment models. We expect continuing efforts by third-party payers, including in their rules, practices and policies, to reduce reimbursements, to impose more stringent cost controls and to reduce utilization of clinical testing services. ACOs and IDNs also may undertake efforts to reduce utilization of, or reimbursement for, diagnostic information services.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The healthcare industry has experienced a trend of consolidation among health insurance plans, resulting in fewer but larger insurance plans with significant bargaining power to negotiate fee arrangements with clinical testing providers.  The increased consolidation among health plans also has increased pricing transparency, insurer bargaining power and the potential adverse impact of ceasing to be a contracted provider with an insurer.  Health plans, and independent physician associations, may demand that clinical testing providers accept discounted fee structures or assume all or a portion of the financial risk associated with providing testing services to their members through capitated payment arrangements. Some health plans also are reviewing test coding, evaluating coverage decisions and requiring preauthorization of certain testing. There are also an increasing number of patients enrolling in consumer driven products and high deductible plans that involve greater patient cost-sharing.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Other steps taken to reduce utilization and reimbursement include requirements to obtain diagnosis codes to obtain  payment, increased documentation requirements, limiting the allowable number of tests or ordering frequency, expanded prior authorization programs and otherwise increasing payment denials.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Steps to reduce utilization and reimbursement also discourage innovation and access to innovative solutions that we may offer.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Failure to develop, or acquire licenses for, new tests, technology and services could negatively impact our testing volume and revenues.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The diagnostic information services industry is faced with changing technology and new product introductions. Other companies or individuals, including our competitors, may obtain patents or other property rights that would prevent, limit or interfere with our ability to develop, perform or sell our solutions or operate our business or increase our costs. In addition, they could introduce new tests, technologies or services that may result in a decrease in the demand for our services or cause us to reduce the prices of our services. Our success in continuing to introduce new solutions, technology and services will depend, in part, on our ability to license new and improved technologies on favorable terms. We may be unable to develop or introduce new solutions or services. Other companies or individuals, including our competitors, may obtain patents or other property rights on tests or processes that we may be performing, that could prevent, limit or interfere with our ability to develop, perform or sell our tests or operate our business.  We also may be unable to continue to negotiate acceptable licensing arrangements, and arrangements that we do conclude may not yield commercially successful clinical tests. If we are unable to license these testing methods at competitive rates, our research and development costs may increase as a result. In addition, if we are unable to develop and introduce, or license, new solutions, technology and services to expand our advanced testing capabilities, our services may become outdated when compared with our competition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Failure to establish, and perform to, appropriate quality standards, or to assure that the appropriate standard of quality is observed in the performance of our diagnostic information services, could adversely affect the results of our operations and adversely impact our reputation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The provision of diagnostic information services involves certain inherent risks. The services that we provide are intended to provide information in providing patient care. Therefore, users of our services may have a greater sensitivity to errors than the users of services or products that are intended for other purposes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Negligence in performing our services can lead to injury or other adverse events. We may be sued under physician liability or other liability law for acts or omissions by our pathologists, laboratory personnel and IDN employees who are under our supervision. We are subject to the attendant risk of substantial damages awards and risk to our reputation.</span></div><div><span><br/></span></div><div><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_49"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO CHANGE IN PUBLIC POLICY </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AND THE REGULATORY AND LEGAL ENVIRONMENT</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are subject to numerous legal and regulatory requirements governing our activities, and we may face substantial fines and penalties, and our business activities may be impacted, if we fail to comply.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our business is subject to or impacted by extensive and frequently changing laws and regulations in the United States (including at both the federal and state levels) and the other jurisdictions in which we engage in business. While we seek to conduct our business in compliance with all applicable laws, many of the laws and regulations applicable to us are vague or indefinite and have not been extensively interpreted by the courts, including many of those relating to:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">billing and reimbursement of clinical testing;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">certification or licensure of clinical laboratories;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the anti-self-referral and anti-kickback laws and regulations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the laws and regulations administered by the FDA;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the corporate practice of medicine;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operational, personnel and quality requirements intended to ensure that clinical testing services are accurate, reliable and timely;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">physician fee splitting;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">relationships with physicians and IDNs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">marketing to consumers;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">privacy of patient data and other personal information;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safety and health of laboratory employees; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">handling, transportation and disposal of medical specimens, infectious and hazardous waste and radioactive materials.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;These laws and regulations may be interpreted or applied by a prosecutorial, regulatory or judicial authority in a manner that could require us to make changes in our operations, including our pricing and/or billing practices. We may not be able to maintain, renew or secure required permits, licenses or any other regulatory approvals needed to operate our business or commercialize our services. If we fail to comply with applicable laws and regulations, or if we fail to maintain, renew or obtain necessary permits, licenses and approvals, we could suffer civil and criminal penalties, fines, exclusion from participation in governmental healthcare programs and the loss of various licenses, certificates and authorizations necessary to operate our business, as well as incur additional liabilities from third-party claims. If any of the foregoing were to occur, our reputation could be damaged and important business relationships with third parties could be adversely affected.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We regularly receive requests for information, and occasionally subpoenas, from governmental authorities. We also are subject from time to time to qui tam claims brought by former employees or other &#8220;whistleblowers.&#8221; The federal and state governments continue aggressive enforcement efforts against perceived healthcare fraud.  Legislative provisions relating to healthcare fraud and abuse provide government enforcement personnel substantial funding, powers, penalties and remedies to pursue suspected cases of fraud and abuse.  In addition, the government has substantial leverage in negotiating settlements since the amount of potential damages far exceeds the rates at which we are reimbursed for our services, and the government has the remedy of excluding a non-compliant provider from participation in the Medicare and Medicaid programs. Regardless of merit or eventual outcome, these types of investigations and related litigation can result in:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of management time and attention;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenditure of large amounts of cash on legal fees, costs and payment of damages;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increases to our administrative, billing or other operating costs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations on our ability to continue some of our operations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enforcement actions, fines and penalties or the assertion of private litigation claims and damages;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreases to the amount of reimbursement related to diagnostic information services performed;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse affects to important business relationships with third parties;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our services; and/or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injury to our reputation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Changes in applicable laws and regulations may result in existing practices becoming more restricted, or subject our existing or proposed services to additional costs, delay, modification or withdrawal. Such changes also could require us to modify our business objectives.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our business could be adversely impacted by the FDA's approach to regulation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The FDA has regulatory responsibility over, among other areas, instruments, software, test kits, reagents and other devices used by clinical laboratories to perform diagnostic testing in the U.S.  A number of tests we develop internally are offered as LDTs. The FDA has claimed regulatory authority over all LDTs, but has stated that it exercised enforcement discretion with regard to most LDTs performed by high complexity CLIA-certified laboratories. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As the FDA moves to regulate more clinical laboratory testing, its approach to regulation is impacting industry practices and participants, new competitors may enter the industry, and competition may come in new forms.  The FDA and HHS have expressed views regarding the regulation of LDTs.  Legislation introduced in recent sessions of Congress that would authorize the FDA to regulate LDTs has not become law.  If legislation that authorizes the FDA to regulate LDTs were to become law, it could have a significant impact on the clinical laboratory testing industry, including regulating LDTs in new ways, while creating avenues of opportunity and competition regarding clinical laboratory testing.  New competitors may enter the industry, and competition may come in new forms.   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pursuant to the 21st Century Cures Act, the FDA issued final guidance regarding its position on the regulation of clinical decision software, which may be used in connection with LDTs. The guidance attempts to clarify whether FDA approval of certain software is required.  It has been used by the FDA, in part, to assert authority over the annotation software aspects of pharmacogenetic testing services.  </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Failure to accurately bill for our services, or to comply with applicable laws relating to government healthcare programs, could have a material adverse effect on our business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Billing for diagnostic information services is complex and subject to extensive and non-uniform rules and administrative requirements. Depending on the billing arrangement and applicable law, we bill various payers, such as patients, insurance companies, Medicare, Medicaid, clinicians, IDNs and employer groups.  The majority of billing and related operations for our Company are being provided by a third party under the Company's oversight.  Failure to accurately bill for our services could have a material adverse effect on our business.  In addition, failure to comply with applicable laws relating to billing government healthcare programs may result in various consequences, including: civil and criminal fines and penalties, exclusion from participation in governmental healthcare programs and the loss of various licenses, certificates and authorizations necessary to operate our business, as well as incur additional liabilities from third-party claims.  Certain violations of these laws may also provide the basis for a civil remedy under the federal False Claims Act, including fines and damages of up to three times the amount claimed.  The qui tam provisions of the federal False Claims Act and similar provisions in certain state false claims acts allow private individuals to bring lawsuits against healthcare companies on behalf of government payers, private payers and/or patients alleging inappropriate billing practices.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Although we believe that we are in compliance, in all material respects, with applicable laws and regulations, there can be no assurance that a regulatory agency or tribunal would not reach a different conclusion.  The federal or state government may bring claims based on our current practices, which we believe are lawful.  The federal and state governments have substantial leverage in negotiating settlements since the amount of potential damages and fines far exceeds the rates at which we are reimbursed, and the government has the remedy of excluding a non-compliant provider from participation in the Medicare and Medicaid programs.  We believe that federal and state governments continue aggressive enforcement efforts against perceived healthcare fraud.  Legislative provisions relating to healthcare fraud and abuse provide government enforcement personnel with substantial funding, powers, penalties and remedies to pursue suspected cases of fraud and abuse. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are subject to numerous political, legal, operational and other risks as a result of our international operations which could impact our business in many ways.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our international operations increase our exposure to risks inherent in doing business in non-U.S. markets, which may vary by market and include: intellectual property legal protections and remedies; weak legal systems which may, among other things, affect our ability to enforce contractual rights; trade regulations and procedures and actions affecting approval, production, pricing, reimbursement and marketing of services; existing and emerging data privacy regulations affecting the processing and transfer of personal data; and challenges based on differing languages and cultures.  International operations also require us to devote management resources to implement our controls and systems in new markets, and to comply with the U.S. Foreign Corrupt Practices Act and similar anti-corruption laws in non-U.S. jurisdictions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may be unable to obtain, maintain or enforce our intellectual property rights and may be subject to intellectual property litigation that could adversely impact our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We may be unable to obtain or maintain adequate patent or other proprietary rights for our solutions or services or to successfully enforce our proprietary rights. In addition, we may be subject to intellectual property litigation, and we may be found to infringe on the proprietary rights of others, which could force us to do one or more of the following:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cease developing, performing or selling solutions or services that incorporate the challenged intellectual property;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain and pay for licenses from the holder of the infringed intellectual property right;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">redesign or re-engineer our tests;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">change our business processes; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pay substantial damages, court costs and attorneys' fees, including potentially increased damages for any infringement held to be willful.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adverse results in material litigation could have an adverse financial impact and an adverse impact on our client base and reputation.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We are involved in various legal proceedings arising in the ordinary course of business including, among other things, disputes as to intellectual property, professional liability and employee-related matters, as well as inquiries from governmental agencies and Medicare or Medicaid carriers. Some proceedings against us involve claims that are substantial in amount and could divert management's attention from operations. These proceedings also may result in substantial monetary damages.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37 </span></div></div></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_52"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">RISKS RELATED TO OUR INDEBTEDNESS</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our outstanding debt may impair our financial and operating flexibility.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of December 31, 2022, we had approximately $4.0 billion of debt outstanding.  Other than credit facilities in the normal course of business, we do not have any off-balance sheet financing arrangements in place or available. Our debt agreements contain various restrictive covenants. These restrictions could limit our ability to use operating cash flow in other areas of our business because we must use a portion of these funds to make principal and interest payments on our debt. We have obtained ratings on our public debt from Standard and Poor's, Moody's Investor Services and Fitch Ratings. There can be no assurance that any rating so assigned will remain for any given period of time or that a rating will not be lowered or withdrawn entirely by a rating agency if in that rating agency's judgment future circumstances relating to the basis of the rating, such as adverse changes in our Company or our industry, so warrant. If such ratings are lowered, our borrowing costs could increase. Changes in our credit ratings, however, do not require repayment or acceleration of any of our debt.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;Borrowings under our unsecured credit facility may be made at interest rates that are based on the London Interbank Offered Rate (&#8220;LIBOR&#8221;), which has been a widely used benchmark for establishing interest rates globally, but which is being phased out as a reference rate.  While we expect to be able to transition the facility to an alternative reference rate upon the cessation of LIBOR, there is no guarantee that we will be able to do so.  Changes in market interest rates may negatively influence our financing costs and the valuation of derivative instruments. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;We or our subsidiaries may incur additional indebtedness in the future. Our ability to make principal and interest payments will depend on our ability to generate cash in the future. If we incur additional debt, a greater portion of our cash flows may be needed to satisfy our debt service obligations and if we do not generate sufficient cash to meet our debt service requirements, we may need to seek additional financing.  In that case, it may be more difficult, or we may be unable, to obtain financing on terms that are acceptable to us. As a result, we would be more vulnerable to general adverse economic, industry and capital markets conditions as well as the other risks associated with indebtedness.</span></div><div><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_55"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO OUR OPERATIONS</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The development of new technologies (including artificial intelligence technologies) may impact the healthcare industry, and the development of new, more cost-effective solutions that can be performed by our customers or by patients, and the continued internalization of testing by IDNs or clinicians, could negatively impact our testing volume and revenues.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The diagnostic information services industry is faced with changing technology and new product introductions, including technology that enables more convenient or cost-effective testing.  For example, digital pathology is an emerging technology that may change the practice of pathology.  Information technology that includes self-learning or "artificial intelligence" features is growing and may impact the healthcare industry.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Competitors also may offer testing to be performed outside of a commercial clinical laboratory, such as (1) point-of-care testing that can be performed by clinicians in their offices; (2) complex testing that can be performed by IDNs in their own laboratories; and (3) home testing that can be carried out without requiring the services of outside providers.  Advances in technology also may lead to the need for less frequent testing.  Further, diagnostic tests approved or cleared by the FDA for home use are automatically deemed to be &#8220;waived&#8221; tests under CLIA and may be performed by consumers in their homes; test kit manufacturers could seek to increase sales to patients of such test kits. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Some traditional customers for anatomic pathology services, including specialty physicians that generate biopsies through surgical procedures, such as dermatologists, gastroenterologists, urologists and oncologists, are consolidating, have added in-office histology labs or have retained pathologists to read cases on site.  IDNs also are internalizing clinical laboratory testing, including some non-routine and advanced testing.  Internalization of testing may reduce demand for services previously referred to outside service providers, such as the Company. </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hardware and software failures or delays in our information technology systems, including failures resulting from our systems conversions or otherwise, could disrupt our operations and cause the loss of confidential information, customers and business opportunities or otherwise adversely impact our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;IT systems are used extensively in virtually all aspects of our business, including clinical testing, test reporting, billing, customer service, logistics and management of medical data. Our success depends, in part, on the continued and uninterrupted performance of our IT systems.  A failure or delay in our IT systems could impede our ability to serve our customers and patients and protect their confidential data.  Despite redundancy and backup measures and precautions that we have implemented, our IT systems may be vulnerable to damage, disruptions and shutdown from a variety of sources, including telecommunications or network failures, system conversion or standardization initiatives, human acts and natural disasters.  These issues can also arise as a result of failures by third parties with whom we do business and over which we have limited control.  Any disruption or failure of our IT systems could have a material impact on our ability to serve our customers and patients, including negatively affecting our reputation in the marketplace.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our business could be negatively affected if we are unable to continue to strengthen our efficiency.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;It is important that we continue to strengthen our efficiency to promote our competitive position and to enable us to mitigate the impact on our profitability of steps taken by government payers and health insurers to reduce the utilization and reimbursement of diagnostic information services.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our business operations and reputation may be materially impaired if we do not comply with privacy laws or information security policies.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In our business, we collect, generate, process or maintain sensitive information, such as patient data and other personal information. If we do not use or adequately safeguard that information in compliance with applicable requirements under federal, state and international laws, or if it were disclosed to persons or entities that should not have access to it, our business could be materially impaired, our reputation could suffer and we could be subject to fines, penalties and litigation.  In the event of a data security breach, we may be subject to notification obligations, litigation and governmental investigation or sanctions, and may suffer reputational damage, which could have an adverse impact on our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We are subject to laws and regulations regarding protecting the security and privacy of certain healthcare and personal information, including: (a) the federal Health Insurance Portability and Accountability Act and the regulations thereunder, which establish (i) a complex regulatory framework including requirements for safeguarding protected health information and (ii) comprehensive federal standards regarding the uses and disclosures of protected health information; (b) state laws (e.g., California) and similar laws in other states; and (c) laws outside the U.S., including the European Union's General Data Protection Regulation and similar laws in other jurisdictions.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Our approach to environmental, social and governance (ESG) matters may not satisfy all our stakeholders.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;We regularly assess opportunities and risks related to environmental, social and governance (ESG) matters.  As part of this process, we make decisions related to ESG matters and may set goals and targets related to ESG matters. We have a broad range of stakeholders, including our stockholders, employees, patients and communities we serve, some of whom increasingly focus on ESG matters. In addition, some of our stockholders, employees and patients may consider ESG factors in making investment, employment and service provider decisions. Our ability to achieve the goals we may set related to ESG matters are subject to numerous risks and uncertainties, many of which are outside of our control. Despite our efforts, we may not achieve our ESG goals on the timetable we set or at all. Additionally, certain of our stakeholders may not be satisfied with our decisions related to ESG matters, the goals we set regarding ESG matters, our progress towards these goals or the resulting outcomes. This could lead to negative perceptions of, or loss of support for our business, difficulty recruiting or attracting new employees and our stock price being negatively impacted.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">The IT systems that we rely on may be subject to unauthorized tampering, cyberattack or other security breach.   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our IT systems have been and are subject to potential cyberattacks, tampering or other security breaches. These attacks, if successful, could result in shutdowns or significant disruptions of our IT systems and/or in unauthorized persons exfiltrating and misappropriating intellectual property and other confidential information, including patient and employee data that we collect, transmit and store on and through our IT systems.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;External actors may develop and deploy viruses, other malicious software programs, ransomware attacks, distributed denial of service attacks or other attempts to harm or obtain unauthorized access to our systems. External actors may also deploy programs targeting our employees which are designed to attack our IT systems or otherwise exploit security vulnerabilities through programs such as electronic spamming, phishing, smishing, spear phishing or similar tactics. As a result of the difficulty in detecting many of these attacks, intrusions and breaches, failures or losses may be repeated or compounded before they are discovered or rectified, which could further increase these costs and consequences.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Although the Company has robust security measures implemented, which are monitored and routinely tested both by internal resources and external parties, cyber threats against us continue to evolve and may not be recognized until after an incident. In August 2021, ReproSource, our subsidiary, experienced a data security incident in which an unauthorized party may have accessed or acquired protected health information and personally identifiable information of ReproSource patients (in connection with the incident, ReproSource discovered and contained ransomware). The Company&#8217;s other systems were not impacted or compromised by this incident. Although the attacks we have experienced have not materially disrupted, interrupted, damaged or shutdown the Company's IT systems, or materially disrupted the Company's performance of its business, the mitigation or remediation efforts that we have undertaken, and may undertake in the future, require the attention of management and expenditures of resources, which can be significant. There can be no assurance that the Company can anticipate all evolving future attacks, viruses or intrusions, implement adequate preventative measures, or remediate any security vulnerabilities. If our IT systems are successfully attacked, it could result in major disruption of our business, compromise confidential information, and result in litigation and potential liability for the Company, government investigation, significant damage to our reputation or otherwise adversely affect our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In addition, third parties to whom we outsource certain of our services or functions, or with whom we interface, store or process confidential patient and employee data or other confidential information, as well as those third parties&#8217; providers, are also subject to the risks outlined above. For example, in June 2019, the Company reported that Retrieval-Masters Creditors Bureau, Inc./American Medical Collection Agency (&#8220;AMCA&#8221;), informed the Company about a data security incident involving AMCA. AMCA, which provided debt collection services for a company that provides revenue management services to the Company, informed the Company in May 2019 that AMCA had learned that an unauthorized user had access to AMCA&#8217;s system during 2018 and 2019. AMCA&#8217;s affected system included financial, medical and other personal information. The Company&#8217;s systems or databases were not involved in this incident. A breach or attack affecting third parties with whom we engage could also harm our business, results of operations and reputation and subject us to liability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have taken, and continue to take, precautionary measures to reduce the risk of, and detect and respond to, future cyber threats, and prevent or minimize vulnerabilities in our IT systems, including the loss or theft of intellectual property, patient and employee data or other confidential information that we obtain and store on our systems. We also have taken, and will continue to take, measures to assess the cybersecurity protections used by third parties to whom we outsource certain of our services or functions, or with whom we interface, store or process confidential patient and employee data or other confidential information. In addition, we collaborate with government agencies regarding potential cyber threats and have worked with firms that have cyber security expertise to evaluate our systems and the attacks we experience and strengthen our systems. There can be no assurances that our precautionary measures or measures used by our third party providers will prevent, contain or successfully defend against cyber or information security threats that could have a significant impact on our business, results of operations and reputation and subject us to liability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our ability to attract and retain qualified employees is critical to the success of our business and the failure to do so may materially adversely affect our performance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The supply of qualified technical, professional, managerial and other personnel, including cytotechs, phlebotomists and processors, is currently constrained; competition for qualified employees, even across different industries, is intense, including as individuals leave the job market.  We may lose, or fail to attract and retain, key management personnel, or qualified skilled technical, professional or other employees. </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Business development activities are inherently risky and integrating our operations with businesses we acquire may be difficult.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We plan selectively to enhance our business from time to time through business development activities, such as acquisitions, licensing arrangements, investments and alliances. However, these plans are subject to the availability of appropriate opportunities and competition from other companies seeking similar opportunities. Moreover, the success of any such effort may be affected by a number of factors, including our ability to properly assess and value the potential business opportunity, and to integrate it into our business. The success of our strategic alliances depends not only on our contributions and capabilities, but also on the property, resources, efforts and skills contributed by our strategic partners. Further, disputes may arise with strategic partners, due to conflicting priorities or conflicts of interests.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Acquisitions are not all the same (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., asset acquisitions differ from acquisitions of equity interests); different acquisitions offer different risks.  Acquisitions may involve the integration of a separate company that has different systems, processes, policies and cultures. Integration of acquisitions involves a number of risks including the diversion of management's attention to the assimilation of the operations of assets or businesses we have acquired, difficulties in the integration of operations and systems and the realization of potential operating synergies, the assimilation and retention of the personnel of the acquired businesses, challenges in retaining the customers of the combined businesses, and potential adverse effects on operating results. The process of combining acquisitions may be disruptive to our businesses and may cause an interruption of, or a loss of momentum in, such businesses as a result of the following difficulties, among others:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of key customers or employees;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty in standardizing information and other systems;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty in consolidating facilities and infrastructure;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to maintain the quality or timeliness of services that our Company has historically provided;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of management's attention from the day-to-day business of our Company as a result of the need to deal with the foregoing disruptions and difficulties; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the added costs of dealing with such disruptions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If we are unable successfully to integrate strategic acquisitions in a timely manner, our business and our growth strategies could be negatively affected. Even if we are able to successfully complete the integration of the operations of other assets or businesses we may acquire in the future, we may not be able to realize all or any of the benefits that we expect to result from such integration, either in monetary terms or in a timely manner. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our operations may be adversely impacted by the effects of natural disasters such as hurricanes and earthquakes, public health emergencies and health pandemics, hostilities or acts of terrorism and other criminal activities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;We operate facilities across the United States, and consumers frequently visit our facilities in person.  The ability of our employees and consumers to access our facilities may be adversely impacted by the effects of extreme weather events and natural disasters, such as hurricanes, earthquakes, tropical storms, floods, fires, earthquakes or other extreme weather conditions, including major winter storms, droughts and heat waves, whether as a result of climate change or otherwise; public health emergencies and health pandemics; hostilities or acts of terrorism or other activities. Although we maintain a business continuity program to prepare for and respond to such events, because of their unpredictable nature, these events may limit or interrupt our ability to conduct operations.  Additionally, such events may interrupt our ability to transport specimens, to receive materials from our suppliers or otherwise to provide our services.  These events also may result in a decline in the number of patients who seek clinical testing services or in our employees' ability to perform their job duties.    </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The COVID-19 pandemic or any future pandemic may negatively affect us, including through its impact on the labor force and supply chain. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;A pandemic caused by a novel strain of coronavirus (COVID-19) has severely impacted the economy of the United States and other countries around the world, including affecting labor supply and causing supply chain disruptions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While certain of the economic impacts of the COVID-19 pandemic have eased and many COVID-19 related restrictions have been lifted or relaxed as a result of progress in COVID-19 vaccination, testing and treatment, a rise in infection rates, the emergence of new COVID-19 variants or any future pandemic could result in, among other things, a reduction in physician office visits and diagnostic testing volume, the cancellation of elective medical procedures, or customers closing or curtailing their operations, as well as increased unemployment and loss of health insurance. We may also experience labor shortages and supply chain disruptions, including shortages, delays and price increases in testing equipment and supplies, as a result of the COVID-19 pandemic or any future pandemic.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of suppliers and manufacturers we rely upon have experienced, and may continue to experience, disruptions and delays stemming from raw material and labor shortages, supply challenges and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant disruptions in transport and logistics services due to facility closures, labor constraints and other challenges. These challenges may affect our ability to transport specimens, receive equipment, supplies or materials, or otherwise provide our services in a timely manner or at a reasonable price.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, labor shortages may affect our ability to achieve our staffing or productivity goals.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These conditions may continue or deteriorate in the future, including in the event of a future pandemic outbreak. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;The extent to which we may be impacted by the COVID-19 pandemic or any future pandemic will depend on many factors beyond our knowledge or control. These factors include: the timing, extent, trajectory and duration of any pandemic; increases in COVID-19 infection rates and the geographic location of such increases; the development, availability, distribution and effectiveness of vaccines and treatments; the imposition of protective public safety measures; and the impact of any pandemic on supply chain and the global economy. To the extent the COVID-19 pandemic or any future pandemic adversely affects our business, results of operations and financial condition, it may also have the effect of heightening other risks described in this Report.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:109%">Inflationary pressures could adversely impact us because of increases in the costs of materials, supplies and services, and increased labor and people-related expenses.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;Inflationary pressures have resulted in increases in the costs of the testing equipment, supplies and other goods and services that we purchase from manufacturers, suppliers and others.  Inflationary pressures, along with the competition for labor, have also resulted in a rise of our labor costs, which include the costs of compensation, benefits, and recruiting and training new hires.  Our ability to raise the prices and fees we charge for the services we provide is limited.   Continuation of the current inflationary environment may adversely impact us.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</span></div><div><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_58"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Some statements and disclosures in this document are forward-looking statements. Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the use of words such as &#8220;may,&#8221; &#8220;believe,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;anticipate,&#8221; &#8220;plan&#8221; or &#8220;continue.&#8221; These forward-looking statements are based on our current plans and expectations and are subject to a number of risks and uncertainties that could cause our plans and expectations, including actual results, to differ materially from the forward-looking statements. Investors are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this document. The following important factors could cause our actual financial results to differ materially from those projected, forecasted or estimated by us in forward-looking statements:</span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Heightened competition from commercial clinical testing companies, IDNs, physicians and others.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Increased pricing pressure from customers, including payers and patients, and changing relationships with customers, payers, suppliers or strategic partners.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;A decline in economic conditions, including the impact of an inflationary environment.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Impact of changes in payment mix, including increased patient financial responsibility and any shift from fee-for-service to discounted, capitated or bundled fee arrangements.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Adverse actions by government or other third-party payers, including healthcare reform that focuses on reducing healthcare costs but does not recognize the value and importance to healthcare of clinical testing or innovative solutions, unilateral reduction of fee schedules payable to us, unilateral recoupment of amounts allegedly owed and competitive bidding.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;The impact upon our testing volume and collected revenue or general or administrative expenses resulting from compliance with policies and requirements imposed by Medicare, Medicaid and other third-party payers. These include:</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;the requirements of government and other payers to provide diagnosis codes and other information for many tests;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;inability to obtain from patients a valid advance consent form for tests that cannot be billed without prior receipt of the form; </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;the impact of additional or expanded limited coverage policies and limits on the allowable number of test units or ordering frequency of same; and</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;the impact of increased prior authorization programs.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;Adverse results from pending or future government investigations, lawsuits or private actions. These include, in particular, monetary damages, loss or suspension of licenses, and/or suspension or exclusion from the Medicare and Medicaid programs and/or criminal penalties.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;Failure to efficiently integrate acquired businesses and to manage the costs related to any such integration, or to retain key technical, professional or management personnel.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Denial, suspension or revocation of CLIA certification or other licenses for any of our clinical laboratories under the CLIA standards, revocation or suspension of the right to bill the Medicare and Medicaid programs or other adverse regulatory actions by federal, state and local agencies.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;Changes in and complexity of federal, state or local laws or regulations, including changes that result in new or increased federal or state regulation of commercial clinical laboratories, tests developed by commercial clinical laboratories or other products or services that we offer or activities in which we are engaged, including regulation by the FDA.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160;Inability to achieve expected benefits from our acquisitions of other businesses.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(l)&#160;&#160;&#160;&#160;Inability to achieve additional benefits from our business performance tools and efficiency initiatives.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(m)&#160;&#160;&#160;&#160;Adverse publicity and news coverage about the diagnostic information services industry or us.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(n)&#160;&#160;&#160;&#160;Failure of the Company to maintain, defend and secure its financial, accounting, technology, customer data and other operational systems from cyberattacks, IT system outages, telecommunications failures, malicious human acts and failure of the systems of third parties upon which the Company relies.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(o)&#160;&#160;&#160;&#160;Development of technologies that substantially alter the practice of clinical testing, including technology changes that lead to the development of more convenient or cost-effective testing, or testing to be performed outside of a commercial clinical laboratory, such as (1) point-of-care testing that can be performed by physicians in their offices, (2) advanced testing that can be performed by IDNs in their own laboratories or (3) home testing that can be carried out without requiring the services of clinical laboratories.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(p)&#160;&#160;&#160;&#160;Negative developments regarding intellectual property and other property rights that could prevent, limit or interfere with our ability to develop, perform or sell our tests or operate our business. These include:</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;issuance of patents or other property rights to our competitors or others; and</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;inability to obtain or maintain adequate patent or other proprietary rights for our products and services or to successfully enforce our proprietary rights.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(q)&#160;&#160;&#160;&#160;Development of tests by our competitors or others which we may not be able to license, or usage (or theft) of our technology or similar technologies or our trade secrets or other intellectual property by competitors, any of which could negatively affect our competitive position.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(r)&#160;&#160;&#160;&#160;Regulatory delay or inability to commercialize newly developed or licensed tests or technologies or to obtain appropriate reimbursements for such tests.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(s)&#160;&#160;&#160;&#160;The complexity of billing and revenue recognition for clinical laboratory testing.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(t)&#160;&#160;&#160;&#160;Increases in interest rates and negative changes in our credit ratings from Standard &amp; Poor's, Moody's Investor Services or Fitch Ratings causing an unfavorable impact on our cost of or access to capital.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(u)&#160;&#160;&#160;&#160;Inability to hire or retain qualified employees, including key senior management personnel.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;Terrorist and other criminal activities, hurricanes, earthquakes or other natural disasters, and public health emergencies and health pandemics, which could affect our customers or suppliers, transportation or systems, or our facilities, and for which insurance may not adequately reimburse us.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(w)&#160;&#160;&#160;&#160;Difficulties and uncertainties in the discovery, development, regulatory environment and/or marketing of new services or solutions or new uses of existing tests.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(x)&#160;&#160;&#160;&#160;Failure to adapt to changes in the healthcare system (including the medical laboratory testing market) and healthcare delivery, including those stemming from PAMA, trends in utilization of the healthcare system and increased patient financial responsibility for services.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(y) &#160;&#160;&#160;&#160;Results and consequences of governmental inquiries.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(z)   Difficulty in implementing, or lack of success with, our strategic plan.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(aa) The impact of healthcare data analysis on our industry and the ability of our Company to adapt to that impact.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(bb) Failure to adequately operationalize appropriate controls around use of our data, including risk of non-compliance with privacy law requirements.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(cc) The COVID-19 pandemic.  </span></div><div style="padding-left:54pt;text-indent:-18pt"><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_61"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item 1B. Unresolved Staff Comments</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;There are no unresolved SEC comments that require disclosure.</span></div><div><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_64"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item 2. Properties</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our executive offices are located at 500 Plaza Drive, Secaucus, New Jersey.  We maintain clinical testing laboratories throughout the continental United States; in several instances a joint venture of which we are a partner maintains the laboratory.  We also maintain offices, data centers, call centers, distribution centers and patient service centers at locations throughout the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States.  In addition, we maintain offices, patient service centers and clinical laboratories in locations outside the United States, including in Finland, Puerto Rico and Mexico.  Our properties that are not owned are leased on terms and for durations that are reflective of commercial standards in the communities where these properties are located. We believe that, in general, our facilities are suitable and adequate for our current and anticipated future levels of operation and are adequately maintained.  We believe that if we were unable to renew a lease on any of our facilities, we could find alternative space at competitive market rates and relocate our operations to such new location without material disruption to our business.  Several of our principal facilities are highlighted below.</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:77.639%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.428%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Leased or Owned</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3600 Northgate Blvd., Sacramento, California  95834  (laboratory)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8401 Fallbrook Avenue, West Hills, California  91304 (laboratory)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">33608 Ortega Hwy., San Juan Capistrano, California 92675 (laboratory)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4151C East Fowler Avenue, Tampa, Florida  33617 (laboratory)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1777 Montreal Circle, Tucker, Georgia 30084-6802  (laboratory)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">506 E State Parkway, Schaumburg, Illinois 60173 (laboratory)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1355 Mittle Blvd., Wood Dale, Illinois 60191 (laboratory)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">200 Forest Street, Marlborough, Massachusetts  01752  (laboratories)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">800 Business Center Drive, Horsham, Pennsylvania 19044  (laboratory)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4770 Regent Blvd., Irving, Texas  75063 (laboratory)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14225 Newbrook Drive, Chantilly, Virginia 22021  (laboratory)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10101 Renner Blvd., Lenexa, Kansas  66219 (laboratory)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4380 Federal Drive, Greensboro, North Carolina  27410 (laboratory)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2501 South State Hwy 121, Lewisville, Texas 75067 (laboratory)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6700 Euclid Avenue, Cleveland, Ohio 44103 (laboratory)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">One Insights Drive, Clifton, NJ  07012 (laboratory)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owned</span></td></tr></table></div><div><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_67"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item 3. Legal Proceedings</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;See Note 19 to the Consolidated Financial Statements (Part II, Item</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;8 of th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is Report) for information regarding legal proceedings in which we are involved.</span></div><div><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_70"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item 4. Mine Safety Disclosures</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Not applicable.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44 </span></div></div></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_73"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_76"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our common stock is listed and traded on the New York Stock Exchange under the symbol &#8220;DGX.&#8221; As of February 1, 2023, we had approximately 2,225 record holders of our common stock; we believe that the number of beneficial holders of our common stock exceeds the number of record holders. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The table below sets forth the information with respect to purchases made by or on behalf of the Company of its common stock during the fourth quarter of 2022. </span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.318%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.704%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.704%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.704%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.704%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.706%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ISSUER PURCHASES OF EQUITY SECURITIES</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Number of<br/>Shares<br/>Purchased</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Price<br/>Paid per Share</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Number of<br/>Shares Purchased<br/>as Part of Publicly<br/>Announced Plans<br/>or Programs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Approximate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dollar Value of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares that May</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Yet Be Purchased</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Under the Plans</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">or Programs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 1, 2022 &#8211; October 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share Repurchase Program (A)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457,049&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457,049&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680,909&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Transactions (B)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 1, 2022 &#8211; November 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share Repurchase Program (A)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,332,783&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.01&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,332,783&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484,973&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Transactions (B)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145.44&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 1, 2022 &#8211; December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share Repurchase Program (A)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151,247&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151,247&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,909&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Transactions (B)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share Repurchase Program (A)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,941,079&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.90&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,941,079&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,909&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Transactions (B)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145.44&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(A)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.82pt">In February 2022, our Board of Directors increased the size of our share repurchase program by $1&#160;billion.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of December&#160;31, 2022, $<ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-8" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV83Ni9mcmFnOjY3ZWM2OWRlYjY5ZjQyYTQ4NjViOTAzN2QwMmIwOGQyL3RleHRyZWdpb246NjdlYzY5ZGViNjlmNDJhNDg2NWI5MDM3ZDAyYjA4ZDJfMTA5OTUxMTYzMjUxNw_293e45b4-5299-4374-a527-94d1b6f55e1c">0.3</ix:nonFraction> billion remained available under our share repurchase authorization.  In February 2023, we announced that our Board of Directors authorized us to repurchase an additional $<ix:nonFraction unitRef="usd" contextRef="i6f31e868418c42c5abbd3bb28b8a4277_D20230202-20230202" decimals="INF" name="dgx:StockRepurchaseProgramAdditionalAmountAuthorized" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV83Ni9mcmFnOjY3ZWM2OWRlYjY5ZjQyYTQ4NjViOTAzN2QwMmIwOGQyL3RleHRyZWdpb246NjdlYzY5ZGViNjlmNDJhNDg2NWI5MDM3ZDAyYjA4ZDJfMTA5OTUxMTYzMjY4NA_67132518-25f7-4e9d-ad3c-8ea05c8a28e2">1</ix:nonFraction>&#160;billion of our common stock.   Since the share repurchase program's inception in May 2003, our Board of Directors has authorized $13&#160;billion of share repurchases of our common stock, including the $1&#160;billion increase in February 2023. The share repurchase authorization has no set expiration or termination date. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(B)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.68pt">Includes: (1) shares delivered or attested to in satisfaction of the exercise price and/or tax withholding obligations by holders of stock options (granted under the Company's Amended and Restated Employee Long-Term Incentive Plan) who exercised options; and (2) shares withheld (under the terms of grants under the Amended and Restated Employee Long-Term Incentive Plan) to offset tax withholding obligations that occur upon the delivery of outstanding common shares underlying restricted share units and performance share units.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Graph</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Set forth below is a line graph comparing the cumulative total shareholder return on Quest Diagnostics' common stock since December&#160;31, 2017 based on the market price of the Company's common stock and assuming reinvestment of dividends, with the cumulative total shareholder return of companies on the Standard &amp; Poor's (S&amp;P) 500 Stock Index and the S&amp;P 500 Health Care (Sector) Index.</span></div><div><span><br/></span></div><div style="text-align:center"><img src="dgx-20221231_g5.jpg" alt="dgx-20221231_g5.jpg" style="height:480px;margin-bottom:5pt;vertical-align:text-bottom;width:613px"/></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:18.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.676%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Closing DGX Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Shareholder Return</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance Graph Values</span></td></tr><tr style="height:30pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DGX</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">S&amp;P 500</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">S&amp;P 500 Health Care (Sector)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DGX</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">S&amp;P 500</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">S&amp;P 500 Health Care (Sector)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/31/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.27&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.84)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.38)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.47&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.16&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.62&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.47&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/31/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.79&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.82&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.72&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.64&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/31/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.04&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.86&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145.93&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/31/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173.01&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.86&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.71&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190.52&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.58&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.07&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/30/2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.44&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.79)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.95)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180.47&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_79"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item 6 [Reserved]</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"><div style="padding-left:29.25pt;text-indent:-31.5pt"><span><br/></span></div></td></tr></table></div><div><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_82"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;See page </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_133">58</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46 </span></div></div></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_85"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;See Management's Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_88"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item 8. Financial Statements and Supplementary Data</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;See Item 15(a)1 and Item 15(a)2.</span></div><div><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_91"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;None.</span></div><div><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_94"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item 9A. Controls and Procedures</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conclusion Regarding Effectiveness of Disclosure Controls and Procedures</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, we have evaluated the effectiveness of our disclosure controls and procedures (as defined under Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended).  Based upon that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this annual report.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Management on Internal Control Over Financial Reporting</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;See page </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_148">74</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the fourth quarter of 2022, there were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended) that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_97"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item 9B. Other Information</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#160;&#160;&#160;&#160;During February 2023, the Company announced that its Board of Directors increased the Company's share repurchase authorization by $1 billion. The increased authority is in addition to the $0.3 billion that was available as of December 31, 2022 under the Company's share repurchase program.</span></div><div><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_100"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Not applicable.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47 </span></div></div></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_103"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_106"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item 10. Directors, Executive Officers and Corporate Governance</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our Code of Ethics applies to all employees, executive officers and directors, including our Chief Executive Officer, Chief Financial Officer and Corporate Controller.  You can find our Code of Ethics on our corporate governance website,  www.QuestDiagnostics.com/investor.  We will post any amendments to the Code of Ethics, and any waivers that are required to be disclosed by the rules of either the SEC or the New York Stock Exchange, on our website.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Information regarding the Company's executive officers is contained in Part I, Item 1 of this Report under &#8220;Information about our Executive Officers.&#8221;  Information regarding the directors and executive off</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">icers of the Company appearing in our Proxy Statement to be filed by April&#160;30, 2023 (&#8220;Proxy Statement&#8221;) under the captions &#8220;Proposal No. 1 - Election of Directors,&#8221; &#8220;Director Independence,&#8221; &#8220;Board Committees&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and "Delinquent Section 16(a) Reports" is incorporated by reference herein.</span></div><div><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_109"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item 11. Executive Compensation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Information appearing in our Proxy Statement under the captions &#8220;2022 Director Compensation Table,&#8221; &#8220;Compensation Discussion and Analysis,&#8221; &#8220;Information Regarding Executive Compensation&#8221; (excluding the information under the subheading "Pay Versus Performance") and &#8220;Compensation Committee Report&#8221; is incorporated by reference herein.  </span></div><div><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_112"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholders' Matters</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Information regarding security ownership of certain beneficial owners and management appearing in our Proxy Statement under the captions &#8220;Stock Ownership Information&#8221; and "Equity Compensation Plan Information" is incorporated by reference herein. </span></div><div><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_115"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item 13. Certain Relationships and Related Transactions, and Director Independence</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Information regarding certain relationships and related transactions appearing in our Proxy Statement under the captions &#8220;Related Person Transactions&#8221; and &#8220;Director Independence&#8221; is incorporated by reference herein. </span></div><div><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_118"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item 14. Principal Accounting Fees and Services</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Information regarding principal accountant fees and services appearing in our Proxy Statement under the caption &#8220;Audit" (excluding the information under the subheading &#8220;Audit and Finance Committee Report&#8221;) is incorporated by reference herein. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48 </span></div></div></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_121"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_124"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item 15. Exhibits, Financial Statement Schedules</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Documents filed as part of this Report.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Index to financial statements and supplementary data filed as part of this Report.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:85.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.224%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Item</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_151">Report of Independent Registered Public Accounting Firm (PCAOB ID </a></span><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xMjQvZnJhZzo0MzNjOWRhZDU3MTQ0NzM1OWJkNTI3NDViZWJlZDM5Ny90YWJsZTowNGIyMGRjMDFiNDM0YTE3OTM2N2M3NTUxYmEyMmQ4Ni90YWJsZXJhbmdlOjA0YjIwZGMwMWI0MzRhMTc5MzY3Yzc1NTFiYTIyZDg2XzItMC0xLTEtNzgyMTUvdGV4dHJlZ2lvbjpmMmU2N2Y3NzI5MTE0OTRmOWJkODViM2VjZDIwODI2Nl83MA_6d5bbdcf-5a98-402d-8a31-e4887c718544">238</ix:nonNumeric></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_151">)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F- <a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_151">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_157">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F- <a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_157">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_160">Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F- <a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_160">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_163">Consolidated Statements of Comprehensive Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F- <a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_163">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_166">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F- <a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_166">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_169">Consolidated Statements of Stockholders' Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F- <a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_169">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_172">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F- <a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_172">8</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     3.    Exhibits </span></div><div><span><br/></span></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.721%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000102207922000140/dgx09302022ex31.htm">Restated Certificate of Incorporation (filed as an Exhibit to the Company's quarterly report on Form 10-Q for the quarter ended September 30, 2022 and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1022079/000102207922000157/dgx11142022ex31.htm">Amended and Restated By-Laws of the Company, as amended  November 14, 2022 (filed as an Exhibit to the Company's current report on Form 8-K (Date of Report: November 14, 2022) and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000093041307005477/c49146_ex10-1.htm">Form of 6.95% Senior Note due 2037 (filed as an Exhibit to the Company's current report on Form 8-K (Date of Report: June 19, 2007) and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000093041309005747/c59372_ex1-1.htm">Form of 5.750% Senior Note due 2040 (filed as an Exhibit to the Company's current report on Form 8-K (Date of Report: November 17, 2009) and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000094787114000160/ss206544_ex0101.htm">Form of 4.250% Senior Note due 2024 (filed as an Exhibit to the Company's current report on Form 8-K (Date of Report: March 12, 2014) and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000094787115000168/ss419933_ex0101.htm">Form of 3.500% Senior Note due 2025 (filed as an Exhibit to the Company's current report on Form 8-K (Date of Report: March 5, 2015) and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000094787115000168/ss419933_ex0101.htm">Form of 4.700% Senior Note due 2045 (filed as an Exhibit to the Company's current report on Form 8-K (Date of Report: March 5, 2015) and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000094787116001220/ss1485098_ex0101.htm">Form of 3.450% Senior Note due 2026 (filed as an Exhibit to the Company&#8217;s current report on Form 8-K (Date of Report: May 23, 2016) and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000094787119000202/ss128814_ex0101.htm">Form of 4.200% Senior Note due 2029 (filed as an Exhibit to the Company&#8217;s current report on Form 8-K (Date of Report: March 7, 2019) and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000094787119000957/ss159854_ex0101.htm">Form of 2.950% Senior Note due 2030 (filed as an Exhibit to the Company&#8217;s current report on Form 8-K (Date of Report: December 9, 2019) and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.721%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000094787120000458/ss173511_ex0101.htm">Form of 2.800% Senior Note due 2031 (filed as an Exhibit to the Company&#8217;s current report on Form 8-K (Date of Report: May 11, 2020) and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.10</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1022079/000094787101500290/ex4-3_062801.txt">Indenture dated as of June 27, 2001, among the Company, the Subsidiary Guarantors, and The Bank of New York (filed as an Exhibit to the Company's current report on Form 8-K (Date of Report: June 27, 2001) and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.11</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000094787101500290/ex4-4_062801.txt">First Supplemental Indenture, dated as of June 27, 2001, among the Company, the Initial Subsidiary Guarantors, and The Bank of New York (filed as an Exhibit to the Company's current report on Form 8-K (Date of Report: June 27, 2001) and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.12</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000094787101501115/ex4-1_112601.txt">Second Supplemental Indenture, dated as of November 26, 2001, among the Company, the Subsidiary Guarantors, and The Bank of New York (filed as an Exhibit to the Company's current report on Form 8-K (Date of Report: November 26, 2001) and incorporated herein by reference) (Commission File Number 001-12215)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.13</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000094787102000692/ex4-1_040902.txt">Third Supplemental Indenture, dated as of April 4, 2002, among the Company, the Additional Subsidiary Guarantors, and The Bank of New York (filed as an Exhibit to the Company's current report on Form 8-K (Date of Report: April 1, 2002) and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.14</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1022079/000095011703001797/ex10-1.txt">Fourth Supplemental Indenture dated as of March 19, 2003, among Unilab Corporation (f/k/a Quest Diagnostics Newco Incorporated), the Company, The Bank of New York, and the Additional Subsidiary Guarantors (filed as an Exhibit to the Company's quarterly report on Form 10-Q for the quarter ended March 31, 2003 and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000095011704001657/ex10-1.txt">Fifth Supplemental Indenture dated as of April 16, 2004, among Unilab Acquisition Corporation (d/b/a FNA Clinics of America), the Company, The Bank of New York, and the Additional Subsidiary Guarantors (filed as an Exhibit to the Company's quarterly report on Form 10-Q for the quarter ended March 31, 2004 and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.16</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000095011705004157/ex4-7.htm">Sixth Supplemental Indenture dated as of October 31, 2005, among the Company, The Bank of New York, and the Subsidiary Guarantors (filed as an Exhibit to the Company's current report on Form 8-K (Date of Report: October 31, 2005) and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.17</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000095011705004480/ex4-1.htm">Seventh Supplemental Indenture dated as of November 21, 2005, among the Company, The Bank of New York, and the Additional Subsidiary Guarantors (filed as an Exhibit to the Company's current report on Form 8-K (Date of Report: November 21, 2005) and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.18</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000095011706003285/ex4-1.htm">Eighth Supplemental Indenture dated as of July 31, 2006, among the Company, The Bank of New York, and the Additional Subsidiary Guarantors (filed as an Exhibit to the Company's current report on Form 8-K (Date of Report: July 31, 2006) and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.19</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000095011706004130/ex4-1.htm">Ninth Supplemental Indenture dated as of September 30, 2006, among the Company, The Bank of New York, and the Additional Subsidiary Guarantors (filed as an Exhibit to the Company's current report on Form 8-K (Date of Report: September 30, 2006) and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.20</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000093041307005477/c49146_ex4-11.htm">Tenth Supplemental Indenture dated as of June 22, 2007, among the Company, The Bank of New York, and the Subsidiary Guarantors (filed as an Exhibit to the Company's current report on Form 8-K (Date of Report: June 19, 2007) and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.21</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000093041307005477/c49146_ex4-14.htm">Eleventh Supplemental Indenture dated as of June 22, 2007, among the Company, The Bank of New York, and the Additional Subsidiary Guarantors (filed as an Exhibit to the Company's current report on Form 8-K (Date of Report: June 19, 2007) and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.721%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.22</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000093041307005477/c49146_ex4-15.htm">Twelfth Supplemental Indenture dated as of June 25, 2007, among the Company, The Bank of New York, and the Additional Subsidiary Guarantors (filed as an Exhibit to the Company's current report on Form 8-K (Date of Report: June 19, 2007) and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.23</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000093041309005838/c59427_ex4-14.htm">Thirteenth Supplemental Indenture dated as of November 17, 2009, among the Company, The Bank of New York Mellon, and the Subsidiary Guarantors (filed as an Exhibit to the Company's current report on Form 8-K (Date of Report: November 17, 2009) and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.24</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000093041311002247/c64911_ex4-15.htm">Fourteenth Supplemental Indenture dated as of March 24, 2011, among the Company, The Bank of New York Mellon, and the Subsidiary Guarantors (filed as an Exhibit to the Company's current report on Form 8-K (Date of Report: March 21, 2011) and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000093041312000949/c68209_ex4-24.htm">Fifteenth Supplemental Indenture dated as of November 30, 2011, among the Company, The Bank of New York Mellon, and the Additional Subsidiary Guarantors (filed as an Exhibit to the Company's 2011 annual report on Form 10-K and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.26</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000094787114000160/ss206544_ex0417.htm">Sixteenth Supplemental Indenture dated as of March 17, 2014, between the Company and  The Bank of New York Mellon (filed as an Exhibit to the Company's current report on Form 8-K (Date of Report: March 12, 2014) and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.27</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000094787115000168/ss419933_ex0418.htm">Seventeenth Supplemental Indenture dated as of March 10, 2015, between the Company and The Bank of New York Mellon (filed as an Exhibit to the Company&#8217;s current report on Form 8-K (Date of Report: March 5, 2015) and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.28</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000094787116001220/ss1485098_ex0419.htm">Eighteenth Supplemental Indenture dated as of May 26, 2016, between the Company and The Bank of New York Mellon (filed as an Exhibit to the Company&#8217;s current report on Form 8-K (Date of Report: May 23, 2016) and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.29</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000094787119000202/ss128814_ex0402.htm">Nineteenth Supplemental Indenture dated as of March 12 2019, between the Company and The Bank of New York Mellon (filed as an Exhibit to the Company&#8217;s current report on Form 8-K (Date of Report: March 7, 2019) and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.30</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000094787119000973/ss160605_ex0402.htm">Twentieth Supplemental Indenture dated as of December 16, 2019, between the Company and The Bank of New York Mellon (filed as an Exhibit to the Company&#8217;s current report on Form 8-K (Date of Report: December 16, 2019) and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.31</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000094787120000458/ss173511_ex0402.htm">Twenty-First Supplemental Indenture dated as of May 13, 2020, between the Company and The Bank of New York Mellon (filed as an Exhibit to the Company&#8217;s current report on Form 8-K (Date of Report: May 11, 2020) and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.32*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dgx12312022ex432.htm">Description of Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#8225;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000102207919000118/dgx03312019ex101.htm">Amended and Restated Employee Stock Purchase Plan, as amended, effective February 18, 2019 (filed as an Exhibit to the Company's quarterly report on Form 10-Q for the quarter ended March 31, 2019 and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#8225;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000102207919000166/dgx063019ex101.htm">Amended and Restated Quest Diagnostics Incorporated Employee Long-Term Incentive Plan as amended May 14, 2019 (filed as an Exhibit to the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2019 and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#8225;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000102207921000070/dgx03312021ex101.htm">Form of Equity Award Agreement dated as of February ___, 2021 (filed as an Exhibit to the Company&#8217;s quarterly report on Form 10-Q for the quarter ended March 31, 2021 and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.721%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#8225;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001022079/000102207921000144/dgx09302021ex102.htm">Quest Diagnostics Supplemental Deferred Compensation Plan (Post 2004) amended and restated as of December 1, 2020 </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001022079/000102207921000144/dgx09302021ex102.htm">(filed as an Exhibit to the Company&#8217;s quarterly report on Form 10-Q for the quarter ending September 30, 2021 and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#8225;*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dgx12312022ex105.htm">Amendment No. 1 to Quest Diagnostics Supplemental Deferred Compensation Plan (Post 2004) (as amended and restated December 1, 2020), dated as of November 29, 2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#8225;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000102207921000029/dgx12312020ex105.htm">Quest Diagnostics Supplemental Deferred Compensation Plan (Pre-2005) amended and restated December 1, 2020</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">(filed as an Exhibit to the Company&#8217;s 2020 annual report on Form 10-K and incorporated herein by reference) (Commission File Number 001-12215)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#8225;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000102207919000118/dgx03312019ex102.htm">Quest Diagnostics Incorporated Senior Management Incentive Plan, as amended and restated February 18, 2019 (filed as an Exhibit to the Company's quarterly report on Form 10-Q for the quarter ended March 31, 2019 and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#8225;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000102207922000157/dgx11142022ex101.htm">Amended and Restated Quest Diagnostics Incorporated Executive Officer Severance Plan, as amended November 16, 2022 (filed as an Exhibit to the Company's current report on Form 8-K (Date of Report: November 14, 2022) and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#8225;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001022079/000102207921000144/dgx09302021ex101.htm">The Quest Diagnostics Incorporated Profit Sharing Plan (Amendment and Restatement, effective as of August 15, 2021) (filed as an Exhibit to the Company&#8217;s quarterly report on Form 10-Q for the quarter ending September 30, 2021 and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10&#8225;*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dgx12312022ex1010.htm">Amendment No. 1 To the Quest Diagnostics Profit Sharing Plan (as amended and restated effective August 15, 2021) dated as of December 5, 2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11&#8225;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000102207920000017/dgx12312019ex1012.htm">Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan For Directors as amended effective February 18, 2020 (filed as an Exhibit to the Company&#8217;s 2019 annual report on Form 10-K and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12&#8225;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001022079/000102207921000029/dgx12312020ex1017.htm">Amended and Restated Quest Diagnostics Incorporated Long-Term Incentive Plan for Non-Employee Directors, as amended and restated as of November 18, 2020 </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001022079/000102207921000029/dgx12312020ex1017.htm">(filed as an Exhibit to the Company&#8217;s 2020 annual report on Form 10-K and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13&#8225;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000093041312000949/c68209_ex10-40.htm">Form of Non-Employee Director Equity Award Agreement (filed as an Exhibit to the Company's 2011 annual report on Form 10-K and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14&#8225;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000102207916000195/dgx12312015ex1015.htm">Form of Non-Employee Director Equity Award Agreement dated May 15, 2015 (filed as an Exhibit to the Company&#8217;s 2015 annual report on Form 10-K and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15&#8225;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000093041312000949/c68209_ex10-41.htm">Form of Non-Employee Director Elective Option Award Agreement (filed as an Exhibit to the Company's 2011 annual report on Form 10-K and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16&#8225;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000094787112000371/ss142217_ex1001.htm">Employment Agreement between Stephen H. Rusckowski and Quest Diagnostics Incorporated, dated April 3, 2012 (filed as an Exhibit to the Company's current report on Form 8-K (Date of Report: April 9, 2012) and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17&#8225;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000102207915000099/ex101061115.htm">Amendment to Employment Agreement between Stephen H. Rusckowski and Quest Diagnostics Incorporated, dated June 11, 2015 (filed as an Exhibit to the Company&#8217;s current report on Form 8-K (Date of Report: June 11, 2015) and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.721%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18&#8225;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000102207914000013/dgx12312013ex1030.htm">Aircraft Timesharing Agreement dated as of December 17, 2013 between Quest Diagnostics Incorporated and Stephen H. Rusckowski (filed as an Exhibit to the Company&#8217;s 2013 annual report on Form 10-K and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19&#8225;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000102207919000166/dgx063019ex102.htm">Assignment and Amendment No. 1 to Aircraft Timesharing Agreement dated as of May 29, 2019 between Quest Diagnostics Incorporated and Stephen H. Rusckowski (filed as an Exhibit to the Company&#8217;s quarterly report on Form 10-Q for the quarter ended June 30, 2019 and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20&#8225;*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dgx12312022ex1020.htm">Aircraft Time Sharing Agreement dated as of February 16, 2023 between Quest Diagnostics Incorporated and James E. Davis</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dgx12312022ex211.htm">Subsidiaries of Quest Diagnostics Incorporated</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dgx12312022ex22.htm">Subsidiary Guarantors of Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dgx12312022ex231.htm">Consent of PricewaterhouseCoopers LLP</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_130">Power of Attorney (included on signature page)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dgx12312022ex311.htm">Rule 13a-14(a) Certification of Chief Executive Officer</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dgx12312022ex312.htm">Rule 13a-14(a) Certification of Chief Financial Officer</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dgx12312022ex321.htm">Section 1350 Certification of Chief Executive Officer</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dgx12312022ex322.htm">Section 1350 Certification of Chief Financial Officer</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001022079/000094787120000426/ss171981_ex9901.htm">Fourth Amended and Restated Receivables Sale Agreement, dated as of October 28, 2015, between Quest Diagnostics Incorporated and the subsidiaries party thereto from time to time, as Sellers, and Quest Diagnostics Receivables Inc., as Buyer (filed as an Exhibit to the Company&#8217;s current report on Form 8-K (Date of Report: May 4, 2020) and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000094787120000426/ss171981_ex9902.htm">Amendment No. 1 to Fourth Amended and Restated Receivables Sale Agreement, dated October 25, 2019 (filed as an Exhibit to the Company&#8217;s current report on Form 8-K (Date of Report: May 4, 2020) and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001022079/000094787120000426/ss171981_ex9903.htm">Sixth Amended and Restated Credit and Security Agreement, dated as of October 27, 2017 among Quest Diagnostics Receivables Inc., as Borrower, Quest Diagnostics Incorporated, as Initial Servicer, MUFG Bank, Ltd. (formerly known as The Bank of Tokyo Mitsubishi UFJ, Ltd.), as Administrative Agent, the Lenders party thereto, the financial institutions party thereto as agents for the conduit lenders (filed as an Exhibit to the Company&#8217;s current report on Form 8-K (Date of Report: May 4, 2020) and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000094787120000426/ss171981_ex9904.htm">Amendment No. 1 to Sixth Amended and Restated Credit and Security Agreement, dated as of October 26, 2018 (filed as an Exhibit to the Company&#8217;s current report on Form 8-K (Date of Report: May 4, 2020) and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000094787120000426/ss171981_ex9905.htm">Amendment No. 2 to Sixth Amended and Restated Credit and Security Agreement, dated as of June 14, 2019 (filed as an Exhibit to the Company&#8217;s current report on Form 8-K (Date of Report: May 4, 2020) and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.721%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000094787120000426/ss171981_ex9906.htm">Amendment No. 3 to Sixth Amended and Restated Credit and Security Agreement, dated as of October 25, 2019 (filed as an Exhibit to the Company&#8217;s current report on Form 8-K (Date of Report: May 4, 2020) and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000102207921000029/dgx12312020ex997.htm">Amendment No. 4 to Sixth Amended and Restated Credit and Security Agreement, dated as of October 22, 2020  (filed as an Exhibit to the Company's 2020 annual report of Form 10-K and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.8</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001022079/000102207921000144/dgx09302021ex991.htm">Amendment No. 5 to Sixth Amended and Restated Credit and Security Agreement, dated as of August 13, 2021 (filed as an Exhibit to the Company&#8217;s quarterly report on Form 10-Q for the quarter ended September 30, 2021 and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.9</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000102207922000027/dgx12312021ex999.htm">Amendment No. 6 to Sixth Amended and Restated Credit and Security Agreement, dated as of October 21, 2021  (filed as an Exhibit to the Company's 2021 annual report on Form 10-K and incorporated herein by reference) (Commission File Number 001-12215)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.10*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dgx12312022ex9910.htm">Amendment No. 7 to Sixth Amended and Restated Credit and Security Agreement, dated as of October 20, 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.11</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000102207922000027/dgx12312021ex9910.htm">Amendment and Restatement Agreement, dated as of November 23, 2021, relating to the Second Amended and Restated Credit Agreement, dated as of March 22, 2018, among Quest Diagnostics Incorporated, as Borrower, the lenders party thereto, JPMorgan Chase Bank, N.A., as Administrative Agent, and other agents party thereto and which includes, as Exhibit A, the Third Restated Credit Agreement (filed as an Exhibit to the Company's 2021 annual report on Form 10-k and incorporated herein by reference) (Commission File Number 001-12215</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022079/000102207922000027/dgx12312021ex9910.htm">)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.12*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dgx12312022ex9912.htm">Group Joinder Agreement, among Reprosource Fertility Diagnostics, Inc., Blueprint Genetics, Inc., and Mid America Clinical Laboratories, LLC,  dated as of August 13, 2021, related to the Fourth Amended and Restated Receivables Sales Agreement, dated October 28, 2015, among Quest Diagnostics Incorporated and certain of its subsidiaries</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document - dgx-20221231.xsd</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document - dgx-20221231_cal.xml</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document - dgx-20221231_def.xml</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document - dgx-20221231_lab.xml</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document - dgx-20221231_pre.xml</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page from this annual report on Form 10-K, formatted in Inline XBRL.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furnished herewith.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#8225;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management contract or compensatory plan or arrangement required to be filed as an Exhibit to this Form 10-K pursuant to Item 15(b) of Form 10-K.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Exhibits filed as part of this Report.</span></div><div style="padding-left:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The exhibit index in (a) above is incorporated herein by reference.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">None.</span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_127"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item 16. Form 10-K Summary</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_130"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signatures</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pursuant to the requirements of Sections 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on February&#160;21, 2023.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:53.459%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">QUEST DIAGNOSTICS INCORPORATED</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ James E. Davis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James E. Davis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and President </span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Each individual whose signature appears below constitutes and appoints Michael E. Prevoznik and William J. O'Shaughnessy, Jr., and each of them singly, his or her true and lawful attorneys-in-fact and agents with full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K filed with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all the said attorneys-in-fact and agents or any of them or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities indicated on February&#160;21, 2023.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:449.25pt"><tr><td style="width:1.0pt"></td><td style="width:123.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:123.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:196.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Capacity</span></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/James E. Davis</span></div><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James E. Davis</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and President; Director<br/>(Principal Executive Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/Sam A. Samad</span></div><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sam A. Samad</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer<br/>(Principal Financial Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/Michael J. Deppe</span></div><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael J. Deppe</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Corporate Controller and Chief Accounting Officer<br/>(Principal Accounting Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/Tracey C. Doi</span></div><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tracey C. Doi </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/Vicky B. Gregg</span></div><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicky B. Gregg</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/Wright L. Lassiter, III</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wright L. Lassiter, III</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:26pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/Timothy L. Main</span></div><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Timothy L. Main</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/Denise M. Morrison</span></div><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denise M. Morrison</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/Gary M. Pfeiffer</span></div><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gary M. Pfeiffer</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/Timothy M. Ring</span></div><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Timothy M. Ring</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/Stephen H. Rusckowski </span></div><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stephen H. Rusckowski</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/Gail R. Wilensky</span></div><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gail R. Wilensky</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57 </span></div></div></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_133"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Company </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Diagnostic Information Services</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Quest Diagnostics empowers people to take action to improve health outcomes.  We use our extensive database of clinical lab results to derive diagnostic insights that reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management.  Our diagnostic information services business ("DIS") provides information and insights based on an industry-leading menu of routine, non-routine and advanced clinical testing and anatomic pathology testing, and other diagnostic information services.  We provide services to a broad range of customers, including patients, clinicians, hospitals, independent delivery networks ("IDNs"), health plans, employers, consumers, and accountable care organizations ("ACOs").  We offer the broadest access in the United States to diagnostic information services through our nationwide network of laboratories, patient service centers and phlebotomists in physician offices and our connectivity resources, including call centers and mobile paramedics, nurses and other health and wellness professionals.  We are the world's leading provider of diagnostic information services.  We provide interpretive consultation with one of the largest medical and scientific staffs in the industry.  Our DIS business makes up greater than 95% of our consolidated net revenues.  During 2022, we processed approximately 208 million test requisitions through our extensive laboratory network. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The clinical testing that we perform is an essential element in the delivery of healthcare services.  Clinicians use clinical testing for predisposition, screening, monitoring, diagnosis, prognosis and treatment choices of diseases and other medical conditions.  The United States clinical testing industry consists of two segments.  One segment includes hospital inpatient and outpatient testing.  The second segment includes testing of persons who are not hospital patients, including testing done in commercial clinical laboratories, physician-office laboratories and other locations, as well as hospital outreach (non-hospital patients) and consumer-initiated testing.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The clinical testing industry is subject to seasonal fluctuations in operating results and cash flows.  Typically, testing volume declines during vacation and major holiday periods, reducing net revenues and operating cash flows below annual averages.  Testing volume is also subject to declines due to severe weather or other events (such as public health emergencies and health pandemics), which can deter patients from having testing performed and which can vary in duration and severity from year to year.  Additionally, orders for clinical testing generated from clinician offices, hospitals, employers and consumers can be affected by factors such as changes in the United States economy and regulatory environment, which affect the number of unemployed and uninsured, and design changes in healthcare plans, which affect utilization as well as patient responsibility for healthcare costs.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We assess our revenue performance for the DIS business based upon, among other factors, volume (measured by test requisitions) and revenue per requisition.  Each requisition accompanies patient specimens, indicating the test(s) to be performed and the party to be billed for the test(s).  Revenue per requisition is impacted by various factors, including, among other items, the impact of fee schedule changes (i.e. unit price), test mix, payer mix, and the number of tests per requisition.  Management uses number of requisitions and revenue per requisition data to assist with assessing the growth and performance of the business, including understanding trends affecting number of requisitions, pricing and test mix. Therefore, we believe that information related to changes in these metrics from period to period are useful information for investors as it allows them to assess the performance of the business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Diagnostic Solutions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In our Diagnostic Solutions ("DS") businesses, which represent the balance of our consolidated net revenues, we offer a variety of solutions for life insurers and healthcare organizations and clinicians.  We are the leading provider of risk assessment services for the life insurance industry.  In addition, we offer healthcare organizations and clinicians robust information technology solutions. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022 Highlights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(dollars in millions, except per share data)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9,883</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$10,788</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9,437</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Base business revenues (a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$8,429</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$8,018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6,714</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19 testing revenues</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,454</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2,770</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2,723</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DIS revenues</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9,609</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$10,494</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9,139</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue per requisition change</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Requisition volume change</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.5%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Organic requisition volume change</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DS revenues</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$274</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$294</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$298</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,428</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2,381</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,971</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Quest Diagnostics</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$946</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,995</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,431</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$7.97</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.55</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$10.47</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,718</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2,233</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2,005</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$404</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$403</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$418</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Excludes COVID-19 testing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impact that the COVID-19 pandemic had on our DIS revenues, including requisition volume and revenue per requisition are discussed further below under "Impact of COVID-19" and "Results of Operations".</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further discussion of the year-over-year changes for the year ended December&#160;31, 2022 compared to the year ended December&#160;31, 2021, see "Results of Operations" below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of COVID-19</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Since 2020, a novel strain of coronavirus has impacted the economy of the United States and other countries around the world.  As a result of the pandemic, we have made substantial investments to expand and maintain the amount of COVID-19 testing available to the country. We have been effectively managing challenges in the global supply chain and, at this point, we have sufficient supplies to conduct our business.  As the impact of COVID-19 moderates, we remain active in the continued response to COVID-19.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Due to the pandemic, since 2020 we have experienced significant volatility, including periods of material decline compared to prior year periods in testing volume in our base business (which excludes COVID-19 testing) and periods of significant demand for COVID-19 testing services.  Additionally, compared to pre-2020 historical levels, our revenue per requisition has been positively impacted by COVID-19 molecular testing.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Two Point Strategy </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our two point strategy and our operating principles are described in detail in "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">". We continued to execute our strategy and leverage our operating principles during 2022 as follows:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Acquisition of Pack Health, LLC ("Pack Health")</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On February 1, 2022, we completed the acquisition of Pack Health, a patient engagement company that helps individuals adopt healthier behaviors to improve outcomes, in an all cash transaction for $123&#160;million, net of $4&#160;million cash acquired, which consisted of cash consideration of $105&#160;million and contingent consideration initially estimated at $18&#160;million.  The acquired business is included in our DIS business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;For further details, see Notes 6 and 8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">to the audited consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Invigorate Program</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We are engaged in a multi-year program called Invigorate, which is designed to reduce our cost structure and improve our performance.  We currently aim annually to achieve savings and productivity improvements of approximately 3% of our costs, which we believe will help offset pressures from the current inflationary environment.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Invigorate has consisted of several flagship programs, with structured plans in each, to drive savings and improve performance across the customer value chain. These flagship programs include: organization excellence; information technology excellence; procurement excellence; field and customer service excellence; lab excellence; and revenue services excellence. In addition to these programs, we have identified key themes to change how we operate including reducing denials and patient price concessions; further digitizing our business; standardization; automation; optimization and selecting and retaining talent. We believe that our efforts to standardize our information technology systems, equipment and data also foster our efforts to strengthen our foundation for growth and support the value creation initiatives of our clinical franchises by enhancing our operational flexibility, empowering and enhancing the customer experience, facilitating the delivery of actionable insights and bolstering our large data platform.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the year ended December&#160;31, 2022, we incurred $88&#160;million of pre-tax charges in connection with our Invigorate program and other restructuring activities, including $55&#160;million of employee separation costs, with the remainder primarily consisting of systems conversion and integration costs.  Most of the charges will result in cash expenditures.  Additional restructuring charges may be incurred in future periods, including as we identify additional opportunities to achieve further savings and productivity improvements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further details of the Invigorate program and associated costs, see Note 5 to the audited consolidated financial statements.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outlook and Trends</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The healthcare system in the United States is evolving.   We expect that the evolution of the healthcare industry, including impacts of the COVID-19 pandemic, which include the increased adoption of telemedicine, will continue, and that industry change is likely to be extensive.  There are a number of key trends that we expect will continue to have a significant impact on the diagnostic information services business in the United States and on our business.  We believe that several of the trends, including increased focus on value, consolidation, price transparency and consumerization, are favorable to our business.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Healthcare market participants, including governments, are focusing on controlling costs, including potentially by reducing reimbursement for healthcare services, changing reimbursement for healthcare services (including but not limited to a shift from fee-for-service to capitation), changing medical coverage policies (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., healthcare benefits design), denying coverage for services, requiring preauthorization of laboratory testing, requiring co-pays, introducing laboratory spend management utilities and payment and patient care innovations such as ACOs and patient-centered medical homes.  In recent years, there has been an ongoing trend of rising patient responsibility (including attributable to payer denials) which has resulted in an increase in our reserves for patient price concessions.  As health plans and government programs require greater levels of patient cost-sharing, our patient price concessions may continue to be negatively impacted and adversely impact our results of operations.  As previously mentioned, there could be a shift to capitation arrangements where we agree to a predetermined monthly reimbursement rate for each member enrolled in a restricted plan, generally regardless of the number or cost of services provided by us.  In both 2022 and 2021, we derived approximately 3% of our consolidated net revenues from capitated payment arrangements.  In both 2022 and 2021, we derived approximately 8% of our testing volume from capitated payment arrangements.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Historically, the Medicare Clinical Laboratory Fee Schedule ("CLFS") and the Medicare Physician Fee Schedule established under Part B of the Medicare program have been subject to change, including each year.  Pursuant to the Protecting Access to Medicare Act ("PAMA"), reimbursement rates for clinical laboratory testing were reduced from 2018 - 2020.   </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PAMA calls for further revision of the CLFS for years after 2020, based on future surveys of market rates; reimbursement reduction from 2024 - 2026 is capped by PAMA at 15% annually.  PAMA's next data collection and reporting period have been delayed, most recently by federal legislation adopted in December 2022, which further delayed the reimbursement rate reductions and reporting requirements until January 1, 2024.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In addition, the trend of consolidating, converging and diversifying among our customers, payers and other healthcare industry participants has continued and may result in increased price transparency and bargaining power, and may encourage internalization of clinical testing.  We also believe that PAMA, among other factors, may be a further catalyst for consolidation as diagnostic information services providers realize lower Medicare reimbursement rates and large diagnostic information services providers may be able to increase their share of the overall diagnostic information services industry due to their large networks and lower cost structures.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For a discussion of the impact of the COVID-19 pandemic on our business, see "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impact of COVID-19" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">above.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our key trends, which present both opportunities and risks, see "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business: The Clinical Testing Industry</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">." </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions and select accounting policies that affect our reported financial results and the disclosure of contingent assets and liabilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our revenues are primarily comprised of a high volume of relatively low-dollar transactions, and about one-half of our total costs and expenses consist of employee compensation and benefits.  Due to the nature of our business, several of our accounting policies involve significant estimates and judgments: </span></div><div><span><br/></span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">revenues and accounts receivable associated with DIS; </span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reserves for general and professional liability claims; </span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reserves for other legal proceedings; and</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">accounting for and recoverability of goodwill.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Revenues and accounts receivable associated with DIS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The process for estimating revenues and the ultimate collection of receivables associated with our DIS business involves significant assumptions and judgments.  We recognize as revenue the amount of consideration to which we expect to be entitled primarily upon completion of the testing process (when results are reported) or when services have been rendered.  We estimate the amount of consideration we expect to be entitled to receive from customer groups in exchange for providing services using the portfolio approach.  These estimates include the impact of contractual allowances (including payer denials), and patient price concessions, as discussed below.  The portfolios determined using the portfolio approach consist of the following customers:  </span></div><div><span><br/></span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Healthcare Insurers</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Government Payers</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Client Payers</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patients</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have a standardized approach to estimate the amount of consideration that we expect to be entitled to, including the impact of contractual allowances (including payer denials), and patient price concessions.  Historical collection and payer reimbursement experience (along with the period of time that the receivables have been outstanding) is an integral part of the estimation process related to revenues and receivables.  Adjustments to our estimated contractual allowances and implicit patient price concessions are recorded in the current period as changes in estimates. Further adjustments to the allowances, based on actual receipts, may be recorded upon settlement.  </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We regularly assess the state of our billing operations in order to identify issues which may impact the collectability of receivables or revenue estimates. We believe that the collectability of our receivables is directly linked to the quality of our billing processes, most notably those related to obtaining the correct information in order to bill effectively for the services we provide. As such, we strive to implement &#8220;best practices&#8221; and endeavor to increase the use of electronic ordering to reduce the number of requisitions that we receive from healthcare providers with missing or incorrect billing information. We believe that our collection and revenue estimation processes, along with our close monitoring of our billing operations, help to reduce the risk associated with material adjustments to reserve estimates.  However, changes to our estimate of the impact of contractual allowances (including payer denials) and patient price concessions could have a material impact on our results of operations and financial condition in the period that the estimates are adjusted.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following table shows the approximate percentage of our total requisition volume and net revenues associated with our DIS business during 2022 applicable to each customer group: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:68.006%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.982%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Volume</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Revenues</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare insurers</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government payers</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Client payers</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients *</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total DIS</span></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97%</span></td></tr></table></div><div style="padding-left:9pt;text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Patients revenue includes coinsurance and deductible responsibilities; but volume associated with such revenue is reported under Healthcare insurers.</span></div><div style="padding-left:9pt;text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following table shows net accounts receivable as of December&#160;31, 2022 applicable to each customer group:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:83.819%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.981%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Accounts</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Receivable</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare insurers </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government payers</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Client payers</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients (including coinsurance and deductible responsibilities)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total DIS</span></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Healthcare insurers</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Reimbursements from healthcare insurers are based on fee-for-service schedules and on capitated payment rates.  Under fee-for-service arrangements, healthcare insurers are billed at our list price.  Net revenues recognized consist of amounts billed net of contractual allowances for differences between amounts billed and the estimated consideration we expect to receive from such payers, which considers historical denial and collection experience and the terms of our contractual arrangements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Substantially all of the accounts receivable due from healthcare insurers represent amounts billed under fee-for-service arrangements.  Collection of our net revenues from healthcare insurers is normally a function of providing complete and correct billing information to the healthcare insurers within the various filing deadlines and generally occurs within 30 to 60 days of billing.  Provided we have billed healthcare insurers accurately with complete information prior to the established filing deadline, there has historically been little to no credit risk.  If there has been a delay in billing, we determine if the amounts in question will likely go past the filing deadline, and if so, we will reserve accordingly for the billing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Under capitated arrangements with healthcare insurers, we recognize revenue based on a predetermined monthly reimbursement rate for each member of an insurer's health plan regardless of the number or cost of services provided by us.  Under capitated payment arrangements, the healthcare insurers typically reimburse us in the same month services are performed, essentially giving rise to no outstanding accounts receivable at the end of a reporting period.  If any capitated </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payments are not received on a timely basis, we determine the cause and make a separate determination as to whether or not the collection of the amount from the healthcare insurer is at risk and, if so, would reserve accordingly.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Government payers</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Reimbursements from government payers are based on fee-for-service schedules set by governmental authorities, including traditional Medicare and Medicaid.  Net revenues recognized consist of amounts billed net of contractual allowances for differences between amounts billed and the estimated consideration we expect to receive from such payers, which considers historical denial and collection experience.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Collection of our net revenues from government payers is normally a function of providing the complete and correct billing information within the various filing deadlines.  Collection generally occurs within 30 days of billing.  Provided we have billed government payers accurately with complete information prior to the established filing deadline, there has historically been little to no credit risk.  If there has been a delay in billing, we determine if the amounts in question will likely go past the filing deadline, and, if so, we will reserve for the billing accordingly.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Client payers</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Client payers include physicians, hospitals, ACOs, IDNs, employers, other commercial laboratories and institutions for which services are performed on a wholesale basis, and are billed based on a negotiated fee schedule.  Credit risk and ability to pay are more of a consideration for these payers than healthcare insurers and government payers.  Collection of consideration we expect to receive generally occurs within 60 to 90 days of billing.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We principally estimate the allowance for credit losses for client payers based on historical collection experience, the current credit worthiness of the customers, current economic conditions, expectations of future economic conditions and the period of time that the receivables have been outstanding. To the extent that any individual client payers are identified that have deteriorated in credit quality, we establish allowances based on the individual risk characteristics of such customers.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Patients</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Uninsured patients are billed based on established patient fee schedules or fees negotiated with physicians on behalf of their patients.  Insured patients (includes coinsurance and deductible responsibilities) are billed based on fees negotiated with healthcare insurers.  Collection of billings from patients is subject to credit risk and ability of the patients to pay.  Net revenues consist of amounts billed net of discounts provided to uninsured patients in accordance with our policies and implicit price concessions.  Implicit price concessions represent differences between amounts billed and the estimated consideration we expect to receive from patients, which considers historical collection experience (along with the period of time that the receivables have been outstanding) and other factors including current market conditions.  Patient billings are generally fully reserved for when the related service reaches 210 days outstanding.  Balances are automatically written off when they are sent to collection agencies.  Allowances are further adjusted for estimated recoveries of amounts sent to collection agencies based on historical collection experience, which is regularly monitored.  Collection of consideration we expect to receive generally occurs within 30 to 60 days of billing.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Reserves for general and professional liability claims</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As a general matter, providers of diagnostic information services may be subject to lawsuits alleging negligence or other similar claims.  These suits could involve claims for substantial damages.  Any professional liability litigation could also have an adverse impact on our client base and reputation.  We maintain various liability insurance coverages for claims that could result from providing, or failing to provide, clinical testing services, including inaccurate testing results, and other exposures.  Our insurance coverage limits our maximum exposure on individual claims; however, we are essentially self-insured for a significant portion of these claims.  While the basis for claims reserves is actuarially determined losses based upon our historical and projected loss experience, the process of analyzing, assessing and establishing reserve estimates relative to these types of claims involves a high degree of judgment.  Although we believe that our present reserves and insurance coverage are sufficient to cover currently estimated exposures, it is possible that we may incur liabilities in excess of our recorded reserves or insurance coverage.  Changes in the facts and circumstances associated with claims could have a material impact on our results of operations (principally costs of services), cash flows and financial condition in the period that reserve estimates are adjusted or paid.  See Note 19 to the audited consolidated financial statements for a discussion of our reserves for general and professional liability claims. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Reserves for other legal proceedings</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our businesses are subject to or impacted by extensive and frequently changing laws and regulations, including inspections and audits by governmental agencies, in the United States (at both the federal and state levels) and the other jurisdictions in which we conduct business.  Although we believe that we are in compliance, in all material respects, with applicable laws and regulations, there can be no assurance that a regulatory agency would not reach a different conclusion.  Any noncompliance by us with applicable laws and regulations could have a material adverse effect on our results of operations.  In addition, these laws and regulations may be interpreted or applied by a prosecutorial, regulatory or judicial authority in a manner that could require us to make changes in our operations, including our pricing and/or billing practices.  In addition, certain federal and state statutes, including the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> provisions of federal and state false claims acts, allow private individuals to bring lawsuits against healthcare companies on behalf of government or private payers alleging inappropriate billing practices.  We are aware of certain pending lawsuits including class action lawsuits, and have received subpoenas related to billing practices.  See Note 19 to the audited consolidated financial statements for a discussion of the various legal proceedings that we are involved in. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The process of analyzing, assessing and establishing reserve estimates relative to legal proceedings involves a high degree of judgment.  Management has established reserves for legal proceedings in accordance with generally accepted accounting principles in the United States.  Changes in facts and circumstances related to such proceedings could lead to significant adjustments to reserve estimates for such matters and could have a material impact on our results of operations, cash flows and financial condition in the period that reserve estimates are adjusted or paid.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Accounting for and recoverability of goodwill</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We do not amortize goodwill, but evaluate the recoverability and measure the potential impairment of our goodwill annually, or more frequently, in the case of other events that indicate a potential impairment.  We identified the following reporting units for goodwill impairment testing in 2022:</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">DIS business;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk assessment services business, which is part of our DS businesses</span></div><div style="padding-left:63pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The DIS reporting unit components have been aggregated into a single reporting unit because they have similar economic characteristics, including similarities in financial performance, nature of products or services, nature of production processes and types of customers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On a quarterly basis, we perform a review of our business to determine if events or changes in circumstances have occurred which could have a material adverse effect on our fair value and our goodwill.  If such events or changes in circumstances were deemed to have occurred, we would perform an impairment test of goodwill and record any noted impairment loss.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The annual impairment test for goodwill includes an option to perform a qualitative assessment of whether it is more likely than not that a reporting unit's fair value is less than its carrying value; the qualitative analysis may be performed prior to, or as an alternative to, performing a quantitative goodwill impairment test.  In evaluating whether it is more likely than not that the fair value of a reporting unit is less than its carrying value, we assess relevant events and circumstances, such as: (a) macroeconomic conditions; (b) industry and market considerations; (c) cost factors; (d) overall financial performance; (e) other relevant entity-specific events; (f) events affecting a reporting unit; and (g) a sustained decrease in share price.  If, after assessing the totality of events or circumstances, we determine that it is more likely than not that the fair value of a reporting unit is less than its carrying value, then we are required to perform the quantitative goodwill impairment test.  Otherwise, no further analysis is required.  Additionally, our policy is to update the fair value calculation of our reporting units and perform the quantitative goodwill impairment test on a periodic basis.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The quantitative impairment test involves the comparison of the fair value of the reporting unit to its carrying value.  If the carrying value is greater than our estimate of fair value, an impairment loss will be recognized in the amount of the excess.   We calculate the fair value of each reporting unit using either (i) a discounted cash flows analysis that converts future cash flow amounts into a single discounted present value amount or (ii) a market approach.  We assess the valuation methodology based upon the relevance and availability of the data at the time we perform the valuation.  The discounted cash flows analysis includes several unobservable inputs related to our own assumptions.  The assumptions and estimates used in the discounted cash flows model are based upon the best available information in the circumstances and include a forecast of expected future cash flows, long-term growth rates, discount rates that are commensurate with economic risks, assumed income tax rates and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">estimates of capital expenditures and working capital.  The fair values of the reporting units could be different if, for example, forecasted revenue growth rates, economic conditions, government regulations or actions by payers to control utilization of or reimbursement for healthcare services, turn out to be different than our assumptions or estimates.  Changes in the assumed discount rates due to changes in interest rates could also affect the estimated fair values of the reporting units.  We use a discount rate that considers a weighted average cost of capital plus an appropriate risk premium based upon the reporting unit being valued.  Our analysis also considers publicly available information regarding our market capitalization, as well as (i) the financial projections and future prospects of our business, including its growth opportunities and likely operational improvements, and (ii) comparable sales prices, if available.  We believe our estimation methods are reasonable and reflect common valuation practices.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We perform our annual impairment test during the fourth quarter of the fiscal year.  For the year ended December&#160;31, 2022, we performed a qualitative assessment for our DIS reporting unit.  Based on the totality of the information available for the DIS reporting unit, we concluded that it was more likely than not that the estimated fair value was greater than the carrying value of the reporting unit, and as such, no further analysis was required.  As a sensitivity, in conjunction with the most recent quantitative test performed for the year ended December 31, 2020, if the estimated fair value of the DIS reporting unit decreased by 10%, we would have still concluded that the goodwill for our DIS reporting unit was not impaired.  For the year ended December&#160;31, 2022, we updated the fair value calculation for our risk assessment reporting unit, performed a quantitative impairment test and concluded that goodwill for the reporting unit was not impaired.  As a sensitivity, if the estimated fair value of the risk assessment reporting unit decreased by 10%, we would have still concluded that the goodwill for the reporting unit was not impaired.</span></div><div><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_136"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">For a comparison of results of operations for the year ended December 31, 2021 compared to December 31, 2020, along with the results of operations for the year ended December 31, 2020, see "Item 7 - Management's Discussion and Analysis of Financial Condition and Result of Operations" of our Annual Report on Form 10-K for the year ended December 31, 2021.  See "Available Information."</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Basis of Presentation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our DIS business currently represents our one reportable business segment.  The DIS business for the years ended December&#160;31, 2022 and 2021 accounted for greater than 95% of our consolidated net revenues.  Our other operating segments consist of our DS businesses.  For further details regarding our business segment information, see Note</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20 to the audited consolidated financial statements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following table sets forth certain results of operations data for the periods presented:&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:57.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(dollars in millions, except per share data)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net revenues:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DIS business</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,609&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,494&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(885)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DS businesses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,883&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,788&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(905)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating costs and expenses and other operating income:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of services</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,450&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,579&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,874&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,727&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expense (income), net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating costs and expenses, net</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,455&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,407&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,428&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,381&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(953)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(40.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:57.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income (expense):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(151)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(424)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-operating (expense) income, net</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(193)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(411)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income tax expense</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(264)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(597)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity in earnings of equity method investees, net of taxes</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to Quest Diagnostics</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,995&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,049)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted earnings per share attributable to Quest Diagnostics&#8217; common stockholders</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.97&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.55&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.58)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NM - Not Meaningful</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following table sets forth certain results of operations data as a percentage of net revenues for the periods presented:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:78.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net revenues:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DIS business</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DS businesses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating costs and expenses and other operating income:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expense (income), net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating costs and expenses, net</span></div></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Operating Results</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Results for the year ended December&#160;31, 2022 were affected by certain items that on a net basis decreased diluted earnings per share by $1.98 as follows:</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pre-tax amortization expense of $120 million recorded in amortization of intangible assets or $0.74 per diluted share;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pre-tax charges of $93 million recorded in selling, general and administrative expenses, or $0.59 per diluted share, representing costs associated with donations, contributions and other financial support through Quest for Health Equity (our initiative with the Quest Diagnostics Foundation to reduce health disparities in underserved communities);</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pre-tax charges of $88 million ($32 million recorded in cost of services and $56 million recorded in selling, general and administrative expenses), or $0.56 per diluted share, primarily associated with workforce reductions, systems conversions and integration incurred in connection with further restructuring and integrating our business; </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pre-tax charges of $42 million ($30 million recorded in other (expense) income, net, and $12 million recorded in equity in earnings of equity method investees), or $0.26 per diluted share, representing net losses associated with changes in the carrying value of our strategic investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.68pt">net pre-tax charges of $13 million ($2 million recorded in cost of services and $11 million recorded in other operating expense (income), net), or $0.09 per diluted share, primarily representing a $14&#160;million impairment charge on certain property, plant and equipment and a $5 million loss associated with the increase in the fair value of the contingent consideration accrual associated with previous acquisitions, partially offset by a $10&#160;million gain from a payroll tax credit under the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") associated with the retention of employees; partially offset by</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an income tax benefit of $18&#160;million, recorded in income tax expense, or $0.14 per diluted share, due to a cumulative adjustment to state deferred tax liabilities related to depreciation expense; and</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">excess tax benefits associated with stock-based compensation arrangements of $14 million, or $0.12 per diluted share, recorded in income tax expense.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the year ended December&#160;31, 2022, diluted earnings per share benefited from the impact of share repurchases, including under accelerated share repurchase agreements ("ASRs") entered into in April 2021 to repurchase $1.5&#160;billion of our common stock, on our weighted average shares outstanding as compared to the prior year.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Results for the year ended December&#160;31, 2021 were affected by certain items that on a net basis increased diluted earnings per share by $1.31 as follows:</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a pre-tax gain recorded in other (expense) income, net of $314&#160;million, or $2.02 per diluted share, on the sale of our 40% ownership interest in Q</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Solutions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("Q</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Solutions"), our clinical trials central laboratory services joint venture, to IQVIA Holdings, Inc. ("IQVIA"), our joint venture partner (see Note 7 to the audited consolidated financial statements);</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a net pre-tax gain of $39 million recorded in other (expense) income, net, or $0.24 per diluted share, primarily due to gains associated with changes in the carrying value of our strategic investments, partially offset by a non-cash impairment charge to the carrying value of an equity method investment; and </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">excess tax benefits associated with stock-based compensation arrangements of $19 million, or $0.14 per diluted share, recorded in income tax expense; partially offset by</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pre-tax amortization expense of $105 million ($103 million recorded in amortization of intangible assets and $2 million recorded in equity in earnings of equity method investees, net of taxes) or $0.62 per diluted share;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.68pt">pre-tax charges of $61 million ($30 million recorded in cost of services and $31 million recorded in selling, general and administrative expenses), or $0.36 per diluted share, primarily associated with systems conversions and integration incurred in connection with further restructuring and integrating our business; </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pre-tax charges of $16 million recorded in selling, general and administrative expenses, or $0.08 per diluted share, primarily due to costs associated with donations, contributions and other financial support through Quest for Health Equity; and</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pre-tax charges of $4 million recorded in cost of services, or $0.03 per diluted share, representing the impact of certain items resulting from the COVID-19 pandemic, including incremental costs incurred to protect the health and safety of our employees and customers.</span></div><div style="padding-left:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Revenues </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Net revenues for the year ended December&#160;31, 2022 decreased by 8.4% compared to the prior year. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;DIS revenues for the year ended December&#160;31, 2022 decreased by 8.4% compared to the prior year.  For the year ended December&#160;31, 2022:  </span></div><div><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The decrease in revenue compared to the prior year was driven by a decrease in COVID-19 testing, partially offset by growth in the base business and the impact of recent acquisitions.  For the year ended December&#160;31, 2022, recent acquisitions contributed approximately 0.8% to DIS revenues.</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">DIS volume decreased by 4.5% compared to the prior year driven by a decrease in COVID-19 testing, partially offset by growth in the base business and the impact of recent acquisitions, which contributed approximately 0.6% to DIS volume.</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Revenue per requisition decreased by 4.5% compared to the prior year driven in large part by the decrease in COVID-19 molecular testing and unit price pressure of approximately 0.5%, partially offset by favorable mix. </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Revenues in the base business (including the impact of recent acquisitions) increased by 5.6% compared to the prior year.  </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Testing volume in the base business (including the impact of recent acquisitions) was up 2.2% compared to the prior year.      </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Revenue per requisition in the base business increased by 3.0% compared to the prior year primarily due to favorable test and payer mix.</span></div><div style="padding-left:72pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;DS revenues for the year ended December&#160;31, 2022 decreased by 7.0% compared to the prior year primarily due to lower revenues associated with our risk assessment services offered to the life insurance industry.</span></div><div style="padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Cost of Services</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Cost of services consists principally of costs for obtaining, transporting and testing specimens as well as facility costs used for the delivery of our services.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Cost of services decreased by $129 million for the year ended December&#160;31, 2022 compared to the prior year.  The decrease was primarily driven by lower supplies and collection expenses associated with reduced COVID-19 testing volumes, partially offset by higher compensation and benefits costs (primarily related to wage increases) and additional costs associated with our acquisitions.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses ("SG&amp;A")</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;SG&amp;A consists principally of the costs associated with our sales and marketing efforts, billing operations, credit loss expense and general management and administrative support, as well as administrative facility costs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;SG&amp;A increased by $147 million for the year ended December&#160;31, 2022, compared to the prior year, primarily driven by additional costs associated with investments in our strategic growth initiatives, costs associated with donations, contributions and other financial support through Quest for Health Equity, and higher compensation and benefits costs (including headcount and wage increases), partially offset by $42&#160;million of lower costs associated with changes in the value of our deferred compensation obligations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The changes in the value of our deferred compensation obligations is largely offset by changes in the value of the associated investments, which are recorded in other (expense) income, net. For further details regarding our deferred compensation plans, see Note 18 to the audited consolidated financial statements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortization of Intangible Assets</span></div><div style="text-indent:29.25pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the year ended December&#160;31, 2022, amortization expense increased by $17&#160;million compared to the prior year primarily due to an adjustment to the useful life of a customer-related intangible asset and, to a lesser extent, the impact of recent acquisitions.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Operating Expense (Income), Net</span></div><div style="text-indent:29.25pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Other operating expense (income), net includes miscellaneous income and expense items and other charges related to operating activities.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the year ended December 31, 2022, other operating expense (income), net includes a $14&#160;million impairment charge on certain property, plant and equipment and a $5 million loss associated with the increase in the fair value of the contingent consideration accrual associated with previous acquisitions, partially offset by a $10&#160;million gain from a payroll tax credit under the CARES Act associated with the retention of employees.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Interest Expense, Net</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net decreased by $13 million for the year ended December&#160;31, 2022 compared to the prior year, primarily due to increased interest income resulting from the impact of rising interest rates on our cash and cash equivalents.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other (Expense) Income, Net</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Other income, net represents miscellaneous income and expense items related to non-operating activities, such as gains and losses associated with investments and other non-operating assets.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the year ended December&#160;31, 2022, other (expense) income, net included $30&#160;million of losses associated with changes in the carrying value of our strategic investments and $25&#160;million of losses associated with investments in our deferred compensation plans.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the year ended December&#160;31, 2021, other (expense) income, net included a $314&#160;million pre-tax gain on the sale of our 40% ownership interest in Q</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Solutions, our clinical trials central laboratory services joint venture, to IQVIA, our joint venture partner (see Note 7 to the audited consolidated financial statements), $39&#160;million in gains associated with changes in the carrying value of our strategic investments, and $17&#160;million in gains associated with investments in our deferred compensation plans.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Expense</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Income tax expense for the years ended December&#160;31, 2022 and 2021 was $264 million and $597 million, respectively.  The decrease in income tax expense compared to the prior year was primarily driven by a decrease in income before income taxes and equity in earnings of equity method investees.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The effective income tax rate for the years ended December&#160;31, 2022 and 2021 was 21.4% and 23.0%, respectively.  The year ended December 31, 2022 includes an $18&#160;million income tax benefit due to a cumulative adjustment to state deferred tax liabilities related to depreciation expense, which impacted the effective income tax rate by 1.5%.  The effective income tax rate for the year ended December&#160;31, 2021 benefited from a lower effective income tax rate, 17.6%, on the gain on the sale of our 40% ownership interest in Q</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Solutions.  In addition, the effective income tax rates benefited from $14 million and $19 million of excess tax benefits associated with stock-based compensation arrangements for the years ended December&#160;31, 2022 and 2021, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity in Earnings of Equity Method Investees, Net of Taxes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the year ended December&#160;31, 2022, there was a $34 million decrease in equity in earnings of equity method investees, net of taxes, compared to the prior year primarily due to $21&#160;million of lower equity earnings in the current year period associated with changes in the carrying value of strategic investments of an equity method investee and lower demand for COVID-19 testing services at our diagnostic information services joint venture, partially offset by a non-cash impairment to the carrying value of an equity method investment of $8&#160;million in the prior year period.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69 </span></div></div></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_139"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="text-indent:29.25pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We address our exposure to market risks, principally the risk of changes in interest rates, through a controlled program of risk management that includes the use of derivative financial instruments.  We do not hold or issue derivative financial instruments for speculative purposes.  We seek to mitigate the variability in cash outflows that result from changes in interest rates by maintaining a balanced mix of fixed-rate and variable-rate debt obligations.  In order to achieve this objective, we have historically entered into interest rate swap agreements.  Interest rate swap agreements involve the periodic exchange of payments without the exchange of underlying principal or notional amounts.  Net settlements are recognized as an adjustment to interest expense, net.  We believe that our exposures to foreign exchange impacts and changes in commodity prices are not material to our consolidated results of operations, financial position or cash flows.  For further details regarding our significant accounting policies on interest rate risk and foreign currency, see Note 2 to the audited consolidated financial statements. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of December&#160;31, 2022 and 2021, the fair value of our debt was estimated at approximately $<ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-8" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xMzkvZnJhZzpjZGQzYWY5YmY0YmY0ZWIwOTEwNWFkOTA2NWMyNTQ3MC90ZXh0cmVnaW9uOmNkZDNhZjliZjRiZjRlYjA5MTA1YWQ5MDY1YzI1NDcwXzEyNzk_2bc3b26c-e382-4a0b-bef0-4ed6237cd75b">3.7</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-8" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xMzkvZnJhZzpjZGQzYWY5YmY0YmY0ZWIwOTEwNWFkOTA2NWMyNTQ3MC90ZXh0cmVnaW9uOmNkZDNhZjliZjRiZjRlYjA5MTA1YWQ5MDY1YzI1NDcwXzEyODY_9bdf270d-3ffc-4bae-b633-93740f8d7ce8">4.4</ix:nonFraction> billion, respectively, principally using quoted prices in active markets and yields for the same or similar types of borrowings, taking into account the underlying terms of the debt instruments.  As of December&#160;31, 2022 and 2021, the estimated fair value (was less than) exceeded the carrying value of the debt by $(318) million and $403&#160;million, respectively.  A hypothetical 10% increase in interest rates (representing 51 basis points as of December&#160;31, 2022 and 23 basis points as of December&#160;31, 2021) would potentially reduce the estimated fair value of our debt by approximately $120&#160;million and $89&#160;million as of December&#160;31, 2022 and 2021, respectively.</span></div><div style="text-indent:29.25pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Borrowings under our secured receivables credit facility and our senior unsecured revolving credit facility are subject to variable interest rates.  Interest on our secured receivables credit facility is based on either commercial paper rates for highly-rated issuers or the Term Secured Overnight Financing Rate ("Term SOFR"), plus a spread.  Interest on our senior unsecured revolving credit facility is based on certain published rates plus an applicable margin based on changes in our public debt ratings. As such, our borrowing cost under this credit arrangement is subject to fluctuations in interest rates and changes in our public debt ratings.  As of December&#160;31, 2022, the borrowing rates under these debt instruments were: for our secured receivables credit facility, commercial paper rates for highly-rated issuers or the Term SOFR, plus a spread of <ix:nonFraction unitRef="number" contextRef="icb3e78d19c4a46b8a67dec2f47339bab_D20220101-20221231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xMzkvZnJhZzpjZGQzYWY5YmY0YmY0ZWIwOTEwNWFkOTA2NWMyNTQ3MC90ZXh0cmVnaW9uOmNkZDNhZjliZjRiZjRlYjA5MTA1YWQ5MDY1YzI1NDcwXzU0OTc1NTgyMTg3Mw_9d68e870-1bbd-4dc2-ab20-244ae1b75149">0.725</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i56456ee32fec497ca7d092cc9d8721eb_D20220101-20221231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xMzkvZnJhZzpjZGQzYWY5YmY0YmY0ZWIwOTEwNWFkOTA2NWMyNTQ3MC90ZXh0cmVnaW9uOmNkZDNhZjliZjRiZjRlYjA5MTA1YWQ5MDY1YzI1NDcwXzU0OTc1NTgyMTg4MQ_d6ba1c2c-bfa2-4cbd-bfd7-ff2d4fa62b82">0.80</ix:nonFraction>%; and for our senior unsecured revolving credit facility, London Interbank Offered Rate ("LIBOR"), plus <ix:nonFraction unitRef="number" contextRef="iec0fa8127aa846ccb173e5c0dac001e5_D20220101-20221231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xMzkvZnJhZzpjZGQzYWY5YmY0YmY0ZWIwOTEwNWFkOTA2NWMyNTQ3MC90ZXh0cmVnaW9uOmNkZDNhZjliZjRiZjRlYjA5MTA1YWQ5MDY1YzI1NDcwXzI3MzY_8c5d2d00-c19d-48ec-b417-afdbfd124f59">1.00</ix:nonFraction>%.  As of December&#160;31, 2022, there were no borrowings outstanding under either our $<ix:nonFraction unitRef="usd" contextRef="iddbc623b9422462099ee73f0b8dd8181_I20221021" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xMzkvZnJhZzpjZGQzYWY5YmY0YmY0ZWIwOTEwNWFkOTA2NWMyNTQ3MC90ZXh0cmVnaW9uOmNkZDNhZjliZjRiZjRlYjA5MTA1YWQ5MDY1YzI1NDcwXzI4MDU_c0286930-2613-4925-b9ff-937a812ab798">525</ix:nonFraction>&#160;million secured receivables credit facility or our $750&#160;million senior unsecured revolving credit facility. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;A hypothetical 10% change to the variable rate component of our variable rate indebtedness would not materially change our annual interest expense. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For further details regarding our outstanding debt and our financial instruments and hedging activities, see Notes 14 and 16, respectively, to the audited consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risk Associated with Investment Portfolio</span></div><div style="text-indent:29.25pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our investment portfolio primarily includes equity investments comprised mostly of strategic holdings in companies concentrated in the life sciences and healthcare industries.  Equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) with readily determinable fair values are measured at fair value in prepaid expenses and other current assets in our consolidated balance sheet with changes in fair value recorded in current earnings in our consolidated statement of operations.  Equity investments that do not have readily determinable fair values (which consist of investments in preferred and common shares of private companies) are measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We regularly evaluate equity investments that do not have readily determinable fair values to determine if there are any indicators that the investments are impaired.  The carrying value of our equity investments that do not have readily determinable fair values was $4&#160;million as of December&#160;31, 2022.  In conjunction with the preparation of our audited consolidated financial statements for the year ended December&#160;31, 2022, we considered whether the carrying values of our investments were impaired and concluded that no such impairment existed.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We do not hedge our equity price risk.  The impact of an adverse movement in equity prices on our holdings in privately held companies cannot be easily quantified, as our ability to realize returns on investments depends on, among other things, the enterprises&#8217; ability to raise additional capital or derive cash inflows from continuing operations or through liquidity events such as initial public offerings, mergers or private sales.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70 </span></div></div></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_142"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,718&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,233&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(515)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(543)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(564)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,732)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,540)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net change in cash and cash equivalents and restricted cash</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(557)</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(286)</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(271)</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="text-indent:29.25pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Cash and cash equivalents consist of cash and highly-liquid short-term investments.  Cash and cash equivalents as of December&#160;31, 2022 and 2021 totaled $315 million and $872 million, respectively.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of December&#160;31, 2022, approximately 10% of our $315 million of consolidated cash and cash equivalents were held outside of the United States.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Operating Activities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Net cash provided by operating activities for the year ended December&#160;31, 2022 was $1,718 million, and decreased $515 million compared to the prior year primarily as a result of:</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lower operating income in 2022 as compared to 2021; partially offset by </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a $426 million decrease in income tax payments in 2022 as compared to 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Days sales outstanding ("DSO"), a measure of billing and collection efficiency, was 47 days as of December&#160;31, 2022 and 48 days as of December&#160;31, 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Investing Activities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Net cash used in investing activities for the year ended December&#160;31, 2022 was $543 million, compared to net cash provided by investing activities of $21 million for the year ended December&#160;31, 2021.  This $564 million change in cash (used in) provided by investing activities was primarily a result of $755 million of net cash proceeds received in 2021 from the sale of our 40% ownership interest in Q</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Solutions, partially offset by a $187 million decrease in net cash paid for acquisitions.</span></div><div style="padding-left:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Financing Activities </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Net cash used in financing activities for the year ended December&#160;31, 2022 was $1,732 million, compared to $2,540 million for the year ended December&#160;31, 2021.  This $808 million decrease in cash used in financing activities was primarily a result of:</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a $791 million decrease in repurchases of our common stock (see "Share Repurchases" for further details); and, to a lesser extent,</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a $26 million decrease in distributions to noncontrolling interest partners.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the years ended December&#160;31, 2022 and 2021, there were no borrowings or repayments under our secured receivables credit facility or our senior unsecured revolving credit facility.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For details regarding our debt and related transactions, see Note 14 to the audited consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividend Program</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During each of the four quarters of 2022, our Board of Directors declared a quarterly cash dividend of $0.66 per common share.  During each of the four quarters of 2021, our Board of Directors declared a quarterly cash dividend of $0.62 per common share.  In February 2023, we announced that our Board of Directors authorized a 7.6% increase in our quarterly cash dividend from $0.66 to $0.71 per share, or $2.84 per share annually, commencing with the dividend payable in April 2023.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In February 2022, our Board of Directors increased the size of our share repurchase program by $1&#160;billion.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of December&#160;31, 2022, $0.3 billion remained available under our share repurchase authorization.  In February 2023, we announced that our Board of Directors authorized us to repurchase an additional $1&#160;billion of our common stock.  The share repurchase authorization has no set expiration or termination date. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the year ended December&#160;31, 2022, we repurchased 10.1 million shares of our common stock for $1.4 billion.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the year ended December&#160;31, 2021, we repurchased 16.0 million shares of our common stock for $2.2 billion, including 10.7 million shares repurchased under ASRs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For further details regarding our share repurchases, see Note 17 to the audited consolidated financial statements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations and Commitments</span></div><div style="text-align:center;text-indent:29.25pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160; A description of the terms of our indebtedness and related debt service requirements is contained in Note 14 to the audited consolidated financial statements.</span></div><div style="text-indent:29.25pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;A discussion of our lease obligations is contained in Note 15 to the audited consolidated financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;A discussion of our noncancellable commitments to purchase products or services is contained in Note 19 to the audited consolidated financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Method Investees</span></div><div style="text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our equity method investees primarily consist of a diagnostic information services joint venture and an investment in a fund that purchases strategic holdings in private companies in the healthcare industry.  Such investees are accounted for under the equity method of accounting.  Our investment in equity method investees is less than 5% of our consolidated total assets.  Our proportionate share of income before income taxes associated with our equity method investees is less than 5% of our consolidated income before income taxes and equity in earnings of equity method investees.  We have no material unconditional obligations or guarantees to, or in support of, our equity method investees and their operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In conjunction with the preparation of our audited consolidated financial statements for the year ended December&#160;31, 2022, we considered whether the carrying values of our equity method investments were impaired and concluded that no such impairment existed.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Requirements and Capital Resources</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We estimate that we will invest approximately $400 million during 2023 for capital expenditures to support and grow our existing operations, principally related to investments in laboratory equipment and facilities, including laboratory automations and information technology to support our diagnostic offerings.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of December&#160;31, 2022, we had $1.2&#160;billion of borrowing capacity available under our existing credit facilities, including $455&#160;million available under our secured receivables credit facility and $750&#160;million available under our senior unsecured revolving credit facility.  There were no borrowings under these credit facilities as of December&#160;31, 2022. In support of our risk management program, $70 million in letters of credit under the secured receivables credit facility were outstanding as of December&#160;31, 2022.  During October 2022, we amended our secured receivables credit facility and decreased the aggregate borrowing capacity under the secured receivables credit facility to $525&#160;million.  The amended secured receivables credit facility includes a $425&#160;million loan commitment, half of which matures in October 2023 and half of which matures in October 2024.  Additionally, the amended secured receivables credit facility includes a $100&#160;million letter of credit facility which matures in October 2024.  The senior unsecured revolving credit facility matures in November 2026. For further details regarding our credit facilities, see Note 14 to the audited consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our secured receivables credit facility is subject to customary affirmative and negative covenants, and certain financial covenants with respect to the receivables that comprise the borrowing base and secure the borrowings under the facility. Our senior unsecured revolving credit facility is also subject to certain financial covenants and limitations on indebtedness.  As of December&#160;31, 2022, we were in compliance with all such applicable financial covenants.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have assessed the impact of the cessation of LIBOR and have identified and evaluated financial instruments and other contracts that refer to LIBOR. Our underlying exposure to LIBOR includes our senior unsecured revolving credit facility (see discussion above) under which we had no outstanding borrowings as of December&#160;31, 2022.  We expect to be able to transition all LIBOR based instruments and contracts to an alternative reference rate on or before the cessation of LIBOR and we do not believe that the cessation of LIBOR, or its replacement with an alternative reference rate or rates, will have a material impact on us.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We believe that our cash and cash equivalents and cash from operations, together with our borrowing capacity under our credit facilities, will provide sufficient financial flexibility to fund seasonal and other working capital requirements, capital expenditures, debt service requirements and other obligations, cash dividends on common shares, share repurchases and additional growth opportunities for the foreseeable future.  However, should it become necessary, we believe that our credit profile should provide us with access to additional financing in order to fund normal business operations, make interest payments, fund growth opportunities and satisfy upcoming debt maturities.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_145"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of New Accounting Standards</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#160;&#160;&#160;&#160;The adoption of new accounting standards (if any) is discussed in Note 2 to the audited consolidated financial statements.&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The impacts of recent accounting pronouncements not yet effective (if any) on our audited consolidated financial statements are discussed in Note 2 to the audited consolidated financial statements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73 </span></div></div></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_148"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF MANAGEMENT ON INTERNAL CONTROL OVER FINANCIAL REPORTING</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The management of the Company, including its Chief Executive Officer and Chief Financial Officer, is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended.  Management assessed the effectiveness of the Company's internal control over financial reporting as of December&#160;31, 2022 based on criteria for effective internal control over financial reporting described in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Internal Control - Integrated Framework (2013)&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission.  Based on this assessment, management has determined that the Company's internal control over financial reporting as of December&#160;31, 2022 is effective.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America.  Internal control over financial reporting includes policies and procedures that: (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with accounting principles generally accepted in the United States of America, and that receipts and expenditures of the Company are being made only in accordance with authorization of management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of assets that could have a material effect on the consolidated financial statements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.  Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;PricewaterhouseCoopers LLP, the independent registered public accounting firm that audited the financial statements included in this annual report, audited the Company's internal control over financial reporting as of December&#160;31, 2022 and issued their audit report on the Company's internal control over financial reporting included herein. </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74 </span></div></div></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_151"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and Stockholders of Quest Diagnostics Incorporated</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Opinions on the Financial Statements and Internal Control over Financial Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have audited the accompanying consolidated balance sheets of Quest Diagnostics Incorporated and its subsidiaries</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(the &#8220;Company&#8221;) as of December 31, 2022 and 2021,</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and the related consolidated</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">statements of operations, comprehensive income, stockholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2022, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We also have audited the Company's internal control over financial reporting as of December 31, 2022, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Internal Control - Integrated Framework</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(2013)</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on criteria established in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> Internal Control - Integrated Framework </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(2013) issued by the COSO.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis for Opinions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Report of Management on Internal Control Over Financial Reporting. Our responsibility is to express opinions on the Company&#8217;s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our audits of the  consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of Diagnostic Information Services (DIS) Business Accounts Receivable - Contractual Allowances</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 3 to the consolidated financial statements, management estimates the amount of consideration it expects to be entitled to receive from customer groups in exchange for providing services using the portfolio approach. These estimates include the impact of contractual allowances (including payer denials) and patient price concessions. The portfolio approach includes the following groups of customers: healthcare insurers, government payers, client payers and patients (28%, 6%, 44% and 18% of consolidated net accounts receivable as of December 31, 2022, respectively, as disclosed by management). The DIS business accounted for 96% of consolidated net accounts receivable ($1,195 million) as of December 31, 2022. Net revenues and accounts receivable recognized from healthcare insurers and government payers consist of amounts billed net of contractual allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payers, which considers historical denial and collection experience and, additionally for healthcare insurers, the terms of the Company&#8217;s contractual arrangements. As disclosed by management, the process for estimating revenues and the ultimate collection of receivables associated with the DIS business involves significant assumptions and judgments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal considerations for our determination that performing procedures relating to the valuation of DIS business accounts receivable - contractual allowances is a critical audit matter are the estimate of net collectible accounts receivable, specifically contractual allowances, involves significant judgment and estimation on the part of management; this in turn led to significant auditor judgment, subjectivity and effort in performing procedures to evaluate the audit evidence related to the contractual allowances. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to the valuation of DIS business accounts receivable, which included controls over management&#8217;s methodology and data used to estimate contractual allowances. These procedures also included, among others, testing management's process for developing the estimate for contractual allowances, including (i) evaluating the appropriateness of the methodology, (ii) testing the completeness and accuracy of the historical contractual allowance and collection data from the Company&#8217;s billing system, which is an input to the methodology, and (iii) evaluating the reasonableness of management&#8217;s assumptions used to estimate contractual allowances by comparing actual cash collected to the prior year estimate (net accounts receivable). </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:34.064%"><tr><td style="width:1.0%"></td><td style="width:13.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.737%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTEvZnJhZzpiYzJlOTdkYzAxOWY0MmUyOGMwZmQ0YmM5NmE1M2Y1Ni90YWJsZTpjMWEwYWY5YjFkZWI0ODA4ODEyZWI5NDllOTVkYTQwYi90YWJsZXJhbmdlOmMxYTBhZjliMWRlYjQ4MDg4MTJlYjk0OWU5NWRhNDBiXzAtMS0xLTEtNzgyMTU_111e0d85-f858-4afb-9319-543c6d3aff81">PricewaterhouseCoopers LLP</ix:nonNumeric></span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTEvZnJhZzpiYzJlOTdkYzAxOWY0MmUyOGMwZmQ0YmM5NmE1M2Y1Ni90YWJsZTpjMWEwYWY5YjFkZWI0ODA4ODEyZWI5NDllOTVkYTQwYi90YWJsZXJhbmdlOmMxYTBhZjliMWRlYjQ4MDg4MTJlYjk0OWU5NWRhNDBiXzItMS0xLTEtNzgyMTU_227518e1-1223-403c-a849-eba35b35324a">Florham Park, New Jersey</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 21, 2023</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 1995.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_154"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DECEMBER&#160;31, 2022 AND 2021 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions, except per share data)</span></div></div><div style="text-align:center"><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_157"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzMtMS0xLTEtNzgyMTU_d44d30f3-7f12-43e8-ba0d-ddfa8c9a7a01">315</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzMtMy0xLTEtNzgyMTU_4ba70290-7550-44fc-9df6-2fc95a5b1097">872</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net of allowance for credit losses of $<ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzQtMC0xLTEtNzgyMTUvdGV4dHJlZ2lvbjphNWQ4MmMwYzE3Zjk0YWQwYmFhNmQ1ZTJhN2ZmMWVjYl82NA_6b4b212f-9c0f-453b-9a0b-49cc5844852a">30</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzQtMC0xLTEtNzgyMTUvdGV4dHJlZ2lvbjphNWQ4MmMwYzE3Zjk0YWQwYmFhNmQ1ZTJhN2ZmMWVjYl83MQ_dcc85d5f-5b36-4ad8-a8ac-03370711b610">31</ix:nonFraction> as of December&#160;31, 2022 and 2021, respectively</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzQtMS0xLTEtNzgyMTU_02ac65d8-3cf5-4d6b-b594-df120f53acfc">1,195</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzQtMy0xLTEtNzgyMTU_f55b9f7e-3dc5-4451-9ace-1e3a428eb084">1,438</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzUtMS0xLTEtNzgyMTU_db9cf3eb-2b71-486b-abbb-8a776512f31b">192</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzUtMy0xLTEtNzgyMTU_d5a29e58-fbc2-4815-958d-48e9d01cc5f8">208</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzYtMS0xLTEtNzgyMTU_48ca8822-1884-4ae9-92e2-1fa7c745c1f7">196</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzYtMy0xLTEtNzgyMTU_303bc50f-8b50-411d-be46-826c0b3be023">223</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzgtMS0xLTEtNzgyMTU_4c6642ca-4dce-4e25-81f9-4084a9eab3a4">1,898</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzgtMy0xLTEtNzgyMTU_486eea32-f9b7-46d5-a7ea-f5afdcf8f63e">2,741</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzktMS0xLTEtNzgyMTU_4f2be92f-f923-440a-8f88-5fee867306c4">1,766</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzktMy0xLTEtNzgyMTU_3934127b-21ce-4e16-bd57-1e15c9fc441e">1,707</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzEwLTEtMS0xLTc4MjE1_2a23607f-5be3-47e1-9cae-bca10fc2296d">585</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzEwLTMtMS0xLTc4MjE1_cb359a95-9e69-4431-88d0-090d0e0bf8a8">597</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzExLTEtMS0xLTc4MjE1_6ad963f7-ddcf-4e08-bfc1-7046d4d32533">7,220</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzExLTMtMS0xLTc4MjE1_0f232e8e-8817-4043-8b6b-dd897e0e704a">7,095</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzEyLTEtMS0xLTc4MjE1_69a14998-ecdd-4a4c-905e-175c5e480826">1,092</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzEyLTMtMS0xLTc4MjE1_fb3070fa-6419-40af-8149-b23862ffe7ed">1,167</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investments in equity method investees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzEzLTEtMS0xLTc4MjE1_3f2e0f2a-5a70-4b48-8ffe-32d0d9f74709">132</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzEzLTMtMS0xLTc4MjE1_ac73b6f4-cef9-41c1-845c-57bc0fabdfca">141</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzE0LTEtMS0xLTc4MjE1_5bd68357-20e6-4c53-b305-69e5c65ec49c">144</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzE0LTMtMS0xLTc4MjE1_c09eba8d-26f0-4b5e-82df-a8f0763b3fbd">163</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzE2LTEtMS0xLTc4MjE1_4b84a61d-cf27-4d4b-baaa-a67c183e444a">12,837</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzE2LTMtMS0xLTc4MjE1_70e93a04-f780-4cad-929d-8fe6c779483c">13,611</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzIwLTEtMS0xLTc4MjE1_4dcc085d-dbee-4123-94dd-ced950550f8d">1,396</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzIwLTMtMS0xLTc4MjE1_173ca221-4d64-4a01-b049-570e57593d06">1,600</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzIxLTEtMS0xLTc4MjE1_5f49b4b6-9c69-45cf-a195-cdf1fe6f0d80">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzIxLTMtMS0xLTc4MjE1_af45c9a6-ea43-4003-b788-8a492ef8e7f1">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term operating lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzIyLTEtMS0xLTc4MjE1_a3d89de6-36cf-40a1-9c93-6d6c0d00227a">153</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzIyLTMtMS0xLTc4MjE1_8cf94bb0-81a8-4478-b077-1ecd3298d268">151</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzIzLTEtMS0xLTc4MjE1_e5da209b-f017-4be1-ab7e-efbf99b8c0d6">1,551</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzIzLTMtMS0xLTc4MjE1_12984ae9-9ed7-4881-aa43-970957ed62fb">1,753</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzI0LTEtMS0xLTc4MjE1_4422fb2b-2593-4cbe-b6bc-0a664e2498fc">3,978</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzI0LTMtMS0xLTc4MjE1_1837d8db-0eac-4240-bd15-3a149de33ebf">4,010</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzI1LTEtMS0xLTc4MjE1_6432681c-e191-457e-bce8-501f8ce635a0">489</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzI1LTMtMS0xLTc4MjE1_00012651-b80e-4dd7-b499-134880ebf476">494</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzI2LTEtMS0xLTc4MjE1_7cd7d49d-cfff-4393-8f81-08add98f3085">812</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzI2LTMtMS0xLTc4MjE1_2fb07fc7-7c5b-4dea-8c81-85ada096c758">792</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzI4LTEtMS0xLTc4MjE1_d3dad885-6fbd-406a-be6a-d036cc7298de"></ix:nonFraction></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzI4LTMtMS0xLTc4MjE1_48d9dc67-752c-48d4-8bfe-968ad5f31b04"></ix:nonFraction></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redeemable noncontrolling interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzI5LTEtMS0xLTc4MjE1_eb3f1175-a5a5-4f16-8e16-ace03c4abf69">77</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzI5LTMtMS0xLTc4MjE1_0aebb405-8cb4-4908-afb6-5854b9af29ef">79</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quest Diagnostics stockholders&#8217; equity:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzMyLTAtMS0xLTc4MjE1L3RleHRyZWdpb246NWI2ZGQ4ZjNjZTNkNGQ5ZDkyZGY4ZmY0MWFjMDNiNWRfMjg_82793bdf-7bc9-4a91-aed3-a5a1011c7214"><ix:nonFraction unitRef="usdPerShare" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzMyLTAtMS0xLTc4MjE1L3RleHRyZWdpb246NWI2ZGQ4ZjNjZTNkNGQ5ZDkyZGY4ZmY0MWFjMDNiNWRfMjg_f4a71998-71c6-4557-a7c5-ae6a28fd6e2b">0.01</ix:nonFraction></ix:nonFraction> per share; <ix:nonFraction unitRef="shares" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzMyLTAtMS0xLTc4MjE1L3RleHRyZWdpb246NWI2ZGQ4ZjNjZTNkNGQ5ZDkyZGY4ZmY0MWFjMDNiNWRfNDI_09105e3b-1455-4ab8-ad01-71ee3d9c32a9"><ix:nonFraction unitRef="shares" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzMyLTAtMS0xLTc4MjE1L3RleHRyZWdpb246NWI2ZGQ4ZjNjZTNkNGQ5ZDkyZGY4ZmY0MWFjMDNiNWRfNDI_9e793718-382f-46a0-8e76-a0c7e767821f">600</ix:nonFraction></ix:nonFraction> shares authorized as of both December&#160;31, 2022 and 2021; <ix:nonFraction unitRef="shares" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzMyLTAtMS0xLTc4MjE1L3RleHRyZWdpb246NWI2ZGQ4ZjNjZTNkNGQ5ZDkyZGY4ZmY0MWFjMDNiNWRfMTA5_516fd8b7-3b26-4db5-b104-7da491f12012">162</ix:nonFraction> shares issued as of both December&#160;31, 2022 and 2021</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzMyLTEtMS0xLTc4MjE1_10de332d-65a4-402c-8357-9669929ffe08">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzMyLTMtMS0xLTc4MjE1_95536f01-5843-4b3e-8d95-fe91d0950492">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzMzLTEtMS0xLTc4MjE1_b584e495-6b10-4c79-9407-6663c21ed130">2,295</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzMzLTMtMS0xLTc4MjE1_7442a6d8-0b6c-46b3-865a-7680d8fa779c">2,260</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzM0LTEtMS0xLTc4MjE1_320dbf79-95aa-47fe-86ae-6d3929809441">8,290</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzM0LTMtMS0xLTc4MjE1_c3fbb909-7d89-47c4-b838-978f112c7f4c">7,649</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzM1LTEtMS0xLTc4MjE1_7add56e3-e204-44ef-a880-e6121f5dda1c">21</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzM1LTMtMS0xLTc4MjE1_cd937d83-662c-4160-8464-1745f2ebe0e3">14</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock, at cost; <ix:nonFraction unitRef="shares" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzM2LTAtMS0xLTc4MjE1L3RleHRyZWdpb246NjhmMDY4ZjA3MDg1NGQ1ZmJkNThjZDY4NWVlYzRhZDNfMjk_97fb7526-2fd6-47a2-8db5-96f63b8ecb4f">51</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzM2LTAtMS0xLTc4MjE1L3RleHRyZWdpb246NjhmMDY4ZjA3MDg1NGQ1ZmJkNThjZDY4NWVlYzRhZDNfMzY_0aadbbdc-2d3c-472e-9ba7-4637f9582b3f">43</ix:nonFraction> shares as of December&#160;31, 2022 and 2021, respectively</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzM2LTEtMS0xLTc4MjE1_5573647b-8a67-4bef-878b-c3f509622b2d">4,673</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzM2LTMtMS0xLTc4MjE1_d0a944bb-9c50-4c9d-be35-66d728f99739">3,453</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Quest Diagnostics stockholders&#8217; equity</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzM3LTEtMS0xLTc4MjE1_739ef55d-dfaa-4f50-a283-c56079ce1e50">5,893</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzM3LTMtMS0xLTc4MjE1_9ebd8697-77c2-4ce0-8b47-b2de33b7f255">6,444</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzM4LTEtMS0xLTc4MjE1_66bbd0dd-1570-4df3-a308-4dab0dece8b3">37</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzM4LTMtMS0xLTc4MjE1_e1700b7f-11d7-4081-86f6-ba226bc1e6d3">39</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzM5LTEtMS0xLTc4MjE1_28d0504a-aa59-4aa1-b610-6c815a38382f">5,930</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzM5LTMtMS0xLTc4MjE1_b7333bfc-3cc0-4584-a90e-fa48e5d9d2a8">6,483</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzQwLTEtMS0xLTc4MjE1_655cabc0-d0cc-4278-ad14-8afc0d50508a">12,837</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzQwLTMtMS0xLTc4MjE1_c9b26607-3081-4869-8880-92f71c965c1b">13,611</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_160"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER&#160;31, 2022, 2021 AND 2020 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions, except per share data)</span></div></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.003%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.615%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net revenues</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzItMS0xLTEtNzgyMTU_efe8c69a-1447-48f9-843d-1aa2636890fd">9,883</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzItMy0xLTEtNzgyMTU_91c407c7-6e63-47b0-ad58-fa5bfac4985b">10,788</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzItNS0xLTEtNzgyMTU_54618871-584a-4fe1-82dd-f851ee2f2e06">9,437</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating costs and expenses and other operating income:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzUtMS0xLTEtNzgyMTU_8620b7c1-24cd-4eaf-b350-ddb07a240e59">6,450</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzUtMy0xLTEtNzgyMTU_a96f69df-178c-4a44-a1dd-c386162dcb8b">6,579</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzUtNS0xLTEtNzgyMTU_6150efae-ee34-4da9-931e-d0b736c9f67e">5,804</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzYtMS0xLTEtNzgyMTU_a4d44fe9-4ecb-42a4-b19b-06d29d9898fb">1,874</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzYtMy0xLTEtNzgyMTU_fb23e626-ab37-4205-9dc5-c4343d6042b1">1,727</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzYtNS0xLTEtNzgyMTU_ce5fbf3c-9a2e-4a82-810c-1eab455b1807">1,550</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzctMS0xLTEtNzgyMTU_e2fd5e9d-c40a-45ce-85b1-263a08026e06">120</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzctMy0xLTEtNzgyMTU_b824a99b-8850-4f0a-8a09-ea28e2ff3266">103</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzctNS0xLTEtNzgyMTU_91d5387f-8ade-4fcb-b60c-c939a42ba426">103</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expense (income), net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzgtMS0xLTEtNzgyMTU_22b7c066-00bb-412d-a1e4-409ce0d82207">11</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzgtMy0xLTEtNzgyMTU_da6a0a9f-182b-4afe-98db-56a6b6ef0327">2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzgtNS0xLTEtNzgyMTU_722d3721-e783-4e47-ba59-8b3b328fc1dd">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating costs and expenses, net</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzktMS0xLTEtNzgyMTU_3101c8d1-4496-492d-85cf-8957ef878227">8,455</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzktMy0xLTEtNzgyMTU_8e38ad44-3344-424a-9229-d1a13491accd">8,407</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzktNS0xLTEtNzgyMTU_7b90a2f7-5f7c-4ead-9140-747b60f4ee8c">7,466</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzExLTEtMS0xLTc4MjE1_a396dd97-b9e0-4098-8221-d3cb487403d9">1,428</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzExLTMtMS0xLTc4MjE1_9a3bca9f-e53e-4a19-9d4c-896de72c5d12">2,381</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzExLTUtMS0xLTc4MjE1_e1e59cb2-caf7-4a1b-83cf-716f561d8d04">1,971</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income (expense):</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:InterestIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzE0LTEtMS0xLTc4MjE1_2484c687-6c6e-41d1-bdb7-51f05bae697a">138</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:InterestIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzE0LTMtMS0xLTc4MjE1_94b3e03a-fbf5-434c-8690-27d742942b93">151</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:InterestIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzE0LTUtMS0xLTc4MjE1_69b448b3-926a-44f9-b6ab-1d35e831bf94">163</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzE1LTEtMS0xLTc4MjE1_569f10c8-c009-43fd-9ebe-01728aa2d7b5">55</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzE1LTMtMS0xLTc4MjE1_3f3ce883-02db-4662-9ec7-a2e93333f45a">369</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzE1LTUtMS0xLTc4MjE1_3fc93c78-4ffa-4752-9ca0-59dbf666ca08">76</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-operating (expense) income, net</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzE2LTEtMS0xLTc4MjE1_762e50aa-5e91-46b5-8d8c-f90c9c5d7bbf">193</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzE2LTMtMS0xLTc4MjE1_829ce789-86b1-42a2-8508-509d2164afa0">218</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzE2LTUtMS0xLTc4MjE1_1d9cb710-c878-4bdf-866d-3612f7d8b954">87</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before income taxes and equity in earnings of equity method investees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzE4LTEtMS0xLTc4MjE1_f1d66541-6b7c-4a5d-8b95-44b567947104">1,235</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzE4LTMtMS0xLTc4MjE1_2a2c7185-f222-47c7-9fb3-c89596ba2d11">2,599</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzE4LTUtMS0xLTc4MjE1_2e662f83-1696-45b8-a545-054a5b07060c">1,884</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income tax expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzE5LTEtMS0xLTc4MjE1_d1fed1b9-9f1c-46a1-94f2-8f1fb0030980">264</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzE5LTMtMS0xLTc4MjE1_30c470a1-4439-4ba8-983f-275f9dbc402a">597</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzE5LTUtMS0xLTc4MjE1_5af5097d-f91b-4173-8fe9-b8576fe99f5b">460</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity in earnings of equity method investees, net of taxes</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzIwLTEtMS0xLTc4MjE1_62327402-df7b-4e5b-b138-68dad07e93a1">44</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzIwLTMtMS0xLTc4MjE1_94d14ea2-60d9-49a9-9784-463a6182044b">78</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzIwLTUtMS0xLTc4MjE1_aeb36c21-d39a-408a-b66f-9677a2fd4ff4">75</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzI1LTEtMS0xLTc4MjE1_a14360b7-f42e-4bf5-9563-f371ae9455db">1,015</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzI1LTMtMS0xLTc4MjE1_31f29a98-a921-4f98-ab22-39f78bb9d52e">2,080</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzI1LTUtMS0xLTc4MjE1_ecf66436-59b1-48ab-af3b-9aed111909e6">1,499</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less: Net income attributable to noncontrolling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzI2LTEtMS0xLTc4MjE1_437619ce-8e8f-40a8-be51-8226bb3f9783">69</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzI2LTMtMS0xLTc4MjE1_42927960-86e6-496b-9d20-bc5ed521fb06">85</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzI2LTUtMS0xLTc4MjE1_fec8336a-9098-4e10-bfba-31a2dce5cf80">68</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to Quest Diagnostics</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzI3LTEtMS0xLTc4MjE1_266fbf2f-805c-4d79-bdcb-89d29da2625e">946</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzI3LTMtMS0xLTc4MjE1_da3aa183-af1b-4e86-bae8-96892871a86c">1,995</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzI3LTUtMS0xLTc4MjE1_cda909b7-3f63-47a0-ae2f-c91755d7ac18">1,431</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings per share attributable to Quest Diagnostics&#8217; common stockholders:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzM1LTEtMS0xLTc4MjE1_1217a075-4845-4761-82d9-18973d17e30d">8.10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzM1LTMtMS0xLTc4MjE1_7842517a-4c4a-46ef-aa35-f3a8ab523c43">15.85</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzM1LTUtMS0xLTc4MjE1_450a1225-bbfa-4047-a130-804a63759f28">10.62</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzQwLTEtMS0xLTc4MjE1_3908523d-46cb-4184-bc7d-4257c2fd183b">7.97</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzQwLTMtMS0xLTc4MjE1_1de0acf7-a9ee-437f-a674-775da169bd4a">15.55</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzQwLTUtMS0xLTc4MjE1_612983cc-cc57-408f-ba9d-eb29276a0254">10.47</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_163"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER&#160;31, 2022, 2021 AND 2020 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions)</span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzItMS0xLTEtNzgyMTU_a14360b7-f42e-4bf5-9563-f371ae9455db">1,015</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzItMy0xLTEtNzgyMTU_107bfa50-dc1e-4f9c-9e89-e4b232c2d7ce">2,080</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzItNS0xLTEtNzgyMTU_de454d06-b23f-4020-a7b6-51c9c0bb782f">1,499</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzUtMS0xLTEtNzgyMTU_f5a6ded0-a4db-44e6-822f-261e66bb8bef">8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzUtMy0xLTEtNzgyMTU_46bb6296-3bbb-496a-8415-5ca8a7217193">13</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzUtNS0xLTEtNzgyMTU_f46eb879-6fec-42b6-ad8f-b2fb4d5567f4">15</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in available-for-sale debt securities, net of taxes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzYtMS0xLTEtNzgyMTU_83936c06-2a09-4c9a-8938-9958708b4376">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzYtMy0xLTEtNzgyMTU_381e7ab3-8554-496a-9e3e-b4a71d9a93c2">7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzYtNS0xLTEtNzgyMTU_1699cabc-0d8e-4230-bf70-3d3f508b4a32">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred gain on cash flow hedges, net of taxes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzctMS0xLTEtNzgyMTU_bced750f-cd49-4d6d-9124-ccdb86279437">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzctMy0xLTEtNzgyMTU_75d5ef97-ab42-427c-ae61-193483252db8">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzctNS0xLTEtNzgyMTU_bc705f09-f3ff-4df1-892e-a37856ce6d1f">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzktMS0xLTEtNzgyMTU_41cf06a9-bbc8-4683-9fc0-8d4360925adc">7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzktMy0xLTEtNzgyMTU_ad545ae2-5a14-493b-8429-0ceb7c98386e">7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzktNS0xLTEtNzgyMTU_1df25a9d-7d83-4481-8d2c-3f556ceb9d59">18</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzExLTEtMS0xLTc4MjE1_6046e592-2ec9-4630-9e9c-1eccad4e5d90">1,008</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzExLTMtMS0xLTc4MjE1_dcd7b681-2702-47eb-a59b-abd3abc24403">2,087</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzExLTUtMS0xLTc4MjE1_64256c53-66c0-46e0-828d-72d703108975">1,517</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less: Comprehensive income attributable to noncontrolling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzEyLTEtMS0xLTc4MjE1_53e3aa4e-7cc3-4328-83b7-f79d9540a6ea">69</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzEyLTMtMS0xLTc4MjE1_6b7e651b-d1ee-4b2d-8d7f-f6272fc918c6">85</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzEyLTUtMS0xLTc4MjE1_93cdbba2-7014-492a-8c0b-8ee473fd5c12">68</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive income attributable to Quest Diagnostics</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzEzLTEtMS0xLTc4MjE1_84d8f353-8d63-4f2b-9e9d-9d4df8c7e5dd">939</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzEzLTMtMS0xLTc4MjE1_83ff8fac-a670-43b5-b528-66525e247d10">2,002</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzEzLTUtMS0xLTc4MjE1_5980f48e-1f00-4d1b-9658-f64dcc72cdc5">1,449</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_166"></div><hr style="page-break-after:always"/><div style="min-height:67.32pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER&#160;31, 2022, 2021 AND 2020 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions)</span></div></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzItMS0xLTEtNzgyMTU_207ca5a1-b8a1-4760-a6af-4232340fe8b9">1,015</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzItMy0xLTEtNzgyMTU_7be68600-dd92-4b41-9756-046fa6643241">2,080</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzItNS0xLTEtNzgyMTU_513c016e-3357-418a-8b56-34db3f5025ce">1,499</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzQtMS0xLTEtNzgyMTU_9ead1b44-886b-4a2a-9389-ab22023cb312">437</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzQtMy0xLTEtNzgyMTU_ec9f2afb-67ad-42d3-8983-0d4096e217b8">408</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzQtNS0xLTEtNzgyMTU_4223328e-2529-45b6-a870-1f799d828ada">361</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for credit losses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzUtMS0xLTEtNzgyMTU_58b52080-ed67-4986-b0b7-beb49cfb4695">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzUtMy0xLTEtNzgyMTU_78ea10f7-69ce-435d-afe3-b5557650c77a">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzUtNS0xLTEtNzgyMTU_e2941e31-86d4-4a58-89f6-b63ab838086e">19</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income tax provision (benefit)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzYtMS0xLTEtNzgyMTU_2c71b19a-de06-438c-afa3-2e379bfdea94">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzYtMy0xLTEtNzgyMTU_0a9335e9-29b0-447b-8a87-cd60836dd84c">57</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzYtNS0xLTEtNzgyMTU_8654e475-7967-4a7a-8885-5767ece6776d">85</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzctMS0xLTEtNzgyMTU_72a540ba-48d6-4c08-843b-b8565f3453d3">77</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzctMy0xLTEtNzgyMTU_fd1d6a03-9d40-433d-bc05-805c0af8e51f">79</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzctNS0xLTEtNzgyMTU_ff83b681-c4fd-4983-9399-6199f7d18309">97</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on disposition of joint venture</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="dgx:GainLossOnDispositionOfJointVenture" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzgtMS0xLTEtNzgyMTU_7cf6c774-51d2-4de6-8742-1c9240753c0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="dgx:GainLossOnDispositionOfJointVenture" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzgtMy0xLTEtNzgyMTU_0438c0ad-265b-4cf6-a683-58ac1c888a7b">314</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="dgx:GainLossOnDispositionOfJointVenture" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzgtNS0xLTEtNzgyMTU_94f58a50-a0b5-4a89-a8a8-263fd1b2e2de">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzE0LTEtMS0xLTc4MjE1_be66b43b-f0de-4eae-ab74-a44d39863d53">66</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzE0LTMtMS0xLTc4MjE1_1bba35d4-12a8-44a9-b4e7-0f6afbcd31d6">54</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzE0LTUtMS0xLTc4MjE1_fcc24eec-9c2e-41ea-91d3-6413735ff88c">78</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzE2LTEtMS0xLTc4MjE1_f3e7dfb0-d49a-46cf-9833-a83705b6b84c">246</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzE2LTMtMS0xLTc4MjE1_935a4550-be18-41c9-9a55-3255b0042bda">81</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzE2LTUtMS0xLTc4MjE1_2f22026e-0287-46c2-a5a2-d3bde71b9bb4">455</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzE3LTEtMS0xLTc4MjE1_4be4768f-2f1c-4e6a-8c7e-a059e9333504">149</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzE3LTMtMS0xLTc4MjE1_ad47871b-b082-47ff-a2c3-11d7ac4160fc">35</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzE3LTUtMS0xLTc4MjE1_ea377096-e9ec-48a1-ad93-fcb8ecfca49c">452</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzE5LTEtMS0xLTc4MjE1_d64e5b54-1c6f-4f63-90ab-110511147c11">31</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzE5LTMtMS0xLTc4MjE1_ec337199-06e5-424c-aecc-ba8e14436900">20</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzE5LTUtMS0xLTc4MjE1_6247798f-4158-414c-a09d-269c6a7a6fb4">22</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Termination of interest rate swap agreements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="dgx:TerminationOfInterestRateSwapAgreements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzIwLTEtMS0xLTc4MjE1_60b01faf-7a48-429d-9e68-d1beded8274b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="dgx:TerminationOfInterestRateSwapAgreements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzIwLTMtMS0xLTc4MjE1_9f002fce-686b-4615-9493-1b852556e8ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="dgx:TerminationOfInterestRateSwapAgreements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzIwLTUtMS0xLTc4MjE1_7899069e-f250-46fa-8ff6-1dca60089e46">40</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzIxLTEtMS0xLTc4MjE1_b55dc194-0e03-4c4e-9006-c7b88e8fa388">53</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzIxLTMtMS0xLTc4MjE1_32e0f29b-ab0e-4ac4-bf6b-ebef4636ff17">9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzIxLTUtMS0xLTc4MjE1_38a4f99d-a547-45bb-912b-cda2370614ef">37</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzIyLTEtMS0xLTc4MjE1_4088e37b-9748-4195-a361-6841d5e4df04">1,718</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzIyLTMtMS0xLTc4MjE1_fcc30b68-e3da-4aab-af0c-1cdf4dd2cb42">2,233</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzIyLTUtMS0xLTc4MjE1_ff66707f-4b43-4899-b7e9-c316aea1420a">2,005</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Business acquisitions, net of cash acquired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzI1LTEtMS0xLTc4MjE1_327cd0cf-7d97-4c7d-9d8e-d5783cd6539c">144</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzI1LTMtMS0xLTc4MjE1_b83c0a63-65fc-42ed-8b49-597fe63b7b67">331</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzI1LTUtMS0xLTc4MjE1_3a5daf0f-e343-4e9f-8b61-78665865093c">330</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from disposition of joint venture</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzI2LTEtMS0xLTc4MjE1_872a1162-5606-47a1-824a-d07326292631">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzI2LTMtMS0xLTc4MjE1_7edfc383-8779-47b6-9122-85b7cb2443ad">755</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzI2LTUtMS0xLTc4MjE1_8fb88f93-d8b9-4bc9-8a57-adf1988d6144">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzI5LTEtMS0xLTc4MjE1_aa066287-5903-43d1-a10c-071f67cb6949">404</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzI5LTMtMS0xLTc4MjE1_43956624-8a3b-4abc-b9ac-a2c46ad9aeb2">403</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzI5LTUtMS0xLTc4MjE1_66e5f88c-de5e-4d78-ba31-140fda03ac62">418</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease (increase) in investments and other assets, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzMxLTEtMS0xLTc4MjE1_814ba3cd-b4a4-40a9-85dc-b50bfba440d4">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzMxLTMtMS0xLTc4MjE1_e2f50db7-3ec6-4b9b-b29e-9527ed4df109">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzMxLTUtMS0xLTc4MjE1_95980216-c536-4427-bf30-8b77ac4a3301">24</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzMyLTEtMS0xLTc4MjE1_a04c9a51-26dc-49fc-bc73-c71ab2b42a37">543</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzMyLTMtMS0xLTc4MjE1_624f7587-06d1-41dc-8e6c-ea189d2912e2">21</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzMyLTUtMS0xLTc4MjE1_f74a6a61-e9ee-4e76-84b9-dd777d158cdc">772</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from borrowings</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzM1LTEtMS0xLTc4MjE1_8a02061e-66a6-462d-9752-cd0c7c92229a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzM1LTMtMS0xLTc4MjE1_7f888003-b691-408d-bbc6-0d029b5518e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzM1LTUtMS0xLTc4MjE1_5c585bb6-4a02-46bd-9302-dfcc164bc1aa">749</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayments of debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzM2LTEtMS0xLTc4MjE1_65eece06-8d3c-4558-a4a1-e49a7a62537a">2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzM2LTMtMS0xLTc4MjE1_cb7e67bf-d8e0-4f18-abbf-c554f4141ae0">2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzM2LTUtMS0xLTc4MjE1_e40c9b0c-f547-441b-a6eb-da8542034882">1,554</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzM3LTEtMS0xLTc4MjE1_027cfc17-eb38-495d-a794-f743292761d5">1,408</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzM3LTMtMS0xLTc4MjE1_fd37f5ea-e4ad-4f0d-af0e-3a4446cab683">2,199</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzM3LTUtMS0xLTc4MjE1_deaab6ec-e4b8-44fc-b5ae-86f9ffa186d4">325</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzM4LTEtMS0xLTc4MjE1_7853bb8a-0ee9-429b-b7ca-564c80663116">123</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzM4LTMtMS0xLTc4MjE1_dc2ba048-df4d-46ea-828d-5b8d5cdaeca7">129</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzM4LTUtMS0xLTc4MjE1_70221699-82f5-4f72-b387-ada415d275ee">189</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee payroll tax withholdings on stock issued under stock-based compensation plans</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzM5LTEtMS0xLTc4MjE1_cbbe4679-feca-4a9c-8464-bff06dee7ca5">28</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzM5LTMtMS0xLTc4MjE1_a81a0ab3-3c35-477c-aa52-a7eaebb11d3a">22</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzM5LTUtMS0xLTc4MjE1_15d9e0d1-598c-4de4-9095-43d1f940db1f">15</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividends paid</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzQwLTEtMS0xLTc4MjE1_76d76b97-a430-4452-b31b-6d512e60a422">305</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzQwLTMtMS0xLTc4MjE1_5b5c125f-3da5-4aa8-8d79-a115fcefaa0f">309</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzQwLTUtMS0xLTc4MjE1_70de473c-e408-48a7-99ff-36161b49c0ea">297</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions to noncontrolling interest partners</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsOfDividendsMinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzQxLTEtMS0xLTc4MjE1_98062ee7-5457-4f23-844d-a8bb9fd56c90">73</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsOfDividendsMinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzQxLTMtMS0xLTc4MjE1_8e0d312f-31b6-44b7-9a64-a3f5dda91a5b">99</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsOfDividendsMinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzQxLTUtMS0xLTc4MjE1_03dc7f68-1035-4bbb-b6f9-e61be73536a5">58</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other financing activities, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzQ1LTEtMS0xLTc4MjE1_6b936252-ef99-42c1-9c43-06864e42d3a9">39</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzQ1LTMtMS0xLTc4MjE1_ee449128-6638-4ed8-8bf6-c415ef28778e">38</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzQ1LTUtMS0xLTc4MjE1_da8e430b-8719-49fe-9de8-f11d76c76a61">44</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzQ2LTEtMS0xLTc4MjE1_07913910-eb6e-4967-a00c-b757cdabb091">1,732</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzQ2LTMtMS0xLTc4MjE1_f4c9fd6e-f8df-4725-a5e3-13f4d232acdc">2,540</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzQ2LTUtMS0xLTc4MjE1_7d741074-76e9-4449-9243-1fce7ddf8071">1,267</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net change in cash and cash equivalents and restricted cash</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzQ4LTEtMS0xLTc4MjE1_bdc3e6de-1a6c-4f36-a34c-385f1fc19cba">557</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzQ4LTMtMS0xLTc4MjE1_f716f041-4cde-4851-990d-7ef4887a0a2d">286</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzQ4LTUtMS0xLTc4MjE1_79e569c5-3d8f-46fb-9485-1c8d34540847">34</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and cash equivalents and restricted cash, beginning of year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzUwLTEtMS0xLTc4MjE1_af9bdc9f-5c33-463e-be97-4b5ab99c66c4">872</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872b3ea2e369403f8c0129ff07e0b538_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzUwLTMtMS0xLTc4MjE1_65415025-2c7f-4b94-b92f-0f5d758aa25a">1,158</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1240b052d8214432b601d5bcbb753f11_I20191231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzUwLTUtMS0xLTc4MjE1_461c14c2-f790-4c90-8860-3275c745cd44">1,192</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and cash equivalents and restricted cash, end of year</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzUxLTEtMS0xLTc4MjE1_191e5469-4bc4-4dea-a3ec-e506fecba9fc">315</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzUxLTMtMS0xLTc4MjE1_646aade5-2385-4c58-b2e0-5c912b4ce44a">872</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872b3ea2e369403f8c0129ff07e0b538_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzUxLTUtMS0xLTc4MjE1_b7a71ef7-ce33-4d9d-866b-74102098746c">1,158</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these statements.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_169"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER&#160;31, 2022, 2021 AND 2020 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions)</span></div></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:21.187%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.257%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.084%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.084%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.257%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.436%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:700;line-height:100%">Quest Diagnostics Stockholders&#8217; Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:700;line-height:100%">Shares of<br/>Common<br/>Stock Out-<br/>standing</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:700;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>&#160;Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:700;line-height:100%">Treasury<br/>Stock, at<br/>Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:700;line-height:100%">Non-<br/>controlling<br/>Interests</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:700;line-height:100%">Total Stock-holders&#8217;<br/>Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:700;line-height:100%">Redeemable Non-controlling Interest</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-style:italic;font-weight:700;line-height:100%">Balance, December 31, 2019</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i60096e15242147fba12636c6498e0696_I20191231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzItMS0xLTEtNzgyMTU_3a933e4e-a0fe-49f4-8678-0b869f98c639">133</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60096e15242147fba12636c6498e0696_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzItMi0xLTEtNzgyMTU_43bfa16e-ae55-4ef9-823f-d1bb780c46b6">2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide8bb1978e06466ca724c39081cca9e9_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzItMy0xLTEtNzgyMTU_e147f640-82f7-4380-8cba-a66932a522ed">2,722</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i288558364eaf483197b8585096922212_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzItNC0xLTEtNzgyMTU_f9ba5bc8-7013-42e9-974a-d861c69d3b9d">8,174</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i472db09b826445d8914756bb3c893218_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzItNS0xLTEtNzgyMTU_74539b47-a8c6-4132-86d1-bae17f12e874">39</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cb753814e7c442992f309372e45e63f_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzItNi0xLTEtNzgyMTU_24c9fbc2-10d2-44a2-bb34-4078a8e301a9">5,218</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9986f08efdbe402bbac2c867d4d5b49a_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzItNy0xLTEtNzgyMTU_732ce549-4901-4738-b05d-b9615b5efa01">46</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1240b052d8214432b601d5bcbb753f11_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzItOC0xLTEtNzgyMTU_e2c527f2-d9ac-4062-87db-34416907fa38">5,687</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1240b052d8214432b601d5bcbb753f11_I20191231" decimals="-6" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzItMTEtMS0xLTc4MjE1_4016539b-38cf-4c09-b1e8-cf35ace33a36">76</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a99166a414743a488765966d2720acc_D20200101-20201231" decimals="-6" name="dgx:NetIncomeLossExcludingRedeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMtNC0xLTEtNzgyMTU_4842779d-59c1-420b-9187-68a68cd8405b">1,431</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10198ce773244072a76824474330a1cf_D20200101-20201231" decimals="-6" name="dgx:NetIncomeLossExcludingRedeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMtNy0xLTEtNzgyMTU_e96fb1c5-61ce-4620-bcbe-ef6076e9d86a">53</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="dgx:NetIncomeLossExcludingRedeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMtOC0xLTEtNzgyMTU_88da13aa-2c95-42a6-9992-1ddb2931f09c">1,484</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:TemporaryEquityNetIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMtMTEtMS0xLTc4MjE1_813b79e9-7897-40a1-b7af-d8ce95c2c859">15</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c187eb3582c4c4a85507116a2a9051a_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzQtNS0xLTEtNzgyMTU_1a7287a0-c28a-4a86-84b5-8b32faafbe12">18</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzQtOC0xLTEtNzgyMTU_2ee45e71-32f1-43e7-a7a8-b5b50637dffe">18</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a99166a414743a488765966d2720acc_D20200101-20201231" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzUtNC0xLTEtNzgyMTU_c535ae46-5b82-4b24-948b-6082fbe384f0">302</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzUtOC0xLTEtNzgyMTU_ebd36475-b380-4cb2-9c86-96d7d6004844">302</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">Distributions to noncontrolling interest partners</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i10198ce773244072a76824474330a1cf_D20200101-20201231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzYtNy0xLTEtNzgyMTU_db13a9ab-f37f-4018-8300-a624aa9ef56d">49</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzYtOC0xLTEtNzgyMTU_45307b36-5a88-48ee-b321-af935e68f89a">49</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="dgx:TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzYtMTEtMS0xLTc4MjE1_557a8435-e72c-4d92-95bc-71cec2c3760b">9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">Issuance of common stock under benefit plans</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i65ea28f7aede4d8cb4a1add480265c52_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzctMS0xLTEtNzgyMTU_850798ca-8e4a-4dec-bb60-36af1122c613">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ba9cb930d94eb9a0e61b9e0381a8d8_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzctMy0xLTEtNzgyMTU_8663a381-c9db-49f1-a22c-522ac933b73d">11</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2998701e47ab4c2da75bc84322736ac6_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzctNi0xLTEtNzgyMTU_e084672d-fefd-4413-9eaf-1a2101be73f0">14</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzctOC0xLTEtNzgyMTU_0e000b6c-1360-4620-8356-ff7625dd4a2b">25</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ba9cb930d94eb9a0e61b9e0381a8d8_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzgtMy0xLTEtNzgyMTU_f2be223d-2792-44b2-9120-eb24c3b91e02">97</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzgtOC0xLTEtNzgyMTU_68fa374a-18b3-4f09-a0b7-17d6c72b7245">97</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i65ea28f7aede4d8cb4a1add480265c52_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzktMS0xLTEtNzgyMTU_f7c7b1fa-be88-467b-ae1f-0f70e172bb8e">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ba9cb930d94eb9a0e61b9e0381a8d8_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzktMy0xLTEtNzgyMTU_d910d1c9-1bde-4d7e-9f35-4e31aa46adc5">26</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2998701e47ab4c2da75bc84322736ac6_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzktNi0xLTEtNzgyMTU_9eaa812e-eadb-4d6f-adb0-74a7e4d52ae5">163</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzktOC0xLTEtNzgyMTU_b460fd66-9b64-4189-b063-e8186a9df283">189</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">Shares to cover employee payroll tax withholdings on stock issued under stock-based compensation plans</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35ba9cb930d94eb9a0e61b9e0381a8d8_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzEwLTMtMS0xLTc4MjE1_753f0859-e871-4674-8bb1-f7718f90ac9c">15</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzEwLTgtMS0xLTc4MjE1_a5520f41-8b6f-4a6a-a156-2ea5dac62697">15</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i65ea28f7aede4d8cb4a1add480265c52_D20200101-20201231" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzEyLTEtMS0xLTc4MjE1_6847f4b9-fa31-46df-a1c3-54ead8d997ea">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2998701e47ab4c2da75bc84322736ac6_D20200101-20201231" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzEyLTYtMS0xLTc4MjE1_68c75ea3-eee6-4fbe-b206-dc13225586bc">325</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzEyLTgtMS0xLTc4MjE1_4e5a3128-5f17-4133-9e08-e385e6f947ac">325</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-style:italic;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1339fcf6a344dd38e3445336c362756_I20201231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzE2LTEtMS0xLTc4MjE1_4f66ce0f-187d-47f0-9513-9267d25731b9">133</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1339fcf6a344dd38e3445336c362756_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzE2LTItMS0xLTc4MjE1_9652ee6f-4aaa-4671-b302-cdf5c33154f5">2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3df6ca3ffce342b4877024296cfa0551_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzE2LTMtMS0xLTc4MjE1_91067350-a7aa-42fc-b436-3a43ae4da3c5">2,841</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib876f54cbcd740bbaa56a7f098ffd2ac_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzE2LTQtMS0xLTc4MjE1_44ab0ed0-fd2c-4801-88a2-e0780b0349b3">9,303</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic144ab8f0cf34804be4018d616f6d4ac_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzE2LTUtMS0xLTc4MjE1_666b88b3-4ddf-480c-9598-0e9c63dcb3f3">21</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb272b75d2c44e3689c068a802c47179_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzE2LTYtMS0xLTc4MjE1_eb5176e7-5f97-4f45-ad71-673e6e4cdfa8">5,366</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2b0c92f23149e9923b4ac5d5a66fc9_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzE2LTctMS0xLTc4MjE1_c1f6daba-3d9e-4323-ad4e-cca2f8fd1834">50</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872b3ea2e369403f8c0129ff07e0b538_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzE2LTgtMS0xLTc4MjE1_8cbe26f2-cf76-4005-8249-12de81f7dee1">6,809</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872b3ea2e369403f8c0129ff07e0b538_I20201231" decimals="-6" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzE2LTExLTEtMS03ODIxNQ_c25eb189-48b5-47bf-8ae6-aa53e30cb9d7">82</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b1b2d14ccd04831986cecdccfec9b2d_D20210101-20211231" decimals="-6" name="dgx:NetIncomeLossExcludingRedeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzE3LTQtMS0xLTc4MjE1_6ab45574-1e79-44b6-88b3-2f969bc49d0d">1,995</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b667d9c2eff4eebb2ac4e52f720ef07_D20210101-20211231" decimals="-6" name="dgx:NetIncomeLossExcludingRedeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzE3LTctMS0xLTc4MjE1_be54df66-d084-4cd2-ba36-87fb01fb5187">72</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="dgx:NetIncomeLossExcludingRedeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzE3LTgtMS0xLTc4MjE1_e4a392ca-9c48-4cc9-94fe-f5b7bdfd2dff">2,067</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:TemporaryEquityNetIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzE3LTExLTEtMS03ODIxNQ_667f2966-815b-40e0-970f-24d9b596f713">13</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095b5e9afd734c41af3e81c20d90f712_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzE4LTUtMS0xLTc4MjE1_57b2a225-eedb-4770-83a7-98ab9c00c391">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzE4LTgtMS0xLTc4MjE1_4bb4dfa3-68bb-4fca-b94a-e869879bb1f7">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b1b2d14ccd04831986cecdccfec9b2d_D20210101-20211231" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzE5LTQtMS0xLTc4MjE1_cf7b6a63-ec15-4bd7-b017-66f30ea9ab7e">307</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzE5LTgtMS0xLTc4MjE1_e9daf5f2-7350-4c75-9ace-d261c949fcbe">307</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">Distributions to noncontrolling interest partners</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b667d9c2eff4eebb2ac4e52f720ef07_D20210101-20211231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzIwLTctMS0xLTc4MjE1_91c06cba-a2c8-4013-88b5-5942950a6e57">83</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzIwLTgtMS0xLTc4MjE1_49a88358-230b-4dfc-badf-3df544bd76d5">83</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="dgx:TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzIwLTExLTEtMS03ODIxNQ_98876322-2c18-4b35-bddd-ec8a2f6ab797">16</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">Issuance of common stock under benefit plans</span></div></td><td colspan="3" style="padding:0 1pt"><ix:nonFraction unitRef="shares" contextRef="ibf09d963d3644445a1026aa035d87436_D20210101-20211231" xsi:nil="true" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzIxLTEtMS0xLTc4MjE1_8e1dc421-d45c-4a94-8d31-5db5fd58397b"></ix:nonFraction></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bf24e1056814b529c1aaa4c1d657c4a_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzIxLTMtMS0xLTc4MjE1_5089180a-1b36-4188-8884-ee96d07aac88">21</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4718e0f26e04ae097941f11f8d84f52_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzIxLTYtMS0xLTc4MjE1_85641155-70ec-4584-9908-598237c69de9">47</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzIxLTgtMS0xLTc4MjE1_647e1606-36b0-4c03-ba2a-4546d4a5579f">26</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bf24e1056814b529c1aaa4c1d657c4a_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzIyLTMtMS0xLTc4MjE1_f3b73b44-e4d6-494a-b5dc-e5691f081f55">79</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzIyLTgtMS0xLTc4MjE1_36d97033-40e5-41e9-bd49-f9e4a75fccad">79</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf09d963d3644445a1026aa035d87436_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzIzLTEtMS0xLTc4MjE1_0e486155-be8a-45ac-ab6b-8ff63a6da792">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bf24e1056814b529c1aaa4c1d657c4a_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzIzLTMtMS0xLTc4MjE1_6ce5f062-9cb8-480b-86f3-d58270ebb47f">20</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4718e0f26e04ae097941f11f8d84f52_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzIzLTYtMS0xLTc4MjE1_d94bcebb-9a75-4117-8b10-9acf70588239">109</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzIzLTgtMS0xLTc4MjE1_05c97390-c5ea-41d1-90ab-9af48436e15c">129</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">Shares to cover employee payroll tax withholdings on stock issued under stock-based compensation plans</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bf24e1056814b529c1aaa4c1d657c4a_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzI0LTMtMS0xLTc4MjE1_34933df9-8d05-4aea-ad97-b8e8e47fea27">10</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4718e0f26e04ae097941f11f8d84f52_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzI0LTYtMS0xLTc4MjE1_7f1a2065-f913-424d-af72-90cf8ea78dce">12</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzI0LTgtMS0xLTc4MjE1_3b91645d-5822-46b5-965d-f065aa6bdf16">22</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibf09d963d3644445a1026aa035d87436_D20210101-20211231" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzI2LTEtMS0xLTc4MjE1_2bcf1159-fc8a-418a-a9d2-fef4b9aff7ed">16</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4718e0f26e04ae097941f11f8d84f52_D20210101-20211231" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzI2LTYtMS0xLTc4MjE1_ff5df8ba-d853-4235-a4ca-5157953749a9">2,222</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzI2LTgtMS0xLTc4MjE1_8bddc66e-8b10-4359-b7f0-e3dccb9e130a">2,222</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">Retirement of treasury stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bf24e1056814b529c1aaa4c1d657c4a_D20210101-20211231" decimals="-6" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzI5LTMtMS0xLTc4MjE1_efcb956a-2323-49ad-be4d-9c42e272902d">649</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b1b2d14ccd04831986cecdccfec9b2d_D20210101-20211231" decimals="-6" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzI5LTQtMS0xLTc4MjE1_3673ee8c-71f1-450c-9bd1-e0941f485487">3,342</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4718e0f26e04ae097941f11f8d84f52_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzI5LTYtMS0xLTc4MjE1_5c7c085d-9510-448d-818c-98b0e63c0f2a">3,991</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzI5LTgtMS0xLTc4MjE1_15aa7510-4bea-4b82-9dd8-83972b154a7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-style:italic;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf9d22d584794a70962f2aa7e63d53ed_I20211231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMwLTEtMS0xLTc4MjE1_6a1c80f5-9411-4c3d-9e25-44d984708c0b">119</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf9d22d584794a70962f2aa7e63d53ed_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMwLTItMS0xLTc4MjE1_48183045-1bdc-4670-802a-40ad040d6a3e">2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46c3bce145ea4fa5aa062add4078cdfe_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMwLTMtMS0xLTc4MjE1_f2f9413d-7fe1-4b65-8786-9ecc0511c344">2,260</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide97930b20624098ba7878ad5bcd0d94_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMwLTQtMS0xLTc4MjE1_02e95fb7-8527-49d4-8c3e-0ab2227b7267">7,649</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3c04cff9ac445b78c60050390c6354a_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMwLTUtMS0xLTc4MjE1_09761ac2-fdc7-4942-898f-f3095abbb0bb">14</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a13b74a4feb49a384914744e3913d6d_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMwLTYtMS0xLTc4MjE1_0d864412-f1a7-48c3-8bef-4b478f96c74c">3,453</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fa9e0c121174bc7b51c26277e515b9b_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMwLTctMS0xLTc4MjE1_e8f53e11-7902-47ac-8df0-c31b6a8b0e8e">39</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMwLTgtMS0xLTc4MjE1_22a580de-ec93-49c0-84ba-5d800387e6e0">6,483</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMwLTExLTEtMS03ODIxNQ_3b950d97-2563-4fbb-bbf2-3b0408357a66">79</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">Net income</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cc12e58d5654ed5b8115cae8aed17f6_D20220101-20221231" decimals="-6" name="dgx:NetIncomeLossExcludingRedeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMxLTQtMS0xLTc4MjE1_351f7635-4a7a-4082-8a71-045cb7aa7d5a">946</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie63ea040842e454a8a302897c8462f6f_D20220101-20221231" decimals="-6" name="dgx:NetIncomeLossExcludingRedeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMxLTctMS0xLTc4MjE1_ee6fc63a-348e-4f4e-a12d-ef70b04a0337">62</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="dgx:NetIncomeLossExcludingRedeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMxLTgtMS0xLTc4MjE1_42bcb1ed-b53b-4144-a2b0-06f5f8d0836f">1,008</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:TemporaryEquityNetIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMxLTExLTEtMS03ODIxNQ_53c203f1-82ae-4c5f-aa93-9867dab10a44">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7dd85f38ce14e469eb57e11ba9cfd32_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMyLTUtMS0xLTc4MjE1_2ba6bd77-77a4-4ae9-bd89-b352cb020ad3">7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMyLTgtMS0xLTc4MjE1_6b02b928-73c2-4521-983e-aa365a519b5b">7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">Dividends declared</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cc12e58d5654ed5b8115cae8aed17f6_D20220101-20221231" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMzLTQtMS0xLTc4MjE1_b4e55739-4ee9-4a22-982b-c16fcc54e3f1">305</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMzLTgtMS0xLTc4MjE1_7fa7566b-e2a6-4110-853c-7b96b33c8dfd">305</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">Distributions to noncontrolling interest partners</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie63ea040842e454a8a302897c8462f6f_D20220101-20221231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzM0LTctMS0xLTc4MjE1_1f322a1e-f6be-4035-a183-eb16df2a3bb3">64</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzM0LTgtMS0xLTc4MjE1_3f1031fc-18e0-4e15-9621-378be5e58529">64</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="dgx:TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzM0LTExLTEtMS03ODIxNQ_5e12879d-a4b0-4601-af2c-b8df22fefb1e">9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">Issuance of common stock under benefit plans</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2e6f2503a5bd421392c0a3810d1d34b3_D20220101-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzM1LTEtMS0xLTc4MjE1_6e62177b-c111-4689-b39b-2c7430561aa5">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08ee5ae92da64f5088e4f441aadc7efd_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzM1LTMtMS0xLTc4MjE1_523f5feb-2aec-492a-80e3-7e68077b78c3">36</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7840e393be1c4cfaafc766cd6a649f57_D20220101-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzM1LTYtMS0xLTc4MjE1_f7674d73-5e43-4217-ad01-a2902251fbf9">64</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzM1LTgtMS0xLTc4MjE1_6325b752-f2f4-4a90-8733-0acfb2f77a01">28</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ee5ae92da64f5088e4f441aadc7efd_D20220101-20221231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzM2LTMtMS0xLTc4MjE1_68b81e76-f970-4e3d-a224-d1f1f0b58084">77</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzM2LTgtMS0xLTc4MjE1_cf47bd6f-ca65-451d-97e2-e8823c2e4b62">77</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">Exercise of stock options</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2e6f2503a5bd421392c0a3810d1d34b3_D20220101-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzM3LTEtMS0xLTc4MjE1_f747cfa9-1ad5-4b3b-876e-f1cd97a3ebb3">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ee5ae92da64f5088e4f441aadc7efd_D20220101-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzM3LTMtMS0xLTc4MjE1_4a76c57a-5176-4ba2-9222-b51ddcbf40a6">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7840e393be1c4cfaafc766cd6a649f57_D20220101-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzM3LTYtMS0xLTc4MjE1_ed2fbb74-d439-4f77-ac7d-53eebb41b279">119</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzM3LTgtMS0xLTc4MjE1_97455b17-9eef-4ab5-9d2c-fe03adc33539">123</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">Shares to cover employee payroll tax withholdings on stock issued under stock-based compensation plans</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08ee5ae92da64f5088e4f441aadc7efd_D20220101-20221231" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzM4LTMtMS0xLTc4MjE1_b7ee20e1-6ea8-4d9b-a0a1-4d5a5fba31b9">10</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7840e393be1c4cfaafc766cd6a649f57_D20220101-20221231" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzM4LTYtMS0xLTc4MjE1_65fdd565-6128-41e6-9a84-19971e85f891">18</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzM4LTgtMS0xLTc4MjE1_9645970c-aff5-4a15-9a10-f1fc650f4f52">28</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2e6f2503a5bd421392c0a3810d1d34b3_D20220101-20221231" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzM5LTEtMS0xLTc4MjE1_5f7cadb3-badd-43da-87bb-340a1858ab79">10</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7840e393be1c4cfaafc766cd6a649f57_D20220101-20221231" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzM5LTYtMS0xLTc4MjE1_f4394762-e68a-4ff0-89ca-5ed61431e0a3">1,385</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzM5LTgtMS0xLTc4MjE1_4d1f0b26-e758-4b11-ab29-ecfe62d415d4">1,385</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-style:italic;font-weight:700;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i87e8a4e1a2e74540b572c7f19b5a4c4d_I20221231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzQzLTEtMS0xLTc4MjE1_07dee6cf-409b-4889-b18d-c70bfce6d391">111</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87e8a4e1a2e74540b572c7f19b5a4c4d_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzQzLTItMS0xLTc4MjE1_3c850d19-470e-471d-af25-0df550da8776">2</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1e66f8b2302475fb1c8bca2f57488d3_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzQzLTMtMS0xLTc4MjE1_534ad7df-25da-4f39-b760-526a27942af9">2,295</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4abbc656bb9d4006bae9f455034d8851_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzQzLTQtMS0xLTc4MjE1_d9aaac0b-0e76-49b9-8cba-7e7e34461769">8,290</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4848abb5a7147028c83ac30e5fcf981_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzQzLTUtMS0xLTc4MjE1_4cd942f3-98e3-45ba-868d-86fe89f0edf1">21</ix:nonFraction>)</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3448ddb537854f44a9c15ae5f60d4048_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzQzLTYtMS0xLTc4MjE1_7ac676c9-0737-40be-8bad-8095412add51">4,673</ix:nonFraction>)</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fcf55e48b7c44a8aa6c6dce683057f7_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzQzLTctMS0xLTc4MjE1_531dff2b-9ec3-4d3a-9b86-ce4313a75b74">37</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzQzLTgtMS0xLTc4MjE1_e3e24576-c479-4723-83af-8cb0e34a0f9d">5,930</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzQzLTExLTEtMS03ODIxNQ_6d29d152-8827-4074-89c9-58d604ad918c">77</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_172"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents </a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions unless otherwise indicated)</span></div></div><div style="text-align:center"><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_175"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzUvZnJhZzozOGY0NjI0MGEzNWI0NGI1YmI5NTk5MmE4MTIyYzgzMC90ZXh0cmVnaW9uOjM4ZjQ2MjQwYTM1YjQ0YjViYjk1OTkyYTgxMjJjODMwXzE3MDI_4d1320a4-a15c-444e-b5b7-3e45cee7bdfc" continuedAt="i096a56bf78f24b8a945186480ca722f9" escape="true">DESCRIPTION OF BUSINESS</ix:nonNumeric></span></div><ix:continuation id="i096a56bf78f24b8a945186480ca722f9"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Background</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Quest Diagnostics Incorporated and its subsidiaries ("Quest Diagnostics" or the "Company") empower people to take action to improve health outcomes.&#160; The Company uses its extensive database of clinical lab results to derive diagnostic insights that reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management.&#160; The Company's diagnostic information services business ("DIS") provides information and insights based on an industry-leading menu of routine, non-routine and advanced clinical testing and anatomic pathology testing, and other diagnostic information services.  The Company provides services to a broad range of customers, including patients, clinicians, hospitals, independent delivery networks ("IDNs"), health plans, employers, consumers, and accountable care organizations ("ACOs").  The Company offers the broadest access in the United States to diagnostic information services through its nationwide network of laboratories, patient service centers and phlebotomists in physician offices and the Company's connectivity resources, including call centers and mobile paramedics, nurses and other health and wellness professionals.  The Company is the world's leading provider of diagnostic information services.  The Company provides interpretive consultation with one of the largest medical and scientific staffs in the industry. The Company's Diagnostic Solutions businesses ("DS") are the leading provider of risk assessment services for the life insurance industry and offer healthcare organizations and clinicians robust information technology solutions.</span></div></ix:continuation><div><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_178"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MTI0_23b82634-541a-49b7-b767-39ab73e54ab7" continuedAt="i3f34f73d171b475880126e08048e759a" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i3f34f73d171b475880126e08048e759a" continuedAt="iece6cd367ee84650ba112394b0795e31"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MDQ2_c56374e1-897a-4ad5-b74b-af70aa94a7aa" continuedAt="i3c7d80a5f2614377b5117d629920e111" escape="true">The consolidated financial statements include the accounts of all entities controlled by the Company through its direct or indirect ownership of a majority voting interest.  Additionally, the consolidated financial statements include the accounts of variable interest entities (&#8220;VIEs&#8221;) in which the Company has a variable interest and for which the Company is the &#8220;primary beneficiary&#8221; as it has both: (1) the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and (2) the obligation to absorb losses of the VIE that potentially could be significant to the VIE or the right to receive benefits from the VIE that potentially could be significant to the VIE.  All significant intercompany accounts and transactions are eliminated in consolidation.</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3c7d80a5f2614377b5117d629920e111">&#160;&#160;&#160;&#160;Income attributable to the minority interest in the Company's majority owned and controlled consolidated subsidiaries is recorded as net income attributable to noncontrolling interests in the consolidated statements of operations and the noncontrolling interest is reflected as a separate component of consolidated stockholders' equity in the consolidated balance sheet.</ix:continuation></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Reclassifications</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI3NDg3NzkxMDM3NDQ_75c8848c-72f9-465c-aeaa-07b58d0628f9" escape="true">Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements.</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Method Investments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:EquityMethodInvestmentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MDMy_ff61deec-3b67-4832-a3aa-3e0111003e78" escape="true">Investments in entities which the Company does not control, but in which it has a substantial ownership interest (generally between <ix:nonFraction unitRef="number" contextRef="iedbe1fc06b5345c38cc97c62d3b664a3_I20221231" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzE4ODc_76a63277-0249-4d40-a72d-2c34366d5cf0">20</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i4b416adaeaac49cfb869af6c8e627c39_I20221231" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzE4OTQ_891d6c36-33ef-4833-a0c1-96ac1e707969">49</ix:nonFraction>%) and can exercise significant influence, are accounted for using the equity method of accounting.  These investments are classified as investments in equity method investees in the consolidated balance sheet.  The Company records its pro rata share of the earnings, adjusted for accretion of basis difference, of these investments in equity in earnings of equity method investees, net of taxes in the consolidated statements of operations.  The Company reviews its investments in equity method investees for impairment whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable.</ix:nonNumeric>  </span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211; CONTINUED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions unless otherwise indicated)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><ix:continuation id="iece6cd367ee84650ba112394b0795e31" continuedAt="i9b954e89d8304482bdfd9092bce0bf85"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MTE4_24138090-76d1-4e8d-94e6-3f4687fbae5b" escape="true">The preparation of financial statements in conformity with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.</ix:nonNumeric>  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MDg4_baaa60e1-02f2-4a91-b107-874a7a9fa7fe" escape="true">The Company recognizes as revenue the amount that reflects the consideration to which it expects to be entitled in exchange for goods sold or services rendered primarily upon completion of the testing process (when results are reported) or when services have been rendered (see Note 3).  Net revenues from Medicare and Medicaid programs were approximately <ix:nonFraction unitRef="number" contextRef="ib62f2d7bef64474dbe05584de6966e18_D20220101-20221231" decimals="2" name="dgx:PercentageofNetRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzMzOTA_ca41b615-264d-43e5-a406-fba07bba850f">11</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i316b4c39b6be48408e5109495bc92124_D20210101-20211231" decimals="2" name="dgx:PercentageofNetRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzMzOTQ_e6b31b3d-ccd6-4808-b71b-4faa236421a2">10</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i27098106112f421c94055f0cdae93371_D20200101-20201231" decimals="2" name="dgx:PercentageofNetRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzM0MDE_718b3ffd-82c6-4dd8-80cb-d91a8cdf70b8">11</ix:nonFraction>% of the Company's consolidated net revenues for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Taxes on Income</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MTM3_f6fca248-1fe7-4454-91a5-1e795dd3484c" escape="true">The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the year.  Current and deferred income taxes are measured based on the tax laws that are enacted as of the balance sheet date of the relevant reporting period.  Deferred tax assets and liabilities are recognized for the expected future tax consequences of differences between the carrying amounts of assets and liabilities and their respective tax bases using tax rates in effect for the year in which the differences are expected to reverse.  A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period when the change is enacted.  Tax benefits from uncertain tax positions are recognized only if the tax position is more likely than not to be sustained upon examination by taxing authorities based on the technical merits of the position.</ix:nonNumeric> </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings Per Share</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MDY3_d74ebf33-a620-45dc-a404-77aee393d1d0" escape="true">The Company's unvested restricted stock units that contain non-forfeitable rights to dividends are participating securities and, therefore, are included in the earnings allocation in computing earnings per share using the two-class method.  Basic earnings per common share is calculated by dividing net income attributable to Quest Diagnostics, adjusted for earnings allocated to participating securities, by the weighted average number of common shares outstanding.  Diluted earnings per common share is calculated by dividing net income attributable to Quest Diagnostics, adjusted for earnings allocated to participating securities, by the weighted average number of common shares outstanding after giving effect to all potentially dilutive common shares outstanding during the period.  Potentially dilutive common shares include the dilutive effect of outstanding stock options and performance share units granted under the Company's Amended and Restated Employee Long-Term Incentive Plan (&#8220;ELTIP&#8221;) and its Amended and Restated Non-Employee Director Long-Term Incentive Plan (&#8220;DLTIP&#8221;), as well as the dilutive effect of accelerated share repurchase agreements ("ASRs"), if applicable.  Earnings allocable to participating securities include the portion of dividends declared as well as the portion of undistributed earnings during the period allocable to participating securities.</ix:nonNumeric></span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211; CONTINUED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions unless otherwise indicated)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><ix:continuation id="i9b954e89d8304482bdfd9092bce0bf85" continuedAt="ia0cb490aa79c4f6fb39129b05da934c2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MTM5_36c13a2b-0db3-48b1-9cc1-407e50535914" continuedAt="idbc86f9a2f43437e822c431d701b5b3c" escape="true">The Company measures stock-based compensation for equity awards at fair value on the date of grant and records stock-based compensation as a charge to earnings net of the estimated impact of forfeited awards.  As such, the Company recognizes stock-based compensation cost</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="idbc86f9a2f43437e822c431d701b5b3c" continuedAt="i060c99e8ac7d44be98c85a432ba1b21d"> </ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i060c99e8ac7d44be98c85a432ba1b21d">only for those stock-based awards that are estimated to ultimately vest over their requisite service period, based on the vesting provisions of the individual grants.  The cumulative effect on current and prior periods of a change in the estimated forfeiture rate is recognized as compensation cost in earnings in the period of the change.  The terms of the Company's performance share units allow the recipients of such awards to earn a variable number of shares based on the achievement of the performance goals, which are based on the financial performance of the Company and the total shareholder return of the Company relative to an index of peer companies ("relative TSR"), specified in the awards.  For performance share units with a goal based on the financial performance of the Company, stock-based compensation expense is recognized based on management's best estimates of the achievement of the performance goals specified in such awards and the resulting number of shares that will be earned.  The cumulative effect on current and prior periods of a change in the estimated number of performance share units expected to be earned for these awards is recognized as compensation cost in earnings in the period of the change.  For performance share units with a market-based relative TSR goal, stock-based compensation expense is recognized based on the estimated fair value of the award regardless of the actual number of shares earned.</ix:continuation>  For further details regarding stock-based compensation, see Note&#160;18.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MTA0_1436ab5c-4837-4fea-b3cb-81f8115d1ec8" continuedAt="i5a07896ab81447bd9f326ee4ea1c476e" escape="true">The Company determines fair value measurements used in its consolidated financial statements based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants exclusive of any transaction costs, as determined by either the principal market or the most advantageous market.</ix:nonNumeric></span></div><div style="text-indent:36pt"><span><br/></span></div><ix:continuation id="i5a07896ab81447bd9f326ee4ea1c476e"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Inputs used in the valuation techniques to derive fair values are classified based on a three-level hierarchy.  The basis for fair value measurements for each level within the hierarchy is described below with Level 1 having the highest priority and Level 3 having the lowest.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1: Quoted prices in active markets for identical assets or liabilities.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3: Valuations derived from valuation techniques in which one or more significant inputs are unobservable.</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MDM1_df599ac8-a8ad-423f-948a-7ca2eb94a0d7" escape="true">The Company predominately uses the U.S. dollar as its functional currency.  The functional currency of the Company's foreign operating subsidiaries generally is the applicable local currency.  Assets and liabilities denominated in non-U.S. dollars are translated into U.S. dollars at exchange rates as of the end of the reporting period.  Income and expense items are translated at the average monthly exchange rates during the year.  Resulting translation adjustments are recorded as a component of accumulated other comprehensive loss within stockholders' equity.  Gains and losses from foreign currency transactions, which are denominated in a currency other than the functional currency, are included within other operating expense (income), net in the consolidated statements of operations.  Foreign currency transaction gains and losses have historically not been material.  The Company may be exposed to market risk for changes in foreign exchange rates primarily under certain intercompany receivables and payables.  From time to time, the Company uses foreign exchange forward contracts to mitigate the exposure of the eventual net cash inflows or outflows resulting from these intercompany transactions.  The Company's foreign exchange exposure is not material to the Company's consolidated financial condition.  The Company does not hedge its net investment in non-U.S. subsidiaries because it views those investments as long-term in nature.</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MDAx_d188d1f2-cc41-43b1-87b9-288f3df31691" escape="true">Cash and cash equivalents include all highly-liquid investments with original maturities, at the time acquired by the Company, of three months or less.</ix:nonNumeric></span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211; CONTINUED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions unless otherwise indicated)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><ix:continuation id="ia0cb490aa79c4f6fb39129b05da934c2" continuedAt="ic84d7c4501c545ee827b4e68fb32d58b"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:ConcentrationRiskDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MDcz_00f14b55-6b05-47e3-bf82-341cc40e53a6" escape="true">Financial instruments that potentially subject the Company to concentrations of credit risk are principally cash, cash equivalents, short-term investments, accounts receivable and derivative financial instruments.  The Company's policy is to place its cash, cash equivalents and short-term investments in highly-rated financial instruments and institutions.  Concentration of credit risk with respect to accounts receivable is mitigated by the diversity of the Company's payers and their dispersion across many different geographic regions, and credit risk is concentrated among certain payers who are large buyers of the Company's services.  To reduce risk, the Company routinely assesses the financial strength of these payers and, consequently, believes that its accounts receivable credit risk exposure, with respect to these payers, is limited.  While the Company has receivables due from federal and state governmental agencies, the Company does not believe that such receivables represent a credit risk since the related healthcare programs are funded by federal and state governments, and payment is primarily dependent on submitting appropriate documentation timely.  As of both December&#160;31, 2022 and 2021, receivables due from government payers under the Medicare and Medicaid programs represented approximately <ix:nonFraction unitRef="number" contextRef="iba76f6181ce848fcbd7af0ece345152c_I20221231" decimals="2" name="dgx:PercentageofNetAccountsReceivable" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzExODg5_936350dc-beac-4561-aea8-42eadb5f0cf5">6</ix:nonFraction>% of the Company's consolidated net accounts receivable.  The portion of the Company's accounts receivable due from patients comprises the largest portion of credit risk.  As of December&#160;31, 2022 and 2021, receivables due from patients represented approximately <ix:nonFraction unitRef="number" contextRef="i81be56c5955845f49525165bab74c70f_I20221231" decimals="2" name="dgx:PercentageofNetAccountsReceivable" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzEyMTM1_837db2ce-c5d8-4624-9713-8dcc26271237">18</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i915edbec2fea42159bcc1ba9f3179a51_I20211231" decimals="2" name="dgx:PercentageofNetAccountsReceivable" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzEyMTQy_8701ee87-ae54-4b52-b0b3-e85111b765a1">21</ix:nonFraction>%, respectively, of the Company's consolidated net accounts receivable.  The Company applies assumptions and judgments including historical collection experience (including the period of time that the receivables have been outstanding) for assessing collectability and determining net revenues and accounts receivable from patients.</ix:nonNumeric></span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Credit Losses</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="dgx:AccountsReceivableAndAllowanceForCreditLossesPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MTQw_3340de95-a6b8-4145-87b1-1e3c9cb66fd7" continuedAt="i4d1485e746f645d888af9c7963074878" escape="true">Accounts receivable are reported net of allowances for credit losses.  </ix:nonNumeric></span></div><ix:continuation id="i4d1485e746f645d888af9c7963074878"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;When estimating its allowance for credit losses, the Company pools its trade receivables based on the following customer types: healthcare insurers, government payers, client payers and patients, which are described in Note 3.&#160; The Company principally estimates the allowance for credit losses by pool based on historical collection experience, the current credit worthiness of the customers, current economic conditions, expectations of future economic conditions and the period of time that the receivables have been outstanding.&#160; To the extent that any individual payers are identified that have deteriorated in credit quality, the Company removes the customers from their respective pools and establishes allowances based on the individual risk characteristics of such customers.</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MDk5_382bd057-c2ac-48ed-8b6a-2bf8d60ccaf7" escape="true">Inventories, which consist principally of finished goods testing supplies and reagents, are valued at the lower of cost (first in, first out method) or net realizable value.</ix:nonNumeric>  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MDQ5_25db0b4c-b69c-481a-92f1-c4fe37f52d3d" continuedAt="i6d7009733bbf4a67afeb48a3968f7546" escape="true">Property, plant and equipment is recorded at cost.  Major renewals and improvements are capitalized, while maintenance and repairs are expensed as incurred.  Costs incurred for computer software developed or obtained for internal use are capitalized for application development activities and expensed as incurred for preliminary project activities and post-implementation activities.  Capitalized costs include external direct costs of materials and services consumed in developing or obtaining internal-use software, payroll and payroll-related costs for employees who are directly associated with the internal-use software project, and interest costs incurred, when material, while developing internal-use software.  Capitalization of such costs ceases when the project is substantially complete and ready for its intended purpose.  Costs for maintenance and training are expensed as incurred.  The Company capitalizes interest on borrowings during the active construction period of major capital projects.  Capitalized interest is added to the cost of the underlying assets and is amortized over the expected useful lives of the assets.  Depreciation and amortization are provided on the straight-line method over expected useful asset lives as of December&#160;31, 2022 as follows: </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i6d7009733bbf4a67afeb48a3968f7546"><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">buildings and improvements, ranging up to thirty-one and a half years; </span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">laboratory equipment and furniture and fixtures, ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzE1MDA1_cf798870-e9ec-4915-8333-6fffdab241e2">five</span> to <ix:nonNumeric contextRef="i05ea7f33f7e549de90d8144e632a0571_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzE1MDEx_e5c74e81-babe-45e1-8478-7eb6d4b741c7">twelve years</ix:nonNumeric>; </span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">leasehold improvements, the lesser of the useful life of the improvement or the remaining life of the building or lease, as applicable; and </span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">computer software developed or obtained for internal use, principally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzE1MjE1_15232aa9-a205-41d3-834e-46d37c844c97">five</span> to <ix:nonNumeric contextRef="ifa192df489ca4b7eb7ca0059b95703b2_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzE1MjIx_247ef8e2-ddcb-4b77-8804-70d3522fea99">ten years</ix:nonNumeric>.</span></div></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211; CONTINUED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions unless otherwise indicated)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><ix:continuation id="ic84d7c4501c545ee827b4e68fb32d58b" continuedAt="ida294cdc6bc743658ea2802d1cc50b12"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MDQy_d7b789b3-018a-4725-a6b0-eeb5d3a48651" continuedAt="i55263a1db0564c56a73cae476a9bbf2e" escape="true">Goodwill represents the excess of the fair value of the acquiree (including the fair value of non-controlling interests) over the recognized bases of the net identifiable assets acquired and includes the future economic benefits from other assets that could not be individually identified and separately recognized.  Goodwill is not amortized, but instead is periodically reviewed for impairment and an impairment charge is recorded in the periods in which the recorded carrying value of goodwill exceeds its fair value.  </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i55263a1db0564c56a73cae476a9bbf2e"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On a quarterly basis, the Company performs a review of its business to determine if events or changes in circumstances have occurred which could have a material adverse effect on the fair value of the Company and its goodwill.  If such events or changes in circumstances were deemed to have occurred, the Company would perform an impairment test of goodwill as of the end of the quarter and record any noted impairment loss.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The goodwill test is performed at least annually, or more frequently if events or changes in circumstances indicate that the asset might be impaired.  The annual impairment test includes an option to perform a qualitative assessment of whether it is more likely than not that a reporting unit's fair value is less than its carrying value; the qualitative test may be performed prior to, or as an alternative to, performing a quantitative goodwill impairment test.  If, after assessing the totality of events or circumstances, the Company determines that it is more likely than not that the fair value of a reporting unit is less than its carrying value, then the Company is required to perform the quantitative goodwill impairment test.  Otherwise, no further analysis is required.  Additionally, the Company's policy is to update the fair value calculation of its reporting units and perform the quantitative goodwill impairment test on a periodic basis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The quantitative impairment test involves the comparison of the fair value of the reporting unit to its carrying value.  The Company calculates the fair value of each reporting unit using either (i) a discounted cash flows analysis that converts future cash flow amounts into a single discounted present value amount or (ii) a market approach.  The Company assesses the valuation methodology based upon the relevance and availability of the data at the time that the valuation is performed.  The Company compares the estimate of fair value for the reporting unit to the carrying value of the reporting unit.  If the carrying value is greater than the estimate of fair value, an impairment loss will be recognized in the amount of the excess. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company performs its annual impairment test during the fourth quarter of the fiscal year.  For the years ended December&#160;31, 2022 and 2021, the Company performed a qualitative impairment test for its DIS reporting unit and, based on the totality of information available, the Company concluded that it was more-likely-than-not that the estimated fair value of its DIS reporting unit was greater than the carrying value of the reporting unit and, as such, no further analysis was required.  For the year ended December&#160;31, 2022, the Company updated the fair value calculation of its risk assessment services reporting unit, performed the quantitative impairment test and concluded that goodwill for the reporting unit was not impaired.  For the year ended December 31, 2021, the Company performed a qualitative impairment test for its risk assessment reporting unit and, based on the totality of information available, the Company concluded that it was more-likely-than-not that the estimated fair value of the reporting unit was greater than the carrying value of the reporting unit and, as such, no further analysis was required.</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MDY0_298380e3-4361-4e89-a2c3-cf540457586c" continuedAt="i45a2f0bdfb7642e1b81f456cb38ca70e" escape="true">Intangible assets are recognized at fair value, as an asset apart from goodwill if the asset (i) arises from contractual or other legal rights, or (ii) is separable.  Intangible assets, principally representing the cost of customer-related intangibles, non-competition agreements and technology acquired, are capitalized and amortized on the straight-line method over their expected useful lives, which generally range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzE5MDc3_e109cd52-340f-452f-8421-53cd708ea892">five</span> to <ix:nonNumeric contextRef="i4c9530356f3242cdb77f114a2aa32961_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzE5MDgz_6e37a90a-194f-41dd-8faf-f055479df330">twenty years</ix:nonNumeric>.  Intangible assets with indefinite useful lives, consisting principally of acquired tradenames, are not amortized, but instead are periodically reviewed for impairment.  </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i45a2f0bdfb7642e1b81f456cb38ca70e" continuedAt="i85ccab1bc2844e0e84caeeb6d3c0ec92"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company reviews indefinite-lived intangible assets periodically for impairment and an impairment charge is recorded in the periods in which the recorded carrying value of an indefinite-lived intangible asset is more than its estimated fair value.  The indefinite-lived intangible asset impairment test is performed at least annually, or more frequently in the case of other events that indicate a potential impairment.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Based upon the Company&#8217;s most recent annual impairment tests completed during the fourth quarters of the years ended December&#160;31, 2022 and 2021, the Company concluded that indefinite-lived intangible assets were not impaired.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211; CONTINUED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions unless otherwise indicated)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><div style="padding-right:4.5pt"><span><br/></span></div><ix:continuation id="ida294cdc6bc743658ea2802d1cc50b12" continuedAt="icf0f5991960d4c36b15980313a92315f"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i85ccab1bc2844e0e84caeeb6d3c0ec92">&#160;&#160;&#160;&#160;The Company reviews the recoverability of its long-lived assets (including amortizable intangible assets), other than goodwill and indefinite-lived intangible assets, when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable.  Evaluation of possible impairment is based on the Company's ability to recover the asset from the expected future pre-tax cash flows (undiscounted and without interest charges) of the related operations.  If these cash flows are less than the carrying amount of such asset, an impairment loss is recognized for the difference between the estimated fair value and carrying amount of the asset.</ix:continuation></span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MDgz_c48bb8b4-0fba-4a8b-8685-2ead6d230cb7" continuedAt="i6f48ad3a4bfc46799cded9cc8a0ee0c2" escape="true">The Company's investments (except for those accounted for under the equity method of accounting) include:</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i6f48ad3a4bfc46799cded9cc8a0ee0c2" continuedAt="i069bd0f9a02d4813b1a69ca1af45ab61"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Equity investments with readily determinable fair values, including investments comprised mostly of strategic holdings in companies concentrated in the life sciences and healthcare industries (such investments, which previously did not have readily determinable fair values, became publicly-traded during the year ended December 31, 2021); as well as participant-directed investments of deferred employee compensation and related Company matching contributions held in trusts pursuant to the Company's supplemental deferred compensation plans (see Note 18).  These investments are measured at fair value with both realized and unrealized gains and losses recorded in current earnings within other (expense) income, net in the consolidated statements of operations.  For the years ended December&#160;31, 2022, 2021 and 2020, (losses)/gains from all equity investments with readily determinable fair values totaled $(<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzIxNTYx_307dcf12-4d47-4b92-99ee-3bd6465ab3d3">55</ix:nonFraction>) million, $<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzIxNTY1_c5cc29d6-7bf6-4d5c-9fe4-61212e17b00c">56</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzIxNTcz_168681cd-b25d-418d-a7ab-f349a5577634">8</ix:nonFraction> million, respectively.  See Note 8 for a discussion of the fair value of such investments. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Equity investments that do not have readily determinable fair values, which consist of investments in preferred and common shares of privately held companies.  These investments are measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes.  The Company regularly evaluates these equity investments to determine if there are any indicators that the investment is impaired; <ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="INF" name="dgx:InvestmentwithoutReadilyDeterminableFairValueImpairment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzIyMzY0_25013ac6-8b15-488c-b139-b2759345a359"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="INF" name="dgx:InvestmentwithoutReadilyDeterminableFairValueImpairment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzIyMzY0_250f160d-cd2e-48a3-8214-56bccc1228e4"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="INF" name="dgx:InvestmentwithoutReadilyDeterminableFairValueImpairment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzIyMzY0_97749a40-7e87-4ecc-897c-f65947a9952b">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment charges were recognized related to these investments for the years ended December&#160;31, 2022, 2021 and 2020.  The carrying value of these investments was $<ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzEwOTk1MTE2NjY5OTY_6bb1c5ca-adf1-4c05-aa6a-8c81e2e99bd9"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzEwOTk1MTE2NjY5OTY_829e1408-8528-40d9-b58c-17c09d6e60c3">4</ix:nonFraction></ix:nonFraction>&#160;million at both December&#160;31, 2022 and 2021.  Such amounts were included in other assets in the consolidated balance sheet.</span></div></ix:continuation><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:continuation id="i069bd0f9a02d4813b1a69ca1af45ab61" continuedAt="i4bb27ee4d62d4a238bca091c68a34e98">&#8226;</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"><ix:continuation id="i4bb27ee4d62d4a238bca091c68a34e98">Available-for-sale debt securities of privately-held companies.  These investments are measured at fair value with unrealized gains and losses presented in other comprehensive (loss) income.  The carrying amount of these investments was $<ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzIyODY1_287083d9-b80f-46cd-a7a9-2364c4b74243">2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzIyODcy_7df8db56-5b2e-4395-8cbd-0580d08e824b">1</ix:nonFraction> million at December&#160;31, 2022 and 2021, respectively.  See Note 8 for a discussion of the fair value of such investments.</ix:continuation> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Financial Instruments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MDA5_f842d9ce-4b72-4504-b769-991ecf9abba6" continuedAt="i58a5743ab6f0420e92e75c3b06fc1395" escape="true">The Company uses derivative financial instruments, from time to time, to manage its exposure to market risks for changes in interest rates and foreign currencies.  This strategy includes the use of interest rate swap agreements, forward-starting interest rate swap agreements, interest rate lock agreements and foreign currency forward contracts to manage its exposure to movements in interest and currency rates.  The Company has established policies and procedures for risk assessment and the approval, reporting and monitoring of derivative financial instrument activities.  These policies prohibit holding or issuing derivative financial instruments for speculative purposes.  The Company does not enter into derivative financial instruments that contain credit risk-related contingent features or requirements to post collateral.</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i58a5743ab6f0420e92e75c3b06fc1395" continuedAt="ida695fbcc20e4635aee943fddf621e78"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company is exposed to interest rate risk on its cash and cash equivalents and its debt obligations.  Interest income earned on cash and cash equivalents may fluctuate as interest rates change; however, due to their relatively short maturities, the Company does not hedge these assets or their investment cash flows and the impact of interest rate risk is not material.  The Company's debt obligations consist of fixed-rate and, from time to time, variable-rate debt instruments.  The Company's primary objective is to achieve the lowest overall cost of funding while managing the variability in cash outflows within an acceptable range.  In order to achieve this objective, the Company has historically entered into interest rate swap agreements.  Interest rate swap agreements involve the periodic exchange of payments without the exchange of underlying principal or notional amounts.  Net settlements between the counterparties are recognized as an adjustment to interest expense, net.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company accounts for these derivatives as either an asset or liability measured at its fair value.  The fair value is based upon model-derived valuations in which all significant inputs are observable in active markets including certain financial </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211; CONTINUED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions unless otherwise indicated)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><ix:continuation id="icf0f5991960d4c36b15980313a92315f" continuedAt="id2291053a3b346988ee3a5b740307246"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ida695fbcc20e4635aee943fddf621e78">information and certain assumptions regarding past, present and future market conditions.  For a derivative instrument that has been formally designated as a fair value hedge, fair value gains or losses on the derivative instrument along with offsetting fair value gains or losses on the hedged item that are attributable to the risk being hedged are reported in other (expense) income, net in the consolidated statements of operations.  For derivatives that have been formally designated as a cash flow hedge, the change in the fair value of the derivatives is recorded in accumulated other comprehensive loss.  Upon maturity or early termination of an effective interest rate swap agreement designated as a cash flow hedge, unrealized gains or losses are deferred in stockholders' equity, as a component of accumulated other comprehensive loss, and are amortized as an adjustment to interest expense over the period during which the hedged forecasted transaction affects earnings, which is when the Company recognizes interest expense on the hedged cash flows.  At inception and quarterly thereafter, the Company formally assesses whether the derivatives that are used in hedging transactions are highly effective in offsetting changes in the fair value or cash flows of the hedged item.  After the initial quantitative assessment, this analysis is initially performed on a qualitative basis and, if it is determined that the hedging relationship was and continues to be highly effective, no further analysis is required.  All components of each derivative financial instrument's gain or loss are included in the assessment of hedge effectiveness.  If it is determined that a derivative ceases to be a highly effective hedge, the Company discontinues hedge accounting and any deferred gains or losses related to a discontinued cash flow hedge shall continue to be reported in accumulated other comprehensive loss, unless it is probable that the forecasted transaction will not occur.  If it is probable that the forecasted transaction will not occur by the originally specified time period, the Company discontinues hedge accounting and any deferred gains or losses reported in accumulated other comprehensive loss are classified into earnings immediately.</ix:continuation>  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:StockholdersEquityPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MTMy_5f33774e-c3f8-47c7-9787-6ce2dbaf76fb" continuedAt="i04f178066f8d40429bc1d454a5dad34c" escape="true">Comprehensive income (loss) encompasses all changes in stockholders' equity (except those arising from transactions with stockholders) and includes:</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i04f178066f8d40429bc1d454a5dad34c"><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Foreign currency translation adjustments; </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net deferred gains (losses) on cash flow hedges, which represent deferred gains (losses), net of tax, on interest rate-related derivative financial instruments designated as cash flow hedges, net of amounts reclassified to interest expense (see Notes 16 and 17); and</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net changes in available-for-sale debt securities, which represent unrealized holding gains (losses), net of tax, on available-for-sale debt securities.</span></div></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Costs&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MDA3_e9ff3b83-9cb7-4732-8050-9bf97241ebe2" escape="true">Advertising costs are expensed as incurred.  For the years ended December&#160;31, 2022, 2021 and 2020, advertising costs were $<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI4MTY5_59618dbb-915e-4a51-835c-014361317dd0">74</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI4MTcz_e1fde760-001b-4609-b365-dd2e24ca0429">78</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI4MTgw_49e30dfc-504b-47af-b36b-b851d8649ba9">38</ix:nonFraction>&#160;million, respectively.</ix:nonNumeric></span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Standards </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI4OTk5_eb7e6f7b-45a2-4148-a9df-cae140f63214" continuedAt="i37b7ce6e425948e5bc24e2ed88e8a4b4" escape="true">New Accounting Standards To Be Adopted</ix:nonNumeric></span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="id2291053a3b346988ee3a5b740307246" continuedAt="id680efd92f1f4d85bb1abe25984e631a"><ix:continuation id="i37b7ce6e425948e5bc24e2ed88e8a4b4" continuedAt="if85ba91806f046658405c4109204b5fd">&#160;&#160;&#160;&#160;</ix:continuation></ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id680efd92f1f4d85bb1abe25984e631a"><ix:continuation id="if85ba91806f046658405c4109204b5fd">In March 2020, the Financial Accounting Standards Board ("FASB") issued a new accounting standard which provides temporary optional guidance to ease the potential burden in accounting for reference rate reform due to the risk of cessation of the London Interbank Offered Rate ("LIBOR").  The amendments apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform.  The pronouncement was effective immediately and, due to an accounting standards update which the FASB issued in December 2022, can be applied to contract modifications through December 31, 2024.  To the extent that, prior to December 31, 2024, the Company enters into any contract modifications for which the optional expedients are applied, the adoption of this standard is not expected to have a material impact on the Company&#8217;s consolidated results of operations, financial position or cash flows.</ix:continuation></ix:continuation>&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_184"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211; CONTINUED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions unless otherwise indicated)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90ZXh0cmVnaW9uOmQxNDYxNDJhODllZTQ3NGFiYzI2MTkyNDIyNWU1MjE1Xzc5NzM_a42b11a6-df6e-4e43-866e-e5a3cbde61f8" continuedAt="ic0111967af0f4eafacd2d27b65da37d2" escape="true">REVENUE RECOGNITION</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ic0111967af0f4eafacd2d27b65da37d2" continuedAt="i766c6e35087d47ab91c12c8e347f21d1"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DIS</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Net revenues in the Company&#8217;s DIS business accounted for greater than <ix:nonFraction unitRef="number" contextRef="i73714e6410064c5eac002e398216cb2c_D20210101-20211231" decimals="2" name="dgx:PercentageofNetRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90ZXh0cmVnaW9uOmQxNDYxNDJhODllZTQ3NGFiYzI2MTkyNDIyNWU1MjE1XzEwNw_993afb16-bb09-437b-93ae-7376bdae3b00"><ix:nonFraction unitRef="number" contextRef="id9ea9ce1f68f4cde8b57ba97522e9899_D20220101-20221231" decimals="2" name="dgx:PercentageofNetRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90ZXh0cmVnaW9uOmQxNDYxNDJhODllZTQ3NGFiYzI2MTkyNDIyNWU1MjE1XzEwNw_b32b3c7f-34ab-463d-92cd-cd9117a85934"><ix:nonFraction unitRef="number" contextRef="ifbf8633ce3e245ac94d164f390ff90af_D20200101-20201231" decimals="2" name="dgx:PercentageofNetRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90ZXh0cmVnaW9uOmQxNDYxNDJhODllZTQ3NGFiYzI2MTkyNDIyNWU1MjE1XzEwNw_dad166fc-e478-46e9-bac5-c0984ba1f529">95</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of the Company&#8217;s consolidated net revenues for the years ended December&#160;31, 2022, 2021 and 2020 and are primarily comprised of a high volume of relatively low-dollar transactions.  The DIS business, which provides clinical testing services and other services, satisfies its performance obligation and recognizes revenues primarily upon completion of the testing process (when results are reported) or when services have been rendered.  The Company estimates the amount of consideration it expects to be entitled to receive from customer groups in exchange for providing services using the portfolio approach. These estimates include the impact of contractual allowances (including payer denials), and patient price concessions, as discussed below. The portfolios determined using the portfolio approach consist of the following groups of customers: healthcare insurers, government payers (Medicare and Medicaid programs), client payers and patients.  Contracts with customers in the DIS business do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation.  The Company follows a standard process, which considers historical denial and collection experience and other factors (including the period of time that the receivables have been outstanding), to estimate contractual allowances and implicit price concessions, recording adjustments in the current period as changes in estimates.  Further adjustments to the allowances, based on actual receipts, may be recorded upon settlement.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following are descriptions of the DIS business&#8217; portfolios:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healthcare Insurers </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Reimbursements from healthcare insurers are based on negotiated fee-for-service schedules and on capitated payment rates.  Under fee-for-service arrangements, healthcare insurers are billed at the Company's list price.  Net revenues recognized consist of amounts billed net of contractual allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payers, which considers historical denial and collection experience and the terms of the Company&#8217;s contractual arrangements. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Collection of the Company's net revenues from healthcare insurers is normally a function of providing complete and correct billing information to the healthcare insurers within the various filing deadlines and generally occurs within <ix:nonNumeric contextRef="i7d71e5c8af24471ca79d701791aa2094_D20220101-20221231" name="dgx:RevenueCollectionofConsiderationPeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90ZXh0cmVnaW9uOmQxNDYxNDJhODllZTQ3NGFiYzI2MTkyNDIyNWU1MjE1XzI2NjU_def9d786-e706-4aa5-ad55-43ac39739920">30</ix:nonNumeric> to <ix:nonNumeric contextRef="i1d2e4bb54e5b41c9be7d8748b8f55367_D20220101-20221231" name="dgx:RevenueCollectionofConsiderationPeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90ZXh0cmVnaW9uOmQxNDYxNDJhODllZTQ3NGFiYzI2MTkyNDIyNWU1MjE1XzI2NzE_e7ce2004-731d-4fb8-85c2-70be7791a00d">60</ix:nonNumeric> days of billing.  Provided the Company has billed healthcare insurers accurately with complete information prior to the established filing deadline, there has historically been little to no credit risk.  If there has been a delay in billing, the Company determines if the amounts in question will likely go past the filing deadline, and if so, it will reserve accordingly for the billing.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Under capitated arrangements with healthcare insurers, the Company recognizes revenue based on a predetermined monthly reimbursement rate for each member of an insurer's health plan regardless of the number or cost of services provided by the Company.  Healthcare insurers typically reimburse the Company under capitated arrangements in the same month services are performed, essentially giving rise to no outstanding accounts receivable at the end of a reporting period.  If any capitated payments are not received on a timely basis, the Company determines the cause and makes a separate determination as to whether or not the collection of the amount from the healthcare insurer is at risk and, if so, would reserve accordingly.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Payers</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211; CONTINUED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions unless otherwise indicated)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><ix:continuation id="i766c6e35087d47ab91c12c8e347f21d1" continuedAt="i43c04904c97d49818cb6b527581bd27b"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Reimbursements from government payers are based on fee-for-service schedules set by governmental authorities, including traditional Medicare and Medicaid.  Net revenues recognized consist of amounts billed net of contractual allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payers, which considers historical denial and collection experience and other factors. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Collection of the Company's net revenues from government payers is normally a function of providing the complete and correct billing information within the various filing deadlines and generally occurs within <ix:nonNumeric contextRef="ic16acd3f5abe4057b2ded728e43030c9_D20220101-20221231" name="dgx:RevenueCollectionofConsiderationPeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90ZXh0cmVnaW9uOmQxNDYxNDJhODllZTQ3NGFiYzI2MTkyNDIyNWU1MjE1XzQ0NjU_6483b2ac-2577-47d9-8764-fd40146d7d68">30</ix:nonNumeric> days of billing.  Provided the Company has billed government payers accurately with complete information prior to the established filing deadline, there has historically been little to no credit risk.  If there has been a delay in billing, the Company determines if the amounts in question will likely go past the filing deadline, and, if so, it will reserve for the billing accordingly.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Client Payers </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Client payers include physicians, hospitals, ACOs, IDNs, employers, other commercial laboratories and institutions for which services are performed on a wholesale basis, and are billed based on negotiated fee schedules.  Credit risk and ability to pay are more of a consideration for these payers than healthcare insurers and government payers.  Collection of consideration the Company expects to receive generally occurs within <ix:nonNumeric contextRef="ifa2bee4df39349539bed4c4b3462277a_D20220101-20221231" name="dgx:RevenueCollectionofConsiderationPeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90ZXh0cmVnaW9uOmQxNDYxNDJhODllZTQ3NGFiYzI2MTkyNDIyNWU1MjE1XzUzMTA_53b6161f-a0f5-4935-9cf1-f373e210d776">60</ix:nonNumeric> to <ix:nonNumeric contextRef="i94893ea869b54dd78d6d051a6bad548d_D20220101-20221231" name="dgx:RevenueCollectionofConsiderationPeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90ZXh0cmVnaW9uOmQxNDYxNDJhODllZTQ3NGFiYzI2MTkyNDIyNWU1MjE1XzUzMTY_a7f19d31-ec56-4586-9eb8-c52432a61495">90</ix:nonNumeric> days of billing.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company principally estimates the allowance for credit losses for client payers based on historical collection experience, the current credit worthiness of the customers, current economic conditions, expectations of future economic conditions and the period of time that the receivables have been outstanding. To the extent that any individual client payers are identified that have deteriorated in credit quality, the Company establishes allowances based on the individual risk characteristics of such customers.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patients</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Uninsured patients are billed based on established patient fee schedules or fees negotiated with physicians on behalf of their patients.  Insured patients (includes coinsurance and deductible responsibilities) are billed based on fees negotiated with healthcare insurers.  Collection of billings from patients is subject to credit risk and ability of the patients to pay.  Net revenues consist of amounts billed net of discounts provided to uninsured patients in accordance with the Company&#8217;s policies and implicit price concessions.  Implicit price concessions represent differences between amounts billed and the estimated consideration the Company expects to receive from patients, which considers historical collection experience (including the period of time that the receivables have been outstanding) and other factors including current market conditions. Patient billings are generally fully reserved for when the related service reaches <ix:nonNumeric contextRef="icf5f880be7d24d7a8c69fe4843654a88_D20220101-20221231" name="dgx:PeriodofBillingFullyReserve" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90ZXh0cmVnaW9uOmQxNDYxNDJhODllZTQ3NGFiYzI2MTkyNDIyNWU1MjE1XzY4MTc_ce5257ee-bd02-4b2c-838a-d11435476c98">210</ix:nonNumeric> days outstanding.  Balances are automatically written off when they are sent to collection agencies.  Allowances are further adjusted for estimated recoveries of amounts sent to collection agencies based on historical collection experience, which is regularly monitored.  Collection of consideration the Company expects to receive generally occurs within <ix:nonNumeric contextRef="ib881549de5d14c42a72abbd13bb6179b_D20220101-20221231" name="dgx:RevenueCollectionofConsiderationPeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90ZXh0cmVnaW9uOmQxNDYxNDJhODllZTQ3NGFiYzI2MTkyNDIyNWU1MjE1XzcxNzU_47306fce-1196-4801-a6dc-2ddfd6969447">30</ix:nonNumeric> to <ix:nonNumeric contextRef="i25375b7fc67348ac91275e0d3f7a1f4b_D20220101-20221231" name="dgx:RevenueCollectionofConsiderationPeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90ZXh0cmVnaW9uOmQxNDYxNDJhODllZTQ3NGFiYzI2MTkyNDIyNWU1MjE1XzcxODE_5dbc759f-c915-411b-9fdf-f4246f92aed6">60</ix:nonNumeric> days of billing.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DS</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company&#8217;s DS businesses primarily satisfy their performance obligations and recognize revenues when delivery has occurred or services have been rendered.  Collection of consideration the Company expects to receive generally occurs within <ix:nonNumeric contextRef="i4f428209a39d4b7b8a174be53283b875_D20220101-20221231" name="dgx:RevenueCollectionofConsiderationPeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90ZXh0cmVnaW9uOmQxNDYxNDJhODllZTQ3NGFiYzI2MTkyNDIyNWU1MjE1Xzc0NTA_34327fbd-e894-493e-aaba-508f23487fd3">30</ix:nonNumeric> to <ix:nonNumeric contextRef="i9fd62e07b13c458892bd229457bbe1b5_D20220101-20221231" name="dgx:RevenueCollectionofConsiderationPeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90ZXh0cmVnaW9uOmQxNDYxNDJhODllZTQ3NGFiYzI2MTkyNDIyNWU1MjE1Xzc0NTY_fab5c063-a0e2-4223-bff1-0f07dfc3c737">60</ix:nonNumeric> days of billing.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211; CONTINUED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions unless otherwise indicated)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><ix:continuation id="i43c04904c97d49818cb6b527581bd27b"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90ZXh0cmVnaW9uOmQxNDYxNDJhODllZTQ3NGFiYzI2MTkyNDIyNWU1MjE1Xzc5Nzg_844160dc-3698-4827-8355-25cad1f446c5" continuedAt="i2a21d8a66fe5469694b22be6c8e8e4e1" escape="true">The approximate percentage of net revenues by type of customer was as follows:</ix:nonNumeric></span></div><div style="text-align:center;text-indent:36pt"><ix:continuation id="i2a21d8a66fe5469694b22be6c8e8e4e1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:62.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.699%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.699%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.702%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare insurers:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fee-for-service</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i01555413d91d42e3b436c505bbc70a67_D20220101-20221231" decimals="2" name="dgx:PercentageofNetRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzMtMS0xLTEtNzgyMTU_775fe213-8eeb-49f0-8763-f4dedf7418b3">38</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i82dfa27313e34853973b9607939068a5_D20210101-20211231" decimals="2" name="dgx:PercentageofNetRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzMtMy0xLTEtNzgyMTU_9690ab6e-1bcc-4feb-bbd8-bd2c82331b79">39</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i391fa00d0a7e46b0bc4a34ff6434ba24_D20200101-20201231" decimals="2" name="dgx:PercentageofNetRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzMtNS0xLTEtNzgyMTU_959d3213-0f6c-4253-b8b1-432902a5c838">34</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitated</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idd41f50ca74e49ffadac56ef4c8022aa_D20220101-20221231" decimals="2" name="dgx:PercentageofNetRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzQtMS0xLTEtNzgyMTU_0165f04b-8458-4a57-a4a9-e1258e5024a1">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0be3de26f2574a208f21fd35944e0cad_D20210101-20211231" decimals="2" name="dgx:PercentageofNetRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzQtMy0xLTEtNzgyMTU_abcb0422-1f69-4dee-85c3-2785019b0667">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4ee750c8e58548218454f6b303208917_D20200101-20201231" decimals="2" name="dgx:PercentageofNetRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzQtNS0xLTEtNzgyMTU_55ea4db7-81ad-4594-97ee-05c0f5ff61b2">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total healthcare insurers</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5a3f190b89e94247905769314473af12_D20220101-20221231" decimals="2" name="dgx:PercentageofNetRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzUtMS0xLTEtNzgyMTU_88f099a4-0525-4057-a194-f71d1da45fd5">41</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i509d8b446ac14984bc658ece06fea971_D20210101-20211231" decimals="2" name="dgx:PercentageofNetRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzUtMy0xLTEtNzgyMTU_fc009f75-f626-44f1-bda4-0588672bbfb5">42</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i18a0eea57b5d4a778b3c4fc7048a92d0_D20200101-20201231" decimals="2" name="dgx:PercentageofNetRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzUtNS0xLTEtNzgyMTU_77b819c4-52c3-44b1-abe3-ecf46ab185d9">37</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government payers</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib62f2d7bef64474dbe05584de6966e18_D20220101-20221231" decimals="2" name="dgx:PercentageofNetRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzYtMS0xLTEtNzgyMTU_ca41b615-264d-43e5-a406-fba07bba850f">11</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i316b4c39b6be48408e5109495bc92124_D20210101-20211231" decimals="2" name="dgx:PercentageofNetRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzYtMy0xLTEtNzgyMTU_e6b31b3d-ccd6-4808-b71b-4faa236421a2">10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i27098106112f421c94055f0cdae93371_D20200101-20201231" decimals="2" name="dgx:PercentageofNetRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzYtNS0xLTEtNzgyMTU_718b3ffd-82c6-4dd8-80cb-d91a8cdf70b8">11</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Client payers</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i99d6e0655d0f4b178b998f09b7ac1aa5_D20220101-20221231" decimals="2" name="dgx:PercentageofNetRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzctMS0xLTEtNzgyMTU_47114b64-4c0e-4703-8c21-5ca0826bc98d">33</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if95a07a0521045d7aa3fd6eca9554b97_D20210101-20211231" decimals="2" name="dgx:PercentageofNetRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzctMy0xLTEtNzgyMTU_ad318e1f-794a-49ec-acc5-1183a56cf2d7">33</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i397e6f4394d44cd0bbe7d033eb4fb637_D20200101-20201231" decimals="2" name="dgx:PercentageofNetRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzctNS0xLTEtNzgyMTU_01bfb8a6-3807-43db-ad7d-357c295201c0">38</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients (including coinsurance and deductible responsibilities)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icf5f880be7d24d7a8c69fe4843654a88_D20220101-20221231" decimals="2" name="dgx:PercentageofNetRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzgtMS0xLTEtNzgyMTU_a7bfc11d-5a5d-498f-989b-72f119f84ea6">12</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibcdd11aeccf94ec496587c6ccc6a4281_D20210101-20211231" decimals="2" name="dgx:PercentageofNetRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzgtMy0xLTEtNzgyMTU_23ac0175-a8c2-4c06-9449-601f5de355c4">12</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8f3ad29ae1e34df5b6995f7ffaeaa6cf_D20200101-20201231" decimals="2" name="dgx:PercentageofNetRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzgtNS0xLTEtNzgyMTU_fe3973f8-83da-42f5-b393-04614eb0dcaa">11</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total DIS</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i74ad488f1dfb40baa83701a002b6d98f_D20220101-20221231" decimals="2" name="dgx:PercentageofNetRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzktMS0xLTEtNzgyMTU_fb3675ab-82af-45a5-89e7-daf6a4482b57">97</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i680bf76bfe8647638c33f242f0ef1980_D20210101-20211231" decimals="2" name="dgx:PercentageofNetRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzktMy0xLTEtNzgyMTU_8c185403-6304-4f53-8b1c-cd0f26580dc5">97</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic662fc7ebbb744a885416e3447893d64_D20200101-20201231" decimals="2" name="dgx:PercentageofNetRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzktNS0xLTEtNzgyMTU_407ace74-7622-44a6-9d67-6c52e06b90b9">97</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DS</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie0468d2fc9ab47638da16013b1893683_D20220101-20221231" decimals="2" name="dgx:PercentageofNetRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzEwLTEtMS0xLTc4MjE1_6ef9eff3-a68a-4974-aa16-8a9ed09bc4dd">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idd3a7338f2d040dda1e6639ac9f7d70f_D20210101-20211231" decimals="2" name="dgx:PercentageofNetRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzEwLTMtMS0xLTc4MjE1_30f56d15-bc91-44eb-9a0d-622659ecac67">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic76d3eea03004ba5aed3d7cc7917604b_D20200101-20201231" decimals="2" name="dgx:PercentageofNetRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzEwLTUtMS0xLTc4MjE1_4d737021-f484-46b9-af96-73569ca5e26c">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="INF" name="dgx:PercentageofNetRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzExLTEtMS0xLTc4MjE1_a89a8009-4e38-4e47-b74b-7c17c3c8295c">100</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="INF" name="dgx:PercentageofNetRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzExLTMtMS0xLTc4MjE1_34b70b1d-2df4-4425-9489-6bfb1c61f642">100</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="INF" name="dgx:PercentageofNetRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzExLTUtMS0xLTc4MjE1_3386dfb6-5c3a-4f7d-b60f-354535490d9d">100</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the years ended December&#160;31, 2022, 2021 and 2020, substantially all of the Company&#8217;s services were provided within the United States, see Note 20.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="dgx:AccountsReceivableDisaggregationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90ZXh0cmVnaW9uOmQxNDYxNDJhODllZTQ3NGFiYzI2MTkyNDIyNWU1MjE1Xzc5Nzc_a3bc694f-6a4c-4400-b47b-4f4140754db3" continuedAt="ie17fb88ccf7647edac1960b85e2a472d" escape="true">The approximate percentage of net accounts receivable by type of customer as of December&#160;31, 2022 and 2021 was as follows:</ix:nonNumeric></span></div><div style="text-align:center"><ix:continuation id="ie17fb88ccf7647edac1960b85e2a472d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:74.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.771%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare insurers</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia6826b0f73ee4f00ab77a97be130c154_I20221231" decimals="2" name="dgx:PercentageofNetAccountsReceivable" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTo0MjI4NGM1N2JjNDg0MGQ3YTkwYmQ5ZjU2OWVlZTYzZC90YWJsZXJhbmdlOjQyMjg0YzU3YmM0ODQwZDdhOTBiZDlmNTY5ZWVlNjNkXzItMS0xLTEtNzgyMTU_1ba4cf20-5cf1-442d-91f7-09406ca1c700">28</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic12c618fa4d74532b772090eef552ce5_I20211231" decimals="2" name="dgx:PercentageofNetAccountsReceivable" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTo0MjI4NGM1N2JjNDg0MGQ3YTkwYmQ5ZjU2OWVlZTYzZC90YWJsZXJhbmdlOjQyMjg0YzU3YmM0ODQwZDdhOTBiZDlmNTY5ZWVlNjNkXzItMy0xLTEtNzgyMTU_60efe44d-8f2d-416a-9ec0-616295b8559e">32</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government payers</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iba76f6181ce848fcbd7af0ece345152c_I20221231" decimals="2" name="dgx:PercentageofNetAccountsReceivable" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTo0MjI4NGM1N2JjNDg0MGQ3YTkwYmQ5ZjU2OWVlZTYzZC90YWJsZXJhbmdlOjQyMjg0YzU3YmM0ODQwZDdhOTBiZDlmNTY5ZWVlNjNkXzMtMS0xLTEtNzgyMTU_936350dc-beac-4561-aea8-42eadb5f0cf5">6</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i34f778b2b04c48679029b462c5367cb2_I20211231" decimals="2" name="dgx:PercentageofNetAccountsReceivable" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTo0MjI4NGM1N2JjNDg0MGQ3YTkwYmQ5ZjU2OWVlZTYzZC90YWJsZXJhbmdlOjQyMjg0YzU3YmM0ODQwZDdhOTBiZDlmNTY5ZWVlNjNkXzMtMy0xLTEtNzgyMTU_8a87f053-fa56-4ae2-a965-2147bcc6fcac">6</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Client payers</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibaf0eafb0e0a4b05aa543fafe1dafb0a_I20221231" decimals="2" name="dgx:PercentageofNetAccountsReceivable" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTo0MjI4NGM1N2JjNDg0MGQ3YTkwYmQ5ZjU2OWVlZTYzZC90YWJsZXJhbmdlOjQyMjg0YzU3YmM0ODQwZDdhOTBiZDlmNTY5ZWVlNjNkXzQtMS0xLTEtNzgyMTU_f5cffab1-59d3-4772-a09e-c33616ef1bac">44</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e02c394b9084450982de162d83141b3_I20211231" decimals="2" name="dgx:PercentageofNetAccountsReceivable" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTo0MjI4NGM1N2JjNDg0MGQ3YTkwYmQ5ZjU2OWVlZTYzZC90YWJsZXJhbmdlOjQyMjg0YzU3YmM0ODQwZDdhOTBiZDlmNTY5ZWVlNjNkXzQtMy0xLTEtNzgyMTU_f76a2b99-0c36-4452-a1b6-d8a59983f249">38</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients (including coinsurance and deductible responsibilities)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i81be56c5955845f49525165bab74c70f_I20221231" decimals="2" name="dgx:PercentageofNetAccountsReceivable" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTo0MjI4NGM1N2JjNDg0MGQ3YTkwYmQ5ZjU2OWVlZTYzZC90YWJsZXJhbmdlOjQyMjg0YzU3YmM0ODQwZDdhOTBiZDlmNTY5ZWVlNjNkXzUtMS0xLTEtNzgyMTU_837db2ce-c5d8-4624-9713-8dcc26271237">18</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i915edbec2fea42159bcc1ba9f3179a51_I20211231" decimals="2" name="dgx:PercentageofNetAccountsReceivable" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTo0MjI4NGM1N2JjNDg0MGQ3YTkwYmQ5ZjU2OWVlZTYzZC90YWJsZXJhbmdlOjQyMjg0YzU3YmM0ODQwZDdhOTBiZDlmNTY5ZWVlNjNkXzUtMy0xLTEtNzgyMTU_8701ee87-ae54-4b52-b0b3-e85111b765a1">21</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total DIS</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6a770caf14c1492f8e3fbcaf507b29ae_I20221231" decimals="2" name="dgx:PercentageofNetAccountsReceivable" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTo0MjI4NGM1N2JjNDg0MGQ3YTkwYmQ5ZjU2OWVlZTYzZC90YWJsZXJhbmdlOjQyMjg0YzU3YmM0ODQwZDdhOTBiZDlmNTY5ZWVlNjNkXzYtMS0xLTEtNzgyMTU_bb9cfbdb-4b45-4e36-ae34-2232fc6bdd85">96</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i762548338af343bcbc7df9361e2ba54e_I20211231" decimals="2" name="dgx:PercentageofNetAccountsReceivable" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTo0MjI4NGM1N2JjNDg0MGQ3YTkwYmQ5ZjU2OWVlZTYzZC90YWJsZXJhbmdlOjQyMjg0YzU3YmM0ODQwZDdhOTBiZDlmNTY5ZWVlNjNkXzYtMy0xLTEtNzgyMTU_74f24464-f9b4-40d4-8bbb-e7ffa53eb433">97</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DS</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia340b53589ac4a729154593b434a8b5b_I20221231" decimals="2" name="dgx:PercentageofNetAccountsReceivable" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTo0MjI4NGM1N2JjNDg0MGQ3YTkwYmQ5ZjU2OWVlZTYzZC90YWJsZXJhbmdlOjQyMjg0YzU3YmM0ODQwZDdhOTBiZDlmNTY5ZWVlNjNkXzctMS0xLTEtNzgyMTU_01eddaa4-8821-4ac8-ae65-722f58d1b0f3">4</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i69908b0e9ded44c68e9a26989fdf9843_I20211231" decimals="2" name="dgx:PercentageofNetAccountsReceivable" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTo0MjI4NGM1N2JjNDg0MGQ3YTkwYmQ5ZjU2OWVlZTYzZC90YWJsZXJhbmdlOjQyMjg0YzU3YmM0ODQwZDdhOTBiZDlmNTY5ZWVlNjNkXzctMy0xLTEtNzgyMTU_7b06eec7-57c2-4e68-a8b6-f95f7fc141c5">3</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net accounts receivable</span></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="INF" name="dgx:PercentageofNetAccountsReceivable" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTo0MjI4NGM1N2JjNDg0MGQ3YTkwYmQ5ZjU2OWVlZTYzZC90YWJsZXJhbmdlOjQyMjg0YzU3YmM0ODQwZDdhOTBiZDlmNTY5ZWVlNjNkXzgtMS0xLTEtNzgyMTU_20b3e52e-93ff-4247-b782-4492c67e5414">100</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="INF" name="dgx:PercentageofNetAccountsReceivable" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTo0MjI4NGM1N2JjNDg0MGQ3YTkwYmQ5ZjU2OWVlZTYzZC90YWJsZXJhbmdlOjQyMjg0YzU3YmM0ODQwZDdhOTBiZDlmNTY5ZWVlNjNkXzgtMy0xLTEtNzgyMTU_67e5941c-fd5b-4fed-827c-4821a72900b1">100</ix:nonFraction>%</span></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90ZXh0cmVnaW9uOmQxNDYxNDJhODllZTQ3NGFiYzI2MTkyNDIyNWU1MjE1Xzc5ODA_ecc4024f-6e5c-4044-af35-c542dac28a3f" continuedAt="i7c5e05a6fd3340e6bece1fc6fe8deae5" escape="true">The following table summarizes the activity for the Company's allowance for credit losses during the years ended December&#160;31, 2022 and 2021, which principally relates to client payers:</ix:nonNumeric></span></div><div style="text-align:center"><ix:continuation id="i7c5e05a6fd3340e6bece1fc6fe8deae5"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Allowance for Credit Losses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872b3ea2e369403f8c0129ff07e0b538_I20201231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTplZWVhZTY0OGEyMTc0ODQzYmYzNWIzMGE1NmUyNjUzNi90YWJsZXJhbmdlOmVlZWFlNjQ4YTIxNzQ4NDNiZjM1YjMwYTU2ZTI2NTM2XzItMS0xLTEtNzgyMTU_15e091eb-5d55-4595-926d-539f05bee841">28</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for credit losses</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTplZWVhZTY0OGEyMTc0ODQzYmYzNWIzMGE1NmUyNjUzNi90YWJsZXJhbmdlOmVlZWFlNjQ4YTIxNzQ4NDNiZjM1YjMwYTU2ZTI2NTM2XzMtMS0xLTEtNzgyMTU_57346205-a772-4ab6-ba35-39864e02e45e">4</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs of accounts receivable, net of recoveries</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTplZWVhZTY0OGEyMTc0ODQzYmYzNWIzMGE1NmUyNjUzNi90YWJsZXJhbmdlOmVlZWFlNjQ4YTIxNzQ4NDNiZjM1YjMwYTU2ZTI2NTM2XzQtMS0xLTEtNzgyMTU_18b9718b-55c8-456f-942b-ee47b0c2863e">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTplZWVhZTY0OGEyMTc0ODQzYmYzNWIzMGE1NmUyNjUzNi90YWJsZXJhbmdlOmVlZWFlNjQ4YTIxNzQ4NDNiZjM1YjMwYTU2ZTI2NTM2XzUtMS0xLTEtNzgyMTU_84160d8a-eeee-4475-b333-35300f5901d8">31</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for credit losses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTplZWVhZTY0OGEyMTc0ODQzYmYzNWIzMGE1NmUyNjUzNi90YWJsZXJhbmdlOmVlZWFlNjQ4YTIxNzQ4NDNiZjM1YjMwYTU2ZTI2NTM2XzYtMS0xLTEtNzgyMTU_58b52080-ed67-4986-b0b7-beb49cfb4695">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs of accounts receivable, net of recoveries</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTplZWVhZTY0OGEyMTc0ODQzYmYzNWIzMGE1NmUyNjUzNi90YWJsZXJhbmdlOmVlZWFlNjQ4YTIxNzQ4NDNiZjM1YjMwYTU2ZTI2NTM2XzctMS0xLTEtNzgyMTU_9cda3ad6-e76e-4060-a5ea-08a7982ec736">4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, December&#160;31, 2022</span></div></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTplZWVhZTY0OGEyMTc0ODQzYmYzNWIzMGE1NmUyNjUzNi90YWJsZXJhbmdlOmVlZWFlNjQ4YTIxNzQ4NDNiZjM1YjMwYTU2ZTI2NTM2XzgtMS0xLTEtNzgyMTU_5161d36f-6415-4bea-88fb-65405061b222">30</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_187"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211; CONTINUED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions unless otherwise indicated)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90ZXh0cmVnaW9uOjNhMGFmYWU5NWY2OTQyYjRhMmM4NTNhNGIxMWJiODYzXzUwNg_710bcc44-0df7-452a-959c-79d8c439fba6" continuedAt="ia09ec55700714a92be6bbe28b31d30ef" escape="true">EARNINGS PER SHARE</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ia09ec55700714a92be6bbe28b31d30ef"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90ZXh0cmVnaW9uOjNhMGFmYWU5NWY2OTQyYjRhMmM4NTNhNGIxMWJiODYzXzQ5OA_d8be5321-e2d9-42d4-bd85-11cdd5887ac5" continuedAt="i4961799ba9254ebba77470b0c3ea520f" escape="true">The computation of basic and diluted earnings per common share is as follows (in millions, except per share data):</ix:nonNumeric></span></div><div style="text-align:center"><ix:continuation id="i4961799ba9254ebba77470b0c3ea520f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts attributable to Quest Diagnostics&#8217; common stockholders:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Quest Diagnostics</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzQtMS0xLTEtNzgyMTU_7118c3b8-096c-4d38-80af-423140b9db32">946</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzQtMy0xLTEtNzgyMTU_64d76494-204b-439d-b6ce-19b3ad78b074">1,995</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzQtNS0xLTEtNzgyMTU_cea17a75-c081-486d-a7a4-2fe6236a5081">1,431</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Earnings allocated to participating securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzctMS0xLTEtNzgyMTU_03a5c938-8440-4488-90f3-2cf0208a9c01">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzctMy0xLTEtNzgyMTU_fdf346ea-5f3b-473f-bb87-ec1aeca41fda">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzctNS0xLTEtNzgyMTU_b048efb1-c3c7-4b70-ba7c-071474568138">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings available to Quest Diagnostics&#8217; common stockholders &#8211; basic and diluted</span></div></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzgtMS0xLTEtNzgyMTU_8c8cba7b-947e-4304-babb-b42bb5d3b57b">942</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzgtMy0xLTEtNzgyMTU_592da970-f9b6-4add-a0f4-83f239d65bac">1,988</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzgtNS0xLTEtNzgyMTU_6daa96cd-6bda-4a9f-92ce-e47a362f06d2">1,425</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding &#8211; basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzEwLTEtMS0xLTc4MjE1_e2f2ca7d-0f16-427f-81a0-487845ee5f03">116</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzEwLTMtMS0xLTc4MjE1_1ea447f1-29ab-413f-8754-133e6b207aa2">125</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzEwLTUtMS0xLTc4MjE1_307dbbb2-c0a0-49d0-b8fa-9b1c639ad8fd">134</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and performance share units</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzEyLTEtMS0xLTc4MjE1_0a368a69-f8fd-42a3-a64e-9edd54ca1098">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzEyLTMtMS0xLTc4MjE1_6140b8e4-64e0-4571-8ae0-bfa4a5d841fa">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzEyLTUtMS0xLTc4MjE1_4d3ad67c-c36d-49f3-b313-6cc795112e26">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding &#8211; diluted</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzEzLTEtMS0xLTc4MjE1_7a759291-ca09-44f1-afbf-6db81d032846">118</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzEzLTMtMS0xLTc4MjE1_d05ed9c4-9e54-4e82-9ecb-927c595a32d0">128</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzEzLTUtMS0xLTc4MjE1_a5f992bd-0ee7-4a06-adb9-4c59ea111e80">136</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings per share attributable to Quest Diagnostics&#8217; common stockholders:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzE4LTEtMS0xLTc4MjE1_8bf09634-c2ad-4311-a117-f3c9afa68c55">8.10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzE4LTMtMS0xLTc4MjE1_adbaf1b2-9a7a-4541-9162-b328ebab959a">15.85</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzE4LTUtMS0xLTc4MjE1_94c82c26-64f8-4a52-bb35-300c62640f12">10.62</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzIzLTEtMS0xLTc4MjE1_5d894d25-df6a-4e5a-aad8-bf516183a276">7.97</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzIzLTMtMS0xLTc4MjE1_cffe72d2-9106-4c58-9908-7c97f44bf96a">15.55</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzIzLTUtMS0xLTc4MjE1_691fcd0a-b659-4664-83fc-06e696d7dec9">10.47</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90ZXh0cmVnaW9uOjNhMGFmYWU5NWY2OTQyYjRhMmM4NTNhNGIxMWJiODYzXzUxMA_b08940d3-94ad-4e60-a441-51cec38c2253" continuedAt="i9f1634b4c3ba4a01a4a057c616c9a4e7" escape="true">The following securities were not included in the calculation of diluted earnings per share due to their antidilutive effect:</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="i9f1634b4c3ba4a01a4a057c616c9a4e7"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and performance share units</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTo0ZGQ2MWU4MGI0ZjE0ZTgyOGQzZjRiYWE0ZmJmMmZlNC90YWJsZXJhbmdlOjRkZDYxZTgwYjRmMTRlODI4ZDNmNGJhYTRmYmYyZmU0XzItMS0xLTEtNzgyMTU_1b53dc19-bc52-46d8-9c50-f2247297f12d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTo0ZGQ2MWU4MGI0ZjE0ZTgyOGQzZjRiYWE0ZmJmMmZlNC90YWJsZXJhbmdlOjRkZDYxZTgwYjRmMTRlODI4ZDNmNGJhYTRmYmYyZmU0XzItMy0xLTEtNzgyMTU_3e50c207-ec81-456a-928d-7f026307c8ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTo0ZGQ2MWU4MGI0ZjE0ZTgyOGQzZjRiYWE0ZmJmMmZlNC90YWJsZXJhbmdlOjRkZDYxZTgwYjRmMTRlODI4ZDNmNGJhYTRmYmYyZmU0XzItNS0xLTEtNzgyMTU_e475b355-dc04-4d6d-9fd4-efb2eb0938a6">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_1994"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211; CONTINUED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions unless otherwise indicated)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGV4dHJlZ2lvbjpjN2EzMmYzNzk0YjU0NGE2YmM1YTIxMzhiZTM0MjE3NF8yNzQ4Nzc5MDcyOTk3_38bef7b7-fe38-4341-8ed2-82d658b84207" continuedAt="i93d0d3d06ea24206bb31899423211d62" escape="true">RESTRUCTURING ACTIVITIES</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:continuation id="i93d0d3d06ea24206bb31899423211d62" continuedAt="i0266ac475e834e1ea64f4c39913bcd52"> </ix:continuation></span></div><div><span><br/></span></div><ix:continuation id="i0266ac475e834e1ea64f4c39913bcd52"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Invigorate Program</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company is committed to a program called Invigorate which is designed to reduce its cost structure and improve performance.  Invigorate consists of several flagship programs, with structured plans in each, to drive savings and improve performance across the customer value chain.  These flagship programs include: organization excellence; information technology excellence; procurement excellence; field and customer service excellence; lab excellence; and revenue services excellence.  In addition to these programs, the Company identified key themes to change how it operates including reducing denials and patient price concessions; further digitizing the business; standardization; automation; optimization and selecting and retaining talent. The Invigorate program is intended to offset reimbursement pressures and labor and benefit cost increases; free up additional resources to invest in innovation and other growth initiatives; and enable the Company to improve service quality and operating profitability. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Restructuring Charges</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGV4dHJlZ2lvbjpjN2EzMmYzNzk0YjU0NGE2YmM1YTIxMzhiZTM0MjE3NF8yNzQ4Nzc5MDcyOTk4_d6c6b631-b9ae-4202-8a43-bc0a7adb516d" continuedAt="i988dda229eb443419c7f03cb56cdad86" escape="true">The following table provides a summary of the Company's pre-tax restructuring charges for the years ended December&#160;31, 2022, 2021 and 2020: </ix:nonNumeric></span></div><div><ix:continuation id="i988dda229eb443419c7f03cb56cdad86"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee separation costs</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2188840dc2a3430ebc240517ab668786_D20220101-20221231" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6NTgzNzkxMWRhOTMyNDFmMmE2OTg1ZjEwMjM1NmE3YzAvdGFibGVyYW5nZTo1ODM3OTExZGE5MzI0MWYyYTY5ODVmMTAyMzU2YTdjMF8yLTEtMS0xLTc4MzY3_0c842e23-81d1-4c78-958a-82967fdeb7e3">55</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac2da26b5ef14b8f8e69ce008fd54d9b_D20210101-20211231" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6NTgzNzkxMWRhOTMyNDFmMmE2OTg1ZjEwMjM1NmE3YzAvdGFibGVyYW5nZTo1ODM3OTExZGE5MzI0MWYyYTY5ODVmMTAyMzU2YTdjMF8yLTMtMS0xLTc4MzY3_7c3e96e1-5f29-4ef7-9ee5-85f55a441b1b">11</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f2e4d03479a4236a60beb9b0835a79f_D20200101-20201231" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6NTgzNzkxMWRhOTMyNDFmMmE2OTg1ZjEwMjM1NmE3YzAvdGFibGVyYW5nZTo1ODM3OTExZGE5MzI0MWYyYTY5ODVmMTAyMzU2YTdjMF8yLTUtMS0xLTc4MzY3_71b7724a-10a5-425c-b8df-fb5dcc057e95">14</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility-related costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2188840dc2a3430ebc240517ab668786_D20220101-20221231" decimals="-6" name="us-gaap:OtherRestructuringCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6NTgzNzkxMWRhOTMyNDFmMmE2OTg1ZjEwMjM1NmE3YzAvdGFibGVyYW5nZTo1ODM3OTExZGE5MzI0MWYyYTY5ODVmMTAyMzU2YTdjMF8zLTEtMS0xLTc4MzY3_806831b4-5715-42b4-aaec-10883a2cd33c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac2da26b5ef14b8f8e69ce008fd54d9b_D20210101-20211231" decimals="-6" name="us-gaap:OtherRestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6NTgzNzkxMWRhOTMyNDFmMmE2OTg1ZjEwMjM1NmE3YzAvdGFibGVyYW5nZTo1ODM3OTExZGE5MzI0MWYyYTY5ODVmMTAyMzU2YTdjMF8zLTMtMS0xLTc4MzY3_17fda193-3cb2-49fb-a254-7177b3aaee2b">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f2e4d03479a4236a60beb9b0835a79f_D20200101-20201231" decimals="-6" name="us-gaap:OtherRestructuringCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6NTgzNzkxMWRhOTMyNDFmMmE2OTg1ZjEwMjM1NmE3YzAvdGFibGVyYW5nZTo1ODM3OTExZGE5MzI0MWYyYTY5ODVmMTAyMzU2YTdjMF8zLTUtMS0xLTc4MzY3_bca41fef-1966-4c76-a195-fc5f2ac1fa86">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment charges</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2188840dc2a3430ebc240517ab668786_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringCostsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6NTgzNzkxMWRhOTMyNDFmMmE2OTg1ZjEwMjM1NmE3YzAvdGFibGVyYW5nZTo1ODM3OTExZGE5MzI0MWYyYTY5ODVmMTAyMzU2YTdjMF80LTEtMS0xLTc4MzY3_0772f272-1edb-4eb8-954b-69b756b3a7d2">14</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac2da26b5ef14b8f8e69ce008fd54d9b_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringCostsAndAssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6NTgzNzkxMWRhOTMyNDFmMmE2OTg1ZjEwMjM1NmE3YzAvdGFibGVyYW5nZTo1ODM3OTExZGE5MzI0MWYyYTY5ODVmMTAyMzU2YTdjMF80LTMtMS0xLTc4MzY3_8cb36ed6-cc36-4a6c-8650-72ad0510cce2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f2e4d03479a4236a60beb9b0835a79f_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringCostsAndAssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6NTgzNzkxMWRhOTMyNDFmMmE2OTg1ZjEwMjM1NmE3YzAvdGFibGVyYW5nZTo1ODM3OTExZGE5MzI0MWYyYTY5ODVmMTAyMzU2YTdjMF80LTUtMS0xLTc4MzY3_633e495f-e0a4-4756-a898-6a53c80fd059">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restructuring charges</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2188840dc2a3430ebc240517ab668786_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6NTgzNzkxMWRhOTMyNDFmMmE2OTg1ZjEwMjM1NmE3YzAvdGFibGVyYW5nZTo1ODM3OTExZGE5MzI0MWYyYTY5ODVmMTAyMzU2YTdjMF82LTEtMS0xLTc4MzY3_9a3f7085-ace4-4ba9-85c8-e8fa805c6755">69</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac2da26b5ef14b8f8e69ce008fd54d9b_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6NTgzNzkxMWRhOTMyNDFmMmE2OTg1ZjEwMjM1NmE3YzAvdGFibGVyYW5nZTo1ODM3OTExZGE5MzI0MWYyYTY5ODVmMTAyMzU2YTdjMF82LTMtMS0xLTc4MzY3_b7cbeadc-c621-422d-942c-bb85e7247c18">12</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f2e4d03479a4236a60beb9b0835a79f_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6NTgzNzkxMWRhOTMyNDFmMmE2OTg1ZjEwMjM1NmE3YzAvdGFibGVyYW5nZTo1ODM3OTExZGE5MzI0MWYyYTY5ODVmMTAyMzU2YTdjMF82LTUtMS0xLTc4MzY3_9aafbba3-71e5-4bd3-af06-d5485fbac767">14</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The restructuring charges incurred for the years ended December&#160;31, 2022, 2021 and 2020 were primarily associated with various workforce reduction initiatives as the Company continued to restructure its organization. Additionally, during the year ended December 31, 2022, the Company fully impaired certain property, plant and equipment (see Note 8).  Of the total restructuring charges incurred during the year ended December&#160;31, 2022, $<ix:nonFraction unitRef="usd" contextRef="ic2dc2704459f476aa2a7a5bdd5d24a31_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGV4dHJlZ2lvbjpjN2EzMmYzNzk0YjU0NGE2YmM1YTIxMzhiZTM0MjE3NF8yNzQ4Nzc5MDczMDAx_06780716-5921-4e01-be58-4339cd3ab77a">19</ix:nonFraction>&#160;million,  $<ix:nonFraction unitRef="usd" contextRef="i5c94d4fa6b2c4f048fbd732ba22d94f5_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGV4dHJlZ2lvbjpjN2EzMmYzNzk0YjU0NGE2YmM1YTIxMzhiZTM0MjE3NF8yNzQ4Nzc5MDczMDEz_053ac3f8-6d53-4edb-9f01-1d7c8090994d">36</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i6c9c73f96c044bfe81dabb5b4fad4570_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGV4dHJlZ2lvbjpjN2EzMmYzNzk0YjU0NGE2YmM1YTIxMzhiZTM0MjE3NF8xNjQ5MjY3NDQ1Njk1_26d48109-1fe3-4981-9dca-4495ccc797f7">14</ix:nonFraction>&#160;million were recorded in cost of services, selling, general and administrative expenses and other operating expense (income), net, respectively.  Of the total restructuring charges incurred during the year ended December&#160;31, 2021, $<ix:nonFraction unitRef="usd" contextRef="i390853c339b546a497c9c3581d6c33ec_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGV4dHJlZ2lvbjpjN2EzMmYzNzk0YjU0NGE2YmM1YTIxMzhiZTM0MjE3NF8xNjQ5MjY3NDQ1NjYw_6540208a-9824-4c96-acea-604c89d9f0a9">8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9dfd2596231f42d583a3e66c7908bd62_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGV4dHJlZ2lvbjpjN2EzMmYzNzk0YjU0NGE2YmM1YTIxMzhiZTM0MjE3NF8xNjQ5MjY3NDQ1NjQ4_f0bb74b4-4289-43d4-b4e6-cea4bc627e17">4</ix:nonFraction>&#160;million were recorded in cost of services and selling, general and administrative expenses, respectively.  Of the total restructuring charges incurred during the year ended December&#160;31, 2020, $<ix:nonFraction unitRef="usd" contextRef="i17932ddd3fbd4fa39599486002e2399c_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGV4dHJlZ2lvbjpjN2EzMmYzNzk0YjU0NGE2YmM1YTIxMzhiZTM0MjE3NF8yNzQ4Nzc5MDczMDM3_99e0f336-67eb-4864-9eb0-fbc80fb5d626">9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i7641ac8ab06549359c0d7224c74f7f8b_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGV4dHJlZ2lvbjpjN2EzMmYzNzk0YjU0NGE2YmM1YTIxMzhiZTM0MjE3NF8yNzQ4Nzc5MDczMDQ5_5986ee80-2368-4fc6-a552-e23a08acdb5d">5</ix:nonFraction>&#160;million were recorded in cost of services and selling, general and administrative expenses, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The employee separation costs for all periods presented were primarily recorded in the Company's DIS business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGV4dHJlZ2lvbjpjN2EzMmYzNzk0YjU0NGE2YmM1YTIxMzhiZTM0MjE3NF8yNzQ4Nzc5MDcyOTk5_db943892-2593-422e-8c28-cbe457ed74d7" continuedAt="i1d44a341906f4f5fbf8cc0395d37e77b" escape="true">The following table summarizes the activity of the restructuring liability during 2022 and 2021, which is included in accrued expenses in Note 13:  </ix:nonNumeric></span></div><div style="text-indent:36pt"><ix:continuation id="i1d44a341906f4f5fbf8cc0395d37e77b"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:62.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.711%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Employee Separation Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Facility-Related Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, December&#160;31, 2020</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d8eee27a6fd4fbe801850524c5786c5_I20201231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M18yLTEtMS0xLTc4MzY3_be47e8f0-2fc0-4cb0-8e76-901fdaadf93c">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd99150341c4b0c873203afdafdd710_I20201231" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M18yLTMtMS0xLTc4MzY3_972b3e14-8e86-497a-ac26-e4bcedeafcdf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872b3ea2e369403f8c0129ff07e0b538_I20201231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M18yLTUtMS0xLTc4MzY3_e50525bd-0331-4a0f-9d7a-b2080e62867a">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income statement expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i475d92c712f048aa906901cd998f7a38_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M18zLTEtMS0xLTc4MzY3_7015fce1-a809-4f9a-aaca-a80c69537f6a">12</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib738456c29b743669e686681cc7a5304_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M18zLTMtMS0xLTc4MzY3_30a8f9d9-5ea9-48e2-9319-8a1b17169725">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M18zLTUtMS0xLTc4MzY3_10d98b7c-3e85-4a64-9dea-d77d51d28a29">13</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i475d92c712f048aa906901cd998f7a38_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M180LTEtMS0xLTc4MzY3_cb144c24-68ff-480d-8791-e16a5a1e9ba1">12</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib738456c29b743669e686681cc7a5304_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M180LTMtMS0xLTc4MzY3_d32237be-18cf-47a7-bbe7-360a288e14df">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M180LTUtMS0xLTc4MzY3_6000d47a-db59-4862-833f-524f462cd84b">13</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, December&#160;31, 2021</span></div></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6084444236f40aca1b0c8796c27af45_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M182LTEtMS0xLTc4MzY3_99ba86a0-e3d3-428b-86aa-e268d56df986">7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50168a95b652435bb092f9dfbde9c76a_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M182LTMtMS0xLTc4MzY3_9eaa795d-2b63-41e9-bb0c-3c9106d39ab9">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M182LTUtMS0xLTc4MzY3_17b4049b-30da-4654-bb51-014d06cabe87">7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income statement expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic24828d839184f6fa08a929719d4b23f_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M183LTEtMS0xLTc4MzY3_d60da5ce-4571-46cb-a272-6d4d0ada5045">55</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57fc38f4b96048cbb2a8e0410884049d_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M183LTMtMS0xLTc4MzY3_50b6815b-a1af-457d-8aeb-3fe97102f0a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M183LTUtMS0xLTc4MzY3_4720d902-8f98-4aac-829b-d08d0807d1c3">55</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic24828d839184f6fa08a929719d4b23f_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M184LTEtMS0xLTc4MzY3_50ab866c-29be-4e9a-8247-9a47b12dba93">18</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57fc38f4b96048cbb2a8e0410884049d_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M184LTMtMS0xLTc4MzY3_1113bd6e-248c-486e-aebe-fca5e4ec75fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M184LTUtMS0xLTc4MzY3_2964a976-2dfc-4538-bdfa-6830e70eac17">18</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, December&#160;31, 2022</span></div></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74144fa02d0949e18fcfdec627d2b59e_I20221231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M18xMC0xLTEtMS04NTU4MQ_fa462339-4186-48a9-832c-c73921db4365">44</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fe6929b64864257bf0e3c4054d32428_I20221231" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M18xMC0zLTEtMS04NTU4MQ_6df36e0c-258d-418b-af34-8cc05f5cc6d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M18xMC01LTEtMS04NTU4MQ_54ca0b9c-24c8-4e57-90f1-303605f1d1e7">44</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_190"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211; CONTINUED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions unless otherwise indicated)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5Xzc5Mjc_0fc69918-0fee-4712-9105-598b0aea6099" continuedAt="ib208d12c72d04d0ba2d41787610b9d9b" escape="true">BUSINESS ACQUISITIONS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ib208d12c72d04d0ba2d41787610b9d9b" continuedAt="ie1318c92fa534bc4bb31c434ccb81c40"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;2022 Acquisitions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, the Company completed acquisitions for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzI3NDg3NzkwODA4OTc_a13c6180-b701-4173-abb5-6d1d0bc8e37c">162</ix:nonFraction>&#160;million, net of cash acquired, including the acquisition discussed below.  The 2022 acquisitions resulted in goodwill of $<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzI3NDg3NzkwODA5MjE_7a2c3f0a-3462-45b9-ac47-05490c09cdeb">121</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzI3NDg3NzkwODA5MDk_f42aa90e-e6ed-4cc0-9b58-a8aef895883f">103</ix:nonFraction>&#160;million is deductible for tax purposes.  These acquisitions also resulted in $<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="dgx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFiniteLivedIntangibles1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzI3NDg3NzkwODA5MzM_b69f9d08-6a42-4784-a196-85e776934ee1">45</ix:nonFraction>&#160;million of intangible assets, principally comprised of customer-related intangible assets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Pack Health, LLC</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2022, the Company acquired Pack Health, LLC ("Pack Health"), a patient engagement company that helps individuals adopt healthier behaviors to improve outcomes, in an all cash transaction for $<ix:nonFraction unitRef="usd" contextRef="ib3022bb32f9b457dac0b1400e74fad49_D20220201-20220201" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzIxOTkwMjMyNjY4Njg_d32b596d-96ab-4e4b-b0dd-4cbcfcb73044">123</ix:nonFraction>&#160;million, net of $<ix:nonFraction unitRef="usd" contextRef="ib3022bb32f9b457dac0b1400e74fad49_D20220201-20220201" decimals="-6" name="us-gaap:CashAcquiredFromAcquisition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzIxOTkwMjMyNjY4ODI_d2161907-3ab6-46a8-9af7-b2ffe74c914b">4</ix:nonFraction>&#160;million cash acquired, which consisted of cash consideration of $<ix:nonFraction unitRef="usd" contextRef="ib3022bb32f9b457dac0b1400e74fad49_D20220201-20220201" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzIxOTkwMjMyNjY4OTQ_6a046da6-b068-453d-9227-856a561752e5">105</ix:nonFraction>&#160;million and contingent consideration initially estimated at $<ix:nonFraction unitRef="usd" contextRef="idc2a90ebfed1402e9780a6ef5de70976_I20220201" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzIxOTkwMjMyNjY5MDg_3dc10478-cccd-42a1-81a5-8c4fb2ce0c26">18</ix:nonFraction>&#160;million.  The contingent consideration arrangement was dependent upon the achievement of certain revenue benchmarks.  Based on the purchase price allocation, the assets acquired and liabilities assumed consist of $<ix:nonFraction unitRef="usd" contextRef="idc2a90ebfed1402e9780a6ef5de70976_I20220201" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzIxOTkwMjMyNjY5MjE_8fee0117-78f5-413f-a20c-5f39590805de">96</ix:nonFraction>&#160;million of goodwill (of which $<ix:nonFraction unitRef="usd" contextRef="idc2a90ebfed1402e9780a6ef5de70976_I20220201" decimals="-6" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzIxOTkwMjMyNjY5MzQ_d2f4acce-63f2-4edc-a840-29ad776b4311">78</ix:nonFraction>&#160;million was tax-deductible on the acquisition date), $<ix:nonFraction unitRef="usd" contextRef="idc2a90ebfed1402e9780a6ef5de70976_I20220201" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzIxOTkwMjMyNjY5NDc_d58a2556-b2ea-4e4c-9753-ece8d108de11">30</ix:nonFraction>&#160;million of intangible assets, $<ix:nonFraction unitRef="usd" contextRef="idc2a90ebfed1402e9780a6ef5de70976_I20220201" decimals="-6" name="dgx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzIxOTkwMjMyNjY5NjA_5ab619c7-8dbe-4bcf-9ff0-6daa5c8a6a79">5</ix:nonFraction>&#160;million of operating lease right-of-use assets, $<ix:nonFraction unitRef="usd" contextRef="idc2a90ebfed1402e9780a6ef5de70976_I20220201" decimals="-6" name="dgx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzIxOTkwMjMyNjY5NzI_1073cc33-ee6d-4152-b64f-b65225b75f0a">5</ix:nonFraction>&#160;million of operating lease liabilities and $(<ix:nonFraction unitRef="usd" contextRef="idc2a90ebfed1402e9780a6ef5de70976_I20220201" decimals="-6" sign="-" name="dgx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedWorkingCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzIxOTkwMjMyNjY5ODQ_b269b6d4-e4a4-4e8b-83e3-fe80b23386e2">3</ix:nonFraction>)&#160;million of working capital. The intangible assets consist primarily of customer-related assets which are being amortized over a useful life of <ix:nonNumeric contextRef="i0a5b8ece9a5340aa9b88329c3be13301_D20220201-20220201" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzIxOTkwMjMyNjY5OTY_516515d3-a970-486c-9f7d-2e012c5a08ee">15</ix:nonNumeric> years.  For further details regarding the fair value of the contingent consideration, see Note 8.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;2021 Acquisitions</span></div><div style="padding-left:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the Company completed acquisitions for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzEzNg_6e49ff3e-d089-4b99-858f-f648301fe1d6">346</ix:nonFraction>&#160;million, net of cash acquired, including the acquisitions discussed below.  The 2021 acquisitions resulted in goodwill of $<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="dgx:GoodwillAcquiredDuringPeriodBeforeAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzI1Mw_cd3a2da9-3955-4332-aaa8-8304a582b3af">236</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzI2Ng_26d8323e-53be-41aa-beb0-357b0200a8a5">221</ix:nonFraction>&#160;million is deductible for tax purposes. These acquisitions also resulted in $<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="dgx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFiniteLivedIntangibles1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzMzOA_7b69007d-4fbe-4dca-a3aa-6de691194c30">107</ix:nonFraction>&#160;million of intangible assets, principally comprised of customer-related intangible assets.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of the outreach laboratory services business of Mercy Health</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2021, the Company completed the acquisition of the outreach laboratory services business of Mercy Health ("Mercy Health"), which serves providers and patients in Arkansas, Kansas, Missouri and Oklahoma, in an all-cash transaction for $<ix:nonFraction unitRef="usd" contextRef="i48a2f820f01a423fa5d8fb263ceee2c0_D20210601-20210601" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5Xzc0OA_e46149e8-def8-40a5-8c11-5c5792b351f1">225</ix:nonFraction>&#160;million.  Based on the purchase price allocation, the assets acquired primarily consist of $<ix:nonFraction unitRef="usd" contextRef="i7c718b40c7aa46b79dd5ad4b49064a03_I20210601" decimals="-6" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzEyNDQ1_f760043a-d182-471d-91bd-7bcad56141ed">171</ix:nonFraction>&#160;million of tax-deductible goodwill and $<ix:nonFraction unitRef="usd" contextRef="i5e9e75dc29624f80957117764e6a8712_I20210601" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5Xzk0Mg_cf6e1c97-9957-4411-af7a-3799f44f259e">54</ix:nonFraction>&#160;million of customer-related intangible assets.  The intangible assets are being amortized over a useful life of <ix:nonNumeric contextRef="ib254cb5566f04ccb957b18919eed9f8d_D20210601-20210601" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzEwODM_074467e6-dab3-4be6-91d5-fd3caea83bbe">15</ix:nonNumeric> years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of assets of Labtech Diagnostics, LLC</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 13, 2021, the Company completed the acquisition of assets of Labtech Diagnostics, LLC ("Labtech"), an independent clinical diagnostic laboratory provider serving physicians and patients primarily in South Carolina, North Carolina, Florida and Georgia, in an all cash transaction for $<ix:nonFraction unitRef="usd" contextRef="i1b56aef5907945b3abd0ec2ca54428c0_D20211213-20211213" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzE0MTk_991f8697-d422-4269-8c5a-83776186d993">95</ix:nonFraction>&#160;million, which consisted of cash consideration of $<ix:nonFraction unitRef="usd" contextRef="i1b56aef5907945b3abd0ec2ca54428c0_D20211213-20211213" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzE0NjQ_8b9da566-c3da-4d0b-b4ae-8cbaae315062">80</ix:nonFraction>&#160;million and contingent consideration estimated at $<ix:nonFraction unitRef="usd" contextRef="i52f75c68a74542ba8c151adcd5b7c6c1_I20211213" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzE1MTk_1cb11e90-9c61-45e0-a343-256bcce7bc1f">15</ix:nonFraction>&#160;million. The contingent consideration arrangement was dependent upon the achievement of certain testing volume benchmarks.  Based on the purchase price allocation, which was finalized during the three months ended March 31, 2022, the assets acquired and liabilities assumed consist of $<ix:nonFraction unitRef="usd" contextRef="i52f75c68a74542ba8c151adcd5b7c6c1_I20211213" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzE4NjU_5f6a66fd-6bd1-4e9a-8daa-78e0907a9896">48</ix:nonFraction>&#160;million of goodwill (of which $<ix:nonFraction unitRef="usd" contextRef="i52f75c68a74542ba8c151adcd5b7c6c1_I20211213" decimals="-6" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzE4OTA_78534cd1-e9ed-4fe8-801a-1a8325d1ae02">33</ix:nonFraction>&#160;million was tax deductible on the acquisition date), $<ix:nonFraction unitRef="usd" contextRef="if8ace4c429434da1b559d5ea5059ac8a_I20211213" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzEyNDk4_d80d48db-f7a7-42ed-ae7c-bdc33ac1091d">44</ix:nonFraction>&#160;million of intangible assets, $<ix:nonFraction unitRef="usd" contextRef="i52f75c68a74542ba8c151adcd5b7c6c1_I20211213" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzE5MTM_18155ca2-17dd-439b-b981-8d8a25caa89a">11</ix:nonFraction>&#160;million of property, plant and equipment, $<ix:nonFraction unitRef="usd" contextRef="i52f75c68a74542ba8c151adcd5b7c6c1_I20211213" decimals="-6" name="dgx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinanceLeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzE5NTA_bf92b010-1cfe-4ea3-b360-fdde53c37029">9</ix:nonFraction>&#160;million of finance lease liabilities, $<ix:nonFraction unitRef="usd" contextRef="i52f75c68a74542ba8c151adcd5b7c6c1_I20211213" decimals="-6" name="dgx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzE5ODM_99191d1c-28a8-4fad-a6b8-3dccdcd5333b">6</ix:nonFraction>&#160;million of operating lease right-of-use assets, $<ix:nonFraction unitRef="usd" contextRef="i52f75c68a74542ba8c151adcd5b7c6c1_I20211213" decimals="-6" name="dgx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzIwMjY_1471a2ec-029c-4aec-9b25-227a1c083914">6</ix:nonFraction>&#160;million of operating lease liabilities, and $<ix:nonFraction unitRef="usd" contextRef="i52f75c68a74542ba8c151adcd5b7c6c1_I20211213" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzIwNjU_26978981-d367-4f0e-a637-84ccec87da28">1</ix:nonFraction>&#160;million of inventories. The intangible assets consist primarily of customer-related assets which are being amortized over a useful life of <ix:nonNumeric contextRef="i16f34a8359cd44c7a2ed3560a9171968_D20211213-20211213" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzIxOTk_298317a7-9d9c-491b-99cb-b29047bc86e0">15</ix:nonNumeric> years.  For further details regarding the fair value of the contingent consideration, see Note 8.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;2020 Acquisitions</span></div><div style="padding-left:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, the Company completed acquisitions for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzIzMDg_87c0ea90-4d71-4d3e-895e-1c42ba4b6e77">330</ix:nonFraction>&#160;million, net of cash acquired, including the acquisitions discussed below.  The 2020 acquisitions resulted in goodwill of $<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzI0MjU_83589e47-af93-455e-9fc1-782e11c7eb92">247</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="i872b3ea2e369403f8c0129ff07e0b538_I20201231" decimals="-6" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzI0Mzg_9d2ec457-3127-41dd-be5e-d4faa97a545f">210</ix:nonFraction>&#160;million is deductible for tax purposes.  These acquisitions also resulted in $<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="dgx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFiniteLivedIntangibles1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzI1MTA_fc535f3a-a6fc-4720-8b1e-4b569e4eb026">146</ix:nonFraction>&#160;million of intangible assets, principally comprised of customer-related and technology intangible assets.  Net revenues attributable to the 2020 acquisitions were $<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="dgx:BusinessAcquisitionPostacquisitionRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzI2Njg_24a4f73e-043f-44bb-900d-9aa55e8561ec">127</ix:nonFraction>&#160;million for the year ended December 31, 2020.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211; CONTINUED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions unless otherwise indicated)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><div style="text-indent:36pt"><span><br/></span></div><ix:continuation id="ie1318c92fa534bc4bb31c434ccb81c40" continuedAt="i0993f6f09cbd4c2288facca43757857b"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Blueprint Genetics Oy</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 21, 2020, the Company completed the acquisition of Blueprint Genetics Oy ("Blueprint Genetics"), in an all cash transaction for $<ix:nonFraction unitRef="usd" contextRef="i7198b30a0f3543f8b7624f5a08626715_D20200121-20200121" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzI4ODk_e6149a4b-f303-40b8-a6c2-b3b3a84060f3">108</ix:nonFraction>&#160;million, net of $<ix:nonFraction unitRef="usd" contextRef="i7198b30a0f3543f8b7624f5a08626715_D20200121-20200121" decimals="-6" name="us-gaap:CashAcquiredFromAcquisition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzI5MDA_fb5b0c9a-9d4c-43e9-a2c0-58bb39c0ee73">3</ix:nonFraction>&#160;million cash acquired.  Blueprint Genetics is a leading specialty genetic testing company with expertise in gene variant interpretation based on next generation sequencing and proprietary bioinformatics.  Through the acquisition, the Company acquired all of Blueprint Genetics' operations.  Based on the purchase price allocation, the assets acquired and liabilities assumed primarily consist of $<ix:nonFraction unitRef="usd" contextRef="i5c6b2d78cc5544cea4ff096768c26e2f_I20200121" decimals="-6" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzMyOTE_07f651fd-26d2-454c-9284-4c21ad2c5173"><ix:nonFraction unitRef="usd" contextRef="i5c6b2d78cc5544cea4ff096768c26e2f_I20200121" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzMyOTE_74a53d34-b23a-4f4b-a533-ac6d9ece6a28">66</ix:nonFraction></ix:nonFraction>&#160;million of tax-deductible goodwill, $<ix:nonFraction unitRef="usd" contextRef="i5c6b2d78cc5544cea4ff096768c26e2f_I20200121" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzMzMjI_9d291029-ebd2-46f4-a110-0c5af8d41b8c">43</ix:nonFraction>&#160;million of intangible assets, and $<ix:nonFraction unitRef="usd" contextRef="i5c6b2d78cc5544cea4ff096768c26e2f_I20200121" decimals="-6" name="dgx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedPropertyPlantandEquipmentandWorkingCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzMzNTE_89101ed6-19f6-4848-9fbc-ee395131404e">2</ix:nonFraction>&#160;million of property, plant and equipment and working capital.  The intangible assets primarily consist of technology and customer-related assets which are being amortized over a useful life of <ix:nonNumeric contextRef="ia0752516755c42d4b6bd8c225ce45827_D20200121-20200121" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzM1Mzk_e98dd22c-3377-4049-88cb-0866efc68585">10</ix:nonNumeric> years and <ix:nonNumeric contextRef="iffd12e5591e7425f9d86856d3c9e755a_D20200121-20200121" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzM1NDY_c0417501-1127-4f69-989d-beffb669b171">15</ix:nonNumeric> years, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of the Outreach Laboratory Services Business of Memorial Hermann Health System</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 6, 2020, the Company completed the acquisition of select assets which constitute substantially all of the operations of Memorial Hermann Diagnostic Laboratories, the outreach laboratory division of Memorial Hermann Health System ("Memorial Hermann"), in an all cash transaction for $<ix:nonFraction unitRef="usd" contextRef="ibbfa5abb43c94c9b95f08bbd21c21a95_D20200406-20200406" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzM5NTA_9880cab6-dbe8-48f2-b394-7a71bf333cc7">120</ix:nonFraction>&#160;million.  Memorial Hermann is a not-for-profit health system in Southeast Texas.  Based on the purchase price allocation, the assets acquired primarily consist of $<ix:nonFraction unitRef="usd" contextRef="i97014f982e65418d980efc0a485ac0d0_I20200406" decimals="-6" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzEyNTcz_1dcae439-09b1-43f3-900a-03aa2fcb1b89">93</ix:nonFraction>&#160;million of tax-deductible goodwill and $<ix:nonFraction unitRef="usd" contextRef="ib0b5a278261f4aeaa3c8450f4ab8f98b_I20200406" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzQxMDg_e8d86e4a-5b95-433d-bf2d-8218def08791">27</ix:nonFraction>&#160;million of customer-related intangible assets.  The intangible assets are being amortized over a useful life of <ix:nonNumeric contextRef="idc562163c50f4774ba7552b47b943aa8_D20200406-20200406" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzQyNDk_cfe0d7b8-5bb7-4686-94f7-343a1c926fa8">15</ix:nonNumeric> years.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of the Remaining <ix:nonFraction unitRef="number" contextRef="i318abc26c57d45e199c441d6a27fb59b_I20200801" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzQyODY_cf7f9911-5029-43ab-9752-db8d78aeccf8">56</ix:nonFraction>% Interest in Mid America Clinical Laboratories, LLC</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On August 1, 2020, the Company completed the acquisition of the remaining <ix:nonFraction unitRef="number" contextRef="i318abc26c57d45e199c441d6a27fb59b_I20200801" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzQ0MTY_8236b0f3-54ac-4db8-92fe-e2ca72cbdcd3">56</ix:nonFraction>% interest in Mid America Clinical Laboratories, LLC ("MACL") from its joint venture partners in an all cash transaction for $<ix:nonFraction unitRef="usd" contextRef="i8e330046544a4466b899b21db4a44981_D20200801-20200801" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzQ1NDI_4f5617b6-78a8-4e99-894b-da922a313477">93</ix:nonFraction>&#160;million, net of $<ix:nonFraction unitRef="usd" contextRef="i8e330046544a4466b899b21db4a44981_D20200801-20200801" decimals="-6" name="us-gaap:CashAcquiredFromAcquisition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzQ1NTM_2bb7bfa8-2e16-4f23-b63d-a5c72faf919c">18</ix:nonFraction>&#160;million cash acquired.  MACL was the largest independent clinical laboratory provider in Indiana.  Prior to the acquisition, the Company accounted for its <ix:nonFraction unitRef="number" contextRef="ia4132aab88954f808a22077ce48c7778_I20200731" decimals="2" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzQ3MDI_268aa092-45ec-41a2-8799-250178ea086d">44</ix:nonFraction>% interest in MACL as an equity method investment, which was remeasured to its fair value of $<ix:nonFraction unitRef="usd" contextRef="if02f69bfea444e448def3a82a65cb96b_D20200731-20200731" decimals="-6" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzQ3OTY_aebe1715-e5e9-4e75-ae18-89a72a59edd5">87</ix:nonFraction>&#160;million on the acquisition date, resulting in a gain of $<ix:nonFraction unitRef="usd" contextRef="i56f4083aa1ed47fbbfc4bd4e9a05cc0f_D20200801-20200801" decimals="-6" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzQ4NDc_a999aab6-fe8c-4d75-9c4f-9c14687f63b2">70</ix:nonFraction>&#160;million that was recognized in other (expense) income, net in the consolidated statements of operations.  The fair value of the previously held equity interest was determined using a discounted cash flow analysis that took into account, among other items, MACL's expected future cash flows, long-term growth rate (<ix:nonFraction unitRef="number" contextRef="i318abc26c57d45e199c441d6a27fb59b_I20200801" decimals="3" name="dgx:BusinessCombinationStepAcquisitionEquityInterestInAcquireeLongTermGrowthRateUsedToDetermineFairValue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzUxMzE_5f1df13f-61fc-4307-bde1-633da719bf85">1.5</ix:nonFraction>%), and a discount rate commensurate with economic risk (<ix:nonFraction unitRef="number" contextRef="i318abc26c57d45e199c441d6a27fb59b_I20200801" decimals="3" name="dgx:BusinessCombinationStepAcquisitionEquityInterestInAcquireeDicountRateUsedToDetermineFairValue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzUxODk_0d731389-430e-400d-9ffe-6e4a239e2c5d">7.5</ix:nonFraction>%).  Based on the purchase price allocation, the assets acquired and liabilities assumed consist of $<ix:nonFraction unitRef="usd" contextRef="i318abc26c57d45e199c441d6a27fb59b_I20200801" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzUyOTA_dc830fda-aa6f-4129-9984-e607ab4ab1dc">84</ix:nonFraction>&#160;million of goodwill (of which $<ix:nonFraction unitRef="usd" contextRef="i318abc26c57d45e199c441d6a27fb59b_I20200801" decimals="-6" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzUzMTU_496b54ef-aa0f-4df0-abde-8dfa274b97dd">47</ix:nonFraction>&#160;million is tax-deductible), $<ix:nonFraction unitRef="usd" contextRef="ibd44c8b9d5c649278afdc75ade9c679b_I20200801" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzUzMzg_e5c08b1f-e878-493b-b18b-789d37d3b7cc">74</ix:nonFraction>&#160;million of intangible assets, $<ix:nonFraction unitRef="usd" contextRef="i318abc26c57d45e199c441d6a27fb59b_I20200801" decimals="-6" name="dgx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedWorkingCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzUzNjM_3e94b2d5-efed-4871-be99-da4b9dbb016b">11</ix:nonFraction>&#160;million of working capital and $<ix:nonFraction unitRef="usd" contextRef="i318abc26c57d45e199c441d6a27fb59b_I20200801" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzUzODk_cf2dea3d-76f1-4f6a-8b82-a3a62655d5de">11</ix:nonFraction>&#160;million of property, plant and equipment.  The intangible assets consist of customer-related assets which are being amortized over a useful life of <ix:nonNumeric contextRef="if6cc04f23f064d64bc9599f898569338_D20200801-20200801" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzU1MzI_a419199f-e1b7-48b2-b56f-f571e26c6db2">15</ix:nonNumeric> years.  As a result of the acquisition, MACL became a wholly owned subsidiary of the Company.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;General Information</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0993f6f09cbd4c2288facca43757857b">&#160;&#160;&#160;&#160;The acquisitions described above were accounted for under the acquisition method of accounting.  As such, the assets acquired and liabilities assumed are recorded based on their estimated fair values as of the closing date.  Supplemental pro forma combined financial information has not been presented as the impact of the acquisitions is not material to the Company's consolidated financial statements.  The goodwill recorded primarily includes the expected synergies resulting from combining the operations of the acquired entities with those of the Company and the value associated with an&#160;assembled workforce and other intangible assets that do not qualify for separate recognition.  All of the goodwill acquired in connection with these acquisitions has been allocated to the Company's DIS business.  For further details regarding business segment information, see Note 20.</ix:continuation> </span></div><div><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_193"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTMvZnJhZzoyMjQ3YjJkZWM1ZWM0M2U1YTFjY2I3YTAwODgwZDI1ZS90ZXh0cmVnaW9uOjIyNDdiMmRlYzVlYzQzZTVhMWNjYjdhMDA4ODBkMjVlXzEyODA_602efe99-f9b9-4a4e-b2a5-8c741eaad6d5" continuedAt="i00c32cbbd7cc4f9c8f28f5eed6d78a61" escape="true">DISPOSITION</ix:nonNumeric></span></div><div><span><br/></span></div><div><ix:continuation id="i00c32cbbd7cc4f9c8f28f5eed6d78a61" continuedAt="i0b8e8f8b30d64b848417aac69c68c0b4"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On April 1, 2021, the Company sold its <ix:nonFraction unitRef="number" contextRef="i0c20173d8dc64ebdb79161256ab69f0d_I20210401" decimals="2" name="dgx:EquityMethodInvestmentOwnershipPercentDisposedOf" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTMvZnJhZzoyMjQ3YjJkZWM1ZWM0M2U1YTFjY2I3YTAwODgwZDI1ZS90ZXh0cmVnaW9uOjIyNDdiMmRlYzVlYzQzZTVhMWNjYjdhMDA4ODBkMjVlXzYx_439a551c-3366-410e-a137-1e036afe5a23">40</ix:nonFraction>% ownership interest in Q</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Solutions&#174; ("Q</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Solutions"), its clinical trials central laboratory services joint venture, to IQVIA Holdings, Inc. ("IQVIA"), its joint venture partner, for $<ix:nonFraction unitRef="usd" contextRef="i5953c712e4234176ac0378246142fc74_D20210401-20210401" decimals="-6" name="dgx:ProceedsFromSaleOfEquityMethodInvestmentsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTMvZnJhZzoyMjQ3YjJkZWM1ZWM0M2U1YTFjY2I3YTAwODgwZDI1ZS90ZXh0cmVnaW9uOjIyNDdiMmRlYzVlYzQzZTVhMWNjYjdhMDA4ODBkMjVlXzI0Nw_5ff3128c-2424-495f-8cf2-90d99448efe8">760</ix:nonFraction>&#160;million in an all-cash transaction.  Prior to the transaction, the Company accounted for its minority interest as an equity method investment.  As a result of the transaction, during the year ended December 31, 2021, the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="i8a3a680061ef49fcac90a1aabb89821b_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTMvZnJhZzoyMjQ3YjJkZWM1ZWM0M2U1YTFjY2I3YTAwODgwZDI1ZS90ZXh0cmVnaW9uOjIyNDdiMmRlYzVlYzQzZTVhMWNjYjdhMDA4ODBkMjVlXzUzNA_7b53549c-00f3-4579-b5cb-11cb0f865e1f">314</ix:nonFraction>&#160;million pre-tax gain in other (expense) income, net in the consolidated statement of operations based on the difference between the net sales proceeds and the carrying value of the investment, including $<ix:nonFraction unitRef="usd" contextRef="idcd7cd9e61214881b085d41e21b23992_D20210101-20211231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTMvZnJhZzoyMjQ3YjJkZWM1ZWM0M2U1YTFjY2I3YTAwODgwZDI1ZS90ZXh0cmVnaW9uOjIyNDdiMmRlYzVlYzQzZTVhMWNjYjdhMDA4ODBkMjVlXzcwNw_97e13888-1af6-4943-87d8-0b6842bc61ad">20</ix:nonFraction>&#160;million of cumulative translation losses which were previously recorded in accumulated other comprehensive loss.  During the year ended December 31, 2021, the Company also recorded $<ix:nonFraction unitRef="usd" contextRef="i309534767ce0403ba44362e2a393aa76_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTMvZnJhZzoyMjQ3YjJkZWM1ZWM0M2U1YTFjY2I3YTAwODgwZDI1ZS90ZXh0cmVnaW9uOjIyNDdiMmRlYzVlYzQzZTVhMWNjYjdhMDA4ODBkMjVlXzg2OA_6556572b-8115-4684-b43d-d852df057416">55</ix:nonFraction>&#160;million </span></ix:continuation></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211; CONTINUED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions unless otherwise indicated)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0b8e8f8b30d64b848417aac69c68c0b4">of income tax expense related to the gain, consisting of $<ix:nonFraction unitRef="usd" contextRef="i309534767ce0403ba44362e2a393aa76_D20210101-20211231" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTMvZnJhZzoyMjQ3YjJkZWM1ZWM0M2U1YTFjY2I3YTAwODgwZDI1ZS90ZXh0cmVnaW9uOjIyNDdiMmRlYzVlYzQzZTVhMWNjYjdhMDA4ODBkMjVlXzkyOA_55612f3b-37ea-4451-a1e3-f6e55b750e60">127</ix:nonFraction>&#160;million of current income tax expense, partially offset by $<ix:nonFraction unitRef="usd" contextRef="i309534767ce0403ba44362e2a393aa76_D20210101-20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTMvZnJhZzoyMjQ3YjJkZWM1ZWM0M2U1YTFjY2I3YTAwODgwZDI1ZS90ZXh0cmVnaW9uOjIyNDdiMmRlYzVlYzQzZTVhMWNjYjdhMDA4ODBkMjVlXzk4Mg_353efe59-d3ce-4f60-88b0-66bd69043ba4">72</ix:nonFraction>&#160;million of deferred income tax benefit.</ix:continuation></span></div><div><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_196"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90ZXh0cmVnaW9uOjBlMmU5NWZhNmI2ZjQ2NjU5NmI1Y2Q1MDgyNmI1MTI5XzY3OTk_80be8f10-123d-4530-94ea-5d09f9fc9dce" continuedAt="ic9c71437548b464394572251b004e804" escape="true">FAIR VALUE MEASUREMENTS </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ic9c71437548b464394572251b004e804" continuedAt="ifa54b33cb98848d984985686bd8be52b"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90ZXh0cmVnaW9uOjBlMmU5NWZhNmI2ZjQ2NjU5NmI1Y2Q1MDgyNmI1MTI5XzY4MDA_346c1513-1070-4ca9-bfe6-3158067e444d" continuedAt="i99e269b48fb34a648895dcb074568c50" escape="true">The following table provides a summary of the recognized assets and liabilities that are measured at fair value on a recurring basis:</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="i99e269b48fb34a648895dcb074568c50"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of Fair Value Measurements</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation trading securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a46256065f64a1f83735b542ac8cd05_I20221231" decimals="-6" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzUtMS0xLTEtNzgyMTU_040c8411-2d1b-45c4-b041-f95ec6d68755">68</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifacb18823a32464e8277a40cd0e40141_I20221231" decimals="-6" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzUtMy0xLTEtNzgyMTU_dc8cb6b2-99a5-41a3-9d7c-bddd41b37d58">68</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939ef35c1b364fccb6c395109ba883a8_I20221231" decimals="-6" name="us-gaap:TradingSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzUtNS0xLTEtNzgyMTU_cc478dd9-92a7-46ce-93d4-b21c4ac70633">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i806fc0b55bb0418c955d42a8e1e2a9d5_I20221231" decimals="-6" name="us-gaap:TradingSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzUtNy0xLTEtNzgyMTU_c6b60bd5-0625-494b-9117-bca65c6e51d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash surrender value of life insurance policies</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a46256065f64a1f83735b542ac8cd05_I20221231" decimals="-6" name="us-gaap:CashSurrenderValueFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzYtMS0xLTEtNzgyMTU_5f209a0a-e98a-40ed-a2d3-b08055b5fe5b">46</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifacb18823a32464e8277a40cd0e40141_I20221231" decimals="-6" name="us-gaap:CashSurrenderValueFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzYtMy0xLTEtNzgyMTU_d11e94cb-840b-44b0-b3dd-b8cc464a720b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939ef35c1b364fccb6c395109ba883a8_I20221231" decimals="-6" name="us-gaap:CashSurrenderValueFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzYtNS0xLTEtNzgyMTU_91ed14f3-d1f0-4925-9bb1-b1cd49723208">46</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i806fc0b55bb0418c955d42a8e1e2a9d5_I20221231" decimals="-6" name="us-gaap:CashSurrenderValueFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzYtNy0xLTEtNzgyMTU_1aa75c16-81ea-4511-a795-5d6da70e5aa9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a46256065f64a1f83735b542ac8cd05_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzktMS0xLTEtNzgyMTU_6877498b-2e5b-47c4-9b40-336b715e958d">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifacb18823a32464e8277a40cd0e40141_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzktMy0xLTEtNzgyMTU_3d84cc5f-03a0-4f2f-b7e6-6b113f121186">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939ef35c1b364fccb6c395109ba883a8_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzktNS0xLTEtNzgyMTU_f85bb497-a082-45a6-9b1b-e52afc4ea77d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i806fc0b55bb0418c955d42a8e1e2a9d5_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzktNy0xLTEtNzgyMTU_01883d87-ccd5-484c-811b-2a7c1bad6568">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a46256065f64a1f83735b542ac8cd05_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzEyLTEtMS0xLTc4MjE1_5175ba1d-35d5-44e8-b2c8-0dfbc1cc5215">116</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifacb18823a32464e8277a40cd0e40141_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzEyLTMtMS0xLTc4MjE1_a06e20e6-1a79-495c-82ee-3eede61f53ea">68</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939ef35c1b364fccb6c395109ba883a8_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzEyLTUtMS0xLTc4MjE1_607bf6f8-8111-457b-8f12-89ab2c320acf">46</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i806fc0b55bb0418c955d42a8e1e2a9d5_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzEyLTctMS0xLTc4MjE1_76547a8f-cf9c-4d64-a3d2-eb92fc21a35f">2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liabilities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a46256065f64a1f83735b542ac8cd05_I20221231" decimals="-6" name="us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzE1LTEtMS0xLTc4MjE1_636bd8cd-165c-44a5-b99d-e6008793fb6d">120</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifacb18823a32464e8277a40cd0e40141_I20221231" decimals="-6" name="us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzE1LTMtMS0xLTc4MjE1_ebdfb51a-b4db-4032-9918-8c6913922f10">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939ef35c1b364fccb6c395109ba883a8_I20221231" decimals="-6" name="us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzE1LTUtMS0xLTc4MjE1_2b3e8c6f-0089-4bb7-be88-f51ac127a283">120</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i806fc0b55bb0418c955d42a8e1e2a9d5_I20221231" decimals="-6" name="us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzE1LTctMS0xLTc4MjE1_54e1ea61-6343-460c-ba83-799648fc64e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a46256065f64a1f83735b542ac8cd05_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzE3LTEtMS0xLTc4MjE1_f8b4101e-ecb0-4289-b47b-c2d7c668e300">23</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifacb18823a32464e8277a40cd0e40141_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzE3LTMtMS0xLTc4MjE1_774a8714-b1ea-4886-ad48-c1c68159b165">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939ef35c1b364fccb6c395109ba883a8_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzE3LTUtMS0xLTc4MjE1_23261b9b-c09f-4d3d-83a3-3fc00224745c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i806fc0b55bb0418c955d42a8e1e2a9d5_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzE3LTctMS0xLTc4MjE1_db859fe9-7e23-4369-b861-54dabc259804">23</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a46256065f64a1f83735b542ac8cd05_I20221231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzIwLTEtMS0xLTc4MjE1_3767b151-3aa2-4583-a4ea-88f0a03a2e55">143</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifacb18823a32464e8277a40cd0e40141_I20221231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzIwLTMtMS0xLTc4MjE1_684cc193-800d-488b-8178-dcbac242c596">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939ef35c1b364fccb6c395109ba883a8_I20221231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzIwLTUtMS0xLTc4MjE1_3df65495-4472-4e59-ad25-e7fcacbc31cf">120</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i806fc0b55bb0418c955d42a8e1e2a9d5_I20221231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzIwLTctMS0xLTc4MjE1_9b4256dd-748c-4440-b846-9d07d9563a5d">23</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redeemable noncontrolling interest</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a46256065f64a1f83735b542ac8cd05_I20221231" decimals="-6" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzIyLTEtMS0xLTc4MjE1_5afd0ed2-1eab-4ead-af4b-c406d7e905cd">77</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifacb18823a32464e8277a40cd0e40141_I20221231" decimals="-6" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzIyLTMtMS0xLTc4MjE1_b6eb2125-5eb3-4269-a8bc-3a66b54cb073">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i806fc0b55bb0418c955d42a8e1e2a9d5_I20221231" decimals="-6" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzIyLTctMS0xLTc4MjE1_5da5e59b-0db6-4e7e-b4ab-5125155f11b5">77</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation trading securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec46d6b614174b4a84f77d9cff2de05f_I20211231" decimals="-6" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzI2LTEtMS0xLTc4MjE1_0a255b1f-c627-40bc-af6d-7a9660d4abe8">77</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e74f4a4c6c44d98bda7c8be9f02a6b2_I20211231" decimals="-6" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzI2LTMtMS0xLTc4MjE1_f8c62d71-e153-40ba-900d-01a9ae4c4327">77</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i454f20bc7ea343f5a803483a6773d323_I20211231" decimals="-6" name="us-gaap:TradingSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzI2LTUtMS0xLTc4MjE1_82cfb7c6-dd1e-4a74-b1b4-337da53ca752">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08e7768575cf494bab1f563baab11bdc_I20211231" decimals="-6" name="us-gaap:TradingSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzI2LTctMS0xLTc4MjE1_c67c473f-ac0e-4bbb-aec8-96fa833ef66b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash surrender value of life insurance policies</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec46d6b614174b4a84f77d9cff2de05f_I20211231" decimals="-6" name="us-gaap:CashSurrenderValueFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzI3LTEtMS0xLTc4MjE1_eda8ebd2-d715-4214-81d0-3ec5c6bd6a39">57</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e74f4a4c6c44d98bda7c8be9f02a6b2_I20211231" decimals="-6" name="us-gaap:CashSurrenderValueFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzI3LTMtMS0xLTc4MjE1_b6997fa5-e3ef-470c-9679-9714c0b1d239">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i454f20bc7ea343f5a803483a6773d323_I20211231" decimals="-6" name="us-gaap:CashSurrenderValueFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzI3LTUtMS0xLTc4MjE1_e694fba3-725a-46ec-9618-7e10df34b4bc">57</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08e7768575cf494bab1f563baab11bdc_I20211231" decimals="-6" name="us-gaap:CashSurrenderValueFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzI3LTctMS0xLTc4MjE1_46b550ec-2509-49dc-8629-1712dcd45645">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec46d6b614174b4a84f77d9cff2de05f_I20211231" decimals="-6" name="dgx:EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzI4LTEtMS0xLTc4MjE1_51a969a3-e15c-458b-988c-1df8fec179be">44</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e74f4a4c6c44d98bda7c8be9f02a6b2_I20211231" decimals="-6" name="dgx:EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzI4LTMtMS0xLTc4MjE1_c152d82a-1fa8-473f-a0fc-093c21ccaa77">44</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i454f20bc7ea343f5a803483a6773d323_I20211231" decimals="-6" name="dgx:EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzI4LTUtMS0xLTc4MjE1_8b963335-7bf9-4dd7-99e0-280618cf6573">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08e7768575cf494bab1f563baab11bdc_I20211231" decimals="-6" name="dgx:EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzI4LTctMS0xLTc4MjE1_79947eed-e7e6-4457-b9e5-57758533d962">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec46d6b614174b4a84f77d9cff2de05f_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzMwLTEtMS0xLTc4MjE1_342134ca-634f-4fab-9403-0b53d4c91bbe">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e74f4a4c6c44d98bda7c8be9f02a6b2_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzMwLTMtMS0xLTc4MjE1_17b19021-fee1-4470-a0cf-4fd86efed65f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i454f20bc7ea343f5a803483a6773d323_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzMwLTUtMS0xLTc4MjE1_0474e06d-722a-4445-bcd4-0ade1e543fe3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08e7768575cf494bab1f563baab11bdc_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzMwLTctMS0xLTc4MjE1_c3382274-9cd6-4078-83a9-57e11f2f1a6b">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec46d6b614174b4a84f77d9cff2de05f_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzMyLTEtMS0xLTc4MjE1_9b8c48e9-a4f3-4d5c-97a7-d0019255f871">179</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e74f4a4c6c44d98bda7c8be9f02a6b2_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzMyLTMtMS0xLTc4MjE1_acbbf77a-69ad-43ff-bdc8-4d87ec3f261d">121</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i454f20bc7ea343f5a803483a6773d323_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzMyLTUtMS0xLTc4MjE1_6d90e25c-1349-4b2c-90bb-d1e1a8e033ec">57</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08e7768575cf494bab1f563baab11bdc_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzMyLTctMS0xLTc4MjE1_09166055-4bf2-4d32-a763-d2964d6a0f4b">1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liabilities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec46d6b614174b4a84f77d9cff2de05f_I20211231" decimals="-6" name="us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzM1LTEtMS0xLTc4MjE1_e42e2d2b-6baf-41aa-af17-1fb4ef01d14b">143</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e74f4a4c6c44d98bda7c8be9f02a6b2_I20211231" decimals="-6" name="us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzM1LTMtMS0xLTc4MjE1_0c3dbab8-cdfa-4efa-93f2-ad5e0ef718f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i454f20bc7ea343f5a803483a6773d323_I20211231" decimals="-6" name="us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzM1LTUtMS0xLTc4MjE1_a7059350-9165-4760-a29f-dbf7830eb983">143</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08e7768575cf494bab1f563baab11bdc_I20211231" decimals="-6" name="us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzM1LTctMS0xLTc4MjE1_0b730083-4749-4beb-b5b0-f91c867be3ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec46d6b614174b4a84f77d9cff2de05f_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzM3LTEtMS0xLTc4MjE1_04912852-b20e-44f3-b125-ed683b4109c2">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e74f4a4c6c44d98bda7c8be9f02a6b2_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzM3LTMtMS0xLTc4MjE1_986123ec-fbb6-4c2c-b38d-0dcf0608f792">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i454f20bc7ea343f5a803483a6773d323_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzM3LTUtMS0xLTc4MjE1_bad18442-3faa-4e99-a660-30e8649d5e3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08e7768575cf494bab1f563baab11bdc_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzM3LTctMS0xLTc4MjE1_52c1db5f-4634-4174-99df-9baf81c714e3">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec46d6b614174b4a84f77d9cff2de05f_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzQwLTEtMS0xLTc4MjE1_8a8e05d4-3eaa-4b04-acc6-ef7dc4deef25">148</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e74f4a4c6c44d98bda7c8be9f02a6b2_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzQwLTMtMS0xLTc4MjE1_b7374b0d-61d6-4c5b-828f-41aeaf2a4d78">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i454f20bc7ea343f5a803483a6773d323_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzQwLTUtMS0xLTc4MjE1_9014c631-b9d0-463a-be96-d6d8e505d4b3">143</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08e7768575cf494bab1f563baab11bdc_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzQwLTctMS0xLTc4MjE1_914fc1c6-a9dc-4270-ad8c-2ff924a14879">5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redeemable noncontrolling interest</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec46d6b614174b4a84f77d9cff2de05f_I20211231" decimals="-6" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzQyLTEtMS0xLTc4MjE1_539fecf5-fa0d-44a4-8737-25fd56f0febf">79</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e74f4a4c6c44d98bda7c8be9f02a6b2_I20211231" decimals="-6" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzQyLTMtMS0xLTc4MjE1_4d5d87e5-4b83-4198-aca5-07d992567dbf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08e7768575cf494bab1f563baab11bdc_I20211231" decimals="-6" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzQyLTctMS0xLTc4MjE1_58f1ad02-1ef0-411b-8794-75df69467ce5">79</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company offers certain employees the opportunity to participate in a non-qualified supplemental deferred compensation plan.  A participant's deferrals, together with Company matching credits, are invested in a variety of participant-directed stock and bond mutual funds that are classified as trading securities.  The trading securities are classified within Level 1 of the fair value hierarchy because the changes in the fair value of these securities, which are recorded in other assets in the Company's consolidated balance sheet, are measured using quoted prices in active markets based on the market price per unit multiplied by the number of units held, exclusive of any transaction costs.  A corresponding adjustment for changes in fair value of the trading securities is also reflected in the changes in fair value of the deferred compensation obligation.  The deferred compensation liabilities are classified within Level 2 of the fair value hierarchy because their inputs are derived principally from observable market data by correlation to the trading securities.</span></div></ix:continuation><div style="padding-right:72pt;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211; CONTINUED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions unless otherwise indicated)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><ix:continuation id="ifa54b33cb98848d984985686bd8be52b" continuedAt="ic214aa931c3e47aa981b7ce7a9c2724b"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company offers certain employees the opportunity to participate in a non-qualified deferred compensation program.  A participant's deferrals, together with Company matching credits, are &#8220;invested&#8221; at the direction of the employee in a hypothetical portfolio of investments which are tracked by an administrator.  The Company purchases life insurance policies, with the Company named as beneficiary of the policies, for the purpose of funding the program's liability.  Changes in the cash surrender value of the life insurance policies are based upon earnings and changes in the value of the underlying investments.  Changes in the fair value of the deferred compensation obligation are derived using quoted prices in active markets based on the market price per unit multiplied by the number of units.  The cash surrender value, which is recorded in other assets in the Company's consolidated balance sheet, and the deferred compensation obligation are classified within Level 2 of the fair value hierarchy because their inputs are derived principally from observable market data by correlation to the hypothetical investments. Deferrals under the plan currently may only be made by participants who made deferrals under the plan in 2017. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company's investment portfolio primarily includes equity investments comprised mostly of strategic holdings in companies concentrated in the life sciences and healthcare industries.  Equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) with readily determinable fair values are measured at fair value in prepaid expenses and other current assets in the Company's consolidated balance sheet.  Such equity investments are classified within Level 1 of the fair value hierarchy because the changes in the fair values of the securities are measured using quoted prices in active markets based on the market price per share multiplied by the number of shares held, exclusive of any transaction costs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company's available-for-sale debt securities are measured at fair value using discounted cash flows.  These fair value measurements are classified within Level 3 of the fair value hierarchy as the fair value is based on significant inputs that are not observable.  Significant inputs include cash flows projections and a discount rate.  The investments are recorded in other assets in the Company's consolidated balance sheet.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In connection with the acquisitions of Pack Health and Labtech (see Note 6), the Company has contingent consideration obligations, with a potential maximum aggregate payment of $<ix:nonFraction unitRef="usd" contextRef="iec1e53779a1a46e382c71420c86a8e65_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90ZXh0cmVnaW9uOjBlMmU5NWZhNmI2ZjQ2NjU5NmI1Y2Q1MDgyNmI1MTI5XzQwNDQ_a2b3cf6b-e69f-42fb-899a-1cd01cffde91">40</ix:nonFraction>&#160;million, that are to be paid based on the achievement of certain testing volume or revenue benchmarks.  Contingent consideration accruals are measured at fair value using either an option-pricing method or a Monte Carlo method and are classified within Level 3 of the fair value hierarchy as the fair value is determined based on significant inputs that are not observable.  Significant inputs include management&#8217;s estimate of volume or revenue and other market inputs, including comparable company revenue volatility (<ix:nonFraction unitRef="number" contextRef="ia070c0d807ae41f189d8789aa235216b_I20221231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90ZXh0cmVnaW9uOjBlMmU5NWZhNmI2ZjQ2NjU5NmI1Y2Q1MDgyNmI1MTI5XzQ1NTE_66ab5341-065a-499e-9643-128e9e118ddc">7.5</ix:nonFraction>%) and a discount rate (ranging from <ix:nonFraction unitRef="number" contextRef="i23329615d047484080f7bc81509ea79e_I20221231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90ZXh0cmVnaW9uOjBlMmU5NWZhNmI2ZjQ2NjU5NmI1Y2Q1MDgyNmI1MTI5XzQ1NzY_e66dfe4e-818b-4b12-8744-0041b5e182a7">2.5</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i435823dcec83485dbadc7a18b519986a_I20221231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90ZXh0cmVnaW9uOjBlMmU5NWZhNmI2ZjQ2NjU5NmI1Y2Q1MDgyNmI1MTI5XzIxOTkwMjMyNjY4ODE_7ede8b73-28f5-406b-be0d-25896e24b8a0">3.0</ix:nonFraction>%).</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90ZXh0cmVnaW9uOjBlMmU5NWZhNmI2ZjQ2NjU5NmI1Y2Q1MDgyNmI1MTI5XzY3ODY_d3f5e4c1-3f16-4849-999a-8f2a033fa6dd" continuedAt="if80e53fd3b124dc3bf26c73ace965b7b" escape="true">The following table provides a reconciliation of the beginning and ending balances of liabilities using significant unobservable inputs (Level 3):</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="if80e53fd3b124dc3bf26c73ace965b7b"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.912%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent Consideration</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2740945331a4803b48ca4d039b3724f_I20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTo3NjNhZWFhMTk0Yjg0ZDMyOTM2YWZlZDUyNzdhMDk0My90YWJsZXJhbmdlOjc2M2FlYWExOTRiODRkMzI5MzZhZmVkNTI3N2EwOTQzXzItMS0xLTEtNzgyMTU_2f11e525-22c6-436a-9977-0d32602eced0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases, additions and issuances</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd12294595f84e56a311bfb11080c96c_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTo3NjNhZWFhMTk0Yjg0ZDMyOTM2YWZlZDUyNzdhMDk0My90YWJsZXJhbmdlOjc2M2FlYWExOTRiODRkMzI5MzZhZmVkNTI3N2EwOTQzXzMtMS0xLTEtNzgyMTU_43de4c1f-d5fe-4552-9ab6-9d5139d9d2d3">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1029a7e4535b4243bba665741dbd11de_I20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTo3NjNhZWFhMTk0Yjg0ZDMyOTM2YWZlZDUyNzdhMDk0My90YWJsZXJhbmdlOjc2M2FlYWExOTRiODRkMzI5MzZhZmVkNTI3N2EwOTQzXzktMS0xLTEtNzgyMTU_d8b79a45-70d9-4285-81dc-3c060ac16eda">5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases, additions and issuances</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a23e14d23244c8a2e550a645bbdcd1_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTo3NjNhZWFhMTk0Yjg0ZDMyOTM2YWZlZDUyNzdhMDk0My90YWJsZXJhbmdlOjc2M2FlYWExOTRiODRkMzI5MzZhZmVkNTI3N2EwOTQzXzExLTEtMS0xLTc4MjE1_36d0cfe9-15cb-4a4a-bd16-abaf85f43ac2">28</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38a23e14d23244c8a2e550a645bbdcd1_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTo3NjNhZWFhMTk0Yjg0ZDMyOTM2YWZlZDUyNzdhMDk0My90YWJsZXJhbmdlOjc2M2FlYWExOTRiODRkMzI5MzZhZmVkNTI3N2EwOTQzXzEyLTEtMS0xLTc4MjE1_0c42f959-a8a9-4729-943b-f17cc9cabe25">15</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value adjustments included in earnings - realized/unrealized</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a23e14d23244c8a2e550a645bbdcd1_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTo3NjNhZWFhMTk0Yjg0ZDMyOTM2YWZlZDUyNzdhMDk0My90YWJsZXJhbmdlOjc2M2FlYWExOTRiODRkMzI5MzZhZmVkNTI3N2EwOTQzXzEzLTEtMS0xLTc4MjE1_62bec608-7d0f-483c-b2d7-c40cc3eea005">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i341269c4649443fbbe35b79f45362759_I20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTo3NjNhZWFhMTk0Yjg0ZDMyOTM2YWZlZDUyNzdhMDk0My90YWJsZXJhbmdlOjc2M2FlYWExOTRiODRkMzI5MzZhZmVkNTI3N2EwOTQzXzE0LTEtMS0xLTc4MjE1_2a07cb66-1627-47dc-b711-701c1bcb7710">23</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The $<ix:nonFraction unitRef="usd" contextRef="i38a23e14d23244c8a2e550a645bbdcd1_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90ZXh0cmVnaW9uOjBlMmU5NWZhNmI2ZjQ2NjU5NmI1Y2Q1MDgyNmI1MTI5XzIxOTkwMjMyNjY5MDM_4fe43e86-ec06-4c60-926f-f58b80191d0c">5</ix:nonFraction> million net loss included in earnings associated with the change in the fair value of contingent consideration for the year ended December&#160;31, 2022 is reported in other operating expense (income), net.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In connection with the sale of an <ix:nonFraction unitRef="number" contextRef="ia809ec8fd18c4ad48fc0dd81f2cdd760_I20150701" decimals="3" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90ZXh0cmVnaW9uOjBlMmU5NWZhNmI2ZjQ2NjU5NmI1Y2Q1MDgyNmI1MTI5XzQ5MjM_3f379efb-619d-45e1-aaa6-b89e8053d9af">18.9</ix:nonFraction>% noncontrolling interest in a subsidiary to UMass Memorial Medical Center ("UMass") on July 1, 2015, the Company granted UMass the right to require the Company to purchase all of its interest in the subsidiary at fair value commencing July 1, 2020.  As of December&#160;31, 2022, the redeemable noncontrolling interest was presented at its fair value.  The fair value measurement of the redeemable noncontrolling interest is classified within Level 3 of the fair value hierarchy because the fair value is based on a discounted cash flow analysis that takes into account, among other items, the joint venture's expected future cash flows, long-term growth rates, and a discount rate commensurate with economic risk.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211; CONTINUED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions unless otherwise indicated)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><div><span><br/></span></div><ix:continuation id="ic214aa931c3e47aa981b7ce7a9c2724b"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the year ended December 31, 2022, the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="i1880b74088be4b518518151d49b3c3d9_D20220101-20221231" decimals="-6" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90ZXh0cmVnaW9uOjBlMmU5NWZhNmI2ZjQ2NjU5NmI1Y2Q1MDgyNmI1MTI5XzEwOTk1MTE2NDIwMTg_7ed0f8b1-76e3-4734-b394-0896e43935ea">14</ix:nonFraction>&#160;million impairment charge, which is included in other operating expense (income), net, in order to fully impair certain property, plant and equipment.  The fair value measurement was classified within Level 3 of the fair value hierarchy as it was based on significant inputs that are not observable, including cash flow projections.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The carrying amounts of cash and cash equivalents, accounts receivable and accounts payable and accrued expenses approximate fair value based on the short maturities of these instruments.  As of December&#160;31, 2022 and 2021, the fair value of the Company&#8217;s debt was estimated at $<ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-8" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90ZXh0cmVnaW9uOjBlMmU5NWZhNmI2ZjQ2NjU5NmI1Y2Q1MDgyNmI1MTI5XzY0MTc_2bc3b26c-e382-4a0b-bef0-4ed6237cd75b">3.7</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-8" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90ZXh0cmVnaW9uOjBlMmU5NWZhNmI2ZjQ2NjU5NmI1Y2Q1MDgyNmI1MTI5XzY0MjQ_9bdf270d-3ffc-4bae-b633-93740f8d7ce8">4.4</ix:nonFraction> billion, respectively.  Principally all of the Company's debt is classified within Level 1 of the fair value hierarchy because the fair value of the debt is estimated based on rates currently offered to the Company with identical terms and maturities, using quoted active market prices and yields, taking into account the underlying terms of the debt instruments.</span></div></ix:continuation><div style="text-indent:29.25pt"><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_199"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzUzMjE_722a6394-30fd-4d7a-9cc8-82f54b53fd65" continuedAt="i27c11a503a604e0cbe7fc32dab63080a" escape="true">TAXES ON INCOME</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i27c11a503a604e0cbe7fc32dab63080a" continuedAt="i989c6d72b88f4ff780c3f704ca1f5836"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company's pre-tax income before equity in earnings of equity method investees consisted of approximately $<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-8" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzE2Mw_f5906071-c7db-4367-988e-ea57df514040">1.2</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-8" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzE2Nw_14e4d72c-bfd3-48cf-9f7c-b684c6e3cb59">2.5</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-8" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzE3NA_4550ea47-0e84-482b-a31f-78a012867c0c">1.9</ix:nonFraction> billion from U.S. operations and pre-tax income (loss) of $<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzIyNw_e6252223-ba5c-4547-a329-3418cce82eea">2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzIzMQ_8b1834e4-7990-4c73-8427-1a1e65952ca9">148</ix:nonFraction> million and $(<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzIzOA_01dbe790-dfc3-49ec-be2c-66c96175e3b2">7</ix:nonFraction>) million from foreign operations for the years ended December&#160;31, 2022, 2021 and 2020, respectively. &#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzUzMjg_d42c2fd3-8ff5-49ca-af20-734856d166ce" continuedAt="icd1f5c9dae474dafba901e800d3094a3" escape="true">The components of income tax expense (benefit) for 2022, 2021 and 2020 were as follows: </ix:nonNumeric></span></div><div style="text-align:center"><ix:continuation id="icd1f5c9dae474dafba901e800d3094a3"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzItMS0xLTEtNzgyMTU_eec42518-61f4-4e06-9ffd-349da95dba28">200</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzItMy0xLTEtNzgyMTU_763a5867-1c5a-46ac-a706-a627a115495b">528</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzItNS0xLTEtNzgyMTU_b27e9a46-fc93-4cfc-98b0-0faed324c542">300</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzMtMS0xLTEtNzgyMTU_0d9a9e1a-c645-4811-9d2b-740143078450">62</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzMtMy0xLTEtNzgyMTU_90765054-26a4-42c8-a5eb-8a45be3e3144">123</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzMtNS0xLTEtNzgyMTU_586803bc-a317-4ade-8366-1c7545b38f6e">74</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzQtMS0xLTEtNzgyMTU_b147bdac-6924-453c-8b8c-d713a06368ed">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzQtMy0xLTEtNzgyMTU_9fdd0194-363f-414f-8268-0ca0344a0577">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzQtNS0xLTEtNzgyMTU_9963bd84-d8ac-413e-8d32-3be1e4c5624f">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzYtMS0xLTEtNzgyMTU_da66c5e8-8bf5-4389-8266-f08c6cbb2fe7">29</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzYtMy0xLTEtNzgyMTU_fd59c077-eb1e-40cf-bc97-0c394ca73b8b">61</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzYtNS0xLTEtNzgyMTU_35876fde-ff28-4e13-a3e8-6180617e50f0">55</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzctMS0xLTEtNzgyMTU_75398ac0-a203-4a74-8f85-9ea7efde793f">27</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzctMy0xLTEtNzgyMTU_cc66e0d0-0330-4041-b138-d677c7da3a22">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzctNS0xLTEtNzgyMTU_916e6042-a3f2-4732-894a-e6a207e2130c">29</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzgtMS0xLTEtNzgyMTU_2d19fe41-3585-4ce2-af9a-18650528f1eb">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzgtMy0xLTEtNzgyMTU_d1883c3f-af64-4b17-8c15-208a94e07ea5">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzgtNS0xLTEtNzgyMTU_fd8810a8-5aa3-4b1d-906f-f444f27ac209">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzktMS0xLTEtNzgyMTU_704164ae-6fe6-42c3-9a11-b3aa25864461">264</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzktMy0xLTEtNzgyMTU_bec8fd98-84f4-4102-8e46-8ec972506a84">597</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzktNS0xLTEtNzgyMTU_0c1cdbeb-9945-4c81-aeb5-c4ee1e1bdb01">460</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-indent:42.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzUzMjM_a0fbe8ca-744b-4e9f-9e65-cdf495be5edb" continuedAt="i3623e3f921144243aa742aceba53309f" escape="true">A reconciliation of the federal statutory income tax rate to the Company's effective income tax rate for 2022, 2021 and 2020 was as follows: </ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="i3623e3f921144243aa742aceba53309f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax provision at statutory rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzItMS0xLTEtNzgyMTU_b9da69cb-04c2-4beb-8cbb-01ce6cc19f4d">21.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzItMy0xLTEtNzgyMTU_7585421b-e41d-4d58-8934-c817aa36b386">21.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzItNS0xLTEtNzgyMTU_5519e7d4-d098-4c59-ba5a-9bdcadf7cbb7">21.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local income taxes, net of federal benefit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzMtMS0xLTEtNzgyMTU_36439cee-c9a2-4da1-8b41-b1d766284afb">4.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzMtMy0xLTEtNzgyMTU_7d42b74a-d22a-469b-a32e-be6e0f60b3e3">4.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzMtNS0xLTEtNzgyMTU_4532e655-bdbc-4cdf-89cf-e9136766d859">4.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of noncontrolling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzgtMS0xLTEtNzgyMTU_d480a333-605c-419a-b226-125858e84388">1.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzgtMy0xLTEtNzgyMTU_5ad2deaa-0504-4b91-89b9-753a81837241">0.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzgtNS0xLTEtNzgyMTU_71364748-a0a3-486f-8cac-9516603cb006">0.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment to state deferred tax liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="3" sign="-" name="dgx:EffectiveIncomeTaxRateReconciliationAdjustmentToStateDeferredTaxLiabilities" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzktMS0xLTEtNzgyMTU_5a3a8f34-a6a5-4624-8a85-05ab50b4a641">1.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="3" name="dgx:EffectiveIncomeTaxRateReconciliationAdjustmentToStateDeferredTaxLiabilities" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzktMy0xLTEtNzgyMTU_6da41182-96fd-4b0f-bd95-61c3b04c48af">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="3" name="dgx:EffectiveIncomeTaxRateReconciliationAdjustmentToStateDeferredTaxLiabilities" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzktNS0xLTEtNzgyMTU_56f1c03a-7ba3-4b18-b80e-cd46745e8c76">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess tax benefits on stock-based compensation arrangements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzEwLTEtMS0xLTc4MjE1_25e4cf1c-c136-415b-b04b-fea6efcbd8f8">1.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzEwLTMtMS0xLTc4MjE1_95df9435-7354-412f-83e2-4da160c08efe">0.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzEwLTUtMS0xLTc4MjE1_17b4a902-abe7-4722-ae10-2ff08708b7d1">1.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return to provision true-ups </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzExLTEtMS0xLTc4MjE1_5a615742-cbd2-4398-9ac2-4a89dcfadc27">1.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzExLTMtMS0xLTc4MjE1_5a2b5b24-0c6d-4f2d-9b94-0186746559cb">0.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzExLTUtMS0xLTc4MjE1_50180417-adcb-4817-aa7c-60b37a27ee41">0.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of equity earnings</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzE0LTEtMS0xLTc4MjE1_c6af7ae4-23fa-4340-a9b6-acc2e93fe882">0.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzE0LTMtMS0xLTc4MjE1_1df14cd6-ba70-44dd-8f92-91cac52ba077">0.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzE0LTUtMS0xLTc4MjE1_4e1ca6cc-71ae-4c25-b27e-8099c1cd7f5e">0.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in reserves for uncertain tax positions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="3" name="dgx:EffectiveIncomeTaxRateReconciliationChangeForUncertainTaxPosition" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzE1LTEtMS0xLTc4MjE1_f9f8bfb5-bd34-4e19-87d7-d98d3f320f6a">0.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="3" name="dgx:EffectiveIncomeTaxRateReconciliationChangeForUncertainTaxPosition" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzE1LTMtMS0xLTc4MjE1_921464eb-c15f-44ec-96f8-a9dd785d4e4a">0.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="3" name="dgx:EffectiveIncomeTaxRateReconciliationChangeForUncertainTaxPosition" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzE1LTUtMS0xLTc4MjE1_4274a97f-8040-42e2-877f-95d8da674f28">0.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowances associated with certain net operating losses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzE2LTEtMS0xLTc4MjE1_a4076b62-6b51-43d4-a33d-9e4eb143470a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzE2LTMtMS0xLTc4MjE1_e2851244-d7d9-4b0e-9211-b9acddb36b25">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzE2LTUtMS0xLTc4MjE1_c60a3bdf-08b0-414d-a58a-ea108446e0fe">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzE3LTEtMS0xLTc4MjE1_0188fac3-e1c5-48a8-a54a-fb4329ce67ca">0.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzE3LTMtMS0xLTc4MjE1_1c9a91a3-f275-4c9d-92b5-1573bbd538d3">0.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzE3LTUtMS0xLTc4MjE1_2f59b8ab-0e81-41a1-9f86-50001bbb0ba5">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzE4LTEtMS0xLTc4MjE1_a6e995a6-5356-4868-b559-ce95963e2164">21.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzE4LTMtMS0xLTc4MjE1_d95593b8-1fb6-49b1-b2cb-e86dccd808ab">23.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzE4LTUtMS0xLTc4MjE1_4aef52da-da80-47e4-bebd-964ae8d57c79">24.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzUzNTE_029614c0-b85e-4252-b140-1279054ac83f" continuedAt="ibda695c803664fd3b2f2229a228c0376" escape="true">The tax effects of temporary differences that give rise to significant portions of the deferred tax assets (liabilities) as of December&#160;31, 2022 and 2021 were as follows: </ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211; CONTINUED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions unless otherwise indicated)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><ix:continuation id="i989c6d72b88f4ff780c3f704ca1f5836" continuedAt="icbc23101df594eb3bdd6a6c1ce94797a"><div style="margin-top:5pt;text-align:center"><ix:continuation id="ibda695c803664fd3b2f2229a228c0376"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current deferred tax assets (liabilities):</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable reserves</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="dgx:DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsAccountsReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpiZTJkYzVkNThlN2U0Yzk4YTZiMTc5YjY0YjlkOTE0OS90YWJsZXJhbmdlOmJlMmRjNWQ1OGU3ZTRjOThhNmIxNzliNjRiOWQ5MTQ5XzItMS0xLTEtNzgyMTU_3ed0b1cc-8296-4d59-81d1-6d091fe0603d">15</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="dgx:DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsAccountsReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpiZTJkYzVkNThlN2U0Yzk4YTZiMTc5YjY0YjlkOTE0OS90YWJsZXJhbmdlOmJlMmRjNWQ1OGU3ZTRjOThhNmIxNzliNjRiOWQ5MTQ5XzItMy0xLTEtNzgyMTU_d03fb56a-bbe4-4464-993d-035a9382f111">89</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities not currently deductible</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpiZTJkYzVkNThlN2U0Yzk4YTZiMTc5YjY0YjlkOTE0OS90YWJsZXJhbmdlOmJlMmRjNWQ1OGU3ZTRjOThhNmIxNzliNjRiOWQ5MTQ5XzMtMS0xLTEtNzgyMTU_5a3c3728-29cb-4603-a758-63d76ba178bc">174</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpiZTJkYzVkNThlN2U0Yzk4YTZiMTc5YjY0YjlkOTE0OS90YWJsZXJhbmdlOmJlMmRjNWQ1OGU3ZTRjOThhNmIxNzliNjRiOWQ5MTQ5XzMtMy0xLTEtNzgyMTU_d579b7c2-bdbd-4225-a891-aa6fb2262837">180</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpiZTJkYzVkNThlN2U0Yzk4YTZiMTc5YjY0YjlkOTE0OS90YWJsZXJhbmdlOmJlMmRjNWQ1OGU3ZTRjOThhNmIxNzliNjRiOWQ5MTQ5XzQtMS0xLTEtNzgyMTU_ff093905-a4d2-4d8a-83be-57a44c561591">32</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpiZTJkYzVkNThlN2U0Yzk4YTZiMTc5YjY0YjlkOTE0OS90YWJsZXJhbmdlOmJlMmRjNWQ1OGU3ZTRjOThhNmIxNzliNjRiOWQ5MTQ5XzQtMy0xLTEtNzgyMTU_a3982e49-1f3f-41b6-b19b-1682dfc7e4d2">32</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basis differences in investments, joint ventures and subsidiaries </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="dgx:DeferredTaxLiabilityInvestmentsInvestmentsinSubsidiariesandEquitymethodinvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpiZTJkYzVkNThlN2U0Yzk4YTZiMTc5YjY0YjlkOTE0OS90YWJsZXJhbmdlOmJlMmRjNWQ1OGU3ZTRjOThhNmIxNzliNjRiOWQ5MTQ5XzYtMS0xLTEtNzgyMTU_670b237b-76a5-442b-8fc0-4696a3e37c9f">11</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="dgx:DeferredTaxLiabilityInvestmentsInvestmentsinSubsidiariesandEquitymethodinvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpiZTJkYzVkNThlN2U0Yzk4YTZiMTc5YjY0YjlkOTE0OS90YWJsZXJhbmdlOmJlMmRjNWQ1OGU3ZTRjOThhNmIxNzliNjRiOWQ5MTQ5XzYtMy0xLTEtNzgyMTU_40686d3f-33e1-456e-9b80-24523e50937f">12</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards, net of valuation allowance</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="dgx:NetOperatingLossCarryfowardsNetOfValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpiZTJkYzVkNThlN2U0Yzk4YTZiMTc5YjY0YjlkOTE0OS90YWJsZXJhbmdlOmJlMmRjNWQ1OGU3ZTRjOThhNmIxNzliNjRiOWQ5MTQ5XzctMS0xLTEtNzgyMTU_10acfe83-d951-46dc-b0df-05bfc512fc86">49</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="dgx:NetOperatingLossCarryfowardsNetOfValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpiZTJkYzVkNThlN2U0Yzk4YTZiMTc5YjY0YjlkOTE0OS90YWJsZXJhbmdlOmJlMmRjNWQ1OGU3ZTRjOThhNmIxNzliNjRiOWQ5MTQ5XzctMy0xLTEtNzgyMTU_8d1c95fc-c094-41d1-87b8-cc480bc92083">42</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpiZTJkYzVkNThlN2U0Yzk4YTZiMTc5YjY0YjlkOTE0OS90YWJsZXJhbmdlOmJlMmRjNWQ1OGU3ZTRjOThhNmIxNzliNjRiOWQ5MTQ5XzgtMS0xLTEtNzgyMTU_425adb9f-749b-4972-8812-22d431ff313a">147</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpiZTJkYzVkNThlN2U0Yzk4YTZiMTc5YjY0YjlkOTE0OS90YWJsZXJhbmdlOmJlMmRjNWQ1OGU3ZTRjOThhNmIxNzliNjRiOWQ5MTQ5XzgtMy0xLTEtNzgyMTU_5bce6e7b-bcf5-4951-981f-795609d2e6ce">150</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="dgx:DeferredTaxAssetsOperatingLeaseLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpiZTJkYzVkNThlN2U0Yzk4YTZiMTc5YjY0YjlkOTE0OS90YWJsZXJhbmdlOmJlMmRjNWQ1OGU3ZTRjOThhNmIxNzliNjRiOWQ5MTQ5XzktMS0xLTEtNzgyMTU_93a09dfe-3398-4a68-815a-1a5a03cde10b">161</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="dgx:DeferredTaxAssetsOperatingLeaseLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpiZTJkYzVkNThlN2U0Yzk4YTZiMTc5YjY0YjlkOTE0OS90YWJsZXJhbmdlOmJlMmRjNWQ1OGU3ZTRjOThhNmIxNzliNjRiOWQ5MTQ5XzktMy0xLTEtNzgyMTU_12f3bf1d-0fb3-4ed1-b961-d6a62a1ca72c">162</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpiZTJkYzVkNThlN2U0Yzk4YTZiMTc5YjY0YjlkOTE0OS90YWJsZXJhbmdlOmJlMmRjNWQ1OGU3ZTRjOThhNmIxNzliNjRiOWQ5MTQ5XzEwLTEtMS0xLTc4MjE1_f87701dd-3c6d-4aca-8efe-ba7d0547de07">568</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpiZTJkYzVkNThlN2U0Yzk4YTZiMTc5YjY0YjlkOTE0OS90YWJsZXJhbmdlOmJlMmRjNWQ1OGU3ZTRjOThhNmIxNzliNjRiOWQ5MTQ5XzEwLTMtMS0xLTc4MjE1_486e1bf6-f7b7-484f-b968-ebec6d0c7328">633</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current deferred tax liabilities, net</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:DeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpiZTJkYzVkNThlN2U0Yzk4YTZiMTc5YjY0YjlkOTE0OS90YWJsZXJhbmdlOmJlMmRjNWQ1OGU3ZTRjOThhNmIxNzliNjRiOWQ5MTQ5XzExLTEtMS0xLTc4MjE1_9c2dc1ec-824c-416b-bf66-c1449e4b02d4">295</ix:nonFraction>)</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpiZTJkYzVkNThlN2U0Yzk4YTZiMTc5YjY0YjlkOTE0OS90YWJsZXJhbmdlOmJlMmRjNWQ1OGU3ZTRjOThhNmIxNzliNjRiOWQ5MTQ5XzExLTMtMS0xLTc4MjE1_bd19c83c-6389-4ebe-9365-5a8304987ad1">290</ix:nonFraction>)</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of December&#160;31, 2022 and 2021, non-current deferred tax liabilities of $<ix:nonFraction unitRef="usd" contextRef="i71e02c56049a42c4a6be7ec8bf9a657b_I20221231" decimals="-6" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzE0MDc_e9090af4-1cac-4373-af5c-e19966c77d1b">295</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia3f1c4f0d1ab416eb53e5a18510fd0dd_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzE0MTQ_47318c1d-ca95-41e4-94b9-17f62933d14d">290</ix:nonFraction> million, respectively, are included in other liabilities in the consolidated balance sheet. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of December&#160;31, 2022, the Company had estimated net operating loss carryforwards for federal and state income tax purposes of $<ix:nonFraction unitRef="usd" contextRef="i585fd94209a4454c885f38e54a3ac3d2_I20221231" decimals="-6" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzE2MTg_6c6c1e56-3c4f-4b99-bfb3-6188aeefb3e9">12</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if150c31900d447178580723791094470_I20221231" decimals="-6" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzE2MjU_76d7579b-28be-48c2-a20d-ecdc60f42669">732</ix:nonFraction> million, respectively, which expire at various dates through 2042.  Estimated net operating loss carryforwards for foreign income tax purposes are $<ix:nonFraction unitRef="usd" contextRef="i3d1d68fb080a45eaa9d48446425aaa2a_I20221231" decimals="-6" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzE3NjU_8d11cc39-e059-44ed-b3a7-cf55ba06fde2">73</ix:nonFraction> million as of December&#160;31, 2022, some of which can be carried forward indefinitely while others expire at various dates through 2032.  As of December&#160;31, 2022 and 2021, deferred tax assets associated with net operating loss carryforwards of $<ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzE5Njc_da8371ad-4bee-4d8a-8424-9d16a3777e65">77</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzE5NzQ_8a8cb407-9553-418a-a923-a3c1702cf22c">71</ix:nonFraction> million, respectively, have each been reduced by valuation allowances of $<ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzIwNDI_01480b0e-ee24-4c2b-a45b-bfb00f8dc749">28</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzIwNDk_13159291-094c-4709-9bec-0c878fb7fdc9">29</ix:nonFraction> million, respectively.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Income taxes payable, including those classified as long-term in other liabilities in the consolidated balance sheet as of December&#160;31, 2022 and 2021, were $<ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:AccruedIncomeTaxes" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzIyMTE_121d076e-ab68-4c42-807d-e58ddd57c067">81</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:AccruedIncomeTaxes" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzIyMTg_ece31126-8cb3-4500-8bc6-8c2986906301">106</ix:nonFraction> million, respectively.  Prepaid income taxes were $<ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:PrepaidTaxes" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzIyNjM_49719096-e505-4dd0-bf32-bd7b9a780047">26</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:PrepaidTaxes" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzIyNzA_c168d3cf-8c68-4fa4-acef-8b34b64b9bff">36</ix:nonFraction> million as of December&#160;31, 2022 and 2021, respectively, and were recorded in prepaid expenses and other current assets in the consolidated balance sheet. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzUzMjY_e99a8df1-481a-41ee-8605-cc38d94dddd4" continuedAt="i54e4431f8bef4d869630f080688bb1d0" escape="true">The total amount of unrecognized tax benefits as of and for the years ended December&#160;31, 2022, 2021 and 2020 consisted of the following:</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="i54e4431f8bef4d869630f080688bb1d0"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzItMS0xLTEtNzgyMTU_77f38d0a-11ef-4ce0-89ee-7a03f6c76abf">110</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872b3ea2e369403f8c0129ff07e0b538_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzItMy0xLTEtNzgyMTU_d7ff478e-2754-4b08-aec4-f759dcd28775">93</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1240b052d8214432b601d5bcbb753f11_I20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzItNS0xLTEtNzgyMTU_9f2293c4-35ed-497d-87a6-f7aab08547a7">88</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For tax positions of current year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzQtMS0xLTEtNzgyMTU_2cb5242e-4522-4170-a47b-df351dbcf1c0">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzQtMy0xLTEtNzgyMTU_9142f3ce-6e5e-4849-9f19-ed47645ebe3f">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzQtNS0xLTEtNzgyMTU_d3c2e317-cfe8-44dd-8b48-7a63ad11d25b">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For tax positions of prior years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzUtMS0xLTEtNzgyMTU_9cdc50e3-e899-49c4-8dff-e0a52a20b88d">18</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzUtMy0xLTEtNzgyMTU_c3622434-98cd-4094-95c3-11e3301e07bc">30</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzUtNS0xLTEtNzgyMTU_5a93b020-a111-4e0b-a137-f2de7118dba1">25</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in judgment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="dgx:ReductionsForChangesInJudgment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzctMS0xLTEtNzgyMTU_720574b9-25da-4758-86ef-73c1c7c595cd">7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="dgx:ReductionsForChangesInJudgment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzctMy0xLTEtNzgyMTU_2eb13588-de63-42bb-b301-5568300cc2a5">6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="dgx:ReductionsForChangesInJudgment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzctNS0xLTEtNzgyMTU_a112bace-cb2f-48f1-880a-e3fd04994890">9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expirations of statutes of limitations</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzgtMS0xLTEtNzgyMTU_cb6f85e3-2dfc-48c8-b156-db410e8812c9">4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzgtMy0xLTEtNzgyMTU_39abaa5f-4405-4c83-91ed-7f1133c8f8fc">8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzgtNS0xLTEtNzgyMTU_920c745d-9e0b-472c-acfe-dc69512c2511">4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzktMS0xLTEtNzgyMTU_e39b4e3c-4be1-4df1-a209-312ebe02d0b6">24</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzktMy0xLTEtNzgyMTU_4713ae34-f245-4c25-926b-17d25da3283b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzktNS0xLTEtNzgyMTU_918c8c9e-e91c-473a-9a99-51cbe9978c54">9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzEwLTEtMS0xLTc4MjE1_1ee24f80-5668-4d41-b73f-19a9e9d995c3">94</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzEwLTMtMS0xLTc4MjE1_47a503be-0db7-46d0-ae1d-71728f9bb0d8">110</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872b3ea2e369403f8c0129ff07e0b538_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzEwLTUtMS0xLTc4MjE1_eb126211-60e1-4992-a090-2b9fb623abcd">93</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The contingent liabilities for tax positions primarily relate to uncertainties associated with the realization of tax benefits derived from the allocation of income and expense among state jurisdictions, the characterization and timing of certain tax deductions associated with business combinations, certain tax credits and the deductibility of certain expenses and settlement payments.   </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The total amount of unrecognized tax benefits as of December&#160;31, 2022, that, if recognized, would affect the effective income tax rate is $<ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzMwNDM_4f343fc5-02bc-40da-810b-4cd769f1ae00">78</ix:nonFraction> million.  Based upon the expiration of statutes of limitations, settlements and/or the conclusion of tax examinations, the Company believes it is reasonably possible that the total amount of unrecognized tax benefits may decrease by up to $<ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzMyNzc_f41f50f2-ad75-4392-b772-69e4a860b61c">13</ix:nonFraction> million within the next twelve months.</span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211; CONTINUED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions unless otherwise indicated)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><ix:continuation id="icbc23101df594eb3bdd6a6c1ce94797a" continuedAt="i8c2791c78b344cefa918e4ff413a0862"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Accruals for interest expense on contingent tax liabilities are classified in income tax expense in the consolidated statements of operations.  Accruals for penalties have historically been immaterial.  Interest expense (income) included in income tax expense in each of the years ended December&#160;31, 2022, 2021 and 2020 was approximately $<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzM2MzI_df6fc15f-dfe6-443a-a634-1ae8a264c770">3</ix:nonFraction> million, $(<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzM2MzY_5af9c1ee-c0bb-4202-8d20-8c3e1ee3afee">2</ix:nonFraction>) million and $<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzM2NDM_cd99df63-ace7-4e95-8543-771e539c0ed7">6</ix:nonFraction> million, respectively.  As of December&#160;31, 2022 and 2021, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzM3MDk_e2629b92-f675-4d77-9669-481c0194a76e">16</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzM3MTY_01231e6a-6880-46d0-82c0-dd73c936d765">20</ix:nonFraction> million, respectively, accrued, net of the benefit of a federal and state deduction, for the payment of interest on uncertain tax positions.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The recognition and measurement of certain tax benefits includes estimates and judgment by management and inherently involves subjectivity.  Changes in estimates may create volatility in the Company's effective tax rate in future periods and may be due to settlements with various tax authorities (either favorable or unfavorable), the expiration of the statute of limitations on certain tax positions and obtaining new information about particular tax positions that may cause management to change its estimates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In the regular course of business, various federal, state, local and foreign tax authorities conduct examinations of the Company's income tax filings and the Company generally remains subject to examination until the statute of limitations expires for the respective jurisdiction.  The Internal Revenue Service has either completed its examinations of the Company's consolidated federal income tax returns or the statute of limitations has expired up through and including the 2018 tax year.  At this time, the Company does not believe that there will be any material additional payments beyond its recorded contingent liability reserves that may be required as a result of these tax audits.  As of December&#160;31, 2022, a summary of the tax years that remain subject to examination, awaiting approval, are under appeal, or are otherwise unresolved for the Company's major jurisdictions are:</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;United States - federal&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2019 - 2021 </span></div></ix:continuation><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8c2791c78b344cefa918e4ff413a0862">&#160;&#160;&#160;&#160;United States - various states&#160;&#160;&#160;&#160;2007 - 2021</ix:continuation> </span></div><div style="margin-top:5pt;text-align:center;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_202"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211; CONTINUED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions unless otherwise indicated)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90ZXh0cmVnaW9uOjc5OTUxNmE0MzQ3NTQ5Njg4NThkYTgyYWI2Yzc1ZjZhXzE1Nw_f1e31031-fc02-434f-a5a7-4051acb00ac4" continuedAt="i2e79755c257940afbce838b3140ce033" escape="true">SUPPLEMENTAL CASH FLOW AND OTHER DATA </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i2e79755c257940afbce838b3140ce033"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90ZXh0cmVnaW9uOjc5OTUxNmE0MzQ3NTQ5Njg4NThkYTgyYWI2Yzc1ZjZhXzE2MA_0a01e125-1ea2-42bb-b6b7-60a9026b47f0" continuedAt="id7c461a7d91447cd9c2e2b1a354f553a" escape="true">Supplemental cash flow and other data for the years ended December&#160;31, 2022, 2021 and 2020 was as follows:</ix:nonNumeric></span></div><ix:continuation id="id7c461a7d91447cd9c2e2b1a354f553a"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzItMS0xLTEtNzgyMTU_4db0d78c-dad5-48f0-a33d-86c33d49b7a8">317</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzItMy0xLTEtNzgyMTU_27d599bc-d207-442b-b1d3-f5b2230f8b7e">305</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzItNS0xLTEtNzgyMTU_58fa8c06-c261-4611-88da-59abb8ad7997">258</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzMtMS0xLTEtNzgyMTU_24ab52bd-efac-4b69-9dba-6cee21d00e21">120</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzMtMy0xLTEtNzgyMTU_f6f9a3e4-f52a-46fe-9ecd-73cd35d16419">103</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzMtNS0xLTEtNzgyMTU_ff83543c-7719-415b-bd30-19be2be12610">103</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzQtMS0xLTEtNzgyMTU_52d16c17-675d-47ac-804e-ea84e2b95071">437</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzQtMy0xLTEtNzgyMTU_712310ce-075a-4436-b3ae-e20d286ec057">408</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzQtNS0xLTEtNzgyMTU_ef9c34fa-0001-4399-b177-eb2bc13d4bd3">361</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzYtMS0xLTEtNzgyMTU_d59f002c-c71a-40bc-846e-ae6871957fab">148</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzYtMy0xLTEtNzgyMTU_0cce88d9-5ed6-4987-a248-7c6acbcf118c">152</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzYtNS0xLTEtNzgyMTU_1313ddc5-ab13-4456-b034-0abaf89a592a">166</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:InterestAndDividendIncomeOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzctMS0xLTEtNzgyMTU_7a6181ae-1a83-44ca-8caf-361725a63a65">10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:InterestAndDividendIncomeOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzctMy0xLTEtNzgyMTU_863c921e-319d-4093-a39d-24545ddd1b7c">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:InterestAndDividendIncomeOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzctNS0xLTEtNzgyMTU_49bfbc83-f8c5-46bc-9279-4c8643b968e5">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:InterestIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzgtMS0xLTEtNzgyMTU_3e1271ab-6a73-4fd3-b529-8371abbca911">138</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:InterestIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzgtMy0xLTEtNzgyMTU_22622d87-4cc5-4538-98cc-05783c038eb4">151</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:InterestIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzgtNS0xLTEtNzgyMTU_cd68a95b-7e18-417c-8687-68bb78b616d9">163</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzEwLTEtMS0xLTc4MjE1_dfea8138-e264-4f32-8d88-ee7540f1aac5">156</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzEwLTMtMS0xLTc4MjE1_682e29f4-55af-4324-ac1b-4ea92e6c2b04">159</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzEwLTUtMS0xLTc4MjE1_e4259023-a7d8-41a3-8f70-44132ec817ef">201</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzExLTEtMS0xLTc4MjE1_a47ef209-b60f-4f6a-965f-d8802ddf0a8b">283</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzExLTMtMS0xLTc4MjE1_140a15b8-ca9c-4957-b942-2f7c9c365e49">709</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzExLTUtMS0xLTc4MjE1_4db9bb6e-7af7-41a0-837e-f1e6dfc1f082">360</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable associated with capital expenditures</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzEzLTEtMS0xLTc4MjE1_414081ee-70d3-43a6-b1b5-64f905f2e80a">38</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzEzLTMtMS0xLTc4MjE1_b0ed045e-57b9-46b3-9063-e60e653f3219">26</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzEzLTUtMS0xLTc4MjE1_3cf296ce-1c5d-433e-a5fc-e05ab6b8dd0a">46</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable associated with purchases of treasury stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="dgx:TreasuryStockPurchasedbutNotyetPaid" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzE0LTEtMS0xLTc4MjE1_d09123ac-d1f0-4fee-920e-c380c288f10c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="dgx:TreasuryStockPurchasedbutNotyetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzE0LTMtMS0xLTc4MjE1_99d701b1-e8d3-4510-9dea-5963d61b73c6">23</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872b3ea2e369403f8c0129ff07e0b538_I20201231" decimals="-6" name="dgx:TreasuryStockPurchasedbutNotyetPaid" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzE0LTUtMS0xLTc4MjE1_8988b5ce-8026-4242-b372-de73f0e7f854">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend payable</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:DividendsPayableCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzE1LTEtMS0xLTc4MjE1_62d950d6-890c-41bf-86cf-11ea0da4288b">74</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:DividendsPayableCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzE1LTMtMS0xLTc4MjE1_fe9a89a1-3b23-4d51-9e2c-f160425ed94e">74</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872b3ea2e369403f8c0129ff07e0b538_I20201231" decimals="-6" name="us-gaap:DividendsPayableCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzE1LTUtMS0xLTc4MjE1_cd25d315-c1a6-45d3-b860-9ef0b1290803">76</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends received from equity method investees</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzE3LTEtMS0xLTc4MjE1_d4e5f538-2334-4187-8189-5ac7844c88fe">61</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzE3LTMtMS0xLTc4MjE1_204678cf-3bff-4db3-be97-47f7ffcf2670">60</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzE3LTUtMS0xLTc4MjE1_d5334a99-2a61-42f6-9b13-17a0366c77bc">54</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Businesses acquired:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:FairValueOfAssetsAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzIwLTEtMS0xLTc4MjE1_2ade47d8-5b82-4f2c-a841-8c7ffa3aa46c">182</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:FairValueOfAssetsAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzIwLTMtMS0xLTc4MjE1_03f2ad8b-51ef-43a8-b1dc-b7fdb79ef59a">364</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:FairValueOfAssetsAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzIwLTUtMS0xLTc4MjE1_98ab0d56-d524-45ab-8d57-93114567fc5e">368</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of liabilities assumed</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:LiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzIxLTEtMS0xLTc4MjE1_f27103cf-157f-4a73-9485-de3d9d0ce66f">16</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:LiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzIxLTMtMS0xLTc4MjE1_98f50ba9-59f7-461e-b707-0addf937962e">18</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:LiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzIxLTUtMS0xLTc4MjE1_35912ede-7048-44d7-b53f-c5db37d21616">17</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of net assets acquired</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="dgx:FairValueOfNetAssetsAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzIyLTEtMS0xLTc4MjE1_07f3848d-079c-409b-a86a-6d626b400e5d">166</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="dgx:FairValueOfNetAssetsAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzIyLTMtMS0xLTc4MjE1_b3f60fb1-1704-48fe-ad8c-05410704f4cc">346</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="dgx:FairValueOfNetAssetsAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzIyLTUtMS0xLTc4MjE1_fa9f9e9b-5669-40c3-bb3d-96efb03fe3b9">351</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merger consideration payable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" sign="-" name="dgx:Mergerconsiderationpaidpayablenet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzIzLTEtMS0xLTc4MjE1_3538dfd3-e0c9-4115-8ab9-65fc6e18dc9b">18</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" sign="-" name="dgx:Mergerconsiderationpaidpayablenet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzIzLTMtMS0xLTc4MjE1_747088ea-8ed1-4d87-b195-c31e4ce24dc5">15</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for business acquisitions</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzI0LTEtMS0xLTc4MjE1_a662faa3-166c-46fd-83a0-41f72c53872d">148</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzI0LTMtMS0xLTc4MjE1_da1175d6-32b2-48e0-b919-c72dc9bd442d">331</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzI0LTUtMS0xLTc4MjE1_311e22ac-01bb-4560-a10b-aafd24b4ca67">351</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Cash acquired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:CashAcquiredFromAcquisition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzI1LTEtMS0xLTc4MjE1_18cd5d0d-7c23-4cdd-b676-3aa247477857">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:CashAcquiredFromAcquisition" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzI1LTMtMS0xLTc4MjE1_ce573ff5-072a-4060-9bd9-38e3d0bb96c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:CashAcquiredFromAcquisition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzI1LTUtMS0xLTc4MjE1_54675ebf-ebdc-4423-9e87-10260184ad6b">21</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business acquisitions, net of cash acquired</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzI2LTEtMS0xLTc4MjE1_a6b04955-3191-44e6-be2e-c20eb55f6aad">144</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzI2LTMtMS0xLTc4MjE1_3a92e5aa-aa72-4e3d-b655-dafb2d4fe5b3">331</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzI2LTUtMS0xLTc4MjE1_f9345ebe-9c93-46fa-b7f2-569c42ce2ee2">330</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.296%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Leases:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTowYzYxOTRmMjExYmM0MzYzOTZkNzA2OWM2NmY0N2Q2Ny90YWJsZXJhbmdlOjBjNjE5NGYyMTFiYzQzNjM5NmQ3MDY5YzY2ZjQ3ZDY3XzMtNC0xLTEtNzgyMTU_1bfc5d04-be5c-453d-b4bf-f7911a2e6fb3">185</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTowYzYxOTRmMjExYmM0MzYzOTZkNzA2OWM2NmY0N2Q2Ny90YWJsZXJhbmdlOjBjNjE5NGYyMTFiYzQzNjM5NmQ3MDY5YzY2ZjQ3ZDY3XzMtNi0xLTEtNzgyMTU_936a744b-f7ff-4e48-9514-7711dbf49b6a">185</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTowYzYxOTRmMjExYmM0MzYzOTZkNzA2OWM2NmY0N2Q2Ny90YWJsZXJhbmdlOjBjNjE5NGYyMTFiYzQzNjM5NmQ3MDY5YzY2ZjQ3ZDY3XzMtOC0xLTEtNzgyMTU_40901750-ae17-4702-94c2-7606baf5d5ec">185</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTowYzYxOTRmMjExYmM0MzYzOTZkNzA2OWM2NmY0N2Q2Ny90YWJsZXJhbmdlOjBjNjE5NGYyMTFiYzQzNjM5NmQ3MDY5YzY2ZjQ3ZDY3XzQtNC0xLTEtNzgyMTU_92a25201-dd83-4eac-9288-61531bd16732">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTowYzYxOTRmMjExYmM0MzYzOTZkNzA2OWM2NmY0N2Q2Ny90YWJsZXJhbmdlOjBjNjE5NGYyMTFiYzQzNjM5NmQ3MDY5YzY2ZjQ3ZDY3XzQtNi0xLTEtNzgyMTU_b91ba8bf-d118-4c1e-9eee-fb91f5096bcb">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTowYzYxOTRmMjExYmM0MzYzOTZkNzA2OWM2NmY0N2Q2Ny90YWJsZXJhbmdlOjBjNjE5NGYyMTFiYzQzNjM5NmQ3MDY5YzY2ZjQ3ZDY3XzQtOC0xLTEtNzgyMTU_6ad9c841-437c-4b80-ab2a-18b9eb8e0f51">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTowYzYxOTRmMjExYmM0MzYzOTZkNzA2OWM2NmY0N2Q2Ny90YWJsZXJhbmdlOjBjNjE5NGYyMTFiYzQzNjM5NmQ3MDY5YzY2ZjQ3ZDY3XzUtNC0xLTEtNzgyMTU_0fd9b714-9b3b-4ed2-816b-28efa148c0ea">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTowYzYxOTRmMjExYmM0MzYzOTZkNzA2OWM2NmY0N2Q2Ny90YWJsZXJhbmdlOjBjNjE5NGYyMTFiYzQzNjM5NmQ3MDY5YzY2ZjQ3ZDY3XzUtNi0xLTEtNzgyMTU_a92d2061-9d2f-42a2-b1dd-ccbe1a55c097">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTowYzYxOTRmMjExYmM0MzYzOTZkNzA2OWM2NmY0N2Q2Ny90YWJsZXJhbmdlOjBjNjE5NGYyMTFiYzQzNjM5NmQ3MDY5YzY2ZjQ3ZDY3XzUtOC0xLTEtNzgyMTU_361f3765-51df-460d-a7bb-d8b249ae4ea8">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased assets obtained in exchange for new operating lease liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTowYzYxOTRmMjExYmM0MzYzOTZkNzA2OWM2NmY0N2Q2Ny90YWJsZXJhbmdlOjBjNjE5NGYyMTFiYzQzNjM5NmQ3MDY5YzY2ZjQ3ZDY3XzYtNC0xLTEtNzgyMTU_70d130a7-3097-45a9-9d70-211ebcc81ebd">154</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTowYzYxOTRmMjExYmM0MzYzOTZkNzA2OWM2NmY0N2Q2Ny90YWJsZXJhbmdlOjBjNjE5NGYyMTFiYzQzNjM5NmQ3MDY5YzY2ZjQ3ZDY3XzYtNi0xLTEtNzgyMTU_78896e58-0618-4ae6-8f5c-5e33cdbd6a19">150</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTowYzYxOTRmMjExYmM0MzYzOTZkNzA2OWM2NmY0N2Q2Ny90YWJsZXJhbmdlOjBjNjE5NGYyMTFiYzQzNjM5NmQ3MDY5YzY2ZjQ3ZDY3XzYtOC0xLTEtNzgyMTU_e8562513-7054-4098-9d11-22caa1b41d90">219</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the year ended December 31, 2022, the Company amended a real estate lease and, based on the updated terms, the classification of the lease changed from a finance lease to an operating lease. As a result, the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="i0cc8a896b5014eec950deeb2b23e329e_I20221231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90ZXh0cmVnaW9uOjc5OTUxNmE0MzQ3NTQ5Njg4NThkYTgyYWI2Yzc1ZjZhXzEwOTk1MTE2MjgyNzI_a06b29e3-b81c-41df-be2f-cea31c076984">31</ix:nonFraction>&#160;million operating lease right-of-use asset.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the years ended December 31, 2022, 2021 and 2020, costs associated with donations, contributions, and other financial support through Quest for Health Equity, the Company's initiative with the Quest Diagnostics Foundation to reduce health disparities in underserved communities, were $<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="dgx:DonationsContributionsAndOtherFinancialSupport" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90ZXh0cmVnaW9uOjc5OTUxNmE0MzQ3NTQ5Njg4NThkYTgyYWI2Yzc1ZjZhXzE2NDkyNjc0NDI3NjE_e6eacb94-e6a3-43f0-96bd-b620a3cca059">93</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="dgx:DonationsContributionsAndOtherFinancialSupport" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90ZXh0cmVnaW9uOjc5OTUxNmE0MzQ3NTQ5Njg4NThkYTgyYWI2Yzc1ZjZhXzE2NDkyNjc0NDI3NzQ_74f860d4-361b-4010-a04a-7f7d83e64904">16</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="dgx:DonationsContributionsAndOtherFinancialSupport" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90ZXh0cmVnaW9uOjc5OTUxNmE0MzQ3NTQ5Njg4NThkYTgyYWI2Yzc1ZjZhXzE2NDkyNjc0NDI3ODc_07e0bfe1-5aba-4d0a-bf9f-3136a7d12f49">2</ix:nonFraction>&#160;million, respectively.  Such amounts are included in selling, general and administrative expenses in the Company's consolidated statement of operations.  Costs incurred during the year ended December 31, 2022 will be donated and contributed over several years.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_205"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211; CONTINUED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions unless otherwise indicated)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDUvZnJhZzo2Y2Q3OWQzYjU0YzM0Nzc3Yjc4NTM0ZDQzZjFjNjljMi90ZXh0cmVnaW9uOjZjZDc5ZDNiNTRjMzQ3NzdiNzg1MzRkNDNmMWM2OWMyXzI0NQ_64e06dd8-80b0-453e-98c4-b1b321e3b5c6" continuedAt="i4a36462f8b9b4a0c930c5c5e4abe766d" escape="true">PROPERTY, PLANT AND EQUIPMENT</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i4a36462f8b9b4a0c930c5c5e4abe766d"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDUvZnJhZzo2Y2Q3OWQzYjU0YzM0Nzc3Yjc4NTM0ZDQzZjFjNjljMi90ZXh0cmVnaW9uOjZjZDc5ZDNiNTRjMzQ3NzdiNzg1MzRkNDNmMWM2OWMyXzI0Mg_41b2f616-fecf-4006-a015-72ef48331a69" continuedAt="ib54a3a86d8024c8aa291bd7a98bd56fa" escape="true">Property, plant and equipment as of December&#160;31, 2022 and 2021 consisted of the following: </ix:nonNumeric></span></div><div style="text-align:center"><ix:continuation id="ib54a3a86d8024c8aa291bd7a98bd56fa"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8c3207c09bd46528b441166ed00ce51_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDUvZnJhZzo2Y2Q3OWQzYjU0YzM0Nzc3Yjc4NTM0ZDQzZjFjNjljMi90YWJsZTo4MDQ0ZTcwYTY0ODY0NzVmYWE1NzMxYjY4ZmRjNGM5Zi90YWJsZXJhbmdlOjgwNDRlNzBhNjQ4NjQ3NWZhYTU3MzFiNjhmZGM0YzlmXzItMS0xLTEtNzgyMTU_2950cf7d-e380-4149-bb73-6b41d6e919b2">43</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a0fe7e6792a43c6948edd202dfa3610_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDUvZnJhZzo2Y2Q3OWQzYjU0YzM0Nzc3Yjc4NTM0ZDQzZjFjNjljMi90YWJsZTo4MDQ0ZTcwYTY0ODY0NzVmYWE1NzMxYjY4ZmRjNGM5Zi90YWJsZXJhbmdlOjgwNDRlNzBhNjQ4NjQ3NWZhYTU3MzFiNjhmZGM0YzlmXzItMy0xLTEtNzgyMTU_2ed99bb8-b888-444e-adee-f4e5a36f0c95">43</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67120ecad309432da683bc8101a2349a_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDUvZnJhZzo2Y2Q3OWQzYjU0YzM0Nzc3Yjc4NTM0ZDQzZjFjNjljMi90YWJsZTo4MDQ0ZTcwYTY0ODY0NzVmYWE1NzMxYjY4ZmRjNGM5Zi90YWJsZXJhbmdlOjgwNDRlNzBhNjQ4NjQ3NWZhYTU3MzFiNjhmZGM0YzlmXzMtMS0xLTEtNzgyMTU_deb45686-ff37-44d7-9934-581b6838a143">520</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16c4c9b2568544898fd08b624fe50b66_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDUvZnJhZzo2Y2Q3OWQzYjU0YzM0Nzc3Yjc4NTM0ZDQzZjFjNjljMi90YWJsZTo4MDQ0ZTcwYTY0ODY0NzVmYWE1NzMxYjY4ZmRjNGM5Zi90YWJsZXJhbmdlOjgwNDRlNzBhNjQ4NjQ3NWZhYTU3MzFiNjhmZGM0YzlmXzMtMy0xLTEtNzgyMTU_11a78fc5-9e2c-4f58-a4f4-3651b098afec">532</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment and furniture and fixtures</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98ddc5b3f9b247d7aff2886d77af5203_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDUvZnJhZzo2Y2Q3OWQzYjU0YzM0Nzc3Yjc4NTM0ZDQzZjFjNjljMi90YWJsZTo4MDQ0ZTcwYTY0ODY0NzVmYWE1NzMxYjY4ZmRjNGM5Zi90YWJsZXJhbmdlOjgwNDRlNzBhNjQ4NjQ3NWZhYTU3MzFiNjhmZGM0YzlmXzQtMS0xLTEtNzgyMTU_773be802-819e-43f1-81cc-1dd1b7ec74c9">2,140</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3b24be39ce649f0b555d02d17abd4b5_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDUvZnJhZzo2Y2Q3OWQzYjU0YzM0Nzc3Yjc4NTM0ZDQzZjFjNjljMi90YWJsZTo4MDQ0ZTcwYTY0ODY0NzVmYWE1NzMxYjY4ZmRjNGM5Zi90YWJsZXJhbmdlOjgwNDRlNzBhNjQ4NjQ3NWZhYTU3MzFiNjhmZGM0YzlmXzQtMy0xLTEtNzgyMTU_919be72a-f8c1-4d99-9969-aefdcfefef7e">2,009</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i556301e56725415db5e0e99af8881ab2_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDUvZnJhZzo2Y2Q3OWQzYjU0YzM0Nzc3Yjc4NTM0ZDQzZjFjNjljMi90YWJsZTo4MDQ0ZTcwYTY0ODY0NzVmYWE1NzMxYjY4ZmRjNGM5Zi90YWJsZXJhbmdlOjgwNDRlNzBhNjQ4NjQ3NWZhYTU3MzFiNjhmZGM0YzlmXzUtMS0xLTEtNzgyMTU_5ee12b0c-3221-45d6-92d5-e1e668f25c99">760</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2941ae72a36c43deb9d71ecae5604733_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDUvZnJhZzo2Y2Q3OWQzYjU0YzM0Nzc3Yjc4NTM0ZDQzZjFjNjljMi90YWJsZTo4MDQ0ZTcwYTY0ODY0NzVmYWE1NzMxYjY4ZmRjNGM5Zi90YWJsZXJhbmdlOjgwNDRlNzBhNjQ4NjQ3NWZhYTU3MzFiNjhmZGM0YzlmXzUtMy0xLTEtNzgyMTU_d36f1de4-020c-4d25-adf5-131b2a404459">705</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software developed or obtained for internal use</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cd92532b444421cbbef1840ffb1e964_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDUvZnJhZzo2Y2Q3OWQzYjU0YzM0Nzc3Yjc4NTM0ZDQzZjFjNjljMi90YWJsZTo4MDQ0ZTcwYTY0ODY0NzVmYWE1NzMxYjY4ZmRjNGM5Zi90YWJsZXJhbmdlOjgwNDRlNzBhNjQ4NjQ3NWZhYTU3MzFiNjhmZGM0YzlmXzYtMS0xLTEtNzgyMTU_599c35ad-a95d-446a-891f-45dd5ffbdfd0">1,363</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26ad136d73174bb492bfb4eb3f70e8ac_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDUvZnJhZzo2Y2Q3OWQzYjU0YzM0Nzc3Yjc4NTM0ZDQzZjFjNjljMi90YWJsZTo4MDQ0ZTcwYTY0ODY0NzVmYWE1NzMxYjY4ZmRjNGM5Zi90YWJsZXJhbmdlOjgwNDRlNzBhNjQ4NjQ3NWZhYTU3MzFiNjhmZGM0YzlmXzYtMy0xLTEtNzgyMTU_e001dc0a-b9d2-40c3-8b8d-f09797cec679">1,292</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie438daf2fc794813a4a9dc699c36d20a_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDUvZnJhZzo2Y2Q3OWQzYjU0YzM0Nzc3Yjc4NTM0ZDQzZjFjNjljMi90YWJsZTo4MDQ0ZTcwYTY0ODY0NzVmYWE1NzMxYjY4ZmRjNGM5Zi90YWJsZXJhbmdlOjgwNDRlNzBhNjQ4NjQ3NWZhYTU3MzFiNjhmZGM0YzlmXzctMS0xLTEtNzgyMTU_ee1ac02c-08ce-43cd-8793-95bc2a3808e4">277</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5cf2176ed3c4e77a2914da13e51e940_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDUvZnJhZzo2Y2Q3OWQzYjU0YzM0Nzc3Yjc4NTM0ZDQzZjFjNjljMi90YWJsZTo4MDQ0ZTcwYTY0ODY0NzVmYWE1NzMxYjY4ZmRjNGM5Zi90YWJsZXJhbmdlOjgwNDRlNzBhNjQ4NjQ3NWZhYTU3MzFiNjhmZGM0YzlmXzctMy0xLTEtNzgyMTU_0e95abef-cc1e-406d-b3b4-fd31238e03d8">214</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDUvZnJhZzo2Y2Q3OWQzYjU0YzM0Nzc3Yjc4NTM0ZDQzZjFjNjljMi90YWJsZTo4MDQ0ZTcwYTY0ODY0NzVmYWE1NzMxYjY4ZmRjNGM5Zi90YWJsZXJhbmdlOjgwNDRlNzBhNjQ4NjQ3NWZhYTU3MzFiNjhmZGM0YzlmXzgtMS0xLTEtNzgyMTU_bfaab681-d635-42db-b8e4-ad185ba38792">5,103</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDUvZnJhZzo2Y2Q3OWQzYjU0YzM0Nzc3Yjc4NTM0ZDQzZjFjNjljMi90YWJsZTo4MDQ0ZTcwYTY0ODY0NzVmYWE1NzMxYjY4ZmRjNGM5Zi90YWJsZXJhbmdlOjgwNDRlNzBhNjQ4NjQ3NWZhYTU3MzFiNjhmZGM0YzlmXzgtMy0xLTEtNzgyMTU_5c99a722-02f0-47be-89aa-1ac316c048c1">4,795</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDUvZnJhZzo2Y2Q3OWQzYjU0YzM0Nzc3Yjc4NTM0ZDQzZjFjNjljMi90YWJsZTo4MDQ0ZTcwYTY0ODY0NzVmYWE1NzMxYjY4ZmRjNGM5Zi90YWJsZXJhbmdlOjgwNDRlNzBhNjQ4NjQ3NWZhYTU3MzFiNjhmZGM0YzlmXzktMS0xLTEtNzgyMTU_d53490e2-2809-44da-af56-66eaa21c3a0f">3,337</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDUvZnJhZzo2Y2Q3OWQzYjU0YzM0Nzc3Yjc4NTM0ZDQzZjFjNjljMi90YWJsZTo4MDQ0ZTcwYTY0ODY0NzVmYWE1NzMxYjY4ZmRjNGM5Zi90YWJsZXJhbmdlOjgwNDRlNzBhNjQ4NjQ3NWZhYTU3MzFiNjhmZGM0YzlmXzktMy0xLTEtNzgyMTU_b41fb5e7-5f3c-48b6-8e56-8c9c65f9bcf5">3,088</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDUvZnJhZzo2Y2Q3OWQzYjU0YzM0Nzc3Yjc4NTM0ZDQzZjFjNjljMi90YWJsZTo4MDQ0ZTcwYTY0ODY0NzVmYWE1NzMxYjY4ZmRjNGM5Zi90YWJsZXJhbmdlOjgwNDRlNzBhNjQ4NjQ3NWZhYTU3MzFiNjhmZGM0YzlmXzEwLTEtMS0xLTc4MjE1_a949a152-d473-476c-b2b7-a8e94b92b0ea">1,766</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDUvZnJhZzo2Y2Q3OWQzYjU0YzM0Nzc3Yjc4NTM0ZDQzZjFjNjljMi90YWJsZTo4MDQ0ZTcwYTY0ODY0NzVmYWE1NzMxYjY4ZmRjNGM5Zi90YWJsZXJhbmdlOjgwNDRlNzBhNjQ4NjQ3NWZhYTU3MzFiNjhmZGM0YzlmXzEwLTMtMS0xLTc4MjE1_6c6e0bf9-b196-4957-a032-ce24db034f31">1,707</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="text-align:center"><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_208"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90ZXh0cmVnaW9uOmI3MDNlNWE3YTk1ZjRlMjM4ZjU4NjhkZTMzOWQ5ZjEyXzk4OA_833d756e-9e7e-4a08-9ad3-4fbe82abd726" continuedAt="i9b86057d752e4fd78739a58138a567e4" escape="true">GOODWILL AND INTANGIBLE ASSETS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i9b86057d752e4fd78739a58138a567e4" continuedAt="i24faeda158234d4ab33f745cbb333ad5"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90ZXh0cmVnaW9uOmI3MDNlNWE3YTk1ZjRlMjM4ZjU4NjhkZTMzOWQ5ZjEyXzk5NA_311d2f35-7bd9-49d3-9e04-ec62adeb03e9" continuedAt="ica5cdb66971a4936bb9700e221826a69" escape="true">The changes in goodwill for the years ended December&#160;31, 2022 and 2021 were as follows:</ix:nonNumeric></span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="ica5cdb66971a4936bb9700e221826a69"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpiN2NkYzQyMzRjOGE0MTExOGE2NDI2NzM2M2FiNjk1NS90YWJsZXJhbmdlOmI3Y2RjNDIzNGM4YTQxMTE4YTY0MjY3MzYzYWI2OTU1XzItMS0xLTEtNzgyMTU_1a22ed72-ec90-4fd9-8299-78ca61da442e">7,095</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872b3ea2e369403f8c0129ff07e0b538_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpiN2NkYzQyMzRjOGE0MTExOGE2NDI2NzM2M2FiNjk1NS90YWJsZXJhbmdlOmI3Y2RjNDIzNGM4YTQxMTE4YTY0MjY3MzYzYWI2OTU1XzItMy0xLTEtNzgyMTU_dda13cb4-d7ca-4cdb-ba3e-9f3a0df8e317">6,873</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired during the year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpiN2NkYzQyMzRjOGE0MTExOGE2NDI2NzM2M2FiNjk1NS90YWJsZXJhbmdlOmI3Y2RjNDIzNGM4YTQxMTE4YTY0MjY3MzYzYWI2OTU1XzMtMS0xLTEtNzgyMTU_f1933609-e081-4276-aeda-04613547055c">121</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpiN2NkYzQyMzRjOGE0MTExOGE2NDI2NzM2M2FiNjk1NS90YWJsZXJhbmdlOmI3Y2RjNDIzNGM4YTQxMTE4YTY0MjY3MzYzYWI2OTU1XzMtMy0xLTEtNzgyMTU_d0e7e469-2059-4276-a99f-0c172dea2ae9">228</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to goodwill</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpiN2NkYzQyMzRjOGE0MTExOGE2NDI2NzM2M2FiNjk1NS90YWJsZXJhbmdlOmI3Y2RjNDIzNGM4YTQxMTE4YTY0MjY3MzYzYWI2OTU1XzQtMS0xLTEtNzgyMTU_e88a5dce-4035-4fb4-aa3c-42333cbd4fec">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpiN2NkYzQyMzRjOGE0MTExOGE2NDI2NzM2M2FiNjk1NS90YWJsZXJhbmdlOmI3Y2RjNDIzNGM4YTQxMTE4YTY0MjY3MzYzYWI2OTU1XzQtMy0xLTEtNzgyMTU_615d19f6-ed39-4f0f-badf-17ba9f594613">6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpiN2NkYzQyMzRjOGE0MTExOGE2NDI2NzM2M2FiNjk1NS90YWJsZXJhbmdlOmI3Y2RjNDIzNGM4YTQxMTE4YTY0MjY3MzYzYWI2OTU1XzUtMS0xLTEtNzgyMTU_8232bd9e-4f9a-4da6-b454-1f80caf9de99">7,220</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpiN2NkYzQyMzRjOGE0MTExOGE2NDI2NzM2M2FiNjk1NS90YWJsZXJhbmdlOmI3Y2RjNDIzNGM4YTQxMTE4YTY0MjY3MzYzYWI2OTU1XzUtMy0xLTEtNzgyMTU_b5b40d8f-b214-46da-9ce0-58e2537010a0">7,095</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Principally all of the Company&#8217;s goodwill as of December&#160;31, 2022 and 2021 was associated with its DIS business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the year ended December&#160;31, 2022, goodwill acquired was principally associated with the acquisition of Pack Health (see Note 6).  For the year ended December&#160;31, 2022, adjustments to goodwill related to an adjustment of the purchase price allocation for Labtech, partially offset by foreign currency translation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the year ended December&#160;31, 2021, goodwill acquired was principally associated with the acquisitions of the assets of the outreach laboratory business of Mercy Health and the assets of Labtech (see Note 6). For the year ended December&#160;31, 2021, adjustments to goodwill related to foreign currency translation. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90ZXh0cmVnaW9uOmI3MDNlNWE3YTk1ZjRlMjM4ZjU4NjhkZTMzOWQ5ZjEyXzEwMDQ_dfdd8ab1-bfab-482d-ad53-41e36a1449a6" continuedAt="if30753516f424453b6eaa95a2b5666fb" escape="true">Intangible assets as of December&#160;31, 2022 and 2021 consisted of the following:</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211; CONTINUED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions unless otherwise indicated)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><ix:continuation id="i24faeda158234d4ab33f745cbb333ad5"><div style="margin-top:5pt"><ix:continuation id="if30753516f424453b6eaa95a2b5666fb"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.436%"></td><td style="width:0.1%"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Amortization<br/>Period (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizing intangible assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer-related</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie457eb795c6c447ab93368b3aed4f823_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzMtMS0xLTEtNzgyMTU_dcc51485-caef-4b73-bc1c-f8d14b73a79d">17</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9f9ea06f7194197817bb2efd0215f53_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzMtMy0xLTEtNzgyMTU_6f589e54-30e6-40b0-a133-23df98366d6a">1,623</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9f9ea06f7194197817bb2efd0215f53_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzMtNS0xLTEtNzgyMTU_f50d8e29-938d-4e71-9a0e-c54a93e01704">832</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9f9ea06f7194197817bb2efd0215f53_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzMtNy0xLTEtNzgyMTU_c2e1f260-6c42-4f71-a254-e376c94b0fa7">791</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c904f919f5841dab0cc8a467bfece73_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzMtOS0xLTEtNzgyMTU_624571da-4772-4ce1-9b37-68b9d7b31d88">1,581</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c904f919f5841dab0cc8a467bfece73_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzMtMTEtMS0xLTc4MjE1_3b180432-ef4d-4438-ab40-110be48977f8">726</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c904f919f5841dab0cc8a467bfece73_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzMtMTMtMS0xLTc4MjE1_dd5f0f54-704c-48da-9a56-c10a2c727f56">855</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-compete agreements</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie5d6933739c34b618deb542c4712132c_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzQtMS0xLTEtNzgyMTU_4683526e-3059-4920-bc74-62e0a640d25e">10</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91553244d95f431f99ff6af124bfc732_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzQtMy0xLTEtNzgyMTU_2aaf4543-5b66-4447-a4ae-44f3790b9f15">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91553244d95f431f99ff6af124bfc732_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzQtNS0xLTEtNzgyMTU_452bdd9b-4159-4934-9850-15597f9fa414">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91553244d95f431f99ff6af124bfc732_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzQtNy0xLTEtNzgyMTU_5ed00104-9d17-462a-9cd3-8e0d77e0e58c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb82f3cff9fb4367b9527abfc041ea6d_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzQtOS0xLTEtNzgyMTU_cfe88fe7-e76f-4c5e-966a-2feade54679a">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb82f3cff9fb4367b9527abfc041ea6d_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzQtMTEtMS0xLTc4MjE1_33099d3e-2b4e-41c6-b433-3ef9b36ec617">2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb82f3cff9fb4367b9527abfc041ea6d_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzQtMTMtMS0xLTc4MjE1_c3558295-c71f-4dff-9ade-cf601f3aeb88">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icfe0b2f1d56541548f5ba20eedeeffdf_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzUtMS0xLTEtNzgyMTU_288fc58a-a562-4a27-95b5-7391194a12cf">15</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb995e58236640a2bebf429f0ef15cf6_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzUtMy0xLTEtNzgyMTU_2d42831c-6d73-46d7-8ebd-44f34dc513d4">138</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb995e58236640a2bebf429f0ef15cf6_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzUtNS0xLTEtNzgyMTU_26506fc9-cd1d-4a6b-9ab1-28ebe0570169">81</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb995e58236640a2bebf429f0ef15cf6_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzUtNy0xLTEtNzgyMTU_75baee0c-e986-471c-9646-c51511f8a56e">57</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icae1953df1b64580906887b236811607_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzUtOS0xLTEtNzgyMTU_666ef1a0-8e67-42d9-877d-522d23c58a7b">141</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icae1953df1b64580906887b236811607_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzUtMTEtMS0xLTc4MjE1_0398d142-fc45-44a0-b195-fd7f7f05d9c4">74</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icae1953df1b64580906887b236811607_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzUtMTMtMS0xLTc4MjE1_2dbc4b8b-0859-4022-b0f4-942bd171d6d5">67</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i309a355e12ca4ac8aebec7a6a293b7f1_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzYtMS0xLTEtNzgyMTU_2e1d9b4f-5f70-481e-b6d5-b7bdb9a17f39">6</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d5911f3c604626be8defe10191d842_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzYtMy0xLTEtNzgyMTU_64ba0901-8879-4bc0-a207-bbcab68f88e0">114</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34d5911f3c604626be8defe10191d842_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzYtNS0xLTEtNzgyMTU_d85ce958-8577-4884-b3a3-8d50c28f3094">106</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d5911f3c604626be8defe10191d842_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzYtNy0xLTEtNzgyMTU_c3310d11-7edd-4e2d-aba2-34a96a46e7e8">8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c028f5ff27446fa49dcddeadcef5ff_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzYtOS0xLTEtNzgyMTU_7c3e1c94-1eed-423b-ab12-81936796f778">109</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73c028f5ff27446fa49dcddeadcef5ff_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzYtMTEtMS0xLTc4MjE1_f665d4b4-86d6-4668-9d21-1b88598d6618">101</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c028f5ff27446fa49dcddeadcef5ff_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzYtMTMtMS0xLTc4MjE1_403b5d6d-d504-4bca-8957-022800e354a4">8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if532e9c222b34f83ac093a3483e120ea_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzctMS0xLTEtNzgyMTU_f75683f4-2bf8-4c77-a494-c58eb6c2e057">17</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf0044ebfdf413bac60a2d162bc3800_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzctMy0xLTEtNzgyMTU_ee9faed1-51c2-4103-bf28-b06d62b77b23">1,878</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibdf0044ebfdf413bac60a2d162bc3800_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzctNS0xLTEtNzgyMTU_08848d22-9d5b-4742-8c48-152d2ac0104a">1,022</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf0044ebfdf413bac60a2d162bc3800_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzctNy0xLTEtNzgyMTU_fbdee4a7-4634-4a2e-a4ee-ef85934c7805">856</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia02c4586208e4e3ba284b0ed0d180568_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzctOS0xLTEtNzgyMTU_23517489-af6f-485d-904b-754dc3b5060b">1,834</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia02c4586208e4e3ba284b0ed0d180568_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzctMTEtMS0xLTc4MjE1_ba46a7f6-3365-4dba-ac89-e3b7dec1fe3a">903</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia02c4586208e4e3ba284b0ed0d180568_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzctMTMtMS0xLTc4MjE1_116ef9e9-6806-421e-9a8c-28ea61094ffd">931</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets not subject to amortization:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12811850249e482399304d53d433f814_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzEwLTMtMS0xLTc4MjE1_30e61462-28f9-4b32-a42c-e527689b89d8">235</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12811850249e482399304d53d433f814_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzEwLTctMS0xLTc4MjE1_51734fea-7eae-401f-826c-e158ad45d61d">235</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16c67c4eb43e4026aebad131b1687d4c_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzEwLTktMS0xLTc4MjE1_1cc60eec-f5a2-4705-9d74-335e811cb8c8">235</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16c67c4eb43e4026aebad131b1687d4c_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzEwLTEzLTEtMS03ODIxNQ_d8b22fbe-d6c8-4f31-8cd7-9ba183e62fc5">235</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i607e1bfaecc64044abfb3030ef16268d_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzExLTMtMS0xLTc4MjE1_38f669b7-5609-41da-9572-240188075367">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i607e1bfaecc64044abfb3030ef16268d_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzExLTctMS0xLTc4MjE1_3ed463e5-4829-4bf1-870b-2ec22e0c8c53">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e42f87022b0417485ee3c3cae380452_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzExLTktMS0xLTc4MjE1_73739aff-bde9-4634-b2a5-acd9a0583295">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e42f87022b0417485ee3c3cae380452_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzExLTEzLTEtMS03ODIxNQ_1968cb74-affd-48e3-9baf-693aeef2a462">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzEyLTMtMS0xLTc4MjE1_1a393fea-d885-4416-95a3-5537b7688461">2,114</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzEyLTUtMS0xLTc4MjE1_c05714bc-735c-48ab-8e48-812f60ad78dc">1,022</ix:nonFraction>)</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzEyLTctMS0xLTc4MjE1_63f74890-176e-488a-976f-f03331409ae2">1,092</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzEyLTktMS0xLTc4MjE1_443a396c-a432-470f-a52d-47419d4e2833">2,070</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzEyLTExLTEtMS03ODIxNQ_744c02fb-0437-47b9-a870-6f1de7c78d3b">903</ix:nonFraction>)</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzEyLTEzLTEtMS03ODIxNQ_793e8a80-a408-4826-8f53-0924b0f3b73c">1,167</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90ZXh0cmVnaW9uOmI3MDNlNWE3YTk1ZjRlMjM4ZjU4NjhkZTMzOWQ5ZjEyXzEwMDU_8da6f22b-0b78-4b77-a52d-079312c87172" continuedAt="i3c8f90ac1f994903b10e38b0652de3f8" escape="true">The estimated amortization expense related to amortizable intangible assets for each of the five succeeding fiscal years and thereafter as of December&#160;31, 2022 is as follows:</ix:nonNumeric></span></div><div style="text-align:center"><ix:continuation id="i3c8f90ac1f994903b10e38b0652de3f8"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:41.959%"><tr><td style="width:1.0%"></td><td style="width:71.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.775%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZToxNzNlOTgyZjZmNjE0NzkxOTc1MjBlN2UwODhhMjM4NS90YWJsZXJhbmdlOjE3M2U5ODJmNmY2MTQ3OTE5NzUyMGU3ZTA4OGEyMzg1XzEtMS0xLTEtNzgyMTU_551853f6-d642-46f4-b60e-f7bcc94a2f78">106</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZToxNzNlOTgyZjZmNjE0NzkxOTc1MjBlN2UwODhhMjM4NS90YWJsZXJhbmdlOjE3M2U5ODJmNmY2MTQ3OTE5NzUyMGU3ZTA4OGEyMzg1XzItMS0xLTEtNzgyMTU_e5ba5d42-ea26-42db-8a47-b858e7501303">103</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZToxNzNlOTgyZjZmNjE0NzkxOTc1MjBlN2UwODhhMjM4NS90YWJsZXJhbmdlOjE3M2U5ODJmNmY2MTQ3OTE5NzUyMGU3ZTA4OGEyMzg1XzMtMS0xLTEtNzgyMTU_238daa79-808e-459d-98a3-344227e7f5e5">102</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZToxNzNlOTgyZjZmNjE0NzkxOTc1MjBlN2UwODhhMjM4NS90YWJsZXJhbmdlOjE3M2U5ODJmNmY2MTQ3OTE5NzUyMGU3ZTA4OGEyMzg1XzQtMS0xLTEtNzgyMTU_2ea35101-3076-4b8d-85c2-ffa4ac1a55bb">96</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZToxNzNlOTgyZjZmNjE0NzkxOTc1MjBlN2UwODhhMjM4NS90YWJsZXJhbmdlOjE3M2U5ODJmNmY2MTQ3OTE5NzUyMGU3ZTA4OGEyMzg1XzUtMS0xLTEtNzgyMTU_3b71d2de-e73d-4a2d-96d1-326c3a706bbc">85</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZToxNzNlOTgyZjZmNjE0NzkxOTc1MjBlN2UwODhhMjM4NS90YWJsZXJhbmdlOjE3M2U5ODJmNmY2MTQ3OTE5NzUyMGU3ZTA4OGEyMzg1XzYtMS0xLTEtNzgyMTU_489331ad-9d43-447c-b302-0a8c79893eff">364</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="dgx:FiniteLivedIntangibleAssetsEstimatedAmortizationExpenseTotal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZToxNzNlOTgyZjZmNjE0NzkxOTc1MjBlN2UwODhhMjM4NS90YWJsZXJhbmdlOjE3M2U5ODJmNmY2MTQ3OTE5NzUyMGU3ZTA4OGEyMzg1XzctMS0xLTEtNzgyMTU_d0f78f45-ca01-43cd-88c4-87890520d925">856</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_211"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90ZXh0cmVnaW9uOjI5N2YyZTE0ZDI1ZDQyOWRhYmU0NDc0MWQ3ZWRhMzRiXzE0NA_0f7640cd-ab3d-4473-b094-0814d43580df" continuedAt="i80a4960bb34948c78e666a25c99f8486" escape="true">ACCOUNTS PAYABLE AND ACCRUED EXPENSES </ix:nonNumeric></span></div><ix:continuation id="i80a4960bb34948c78e666a25c99f8486"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90ZXh0cmVnaW9uOjI5N2YyZTE0ZDI1ZDQyOWRhYmU0NDc0MWQ3ZWRhMzRiXzE0Mw_8b6c45a2-638f-4de0-9391-aa4e49a2e5cf" continuedAt="if023969be58e4b73a7077bb37d26d5ae" escape="true">Accounts payable and accrued expenses as of December&#160;31, 2022 and 2021 consisted of the following: </ix:nonNumeric></span></div><div style="text-align:center;text-indent:36pt"><ix:continuation id="if023969be58e4b73a7077bb37d26d5ae"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.105%"><tr><td style="width:1.0%"></td><td style="width:72.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued wages and benefits (including incentive compensation)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90YWJsZTpmYWYwZThkM2Y0MzE0NjZiYjhhZTlkYWUxYzNjMzg3ZC90YWJsZXJhbmdlOmZhZjBlOGQzZjQzMTQ2NmJiOGFlOWRhZTFjM2MzODdkXzItMS0xLTEtNzgyMTU_0e897c94-33df-4d28-9421-abefe086102f">428</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90YWJsZTpmYWYwZThkM2Y0MzE0NjZiYjhhZTlkYWUxYzNjMzg3ZC90YWJsZXJhbmdlOmZhZjBlOGQzZjQzMTQ2NmJiOGFlOWRhZTFjM2MzODdkXzItMy0xLTEtNzgyMTU_07c88aa5-d186-4250-b868-605a800e7fd5">518</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90YWJsZTpmYWYwZThkM2Y0MzE0NjZiYjhhZTlkYWUxYzNjMzg3ZC90YWJsZXJhbmdlOmZhZjBlOGQzZjQzMTQ2NmJiOGFlOWRhZTFjM2MzODdkXzMtMS0xLTEtNzgyMTU_433c9e7b-3acb-43cd-8f28-797a8aed55c1">392</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90YWJsZTpmYWYwZThkM2Y0MzE0NjZiYjhhZTlkYWUxYzNjMzg3ZC90YWJsZXJhbmdlOmZhZjBlOGQzZjQzMTQ2NmJiOGFlOWRhZTFjM2MzODdkXzMtMy0xLTEtNzgyMTU_034993b3-2056-4079-8f64-475e6b7669e7">460</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:AccountsPayableTradeCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90YWJsZTpmYWYwZThkM2Y0MzE0NjZiYjhhZTlkYWUxYzNjMzg3ZC90YWJsZXJhbmdlOmZhZjBlOGQzZjQzMTQ2NmJiOGFlOWRhZTFjM2MzODdkXzQtMS0xLTEtNzgyMTU_7f4f8ee1-94fd-45b3-9533-a269a0e79b7a">324</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:AccountsPayableTradeCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90YWJsZTpmYWYwZThkM2Y0MzE0NjZiYjhhZTlkYWUxYzNjMzg3ZC90YWJsZXJhbmdlOmZhZjBlOGQzZjQzMTQ2NmJiOGFlOWRhZTFjM2MzODdkXzQtMy0xLTEtNzgyMTU_b95e6beb-9f3c-4b5f-b46e-37d20fed8b01">357</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Overdrafts</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:BankOverdrafts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90YWJsZTpmYWYwZThkM2Y0MzE0NjZiYjhhZTlkYWUxYzNjMzg3ZC90YWJsZXJhbmdlOmZhZjBlOGQzZjQzMTQ2NmJiOGFlOWRhZTFjM2MzODdkXzUtMS0xLTEtNzgyMTU_d953d8ba-f954-442e-bb82-743e5a79b8ba">92</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:BankOverdrafts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90YWJsZTpmYWYwZThkM2Y0MzE0NjZiYjhhZTlkYWUxYzNjMzg3ZC90YWJsZXJhbmdlOmZhZjBlOGQzZjQzMTQ2NmJiOGFlOWRhZTFjM2MzODdkXzUtMy0xLTEtNzgyMTU_42f65901-54ac-4720-bf1b-2ecd9c69dcb5">116</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend payable</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:DividendsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90YWJsZTpmYWYwZThkM2Y0MzE0NjZiYjhhZTlkYWUxYzNjMzg3ZC90YWJsZXJhbmdlOmZhZjBlOGQzZjQzMTQ2NmJiOGFlOWRhZTFjM2MzODdkXzYtMS0xLTEtNzgyMTU_832ec74c-58cb-4671-941c-177f9fd1e40e">74</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:DividendsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90YWJsZTpmYWYwZThkM2Y0MzE0NjZiYjhhZTlkYWUxYzNjMzg3ZC90YWJsZXJhbmdlOmZhZjBlOGQzZjQzMTQ2NmJiOGFlOWRhZTFjM2MzODdkXzYtMy0xLTEtNzgyMTU_9d8e2519-3190-4e0b-8995-4a1255d3adb5">74</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued insurance</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:AccruedInsuranceCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90YWJsZTpmYWYwZThkM2Y0MzE0NjZiYjhhZTlkYWUxYzNjMzg3ZC90YWJsZXJhbmdlOmZhZjBlOGQzZjQzMTQ2NmJiOGFlOWRhZTFjM2MzODdkXzctMS0xLTEtNzgyMTU_81ef21cf-8311-4634-b12f-53f5c81280ae">35</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:AccruedInsuranceCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90YWJsZTpmYWYwZThkM2Y0MzE0NjZiYjhhZTlkYWUxYzNjMzg3ZC90YWJsZXJhbmdlOmZhZjBlOGQzZjQzMTQ2NmJiOGFlOWRhZTFjM2MzODdkXzctMy0xLTEtNzgyMTU_8df7a6f8-c934-4c36-8986-eda82ef5ad96">34</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:InterestPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90YWJsZTpmYWYwZThkM2Y0MzE0NjZiYjhhZTlkYWUxYzNjMzg3ZC90YWJsZXJhbmdlOmZhZjBlOGQzZjQzMTQ2NmJiOGFlOWRhZTFjM2MzODdkXzgtMS0xLTEtNzgyMTU_74f796c8-b3c5-4bbf-bdde-09666eb3a966">26</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:InterestPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90YWJsZTpmYWYwZThkM2Y0MzE0NjZiYjhhZTlkYWUxYzNjMzg3ZC90YWJsZXJhbmdlOmZhZjBlOGQzZjQzMTQ2NmJiOGFlOWRhZTFjM2MzODdkXzgtMy0xLTEtNzgyMTU_bef4989a-0bc7-487f-9e60-9692cfff9089">26</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merger consideration payable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="dgx:MergerConsiderationPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90YWJsZTpmYWYwZThkM2Y0MzE0NjZiYjhhZTlkYWUxYzNjMzg3ZC90YWJsZXJhbmdlOmZhZjBlOGQzZjQzMTQ2NmJiOGFlOWRhZTFjM2MzODdkXzktMS0xLTEtOTMwOTA_30a00388-d6f3-49d6-8f42-a5c972ed2b33">23</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="dgx:MergerConsiderationPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90YWJsZTpmYWYwZThkM2Y0MzE0NjZiYjhhZTlkYWUxYzNjMzg3ZC90YWJsZXJhbmdlOmZhZjBlOGQzZjQzMTQ2NmJiOGFlOWRhZTFjM2MzODdkXzktMy0xLTEtOTMwOTQ_b18b7303-d5ab-4dd9-a1a3-4be8f84043f6">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90YWJsZTpmYWYwZThkM2Y0MzE0NjZiYjhhZTlkYWUxYzNjMzg3ZC90YWJsZXJhbmdlOmZhZjBlOGQzZjQzMTQ2NmJiOGFlOWRhZTFjM2MzODdkXzktMS0xLTEtNzgyMTU_9b86eb8b-d9c4-4237-a741-634c7c96dae0">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90YWJsZTpmYWYwZThkM2Y0MzE0NjZiYjhhZTlkYWUxYzNjMzg3ZC90YWJsZXJhbmdlOmZhZjBlOGQzZjQzMTQ2NmJiOGFlOWRhZTFjM2MzODdkXzktMy0xLTEtNzgyMTU_d46ce0e9-686c-47ad-a560-8c247a297629">10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90YWJsZTpmYWYwZThkM2Y0MzE0NjZiYjhhZTlkYWUxYzNjMzg3ZC90YWJsZXJhbmdlOmZhZjBlOGQzZjQzMTQ2NmJiOGFlOWRhZTFjM2MzODdkXzExLTEtMS0xLTc4MjE1_c8fd1146-bdfb-4be0-a36e-0d07403e0dce">1,396</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90YWJsZTpmYWYwZThkM2Y0MzE0NjZiYjhhZTlkYWUxYzNjMzg3ZC90YWJsZXJhbmdlOmZhZjBlOGQzZjQzMTQ2NmJiOGFlOWRhZTFjM2MzODdkXzExLTMtMS0xLTc4MjE1_6136702d-3df8-4c11-894b-4721e18e6ace">1,600</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div></div></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_214"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211; CONTINUED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions unless otherwise indicated)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90ZXh0cmVnaW9uOjRmYzg0NDliZjgzOTQ2ZWY4N2E1YTA1NjdmOGNlZWQwXzQ3NzM_764d296f-785b-4438-8a04-8c61e2e5dcf4" continuedAt="ifc9a38e42f1645e79d155107cb378d2b" escape="true">DEBT</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ifc9a38e42f1645e79d155107cb378d2b" continuedAt="idcb84cdb84eb4ba889fde34fd244f954"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:LongTermDebtTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90ZXh0cmVnaW9uOjRmYzg0NDliZjgzOTQ2ZWY4N2E1YTA1NjdmOGNlZWQwXzQ3NjU_ce24927b-bd16-4a36-9c88-1ee73994c18e" continuedAt="ib23f2fbb037941da81ee565d2f6bead7" escape="true">Long-term debt (including finance lease obligations) as of December&#160;31, 2022 and 2021 consisted of the following: </ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="ib23f2fbb037941da81ee565d2f6bead7"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:77.962%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.004%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i73f9034273a34d5687d848b3ebe178b2_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzItMC0xLTEtNzgyMTUvdGV4dHJlZ2lvbjozZDJmN2ZmYjM5MDc0ZDgzYWMwMTRlYzgzNGUxMWE3Zl80_d374bcc2-8c02-4fed-a91c-489d46d02251">4.25</ix:nonFraction>% Senior Notes due April 2024</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f9034273a34d5687d848b3ebe178b2_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzItMS0xLTEtNzgyMTU_0808812f-6b21-4e40-913f-b600d93c550b">306</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafc4f10dcb30465792e3db376f9db383_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzItMy0xLTEtNzgyMTU_6c697744-2a42-492f-b933-08ae5fb05bcc">311</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i36d2de3414984080b11b7ed1f9472589_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzMtMC0xLTEtNzgyMTUvdGV4dHJlZ2lvbjo3ODk4MDk2NWUwMGQ0NmExYWUxZjZhNDEwNmZlN2E4NV80_1db90da3-7cf7-46b4-9831-5ddb3ec2c7f1">3.50</ix:nonFraction>% Senior Notes due March 2025</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36d2de3414984080b11b7ed1f9472589_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzMtMS0xLTEtNzgyMTU_2620f226-be63-4244-9542-b14e63b74441">612</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35159921eda04fbdb92fa45ac28509d5_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzMtMy0xLTEtNzgyMTU_0466094d-b837-41df-a65c-31333e34d23e">616</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i744959a3bc17412a9e5af1fd1d359295_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzQtMC0xLTEtNzgyMTUvdGV4dHJlZ2lvbjoxOGNlM2RmOTg2M2Y0MzgxYWZlYzI3YjY4MmQ3MmIxMV80_beee190c-4d72-4af5-8caa-3e7840c85226">3.45</ix:nonFraction>% Senior Notes due June 2026</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744959a3bc17412a9e5af1fd1d359295_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzQtMS0xLTEtNzgyMTU_66e8fa40-afa9-495e-8007-4fc9590dd413">508</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d5ca1c0cd5d40019d0db21e80203f2c_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzQtMy0xLTEtNzgyMTU_c07f8111-6962-456a-8d59-168e3d02b182">510</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6e6f9e7f0256442db64c6fa43a0ced20_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzUtMC0xLTEtNzgyMTUvdGV4dHJlZ2lvbjo3NTZjZWJlMjE0N2U0MzAzYjYzYWFmY2YxYTM2NzcyM180_0ea3676b-a9d1-4557-a2ff-236c5987f282">4.20</ix:nonFraction>% Senior Notes due June 2029</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e6f9e7f0256442db64c6fa43a0ced20_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzUtMS0xLTEtNzgyMTU_b0625036-6d25-4d52-90e4-83e298254e3a">499</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3b4fa91393e4b0e8d2f092086ab0bdf_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzUtMy0xLTEtNzgyMTU_0be94618-6659-4423-b7e5-561c5ca81530">499</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7e13bac0fccd4f16898a65173f8a921b_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzYtMC0xLTEtNzgyMTUvdGV4dHJlZ2lvbjo2NzVlOGM1NDkxZGQ0ZTg2OTMxODcxYjJmMDIxOWFiM180_033afbf2-2700-46b2-a2af-e939c2a3d815">2.95</ix:nonFraction>% Senior Notes due June 2030</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e13bac0fccd4f16898a65173f8a921b_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzYtMS0xLTEtNzgyMTU_1696248b-bc31-445a-bb51-6dc1caf1dd46">799</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1c4a18ddf92439da82f42ca78db7257_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzYtMy0xLTEtNzgyMTU_04145a77-43b0-4cb4-ac7e-28f4ca86afc3">798</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3bb1349879f5435fa9e912e4cf525b01_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzctMC0xLTEtNzgyMTUvdGV4dHJlZ2lvbjo1MmFhY2VlYjE1OTY0MTgzODI3NWM0NDAwODUwMjg2OV80_756c74a2-6112-4c53-91c7-9239a2180485">2.80</ix:nonFraction>% Senior Notes due June 2031</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bb1349879f5435fa9e912e4cf525b01_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzctMS0xLTEtNzgyMTU_e0ff252e-54d4-440b-8b88-d9c05aa0a573">549</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42e6dc0040114c70b13940e177bb3b1f_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzctMy0xLTEtNzgyMTU_45536b53-48ec-4159-b20f-21e62b2ffebf">549</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iae49dd1a44e743bdb49b617b9cfbaed7_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzgtMC0xLTEtNzgyMTUvdGV4dHJlZ2lvbjowNmUzNGU2YWUxYjA0NDUwYWUyZTg0YTZkMGYyNTkzOV80_ebf5650b-d9c9-4b9f-ac33-212fa112f218">6.95</ix:nonFraction>% Senior Notes due July 2037</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae49dd1a44e743bdb49b617b9cfbaed7_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzgtMS0xLTEtNzgyMTU_b9560ce1-04c7-42f4-a3d6-53d4f75b445c">175</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b3b2a9d05bf465db9db7f32f4c7f461_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzgtMy0xLTEtNzgyMTU_a03db56a-db25-4423-99d0-cc563d8b47b8">175</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2eb4e252832c4cd59e4e6274194a0627_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzktMC0xLTEtNzgyMTUvdGV4dHJlZ2lvbjoyZWU5MTZhMGRlZDI0MWZlOGVlZWNmMGQ1ZDc5MTk2ZV80_64c49270-3f12-4174-b0c8-9c8146bcaada">5.75</ix:nonFraction>% Senior Notes due January 2040</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eb4e252832c4cd59e4e6274194a0627_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzktMS0xLTEtNzgyMTU_34c4dac3-2971-4e70-8537-d2bc5a98dbad">245</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c8de336b3a044bfa41bbd2480192421_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzktMy0xLTEtNzgyMTU_4eb717d4-60d2-40aa-b044-5c2a06a8dfd3">245</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifaf7d8fd470f4603bcbefc2804dc479c_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzEwLTAtMS0xLTc4MjE1L3RleHRyZWdpb246MDFlYTQ5N2VjZjc5NGY3ZWE3NDAwM2QwNWE5ODdkZDlfNA_9370b61b-8ba8-4aba-8a53-01b2bf088b7d">4.70</ix:nonFraction>% Senior Notes due March 2045</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaf7d8fd470f4603bcbefc2804dc479c_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzEwLTEtMS0xLTc4MjE1_cfbfdcf5-83e4-4855-9122-871bd1a642b9">300</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b933ae20f7405ea1d07a3a04b5d06a_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzEwLTMtMS0xLTc4MjE1_0cab734d-e16e-47e3-b773-7f00b7d799e1">300</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e9c816b535f468b832f1fb4f7578811_I20221231" decimals="-6" name="us-gaap:OtherLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzExLTEtMS0xLTc4MjE1_9fb9bf0b-3fa5-41ed-bb26-800938729ca2">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f456f42e2b64e4cb74fbc8ba3ba7668_I20211231" decimals="-6" name="us-gaap:OtherLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzExLTMtMS0xLTc4MjE1_7d8088b3-290b-4c7a-98cd-ccb76c9dc00f">34</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:UnamortizedDebtIssuanceExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzEyLTEtMS0xLTc4MjE1_1f2fdae1-ab0d-4a85-951b-107f886a2b0f">22</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:UnamortizedDebtIssuanceExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzEyLTMtMS0xLTc4MjE1_cee5c588-ac8a-497d-bac5-ba658bf350e3">25</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzEzLTEtMS0xLTc4MjE1_78c787e8-ad10-4d82-afc5-6076e6ba7b39">3,980</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzEzLTMtMS0xLTc4MjE1_48718d91-d60e-45c9-869d-56b3b3422a8d">4,012</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzE0LTEtMS0xLTc4MjE1_5f49b4b6-9c69-45cf-a195-cdf1fe6f0d80">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzE0LTMtMS0xLTc4MjE1_26ae1b11-865a-4941-b647-a5e2134d1153">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, net of current portion</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzE1LTEtMS0xLTc4MjE1_1180e3be-dfc9-4216-8694-4ae8fbf1aa3a">3,978</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzE1LTMtMS0xLTc4MjE1_7338bcc1-f2ac-4fce-a877-c66490741b42">4,010</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Finance Lease</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the year ended December 31, 2022, the Company amended a real estate lease and, based on the updated terms, the classification of the lease changed from a finance lease to an operating lease.  As of December 31, 2021, the $<ix:nonFraction unitRef="usd" contextRef="i3f456f42e2b64e4cb74fbc8ba3ba7668_I20211231" decimals="-6" name="dgx:FinanceLeaseLiabilityRealEstate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90ZXh0cmVnaW9uOjRmYzg0NDliZjgzOTQ2ZWY4N2E1YTA1NjdmOGNlZWQwXzEwOTk1MTE2NDkwNDg_edb91d3e-40ee-4b54-a1f5-7da6ae065f38">25</ix:nonFraction>&#160;million carrying value of the finance lease was included in "other" in the table above.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Secured Receivables Credit Facility </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During October 2022, the Company amended its secured receivables credit facility (the &#8220;Secured Receivables Credit Facility&#8221;), previously amended in October 2021, to extend the maturity dates for each underlying commitment by <ix:nonNumeric contextRef="ie3e292d5aced49a991453002828a13bf_D20221001-20221031" name="dgx:DebtInstrumentExtensionPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90ZXh0cmVnaW9uOjRmYzg0NDliZjgzOTQ2ZWY4N2E1YTA1NjdmOGNlZWQwXzI3NDg3NzkwOTA3Mzc_0431ef1c-fb9b-4731-81f0-fe356406ee89">one year</ix:nonNumeric>, while decreasing the aggregate borrowing capacity under the facility from $<ix:nonFraction unitRef="usd" contextRef="i2473c6e1cff643f4807fa97482f2514c_I20220930" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90ZXh0cmVnaW9uOjRmYzg0NDliZjgzOTQ2ZWY4N2E1YTA1NjdmOGNlZWQwXzEwOTk1MTE2NDU1NDA_6d18f7a5-3bb4-482f-b7c5-e37b4da45d12">600</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="i7ee94c3ad75540f2895fbc6c74806807_I20221031" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90ZXh0cmVnaW9uOjRmYzg0NDliZjgzOTQ2ZWY4N2E1YTA1NjdmOGNlZWQwXzEwOTk1MTE2NDU1NTQ_ea2d0f70-5fff-4344-bc6c-cec922f49a9e">525</ix:nonFraction>&#160;million. Under the Secured Receivables Credit Facility, the Company can borrow against a $<ix:nonFraction unitRef="usd" contextRef="id3f22fe062a74e759fbf551f8c1b5809_I20221031" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90ZXh0cmVnaW9uOjRmYzg0NDliZjgzOTQ2ZWY4N2E1YTA1NjdmOGNlZWQwXzEwOTk1MTE2NDU4OTU_04d91a2c-d5d9-464b-b328-cfbfc422b315">425</ix:nonFraction>&#160;million loan commitment, half of which matures in October 2023 and half of which matures in October 2024. Additionally, the Company can issue up to $<ix:nonFraction unitRef="usd" contextRef="ia223c678f59d4b39a7af63150694192c_I20221031" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90ZXh0cmVnaW9uOjRmYzg0NDliZjgzOTQ2ZWY4N2E1YTA1NjdmOGNlZWQwXzEwOTk1MTE2NDU5MDk_d1516519-a82c-4ea2-a8bb-08e1028aea23">100</ix:nonFraction>&#160;million of letters of credit (see Note 19) through October 2024.  Borrowings under the Secured Receivables Credit Facility are collateralized by certain domestic receivables.  Interest on borrowings under the facility is based on either commercial paper rates for highly-rated issuers or the Term Secured Overnight Financing Rate, plus a spread of <ix:nonFraction unitRef="number" contextRef="i03277559f860449c9b5e26471a9ae119_D20221001-20221031" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90ZXh0cmVnaW9uOjRmYzg0NDliZjgzOTQ2ZWY4N2E1YTA1NjdmOGNlZWQwXzEwOTk1MTE2NDc0NjQ_81569a53-aaf4-4809-b0c5-4ccb863837ff">0.725</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i71d143709b514b99a2a4f28f2a601632_D20221001-20221031" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90ZXh0cmVnaW9uOjRmYzg0NDliZjgzOTQ2ZWY4N2E1YTA1NjdmOGNlZWQwXzEwOTk1MTE2NDc0NzI_b3be111b-60a5-4070-89ad-bc4c9d125b1c">0.80</ix:nonFraction>%.  The Secured Receivables Credit Facility is subject to customary affirmative and negative covenants and certain financial covenants with respect to the receivables that comprise the borrowing base and secure the borrowings under the facility. As of both December&#160;31, 2022 and 2021, there were <ix:nonFraction unitRef="usd" contextRef="ibf24b8c7cb904d33aca6b6f9275180b7_I20211231" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90ZXh0cmVnaW9uOjRmYzg0NDliZjgzOTQ2ZWY4N2E1YTA1NjdmOGNlZWQwXzEwOTk1MTE2NDc1ODM_417d71aa-e689-4ed7-87f9-60a2b5fe778c"><ix:nonFraction unitRef="usd" contextRef="i8e3820f04333496f8fc57291a5c51523_I20221231" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90ZXh0cmVnaW9uOjRmYzg0NDliZjgzOTQ2ZWY4N2E1YTA1NjdmOGNlZWQwXzEwOTk1MTE2NDc1ODM_678a2830-fdcc-4f07-a88a-4ec4dabe19d0">no</ix:nonFraction></ix:nonFraction> outstanding borrowings under the Secured Receivables Credit Facility.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211; CONTINUED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions unless otherwise indicated)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><ix:continuation id="idcb84cdb84eb4ba889fde34fd244f954"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Unsecured Revolving Credit Facility</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company is party to a $<ix:nonFraction unitRef="usd" contextRef="ied9b303df1ae4f6daa7db9f2e1d5d9f0_I20211130" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90ZXh0cmVnaW9uOjRmYzg0NDliZjgzOTQ2ZWY4N2E1YTA1NjdmOGNlZWQwXzU0OTc1NTgyNzYzNQ_fbbeabeb-6837-4dd7-a987-9d97ac2376f8">750</ix:nonFraction>&#160;million senior unsecured revolving credit facility (the &#8220;Credit Facility&#8221; or "Senior Unsecured Revolving Credit Facility") which matures in November 2026.  Under the Credit Facility, the Company can issue letters of credit totaling $<ix:nonFraction unitRef="usd" contextRef="iba1e578b1a6c4c79882ebb5fa88eae23_I20211130" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90ZXh0cmVnaW9uOjRmYzg0NDliZjgzOTQ2ZWY4N2E1YTA1NjdmOGNlZWQwXzE3NDg_74a6f037-2f8e-4083-95f7-c2c77045724c">150</ix:nonFraction>&#160;million (see Note 19).  Issued letters of credit reduce the available borrowing capacity under the Credit Facility.  Interest on the Credit Facility is based on certain published rates plus an applicable margin based on changes in the Company's public debt ratings.  At the option of the Company, it may elect to lock into LIBOR-based interest rates for periods up to six months.  Interest on any outstanding amounts not covered under LIBOR-based interest rate contracts is based on an alternate base rate, which is calculated by reference to the prime rate, the federal funds rate or an adjusted LIBOR rate.  As of December&#160;31, 2022, the Company's borrowing rate for LIBOR-based loans under the Credit Facility was LIBOR plus <ix:nonFraction unitRef="number" contextRef="iec0fa8127aa846ccb173e5c0dac001e5_D20220101-20221231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90ZXh0cmVnaW9uOjRmYzg0NDliZjgzOTQ2ZWY4N2E1YTA1NjdmOGNlZWQwXzI0NDc_8c5d2d00-c19d-48ec-b417-afdbfd124f59">1.00</ix:nonFraction>%.  The Credit Facility contains various covenants, including the maintenance of a financial leverage ratio, which could impact the Company's ability to, among other things, incur additional indebtedness.  As of both December&#160;31, 2022 and 2021, there were <ix:nonFraction unitRef="usd" contextRef="if73e958db14b401a8087839f76ce387c_I20211231" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90ZXh0cmVnaW9uOjRmYzg0NDliZjgzOTQ2ZWY4N2E1YTA1NjdmOGNlZWQwXzI2ODc_2d139e73-0aa7-416d-a3a7-9cc7ef8fdae8"><ix:nonFraction unitRef="usd" contextRef="if79143d725024a98b36d4ee85edf5cee_I20221231" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90ZXh0cmVnaW9uOjRmYzg0NDliZjgzOTQ2ZWY4N2E1YTA1NjdmOGNlZWQwXzI2ODc_bd8d2f18-a56c-4b86-b58f-03b3e08efc5d">no</ix:nonFraction></ix:nonFraction> outstanding borrowings under the Senior Unsecured Revolving Credit Facility.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Notes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;All of the senior notes are unsecured obligations of the Company and rank equally with the Company's other senior unsecured obligations.  None of the Company's senior notes have a sinking fund requirement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company may redeem its outstanding senior notes prior to scheduled maturity, as a whole or in part, at a redemption price equal to the present value of the remaining scheduled payments of principal and interest, except for certain notes for which the Company also has an option to redeem such instruments at par value on or after dates specified in the indentures governing the notes ("the par value redemption option"). &#160;For notes with the par value redemption option, if such notes are redeemed prior to the specified dates, the redemption price calculations exclude any interest that would have been due after such dates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Maturities of Long-Term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90ZXh0cmVnaW9uOjRmYzg0NDliZjgzOTQ2ZWY4N2E1YTA1NjdmOGNlZWQwXzQ3Njc_4db341d0-2e4c-4df2-9306-2dee39ee8887" continuedAt="i1d5ee17835bd463dbe032371d29722cc" escape="true">As of December&#160;31, 2022, long-term debt matures as follows:</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="i1d5ee17835bd463dbe032371d29722cc"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:297.00pt"><tr><td style="width:1.0pt"></td><td style="width:235.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTo1ODMwOTdhMDdmMWU0OGJhYjU4MjdhMzZjN2JiZTI0OS90YWJsZXJhbmdlOjU4MzA5N2EwN2YxZTQ4YmFiNTgyN2EzNmM3YmJlMjQ5XzEtMS0xLTEtNzgyMTU_9dafe759-a16e-4879-aebb-e56a9db6042c">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTo1ODMwOTdhMDdmMWU0OGJhYjU4MjdhMzZjN2JiZTI0OS90YWJsZXJhbmdlOjU4MzA5N2EwN2YxZTQ4YmFiNTgyN2EzNmM3YmJlMjQ5XzItMS0xLTEtNzgyMTU_9c049728-3174-4930-b256-64dbd42a5997">302</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTo1ODMwOTdhMDdmMWU0OGJhYjU4MjdhMzZjN2JiZTI0OS90YWJsZXJhbmdlOjU4MzA5N2EwN2YxZTQ4YmFiNTgyN2EzNmM3YmJlMjQ5XzMtMS0xLTEtNzgyMTU_1a5af5a5-d6a2-4c8a-b328-d1b1aa1932c3">601</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTo1ODMwOTdhMDdmMWU0OGJhYjU4MjdhMzZjN2JiZTI0OS90YWJsZXJhbmdlOjU4MzA5N2EwN2YxZTQ4YmFiNTgyN2EzNmM3YmJlMjQ5XzQtMS0xLTEtNzgyMTU_49fd90eb-3596-4870-81fb-e06dd51bedbe">502</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTo1ODMwOTdhMDdmMWU0OGJhYjU4MjdhMzZjN2JiZTI0OS90YWJsZXJhbmdlOjU4MzA5N2EwN2YxZTQ4YmFiNTgyN2EzNmM3YmJlMjQ5XzUtMS0xLTEtNzgyMTU_07f19f53-87ad-4746-827a-be07f59cefc8">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTo1ODMwOTdhMDdmMWU0OGJhYjU4MjdhMzZjN2JiZTI0OS90YWJsZXJhbmdlOjU4MzA5N2EwN2YxZTQ4YmFiNTgyN2EzNmM3YmJlMjQ5XzYtMS0xLTEtNzgyMTU_ecf59738-5488-4801-9ac7-726b197cb1f4">2,576</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturities of long-term debt</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="dgx:LongTermDebtMaturitiesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTo1ODMwOTdhMDdmMWU0OGJhYjU4MjdhMzZjN2JiZTI0OS90YWJsZXJhbmdlOjU4MzA5N2EwN2YxZTQ4YmFiNTgyN2EzNmM3YmJlMjQ5XzctMS0xLTEtNzgyMTU_26313902-214a-4b55-b17c-ce473803054f">3,985</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized discount</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTo1ODMwOTdhMDdmMWU0OGJhYjU4MjdhMzZjN2JiZTI0OS90YWJsZXJhbmdlOjU4MzA5N2EwN2YxZTQ4YmFiNTgyN2EzNmM3YmJlMjQ5XzgtMS0xLTEtNzgyMTU_5fe7bcc3-2aad-4ad4-aed9-cc8895ff42be">9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:UnamortizedDebtIssuanceExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTo1ODMwOTdhMDdmMWU0OGJhYjU4MjdhMzZjN2JiZTI0OS90YWJsZXJhbmdlOjU4MzA5N2EwN2YxZTQ4YmFiNTgyN2EzNmM3YmJlMjQ5XzktMS0xLTEtNzgyMTU_1f2fdae1-ab0d-4a85-951b-107f886a2b0f">22</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value basis adjustments attributable to hedged debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" sign="-" name="dgx:DebtInstrumentFairValueBasisAdjustmentAttributableToHedgedDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTo1ODMwOTdhMDdmMWU0OGJhYjU4MjdhMzZjN2JiZTI0OS90YWJsZXJhbmdlOjU4MzA5N2EwN2YxZTQ4YmFiNTgyN2EzNmM3YmJlMjQ5XzEwLTEtMS0xLTc4MjE1_2a2b9300-bb95-45ea-af2f-1611602ace14">26</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTo1ODMwOTdhMDdmMWU0OGJhYjU4MjdhMzZjN2JiZTI0OS90YWJsZXJhbmdlOjU4MzA5N2EwN2YxZTQ4YmFiNTgyN2EzNmM3YmJlMjQ5XzExLTEtMS0xLTc4MjE1_ac5b3885-b809-4a27-ad17-6c3effc9cbc8">3,980</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTo1ODMwOTdhMDdmMWU0OGJhYjU4MjdhMzZjN2JiZTI0OS90YWJsZXJhbmdlOjU4MzA5N2EwN2YxZTQ4YmFiNTgyN2EzNmM3YmJlMjQ5XzEyLTEtMS0xLTc4MjE1_1abec6c6-95cd-44d3-8e59-305b23b7fbbd">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, net of current portion</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTo1ODMwOTdhMDdmMWU0OGJhYjU4MjdhMzZjN2JiZTI0OS90YWJsZXJhbmdlOjU4MzA5N2EwN2YxZTQ4YmFiNTgyN2EzNmM3YmJlMjQ5XzEzLTEtMS0xLTc4MjE1_01d63b68-99e5-4652-861a-68391933cee7">3,978</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-31</span></div></div></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_217"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211; CONTINUED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions unless otherwise indicated)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTE_801a284d-90fc-484c-abe6-6c5abc50b76c" continuedAt="i2a70332ad926416193d08a48d7cb86b7" escape="true"><ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTI_5a71e417-db60-4584-9cb9-bb92bf1cf18e" continuedAt="i8b45238b7bb24406be1179d3fd2babd7" escape="true">LEASES</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i2a70332ad926416193d08a48d7cb86b7" continuedAt="ib8b238bad6cc4f2695f4824024b97f6a"><ix:continuation id="i8b45238b7bb24406be1179d3fd2babd7" continuedAt="i28330a3f3f094ad5a8d59d3c3b470ac8"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTM_981c240f-e9c1-4e35-a1aa-563f844cad72" escape="true">The Company determines if an arrangement is or contains a lease at contract inception. The Company leases office space, patient service centers, clinical laboratories, warehouses, logistic hubs and equipment primarily through operating leases, with a limited number of finance leases. A <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NDc_562c010d-bbaa-4f52-a8ac-de2660c01cb7"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NDc_da6e8994-01f0-4a9a-83e2-083574a1b91f">right-of-use asset</span></span>, representing the underlying asset during the lease term, and a lease <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTQ_323fe1c8-01d7-47a9-afae-473da3defda0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTQ_4bd99473-36cb-4abf-841b-9d98e467569f">liability</span></span>, representing the payment obligation arising from the lease, are recognized on the balance sheet at lease commencement based on the present value of the payment obligation. For operating leases, expense is recognized on a straight-line basis over the lease term. For finance leases, interest expense on the lease <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTU_6f606824-b677-4250-a7ed-24f9f3915ac5"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTU_8ee62599-1731-4db2-b098-6e0dac4293f9">liability</span></span> is recognized using the effective interest method and amortization of the right-of-use asset is recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term.  Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet; the Company recognizes lease expense for these leases on a straight-line basis over the lease term.</ix:nonNumeric>  For the years ended December&#160;31, 2022, 2021, and 2020, lease expense associated with short-term leases was not material.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company primarily uses its collateralized incremental borrowing rate in determining the present value of lease payments as the Company's leases generally do not provide an implicit rate.  Such incremental borrowing rates, which take into account interest rates offered to companies that have similar credit ratings to the Company, are determined using a portfolio approach which groups the Company&#8217;s leases based on tenor.</span></div><div style="padding-left:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company has lease agreements with (i) right-of-use asset payments and (ii) non-lease components (i.e., payments related to maintenance fees, utilities, etc.) which have been combined and accounted for as a single lease component. </span></div><div style="padding-left:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company's leases have remaining terms of less than <ix:nonNumeric contextRef="i4a8532c66ad64ac990f07caabad868b2_D20220101-20221231" name="dgx:LeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzE5NjU_56fb4871-d1b2-4ad5-9ec9-8b0189e7b7af">1</ix:nonNumeric> year to <ix:nonNumeric contextRef="i4c9530356f3242cdb77f114a2aa32961_D20220101-20221231" name="dgx:LeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzE5NzE_d2e9d8a4-575f-443b-9423-64b74d1c3bfa">15</ix:nonNumeric> years, some of which include options to extend the leases for up to <ix:nonNumeric contextRef="i4c9530356f3242cdb77f114a2aa32961_D20220101-20221231" name="dgx:LeaseRenewalTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzIwMzY_bf46933e-b47a-4ff7-874e-2e8793edbdc4">15</ix:nonNumeric> years. The Company's lease terms may include renewal options that are reasonably certain to be exercised and termination options that are reasonably certain not to be exercised. Certain leases also include options to purchase the leased property.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Certain of the Company's lease agreements include rental payments adjusted periodically for inflation or a market rate which are included in the lease liabilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the year ended December 31, 2022, the Company amended a real estate lease and, based on the updated terms, the classification of the lease changed from a finance lease to an operating lease. As a result, the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="i0cc8a896b5014eec950deeb2b23e329e_I20221231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzEwOTk1MTE2MzIwNzQ_a06b29e3-b81c-41df-be2f-cea31c076984">31</ix:nonFraction>&#160;million operating lease right-of-use asset.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="dgx:ScheduleOfLeaseByAssetTypeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTY_5dddc570-d12f-4355-9252-611accadf959" continuedAt="i4e91442fd18a4bd9a430a8f4838e147d" escape="true">The Company's assets and liabilities for its lease agreements as of December&#160;31, 2022 and 2021 were as follows:</ix:nonNumeric></span></div><ix:continuation id="i4e91442fd18a4bd9a430a8f4838e147d"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:21.634%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.672%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.571%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.573%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzItNC0xLTEtNzgyMTU_2a23607f-5be3-47e1-9cae-bca10fc2296d">585</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzItNi0xLTEtNzgyMTU_cb359a95-9e69-4431-88d0-090d0e0bf8a8">597</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net (a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzMtNC0xLTEtNzgyMTU_3b3f9292-8664-4665-ae71-231bb0e95c24">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzMtNi0xLTEtNzgyMTU_151bc0c3-ab96-4409-bcfe-1c3f243e8e66">29</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="dgx:LeaseRightofUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzQtNC0xLTEtNzgyMTU_6125d843-583d-46b1-9daf-36ec97f9f21c">594</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="dgx:LeaseRightofUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzQtNi0xLTEtNzgyMTU_b8ad5106-0503-4946-b7d3-b76c1b5d6904">626</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzgtNC0xLTEtNzgyMTU_a3d89de6-36cf-40a1-9c93-6d6c0d00227a">153</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzgtNi0xLTEtNzgyMTU_8cf94bb0-81a8-4478-b077-1ecd3298d268">151</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzktNC0xLTEtNzgyMTU_2eaf8cd9-c1a9-44f1-a32f-fe8c5b1d4683">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzktNi0xLTEtNzgyMTU_cb26f99c-8260-4541-a6da-17a5e36b6163">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzExLTQtMS0xLTc4MjE1_6432681c-e191-457e-bce8-501f8ce635a0">489</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzExLTYtMS0xLTc4MjE1_00012651-b80e-4dd7-b499-134880ebf476">494</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzEyLTItMS0xLTc4MjE1_1c2a9643-64b7-48eb-992f-a3efa9e86f06"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzEyLTItMS0xLTc4MjE1_5bf1d7b4-f29c-4002-9627-e2075dfadeb9">Long-term debt</span></span></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzEyLTQtMS0xLTc4MjE1_0ce654df-abc1-4fce-a715-c8dd373d888f">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzEyLTYtMS0xLTc4MjE1_741b085d-837d-4b6e-a2cf-6c4d63c6ef85">32</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="dgx:LeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzEzLTQtMS0xLTc4MjE1_7436fbd4-3d90-42fd-8bad-156232a68f3c">651</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="dgx:LeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzEzLTYtMS0xLTc4MjE1_ba7a189c-d4ac-4931-baa2-4f7310b7ccb7">679</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Finance lease assets as of December&#160;31, 2022 and 2021 were recorded net of accumulated amortization of $<ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzI2MzU_a5163b0a-0dab-431a-9351-bfe3f90aabab">3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzI2NDI_8fc9629f-cce1-4659-b40e-7436ae9c7ac6">8</ix:nonFraction>&#160;million, respectively.</span></div></ix:continuation></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211; CONTINUED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions unless otherwise indicated)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><ix:continuation id="ib8b238bad6cc4f2695f4824024b97f6a"><ix:continuation id="i28330a3f3f094ad5a8d59d3c3b470ac8"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NDg_75cb7b5d-05b1-4f9b-aad7-0959b4974fa1" continuedAt="ifa478320cd484aa88761523e2454b73e" escape="true">Components of lease cost for the years ended December&#160;31, 2022, 2021 and 2020 were as follows:</ix:nonNumeric></span></div><ix:continuation id="ifa478320cd484aa88761523e2454b73e"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:468.75pt"><tr><td style="width:1.0pt"></td><td style="width:247.75pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Lease cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost (a)</span></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="dgx:OperatingLeaseFixedAndVariableCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTo0N2EyZDE5Y2NmNjU0NmIzYjQ3ZGY5NDdkNTIyZWVjNC90YWJsZXJhbmdlOjQ3YTJkMTljY2Y2NTQ2YjNiNDdkZjk0N2Q1MjJlZWM0XzItMi0xLTEtNzgyMTU_dc75282d-1c78-4ce9-b279-4cc9262a7348">345</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="dgx:OperatingLeaseFixedAndVariableCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTo0N2EyZDE5Y2NmNjU0NmIzYjQ3ZGY5NDdkNTIyZWVjNC90YWJsZXJhbmdlOjQ3YTJkMTljY2Y2NTQ2YjNiNDdkZjk0N2Q1MjJlZWM0XzItNC0xLTEtNzgyMTU_27195652-aaf4-4403-a4b6-5ab545b3dc5c">321</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="dgx:OperatingLeaseFixedAndVariableCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTo0N2EyZDE5Y2NmNjU0NmIzYjQ3ZGY5NDdkNTIyZWVjNC90YWJsZXJhbmdlOjQ3YTJkMTljY2Y2NTQ2YjNiNDdkZjk0N2Q1MjJlZWM0XzItNS0xLTEtNzgyMTU_00183c4b-97a3-43ac-9e8c-3a2983e628a0">300</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of leased assets</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTo0N2EyZDE5Y2NmNjU0NmIzYjQ3ZGY5NDdkNTIyZWVjNC90YWJsZXJhbmdlOjQ3YTJkMTljY2Y2NTQ2YjNiNDdkZjk0N2Q1MjJlZWM0XzUtMi0xLTEtNzgyMTU_dc37ce96-f678-48ef-8d4b-cd9af7563c0b">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTo0N2EyZDE5Y2NmNjU0NmIzYjQ3ZGY5NDdkNTIyZWVjNC90YWJsZXJhbmdlOjQ3YTJkMTljY2Y2NTQ2YjNiNDdkZjk0N2Q1MjJlZWM0XzUtNC0xLTEtNzgyMTU_70e36d47-62b2-4d97-a589-f35d742c3aaf">2</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTo0N2EyZDE5Y2NmNjU0NmIzYjQ3ZGY5NDdkNTIyZWVjNC90YWJsZXJhbmdlOjQ3YTJkMTljY2Y2NTQ2YjNiNDdkZjk0N2Q1MjJlZWM0XzUtNS0xLTEtNzgyMTU_2555273b-9094-4527-a39b-e7d1b1629cf3">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTo0N2EyZDE5Y2NmNjU0NmIzYjQ3ZGY5NDdkNTIyZWVjNC90YWJsZXJhbmdlOjQ3YTJkMTljY2Y2NTQ2YjNiNDdkZjk0N2Q1MjJlZWM0XzYtMi0xLTEtNzgyMTU_0cf20c10-1891-4706-89eb-17933d430e0e">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTo0N2EyZDE5Y2NmNjU0NmIzYjQ3ZGY5NDdkNTIyZWVjNC90YWJsZXJhbmdlOjQ3YTJkMTljY2Y2NTQ2YjNiNDdkZjk0N2Q1MjJlZWM0XzYtNC0xLTEtNzgyMTU_76018635-78d3-4946-a595-b0ecd39191c8">2</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTo0N2EyZDE5Y2NmNjU0NmIzYjQ3ZGY5NDdkNTIyZWVjNC90YWJsZXJhbmdlOjQ3YTJkMTljY2Y2NTQ2YjNiNDdkZjk0N2Q1MjJlZWM0XzYtNS0xLTEtNzgyMTU_e536e15d-f6fa-4a83-8662-9fc43925d7d7">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net lease cost</span></td><td colspan="3" style="display:none"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTo0N2EyZDE5Y2NmNjU0NmIzYjQ3ZGY5NDdkNTIyZWVjNC90YWJsZXJhbmdlOjQ3YTJkMTljY2Y2NTQ2YjNiNDdkZjk0N2Q1MjJlZWM0XzctMi0xLTEtNzgyMTU_3f6524cf-3505-4c1b-855d-a8aa6cf3dbb6">348</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTo0N2EyZDE5Y2NmNjU0NmIzYjQ3ZGY5NDdkNTIyZWVjNC90YWJsZXJhbmdlOjQ3YTJkMTljY2Y2NTQ2YjNiNDdkZjk0N2Q1MjJlZWM0XzctNC0xLTEtNzgyMTU_9ac4c9a1-f506-4188-b3a2-85ae3d3d3e29">325</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTo0N2EyZDE5Y2NmNjU0NmIzYjQ3ZGY5NDdkNTIyZWVjNC90YWJsZXJhbmdlOjQ3YTJkMTljY2Y2NTQ2YjNiNDdkZjk0N2Q1MjJlZWM0XzctNS0xLTEtNzgyMTU_df0ab8a5-0df1-4815-8831-091e2d2094ac">309</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Includes short-term leases and variable lease costs (primarily usage-based maintenance fees and utilities related to real estate leases and certain equipment-related and vehicle-related costs) of $<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="dgx:ShorttermLeaseandVariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzU0OTc1NTgxNzY3Ng_22637482-7f63-4efa-85d9-b247f773b271">160</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="dgx:ShorttermLeaseandVariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzI5NDY_710bdff9-79e8-4d24-9fea-779e0aeaa23f">140</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="dgx:ShorttermLeaseandVariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzI5NTM_61f53b6c-413f-499f-a19a-236bdde32783">120</ix:nonFraction>&#160;million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NDk_f93bcd7f-9bdc-42cf-83c9-91fe6943728a" continuedAt="i716618a735da4cb48a3ebc5a39ed8da2" escape="true"><ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTc_6a5e95a5-366a-4059-9fdc-1654eeeb258e" continuedAt="i369fb9dbdeae4022b8d34c2c5a4104e8" escape="true">The maturity of the Company's lease liabilities as of December&#160;31, 2022 is as follows:</ix:nonNumeric></ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="i716618a735da4cb48a3ebc5a39ed8da2"><ix:continuation id="i369fb9dbdeae4022b8d34c2c5a4104e8"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:365.25pt"><tr><td style="width:1.0pt"></td><td style="width:163.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.00pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:29pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzEtMi0xLTEtNzgyMTU_7ab4e6cf-27c5-4481-ad95-d3cc3ec6939c">167</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzEtNC0xLTEtNzgyMTU_a55ebb5a-8f6f-4199-9d82-7b673b8b9da5">2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="dgx:LesseeOperatingandFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzEtNi0xLTEtNzgyMTU_d92736e7-86f7-4088-9113-a90577cdf32e">169</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzItMi0xLTEtNzgyMTU_8eab6117-dc70-48bd-b8d0-1527eb3ff03a">137</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzItNC0xLTEtNzgyMTU_a14abf6e-3bf6-4797-b101-c51be9f5d04c">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="dgx:LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzItNi0xLTEtNzgyMTU_b8cdb49c-aef8-487e-bb54-40c2b114d1e5">139</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzMtMi0xLTEtNzgyMTU_833d614d-15e9-4fa9-9f8e-ce88380c3171">104</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzMtNC0xLTEtNzgyMTU_5e4df9fa-af1c-47b4-8b82-f619a51ef0c2">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="dgx:LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzMtNi0xLTEtNzgyMTU_cf2723b8-1607-46dd-9849-69fb6c70a459">106</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzQtMi0xLTEtNzgyMTU_c04a1a9e-f791-4393-b847-078a3b560d0c">75</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzQtNC0xLTEtNzgyMTU_51f24a9b-b666-46b6-97e3-c7bada620fac">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="dgx:LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzQtNi0xLTEtNzgyMTU_3cb847eb-fa38-43af-a9ec-02f025aa3c0f">77</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzUtMi0xLTEtNzgyMTU_4cb540db-0e37-4cad-a80f-cd8a8f6c78c9">59</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzUtNC0xLTEtNzgyMTU_c3776e46-697e-46fa-86d0-1fc6c5559bc8">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="dgx:LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzUtNi0xLTEtNzgyMTU_14802f77-7bdb-4f19-8049-67b95e07ee29">60</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzYtMi0xLTEtNzgyMTU_074ff12a-024f-4c93-9899-181791b8b2ab">173</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzYtNC0xLTEtNzgyMTU_9702105f-2252-4cb0-b174-75d23f6fb955">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="dgx:LesseeOperatingandFinanceLeaseLiabilityPaymentsDueafterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzYtNi0xLTEtNzgyMTU_22c0e827-03d1-4079-8c02-20e0157ee55b">174</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzctMi0xLTEtNzgyMTU_25030233-4c57-434b-a1bb-8c481cb1e9c5">715</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzctNC0xLTEtNzgyMTU_0ae08370-458b-4411-b3dd-63b5558f0cc5">10</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="dgx:LesseeOperatingandFinanceLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzctNi0xLTEtNzgyMTU_a6aff095-0fe6-4da9-9944-11446674ed79">725</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzgtMi0xLTEtNzgyMTU_8cf11e0a-57bc-4099-8f34-8363078cf0eb">73</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzgtNC0xLTEtNzgyMTU_57ea5660-ee42-4442-b989-2e10b4197bc9">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="dgx:LesseeOperatingandFinanceLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzgtNi0xLTEtNzgyMTU_92afcd43-a8f9-4723-a54c-3971286053eb">74</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzktMi0xLTEtNzgyMTU_fbbca144-1327-4d12-97db-acf8547f43dc">642</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzktNC0xLTEtNzgyMTU_6e0f9449-fca0-486c-9907-1619ec85b1af">9</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="dgx:OperatingandFinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzktNi0xLTEtNzgyMTU_3f17ab16-c07f-4ec9-bf9d-d1eb464b488d">651</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></ix:continuation></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="dgx:ScheduleofLeaseTermandDiscountRateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTA_f5c2ef36-f83e-4385-b6d3-7dc463f07d5f" continuedAt="iafd2927795ab4426901a1850d61127bc" escape="true">Lease term and discount rate as of December&#160;31, 2022 and 2021 were as follows:</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="iafd2927795ab4426901a1850d61127bc"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:363.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Lease term and discount rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years):</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTphMDMyNTc4MjMyMzE0YjMxYjc4MmJiZTRkYTkzYjUyMi90YWJsZXJhbmdlOmEwMzI1NzgyMzIzMTRiMzFiNzgyYmJlNGRhOTNiNTIyXzItMS0xLTEtNzgyMTU_9c6410d8-19e7-4e24-b5f5-0b1f22efc4ab">6</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTphMDMyNTc4MjMyMzE0YjMxYjc4MmJiZTRkYTkzYjUyMi90YWJsZXJhbmdlOmEwMzI1NzgyMzIzMTRiMzFiNzgyYmJlNGRhOTNiNTIyXzItMy0xLTEtNzgyMTU_1ec69b49-28a2-418a-ad8e-b4591c2fbfc1">6</ix:nonNumeric></span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTphMDMyNTc4MjMyMzE0YjMxYjc4MmJiZTRkYTkzYjUyMi90YWJsZXJhbmdlOmEwMzI1NzgyMzIzMTRiMzFiNzgyYmJlNGRhOTNiNTIyXzMtMS0xLTEtNzgyMTU_000c3337-b1a4-4004-ae42-fb90f09f5251">6</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTphMDMyNTc4MjMyMzE0YjMxYjc4MmJiZTRkYTkzYjUyMi90YWJsZXJhbmdlOmEwMzI1NzgyMzIzMTRiMzFiNzgyYmJlNGRhOTNiNTIyXzMtMy0xLTEtNzgyMTU_60a39f96-da96-4739-9a7b-07c6e3e95c32">11</ix:nonNumeric></span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTphMDMyNTc4MjMyMzE0YjMxYjc4MmJiZTRkYTkzYjUyMi90YWJsZXJhbmdlOmEwMzI1NzgyMzIzMTRiMzFiNzgyYmJlNGRhOTNiNTIyXzYtMS0xLTEtNzgyMTU_6d811526-840e-4067-a374-a127b9651584">3.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTphMDMyNTc4MjMyMzE0YjMxYjc4MmJiZTRkYTkzYjUyMi90YWJsZXJhbmdlOmEwMzI1NzgyMzIzMTRiMzFiNzgyYmJlNGRhOTNiNTIyXzYtMy0xLTEtNzgyMTU_bab52c2b-6c1b-426a-9cae-75972661997a">3.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTphMDMyNTc4MjMyMzE0YjMxYjc4MmJiZTRkYTkzYjUyMi90YWJsZXJhbmdlOmEwMzI1NzgyMzIzMTRiMzFiNzgyYmJlNGRhOTNiNTIyXzctMS0xLTEtNzgyMTU_88e675b6-1a59-4b58-8705-1f5e0cf9cb97">2.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTphMDMyNTc4MjMyMzE0YjMxYjc4MmJiZTRkYTkzYjUyMi90YWJsZXJhbmdlOmEwMzI1NzgyMzIzMTRiMzFiNzgyYmJlNGRhOTNiNTIyXzctMy0xLTEtNzgyMTU_219c562e-13d0-407b-8126-9354b297fa7a">6.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company's discount rates for its operating leases were primarily determined using the Company's incremental borrowing rate.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;See Note 10 for cash flow information on cash paid for amounts included in the measurement of lease liabilities and leased assets obtained in exchange for new operating lease liabilities for the years ended December&#160;31, 2022, 2021 and 2020.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-33</span></div></div></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_220"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211; CONTINUED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions unless otherwise indicated)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjAvZnJhZzo2ZjIxMGQ2OGJiMDU0YmNkYmE3N2ZhZTAzNjQxNjMxMS90ZXh0cmVnaW9uOjZmMjEwZDY4YmIwNTRiY2RiYTc3ZmFlMDM2NDE2MzExXzE0Mzg_aa059164-05ea-485e-8195-aa4bb15b00ea" continuedAt="i6baa8752fe464990a9f48064dbc64d17" escape="true">FINANCIAL INSTRUMENTS </ix:nonNumeric></span></div><ix:continuation id="i6baa8752fe464990a9f48064dbc64d17"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Interest Rate Derivatives &#8211; Cash Flow Hedges</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;From time to time, the Company has entered into various interest rate lock agreements and forward-starting interest rate swap agreements to hedge part of the Company's interest rate exposure associated with the variability in future cash flows attributable to changes in interest rates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Derivatives &#8211; Fair Value Hedges </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Historically, the Company has entered into various fixed-to-variable interest rate swap agreements in order to convert a portion of the Company's long-term debt into variable interest rate debt. All such fixed-to-variable interest rate swap agreements have been terminated and proceeds from the terminations have been reflected as basis adjustments to the hedged debt instruments and are being amortized as a reduction of interest expense, net over the remaining terms of such debt instruments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjAvZnJhZzo2ZjIxMGQ2OGJiMDU0YmNkYmE3N2ZhZTAzNjQxNjMxMS90ZXh0cmVnaW9uOjZmMjEwZDY4YmIwNTRiY2RiYTc3ZmFlMDM2NDE2MzExXzE0MzU_63447359-6611-49f7-97d4-973d3f820a18" continuedAt="i53f07ad29780482b8ed7b33da44aa766" escape="true">As of December&#160;31, 2022 and 2021, the following amounts were recorded on the consolidated balance sheets related to cumulative basis adjustments for fair value hedges included in the carrying amount of long-term debt:</ix:nonNumeric></span></div><ix:continuation id="i53f07ad29780482b8ed7b33da44aa766"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.098%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hedge Accounting Basis Adjustment (a)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i723c452601804300bcd7029176377b7a_I20221231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjAvZnJhZzo2ZjIxMGQ2OGJiMDU0YmNkYmE3N2ZhZTAzNjQxNjMxMS90YWJsZTo5Nzk2ZTFhZTEwNGY0MDRjOWRiODc5NTVjZjBlZGFkMi90YWJsZXJhbmdlOjk3OTZlMWFlMTA0ZjQwNGM5ZGI4Nzk1NWNmMGVkYWQyXzItNS0xLTEtNzgyMTU_8fe2d1dc-e2bb-4cf3-8c9b-e8bb2bacbc5a">26</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b93c42f53bc4c24b90b5c3989b66730_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjAvZnJhZzo2ZjIxMGQ2OGJiMDU0YmNkYmE3N2ZhZTAzNjQxNjMxMS90YWJsZTo5Nzk2ZTFhZTEwNGY0MDRjOWRiODc5NTVjZjBlZGFkMi90YWJsZXJhbmdlOjk3OTZlMWFlMTA0ZjQwNGM5ZGI4Nzk1NWNmMGVkYWQyXzItOS0xLTEtNzgyMTU_e3b88d27-92e8-414a-b19a-89e2a54b14ea">38</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) As of both December&#160;31, 2022 and 2021, the entire balance is associated with remaining unamortized hedging adjustments on discontinued relationships. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following table presents the effect of fair value hedge accounting on the consolidated statements of operations for the years ended December&#160;31, 2022, 2021 and 2020, respectively:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:14.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.246%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other (expense) income, net</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total for line item in which the effects of fair value hedges are recorded</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjAvZnJhZzo2ZjIxMGQ2OGJiMDU0YmNkYmE3N2ZhZTAzNjQxNjMxMS90YWJsZTo0MTQwMzFmNDljMDk0OWE5YmE0YTc1ZmY0MTI5OTI1YS90YWJsZXJhbmdlOjQxNDAzMWY0OWMwOTQ5YTliYTRhNzVmZjQxMjk5MjVhXzMtMy0xLTEtNzgyMTU_569f10c8-c009-43fd-9ebe-01728aa2d7b5">55</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjAvZnJhZzo2ZjIxMGQ2OGJiMDU0YmNkYmE3N2ZhZTAzNjQxNjMxMS90YWJsZTo0MTQwMzFmNDljMDk0OWE5YmE0YTc1ZmY0MTI5OTI1YS90YWJsZXJhbmdlOjQxNDAzMWY0OWMwOTQ5YTliYTRhNzVmZjQxMjk5MjVhXzMtNS0xLTEtNzgyMTU_3f3ce883-02db-4662-9ec7-a2e93333f45a">369</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjAvZnJhZzo2ZjIxMGQ2OGJiMDU0YmNkYmE3N2ZhZTAzNjQxNjMxMS90YWJsZTo0MTQwMzFmNDljMDk0OWE5YmE0YTc1ZmY0MTI5OTI1YS90YWJsZXJhbmdlOjQxNDAzMWY0OWMwOTQ5YTliYTRhNzVmZjQxMjk5MjVhXzMtNy0xLTEtNzgyMTU_3fc93c78-4ffa-4752-9ca0-59dbf666ca08">76</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gain (loss) on fair value hedging relationships:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items (Long-term debt)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjAvZnJhZzo2ZjIxMGQ2OGJiMDU0YmNkYmE3N2ZhZTAzNjQxNjMxMS90YWJsZTo0MTQwMzFmNDljMDk0OWE5YmE0YTc1ZmY0MTI5OTI1YS90YWJsZXJhbmdlOjQxNDAzMWY0OWMwOTQ5YTliYTRhNzVmZjQxMjk5MjVhXzYtMy0xLTEtNzgyMTU_8c357099-cf07-44ba-ab60-1b94429a05cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjAvZnJhZzo2ZjIxMGQ2OGJiMDU0YmNkYmE3N2ZhZTAzNjQxNjMxMS90YWJsZTo0MTQwMzFmNDljMDk0OWE5YmE0YTc1ZmY0MTI5OTI1YS90YWJsZXJhbmdlOjQxNDAzMWY0OWMwOTQ5YTliYTRhNzVmZjQxMjk5MjVhXzYtNS0xLTEtNzgyMTU_668d8416-6a39-45ee-8336-17222310af92">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjAvZnJhZzo2ZjIxMGQ2OGJiMDU0YmNkYmE3N2ZhZTAzNjQxNjMxMS90YWJsZTo0MTQwMzFmNDljMDk0OWE5YmE0YTc1ZmY0MTI5OTI1YS90YWJsZXJhbmdlOjQxNDAzMWY0OWMwOTQ5YTliYTRhNzVmZjQxMjk5MjVhXzYtNy0xLTEtNzgyMTU_1e07962f-6cdc-488e-bd1d-33f28543c1d2">68</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04612297cd0342579339c26a21934632_D20220101-20221231" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjAvZnJhZzo2ZjIxMGQ2OGJiMDU0YmNkYmE3N2ZhZTAzNjQxNjMxMS90YWJsZTo0MTQwMzFmNDljMDk0OWE5YmE0YTc1ZmY0MTI5OTI1YS90YWJsZXJhbmdlOjQxNDAzMWY0OWMwOTQ5YTliYTRhNzVmZjQxMjk5MjVhXzctMy0xLTEtNzgyMTU_b4a159b1-5d18-45f6-ac0e-d4c7fd447a9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60fd27e051b74dd08de8773691041dd4_D20210101-20211231" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjAvZnJhZzo2ZjIxMGQ2OGJiMDU0YmNkYmE3N2ZhZTAzNjQxNjMxMS90YWJsZTo0MTQwMzFmNDljMDk0OWE5YmE0YTc1ZmY0MTI5OTI1YS90YWJsZXJhbmdlOjQxNDAzMWY0OWMwOTQ5YTliYTRhNzVmZjQxMjk5MjVhXzctNS0xLTEtNzgyMTU_afa88cac-263d-4633-bac4-79066a19c8d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fe1409e54674ca0be0e82d1932f97ca_D20200101-20201231" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjAvZnJhZzo2ZjIxMGQ2OGJiMDU0YmNkYmE3N2ZhZTAzNjQxNjMxMS90YWJsZTo0MTQwMzFmNDljMDk0OWE5YmE0YTc1ZmY0MTI5OTI1YS90YWJsZXJhbmdlOjQxNDAzMWY0OWMwOTQ5YTliYTRhNzVmZjQxMjk5MjVhXzctNy0xLTEtNzgyMTU_b324da05-9404-4fc5-a0aa-dc55e7c936ab">68</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_223"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzYxNDM_1a6f85f1-ce45-4f8d-bdd5-0cb86af18226" continuedAt="i603735af6dcd4b62bc94480191013b79" escape="true">STOCKHOLDERS&#8217; EQUITY AND REDEEMABLE NONCONTROLLING INTEREST</ix:nonNumeric></span></div><ix:continuation id="i603735af6dcd4b62bc94480191013b79" continuedAt="i9cd4453ad89343d39b992711a3dc7f4b"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Stockholders' Equity</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Series Preferred Stock </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Quest Diagnostics is authorized to issue up to <ix:nonFraction unitRef="shares" contextRef="i6f4546cb1b9c4a1693b7d8224d2b29b1_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzE2OQ_aa819c62-d713-4587-a062-bc77b7348ba7">10</ix:nonFraction> million shares of Series Preferred Stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzIxNg_ac6d35e5-1638-464b-aa57-315b2bc7ffce">1.00</ix:nonFraction> per share.  The Company's Board of Directors has the authority to issue such shares without stockholder approval and to determine the designations, preferences, rights and restrictions of such shares.  <ix:nonFraction unitRef="shares" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzQyMQ_1d1c40de-18d1-4a5b-a5f2-c5cebedc7c34">No</ix:nonFraction> shares are currently outstanding.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Common Stock</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Under the Company's Restated Certificate of Incorporation the number of authorized shares of common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzU5NQ_e07786ab-744a-4d8e-8ece-28d80fb52d9c">0.01</ix:nonFraction> per share, is <ix:nonFraction unitRef="shares" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzYxMg_a4ce3829-edb1-49bf-8d5b-1677b2316a26">600</ix:nonFraction> million shares.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211; CONTINUED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions unless otherwise indicated)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><ix:continuation id="i9cd4453ad89343d39b992711a3dc7f4b" continuedAt="i4b1906b9988f41dd9f6dc48fc81ae14b"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Changes in Accumulated Other Comprehensive Loss by Component</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Comprehensive income (loss) includes:</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Foreign currency translation adjustments; </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net deferred gains (losses) on cash flow hedges, which represent deferred gains (losses), net of tax, on interest rate-related derivative financial instruments designated as cash flow hedges, net of amounts reclassified to interest expense (see Note 16); and</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net changes in available-for-sale debt securities, which represent unrealized holding gains (losses), net of tax, on available-for-sale debt securities.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the years ended December&#160;31, 2022, 2021, and 2020, the tax effects related to the deferred gains (losses) on cash flow hedges and net changes in available-for-sale debt securities were not material.  Foreign currency translation adjustments related to indefinite investments in non-U.S. subsidiaries are not adjusted for income taxes. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzYxNDg_ec1f0d20-a41d-46b8-99a5-53d5833b04ed" continuedAt="i6521928f1e60475496a0f80eb4c1aa1d" escape="true">The changes in accumulated other comprehensive loss by component for 2022, 2021 and 2020 were as follows:</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="i6521928f1e60475496a0f80eb4c1aa1d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.379%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Changes in Available-for-Sale Debt Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Deferred Losses on Cash Flow Hedges, net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb6d00d91a6d489898ca322307bd7551_I20191231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzItMS0xLTEtNzgyMTU_bc29047e-16a9-42dd-93d5-e378f0e2373c">42</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7a65c0363624e68becc030a94a0ab77_I20191231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzItMy0xLTEtNzgyMTU_fa1c5779-3cf1-4613-9157-e2a3dc7067f7">8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c59c3612c6041ba80e0a3204b427ce3_I20191231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzItNS0xLTEtNzgyMTU_6d484891-9ad8-4711-a873-9d7bcc903c1b">4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i78646261649e4ab5b1d6101a7499cb08_I20191231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzItNy0xLTEtNzgyMTU_4b6bdead-025c-4620-a169-665fdcf01359">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i472db09b826445d8914756bb3c893218_I20191231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzItOS0xLTEtNzgyMTU_6eb70165-eaa0-4ed3-977a-0447abd9e714">39</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income before reclassifications</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78b2c70c8a144740bff9b6549c2df838_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzMtMS0xLTEtNzgyMTU_7051703d-17e6-4a61-9724-d947a3452a9f">12</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i339059f763014b84a165529202925717_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzMtMy0xLTEtNzgyMTU_4139b6c5-ec4f-43bd-a855-7fe8a1b89dc8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35e31e8eeed44389aab551248c319740_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzMtNS0xLTEtNzgyMTU_a942bb48-2b21-40e3-9706-6871fce54328">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8a22be73b2240fe97a3e930cdf33583_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzMtNy0xLTEtNzgyMTU_7d6986c0-3c9e-4ac4-b2ec-5fd5c11d139d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c187eb3582c4c4a85507116a2a9051a_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzMtOS0xLTEtNzgyMTU_5dd22a8c-e289-4237-ac61-bbd0ff9fcc6d">13</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78b2c70c8a144740bff9b6549c2df838_D20200101-20201231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzQtMS0xLTEtNzgyMTU_d8e66ed0-9730-41b7-b67b-4ea22a22032d">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i339059f763014b84a165529202925717_D20200101-20201231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzQtMy0xLTEtNzgyMTU_87595815-6345-48eb-8d5d-ec5c2c5ee0e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35e31e8eeed44389aab551248c319740_D20200101-20201231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzQtNS0xLTEtNzgyMTU_f4f8f7eb-80be-4577-aff0-5d456fd8842d">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8a22be73b2240fe97a3e930cdf33583_D20200101-20201231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzQtNy0xLTEtNzgyMTU_5d0985d4-9499-41fc-af2e-cad1229946ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c187eb3582c4c4a85507116a2a9051a_D20200101-20201231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzQtOS0xLTEtNzgyMTU_e52c857c-c2b4-43a6-ab41-8371ef28003a">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78b2c70c8a144740bff9b6549c2df838_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzUtMS0xLTEtNzgyMTU_1de0c262-9c37-486e-bed7-c1db86ae6bf8">15</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i339059f763014b84a165529202925717_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzUtMy0xLTEtNzgyMTU_12a8a914-98a4-4af4-b4af-26eae6363978">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35e31e8eeed44389aab551248c319740_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzUtNS0xLTEtNzgyMTU_ec8688e5-e0d6-4ba1-8f9a-8f71e44c1a21">3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8a22be73b2240fe97a3e930cdf33583_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzUtNy0xLTEtNzgyMTU_51d5e4d0-38d3-4dcd-ae4f-9114474b73f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c187eb3582c4c4a85507116a2a9051a_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzUtOS0xLTEtNzgyMTU_e78a41de-7039-4746-9284-4f93aaff1822">18</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1a47bc1d3184e49a881195d814db2bc_I20201231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzctMS0xLTEtNzgyMTU_6e40b304-140f-4056-b749-225947183a52">27</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e971db364844d9d9d8d92ab27c1ed37_I20201231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzctMy0xLTEtNzgyMTU_1d1053ed-58e2-479f-b528-759e289a3244">8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90b395d6ce534de0bc8b53e2fca569ff_I20201231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzctNS0xLTEtNzgyMTU_cba31c4f-ebb6-4829-a967-bbcf79dd7b1f">1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iafd3f192541f4ebabada939564433870_I20201231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzctNy0xLTEtNzgyMTU_9328138c-f1ae-4b67-9625-61bbc6562653">1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic144ab8f0cf34804be4018d616f6d4ac_I20201231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzctOS0xLTEtNzgyMTU_8b56525e-0630-4793-b610-82ff6fcfa8a8">21</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss before reclassifications</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06cf1391d00e4b208aa2ec8b206f2b32_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzgtMS0xLTEtNzgyMTU_42b83f99-d324-4da6-a9fd-367cd2a6c492">7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1a523db0fd148b6b27ba256f8d6079a_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzgtMy0xLTEtNzgyMTU_5fb7b9eb-3aff-4c2d-8864-67a43a604765">7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i580c408beba54cb7a6726b2b9bdd3f50_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzgtNS0xLTEtNzgyMTU_806ac5a3-7576-49c0-b8cb-6f6659e76c65">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1a794ae52b4383b4bd9c5a8df17404_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzgtNy0xLTEtNzgyMTU_40806b4c-861c-4868-9906-42988cb1c82e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i095b5e9afd734c41af3e81c20d90f712_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzgtOS0xLTEtNzgyMTU_cafcacce-6846-4316-bd78-925728d22f85">14</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06cf1391d00e4b208aa2ec8b206f2b32_D20210101-20211231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzktMS0xLTEtNzgyMTU_5ffda830-9835-43df-8e21-0d8c35957903">20</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1a523db0fd148b6b27ba256f8d6079a_D20210101-20211231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzktMy0xLTEtNzgyMTU_8d1988f7-6244-46c2-a612-4e74f0cd313d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i580c408beba54cb7a6726b2b9bdd3f50_D20210101-20211231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzktNS0xLTEtNzgyMTU_be383cc2-3de0-4849-b15b-2fdd9a4d4d65">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1a794ae52b4383b4bd9c5a8df17404_D20210101-20211231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzktNy0xLTEtNzgyMTU_d0ffee28-e3b0-4e84-9ac9-99da0e061aeb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095b5e9afd734c41af3e81c20d90f712_D20210101-20211231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzktOS0xLTEtNzgyMTU_c70c59d9-e8b1-4dc1-8220-c6222abde70b">21</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06cf1391d00e4b208aa2ec8b206f2b32_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzEwLTEtMS0xLTc4MjE1_99a6c2b5-1b34-4858-8392-0926eca9ac8c">13</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1a523db0fd148b6b27ba256f8d6079a_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzEwLTMtMS0xLTc4MjE1_76a8cbed-8f20-4e52-9019-82b0ab0ba42c">7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i580c408beba54cb7a6726b2b9bdd3f50_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzEwLTUtMS0xLTc4MjE1_f585359d-4264-4942-a045-446871948885">1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1a794ae52b4383b4bd9c5a8df17404_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzEwLTctMS0xLTc4MjE1_fe764f61-599d-4d13-a195-387323e48c60">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095b5e9afd734c41af3e81c20d90f712_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzEwLTktMS0xLTc4MjE1_00486fb7-1ef1-4ce2-aa31-649ad1931498">7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ebd65fb3e6947f2a405a8aeaf512a19_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzEyLTEtMS0xLTc4MjE1_903ada0d-216c-46b2-a6f3-155817559ed6">14</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7541d2de1e4457b8836169fd42ffe28_I20211231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzEyLTMtMS0xLTc4MjE1_b604470f-23c6-4a8b-887c-4f96e7e31357">1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0788f175bb734eec93e8a4d7abcbb8e0_I20211231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzEyLTUtMS0xLTc4MjE1_71cd948d-1aec-435e-93e0-6721776b4953">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38b5a632e224465fb4d85fbc4eff5dd8_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzEyLTctMS0xLTc4MjE1_f921ae90-dce8-4901-850a-c029b6eb68e2">1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3c04cff9ac445b78c60050390c6354a_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzEyLTktMS0xLTc4MjE1_6c7195d2-1563-410f-8da4-edf601aea1e8">14</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss before reclassifications</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66bf6627917044748f98d7c18e1307e2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzEzLTEtMS0xLTc4MjE1_bbfd2528-1d56-4c98-82d4-ce19a88e37a1">8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i109b68d4a89d48ec97b242717a341fdf_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzEzLTMtMS0xLTc4MjE1_bae0b8ee-865f-4851-bf57-93da16482a35">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i933dedd678a149a484d0a02f4c2d33e0_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzEzLTUtMS0xLTc4MjE1_dd0f7182-f823-485d-8332-b13c8eaaf596">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a52a88c88684f908d9a67c0b1361c4e_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzEzLTctMS0xLTc4MjE1_1315f8bb-1372-4ba8-b5be-8e62e64db02d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7dd85f38ce14e469eb57e11ba9cfd32_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzEzLTktMS0xLTc4MjE1_d8fde155-080c-45f9-8ea1-fa2c5b3b0ebd">8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66bf6627917044748f98d7c18e1307e2_D20220101-20221231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzE0LTEtMS0xLTc4MjE1_f7a54fea-3cc6-4441-b32b-7a0724aeee0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i109b68d4a89d48ec97b242717a341fdf_D20220101-20221231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzE0LTMtMS0xLTc4MjE1_263aa890-fec2-40fb-90d5-deaf88c62ec5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i933dedd678a149a484d0a02f4c2d33e0_D20220101-20221231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzE0LTUtMS0xLTc4MjE1_d3316e12-1ca2-4ca7-bed4-da328504bff3">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a52a88c88684f908d9a67c0b1361c4e_D20220101-20221231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzE0LTctMS0xLTc4MjE1_995d5e38-ad4a-40c6-8fa3-71640b72e40a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7dd85f38ce14e469eb57e11ba9cfd32_D20220101-20221231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzE0LTktMS0xLTc4MjE1_86a3def1-5026-423c-8f74-81fb780fe497">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive (loss) income</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66bf6627917044748f98d7c18e1307e2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzE1LTEtMS0xLTc4MjE1_70eb8c71-d661-464f-8ff6-5c18073640ea">8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i109b68d4a89d48ec97b242717a341fdf_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzE1LTMtMS0xLTc4MjE1_b782e0f4-4f94-4b00-a6e3-4293ad442c9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i933dedd678a149a484d0a02f4c2d33e0_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzE1LTUtMS0xLTc4MjE1_a74cdead-ba11-4f70-82f7-5d4e588b7c80">1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a52a88c88684f908d9a67c0b1361c4e_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzE1LTctMS0xLTc4MjE1_dd38becd-b123-455c-928c-c20f3b9198d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7dd85f38ce14e469eb57e11ba9cfd32_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzE1LTktMS0xLTc4MjE1_dd24e198-314b-4416-ad73-e1934c7fbc48">7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71a45e6a745e4ddf8252c87f04dd758e_I20221231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzE3LTEtMS0xLTc4MjE1_aac851cc-853a-4ce8-9d65-86638cb5c44d">22</ix:nonFraction>)</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1423840c822742dc9fdf987c08a9badf_I20221231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzE3LTMtMS0xLTc4MjE1_fc453c77-bbe4-4c4d-879e-52b1a7e9fe9d">1</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4cc611bd437409a9457b4e8ca870211_I20221231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzE3LTUtMS0xLTc4MjE1_2c4980ae-93ce-477b-ae75-42245dcd1e50">1</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i920e105da0ab40dcba086a031fe03430_I20221231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzE3LTctMS0xLTc4MjE1_af5d3fa4-fc9b-446a-bbf7-5dd87e2441b2">1</ix:nonFraction>)</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4848abb5a7147028c83ac30e5fcf981_I20221231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzE3LTktMS0xLTc4MjE1_819e6683-53aa-40d0-877a-a2a7eec8f3e6">21</ix:nonFraction>)</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On April 1, 2021, the Company sold its <ix:nonFraction unitRef="number" contextRef="i0c20173d8dc64ebdb79161256ab69f0d_I20210401" decimals="2" name="dgx:EquityMethodInvestmentOwnershipPercentDisposedOf" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzE2NTU_439a551c-3366-410e-a137-1e036afe5a23">40</ix:nonFraction>% ownership interest in Q</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Solutions, its clinical trials central laboratory services joint venture, to IQVIA, its joint venture partner.  As a result of the transaction, during the year ended December 31, 2021, $<ix:nonFraction unitRef="usd" contextRef="idcd7cd9e61214881b085d41e21b23992_D20210101-20211231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzE4NTM_45fa4115-b802-4672-ae0d-f9c1767dd0d3">20</ix:nonFraction>&#160;million of cumulative translation losses were reclassified from accumulated other comprehensive loss to other (expense) income, net.  See Note 7 for further details. &#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Additionally, for the year ended December 31, 2020, $<ix:nonFraction unitRef="usd" contextRef="i78b2c70c8a144740bff9b6549c2df838_D20200101-20201231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzIwNDY_9124231a-ec26-4b64-856e-95d8f553062b">3</ix:nonFraction>&#160;million of cumulative translation losses were reclassified from accumulated other comprehensive loss to other operating expense (income), net as a result of the sale of foreign subsidiaries.</span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211; CONTINUED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions unless otherwise indicated)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><ix:continuation id="i4b1906b9988f41dd9f6dc48fc81ae14b" continuedAt="ided9fa9c824d432692623ee8d5c948c2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the years ended December&#160;31, 2022, 2021 and 2020, the gross deferred losses on cash flow hedges were reclassified from accumulated other comprehensive loss to interest expense, net.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividend Program</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During each of the four quarters of 2022, the Company's Board of Directors declared a quarterly cash dividend of $<ix:nonFraction unitRef="usdPerShare" contextRef="i6e808f2e2e6543d1a2b3a31c4bb749dc_D20220101-20220331" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzI0OTk_58fdc8ad-9774-4004-905e-e000134bf434"><ix:nonFraction unitRef="usdPerShare" contextRef="ia40f541edc5a4e009d95c57cd1bcb927_D20220401-20220630" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzI0OTk_74c28383-56c1-4783-9915-7f9785cb550c"><ix:nonFraction unitRef="usdPerShare" contextRef="ie092f7c613574f36ac6303f206cea249_D20220701-20220930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzI0OTk_954d8690-a876-4571-a47a-0f9209285188"><ix:nonFraction unitRef="usdPerShare" contextRef="i7f7bde7107be4688966df19bafdeea10_D20221001-20221231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzI0OTk_f739f6da-34f5-4674-9487-b6ef81ef841f">0.66</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> per common share.  During each of the four quarters of 2021, the Company's Board of Directors declared a quarterly cash dividend of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib70de56c8cc94b818521ce47775ed911_D20210101-20210331" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzI2MzI_133c58ed-e1cb-43b9-af2e-4bcc523f3323"><ix:nonFraction unitRef="usdPerShare" contextRef="i5bb911fffd174a0aa2ac5f0facc0999e_D20210401-20210630" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzI2MzI_51fbd632-34cb-4ce7-9d86-856c60277d17"><ix:nonFraction unitRef="usdPerShare" contextRef="ic46672a2c9fc4d0e990f241632df20c6_D20211001-20211231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzI2MzI_5ec430ab-cebc-4040-9b29-7918e5220705"><ix:nonFraction unitRef="usdPerShare" contextRef="ib82daccc7a0640b288f5167661d2539c_D20210701-20210930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzI2MzI_a4604203-64cf-48af-ad58-fb182884c345">0.62</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> per common share.  During each of the four quarters of 2020, the Company's Board of Directors declared a quarterly cash dividend of $<ix:nonFraction unitRef="usdPerShare" contextRef="ida73f1775008469a8c0cf852ee5a1c29_D20200101-20200331" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzI3NjU_52439cb6-0522-4aae-a594-6b56802f6f03"><ix:nonFraction unitRef="usdPerShare" contextRef="id98e1b95cd5d4adf98b2c4cb2f733c61_D20200701-20200930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzI3NjU_78224b75-5af8-4007-8550-b9b8a9f84a13"><ix:nonFraction unitRef="usdPerShare" contextRef="i145904e8a701484d92f0e52d1adeca1f_D20201001-20201231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzI3NjU_79518c3d-31bb-49b4-8680-95f5b40908ea"><ix:nonFraction unitRef="usdPerShare" contextRef="i8aae4e22f3264196b0bfa35291c77a16_D20200401-20200630" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzI3NjU_f5c6ed25-7376-42d9-b9a5-95e1a126b80c">0.56</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> per common share.  In February 2023, the Company announced that its Board of Directors authorized a <ix:nonFraction unitRef="number" contextRef="i62fbbac4e0dc4fa697878a348ac0758e_I20230202" decimals="INF" name="dgx:IncreaseDecreaseinCommonStockDividendsDeclaredasPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzI4NTc_2ecf22bc-e5fa-48c1-b0b1-00c1528b02e8">7.6</ix:nonFraction>% increase in its quarterly cash dividend from $<ix:nonFraction unitRef="usdPerShare" contextRef="i6e808f2e2e6543d1a2b3a31c4bb749dc_D20220101-20220331" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzU0OTc1NTgyMDA4NQ_58fdc8ad-9774-4004-905e-e000134bf434"><ix:nonFraction unitRef="usdPerShare" contextRef="ia40f541edc5a4e009d95c57cd1bcb927_D20220401-20220630" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzU0OTc1NTgyMDA4NQ_74c28383-56c1-4783-9915-7f9785cb550c"><ix:nonFraction unitRef="usdPerShare" contextRef="ie092f7c613574f36ac6303f206cea249_D20220701-20220930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzU0OTc1NTgyMDA4NQ_954d8690-a876-4571-a47a-0f9209285188"><ix:nonFraction unitRef="usdPerShare" contextRef="i7f7bde7107be4688966df19bafdeea10_D20221001-20221231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzU0OTc1NTgyMDA4NQ_f739f6da-34f5-4674-9487-b6ef81ef841f">0.66</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="i6f31e868418c42c5abbd3bb28b8a4277_D20230202-20230202" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzI5MTE_a18f0c56-d7fc-4c80-8ad4-00edfba53686">0.71</ix:nonFraction> per share, or $<ix:nonFraction unitRef="usdPerShare" contextRef="ia76a036d7fa340e7b4834c31bf563b49_D20230101-20231231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzI5Mjg_ca799468-ecff-4357-b1d9-71643c79d528">2.84</ix:nonFraction> per share annually, commencing with the dividend payable in April 2023.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Repurchase Program</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In February 2022, the Company's Board of Directors increased the size of its share repurchase program by $<ix:nonFraction unitRef="usd" contextRef="ie4d8aae1ad91426ab8c1e84816ea8730_D20220201-20220228" decimals="INF" name="dgx:StockRepurchaseProgramAdditionalAmountAuthorized" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzI3NDg3NzkwODA3Mzg_3359ff75-2eaa-42c5-bc98-6830c8fee9df">1</ix:nonFraction>&#160;billion.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of December&#160;31, 2022, $<ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-8" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzU0OTc1NTgyMDIwMw_293e45b4-5299-4374-a527-94d1b6f55e1c">0.3</ix:nonFraction> billion remained available under the Company's share repurchase authorization.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In February 2023, the Company announced that its Board of Directors authorized the Company to repurchase an additional $<ix:nonFraction unitRef="usd" contextRef="i6f31e868418c42c5abbd3bb28b8a4277_D20230202-20230202" decimals="INF" name="dgx:StockRepurchaseProgramAdditionalAmountAuthorized" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzEwOTk1MTE2NDA2NDA_67132518-25f7-4e9d-ad3c-8ea05c8a28e2">1</ix:nonFraction>&#160;billion of the Company's common stock.  The share repurchase authorization has no set expiration or termination date.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Repurchases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the year ended December&#160;31, 2022, the Company repurchased <ix:nonFraction unitRef="shares" contextRef="i7840e393be1c4cfaafc766cd6a649f57_D20220101-20221231" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzM1MzE_a7857b2c-b1a2-4d4a-abf1-4dcbf816282a">10.1</ix:nonFraction> million shares of its common stock for $<ix:nonFraction unitRef="usd" contextRef="i7840e393be1c4cfaafc766cd6a649f57_D20220101-20221231" decimals="-8" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzM1NjU_aa7dd19d-4228-4c29-8269-e623de6d002f">1.4</ix:nonFraction> billion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021, the Company repurchased <ix:nonFraction unitRef="shares" contextRef="ic4718e0f26e04ae097941f11f8d84f52_D20210101-20211231" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzQ1MjI_97231abb-d051-4dfb-89da-63c9489e7b2e">16.0</ix:nonFraction> million shares of its common stock for $<ix:nonFraction unitRef="usd" contextRef="ic4718e0f26e04ae097941f11f8d84f52_D20210101-20211231" decimals="-8" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzQ1NTY_47d60d46-eadf-4b8b-bfe4-0f7b595fbbed">2.2</ix:nonFraction> billion, including shares repurchased under ASRs. The repurchases during the year included an accrual of $<ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="dgx:TreasuryStockPurchasedbutNotyetPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzEwOTk1MTE2Mzk1OTI_7d0bade1-6b22-4c15-a443-43ded83aabdf">23</ix:nonFraction>&#160;million recorded in accounts payable and accrued expenses in the consolidated balance sheet for share repurchases not settled until after December 31, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In April 2021, the Company entered into ASRs with several financial institutions to repurchase its common stock as part of a share repurchase program.  Each of the ASRs was structured to permit the Company to purchase shares immediately with the final purchase price of those shares determined by the volume-weighted average price of the Company's common stock during the repurchase period, less a fixed discount, and was accounted for as two transactions: (1) a treasury stock repurchase and (2) a forward contract.  During the year ended December&#160;31, 2021, the Company paid $<ix:nonFraction unitRef="usd" contextRef="ic235750c5b474440bd8465c5df75988a_D20210101-20211231" decimals="-6" name="dgx:AcceleratedShareRepurchasesPayment" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzU0OTc1NTgyNDcyMA_d5053bc4-41a5-4553-abce-41770939fa89">1.5</ix:nonFraction>&#160;billion to the financial institutions and received <ix:nonFraction unitRef="shares" contextRef="i47113d1bbe9f4fea9bec3bbe1f7f5d91_D20210101-20211231" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzU0OTc1NTgyNDc0Nw_bb55c613-194f-4c05-986f-4d17ff256f97">10.7</ix:nonFraction>&#160;million shares of its common stock under the ASRs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the year ended December&#160;31, 2020, the Company repurchased <ix:nonFraction unitRef="shares" contextRef="i2998701e47ab4c2da75bc84322736ac6_D20200101-20201231" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzQ2MDk_a78ab44d-b9d0-4c60-a799-68a259fd0ebc">2.7</ix:nonFraction> million shares of its common stock for $<ix:nonFraction unitRef="usd" contextRef="i2998701e47ab4c2da75bc84322736ac6_D20200101-20201231" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzQ2NDM_a0ea7f53-9728-441e-9b37-862b9ddd05c4">325</ix:nonFraction> million.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;  &#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Shares Reissued from Treasury Stock</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the years ended December&#160;31, 2022, 2021 and 2020, the Company reissued <ix:nonFraction unitRef="shares" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzQ3NDc_e5f0e35e-7ce5-4991-b583-bb28ed99c874">2</ix:nonFraction> million shares, <ix:nonFraction unitRef="shares" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzQ3NTg_b62c8b3e-5ce2-463a-bd10-8a2aead261ee">2</ix:nonFraction> million shares and <ix:nonFraction unitRef="shares" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzQ3NzI_20991392-84dc-4e46-97c8-d2b0d2c19f8b">3</ix:nonFraction> million shares, respectively, from treasury stock for shares issued under the Employee Stock Purchase Plan ("ESPP") and stock-based compensation program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Treasury Stock Retirement &#160;&#160;&#160;&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the year ended December&#160;31, 2021, the Company retired <ix:nonFraction unitRef="shares" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzU0OTc1NTgyNTE2MQ_8af7c742-44f2-4229-8581-5e7f414cc13d">55</ix:nonFraction>&#160;million shares of treasury stock.  In accordance with the Company's policy, the amount paid to repurchase the shares in excess of par value was allocated between retained earnings and additional paid-in capital based on a pro-rata allocation of additional paid-in capital at the time of the share retirement.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211; CONTINUED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions unless otherwise indicated)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><ix:continuation id="ided9fa9c824d432692623ee8d5c948c2" continuedAt="i3e796bb5f2ec4138b7956dcb6a8fa6ba"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redeemable Noncontrolling Interest</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3e796bb5f2ec4138b7956dcb6a8fa6ba">&#160;&#160;&#160;&#160;In connection with the sale of an <ix:nonFraction unitRef="number" contextRef="ia809ec8fd18c4ad48fc0dd81f2cdd760_I20150701" decimals="3" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzUzNzY_664d8456-d7ad-4c1e-87e9-ca98229c8454">18.9</ix:nonFraction>% noncontrolling interest in a subsidiary to UMass on July 1, 2015, the Company granted UMass the right to require the Company to purchase all of its interest in the subsidiary at fair value commencing July 1, 2020.  The subsidiary performs diagnostic information services in a defined territory within the state of Massachusetts.  Since the redemption of the noncontrolling interest is outside of the Company's control, it has been presented outside of stockholders' equity at the greater of its carrying amount or its fair value.  The Company records changes in the fair value of the noncontrolling interest immediately as they occur.  As of December&#160;31, 2022 and 2021, the redeemable noncontrolling interest was $<ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzYwNzU_6d29d152-8827-4074-89c9-58d604ad918c">77</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzYwODI_3b950d97-2563-4fbb-bbf2-3b0408357a66">79</ix:nonFraction> million, respectively, and was presented at its fair value.</ix:continuation> </span></div><div><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_226"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzExMTgw_fd803b61-fbe3-4c67-8400-e9c7a97fd40e" continuedAt="i16bb980a93214574809e7a0791e76b99" escape="true">STOCK OWNERSHIP AND COMPENSATION PLANS</ix:nonNumeric></span></div><ix:continuation id="i16bb980a93214574809e7a0791e76b99" continuedAt="ifd3b9863d15848e98c36adb8716c732d"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee and Non-employee Directors Stock Ownership Programs</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The ELTIP provides for three types of awards: (a) stock options, (b) stock appreciation rights and (c) stock awards.  The ELTIP provides for the grant to eligible employees of either non-qualified or incentive stock options, or both, to purchase shares of Company common stock at an exercise price no less than the fair market value of the Company's common stock on the date of grant.  Grants of stock appreciation rights allow eligible employees to receive a payment based on the appreciation of Company common stock in cash, shares of Company common stock or a combination thereof.  The stock appreciation rights are granted at an exercise price no less than the fair market value of the Company's common stock on the date of grant.  Stock options and stock appreciation rights granted under the ELTIP expire on the date designated by the Board of Directors but in no event more than <ix:nonNumeric contextRef="i73f261b4c48d49e994b979548d66b542_D20220101-20221231" name="dgx:ContractualLifeOfStockOptionsAndOtherAwardsUnderSharedBasedCompensationPlans" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzEwMDE_15872580-fe82-4d76-ab1a-abfbe31c55eb">ten years</ix:nonNumeric> from date of grant.  No stock appreciation rights have been granted under the ELTIP.  Under the ELTIP, awards are subject to forfeiture if employment terminates prior to the end of the vesting period prescribed by the Board of Directors.  For all award types, the vesting period is generally over <ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzEzMDE_e119f39b-38eb-4135-a0bc-58767e028492">three years</ix:nonNumeric> from the date of grant.  For performance share units, the actual amount of shares earned is based on the achievement of the performance goals specified in the awards.  The performance goals for awards granted in 2020, 2021 and 2022 were based on the financial performance of the Company, as well as relative TSR.  The maximum number of shares of Company common stock in respect of which awards may be granted under the ELTIP is approximately <ix:nonFraction unitRef="shares" contextRef="idca3214cc24d4df2accb5f1aee19ee63_I20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzE4NDc_195bf044-4c2b-4409-8335-29e8b815e2d1">79</ix:nonFraction> million shares.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The DLTIP provides for the grant to non-employee directors of non-qualified stock options to purchase shares of Company common stock at an exercise price no less than the fair market value of the Company's common stock on the date of grant.  The DLTIP also permits awards of restricted stock and restricted stock units to non-employee directors.  Stock options granted under the DLTIP expire on the date designated by the Board of Directors but in no event more than <ix:nonNumeric contextRef="i8ad2a8b3713f4742b9996055520adc29_D20220101-20221231" name="dgx:ContractualLifeOfStockOptionsAndOtherAwardsUnderSharedBasedCompensationPlans" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzIzMjk_9839098f-5eb1-40b1-9e51-a7c14556f5ff">ten years</ix:nonNumeric> from date of grant.  For all award types, the vesting period is generally over <ix:nonNumeric contextRef="i8ad2a8b3713f4742b9996055520adc29_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzI0MTE_059492df-946a-4b3b-8df0-667621c7b038">three years</ix:nonNumeric> from the date of grant, regardless of whether the award recipient remains a director of the Company.  The maximum number of shares that may be issued under the DLTIP is <ix:nonFraction unitRef="shares" contextRef="ic372c83c8186472099c6d4d6461f9670_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzI1ODM_89be6491-b336-473e-9563-cd51b1b89847">2.4</ix:nonFraction> million shares.  For the years ended December&#160;31, 2022, 2021 and 2020, grants under the DLTIP totaled <ix:nonFraction unitRef="shares" contextRef="i8ad2a8b3713f4742b9996055520adc29_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzI2NjE_c2f5ca36-5e89-41b7-a1bf-1328ddb5e2ea">10</ix:nonFraction> thousand shares, <ix:nonFraction unitRef="shares" contextRef="i2e67e2f9ed6e486593285a490abea14a_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzI2NzI_74dc2b46-636a-4208-b9ce-6994a23aedad">12</ix:nonFraction> thousand shares and <ix:nonFraction unitRef="shares" contextRef="i9a2a79f2f8da4bf5859f277ed9314d52_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzI2ODY_1c4b96c0-443f-49c1-b960-3a162490c99f">14</ix:nonFraction> thousand shares, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company's practice had been to issue shares related to its stock-based compensation program from shares of its common stock held in treasury or by issuing new shares of its common stock.  In January 2021, the Company began to issue shares related to its ESPP and stock-based compensation program solely from common stock held in treasury.  See Note 17 for further information regarding the Company's share repurchase program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The fair value of each stock option award granted was estimated on the date of grant using a Black-Scholes option-valuation model.  The expected volatility under the Black-Scholes option-valuation model was based on historical volatilities of the Company's common stock.  The dividend yield was based on the approved annual dividend rate in effect and current market price of the underlying common stock at the time of grant.  The risk-free interest rate was based on the U.S. Treasury yield curve in effect at the time of grant for bonds with maturities consistent with the expected holding period of the related award.  The expected holding period was estimated using the historical stock option exercise behavior of employees. The Black-Scholes option-valuation model also incorporates the average market price of the Company's common stock at the date of grant.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211; CONTINUED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions unless otherwise indicated)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><div><span><br/></span></div><ix:continuation id="ifd3b9863d15848e98c36adb8716c732d" continuedAt="i4ea595072207487eb6362b4bc425058f"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzExMTgx_9c7232cd-c86e-4c79-9993-3729ec2f4a29" continuedAt="i56058b1ee06644d5b7b79f6c26a1ae49" escape="true">The weighted average assumptions used in valuing stock options granted in the periods presented were:  </ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="i56058b1ee06644d5b7b79f6c26a1ae49"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:61.216%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.219%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at grant date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3MDBkOTYxOTZjNjE0Zjk3YTMwMTNiODc2YzQ1OTc5NS90YWJsZXJhbmdlOjcwMGQ5NjE5NmM2MTRmOTdhMzAxM2I4NzZjNDU5Nzk1XzItMS0xLTEtNzgyMTU_c800782a-4fbf-46b7-9ccc-d8902b778a68">26.80</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3MDBkOTYxOTZjNjE0Zjk3YTMwMTNiODc2YzQ1OTc5NS90YWJsZXJhbmdlOjcwMGQ5NjE5NmM2MTRmOTdhMzAxM2I4NzZjNDU5Nzk1XzItMy0xLTEtNzgyMTU_46278225-ecbc-4b40-9a65-579abf69915f">21.82</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3MDBkOTYxOTZjNjE0Zjk3YTMwMTNiODc2YzQ1OTc5NS90YWJsZXJhbmdlOjcwMGQ5NjE5NmM2MTRmOTdhMzAxM2I4NzZjNDU5Nzk1XzItNS0xLTEtNzgyMTU_a485929b-3c97-4ce3-96e5-3dea2414ca8e">17.25</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3MDBkOTYxOTZjNjE0Zjk3YTMwMTNiODc2YzQ1OTc5NS90YWJsZXJhbmdlOjcwMGQ5NjE5NmM2MTRmOTdhMzAxM2I4NzZjNDU5Nzk1XzMtMS0xLTEtNzgyMTU_d8df9e97-fb0f-489f-96f8-d1b2d9981e1e">26.4</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3MDBkOTYxOTZjNjE0Zjk3YTMwMTNiODc2YzQ1OTc5NS90YWJsZXJhbmdlOjcwMGQ5NjE5NmM2MTRmOTdhMzAxM2I4NzZjNDU5Nzk1XzMtMy0xLTEtNzgyMTU_1627dc60-7665-46c6-85d3-703ae0c1a731">25.6</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3MDBkOTYxOTZjNjE0Zjk3YTMwMTNiODc2YzQ1OTc5NS90YWJsZXJhbmdlOjcwMGQ5NjE5NmM2MTRmOTdhMzAxM2I4NzZjNDU5Nzk1XzMtNS0xLTEtNzgyMTU_2687908c-f63a-406f-a624-204ae4fb9a64">20.3</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3MDBkOTYxOTZjNjE0Zjk3YTMwMTNiODc2YzQ1OTc5NS90YWJsZXJhbmdlOjcwMGQ5NjE5NmM2MTRmOTdhMzAxM2I4NzZjNDU5Nzk1XzQtMS0xLTEtNzgyMTU_54d2222d-9094-4f07-904a-53f8522ced6f">2.0</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3MDBkOTYxOTZjNjE0Zjk3YTMwMTNiODc2YzQ1OTc5NS90YWJsZXJhbmdlOjcwMGQ5NjE5NmM2MTRmOTdhMzAxM2I4NzZjNDU5Nzk1XzQtMy0xLTEtNzgyMTU_18263ed0-bc88-44e2-b2a0-5df395a4f03f">2.0</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3MDBkOTYxOTZjNjE0Zjk3YTMwMTNiODc2YzQ1OTc5NS90YWJsZXJhbmdlOjcwMGQ5NjE5NmM2MTRmOTdhMzAxM2I4NzZjNDU5Nzk1XzQtNS0xLTEtNzgyMTU_49ab281a-f20a-4f58-aa78-bfeb396c01e7">2.0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3MDBkOTYxOTZjNjE0Zjk3YTMwMTNiODc2YzQ1OTc5NS90YWJsZXJhbmdlOjcwMGQ5NjE5NmM2MTRmOTdhMzAxM2I4NzZjNDU5Nzk1XzUtMS0xLTEtNzgyMTU_3638fff3-6a3d-4c9d-ab11-f01290816d8c">2.0</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3MDBkOTYxOTZjNjE0Zjk3YTMwMTNiODc2YzQ1OTc5NS90YWJsZXJhbmdlOjcwMGQ5NjE5NmM2MTRmOTdhMzAxM2I4NzZjNDU5Nzk1XzUtMy0xLTEtNzgyMTU_2beb1b49-6a46-4b48-a9f2-d8ea3fbc163e">0.6</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3MDBkOTYxOTZjNjE0Zjk3YTMwMTNiODc2YzQ1OTc5NS90YWJsZXJhbmdlOjcwMGQ5NjE5NmM2MTRmOTdhMzAxM2I4NzZjNDU5Nzk1XzUtNS0xLTEtNzgyMTU_2eefc65a-ba05-4972-9b38-22b6f0ecfae2">1.5</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected holding period, in years</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3MDBkOTYxOTZjNjE0Zjk3YTMwMTNiODc2YzQ1OTc5NS90YWJsZXJhbmdlOjcwMGQ5NjE5NmM2MTRmOTdhMzAxM2I4NzZjNDU5Nzk1XzYtMS0xLTEtNzgyMTU_64628d22-74a3-4a1a-a0e8-e6329fb2d35b">4.9</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3MDBkOTYxOTZjNjE0Zjk3YTMwMTNiODc2YzQ1OTc5NS90YWJsZXJhbmdlOjcwMGQ5NjE5NmM2MTRmOTdhMzAxM2I4NzZjNDU5Nzk1XzYtMy0xLTEtNzgyMTU_c4c6dd59-ad35-4fc5-8a0a-d04dbb037733">4.8</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3MDBkOTYxOTZjNjE0Zjk3YTMwMTNiODc2YzQ1OTc5NS90YWJsZXJhbmdlOjcwMGQ5NjE5NmM2MTRmOTdhMzAxM2I4NzZjNDU5Nzk1XzYtNS0xLTEtNzgyMTU_1255db4e-9976-4a92-83e4-908c45bedf66">5.0</ix:nonNumeric></span></td></tr></table></ix:continuation></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzExMjAx_b1e576c5-1dea-46c6-b42d-627f5ffc287f" continuedAt="i11a9a36fadbe4eee9f3f5b74228f145c" escape="true">The following summarizes the activity relative to stock option awards for 2022: </ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="i11a9a36fadbe4eee9f3f5b74228f145c"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:54.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.459%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, beginning of year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie7fd18a6db5a4c6bb7e209edcc7ba998_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTpmZjcyZjUwOGE0OWM0OTM5OGUwN2Y4YjI0YmJiOWIxOS90YWJsZXJhbmdlOmZmNzJmNTA4YTQ5YzQ5Mzk4ZTA3ZjhiMjRiYmI5YjE5XzItMS0xLTEtNzgyMTU_cdc0c329-a924-4d1d-ba30-d2199f7a41bd">5.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie7fd18a6db5a4c6bb7e209edcc7ba998_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTpmZjcyZjUwOGE0OWM0OTM5OGUwN2Y4YjI0YmJiOWIxOS90YWJsZXJhbmdlOmZmNzJmNTA4YTQ5YzQ5Mzk4ZTA3ZjhiMjRiYmI5YjE5XzItMy0xLTEtNzgyMTU_13f3c5ff-a4f8-4f20-92d7-b0017cb03ba5">96.44</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iecaf266ba15d4c5da2f6be8c3e8e76bd_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTpmZjcyZjUwOGE0OWM0OTM5OGUwN2Y4YjI0YmJiOWIxOS90YWJsZXJhbmdlOmZmNzJmNTA4YTQ5YzQ5Mzk4ZTA3ZjhiMjRiYmI5YjE5XzMtMS0xLTEtNzgyMTU_d6babb25-2c05-4dbb-8cbc-6d0b08dd0cfa">0.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iecaf266ba15d4c5da2f6be8c3e8e76bd_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTpmZjcyZjUwOGE0OWM0OTM5OGUwN2Y4YjI0YmJiOWIxOS90YWJsZXJhbmdlOmZmNzJmNTA4YTQ5YzQ5Mzk4ZTA3ZjhiMjRiYmI5YjE5XzMtMy0xLTEtNzgyMTU_b9cd396b-9aa0-4c29-aeec-b0c0770a973b">128.51</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iecaf266ba15d4c5da2f6be8c3e8e76bd_D20220101-20221231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTpmZjcyZjUwOGE0OWM0OTM5OGUwN2Y4YjI0YmJiOWIxOS90YWJsZXJhbmdlOmZmNzJmNTA4YTQ5YzQ5Mzk4ZTA3ZjhiMjRiYmI5YjE5XzQtMS0xLTEtNzgyMTU_1dfee15e-3b7d-4dd9-8946-a9dda72525ca">1.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iecaf266ba15d4c5da2f6be8c3e8e76bd_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTpmZjcyZjUwOGE0OWM0OTM5OGUwN2Y4YjI0YmJiOWIxOS90YWJsZXJhbmdlOmZmNzJmNTA4YTQ5YzQ5Mzk4ZTA3ZjhiMjRiYmI5YjE5XzQtMy0xLTEtNzgyMTU_7e11bfb4-5de4-4bfa-b8bb-dbbcc3a5d7f7">89.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited and canceled</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iecaf266ba15d4c5da2f6be8c3e8e76bd_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTpmZjcyZjUwOGE0OWM0OTM5OGUwN2Y4YjI0YmJiOWIxOS90YWJsZXJhbmdlOmZmNzJmNTA4YTQ5YzQ5Mzk4ZTA3ZjhiMjRiYmI5YjE5XzUtMS0xLTEtNzgyMTU_98684b93-e6d9-448b-b571-8d8783dd5495">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iecaf266ba15d4c5da2f6be8c3e8e76bd_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTpmZjcyZjUwOGE0OWM0OTM5OGUwN2Y4YjI0YmJiOWIxOS90YWJsZXJhbmdlOmZmNzJmNTA4YTQ5YzQ5Mzk4ZTA3ZjhiMjRiYmI5YjE5XzUtMy0xLTEtNzgyMTU_37f18aa0-e1db-4c31-a7e0-c1a85e894f22">120.31</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, end of year</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c80ac26791d4a08826451cfe6ab22a4_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTpmZjcyZjUwOGE0OWM0OTM5OGUwN2Y4YjI0YmJiOWIxOS90YWJsZXJhbmdlOmZmNzJmNTA4YTQ5YzQ5Mzk4ZTA3ZjhiMjRiYmI5YjE5XzYtMS0xLTEtNzgyMTU_84c82d7e-13e5-48f2-9ee9-65855c394709">4.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0c80ac26791d4a08826451cfe6ab22a4_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTpmZjcyZjUwOGE0OWM0OTM5OGUwN2Y4YjI0YmJiOWIxOS90YWJsZXJhbmdlOmZmNzJmNTA4YTQ5YzQ5Mzk4ZTA3ZjhiMjRiYmI5YjE5XzYtMy0xLTEtNzgyMTU_f0c85893-a7ad-411e-90a7-1a0d49bf29e4">101.78</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iecaf266ba15d4c5da2f6be8c3e8e76bd_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTpmZjcyZjUwOGE0OWM0OTM5OGUwN2Y4YjI0YmJiOWIxOS90YWJsZXJhbmdlOmZmNzJmNTA4YTQ5YzQ5Mzk4ZTA3ZjhiMjRiYmI5YjE5XzYtNS0xLTEtNzgyMTU_ee03b3a4-0340-4236-a4c2-eea6803a29f0">5.8</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c80ac26791d4a08826451cfe6ab22a4_I20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTpmZjcyZjUwOGE0OWM0OTM5OGUwN2Y4YjI0YmJiOWIxOS90YWJsZXJhbmdlOmZmNzJmNTA4YTQ5YzQ5Mzk4ZTA3ZjhiMjRiYmI5YjE5XzYtNy0xLTEtNzgyMTU_f769d790-e394-4924-a4b5-0e0e1b749170">257</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable, end of year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c80ac26791d4a08826451cfe6ab22a4_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTpmZjcyZjUwOGE0OWM0OTM5OGUwN2Y4YjI0YmJiOWIxOS90YWJsZXJhbmdlOmZmNzJmNTA4YTQ5YzQ5Mzk4ZTA3ZjhiMjRiYmI5YjE5XzgtMS0xLTEtNzgyMTU_971feb37-1a11-47c6-9b11-90d0613e81a1">3.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0c80ac26791d4a08826451cfe6ab22a4_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTpmZjcyZjUwOGE0OWM0OTM5OGUwN2Y4YjI0YmJiOWIxOS90YWJsZXJhbmdlOmZmNzJmNTA4YTQ5YzQ5Mzk4ZTA3ZjhiMjRiYmI5YjE5XzgtMy0xLTEtNzgyMTU_0f0412e5-3941-4661-8c31-cd9383332efa">94.36</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iecaf266ba15d4c5da2f6be8c3e8e76bd_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTpmZjcyZjUwOGE0OWM0OTM5OGUwN2Y4YjI0YmJiOWIxOS90YWJsZXJhbmdlOmZmNzJmNTA4YTQ5YzQ5Mzk4ZTA3ZjhiMjRiYmI5YjE5XzgtNS0xLTEtNzgyMTU_7b1ffcbc-453b-4efc-9159-47256b0402c6">4.9</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c80ac26791d4a08826451cfe6ab22a4_I20221231" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTpmZjcyZjUwOGE0OWM0OTM5OGUwN2Y4YjI0YmJiOWIxOS90YWJsZXJhbmdlOmZmNzJmNTA4YTQ5YzQ5Mzk4ZTA3ZjhiMjRiYmI5YjE5XzgtNy0xLTEtNzgyMTU_2ed57b4b-2502-4f2f-85cc-10f75f7a46ca">215</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, end of year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c80ac26791d4a08826451cfe6ab22a4_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTpmZjcyZjUwOGE0OWM0OTM5OGUwN2Y4YjI0YmJiOWIxOS90YWJsZXJhbmdlOmZmNzJmNTA4YTQ5YzQ5Mzk4ZTA3ZjhiMjRiYmI5YjE5XzktMS0xLTEtNzgyMTU_e1e72e24-795b-4ada-ae27-bfdb567f9fec">4.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0c80ac26791d4a08826451cfe6ab22a4_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTpmZjcyZjUwOGE0OWM0OTM5OGUwN2Y4YjI0YmJiOWIxOS90YWJsZXJhbmdlOmZmNzJmNTA4YTQ5YzQ5Mzk4ZTA3ZjhiMjRiYmI5YjE5XzktMy0xLTEtNzgyMTU_1ee7fe97-5342-4099-9d82-d503f277330e">101.61</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iecaf266ba15d4c5da2f6be8c3e8e76bd_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTpmZjcyZjUwOGE0OWM0OTM5OGUwN2Y4YjI0YmJiOWIxOS90YWJsZXJhbmdlOmZmNzJmNTA4YTQ5YzQ5Mzk4ZTA3ZjhiMjRiYmI5YjE5XzktNS0xLTEtNzgyMTU_7f4246d9-e3b5-4742-8f37-b2bf9dc69d14">5.8</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c80ac26791d4a08826451cfe6ab22a4_I20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTpmZjcyZjUwOGE0OWM0OTM5OGUwN2Y4YjI0YmJiOWIxOS90YWJsZXJhbmdlOmZmNzJmNTA4YTQ5YzQ5Mzk4ZTA3ZjhiMjRiYmI5YjE5XzktNy0xLTEtNzgyMTU_ef7a5b06-058e-430c-a549-8b5e1c98458a">256</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value (the difference between the Company's closing common stock price on the last trading day of 2022 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on December&#160;31, 2022.  This amount changes based on the fair market value of the Company's common stock.  Total intrinsic value of options exercised in 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="iecaf266ba15d4c5da2f6be8c3e8e76bd_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzQ3MjU_cce99557-7f5c-4074-aa03-b2ee9a8a6a14">70</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="if4c31ce97f0b4d679967210dea5d4ce8_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzQ3Mjk_d8188320-eed7-4ac6-9d31-275d921f08e3">83</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i50195984ca72444b94471a4f11e6b415_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzQ3MzY_5cf6ec87-d641-47f3-aac9-996b46753ef4">113</ix:nonFraction> million, respectively. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of December&#160;31, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i0c80ac26791d4a08826451cfe6ab22a4_I20221231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzQ3Nzg_93f1d694-8c36-456d-aec3-c2f15b654683">5</ix:nonFraction> million of unrecognized stock-based compensation cost related to nonvested stock options which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="iecaf266ba15d4c5da2f6be8c3e8e76bd_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzQ5MzE_c75e6204-fdcc-4f55-b186-0afe31c038d6">1.5</ix:nonNumeric> years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The fair value of restricted stock awards and restricted stock units is the average market price of the Company's common stock at the date of grant.  For performance share units with a goal based on the financial performance of the Company, the fair value is based on the average market price of the Company's common stock at the date of grant, adjusted for the present value of dividends expected to be paid on the Company's common stock during the vesting period.  For performance share units with a market-based relative TSR goal, the fair value is estimated on the date of grant using a Monte Carlo valuation model.  The expected volatility under the Monte Carlo valuation model is based on the historical volatility of the common stock of the Company and the common stock of the companies in the peer index.  The dividend yield is based on the approved annual dividend rate in effect and current market price of the underlying common stock at the time of grant.  The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for bonds with maturities consistent with the performance period of the related award. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211; CONTINUED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions unless otherwise indicated)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><ix:continuation id="i4ea595072207487eb6362b4bc425058f" continuedAt="id368fc7c03c341c88c6ffd70b5964c5c"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="dgx:ScheduleOfShareBasedPaymentAwardPerformanceShareUnitsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzExMTk0_f486bf42-f681-46ec-bd22-30864dbc46e7" continuedAt="i675839593d23455cab595289732ece08" escape="true">The weighted average assumptions used in valuing performance share units with a market-based relative TSR goal in the periods presented were:</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:continuation id="i675839593d23455cab595289732ece08" continuedAt="id6c3c7948ef04a5e9a22fce8df1aadf3">  </ix:continuation></span></div><div><ix:continuation id="id6c3c7948ef04a5e9a22fce8df1aadf3"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.289%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.385%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at grant date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i0800ecbb791747f4ad71925d6e8c45e7_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo5OTA5ODM4M2RiNGM0OWYxYWZhOGU5YzI0Mjg2Njk1OC90YWJsZXJhbmdlOjk5MDk4MzgzZGI0YzQ5ZjFhZmE4ZTljMjQyODY2OTU4XzItMS0xLTEtNzgyMTU_564f51ef-ab25-41bf-96ef-0c7791ffdf55">130.00</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i94c763d3175548ab80e291e8d327ea98_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo5OTA5ODM4M2RiNGM0OWYxYWZhOGU5YzI0Mjg2Njk1OC90YWJsZXJhbmdlOjk5MDk4MzgzZGI0YzQ5ZjFhZmE4ZTljMjQyODY2OTU4XzItMy0xLTEtNzgyMTU_3136cb4c-e567-4757-a007-8396035a7d88">150.15</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i066c181da1cc4104bc13332037ebc51c_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo5OTA5ODM4M2RiNGM0OWYxYWZhOGU5YzI0Mjg2Njk1OC90YWJsZXJhbmdlOjk5MDk4MzgzZGI0YzQ5ZjFhZmE4ZTljMjQyODY2OTU4XzItNS0xLTEtODc3NDM_d3423e9c-75eb-4255-9bba-a4a81950f176">144.03</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0800ecbb791747f4ad71925d6e8c45e7_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo5OTA5ODM4M2RiNGM0OWYxYWZhOGU5YzI0Mjg2Njk1OC90YWJsZXJhbmdlOjk5MDk4MzgzZGI0YzQ5ZjFhZmE4ZTljMjQyODY2OTU4XzMtMS0xLTEtNzgyMTU_0258d55d-39f2-49d1-a99e-55d09ae220b3">29.9</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i94c763d3175548ab80e291e8d327ea98_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo5OTA5ODM4M2RiNGM0OWYxYWZhOGU5YzI0Mjg2Njk1OC90YWJsZXJhbmdlOjk5MDk4MzgzZGI0YzQ5ZjFhZmE4ZTljMjQyODY2OTU4XzMtMy0xLTEtNzgyMTU_71867c5d-8e47-4139-8bbb-4c6ab2b17b16">30.2</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i066c181da1cc4104bc13332037ebc51c_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo5OTA5ODM4M2RiNGM0OWYxYWZhOGU5YzI0Mjg2Njk1OC90YWJsZXJhbmdlOjk5MDk4MzgzZGI0YzQ5ZjFhZmE4ZTljMjQyODY2OTU4XzMtNS0xLTEtODc3NTg_79f003e1-1a4c-4e2d-b79b-c4369dc71ded">20.1</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0800ecbb791747f4ad71925d6e8c45e7_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo5OTA5ODM4M2RiNGM0OWYxYWZhOGU5YzI0Mjg2Njk1OC90YWJsZXJhbmdlOjk5MDk4MzgzZGI0YzQ5ZjFhZmE4ZTljMjQyODY2OTU4XzQtMS0xLTEtNzgyMTU_f148e0bb-d866-41ac-aa90-bc4030c8c73d">2.0</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i94c763d3175548ab80e291e8d327ea98_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo5OTA5ODM4M2RiNGM0OWYxYWZhOGU5YzI0Mjg2Njk1OC90YWJsZXJhbmdlOjk5MDk4MzgzZGI0YzQ5ZjFhZmE4ZTljMjQyODY2OTU4XzQtMy0xLTEtNzgyMTU_46d14c7d-427a-46bd-94b7-263db0045ed0">2.0</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i066c181da1cc4104bc13332037ebc51c_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo5OTA5ODM4M2RiNGM0OWYxYWZhOGU5YzI0Mjg2Njk1OC90YWJsZXJhbmdlOjk5MDk4MzgzZGI0YzQ5ZjFhZmE4ZTljMjQyODY2OTU4XzQtNS0xLTEtODc3NjY_9693a782-f90f-4d6e-a2f6-836e6eac5920">2.0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0800ecbb791747f4ad71925d6e8c45e7_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo5OTA5ODM4M2RiNGM0OWYxYWZhOGU5YzI0Mjg2Njk1OC90YWJsZXJhbmdlOjk5MDk4MzgzZGI0YzQ5ZjFhZmE4ZTljMjQyODY2OTU4XzUtMS0xLTEtNzgyMTU_9aa0d117-6170-4292-82b8-9c4fe48efe87">1.7</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i94c763d3175548ab80e291e8d327ea98_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo5OTA5ODM4M2RiNGM0OWYxYWZhOGU5YzI0Mjg2Njk1OC90YWJsZXJhbmdlOjk5MDk4MzgzZGI0YzQ5ZjFhZmE4ZTljMjQyODY2OTU4XzUtMy0xLTEtNzgyMTU_ade613b7-f32e-4042-94cc-823ccb80dab7">0.2</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i066c181da1cc4104bc13332037ebc51c_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo5OTA5ODM4M2RiNGM0OWYxYWZhOGU5YzI0Mjg2Njk1OC90YWJsZXJhbmdlOjk5MDk4MzgzZGI0YzQ5ZjFhZmE4ZTljMjQyODY2OTU4XzUtNS0xLTEtODc3NzQ_218f458c-c0d9-41ea-8ce7-cc3165d43566">1.4</ix:nonFraction>%</span></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzExMTg0_ffb8e215-9fe9-4631-9d6e-ecb258d31c5f" continuedAt="i506f2000b4a3412390c191324c10dd92" escape="true">The following summarizes the activity relative to stock awards, including restricted stock units and performance share units, for 2022, 2021 and 2020: </ix:nonNumeric></span></div><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center;text-indent:31.5pt"><ix:continuation id="i506f2000b4a3412390c191324c10dd92"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:31.205%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.478%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares outstanding, beginning of year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia3870621ff0c4e94a8c0db30f0a94950_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzMtMS0xLTEtNzgyMTU_5710bbde-3fa3-4a73-be04-a43bf0aa06f8">1.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia3870621ff0c4e94a8c0db30f0a94950_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzMtMy0xLTEtNzgyMTU_ff5a8a3d-c839-4aee-a867-60d3268ddcae">107.46</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a773294c9f247f4b61dc287d74d2f4a_I20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzMtNS0xLTEtNzgyMTU_17d81d3b-8c8e-4cae-b781-8bd09743caec">1.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2a773294c9f247f4b61dc287d74d2f4a_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzMtNy0xLTEtNzgyMTU_7b1785a7-5f2b-41c5-bbf1-81f96b0c11da">100.12</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f2ed080770b4b799d26a7b0773c6afa_I20191231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzMtOS0xLTEtNzgyMTU_2fc38904-b105-4dbf-9349-62cc7a7263f9">1.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0f2ed080770b4b799d26a7b0773c6afa_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzMtMTEtMS0xLTc4MjE1_a35a56cf-a390-49ab-a54d-3120e9eff442">93.30</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i532fc9e0076b4da684698168d99ecf57_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzQtMS0xLTEtNzgyMTU_76e243f6-c048-44ee-a453-813ae89d7a1c">0.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i532fc9e0076b4da684698168d99ecf57_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzQtMy0xLTEtNzgyMTU_e9dbe980-3417-4e10-a460-a0660fd9d0e7">128.49</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0859d2d438a749bd85c7c9580402ecc9_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzQtNS0xLTEtNzgyMTU_a6c4ad70-60a8-4301-ab21-a54ad8d3aaf3">0.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0859d2d438a749bd85c7c9580402ecc9_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzQtNy0xLTEtNzgyMTU_81e7711c-4127-4193-a3ef-bffbdb1ce43d">122.78</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3510a40b3f92452ca5683687a18ac5b5_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzQtOS0xLTEtNzgyMTU_6c52bd37-b8e0-43a5-9c16-39ffd5641404">0.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3510a40b3f92452ca5683687a18ac5b5_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzQtMTEtMS0xLTc4MjE1_9f549c0a-7aeb-4f29-9bc4-4b94fd4aa607">112.43</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i532fc9e0076b4da684698168d99ecf57_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzUtMS0xLTEtNzgyMTU_9e13cb85-6870-49e0-8013-2a54eafd881c">0.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i532fc9e0076b4da684698168d99ecf57_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzUtMy0xLTEtNzgyMTU_402e74f5-986d-4b94-98d6-3ddac9c2b0b6">92.45</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0859d2d438a749bd85c7c9580402ecc9_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzUtNS0xLTEtNzgyMTU_4e68b4ac-749b-43f5-a207-9ef48fec5eeb">0.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0859d2d438a749bd85c7c9580402ecc9_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzUtNy0xLTEtNzgyMTU_5536e51a-7f2d-4cf1-9abc-03776df54bf0">103.41</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3510a40b3f92452ca5683687a18ac5b5_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzUtOS0xLTEtNzgyMTU_7d791cee-abbd-4464-ad8d-ebb1e8b0a65d">0.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3510a40b3f92452ca5683687a18ac5b5_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzUtMTEtMS0xLTc4MjE1_41e06773-770d-434f-8e25-101b3733bd62">96.36</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares forfeited and canceled</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i532fc9e0076b4da684698168d99ecf57_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzYtMS0xLTEtNzgyMTU_37a3531f-faf0-4dac-88b9-ea4abb5b369c">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i532fc9e0076b4da684698168d99ecf57_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzYtMy0xLTEtNzgyMTU_0c4899ef-fd9d-45d8-acd9-18b882168cb4">122.38</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0859d2d438a749bd85c7c9580402ecc9_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzYtNS0xLTEtNzgyMTU_c0e5a618-f8b7-41da-98a5-73c669c2b561">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0859d2d438a749bd85c7c9580402ecc9_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzYtNy0xLTEtNzgyMTU_e23fb7dc-95df-4add-838c-9c1c2ea8de9d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3510a40b3f92452ca5683687a18ac5b5_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzYtOS0xLTEtNzgyMTU_d7233420-4f50-415f-8b79-b60f4dc70001">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3510a40b3f92452ca5683687a18ac5b5_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzYtMTEtMS0xLTc4MjE1_eab99d09-9d9c-470a-8f6b-d009235f0fc7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares outstanding, end of year</span></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i173f1992d3144e31a2d74876e89770d5_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzgtMS0xLTEtNzgyMTU_e3ae4c97-9adb-4323-b5b5-a8d30a82e94d">1.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i173f1992d3144e31a2d74876e89770d5_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzgtMy0xLTEtNzgyMTU_c892d5c7-c794-4261-aab0-1172bd9ff9f7">122.45</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia3870621ff0c4e94a8c0db30f0a94950_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzgtNS0xLTEtNzgyMTU_0d2f6109-bca1-4f2a-872e-c157b63a0292">1.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia3870621ff0c4e94a8c0db30f0a94950_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzgtNy0xLTEtNzgyMTU_0b409f6a-3aca-4d02-b51a-73ebcd61d99d">107.46</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a773294c9f247f4b61dc287d74d2f4a_I20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzgtOS0xLTEtNzgyMTU_0e21aeda-1e2f-4501-91f9-2ac346c9f56d">1.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2a773294c9f247f4b61dc287d74d2f4a_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzgtMTEtMS0xLTc4MjE1_33188ee4-e9d1-4c26-9522-273c55119f0c">100.12</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of December&#160;31, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i173f1992d3144e31a2d74876e89770d5_I20221231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzY0MTY_c4a7dde0-878c-4ef5-8015-f479b9d26e6a">40</ix:nonFraction> million of unrecognized stock-based compensation cost related to nonvested stock awards, which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="i532fc9e0076b4da684698168d99ecf57_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzY1Njk_0a7e22c4-48f3-4e3a-a539-e37ec413c9b7">1.8</ix:nonNumeric> years.  Total fair value of shares vested was $<ix:nonFraction unitRef="usd" contextRef="i532fc9e0076b4da684698168d99ecf57_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzY2MTI_921cada2-4b14-4813-aa01-20dcc95b427c">72</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i0859d2d438a749bd85c7c9580402ecc9_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzY2MTY_79cfb5e4-c80e-4b87-acdc-44adb910c3dc">59</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3510a40b3f92452ca5683687a18ac5b5_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzY2MjM_40896c10-c16d-4a0d-83d4-fd0661c6ef82">37</ix:nonFraction> million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.  For performance share units with a goal based on financial performance of the Company, the amount of unrecognized stock-based compensation cost is subject to change based on changes, if any, to management's best estimates of the achievement of the performance goals specified in such awards and the resulting number of shares that will be earned at the end of the performance periods.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the years ended December&#160;31, 2022, 2021 and 2020, stock-based compensation expense totaled $<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzcxMzk_404a4ca8-f7fa-4d9f-bace-860a045e2ac6">77</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzcxNDM_ac9d1257-17e4-4391-a47a-1bbe238d3749">79</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzcxNTA_16ee9b94-02bd-4041-931d-920e2c1d942e">97</ix:nonFraction> million, respectively.  Income tax benefits recognized in the consolidated statements of operations related to stock-based compensation expense totaled $<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzcyOTc_cd5f9a74-83bc-48f1-9887-c305fb5d6da6">27</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzczMDE_29468238-ad3c-42cd-9fe4-e38c1b0523e9">32</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzczMDg_b2f2fd95-4462-4bbd-bf3e-e8e3fac07e78">39</ix:nonFraction> million for the years ended December&#160;31, 2022, 2021 and 2020, respectively, which includes excess tax benefits associated with stock-based compensation arrangements of $<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="dgx:Sharebasedcompensationexcesstaxbenefitamount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzc0NTI_de995712-801a-4bb3-999c-2d88a2992589">14</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="dgx:Sharebasedcompensationexcesstaxbenefitamount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzc0NTY_02d1ce49-42d1-4d2a-94ac-ede01dc4cbd8">19</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="dgx:Sharebasedcompensationexcesstaxbenefitamount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzc0NjM_658f5f6c-15ef-45fa-b253-57b7995bb7f2">23</ix:nonFraction> million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Under the Company's ESPP, substantially all employees can elect to have up to <ix:nonFraction unitRef="number" contextRef="i9cf6871cc3fb4fc7964b07d9e8dd6df6_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzc2Mjc_4d6d6ee4-f59b-42c7-bcf3-6888d70fc456">10</ix:nonFraction>% of their annual wages withheld to purchase Quest Diagnostics common stock.  The purchase price of the stock is <ix:nonFraction unitRef="number" contextRef="i0d352bd28a45443e80612ac16c512e54_D20220101-20221231" decimals="INF" name="dgx:MarketPriceOfCompanyStockIssuedAtDiscountUnderEspp" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzc3NDE_f2174d9c-ec83-4a70-9b6e-7dd2bb516564">95</ix:nonFraction>% of the market price of the Company's common stock on the last business day of each calendar month.  Under the ESPP, the maximum number of shares of Quest Diagnostics common stock which may be purchased by eligible employees is <ix:nonFraction unitRef="shares" contextRef="i9cf6871cc3fb4fc7964b07d9e8dd6df6_I20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzc5NzE_f4a343c1-d48a-4a40-aaa5-e75d086077e2">9</ix:nonFraction> million.  Approximately <ix:nonFraction unitRef="shares" contextRef="i0d352bd28a45443e80612ac16c512e54_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzc5OTA_c4240bff-03a6-4805-940d-6ea649f8d222">216</ix:nonFraction> thousand shares, <ix:nonFraction unitRef="shares" contextRef="i061fddd15a744d87ae3c69a6d735a09b_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzgwMDE_21426887-9aae-48f2-9335-830f636cc694">200</ix:nonFraction> thousand shares and <ix:nonFraction unitRef="shares" contextRef="i9bef679f049f4a7589e81ff16e6faf39_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzgwMTU_b3e16ad5-b6b4-4045-b63c-9b5d405c84f0">225</ix:nonFraction> thousand shares of common stock were purchased by eligible employees in 2022, 2021 and 2020, respectively.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defined Contribution Plans </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company maintains qualified defined contribution plans covering substantially all of its employees.  The maximum Company matching contribution is <ix:nonFraction unitRef="number" contextRef="i4c9530356f3242cdb77f114a2aa32961_D20220101-20221231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzgyOTI_c31a3134-2669-45ad-826a-0283ace33fc9">5</ix:nonFraction>% of eligible employee compensation.  During 2020, the Company temporarily suspended matching contributions for certain qualified defined contribution plans; matching contributions were reinstated in the third quarter of 2020.  The Company's expense for contributions to its defined contribution plans aggregated $<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzg2MDY_c154c01b-a0e0-44b4-b901-81b6a339fcec">95</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzg2MTA_d1fc1d05-44e5-4004-bbb3-78d935ebd3af">93</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzg2MTc_5c3a63e5-089e-42dd-817e-cd8860097187">64</ix:nonFraction> million for 2022, 2021 and 2020, respectively. </span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211; CONTINUED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions unless otherwise indicated)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><ix:continuation id="id368fc7c03c341c88c6ffd70b5964c5c"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Supplemental Deferred Compensation Plans</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company has a supplemental deferred compensation plan that is an unfunded, non-qualified plan that provides for certain management and highly compensated employees to defer up to <ix:nonFraction unitRef="number" contextRef="i3984e240129249f2b9f78c9c4f3a1818_D20220101-20221231" decimals="2" name="dgx:SupplementalDeferredCompensationPlanSalaryDeferral" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzg4ODI_ebb4c9ac-6041-4e00-93e3-73b16a44f4e5">50</ix:nonFraction>% of their salary in excess of their defined contribution plan limits and for certain eligible employees, up to <ix:nonFraction unitRef="number" contextRef="i3984e240129249f2b9f78c9c4f3a1818_D20220101-20221231" decimals="2" name="dgx:SupplementalDeferredCompensationPlanVariableIncentiveCompensationDeferral" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzg5OTU_988d7b04-cd0e-481e-b603-0231729190d6">95</ix:nonFraction>% of their variable incentive compensation.  The maximum Company matching contribution is <ix:nonFraction unitRef="number" contextRef="i6bf42c10d101437f98e7eac589472f72_D20220101-20221231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzkwODY_87a2c622-eb42-4847-bacd-863ba652aed9">5</ix:nonFraction>% of eligible employee compensation.  The compensation deferred under this plan, together with Company matching amounts, are credited with earnings or losses measured by the mirrored rate of return on investments elected by plan participants.  Each plan participant is fully vested in all deferred compensation, Company match and earnings credited to their account.  The amounts accrued under the Company's deferred compensation plans were $<ix:nonFraction unitRef="usd" contextRef="i70242db0befe4ca299c35c570e02ae70_I20221231" decimals="-6" name="us-gaap:DeferredCompensationArrangementWithIndividualRecordedLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzk2Njg_5d95606d-09e2-4ced-b842-666a13926c5f">68</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id56d32d3a5174c0f9f67b3b882cf8826_I20211231" decimals="-6" name="us-gaap:DeferredCompensationArrangementWithIndividualRecordedLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzk2NzU_1ea7129f-bd66-492d-8658-29d93907cd37">77</ix:nonFraction> million as of December&#160;31, 2022 and 2021, respectively.  Although the Company is currently contributing all participant deferrals and matching amounts to a trust, the funds in this trust, totaling $<ix:nonFraction unitRef="usd" contextRef="i70242db0befe4ca299c35c570e02ae70_I20221231" decimals="-6" name="dgx:FundsinatrustpertainingtoallparticipantdeferralsandcompanymatchingamountsrelatedtotheSDCP" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzk4NTA_218d08a5-6dcc-4604-86bb-fd065aefc0de">68</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id56d32d3a5174c0f9f67b3b882cf8826_I20211231" decimals="-6" name="dgx:FundsinatrustpertainingtoallparticipantdeferralsandcompanymatchingamountsrelatedtotheSDCP" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzk4NTc_4dbea03b-78cc-45cd-9f02-24c5c20c4f84">77</ix:nonFraction> million as of December&#160;31, 2022 and 2021, respectively, are general assets of the Company and are subject to any claims of the Company's creditors. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company also offers certain employees the opportunity to participate in a non-qualified deferred compensation program.  The Company matches employee contributions equal to <ix:nonFraction unitRef="number" contextRef="icf5e6c8d02cb4230b46883164090ae6c_D20220101-20221231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzEwMTYy_bc804c10-2a12-4251-b49a-45554771dcef">25</ix:nonFraction>%, up to a maximum of $<ix:nonFraction unitRef="usd" contextRef="idd8f2aef04fc44bc86451fb4062847cc_D20220101-20221231" decimals="-3" name="us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzEwMTg1_cedc7909-4a14-4bc2-ab3c-a197124bc726">5</ix:nonFraction> thousand per plan year.  A participant's deferrals, together with Company matching credits, are &#8220;invested&#8221; at the direction of the employee in a hypothetical portfolio of investments which are tracked by an administrator.  Each participant is fully vested in their deferred compensation and vests in Company matching contributions over a period of <ix:nonNumeric contextRef="icf5e6c8d02cb4230b46883164090ae6c_D20220101-20221231" name="us-gaap:DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzEwNTI3_57c0a2a9-2c34-4b49-9532-55c834f79050">four years</ix:nonNumeric> at <ix:nonFraction unitRef="number" contextRef="icf5e6c8d02cb4230b46883164090ae6c_D20220101-20221231" decimals="2" name="dgx:SdcpIiGradedVestingPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzEwNTMz_c92d2672-84a6-4704-a4a2-771cee74bfea">25</ix:nonFraction>% per year.  This plan was amended effective January 1, 2018 so that future deferrals under the plan may only be made by participants who made deferrals under the plan in 2017.  The amounts accrued under this plan were $<ix:nonFraction unitRef="usd" contextRef="ie1765ce7329f47f2a55b699f67f431bf_I20221231" decimals="-6" name="us-gaap:DeferredCompensationArrangementWithIndividualRecordedLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzEwNzUz_e85c8398-fdb5-4aa3-97d9-1accf0c9e678">52</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1b69605427b24c3290b808836c99ad60_I20211231" decimals="-6" name="us-gaap:DeferredCompensationArrangementWithIndividualRecordedLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzEwNzYw_ea4d482f-2d46-4173-9ce1-fce285395dac">66</ix:nonFraction> million as of December&#160;31, 2022 and 2021, respectively.  The Company purchases life insurance policies, with the Company named as beneficiary of the policies, for the purpose of funding the program's liability.  The cash surrender value of such life insurance policies was $<ix:nonFraction unitRef="usd" contextRef="ie1765ce7329f47f2a55b699f67f431bf_I20221231" decimals="-6" name="us-gaap:CashSurrenderValueFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzExMDEx_01d76ff7-cffe-4066-a5fb-66e014a03e86">46</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1b69605427b24c3290b808836c99ad60_I20211231" decimals="-6" name="us-gaap:CashSurrenderValueFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzExMDE4_1e92db5c-99ae-48d5-b1f7-acca755c3451">57</ix:nonFraction> million as of December&#160;31, 2022 and 2021, respectively.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;  For each of the years ended December&#160;31, 2022, 2021 and 2020, the Company's expense for matching contributions to these plans was not material.</span></div></ix:continuation><div><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_229"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjkvZnJhZzoxMjE0Y2U5MTA2NmE0ZjdhODFiMWQ1ZDU3MDliOTUxYy90ZXh0cmVnaW9uOjEyMTRjZTkxMDY2YTRmN2E4MWIxZDVkNTcwOWI5NTFjXzEwNjMw_1f524227-9f4e-4a77-a530-565bfce76da4" continuedAt="ife9d993319f54359bbbe5b5faae23ed9" escape="true">COMMITMENTS AND CONTINGENCIES </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ife9d993319f54359bbbe5b5faae23ed9" continuedAt="i56cf1b922df848adbcc4e8f310645fce"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Letters of Credit and Contractual Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company can issue letters of credit under its Secured Receivables Credit Facility and Senior Unsecured Revolving Credit Facility (see Note 14).  In support of its risk management program, to ensure the Company&#8217;s performance or payment to third parties, $<ix:nonFraction unitRef="usd" contextRef="ie85140ba27db46a5a05080eae640b00a_I20221231" decimals="-6" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjkvZnJhZzoxMjE0Y2U5MTA2NmE0ZjdhODFiMWQ1ZDU3MDliOTUxYy90ZXh0cmVnaW9uOjEyMTRjZTkxMDY2YTRmN2E4MWIxZDVkNTcwOWI5NTFjXzM0OQ_43d6b829-4132-471a-92e1-c61d1f7adcf7">70</ix:nonFraction> million in letters of credit under the Secured Receivables Credit Facility were outstanding as of December&#160;31, 2022.  The letters of credit primarily represent collateral for current and future automobile liability and workers&#8217; compensation loss payments.</span></div><div style="padding-right:13.5pt"><span><br/></span></div><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company has certain noncancelable commitments, primarily under take-or-pay arrangements, to purchase products or services from various suppliers, mainly for consulting and other service agreements, and standing orders to purchase reagents and other laboratory supplies.  As of December&#160;31, 2022, the approximate total future purchase commitments are $<ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjkvZnJhZzoxMjE0Y2U5MTA2NmE0ZjdhODFiMWQ1ZDU3MDliOTUxYy90ZXh0cmVnaW9uOjEyMTRjZTkxMDY2YTRmN2E4MWIxZDVkNTcwOWI5NTFjXzkyNg_94ad311a-460e-4f82-8949-1d9f97436e4c">384</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjkvZnJhZzoxMjE0Y2U5MTA2NmE0ZjdhODFiMWQ1ZDU3MDliOTUxYy90ZXh0cmVnaW9uOjEyMTRjZTkxMDY2YTRmN2E4MWIxZDVkNTcwOWI5NTFjXzkzOQ_bf0b2e03-9a0f-4d4b-88ea-c962046aaac4">125</ix:nonFraction> million are expected to be incurred in 2023, $<ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="dgx:UnrecordedUnconditionalPurchaseObligationDuewithinTwoandThreeYears" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjkvZnJhZzoxMjE0Y2U5MTA2NmE0ZjdhODFiMWQ1ZDU3MDliOTUxYy90ZXh0cmVnaW9uOjEyMTRjZTkxMDY2YTRmN2E4MWIxZDVkNTcwOWI5NTFjXzk3Nw_8f2d1a76-885a-456e-9aa1-4db1dc42f8a0">166</ix:nonFraction> million are expected to be incurred in 2024 through 2025 and the balance thereafter. </span></div></ix:continuation><div style="padding-right:13.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211; CONTINUED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions unless otherwise indicated)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><ix:continuation id="i56cf1b922df848adbcc4e8f310645fce" continuedAt="icf3edf1b54604d258aa528a9240b8380"><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Billing and Collection Agreement</span></div><div style="padding-right:13.5pt"><span><br/></span></div><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In September 2016, the Company entered into a <ix:nonNumeric contextRef="ibb34a0a60bd547a58f8634a55d3ea6e9_D20160901-20160930" name="dgx:AgreementtoOutsourceBillingandCollectionFunction" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjkvZnJhZzoxMjE0Y2U5MTA2NmE0ZjdhODFiMWQ1ZDU3MDliOTUxYy90ZXh0cmVnaW9uOjEyMTRjZTkxMDY2YTRmN2E4MWIxZDVkNTcwOWI5NTFjXzI3NDg3NzkwOTE0Nzc_a2a47e31-8a00-4662-ab45-50416b571d4d">ten-year</ix:nonNumeric> agreement with a third party to outsource its billing and  related operations for the majority of the Company&#8217;s revenues.  Services under the agreement commenced during the fourth quarter of 2016.  The agreement includes an annual fee, which is subject to adjustment based on certain changes in the Company's requisition volume and the achievement of various performance metrics.</span></div><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Lease Obligations</span></div><div style="padding-right:13.5pt"><span><br/></span></div><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company remains subject to contingent obligations under certain real estate leases, including real estate leases that were entered into by certain predecessor companies of a subsidiary prior to the Company's acquisition of the subsidiary.  While over the course of many years, the title to certain properties and interest in the subject leases have been transferred to third parties and the subject leases have been amended several times by such third parties, the lessors have not formally released the subsidiary predecessor companies from their original obligations under the leases and therefore remain contingently liable in the event of default.  The remaining terms of the lease obligations and the Company's corresponding indemnifications range up to <ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="dgx:RemainingTermsofContingentLeaseObligationsMaximum" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjkvZnJhZzoxMjE0Y2U5MTA2NmE0ZjdhODFiMWQ1ZDU3MDliOTUxYy90ZXh0cmVnaW9uOjEyMTRjZTkxMDY2YTRmN2E4MWIxZDVkNTcwOWI5NTFjXzIzMjI_66bee583-07bd-4283-9b81-ed89ef325f6f">25</ix:nonNumeric> years.  The lease payments under certain leases are subject to market value adjustments and contingent rental payments and therefore, the total contingent obligations under the leases cannot be precisely determined but are likely to total several hundred million dollars.  A claim against the Company would be made only upon the current lessee's default and, in certain cases, after a series of claims and corresponding defaults by third parties that precede the Company in the order of liability.  The Company also has certain indemnification rights from other parties to recover losses in the event of default on the lease obligations.  The Company believes that the likelihood of its performance under these contingent obligations is remote and no liability has been recorded for any potential payments under the contingent lease obligations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain Legal Matters</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;The Company may incur losses associated with these proceedings and investigations, but it is not possible to estimate the amount of loss or range of loss, if any, that might result from adverse judgments, settlements, fines, penalties, or other resolution of these proceedings and investigations based on the stage of these proceedings and investigations, the absence of specific allegations as to alleged damages, the uncertainty as to the certification of a class or classes and the size of any certified class, if applicable, and/or the lack of resolution of significant factual and legal issues.  The Company has insurance coverage rights in place (limited in amount; subject to deductible) for certain potential costs and liabilities related to these proceedings and investigations.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">401(k) Plan Lawsuit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;In 2020, two putative class action lawsuits were filed in the U.S. District Court for New Jersey against the Company and other defendants with respect to the Company&#8217;s 401(k) plan. The complaint alleges, among other things, that the fiduciaries of the 401(k) plan breached their duties by failing to disclose the expenses and risks of plan investment options, allowing unreasonable administration expenses to be charged to plan participants, and selecting and retaining high cost and poor performing investments.  In October 2020, the court consolidated the two lawsuits under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">In re: Quest Diagnostics ERISA Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and plaintiffs filed a consolidated amended complaint.  In May 2021, the court denied the Company's motion to dismiss the complaint.  Discovery is proceeding.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">AMCA Data Security Incident</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  </span></div><div style="padding-left:36pt;text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;On June 3, 2019, the Company reported that Retrieval-Masters Creditors Bureau, Inc./American Medical Collection Agency (&#8220;AMCA&#8221;) had informed the Company and Optum360 LLC that an unauthorized user had access to AMCA&#8217;s system between August 1, 2018 and March 30, 2019 (the &#8220;AMCA Data Security Incident&#8221;).  Optum360 provides revenue management services to the Company, and AMCA provided debt collection services to Optum360.  AMCA first informed the Company of the AMCA Data Security Incident on May 14, 2019.  AMCA&#8217;s affected system included financial information (e.g., credit card numbers and bank account information), medical information and other personal information (e.g., social security numbers). Test results were not included.  Neither Optum360&#8217;s nor the Company&#8217;s systems or databases were involved in the incident. AMCA also informed the Company that information pertaining to other laboratories&#8217; customers was also affected.  Following announcement of the AMCA Data Security Incident, AMCA sought protection under the U.S. bankruptcy laws.  The bankruptcy proceeding has been dismissed.</span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211; CONTINUED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions unless otherwise indicated)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><ix:continuation id="icf3edf1b54604d258aa528a9240b8380" continuedAt="i20beeb1428fa445d838bd890f27cb769"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Numerous putative class action lawsuits were filed against the Company related to the AMCA Data Security Incident.  The U.S. Judicial Panel on Multidistrict Litigation transferred the cases that were then still pending to, and consolidated them for pre-trial proceedings in, the U.S. District Court for New Jersey.  In November 2019, the plaintiffs in the multidistrict proceeding filed a consolidated putative class action complaint against the Company and Optum360 that named additional individuals as plaintiffs and that asserted a variety of common law and statutory claims in connection with the AMCA Data Security Incident.  In January 2020, the Company moved to dismiss the consolidated complaint; the motion to dismiss was granted in part and denied in part.  Discovery is proceeding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In addition, the Company has been notified that numerous state attorney general offices were investigating or otherwise seeking information and/or documents, and that certain U.S. senators were seeking information, from the Company related to the AMCA Data Security Incident.  </span></div><div><span><br/></span></div><div style="text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ReproSource Fertility Diagnostics, Inc.</span></div><div style="text-indent:72pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;ReproSource Fertility Diagnostics, Inc. (&#8220;ReproSource&#8221;), a subsidiary of the Company, is subject to two putative class action lawsuits in the U.S. District Court for Massachusetts: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Bickham v. ReproSource Fertility Diagnostics, Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Gordon v. ReproSource Fertility Diagnostics, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> The class actions are related to a data security incident that occurred in August 2021 in which an unauthorized party may have accessed or acquired protected health information and personally identifiable information of ReproSource patients. The complaints generally allege that ReproSource, among other claims, failed to adequately safeguard customers&#8217; private information. ReproSource has moved to dismiss both complaints.  A third putative class action pertaining to the same data security incident, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Trouville v. ReproSource Fertility Diagnostics, Inc.,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> was filed in California state court.  The Company removed the case to federal court and moved to dismiss and/or transfer it to U.S. District Court for Massachusetts.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                       </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cole, et. al v. Quest Diagnostics Incorporated</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;The Company is</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">subject to a putative class action entitled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Cole, et al. v Quest Diagnostics Incorporated</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, which was filed in the U. S. District Court for the Eastern District of California, for allegedly conspiring with Facebook to track customers&#8217; internet communications on Company web platforms without authorization, in violation of the California Invasion of Privacy Act and the California Confidentiality of Medical Information Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  The complaint alleged that the Company&#8217;s actions were an invasion of privacy and contributed to a loss of value in plaintiffs&#8217; personally identifiable information.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company moved to dismiss the case or, in the alternative, transfer venue to the U.S. District Court for New Jersey.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Subsequently, plaintiffs filed an amended complaint.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Other Legal Matters</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In the normal course of business, the Company has been named, from time to time, as a defendant in various legal actions, including arbitrations, class actions and other litigation, arising in connection with the Company's activities as a provider of diagnostic testing, information and services.  These actions could involve claims for substantial compensatory and/or punitive damages or claims for indeterminate amounts of damages, and could have an adverse impact on the Company's client base and reputation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company is also involved, from time to time, in other reviews, investigations and proceedings by governmental agencies regarding the Company's business which may result in adverse judgments, settlements, fines, penalties, injunctions or other relief. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In addition, certain federal and state statutes, including the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> provisions of the federal False Claims Act, allow private individuals to bring lawsuits against healthcare companies on behalf of the government or private payers.  The Company is aware of lawsuits, and from time to time has received subpoenas, related to billing or other practices based on the False Claims Act or other federal and state statutes, regulations or other laws.  The Company understands that there may be other pending qui tam claims brought by former employees or other "whistle blowers" as to which the Company cannot determine the extent of any potential liability.</span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211; CONTINUED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions unless otherwise indicated)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><ix:continuation id="i20beeb1428fa445d838bd890f27cb769" continuedAt="i2a2495b477ff4993add304b17624a71f"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Management cannot predict the outcome of such matters.  Although management does not anticipate that the ultimate outcome of such matters will have a material adverse effect on the Company's financial condition, given the high degree of judgment involved in establishing loss estimates related to these types of matters, the outcome of such matters may be material to the Company's consolidated results of operations or cash flows in the period in which the impact of such matters is determined or paid.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;These matters are in different stages.  Some of these matters are in their early stages.  Matters may involve responding to and cooperating with various government investigations and related subpoenas.  As of December&#160;31, 2022, the Company does not believe that material losses related to legal matters are probable.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Reserves for legal matters totaled $<ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:LitigationReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjkvZnJhZzoxMjE0Y2U5MTA2NmE0ZjdhODFiMWQ1ZDU3MDliOTUxYy90ZXh0cmVnaW9uOjEyMTRjZTkxMDY2YTRmN2E4MWIxZDVkNTcwOWI5NTFjXzkzMzU_1b95a33f-67f7-4c7a-a9f8-e411abeb5eb1">2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:LitigationReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjkvZnJhZzoxMjE0Y2U5MTA2NmE0ZjdhODFiMWQ1ZDU3MDliOTUxYy90ZXh0cmVnaW9uOjEyMTRjZTkxMDY2YTRmN2E4MWIxZDVkNTcwOWI5NTFjXzkzNDI_45e6ee5b-b065-4896-84d8-97a7b6c31f37">4</ix:nonFraction>&#160;million as of December&#160;31, 2022 and December&#160;31, 2021, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reserves for General and Professional Liability Claims</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2a2495b477ff4993add304b17624a71f">&#160;&#160;&#160;&#160;As a general matter, providers of clinical testing services may be subject to lawsuits alleging negligence or other similar legal claims.  These suits could involve claims for substantial damages.  Any professional liability litigation could also have an adverse impact on the Company's client base and reputation.  The Company maintains various liability insurance coverages for, among other things, claims that could result from providing, or failing to provide, clinical testing services, including inaccurate testing results, and other exposures.  The Company's insurance coverage limits its maximum exposure on individual claims; however, the Company is essentially self-insured for a significant portion of these claims.  Reserves for such matters, including those associated with both asserted and incurred but not reported claims, are established on an undiscounted basis by considering actuarially determined losses based upon the Company's historical and projected loss experience.  Such reserves totaled $<ix:nonFraction unitRef="usd" contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231" decimals="-6" name="us-gaap:MalpracticeLossContingencyAccrualUndiscounted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjkvZnJhZzoxMjE0Y2U5MTA2NmE0ZjdhODFiMWQ1ZDU3MDliOTUxYy90ZXh0cmVnaW9uOjEyMTRjZTkxMDY2YTRmN2E4MWIxZDVkNTcwOWI5NTFjXzEwNDUx_e713e46d-5c3c-445c-8144-72af5b2bcc0a">169</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231" decimals="-6" name="us-gaap:MalpracticeLossContingencyAccrualUndiscounted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjkvZnJhZzoxMjE0Y2U5MTA2NmE0ZjdhODFiMWQ1ZDU3MDliOTUxYy90ZXh0cmVnaW9uOjEyMTRjZTkxMDY2YTRmN2E4MWIxZDVkNTcwOWI5NTFjXzEwNDU4_1ae24318-732c-46ab-a919-ea164c8d592e">159</ix:nonFraction> million as of December&#160;31, 2022 and December&#160;31, 2021, respectively.  Management believes that established reserves and present insurance coverage are sufficient to cover currently estimated exposures.</ix:continuation> </span></div><div><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_232"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90ZXh0cmVnaW9uOjc2ZjJiMDRmMjA1ZjRiZmFhNGMxNTQ1MTM3MTZmMTA0XzI0NTI_9c444a3b-cc79-4372-b09e-f84eae71f8d0" continuedAt="i8563b1b6c3e44e839856aa95fdff05f9" escape="true">BUSINESS SEGMENT INFORMATION</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i8563b1b6c3e44e839856aa95fdff05f9" continuedAt="i57801b5f7a06498fb8a77d2cbdf5df07"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company's DIS business is the only reportable segment based on the manner in which the Chief Executive Officer, who is the Company's chief operating decision maker ("CODM"), assesses performance and allocates resources across the organization.  The DIS business provides diagnostic information services to a broad range of customers, including patients, clinicians, hospitals, IDNs, health plans, employers, consumers, and ACOs.  The Company is the world's leading provider of diagnostic information services, which includes providing information and insights based on an industry-leading menu of routine, non-routine and advanced clinical testing and anatomic pathology testing, and other diagnostic information services.  The DIS business accounted for greater than <ix:nonFraction unitRef="number" contextRef="i73714e6410064c5eac002e398216cb2c_D20210101-20211231" decimals="2" name="dgx:PercentageofNetRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90ZXh0cmVnaW9uOjc2ZjJiMDRmMjA1ZjRiZmFhNGMxNTQ1MTM3MTZmMTA0XzgwOQ_993afb16-bb09-437b-93ae-7376bdae3b00"><ix:nonFraction unitRef="number" contextRef="id9ea9ce1f68f4cde8b57ba97522e9899_D20220101-20221231" decimals="2" name="dgx:PercentageofNetRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90ZXh0cmVnaW9uOjc2ZjJiMDRmMjA1ZjRiZmFhNGMxNTQ1MTM3MTZmMTA0XzgwOQ_b32b3c7f-34ab-463d-92cd-cd9117a85934"><ix:nonFraction unitRef="number" contextRef="ifbf8633ce3e245ac94d164f390ff90af_D20200101-20201231" decimals="2" name="dgx:PercentageofNetRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90ZXh0cmVnaW9uOjc2ZjJiMDRmMjA1ZjRiZmFhNGMxNTQ1MTM3MTZmMTA0XzgwOQ_dad166fc-e478-46e9-bac5-c0984ba1f529">95</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of net revenues in 2022, 2021 and 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other operating segments include the Company's DS businesses, which consist of its risk assessment services and healthcare information technology businesses.  The Company's DS businesses are the leading provider of risk assessment services for the life insurance industry and offer healthcare organizations and clinicians robust information technology solutions.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of December&#160;31, 2022, substantially all of the Company&#8217;s services were provided within the United States, and substantially all of the Company&#8217;s assets were located within the United States.</span></div></ix:continuation><div style="text-indent:29.25pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211; CONTINUED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions unless otherwise indicated)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><ix:continuation id="i57801b5f7a06498fb8a77d2cbdf5df07" continuedAt="i1a876143692a4989b85de00febe98e6d"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90ZXh0cmVnaW9uOjc2ZjJiMDRmMjA1ZjRiZmFhNGMxNTQ1MTM3MTZmMTA0XzI0NDQ_a6de8a3e-b563-4e0f-a535-9f2cadf401f3" continuedAt="i95507790802c48bba4cda9b8b74bce47" escape="true">The following table is a summary of segment information for the years ended December&#160;31, 2022, 2021 and 2020. Segment asset information is not presented since it is not used by the CODM at the operating segment level.  Operating earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income (loss) for the segment.  General corporate activities included in the table below are comprised of general management and administrative corporate expenses, amortization and impairment of intangibles assets and other operating income and expenses, net of certain general corporate activity costs that are allocated to the DIS and DS businesses.  The accounting policies of the segments are the same as those of the Company as set forth in Note 2.</ix:nonNumeric></span></div><ix:continuation id="i95507790802c48bba4cda9b8b74bce47" continuedAt="i3ed43445ad6f469594d0aea03343adfe"><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net revenues:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DIS business</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ad488f1dfb40baa83701a002b6d98f_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzItMS0xLTEtNzgyMTU_c50a6ed6-abef-4c32-ae3a-f32a21421a12">9,609</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i680bf76bfe8647638c33f242f0ef1980_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzItMy0xLTEtNzgyMTU_fc753f79-72ce-467c-8ac4-f38890e10ee3">10,494</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic662fc7ebbb744a885416e3447893d64_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzItNS0xLTEtNzgyMTU_c7dc33a7-00fb-4d39-a76e-77a2a5bf5d60">9,139</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other operating segments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i665754908631467fb2b6eca930750884_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzMtMS0xLTEtNzgyMTU_7bfeb489-a4c4-46ba-9e78-7222f6158a0f">274</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5336086104449ec9ccb20ce787e8fa9_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzMtMy0xLTEtNzgyMTU_02dffd3a-b04d-48de-9610-ac22441dd7df">294</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib687289786894660a55bf2477787ca9e_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzMtNS0xLTEtNzgyMTU_62081148-3585-4619-bcbc-d70b54f9cc9c">298</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzQtMS0xLTEtNzgyMTU_8804c162-f37e-44f5-9fdc-fb3b164c7301">9,883</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzQtMy0xLTEtNzgyMTU_feaf82d4-7394-4502-89d0-e06446ec6c6d">10,788</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzQtNS0xLTEtNzgyMTU_d733144b-9042-430f-b453-837521b8e7e4">9,437</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating earnings (loss):</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DIS business</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ad488f1dfb40baa83701a002b6d98f_D20220101-20221231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzctMS0xLTEtNzgyMTU_d5f08743-8917-4719-9b97-53f82d3c9d2e">1,704</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i680bf76bfe8647638c33f242f0ef1980_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzctMy0xLTEtNzgyMTU_2e931179-8f0b-4fe1-9879-b2ce0f7e2911">2,646</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic662fc7ebbb744a885416e3447893d64_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzctNS0xLTEtNzgyMTU_8ad539de-6199-4630-99dd-b5d7752513f5">2,201</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other operating segments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i665754908631467fb2b6eca930750884_D20220101-20221231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzgtMS0xLTEtNzgyMTU_88377d85-56e9-4d24-852b-667cca075947">20</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5336086104449ec9ccb20ce787e8fa9_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzgtMy0xLTEtNzgyMTU_3558e8e4-69b3-4ff7-89cc-0c8281f7c3d6">29</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib687289786894660a55bf2477787ca9e_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzgtNS0xLTEtNzgyMTU_7b2297d1-20dc-4ef0-906b-7c5ea980e3e2">39</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4aca837d0034736866ba4562ecf3fff_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzktMS0xLTEtNzgyMTU_e2dc3b37-f2ae-4bcb-b03d-da88188aff01">296</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ea9a777ccce400dadb97bbedd6fb6f4_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzktMy0xLTEtNzgyMTU_38b490fd-aad8-4dde-bc29-4b9dd1a24f02">294</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i810fd9c44b7c42e0aef7f96144b246dd_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzktNS0xLTEtNzgyMTU_9310c1e3-6dc3-49bd-9712-3b7cad98b17b">269</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating income</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzEwLTEtMS0xLTc4MjE1_563f1244-e36f-41fa-b5d4-1e908435b45c">1,428</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzEwLTMtMS0xLTc4MjE1_5595cd00-a45f-48f9-a80b-191ef7aab0a5">2,381</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzEwLTUtMS0xLTc4MjE1_934a7113-29d1-4a0e-ba5b-1881873e08e8">1,971</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-operating (expense) income, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzExLTEtMS0xLTc4MjE1_762e50aa-5e91-46b5-8d8c-f90c9c5d7bbf">193</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzExLTMtMS0xLTc4MjE1_829ce789-86b1-42a2-8508-509d2164afa0">218</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzExLTUtMS0xLTc4MjE1_1d9cb710-c878-4bdf-866d-3612f7d8b954">87</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before income taxes and equity in earnings of equity method investees</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzEyLTEtMS0xLTc4MjE1_f1d66541-6b7c-4a5d-8b95-44b567947104">1,235</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzEyLTMtMS0xLTc4MjE1_2a2c7185-f222-47c7-9fb3-c89596ba2d11">2,599</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzEyLTUtMS0xLTc4MjE1_2e662f83-1696-45b8-a545-054a5b07060c">1,884</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income tax expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzEzLTEtMS0xLTc4MjE1_d1fed1b9-9f1c-46a1-94f2-8f1fb0030980">264</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzEzLTMtMS0xLTc4MjE1_30c470a1-4439-4ba8-983f-275f9dbc402a">597</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzEzLTUtMS0xLTc4MjE1_5af5097d-f91b-4173-8fe9-b8576fe99f5b">460</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity in earnings of equity method investees, net of taxes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzE0LTEtMS0xLTc4MjE1_62327402-df7b-4e5b-b138-68dad07e93a1">44</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzE0LTMtMS0xLTc4MjE1_94d14ea2-60d9-49a9-9784-463a6182044b">78</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzE0LTUtMS0xLTc4MjE1_aeb36c21-d39a-408a-b66f-9677a2fd4ff4">75</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzE3LTEtMS0xLTc4MjE1_a14360b7-f42e-4bf5-9563-f371ae9455db">1,015</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzE3LTMtMS0xLTc4MjE1_31f29a98-a921-4f98-ab22-39f78bb9d52e">2,080</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzE3LTUtMS0xLTc4MjE1_ecf66436-59b1-48ab-af3b-9aed111909e6">1,499</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less: Net income attributable to noncontrolling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzE4LTEtMS0xLTc4MjE1_437619ce-8e8f-40a8-be51-8226bb3f9783">69</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzE4LTMtMS0xLTc4MjE1_42927960-86e6-496b-9d20-bc5ed521fb06">85</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzE4LTUtMS0xLTc4MjE1_fec8336a-9098-4e10-bfba-31a2dce5cf80">68</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to Quest Diagnostics</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzE5LTEtMS0xLTc4MjE1_266fbf2f-805c-4d79-bdcb-89d29da2625e">946</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzE5LTMtMS0xLTc4MjE1_da3aa183-af1b-4e86-bae8-96892871a86c">1,995</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzE5LTUtMS0xLTc4MjE1_cda909b7-3f63-47a0-ae2f-c91755d7ac18">1,431</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Depreciation and amortization expense for the years ended December&#160;31, 2022, 2021 and 2020 were as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DIS business</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ad488f1dfb40baa83701a002b6d98f_D20220101-20221231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphZjg5MTY2ZWY5ZWQ0YTIwYWY1ZTYzMDBkNDQ3NzVmNi90YWJsZXJhbmdlOmFmODkxNjZlZjllZDRhMjBhZjVlNjMwMGQ0NDc3NWY2XzItMS0xLTEtNzgyMTU_d9946e0b-72a0-40a9-9d11-f157c8937c7c">305</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i680bf76bfe8647638c33f242f0ef1980_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphZjg5MTY2ZWY5ZWQ0YTIwYWY1ZTYzMDBkNDQ3NzVmNi90YWJsZXJhbmdlOmFmODkxNjZlZjllZDRhMjBhZjVlNjMwMGQ0NDc3NWY2XzItMy0xLTEtNzgyMTU_0f220cae-30a2-441b-a4f1-89b6d5ee5421">294</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic662fc7ebbb744a885416e3447893d64_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphZjg5MTY2ZWY5ZWQ0YTIwYWY1ZTYzMDBkNDQ3NzVmNi90YWJsZXJhbmdlOmFmODkxNjZlZjllZDRhMjBhZjVlNjMwMGQ0NDc3NWY2XzItNS0xLTEtNzgyMTU_283f2865-98e2-43c9-a412-2084279c6c0e">249</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other operating segments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i665754908631467fb2b6eca930750884_D20220101-20221231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphZjg5MTY2ZWY5ZWQ0YTIwYWY1ZTYzMDBkNDQ3NzVmNi90YWJsZXJhbmdlOmFmODkxNjZlZjllZDRhMjBhZjVlNjMwMGQ0NDc3NWY2XzMtMS0xLTEtNzgyMTU_1046b58f-d43f-4e74-b37e-60a183ed5667">12</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5336086104449ec9ccb20ce787e8fa9_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphZjg5MTY2ZWY5ZWQ0YTIwYWY1ZTYzMDBkNDQ3NzVmNi90YWJsZXJhbmdlOmFmODkxNjZlZjllZDRhMjBhZjVlNjMwMGQ0NDc3NWY2XzMtMy0xLTEtNzgyMTU_f4f15808-3a5b-4821-a2d4-2e50f932e469">10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib687289786894660a55bf2477787ca9e_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphZjg5MTY2ZWY5ZWQ0YTIwYWY1ZTYzMDBkNDQ3NzVmNi90YWJsZXJhbmdlOmFmODkxNjZlZjllZDRhMjBhZjVlNjMwMGQ0NDc3NWY2XzMtNS0xLTEtNzgyMTU_7070a5f5-83cd-405a-aa70-753986cdbc85">8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4aca837d0034736866ba4562ecf3fff_D20220101-20221231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphZjg5MTY2ZWY5ZWQ0YTIwYWY1ZTYzMDBkNDQ3NzVmNi90YWJsZXJhbmdlOmFmODkxNjZlZjllZDRhMjBhZjVlNjMwMGQ0NDc3NWY2XzQtMS0xLTEtNzgyMTU_b3a7f871-438d-4905-a9a5-fa66f1661d96">120</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ea9a777ccce400dadb97bbedd6fb6f4_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphZjg5MTY2ZWY5ZWQ0YTIwYWY1ZTYzMDBkNDQ3NzVmNi90YWJsZXJhbmdlOmFmODkxNjZlZjllZDRhMjBhZjVlNjMwMGQ0NDc3NWY2XzQtMy0xLTEtNzgyMTU_480ff057-dd3f-4ea2-b047-695aabe0166e">104</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i810fd9c44b7c42e0aef7f96144b246dd_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphZjg5MTY2ZWY5ZWQ0YTIwYWY1ZTYzMDBkNDQ3NzVmNi90YWJsZXJhbmdlOmFmODkxNjZlZjllZDRhMjBhZjVlNjMwMGQ0NDc3NWY2XzQtNS0xLTEtNzgyMTU_52029da5-f4f9-40e1-b7d3-5c3330d48dee">104</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total depreciation and amortization</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphZjg5MTY2ZWY5ZWQ0YTIwYWY1ZTYzMDBkNDQ3NzVmNi90YWJsZXJhbmdlOmFmODkxNjZlZjllZDRhMjBhZjVlNjMwMGQ0NDc3NWY2XzgtMS0xLTEtNzgyMTU_74602c56-fa9a-4940-9156-5823b8c009ce">437</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphZjg5MTY2ZWY5ZWQ0YTIwYWY1ZTYzMDBkNDQ3NzVmNi90YWJsZXJhbmdlOmFmODkxNjZlZjllZDRhMjBhZjVlNjMwMGQ0NDc3NWY2XzgtMy0xLTEtNzgyMTU_d10b2551-10dd-40e9-a6d7-923a16880eba">408</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphZjg5MTY2ZWY5ZWQ0YTIwYWY1ZTYzMDBkNDQ3NzVmNi90YWJsZXJhbmdlOmFmODkxNjZlZjllZDRhMjBhZjVlNjMwMGQ0NDc3NWY2XzgtNS0xLTEtNzgyMTU_362e4cb8-a65e-4405-9353-638e339022d6">361</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie970e5750d9e4558bbcb5cb0dc8ea0a5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211; CONTINUED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions unless otherwise indicated)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div></div><ix:continuation id="i1a876143692a4989b85de00febe98e6d"><ix:continuation id="i3ed43445ad6f469594d0aea03343adfe"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Capital expenditures for the years ended December&#160;31, 2022, 2021 and 2020 were as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DIS business</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ad488f1dfb40baa83701a002b6d98f_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphYzM4NmU3ZmY2Y2E0OTdhODJjZmRlNjViMGUxMDc5Mi90YWJsZXJhbmdlOmFjMzg2ZTdmZjZjYTQ5N2E4MmNmZGU2NWIwZTEwNzkyXzItMS0xLTEtNzgyMTU_8df286e3-2860-4677-bb0f-0969e0a098ca">384</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i680bf76bfe8647638c33f242f0ef1980_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphYzM4NmU3ZmY2Y2E0OTdhODJjZmRlNjViMGUxMDc5Mi90YWJsZXJhbmdlOmFjMzg2ZTdmZjZjYTQ5N2E4MmNmZGU2NWIwZTEwNzkyXzItMy0xLTEtNzgyMTU_8ac441e5-138f-49d9-a37c-e7c36026aa21">379</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic662fc7ebbb744a885416e3447893d64_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphYzM4NmU3ZmY2Y2E0OTdhODJjZmRlNjViMGUxMDc5Mi90YWJsZXJhbmdlOmFjMzg2ZTdmZjZjYTQ5N2E4MmNmZGU2NWIwZTEwNzkyXzItNS0xLTEtNzgyMTU_2af35af9-6ba6-41ca-946c-7b311f86bec7">394</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other operating segments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i665754908631467fb2b6eca930750884_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphYzM4NmU3ZmY2Y2E0OTdhODJjZmRlNjViMGUxMDc5Mi90YWJsZXJhbmdlOmFjMzg2ZTdmZjZjYTQ5N2E4MmNmZGU2NWIwZTEwNzkyXzMtMS0xLTEtNzgyMTU_a5c42201-4580-4633-969b-fc859ef40953">19</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5336086104449ec9ccb20ce787e8fa9_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphYzM4NmU3ZmY2Y2E0OTdhODJjZmRlNjViMGUxMDc5Mi90YWJsZXJhbmdlOmFjMzg2ZTdmZjZjYTQ5N2E4MmNmZGU2NWIwZTEwNzkyXzMtMy0xLTEtNzgyMTU_a872220b-83e9-43f5-a0c0-cc82e380c578">14</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib687289786894660a55bf2477787ca9e_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphYzM4NmU3ZmY2Y2E0OTdhODJjZmRlNjViMGUxMDc5Mi90YWJsZXJhbmdlOmFjMzg2ZTdmZjZjYTQ5N2E4MmNmZGU2NWIwZTEwNzkyXzMtNS0xLTEtNzgyMTU_829cf28f-57e9-456f-bbb5-1ca82cda8469">15</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4aca837d0034736866ba4562ecf3fff_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphYzM4NmU3ZmY2Y2E0OTdhODJjZmRlNjViMGUxMDc5Mi90YWJsZXJhbmdlOmFjMzg2ZTdmZjZjYTQ5N2E4MmNmZGU2NWIwZTEwNzkyXzQtMS0xLTEtNzgyMTU_c845c8b0-54c6-4984-a39e-42c2bc8b703e">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ea9a777ccce400dadb97bbedd6fb6f4_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphYzM4NmU3ZmY2Y2E0OTdhODJjZmRlNjViMGUxMDc5Mi90YWJsZXJhbmdlOmFjMzg2ZTdmZjZjYTQ5N2E4MmNmZGU2NWIwZTEwNzkyXzQtMy0xLTEtNzgyMTU_ea60578b-713f-447c-ab43-b58e63418fce">10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i810fd9c44b7c42e0aef7f96144b246dd_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphYzM4NmU3ZmY2Y2E0OTdhODJjZmRlNjViMGUxMDc5Mi90YWJsZXJhbmdlOmFjMzg2ZTdmZjZjYTQ5N2E4MmNmZGU2NWIwZTEwNzkyXzQtNS0xLTEtNzgyMTU_3e417b6d-62c2-47f9-980b-786662f71888">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total capital expenditures</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphYzM4NmU3ZmY2Y2E0OTdhODJjZmRlNjViMGUxMDc5Mi90YWJsZXJhbmdlOmFjMzg2ZTdmZjZjYTQ5N2E4MmNmZGU2NWIwZTEwNzkyXzgtMS0xLTEtNzgyMTU_0ba6a1f7-9fdb-4af8-bb87-a1493e5423e7">404</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphYzM4NmU3ZmY2Y2E0OTdhODJjZmRlNjViMGUxMDc5Mi90YWJsZXJhbmdlOmFjMzg2ZTdmZjZjYTQ5N2E4MmNmZGU2NWIwZTEwNzkyXzgtMy0xLTEtNzgyMTU_ce5dcc6e-9761-426a-bf0e-8efe80b79be5">403</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphYzM4NmU3ZmY2Y2E0OTdhODJjZmRlNjViMGUxMDc5Mi90YWJsZXJhbmdlOmFjMzg2ZTdmZjZjYTQ5N2E4MmNmZGU2NWIwZTEwNzkyXzgtNS0xLTEtNzgyMTU_477beb04-69a6-4e36-8342-6c0a2bdf8346">418</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The approximate percentage of net revenues by major service for the years ended December&#160;31, 2022, 2021 and 2020 was as follows: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Routine clinical testing and other services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie440446d54134ae79c1720e049889ebd_D20220101-20221231" decimals="2" name="dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZToyYTI2ZDIzNGUzMzk0YWFiOTExNTkzYTc1NzQyNWZkOC90YWJsZXJhbmdlOjJhMjZkMjM0ZTMzOTRhYWI5MTE1OTNhNzU3NDI1ZmQ4XzItMS0xLTEtNzgyMTU_629010b6-6405-40bd-8792-81ea68acad37">44</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibd0d2af9458945a7ab9a6eb6470b7961_D20210101-20211231" decimals="2" name="dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZToyYTI2ZDIzNGUzMzk0YWFiOTExNTkzYTc1NzQyNWZkOC90YWJsZXJhbmdlOjJhMjZkMjM0ZTMzOTRhYWI5MTE1OTNhNzU3NDI1ZmQ4XzItMy0xLTEtNzgyMTU_8a32178c-5587-4af2-b662-550e5c81d035">40</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8b73fe03ff7442f4bd575024a507e151_D20200101-20201231" decimals="2" name="dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZToyYTI2ZDIzNGUzMzk0YWFiOTExNTkzYTc1NzQyNWZkOC90YWJsZXJhbmdlOjJhMjZkMjM0ZTMzOTRhYWI5MTE1OTNhNzU3NDI1ZmQ4XzItNS0xLTEtNzgyMTU_0609cbd4-790c-4efd-9603-6652fe008db3">41</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19 testing services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i641939e760e747a197a3088d7c7a54e4_D20220101-20221231" decimals="2" name="dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZToyYTI2ZDIzNGUzMzk0YWFiOTExNTkzYTc1NzQyNWZkOC90YWJsZXJhbmdlOjJhMjZkMjM0ZTMzOTRhYWI5MTE1OTNhNzU3NDI1ZmQ4XzMtMS0xLTEtNzgyMTU_fe308b9d-bf59-4c2b-bc36-ac6050fa61c7">15</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i89453a368ad04b51b87732034e68487c_D20210101-20211231" decimals="2" name="dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZToyYTI2ZDIzNGUzMzk0YWFiOTExNTkzYTc1NzQyNWZkOC90YWJsZXJhbmdlOjJhMjZkMjM0ZTMzOTRhYWI5MTE1OTNhNzU3NDI1ZmQ4XzMtMy0xLTEtNzgyMTU_8eec5573-ddf7-42ae-9d90-bb5b5b4189a4">26</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0c23351df28247d08a300337a2d833f5_D20200101-20201231" decimals="2" name="dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZToyYTI2ZDIzNGUzMzk0YWFiOTExNTkzYTc1NzQyNWZkOC90YWJsZXJhbmdlOjJhMjZkMjM0ZTMzOTRhYWI5MTE1OTNhNzU3NDI1ZmQ4XzMtNS0xLTEtNzgyMTU_0f61b2d7-aead-43f9-9ffb-cd22d007bbae">29</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gene-based and esoteric (including advanced diagnostics) testing services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3eee41bc2ea54b62a9ae3435b8b4aaa4_D20220101-20221231" decimals="2" name="dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZToyYTI2ZDIzNGUzMzk0YWFiOTExNTkzYTc1NzQyNWZkOC90YWJsZXJhbmdlOjJhMjZkMjM0ZTMzOTRhYWI5MTE1OTNhNzU3NDI1ZmQ4XzQtMS0xLTEtNzgyMTU_9ef7e19f-dcf5-404f-841b-b0fd45297620">32</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i57003099795448e795abfddd003aa4e2_D20210101-20211231" decimals="2" name="dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZToyYTI2ZDIzNGUzMzk0YWFiOTExNTkzYTc1NzQyNWZkOC90YWJsZXJhbmdlOjJhMjZkMjM0ZTMzOTRhYWI5MTE1OTNhNzU3NDI1ZmQ4XzQtMy0xLTEtNzgyMTU_d68d1a22-0f95-4387-88ce-dcae63a5545d">26</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7aec35972bb74cfb959afd84e8d0cffb_D20200101-20201231" decimals="2" name="dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZToyYTI2ZDIzNGUzMzk0YWFiOTExNTkzYTc1NzQyNWZkOC90YWJsZXJhbmdlOjJhMjZkMjM0ZTMzOTRhYWI5MTE1OTNhNzU3NDI1ZmQ4XzQtNS0xLTEtNzgyMTU_4e6cdf7c-310c-4373-8306-53602da50708">22</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anatomic pathology testing services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i726866d00c5c49f1bfa820096ee409a8_D20220101-20221231" decimals="2" name="dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZToyYTI2ZDIzNGUzMzk0YWFiOTExNTkzYTc1NzQyNWZkOC90YWJsZXJhbmdlOjJhMjZkMjM0ZTMzOTRhYWI5MTE1OTNhNzU3NDI1ZmQ4XzUtMS0xLTEtNzgyMTU_3858df94-d83e-4e8c-8073-10e6c3cd4f63">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i12a2b45922a846d39e944bbd98829c1c_D20210101-20211231" decimals="2" name="dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZToyYTI2ZDIzNGUzMzk0YWFiOTExNTkzYTc1NzQyNWZkOC90YWJsZXJhbmdlOjJhMjZkMjM0ZTMzOTRhYWI5MTE1OTNhNzU3NDI1ZmQ4XzUtMy0xLTEtNzgyMTU_e5a514b4-6055-4dd9-9a11-970838b93454">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i258b629fbed9441ea0961341779923f0_D20200101-20201231" decimals="2" name="dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZToyYTI2ZDIzNGUzMzk0YWFiOTExNTkzYTc1NzQyNWZkOC90YWJsZXJhbmdlOjJhMjZkMjM0ZTMzOTRhYWI5MTE1OTNhNzU3NDI1ZmQ4XzUtNS0xLTEtNzgyMTU_7808d0d3-e159-47dd-8846-7faa545750ae">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i862341280d314ae3b1668f3553ff24f3_D20220101-20221231" decimals="2" name="dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZToyYTI2ZDIzNGUzMzk0YWFiOTExNTkzYTc1NzQyNWZkOC90YWJsZXJhbmdlOjJhMjZkMjM0ZTMzOTRhYWI5MTE1OTNhNzU3NDI1ZmQ4XzYtMS0xLTEtNzgyMTU_96cbdad5-10f8-42c8-ae5a-51fefc921c82">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iba77f4a14ac549e4ad21be96084cdd06_D20210101-20211231" decimals="2" name="dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZToyYTI2ZDIzNGUzMzk0YWFiOTExNTkzYTc1NzQyNWZkOC90YWJsZXJhbmdlOjJhMjZkMjM0ZTMzOTRhYWI5MTE1OTNhNzU3NDI1ZmQ4XzYtMy0xLTEtNzgyMTU_cf5c5613-ea26-48d8-b0c3-513410643dde">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7d5572f43c3845b0af34754ce6041d2b_D20200101-20201231" decimals="2" name="dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZToyYTI2ZDIzNGUzMzk0YWFiOTExNTkzYTc1NzQyNWZkOC90YWJsZXJhbmdlOjJhMjZkMjM0ZTMzOTRhYWI5MTE1OTNhNzU3NDI1ZmQ4XzYtNS0xLTEtNzgyMTU_acabf938-e0e0-4e2f-a1ba-ef89fb982e55">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" decimals="INF" name="dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZToyYTI2ZDIzNGUzMzk0YWFiOTExNTkzYTc1NzQyNWZkOC90YWJsZXJhbmdlOjJhMjZkMjM0ZTMzOTRhYWI5MTE1OTNhNzU3NDI1ZmQ4XzctMS0xLTEtNzgyMTU_eb6aed98-6cb7-4db7-a35c-6eb8e87c34a8">100</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231" decimals="INF" name="dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZToyYTI2ZDIzNGUzMzk0YWFiOTExNTkzYTc1NzQyNWZkOC90YWJsZXJhbmdlOjJhMjZkMjM0ZTMzOTRhYWI5MTE1OTNhNzU3NDI1ZmQ4XzctMy0xLTEtNzgyMTU_0353dbaa-53e7-4a0e-aeb9-2a224814e5e9">100</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231" decimals="INF" name="dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZToyYTI2ZDIzNGUzMzk0YWFiOTExNTkzYTc1NzQyNWZkOC90YWJsZXJhbmdlOjJhMjZkMjM0ZTMzOTRhYWI5MTE1OTNhNzU3NDI1ZmQ4XzctNS0xLTEtNzgyMTU_610d1c30-6feb-4d65-ada2-7781b8ba7961">100</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="ie970e5750d9e4558bbcb5cb0dc8ea0a5_238"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">21.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzgvZnJhZzo3OGFlNWNlNzZhYzg0MzQ4OWI1YTg3NGY4YTUyZGE1Yy90ZXh0cmVnaW9uOjc4YWU1Y2U3NmFjODQzNDg5YjVhODc0ZjhhNTJkYTVjXzcyMQ_09eaf2b5-128e-4e84-9b36-025ebef47af1" continuedAt="ie9e427df7bf74338a19337c11b8871c0" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie9e427df7bf74338a19337c11b8871c0">&#160;&#160;&#160;&#160; During February 2023, the Company announced that it had entered into a definitive agreement to acquire select assets of the laboratory services business of New York-Presbyterian, which serves providers and patients in New York, as well as the Tri-State Area and beyond. The transaction, which is expected to close during the three months ended June 30, 2023, remains subject to customary closing conditions.</ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-45</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.32
<SEQUENCE>2
<FILENAME>dgx12312022ex432.htm
<DESCRIPTION>EX-4.32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ib4a6581e9c354070b1200f8c4f897182_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit 4.32</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DESCRIPTION OF COMMON STOCK REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">General</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The following is a description of the material terms of the common stock, par value $0.01 per share (&#8220;common stock&#8221;) of Quest Diagnostics Incorporated (the &#8220;Company&#8221;) included in our restated certificate of incorporation and our amended and restated by-laws and is only a summary. You should refer to our restated certificate of incorporation, as amended, and our amended and restated by-laws, which are incorporated by reference as exhibits to this Annual Report on Form 10-K, for more information.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Our authorized capital stock consists of 600,000,000 shares of common stock and 10,000,000 shares of series preferred stock, par value $1.00 per share (&#8220;preferred stock&#8221;).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Common Stock</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Holders of our common stock are entitled to receive, as, when and if declared by our board of directors, dividends and other distributions in cash, stock or property from our assets or funds legally available for those purposes, subject to any dividend preferences that may be attributable to preferred stock. Holders of common stock are entitled to one vote for each share held of record on all matters on which stockholders may vote. Holders of common stock are not entitled to cumulative voting for the election of directors. There are no preemptive, conversion, redemption or sinking fund provisions applicable to our common stock. All outstanding shares of our common stock are fully paid and non-assessable. In the event of our liquidation, dissolution or winding up, holders of common stock are entitled to share ratably in the assets available for distribution, subject to any prior rights of any holders of preferred stock then outstanding.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Our common stock is traded on the New York Stock Exchange under the symbol &#8220;DGX.&#8221;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Delaware Law and our Certificate of Incorporation and By-Law Provisions may have an Anti-Takeover Effect</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Provisions in our restated certificate of incorporation, amended and restated by-laws and Delaware law could make it harder for someone to acquire us through a tender offer, proxy contest or otherwise.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Section 203 of the Delaware General Corporation Law</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">We are governed by the provisions of Section 203 of the Delaware General Corporation Law, which provides that a person who owns (or within three years, did own) 15% or more of a company&#8217;s voting stock is an &#8220;interested stockholder.&#8221; Section 203 prohibits a public Delaware corporation from engaging in a business combination with an interested stockholder for a period commencing three years from the date in which the person became an interested stockholder unless&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">the board of directors approved the transaction that resulted in the stockholder becoming an interested stockholder&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMERICAS&#47;2023618634.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;1</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234141.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit 4.32</font></div></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owns at least 85% of the voting stock of the corporation (excluding shares owned by officers, directors, or certain employee stock purchase plans)&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">at or subsequent to the time the transaction is approved by the board of directors, there is an affirmative vote of at least 66.67% of the outstanding voting stock.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 203 could prohibit or delay mergers or other takeover attempts against us and accordingly, may discourage attempts to acquire us through tender offer, proxy contest or otherwise.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Potential Issuances of Preferred Stock</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Our restated certificate of incorporation permits us to issue, without prior permission from our stockholders, up to 10,000,000 shares of preferred stock.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Our board of directors may, without further action of the stockholders, issue undesignated preferred stock in one or more classes or series. Any undesignated preferred stock issued by us may rank prior to our common stock as to dividend rights, liquidation preference or both&#59; have full or limited voting rights&#59; and be convertible into shares of common stock or other securities.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The powers, designations, preferences and relative, participating, optional or other special rights, and qualifications, limitations or restrictions, including dividend rights, voting rights, conversion rights, terms of redemption and liquidation preferences, of the preferred stock of each series will be fixed or designated by our board of directors pursuant to a certificate of designation.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The preferred stock will, when issued, be fully paid and non-assessable.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Although our board of directors has no intention at the present time of doing so, it could issue a class or series of preferred stock that could, depending on the terms of such class or series, impede completion of a merger, tender offer or other takeover attempt that some, or a majority, of stockholders might believe to be in their best interests or in which stockholders might receive a premium for their shares over the then-current market price of such shares.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Special Meetings</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Special meetings of the stockholders may be called by our board of directors or by written request of stockholders owning not less than fifteen percent (15%) in the aggregate of our common stock and who have held that amount in a net long position continuously for at least one (1) year.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Stockholder Action by Written Consent</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Our restated certificate of incorporation permits stockholders to take action by written consent in lieu of a meeting of stockholders, with not less than the minimum number of votes that would be necessary to take such action if the matter was presented at a meeting of stockholders at which all shares entitled to vote thereon were present and voted.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMERICAS&#47;2023618634.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234141.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit 4.32</font></div></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Limitations on Liability and Indemnification of Officers and Directors</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Our restated certificate of incorporation limits the liability of directors to the fullest extent permitted by Delaware law. Delaware law provides that directors of a corporation will not be personally liable for monetary damages for breach of their fiduciary duties as directors, including, without limitation, directors serving on committees of our board of directors. Directors remain liable for&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">any breach of the director&#8217;s duty of loyalty to us or our stockholders&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">any act or omission not in good faith or which involves intentional misconduct or a knowing violation of the law&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">any violation of Section 174 of the Delaware General Corporation Law, which proscribes the payment of dividends and stock purchases or redemptions under certain circumstances&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">any transaction from which the directors derive an improper personal benefit.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This provision, however, has no effect on the availability of equitable remedies such as an injunction or rescission. Additionally, this provision will not limit liability under state or federal securities laws. Our restated certificate of incorporation and amended and restated by-laws provide that we shall indemnify our officers and directors to the fullest extent permitted by such law.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMERICAS&#47;2023618634.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;3</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234141.1</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>3
<FILENAME>dgx12312022ex105.htm
<DESCRIPTION>EX-10.5
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i8c847743db9349acb9e4de8c3afc600c_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit 10.5</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amendment No. 1 to<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Quest Diagnostics Supplemental Deferred Compensation Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"><br>(as amended and restated December 1, 2020)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Quest Diagnostics Supplemental Deferred Compensation Plan (Post &#8212; 2004), as amended and restated December 1, 2020, is hereby amended effective November 29, 2022, by amending and restating Section 3.2(a) to provide&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Employer Contributions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. An Employer shall credit an Employer Contribution to the Account maintained on behalf of each Participant who had Deferral Contributions credited to his Account for a payroll period&#59; provided, that such Employer Contributions shall only be credited on Compensation that is in excess of the Section 401(a)(17) Limit. Notwithstanding the preceding sentence, no Employer Contribution shall be credited to the Account of a Participant who is also a participant in the Quest Diagnostics Transferee Pension Plan for former Corning Incorporated employees.  Unless otherwise specifically provided in an Exhibit to this Plan adopted by the Administrator, the amount of the Employer Contribution to be credited on behalf of a Participant shall be equal to the applicable percentage that is specified from time to time in Section 3.2 of the Profit Sharing Plan of the Deferral Contributions made on behalf of the Participant.  Notwithstanding the foregoing, for any period that an Exhibit is in effect, the amount of the Employer Contribution to be credited on behalf of a Participant shall be equal to the amount provided in that Exhibit.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Quest Diagnostics Clinical Laboratories, Inc. has caused this instrument to be signed by its authorized officer.</font></div><div style="margin-bottom:12pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Quest Diagnostics Clinical Laboratories, Inc.</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#58;__&#47;s&#47; Cecilia K. McKenney</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cecilia K. McKenney, Senior Vice President, Chief Human Resources Officer</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">235201.1</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>4
<FILENAME>dgx12312022ex1010.htm
<DESCRIPTION>EX-10.10
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="iae83596bd4604df5a3a89dbe3819238c_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit 10.10</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMENDMENT NO. 1 TO<br>THE QUEST DIAGNOSTICS PROFIT SHARING PLAN<br>(as amended and restated effective August 15, 2021)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Quest Diagnostics Profit Sharing Plan, as presently maintained under an amendment and restatement effective August 15, 2021 (the &#8220;Plan&#8221;), is hereby amended in the following respects, effective as provided&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">Effective January 1, 2022, the first paragraph of the definition of &#8220;Deferral Compensation&#8221; in Article I (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) will be amended and restated to provide&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Deferral Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#8211; An Employee&#8217;s wages as defined in Code Section 3401(a) and all other payments of compensation to an Employee by an Employer (in the course of the Employer&#8217;s trade or business) for which the Employer is required to furnish the Employee a written statement under Code Sections 6041(d), 6051(a)(3) and 6052, excluding reimbursements or other expense allowances, service awards, RecognitionQuest awards, cash and non-cash fringe benefits (e.g., employee discounts), moving expenses, deferred compensation, SDCP sign on bonus, and welfare benefits (including but not limited to payments made by an insurance carrier under an Employer&#8217;s disability program), but including Employee Pre-Tax Contributions to this Plan, pre-tax employee contributions to a Code Section 125 plan and pre-tax employee contributions to purchase qualified transportation fringe benefits pursuant to Code Section 132(f)(4).&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">Effective January 1, 2020, Section 5.8(b) is amended and restated to provide&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;(b)&#160;&#160;&#160;&#160;The requirements of subsections (c) &#8211; (f) of this Section will apply for purposes of determining required minimum distributions and will take precedence over any inconsistent provisions of the Plan.  All distributions required under subsections (c) &#8211; (f) will be determined and made in accordance with the Regulations under Code Section 401(a)(9) and the minimum distribution incidental benefit requirements of Code Section 401(a)(9)(G).  Notwithstanding any provisions of subsections (c) &#8211; (f), a Participant or Beneficiary who would have been required to receive a distribution under this Plan and Code Section 401(a)(9) in 2020 paid after April 1, 2020 (or paid in 2021 for the 2020 calendar year for a Participant with a required beginning date of April 1, 2021) but for the enactment of Code Section 401(a)(9)(I) (the &#8220;2020 RMDs&#8221;), and who would have satisfied that requirement by receiving distributions that are equal to the 2020 RMDs, will not receive those distributions unless such Participant or Beneficiary elects to receive the 2020 RMD. A Participant or Beneficiary who receives a payment with respect to 2020 that otherwise would have qualified as a required minimum distribution, including payments made in 2020 before the implementation of the special rules for 2020 RMDs, may </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit 10.10</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be permitted to roll such distribution over to an eligible retirement plan (as defined in Section 5.9(b)(2)).&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">Effective January 1, 2020, Sections 5.8(f)(5) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Required beginning date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and 5.8(f)(6) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">5% owner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) are amended and restated to provide&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;(5)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Required beginning date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#8211; April 1 of the calendar year following the later of the calendar year in which the Participant attains age 72 (age 70&#189; if the Participant was born before July 1, 1949) or retires, except in the case of a Participant who is a 5% owner in which case it is April 1 of the calendar year following the calendar year in which he attains age 72 (age 70&#189; if the Participant was born before July 1, 1949).</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(6)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">5% owner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#8211; A Participant is treated as a 5% owner for purposes of this Section if he is a 5% owner as defined in Code Section 416 at any time during the Plan Year ending with or within the calendar year in which he attains age 72 (age 70&#189; if the Participant was born before July 1, 1949).  Once required distributions have begun to a 5% owner under this Section, they must continue to be distributed, even if he ceases to be a 5% owner in a subsequent year.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">Effective January 1, 2023, Section 5.12(b) is amended and restated to provide&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;(b)&#160;&#160;&#160;&#160;Notwithstanding any provision of this Plan to the contrary, to the extent that any optional form of benefit under this Plan permits a distribution prior to the Participant&#8217;s attaining age 59&#189;, retirement, death, Total and Permanent Disability or Severance from Service Date and prior to Plan termination, the optional form of benefit is not available with respect to benefits attributable to assets (including the post-transfer earnings thereon) and liabilities that are transferred, within the meaning of Code Section 414(l), to this Plan from a money purchase pension plan or a defined benefit plan qualified under Code Section 401(a) (other than the portion of those transferred assets and liabilities attributable to after-tax voluntary Employee contributions or to a direct or indirect rollover contribution, provided that portion was not subject to such distribution restrictions under the transferor plan or such distribution restrictions have been waived under this Plan).&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">Effective January 1, 2023, Section 6.3 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Hardship Withdrawals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is amended and restated to provide&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;(a)&#160;&#160;&#160;&#160;A Participant who is employed by an Employer or an Affiliate and who has attained age 59&#189; may elect to make a cash withdrawal from his vested Account in the form provided under Article V (or Appendix F, if applicable) at any time following the attainment of such age.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit 10.10</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;In addition to the withdrawals available under Section 6.2, but no more than once in any 12-month period, a Participant shall be allowed to withdraw all or part of the value of his Employee After-Tax Sub-Account (if any) for any reason.</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;(1)&#160;&#160;&#160;&#160;In accordance with Section 113 of the Setting Every Community Up for Retirement Enhancement Act (the &#8220;SECURE Act&#8221;), a Participant may, during the one-year period beginning on the date on which (x) the child of the Participant is born or (y) the legal adoption by the Participant of an eligible adoptee (as defined in Code Section 72(t)(2)(H)(iii)(II)) is finalized,  take a qualified birth or adoption distribution of up to $5,000 per child or eligible adoptee, as certified by the Participant.</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;A Participant who takes a birth or adoption distribution may elect to repay all or a portion of such distribution to the Plan (and those repayments will not be subject to the IRS contribution limits).  The Department shall accept a re-contribution of a birth or adoption distribution provided it reasonably concludes that such re-contribution is eligible for direct rollover treatment under Section 113 of the SECURE Act, and such re-contribution is made in accordance with guidance, rules or regulations established by the Internal Revenue Service.</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;This Section 6.3(c) shall apply notwithstanding anything in the Plan to the contrary, and is intended to be administered in accordance with, and subject to the limitations of the SECURE Act and any guidance, rules or regulations issued by the Internal Revenue Service.</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;Any withdrawal elected pursuant to this Section 6.3 shall be made through an Appropriate Request, and shall be paid as soon as administratively feasible following receipt of the Appropriate Request. Withdrawn amounts (other than a qualified birth or adoption distribution) may not be repaid to the Trust Fund.</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;Withdrawals shall be charged against the available sub-accounts within the Account in such order as the Department shall determine.  Within each sub-account, withdrawals shall be charged against the separate Investment Options under such procedures as the Department may determine.</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;Certain Merged Plans are subject to additional rules contained in an Appendix to the Plan.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)&#160;&#160;&#160;&#160;Notwithstanding the preceding, non-hardship withdrawals may not be made to the extent a disbursement restriction is in effect under Section 5.10(b).&#8221;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit 10.10</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">Effective April 6, 2020, the following new Section 6.7 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Coronavirus-Related Distributions and Loan Relief</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is inserted immediately following Section 6.6 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Qualified Reservist Distribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;6.7  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Coronavirus-Related Distributions and Loan Relief</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any provision of the Plan to the contrary, a Participant who is a &#8220;Qualified Individual&#8221; (as defined in paragraph (a)) may access amounts in the Participant&#8217;s Account through a coronavirus distribution (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">CV Distribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or loan (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">CV Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and may also be eligible for special loan repayment relief during the coronavirus pandemic, as described in this Section. This Section 6.7 is intended to be administered in accordance with, and subject to the limitations of Sections 2202(a) and (b) of the Coronavirus Aid, Relief, and Economic Security (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">CARES</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) Act, and any guidance, rules or regulations issued by the Internal Revenue Service.</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Qualified Individual</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  A Participant shall be a Qualified Individual for purposes of this Section 6.7 if the Participant certifies, in accordance with procedures established by the Department, that the Participant has experienced one of the following events&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;the Participant is diagnosed with the SARS-CoV-2 virus or with coronavirus disease 2019 (COVID-19) by a test approved by the Centers for Disease Control and Prevention (including a test authorized under the Federal Food, Drug, and Cosmetic Act)&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;the Participant&#8217;s spouse or dependent is diagnosed with such virus or disease&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;the Participant experiences adverse financial consequences stemming from the virus or disease as a result of the closing or reduction of hours of a business owned or operated by the Participant, the Participant&#8217;s spouse or a member of the Participant&#8217;s family, or the Participant, the Participant&#8217;s spouse or a member of the Participant&#8217;s household (A) being quarantined, furloughed, laid off, having reduced work hours, (B) being unable to work due to lack of child care, or (C) having a reduction in pay or having a job offer rescinded or start date for a job delayed.</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">CV Distributions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  A Participant who is a Qualified Individual may, for the period beginning April 6, 2020 and before December 31, 2020 (or such other end date as specified in guidance, rules or regulations issued by the Internal Revenue Service), take a CV Distribution from the Participant&#8217;s vested Account (other than from the Participant&#8217;s QJSA Portion) with such sources in the Participant&#8217;s Account being depleted in accordance with procedures established by the Department.  A Participant may take as many CV Distributions as the Participant chooses under the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit 10.10</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Plan&#59; however, the aggregate amount of a Participant&#8217;s CV Distributions under the Plan and any other eligible retirement plan under which the Participant participates may not exceed $100,000, as certified by the Participant. </font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A CV Distribution shall not be subject to the 10% early distribution penalty under Code Section 72(t) or 20% mandatory income tax withholding.  In addition, a Participant who takes a CV Distribution and who is has not incurred a severance from employment may elect to repay all or a portion of such distribution to the Plan within three years of the CV Distribution (and those repayments will not be subject to the IRS contribution limits), and the Plan shall accept a re-contribution of a CV Distribution as described herein provided that such re-contribution is eligible for direct rollover treatment under Section 2202(a)(3) of the CARES Act, and such re-contribution is made in accordance with and guidance, rules or regulations issued by the Internal Revenue Service Notice.</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">CV Loans and Suspension of Loan Repayments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. For a Qualified Individual, the maximum loan amount under Section 6.1 and the provisions of the Loan Policy is increased for loans taken from May 5, 2020 until September 22, 2020 (or such other end date as specified in guidance, rules or regulations issued by the Internal Revenue Service) to the lesser of (1) $100,000 reduced by the excess (if any) of the highest outstanding balance of loans during the one year period ending on the day before the loan is made over the outstanding balance of loans from the Plan on the date the loan is made, or (2) 100% of the Participant&#8217;s vested Account under the Plan.  Loan repayments for any such new loan subject to the increased maximum loan amount described in the previous sentence will be automatically suspended until January 1, 2021. </font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Qualified Individual may suspend until January 1, 2021, loan repayments for any other loan due between May 15, 2020 through December 31, 2020.  When loan payments recommence as soon as administratively feasible after January 1, 2021, they will be reamortized to reflect any suspended payments, adjusted for interest, and the term of the loan will be extended by the suspension period, notwithstanding anything in Section 6.1(d) or the Loan Policy to the contrary.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">Effective November 1, 2022, the chart in Appendix G, A. is amended and restated to provide&#58;</font></div><div style="padding-left:62.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.291%"><tr><td style="width:1.0%"></td><td style="width:60.925%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.875%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d0cece;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:11.75pt;padding-right:11.75pt;text-align:center;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">8. Name of Merged Plan</font></div></td><td colspan="3" style="background-color:#d0cece;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Merger Date</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">med fusion 401(k) Plan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">January 18, 2018</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">MedXM 401(k) Plan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 1, 2019</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Cleveland Heartlab 401(k) Plan</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">May 2, 2019</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit 10.10</font></div></div><div style="padding-left:62.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.291%"><tr><td style="width:1.0%"></td><td style="width:60.925%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.875%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ReproSource, Inc. 401(k) Retirement Plan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">July 25, 2019</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PhenoPath Laboratories 401(k) Plan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">August 1, 2019</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Pack Health 401K</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">November 1, 2022</font></td></tr></table></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">Effective November 1, 2022, the following new Appendix G., B.(a)(6) is inserted immediately following Appendix G., B.(a)(5)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;(6)&#160;&#160;&#160;&#160;Pack Health 401K.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">Effective November 1, 2022, the following new Appendix G., C. (g) is inserted immediately following Appendix G., C.(f)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;(g)&#160;&#160;&#160;&#160;Pack Health 401K</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;A Participant who was a Pack Health 401K participant and who has retired or otherwise terminated employment may make a partial withdrawal of all or any portion of his Pack Health 401K sub-accounts that were transferred to this Plan upon the merger of the Pack Health 401K into this Plan.  Withdrawn amounts may not be repaid to the Trust Fund.  Withdrawals shall be charged against the available sub-accounts within the Account in such order as the Benefits Administration Committee may determine.  Within each sub-account, withdrawals shall be charged against the separate Investment Options under such procedures as the Benefits Administration Committee may determine.&#8221;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As evidence of its adoption of this Amendment, Quest Diagnostics Clinical Laboratories, Inc. has caused this Amendment to be executed December 5, 2022.</font></div><div style="margin-bottom:12pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Quest Diagnostics Clinical Laboratories, Inc.</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Cecilia K. McKenney&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br>Cecilia K. McKenney</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Senior Vice President, Chief Human Resources Officer</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20
<SEQUENCE>5
<FILENAME>dgx12312022ex1020.htm
<DESCRIPTION>EX-10.20
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i464991547ff546b8a634a8db8be553c9_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 10.20</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AIRCRAFT TIME SHARING AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dated as of the 16th day of February, 2023,</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">between</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUEST DIAGNOSTICS CLINICAL LABORATORIES, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as Time Share Lessor,</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JAMES E. DAVIS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as Time Share Lessee,</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">concerning the aircraft listed in Exhibit B hereto</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">*     *     *</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INSTRUCTIONS FOR COMPLIANCE WITH </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#34;TRUTH IN LEASING&#34; REQUIREMENTS UNDER FAR &#167; 91.23</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Within 24 hours after execution of this Agreement&#58; </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">mail a copy of the executed document to the </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">following address via certified mail, return receipt requested&#58;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Federal Aviation Administration</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Aircraft Registration Branch</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ATTN&#58; Technical Section</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">P.O. Box 25724</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Oklahoma City, Oklahoma 73125</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">At least 48 hours prior to the first flight to be conducted under this Agreement&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provide notice, using the FSDO Notification Letter in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the departure airport and proposed time of departure of the</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">first flight, by facsimile, to the Flight Standards</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">District Office located nearest the departure airport.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Carry a copy of this Agreement in the aircraft at all times.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">*     *     *     </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div id="i464991547ff546b8a634a8db8be553c9_4"></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AIRCRAFT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TIME SHARING AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (the &#34;Agreement&#34;) is made and effective as of the 16th day of February, 2023, (the &#34;Effective Date&#34;), by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUEST DIAGNOSTICS CLINICAL LABORATORIES, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, a Delaware corporation (&#34;Time Share Lessor&#34;), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JAMES E. DAVIS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(&#34;Time Share Lessee&#34;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">W I T N E S S E T H &#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Time Share Lessee is an employee of an affiliate of Time Share Lessor who is required to use the Aircraft for business and personal travel whenever possible&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Time Share Lessee desires to lease the Aircraft, with a flight crew, on a non-exclusive basis, from Time Share Lessor on a time sharing basis as defined in Section 91.501(c)(1) of the FAR&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Time Share Lessor is willing to lease the Aircraft, with a flight crew, on a non-exclusive basis, to Time Share Lessee on a time sharing basis&#59; and </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, during the Term of this Agreement, the Aircraft will be subject to use by Time Share Lessor and may be subject to use by one or more other third-parties.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in consideration of the mutual promises herein contained and other good and valid consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Definitions. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The following terms shall have the following meanings for all purposes of this Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#34;Aircraft&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means the Airframe, the Engines, the Parts, and the Aircraft Documents.  The Engines shall be deemed part of the &#34;Aircraft&#34; whether or not from time to time attached to the Airframe or removed from the Airframe.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#34;Aircraft Documents&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means all flight records, maintenance records, historical records, modification records, overhaul records, manuals, logbooks, authorizations, drawings and data relating to the Airframe, any Engine, or any Part, or that are required by Applicable Law to be created or maintained with respect to the maintenance and&#47;or operation of the Aircraft.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#34;Airframe&#34; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means the aircraft listed in Exhibit B hereto, together with any and all Parts (including, but not limited to, landing gear and auxiliary power units but excluding Engines or engines) so long as such Parts shall be either incorporated or installed in or attached to the Airframe.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#34;Applicable Law&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means, without limitation, all applicable laws, treaties, international agreements, decisions and orders of any court, arbitration or governmental agency or authority and rules, regulations, orders, directives, licenses and permits of any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">governmental body, instrumentality, agency or authority, including, without limitation, the FAR and 49 U.S.C. &#167; 41101, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">et seq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">., as amended.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#34;Business Day&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means any day of the year in which banks are not authorized or required to close in the State of New Jersey.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#34;DOT&#34; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means the United States Department of Transportation or any successor agency.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#34;Engines&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means any engine which may be, from time to time, attached to an aircraft listed in Exhibit B hereto.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#34;FAA&#34; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means the Federal Aviation Administration or any successor agency.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#34;FAR&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means collectively the Aeronautics Regulations of the FAA and the DOT, as codified at Title 14, Parts 1 to 399 of the United States Code of Federal Regulations.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#34;Flight Hour&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means one (1) hour of use of the Aircraft in flight operations, as recorded on the Aircraft hour meter and measured in one-tenth (1&#47;10th) of an hour increments.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#34;Operating Base&#34; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means Reading Regional Airport (RDG), in the City of Reading, State of Pennsylvania.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div id="i464991547ff546b8a634a8db8be553c9_7"></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#34;Operational Control&#34; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has the same meaning given the term in Section 1.1 of the FAR.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#34;Parts&#34; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means all appliances, components, parts, instruments, appurtenances, accessories, furnishings or other equipment of whatever nature (other than complete Engines or engines) which may from time to time be incorporated or installed in or attached to the Airframe or any Engine and includes replacement parts.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#34;Pilot in Command&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the same meaning given the term in Section 1.1 of the FAR.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#34;Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#34; means</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all taxes of every kind (excluding any tax measured by or assessed against a taxpayer's income, including, without limitation, any income tax, gross income tax, net income tax, or capital gains tax, and any tax measured by or assessed against the Aircraft&#8217;s value, including, without limitation, any personal property or ad valorem tax) assessed or levied by any federal, state, county, local, airport, district, foreign, or other governmental authority, including, without limitation, sales taxes, use taxes, retailer taxes, federal air transportation excise taxes, federal aviation fuel excise taxes, and other similar duties, fees, and excise taxes.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#34;Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#34; means the entire period from the Effective Date to the date this Agreement is terminated pursuant to Section 3.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Agreement to Lease.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Time Share Lessor agrees to lease the Aircraft to Time Share Lessee from time to time on an &#34;as needed and as available&#34; basis, and to provide a fully qualified flight crew for all Time Share Lessee's flights, in accordance with the terms and conditions </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of this Agreement.  Nothing contained herein shall obligate or entitle Time Share Lessee to any minimum usage of the Aircraft.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Term.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Initial Term.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The initial term of this Agreement shall commence on the Effective Date and continue for a period of one (1) year.  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Renewal.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">At the end of the initial one (1) year term or any subsequent one (1) year term, this Agreement shall automatically be renewed for an additional one (1) year term.  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Termination.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each party shall have the right to terminate this Agreement at any time with or without cause on thirty (30) days prior written notice to the other party. </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Termination of Employment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Notwithstanding anything to the contrary herein, this Agreement shall automatically terminate, if not sooner terminated, concurrent with the last date of employment of Time Share Lessee with Time Share Lessor or an affiliate thereof. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Applicable Regulations.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The parties hereto intend that this Agreement shall constitute, and this Agreement shall be interpreted as, a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Time Sharing Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> as defined in Section 91.501(c)(1) of the FAR.  The parties agree that for all flights under this Agreement, the Aircraft shall be operated under the pertinent provisions of Subpart F of Part 91 of the FAR.  If any provision of this Agreement is determined to be inconsistent with any of the requirements of the provisions of Subpart F of Part 91 of the FAR, such provision shall be deemed amended in any respect necessary to bring it into compliance with such requirements.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Non-Exclusivity.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Time Share Lessee acknowledges that the Aircraft is leased to Time Share Lessee hereunder on a non-exclusive basis, and that the Aircraft will also be subject to use by Time Share Lessor, and may also be subject to non-exclusive leases and lease to others during the Term.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Flight Charges.  </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;6.1 &#160;&#160;&#160;&#160;Time Share Lessee shall not be liable for any costs incurred by Time Share Lessor in any calendar year in connection with the use of the Aircraft by Time Share Lessee for the personal purposes until such time as the sum (the &#8220;Benefit Costs&#8221;) of&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:24.69pt">the aggregate incremental costs incurred by Time Share Lessor for all such flights in such calendar year (calculated on the same basis used by Time Share Lessor to determine the aggregate incremental cost for purposes of disclosure in Time Share Lessor&#8217;s proxy statement issued in connection with its annual meeting of stockholders (the &#8220;Proxy Calculation&#8221;)) of personal aircraft use&#59; plus </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:8pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:21.36pt">the expense to Time Share Lessor (or any affiliate thereof) of the personal use by Time Share Lessee of a company-provided vehicle in such calendar year&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;in the aggregate surpasses One Hundred Seventy-Five Thousand U.S. Dollars ($175,000.00) (the &#8220;Time Share Threshold&#8221;).    </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;6.2&#160;&#160;&#160;&#160;After the Benefit Costs incurred by Time Share Lessor in any calendar year surpasses the Time Share Threshold, Time Share Lessee shall pay to Time Share Lessor, for each personal use flight (or portion thereof) conducted under this Agreement during the remainder of such calendar year, an amount equal to the lesser of (i) Time Share Lessor&#8217;s aggregate incremental costs for such flight, calculated on the same basis as the Proxy Calculation, or (ii) the maximum amount of expense reimbursement permitted in accordance with Section 91.501(d) of the FAR, which expenses include and are limited to&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.2.1&#160;&#160;&#160;&#160;fuel, oil, lubricants, and other additives&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.2.2&#160;&#160;&#160;&#160;travel expenses of the crew, including food, lodging and ground transportation&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.2.3&#160;&#160;&#160;&#160;hangar and tie down costs away from the Aircraft's Operating Base&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.2.4&#160;&#160;&#160;&#160;insurance obtained for the specific flight&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;6.2.5&#160;&#160;&#160;&#160;landing fees, airport taxes and similar assessments&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.2.6&#160;&#160;&#160;&#160;customs, foreign permit, and similar fees directly related to the flight&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.2.7&#160;&#160;&#160;&#160;in-flight food and beverages&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.2.8&#160;&#160;&#160;&#160;passenger ground transportation&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.2.9&#160;&#160;&#160;&#160;flight planning and weather contract services&#59; and</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.2.10&#160;&#160;&#160;&#160;an additional charge equal to 100% of the expenses listed in Section 6.2.1.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Invoices and Payment.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Time Share Lessor will initially pay all expenses related to the operation of the Aircraft when and as such expenses are incurred, provided that within fifteen (15) days after the last day of any calendar month during which any flight for the account of Time Share Lessee has been conducted, Time Share Lessor shall provide an invoice to Time Share Lessee for an amount determined in accordance with Section 6 above&#59; provided that with regard to expenses that remain indeterminable as of the date of any invoice, such expenses shall be included in the next regularly-provided invoice after such expenses have been determined.  Time Share Lessee shall remit the full amount of any such invoice, together with any applicable Taxes under Section 8, to Time Share Lessor promptly within fifteen (15) days following Time Share Lessee&#8217;s receipt of the invoice date.   </font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Taxes. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Time Share Lessee shall be responsible for, shall indemnify and hold harmless Time Share Lessor against, any Taxes which may be assessed or levied as a result of the lease of the Aircraft to Time Share Lessee, or the use of the Aircraft by Time Share Lessee. Without limiting the generality of the foregoing, Time Share Lessee and Time Share Lessor specifically acknowledge that all of Time Share Lessee's Time Share Flights will be subject to commercial air transportation excise taxes pursuant to Section 4261 of the Internal Revenue Code, regardless of whether any such flight is considered &#34;noncommercial&#34; under the FAR.  Time Share Lessee shall remit to Time Share Lessor all such Taxes together with each payment made pursuant to Section 7. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Scheduling Flights.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Time Share Lessee shall submit requests for flight time and proposed flight schedules to the Time Share Lessor as far in advance of any given flight as reasonably possible.  Time Share Lessee shall provide at least the following information for each proposed flight as far in advance as reasonably possible prior to scheduled departure&#58; departure airport&#59; destination airport&#59; date and time of departure&#59; the names of all passengers&#59; the nature and extent of luggage and&#47;or cargo to be carried&#59; the date and time of return flight, if any&#59; and any other information concerning the proposed flight that may be pertinent or required by Time Share Lessor or Time Share Lessor's flight crew.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Aircraft Maintenance.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Time Share Lessor shall be solely responsible for maintenance, preventive maintenance and required or otherwise necessary inspections of the Aircraft, and shall take such requirements into account in scheduling the Aircraft.  No period of maintenance, preventative maintenance, or inspection shall be delayed or postponed for the purpose of scheduling the Aircraft, unless said maintenance or inspection can be safely conducted at a later time in compliance with all Applicable Laws and regulations, and within the sound discretion of the Pilot in Command. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Flight Crews.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Time Share Lessor shall provide, at its sole cost, to Time Share Lessee a qualified flight crew for each flight conducted in accordance with this Agreement.  The members of the flight crew may be either employees or independent contractors of Time Share Lessor.  In either event, the flight crew shall be and remain under the exclusive command and control of Time Share Lessor in all phases of all flights conducted hereunder.  </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;OPERATIONAL CONTROL.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> THE PARTIES EXPRESSLY AGREE THAT TIME SHARE LESSOR SHALL HAVE AND MAINTAIN SOLE OPERATIONAL CONTROL OF THE AIRCRAFT AND EXCLUSIVE POSSESSION, COMMAND AND CONTROL OF THE AIRCRAFT FOR ALL FLIGHTS OPERATED UNDER THIS AGREEMENT, AND THAT THE INTENT OF THE PARTIES IS THAT THIS AGREEMENT CONSTITUTE A &#34;TIME SHARING AGREEMENT&#34; AS SUCH TERM IS DEFINED IN SECTION 91.501(C)(1) OF THE FAR.  TIME SHARE LESSOR SHALL EXERCISE EXCLUSIVE AUTHORITY OVER INITIATING, CONDUCTING, OR TERMINATING ANY FLIGHT CONDUCTED ON BEHALF OF TIME SHARE LESSEE PURSUANT TO THIS AGREEMENT. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Authority of Pilot In Command.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding that Time Share Lessor shall have Operational Control of the Aircraft during any flight conducted pursuant to this Agreement, Time Share Lessor and Time Share Lessee expressly agree that the Pilot in Command, in his or her sole discretion, may terminate any flight, refuse to commence any flight, or take any other flight-related action which in the judgment of the Pilot in Command is necessary to ensure the safety of the Aircraft, the flight crew, the passengers, and persons and property on the ground. The Pilot in Command shall have final and complete authority to postpone or cancel any flight for any reason or condition that in his or her judgment would compromise the safety of the flight. No such action of the Pilot in Command shall create or support any liability of Time Share Lessor to Time Share Lessee for loss, injury, damage or delay. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Passengers and Baggage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   Time Share Lessee may carry on the Aircraft on all flights under this Agreement such passengers and baggage&#47;cargo as Time Share Lessee in its sole but reasonable discretion shall determine&#59; provided, however, that the passengers to be carried on such flights shall be limited to those permitted under the pertinent provisions of Part 91 of the FAR, and that the number of such passengers shall in no event exceed the number of passenger seats legally available in the Aircraft and the total load, including fuel and oil in such quantities as the Pilot in Command shall determine to be required, shall not exceed the maximum allowable load for the Aircraft.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Prohibited Items</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   Time Share Lessee shall not cause or permit to be carried on board the Aircraft, and shall not cause or permit any passenger to carry on board the Aircraft, any contraband, prohibited dangerous goods, or prohibited controlled substances on the Aircraft at any time.  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Force Majeure. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Time Share Lessor shall not be liable for delay or failure to furnish the Aircraft and&#47;or flight crew pursuant to this Agreement when such failure is caused by government regulation or authority, mechanical difficulty, war, civil commotion, strikes or labor disputes, weather conditions, acts of God or other unforeseen or unanticipated circumstances.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Time Share Lessee Representations and Warranties.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Time Share Lessee represents and warrants that&#58;</font></div><div><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;17.1&#160;&#160;&#160;&#160;Time Share Lessee will use the Aircraft solely for and on account of his own personal use, and will not use the Aircraft for the purpose of providing transportation of passengers or cargo for compensation or hire.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;17.2&#160;&#160;&#160;&#160;Time Share Lessee shall refrain from incurring any mechanic's or other lien in connection with inspection, preventative maintenance, maintenance or storage of the Aircraft, whether permissible or impermissible under this Agreement, nor shall there be any attempt by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Time Share Lessee to convey, mortgage, assign, lease, sublease, or any way alienate the Aircraft or create any kind of lien or security interest involving the Aircraft or do anything or take any action that might mature into such a lien.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;17.3&#160;&#160;&#160;&#160;During the Term of this Agreement, Time Share Lessee will abide by and conform to all Applicable Laws, governmental and airport orders, rules and regulations, as shall from time to time be in effect relating in any way to the use of the Aircraft by a time sharing Time Share Lessee.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;No Assignments  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Neither this Agreement nor any party's interest herein shall be assignable to any other party whatsoever without the consent of the parties hereto. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Modification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement may not be modified, altered, or amended except by written agreement executed by both parties.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Entire Agreement. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> This Agreement constitutes the entire agreement of the parties as of the Effective Date and supersedes all prior or independent, oral or written agreements, understandings, statements, representations, commitments, promises, and warranties made with respect to the subject matter of this Agreement.  </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Prohibited or Unenforceable Provisions. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Any provision of this Agreement which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibitions or unenforceability in any jurisdiction.  To the extent permitted by Applicable Law, each of Time Share Lessor and Time Share Lessee hereby waives any provision of Applicable Law which renders any provision hereof prohibited or unenforceable in any respect.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Governing Law.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  This Agreement has been negotiated and delivered in the State of New Jersey and shall in all respects be governed by, and construed in accordance with, the laws of the State of New Jersey, including all matters of construction, validity and performance, without giving effect to its conflict of laws provisions.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DISCLAIMER.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">THE AIRCRAFT IS BEING LEASED BY THE TIME SHARE LESSOR TO THE TIME SHARE LESSEE HEREUNDER ON A COMPLETELY &#34;AS IS, WHERE IS,&#34; BASIS, WHICH IS ACKNOWLEDGED AND AGREED TO BY THE TIME SHARE LESSEE.  THE WARRANTIES AND REPRESENTATIONS SET FORTH IN THIS AGREEMENT ARE EXCLUSIVE AND IN LIEU OF ALL OTHER REPRESENTATIONS OR WARRANTIES WHATSOEVER, EXPRESS OR IMPLIED, AND TIME SHARE LESSOR HAS NOT MADE AND SHALL NOT BE CONSIDERED OR DEEMED TO HAVE MADE (WHETHER BY VIRTUE OF HAVING LEASED THE AIRCRAFT UNDER THIS AGREEMENT, OR HAVING ACQUIRED THE AIRCRAFT, OR HAVING DONE OR FAILED TO DO ANY ACT, OR HAVING ACQUIRED OR FAILED TO ACQUIRE ANY STATUS UNDER OR IN RELATION TO THIS AGREEMENT OR OTHERWISE) ANY OTHER REPRESENTATION OR WARRANTY WHATSOEVER, EXPRESS OR IMPLIED, WITH RESPECT TO THE AIRCRAFT OR TO ANY PART THEREOF, AND SPECIFICALLY, WITHOUT LIMITATION, IN THIS RESPECT TIME SHARE LESSOR DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES CONCERNING THE TITLE, AIRWORTHINESS, VALUE, CONDITION, DESIGN, MERCHANTABILITY, COMPLIANCE WITH SPECIFICATIONS, CONSTRUCTION AND CONDITION OF THE AIRCRAFT, OR FITNESS FOR A PARTICULAR USE OF THE AIRCRAFT AND AS TO THE ABSENCE OF LATENT AND OTHER DEFECTS, WHETHER OR NOT DISCOVERABLE, AND AS TO THE ABSENCE OF ANY INFRINGEMENT OR THE LIKE, HEREUNDER OF ANY PATENT, TRADEMARK OR COPYRIGHT, AND AS TO THE ABSENCE OF OBLIGATIONS BASED ON STRICT LIABILITY IN TORT, OR AS TO THE QUALITY OF THE MATERIAL OR WORKMANSHIP OF THE AIRCRAFT OR ANY PART THEREOF OR ANY OTHER REPRESENTATION OR WARRANTY WHATSOEVER, EXPRESS OR IMPLIED (INCLUDING ANY IMPLIED WARRANTY ARISING FROM A COURSE OF PERFORMANCE OR </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">DEALING OR USAGE OF TRADE), WITH RESPECT TO THE AIRCRAFT OR ANY PART THEREOF.  TIME SHARE LESSEE HEREBY WAIVES, RELEASES, DISCLAIMS AND RENOUNCES ALL EXPECTATION OF OR RELIANCE UPON ANY SUCH AND OTHER WARRANTIES, OBLIGATIONS AND LIABILITIES OF TIME SHARE LESSOR AND RIGHTS, CLAIMS AND REMEDIES OF  TIME SHARE LESSEE AGAINST TIME SHARE LESSOR, EXPRESS OR IMPLIED, ARISING BY LAW OR OTHERWISE, INCLUDING BUT NOT LIMITED TO (I) ANY IMPLIED WARRANTY OF MERCHANTABILITY OF FITNESS FOR ANY PARTICULAR USE, (II) ANY IMPLIED WARRANTY ARISING FROM COURSE OF PERFORMANCE, COURSE OF DEALING OR USAGE OF TRADE, (III) ANY OBLIGATION, LIABILITY, RIGHT, CLAIM OR REMEDY IN TORT, WHETHER OR NOT ARISING FROM THE NEGLIGENCE OF TIME SHARE LESSOR, ACTUAL OR IMPUTED, AND (IV) ANY OBLIGATION, LIABILITY, RIGHT, CLAIM OR REMEDY FOR LOSS OF OR DAMAGE TO THE AIRCRAFT, FOR LOSS OF USE, REVENUE OR PROFIT WITH RESPECT TO THE AIRCRAFT, OR FOR ANY OTHER DIRECT, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES.  </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;COUNTERPARTS. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> This Agreement may be executed by the parties hereto in two (2) or more separate counterparts, each and all of which when so executed and delivered shall be an original, and all of which shall together constitute but one and the same instrument.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;TRUTH IN LEASING.  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">TIME SHARE LESSOR HEREBY CERTIFIES THAT, DURING THE TWELVE (12) MONTH PERIOD PRECEDING THE DATE OF THIS AGREEMENT, THE AIRCRAFT HAS BEEN INSPECTED AND MAINTAINED IN ACCORDANCE WITH THE PROVISIONS OF FAR 91.409.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">THE PARTIES HERETO CERTIFY THAT DURING THE TERM OF THIS AGREEMENT AND FOR OPERATIONS CONDUCTED HEREUNDER, THE AIRCRAFT WILL BE MAINTAINED AND INSPECTED IN ACCORDANCE WITH THE PROVISIONS OF FAR 91.409.</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">TIME SHARE LESSOR ACKNOWLEDGES THAT WHEN IT OPERATES THE AIRCRAFT ON BEHALF OF TIME SHARE LESSEE UNDER THIS AGREEMENT, TIME SHARE LESSOR SHALL BE KNOWN AS, CONSIDERED, AND IN FACT WILL BE THE OPERATOR OF THE AIRCRAFT AND SOLELY RESPONSIBLE FOR OPERATIONAL CONTROL OF THE AIRCRAFT.  EACH PARTY HERETO CERTIFIES THAT IT UNDERSTANDS THE EXTENT OF ITS RESPONSIBILITIES, SET FORTH HEREIN, FOR COMPLIANCE WITH APPLICABLE FEDERAL AVIATION REGULATIONS.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AN EXPLANATION OF FACTORS BEARING ON OPERATIONAL CONTROL AND PERTINENT FEDERAL AVIATION REGULATIONS CAN BE OBTAINED FROM THE NEAREST FEDERAL AVIATION ADMINISTRATION FLIGHT STANDARDS </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">DISTRICT OFFICE.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">THE PARTIES HERETO CERTIFY THAT A TRUE COPY OF THIS AGREEMENT SHALL BE CARRIED ON THE AIRCRAFT AT ALL TIMES, AND SHALL BE MADE AVAILABLE FOR INSPECTION UPON REQUEST BY AN APPROPRIATELY CONSTITUTED IDENTIFIED REPRESENTATIVE OF THE ADMINISTRATOR OF THE FAA.</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the parties have executed this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Aircraft Time Sharing Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> as of the date and year first written above.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TIME SHARE LESSOR&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUEST DIAGNOSTICS CLINICAL LABORATORIES, INC. </font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By&#58;&#160;&#160;&#160;&#160;_</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Cecilia K. McKenney </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">______________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Print&#58;  &#160;&#160;&#160;&#160;Cecilia K. McKenney </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58;  &#160;&#160;&#160;&#160;Senior Vice President, Chief Human Resources Officer</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TIME SHARE LESSEE&#58;</font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JAMES E. DAVIS</font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By&#58;&#160;&#160;&#160;&#160;_</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; James E. Davis_</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">__________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Print&#58;  &#160;&#160;&#160;&#160;James E. Davis</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FSDO Notification Letter</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; ______________</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Via Facsimile</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Fax&#58; __________________</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Federal Aviation Administration</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">__________________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">__________________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">__________________________</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">RE&#58; &#160;&#160;&#160;&#160;FAR Section 91.23 FSDO Notification</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">First Flight Under Time Sharing Agreement</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To whom it may concern&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Pursuant to the requirements of Federal Aviation Regulation Section 91.23(c)(3), please accept this letter as notification that the first flight of the aircraft under a Time Sharing Agreement will depart from ____ Airport on the __ day of ______, 202_, at approximately _____ &#91;am&#47;pm&#93; local time.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Should you require any additional information, please contact our pilot, Mr. _______, at telephone&#58; ________________.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Sincerely, </font></div><div style="text-align:justify;text-indent:252pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;QUEST DIAGNOSTICS CLINICAL LABORATORIES, INC.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By&#58;&#160;&#160;&#160;&#160;_______________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Print&#58;&#160;&#160;&#160;&#160;_______________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58; &#160;&#160;&#160;&#160;_______________________</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT B</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The aircraft subject to this agreement are as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Aircraft #1&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Dassault Falcon 2000EX</font></div><div style="padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">U.S. Registration Number&#58; N197DX</font></div><div style="padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Manufacturer&#8217;s Serial Number&#58; 216</font></div><div style="padding-left:108pt;text-indent:36pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Aircraft #2&#58;     &#160;&#160;&#160;&#160;Pilatus PC-12</font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. Registration Number N432CV</font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Manufacturer&#8217;s Serial Number 119</font></div><div style="padding-left:108pt;text-indent:-108pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Aircraft #3&#58;     &#160;&#160;&#160;&#160;Pilatus PC-12</font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. Registration Number N120QD</font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Manufacturer&#8217;s Serial Number 120</font></div><div style="padding-left:108pt;text-indent:-108pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Aircraft #4&#58;     &#160;&#160;&#160;&#160;Pilatus PC-12</font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. Registration Number N149QD</font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Manufacturer&#8217;s Serial Number 149</font></div><div style="padding-left:108pt;text-indent:-108pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Aircraft #5&#58;     &#160;&#160;&#160;&#160;Pilatus PC-12</font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. Registration Number N338QD</font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Manufacturer&#8217;s Serial Number 338</font></div><div style="padding-left:108pt;text-indent:-108pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Aircraft #6&#58;    &#160;&#160;&#160;&#160;Pilatus PC-12</font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. Registration Number N465PC</font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Manufacturer&#8217;s Serial Number 465</font></div><div style="padding-left:108pt;text-indent:-108pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Aircraft #7&#58;&#160;&#160;&#160;&#160;Pilatus PC-12</font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. Registration Number N26VW</font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Manufacturer&#8217;s Serial Number 478</font></div><div style="padding-left:108pt;text-indent:-108pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Aircraft #8&#58;&#160;&#160;&#160;&#160;Pilatus PC-12</font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. Registration Number N567QD</font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Manufacturer&#8217;s Serial Number 567</font></div><div style="padding-left:108pt;text-indent:-108pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Aircraft #9&#58;&#160;&#160;&#160;&#160;Pilatus PC-12</font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. Registration Number N589QD</font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Manufacturer&#8217;s Serial Number 589</font></div><div style="padding-left:108pt;text-indent:-108pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Aircraft #10&#58;&#160;&#160;&#160;&#160;Pilatus PC-12</font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. Registration Number N687QD</font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Manufacturer&#8217;s Serial Number 687</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="padding-left:108pt;text-indent:-108pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-108pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Aircraft #11&#58;&#160;&#160;&#160;&#160;Pilatus PC-12</font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. Registration Number N399SA</font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Manufacturer&#8217;s Serial Number 407</font></div><div style="padding-left:108pt;text-indent:-108pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Aircraft #12&#58;&#160;&#160;&#160;&#160;Pilatus PC-12</font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. Registration Number N412MD</font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Manufacturer&#8217;s Serial Number 412</font></div><div style="padding-left:108pt;text-indent:-108pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Aircraft #13&#58;&#160;&#160;&#160;&#160;Pilatus PC-12</font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. Registration Number N942TW</font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Manufacturer&#8217;s Serial Number 636</font></div><div style="padding-left:108pt;text-indent:-108pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Aircraft #14&#58;&#160;&#160;&#160;&#160;Embraer Phenom 100</font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. Registration Number N288DX</font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Manufacturer&#8217;s Serial Number 500000166</font></div><div style="padding-left:108pt;text-indent:-108pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Aircraft #15&#58;&#160;&#160;&#160;&#160;Embraer Phenom 100</font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. Registration Number N648DX</font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Manufacturer&#8217;s Serial Number 500000176</font></div><div style="padding-left:108pt;text-indent:-108pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Aircraft #16&#58;&#160;&#160;&#160;&#160;Embraer Phenom 100</font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. Registration Number N899DX</font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Manufacturer&#8217;s Serial Number 500000216</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>6
<FILENAME>dgx12312022ex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ia3417f11727b43079516d1948b1252d8_1"></div><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quest Diagnostics Incorporated (DE)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Incorporated on December 12, 1990 in Delaware&#59; EIN&#58; 16-1387862)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsidiaries, Joint Ventures and Affiliates</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.848%"><tr><td style="width:1.0%"></td><td style="width:3.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:0.0%"></td><td style="width:0.149%"></td><td style="width:0.0%"></td><td style="width:0.1%"></td><td style="width:2.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.149%"></td><td style="width:0.1%"></td><td style="width:0.0%"></td><td style="width:0.149%"></td><td style="width:0.0%"></td><td style="width:1.0%"></td><td style="width:3.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.891%"></td><td style="width:0.1%"></td></tr><tr><td colspan="30" style="background-color:#00b0f0;border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Company</font></td><td colspan="3" style="background-color:#00b0f0;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Registered Alternate name</font></td></tr><tr style="height:15pt"><td colspan="30" style="background-color:#92d050;border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#92d050;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="30" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100% Quest Diagnostics Holdings Incorporated (DE)</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="27" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100% Quest Diagnostics International Holdings Limited (UK)</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="24" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100% Quest Diagnostics Holdings Ltd. (UK)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="18" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="12" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%  ExamOne Canada, Inc. (New Brunswick)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="18" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="12" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.9%  Quest Diagnostics HTAS India Private Limited (India) (0.1% Quest Diagnostics International Holdings Limited (UK)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="18" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="12" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%  Quest Diagnostics of Puerto Rico, Inc. (PR)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="18" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="12" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%  Quest Diagnostics Ireland Limited (Ireland)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="18" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="12" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%  Quest Diagnostics (Shanghai) Co., Ltd. (China)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="27" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100% Quest Diagnostics Clinical Laboratories, Inc. (DE)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advanced Toxicology Network</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Labtech Diagnostics</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quest Diagnostics</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Solstas Lab Partners Group</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Solstas Lab Partners</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smithkline Beecham Clinical      </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;Laboratories</font></div></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="21" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100% Quest Consumer Inc. (DE)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="21" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100% Lab</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">One</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, LLC (MO)</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quest Diagnostics</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LabOne, LLC of Kansas</font></div></td></tr><tr><td colspan="24" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100% Exam</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">One</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> World Wide, Inc. (PA)</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="27" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100% ExamOne LLC (DE)</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="27" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100% ExamOne World Wide of NJ, Inc. (NJ)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="27" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51%  DGXWMT JV, LLC (DE)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Health Check by Quest Diagnostics</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100% PACK Health, LLC (AL)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PACK Health Enterprise LLC</font></td></tr><tr><td colspan="27" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100% Quest HealthConnect, LLC (CA)</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="27" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100%  Quest Diagnostics Health &#38; Wellness, LLC (DE)</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="24" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100% Lab</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">One</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of Ohio, Inc. (DE)</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quest Diagnostics</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LabOne</font></div></td></tr><tr><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="21" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51% Diagnostic Laboratory of Oklahoma LLC (OK)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="21" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100% Mid America Clinical Laboratories, LLC (IN)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="21" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49% Sonora Quest Laboratories LLC (AZ)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="30" style="background-color:#92d050;border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#92d050;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="30" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%  Quest Diagnostics do Brasil Ltda. (Brazil)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="30" style="background-color:#92d050;border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#92d050;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="30" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100% Quest Diagnostics Incorporated (MD)</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="33" style="background-color:#92d050;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="30" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100%  Quest Diagnostics India Private Limited (India)</font></div><div><font><br></font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="33" style="background-color:#92d050;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="30" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100%  Quest Diagnostics International LLC (DE)</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="30" style="background-color:#92d050;border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#92d050;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="30" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100% Quest Diagnostics Investments LLC  (DE)</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="30" style="background-color:#92d050;border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#92d050;border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:21.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1                                                                                                                    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.848%"><tr><td style="width:1.0%"></td><td style="width:3.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:0.0%"></td><td style="width:0.149%"></td><td style="width:0.0%"></td><td style="width:0.1%"></td><td style="width:2.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.149%"></td><td style="width:0.1%"></td><td style="width:0.0%"></td><td style="width:0.149%"></td><td style="width:0.0%"></td><td style="width:1.0%"></td><td style="width:3.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.891%"></td><td style="width:0.1%"></td></tr><tr><td colspan="30" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100% Quest Diagnostics LLC (IL)<br></font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quest Diagnostics LLC</font></td></tr><tr style="height:14pt"><td colspan="30" style="background-color:#92d050;border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#92d050;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="30" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100% Quest Diagnostics LLC (MA)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quest Diagnostics LLC</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Quest Diagnostics of Connecticut LLC</font></div><div><font><br></font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="27" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81.1% Quest Diagnostics Massachusetts LLC (MA)  </font></div><div><font><br></font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="30" style="background-color:#92d050;border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#92d050;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="30" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100% Quest Diagnostics LLC (CT)</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="33" style="background-color:#92d050;border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="33" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%  Quest Diagnostics Mexico, S de RL de CV (Mexico)</font></td></tr><tr style="height:15pt"><td colspan="30" style="background-color:#92d050;border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#92d050;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="30" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100% Quest Diagnostics Nichols Institute (CA)</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nichols Institute<br>Quest Diagnostics Nichols <br>&#160;&#160;&#160;Institute (CA) Inc.<br>Quest Diagnostics Nichols <br>&#160;&#160;&#160;Institute Inc.<br></font></td></tr><tr style="height:15pt"><td colspan="33" style="background-color:#92d050;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="30" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100% Quest Diagnostics of Pennsylvania Inc. (DE)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="27" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51% Quest Diagnostics Venture LLC (PA)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="27" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.5% Associated Clinical Laboratories of Pennsylvania, L.L.C. (PA)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1% Associated Clinical Laboratories, L.P. (PA)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="27" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52.97% Associated Clinical Laboratories, L.P. (PA)</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="33" style="background-color:#92d050;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="30" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100% Quest Diagnostics Receivables Inc. (DE)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="30" style="background-color:#92d050;border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#92d050;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="30" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%  Quest Diagnostics TB, LLC (DE)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="30" style="background-color:#92d050;border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#92d050;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="30" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%  Athena Diagnostics, Inc. (DE)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="30" style="background-color:#92d050;border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#92d050;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="30" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%  American Medical Laboratories, Incorporated (DE)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="27" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100%   Quest Diagnostics Nichols Institute, Inc. (VA)</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nichols Institute<br>Quest Diagnostics<br>Quest Diagnostics Nichols Institute, <br>&#160;&#160;&#160;Institute, Inc. of Virginia</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="27" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%   Quest Diagnostics Incorporated (NV)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.1pt;text-indent:-8.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quest Diagnostics Incorporated of Nevada</font></div><div style="padding-left:8.1pt;text-indent:-8.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quest Diagnostics</font></div></td></tr><tr style="height:12pt"><td colspan="30" style="background-color:#92d050;border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#92d050;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="30" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%  Blueprint Genetics Inc. (DE)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="30" style="background-color:#92d050;border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#92d050;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="30" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%  Blueprint Genetics Oy (Finland)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="27" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%  Blueprint Genetics FZ-LLC (UAE)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="30" style="background-color:#92d050;border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#92d050;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="30" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%  Cleveland HeartLab, Inc. (DE)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cleveland Heartlab Services, Inc.</font></td></tr><tr style="height:15pt"><td colspan="30" style="background-color:#92d050;border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#92d050;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="30" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100%   Isabella Street Urban Renewal, LLC (NJ)</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="30" style="background-color:#92d050;border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#92d050;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="30" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%  Med Fusion, LLC (TX)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">med fusion</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">med fusion clin-trials</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">med fusion clin-labs</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></td></tr><tr style="height:15pt"><td colspan="30" style="background-color:#92d050;border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#92d050;border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:21.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                  </font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.848%"><tr><td style="width:1.0%"></td><td style="width:3.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:0.0%"></td><td style="width:0.149%"></td><td style="width:0.0%"></td><td style="width:0.1%"></td><td style="width:2.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.149%"></td><td style="width:0.1%"></td><td style="width:0.0%"></td><td style="width:0.149%"></td><td style="width:0.0%"></td><td style="width:1.0%"></td><td style="width:3.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.891%"></td><td style="width:0.1%"></td></tr><tr><td colspan="30" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100% Reprosource Fertility Diagnostics, Inc. (MA)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="30" style="background-color:#92d050;border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#92d050;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="30" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%  Unilab Corporation (DE)</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quest Diagnostics</font></td></tr><tr style="height:15pt"><td colspan="33" style="background-color:#92d050;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="30" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%  AmeriPath, Inc. (DE)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="27" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%  AmeriPath Cincinnati, Inc. (OH)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.1pt;text-indent:-8.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Richfield Laboratory of Dermatopathology</font></div><div style="padding-left:8.1pt;text-indent:-8.1pt"><font><br></font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="27" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%  AmeriPath Cleveland, Inc. (OH)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AmeriPath GI Institute</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dermpath Diagnostics</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="27" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%  AmeriPath Consolidated Labs, Inc. (FL)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="27" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%  AmeriPath Florida, LLC (DE)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AmeriPath Central Florida </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AmeriPath Northeast Florida</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AmeriPath Southwest Florida</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bay Area Dermatopathology</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dermpath Diagnostics</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dermpath Diagnostics Bay Area Dermpath Diagnostics </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;South Florida</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Institute for Immunofluorescence</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Institute for Podiatric Pathology</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="27" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%  AmeriPath Hospital Services Florida, LLC (DE)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="27" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%  AmeriPath Kentucky, Inc. (KY)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="27" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%  AmeriPath Lubbock 5.01(A) Corporation (TX)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arlington Pathology Associates</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dermpath Diagnostics Texas</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">North Arlington Pathology </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;Associates</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pathology Associates of Texas</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="27" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%  AmeriPath New York, LLC (DE)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.1pt;text-indent:-8.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AmeriPath East</font></div><div style="padding-left:8.1pt;text-indent:-8.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AmeriPath Gastrointestinal Diagnostics</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AmeriPath Northeast</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dermpath Diagnostics</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dermpath Diagnostics </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;NE-Braintree</font></div><div style="padding-left:8.1pt;text-indent:-8.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ackerman Academy of Dermatopathology</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dermpath Diagnostics New York</font></div><div><font><br></font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="27" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%  AmeriPath Texas Inc. (DE)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="27" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%  AmeriPath Tucson, Inc. (AZ)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmeriPath Arizona</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="27" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%  Consolidated DermPath, Inc. (DE)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="27" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%  DFW 5.01(a) Corporation (TX)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AmeriPath North Texas</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AmeriPath Dallas</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AmeriPath DFW 5.01(a) </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;Corporation</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="27" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%  Diagnostic Pathology Services, Inc. (OK)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmeriPath Oklahoma</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="27" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%  Kailash B. Sharma, M.D., Inc. (GA)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="18" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%  Nuclear Medicine and Pathology Associates (GA)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="27" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%  Institute for Dermatopathology, Inc. (PA)</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AmeriPath Mid Atlantic</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dermpath Diagnostics</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Dermatopathology </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;Laboratory</font></div></td></tr></table></div><div style="height:21.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                  </font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.848%"><tr><td style="width:1.0%"></td><td style="width:3.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:0.0%"></td><td style="width:0.149%"></td><td style="width:0.0%"></td><td style="width:0.1%"></td><td style="width:2.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.149%"></td><td style="width:0.1%"></td><td style="width:0.0%"></td><td style="width:0.149%"></td><td style="width:0.0%"></td><td style="width:1.0%"></td><td style="width:3.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.891%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="27" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%  Ocmulgee Medical Pathology Association, Inc. (GA)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.1pt;text-indent:-8.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AmeriPath Georgia Gastrointestinal Diagnostics</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dermpath Diagnostics</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="27" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%  Specialty Laboratories, Inc. (CA)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quest Diagnostics Nichols </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;Institute of Valencia, Inc.</font></div></td></tr><tr><td colspan="30" style="background-color:#00b0f0;border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Entities Consolidated for Accounting Purposes</font></td><td colspan="3" style="background-color:#00b0f0;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="30" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.6pt;text-indent:-4.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AmeriPath Indianapolis, PC (IN)&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AmeriPath Indianapolis, PSC</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmeriPath Indianapolis Medical </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Pathology</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dermpath Diagnostics</font></div></td></tr><tr><td colspan="30" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colorado Pathology Consultants, P.C. (CO)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AmeriPath Colorado</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dermpath Diagnostics</font></div></td></tr><tr><td colspan="30" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dermatopathology of Wisconsin, S.C. (WI)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmeriPath Great Lakes</font></td></tr><tr><td colspan="30" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hoffman, M.D., Associated Pathologists, Chartered (NV)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Associated Pathologists, </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;Chartered</font></div></td></tr><tr><td colspan="30" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kilpatrick Pathology, P.A. (NC)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="30" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PhenoPath Laboratories, PLLC (WA)</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:21.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                  </font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-22
<SEQUENCE>7
<FILENAME>dgx12312022ex22.htm
<DESCRIPTION>EX-22
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i30712d4ea0244808bf87b2a735649cba_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">Exhibit 22</font></div><div style="text-align:right;text-indent:36pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">Subsidiary Guarantors of Securities</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">As of February 21, 2023, the following subsidiaries of Quest Diagnostics Incorporated provided, subject to the terms of such senior notes, unconditional and irrevocable guarantees to the senior notes listed below that were issued by Quest Diagnostics Incorporated pursuant to an offering registered under the Securities Act of 1933, as amended&#58;</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:27.517%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.174%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#dfdfdf;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Securities</font></div></td><td colspan="3" style="background-color:#dfdfdf;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Issuer</font></div></td><td colspan="3" style="background-color:#dfdfdf;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Subsidiary Guarantor</font></div></td><td colspan="3" style="background-color:#dfdfdf;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">State of Organization</font></div></td></tr><tr style="height:14pt"><td colspan="3" rowspan="30" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6.95% Senior Notes due 2037</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5.75% Senior Notes due 2040</font></div></td><td colspan="3" rowspan="30" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Quest Diagnostics Incorporated</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">American Medical Laboratories, Incorporated</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">AmeriPath, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">AmeriPath Consolidated Labs, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Florida</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">AmeriPath Florida, LLC</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">AmeriPath Hospital Services Florida, LLC</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">AmeriPath Kentucky, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Kentucky</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">AmeriPath New York, LLC</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">AmeriPath Texas, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Athena Diagnostics, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Diagnostic Pathology Services, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Oklahoma</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ExamOne World Wide, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pennsylvania</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ExamOne World Wide of NJ, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">New Jersey</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Kailash B. Sharma, M.D., Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Georgia</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LabOne, LLC</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Missouri</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LabOne of Ohio, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ocmulgee Medical Pathology Association, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Georgia</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Quest Diagnostics Clinical Laboratories, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Quest Diagnostics Holdings Incorporated</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Quest Diagnostics Incorporated</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Maryland</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Quest Diagnostics Incorporated</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Nevada</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Quest Diagnostics Infectious Disease, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Quest Diagnostics Investments LLC</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Quest Diagnostics LLC</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Connecticut</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Quest Diagnostics LLC</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Illinois</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Quest Diagnostics LLC</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Massachusetts</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Quest Diagnostics Nichols Institute</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">California</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Quest Diagnostics Nichols Institute, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Virginia</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Quest Diagnostics of Pennsylvania Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Specialty Laboratories, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">California</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Unilab Corporation</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>8
<FILENAME>dgx12312022ex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i4ed48d75212148e080bcb5b01accc830_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-266315) and Form S-8 (Nos. 333-184580, 333-182863, 333-143889, 333-136196, 333-60758, 333-60477, 333-157447, 333-162710, 333-162711, 333-207746, 333-214215, 333-221076 and 333-234328) of Quest Diagnostics Incorporated of our report dated February&#160;21, 2023 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:32.163%"><tr><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; PricewaterhouseCoopers LLP</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florham Park, New Jersey</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;21, 2023</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>9
<FILENAME>dgx12312022ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i8f01a5fbfab24d9aa4ef509f29f78507_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, James E. Davis, certify that&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this annual report on Form 10-K of Quest Diagnostics Incorporated&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;21, 2023 </font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:36.988%"><tr><td style="width:1.0%"></td><td style="width:11.943%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.857%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; James E. Davis</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James E. Davis</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President</font></td></tr></table></div><div style="margin-bottom:5pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>10
<FILENAME>dgx12312022ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i11e42f5264aa452b880396f1e49e420e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Sam A. Samad, certify that&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this annual report on Form 10-K of Quest Diagnostics Incorporated&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;21, 2023 </font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:29.239%"><tr><td style="width:1.0%"></td><td style="width:15.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Sam A. Samad</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sam A. Samad</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="margin-bottom:5pt"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>11
<FILENAME>dgx12312022ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i430a4d6adb6e46f49f3ae214b792d635_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. &#167; 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. &#167; 1350, the undersigned certifies that, to the best of my knowledge, the Annual Report on Form 10-K for the period ended December&#160;31, 2022 of Quest Diagnostics Incorporated, as being filed with the Securities and Exchange Commission concurrently herewith, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. &#167; 78m or 78o(d)) and that the information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of Quest Diagnostics Incorporated.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.029%"><tr><td style="width:1.0%"></td><td style="width:5.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.748%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 21, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; James E. Davis</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James E. Davis</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>12
<FILENAME>dgx12312022ex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i78d0fc59e24d4b3f99e3e8d073df56f7_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. &#167; 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. &#167; 1350, the undersigned certifies that, to the best of my knowledge, the Annual Report on Form 10-K for the period ended December&#160;31, 2022 of Quest Diagnostics Incorporated, as being filed with the Securities and Exchange Commission concurrently herewith, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. &#167; 78m or 78o(d)) and that the information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of Quest Diagnostics Incorporated.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.394%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 21, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Sam A. Samad</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sam A. Samad</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.10
<SEQUENCE>13
<FILENAME>dgx12312022ex9910.htm
<DESCRIPTION>EX-99.10
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i615d55f475cc4fe782b657a8835a3ce3_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 99.10</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AMENDMENT NO. 7 TO SIXTH AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Amendment No. 7 to Sixth Amended and Restated Credit and Security Agreement (this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Amendment&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) is entered into as of October 20, 2022 (the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Effective Date&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), by and among&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(1) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">QUEST DIAGNOSTICS RECEIVABLES INC., a Delaware corporation (together with its successors and permitted assigns, the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Borrower&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">),</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(2) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">QUEST DIAGNOSTICS INCORPORATED, a Delaware corporation, as initial servicer (in such capacity, together with any successor servicer or sub-servicer, the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Servicer&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">),</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(3) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">PNC BANK, NATIONAL ASSOCIATION, in its individual capacity as a Lender (together with its successors, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;PNC&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;PNC Group&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) and as issuer of the Letters of Credit,</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(4) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GOTHAM FUNDING CORPORATION, a Delaware corporation (together with its successors, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Gotham&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), and MUFG BANK, LTD. (F&#47;K&#47;A THE BANK OF TOKYO-MITSUBISHI UFJ, LTD.), in its capacity as a Liquidity Bank to Gotham (together with its successors, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;MUFG&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and, together with Gotham, the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Gotham Group&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">),</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(5)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> ATLANTIC ASSET SECURITIZATION LLC, a Delaware limited liability company (together with its successors, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Atlantic&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), and CR&#201;DIT AGRICOLE CORPORATE AND INVESTMENT BANK, in its capacity as a Liquidity Bank to Atlantic (together with its successors, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;CACIB&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and, together with Atlantic, the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Atlantic Group&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">),</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(6) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">PNC BANK, NATIONAL ASSOCIATION, in its capacity as agent for the PNC Group (together with its successors in such capacity, a </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Co-Agent&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), CR&#201;DIT AGRICOLE CORPORATE AND INVESTMENT BANK, in its capacity as agent for the Atlantic Group (together with its successors in such capacity, a </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Co-Agent&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), and MUFG BANK, LTD. (F&#47;K&#47;A THE BANK OF TOKYO-MITSUBISHI UFJ, LTD.), in its capacity as agent for the Gotham Group (together with its successors in such capacity, a </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Co-Agent&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), </font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(7) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">PNC BANK, NATIONAL ASSOCIATION, in its capacity as Letter of Credit issuer (together with its successors in such capacity, the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;LC Issuer&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), and</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(8) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MUFG BANK, LTD. (F&#47;K&#47;A THE BANK OF TOKYO-MITSUBISHI UFJ, LTD.), as administrative agent for the Atlantic Group, the PNC Group, the Gotham Group and the Co-Agents (in such capacity, together with any successors thereto in such capacity, the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Administrative Agent&#8221; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and together with each of the Co-Agents, the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Agents&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">RECITALS&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.87pt">The Borrower, the Servicer, the PNC Group, the Gotham Group, the Atlantic Group and the Agents are parties to that certain Sixth Amended and Restated Credit and Security Agreement, dated as of October 27, 2017 (as amended, restated or otherwise modified from time to time, the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Credit and Security Agreement&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#59; capitalized terms used and not otherwise defined herein are used with the meanings attributed thereto in the Credit and Security Agreement).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Quest Amendment No. 7 to 6</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> A&#38;R CSA</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154782977v1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;Each of the parties hereto desires to amend the Credit and Security Agreement as hereinafter set forth.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">NOW, THEREFORE,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> in consideration of the premises, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows&#58;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SECTION 1. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.91pt;text-decoration:underline">Amendments to the Credit and Security Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to the satisfaction of the conditions set forth in Section 2 below, as of the Effective Date, (i) the Credit and Security Agreement is amended in accordance with </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit A-1 (Redline)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereto&#58;  (a) by deleting all language which appears in strikethrough text on </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit A-1 (Redline)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and (b) by inserting all language which appears in double-underlined text on </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit A-1 (Redline)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, (ii) the outstanding A-Loans, B-Loans and participations in Letters of Credit shall be automatically reallocated among the Lenders so that each Lender (or with respect to any Group that has more than one Lender, the Lenders in such Group on a combined basis) is holding its Ratable Share, in each case after giving effect to this Amendment, of such outstanding A- Loans, B-Loans and participations in Letters of Credit, and (iii) any outstanding LMIR Loans (as defined in the Credit and Security Agreement prior to giving effect to this Amendment) shall be automatically and immediately converted into Daily Term SOFR Loans bearing interest at Adjusted Daily One Month Term SOFR.  For the avoidance of doubt, notwithstanding anything to the contrary contained in any prior amendment or amendments to the Credit and Security Agreement, the Credit and Security Agreement set forth in </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit A-1 (Redline)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereto and </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit A-2 (Clean)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereto reflect the current agreement of the parties hereto as to all of the terms and provisions of the Credit and Security Agreement as of the Effective Date.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SECTION 2. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.91pt;text-decoration:underline">Conditions to Effectiveness</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Amendment shall become effective as of the Effective Date provided that each of the following conditions precedent is satisfied&#58;  (a) The Administrative Agent shall have received counterparts of this Amendment (whether by electronic mail or otherwise) duly executed by each of the parties hereto&#59; (b) the Fee Letter dated of even date herewith shall have been duly executed by all parties thereto, and each of the Co-Agents shall have received payment in immediately available funds of their respective fees&#59; and (c) each of the representations and warranties set forth in Section 3 of this Amendment is true and correct as of the Effective Date. </font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SECTION 3. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.91pt;text-decoration:underline">Representations and Warranties</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Borrower hereby represents and warrants to the Agents and the Lenders as of the Effective Date as follows&#58;</font></div><div style="margin-bottom:6pt;padding-left:49.5pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:6.08pt;text-decoration:underline">Representations and Warranties</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The representations and warranties contained in </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article VI</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Credit and Security Agreement are true and correct as of the date hereof (unless stated to relate solely to an earlier date, in which case such representations or warranties were true and correct as of such earlier date).</font></div><div style="margin-bottom:6pt;padding-left:49.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.07pt;text-decoration:underline">Enforceability</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The execution and delivery by each of the Borrower and the Servicer of this Amendment, and the performance of each of its obligations under this Amendment and the Credit and Security Agreement, as amended hereby, are within each of its organizational powers and have been duly authorized by all necessary action on each of its parts.  This Amendment and the Credit and Security Agreement, as amended hereby, are each of the Borrower&#8217;s and the Servicer&#8217;s valid and legally binding obligations, enforceable in accordance with its terms.</font></div><div style="padding-left:49.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.19pt;text-decoration:underline">No Default</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Immediately after giving effect to this Amendment and the transactions contemplated hereby, no Event of Default or Unmatured Default exists or shall exist.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br>2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Quest Amendment No. 7 to 6</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> A&#38;R CSA</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154782977v1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:13.5pt;text-align:justify;text-indent:54pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SECTION 4. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.91pt;text-decoration:underline">Legal Fees and Disbursements</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Borrower hereby acknowledges and agrees that this Amendment constitutes a Transaction Document and that the provisions of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 14.5(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Credit and Security Agreement apply hereto.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SECTION 5. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.91pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Amendment shall be governed by, and construed in accordance with, the internal laws of the State of New York without regard to any otherwise applicable conflicts of law principles (other than Sections 5-1401 and 5-1402 of the New York General Obligations Law which shall apply hereto).</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SECTION 6. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.91pt;text-decoration:underline">Effect of Amendment&#59; Ratification</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as specifically amended hereby, the Credit and Security Agreement is hereby ratified and confirmed in all respects, and all of its provisions shall remain in full force and effect.  After this Amendment becomes effective, all references in the Credit and Security Agreement (or in any other Transaction Document) to &#8220;the Credit and Security Agreement&#8221;, &#8220;this Agreement&#8221;, &#8220;hereof&#8221;, &#8220;herein&#8221;, or words of similar effect, in each case referring to the Credit and Security Agreement, shall be deemed to be references to the Credit and Security Agreement as amended hereby.  This Amendment shall not be deemed to expressly or impliedly waive, amend, or supplement any provision of the Credit and Security Agreement other than as specifically set forth herein. The Borrower, the Servicer, the PNC Group, the Gotham Group, the Atlantic Group and the Agents shall treat this Amendment as not resulting in a significant modification of the Loans for U.S. federal, state and local income tax purposes.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SECTION 7. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.91pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Amendment may be executed in any number of counterparts and by different parties on separate counterparts, and each counterpart shall be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument.  To the fullest extent permitted by applicable law, delivery of an executed counterpart of a signature page of this Amendment by telefacsimile or electronic image scan transmission (such as a &#8220;pdf&#8221; file) will be effective to the same extent as delivery of a manually executed original counterpart of this Amendment.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SECTION 8. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.91pt;text-decoration:underline">Section Headings</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The various headings of this Amendment are inserted for convenience only and shall not affect the meaning or interpretation of this Amendment or the Credit and Security Agreement or any provision hereof or thereof.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SECTION 9. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.91pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Amendment shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and assigns.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SECTION 10. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.34pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If any one or more of the provisions or terms of this Amendment shall for any reason whatsoever be held invalid or unenforceable, then such agreements, provisions or terms shall be deemed severable from the remaining agreements, provisions and terms of this Amendment and shall in no way affect the validity or enforceability of the provisions of this Amendment or the Credit and Security Agreement.</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#60;Balance of page intentionally left blank&#62;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br>3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Quest Amendment No. 7 to 6</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> A&#38;R CSA</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154782977v1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><font><br></font></div><div id="i615d55f475cc4fe782b657a8835a3ce3_4"></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">IN WITNESS WHEREOF,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> the parties have executed this Amendment as of the date first written above.</font></div><div style="text-indent:-1.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">QUEST DIAGNOSTICS RECEIVABLES INC.<br></font></div><div style="text-indent:-1.25pt"><font><br></font></div><div style="text-indent:-1.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">_&#47;s&#47; Sandip R Patel</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">__________ &#160;&#160;&#160;&#160;<br>Name&#58;   Sandip R. Patel<br>Title&#58;     Vice President and Treasurer</font></div><div style="text-indent:-1.25pt"><font><br></font></div><div style="text-indent:-1.25pt"><font><br></font></div><div style="text-indent:-1.25pt"><font><br></font></div><div style="text-indent:-1.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">QUEST DIAGNOSTICS INCORPORATED, as Servicer and as Performance Guarantor<br></font></div><div style="text-indent:-1.25pt"><font><br></font></div><div style="text-indent:-1.25pt"><font><br></font></div><div style="text-indent:-1.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; ___</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Sandip R. Patel__________</font></div><div style="text-indent:-1.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;   Sandip R. Patel<br>Title&#58;     Vice President and Treasurer</font></div><div style="text-align:center;text-indent:-1.25pt"><font><br></font></div><div style="text-align:center;text-indent:-1.25pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br>4</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Quest Amendment No. 7 to 6</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> A&#38;R CSA</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154782977v1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:-1.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ATLANTIC ASSET SECURITIZATION LLC, as a Conduit</font></div><div style="text-indent:-1.25pt"><font><br></font></div><div style="text-indent:-1.25pt"><font><br></font></div><div style="text-indent:-1.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">____&#47;s&#47; Konstantina Kourmpetis______</font></div><div style="text-indent:-1.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;  Konstantina Kourmpetis</font></div><div style="text-indent:-1.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;   Managing Director</font></div><div style="text-indent:-1.25pt"><font><br></font></div><div style="text-indent:-1.25pt"><font><br></font></div><div style="text-indent:-1.25pt"><font><br></font></div><div style="text-indent:-1.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">__&#47;s&#47; Richard McBride</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">_______________<br>Name&#58;  Richard McBride<br>Title&#58;  Director  </font></div><div style="text-align:center;text-indent:-1.25pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Quest Amendment No. 7 to 6</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> A&#38;R CSA</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154782977v1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:-1.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CR&#201;DIT AGRICOLE CORPORATE AND INVESTMENT BANK, individually as a Liquidity Bank for Atlantic and as Atlantic Group Agent</font></div><div style="text-indent:-1.25pt"><font><br></font></div><div style="text-indent:-1.25pt"><font><br></font></div><div style="text-indent:-1.25pt"><font><br></font></div><div style="text-indent:-1.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">____&#47;s&#47; Konstantina Kourmpetis______</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><br>Name&#58; Konstantina Kourmpetis</font></div><div style="text-indent:-1.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;  Managing Director</font></div><div style="text-indent:-1.25pt"><font><br></font></div><div style="text-indent:-1.25pt"><font><br></font></div><div style="text-indent:-1.25pt"><font><br></font></div><div style="text-indent:-1.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">__&#47;s&#47; Richard McBride</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">_______________<br>Name&#58;  Richard McBride<br>Title&#58;  Director  </font></div><div style="text-align:center;text-indent:-1.25pt"><font><br></font></div><div style="text-align:center;text-indent:-1.25pt"><font><br></font></div><div style="text-align:center;text-indent:-1.25pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Quest Amendment No. 7 to 6</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> A&#38;R CSA</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154782977v1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:-1.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">PNC BANK, NATIONAL ASSOCIATION,</font></div><div style="text-indent:-1.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">individually as a Lender, as PNC Group Agent and as LC Issuer</font></div><div style="text-indent:-1.25pt"><font><br></font></div><div style="text-indent:-1.25pt"><font><br></font></div><div style="text-indent:-1.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">_&#47;s&#47; Henry Chan</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">______<br>Name&#58;  Henry Chan<br>Title&#58;  Senior Vice President</font></div><div><font><br></font></div><div style="padding-left:72pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Quest Amendment No. 7 to 6</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> A&#38;R CSA</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154782977v1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:-1.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GOTHAM FUNDING CORPORATION, as a Conduit</font></div><div style="text-indent:-1.25pt"><font><br></font></div><div style="text-indent:-1.25pt"><font><br></font></div><div style="text-indent:-1.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">__&#47;s&#47; Kevin J. Corrigan</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">________&#160;&#160;&#160;&#160;<br>Name&#58; Kevin J. Corrigan<br>Title&#58;  Vice President</font></div><div><font><br></font></div><div style="margin-bottom:6pt;padding-left:72pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Quest Amendment No. 7 to 6</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> A&#38;R CSA</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154782977v1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:-1.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MUFG BANK, LTD. (F&#47;K&#47;A THE BANK OF TOKYO-MITSUBISHI UFJ, LTD.), individually as a Liquidity Bank for Gotham</font></div><div style="text-indent:-1.25pt"><font><br></font></div><div style="text-indent:-1.25pt"><font><br></font></div><div style="text-indent:-1.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">__&#47;s&#47; Eric Williams</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">__________________</font></div><div style="text-indent:-1.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;  Eric Williams</font></div><div style="text-indent:-1.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;  Managing Director</font></div><div style="text-indent:-1.25pt"><font><br></font></div><div style="text-indent:-1.25pt"><font><br></font></div><div style="text-indent:-1.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MUFG BANK, LTD. (F&#47;K&#47;A THE BANK OF TOKYO-MITSUBISHI UFJ, LTD.), as Gotham Agent</font></div><div style="text-indent:-1.25pt"><font><br></font></div><div style="text-indent:-1.25pt"><font><br></font></div><div style="text-indent:-1.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">__&#47;s&#47; Eric Williams</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">__________________</font></div><div style="text-indent:-1.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;  Eric Williams</font></div><div style="text-indent:-1.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;  Managing Director</font></div><div style="text-indent:-1.25pt"><font><br></font></div><div style="text-indent:-1.25pt"><font><br></font></div><div style="text-indent:-1.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MUFG BANK, LTD. (F&#47;K&#47;A THE BANK OF TOKYO-MITSUBISHI UFJ, LTD.), as Administrative Agent</font></div><div style="text-indent:-1.25pt"><font><br></font></div><div style="text-indent:-1.25pt"><font><br></font></div><div style="text-indent:-1.25pt"><font><br></font></div><div style="text-indent:-1.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">__&#47;s&#47; Eric Williams</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">__________________</font></div><div style="text-indent:-1.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;  Eric Williams</font></div><div style="text-indent:-1.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;  Managing Director</font></div><div style="text-indent:-1.25pt"><font><br></font></div><div style="text-align:center;text-indent:-1.25pt"><font><br></font></div><div><font><br></font></div><div style="text-align:center;text-indent:-1.25pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Quest Amendment No. 7 to 6</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> A&#38;R CSA</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154782977v1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center;text-indent:-1.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit A-1</font></div><div style="text-align:center;text-indent:-1.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Credit and Security Agreement (Redlined)</font></div><div style="text-align:center;text-indent:-1.25pt"><font><br></font></div><div style="text-align:center;text-indent:-1.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;See attached&#93;</font></div><div style="text-align:center;text-indent:-1.25pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Quest Amendment No. 7 to 6</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> A&#38;R CSA</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154782977v1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center;text-indent:-1.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit A-2</font></div><div style="text-align:center;text-indent:-1.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Credit and Security Agreement (Clean)</font></div><div style="text-align:center;text-indent:-1.25pt"><font><br></font></div><div style="text-align:center;text-indent:-1.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;See attached&#93;</font></div><div style="text-align:center;text-indent:-1.25pt"><font><br></font></div><div style="text-align:center;text-indent:-1.25pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Quest Amendment No. 7 to 6</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> A&#38;R CSA</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154782977v1</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.12
<SEQUENCE>14
<FILENAME>dgx12312022ex9912.htm
<DESCRIPTION>EX-99.12
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i503c2de34ad645e08e89dee7c44c80b2_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri Light',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 99.12</font></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GROUP JOINDER AGREEMENT</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Dated as of August 13, 2021</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">THIS GROUP JOINDER AGREEMENT</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Joinder Agreement&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) is executed and delivered by Reprosource Fertility Diagnostics, Inc., a Massachusetts corporation, Blueprint Genetics, Inc., a Delaware corporation, and Mid America Clinical Laboratories, LLC, an Indiana limited liability company (each, a </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;New Seller&#8221; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and collectively, the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;New Sellers&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) in favor of Quest Diagnostics Receivables Inc., a Delaware corporation, as purchaser (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Buyer</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), with respect to that certain Fourth Amended and Restated Receivables Sale Agreement dated as of October 28, 2015 by and between Quest Diagnostics Incorporated and certain of its subsidiaries from time to time party thereto as &#8220;Sellers&#8221; and the Buyer (as amended, supplemented, joined, restated and&#47;or otherwise modified from time to time, the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Sale Agreement&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">).  Capitalized terms used and not otherwise defined herein are used with the meanings attributed thereto in the Sale Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subject to receipt of counterparts hereof signed by the Administrative Agent and the Buyer, by its signature below, each New Seller hereby absolutely and unconditionally agrees to become a party to the Sale Agreement as a Seller thereunder and to be bound by the provisions thereof, including, without limitation, the provisions of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.12</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attached hereto is an amended and restated version of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 2.1(o)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> to the Sale Agreement.  After giving effect to the amendments and restatements embodied therein, each of the representations and warranties contained in Article II of the Sale Agreement will be true and correct as to each New Seller.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Responsible Officers&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of each New Seller will be any of its Treasurer or any Vice President, acting singly.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delivered herewith are each of the documents, certificates and opinions required to be delivered by each New Seller pursuant to </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article V</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Sale Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The provisions of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article VIII</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Sale Agreement are incorporated in this Joinder Agreement by this reference with the same force and effect as if set forth in full herein except that references in such Article VIII to &#8220;this Agreement&#8221; shall be deemed to refer to &#8220;this Joinder Agreement and to the Sale Agreement as modified by this Joinder Agreement.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Please acknowledge your consent to each New Seller&#8217;s joinder in the Sale Agreement by signing the enclosed copy hereof in the appropriate space provided below and Emailing a scanned image of such counterpart to the Administrative Agent and to each New Seller at the Email addresses set forth below their respective signatures hereto.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">IN WITNESS WHEREOF, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">each New Seller has executed this Group Joinder Agreement as of the date first above written.</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.660%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:10.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">REPROSOURCE FERTILITY DIAGNOSTICS, INC., a Massachusetts corporation</font></div><div style="padding-left:10.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:10.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:10.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:10.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;_</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47;Sandip R. Patel           </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">________________<br>Name&#58; Sandip R. Patel</font></div><div style="padding-left:10.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;  Vice President &#38; Treasurer</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:10.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Quest Diagnostics</font></div><div style="padding-left:10.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">500 Plaza Drive</font></div><div style="padding-left:10.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Secaucus, NJ 07094</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:10.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BLUEPRINT GENETICS, INC., a Delaware corporation</font></div><div style="padding-left:10.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:10.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:10.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:10.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#58;_&#47;s&#47;Sandip R. Patel           </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">________________<br>Name&#58; Sandip R. Patel</font></div><div style="padding-left:10.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;  Vice President &#38; Treasurer</font></div><div style="padding-left:10.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:10.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Quest Diagnostics</font></div><div style="padding-left:10.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">500 Plaza Drive</font></div><div style="padding-left:10.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Secaucus, NJ 07094</font></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:10.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MID AMERICA CLINICAL LABORATORIES, LLC, an Indiana limited liability company</font></div><div style="padding-left:10.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:10.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:10.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#58;_&#47;s&#47;Sandip R. Patel           </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">________________<br>Name&#58; Sandip R. Patel</font></div><div style="padding-left:10.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;  Vice President &#38; Treasurer</font></div><div style="padding-left:10.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:10.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:10.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Quest Diagnostics</font></div><div style="padding-left:10.65pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">500 Plaza Drive</font></div><div style="margin-bottom:12pt;padding-left:9.95pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Secaucus, NJ 07094</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">The undersigned hereby consents to each New Seller&#8217;s joinder in the Sale Agreement&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">QUEST DIAGNOSTICS RECEIVABLES INC., as Buyer</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:10.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#58;_&#47;s&#47;Sandip R. Patel           </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">________________<br>Name&#58; Sandip R. Patel</font></div><div style="padding-left:10.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;  Vice President &#38; Treasurer</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Quest Diagnostics</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">500 Plaza Drive</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Secaucus, NJ 07094</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri Light',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">The  undersigned hereby consents</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">to each New Seller&#8217;s joinder in the Sale Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MUFG BANK, LTD., as Administrative Agent</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;_</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Eric Williams</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">_______________________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58;&#160;&#160;&#160;&#160;Eric Williams</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Title&#58;&#160;&#160;&#160;&#160;Managing Director</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri Light',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">AMENDED AND RESTATED SCHEDULE 2.1(o)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SELLERS&#8217; FEDERAL TAXPAYER ID NUMBERS&#59; AND LOCATION OF RECORDS</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.810%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.004%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.857%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#b4c6e7;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Location of Records</font></td><td colspan="3" style="background-color:#b4c6e7;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Federal EIN</font></td><td colspan="3" style="background-color:#b4c6e7;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Legal Name of Seller</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline">i</font></div></td><td colspan="3" style="background-color:#b4c6e7;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Fictitious Name (DBA)</font></td><td colspan="3" style="background-color:#b4c6e7;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Prior Legal Name</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline">ii</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"> </font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5785 Corporate Avenue</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cypress, CA 90630</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52-1604494</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Quest Diagnostics Infectious Disease, Inc. (DE)</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Focus Diagnostics, Inc.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(This was a name change)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33608 Ortega Highway</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">San Juan Capistrano, CA 92675</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95-2701802</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quest Diagnostics Nichols Institute  (CA)</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nichols Institute</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:125%">8401 Fallbrook Avenue<br>West Hills, CA  91304</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71-8097031</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unilab Corporation (DE)</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quest Diagnostics</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:125%">27027 Tourney Road<br>Valencia, CA 91355-5386</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95-2961036</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specialty Laboratories, Inc. (CA)</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quest Diagnostics Nichols Institute of Valencia, Inc.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 Sterling Drive</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Wallingford, CT 06492</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">06-0460613</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quest Diagnostics LLC (CT)</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N&#47;A</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1001 Adams Avenue</font><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Norristown, PA  19403</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38-2084239</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Quest Diagnostics Clinical Laboratories, Inc. (DE)</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N&#47;A</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1355 Mittel Blvd.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Wood Dale, IL  60191</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36-4257926</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Quest Diagnostics LLC (IL)</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N&#47;A</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10101 Renner Blvd.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lenexa, KS  66219</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43-1039532</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LabOne, LLC (MO)</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quest Diagnostics</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200 Forest Street</font><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marlborough, MA  01752</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31-1805826</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Athena Diagnostics, Inc. (DE)</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N&#47;A</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200 Forest Street</font><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marlborough, MA  01752</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">04-3248020</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quest Diagnostics LLC (MA)</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quest Diagnostics of Connecticut LLC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1901 Sulphur Spring Road</font><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Baltimore, MD  21227</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52-0890739</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Quest Diagnostics Incorporated (MD)</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N&#47;A</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">506 E. State Parkway</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Schaumburg, IL 60173</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38-2084239</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Quest Diagnostics Clinical Laboratories, Inc. (DE)</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N&#47;A</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quest Diagnostics Incorporated (MI) (merged into QDCL)</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10101 Renner Blvd.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lenexa, KS  66219</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20-1908041</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quest Diagnostics Health and Wellness LLC (DE)</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Summit Health, Inc.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(this was a change of name and entity type)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 Insights Drive</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clifton, NJ 07012</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16-1387862</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quest Diagnostics Incorporated (DE)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> iii</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">QDI Delaware Incorporated</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4380 Federal Drive, Suite 100</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Greensboro, NC 27410</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38-2084239</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quest Diagnostics Clinical Laboratories, Inc. (DE)</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Solstas Lab Partners</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Solstas Lab Partners Group</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Solstas Lab Partners, LLC and Solstas Lab Partners Group, LLC (merged into QDCL)</font></td></tr><tr><td colspan="3" style="background-color:#b4c6e7;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Location of Records</font></td><td colspan="3" style="background-color:#b4c6e7;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Federal EIN</font></td><td colspan="3" style="background-color:#b4c6e7;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Legal Name of Seller</font></td><td colspan="3" style="background-color:#b4c6e7;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Fictitious Name (DBA)</font></td><td colspan="3" style="background-color:#b4c6e7;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Prior Legal Name</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4380 Federal Drive, Suite 100</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Greensboro, NC 27410</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8220;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8220;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4230 Burnham Avenue</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Las Vegas, NV 89119</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88-0099333</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Quest Diagnostics Incorporated  (NV)</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.8pt;padding-right:6.8pt;text-align:center;text-indent:-8.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quest Diagnostics Incorporated of Nevada</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quest Diagnostics</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6700 Steger Drive</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cincinnati, OH 45237</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20-0310967</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LabOne of Ohio, Inc.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(DE)</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LabOne</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quest Diagnostics</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri Light',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.810%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.004%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.857%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4690 Parkway Drive</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mason, OH  45040</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38-2084239</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quest Diagnostics Clinical Laboratories, Inc. (DE)</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MedPlus, Inc. (OH) (merged into QDCL)</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 Parkway Center</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">875 Greentree Road</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pittsburgh, PA  15220</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22-3137283</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quest Diagnostics of Pennsylvania Inc. (DE)</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N&#47;A</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14225 Newbook Drive</font><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chantilly, VA  20153</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54-0854787</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quest Diagnostics Nichols Institute, Inc.  (VA)</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nichols Institute</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10101 Renner Blvd.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lenexa, KS  66219</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:125%">23-2057350</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ExamOne World Wide, Inc. (PA)</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N&#47;A</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2505 3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Avenue, Suite 204</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Seattle, WA  98121</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:125%">37-1768269</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Blueprint Genetics Inc. (DE)</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2560 N. Shadeland Avenue</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indianapolis, IN 46219</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:125%">35-2014838</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mid America Clinical Laboratories, LLC (IN)</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200 Forest Street</font><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marlborough, MA  01752</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:125%">26-2679473</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Reprosource Fertility Diagnostics, Inc. (MA)</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri Light',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri Light',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">                                               </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">i</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  State designations represent the states in which entity is incorporated or organized.  These designations are not part of the legal corporate name, but are included here for reference purposes only.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">ii</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  No prior legal names within the past five years.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">iii</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Corporate office located at 500 Plaza Drive, Secaucus, NJ  07094.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri Light',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>15
<FILENAME>dgx-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:069b4a79-e86e-41e0-954a-e49896ade77c,g:4f5772c6-ef68-44f6-b836-f5065845bef2-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dgx="http://questdiagnostics.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://questdiagnostics.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dgx-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dgx-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dgx-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dgx-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://questdiagnostics.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://questdiagnostics.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" roleURI="http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS">
        <link:definition>0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>0000008 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESS" roleURI="http://questdiagnostics.com/role/DESCRIPTIONOFBUSINESS">
        <link:definition>0000009 - Disclosure - DESCRIPTION OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>0000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITION" roleURI="http://questdiagnostics.com/role/REVENUERECOGNITION">
        <link:definition>0000011 - Disclosure - REVENUE RECOGNITION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSPERSHARE" roleURI="http://questdiagnostics.com/role/EARNINGSPERSHARE">
        <link:definition>0000012 - Disclosure - EARNINGS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGACTIVITIES" roleURI="http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIES">
        <link:definition>0000013 - Disclosure - RESTRUCTURING ACTIVITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSACQUISITIONS" roleURI="http://questdiagnostics.com/role/BUSINESSACQUISITIONS">
        <link:definition>0000014 - Disclosure - BUSINESS ACQUISITIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DISPOSITION" roleURI="http://questdiagnostics.com/role/DISPOSITION">
        <link:definition>0000015 - Disclosure - DISPOSITION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTS" roleURI="http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTS">
        <link:definition>0000016 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TAXESONINCOME" roleURI="http://questdiagnostics.com/role/TAXESONINCOME">
        <link:definition>0000017 - Disclosure - TAXES ON INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUPPLEMENTALCASHFLOWANDOTHERDATA" roleURI="http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATA">
        <link:definition>0000018 - Disclosure - SUPPLEMENTAL CASH FLOW AND OTHER DATA</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYPLANTANDEQUIPMENT" roleURI="http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENT">
        <link:definition>0000019 - Disclosure - PROPERTY, PLANT AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDINTANGIBLEASSETS" roleURI="http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETS">
        <link:definition>0000020 - Disclosure - GOODWILL AND INTANGIBLE ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCOUNTSPAYABLEANDACCRUEDEXPENSES" roleURI="http://questdiagnostics.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSES">
        <link:definition>0000021 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBT" roleURI="http://questdiagnostics.com/role/DEBT">
        <link:definition>0000022 - Disclosure - DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASES" roleURI="http://questdiagnostics.com/role/LEASES">
        <link:definition>0000023 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTS" roleURI="http://questdiagnostics.com/role/FINANCIALINSTRUMENTS">
        <link:definition>0000024 - Disclosure - FINANCIAL INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTEREST" roleURI="http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTEREST">
        <link:definition>0000025 - Disclosure - STOCKHOLDERS&#8217; EQUITY AND REDEEMABLE NONCONTROLLING INTEREST</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKOWNERSHIPANDCOMPENSATIONPLANS" roleURI="http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANS">
        <link:definition>0000026 - Disclosure - STOCK OWNERSHIP AND COMPENSATION PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>0000027 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSSEGMENTINFORMATION" roleURI="http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATION">
        <link:definition>0000028 - Disclosure - BUSINESS SEGMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTS" roleURI="http://questdiagnostics.com/role/SUBSEQUENTEVENTS">
        <link:definition>0000029 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>0000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITIONTables" roleURI="http://questdiagnostics.com/role/REVENUERECOGNITIONTables">
        <link:definition>0000031 - Disclosure - REVENUE RECOGNITION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHARETables" roleURI="http://questdiagnostics.com/role/EARNINGSLOSSPERSHARETables">
        <link:definition>0000032 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGACTIVITIESTables" roleURI="http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESTables">
        <link:definition>0000033 - Disclosure - RESTRUCTURING ACTIVITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSTables" roleURI="http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSTables">
        <link:definition>0000034 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TAXESONINCOMETables" roleURI="http://questdiagnostics.com/role/TAXESONINCOMETables">
        <link:definition>0000035 - Disclosure - TAXES ON INCOME (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUPPLEMENTALCASHFLOWANDOTHERDATATables" roleURI="http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATATables">
        <link:definition>0000036 - Disclosure - SUPPLEMENTAL CASH FLOW AND OTHER DATA (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYPLANTANDEQUIPMENTTables" roleURI="http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENTTables">
        <link:definition>0000037 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDINTANGIBLEASSETSTables" roleURI="http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSTables">
        <link:definition>0000038 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables" roleURI="http://questdiagnostics.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables">
        <link:definition>0000039 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTTables" roleURI="http://questdiagnostics.com/role/DEBTTables">
        <link:definition>0000040 - Disclosure - DEBT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESTables" roleURI="http://questdiagnostics.com/role/LEASESTables">
        <link:definition>0000041 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSTables" roleURI="http://questdiagnostics.com/role/FINANCIALINSTRUMENTSTables">
        <link:definition>0000042 - Disclosure - FINANCIAL INSTRUMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTTables" roleURI="http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTTables">
        <link:definition>0000043 - Disclosure - STOCKHOLDERS&#8217; EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKOWNERSHIPANDCOMPENSATIONPLANSTables" roleURI="http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTables">
        <link:definition>0000044 - Disclosure - STOCK OWNERSHIP AND COMPENSATION PLANS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSSEGMENTINFORMATIONTables" roleURI="http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONTables">
        <link:definition>0000045 - Disclosure - BUSINESS SEGMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" roleURI="http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails">
        <link:definition>0000046 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITIONDetails" roleURI="http://questdiagnostics.com/role/REVENUERECOGNITIONDetails">
        <link:definition>0000047 - Disclosure - REVENUE RECOGNITION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHAREDetails" roleURI="http://questdiagnostics.com/role/EARNINGSLOSSPERSHAREDetails">
        <link:definition>0000048 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGACTIVITIESPreTaxRestructuringchargesDetails" roleURI="http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESPreTaxRestructuringchargesDetails">
        <link:definition>0000049 - Disclosure - RESTRUCTURING ACTIVITIES (Pre-Tax Restructuring charges) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGACTIVITIESNarrativeDetails" roleURI="http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESNarrativeDetails">
        <link:definition>0000050 - Disclosure - RESTRUCTURING ACTIVITIES (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGACTIVITIESActivitiesofRestructuringLiabilitiesDetails" roleURI="http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESActivitiesofRestructuringLiabilitiesDetails">
        <link:definition>0000051 - Disclosure - RESTRUCTURING ACTIVITIES (Activities of Restructuring Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSACQUISITIONSDetails" roleURI="http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails">
        <link:definition>0000052 - Disclosure - BUSINESS ACQUISITIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DISPOSITIONDetails" roleURI="http://questdiagnostics.com/role/DISPOSITIONDetails">
        <link:definition>0000053 - Disclosure - DISPOSITION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails" roleURI="http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails">
        <link:definition>0000054 - Disclosure - FAIR VALUE MEASUREMENTS (Recognized Assets and Liabilities at Fair Value) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSBusinessAcquisitionDetails" roleURI="http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSBusinessAcquisitionDetails">
        <link:definition>0000055 - Disclosure - FAIR VALUE MEASUREMENTS (Business Acquisition) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSNarrativeDetails" roleURI="http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails">
        <link:definition>0000056 - Disclosure - FAIR VALUE MEASUREMENTS (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSReconciliationofBeginningandEndingBalancesofLiabilitiesUnobservableInputsDetails" roleURI="http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSReconciliationofBeginningandEndingBalancesofLiabilitiesUnobservableInputsDetails">
        <link:definition>0000057 - Disclosure - FAIR VALUE MEASUREMENTS (Reconciliation of Beginning and Ending Balances of Liabilities Unobservable Inputs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TAXESONINCOMEDetails" roleURI="http://questdiagnostics.com/role/TAXESONINCOMEDetails">
        <link:definition>0000058 - Disclosure - TAXES ON INCOME (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUPPLEMENTALCASHFLOWANDOTHERDATADetails" roleURI="http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails">
        <link:definition>0000059 - Disclosure - SUPPLEMENTAL CASH FLOW AND OTHER DATA (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYPLANTANDEQUIPMENTDetails" roleURI="http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENTDetails">
        <link:definition>0000060 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDINTANGIBLEASSETSDetails" roleURI="http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails">
        <link:definition>0000061 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails" roleURI="http://questdiagnostics.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails">
        <link:definition>0000062 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTLongTermDebtDetails" roleURI="http://questdiagnostics.com/role/DEBTLongTermDebtDetails">
        <link:definition>0000063 - Disclosure - DEBT (Long-Term Debt) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTFinanceLeaseDetails" roleURI="http://questdiagnostics.com/role/DEBTFinanceLeaseDetails">
        <link:definition>0000064 - Disclosure - DEBT (Finance Lease) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTSecuredReceivablesCreditFacilityNarrativeDetails" roleURI="http://questdiagnostics.com/role/DEBTSecuredReceivablesCreditFacilityNarrativeDetails">
        <link:definition>0000065 - Disclosure - DEBT (Secured Receivables Credit Facility) (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTSeniorUnsecuredRevolvingCreditFacilityNarrativeDetails" roleURI="http://questdiagnostics.com/role/DEBTSeniorUnsecuredRevolvingCreditFacilityNarrativeDetails">
        <link:definition>0000066 - Disclosure - DEBT (Senior Unsecured Revolving Credit Facility) (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTMaturitiesofLongTermDebtDetails" roleURI="http://questdiagnostics.com/role/DEBTMaturitiesofLongTermDebtDetails">
        <link:definition>0000067 - Disclosure - DEBT (Maturities of Long-Term Debt) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESNarrativeDetails" roleURI="http://questdiagnostics.com/role/LEASESNarrativeDetails">
        <link:definition>0000068 - Disclosure - LEASES (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESLiabilitiesDetails" roleURI="http://questdiagnostics.com/role/LEASESLiabilitiesDetails">
        <link:definition>0000069 - Disclosure - LEASES (Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESCostsDetails" roleURI="http://questdiagnostics.com/role/LEASESCostsDetails">
        <link:definition>0000070 - Disclosure - LEASES (Costs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESMaturityDetails" roleURI="http://questdiagnostics.com/role/LEASESMaturityDetails">
        <link:definition>0000071 - Disclosure - LEASES (Maturity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESTermandRateDetails" roleURI="http://questdiagnostics.com/role/LEASESTermandRateDetails">
        <link:definition>0000072 - Disclosure - LEASES (Term and Rate) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSNarrativeDetails" roleURI="http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails">
        <link:definition>0000073 - Disclosure - FINANCIAL INSTRUMENTS (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSBalanceSheetsDetails" roleURI="http://questdiagnostics.com/role/FINANCIALINSTRUMENTSBalanceSheetsDetails">
        <link:definition>0000074 - Disclosure - FINANCIAL INSTRUMENTS (Balance Sheets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSIncomeStatementDetails" roleURI="http://questdiagnostics.com/role/FINANCIALINSTRUMENTSIncomeStatementDetails">
        <link:definition>0000075 - Disclosure - FINANCIAL INSTRUMENTS (Income Statement) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails" roleURI="http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails">
        <link:definition>0000076 - Disclosure - STOCKHOLDERS&#8217; EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTComponentsofAccumulatedOtherComprehensiveLossIncomeDetails" roleURI="http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTComponentsofAccumulatedOtherComprehensiveLossIncomeDetails">
        <link:definition>0000077 - Disclosure - STOCKHOLDERS&#8217; EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Components of Accumulated Other Comprehensive (Loss) Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeandNonemployeeDirectorsStockOwnershipProgramsDetails" roleURI="http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeandNonemployeeDirectorsStockOwnershipProgramsDetails">
        <link:definition>0000078 - Disclosure - STOCK OWNERSHIP AND COMPENSATION PLANS (Employee and Non-employee Directors Stock Ownership Programs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKOWNERSHIPANDCOMPENSATIONPLANSWeightedAverageAssumptionsUsedinValuingOptionsGrantedDetails" roleURI="http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSWeightedAverageAssumptionsUsedinValuingOptionsGrantedDetails">
        <link:definition>0000079 - Disclosure - STOCK OWNERSHIP AND COMPENSATION PLANS (Weighted Average Assumptions Used in Valuing Options Granted) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKOWNERSHIPANDCOMPENSATIONPLANSTransactionsUnderStockOptionPlansDetails" roleURI="http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTransactionsUnderStockOptionPlansDetails">
        <link:definition>0000080 - Disclosure - STOCK OWNERSHIP AND COMPENSATION PLANS (Transactions Under Stock Option Plans) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKOWNERSHIPANDCOMPENSATIONPLANSActivitiesRelatedtoStockAwardsDetails" roleURI="http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSActivitiesRelatedtoStockAwardsDetails">
        <link:definition>0000081 - Disclosure - STOCK OWNERSHIP AND COMPENSATION PLANS (Activities Related to Stock Awards) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeStockPurchasePlanandDefinedContributionPlansDetails" roleURI="http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeStockPurchasePlanandDefinedContributionPlansDetails">
        <link:definition>0000082 - Disclosure - STOCK OWNERSHIP AND COMPENSATION PLANS (Employee Stock Purchase Plan and Defined Contribution Plans) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKOWNERSHIPANDCOMPENSATIONPLANSSupplementalDeferredCompensationPlansDetails" roleURI="http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSSupplementalDeferredCompensationPlansDetails">
        <link:definition>0000083 - Disclosure - STOCK OWNERSHIP AND COMPENSATION PLANS (Supplemental Deferred Compensation Plans) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>0000084 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSSEGMENTINFORMATIONDetails" roleURI="http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails">
        <link:definition>0000085 - Disclosure - BUSINESS SEGMENT INFORMATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTSDetails" roleURI="http://questdiagnostics.com/role/SUBSEQUENTEVENTSDetails">
        <link:definition>0000086 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="dgx_SupplementalDeferredCompensationPlanMember" abstract="true" name="SupplementalDeferredCompensationPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFour" abstract="false" name="LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_FivePointSevenFivePercentSeniorNotesDue2040Member" abstract="true" name="FivePointSevenFivePercentSeniorNotesDue2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_GovernmentPayersMember" abstract="true" name="GovernmentPayersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_ScheduleOfShareholdersEquityLineItems" abstract="true" name="ScheduleOfShareholdersEquityLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dgx_ScheduleofLeaseTermandDiscountRateTableTextBlock" abstract="false" name="ScheduleofLeaseTermandDiscountRateTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="dgx_NetOperatingLossCarryfowardsNetOfValuationAllowance" abstract="false" name="NetOperatingLossCarryfowardsNetOfValuationAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_FinanceLeaseLiabilityRealEstate" abstract="false" name="FinanceLeaseLiabilityRealEstate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeLongTermGrowthRateUsedToDetermineFairValue" abstract="false" name="BusinessCombinationStepAcquisitionEquityInterestInAcquireeLongTermGrowthRateUsedToDetermineFairValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dgx_DonationsContributionsAndOtherFinancialSupport" abstract="false" name="DonationsContributionsAndOtherFinancialSupport" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_ThreePointFourFivePercentSeniorNotesdueJune2026Member" abstract="true" name="ThreePointFourFivePercentSeniorNotesdueJune2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_AnatomicpathologytestingservicesMember" abstract="true" name="AnatomicpathologytestingservicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_ReductionsForChangesInJudgment" abstract="false" name="ReductionsForChangesInJudgment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_BusinessAcquisitionPostacquisitionRevenue" abstract="false" name="BusinessAcquisitionPostacquisitionRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_CommercialPaperAndTermSecuredOvernightFinancingRateMember" abstract="true" name="CommercialPaperAndTermSecuredOvernightFinancingRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearThree" abstract="false" name="LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_AllotherservicesMember" abstract="true" name="AllotherservicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_RevenueCollectionofConsiderationPeriod" abstract="false" name="RevenueCollectionofConsiderationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dgx_TwoPointNineFivePercentSeniorNotesdueJune2030Member" abstract="true" name="TwoPointNineFivePercentSeniorNotesdueJune2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_LeaseRenewalTerm" abstract="false" name="LeaseRenewalTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dgx_ScheduleOfLeaseByAssetTypeTableTextBlock" abstract="false" name="ScheduleOfLeaseByAssetTypeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="dgx_MercyHealthMember" abstract="true" name="MercyHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_SdcpIiMember" abstract="true" name="SdcpIiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_DiagnosticInformationServicesBusinessMember" abstract="true" name="DiagnosticInformationServicesBusinessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_SummaryOfSignificantAccountingPoliciesTable" abstract="true" name="SummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedWorkingCapital" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedWorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_LeaseTypeChangeMember" abstract="true" name="LeaseTypeChangeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_DeferredTaxLiabilityInvestmentsInvestmentsinSubsidiariesandEquitymethodinvestments" abstract="false" name="DeferredTaxLiabilityInvestmentsInvestmentsinSubsidiariesandEquitymethodinvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_FinanceLeaseObligationsandOtherMember" abstract="true" name="FinanceLeaseObligationsandOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_DebtInstrumentExtensionPeriod" abstract="false" name="DebtInstrumentExtensionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedPropertyPlantandEquipmentandWorkingCapital" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedPropertyPlantandEquipmentandWorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_RestatedDirectorLongTermIncentivePlanDltipMember" abstract="true" name="RestatedDirectorLongTermIncentivePlanDltipMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_COVID19TestingServicesMember" abstract="true" name="COVID19TestingServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_PerformanceShareUnitsWithMarketBasedRelativeTSRGoalMember" abstract="true" name="PerformanceShareUnitsWithMarketBasedRelativeTSRGoalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_FiniteLivedIntangibleAssetsEstimatedAmortizationExpenseTotal" abstract="false" name="FiniteLivedIntangibleAssetsEstimatedAmortizationExpenseTotal" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_GoodwillAcquiredDuringPeriodBeforeAdjustments" abstract="false" name="GoodwillAcquiredDuringPeriodBeforeAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_TreasuryStockPurchasedbutNotyetPaid" abstract="false" name="TreasuryStockPurchasedbutNotyetPaid" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_HealthcareInsurersMember" abstract="true" name="HealthcareInsurersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDue" abstract="false" name="LesseeOperatingandFinanceLeaseLiabilityPaymentsDue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_OtherIncomeExpenseMember" abstract="true" name="OtherIncomeExpenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities" abstract="false" name="EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_PeriodofBillingFullyReserve" abstract="false" name="PeriodofBillingFullyReserve" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dgx_DebtInstrumentFairValueBasisAdjustmentAttributableToHedgedDebt" abstract="false" name="DebtInstrumentFairValueBasisAdjustmentAttributableToHedgedDebt" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_StockAwardsMember" abstract="true" name="StockAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_Sharebasedcompensationexcesstaxbenefitamount" abstract="false" name="Sharebasedcompensationexcesstaxbenefitamount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_AccountsReceivableAndAllowanceForCreditLossesPolicyPolicyTextBlock" abstract="false" name="AccountsReceivableAndAllowanceForCreditLossesPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="dgx_EmployeeLongTermIncentivePlanEltipMember" abstract="true" name="EmployeeLongTermIncentivePlanEltipMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeDicountRateUsedToDetermineFairValue" abstract="false" name="BusinessCombinationStepAcquisitionEquityInterestInAcquireeDicountRateUsedToDetermineFairValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dgx_LeaseRemainingLeaseTerm" abstract="false" name="LeaseRemainingLeaseTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFive" abstract="false" name="LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_PatientMember" abstract="true" name="PatientMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_UnrecordedUnconditionalPurchaseObligationDuewithinTwoandThreeYears" abstract="false" name="UnrecordedUnconditionalPurchaseObligationDuewithinTwoandThreeYears" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" abstract="false" name="LesseeOperatingandFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_PackHealthLLCMember" abstract="true" name="PackHealthLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_BlueprintGeneticsOyMember" abstract="true" name="BlueprintGeneticsOyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_MidAmericaClinicalLaboratoriesLLCMACLMember" abstract="true" name="MidAmericaClinicalLaboratoriesLLCMACLMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_SupplementalDeferredCompensationPlanVariableIncentiveCompensationDeferral" abstract="false" name="SupplementalDeferredCompensationPlanVariableIncentiveCompensationDeferral" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dgx_LaboratoryEquipmentFurnitureAndFixturesMember" abstract="true" name="LaboratoryEquipmentFurnitureAndFixturesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_MeasurementInputComparableCompanyRevenueVolatilityMember" abstract="true" name="MeasurementInputComparableCompanyRevenueVolatilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_SeniorunsecuredrevolvingcreditfacilityMember" abstract="true" name="SeniorunsecuredrevolvingcreditfacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_FourPointSevenZeroPercentSeniorNotesdueMarch2045Member" abstract="true" name="FourPointSevenZeroPercentSeniorNotesdueMarch2045Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_MarketPriceOfCompanyStockIssuedAtDiscountUnderEspp" abstract="false" name="MarketPriceOfCompanyStockIssuedAtDiscountUnderEspp" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dgx_TwoPointEightZeroPercentSeniorNotesDueJune2031Member" abstract="true" name="TwoPointEightZeroPercentSeniorNotesDueJune2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_InvigorateProgramMember" abstract="true" name="InvigorateProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_TerminationOfInterestRateSwapAgreements" abstract="false" name="TerminationOfInterestRateSwapAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_ScheduleOfShareBasedPaymentAwardPerformanceShareUnitsValuationAssumptionsTableTextBlock" abstract="false" name="ScheduleOfShareBasedPaymentAwardPerformanceShareUnitsValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="dgx_SupplementalDeferredCompensationPlanSalaryDeferral" abstract="false" name="SupplementalDeferredCompensationPlanSalaryDeferral" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dgx_LeaseLiability" abstract="false" name="LeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_FeeforserviceMember" abstract="true" name="FeeforserviceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_DeferredTaxAssetsOperatingLeaseLiabilitiesNoncurrent" abstract="false" name="DeferredTaxAssetsOperatingLeaseLiabilitiesNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_PercentageofNetRevenues" abstract="false" name="PercentageofNetRevenues" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dgx_AgreementtoOutsourceBillingandCollectionFunction" abstract="false" name="AgreementtoOutsourceBillingandCollectionFunction" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dgx_LeaseRightofUseAsset" abstract="false" name="LeaseRightofUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_IncreaseDecreaseinCommonStockDividendsDeclaredasPercent" abstract="false" name="IncreaseDecreaseinCommonStockDividendsDeclaredasPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dgx_SdcpIiGradedVestingPercentage" abstract="false" name="SdcpIiGradedVestingPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dgx_NetIncomeLossExcludingRedeemableNoncontrollingInterest" abstract="false" name="NetIncomeLossExcludingRedeemableNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_ProceedsFromSaleOfEquityMethodInvestmentsGross" abstract="false" name="ProceedsFromSaleOfEquityMethodInvestmentsGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_Mergerconsiderationpaidpayablenet" abstract="false" name="Mergerconsiderationpaidpayablenet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_ContingentConsiderationMember" abstract="true" name="ContingentConsiderationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_ForeignCurrencyTranslationMember" abstract="true" name="ForeignCurrencyTranslationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_GenebasedandesoterictestingservicesMember" abstract="true" name="GenebasedandesoterictestingservicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_UMassJointVentureMember" abstract="true" name="UMassJointVentureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_SummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="SummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dgx_FundsinatrustpertainingtoallparticipantdeferralsandcompanymatchingamountsrelatedtotheSDCP" abstract="false" name="FundsinatrustpertainingtoallparticipantdeferralsandcompanymatchingamountsrelatedtotheSDCP" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_LongTermDebtMaturitiesGross" abstract="false" name="LongTermDebtMaturitiesGross" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_FourPointTwoZeroPercentSeniorNotesdueJune2029Member" abstract="true" name="FourPointTwoZeroPercentSeniorNotesdueJune2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_TotalAmortizingIntangibleAssetsMember" abstract="true" name="TotalAmortizingIntangibleAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_LabtechDiagnosticsLLCMember" abstract="true" name="LabtechDiagnosticsLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_SixPointNineFivePercentSeniorNotesDue2037Member" abstract="true" name="SixPointNineFivePercentSeniorNotesDue2037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_RoutineclinicaltestingservicesMember" abstract="true" name="RoutineclinicaltestingservicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_ShorttermLeaseandVariableLeaseCost" abstract="false" name="ShorttermLeaseandVariableLeaseCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsTable" abstract="true" name="FiniteLivedAndIndefiniteLivedIntangibleAssetsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="dgx_OtherEquityComponentsMember" abstract="true" name="OtherEquityComponentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_SubstantialOwnershipInterestMember" abstract="true" name="SubstantialOwnershipInterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_PercentageofNetAccountsReceivable" abstract="false" name="PercentageofNetAccountsReceivable" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dgx_InvestmentwithoutReadilyDeterminableFairValueImpairment" abstract="false" name="InvestmentwithoutReadilyDeterminableFairValueImpairment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_LoanCommitmentMember" abstract="true" name="LoanCommitmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_PackHealthAndLabtechMember" abstract="true" name="PackHealthAndLabtechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_EffectiveIncomeTaxRateReconciliationAdjustmentToStateDeferredTaxLiabilities" abstract="false" name="EffectiveIncomeTaxRateReconciliationAdjustmentToStateDeferredTaxLiabilities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dgx_AcceleratedShareRepurchasesPayment" abstract="false" name="AcceleratedShareRepurchasesPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_ClientPayersMember" abstract="true" name="ClientPayersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_LaboratoryEquipmentAndFurnitureAndFixturesMember" abstract="false" name="LaboratoryEquipmentAndFurnitureAndFixturesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_GainLossOnDispositionOfJointVenture" abstract="false" name="GainLossOnDispositionOfJointVenture" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearTwo" abstract="false" name="LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_MemorialHermannMember" abstract="true" name="MemorialHermannMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsAccountsReceivables" abstract="false" name="DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsAccountsReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_EquityMethodInvestmentOwnershipPercentDisposedOf" abstract="false" name="EquityMethodInvestmentOwnershipPercentDisposedOf" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dgx_OperatingLeaseFixedAndVariableCost" abstract="false" name="OperatingLeaseFixedAndVariableCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_AcceleratedShareRepurchaseAgreementsMember" abstract="true" name="AcceleratedShareRepurchaseAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_ThreePointFiveZeroPercentSeniorNotesdueMarch2025Member" abstract="true" name="ThreePointFiveZeroPercentSeniorNotesdueMarch2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_RemainingTermsofContingentLeaseObligationsMaximum" abstract="false" name="RemainingTermsofContingentLeaseObligationsMaximum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dgx_Q2SolutionsMember" abstract="true" name="Q2SolutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dgx_ScheduleOfShareholdersEquityTable" abstract="true" name="ScheduleOfShareholdersEquityTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_MergerConsiderationPayableCurrent" abstract="false" name="MergerConsiderationPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_StockRepurchaseProgramAdditionalAmountAuthorized" abstract="false" name="StockRepurchaseProgramAdditionalAmountAuthorized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" abstract="true" name="FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dgx_DSBusinessesMember" abstract="true" name="DSBusinessesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_RevenueFromContractWithCustomerExcludingAssessedTaxPercent" abstract="false" name="RevenueFromContractWithCustomerExcludingAssessedTaxPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dgx_FinanceandOperatingLeaseLiabilitiesPaymentsDueAbstract" abstract="true" name="FinanceandOperatingLeaseLiabilitiesPaymentsDueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dgx_EffectiveIncomeTaxRateReconciliationChangeForUncertainTaxPosition" abstract="false" name="EffectiveIncomeTaxRateReconciliationChangeForUncertainTaxPosition" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinanceLeaseLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinanceLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_ContractualLifeOfStockOptionsAndOtherAwardsUnderSharedBasedCompensationPlans" abstract="false" name="ContractualLifeOfStockOptionsAndOtherAwardsUnderSharedBasedCompensationPlans" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dgx_CapitatedMember" abstract="true" name="CapitatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_FourpointtwofivepercentSeniorNotesDue2024Member" abstract="true" name="FourpointtwofivepercentSeniorNotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dgx_FairValueOfNetAssetsAcquired" abstract="false" name="FairValueOfNetAssetsAcquired" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_LesseeOperatingandFinanceLeaseLiabilityUndiscountedExcessAmount" abstract="false" name="LesseeOperatingandFinanceLeaseLiabilityUndiscountedExcessAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders" abstract="false" name="TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_OperatingandFinanceLeaseLiability" abstract="false" name="OperatingandFinanceLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueafterYearFive" abstract="false" name="LesseeOperatingandFinanceLeaseLiabilityPaymentsDueafterYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dgx_AccountsReceivableDisaggregationTableTextBlock" abstract="false" name="AccountsReceivableDisaggregationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFiniteLivedIntangibles1" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFiniteLivedIntangibles1" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>16
<FILENAME>dgx-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:069b4a79-e86e-41e0-954a-e49896ade77c,g:4f5772c6-ef68-44f6-b836-f5065845bef2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="dgx-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6215678e-9d79-4560-81ad-bf3c6cebbcdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4ef72ecc-1781-49d2-bde9-12625c10232d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6215678e-9d79-4560-81ad-bf3c6cebbcdf" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4ef72ecc-1781-49d2-bde9-12625c10232d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_7d184029-8085-4911-819e-507dd2e0ccba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6215678e-9d79-4560-81ad-bf3c6cebbcdf" xlink:to="loc_us-gaap_LongTermDebtCurrent_7d184029-8085-4911-819e-507dd2e0ccba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_497b1272-f35b-4582-88ef-45421ec75ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6215678e-9d79-4560-81ad-bf3c6cebbcdf" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_497b1272-f35b-4582-88ef-45421ec75ceb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_063fa65d-8ff4-414c-8242-eda10761246c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ca06eee1-1964-4069-a690-8eec9fe4b9d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_063fa65d-8ff4-414c-8242-eda10761246c" xlink:to="loc_us-gaap_StockholdersEquity_ca06eee1-1964-4069-a690-8eec9fe4b9d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_8165bbce-5ce1-4483-b2c7-56f8cd053e80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_063fa65d-8ff4-414c-8242-eda10761246c" xlink:to="loc_us-gaap_MinorityInterest_8165bbce-5ce1-4483-b2c7-56f8cd053e80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4bfd6647-6582-425b-9367-c7cb58a1f8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e1083e71-7496-4c64-8a4c-76eaf6b66ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4bfd6647-6582-425b-9367-c7cb58a1f8d7" xlink:to="loc_us-gaap_CommonStockValue_e1083e71-7496-4c64-8a4c-76eaf6b66ee0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8e5345ea-e793-4a83-bda0-fcdb2e0fca70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4bfd6647-6582-425b-9367-c7cb58a1f8d7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8e5345ea-e793-4a83-bda0-fcdb2e0fca70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3aff7c9d-137d-48ce-a3a0-f920f826c372" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4bfd6647-6582-425b-9367-c7cb58a1f8d7" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3aff7c9d-137d-48ce-a3a0-f920f826c372" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_710aada7-18fc-4e0b-b2b5-bcb1945ce37e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4bfd6647-6582-425b-9367-c7cb58a1f8d7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_710aada7-18fc-4e0b-b2b5-bcb1945ce37e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_743fde28-d8dd-488a-8739-35894d00ed68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4bfd6647-6582-425b-9367-c7cb58a1f8d7" xlink:to="loc_us-gaap_TreasuryStockValue_743fde28-d8dd-488a-8739-35894d00ed68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f9c444c5-ecb4-4d46-b12f-7a1626d59d31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6b331b30-d997-48ff-9bca-4198dae9c0c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f9c444c5-ecb4-4d46-b12f-7a1626d59d31" xlink:to="loc_us-gaap_LiabilitiesCurrent_6b331b30-d997-48ff-9bca-4198dae9c0c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_e8b55d8e-62a4-4839-9e76-3aaca28d8499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f9c444c5-ecb4-4d46-b12f-7a1626d59d31" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_e8b55d8e-62a4-4839-9e76-3aaca28d8499" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8b24e6dc-7174-45a2-a1c8-03c975f01f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f9c444c5-ecb4-4d46-b12f-7a1626d59d31" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8b24e6dc-7174-45a2-a1c8-03c975f01f6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_23541d0f-9a21-4de5-93e5-85c50a054220" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f9c444c5-ecb4-4d46-b12f-7a1626d59d31" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_23541d0f-9a21-4de5-93e5-85c50a054220" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4f004d5c-7766-4ae0-9d95-68d7714500b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f9c444c5-ecb4-4d46-b12f-7a1626d59d31" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4f004d5c-7766-4ae0-9d95-68d7714500b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_7ec35e6b-454e-4271-b07b-c97be036fbba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f9c444c5-ecb4-4d46-b12f-7a1626d59d31" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_7ec35e6b-454e-4271-b07b-c97be036fbba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f1a70983-a770-4773-807e-ed19d7bc4e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f9c444c5-ecb4-4d46-b12f-7a1626d59d31" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f1a70983-a770-4773-807e-ed19d7bc4e4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_63cc5943-67d5-453b-a079-d2a9b487ec13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d9ed1f40-fb74-4e74-8865-626cce6f771f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_63cc5943-67d5-453b-a079-d2a9b487ec13" xlink:to="loc_us-gaap_AssetsCurrent_d9ed1f40-fb74-4e74-8865-626cce6f771f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e1dcf77f-a9c2-4ec8-85b1-c9263fd2ac41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_63cc5943-67d5-453b-a079-d2a9b487ec13" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e1dcf77f-a9c2-4ec8-85b1-c9263fd2ac41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_a03649da-ff36-435e-8e12-8ccf3066d398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_63cc5943-67d5-453b-a079-d2a9b487ec13" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_a03649da-ff36-435e-8e12-8ccf3066d398" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4cef5fdf-2aa2-4313-9a4e-f6641d69b55e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_63cc5943-67d5-453b-a079-d2a9b487ec13" xlink:to="loc_us-gaap_Goodwill_4cef5fdf-2aa2-4313-9a4e-f6641d69b55e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_87dfc83c-7901-4746-869e-b00fca2d6233" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_63cc5943-67d5-453b-a079-d2a9b487ec13" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_87dfc83c-7901-4746-869e-b00fca2d6233" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_7df03de4-c92e-4f19-9ef2-4d0abe8dc716" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_63cc5943-67d5-453b-a079-d2a9b487ec13" xlink:to="loc_us-gaap_EquityMethodInvestments_7df03de4-c92e-4f19-9ef2-4d0abe8dc716" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_de79e389-afde-43bb-ba49-957d1cc5e085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_63cc5943-67d5-453b-a079-d2a9b487ec13" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_de79e389-afde-43bb-ba49-957d1cc5e085" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1ea27f98-c179-491f-a0d3-854db6dd0045" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e3709d7e-d165-4e64-84e1-606535dd04c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1ea27f98-c179-491f-a0d3-854db6dd0045" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e3709d7e-d165-4e64-84e1-606535dd04c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dafc4f48-c20d-4d07-a9df-5d2b3239df48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1ea27f98-c179-491f-a0d3-854db6dd0045" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_dafc4f48-c20d-4d07-a9df-5d2b3239df48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_c81d3188-a266-4ea5-b9cc-da07a3d66bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1ea27f98-c179-491f-a0d3-854db6dd0045" xlink:to="loc_us-gaap_InventoryNet_c81d3188-a266-4ea5-b9cc-da07a3d66bfa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_060b889f-81a3-453f-bb1c-b16186d985c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1ea27f98-c179-491f-a0d3-854db6dd0045" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_060b889f-81a3-453f-bb1c-b16186d985c4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="dgx-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_be7060b7-5eee-4669-91c1-9d4ac499dde7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e08fe06e-ee86-482e-9ee4-366cd399013e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_be7060b7-5eee-4669-91c1-9d4ac499dde7" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e08fe06e-ee86-482e-9ee4-366cd399013e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8e29ebcb-5f6a-4ea6-ba92-6f8ac6b357c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_be7060b7-5eee-4669-91c1-9d4ac499dde7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8e29ebcb-5f6a-4ea6-ba92-6f8ac6b357c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b2781439-8afe-400b-b61c-e111ebddaa0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_be7060b7-5eee-4669-91c1-9d4ac499dde7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b2781439-8afe-400b-b61c-e111ebddaa0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9a6cda31-e766-4c09-bf1a-814df23ef7be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_51457a25-f62f-4038-aec7-4d4e80f7ad24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9a6cda31-e766-4c09-bf1a-814df23ef7be" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_51457a25-f62f-4038-aec7-4d4e80f7ad24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_deb0fd89-d9e6-4e38-8b49-dcd5629b2e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9a6cda31-e766-4c09-bf1a-814df23ef7be" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_deb0fd89-d9e6-4e38-8b49-dcd5629b2e6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9adf4066-fe3b-40bc-b893-264789e11212" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_3a16d052-b025-45f2-b5dd-4ade075c63f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9adf4066-fe3b-40bc-b893-264789e11212" xlink:to="loc_us-gaap_CostsAndExpenses_3a16d052-b025-45f2-b5dd-4ade075c63f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c08b731c-6111-4551-b148-00aa9112fc65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9adf4066-fe3b-40bc-b893-264789e11212" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c08b731c-6111-4551-b148-00aa9112fc65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ad510e12-607b-430e-aa6d-d80a3722c674" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0f03a036-fdf6-42af-9c72-3dda3ae8763f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ad510e12-607b-430e-aa6d-d80a3722c674" xlink:to="loc_us-gaap_ProfitLoss_0f03a036-fdf6-42af-9c72-3dda3ae8763f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_10e0a91c-3bc4-47c2-a5ea-87cdf87f6cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ad510e12-607b-430e-aa6d-d80a3722c674" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_10e0a91c-3bc4-47c2-a5ea-87cdf87f6cfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_287e80bf-3404-45dc-8ce6-aab9aad2d154" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_03d71b15-1910-434c-9519-a9cb21310275" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_287e80bf-3404-45dc-8ce6-aab9aad2d154" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_03d71b15-1910-434c-9519-a9cb21310275" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_5d1ff842-fb38-4f90-af18-c918586ba209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_287e80bf-3404-45dc-8ce6-aab9aad2d154" xlink:to="loc_us-gaap_CostOfRevenue_5d1ff842-fb38-4f90-af18-c918586ba209" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_73c7379b-86bf-47be-ab7c-32a943f795a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_287e80bf-3404-45dc-8ce6-aab9aad2d154" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_73c7379b-86bf-47be-ab7c-32a943f795a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_34b1fb28-0bd8-44b5-9eda-9fb9f9a78f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_287e80bf-3404-45dc-8ce6-aab9aad2d154" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_34b1fb28-0bd8-44b5-9eda-9fb9f9a78f4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_89f4c764-9fa6-46a5-86de-e0d906b10d38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_c5c5d391-feda-4dac-89df-84bf6c4eb37c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_89f4c764-9fa6-46a5-86de-e0d906b10d38" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_c5c5d391-feda-4dac-89df-84bf6c4eb37c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5e91c706-f719-4b7d-9e33-b4cff91f6c85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_89f4c764-9fa6-46a5-86de-e0d906b10d38" xlink:to="loc_us-gaap_OperatingIncomeLoss_5e91c706-f719-4b7d-9e33-b4cff91f6c85" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="dgx-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:calculationLink xlink:role="http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_3795017d-e524-42d1-b494-7f010f93cec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_80e50183-1989-4aa2-91ae-be644f82348d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_3795017d-e524-42d1-b494-7f010f93cec9" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_80e50183-1989-4aa2-91ae-be644f82348d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_f80a06e2-be5e-4cdb-b69e-a291808ebd47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_3795017d-e524-42d1-b494-7f010f93cec9" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_f80a06e2-be5e-4cdb-b69e-a291808ebd47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_06948f4a-f7ee-481b-9368-a37da4508543" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_73bb971c-9d8c-4be3-aa61-ac4b165e8b00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_06948f4a-f7ee-481b-9368-a37da4508543" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_73bb971c-9d8c-4be3-aa61-ac4b165e8b00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_757c6f7c-bbd4-4708-b492-b0205a9a23d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_06948f4a-f7ee-481b-9368-a37da4508543" xlink:to="loc_us-gaap_ProfitLoss_757c6f7c-bbd4-4708-b492-b0205a9a23d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9f9253d8-5967-4ab9-9d69-53c941591586" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_02d39f87-fc9a-408f-ad05-7af9fed8aafd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9f9253d8-5967-4ab9-9d69-53c941591586" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_02d39f87-fc9a-408f-ad05-7af9fed8aafd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_77b7514a-e525-4f82-a495-f080bb68fd2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9f9253d8-5967-4ab9-9d69-53c941591586" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_77b7514a-e525-4f82-a495-f080bb68fd2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_313d38e6-3666-4ba0-9b98-0d5b66dfbb84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9f9253d8-5967-4ab9-9d69-53c941591586" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_313d38e6-3666-4ba0-9b98-0d5b66dfbb84" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="dgx-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_94944152-a821-491a-976e-770689d9e33b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8d6ec569-8d0a-467a-a347-903a554702af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_94944152-a821-491a-976e-770689d9e33b" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8d6ec569-8d0a-467a-a347-903a554702af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e8c356cc-e83a-4007-9b39-eeee5c2b0ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_94944152-a821-491a-976e-770689d9e33b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e8c356cc-e83a-4007-9b39-eeee5c2b0ae8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_851e6892-9e6a-4db4-993f-28c99ec78210" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_94944152-a821-491a-976e-770689d9e33b" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_851e6892-9e6a-4db4-993f-28c99ec78210" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_ca4ff5aa-2801-4a53-a18e-c47089fea023" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_94944152-a821-491a-976e-770689d9e33b" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_ca4ff5aa-2801-4a53-a18e-c47089fea023" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_03b5fc23-f7b1-4d22-a315-a42a5fb90fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_9cd19dab-cee6-449b-94d1-45696973ff2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_03b5fc23-f7b1-4d22-a315-a42a5fb90fa4" xlink:to="loc_us-gaap_ProfitLoss_9cd19dab-cee6-449b-94d1-45696973ff2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_dd440629-97c9-4fd6-92ee-600412c0ec10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_03b5fc23-f7b1-4d22-a315-a42a5fb90fa4" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_dd440629-97c9-4fd6-92ee-600412c0ec10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_6de668a6-4ffd-43e9-ad0b-749c7c4b0785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_03b5fc23-f7b1-4d22-a315-a42a5fb90fa4" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_6de668a6-4ffd-43e9-ad0b-749c7c4b0785" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1673800c-c2a5-4bf8-acc6-50590d8a736a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_03b5fc23-f7b1-4d22-a315-a42a5fb90fa4" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1673800c-c2a5-4bf8-acc6-50590d8a736a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_03407f49-2c64-4e6d-88dd-911699554e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_03b5fc23-f7b1-4d22-a315-a42a5fb90fa4" xlink:to="loc_us-gaap_ShareBasedCompensation_03407f49-2c64-4e6d-88dd-911699554e1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_GainLossOnDispositionOfJointVenture_c5057a99-802f-4b96-89cd-922e0ca353d1" xlink:href="dgx-20221231.xsd#dgx_GainLossOnDispositionOfJointVenture"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_03b5fc23-f7b1-4d22-a315-a42a5fb90fa4" xlink:to="loc_dgx_GainLossOnDispositionOfJointVenture_c5057a99-802f-4b96-89cd-922e0ca353d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_e9342d05-6ec0-4ba0-af14-b12c622a3974" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_03b5fc23-f7b1-4d22-a315-a42a5fb90fa4" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_e9342d05-6ec0-4ba0-af14-b12c622a3974" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_bef4d091-c17c-42a3-9000-56043d3d11a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_03b5fc23-f7b1-4d22-a315-a42a5fb90fa4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_bef4d091-c17c-42a3-9000-56043d3d11a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_0e9b14bb-958b-45d5-830b-036b288dd40f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_03b5fc23-f7b1-4d22-a315-a42a5fb90fa4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_0e9b14bb-958b-45d5-830b-036b288dd40f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_TerminationOfInterestRateSwapAgreements_1e54896d-fc7e-456f-8f77-051b35695c8f" xlink:href="dgx-20221231.xsd#dgx_TerminationOfInterestRateSwapAgreements"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_03b5fc23-f7b1-4d22-a315-a42a5fb90fa4" xlink:to="loc_dgx_TerminationOfInterestRateSwapAgreements_1e54896d-fc7e-456f-8f77-051b35695c8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_5bc90868-d623-4132-9527-1cd0346be5b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_03b5fc23-f7b1-4d22-a315-a42a5fb90fa4" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_5bc90868-d623-4132-9527-1cd0346be5b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_baf2543a-fea7-40d3-96ef-78d2a809aa51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_03b5fc23-f7b1-4d22-a315-a42a5fb90fa4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_baf2543a-fea7-40d3-96ef-78d2a809aa51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a6447dc8-266f-4ca2-99a7-0ce9d05d0958" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_8da43a2f-2807-4825-b21f-9717f7444341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a6447dc8-266f-4ca2-99a7-0ce9d05d0958" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_8da43a2f-2807-4825-b21f-9717f7444341" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_82d68edf-7460-43e6-92d7-b83b9fe42e14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a6447dc8-266f-4ca2-99a7-0ce9d05d0958" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_82d68edf-7460-43e6-92d7-b83b9fe42e14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_b8d184e7-f034-465a-a4a6-4d7a1da4061f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a6447dc8-266f-4ca2-99a7-0ce9d05d0958" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_b8d184e7-f034-465a-a4a6-4d7a1da4061f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_685cbfea-d254-4d61-b56d-8a226c2673ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a6447dc8-266f-4ca2-99a7-0ce9d05d0958" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_685cbfea-d254-4d61-b56d-8a226c2673ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_461178ba-6446-4998-80ac-4091bd67f534" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a6447dc8-266f-4ca2-99a7-0ce9d05d0958" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_461178ba-6446-4998-80ac-4091bd67f534" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsMinorityInterest_79fb4737-c34b-49ec-909d-6c8bff03b2e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsMinorityInterest"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a6447dc8-266f-4ca2-99a7-0ce9d05d0958" xlink:to="loc_us-gaap_PaymentsOfDividendsMinorityInterest_79fb4737-c34b-49ec-909d-6c8bff03b2e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_0e1f25eb-dc5c-45a0-9a1b-2ea528b53b82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a6447dc8-266f-4ca2-99a7-0ce9d05d0958" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_0e1f25eb-dc5c-45a0-9a1b-2ea528b53b82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_9d532762-20f9-4a02-97a2-32ee57d8dd4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a6447dc8-266f-4ca2-99a7-0ce9d05d0958" xlink:to="loc_us-gaap_RepaymentsOfDebt_9d532762-20f9-4a02-97a2-32ee57d8dd4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1144b924-fe5f-4088-9bd0-b4a15e82795e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dec2745b-39c9-4442-8222-3a6b43f41337" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1144b924-fe5f-4088-9bd0-b4a15e82795e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dec2745b-39c9-4442-8222-3a6b43f41337" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_68572d42-c2a2-435e-8daa-4583d7a09e72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1144b924-fe5f-4088-9bd0-b4a15e82795e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_68572d42-c2a2-435e-8daa-4583d7a09e72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_61f18599-5015-4b15-84c6-6205210c2ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1144b924-fe5f-4088-9bd0-b4a15e82795e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_61f18599-5015-4b15-84c6-6205210c2ed7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#EARNINGSLOSSPERSHAREDetails"/>
  <link:calculationLink xlink:role="http://questdiagnostics.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_07a06f97-44ee-465d-b4a7-4590350c395c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0f7d40ed-544c-4a68-ad0f-21baa967457d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_07a06f97-44ee-465d-b4a7-4590350c395c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0f7d40ed-544c-4a68-ad0f-21baa967457d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_51a6abe0-30a2-462c-954f-aa9533a02aae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_07a06f97-44ee-465d-b4a7-4590350c395c" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_51a6abe0-30a2-462c-954f-aa9533a02aae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_af3f535c-33c9-4998-99b9-850383802a91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_580e6b97-5e04-4340-ad04-b8c393a55954" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_af3f535c-33c9-4998-99b9-850383802a91" xlink:to="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_580e6b97-5e04-4340-ad04-b8c393a55954" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0e5552d3-d2b7-4e18-97d4-fc0ea4115228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_af3f535c-33c9-4998-99b9-850383802a91" xlink:to="loc_us-gaap_NetIncomeLoss_0e5552d3-d2b7-4e18-97d4-fc0ea4115228" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESPreTaxRestructuringchargesDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#RESTRUCTURINGACTIVITIESPreTaxRestructuringchargesDetails"/>
  <link:calculationLink xlink:role="http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESPreTaxRestructuringchargesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_bcc6354d-2e38-421c-b447-82568e8812fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_f64e7cf2-0c37-45f2-a043-073a6a88a554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_bcc6354d-2e38-421c-b447-82568e8812fb" xlink:to="loc_us-gaap_SeveranceCosts1_f64e7cf2-0c37-45f2-a043-073a6a88a554" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringCosts_faf43fca-f629-4eb0-bb20-e92cf0cbd689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_bcc6354d-2e38-421c-b447-82568e8812fb" xlink:to="loc_us-gaap_OtherRestructuringCosts_faf43fca-f629-4eb0-bb20-e92cf0cbd689" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_49765dde-839e-4aef-9a16-0e66711789d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostsAndAssetImpairmentCharges"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_bcc6354d-2e38-421c-b447-82568e8812fb" xlink:to="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_49765dde-839e-4aef-9a16-0e66711789d5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails"/>
  <link:calculationLink xlink:role="http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_a65a1863-8956-4b54-908c-a15f06f6cc4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_46b6c023-499a-4704-8aa1-a478a52ba206" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_a65a1863-8956-4b54-908c-a15f06f6cc4d" xlink:to="loc_us-gaap_TradingSecurities_46b6c023-499a-4704-8aa1-a478a52ba206" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashSurrenderValueFairValueDisclosure_3e037058-5ea0-441f-a7ed-dba760594eee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashSurrenderValueFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_a65a1863-8956-4b54-908c-a15f06f6cc4d" xlink:to="loc_us-gaap_CashSurrenderValueFairValueDisclosure_3e037058-5ea0-441f-a7ed-dba760594eee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities_d306333c-093b-4b0d-865b-d1b7ca1f8c02" xlink:href="dgx-20221231.xsd#dgx_EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_a65a1863-8956-4b54-908c-a15f06f6cc4d" xlink:to="loc_dgx_EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities_d306333c-093b-4b0d-865b-d1b7ca1f8c02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b46ad95d-3c91-454d-b037-5f03da91d32f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_a65a1863-8956-4b54-908c-a15f06f6cc4d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b46ad95d-3c91-454d-b037-5f03da91d32f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_24b14f91-a4ff-45c8-ba52-ce2f669d7a04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_a2e0131c-329d-4091-99c4-2d9c0806d474" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_24b14f91-a4ff-45c8-ba52-ce2f669d7a04" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_a2e0131c-329d-4091-99c4-2d9c0806d474" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_819836c3-5f39-46b8-bc49-b36697f62025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_24b14f91-a4ff-45c8-ba52-ce2f669d7a04" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_819836c3-5f39-46b8-bc49-b36697f62025" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/TAXESONINCOMEDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#TAXESONINCOMEDetails"/>
  <link:calculationLink xlink:role="http://questdiagnostics.com/role/TAXESONINCOMEDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_00ff8b8d-3316-46cc-b59c-1ca173c65bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8199c9ef-9c04-4b26-87a6-b9d58a659214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_00ff8b8d-3316-46cc-b59c-1ca173c65bdd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8199c9ef-9c04-4b26-87a6-b9d58a659214" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_7ff0d141-2aa1-43eb-9f13-0841ccfe9ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_00ff8b8d-3316-46cc-b59c-1ca173c65bdd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_7ff0d141-2aa1-43eb-9f13-0841ccfe9ffe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_d7c9d6ca-6117-436b-b949-fb283374fd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_00ff8b8d-3316-46cc-b59c-1ca173c65bdd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_d7c9d6ca-6117-436b-b949-fb283374fd7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_EffectiveIncomeTaxRateReconciliationAdjustmentToStateDeferredTaxLiabilities_5c1fb10a-1b37-43d4-8291-54c12fb43d4e" xlink:href="dgx-20221231.xsd#dgx_EffectiveIncomeTaxRateReconciliationAdjustmentToStateDeferredTaxLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_00ff8b8d-3316-46cc-b59c-1ca173c65bdd" xlink:to="loc_dgx_EffectiveIncomeTaxRateReconciliationAdjustmentToStateDeferredTaxLiabilities_5c1fb10a-1b37-43d4-8291-54c12fb43d4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_3d4f1946-6c8c-43d0-8126-79a3221c0e31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_00ff8b8d-3316-46cc-b59c-1ca173c65bdd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_3d4f1946-6c8c-43d0-8126-79a3221c0e31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_ecc0bd3a-3ac4-4b72-9586-5f2acfc2e214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_00ff8b8d-3316-46cc-b59c-1ca173c65bdd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_ecc0bd3a-3ac4-4b72-9586-5f2acfc2e214" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_99afabf4-c119-4538-8168-6ea9478f42ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_00ff8b8d-3316-46cc-b59c-1ca173c65bdd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_99afabf4-c119-4538-8168-6ea9478f42ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_00cf3a86-d905-44c5-8457-67fb332ca1dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_00ff8b8d-3316-46cc-b59c-1ca173c65bdd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_00cf3a86-d905-44c5-8457-67fb332ca1dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_EffectiveIncomeTaxRateReconciliationChangeForUncertainTaxPosition_3229b10c-34c7-4acb-9bc4-fc339bb59f95" xlink:href="dgx-20221231.xsd#dgx_EffectiveIncomeTaxRateReconciliationChangeForUncertainTaxPosition"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_00ff8b8d-3316-46cc-b59c-1ca173c65bdd" xlink:to="loc_dgx_EffectiveIncomeTaxRateReconciliationChangeForUncertainTaxPosition_3229b10c-34c7-4acb-9bc4-fc339bb59f95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_0512febc-f919-4710-bc48-f6888971900f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_00ff8b8d-3316-46cc-b59c-1ca173c65bdd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_0512febc-f919-4710-bc48-f6888971900f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_80086183-2ac5-43fe-a9ac-1de1baab59ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_88b328f8-d42e-4561-9839-51e0e9d0253b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_80086183-2ac5-43fe-a9ac-1de1baab59ae" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_88b328f8-d42e-4561-9839-51e0e9d0253b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_9ff737aa-370d-4ad8-b7f5-4ac851e311f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_80086183-2ac5-43fe-a9ac-1de1baab59ae" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_9ff737aa-370d-4ad8-b7f5-4ac851e311f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_4a245db6-a713-4c9d-803b-616951950160" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_80086183-2ac5-43fe-a9ac-1de1baab59ae" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_4a245db6-a713-4c9d-803b-616951950160" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_33dd89da-0437-4015-a03b-7819653ed15c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_80086183-2ac5-43fe-a9ac-1de1baab59ae" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_33dd89da-0437-4015-a03b-7819653ed15c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_809adef2-1ef2-4cc7-a14e-d46dcf6bce17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_80086183-2ac5-43fe-a9ac-1de1baab59ae" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_809adef2-1ef2-4cc7-a14e-d46dcf6bce17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_942c0b02-274b-4b22-a685-1d637d47c3ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_80086183-2ac5-43fe-a9ac-1de1baab59ae" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_942c0b02-274b-4b22-a685-1d637d47c3ae" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#SUPPLEMENTALCASHFLOWANDOTHERDATADetails"/>
  <link:calculationLink xlink:role="http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8b315de7-af34-4a1b-92aa-d872f51c7f64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_58e681ae-c2af-440b-96c6-0a79db8b50a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8b315de7-af34-4a1b-92aa-d872f51c7f64" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_58e681ae-c2af-440b-96c6-0a79db8b50a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_c7a48aee-84ee-470d-82ab-96f5767f07aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8b315de7-af34-4a1b-92aa-d872f51c7f64" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_c7a48aee-84ee-470d-82ab-96f5767f07aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_FairValueOfNetAssetsAcquired_c9ce451a-7a25-4d95-a8e5-ccb375bc4179" xlink:href="dgx-20221231.xsd#dgx_FairValueOfNetAssetsAcquired"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired_6cabcea0-0424-4cb3-bdec-6a4bc6d331f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_FairValueOfNetAssetsAcquired_c9ce451a-7a25-4d95-a8e5-ccb375bc4179" xlink:to="loc_us-gaap_FairValueOfAssetsAcquired_6cabcea0-0424-4cb3-bdec-6a4bc6d331f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAssumed1_6dd31c8e-8648-4091-9ba9-6d18ec8149dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAssumed1"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_FairValueOfNetAssetsAcquired_c9ce451a-7a25-4d95-a8e5-ccb375bc4179" xlink:to="loc_us-gaap_LiabilitiesAssumed1_6dd31c8e-8648-4091-9ba9-6d18ec8149dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_cea5a09e-9cd7-4eff-9b58-99d5d0f0891e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_15866eec-5f77-440a-a03b-b3fc42007937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestIncomeExpenseNet_cea5a09e-9cd7-4eff-9b58-99d5d0f0891e" xlink:to="loc_us-gaap_InterestExpense_15866eec-5f77-440a-a03b-b3fc42007937" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDividendIncomeOperating_ea00504b-a054-443a-8e91-e6be3c6741dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDividendIncomeOperating"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestIncomeExpenseNet_cea5a09e-9cd7-4eff-9b58-99d5d0f0891e" xlink:to="loc_us-gaap_InterestAndDividendIncomeOperating_ea00504b-a054-443a-8e91-e6be3c6741dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_d1b66e62-e8f7-4cc8-b66f-7b1f54c7dcb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_b0b43f60-98ad-4241-869a-f133f73cd4b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_d1b66e62-e8f7-4cc8-b66f-7b1f54c7dcb5" xlink:to="loc_us-gaap_Depreciation_b0b43f60-98ad-4241-869a-f133f73cd4b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_b9baa51d-b372-45f1-9624-4f0fd0378a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_d1b66e62-e8f7-4cc8-b66f-7b1f54c7dcb5" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_b9baa51d-b372-45f1-9624-4f0fd0378a7b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENTDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#PROPERTYPLANTANDEQUIPMENTDetails"/>
  <link:calculationLink xlink:role="http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENTDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8a9cbc06-b12f-4e42-803a-92b984568c79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_3bdeb5b4-46fd-466d-b3a6-e67d009cb77f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_8a9cbc06-b12f-4e42-803a-92b984568c79" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_3bdeb5b4-46fd-466d-b3a6-e67d009cb77f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9a76963f-3690-4b08-b536-4cf6623ad23e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_8a9cbc06-b12f-4e42-803a-92b984568c79" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9a76963f-3690-4b08-b536-4cf6623ad23e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#GOODWILLANDINTANGIBLEASSETSDetails"/>
  <link:calculationLink xlink:role="http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dgx_FiniteLivedIntangibleAssetsEstimatedAmortizationExpenseTotal_e2122182-6f72-47f2-b890-c78c047bffb0" xlink:href="dgx-20221231.xsd#dgx_FiniteLivedIntangibleAssetsEstimatedAmortizationExpenseTotal"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0ce60d27-88e0-4a92-9836-43d514938cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_FiniteLivedIntangibleAssetsEstimatedAmortizationExpenseTotal_e2122182-6f72-47f2-b890-c78c047bffb0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0ce60d27-88e0-4a92-9836-43d514938cd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_7a5b24d5-024d-4c9c-b86a-177b89955110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_FiniteLivedIntangibleAssetsEstimatedAmortizationExpenseTotal_e2122182-6f72-47f2-b890-c78c047bffb0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_7a5b24d5-024d-4c9c-b86a-177b89955110" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_46ad2546-4a53-4708-9481-93a8f39d6a26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_FiniteLivedIntangibleAssetsEstimatedAmortizationExpenseTotal_e2122182-6f72-47f2-b890-c78c047bffb0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_46ad2546-4a53-4708-9481-93a8f39d6a26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_12b3bf58-ca34-46fb-b14d-342b0fe57708" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_FiniteLivedIntangibleAssetsEstimatedAmortizationExpenseTotal_e2122182-6f72-47f2-b890-c78c047bffb0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_12b3bf58-ca34-46fb-b14d-342b0fe57708" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_d36c948f-eeb8-474f-a253-1bdedc745500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_FiniteLivedIntangibleAssetsEstimatedAmortizationExpenseTotal_e2122182-6f72-47f2-b890-c78c047bffb0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_d36c948f-eeb8-474f-a253-1bdedc745500" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_ae35a70c-15f9-4797-8094-15df0e73bcc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_FiniteLivedIntangibleAssetsEstimatedAmortizationExpenseTotal_e2122182-6f72-47f2-b890-c78c047bffb0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_ae35a70c-15f9-4797-8094-15df0e73bcc3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails"/>
  <link:calculationLink xlink:role="http://questdiagnostics.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4d305a21-cb54-42f6-b2d4-d145e1956173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_8029bc4c-c6d2-46fb-9b7b-3f6467a6e534" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4d305a21-cb54-42f6-b2d4-d145e1956173" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_8029bc4c-c6d2-46fb-9b7b-3f6467a6e534" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_fb6d8a91-0611-4ce8-abe9-05481c2df3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4d305a21-cb54-42f6-b2d4-d145e1956173" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_fb6d8a91-0611-4ce8-abe9-05481c2df3e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_f290afc7-b6ff-46bc-b224-e0fcf8599810" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4d305a21-cb54-42f6-b2d4-d145e1956173" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_f290afc7-b6ff-46bc-b224-e0fcf8599810" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_cb420b79-f8b3-40f4-8b6f-ed8d027fa5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4d305a21-cb54-42f6-b2d4-d145e1956173" xlink:to="loc_us-gaap_InterestPayableCurrent_cb420b79-f8b3-40f4-8b6f-ed8d027fa5e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f133063e-a7ed-4e94-8e07-ae9d3bf3c10e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4d305a21-cb54-42f6-b2d4-d145e1956173" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_f133063e-a7ed-4e94-8e07-ae9d3bf3c10e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_49bf9b05-c92e-47ad-a486-a484a56dd37a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4d305a21-cb54-42f6-b2d4-d145e1956173" xlink:to="loc_us-gaap_DividendsPayableCurrent_49bf9b05-c92e-47ad-a486-a484a56dd37a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent_71a019a0-a051-458c-98a6-898a31f0ddc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4d305a21-cb54-42f6-b2d4-d145e1956173" xlink:to="loc_us-gaap_AccruedInsuranceCurrent_71a019a0-a051-458c-98a6-898a31f0ddc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankOverdrafts_ce155252-9b80-47db-b859-2d5b47f24df7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankOverdrafts"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4d305a21-cb54-42f6-b2d4-d145e1956173" xlink:to="loc_us-gaap_BankOverdrafts_ce155252-9b80-47db-b859-2d5b47f24df7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_MergerConsiderationPayableCurrent_1317d8b9-d61e-463f-9c14-a6fb504db917" xlink:href="dgx-20221231.xsd#dgx_MergerConsiderationPayableCurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4d305a21-cb54-42f6-b2d4-d145e1956173" xlink:to="loc_dgx_MergerConsiderationPayableCurrent_1317d8b9-d61e-463f-9c14-a6fb504db917" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/DEBTLongTermDebtDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#DEBTLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://questdiagnostics.com/role/DEBTLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_b50956aa-84d0-46cb-b3be-6c2328ac6878" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_c04c94c5-c06e-46ce-b350-02c46bdd4a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_b50956aa-84d0-46cb-b3be-6c2328ac6878" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_c04c94c5-c06e-46ce-b350-02c46bdd4a7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_c2271fc6-3cc3-4894-8714-56b51b8b9b25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_b50956aa-84d0-46cb-b3be-6c2328ac6878" xlink:to="loc_us-gaap_LongTermDebtCurrent_c2271fc6-3cc3-4894-8714-56b51b8b9b25" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/DEBTMaturitiesofLongTermDebtDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#DEBTMaturitiesofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://questdiagnostics.com/role/DEBTMaturitiesofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_7525ef9d-29ef-4c18-a46c-eeb9aca6e8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LongTermDebtMaturitiesGross_7a7e680b-f3a7-41ec-af6a-5ae04c2c3095" xlink:href="dgx-20221231.xsd#dgx_LongTermDebtMaturitiesGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_7525ef9d-29ef-4c18-a46c-eeb9aca6e8cd" xlink:to="loc_dgx_LongTermDebtMaturitiesGross_7a7e680b-f3a7-41ec-af6a-5ae04c2c3095" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_8850d141-80eb-41bc-8f48-bcceb591a7b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_7525ef9d-29ef-4c18-a46c-eeb9aca6e8cd" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_8850d141-80eb-41bc-8f48-bcceb591a7b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_7bd5ade9-5f35-4402-bbe5-42f705842992" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_7525ef9d-29ef-4c18-a46c-eeb9aca6e8cd" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_7bd5ade9-5f35-4402-bbe5-42f705842992" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_DebtInstrumentFairValueBasisAdjustmentAttributableToHedgedDebt_8e68bee4-7c26-4fe1-82ee-3671dd35e9a1" xlink:href="dgx-20221231.xsd#dgx_DebtInstrumentFairValueBasisAdjustmentAttributableToHedgedDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_7525ef9d-29ef-4c18-a46c-eeb9aca6e8cd" xlink:to="loc_dgx_DebtInstrumentFairValueBasisAdjustmentAttributableToHedgedDebt_8e68bee4-7c26-4fe1-82ee-3671dd35e9a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LongTermDebtMaturitiesGross_f55f1c07-7bd0-46ad-bce1-0fc3a4a97ca7" xlink:href="dgx-20221231.xsd#dgx_LongTermDebtMaturitiesGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_ebe13972-a152-4429-83a9-fead55bf0754" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_LongTermDebtMaturitiesGross_f55f1c07-7bd0-46ad-bce1-0fc3a4a97ca7" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_ebe13972-a152-4429-83a9-fead55bf0754" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_04938606-19a5-41ba-aa3c-842d6b66e537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_LongTermDebtMaturitiesGross_f55f1c07-7bd0-46ad-bce1-0fc3a4a97ca7" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_04938606-19a5-41ba-aa3c-842d6b66e537" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_15985e54-886b-48a8-9180-9f5176b4b844" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_LongTermDebtMaturitiesGross_f55f1c07-7bd0-46ad-bce1-0fc3a4a97ca7" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_15985e54-886b-48a8-9180-9f5176b4b844" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_4ea3b7f9-08e8-429d-ab67-9fea19519856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_LongTermDebtMaturitiesGross_f55f1c07-7bd0-46ad-bce1-0fc3a4a97ca7" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_4ea3b7f9-08e8-429d-ab67-9fea19519856" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_25866f2d-a443-4dc2-9a87-7ab846f8cb8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_LongTermDebtMaturitiesGross_f55f1c07-7bd0-46ad-bce1-0fc3a4a97ca7" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_25866f2d-a443-4dc2-9a87-7ab846f8cb8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_faf0d2c6-9c9f-4e3e-a4df-5aad58c0868e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_LongTermDebtMaturitiesGross_f55f1c07-7bd0-46ad-bce1-0fc3a4a97ca7" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_faf0d2c6-9c9f-4e3e-a4df-5aad58c0868e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/LEASESLiabilitiesDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#LEASESLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://questdiagnostics.com/role/LEASESLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LeaseRightofUseAsset_a77ea187-42fc-4efd-9624-82f0084d4ff7" xlink:href="dgx-20221231.xsd#dgx_LeaseRightofUseAsset"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_32e4377b-f84f-4c83-8723-1fa3df1130a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_LeaseRightofUseAsset_a77ea187-42fc-4efd-9624-82f0084d4ff7" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_32e4377b-f84f-4c83-8723-1fa3df1130a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_12f596be-5ae1-4e74-85e9-d3e4277e8506" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_LeaseRightofUseAsset_a77ea187-42fc-4efd-9624-82f0084d4ff7" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_12f596be-5ae1-4e74-85e9-d3e4277e8506" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LeaseLiability_dda8b1af-a38f-4ec0-b398-b8b92a08eb18" xlink:href="dgx-20221231.xsd#dgx_LeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8dd9f1af-0278-4bb9-a627-f6295d92043e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_LeaseLiability_dda8b1af-a38f-4ec0-b398-b8b92a08eb18" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8dd9f1af-0278-4bb9-a627-f6295d92043e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_9231ee5c-0607-4724-aa31-7fadffaecc0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_LeaseLiability_dda8b1af-a38f-4ec0-b398-b8b92a08eb18" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_9231ee5c-0607-4724-aa31-7fadffaecc0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_60938e8d-50ab-4d83-94a7-6bea74c9643e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_LeaseLiability_dda8b1af-a38f-4ec0-b398-b8b92a08eb18" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_60938e8d-50ab-4d83-94a7-6bea74c9643e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_29e465f6-579b-4fa9-8345-edce298b66c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_LeaseLiability_dda8b1af-a38f-4ec0-b398-b8b92a08eb18" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_29e465f6-579b-4fa9-8345-edce298b66c2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/LEASESCostsDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#LEASESCostsDetails"/>
  <link:calculationLink xlink:role="http://questdiagnostics.com/role/LEASESCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_a2464cc1-ca0a-4ed9-a252-2a40c8bd5015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_159b863d-8513-4056-a643-0fcda0df1764" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_a2464cc1-ca0a-4ed9-a252-2a40c8bd5015" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_159b863d-8513-4056-a643-0fcda0df1764" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_OperatingLeaseFixedAndVariableCost_535b4506-3b11-4651-8bcb-94e015530123" xlink:href="dgx-20221231.xsd#dgx_OperatingLeaseFixedAndVariableCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_a2464cc1-ca0a-4ed9-a252-2a40c8bd5015" xlink:to="loc_dgx_OperatingLeaseFixedAndVariableCost_535b4506-3b11-4651-8bcb-94e015530123" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_5e66d05f-ee46-4fad-b208-44c034a1bdd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_a2464cc1-ca0a-4ed9-a252-2a40c8bd5015" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_5e66d05f-ee46-4fad-b208-44c034a1bdd9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/LEASESMaturityDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#LEASESMaturityDetails"/>
  <link:calculationLink xlink:role="http://questdiagnostics.com/role/LEASESMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearThree_4a0d9ff9-82c3-48f5-a879-d7f972f9c165" xlink:href="dgx-20221231.xsd#dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_237b12a6-3665-41eb-908c-a14c48891b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearThree_4a0d9ff9-82c3-48f5-a879-d7f972f9c165" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_237b12a6-3665-41eb-908c-a14c48891b9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_770d12d3-28ad-48e4-9673-3ce827d9746e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearThree_4a0d9ff9-82c3-48f5-a879-d7f972f9c165" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_770d12d3-28ad-48e4-9673-3ce827d9746e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_0e1ba399-3ee5-4a53-a415-d8dc56f675a9" xlink:href="dgx-20221231.xsd#dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_cd9b0c70-c91b-472b-a130-fe14894c9585" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_0e1ba399-3ee5-4a53-a415-d8dc56f675a9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_cd9b0c70-c91b-472b-a130-fe14894c9585" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_ad7acb04-b4c6-4272-a5a8-92c6acf30578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_0e1ba399-3ee5-4a53-a415-d8dc56f675a9" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_ad7acb04-b4c6-4272-a5a8-92c6acf30578" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFour_cee39d00-a95b-45b0-b5ea-8069fc0adbf4" xlink:href="dgx-20221231.xsd#dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_83d0b83d-fe26-4f9a-8e90-3e03ec094a57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFour_cee39d00-a95b-45b0-b5ea-8069fc0adbf4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_83d0b83d-fe26-4f9a-8e90-3e03ec094a57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_d76a6740-2e7b-4c6e-819a-63173c5fe23d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFour_cee39d00-a95b-45b0-b5ea-8069fc0adbf4" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_d76a6740-2e7b-4c6e-819a-63173c5fe23d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_OperatingandFinanceLeaseLiability_0f7a2d8c-b036-45fa-a2ad-ae90d3c7b817" xlink:href="dgx-20221231.xsd#dgx_OperatingandFinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_79483b81-e641-4171-a31a-2e0f22a3f808" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_OperatingandFinanceLeaseLiability_0f7a2d8c-b036-45fa-a2ad-ae90d3c7b817" xlink:to="loc_us-gaap_OperatingLeaseLiability_79483b81-e641-4171-a31a-2e0f22a3f808" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_0d08ca49-6467-4bf8-ab9d-6713b70af21a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_OperatingandFinanceLeaseLiability_0f7a2d8c-b036-45fa-a2ad-ae90d3c7b817" xlink:to="loc_us-gaap_FinanceLeaseLiability_0d08ca49-6467-4bf8-ab9d-6713b70af21a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_be66fe49-93b1-478a-a5c6-2cee3f169527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e2afa8a7-592a-4692-8e2b-3c6465576ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_be66fe49-93b1-478a-a5c6-2cee3f169527" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e2afa8a7-592a-4692-8e2b-3c6465576ec0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5356587e-5d5b-484f-b8d3-aa342f5c85dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_be66fe49-93b1-478a-a5c6-2cee3f169527" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5356587e-5d5b-484f-b8d3-aa342f5c85dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2298503a-f0c8-4776-9f9f-32f70fa93a66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_be66fe49-93b1-478a-a5c6-2cee3f169527" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2298503a-f0c8-4776-9f9f-32f70fa93a66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ab73679e-83ba-4755-b883-b8c7b5b70840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_be66fe49-93b1-478a-a5c6-2cee3f169527" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ab73679e-83ba-4755-b883-b8c7b5b70840" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_0fa2060c-5dea-489e-b709-cc2a0a0e7b34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_be66fe49-93b1-478a-a5c6-2cee3f169527" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_0fa2060c-5dea-489e-b709-cc2a0a0e7b34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_3a8d6373-7729-4fba-9b79-9580b60a5691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_be66fe49-93b1-478a-a5c6-2cee3f169527" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_3a8d6373-7729-4fba-9b79-9580b60a5691" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDue_1fff61d1-c8c0-40f3-84ce-87a8f1f3e320" xlink:href="dgx-20221231.xsd#dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_86786aa5-d462-45b7-b740-c2d9a6b30b8a" xlink:href="dgx-20221231.xsd#dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDue_1fff61d1-c8c0-40f3-84ce-87a8f1f3e320" xlink:to="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_86786aa5-d462-45b7-b740-c2d9a6b30b8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearTwo_9d2a52cb-4051-4f5d-80e7-d84d6d2bd054" xlink:href="dgx-20221231.xsd#dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDue_1fff61d1-c8c0-40f3-84ce-87a8f1f3e320" xlink:to="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearTwo_9d2a52cb-4051-4f5d-80e7-d84d6d2bd054" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearThree_788e028e-60b8-447a-a6f0-fbf0630cf050" xlink:href="dgx-20221231.xsd#dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDue_1fff61d1-c8c0-40f3-84ce-87a8f1f3e320" xlink:to="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearThree_788e028e-60b8-447a-a6f0-fbf0630cf050" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFour_ad4ac7ce-aaeb-4237-b67f-85c5121864fd" xlink:href="dgx-20221231.xsd#dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDue_1fff61d1-c8c0-40f3-84ce-87a8f1f3e320" xlink:to="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFour_ad4ac7ce-aaeb-4237-b67f-85c5121864fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFive_f0343c13-0aee-4eee-8d97-63d1600a9055" xlink:href="dgx-20221231.xsd#dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDue_1fff61d1-c8c0-40f3-84ce-87a8f1f3e320" xlink:to="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFive_f0343c13-0aee-4eee-8d97-63d1600a9055" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueafterYearFive_cd491bb8-a115-4ac8-b6e5-cb8307ae5ae9" xlink:href="dgx-20221231.xsd#dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueafterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDue_1fff61d1-c8c0-40f3-84ce-87a8f1f3e320" xlink:to="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueafterYearFive_cd491bb8-a115-4ac8-b6e5-cb8307ae5ae9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFive_823e28a4-18a9-4abf-b057-a26f6848874f" xlink:href="dgx-20221231.xsd#dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7fd4635a-14b4-42b1-a0d8-d2fa360a26c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFive_823e28a4-18a9-4abf-b057-a26f6848874f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7fd4635a-14b4-42b1-a0d8-d2fa360a26c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_e8a6ca08-7236-4877-8923-6bf2526b3b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFive_823e28a4-18a9-4abf-b057-a26f6848874f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_e8a6ca08-7236-4877-8923-6bf2526b3b6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_8e2c72db-3efb-41df-b5a1-0d504a55ff6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_0b0ec6f1-11bf-4051-9eaf-2e9b484547d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_8e2c72db-3efb-41df-b5a1-0d504a55ff6b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_0b0ec6f1-11bf-4051-9eaf-2e9b484547d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_3f0e3ccb-605c-4816-811c-ca89ef6b5506" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_8e2c72db-3efb-41df-b5a1-0d504a55ff6b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_3f0e3ccb-605c-4816-811c-ca89ef6b5506" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_05a10fbe-52e7-43d3-8af0-108e97988783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_8e2c72db-3efb-41df-b5a1-0d504a55ff6b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_05a10fbe-52e7-43d3-8af0-108e97988783" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_88220baf-b746-4003-b465-1e29bed08aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_8e2c72db-3efb-41df-b5a1-0d504a55ff6b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_88220baf-b746-4003-b465-1e29bed08aeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_7ac10495-6dba-4a5d-b463-d7d8e4d3f51b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_8e2c72db-3efb-41df-b5a1-0d504a55ff6b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_7ac10495-6dba-4a5d-b463-d7d8e4d3f51b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_534c135e-6b16-4288-975c-40d499eb729d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_8e2c72db-3efb-41df-b5a1-0d504a55ff6b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_534c135e-6b16-4288-975c-40d499eb729d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearTwo_a2237f82-4d12-4e0d-8164-08517125db0c" xlink:href="dgx-20221231.xsd#dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_63c0dcbc-9e54-4ad4-adc6-d34475e04cac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearTwo_a2237f82-4d12-4e0d-8164-08517125db0c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_63c0dcbc-9e54-4ad4-adc6-d34475e04cac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_d4a932dc-73d4-41d0-a231-5d985e98e295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearTwo_a2237f82-4d12-4e0d-8164-08517125db0c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_d4a932dc-73d4-41d0-a231-5d985e98e295" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityUndiscountedExcessAmount_3295289c-9088-43a6-ac62-1afaa52520f7" xlink:href="dgx-20221231.xsd#dgx_LesseeOperatingandFinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d8f2894d-7363-4383-ad69-73894e13dd73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityUndiscountedExcessAmount_3295289c-9088-43a6-ac62-1afaa52520f7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d8f2894d-7363-4383-ad69-73894e13dd73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_b8a55070-96fb-4b56-84a0-2cc76db7e727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityUndiscountedExcessAmount_3295289c-9088-43a6-ac62-1afaa52520f7" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_b8a55070-96fb-4b56-84a0-2cc76db7e727" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueafterYearFive_f8fec22e-1d2c-48cc-a466-dd0f3ef20820" xlink:href="dgx-20221231.xsd#dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueafterYearFive"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_cb6f81e2-7558-41a2-a853-30029a7d8e85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueafterYearFive_f8fec22e-1d2c-48cc-a466-dd0f3ef20820" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_cb6f81e2-7558-41a2-a853-30029a7d8e85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_551211fe-2527-4664-8f5d-490a1eae65a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueafterYearFive_f8fec22e-1d2c-48cc-a466-dd0f3ef20820" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_551211fe-2527-4664-8f5d-490a1eae65a7" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>17
<FILENAME>dgx-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:069b4a79-e86e-41e0-954a-e49896ade77c,g:4f5772c6-ef68-44f6-b836-f5065845bef2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="dgx-20221231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="ib2ce74689afa461fbee300bd8236f399_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_60a8c085-5cf7-4ca0-9e7d-70f92c863657" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33dad717-beb3-452b-bb49-c60935671fad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_60a8c085-5cf7-4ca0-9e7d-70f92c863657" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33dad717-beb3-452b-bb49-c60935671fad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_800ac6d6-69f2-45d5-9a5f-543a59792734" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33dad717-beb3-452b-bb49-c60935671fad" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_800ac6d6-69f2-45d5-9a5f-543a59792734" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3ecc7b52-0b38-4b95-b8d7-1b78574d9978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33dad717-beb3-452b-bb49-c60935671fad" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3ecc7b52-0b38-4b95-b8d7-1b78574d9978" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_NetIncomeLossExcludingRedeemableNoncontrollingInterest_439d4379-bf6b-4fdd-a161-1471647451dc" xlink:href="dgx-20221231.xsd#dgx_NetIncomeLossExcludingRedeemableNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33dad717-beb3-452b-bb49-c60935671fad" xlink:to="loc_dgx_NetIncomeLossExcludingRedeemableNoncontrollingInterest_439d4379-bf6b-4fdd-a161-1471647451dc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_19ee3427-6642-42d5-90b3-4e4c199e994e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33dad717-beb3-452b-bb49-c60935671fad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_19ee3427-6642-42d5-90b3-4e4c199e994e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_04d24445-2e35-4109-a33e-85688ff67465" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33dad717-beb3-452b-bb49-c60935671fad" xlink:to="loc_us-gaap_DividendsCommonStockCash_04d24445-2e35-4109-a33e-85688ff67465" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_6d005d63-f6cd-4ecb-8d85-b5532e4ede63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33dad717-beb3-452b-bb49-c60935671fad" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_6d005d63-f6cd-4ecb-8d85-b5532e4ede63" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_97f04231-ebc6-4ab3-b612-8ccc4202593e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33dad717-beb3-452b-bb49-c60935671fad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_97f04231-ebc6-4ab3-b612-8ccc4202593e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_60d2ce5d-a3ff-4b85-a827-5e716d942c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33dad717-beb3-452b-bb49-c60935671fad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_60d2ce5d-a3ff-4b85-a827-5e716d942c5a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4d0fa9cf-40e5-4825-9fef-52a63101b2ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33dad717-beb3-452b-bb49-c60935671fad" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4d0fa9cf-40e5-4825-9fef-52a63101b2ae" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9bc90cb1-7afa-4ee0-bb61-88998c450dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33dad717-beb3-452b-bb49-c60935671fad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9bc90cb1-7afa-4ee0-bb61-88998c450dfa" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_bcca0449-b09c-46e8-8d6c-f8c62c5dc053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33dad717-beb3-452b-bb49-c60935671fad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_bcca0449-b09c-46e8-8d6c-f8c62c5dc053" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_288bd04c-5c3d-4ccd-8dd0-7e16a41a1306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33dad717-beb3-452b-bb49-c60935671fad" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_288bd04c-5c3d-4ccd-8dd0-7e16a41a1306" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_1e9df0fd-b4b6-4191-9a36-10ac61e3827d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33dad717-beb3-452b-bb49-c60935671fad" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_1e9df0fd-b4b6-4191-9a36-10ac61e3827d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_91ee759d-f73d-4603-8ccc-fdb7f04be1e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33dad717-beb3-452b-bb49-c60935671fad" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_91ee759d-f73d-4603-8ccc-fdb7f04be1e5" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_c6de5bc6-1c41-45ef-a73f-2fff4e458f04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33dad717-beb3-452b-bb49-c60935671fad" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_c6de5bc6-1c41-45ef-a73f-2fff4e458f04" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7f8755bb-690b-4e54-9d1f-d9e3c0965107" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_204169ae-6633-486e-97ad-23ff97b6a407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5f59402a-9366-4f7a-abf4-6e25249b59e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_60a8c085-5cf7-4ca0-9e7d-70f92c863657" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5f59402a-9366-4f7a-abf4-6e25249b59e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_e585f7d9-9b6c-4faa-a530-b42a237dbbbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5f59402a-9366-4f7a-abf4-6e25249b59e1" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_e585f7d9-9b6c-4faa-a530-b42a237dbbbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityNetIncome_59af26a0-1d12-4e78-9e81-458922b150d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityNetIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5f59402a-9366-4f7a-abf4-6e25249b59e1" xlink:to="loc_us-gaap_TemporaryEquityNetIncome_59af26a0-1d12-4e78-9e81-458922b150d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders_be2ab2da-15dd-44b3-a549-62bfc21765f0" xlink:href="dgx-20221231.xsd#dgx_TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5f59402a-9366-4f7a-abf4-6e25249b59e1" xlink:to="loc_dgx_TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders_be2ab2da-15dd-44b3-a549-62bfc21765f0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_e59f601e-7adc-47d7-94ab-85bc3b4903d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_08b62ac9-609d-42c2-9a43-c41ee4e7a9d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_60a8c085-5cf7-4ca0-9e7d-70f92c863657" xlink:to="loc_us-gaap_StatementTable_08b62ac9-609d-42c2-9a43-c41ee4e7a9d1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_89f40c50-4232-4757-a3fd-25c6285133cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_08b62ac9-609d-42c2-9a43-c41ee4e7a9d1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_89f40c50-4232-4757-a3fd-25c6285133cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_89f40c50-4232-4757-a3fd-25c6285133cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_89f40c50-4232-4757-a3fd-25c6285133cf" xlink:to="loc_us-gaap_EquityComponentDomain_89f40c50-4232-4757-a3fd-25c6285133cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3ae55769-fbae-46d1-b5de-7dc83b3cc329" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_89f40c50-4232-4757-a3fd-25c6285133cf" xlink:to="loc_us-gaap_EquityComponentDomain_3ae55769-fbae-46d1-b5de-7dc83b3cc329" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f506ecae-e2d0-4823-8de8-197109ec14d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3ae55769-fbae-46d1-b5de-7dc83b3cc329" xlink:to="loc_us-gaap_CommonStockMember_f506ecae-e2d0-4823-8de8-197109ec14d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_41c8833d-3d28-4ec9-bfad-8e521c2d4387" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3ae55769-fbae-46d1-b5de-7dc83b3cc329" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_41c8833d-3d28-4ec9-bfad-8e521c2d4387" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_813c722c-0c66-4375-8264-07445ad73321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3ae55769-fbae-46d1-b5de-7dc83b3cc329" xlink:to="loc_us-gaap_RetainedEarningsMember_813c722c-0c66-4375-8264-07445ad73321" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ff8fa9c6-5f6c-4c95-9434-e9fd049be125" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3ae55769-fbae-46d1-b5de-7dc83b3cc329" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ff8fa9c6-5f6c-4c95-9434-e9fd049be125" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_840b3578-45e7-47d8-b561-64945932385d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3ae55769-fbae-46d1-b5de-7dc83b3cc329" xlink:to="loc_us-gaap_TreasuryStockMember_840b3578-45e7-47d8-b561-64945932385d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_7da121c1-d3c6-4220-b268-f1fc5f043c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3ae55769-fbae-46d1-b5de-7dc83b3cc329" xlink:to="loc_us-gaap_NoncontrollingInterestMember_7da121c1-d3c6-4220-b268-f1fc5f043c89" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <link:definitionLink xlink:role="http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="extended" id="i26d369da45734f0eb4eb45193320d4b9_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_dgx_SummaryOfSignificantAccountingPoliciesLineItems_4f36536c-fb46-4974-8902-d97e63716ea3" xlink:href="dgx-20221231.xsd#dgx_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_9ba11a07-4ce4-4d6b-b52c-aae3c7084fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesLineItems_4f36536c-fb46-4974-8902-d97e63716ea3" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_9ba11a07-4ce4-4d6b-b52c-aae3c7084fb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_6e729580-d9d1-4021-836a-c39bfb004135" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesLineItems_4f36536c-fb46-4974-8902-d97e63716ea3" xlink:to="loc_us-gaap_EquityMethodInvestments_6e729580-d9d1-4021-836a-c39bfb004135" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_PercentageofNetRevenues_d806bc9f-bc3b-472f-b3fd-c3710d13d0e1" xlink:href="dgx-20221231.xsd#dgx_PercentageofNetRevenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesLineItems_4f36536c-fb46-4974-8902-d97e63716ea3" xlink:to="loc_dgx_PercentageofNetRevenues_d806bc9f-bc3b-472f-b3fd-c3710d13d0e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3ea35ae1-4e04-4d0b-a830-d35c223827e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesLineItems_4f36536c-fb46-4974-8902-d97e63716ea3" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3ea35ae1-4e04-4d0b-a830-d35c223827e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_PercentageofNetAccountsReceivable_569ea57c-f012-40e7-9250-6394f8bb6146" xlink:href="dgx-20221231.xsd#dgx_PercentageofNetAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesLineItems_4f36536c-fb46-4974-8902-d97e63716ea3" xlink:to="loc_dgx_PercentageofNetAccountsReceivable_569ea57c-f012-40e7-9250-6394f8bb6146" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1ce4989f-e233-418a-867c-ea36e0398729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesLineItems_4f36536c-fb46-4974-8902-d97e63716ea3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1ce4989f-e233-418a-867c-ea36e0398729" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1435c208-5dda-43ca-a93b-2e900ffc6893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesLineItems_4f36536c-fb46-4974-8902-d97e63716ea3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1435c208-5dda-43ca-a93b-2e900ffc6893" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e4dbfed9-fa44-42d3-9cd6-0d01ad91f4f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesLineItems_4f36536c-fb46-4974-8902-d97e63716ea3" xlink:to="loc_us-gaap_OperatingIncomeLoss_e4dbfed9-fa44-42d3-9cd6-0d01ad91f4f4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f4004684-700c-43a6-bef7-cbe9db7a96d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesLineItems_4f36536c-fb46-4974-8902-d97e63716ea3" xlink:to="loc_us-gaap_ProfitLoss_f4004684-700c-43a6-bef7-cbe9db7a96d1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_62a23ca3-1d98-466e-92de-23f2b2e7b228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesLineItems_4f36536c-fb46-4974-8902-d97e63716ea3" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_62a23ca3-1d98-466e-92de-23f2b2e7b228" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_InvestmentwithoutReadilyDeterminableFairValueImpairment_bbccf26a-325d-4d8a-a729-09b396670537" xlink:href="dgx-20221231.xsd#dgx_InvestmentwithoutReadilyDeterminableFairValueImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesLineItems_4f36536c-fb46-4974-8902-d97e63716ea3" xlink:to="loc_dgx_InvestmentwithoutReadilyDeterminableFairValueImpairment_bbccf26a-325d-4d8a-a729-09b396670537" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_321a09c9-3906-49d4-a1ac-6c6b961fbfb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesLineItems_4f36536c-fb46-4974-8902-d97e63716ea3" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_321a09c9-3906-49d4-a1ac-6c6b961fbfb2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8098e9a2-be0e-47ff-8c80-92bbfee55773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesLineItems_4f36536c-fb46-4974-8902-d97e63716ea3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8098e9a2-be0e-47ff-8c80-92bbfee55773" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9c7446e2-6ea7-4806-ba6b-29a29ba0ac3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesLineItems_4f36536c-fb46-4974-8902-d97e63716ea3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9c7446e2-6ea7-4806-ba6b-29a29ba0ac3e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_252b880a-0972-4f04-96d3-e8903dc951b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesLineItems_4f36536c-fb46-4974-8902-d97e63716ea3" xlink:to="loc_us-gaap_OperatingLeaseLiability_252b880a-0972-4f04-96d3-e8903dc951b6" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities_c6446c3e-97a1-4c4d-8a41-d1dfed0f79e7" xlink:href="dgx-20221231.xsd#dgx_EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesLineItems_4f36536c-fb46-4974-8902-d97e63716ea3" xlink:to="loc_dgx_EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities_c6446c3e-97a1-4c4d-8a41-d1dfed0f79e7" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_8d193c1d-eb6b-4dbf-9226-cdac029cd0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesLineItems_4f36536c-fb46-4974-8902-d97e63716ea3" xlink:to="loc_us-gaap_TradingSecurities_8d193c1d-eb6b-4dbf-9226-cdac029cd0cd" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_SummaryOfSignificantAccountingPoliciesTable_a13a4804-ce75-4b72-8635-8d23b4dc380d" xlink:href="dgx-20221231.xsd#dgx_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesLineItems_4f36536c-fb46-4974-8902-d97e63716ea3" xlink:to="loc_dgx_SummaryOfSignificantAccountingPoliciesTable_a13a4804-ce75-4b72-8635-8d23b4dc380d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_22db4a58-9087-499b-a5fe-8294c7920709" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesTable_a13a4804-ce75-4b72-8635-8d23b4dc380d" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_22db4a58-9087-499b-a5fe-8294c7920709" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_22db4a58-9087-499b-a5fe-8294c7920709_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_22db4a58-9087-499b-a5fe-8294c7920709" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_22db4a58-9087-499b-a5fe-8294c7920709_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_6ba0f8d6-04c4-4ad7-8f3a-469408b45e74" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_22db4a58-9087-499b-a5fe-8294c7920709" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_6ba0f8d6-04c4-4ad7-8f3a-469408b45e74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_SubstantialOwnershipInterestMember_b7385898-a413-4cf7-a0a5-ee9f079af2c0" xlink:href="dgx-20221231.xsd#dgx_SubstantialOwnershipInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6ba0f8d6-04c4-4ad7-8f3a-469408b45e74" xlink:to="loc_dgx_SubstantialOwnershipInterestMember_b7385898-a413-4cf7-a0a5-ee9f079af2c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ed8cbb25-056f-4b2f-8035-ae43182b27bd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesTable_a13a4804-ce75-4b72-8635-8d23b4dc380d" xlink:to="loc_srt_RangeAxis_ed8cbb25-056f-4b2f-8035-ae43182b27bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ed8cbb25-056f-4b2f-8035-ae43182b27bd_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ed8cbb25-056f-4b2f-8035-ae43182b27bd" xlink:to="loc_srt_RangeMember_ed8cbb25-056f-4b2f-8035-ae43182b27bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d2fc69d6-b511-4267-9263-cadb5b98976c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ed8cbb25-056f-4b2f-8035-ae43182b27bd" xlink:to="loc_srt_RangeMember_d2fc69d6-b511-4267-9263-cadb5b98976c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_65368125-87e8-408d-8730-c316d22ca92a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d2fc69d6-b511-4267-9263-cadb5b98976c" xlink:to="loc_srt_MinimumMember_65368125-87e8-408d-8730-c316d22ca92a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1b715aae-98d4-44d2-aedc-a60efe953508" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d2fc69d6-b511-4267-9263-cadb5b98976c" xlink:to="loc_srt_MaximumMember_1b715aae-98d4-44d2-aedc-a60efe953508" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7b09e81e-dfe6-4348-94b9-34c134996a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesTable_a13a4804-ce75-4b72-8635-8d23b4dc380d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7b09e81e-dfe6-4348-94b9-34c134996a7b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7b09e81e-dfe6-4348-94b9-34c134996a7b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7b09e81e-dfe6-4348-94b9-34c134996a7b" xlink:to="loc_us-gaap_SegmentDomain_7b09e81e-dfe6-4348-94b9-34c134996a7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_80b22776-6061-42d0-8488-c71b70fe2c74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7b09e81e-dfe6-4348-94b9-34c134996a7b" xlink:to="loc_us-gaap_SegmentDomain_80b22776-6061-42d0-8488-c71b70fe2c74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_DiagnosticInformationServicesBusinessMember_5d99f610-5567-4e87-a73d-42246663da71" xlink:href="dgx-20221231.xsd#dgx_DiagnosticInformationServicesBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_80b22776-6061-42d0-8488-c71b70fe2c74" xlink:to="loc_dgx_DiagnosticInformationServicesBusinessMember_5d99f610-5567-4e87-a73d-42246663da71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_ab5f0aaf-a0a5-4361-a89a-f68e6ddb2566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesTable_a13a4804-ce75-4b72-8635-8d23b4dc380d" xlink:to="loc_us-gaap_SubsegmentsAxis_ab5f0aaf-a0a5-4361-a89a-f68e6ddb2566" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_ab5f0aaf-a0a5-4361-a89a-f68e6ddb2566_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_ab5f0aaf-a0a5-4361-a89a-f68e6ddb2566" xlink:to="loc_us-gaap_SubsegmentsDomain_ab5f0aaf-a0a5-4361-a89a-f68e6ddb2566_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_0e8c7ec3-1bd1-4e4c-8a0d-6dec095244cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_ab5f0aaf-a0a5-4361-a89a-f68e6ddb2566" xlink:to="loc_us-gaap_SubsegmentsDomain_0e8c7ec3-1bd1-4e4c-8a0d-6dec095244cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_GovernmentPayersMember_b7039572-025a-4cca-b388-80feba0c6705" xlink:href="dgx-20221231.xsd#dgx_GovernmentPayersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_0e8c7ec3-1bd1-4e4c-8a0d-6dec095244cc" xlink:to="loc_dgx_GovernmentPayersMember_b7039572-025a-4cca-b388-80feba0c6705" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_PatientMember_ae569e9e-c01e-4fcd-a42c-d5537ac3eb51" xlink:href="dgx-20221231.xsd#dgx_PatientMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_0e8c7ec3-1bd1-4e4c-8a0d-6dec095244cc" xlink:to="loc_dgx_PatientMember_ae569e9e-c01e-4fcd-a42c-d5537ac3eb51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_238c63b1-58c1-4e9d-84af-9a62e9d3db63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesTable_a13a4804-ce75-4b72-8635-8d23b4dc380d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_238c63b1-58c1-4e9d-84af-9a62e9d3db63" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_238c63b1-58c1-4e9d-84af-9a62e9d3db63_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_238c63b1-58c1-4e9d-84af-9a62e9d3db63" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_238c63b1-58c1-4e9d-84af-9a62e9d3db63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9d5048fd-5269-4f05-86d9-a1acc8caabbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_238c63b1-58c1-4e9d-84af-9a62e9d3db63" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9d5048fd-5269-4f05-86d9-a1acc8caabbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_7037ddaa-7127-4454-827f-f8d02f9517e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9d5048fd-5269-4f05-86d9-a1acc8caabbc" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_7037ddaa-7127-4454-827f-f8d02f9517e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LaboratoryEquipmentAndFurnitureAndFixturesMember_fece0cbf-5ad1-4ce1-a481-2959f30a8e31" xlink:href="dgx-20221231.xsd#dgx_LaboratoryEquipmentAndFurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9d5048fd-5269-4f05-86d9-a1acc8caabbc" xlink:to="loc_dgx_LaboratoryEquipmentAndFurnitureAndFixturesMember_fece0cbf-5ad1-4ce1-a481-2959f30a8e31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_f2319f21-23ed-47f7-87c7-146b73aa898b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9d5048fd-5269-4f05-86d9-a1acc8caabbc" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_f2319f21-23ed-47f7-87c7-146b73aa898b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_ddd1b98e-2692-4664-80d7-913d0b52081e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesTable_a13a4804-ce75-4b72-8635-8d23b4dc380d" xlink:to="loc_srt_StatementScenarioAxis_ddd1b98e-2692-4664-80d7-913d0b52081e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_ddd1b98e-2692-4664-80d7-913d0b52081e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_ddd1b98e-2692-4664-80d7-913d0b52081e" xlink:to="loc_srt_ScenarioUnspecifiedDomain_ddd1b98e-2692-4664-80d7-913d0b52081e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_5568c3be-373d-4448-b529-61e524e788cc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_ddd1b98e-2692-4664-80d7-913d0b52081e" xlink:to="loc_srt_ScenarioUnspecifiedDomain_5568c3be-373d-4448-b529-61e524e788cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_6cf97803-f6e0-4a39-b68f-29319fbbbfa1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_5568c3be-373d-4448-b529-61e524e788cc" xlink:to="loc_srt_ScenarioForecastMember_6cf97803-f6e0-4a39-b68f-29319fbbbfa1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9e9a90cb-ab1b-4a7b-9758-d54c11f8138b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesTable_a13a4804-ce75-4b72-8635-8d23b4dc380d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9e9a90cb-ab1b-4a7b-9758-d54c11f8138b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9e9a90cb-ab1b-4a7b-9758-d54c11f8138b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9e9a90cb-ab1b-4a7b-9758-d54c11f8138b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9e9a90cb-ab1b-4a7b-9758-d54c11f8138b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_6dac276e-4e49-48c8-8589-6cb2caa20132" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9e9a90cb-ab1b-4a7b-9758-d54c11f8138b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_6dac276e-4e49-48c8-8589-6cb2caa20132" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_34627fdf-b103-41ee-aacf-afc0d45228d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_6dac276e-4e49-48c8-8589-6cb2caa20132" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_34627fdf-b103-41ee-aacf-afc0d45228d3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/REVENUERECOGNITIONDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#REVENUERECOGNITIONDetails"/>
  <link:definitionLink xlink:role="http://questdiagnostics.com/role/REVENUERECOGNITIONDetails" xlink:type="extended" id="i14bcbc08069241c782a5c1bf06fd1204_REVENUERECOGNITIONDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_d3c0d219-6664-44e9-8a51-1cc8bb936823" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_PercentageofNetRevenues_fca78aea-879a-4c7c-b643-319e1da74fea" xlink:href="dgx-20221231.xsd#dgx_PercentageofNetRevenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d3c0d219-6664-44e9-8a51-1cc8bb936823" xlink:to="loc_dgx_PercentageofNetRevenues_fca78aea-879a-4c7c-b643-319e1da74fea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_RevenueCollectionofConsiderationPeriod_7eb8f708-b120-406a-aca7-c12fb79a400a" xlink:href="dgx-20221231.xsd#dgx_RevenueCollectionofConsiderationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d3c0d219-6664-44e9-8a51-1cc8bb936823" xlink:to="loc_dgx_RevenueCollectionofConsiderationPeriod_7eb8f708-b120-406a-aca7-c12fb79a400a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_PeriodofBillingFullyReserve_79f88eeb-35f0-4d75-ba65-bfa6401fdd6a" xlink:href="dgx-20221231.xsd#dgx_PeriodofBillingFullyReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d3c0d219-6664-44e9-8a51-1cc8bb936823" xlink:to="loc_dgx_PeriodofBillingFullyReserve_79f88eeb-35f0-4d75-ba65-bfa6401fdd6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_PercentageofNetAccountsReceivable_72a913b3-ebce-4c9d-bc0f-6b617dc6170b" xlink:href="dgx-20221231.xsd#dgx_PercentageofNetAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d3c0d219-6664-44e9-8a51-1cc8bb936823" xlink:to="loc_dgx_PercentageofNetAccountsReceivable_72a913b3-ebce-4c9d-bc0f-6b617dc6170b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_7f779ae4-6de0-4925-b010-64854488f562" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d3c0d219-6664-44e9-8a51-1cc8bb936823" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_7f779ae4-6de0-4925-b010-64854488f562" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_65ac2114-d330-4e69-8e05-8c0b925b4aba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_7f779ae4-6de0-4925-b010-64854488f562" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_65ac2114-d330-4e69-8e05-8c0b925b4aba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_bec9201d-b54b-427f-8eb2-ddf15d508e54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_7f779ae4-6de0-4925-b010-64854488f562" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_bec9201d-b54b-427f-8eb2-ddf15d508e54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_426b51c0-cde2-4f8b-9625-dd608b781d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_f7805de3-4305-4d3f-b999-5b043d89fe36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d3c0d219-6664-44e9-8a51-1cc8bb936823" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_f7805de3-4305-4d3f-b999-5b043d89fe36" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f2b0f46b-4956-495a-9538-75641ad33ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d3c0d219-6664-44e9-8a51-1cc8bb936823" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f2b0f46b-4956-495a-9538-75641ad33ba1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_4c1b27dc-3e2f-48bf-9237-f34da6b93c64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f2b0f46b-4956-495a-9538-75641ad33ba1" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_4c1b27dc-3e2f-48bf-9237-f34da6b93c64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4c1b27dc-3e2f-48bf-9237-f34da6b93c64_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4c1b27dc-3e2f-48bf-9237-f34da6b93c64" xlink:to="loc_us-gaap_SegmentDomain_4c1b27dc-3e2f-48bf-9237-f34da6b93c64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_18c69788-e1ee-4034-9c5d-bb19158c0343" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4c1b27dc-3e2f-48bf-9237-f34da6b93c64" xlink:to="loc_us-gaap_SegmentDomain_18c69788-e1ee-4034-9c5d-bb19158c0343" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_DiagnosticInformationServicesBusinessMember_376d25f5-2a55-4e3c-81c0-d07ae2e2c754" xlink:href="dgx-20221231.xsd#dgx_DiagnosticInformationServicesBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_18c69788-e1ee-4034-9c5d-bb19158c0343" xlink:to="loc_dgx_DiagnosticInformationServicesBusinessMember_376d25f5-2a55-4e3c-81c0-d07ae2e2c754" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_79eeaca4-d362-425d-bdd4-5bee36d29d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_18c69788-e1ee-4034-9c5d-bb19158c0343" xlink:to="loc_us-gaap_AllOtherSegmentsMember_79eeaca4-d362-425d-bdd4-5bee36d29d2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_81353cbd-e681-40bd-8167-873e75a13891" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f2b0f46b-4956-495a-9538-75641ad33ba1" xlink:to="loc_us-gaap_SubsegmentsAxis_81353cbd-e681-40bd-8167-873e75a13891" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_81353cbd-e681-40bd-8167-873e75a13891_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_81353cbd-e681-40bd-8167-873e75a13891" xlink:to="loc_us-gaap_SubsegmentsDomain_81353cbd-e681-40bd-8167-873e75a13891_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_3c8a2e3f-7254-42c4-ae37-fbb2accf3876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_81353cbd-e681-40bd-8167-873e75a13891" xlink:to="loc_us-gaap_SubsegmentsDomain_3c8a2e3f-7254-42c4-ae37-fbb2accf3876" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_HealthcareInsurersMember_78dd9073-49d5-44fa-9f77-ba9b7a8f4b84" xlink:href="dgx-20221231.xsd#dgx_HealthcareInsurersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_3c8a2e3f-7254-42c4-ae37-fbb2accf3876" xlink:to="loc_dgx_HealthcareInsurersMember_78dd9073-49d5-44fa-9f77-ba9b7a8f4b84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_GovernmentPayersMember_c54182b8-5475-4846-b44f-d36250bc4d9a" xlink:href="dgx-20221231.xsd#dgx_GovernmentPayersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_3c8a2e3f-7254-42c4-ae37-fbb2accf3876" xlink:to="loc_dgx_GovernmentPayersMember_c54182b8-5475-4846-b44f-d36250bc4d9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ClientPayersMember_d8ec1cee-01b6-4807-a550-1b9129718f8e" xlink:href="dgx-20221231.xsd#dgx_ClientPayersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_3c8a2e3f-7254-42c4-ae37-fbb2accf3876" xlink:to="loc_dgx_ClientPayersMember_d8ec1cee-01b6-4807-a550-1b9129718f8e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_PatientMember_c10eed35-3fd7-4f45-bc59-eb58a08da32a" xlink:href="dgx-20221231.xsd#dgx_PatientMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_3c8a2e3f-7254-42c4-ae37-fbb2accf3876" xlink:to="loc_dgx_PatientMember_c10eed35-3fd7-4f45-bc59-eb58a08da32a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_DSBusinessesMember_5be42483-3849-4248-a380-ffc531252d43" xlink:href="dgx-20221231.xsd#dgx_DSBusinessesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_3c8a2e3f-7254-42c4-ae37-fbb2accf3876" xlink:to="loc_dgx_DSBusinessesMember_5be42483-3849-4248-a380-ffc531252d43" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_285036d8-b21d-433c-8876-eb2a26f0a5e8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f2b0f46b-4956-495a-9538-75641ad33ba1" xlink:to="loc_srt_ProductOrServiceAxis_285036d8-b21d-433c-8876-eb2a26f0a5e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_285036d8-b21d-433c-8876-eb2a26f0a5e8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_285036d8-b21d-433c-8876-eb2a26f0a5e8" xlink:to="loc_srt_ProductsAndServicesDomain_285036d8-b21d-433c-8876-eb2a26f0a5e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c38afb2d-fed9-4ef1-b0f3-5d28fcd12e94" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_285036d8-b21d-433c-8876-eb2a26f0a5e8" xlink:to="loc_srt_ProductsAndServicesDomain_c38afb2d-fed9-4ef1-b0f3-5d28fcd12e94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_FeeforserviceMember_04a42e3f-11ef-4b5e-a750-867c40b89a79" xlink:href="dgx-20221231.xsd#dgx_FeeforserviceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c38afb2d-fed9-4ef1-b0f3-5d28fcd12e94" xlink:to="loc_dgx_FeeforserviceMember_04a42e3f-11ef-4b5e-a750-867c40b89a79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_CapitatedMember_9d8ca0b4-a3c4-4a84-a831-98f6b46e4ce4" xlink:href="dgx-20221231.xsd#dgx_CapitatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c38afb2d-fed9-4ef1-b0f3-5d28fcd12e94" xlink:to="loc_dgx_CapitatedMember_9d8ca0b4-a3c4-4a84-a831-98f6b46e4ce4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_546a587f-75b7-4c21-8a2a-32fd015a4060" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f2b0f46b-4956-495a-9538-75641ad33ba1" xlink:to="loc_srt_RangeAxis_546a587f-75b7-4c21-8a2a-32fd015a4060" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_546a587f-75b7-4c21-8a2a-32fd015a4060_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_546a587f-75b7-4c21-8a2a-32fd015a4060" xlink:to="loc_srt_RangeMember_546a587f-75b7-4c21-8a2a-32fd015a4060_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_015460e1-b2c9-4a24-8af2-96c250d08a6d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_546a587f-75b7-4c21-8a2a-32fd015a4060" xlink:to="loc_srt_RangeMember_015460e1-b2c9-4a24-8af2-96c250d08a6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_552d6bae-b639-4b21-9b53-89974fa51a79" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_015460e1-b2c9-4a24-8af2-96c250d08a6d" xlink:to="loc_srt_MinimumMember_552d6bae-b639-4b21-9b53-89974fa51a79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b1f1a365-da8e-4701-9f81-94d0a62b0a54" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_015460e1-b2c9-4a24-8af2-96c250d08a6d" xlink:to="loc_srt_MaximumMember_b1f1a365-da8e-4701-9f81-94d0a62b0a54" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#EARNINGSLOSSPERSHAREDetails"/>
  <link:definitionLink xlink:role="http://questdiagnostics.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="extended" id="ie4accf660cfe42bf9d27284975b8dd89_EARNINGSLOSSPERSHAREDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesLineItems_29599a53-26fb-4f26-9968-31d848535e78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcceleratedShareRepurchasesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_AcceleratedShareRepurchasesPayment_67bb39d4-7c83-4072-b95e-27218159ead2" xlink:href="dgx-20221231.xsd#dgx_AcceleratedShareRepurchasesPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_29599a53-26fb-4f26-9968-31d848535e78" xlink:to="loc_dgx_AcceleratedShareRepurchasesPayment_67bb39d4-7c83-4072-b95e-27218159ead2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesTable_e56bc3d8-d8c9-4696-80a3-e635d81a9fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcceleratedShareRepurchasesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_29599a53-26fb-4f26-9968-31d848535e78" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesTable_e56bc3d8-d8c9-4696-80a3-e635d81a9fb0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesDateAxis_c76867d9-7b7c-4a0d-b9d9-757c033d31c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcceleratedShareRepurchasesDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesTable_e56bc3d8-d8c9-4696-80a3-e635d81a9fb0" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesDateAxis_c76867d9-7b7c-4a0d-b9d9-757c033d31c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesDateDomain_c76867d9-7b7c-4a0d-b9d9-757c033d31c8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcceleratedShareRepurchasesDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesDateAxis_c76867d9-7b7c-4a0d-b9d9-757c033d31c8" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesDateDomain_c76867d9-7b7c-4a0d-b9d9-757c033d31c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesDateDomain_b27881fc-6c0f-4f85-bc40-fe5bc72eba22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcceleratedShareRepurchasesDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesDateAxis_c76867d9-7b7c-4a0d-b9d9-757c033d31c8" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesDateDomain_b27881fc-6c0f-4f85-bc40-fe5bc72eba22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_AcceleratedShareRepurchaseAgreementsMember_6d20d50a-30a7-43a3-9887-e29c7e6a1bcd" xlink:href="dgx-20221231.xsd#dgx_AcceleratedShareRepurchaseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesDateDomain_b27881fc-6c0f-4f85-bc40-fe5bc72eba22" xlink:to="loc_dgx_AcceleratedShareRepurchaseAgreementsMember_6d20d50a-30a7-43a3-9887-e29c7e6a1bcd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESPreTaxRestructuringchargesDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#RESTRUCTURINGACTIVITIESPreTaxRestructuringchargesDetails"/>
  <link:definitionLink xlink:role="http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESPreTaxRestructuringchargesDetails" xlink:type="extended" id="i7ddd5cf54a714c18915f8fdf03d82d42_RESTRUCTURINGACTIVITIESPreTaxRestructuringchargesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_f5a03810-3648-4e87-a434-8f900b71bea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_18695346-af0f-488e-8373-78d32074581f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f5a03810-3648-4e87-a434-8f900b71bea0" xlink:to="loc_us-gaap_SeveranceCosts1_18695346-af0f-488e-8373-78d32074581f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringCosts_e717cd25-2ad8-45b2-869a-ab6cd7549fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f5a03810-3648-4e87-a434-8f900b71bea0" xlink:to="loc_us-gaap_OtherRestructuringCosts_e717cd25-2ad8-45b2-869a-ab6cd7549fa0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_dabd9b80-709b-4e15-aacb-b863324d0690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostsAndAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f5a03810-3648-4e87-a434-8f900b71bea0" xlink:to="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_dabd9b80-709b-4e15-aacb-b863324d0690" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_c348c6c6-1590-42ec-b0ab-e7e06a2e8f01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f5a03810-3648-4e87-a434-8f900b71bea0" xlink:to="loc_us-gaap_RestructuringCharges_c348c6c6-1590-42ec-b0ab-e7e06a2e8f01" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f5b89b4b-46c6-47d8-ac56-ce7805bcca5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f5a03810-3648-4e87-a434-8f900b71bea0" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f5b89b4b-46c6-47d8-ac56-ce7805bcca5a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_a075adb6-a89f-4315-9ac1-1f7f61f99c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f5b89b4b-46c6-47d8-ac56-ce7805bcca5a" xlink:to="loc_us-gaap_RestructuringPlanAxis_a075adb6-a89f-4315-9ac1-1f7f61f99c4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_a075adb6-a89f-4315-9ac1-1f7f61f99c4a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_a075adb6-a89f-4315-9ac1-1f7f61f99c4a" xlink:to="loc_us-gaap_RestructuringPlanDomain_a075adb6-a89f-4315-9ac1-1f7f61f99c4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_3e37c516-b74c-492c-a1a3-1a289c25d962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_a075adb6-a89f-4315-9ac1-1f7f61f99c4a" xlink:to="loc_us-gaap_RestructuringPlanDomain_3e37c516-b74c-492c-a1a3-1a289c25d962" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_InvigorateProgramMember_30b49b05-5750-46f3-ab65-0e3cbc19a409" xlink:href="dgx-20221231.xsd#dgx_InvigorateProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_3e37c516-b74c-492c-a1a3-1a289c25d962" xlink:to="loc_dgx_InvigorateProgramMember_30b49b05-5750-46f3-ab65-0e3cbc19a409" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESNarrativeDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#RESTRUCTURINGACTIVITIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESNarrativeDetails" xlink:type="extended" id="id34501b9b3af44af9c24f1bd975942b9_RESTRUCTURINGACTIVITIESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_2297361b-38fa-41e9-a79d-2c9e9526bda5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_2967740a-9a3a-40a3-8b12-738098598abd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2297361b-38fa-41e9-a79d-2c9e9526bda5" xlink:to="loc_us-gaap_RestructuringCharges_2967740a-9a3a-40a3-8b12-738098598abd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ed218ac0-94e1-44bd-b89b-4f6b6af98406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2297361b-38fa-41e9-a79d-2c9e9526bda5" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ed218ac0-94e1-44bd-b89b-4f6b6af98406" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_53bdc940-f49b-4c04-9ccd-ab89cdfb1751" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ed218ac0-94e1-44bd-b89b-4f6b6af98406" xlink:to="loc_us-gaap_RestructuringPlanAxis_53bdc940-f49b-4c04-9ccd-ab89cdfb1751" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_53bdc940-f49b-4c04-9ccd-ab89cdfb1751_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_53bdc940-f49b-4c04-9ccd-ab89cdfb1751" xlink:to="loc_us-gaap_RestructuringPlanDomain_53bdc940-f49b-4c04-9ccd-ab89cdfb1751_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_adf8b768-1220-417a-b9c3-8520028ad606" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_53bdc940-f49b-4c04-9ccd-ab89cdfb1751" xlink:to="loc_us-gaap_RestructuringPlanDomain_adf8b768-1220-417a-b9c3-8520028ad606" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_InvigorateProgramMember_5c531ac0-60ba-423a-b616-0266fef872db" xlink:href="dgx-20221231.xsd#dgx_InvigorateProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_adf8b768-1220-417a-b9c3-8520028ad606" xlink:to="loc_dgx_InvigorateProgramMember_5c531ac0-60ba-423a-b616-0266fef872db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_ab20992c-df82-4646-93f6-477022f12912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ed218ac0-94e1-44bd-b89b-4f6b6af98406" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_ab20992c-df82-4646-93f6-477022f12912" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_ab20992c-df82-4646-93f6-477022f12912_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_ab20992c-df82-4646-93f6-477022f12912" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_ab20992c-df82-4646-93f6-477022f12912_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_bbcaed38-6152-40db-8d79-aa227260fac2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_ab20992c-df82-4646-93f6-477022f12912" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_bbcaed38-6152-40db-8d79-aa227260fac2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_6a52d3fe-5853-44de-9cb7-8667bbc0199f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_bbcaed38-6152-40db-8d79-aa227260fac2" xlink:to="loc_us-gaap_CostOfSalesMember_6a52d3fe-5853-44de-9cb7-8667bbc0199f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_226fb6c4-3b57-4df9-bc41-e12819fb99fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_bbcaed38-6152-40db-8d79-aa227260fac2" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_226fb6c4-3b57-4df9-bc41-e12819fb99fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_59b00437-b0b5-4a8a-9bac-f4aa2c73b699" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_bbcaed38-6152-40db-8d79-aa227260fac2" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_59b00437-b0b5-4a8a-9bac-f4aa2c73b699" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESActivitiesofRestructuringLiabilitiesDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#RESTRUCTURINGACTIVITIESActivitiesofRestructuringLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESActivitiesofRestructuringLiabilitiesDetails" xlink:type="extended" id="i53f2f316a91b4c2c8345fefe552b3d07_RESTRUCTURINGACTIVITIESActivitiesofRestructuringLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_736aeb17-87c7-4218-9ff7-059bfede2f43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_e1a000f9-b3a8-4826-a012-97142734deb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_736aeb17-87c7-4218-9ff7-059bfede2f43" xlink:to="loc_us-gaap_RestructuringReserveRollForward_e1a000f9-b3a8-4826-a012-97142734deb8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_42088e81-e187-42f8-bca1-7eae146f4176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_e1a000f9-b3a8-4826-a012-97142734deb8" xlink:to="loc_us-gaap_RestructuringReserve_42088e81-e187-42f8-bca1-7eae146f4176" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_8592f4e9-d477-49be-9020-cd0411b7d0c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_e1a000f9-b3a8-4826-a012-97142734deb8" xlink:to="loc_us-gaap_RestructuringCharges_8592f4e9-d477-49be-9020-cd0411b7d0c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_6c988945-f6f7-4da5-94cc-4bd4e18bc464" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_e1a000f9-b3a8-4826-a012-97142734deb8" xlink:to="loc_us-gaap_PaymentsForRestructuring_6c988945-f6f7-4da5-94cc-4bd4e18bc464" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_5c25f460-c2d5-4443-9705-c7b0fc0d1cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5d70bccc-64aa-422b-8930-b8bf2266a9db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_736aeb17-87c7-4218-9ff7-059bfede2f43" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5d70bccc-64aa-422b-8930-b8bf2266a9db" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_25ce1591-0d86-42eb-b870-52ef1cfd9818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5d70bccc-64aa-422b-8930-b8bf2266a9db" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_25ce1591-0d86-42eb-b870-52ef1cfd9818" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_25ce1591-0d86-42eb-b870-52ef1cfd9818_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_25ce1591-0d86-42eb-b870-52ef1cfd9818" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_25ce1591-0d86-42eb-b870-52ef1cfd9818_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_482bfcc0-0b62-48fd-9936-f2b4e77c71b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_25ce1591-0d86-42eb-b870-52ef1cfd9818" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_482bfcc0-0b62-48fd-9936-f2b4e77c71b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_3c8d3482-b1d6-4cef-bfec-1e84601a4e64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_482bfcc0-0b62-48fd-9936-f2b4e77c71b9" xlink:to="loc_us-gaap_EmployeeSeveranceMember_3c8d3482-b1d6-4cef-bfec-1e84601a4e64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_6664977d-8e4f-4128-9e84-196b9b6b840c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FacilityClosingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_482bfcc0-0b62-48fd-9936-f2b4e77c71b9" xlink:to="loc_us-gaap_FacilityClosingMember_6664977d-8e4f-4128-9e84-196b9b6b840c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#BUSINESSACQUISITIONSDetails"/>
  <link:definitionLink xlink:role="http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails" xlink:type="extended" id="ic88b2bda92a941afaed09a4674bd82d6_BUSINESSACQUISITIONSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_f02954b8-5c5b-4205-b7c5-d57525d41fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_f02954b8-5c5b-4205-b7c5-d57525d41fa2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_bc08a27a-694d-4baa-b978-dda8359098e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_bc08a27a-694d-4baa-b978-dda8359098e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_ebe7b2b1-dbca-4620-bc62-39d991035743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_ebe7b2b1-dbca-4620-bc62-39d991035743" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFiniteLivedIntangibles1_beb8be6a-6179-4636-9508-0a7d3751a58f" xlink:href="dgx-20221231.xsd#dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFiniteLivedIntangibles1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFiniteLivedIntangibles1_beb8be6a-6179-4636-9508-0a7d3751a58f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_d441ba0f-59f9-40a4-a179-88435db7d105" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_d441ba0f-59f9-40a4-a179-88435db7d105" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_3afa7f7e-b095-43f3-a6c2-12cc2ae01c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_3afa7f7e-b095-43f3-a6c2-12cc2ae01c01" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9e39526c-523d-4aaf-a04d-8fcd63e76697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9e39526c-523d-4aaf-a04d-8fcd63e76697" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9f01c13d-6e9f-4459-934a-1dd4b97f1916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_us-gaap_Goodwill_9f01c13d-6e9f-4459-934a-1dd4b97f1916" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_b82a598d-e625-48cd-b2ff-c14983fadc50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_b82a598d-e625-48cd-b2ff-c14983fadc50" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_5a9e3c1e-8cae-4cbf-a7bb-47c7bd1cb206" xlink:href="dgx-20221231.xsd#dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_5a9e3c1e-8cae-4cbf-a7bb-47c7bd1cb206" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities_591c7854-4e76-43d9-942f-26734ed27b42" xlink:href="dgx-20221231.xsd#dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities_591c7854-4e76-43d9-942f-26734ed27b42" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedWorkingCapital_02f35d6e-71de-4fb1-b7d8-716c337ec890" xlink:href="dgx-20221231.xsd#dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedWorkingCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedWorkingCapital_02f35d6e-71de-4fb1-b7d8-716c337ec890" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_10d002ad-363c-46fd-9354-83c794bf17ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_10d002ad-363c-46fd-9354-83c794bf17ba" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_GoodwillAcquiredDuringPeriodBeforeAdjustments_7cdcf457-5d3e-405b-8602-c04c3ee545d1" xlink:href="dgx-20221231.xsd#dgx_GoodwillAcquiredDuringPeriodBeforeAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_dgx_GoodwillAcquiredDuringPeriodBeforeAdjustments_7cdcf457-5d3e-405b-8602-c04c3ee545d1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_46295f66-1952-4c0c-bbc4-2ac3a7cab692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_46295f66-1952-4c0c-bbc4-2ac3a7cab692" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_e794f2d4-4060-4319-8d45-8853a8a79ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_e794f2d4-4060-4319-8d45-8853a8a79ccd" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinanceLeaseLiabilities_472377f3-89a2-4cd9-8100-95008c2f526b" xlink:href="dgx-20221231.xsd#dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinanceLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinanceLeaseLiabilities_472377f3-89a2-4cd9-8100-95008c2f526b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_86be959b-f25c-4be6-b738-92d3fac05609" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_86be959b-f25c-4be6-b738-92d3fac05609" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_BusinessAcquisitionPostacquisitionRevenue_c86f2bf1-01ab-484e-8409-05b595031476" xlink:href="dgx-20221231.xsd#dgx_BusinessAcquisitionPostacquisitionRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_dgx_BusinessAcquisitionPostacquisitionRevenue_c86f2bf1-01ab-484e-8409-05b595031476" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedPropertyPlantandEquipmentandWorkingCapital_ce5d58db-dd80-4eec-8dc0-d1837ab1e872" xlink:href="dgx-20221231.xsd#dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedPropertyPlantandEquipmentandWorkingCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedPropertyPlantandEquipmentandWorkingCapital_ce5d58db-dd80-4eec-8dc0-d1837ab1e872" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_c43f42b4-e5a8-47c2-bf4b-e3967919f21a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_c43f42b4-e5a8-47c2-bf4b-e3967919f21a" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_126665c6-2b22-4571-bc12-24484c482b92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_126665c6-2b22-4571-bc12-24484c482b92" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_d5c68044-a64f-429d-9d42-6627e7849c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_d5c68044-a64f-429d-9d42-6627e7849c9d" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_65af1f5e-e2b5-4705-a616-54e8070d11e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_65af1f5e-e2b5-4705-a616-54e8070d11e4" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeLongTermGrowthRateUsedToDetermineFairValue_3f8b788b-4154-48ca-8d33-663443167d2e" xlink:href="dgx-20221231.xsd#dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeLongTermGrowthRateUsedToDetermineFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeLongTermGrowthRateUsedToDetermineFairValue_3f8b788b-4154-48ca-8d33-663443167d2e" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeDicountRateUsedToDetermineFairValue_6398bb1a-eb98-4f6a-a247-d17cfe338e51" xlink:href="dgx-20221231.xsd#dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeDicountRateUsedToDetermineFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeDicountRateUsedToDetermineFairValue_6398bb1a-eb98-4f6a-a247-d17cfe338e51" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_950f271c-61f9-4ad6-b148-6c2631c81e75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_950f271c-61f9-4ad6-b148-6c2631c81e75" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_56b90a1e-f5d9-4832-b3de-80834c9f5e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_950f271c-61f9-4ad6-b148-6c2631c81e75" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_56b90a1e-f5d9-4832-b3de-80834c9f5e8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_56b90a1e-f5d9-4832-b3de-80834c9f5e8a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_56b90a1e-f5d9-4832-b3de-80834c9f5e8a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_56b90a1e-f5d9-4832-b3de-80834c9f5e8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0be2b74a-3834-44a6-9e92-c46f2a5b6b83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_56b90a1e-f5d9-4832-b3de-80834c9f5e8a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0be2b74a-3834-44a6-9e92-c46f2a5b6b83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_PackHealthLLCMember_90c59336-3257-427e-b6c7-cdf191f1ddb3" xlink:href="dgx-20221231.xsd#dgx_PackHealthLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0be2b74a-3834-44a6-9e92-c46f2a5b6b83" xlink:to="loc_dgx_PackHealthLLCMember_90c59336-3257-427e-b6c7-cdf191f1ddb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_MercyHealthMember_b6548818-1d36-4bd0-a0b2-fd27b3076a64" xlink:href="dgx-20221231.xsd#dgx_MercyHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0be2b74a-3834-44a6-9e92-c46f2a5b6b83" xlink:to="loc_dgx_MercyHealthMember_b6548818-1d36-4bd0-a0b2-fd27b3076a64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LabtechDiagnosticsLLCMember_c3e7af88-2f90-401b-8d00-6c01e2c8bbbc" xlink:href="dgx-20221231.xsd#dgx_LabtechDiagnosticsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0be2b74a-3834-44a6-9e92-c46f2a5b6b83" xlink:to="loc_dgx_LabtechDiagnosticsLLCMember_c3e7af88-2f90-401b-8d00-6c01e2c8bbbc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_BlueprintGeneticsOyMember_fcdf9c41-5d39-44e0-a00d-362c90d07d35" xlink:href="dgx-20221231.xsd#dgx_BlueprintGeneticsOyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0be2b74a-3834-44a6-9e92-c46f2a5b6b83" xlink:to="loc_dgx_BlueprintGeneticsOyMember_fcdf9c41-5d39-44e0-a00d-362c90d07d35" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_MemorialHermannMember_808c07cc-6ee4-4fd8-bb83-2105c61bd8b6" xlink:href="dgx-20221231.xsd#dgx_MemorialHermannMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0be2b74a-3834-44a6-9e92-c46f2a5b6b83" xlink:to="loc_dgx_MemorialHermannMember_808c07cc-6ee4-4fd8-bb83-2105c61bd8b6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_MidAmericaClinicalLaboratoriesLLCMACLMember_e6e124ef-6e58-4f59-b70e-36e993cf97a0" xlink:href="dgx-20221231.xsd#dgx_MidAmericaClinicalLaboratoriesLLCMACLMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0be2b74a-3834-44a6-9e92-c46f2a5b6b83" xlink:to="loc_dgx_MidAmericaClinicalLaboratoriesLLCMACLMember_e6e124ef-6e58-4f59-b70e-36e993cf97a0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_524c77d1-1741-4923-af62-194aa4adfd79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_950f271c-61f9-4ad6-b148-6c2631c81e75" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_524c77d1-1741-4923-af62-194aa4adfd79" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_524c77d1-1741-4923-af62-194aa4adfd79_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_524c77d1-1741-4923-af62-194aa4adfd79" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_524c77d1-1741-4923-af62-194aa4adfd79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_74d33698-284c-4f39-9f1c-92a0c41dc048" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_524c77d1-1741-4923-af62-194aa4adfd79" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_74d33698-284c-4f39-9f1c-92a0c41dc048" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_6bc368a0-6f7c-4798-84bc-c5a1d81a8c61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_74d33698-284c-4f39-9f1c-92a0c41dc048" xlink:to="loc_us-gaap_CustomerRelationshipsMember_6bc368a0-6f7c-4798-84bc-c5a1d81a8c61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_1a9c4636-5fbc-4880-80a3-7401e42dcea7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_74d33698-284c-4f39-9f1c-92a0c41dc048" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_1a9c4636-5fbc-4880-80a3-7401e42dcea7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_63f0f099-6491-4785-82ca-ea92c4c04d07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_950f271c-61f9-4ad6-b148-6c2631c81e75" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_63f0f099-6491-4785-82ca-ea92c4c04d07" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_63f0f099-6491-4785-82ca-ea92c4c04d07_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_63f0f099-6491-4785-82ca-ea92c4c04d07" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_63f0f099-6491-4785-82ca-ea92c4c04d07_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_336e5947-ce4f-4dc5-9a06-1f779eacd6d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_63f0f099-6491-4785-82ca-ea92c4c04d07" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_336e5947-ce4f-4dc5-9a06-1f779eacd6d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_OtherIncomeExpenseMember_aab7cd64-e10d-4fc0-bd5a-de74b1a349b3" xlink:href="dgx-20221231.xsd#dgx_OtherIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_336e5947-ce4f-4dc5-9a06-1f779eacd6d0" xlink:to="loc_dgx_OtherIncomeExpenseMember_aab7cd64-e10d-4fc0-bd5a-de74b1a349b3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/DISPOSITIONDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#DISPOSITIONDetails"/>
  <link:definitionLink xlink:role="http://questdiagnostics.com/role/DISPOSITIONDetails" xlink:type="extended" id="i8617f9700a094b80bbb359d754ca6945_DISPOSITIONDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22db42be-1498-465b-8bae-a55397dbe465" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_EquityMethodInvestmentOwnershipPercentDisposedOf_4279e549-1d66-46b0-8cd4-48f3d94d132c" xlink:href="dgx-20221231.xsd#dgx_EquityMethodInvestmentOwnershipPercentDisposedOf"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22db42be-1498-465b-8bae-a55397dbe465" xlink:to="loc_dgx_EquityMethodInvestmentOwnershipPercentDisposedOf_4279e549-1d66-46b0-8cd4-48f3d94d132c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ProceedsFromSaleOfEquityMethodInvestmentsGross_d9a2509a-4e74-46bc-b878-5505025095ce" xlink:href="dgx-20221231.xsd#dgx_ProceedsFromSaleOfEquityMethodInvestmentsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22db42be-1498-465b-8bae-a55397dbe465" xlink:to="loc_dgx_ProceedsFromSaleOfEquityMethodInvestmentsGross_d9a2509a-4e74-46bc-b878-5505025095ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_79dea128-fad3-4b15-b86e-eac2a1b81199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22db42be-1498-465b-8bae-a55397dbe465" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_79dea128-fad3-4b15-b86e-eac2a1b81199" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_1caa8b8f-752c-4515-843f-2ed588682f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22db42be-1498-465b-8bae-a55397dbe465" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_1caa8b8f-752c-4515-843f-2ed588682f5b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_254c21ee-cd62-43e3-b972-e1af25b03c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22db42be-1498-465b-8bae-a55397dbe465" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_254c21ee-cd62-43e3-b972-e1af25b03c1a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_0011844c-ce44-474d-879a-b2551bc05b31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22db42be-1498-465b-8bae-a55397dbe465" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_0011844c-ce44-474d-879a-b2551bc05b31" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5530db43-578b-42eb-bd7c-bbb43425d742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22db42be-1498-465b-8bae-a55397dbe465" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5530db43-578b-42eb-bd7c-bbb43425d742" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6e6f315c-4dea-4d4c-b820-dd6f3fe0f6b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22db42be-1498-465b-8bae-a55397dbe465" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6e6f315c-4dea-4d4c-b820-dd6f3fe0f6b2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0106303b-9c91-4132-83c0-3f64a3ead7e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6e6f315c-4dea-4d4c-b820-dd6f3fe0f6b2" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0106303b-9c91-4132-83c0-3f64a3ead7e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0106303b-9c91-4132-83c0-3f64a3ead7e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0106303b-9c91-4132-83c0-3f64a3ead7e7" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0106303b-9c91-4132-83c0-3f64a3ead7e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4237c6e4-7b5c-4695-94ae-33d583324ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0106303b-9c91-4132-83c0-3f64a3ead7e7" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4237c6e4-7b5c-4695-94ae-33d583324ea0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_Q2SolutionsMember_473203f0-beab-4929-8c33-2240db6a4a4c" xlink:href="dgx-20221231.xsd#dgx_Q2SolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4237c6e4-7b5c-4695-94ae-33d583324ea0" xlink:to="loc_dgx_Q2SolutionsMember_473203f0-beab-4929-8c33-2240db6a4a4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_7d6894b7-6955-4fb1-aec8-b96e8021efcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6e6f315c-4dea-4d4c-b820-dd6f3fe0f6b2" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_7d6894b7-6955-4fb1-aec8-b96e8021efcb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_7d6894b7-6955-4fb1-aec8-b96e8021efcb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_7d6894b7-6955-4fb1-aec8-b96e8021efcb" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_7d6894b7-6955-4fb1-aec8-b96e8021efcb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_0e8d838d-a8e1-49b3-9dad-8804fe6b82ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_7d6894b7-6955-4fb1-aec8-b96e8021efcb" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_0e8d838d-a8e1-49b3-9dad-8804fe6b82ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_ddede343-74f6-4e08-a262-8abc41be4e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_0e8d838d-a8e1-49b3-9dad-8804fe6b82ab" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_ddede343-74f6-4e08-a262-8abc41be4e3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9c472741-9f78-4c68-9146-3590fefd6a82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6e6f315c-4dea-4d4c-b820-dd6f3fe0f6b2" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9c472741-9f78-4c68-9146-3590fefd6a82" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9c472741-9f78-4c68-9146-3590fefd6a82_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9c472741-9f78-4c68-9146-3590fefd6a82" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9c472741-9f78-4c68-9146-3590fefd6a82_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f03cfce9-187b-42eb-8f38-1cd079880b52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9c472741-9f78-4c68-9146-3590fefd6a82" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f03cfce9-187b-42eb-8f38-1cd079880b52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeMember_cf7afe4b-ec3a-4797-9b50-404f40742032" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f03cfce9-187b-42eb-8f38-1cd079880b52" xlink:to="loc_us-gaap_OtherIncomeMember_cf7afe4b-ec3a-4797-9b50-404f40742032" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_44bb0a6a-71f0-4b2f-b4e1-e11348f999de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6e6f315c-4dea-4d4c-b820-dd6f3fe0f6b2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_44bb0a6a-71f0-4b2f-b4e1-e11348f999de" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_44bb0a6a-71f0-4b2f-b4e1-e11348f999de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_44bb0a6a-71f0-4b2f-b4e1-e11348f999de" xlink:to="loc_us-gaap_EquityComponentDomain_44bb0a6a-71f0-4b2f-b4e1-e11348f999de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5eb330e9-1365-42fb-8741-467d2d139919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_44bb0a6a-71f0-4b2f-b4e1-e11348f999de" xlink:to="loc_us-gaap_EquityComponentDomain_5eb330e9-1365-42fb-8741-467d2d139919" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ForeignCurrencyTranslationMember_3b8446f4-76d2-4ca1-98fb-2d11cdaf7f83" xlink:href="dgx-20221231.xsd#dgx_ForeignCurrencyTranslationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5eb330e9-1365-42fb-8741-467d2d139919" xlink:to="loc_dgx_ForeignCurrencyTranslationMember_3b8446f4-76d2-4ca1-98fb-2d11cdaf7f83" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails"/>
  <link:definitionLink xlink:role="http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails" xlink:type="extended" id="i4aaea839f77a4b8e9c4303abc9e44173_FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cb6ec1f8-9f42-45b4-a04a-73033671e710" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_3a6a8e4e-3d3a-4733-8eb6-388757e49919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cb6ec1f8-9f42-45b4-a04a-73033671e710" xlink:to="loc_us-gaap_TradingSecurities_3a6a8e4e-3d3a-4733-8eb6-388757e49919" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashSurrenderValueFairValueDisclosure_716148bb-c54b-4a42-b983-610afe1af9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashSurrenderValueFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cb6ec1f8-9f42-45b4-a04a-73033671e710" xlink:to="loc_us-gaap_CashSurrenderValueFairValueDisclosure_716148bb-c54b-4a42-b983-610afe1af9bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities_ce86b088-eca7-489f-98ad-00e045118ba9" xlink:href="dgx-20221231.xsd#dgx_EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cb6ec1f8-9f42-45b4-a04a-73033671e710" xlink:to="loc_dgx_EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities_ce86b088-eca7-489f-98ad-00e045118ba9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0aefcf67-2780-461e-998f-18d06a523a01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cb6ec1f8-9f42-45b4-a04a-73033671e710" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0aefcf67-2780-461e-998f-18d06a523a01" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_1fc9ef31-d3cd-4b23-a549-44be6d0bef02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cb6ec1f8-9f42-45b4-a04a-73033671e710" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_1fc9ef31-d3cd-4b23-a549-44be6d0bef02" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_4ab68ada-9889-4d26-b1e6-2c3eb027ba47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cb6ec1f8-9f42-45b4-a04a-73033671e710" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_4ab68ada-9889-4d26-b1e6-2c3eb027ba47" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3a4bad1e-7a5a-4a0f-9693-87c0a7d44924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cb6ec1f8-9f42-45b4-a04a-73033671e710" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3a4bad1e-7a5a-4a0f-9693-87c0a7d44924" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_2b63b294-9898-453d-8eb9-0fab2c16c6df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cb6ec1f8-9f42-45b4-a04a-73033671e710" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_2b63b294-9898-453d-8eb9-0fab2c16c6df" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_fba1f25d-a2d1-4df6-9bed-46e994ab50b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cb6ec1f8-9f42-45b4-a04a-73033671e710" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_fba1f25d-a2d1-4df6-9bed-46e994ab50b3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_0a9743be-2d8d-4532-ad88-1fd8bac656cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cb6ec1f8-9f42-45b4-a04a-73033671e710" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_0a9743be-2d8d-4532-ad88-1fd8bac656cf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_64f3d8a0-b88e-4b9f-9c69-12b5ed31c948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_0a9743be-2d8d-4532-ad88-1fd8bac656cf" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_64f3d8a0-b88e-4b9f-9c69-12b5ed31c948" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_64f3d8a0-b88e-4b9f-9c69-12b5ed31c948_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_64f3d8a0-b88e-4b9f-9c69-12b5ed31c948" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_64f3d8a0-b88e-4b9f-9c69-12b5ed31c948_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_cedf6232-e075-4552-8eea-344ede66bd98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_64f3d8a0-b88e-4b9f-9c69-12b5ed31c948" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_cedf6232-e075-4552-8eea-344ede66bd98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_e36c026b-ca28-4627-bcd6-545bccdef73b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_cedf6232-e075-4552-8eea-344ede66bd98" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_e36c026b-ca28-4627-bcd6-545bccdef73b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2fd03575-6feb-46ec-b81b-9aa70e00dacc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_0a9743be-2d8d-4532-ad88-1fd8bac656cf" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2fd03575-6feb-46ec-b81b-9aa70e00dacc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2fd03575-6feb-46ec-b81b-9aa70e00dacc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2fd03575-6feb-46ec-b81b-9aa70e00dacc" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2fd03575-6feb-46ec-b81b-9aa70e00dacc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_67161526-1f43-4bef-97f2-b3f9f10e1cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2fd03575-6feb-46ec-b81b-9aa70e00dacc" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_67161526-1f43-4bef-97f2-b3f9f10e1cc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_74caa1b6-a960-4ab3-8b2b-248161158b46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_67161526-1f43-4bef-97f2-b3f9f10e1cc6" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_74caa1b6-a960-4ab3-8b2b-248161158b46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_3e3dc64a-3310-45ed-9870-9c1a25775df5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_67161526-1f43-4bef-97f2-b3f9f10e1cc6" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_3e3dc64a-3310-45ed-9870-9c1a25775df5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_778a6d8a-6d06-4372-b24b-1ebe172b863c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_67161526-1f43-4bef-97f2-b3f9f10e1cc6" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_778a6d8a-6d06-4372-b24b-1ebe172b863c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSBusinessAcquisitionDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#FAIRVALUEMEASUREMENTSBusinessAcquisitionDetails"/>
  <link:definitionLink xlink:role="http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSBusinessAcquisitionDetails" xlink:type="extended" id="ia2f6488fbcf44fc2af8038e299e55407_FAIRVALUEMEASUREMENTSBusinessAcquisitionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_59d864e7-8505-4547-9b09-81c2540d2eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_3ddaafcd-289d-4cfb-b0ff-7866580af317" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_59d864e7-8505-4547-9b09-81c2540d2eb5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_3ddaafcd-289d-4cfb-b0ff-7866580af317" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_beb719a3-8ffc-479e-9bf0-dcf7715bbc40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_59d864e7-8505-4547-9b09-81c2540d2eb5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_beb719a3-8ffc-479e-9bf0-dcf7715bbc40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d832b39b-4c2f-4131-bc7a-4c5f165139b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_59d864e7-8505-4547-9b09-81c2540d2eb5" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d832b39b-4c2f-4131-bc7a-4c5f165139b3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0b5ad58b-50bc-4dd7-8b3a-fee46ae025c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d832b39b-4c2f-4131-bc7a-4c5f165139b3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0b5ad58b-50bc-4dd7-8b3a-fee46ae025c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0b5ad58b-50bc-4dd7-8b3a-fee46ae025c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0b5ad58b-50bc-4dd7-8b3a-fee46ae025c9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0b5ad58b-50bc-4dd7-8b3a-fee46ae025c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9cdfe696-abf1-4468-b658-9b2afc0833e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0b5ad58b-50bc-4dd7-8b3a-fee46ae025c9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9cdfe696-abf1-4468-b658-9b2afc0833e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_PackHealthAndLabtechMember_cf7546f8-1dfb-4e65-8109-1bc7f7f2f59a" xlink:href="dgx-20221231.xsd#dgx_PackHealthAndLabtechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9cdfe696-abf1-4468-b658-9b2afc0833e6" xlink:to="loc_dgx_PackHealthAndLabtechMember_cf7546f8-1dfb-4e65-8109-1bc7f7f2f59a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_c31d38d7-65d2-4c07-981d-9052e3c73768" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d832b39b-4c2f-4131-bc7a-4c5f165139b3" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_c31d38d7-65d2-4c07-981d-9052e3c73768" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_c31d38d7-65d2-4c07-981d-9052e3c73768_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_c31d38d7-65d2-4c07-981d-9052e3c73768" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_c31d38d7-65d2-4c07-981d-9052e3c73768_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_35c32461-acdf-408d-acb9-0b670a426fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_c31d38d7-65d2-4c07-981d-9052e3c73768" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_35c32461-acdf-408d-acb9-0b670a426fd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_MeasurementInputComparableCompanyRevenueVolatilityMember_202a644b-0f28-444c-9fc0-778344c4298b" xlink:href="dgx-20221231.xsd#dgx_MeasurementInputComparableCompanyRevenueVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_35c32461-acdf-408d-acb9-0b670a426fd8" xlink:to="loc_dgx_MeasurementInputComparableCompanyRevenueVolatilityMember_202a644b-0f28-444c-9fc0-778344c4298b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_69fbfd08-a378-40db-bbf2-e4a6afc8b030" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_35c32461-acdf-408d-acb9-0b670a426fd8" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_69fbfd08-a378-40db-bbf2-e4a6afc8b030" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_61721f21-119e-4436-ae7c-99ced9c6350c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d832b39b-4c2f-4131-bc7a-4c5f165139b3" xlink:to="loc_srt_RangeAxis_61721f21-119e-4436-ae7c-99ced9c6350c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_61721f21-119e-4436-ae7c-99ced9c6350c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_61721f21-119e-4436-ae7c-99ced9c6350c" xlink:to="loc_srt_RangeMember_61721f21-119e-4436-ae7c-99ced9c6350c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5212f319-2901-4633-99ca-65a46b6ef790" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_61721f21-119e-4436-ae7c-99ced9c6350c" xlink:to="loc_srt_RangeMember_5212f319-2901-4633-99ca-65a46b6ef790" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d9efb54a-7d54-40af-b072-146a3a9203da" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5212f319-2901-4633-99ca-65a46b6ef790" xlink:to="loc_srt_MinimumMember_d9efb54a-7d54-40af-b072-146a3a9203da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8cd26f6a-31d8-4edc-82fb-6696f7a68657" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5212f319-2901-4633-99ca-65a46b6ef790" xlink:to="loc_srt_MaximumMember_8cd26f6a-31d8-4edc-82fb-6696f7a68657" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#FAIRVALUEMEASUREMENTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" xlink:type="extended" id="id7adbfa020d0410da94c20d58dbbcf64_FAIRVALUEMEASUREMENTSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9b9c5ebe-6980-4ef4-a377-6790af709c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_e1d1257c-e80a-4990-8a6d-7385a849e953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9b9c5ebe-6980-4ef4-a377-6790af709c5f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_e1d1257c-e80a-4990-8a6d-7385a849e953" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0e79d33a-113f-4700-bc92-4a1c613a7a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9b9c5ebe-6980-4ef4-a377-6790af709c5f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0e79d33a-113f-4700-bc92-4a1c613a7a8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_21e97f98-0a68-4014-bd60-f1bd87c61acf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9b9c5ebe-6980-4ef4-a377-6790af709c5f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_21e97f98-0a68-4014-bd60-f1bd87c61acf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_52495282-f7f8-43af-b65d-7fc693ebe081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9b9c5ebe-6980-4ef4-a377-6790af709c5f" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_52495282-f7f8-43af-b65d-7fc693ebe081" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_c882cd8d-58c5-4e6a-9cc5-f93a9fc54962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9b9c5ebe-6980-4ef4-a377-6790af709c5f" xlink:to="loc_us-gaap_AssetImpairmentCharges_c882cd8d-58c5-4e6a-9cc5-f93a9fc54962" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_4b7079d0-d1e9-40b0-a98c-6a38e2b48cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9b9c5ebe-6980-4ef4-a377-6790af709c5f" xlink:to="loc_us-gaap_DebtInstrumentFairValue_4b7079d0-d1e9-40b0-a98c-6a38e2b48cc2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a7b19df4-6771-48c4-8522-6fc2af3187a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9b9c5ebe-6980-4ef4-a377-6790af709c5f" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a7b19df4-6771-48c4-8522-6fc2af3187a8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9dd21029-3afb-4b3d-b7e8-511a4bb76579" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a7b19df4-6771-48c4-8522-6fc2af3187a8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9dd21029-3afb-4b3d-b7e8-511a4bb76579" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9dd21029-3afb-4b3d-b7e8-511a4bb76579_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9dd21029-3afb-4b3d-b7e8-511a4bb76579" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9dd21029-3afb-4b3d-b7e8-511a4bb76579_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b780aa7-38a5-4a88-8832-9607f80ec44a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9dd21029-3afb-4b3d-b7e8-511a4bb76579" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b780aa7-38a5-4a88-8832-9607f80ec44a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_990c6f19-1a14-40e3-87e3-dd4c9ae51af2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b780aa7-38a5-4a88-8832-9607f80ec44a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_990c6f19-1a14-40e3-87e3-dd4c9ae51af2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_8e405fd5-7249-43d9-87e9-d4c5d551e242" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a7b19df4-6771-48c4-8522-6fc2af3187a8" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_8e405fd5-7249-43d9-87e9-d4c5d551e242" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8e405fd5-7249-43d9-87e9-d4c5d551e242_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_8e405fd5-7249-43d9-87e9-d4c5d551e242" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8e405fd5-7249-43d9-87e9-d4c5d551e242_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_82bae8c1-f0d7-44d8-8993-ce377e93fdd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_8e405fd5-7249-43d9-87e9-d4c5d551e242" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_82bae8c1-f0d7-44d8-8993-ce377e93fdd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ContingentConsiderationMember_a46284c7-57b1-4b60-ac98-9840a739ef2a" xlink:href="dgx-20221231.xsd#dgx_ContingentConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_82bae8c1-f0d7-44d8-8993-ce377e93fdd7" xlink:to="loc_dgx_ContingentConsiderationMember_a46284c7-57b1-4b60-ac98-9840a739ef2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_77f83c7a-bd08-4546-be3d-038c2d04f86a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a7b19df4-6771-48c4-8522-6fc2af3187a8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_77f83c7a-bd08-4546-be3d-038c2d04f86a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_77f83c7a-bd08-4546-be3d-038c2d04f86a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_77f83c7a-bd08-4546-be3d-038c2d04f86a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_77f83c7a-bd08-4546-be3d-038c2d04f86a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_505c6c5d-782a-4aaa-b324-1c46c1297104" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_77f83c7a-bd08-4546-be3d-038c2d04f86a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_505c6c5d-782a-4aaa-b324-1c46c1297104" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_22a2030a-92cb-4187-9d8b-8c27ccceb341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_505c6c5d-782a-4aaa-b324-1c46c1297104" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_22a2030a-92cb-4187-9d8b-8c27ccceb341" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_3ec8e9ab-053f-4522-9bf7-7dc240fea4b8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a7b19df4-6771-48c4-8522-6fc2af3187a8" xlink:to="loc_srt_OwnershipAxis_3ec8e9ab-053f-4522-9bf7-7dc240fea4b8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_3ec8e9ab-053f-4522-9bf7-7dc240fea4b8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_3ec8e9ab-053f-4522-9bf7-7dc240fea4b8" xlink:to="loc_srt_OwnershipDomain_3ec8e9ab-053f-4522-9bf7-7dc240fea4b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_81829d9c-6a72-4135-a454-c1d1b761bfbb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_3ec8e9ab-053f-4522-9bf7-7dc240fea4b8" xlink:to="loc_srt_OwnershipDomain_81829d9c-6a72-4135-a454-c1d1b761bfbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_UMassJointVentureMember_26104279-b597-4f52-8ec6-d301ebec5104" xlink:href="dgx-20221231.xsd#dgx_UMassJointVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_81829d9c-6a72-4135-a454-c1d1b761bfbb" xlink:to="loc_dgx_UMassJointVentureMember_26104279-b597-4f52-8ec6-d301ebec5104" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSReconciliationofBeginningandEndingBalancesofLiabilitiesUnobservableInputsDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#FAIRVALUEMEASUREMENTSReconciliationofBeginningandEndingBalancesofLiabilitiesUnobservableInputsDetails"/>
  <link:definitionLink xlink:role="http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSReconciliationofBeginningandEndingBalancesofLiabilitiesUnobservableInputsDetails" xlink:type="extended" id="i9da52c407b264b94888db25273ce0989_FAIRVALUEMEASUREMENTSReconciliationofBeginningandEndingBalancesofLiabilitiesUnobservableInputsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_29ec4410-0ddf-4b9b-878f-5bb6da0e20a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1c2cb51f-2706-422a-8e18-db782a029955" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_29ec4410-0ddf-4b9b-878f-5bb6da0e20a9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1c2cb51f-2706-422a-8e18-db782a029955" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4ff99501-3de2-4292-93d2-24b6491838e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1c2cb51f-2706-422a-8e18-db782a029955" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4ff99501-3de2-4292-93d2-24b6491838e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_8e5e561d-b519-4969-a8d8-b51068c64d07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1c2cb51f-2706-422a-8e18-db782a029955" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_8e5e561d-b519-4969-a8d8-b51068c64d07" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_e633c634-b39c-49cd-ac96-d2cdca11c468" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1c2cb51f-2706-422a-8e18-db782a029955" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_e633c634-b39c-49cd-ac96-d2cdca11c468" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_7fac58e6-d1ab-4eaa-af7b-cf90b841bb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1c2cb51f-2706-422a-8e18-db782a029955" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_7fac58e6-d1ab-4eaa-af7b-cf90b841bb3b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_8d474f5e-3d79-4ade-a1de-1199bccb48ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_dcb4b40f-a32d-470f-8fef-32877620992e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_29ec4410-0ddf-4b9b-878f-5bb6da0e20a9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_dcb4b40f-a32d-470f-8fef-32877620992e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a9f35051-a19c-453c-8a5c-e7f849225716" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_dcb4b40f-a32d-470f-8fef-32877620992e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a9f35051-a19c-453c-8a5c-e7f849225716" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a9f35051-a19c-453c-8a5c-e7f849225716_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a9f35051-a19c-453c-8a5c-e7f849225716" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a9f35051-a19c-453c-8a5c-e7f849225716_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b97e46ee-dda3-4ccb-9055-df10ac66fdac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a9f35051-a19c-453c-8a5c-e7f849225716" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b97e46ee-dda3-4ccb-9055-df10ac66fdac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_89e06b93-d61c-4bd6-82bf-b11cef675f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b97e46ee-dda3-4ccb-9055-df10ac66fdac" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_89e06b93-d61c-4bd6-82bf-b11cef675f6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_92656b55-aed7-4c21-8cde-60a0b21f98b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_dcb4b40f-a32d-470f-8fef-32877620992e" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_92656b55-aed7-4c21-8cde-60a0b21f98b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_92656b55-aed7-4c21-8cde-60a0b21f98b3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_92656b55-aed7-4c21-8cde-60a0b21f98b3" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_92656b55-aed7-4c21-8cde-60a0b21f98b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_eb5ff7ef-5923-42f2-92a9-c8ea1d5f033f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_92656b55-aed7-4c21-8cde-60a0b21f98b3" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_eb5ff7ef-5923-42f2-92a9-c8ea1d5f033f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ContingentConsiderationMember_706c9082-f341-4726-87de-397aefd9733c" xlink:href="dgx-20221231.xsd#dgx_ContingentConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_eb5ff7ef-5923-42f2-92a9-c8ea1d5f033f" xlink:to="loc_dgx_ContingentConsiderationMember_706c9082-f341-4726-87de-397aefd9733c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/TAXESONINCOMEDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#TAXESONINCOMEDetails"/>
  <link:definitionLink xlink:role="http://questdiagnostics.com/role/TAXESONINCOMEDetails" xlink:type="extended" id="ifae0e4ed87324a6a903abcc780b8e674_TAXESONINCOMEDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_ccc8516a-4658-4e2e-8cd6-cc9cc0babc89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_ccc8516a-4658-4e2e-8cd6-cc9cc0babc89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_ecf98bfb-c3d1-42c4-b55f-d6ec1ff1a8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_ecf98bfb-c3d1-42c4-b55f-d6ec1ff1a8fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_EquityMethodInvestmentOwnershipPercentDisposedOf_1a3509d6-2d8f-4c56-9848-e7382876324b" xlink:href="dgx-20221231.xsd#dgx_EquityMethodInvestmentOwnershipPercentDisposedOf"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_dgx_EquityMethodInvestmentOwnershipPercentDisposedOf_1a3509d6-2d8f-4c56-9848-e7382876324b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_088fe09a-d7df-439c-8548-dc901a2f4962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_088fe09a-d7df-439c-8548-dc901a2f4962" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_59c34211-0154-4914-9802-df2afecfa6f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_59c34211-0154-4914-9802-df2afecfa6f9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_5138eb5f-4e30-4464-a1b3-e2b81f43dce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_5138eb5f-4e30-4464-a1b3-e2b81f43dce6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_f2ba9e7c-9f3a-498d-a635-7c5dcc0f64be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_f2ba9e7c-9f3a-498d-a635-7c5dcc0f64be" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_d7df827e-f111-4fbf-8307-6d9caec958ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_d7df827e-f111-4fbf-8307-6d9caec958ec" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_40f14a55-63da-46e1-9297-58b63b455cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_40f14a55-63da-46e1-9297-58b63b455cfb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_764352ab-3f4c-4242-b2d8-c92d84f4c901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_764352ab-3f4c-4242-b2d8-c92d84f4c901" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_16771596-43d0-4ba9-913e-000e41c84527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_16771596-43d0-4ba9-913e-000e41c84527" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_722e97ed-e4b7-4fa4-a926-d0125f661e03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_722e97ed-e4b7-4fa4-a926-d0125f661e03" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dc5b0d1b-f286-4eb7-a2bd-94a650051dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dc5b0d1b-f286-4eb7-a2bd-94a650051dc8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_3e786b8e-0740-44c0-90d2-e061d151e4de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_3e786b8e-0740-44c0-90d2-e061d151e4de" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_EffectiveIncomeTaxRateReconciliationAdjustmentToStateDeferredTaxLiabilities_6c0270e2-cbb8-4c25-ae50-07aa9c3ce274" xlink:href="dgx-20221231.xsd#dgx_EffectiveIncomeTaxRateReconciliationAdjustmentToStateDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_dgx_EffectiveIncomeTaxRateReconciliationAdjustmentToStateDeferredTaxLiabilities_6c0270e2-cbb8-4c25-ae50-07aa9c3ce274" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_033c2a86-7c47-40be-8e3c-d59498d0c33d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_033c2a86-7c47-40be-8e3c-d59498d0c33d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_d2b50515-b08c-43e3-a45c-652764fc18cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_d2b50515-b08c-43e3-a45c-652764fc18cf" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_d99f2524-0ac9-4839-b872-cd49ca242687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_d99f2524-0ac9-4839-b872-cd49ca242687" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_EffectiveIncomeTaxRateReconciliationChangeForUncertainTaxPosition_f75a412c-0b68-4a83-a0e5-3b8201490d98" xlink:href="dgx-20221231.xsd#dgx_EffectiveIncomeTaxRateReconciliationChangeForUncertainTaxPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_dgx_EffectiveIncomeTaxRateReconciliationChangeForUncertainTaxPosition_f75a412c-0b68-4a83-a0e5-3b8201490d98" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_4d41c133-3d35-4ddf-83f4-036813300f07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_4d41c133-3d35-4ddf-83f4-036813300f07" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_be033d88-ee9e-4aec-8ba2-64c16c6e47d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_be033d88-ee9e-4aec-8ba2-64c16c6e47d5" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1e5095f8-2428-4b59-9a67-f6be838f3226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1e5095f8-2428-4b59-9a67-f6be838f3226" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsAccountsReceivables_e08f01b3-874b-4be0-8764-53419797884e" xlink:href="dgx-20221231.xsd#dgx_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsAccountsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_dgx_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsAccountsReceivables_e08f01b3-874b-4be0-8764-53419797884e" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_800d7182-3282-4966-b899-b100283bf866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_800d7182-3282-4966-b899-b100283bf866" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_53806aba-1c66-4490-9605-b2f2a5cb71cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_53806aba-1c66-4490-9605-b2f2a5cb71cf" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_DeferredTaxLiabilityInvestmentsInvestmentsinSubsidiariesandEquitymethodinvestments_cdc00508-c3ee-4346-a7b3-ab81ab8be154" xlink:href="dgx-20221231.xsd#dgx_DeferredTaxLiabilityInvestmentsInvestmentsinSubsidiariesandEquitymethodinvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_dgx_DeferredTaxLiabilityInvestmentsInvestmentsinSubsidiariesandEquitymethodinvestments_cdc00508-c3ee-4346-a7b3-ab81ab8be154" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_NetOperatingLossCarryfowardsNetOfValuationAllowance_a8920b03-4cfb-4ac0-94ce-c22a3519a679" xlink:href="dgx-20221231.xsd#dgx_NetOperatingLossCarryfowardsNetOfValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_dgx_NetOperatingLossCarryfowardsNetOfValuationAllowance_a8920b03-4cfb-4ac0-94ce-c22a3519a679" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_3fd76a3b-552a-4089-bd57-1adee1efe339" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_3fd76a3b-552a-4089-bd57-1adee1efe339" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_DeferredTaxAssetsOperatingLeaseLiabilitiesNoncurrent_d44e102e-b64f-433f-b536-f24add0dbb6f" xlink:href="dgx-20221231.xsd#dgx_DeferredTaxAssetsOperatingLeaseLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_dgx_DeferredTaxAssetsOperatingLeaseLiabilitiesNoncurrent_d44e102e-b64f-433f-b536-f24add0dbb6f" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_45e2e4f8-7b18-43ea-8b71-f7c0ce27bd32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_45e2e4f8-7b18-43ea-8b71-f7c0ce27bd32" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_a63cde55-81bf-43cb-bed9-fa489adbd721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_DeferredTaxLiabilities_a63cde55-81bf-43cb-bed9-fa489adbd721" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_bee8461e-de7a-4fe1-9b9c-cec54a0489a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_OperatingLossCarryforwards_bee8461e-de7a-4fe1-9b9c-cec54a0489a5" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_b12ad15d-668a-4377-a269-25e514cce96a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_b12ad15d-668a-4377-a269-25e514cce96a" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_4437fa4a-4467-4f8e-9f48-5c2af015975c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_4437fa4a-4467-4f8e-9f48-5c2af015975c" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxes_446ad168-1843-4747-90e9-e368bd6c409c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_AccruedIncomeTaxes_446ad168-1843-4747-90e9-e368bd6c409c" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_70cec720-fd1c-4f40-bf1c-af9dbdd324f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_PrepaidTaxes_70cec720-fd1c-4f40-bf1c-af9dbdd324f2" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3a8cd2b7-2672-431a-b76f-0f748803cd95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3a8cd2b7-2672-431a-b76f-0f748803cd95" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_5f501a4c-63f7-4fed-ba41-9d8fad5340ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3a8cd2b7-2672-431a-b76f-0f748803cd95" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_5f501a4c-63f7-4fed-ba41-9d8fad5340ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_ba2fc996-5a15-445f-b536-6419ba117acd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3a8cd2b7-2672-431a-b76f-0f748803cd95" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_ba2fc996-5a15-445f-b536-6419ba117acd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_d5be96f5-92ca-4c21-81de-c300f4a233cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3a8cd2b7-2672-431a-b76f-0f748803cd95" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_d5be96f5-92ca-4c21-81de-c300f4a233cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ReductionsForChangesInJudgment_987708b0-37f8-4ddd-b6ab-0afc93706274" xlink:href="dgx-20221231.xsd#dgx_ReductionsForChangesInJudgment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3a8cd2b7-2672-431a-b76f-0f748803cd95" xlink:to="loc_dgx_ReductionsForChangesInJudgment_987708b0-37f8-4ddd-b6ab-0afc93706274" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_2a3c95b2-a2ad-4f9e-8e07-00433ad76187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3a8cd2b7-2672-431a-b76f-0f748803cd95" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_2a3c95b2-a2ad-4f9e-8e07-00433ad76187" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_2bee5549-4b5c-4bd3-a2bf-c656f4ce87cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3a8cd2b7-2672-431a-b76f-0f748803cd95" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_2bee5549-4b5c-4bd3-a2bf-c656f4ce87cf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_9ed51ad8-1c91-42f5-a58e-5bb96ec00b49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_29a7689d-45da-4641-b3c1-68e515c5a267" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_29a7689d-45da-4641-b3c1-68e515c5a267" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_f6324b7e-fa6f-4ff3-a971-145d749676c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_f6324b7e-fa6f-4ff3-a971-145d749676c9" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_bb2e579c-f7b4-42e6-bd82-ccb16e7c0925" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_bb2e579c-f7b4-42e6-bd82-ccb16e7c0925" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_34b59af2-f33d-48e9-b1bb-0c9c8e3d2ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_34b59af2-f33d-48e9-b1bb-0c9c8e3d2ddc" xlink:type="arc" order="40"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_4db0bbbd-f5e1-4e4a-83c6-bb2e8589f6da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_4db0bbbd-f5e1-4e4a-83c6-bb2e8589f6da" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_747ba63a-77dc-4827-b18f-4daa62986fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_4db0bbbd-f5e1-4e4a-83c6-bb2e8589f6da" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_747ba63a-77dc-4827-b18f-4daa62986fb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_747ba63a-77dc-4827-b18f-4daa62986fb9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_747ba63a-77dc-4827-b18f-4daa62986fb9" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_747ba63a-77dc-4827-b18f-4daa62986fb9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_214184d7-5454-44d4-8779-2bd4f2de66c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_747ba63a-77dc-4827-b18f-4daa62986fb9" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_214184d7-5454-44d4-8779-2bd4f2de66c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_Q2SolutionsMember_5df3b932-db1b-4438-ae41-12b64a2051e9" xlink:href="dgx-20221231.xsd#dgx_Q2SolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_214184d7-5454-44d4-8779-2bd4f2de66c3" xlink:to="loc_dgx_Q2SolutionsMember_5df3b932-db1b-4438-ae41-12b64a2051e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_e69f4150-13df-409b-9d34-d2854ef074b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_4db0bbbd-f5e1-4e4a-83c6-bb2e8589f6da" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_e69f4150-13df-409b-9d34-d2854ef074b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_e69f4150-13df-409b-9d34-d2854ef074b6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_e69f4150-13df-409b-9d34-d2854ef074b6" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_e69f4150-13df-409b-9d34-d2854ef074b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_baa7d414-5518-41a5-975d-74e429c6692d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_e69f4150-13df-409b-9d34-d2854ef074b6" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_baa7d414-5518-41a5-975d-74e429c6692d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_73c4a0e5-52ee-4d46-a520-4a619a82b363" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_baa7d414-5518-41a5-975d-74e429c6692d" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_73c4a0e5-52ee-4d46-a520-4a619a82b363" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_094fff84-1d6a-4f5e-9a50-3e4a2443a4bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_4db0bbbd-f5e1-4e4a-83c6-bb2e8589f6da" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_094fff84-1d6a-4f5e-9a50-3e4a2443a4bf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_094fff84-1d6a-4f5e-9a50-3e4a2443a4bf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_094fff84-1d6a-4f5e-9a50-3e4a2443a4bf" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_094fff84-1d6a-4f5e-9a50-3e4a2443a4bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3345bb9a-5332-432b-af16-5229b8838bca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_094fff84-1d6a-4f5e-9a50-3e4a2443a4bf" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_3345bb9a-5332-432b-af16-5229b8838bca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_2a2d1081-a3ca-456c-8524-44f7f4a734ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3345bb9a-5332-432b-af16-5229b8838bca" xlink:to="loc_us-gaap_DomesticCountryMember_2a2d1081-a3ca-456c-8524-44f7f4a734ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_f7d73fbb-775f-4cce-8041-a9d680ec30df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3345bb9a-5332-432b-af16-5229b8838bca" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_f7d73fbb-775f-4cce-8041-a9d680ec30df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_8c9b2977-f7d8-4dcc-b59e-6b9fa64bc619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3345bb9a-5332-432b-af16-5229b8838bca" xlink:to="loc_us-gaap_ForeignCountryMember_8c9b2977-f7d8-4dcc-b59e-6b9fa64bc619" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_cc45094c-c3f6-4154-96f0-d366ed84e424" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_4db0bbbd-f5e1-4e4a-83c6-bb2e8589f6da" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_cc45094c-c3f6-4154-96f0-d366ed84e424" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_cc45094c-c3f6-4154-96f0-d366ed84e424_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_cc45094c-c3f6-4154-96f0-d366ed84e424" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_cc45094c-c3f6-4154-96f0-d366ed84e424_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_886636ee-cd49-4a4b-afbc-8face3d6f878" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_cc45094c-c3f6-4154-96f0-d366ed84e424" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_886636ee-cd49-4a4b-afbc-8face3d6f878" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember_b69fe624-84e0-4c02-88af-3d66bbfc3945" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_886636ee-cd49-4a4b-afbc-8face3d6f878" xlink:to="loc_us-gaap_OtherLiabilitiesMember_b69fe624-84e0-4c02-88af-3d66bbfc3945" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#SUPPLEMENTALCASHFLOWANDOTHERDATADetails"/>
  <link:definitionLink xlink:role="http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails" xlink:type="extended" id="i899fd7d52e5a41739273acca75438a38_SUPPLEMENTALCASHFLOWANDOTHERDATADetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationLineItems_293428f8-ce2f-48bf-a1ce-b892daa2eeb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c17c46b4-a2cd-4f4e-9cb3-617dd38e2173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationLineItems_293428f8-ce2f-48bf-a1ce-b892daa2eeb9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c17c46b4-a2cd-4f4e-9cb3-617dd38e2173" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationTable_4f3cadad-7742-456a-9aa3-c7c129751c12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationLineItems_293428f8-ce2f-48bf-a1ce-b892daa2eeb9" xlink:to="loc_us-gaap_ReclassificationTable_4f3cadad-7742-456a-9aa3-c7c129751c12" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationTypeAxis_716d0e0d-bd6a-4612-ba9e-c85134d408d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationTable_4f3cadad-7742-456a-9aa3-c7c129751c12" xlink:to="loc_us-gaap_ReclassificationTypeAxis_716d0e0d-bd6a-4612-ba9e-c85134d408d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationTypeDomain_716d0e0d-bd6a-4612-ba9e-c85134d408d9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationTypeAxis_716d0e0d-bd6a-4612-ba9e-c85134d408d9" xlink:to="loc_us-gaap_ReclassificationTypeDomain_716d0e0d-bd6a-4612-ba9e-c85134d408d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationTypeDomain_3a9b64c0-5115-4091-837d-25a4d8312474" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationTypeAxis_716d0e0d-bd6a-4612-ba9e-c85134d408d9" xlink:to="loc_us-gaap_ReclassificationTypeDomain_3a9b64c0-5115-4091-837d-25a4d8312474" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LeaseTypeChangeMember_7c3d568d-257e-4d07-a512-f3a33f84fad2" xlink:href="dgx-20221231.xsd#dgx_LeaseTypeChangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationTypeDomain_3a9b64c0-5115-4091-837d-25a4d8312474" xlink:to="loc_dgx_LeaseTypeChangeMember_7c3d568d-257e-4d07-a512-f3a33f84fad2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENTDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#PROPERTYPLANTANDEQUIPMENTDetails"/>
  <link:definitionLink xlink:role="http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENTDetails" xlink:type="extended" id="id3c1c99ca8714350aa5437bbe9acfbcd_PROPERTYPLANTANDEQUIPMENTDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f5de4428-9bcc-44bf-964a-f7be9767fabf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1f3c9e0e-8493-4897-b62d-f406a9949cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f5de4428-9bcc-44bf-964a-f7be9767fabf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1f3c9e0e-8493-4897-b62d-f406a9949cfa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1b0e20a5-d890-425d-8c38-5cfc8ed878b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f5de4428-9bcc-44bf-964a-f7be9767fabf" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1b0e20a5-d890-425d-8c38-5cfc8ed878b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_59ebae22-977b-4da0-8dbd-654f04141c98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f5de4428-9bcc-44bf-964a-f7be9767fabf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_59ebae22-977b-4da0-8dbd-654f04141c98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c5885da6-8a42-47ec-8c8e-00aee8cc571d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f5de4428-9bcc-44bf-964a-f7be9767fabf" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c5885da6-8a42-47ec-8c8e-00aee8cc571d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_49098f5c-d939-41a0-954e-494cefb254d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c5885da6-8a42-47ec-8c8e-00aee8cc571d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_49098f5c-d939-41a0-954e-494cefb254d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_49098f5c-d939-41a0-954e-494cefb254d4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_49098f5c-d939-41a0-954e-494cefb254d4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_49098f5c-d939-41a0-954e-494cefb254d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_42a73cf1-7c11-4dcd-aadf-9ed3d4d98cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_49098f5c-d939-41a0-954e-494cefb254d4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_42a73cf1-7c11-4dcd-aadf-9ed3d4d98cbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_1e9966b5-ea47-4157-a818-f7d52560e078" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_42a73cf1-7c11-4dcd-aadf-9ed3d4d98cbf" xlink:to="loc_us-gaap_LandMember_1e9966b5-ea47-4157-a818-f7d52560e078" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_a0cf08c1-1f79-442b-96ab-b3f0ff18fb08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_42a73cf1-7c11-4dcd-aadf-9ed3d4d98cbf" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_a0cf08c1-1f79-442b-96ab-b3f0ff18fb08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LaboratoryEquipmentFurnitureAndFixturesMember_508eca23-3bc9-4f10-9691-4aed8cd3e280" xlink:href="dgx-20221231.xsd#dgx_LaboratoryEquipmentFurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_42a73cf1-7c11-4dcd-aadf-9ed3d4d98cbf" xlink:to="loc_dgx_LaboratoryEquipmentFurnitureAndFixturesMember_508eca23-3bc9-4f10-9691-4aed8cd3e280" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_849094c0-c1b4-4617-9421-f9c7711bcd4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_42a73cf1-7c11-4dcd-aadf-9ed3d4d98cbf" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_849094c0-c1b4-4617-9421-f9c7711bcd4d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_0cf1a5f7-66d2-48b8-a133-6af08edf422a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_42a73cf1-7c11-4dcd-aadf-9ed3d4d98cbf" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_0cf1a5f7-66d2-48b8-a133-6af08edf422a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_8e508cda-0b07-4b09-abf4-c7e398823289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_42a73cf1-7c11-4dcd-aadf-9ed3d4d98cbf" xlink:to="loc_us-gaap_ConstructionInProgressMember_8e508cda-0b07-4b09-abf4-c7e398823289" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_94fb8405-47c7-4f35-8c46-3f9dd5470ace" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c5885da6-8a42-47ec-8c8e-00aee8cc571d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_94fb8405-47c7-4f35-8c46-3f9dd5470ace" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_94fb8405-47c7-4f35-8c46-3f9dd5470ace_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_94fb8405-47c7-4f35-8c46-3f9dd5470ace" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_94fb8405-47c7-4f35-8c46-3f9dd5470ace_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f1ba31c2-ad5a-4223-a5de-7a91ae931dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_94fb8405-47c7-4f35-8c46-3f9dd5470ace" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f1ba31c2-ad5a-4223-a5de-7a91ae931dc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_8a4b7b1b-1898-4b63-980f-48424d6ff3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f1ba31c2-ad5a-4223-a5de-7a91ae931dc5" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_8a4b7b1b-1898-4b63-980f-48424d6ff3ee" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#GOODWILLANDINTANGIBLEASSETSDetails"/>
  <link:definitionLink xlink:role="http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails" xlink:type="extended" id="ic0d5788ee57a4213b8d841aceadfa629_GOODWILLANDINTANGIBLEASSETSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_2392b4ad-a70f-4344-9c23-1db5996637dc" xlink:href="dgx-20221231.xsd#dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_b5e84299-9f6f-4aa6-9810-8caec4f068c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_2392b4ad-a70f-4344-9c23-1db5996637dc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_b5e84299-9f6f-4aa6-9810-8caec4f068c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_aa38e6d8-43d3-449c-8a34-035dae4c057b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_2392b4ad-a70f-4344-9c23-1db5996637dc" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_aa38e6d8-43d3-449c-8a34-035dae4c057b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_acf5563b-1659-4715-a1f0-2333573eef9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_2392b4ad-a70f-4344-9c23-1db5996637dc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_acf5563b-1659-4715-a1f0-2333573eef9b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c916f016-49f8-4dfb-978d-d23b7fb1a1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_2392b4ad-a70f-4344-9c23-1db5996637dc" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c916f016-49f8-4dfb-978d-d23b7fb1a1b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_707d8f83-1f5f-4c3f-8e27-ac9e2d14b956" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_2392b4ad-a70f-4344-9c23-1db5996637dc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_707d8f83-1f5f-4c3f-8e27-ac9e2d14b956" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_ab4f7be3-344a-4ab9-a8e3-25f3950a65d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_707d8f83-1f5f-4c3f-8e27-ac9e2d14b956" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_ab4f7be3-344a-4ab9-a8e3-25f3950a65d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_a3491bcc-f4e0-48a0-8ecc-1bcf20c82067" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_707d8f83-1f5f-4c3f-8e27-ac9e2d14b956" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_a3491bcc-f4e0-48a0-8ecc-1bcf20c82067" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_fda3eb94-e789-457d-b21a-7bddbb0edf7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_707d8f83-1f5f-4c3f-8e27-ac9e2d14b956" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_fda3eb94-e789-457d-b21a-7bddbb0edf7c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ef0c1d75-a823-46e5-b125-910064fc122d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_707d8f83-1f5f-4c3f-8e27-ac9e2d14b956" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ef0c1d75-a823-46e5-b125-910064fc122d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_96a1ac53-f9a1-47a4-b29e-01c01ded9f08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_707d8f83-1f5f-4c3f-8e27-ac9e2d14b956" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_96a1ac53-f9a1-47a4-b29e-01c01ded9f08" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_6486e45e-f191-4809-85e3-4f36575fec9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_707d8f83-1f5f-4c3f-8e27-ac9e2d14b956" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_6486e45e-f191-4809-85e3-4f36575fec9e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_FiniteLivedIntangibleAssetsEstimatedAmortizationExpenseTotal_c1d3578a-0d71-4ebd-ae74-8c2a9911326d" xlink:href="dgx-20221231.xsd#dgx_FiniteLivedIntangibleAssetsEstimatedAmortizationExpenseTotal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_707d8f83-1f5f-4c3f-8e27-ac9e2d14b956" xlink:to="loc_dgx_FiniteLivedIntangibleAssetsEstimatedAmortizationExpenseTotal_c1d3578a-0d71-4ebd-ae74-8c2a9911326d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsTable_7c5e7bf0-a096-49fe-a85e-88eacf6ca5b1" xlink:href="dgx-20221231.xsd#dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_2392b4ad-a70f-4344-9c23-1db5996637dc" xlink:to="loc_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsTable_7c5e7bf0-a096-49fe-a85e-88eacf6ca5b1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a8a2ff92-72a1-4c02-9779-18b9c0eb97f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsTable_7c5e7bf0-a096-49fe-a85e-88eacf6ca5b1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a8a2ff92-72a1-4c02-9779-18b9c0eb97f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a8a2ff92-72a1-4c02-9779-18b9c0eb97f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a8a2ff92-72a1-4c02-9779-18b9c0eb97f6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a8a2ff92-72a1-4c02-9779-18b9c0eb97f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_84e93108-1272-439d-a699-044c7807ee86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a8a2ff92-72a1-4c02-9779-18b9c0eb97f6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_84e93108-1272-439d-a699-044c7807ee86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_74bb3669-be58-4bcc-b07a-e642f28340b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_84e93108-1272-439d-a699-044c7807ee86" xlink:to="loc_us-gaap_CustomerRelationshipsMember_74bb3669-be58-4bcc-b07a-e642f28340b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_0c4eabc5-b8a2-46c1-8582-8e88f2a31767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_84e93108-1272-439d-a699-044c7807ee86" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_0c4eabc5-b8a2-46c1-8582-8e88f2a31767" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_6c299759-0692-4b72-9521-24882510692c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_84e93108-1272-439d-a699-044c7807ee86" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_6c299759-0692-4b72-9521-24882510692c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_962090af-05b2-4eeb-8be8-e1b32fd3ab06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_84e93108-1272-439d-a699-044c7807ee86" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_962090af-05b2-4eeb-8be8-e1b32fd3ab06" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_TotalAmortizingIntangibleAssetsMember_994ae83f-10d1-4d5d-a1d6-17056392c75c" xlink:href="dgx-20221231.xsd#dgx_TotalAmortizingIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_84e93108-1272-439d-a699-044c7807ee86" xlink:to="loc_dgx_TotalAmortizingIntangibleAssetsMember_994ae83f-10d1-4d5d-a1d6-17056392c75c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4b9e97d7-1702-4181-9d8c-3c692e65d4e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsTable_7c5e7bf0-a096-49fe-a85e-88eacf6ca5b1" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4b9e97d7-1702-4181-9d8c-3c692e65d4e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4b9e97d7-1702-4181-9d8c-3c692e65d4e9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4b9e97d7-1702-4181-9d8c-3c692e65d4e9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4b9e97d7-1702-4181-9d8c-3c692e65d4e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_68acbff3-c3d2-4da0-ab3a-3024dcca89f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4b9e97d7-1702-4181-9d8c-3c692e65d4e9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_68acbff3-c3d2-4da0-ab3a-3024dcca89f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_6354bc0e-fb77-40bf-a5e0-6fc6b015ec06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_68acbff3-c3d2-4da0-ab3a-3024dcca89f9" xlink:to="loc_us-gaap_TradeNamesMember_6354bc0e-fb77-40bf-a5e0-6fc6b015ec06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnclassifiedIndefinitelivedIntangibleAssetsMember_84a1d5fb-6c9e-406b-9249-b7fa58380961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnclassifiedIndefinitelivedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_68acbff3-c3d2-4da0-ab3a-3024dcca89f9" xlink:to="loc_us-gaap_UnclassifiedIndefinitelivedIntangibleAssetsMember_84a1d5fb-6c9e-406b-9249-b7fa58380961" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/DEBTLongTermDebtDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#DEBTLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://questdiagnostics.com/role/DEBTLongTermDebtDetails" xlink:type="extended" id="i49f923c4670845c998d55f6bedad92db_DEBTLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_33b902ff-5c32-4aff-b441-5117db77f6a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_b3bcf20a-11c5-4ccf-9685-bde8c22d89c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33b902ff-5c32-4aff-b441-5117db77f6a1" xlink:to="loc_us-gaap_LongTermDebt_b3bcf20a-11c5-4ccf-9685-bde8c22d89c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermDebt_7cccb61a-14f0-40f4-b7d2-32e26be8152c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33b902ff-5c32-4aff-b441-5117db77f6a1" xlink:to="loc_us-gaap_OtherLongTermDebt_7cccb61a-14f0-40f4-b7d2-32e26be8152c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_3b8b6869-41d9-4a60-927a-97c42560969c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33b902ff-5c32-4aff-b441-5117db77f6a1" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_3b8b6869-41d9-4a60-927a-97c42560969c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_ef5619e8-bee4-465e-9c07-22f0676e9446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33b902ff-5c32-4aff-b441-5117db77f6a1" xlink:to="loc_us-gaap_LongTermDebtCurrent_ef5619e8-bee4-465e-9c07-22f0676e9446" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_67d6db3b-01dd-4838-aa90-07e951b8c3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33b902ff-5c32-4aff-b441-5117db77f6a1" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_67d6db3b-01dd-4838-aa90-07e951b8c3ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a2178fca-0084-4cea-a1f9-fb4ca44f1d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33b902ff-5c32-4aff-b441-5117db77f6a1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a2178fca-0084-4cea-a1f9-fb4ca44f1d0a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0e413f35-a5bd-4dcb-80be-3134f953ba24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33b902ff-5c32-4aff-b441-5117db77f6a1" xlink:to="loc_us-gaap_DebtInstrumentTable_0e413f35-a5bd-4dcb-80be-3134f953ba24" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b19996d4-3ff7-4dd8-babc-644c259e36b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0e413f35-a5bd-4dcb-80be-3134f953ba24" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b19996d4-3ff7-4dd8-babc-644c259e36b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b19996d4-3ff7-4dd8-babc-644c259e36b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b19996d4-3ff7-4dd8-babc-644c259e36b1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b19996d4-3ff7-4dd8-babc-644c259e36b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e3ad79fa-72b1-4b8d-b313-7a88e184b57d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b19996d4-3ff7-4dd8-babc-644c259e36b1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e3ad79fa-72b1-4b8d-b313-7a88e184b57d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_895023cf-22e1-40e2-b6a3-c0c1d2aae31b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e3ad79fa-72b1-4b8d-b313-7a88e184b57d" xlink:to="loc_us-gaap_SeniorNotesMember_895023cf-22e1-40e2-b6a3-c0c1d2aae31b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e08e5615-6e25-4d8b-a5f6-8ffd1b49c6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0e413f35-a5bd-4dcb-80be-3134f953ba24" xlink:to="loc_us-gaap_DebtInstrumentAxis_e08e5615-6e25-4d8b-a5f6-8ffd1b49c6b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e08e5615-6e25-4d8b-a5f6-8ffd1b49c6b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e08e5615-6e25-4d8b-a5f6-8ffd1b49c6b9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e08e5615-6e25-4d8b-a5f6-8ffd1b49c6b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d9f4fe65-74b3-42f0-8112-4ddcd6347d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e08e5615-6e25-4d8b-a5f6-8ffd1b49c6b9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d9f4fe65-74b3-42f0-8112-4ddcd6347d1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_FourpointtwofivepercentSeniorNotesDue2024Member_282b84d8-83e8-4165-b1f6-2f8481fce008" xlink:href="dgx-20221231.xsd#dgx_FourpointtwofivepercentSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d9f4fe65-74b3-42f0-8112-4ddcd6347d1d" xlink:to="loc_dgx_FourpointtwofivepercentSeniorNotesDue2024Member_282b84d8-83e8-4165-b1f6-2f8481fce008" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ThreePointFiveZeroPercentSeniorNotesdueMarch2025Member_8b2e0a48-442f-48a8-b0df-106b0ea711ee" xlink:href="dgx-20221231.xsd#dgx_ThreePointFiveZeroPercentSeniorNotesdueMarch2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d9f4fe65-74b3-42f0-8112-4ddcd6347d1d" xlink:to="loc_dgx_ThreePointFiveZeroPercentSeniorNotesdueMarch2025Member_8b2e0a48-442f-48a8-b0df-106b0ea711ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ThreePointFourFivePercentSeniorNotesdueJune2026Member_f2cd32c8-56b2-49b2-8cc0-ee737383bb6a" xlink:href="dgx-20221231.xsd#dgx_ThreePointFourFivePercentSeniorNotesdueJune2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d9f4fe65-74b3-42f0-8112-4ddcd6347d1d" xlink:to="loc_dgx_ThreePointFourFivePercentSeniorNotesdueJune2026Member_f2cd32c8-56b2-49b2-8cc0-ee737383bb6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_FourPointTwoZeroPercentSeniorNotesdueJune2029Member_7a9b92ab-6f1b-434a-83c9-cdba68f52b9c" xlink:href="dgx-20221231.xsd#dgx_FourPointTwoZeroPercentSeniorNotesdueJune2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d9f4fe65-74b3-42f0-8112-4ddcd6347d1d" xlink:to="loc_dgx_FourPointTwoZeroPercentSeniorNotesdueJune2029Member_7a9b92ab-6f1b-434a-83c9-cdba68f52b9c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_TwoPointNineFivePercentSeniorNotesdueJune2030Member_7fe4e2c2-d177-4c3b-a3d7-df0b6216edf5" xlink:href="dgx-20221231.xsd#dgx_TwoPointNineFivePercentSeniorNotesdueJune2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d9f4fe65-74b3-42f0-8112-4ddcd6347d1d" xlink:to="loc_dgx_TwoPointNineFivePercentSeniorNotesdueJune2030Member_7fe4e2c2-d177-4c3b-a3d7-df0b6216edf5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_TwoPointEightZeroPercentSeniorNotesDueJune2031Member_d1310806-0e7c-4756-a159-eef0be822b23" xlink:href="dgx-20221231.xsd#dgx_TwoPointEightZeroPercentSeniorNotesDueJune2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d9f4fe65-74b3-42f0-8112-4ddcd6347d1d" xlink:to="loc_dgx_TwoPointEightZeroPercentSeniorNotesDueJune2031Member_d1310806-0e7c-4756-a159-eef0be822b23" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_SixPointNineFivePercentSeniorNotesDue2037Member_830560ac-dda7-430d-8d90-37f20563c35b" xlink:href="dgx-20221231.xsd#dgx_SixPointNineFivePercentSeniorNotesDue2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d9f4fe65-74b3-42f0-8112-4ddcd6347d1d" xlink:to="loc_dgx_SixPointNineFivePercentSeniorNotesDue2037Member_830560ac-dda7-430d-8d90-37f20563c35b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_FivePointSevenFivePercentSeniorNotesDue2040Member_31b690e2-35a0-43ca-9401-dcf157c6cd52" xlink:href="dgx-20221231.xsd#dgx_FivePointSevenFivePercentSeniorNotesDue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d9f4fe65-74b3-42f0-8112-4ddcd6347d1d" xlink:to="loc_dgx_FivePointSevenFivePercentSeniorNotesDue2040Member_31b690e2-35a0-43ca-9401-dcf157c6cd52" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_FourPointSevenZeroPercentSeniorNotesdueMarch2045Member_301b36f2-b397-4935-aadb-d39895987604" xlink:href="dgx-20221231.xsd#dgx_FourPointSevenZeroPercentSeniorNotesdueMarch2045Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d9f4fe65-74b3-42f0-8112-4ddcd6347d1d" xlink:to="loc_dgx_FourPointSevenZeroPercentSeniorNotesdueMarch2045Member_301b36f2-b397-4935-aadb-d39895987604" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_FinanceLeaseObligationsandOtherMember_cb30cbe4-297a-499a-aa62-2fa3cd6f2b28" xlink:href="dgx-20221231.xsd#dgx_FinanceLeaseObligationsandOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d9f4fe65-74b3-42f0-8112-4ddcd6347d1d" xlink:to="loc_dgx_FinanceLeaseObligationsandOtherMember_cb30cbe4-297a-499a-aa62-2fa3cd6f2b28" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/DEBTFinanceLeaseDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#DEBTFinanceLeaseDetails"/>
  <link:definitionLink xlink:role="http://questdiagnostics.com/role/DEBTFinanceLeaseDetails" xlink:type="extended" id="ifbc5e7bf29f54d99bbedd80ba2e42589_DEBTFinanceLeaseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_39f33502-4b8b-4c93-a9db-99ea5fc684e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_FinanceLeaseLiabilityRealEstate_8f140fa1-7d94-4ca5-a478-b88b15138650" xlink:href="dgx-20221231.xsd#dgx_FinanceLeaseLiabilityRealEstate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_39f33502-4b8b-4c93-a9db-99ea5fc684e1" xlink:to="loc_dgx_FinanceLeaseLiabilityRealEstate_8f140fa1-7d94-4ca5-a478-b88b15138650" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8b426992-5018-48a8-9bb8-216f7dab3270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_39f33502-4b8b-4c93-a9db-99ea5fc684e1" xlink:to="loc_us-gaap_DebtInstrumentTable_8b426992-5018-48a8-9bb8-216f7dab3270" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1146f002-254e-4885-9d49-16ab63752138" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8b426992-5018-48a8-9bb8-216f7dab3270" xlink:to="loc_us-gaap_DebtInstrumentAxis_1146f002-254e-4885-9d49-16ab63752138" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1146f002-254e-4885-9d49-16ab63752138_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1146f002-254e-4885-9d49-16ab63752138" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1146f002-254e-4885-9d49-16ab63752138_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bfbe247b-0347-4a0f-989e-4b7a3d878ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1146f002-254e-4885-9d49-16ab63752138" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bfbe247b-0347-4a0f-989e-4b7a3d878ea2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_FinanceLeaseObligationsandOtherMember_319e9aba-f6e1-4283-a7b3-a517cf8eb38e" xlink:href="dgx-20221231.xsd#dgx_FinanceLeaseObligationsandOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bfbe247b-0347-4a0f-989e-4b7a3d878ea2" xlink:to="loc_dgx_FinanceLeaseObligationsandOtherMember_319e9aba-f6e1-4283-a7b3-a517cf8eb38e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/DEBTSecuredReceivablesCreditFacilityNarrativeDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#DEBTSecuredReceivablesCreditFacilityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://questdiagnostics.com/role/DEBTSecuredReceivablesCreditFacilityNarrativeDetails" xlink:type="extended" id="i41fd26f94e3b496eb9828c6f3964f6c6_DEBTSecuredReceivablesCreditFacilityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_835dcc63-38d4-4ba5-bbf2-513f9b82a1ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_DebtInstrumentExtensionPeriod_4cfc2a62-fec0-44d0-8cf9-fa3dfaf41c4f" xlink:href="dgx-20221231.xsd#dgx_DebtInstrumentExtensionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_835dcc63-38d4-4ba5-bbf2-513f9b82a1ad" xlink:to="loc_dgx_DebtInstrumentExtensionPeriod_4cfc2a62-fec0-44d0-8cf9-fa3dfaf41c4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_133e150c-224d-4961-bad7-89367bb10653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_835dcc63-38d4-4ba5-bbf2-513f9b82a1ad" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_133e150c-224d-4961-bad7-89367bb10653" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a7b79d59-67d6-4e6d-bd72-e4d8b5ede10c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_835dcc63-38d4-4ba5-bbf2-513f9b82a1ad" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a7b79d59-67d6-4e6d-bd72-e4d8b5ede10c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_75ce3333-5e0a-4cfc-a5a7-f55803322332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_835dcc63-38d4-4ba5-bbf2-513f9b82a1ad" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_75ce3333-5e0a-4cfc-a5a7-f55803322332" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_61ace9fc-5beb-4385-9aa0-12e43771476c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_835dcc63-38d4-4ba5-bbf2-513f9b82a1ad" xlink:to="loc_us-gaap_DebtInstrumentTable_61ace9fc-5beb-4385-9aa0-12e43771476c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5af54d39-f3ef-4cae-bbf5-5fef9d64d900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_61ace9fc-5beb-4385-9aa0-12e43771476c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5af54d39-f3ef-4cae-bbf5-5fef9d64d900" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5af54d39-f3ef-4cae-bbf5-5fef9d64d900_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5af54d39-f3ef-4cae-bbf5-5fef9d64d900" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5af54d39-f3ef-4cae-bbf5-5fef9d64d900_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fe793b70-734e-42a8-975d-4015f52519ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5af54d39-f3ef-4cae-bbf5-5fef9d64d900" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fe793b70-734e-42a8-975d-4015f52519ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_807289d2-edc9-4b35-8040-ee512f75e732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_fe793b70-734e-42a8-975d-4015f52519ec" xlink:to="loc_us-gaap_SecuredDebtMember_807289d2-edc9-4b35-8040-ee512f75e732" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_246a30f0-d16c-4b0b-8561-4aa928554c25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_61ace9fc-5beb-4385-9aa0-12e43771476c" xlink:to="loc_us-gaap_CreditFacilityAxis_246a30f0-d16c-4b0b-8561-4aa928554c25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_246a30f0-d16c-4b0b-8561-4aa928554c25_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_246a30f0-d16c-4b0b-8561-4aa928554c25" xlink:to="loc_us-gaap_CreditFacilityDomain_246a30f0-d16c-4b0b-8561-4aa928554c25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_8241da14-b03e-4cbf-967a-0de2cdb0fcb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_246a30f0-d16c-4b0b-8561-4aa928554c25" xlink:to="loc_us-gaap_CreditFacilityDomain_8241da14-b03e-4cbf-967a-0de2cdb0fcb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LoanCommitmentMember_f746c824-dd78-4dcd-80ee-db206a0b6260" xlink:href="dgx-20221231.xsd#dgx_LoanCommitmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_8241da14-b03e-4cbf-967a-0de2cdb0fcb3" xlink:to="loc_dgx_LoanCommitmentMember_f746c824-dd78-4dcd-80ee-db206a0b6260" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_44d25b8b-05ac-46f5-8de0-db214605f653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_8241da14-b03e-4cbf-967a-0de2cdb0fcb3" xlink:to="loc_us-gaap_LetterOfCreditMember_44d25b8b-05ac-46f5-8de0-db214605f653" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_d91aadc9-bdb3-4d5e-bbd5-9c3daea9ef78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_61ace9fc-5beb-4385-9aa0-12e43771476c" xlink:to="loc_us-gaap_VariableRateAxis_d91aadc9-bdb3-4d5e-bbd5-9c3daea9ef78" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_d91aadc9-bdb3-4d5e-bbd5-9c3daea9ef78_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_d91aadc9-bdb3-4d5e-bbd5-9c3daea9ef78" xlink:to="loc_us-gaap_VariableRateDomain_d91aadc9-bdb3-4d5e-bbd5-9c3daea9ef78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_cb4b0ee9-19f6-4088-9274-9ab35b3c65f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_d91aadc9-bdb3-4d5e-bbd5-9c3daea9ef78" xlink:to="loc_us-gaap_VariableRateDomain_cb4b0ee9-19f6-4088-9274-9ab35b3c65f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_CommercialPaperAndTermSecuredOvernightFinancingRateMember_1dab5944-7107-4e33-ae02-f8bc2a3f5a8b" xlink:href="dgx-20221231.xsd#dgx_CommercialPaperAndTermSecuredOvernightFinancingRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_cb4b0ee9-19f6-4088-9274-9ab35b3c65f4" xlink:to="loc_dgx_CommercialPaperAndTermSecuredOvernightFinancingRateMember_1dab5944-7107-4e33-ae02-f8bc2a3f5a8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_80198da7-070c-42f6-852f-ef43bcd4c06d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_61ace9fc-5beb-4385-9aa0-12e43771476c" xlink:to="loc_srt_RangeAxis_80198da7-070c-42f6-852f-ef43bcd4c06d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_80198da7-070c-42f6-852f-ef43bcd4c06d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_80198da7-070c-42f6-852f-ef43bcd4c06d" xlink:to="loc_srt_RangeMember_80198da7-070c-42f6-852f-ef43bcd4c06d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e7c80c53-ca42-43f6-8133-fde6573ce60d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_80198da7-070c-42f6-852f-ef43bcd4c06d" xlink:to="loc_srt_RangeMember_e7c80c53-ca42-43f6-8133-fde6573ce60d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a6013c5a-ad5c-4a59-82f7-cbecf69ee4b6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e7c80c53-ca42-43f6-8133-fde6573ce60d" xlink:to="loc_srt_MinimumMember_a6013c5a-ad5c-4a59-82f7-cbecf69ee4b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_35917f0f-a35d-4fcf-bc78-3b1c1bd6b160" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e7c80c53-ca42-43f6-8133-fde6573ce60d" xlink:to="loc_srt_MaximumMember_35917f0f-a35d-4fcf-bc78-3b1c1bd6b160" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/DEBTSeniorUnsecuredRevolvingCreditFacilityNarrativeDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#DEBTSeniorUnsecuredRevolvingCreditFacilityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://questdiagnostics.com/role/DEBTSeniorUnsecuredRevolvingCreditFacilityNarrativeDetails" xlink:type="extended" id="i2af067c492914079acbe0e5254ca67c5_DEBTSeniorUnsecuredRevolvingCreditFacilityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_10a38c6c-2574-4e1f-94a2-4c84345620c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_513064ce-01cd-4f4d-a330-0f1eee41024e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10a38c6c-2574-4e1f-94a2-4c84345620c7" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_513064ce-01cd-4f4d-a330-0f1eee41024e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_f89e39f2-90d2-4803-94a6-447927f0f97c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10a38c6c-2574-4e1f-94a2-4c84345620c7" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_f89e39f2-90d2-4803-94a6-447927f0f97c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_d8de9f0d-8dde-492c-a94f-8f931a8cf781" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10a38c6c-2574-4e1f-94a2-4c84345620c7" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_d8de9f0d-8dde-492c-a94f-8f931a8cf781" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4e3c48da-bcc2-487a-92eb-9ad75fb94c58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10a38c6c-2574-4e1f-94a2-4c84345620c7" xlink:to="loc_us-gaap_DebtInstrumentTable_4e3c48da-bcc2-487a-92eb-9ad75fb94c58" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7384e76c-bb0f-401e-a619-2cce4919d386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4e3c48da-bcc2-487a-92eb-9ad75fb94c58" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7384e76c-bb0f-401e-a619-2cce4919d386" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7384e76c-bb0f-401e-a619-2cce4919d386_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7384e76c-bb0f-401e-a619-2cce4919d386" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7384e76c-bb0f-401e-a619-2cce4919d386_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_dfcfc5e9-0aaf-4d18-9f06-9e7a4fa551ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7384e76c-bb0f-401e-a619-2cce4919d386" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_dfcfc5e9-0aaf-4d18-9f06-9e7a4fa551ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_SeniorunsecuredrevolvingcreditfacilityMember_ea747cb2-e2c2-4a3f-8fde-765582bd3fc0" xlink:href="dgx-20221231.xsd#dgx_SeniorunsecuredrevolvingcreditfacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dfcfc5e9-0aaf-4d18-9f06-9e7a4fa551ad" xlink:to="loc_dgx_SeniorunsecuredrevolvingcreditfacilityMember_ea747cb2-e2c2-4a3f-8fde-765582bd3fc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_981d8554-6e28-4891-90df-162366598d61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4e3c48da-bcc2-487a-92eb-9ad75fb94c58" xlink:to="loc_us-gaap_CreditFacilityAxis_981d8554-6e28-4891-90df-162366598d61" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_981d8554-6e28-4891-90df-162366598d61_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_981d8554-6e28-4891-90df-162366598d61" xlink:to="loc_us-gaap_CreditFacilityDomain_981d8554-6e28-4891-90df-162366598d61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_9810fe4c-f09c-4bda-9eb4-cf3477071003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_981d8554-6e28-4891-90df-162366598d61" xlink:to="loc_us-gaap_CreditFacilityDomain_9810fe4c-f09c-4bda-9eb4-cf3477071003" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_c4771493-ebf3-40e5-a0ed-522af43f910f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_9810fe4c-f09c-4bda-9eb4-cf3477071003" xlink:to="loc_us-gaap_LetterOfCreditMember_c4771493-ebf3-40e5-a0ed-522af43f910f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_f353bfa8-1504-4f2d-8092-81ff68198b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4e3c48da-bcc2-487a-92eb-9ad75fb94c58" xlink:to="loc_us-gaap_VariableRateAxis_f353bfa8-1504-4f2d-8092-81ff68198b0c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_f353bfa8-1504-4f2d-8092-81ff68198b0c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_f353bfa8-1504-4f2d-8092-81ff68198b0c" xlink:to="loc_us-gaap_VariableRateDomain_f353bfa8-1504-4f2d-8092-81ff68198b0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_db541ede-5cb6-41b6-9a14-b93cac9752a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_f353bfa8-1504-4f2d-8092-81ff68198b0c" xlink:to="loc_us-gaap_VariableRateDomain_db541ede-5cb6-41b6-9a14-b93cac9752a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_c118f993-dc98-491c-b0f5-c33e0f1cbdbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_db541ede-5cb6-41b6-9a14-b93cac9752a6" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_c118f993-dc98-491c-b0f5-c33e0f1cbdbc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/LEASESNarrativeDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#LEASESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://questdiagnostics.com/role/LEASESNarrativeDetails" xlink:type="extended" id="i1e1afade097447178afd56bca661b6f7_LEASESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_42dad8d6-79e0-411c-b857-e4e02a0ab839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LeaseRemainingLeaseTerm_1e801fb5-639d-4276-996e-942f10758374" xlink:href="dgx-20221231.xsd#dgx_LeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_42dad8d6-79e0-411c-b857-e4e02a0ab839" xlink:to="loc_dgx_LeaseRemainingLeaseTerm_1e801fb5-639d-4276-996e-942f10758374" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LeaseRenewalTerm_61045e34-4166-49bb-864f-f5762c65bb41" xlink:href="dgx-20221231.xsd#dgx_LeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_42dad8d6-79e0-411c-b857-e4e02a0ab839" xlink:to="loc_dgx_LeaseRenewalTerm_61045e34-4166-49bb-864f-f5762c65bb41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8b81ec67-ecad-4bff-bc42-3e182f137d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_42dad8d6-79e0-411c-b857-e4e02a0ab839" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8b81ec67-ecad-4bff-bc42-3e182f137d6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_5d308cfb-1c7d-475c-8e6a-adab1bfaf3f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_42dad8d6-79e0-411c-b857-e4e02a0ab839" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_5d308cfb-1c7d-475c-8e6a-adab1bfaf3f0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d2309dd3-91d2-4c01-95d1-f4f6b25d9925" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_5d308cfb-1c7d-475c-8e6a-adab1bfaf3f0" xlink:to="loc_srt_RangeAxis_d2309dd3-91d2-4c01-95d1-f4f6b25d9925" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d2309dd3-91d2-4c01-95d1-f4f6b25d9925_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d2309dd3-91d2-4c01-95d1-f4f6b25d9925" xlink:to="loc_srt_RangeMember_d2309dd3-91d2-4c01-95d1-f4f6b25d9925_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b029f4cc-c169-44d9-ae75-21cca2fcf4e7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d2309dd3-91d2-4c01-95d1-f4f6b25d9925" xlink:to="loc_srt_RangeMember_b029f4cc-c169-44d9-ae75-21cca2fcf4e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f701642b-b5cb-4128-a3b5-8589173f877c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b029f4cc-c169-44d9-ae75-21cca2fcf4e7" xlink:to="loc_srt_MinimumMember_f701642b-b5cb-4128-a3b5-8589173f877c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0e9cd9e4-2bef-4bb0-9e89-db18c3371c04" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b029f4cc-c169-44d9-ae75-21cca2fcf4e7" xlink:to="loc_srt_MaximumMember_0e9cd9e4-2bef-4bb0-9e89-db18c3371c04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationTypeAxis_02794222-a8a9-4c45-acd1-6b46172d5047" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_5d308cfb-1c7d-475c-8e6a-adab1bfaf3f0" xlink:to="loc_us-gaap_ReclassificationTypeAxis_02794222-a8a9-4c45-acd1-6b46172d5047" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationTypeDomain_02794222-a8a9-4c45-acd1-6b46172d5047_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationTypeAxis_02794222-a8a9-4c45-acd1-6b46172d5047" xlink:to="loc_us-gaap_ReclassificationTypeDomain_02794222-a8a9-4c45-acd1-6b46172d5047_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationTypeDomain_df7c9b4e-27fa-4c47-92da-ab644dbf6865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationTypeAxis_02794222-a8a9-4c45-acd1-6b46172d5047" xlink:to="loc_us-gaap_ReclassificationTypeDomain_df7c9b4e-27fa-4c47-92da-ab644dbf6865" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LeaseTypeChangeMember_875d354d-eb81-458d-a93f-738645aaabb7" xlink:href="dgx-20221231.xsd#dgx_LeaseTypeChangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationTypeDomain_df7c9b4e-27fa-4c47-92da-ab644dbf6865" xlink:to="loc_dgx_LeaseTypeChangeMember_875d354d-eb81-458d-a93f-738645aaabb7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#FINANCIALINSTRUMENTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails" xlink:type="extended" id="i65c3a95884bc44a989ab04fd26d41d33_FINANCIALINSTRUMENTSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_0fe0854a-3937-443e-8375-66bca82501e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_32ec11cd-127e-4edb-8461-c2d6c295c6f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0fe0854a-3937-443e-8375-66bca82501e5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_32ec11cd-127e-4edb-8461-c2d6c295c6f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_a052bbb5-e015-4d6c-99e0-f12eceed0641" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_0fe0854a-3937-443e-8375-66bca82501e5" xlink:to="loc_us-gaap_DerivativeTable_a052bbb5-e015-4d6c-99e0-f12eceed0641" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5a5495ac-cb22-4f57-a9fb-a2e200178e30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_a052bbb5-e015-4d6c-99e0-f12eceed0641" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5a5495ac-cb22-4f57-a9fb-a2e200178e30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_5a5495ac-cb22-4f57-a9fb-a2e200178e30_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5a5495ac-cb22-4f57-a9fb-a2e200178e30" xlink:to="loc_us-gaap_HedgingRelationshipDomain_5a5495ac-cb22-4f57-a9fb-a2e200178e30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_315ce7f6-354d-478a-ad50-777644d5f6ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5a5495ac-cb22-4f57-a9fb-a2e200178e30" xlink:to="loc_us-gaap_HedgingRelationshipDomain_315ce7f6-354d-478a-ad50-777644d5f6ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_75205421-4de0-4cd5-97db-a7b31cc83a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_315ce7f6-354d-478a-ad50-777644d5f6ae" xlink:to="loc_us-gaap_FairValueHedgingMember_75205421-4de0-4cd5-97db-a7b31cc83a2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_02018962-ff8f-453b-a473-149612978fd6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_a052bbb5-e015-4d6c-99e0-f12eceed0641" xlink:to="loc_srt_StatementScenarioAxis_02018962-ff8f-453b-a473-149612978fd6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_02018962-ff8f-453b-a473-149612978fd6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_02018962-ff8f-453b-a473-149612978fd6" xlink:to="loc_srt_ScenarioUnspecifiedDomain_02018962-ff8f-453b-a473-149612978fd6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_393425fd-1ad3-478e-8ee2-328de00ed52a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_02018962-ff8f-453b-a473-149612978fd6" xlink:to="loc_srt_ScenarioUnspecifiedDomain_393425fd-1ad3-478e-8ee2-328de00ed52a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_300c0deb-de99-40d0-bffc-ed85eb35c1f8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_393425fd-1ad3-478e-8ee2-328de00ed52a" xlink:to="loc_srt_ScenarioForecastMember_300c0deb-de99-40d0-bffc-ed85eb35c1f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_908c805a-c479-440d-87a2-815964f531ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_a052bbb5-e015-4d6c-99e0-f12eceed0641" xlink:to="loc_us-gaap_VariableRateAxis_908c805a-c479-440d-87a2-815964f531ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_908c805a-c479-440d-87a2-815964f531ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_908c805a-c479-440d-87a2-815964f531ef" xlink:to="loc_us-gaap_VariableRateDomain_908c805a-c479-440d-87a2-815964f531ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_8b3ddad2-fb28-401c-87a0-2aa8ff88f69f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_908c805a-c479-440d-87a2-815964f531ef" xlink:to="loc_us-gaap_VariableRateDomain_8b3ddad2-fb28-401c-87a0-2aa8ff88f69f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_9333d456-bf4f-4c4a-aaf7-9809bf621f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_8b3ddad2-fb28-401c-87a0-2aa8ff88f69f" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_9333d456-bf4f-4c4a-aaf7-9809bf621f6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6f377dfd-74ff-441c-b284-8326e93a5c6b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_a052bbb5-e015-4d6c-99e0-f12eceed0641" xlink:to="loc_srt_RangeAxis_6f377dfd-74ff-441c-b284-8326e93a5c6b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6f377dfd-74ff-441c-b284-8326e93a5c6b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6f377dfd-74ff-441c-b284-8326e93a5c6b" xlink:to="loc_srt_RangeMember_6f377dfd-74ff-441c-b284-8326e93a5c6b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4376ba65-34bd-40f5-979f-46e0cc65a785" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6f377dfd-74ff-441c-b284-8326e93a5c6b" xlink:to="loc_srt_RangeMember_4376ba65-34bd-40f5-979f-46e0cc65a785" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_63f079c2-96c6-475b-8665-98448a277d17" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4376ba65-34bd-40f5-979f-46e0cc65a785" xlink:to="loc_srt_MinimumMember_63f079c2-96c6-475b-8665-98448a277d17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e58e841f-c4ac-4d98-a533-1b5db7ccd5aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4376ba65-34bd-40f5-979f-46e0cc65a785" xlink:to="loc_srt_MaximumMember_e58e841f-c4ac-4d98-a533-1b5db7ccd5aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5cdce26f-b1db-41b8-ae97-8151337ee0db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_a052bbb5-e015-4d6c-99e0-f12eceed0641" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5cdce26f-b1db-41b8-ae97-8151337ee0db" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5cdce26f-b1db-41b8-ae97-8151337ee0db_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5cdce26f-b1db-41b8-ae97-8151337ee0db" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5cdce26f-b1db-41b8-ae97-8151337ee0db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_12743295-b355-456a-a42f-3be1c1fa2afd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5cdce26f-b1db-41b8-ae97-8151337ee0db" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_12743295-b355-456a-a42f-3be1c1fa2afd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_006e7771-dec0-4c0d-8aff-279ff57d9053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_12743295-b355-456a-a42f-3be1c1fa2afd" xlink:to="loc_us-gaap_LongTermDebtMember_006e7771-dec0-4c0d-8aff-279ff57d9053" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/FINANCIALINSTRUMENTSBalanceSheetsDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#FINANCIALINSTRUMENTSBalanceSheetsDetails"/>
  <link:definitionLink xlink:role="http://questdiagnostics.com/role/FINANCIALINSTRUMENTSBalanceSheetsDetails" xlink:type="extended" id="i7e0434a00ba444849e68e00ee0dfbd47_FINANCIALINSTRUMENTSBalanceSheetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_c307205a-0fd8-4ed5-83b5-23dd8a0470f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_3b74fcea-ac68-434e-b359-68e02cce4647" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c307205a-0fd8-4ed5-83b5-23dd8a0470f4" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_3b74fcea-ac68-434e-b359-68e02cce4647" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_b654be16-9d50-4d4a-945e-993a203c721c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_c307205a-0fd8-4ed5-83b5-23dd8a0470f4" xlink:to="loc_us-gaap_DerivativeTable_b654be16-9d50-4d4a-945e-993a203c721c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7e9f9744-a1af-4eb5-a646-dcf6db5175da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_b654be16-9d50-4d4a-945e-993a203c721c" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_7e9f9744-a1af-4eb5-a646-dcf6db5175da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7e9f9744-a1af-4eb5-a646-dcf6db5175da_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7e9f9744-a1af-4eb5-a646-dcf6db5175da" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7e9f9744-a1af-4eb5-a646-dcf6db5175da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3a7c4c91-c8cf-4289-80d2-b03decc30f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7e9f9744-a1af-4eb5-a646-dcf6db5175da" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3a7c4c91-c8cf-4289-80d2-b03decc30f8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_0df5cb31-d5bc-403a-aa7d-52d622374e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3a7c4c91-c8cf-4289-80d2-b03decc30f8a" xlink:to="loc_us-gaap_LongTermDebtMember_0df5cb31-d5bc-403a-aa7d-52d622374e77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_87525515-9617-4f18-ac6d-24e528bee721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_b654be16-9d50-4d4a-945e-993a203c721c" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_87525515-9617-4f18-ac6d-24e528bee721" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_87525515-9617-4f18-ac6d-24e528bee721_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_87525515-9617-4f18-ac6d-24e528bee721" xlink:to="loc_us-gaap_HedgingRelationshipDomain_87525515-9617-4f18-ac6d-24e528bee721_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_bf178be9-5f53-42b9-88d8-e042c29804e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_87525515-9617-4f18-ac6d-24e528bee721" xlink:to="loc_us-gaap_HedgingRelationshipDomain_bf178be9-5f53-42b9-88d8-e042c29804e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_0a24da4e-b827-42f6-a02e-4dbdcd326e79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_bf178be9-5f53-42b9-88d8-e042c29804e5" xlink:to="loc_us-gaap_FairValueHedgingMember_0a24da4e-b827-42f6-a02e-4dbdcd326e79" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/FINANCIALINSTRUMENTSIncomeStatementDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#FINANCIALINSTRUMENTSIncomeStatementDetails"/>
  <link:definitionLink xlink:role="http://questdiagnostics.com/role/FINANCIALINSTRUMENTSIncomeStatementDetails" xlink:type="extended" id="i0026b30320ac46f69397d882db00081f_FINANCIALINSTRUMENTSIncomeStatementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_bd32f80c-d27d-4254-b425-ba92e59b1c60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_8439070a-fb51-4af8-a6c3-7b811afdfb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_bd32f80c-d27d-4254-b425-ba92e59b1c60" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_8439070a-fb51-4af8-a6c3-7b811afdfb8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_e17ef5a1-4592-47a3-a27a-57efa8473071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_bd32f80c-d27d-4254-b425-ba92e59b1c60" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_e17ef5a1-4592-47a3-a27a-57efa8473071" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_50ba7130-87ee-4df3-b499-1b994210e596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_bd32f80c-d27d-4254-b425-ba92e59b1c60" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_50ba7130-87ee-4df3-b499-1b994210e596" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_d149a1fb-2c55-4614-9449-71d35753737b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_bd32f80c-d27d-4254-b425-ba92e59b1c60" xlink:to="loc_us-gaap_DerivativeTable_d149a1fb-2c55-4614-9449-71d35753737b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_efee842a-f71c-43aa-ab2b-259848b048fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_d149a1fb-2c55-4614-9449-71d35753737b" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_efee842a-f71c-43aa-ab2b-259848b048fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_efee842a-f71c-43aa-ab2b-259848b048fb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_efee842a-f71c-43aa-ab2b-259848b048fb" xlink:to="loc_us-gaap_HedgingRelationshipDomain_efee842a-f71c-43aa-ab2b-259848b048fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_872e5f70-c0c8-4e4f-ae0f-3bbdbc598e74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_efee842a-f71c-43aa-ab2b-259848b048fb" xlink:to="loc_us-gaap_HedgingRelationshipDomain_872e5f70-c0c8-4e4f-ae0f-3bbdbc598e74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_400cd60b-b9b4-49c5-b6fd-a4c908fde2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_872e5f70-c0c8-4e4f-ae0f-3bbdbc598e74" xlink:to="loc_us-gaap_FairValueHedgingMember_400cd60b-b9b4-49c5-b6fd-a4c908fde2fe" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails"/>
  <link:definitionLink xlink:role="http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails" xlink:type="extended" id="i35a9ead23c5b4f79982d7bf425e981f4_STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ScheduleOfShareholdersEquityLineItems_4b7a2982-00a6-41b1-a39a-1e2ef7162af0" xlink:href="dgx-20221231.xsd#dgx_ScheduleOfShareholdersEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_483bfa41-31f1-4bd7-a0e5-dd338c663d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_4b7a2982-00a6-41b1-a39a-1e2ef7162af0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_483bfa41-31f1-4bd7-a0e5-dd338c663d8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_be0c9e9c-c652-4f45-85cd-76796b13aa1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_4b7a2982-00a6-41b1-a39a-1e2ef7162af0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_be0c9e9c-c652-4f45-85cd-76796b13aa1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_46e42536-3b4c-4a00-bf12-387d9e29675b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_4b7a2982-00a6-41b1-a39a-1e2ef7162af0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_46e42536-3b4c-4a00-bf12-387d9e29675b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_76d8bde6-e8c1-4aff-9d3d-66bc3274141e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_4b7a2982-00a6-41b1-a39a-1e2ef7162af0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_76d8bde6-e8c1-4aff-9d3d-66bc3274141e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_ae7e5f68-86ee-45d8-b3e8-01c12b943299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_4b7a2982-00a6-41b1-a39a-1e2ef7162af0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_ae7e5f68-86ee-45d8-b3e8-01c12b943299" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_EquityMethodInvestmentOwnershipPercentDisposedOf_d9dbace1-41d0-4906-96d7-5ba933943cd5" xlink:href="dgx-20221231.xsd#dgx_EquityMethodInvestmentOwnershipPercentDisposedOf"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_4b7a2982-00a6-41b1-a39a-1e2ef7162af0" xlink:to="loc_dgx_EquityMethodInvestmentOwnershipPercentDisposedOf_d9dbace1-41d0-4906-96d7-5ba933943cd5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_d91fa99f-2f0e-451d-830e-40bc60253fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_4b7a2982-00a6-41b1-a39a-1e2ef7162af0" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_d91fa99f-2f0e-451d-830e-40bc60253fa4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_17664e56-7392-48f6-8ef2-0b27447c58ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_4b7a2982-00a6-41b1-a39a-1e2ef7162af0" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_17664e56-7392-48f6-8ef2-0b27447c58ee" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_IncreaseDecreaseinCommonStockDividendsDeclaredasPercent_33547436-5931-4b01-b973-dde1a26a5749" xlink:href="dgx-20221231.xsd#dgx_IncreaseDecreaseinCommonStockDividendsDeclaredasPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_4b7a2982-00a6-41b1-a39a-1e2ef7162af0" xlink:to="loc_dgx_IncreaseDecreaseinCommonStockDividendsDeclaredasPercent_33547436-5931-4b01-b973-dde1a26a5749" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_StockRepurchaseProgramAdditionalAmountAuthorized_258530e3-304e-41b0-b200-c760acb8bd2f" xlink:href="dgx-20221231.xsd#dgx_StockRepurchaseProgramAdditionalAmountAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_4b7a2982-00a6-41b1-a39a-1e2ef7162af0" xlink:to="loc_dgx_StockRepurchaseProgramAdditionalAmountAuthorized_258530e3-304e-41b0-b200-c760acb8bd2f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_3d7eb57b-2176-4570-9f9c-eecb4cc2e9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_4b7a2982-00a6-41b1-a39a-1e2ef7162af0" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_3d7eb57b-2176-4570-9f9c-eecb4cc2e9f7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_b2062c19-846e-414d-bcb4-ef2e627a16de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_4b7a2982-00a6-41b1-a39a-1e2ef7162af0" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_b2062c19-846e-414d-bcb4-ef2e627a16de" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_ea5c3824-0398-4898-b594-08273597d92f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_4b7a2982-00a6-41b1-a39a-1e2ef7162af0" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_ea5c3824-0398-4898-b594-08273597d92f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_AcceleratedShareRepurchasesPayment_f2610bdd-a3d0-49dc-bef9-49a6526e063e" xlink:href="dgx-20221231.xsd#dgx_AcceleratedShareRepurchasesPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_4b7a2982-00a6-41b1-a39a-1e2ef7162af0" xlink:to="loc_dgx_AcceleratedShareRepurchasesPayment_f2610bdd-a3d0-49dc-bef9-49a6526e063e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_c994e805-2686-480e-9dd5-df85dabeab3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_4b7a2982-00a6-41b1-a39a-1e2ef7162af0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_c994e805-2686-480e-9dd5-df85dabeab3c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_6c6b69cd-9381-4fdc-bf12-592f0216e4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_4b7a2982-00a6-41b1-a39a-1e2ef7162af0" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_6c6b69cd-9381-4fdc-bf12-592f0216e4bb" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_498a56a0-2f7c-4d35-b116-72de22debe5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_4b7a2982-00a6-41b1-a39a-1e2ef7162af0" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_498a56a0-2f7c-4d35-b116-72de22debe5b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_0015e40c-248b-40b3-adc1-a86e18c1bdcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_4b7a2982-00a6-41b1-a39a-1e2ef7162af0" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_0015e40c-248b-40b3-adc1-a86e18c1bdcd" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ScheduleOfShareholdersEquityTable_12cbb3e9-faaa-4d15-9a47-7018fcac7c6e" xlink:href="dgx-20221231.xsd#dgx_ScheduleOfShareholdersEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_4b7a2982-00a6-41b1-a39a-1e2ef7162af0" xlink:to="loc_dgx_ScheduleOfShareholdersEquityTable_12cbb3e9-faaa-4d15-9a47-7018fcac7c6e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_455f3aaf-ec08-4a1c-ab14-ae3e78d26c49" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dgx_ScheduleOfShareholdersEquityTable_12cbb3e9-faaa-4d15-9a47-7018fcac7c6e" xlink:to="loc_srt_RangeAxis_455f3aaf-ec08-4a1c-ab14-ae3e78d26c49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_455f3aaf-ec08-4a1c-ab14-ae3e78d26c49_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_455f3aaf-ec08-4a1c-ab14-ae3e78d26c49" xlink:to="loc_srt_RangeMember_455f3aaf-ec08-4a1c-ab14-ae3e78d26c49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b02cec9c-e971-49b8-be19-a0c33807612e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_455f3aaf-ec08-4a1c-ab14-ae3e78d26c49" xlink:to="loc_srt_RangeMember_b02cec9c-e971-49b8-be19-a0c33807612e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_769e9059-5697-46d0-bc2b-b524c3845663" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b02cec9c-e971-49b8-be19-a0c33807612e" xlink:to="loc_srt_MaximumMember_769e9059-5697-46d0-bc2b-b524c3845663" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_10718479-4d01-4b70-b63e-0b800984354e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dgx_ScheduleOfShareholdersEquityTable_12cbb3e9-faaa-4d15-9a47-7018fcac7c6e" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_10718479-4d01-4b70-b63e-0b800984354e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_10718479-4d01-4b70-b63e-0b800984354e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_10718479-4d01-4b70-b63e-0b800984354e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_10718479-4d01-4b70-b63e-0b800984354e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_bc216c71-d6b4-4399-90e1-d2b4014469a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_10718479-4d01-4b70-b63e-0b800984354e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_bc216c71-d6b4-4399-90e1-d2b4014469a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_e7f36b3e-e9cd-418b-878d-f4867bc24e64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_bc216c71-d6b4-4399-90e1-d2b4014469a6" xlink:to="loc_us-gaap_SubsequentEventMember_e7f36b3e-e9cd-418b-878d-f4867bc24e64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_67d84e99-e03d-4799-9c6c-066bdb21c833" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dgx_ScheduleOfShareholdersEquityTable_12cbb3e9-faaa-4d15-9a47-7018fcac7c6e" xlink:to="loc_srt_StatementScenarioAxis_67d84e99-e03d-4799-9c6c-066bdb21c833" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_67d84e99-e03d-4799-9c6c-066bdb21c833_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_67d84e99-e03d-4799-9c6c-066bdb21c833" xlink:to="loc_srt_ScenarioUnspecifiedDomain_67d84e99-e03d-4799-9c6c-066bdb21c833_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_7cff6f73-b5d8-40b8-9458-45c9a15bfb7b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_67d84e99-e03d-4799-9c6c-066bdb21c833" xlink:to="loc_srt_ScenarioUnspecifiedDomain_7cff6f73-b5d8-40b8-9458-45c9a15bfb7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_49b8e6a2-9910-4faa-a256-fd78189edb6d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_7cff6f73-b5d8-40b8-9458-45c9a15bfb7b" xlink:to="loc_srt_ScenarioForecastMember_49b8e6a2-9910-4faa-a256-fd78189edb6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ebd6483f-5ec2-45b7-aa12-7dbe9c71fff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dgx_ScheduleOfShareholdersEquityTable_12cbb3e9-faaa-4d15-9a47-7018fcac7c6e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ebd6483f-5ec2-45b7-aa12-7dbe9c71fff6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ebd6483f-5ec2-45b7-aa12-7dbe9c71fff6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ebd6483f-5ec2-45b7-aa12-7dbe9c71fff6" xlink:to="loc_us-gaap_EquityComponentDomain_ebd6483f-5ec2-45b7-aa12-7dbe9c71fff6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_595e785f-9628-4422-bbef-741dd46cdc94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ebd6483f-5ec2-45b7-aa12-7dbe9c71fff6" xlink:to="loc_us-gaap_EquityComponentDomain_595e785f-9628-4422-bbef-741dd46cdc94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_0b58a079-f33f-44b7-801e-6da66c74e38d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_595e785f-9628-4422-bbef-741dd46cdc94" xlink:to="loc_us-gaap_TreasuryStockMember_0b58a079-f33f-44b7-801e-6da66c74e38d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ForeignCurrencyTranslationMember_ff5949d3-b3ae-4bcd-9587-55441d8ba250" xlink:href="dgx-20221231.xsd#dgx_ForeignCurrencyTranslationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_595e785f-9628-4422-bbef-741dd46cdc94" xlink:to="loc_dgx_ForeignCurrencyTranslationMember_ff5949d3-b3ae-4bcd-9587-55441d8ba250" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_fd127d05-e12b-4dc0-8269-a9990408ee88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_595e785f-9628-4422-bbef-741dd46cdc94" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_fd127d05-e12b-4dc0-8269-a9990408ee88" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_2e93cef3-b5ef-4924-8d41-cf92ee7076c6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dgx_ScheduleOfShareholdersEquityTable_12cbb3e9-faaa-4d15-9a47-7018fcac7c6e" xlink:to="loc_srt_OwnershipAxis_2e93cef3-b5ef-4924-8d41-cf92ee7076c6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_2e93cef3-b5ef-4924-8d41-cf92ee7076c6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_2e93cef3-b5ef-4924-8d41-cf92ee7076c6" xlink:to="loc_srt_OwnershipDomain_2e93cef3-b5ef-4924-8d41-cf92ee7076c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_1bb524ae-7c2e-4835-8d96-df65bf2d4b8d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_2e93cef3-b5ef-4924-8d41-cf92ee7076c6" xlink:to="loc_srt_OwnershipDomain_1bb524ae-7c2e-4835-8d96-df65bf2d4b8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_UMassJointVentureMember_bdb4573c-c233-4b12-9951-ec708331b85e" xlink:href="dgx-20221231.xsd#dgx_UMassJointVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_1bb524ae-7c2e-4835-8d96-df65bf2d4b8d" xlink:to="loc_dgx_UMassJointVentureMember_bdb4573c-c233-4b12-9951-ec708331b85e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_a6cf59e6-59d8-48f6-9a2f-75b61fc45a92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dgx_ScheduleOfShareholdersEquityTable_12cbb3e9-faaa-4d15-9a47-7018fcac7c6e" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_a6cf59e6-59d8-48f6-9a2f-75b61fc45a92" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_a6cf59e6-59d8-48f6-9a2f-75b61fc45a92_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_a6cf59e6-59d8-48f6-9a2f-75b61fc45a92" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_a6cf59e6-59d8-48f6-9a2f-75b61fc45a92_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_a0d9370b-409c-4214-869f-4b15dd0f2ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_a6cf59e6-59d8-48f6-9a2f-75b61fc45a92" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_a0d9370b-409c-4214-869f-4b15dd0f2ac8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_51dd7480-cace-4e4c-a890-8a2ef13158ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_a0d9370b-409c-4214-869f-4b15dd0f2ac8" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_51dd7480-cace-4e4c-a890-8a2ef13158ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a0516225-5a64-4850-8f85-8c8245e7bb9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dgx_ScheduleOfShareholdersEquityTable_12cbb3e9-faaa-4d15-9a47-7018fcac7c6e" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a0516225-5a64-4850-8f85-8c8245e7bb9c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a0516225-5a64-4850-8f85-8c8245e7bb9c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a0516225-5a64-4850-8f85-8c8245e7bb9c" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a0516225-5a64-4850-8f85-8c8245e7bb9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b71b9623-8d84-4c0b-8cd4-a3b795807d22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a0516225-5a64-4850-8f85-8c8245e7bb9c" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b71b9623-8d84-4c0b-8cd4-a3b795807d22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_Q2SolutionsMember_8c0c0f7d-2c43-48e5-9f79-41a3c9b5f3ea" xlink:href="dgx-20221231.xsd#dgx_Q2SolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b71b9623-8d84-4c0b-8cd4-a3b795807d22" xlink:to="loc_dgx_Q2SolutionsMember_8c0c0f7d-2c43-48e5-9f79-41a3c9b5f3ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesDateAxis_248be143-0a47-497f-999e-cf0ab626aced" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcceleratedShareRepurchasesDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dgx_ScheduleOfShareholdersEquityTable_12cbb3e9-faaa-4d15-9a47-7018fcac7c6e" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesDateAxis_248be143-0a47-497f-999e-cf0ab626aced" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesDateDomain_248be143-0a47-497f-999e-cf0ab626aced_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcceleratedShareRepurchasesDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesDateAxis_248be143-0a47-497f-999e-cf0ab626aced" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesDateDomain_248be143-0a47-497f-999e-cf0ab626aced_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesDateDomain_6437f380-2516-4931-8796-3feb059e9771" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcceleratedShareRepurchasesDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesDateAxis_248be143-0a47-497f-999e-cf0ab626aced" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesDateDomain_6437f380-2516-4931-8796-3feb059e9771" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_AcceleratedShareRepurchaseAgreementsMember_3d2f535c-930a-4f86-a3d5-9f9363a7be77" xlink:href="dgx-20221231.xsd#dgx_AcceleratedShareRepurchaseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesDateDomain_6437f380-2516-4931-8796-3feb059e9771" xlink:to="loc_dgx_AcceleratedShareRepurchaseAgreementsMember_3d2f535c-930a-4f86-a3d5-9f9363a7be77" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTComponentsofAccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTComponentsofAccumulatedOtherComprehensiveLossIncomeDetails"/>
  <link:definitionLink xlink:role="http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTComponentsofAccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="extended" id="idb80d399000e4b1e99abc78a872eac11_STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTComponentsofAccumulatedOtherComprehensiveLossIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ScheduleOfShareholdersEquityLineItems_9a85cfcc-abcf-44e0-9df8-8d25a42c2958" xlink:href="dgx-20221231.xsd#dgx_ScheduleOfShareholdersEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0c7a3bd7-5087-4d82-85c1-ec6beea27d43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_9a85cfcc-abcf-44e0-9df8-8d25a42c2958" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0c7a3bd7-5087-4d82-85c1-ec6beea27d43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_87823d6e-b197-4898-bcb0-9c9bcec350f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_9a85cfcc-abcf-44e0-9df8-8d25a42c2958" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_87823d6e-b197-4898-bcb0-9c9bcec350f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_f0c6e5be-b2d3-4b6e-ba57-41cefaacb1b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_9a85cfcc-abcf-44e0-9df8-8d25a42c2958" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_f0c6e5be-b2d3-4b6e-ba57-41cefaacb1b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_622395fa-cb04-44bb-9438-4027adcd341f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_9a85cfcc-abcf-44e0-9df8-8d25a42c2958" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_622395fa-cb04-44bb-9438-4027adcd341f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e4a70b3d-2f13-44b7-a4a3-cfa8343e4021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ScheduleOfShareholdersEquityTable_a9c58455-653c-45f8-8f0c-756a7cf814a0" xlink:href="dgx-20221231.xsd#dgx_ScheduleOfShareholdersEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_9a85cfcc-abcf-44e0-9df8-8d25a42c2958" xlink:to="loc_dgx_ScheduleOfShareholdersEquityTable_a9c58455-653c-45f8-8f0c-756a7cf814a0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_51232ce5-6940-4f22-822d-00df6eb11dea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dgx_ScheduleOfShareholdersEquityTable_a9c58455-653c-45f8-8f0c-756a7cf814a0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_51232ce5-6940-4f22-822d-00df6eb11dea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_51232ce5-6940-4f22-822d-00df6eb11dea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_51232ce5-6940-4f22-822d-00df6eb11dea" xlink:to="loc_us-gaap_EquityComponentDomain_51232ce5-6940-4f22-822d-00df6eb11dea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ded714e2-cecb-4f25-88e9-8afa5094de43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_51232ce5-6940-4f22-822d-00df6eb11dea" xlink:to="loc_us-gaap_EquityComponentDomain_ded714e2-cecb-4f25-88e9-8afa5094de43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_2378c600-4839-448b-93ef-69c9a5ed89c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ded714e2-cecb-4f25-88e9-8afa5094de43" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_2378c600-4839-448b-93ef-69c9a5ed89c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_f6b9ffa3-faa9-4f71-bbf1-902ea495b7c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ded714e2-cecb-4f25-88e9-8afa5094de43" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_f6b9ffa3-faa9-4f71-bbf1-902ea495b7c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_363d2226-fd55-48c5-8ede-779b0305c60f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ded714e2-cecb-4f25-88e9-8afa5094de43" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_363d2226-fd55-48c5-8ede-779b0305c60f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_OtherEquityComponentsMember_7712a9c5-cc82-4845-951c-77c5ccca9850" xlink:href="dgx-20221231.xsd#dgx_OtherEquityComponentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ded714e2-cecb-4f25-88e9-8afa5094de43" xlink:to="loc_dgx_OtherEquityComponentsMember_7712a9c5-cc82-4845-951c-77c5ccca9850" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_861466e0-f259-448d-8507-fbc84d5e53c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ded714e2-cecb-4f25-88e9-8afa5094de43" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_861466e0-f259-448d-8507-fbc84d5e53c6" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeandNonemployeeDirectorsStockOwnershipProgramsDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeandNonemployeeDirectorsStockOwnershipProgramsDetails"/>
  <link:definitionLink xlink:role="http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeandNonemployeeDirectorsStockOwnershipProgramsDetails" xlink:type="extended" id="ic6baa190844344a7bef8e5250ef901f6_STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeandNonemployeeDirectorsStockOwnershipProgramsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c20dd585-4554-4eaa-99fc-2588ae3c88ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ContractualLifeOfStockOptionsAndOtherAwardsUnderSharedBasedCompensationPlans_3d02b9af-46e7-4fe7-8856-cac052010bf3" xlink:href="dgx-20221231.xsd#dgx_ContractualLifeOfStockOptionsAndOtherAwardsUnderSharedBasedCompensationPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c20dd585-4554-4eaa-99fc-2588ae3c88ab" xlink:to="loc_dgx_ContractualLifeOfStockOptionsAndOtherAwardsUnderSharedBasedCompensationPlans_3d02b9af-46e7-4fe7-8856-cac052010bf3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_22766445-d5d8-42a8-ba56-c00af95c2d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c20dd585-4554-4eaa-99fc-2588ae3c88ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_22766445-d5d8-42a8-ba56-c00af95c2d9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_34b49782-b77a-4e31-8e48-392148f78e97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c20dd585-4554-4eaa-99fc-2588ae3c88ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_34b49782-b77a-4e31-8e48-392148f78e97" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3a1df6bd-b289-4884-bacb-3c651b63cbb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c20dd585-4554-4eaa-99fc-2588ae3c88ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3a1df6bd-b289-4884-bacb-3c651b63cbb6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3612cd74-65a3-45ac-a9f6-5dafeb35b632" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c20dd585-4554-4eaa-99fc-2588ae3c88ab" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3612cd74-65a3-45ac-a9f6-5dafeb35b632" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5f08cfac-2f94-4a87-9705-f3c12c795b83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3612cd74-65a3-45ac-a9f6-5dafeb35b632" xlink:to="loc_us-gaap_AwardTypeAxis_5f08cfac-2f94-4a87-9705-f3c12c795b83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f08cfac-2f94-4a87-9705-f3c12c795b83_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5f08cfac-2f94-4a87-9705-f3c12c795b83" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f08cfac-2f94-4a87-9705-f3c12c795b83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1c6b7bbd-713b-4e95-8a43-b95642a855cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5f08cfac-2f94-4a87-9705-f3c12c795b83" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1c6b7bbd-713b-4e95-8a43-b95642a855cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_EmployeeLongTermIncentivePlanEltipMember_b878b8de-5224-4f10-8ea9-4e3f3f80e35a" xlink:href="dgx-20221231.xsd#dgx_EmployeeLongTermIncentivePlanEltipMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1c6b7bbd-713b-4e95-8a43-b95642a855cc" xlink:to="loc_dgx_EmployeeLongTermIncentivePlanEltipMember_b878b8de-5224-4f10-8ea9-4e3f3f80e35a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_RestatedDirectorLongTermIncentivePlanDltipMember_d9619e72-cfc7-41bc-96a8-442c524da6eb" xlink:href="dgx-20221231.xsd#dgx_RestatedDirectorLongTermIncentivePlanDltipMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1c6b7bbd-713b-4e95-8a43-b95642a855cc" xlink:to="loc_dgx_RestatedDirectorLongTermIncentivePlanDltipMember_d9619e72-cfc7-41bc-96a8-442c524da6eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_fb2023fc-501f-4d2b-bae8-d4fbe9243a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1c6b7bbd-713b-4e95-8a43-b95642a855cc" xlink:to="loc_us-gaap_StockOptionMember_fb2023fc-501f-4d2b-bae8-d4fbe9243a0f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSWeightedAverageAssumptionsUsedinValuingOptionsGrantedDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#STOCKOWNERSHIPANDCOMPENSATIONPLANSWeightedAverageAssumptionsUsedinValuingOptionsGrantedDetails"/>
  <link:definitionLink xlink:role="http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSWeightedAverageAssumptionsUsedinValuingOptionsGrantedDetails" xlink:type="extended" id="i9fccdc59c4e94c819b277c2b98a7e6fc_STOCKOWNERSHIPANDCOMPENSATIONPLANSWeightedAverageAssumptionsUsedinValuingOptionsGrantedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93099684-3985-4618-9166-738ed3550867" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_665d422d-7cd7-4885-9f34-ee1c7eed57c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93099684-3985-4618-9166-738ed3550867" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_665d422d-7cd7-4885-9f34-ee1c7eed57c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a9aa8957-ae03-4628-b0b8-4a6602b1b0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93099684-3985-4618-9166-738ed3550867" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a9aa8957-ae03-4628-b0b8-4a6602b1b0d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3546c254-0539-400a-bf48-48f56b39d678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93099684-3985-4618-9166-738ed3550867" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3546c254-0539-400a-bf48-48f56b39d678" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_22fc9c4e-36fa-45ea-bc02-0c0577898167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93099684-3985-4618-9166-738ed3550867" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_22fc9c4e-36fa-45ea-bc02-0c0577898167" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4c00e09f-4c95-4b24-af23-a7060fd698cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93099684-3985-4618-9166-738ed3550867" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4c00e09f-4c95-4b24-af23-a7060fd698cc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9fcae365-9458-41d9-95a1-0deae5757df8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93099684-3985-4618-9166-738ed3550867" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9fcae365-9458-41d9-95a1-0deae5757df8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b0b82b68-6e41-4d7d-87b7-fcaaf7435ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93099684-3985-4618-9166-738ed3550867" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b0b82b68-6e41-4d7d-87b7-fcaaf7435ba1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0c5992de-f200-4b85-8449-485cb8e77a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b0b82b68-6e41-4d7d-87b7-fcaaf7435ba1" xlink:to="loc_us-gaap_AwardTypeAxis_0c5992de-f200-4b85-8449-485cb8e77a3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c5992de-f200-4b85-8449-485cb8e77a3d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0c5992de-f200-4b85-8449-485cb8e77a3d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c5992de-f200-4b85-8449-485cb8e77a3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e3d6ea7-d938-47d7-bfb4-cfdb7bcdd332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0c5992de-f200-4b85-8449-485cb8e77a3d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e3d6ea7-d938-47d7-bfb4-cfdb7bcdd332" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_PerformanceShareUnitsWithMarketBasedRelativeTSRGoalMember_6a43c024-b0df-4122-9d0b-87bf5243339c" xlink:href="dgx-20221231.xsd#dgx_PerformanceShareUnitsWithMarketBasedRelativeTSRGoalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e3d6ea7-d938-47d7-bfb4-cfdb7bcdd332" xlink:to="loc_dgx_PerformanceShareUnitsWithMarketBasedRelativeTSRGoalMember_6a43c024-b0df-4122-9d0b-87bf5243339c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2cfdb2cc-7219-4842-bf37-fdec4e954868" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b0b82b68-6e41-4d7d-87b7-fcaaf7435ba1" xlink:to="loc_srt_RangeAxis_2cfdb2cc-7219-4842-bf37-fdec4e954868" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2cfdb2cc-7219-4842-bf37-fdec4e954868_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2cfdb2cc-7219-4842-bf37-fdec4e954868" xlink:to="loc_srt_RangeMember_2cfdb2cc-7219-4842-bf37-fdec4e954868_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8697a789-f4a9-4134-af0b-d0822b03841f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2cfdb2cc-7219-4842-bf37-fdec4e954868" xlink:to="loc_srt_RangeMember_8697a789-f4a9-4134-af0b-d0822b03841f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ef9b33a3-07bb-4173-8b48-e388686bea06" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8697a789-f4a9-4134-af0b-d0822b03841f" xlink:to="loc_srt_MinimumMember_ef9b33a3-07bb-4173-8b48-e388686bea06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f2134b16-7923-468c-a079-88bf23b7ba87" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8697a789-f4a9-4134-af0b-d0822b03841f" xlink:to="loc_srt_MaximumMember_f2134b16-7923-468c-a079-88bf23b7ba87" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTransactionsUnderStockOptionPlansDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#STOCKOWNERSHIPANDCOMPENSATIONPLANSTransactionsUnderStockOptionPlansDetails"/>
  <link:definitionLink xlink:role="http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTransactionsUnderStockOptionPlansDetails" xlink:type="extended" id="i7dcc580b814b4eb49a478c648a40b48e_STOCKOWNERSHIPANDCOMPENSATIONPLANSTransactionsUnderStockOptionPlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0656569-8539-41d3-a0a1-fadb45ec9bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4af3f44f-b4a8-474d-9d48-53cdadb6dca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0656569-8539-41d3-a0a1-fadb45ec9bf4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4af3f44f-b4a8-474d-9d48-53cdadb6dca3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_784ccbf3-e481-4d9e-b322-0ac24f74e013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4af3f44f-b4a8-474d-9d48-53cdadb6dca3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_784ccbf3-e481-4d9e-b322-0ac24f74e013" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9a9b78db-8619-45c5-ada0-91c0dcd324f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4af3f44f-b4a8-474d-9d48-53cdadb6dca3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9a9b78db-8619-45c5-ada0-91c0dcd324f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_10617d7f-dc78-488a-a97b-8e32de9df8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4af3f44f-b4a8-474d-9d48-53cdadb6dca3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_10617d7f-dc78-488a-a97b-8e32de9df8a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_14c6b1e1-9f01-466b-b714-4a87ccd81485" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4af3f44f-b4a8-474d-9d48-53cdadb6dca3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_14c6b1e1-9f01-466b-b714-4a87ccd81485" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7116d72e-9f41-4b57-b949-9293d39adddb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d58baf33-341c-439e-81ac-9a23e147c4f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0656569-8539-41d3-a0a1-fadb45ec9bf4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d58baf33-341c-439e-81ac-9a23e147c4f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_36511d17-d8cc-4ef4-a597-de90672835bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d58baf33-341c-439e-81ac-9a23e147c4f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_36511d17-d8cc-4ef4-a597-de90672835bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_388c2d47-ed5c-46dd-bed0-0269633d0330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d58baf33-341c-439e-81ac-9a23e147c4f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_388c2d47-ed5c-46dd-bed0-0269633d0330" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5d74b241-661c-49a0-85a6-25b8eae13a23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d58baf33-341c-439e-81ac-9a23e147c4f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5d74b241-661c-49a0-85a6-25b8eae13a23" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_88a66813-8306-42f4-a26c-811b8d0eb9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d58baf33-341c-439e-81ac-9a23e147c4f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_88a66813-8306-42f4-a26c-811b8d0eb9cc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_98cac151-f7da-4fef-b16e-194d48a0f46f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_899071a5-3fc8-44fa-86ac-0780f37c79c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0656569-8539-41d3-a0a1-fadb45ec9bf4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_899071a5-3fc8-44fa-86ac-0780f37c79c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_538caeae-0afc-47f6-bc67-1b684938a6d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0656569-8539-41d3-a0a1-fadb45ec9bf4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_538caeae-0afc-47f6-bc67-1b684938a6d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9589ba11-fe9f-43da-9251-1434ae3d93bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0656569-8539-41d3-a0a1-fadb45ec9bf4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9589ba11-fe9f-43da-9251-1434ae3d93bf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a02e41d6-fa50-46dd-8fa3-42f294543eca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0656569-8539-41d3-a0a1-fadb45ec9bf4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a02e41d6-fa50-46dd-8fa3-42f294543eca" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_adef63e7-ec4a-431a-9b38-8adf15045822" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0656569-8539-41d3-a0a1-fadb45ec9bf4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_adef63e7-ec4a-431a-9b38-8adf15045822" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_00e2e84d-64e5-46bb-b348-2129e421f04b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0656569-8539-41d3-a0a1-fadb45ec9bf4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_00e2e84d-64e5-46bb-b348-2129e421f04b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_a835e92f-9720-458a-a178-6845cfb4230c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0656569-8539-41d3-a0a1-fadb45ec9bf4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_a835e92f-9720-458a-a178-6845cfb4230c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_8f37a4df-5e38-4543-b096-9233ad99e097" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0656569-8539-41d3-a0a1-fadb45ec9bf4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_8f37a4df-5e38-4543-b096-9233ad99e097" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_b1bfacbd-2800-41dc-8fec-dd1c7ff5625c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0656569-8539-41d3-a0a1-fadb45ec9bf4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_b1bfacbd-2800-41dc-8fec-dd1c7ff5625c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_bdd4a565-e0dd-4e6c-852e-3cbc76f8ccf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0656569-8539-41d3-a0a1-fadb45ec9bf4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_bdd4a565-e0dd-4e6c-852e-3cbc76f8ccf1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_4636ea19-ecb0-47a0-91c9-3cfa055aff48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0656569-8539-41d3-a0a1-fadb45ec9bf4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_4636ea19-ecb0-47a0-91c9-3cfa055aff48" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_6ed4ef57-aeef-442f-b9fc-40fb3ad3a151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0656569-8539-41d3-a0a1-fadb45ec9bf4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_6ed4ef57-aeef-442f-b9fc-40fb3ad3a151" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4c7a8468-9d33-4cf6-a181-b94b1f119f54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0656569-8539-41d3-a0a1-fadb45ec9bf4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4c7a8468-9d33-4cf6-a181-b94b1f119f54" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1252dfa9-0ba8-401f-905f-b4099a84a1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0656569-8539-41d3-a0a1-fadb45ec9bf4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1252dfa9-0ba8-401f-905f-b4099a84a1b8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_47d95c23-a864-4a04-8870-edee11695726" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1252dfa9-0ba8-401f-905f-b4099a84a1b8" xlink:to="loc_us-gaap_AwardTypeAxis_47d95c23-a864-4a04-8870-edee11695726" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_47d95c23-a864-4a04-8870-edee11695726_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_47d95c23-a864-4a04-8870-edee11695726" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_47d95c23-a864-4a04-8870-edee11695726_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_303a9352-1153-49f8-be9a-57dc19d58683" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_47d95c23-a864-4a04-8870-edee11695726" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_303a9352-1153-49f8-be9a-57dc19d58683" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_0fcd853c-dd16-43ce-ab27-e2d681604d68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_303a9352-1153-49f8-be9a-57dc19d58683" xlink:to="loc_us-gaap_StockOptionMember_0fcd853c-dd16-43ce-ab27-e2d681604d68" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSActivitiesRelatedtoStockAwardsDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#STOCKOWNERSHIPANDCOMPENSATIONPLANSActivitiesRelatedtoStockAwardsDetails"/>
  <link:definitionLink xlink:role="http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSActivitiesRelatedtoStockAwardsDetails" xlink:type="extended" id="i457598a55658495f9357bd3e4b3b4864_STOCKOWNERSHIPANDCOMPENSATIONPLANSActivitiesRelatedtoStockAwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85be73fa-0e67-462f-949c-071f5c449813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4960e8a7-1814-4883-9777-d3ac1187b2a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85be73fa-0e67-462f-949c-071f5c449813" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4960e8a7-1814-4883-9777-d3ac1187b2a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_36b2e672-ff7f-4995-aa3b-246ce3cd5ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4960e8a7-1814-4883-9777-d3ac1187b2a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_36b2e672-ff7f-4995-aa3b-246ce3cd5ce7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3c3948c0-d99f-45cf-bb7e-88cb1949db9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4960e8a7-1814-4883-9777-d3ac1187b2a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3c3948c0-d99f-45cf-bb7e-88cb1949db9b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7046dfc3-86ea-49c7-af26-bf2dedb3462a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4960e8a7-1814-4883-9777-d3ac1187b2a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7046dfc3-86ea-49c7-af26-bf2dedb3462a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_34038a5e-43bf-4c82-86d4-e7faa9363e96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4960e8a7-1814-4883-9777-d3ac1187b2a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_34038a5e-43bf-4c82-86d4-e7faa9363e96" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f045c0cc-c899-4833-aeaf-b96518fc9bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8d36044b-e68d-4f7d-8287-377b76224622" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85be73fa-0e67-462f-949c-071f5c449813" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8d36044b-e68d-4f7d-8287-377b76224622" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ccd88587-f033-41c0-b6fa-63f217801ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8d36044b-e68d-4f7d-8287-377b76224622" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ccd88587-f033-41c0-b6fa-63f217801ff7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6916911c-979a-4b9a-8383-ff8fef09ed9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8d36044b-e68d-4f7d-8287-377b76224622" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6916911c-979a-4b9a-8383-ff8fef09ed9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_40e43517-c13c-4487-a7e9-a7400b040057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8d36044b-e68d-4f7d-8287-377b76224622" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_40e43517-c13c-4487-a7e9-a7400b040057" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7395c990-be30-4137-803c-c722946cc466" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8d36044b-e68d-4f7d-8287-377b76224622" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7395c990-be30-4137-803c-c722946cc466" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_52286e2e-103d-43d6-8f15-5369195c632c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6822ebae-3b13-462a-87e9-f4bddd4f2884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85be73fa-0e67-462f-949c-071f5c449813" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6822ebae-3b13-462a-87e9-f4bddd4f2884" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d7323134-c084-473e-aa37-8ae7829cdbe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85be73fa-0e67-462f-949c-071f5c449813" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d7323134-c084-473e-aa37-8ae7829cdbe6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_17029f4a-2aa6-4fa2-9223-6647dd070311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85be73fa-0e67-462f-949c-071f5c449813" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_17029f4a-2aa6-4fa2-9223-6647dd070311" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_ddcad9e8-6105-45cb-94e0-2507c2863226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85be73fa-0e67-462f-949c-071f5c449813" xlink:to="loc_us-gaap_ShareBasedCompensation_ddcad9e8-6105-45cb-94e0-2507c2863226" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_40ff1e4e-fc25-49b7-883d-88bcddea229e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85be73fa-0e67-462f-949c-071f5c449813" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_40ff1e4e-fc25-49b7-883d-88bcddea229e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_Sharebasedcompensationexcesstaxbenefitamount_d92900c5-a2a1-40cc-8ce6-5511f3074a33" xlink:href="dgx-20221231.xsd#dgx_Sharebasedcompensationexcesstaxbenefitamount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85be73fa-0e67-462f-949c-071f5c449813" xlink:to="loc_dgx_Sharebasedcompensationexcesstaxbenefitamount_d92900c5-a2a1-40cc-8ce6-5511f3074a33" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_074176c1-435b-4f9b-ab73-70fd92f97256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85be73fa-0e67-462f-949c-071f5c449813" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_074176c1-435b-4f9b-ab73-70fd92f97256" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f55cc7ed-e704-4f8b-adbf-16794d730936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_074176c1-435b-4f9b-ab73-70fd92f97256" xlink:to="loc_us-gaap_AwardTypeAxis_f55cc7ed-e704-4f8b-adbf-16794d730936" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f55cc7ed-e704-4f8b-adbf-16794d730936_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f55cc7ed-e704-4f8b-adbf-16794d730936" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f55cc7ed-e704-4f8b-adbf-16794d730936_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b625f74c-610e-4312-829f-14788d558047" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f55cc7ed-e704-4f8b-adbf-16794d730936" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b625f74c-610e-4312-829f-14788d558047" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_StockAwardsMember_d3811e1a-37c4-47d7-9684-0505b04702df" xlink:href="dgx-20221231.xsd#dgx_StockAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b625f74c-610e-4312-829f-14788d558047" xlink:to="loc_dgx_StockAwardsMember_d3811e1a-37c4-47d7-9684-0505b04702df" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeStockPurchasePlanandDefinedContributionPlansDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeStockPurchasePlanandDefinedContributionPlansDetails"/>
  <link:definitionLink xlink:role="http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeStockPurchasePlanandDefinedContributionPlansDetails" xlink:type="extended" id="i211542141ced40da8e87c6bc86f9adaf_STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeStockPurchasePlanandDefinedContributionPlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c05c811-e6d5-4b66-a0e5-7eb042777bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_61bf3094-b26b-4fcd-97d0-b2150830db50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c05c811-e6d5-4b66-a0e5-7eb042777bb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_61bf3094-b26b-4fcd-97d0-b2150830db50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_MarketPriceOfCompanyStockIssuedAtDiscountUnderEspp_7b87b97d-ea55-4ec8-8e3f-93e81e0bc6a6" xlink:href="dgx-20221231.xsd#dgx_MarketPriceOfCompanyStockIssuedAtDiscountUnderEspp"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c05c811-e6d5-4b66-a0e5-7eb042777bb4" xlink:to="loc_dgx_MarketPriceOfCompanyStockIssuedAtDiscountUnderEspp_7b87b97d-ea55-4ec8-8e3f-93e81e0bc6a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_848fca2b-8a28-489a-9287-0edc755f4f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c05c811-e6d5-4b66-a0e5-7eb042777bb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_848fca2b-8a28-489a-9287-0edc755f4f9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a67e4b36-df4c-4e7f-974c-67fd4a7ca2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c05c811-e6d5-4b66-a0e5-7eb042777bb4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a67e4b36-df4c-4e7f-974c-67fd4a7ca2cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_993e9b97-3d24-4731-9dad-78144ae540de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c05c811-e6d5-4b66-a0e5-7eb042777bb4" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_993e9b97-3d24-4731-9dad-78144ae540de" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_33889ec4-7038-40e0-b5e8-e30bf4a9f2f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c05c811-e6d5-4b66-a0e5-7eb042777bb4" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_33889ec4-7038-40e0-b5e8-e30bf4a9f2f0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ee6d89d6-6a20-4046-90b0-5addcddbc954" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c05c811-e6d5-4b66-a0e5-7eb042777bb4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ee6d89d6-6a20-4046-90b0-5addcddbc954" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_416b3ab5-ebb8-4537-b795-fc8307ecc84c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ee6d89d6-6a20-4046-90b0-5addcddbc954" xlink:to="loc_us-gaap_AwardTypeAxis_416b3ab5-ebb8-4537-b795-fc8307ecc84c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_416b3ab5-ebb8-4537-b795-fc8307ecc84c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_416b3ab5-ebb8-4537-b795-fc8307ecc84c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_416b3ab5-ebb8-4537-b795-fc8307ecc84c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f7743c79-9fff-47c0-aaf5-e467b7131a65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_416b3ab5-ebb8-4537-b795-fc8307ecc84c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f7743c79-9fff-47c0-aaf5-e467b7131a65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_da8ea110-3c17-4778-ab0d-0a147a1c623d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f7743c79-9fff-47c0-aaf5-e467b7131a65" xlink:to="loc_us-gaap_EmployeeStockMember_da8ea110-3c17-4778-ab0d-0a147a1c623d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_050feb49-9ec6-4268-913e-041af94394e7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ee6d89d6-6a20-4046-90b0-5addcddbc954" xlink:to="loc_srt_RangeAxis_050feb49-9ec6-4268-913e-041af94394e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_050feb49-9ec6-4268-913e-041af94394e7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_050feb49-9ec6-4268-913e-041af94394e7" xlink:to="loc_srt_RangeMember_050feb49-9ec6-4268-913e-041af94394e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b1152f46-3093-4ffd-861f-4fd3ec9493fe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_050feb49-9ec6-4268-913e-041af94394e7" xlink:to="loc_srt_RangeMember_b1152f46-3093-4ffd-861f-4fd3ec9493fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b7727d0a-b6fd-447f-95dc-56bc60c4b70f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b1152f46-3093-4ffd-861f-4fd3ec9493fe" xlink:to="loc_srt_MaximumMember_b7727d0a-b6fd-447f-95dc-56bc60c4b70f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSSupplementalDeferredCompensationPlansDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#STOCKOWNERSHIPANDCOMPENSATIONPLANSSupplementalDeferredCompensationPlansDetails"/>
  <link:definitionLink xlink:role="http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSSupplementalDeferredCompensationPlansDetails" xlink:type="extended" id="idedee8001c154d1087437abe225f163d_STOCKOWNERSHIPANDCOMPENSATIONPLANSSupplementalDeferredCompensationPlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_25fb0b53-8b09-4a8c-8f50-3330baf4dcd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_SupplementalDeferredCompensationPlanSalaryDeferral_a084373f-e369-4f1e-8f10-97875f55f3aa" xlink:href="dgx-20221231.xsd#dgx_SupplementalDeferredCompensationPlanSalaryDeferral"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_25fb0b53-8b09-4a8c-8f50-3330baf4dcd1" xlink:to="loc_dgx_SupplementalDeferredCompensationPlanSalaryDeferral_a084373f-e369-4f1e-8f10-97875f55f3aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_SupplementalDeferredCompensationPlanVariableIncentiveCompensationDeferral_b4936054-a46a-49bf-a043-3221cc568aef" xlink:href="dgx-20221231.xsd#dgx_SupplementalDeferredCompensationPlanVariableIncentiveCompensationDeferral"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_25fb0b53-8b09-4a8c-8f50-3330baf4dcd1" xlink:to="loc_dgx_SupplementalDeferredCompensationPlanVariableIncentiveCompensationDeferral_b4936054-a46a-49bf-a043-3221cc568aef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_107c2f15-9ece-47e1-bb7a-ec3c6adc70c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_25fb0b53-8b09-4a8c-8f50-3330baf4dcd1" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_107c2f15-9ece-47e1-bb7a-ec3c6adc70c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability_1bdd9410-b21f-477c-88b2-7677f40301e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_25fb0b53-8b09-4a8c-8f50-3330baf4dcd1" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability_1bdd9410-b21f-477c-88b2-7677f40301e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_FundsinatrustpertainingtoallparticipantdeferralsandcompanymatchingamountsrelatedtotheSDCP_b09e8b09-9fb5-4377-a651-82fe400ceea0" xlink:href="dgx-20221231.xsd#dgx_FundsinatrustpertainingtoallparticipantdeferralsandcompanymatchingamountsrelatedtotheSDCP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_25fb0b53-8b09-4a8c-8f50-3330baf4dcd1" xlink:to="loc_dgx_FundsinatrustpertainingtoallparticipantdeferralsandcompanymatchingamountsrelatedtotheSDCP_b09e8b09-9fb5-4377-a651-82fe400ceea0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_5e85d3ff-797b-4b40-a080-9490a0b38f73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_25fb0b53-8b09-4a8c-8f50-3330baf4dcd1" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_5e85d3ff-797b-4b40-a080-9490a0b38f73" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1_90b86588-5edf-4e43-a56a-e2918ed89be7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_25fb0b53-8b09-4a8c-8f50-3330baf4dcd1" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1_90b86588-5edf-4e43-a56a-e2918ed89be7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_SdcpIiGradedVestingPercentage_38b5774a-4dd9-4987-8fea-d4f6ade0ca17" xlink:href="dgx-20221231.xsd#dgx_SdcpIiGradedVestingPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_25fb0b53-8b09-4a8c-8f50-3330baf4dcd1" xlink:to="loc_dgx_SdcpIiGradedVestingPercentage_38b5774a-4dd9-4987-8fea-d4f6ade0ca17" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashSurrenderValueFairValueDisclosure_c77f0364-2904-4473-9036-f0b3bf3279aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashSurrenderValueFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_25fb0b53-8b09-4a8c-8f50-3330baf4dcd1" xlink:to="loc_us-gaap_CashSurrenderValueFairValueDisclosure_c77f0364-2904-4473-9036-f0b3bf3279aa" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_ba742a73-aeb4-4f24-8613-2bff6e56ce69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_25fb0b53-8b09-4a8c-8f50-3330baf4dcd1" xlink:to="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_ba742a73-aeb4-4f24-8613-2bff6e56ce69" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_83d4957e-ffb0-4279-a774-6541baf3146e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_ba742a73-aeb4-4f24-8613-2bff6e56ce69" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_83d4957e-ffb0-4279-a774-6541baf3146e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_83d4957e-ffb0-4279-a774-6541baf3146e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_83d4957e-ffb0-4279-a774-6541baf3146e" xlink:to="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_83d4957e-ffb0-4279-a774-6541baf3146e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_b8bfbcd5-4868-4b57-bd15-fe51ff4d5656" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_83d4957e-ffb0-4279-a774-6541baf3146e" xlink:to="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_b8bfbcd5-4868-4b57-bd15-fe51ff4d5656" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_SupplementalDeferredCompensationPlanMember_1884f8e9-9b07-43cb-afc4-d93ab8c68441" xlink:href="dgx-20221231.xsd#dgx_SupplementalDeferredCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_b8bfbcd5-4868-4b57-bd15-fe51ff4d5656" xlink:to="loc_dgx_SupplementalDeferredCompensationPlanMember_1884f8e9-9b07-43cb-afc4-d93ab8c68441" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_SdcpIiMember_0b0a4eea-cfed-4045-80c8-a4544dd8aeeb" xlink:href="dgx-20221231.xsd#dgx_SdcpIiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_b8bfbcd5-4868-4b57-bd15-fe51ff4d5656" xlink:to="loc_dgx_SdcpIiMember_0b0a4eea-cfed-4045-80c8-a4544dd8aeeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_15a2de6f-d9dc-4ad5-8fef-44323bc2bfbc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_ba742a73-aeb4-4f24-8613-2bff6e56ce69" xlink:to="loc_srt_RangeAxis_15a2de6f-d9dc-4ad5-8fef-44323bc2bfbc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_15a2de6f-d9dc-4ad5-8fef-44323bc2bfbc_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_15a2de6f-d9dc-4ad5-8fef-44323bc2bfbc" xlink:to="loc_srt_RangeMember_15a2de6f-d9dc-4ad5-8fef-44323bc2bfbc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9df15ef2-2117-425f-8da1-29024631de75" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_15a2de6f-d9dc-4ad5-8fef-44323bc2bfbc" xlink:to="loc_srt_RangeMember_9df15ef2-2117-425f-8da1-29024631de75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cbe46403-b1f0-4164-914f-a45cd46cb6a2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9df15ef2-2117-425f-8da1-29024631de75" xlink:to="loc_srt_MaximumMember_cbe46403-b1f0-4164-914f-a45cd46cb6a2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:definitionLink xlink:role="http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended" id="i01968033d1c447d2a381375d4e778c1a_COMMITMENTSANDCONTINGENCIESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e99c8010-5eec-4fc9-83c0-b6187a6baada" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_01c078b8-1c51-4e10-ae33-b2c584a7f1c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e99c8010-5eec-4fc9-83c0-b6187a6baada" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_01c078b8-1c51-4e10-ae33-b2c584a7f1c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_eb3e77bf-a816-4be3-982c-c941c55b440a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e99c8010-5eec-4fc9-83c0-b6187a6baada" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_eb3e77bf-a816-4be3-982c-c941c55b440a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_0c74c8e2-c452-4e41-b2e3-aa03f2bc830a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e99c8010-5eec-4fc9-83c0-b6187a6baada" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_0c74c8e2-c452-4e41-b2e3-aa03f2bc830a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary_da4ad286-fd0c-430c-9aae-6cfc3c898643" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e99c8010-5eec-4fc9-83c0-b6187a6baada" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary_da4ad286-fd0c-430c-9aae-6cfc3c898643" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_UnrecordedUnconditionalPurchaseObligationDuewithinTwoandThreeYears_98519090-66fb-41fa-822c-7d7d56e3fcb3" xlink:href="dgx-20221231.xsd#dgx_UnrecordedUnconditionalPurchaseObligationDuewithinTwoandThreeYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e99c8010-5eec-4fc9-83c0-b6187a6baada" xlink:to="loc_dgx_UnrecordedUnconditionalPurchaseObligationDuewithinTwoandThreeYears_98519090-66fb-41fa-822c-7d7d56e3fcb3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_AgreementtoOutsourceBillingandCollectionFunction_a444984f-1a91-45ff-a1cc-bd635198cba5" xlink:href="dgx-20221231.xsd#dgx_AgreementtoOutsourceBillingandCollectionFunction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e99c8010-5eec-4fc9-83c0-b6187a6baada" xlink:to="loc_dgx_AgreementtoOutsourceBillingandCollectionFunction_a444984f-1a91-45ff-a1cc-bd635198cba5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_RemainingTermsofContingentLeaseObligationsMaximum_3ee9f294-5d2f-4d74-9b7d-f2560ceab1d8" xlink:href="dgx-20221231.xsd#dgx_RemainingTermsofContingentLeaseObligationsMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e99c8010-5eec-4fc9-83c0-b6187a6baada" xlink:to="loc_dgx_RemainingTermsofContingentLeaseObligationsMaximum_3ee9f294-5d2f-4d74-9b7d-f2560ceab1d8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_b605e710-fe5f-468a-ba16-105eec28197f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e99c8010-5eec-4fc9-83c0-b6187a6baada" xlink:to="loc_us-gaap_LitigationReserve_b605e710-fe5f-468a-ba16-105eec28197f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscounted_b7007775-5ab4-4f95-b262-22d9bae59bac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscounted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e99c8010-5eec-4fc9-83c0-b6187a6baada" xlink:to="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscounted_b7007775-5ab4-4f95-b262-22d9bae59bac" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d4adc829-231b-45d3-96f9-5cf32cedc79f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e99c8010-5eec-4fc9-83c0-b6187a6baada" xlink:to="loc_us-gaap_DebtInstrumentTable_d4adc829-231b-45d3-96f9-5cf32cedc79f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_df48838c-d80f-47c7-8748-2be5f37deeb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d4adc829-231b-45d3-96f9-5cf32cedc79f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_df48838c-d80f-47c7-8748-2be5f37deeb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_df48838c-d80f-47c7-8748-2be5f37deeb0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_df48838c-d80f-47c7-8748-2be5f37deeb0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_df48838c-d80f-47c7-8748-2be5f37deeb0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_92afde79-9e86-467c-82e4-07e487fb7baa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_df48838c-d80f-47c7-8748-2be5f37deeb0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_92afde79-9e86-467c-82e4-07e487fb7baa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_f400d5c6-4072-410c-90de-27079b456901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_92afde79-9e86-467c-82e4-07e487fb7baa" xlink:to="loc_us-gaap_SecuredDebtMember_f400d5c6-4072-410c-90de-27079b456901" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_247578af-74de-4581-97ee-856fd7dd847b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d4adc829-231b-45d3-96f9-5cf32cedc79f" xlink:to="loc_us-gaap_CreditFacilityAxis_247578af-74de-4581-97ee-856fd7dd847b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_247578af-74de-4581-97ee-856fd7dd847b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_247578af-74de-4581-97ee-856fd7dd847b" xlink:to="loc_us-gaap_CreditFacilityDomain_247578af-74de-4581-97ee-856fd7dd847b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_1d43d6d2-efc9-471c-bc88-af08e2687961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_247578af-74de-4581-97ee-856fd7dd847b" xlink:to="loc_us-gaap_CreditFacilityDomain_1d43d6d2-efc9-471c-bc88-af08e2687961" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_28ed6d30-f3dc-488f-854e-6d31fde929e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_1d43d6d2-efc9-471c-bc88-af08e2687961" xlink:to="loc_us-gaap_LetterOfCreditMember_28ed6d30-f3dc-488f-854e-6d31fde929e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_50afece9-279a-4e08-8cc0-12acc38883b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d4adc829-231b-45d3-96f9-5cf32cedc79f" xlink:to="loc_us-gaap_DebtInstrumentAxis_50afece9-279a-4e08-8cc0-12acc38883b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_50afece9-279a-4e08-8cc0-12acc38883b8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_50afece9-279a-4e08-8cc0-12acc38883b8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_50afece9-279a-4e08-8cc0-12acc38883b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ad127e4c-4572-4173-b4c6-10b792c9b46f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_50afece9-279a-4e08-8cc0-12acc38883b8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ad127e4c-4572-4173-b4c6-10b792c9b46f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_48fc5211-9aed-4f42-8f3c-de27b197e426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ad127e4c-4572-4173-b4c6-10b792c9b46f" xlink:to="loc_us-gaap_LetterOfCreditMember_48fc5211-9aed-4f42-8f3c-de27b197e426" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#BUSINESSSEGMENTINFORMATIONDetails"/>
  <link:definitionLink xlink:role="http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails" xlink:type="extended" id="ia8ad53b5aa2143048bc3020f9bc45862_BUSINESSSEGMENTINFORMATIONDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_80fe6118-45f5-4e6b-9bef-903df5bfd2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_PercentageofNetRevenues_50a6a52d-90f8-4183-a7e8-a9a1822da384" xlink:href="dgx-20221231.xsd#dgx_PercentageofNetRevenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_80fe6118-45f5-4e6b-9bef-903df5bfd2a8" xlink:to="loc_dgx_PercentageofNetRevenues_50a6a52d-90f8-4183-a7e8-a9a1822da384" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0db5db45-3c64-44a0-9160-0a6fc5ca413d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_80fe6118-45f5-4e6b-9bef-903df5bfd2a8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0db5db45-3c64-44a0-9160-0a6fc5ca413d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_08eab82f-ce60-4c36-badb-735f0982e75c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_80fe6118-45f5-4e6b-9bef-903df5bfd2a8" xlink:to="loc_us-gaap_OperatingIncomeLoss_08eab82f-ce60-4c36-badb-735f0982e75c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_ed511ee4-6cef-43c6-9b86-85ed6ca4d14b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_80fe6118-45f5-4e6b-9bef-903df5bfd2a8" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_ed511ee4-6cef-43c6-9b86-85ed6ca4d14b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_976ba800-2e40-41f6-a696-71398d6032a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_80fe6118-45f5-4e6b-9bef-903df5bfd2a8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_976ba800-2e40-41f6-a696-71398d6032a7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_82d5e290-1251-4eb4-bde8-3c306e9144ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_80fe6118-45f5-4e6b-9bef-903df5bfd2a8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_82d5e290-1251-4eb4-bde8-3c306e9144ad" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c1940c03-0fa7-4f68-a2be-5a839d165986" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_80fe6118-45f5-4e6b-9bef-903df5bfd2a8" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c1940c03-0fa7-4f68-a2be-5a839d165986" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2a8d54d5-bcb7-424f-86e5-77b20c31c743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_80fe6118-45f5-4e6b-9bef-903df5bfd2a8" xlink:to="loc_us-gaap_ProfitLoss_2a8d54d5-bcb7-424f-86e5-77b20c31c743" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4e532e22-948c-4da0-abce-02da5972cfb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_80fe6118-45f5-4e6b-9bef-903df5bfd2a8" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4e532e22-948c-4da0-abce-02da5972cfb6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cf8141e2-346c-4c2e-98ae-f9966ca84fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_80fe6118-45f5-4e6b-9bef-903df5bfd2a8" xlink:to="loc_us-gaap_NetIncomeLoss_cf8141e2-346c-4c2e-98ae-f9966ca84fc2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_a2edf721-d532-4389-aec6-62669a77262f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_80fe6118-45f5-4e6b-9bef-903df5bfd2a8" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_a2edf721-d532-4389-aec6-62669a77262f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a2c6202f-36c8-47da-9a81-a33811af2038" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_80fe6118-45f5-4e6b-9bef-903df5bfd2a8" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a2c6202f-36c8-47da-9a81-a33811af2038" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_RevenueFromContractWithCustomerExcludingAssessedTaxPercent_1a4502e6-20bc-420f-83c1-8243b398231f" xlink:href="dgx-20221231.xsd#dgx_RevenueFromContractWithCustomerExcludingAssessedTaxPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_80fe6118-45f5-4e6b-9bef-903df5bfd2a8" xlink:to="loc_dgx_RevenueFromContractWithCustomerExcludingAssessedTaxPercent_1a4502e6-20bc-420f-83c1-8243b398231f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2b1b31f8-17df-48d0-877e-81342c9d41e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_80fe6118-45f5-4e6b-9bef-903df5bfd2a8" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2b1b31f8-17df-48d0-877e-81342c9d41e1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b7166346-0891-47ce-8056-18be2cfa29cb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2b1b31f8-17df-48d0-877e-81342c9d41e1" xlink:to="loc_srt_RangeAxis_b7166346-0891-47ce-8056-18be2cfa29cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b7166346-0891-47ce-8056-18be2cfa29cb_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b7166346-0891-47ce-8056-18be2cfa29cb" xlink:to="loc_srt_RangeMember_b7166346-0891-47ce-8056-18be2cfa29cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_db82f674-0c6f-4cb8-ad9d-ef0819fe1693" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b7166346-0891-47ce-8056-18be2cfa29cb" xlink:to="loc_srt_RangeMember_db82f674-0c6f-4cb8-ad9d-ef0819fe1693" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_876e2f9c-2412-460b-9b53-8ca089df634b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_db82f674-0c6f-4cb8-ad9d-ef0819fe1693" xlink:to="loc_srt_MinimumMember_876e2f9c-2412-460b-9b53-8ca089df634b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a4e7a1e6-44de-4205-9f9a-dab080f4d01e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2b1b31f8-17df-48d0-877e-81342c9d41e1" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a4e7a1e6-44de-4205-9f9a-dab080f4d01e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a4e7a1e6-44de-4205-9f9a-dab080f4d01e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a4e7a1e6-44de-4205-9f9a-dab080f4d01e" xlink:to="loc_us-gaap_SegmentDomain_a4e7a1e6-44de-4205-9f9a-dab080f4d01e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2b3f6d79-5b67-4210-9be2-25e9a990df46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a4e7a1e6-44de-4205-9f9a-dab080f4d01e" xlink:to="loc_us-gaap_SegmentDomain_2b3f6d79-5b67-4210-9be2-25e9a990df46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_DiagnosticInformationServicesBusinessMember_e9a9dc8a-a9ad-4c58-b3df-ffd8db640e6d" xlink:href="dgx-20221231.xsd#dgx_DiagnosticInformationServicesBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2b3f6d79-5b67-4210-9be2-25e9a990df46" xlink:to="loc_dgx_DiagnosticInformationServicesBusinessMember_e9a9dc8a-a9ad-4c58-b3df-ffd8db640e6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_de33b576-613e-48e2-835d-73103bfe80bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2b3f6d79-5b67-4210-9be2-25e9a990df46" xlink:to="loc_us-gaap_AllOtherSegmentsMember_de33b576-613e-48e2-835d-73103bfe80bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateMember_b198a912-ae59-4c34-bb58-15935a131005" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2b3f6d79-5b67-4210-9be2-25e9a990df46" xlink:to="loc_us-gaap_CorporateMember_b198a912-ae59-4c34-bb58-15935a131005" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c0430620-50e6-4586-b931-12447778be1f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2b1b31f8-17df-48d0-877e-81342c9d41e1" xlink:to="loc_srt_ProductOrServiceAxis_c0430620-50e6-4586-b931-12447778be1f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c0430620-50e6-4586-b931-12447778be1f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c0430620-50e6-4586-b931-12447778be1f" xlink:to="loc_srt_ProductsAndServicesDomain_c0430620-50e6-4586-b931-12447778be1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2fa800f3-6614-4eea-bab4-cd432550bebb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c0430620-50e6-4586-b931-12447778be1f" xlink:to="loc_srt_ProductsAndServicesDomain_2fa800f3-6614-4eea-bab4-cd432550bebb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_RoutineclinicaltestingservicesMember_c034c9d7-e95b-457f-9d1f-ea081bfc60f3" xlink:href="dgx-20221231.xsd#dgx_RoutineclinicaltestingservicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2fa800f3-6614-4eea-bab4-cd432550bebb" xlink:to="loc_dgx_RoutineclinicaltestingservicesMember_c034c9d7-e95b-457f-9d1f-ea081bfc60f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_COVID19TestingServicesMember_506fc2bf-2bf6-43ff-a2f1-f4257969ea07" xlink:href="dgx-20221231.xsd#dgx_COVID19TestingServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2fa800f3-6614-4eea-bab4-cd432550bebb" xlink:to="loc_dgx_COVID19TestingServicesMember_506fc2bf-2bf6-43ff-a2f1-f4257969ea07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_GenebasedandesoterictestingservicesMember_8d9ac005-219e-4eeb-85c7-7021b573904c" xlink:href="dgx-20221231.xsd#dgx_GenebasedandesoterictestingservicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2fa800f3-6614-4eea-bab4-cd432550bebb" xlink:to="loc_dgx_GenebasedandesoterictestingservicesMember_8d9ac005-219e-4eeb-85c7-7021b573904c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_AnatomicpathologytestingservicesMember_21825ff2-2ee1-437a-9b45-7aa44134929c" xlink:href="dgx-20221231.xsd#dgx_AnatomicpathologytestingservicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2fa800f3-6614-4eea-bab4-cd432550bebb" xlink:to="loc_dgx_AnatomicpathologytestingservicesMember_21825ff2-2ee1-437a-9b45-7aa44134929c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_AllotherservicesMember_e73bc3a9-8001-4486-bbda-33c0459fd908" xlink:href="dgx-20221231.xsd#dgx_AllotherservicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2fa800f3-6614-4eea-bab4-cd432550bebb" xlink:to="loc_dgx_AllotherservicesMember_e73bc3a9-8001-4486-bbda-33c0459fd908" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:definitionLink xlink:role="http://questdiagnostics.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended" id="ie6ebd99b621949efb80cb4fc145ec851_SUBSEQUENTEVENTSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_bf24cb14-8289-44f6-a3ee-784faae642b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_c24a8c32-be51-4784-88fc-526ecb6f08ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_bf24cb14-8289-44f6-a3ee-784faae642b6" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_c24a8c32-be51-4784-88fc-526ecb6f08ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_7199c1a0-4e1a-4b42-b029-d36565ff45e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_bf24cb14-8289-44f6-a3ee-784faae642b6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_7199c1a0-4e1a-4b42-b029-d36565ff45e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_8cea6b30-fd72-4a02-895a-f86a9393b262" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_bf24cb14-8289-44f6-a3ee-784faae642b6" xlink:to="loc_us-gaap_SubsequentEventTable_8cea6b30-fd72-4a02-895a-f86a9393b262" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_e7629627-63d6-454a-b50b-dfae62bc6654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_8cea6b30-fd72-4a02-895a-f86a9393b262" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_e7629627-63d6-454a-b50b-dfae62bc6654" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e7629627-63d6-454a-b50b-dfae62bc6654_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e7629627-63d6-454a-b50b-dfae62bc6654" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e7629627-63d6-454a-b50b-dfae62bc6654_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_423e1226-a1d2-4e61-98ea-41d91c0c099d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e7629627-63d6-454a-b50b-dfae62bc6654" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_423e1226-a1d2-4e61-98ea-41d91c0c099d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_2c48a627-ef76-4e4d-8a60-9cfea359700f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_423e1226-a1d2-4e61-98ea-41d91c0c099d" xlink:to="loc_us-gaap_SubsequentEventMember_2c48a627-ef76-4e4d-8a60-9cfea359700f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8be6eca9-5723-4499-bc57-e92da698789d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_8cea6b30-fd72-4a02-895a-f86a9393b262" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8be6eca9-5723-4499-bc57-e92da698789d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8be6eca9-5723-4499-bc57-e92da698789d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8be6eca9-5723-4499-bc57-e92da698789d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8be6eca9-5723-4499-bc57-e92da698789d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5a20e5c4-641e-4323-b54f-bd633a97d9da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8be6eca9-5723-4499-bc57-e92da698789d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5a20e5c4-641e-4323-b54f-bd633a97d9da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_PackHealthLLCMember_01a05de0-6839-4132-a063-4169727eefcf" xlink:href="dgx-20221231.xsd#dgx_PackHealthLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5a20e5c4-641e-4323-b54f-bd633a97d9da" xlink:to="loc_dgx_PackHealthLLCMember_01a05de0-6839-4132-a063-4169727eefcf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>18
<FILENAME>dgx-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:069b4a79-e86e-41e0-954a-e49896ade77c,g:4f5772c6-ef68-44f6-b836-f5065845bef2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_e91ea448-094c-4019-a0b3-0f26c6d2b400_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_2b80dba4-9b6b-41ba-9bb1-b357200757ba_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current foreign income tax expense</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_b706b3b9-b1d0-4b69-b9a5-68bc50123c69_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_a4889f19-cf48-44f9-a31b-85fe6b9c4c41_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for credit losses</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_dac4f2c2-ed5e-4519-8eea-8b4988088d56_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount outstanding</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_FiniteLivedIntangibleAssetsEstimatedAmortizationExpenseTotal_b6342ffa-34b7-4661-b84e-d483e60f2d31_totalLabel_en-US" xlink:label="lab_dgx_FiniteLivedIntangibleAssetsEstimatedAmortizationExpenseTotal" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_dgx_FiniteLivedIntangibleAssetsEstimatedAmortizationExpenseTotal_label_en-US" xlink:label="lab_dgx_FiniteLivedIntangibleAssetsEstimatedAmortizationExpenseTotal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets, Estimated amortization expense, total</link:label>
    <link:label id="lab_dgx_FiniteLivedIntangibleAssetsEstimatedAmortizationExpenseTotal_documentation_en-US" xlink:label="lab_dgx_FiniteLivedIntangibleAssetsEstimatedAmortizationExpenseTotal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets, estimated amortization expense, total.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_FiniteLivedIntangibleAssetsEstimatedAmortizationExpenseTotal" xlink:href="dgx-20221231.xsd#dgx_FiniteLivedIntangibleAssetsEstimatedAmortizationExpenseTotal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_FiniteLivedIntangibleAssetsEstimatedAmortizationExpenseTotal" xlink:to="lab_dgx_FiniteLivedIntangibleAssetsEstimatedAmortizationExpenseTotal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_8be2ee09-22a4-4dac-92e9-e724cf416d41_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradingSecurities_94cfdd9b-7f1d-4f6a-b37c-3f9a1120d81f_terseLabel_en-US" xlink:label="lab_us-gaap_TradingSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation trading securities</link:label>
    <link:label id="lab_us-gaap_TradingSecurities_label_en-US" xlink:label="lab_us-gaap_TradingSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingSecurities" xlink:to="lab_us-gaap_TradingSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability_2a16fe1f-3cc6-4bd3-b117-cbd545f06462_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SDCP accrual</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Recorded Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_2129cfab-638a-473c-bcf6-9a068f6d71e7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_195cbf21-f656-4cfb-b70e-c07a600745ec_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_GenebasedandesoterictestingservicesMember_632cc006-2fc7-4c8e-a838-ab16d8637733_terseLabel_en-US" xlink:label="lab_dgx_GenebasedandesoterictestingservicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gene-based and esoteric (including advanced diagnostics) testing services</link:label>
    <link:label id="lab_dgx_GenebasedandesoterictestingservicesMember_label_en-US" xlink:label="lab_dgx_GenebasedandesoterictestingservicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gene-based and esoteric testing services [Member]</link:label>
    <link:label id="lab_dgx_GenebasedandesoterictestingservicesMember_documentation_en-US" xlink:label="lab_dgx_GenebasedandesoterictestingservicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gene-based and esoteric testing services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_GenebasedandesoterictestingservicesMember" xlink:href="dgx-20221231.xsd#dgx_GenebasedandesoterictestingservicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_GenebasedandesoterictestingservicesMember" xlink:to="lab_dgx_GenebasedandesoterictestingservicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_241fd520-f725-4185-9979-9c3b0ba04663_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_a4f838b9-3766-4255-b417-1b5e9476de2c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_1021cc4b-7d0c-485b-9f8d-6756b11b8094_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_d8055d85-c96e-4c9a-8cdb-2a66ad22910c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:to="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_887ccf30-9379-4870-9308-ba1eab3375dd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_LeaseRenewalTerm_8c4031bc-2ae1-4573-b345-a856ea5bfe6e_terseLabel_en-US" xlink:label="lab_dgx_LeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_dgx_LeaseRenewalTerm_label_en-US" xlink:label="lab_dgx_LeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Renewal Term</link:label>
    <link:label id="lab_dgx_LeaseRenewalTerm_documentation_en-US" xlink:label="lab_dgx_LeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LeaseRenewalTerm" xlink:href="dgx-20221231.xsd#dgx_LeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_LeaseRenewalTerm" xlink:to="lab_dgx_LeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_eeb7aecd-8039-4923-a0b2-52f1f1248a20_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate in excess of LIBOR</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_42b039c8-16c7-41f4-bf3c-6e609d636d75_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate in excess of LIBOR</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_492160a1-57fa-4902-81bf-cc909989de3a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_6e957379-eb76-4a30-b22e-53cf2aef00aa_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7b832de8-a77e-43d3-beb9-992179a7769b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f6a7ebb7-69e9-4bdd-88b6-fdbc64ed2d85_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_60bc19fe-04ed-45ab-9944-cd127bd6f5ab_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate, Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_f110ff96-d74f-4e15-98a6-11c40d8ef087_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_LeaseTypeChangeMember_531cbfdf-cda0-4af2-8134-fdba5348313d_terseLabel_en-US" xlink:label="lab_dgx_LeaseTypeChangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Type Change</link:label>
    <link:label id="lab_dgx_LeaseTypeChangeMember_label_en-US" xlink:label="lab_dgx_LeaseTypeChangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Type Change [Member]</link:label>
    <link:label id="lab_dgx_LeaseTypeChangeMember_documentation_en-US" xlink:label="lab_dgx_LeaseTypeChangeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Type Change</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LeaseTypeChangeMember" xlink:href="dgx-20221231.xsd#dgx_LeaseTypeChangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_LeaseTypeChangeMember" xlink:to="lab_dgx_LeaseTypeChangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_c2102ab8-a395-4ffe-82eb-d761b8ecdd3d_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_ff6e81cc-86db-463e-92b0-3f71e49b81bf_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_454d3424-ec77-4329-8b1b-35eedc6f2546_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_a99124eb-4931-4883-bd5f-b1f64b4f1c81_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current state and local income tax expense</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_0e20180d-13b8-41c7-8cca-e4c2272a0843_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_ee7d9c22-52f7-4e4c-adef-b58ba7b89356_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_bce831ec-1c76-41dd-a799-d39e8256b31b_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0746c1a6-a22f-4176-bb5d-f453004d82db_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options and performance share units not included due to their antidilutive effect</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5fda142e-85d4-4daf-ae36-1af53c5c7399_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_11100f5e-37ae-499e-bb9d-d41afd242b95_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_f540e48e-777b-4334-b1b3-253c939f1f45_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_3e2ef3b4-16b5-428c-a559-df8b7c761d36_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_b0c6276f-53a8-4b0c-9cc0-c899409fe376_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_0f29c894-bd7e-4ba3-b7e9-845d2f02d6b3_verboseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Receivables Credit Facility</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_ce3c4551-a776-4e7f-b52a-f07c9d4a11cf_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_ea92a89a-1aab-46b4-89c2-71bbcdf7c891_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_ContractualLifeOfStockOptionsAndOtherAwardsUnderSharedBasedCompensationPlans_66107d7d-d428-4cfa-a046-9cbe81ff7bbe_terseLabel_en-US" xlink:label="lab_dgx_ContractualLifeOfStockOptionsAndOtherAwardsUnderSharedBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual life of stock options and other awards under the shared-based compensation plans</link:label>
    <link:label id="lab_dgx_ContractualLifeOfStockOptionsAndOtherAwardsUnderSharedBasedCompensationPlans_label_en-US" xlink:label="lab_dgx_ContractualLifeOfStockOptionsAndOtherAwardsUnderSharedBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual life of stock options and other awards under the Shared-based compensation plans</link:label>
    <link:label id="lab_dgx_ContractualLifeOfStockOptionsAndOtherAwardsUnderSharedBasedCompensationPlans_documentation_en-US" xlink:label="lab_dgx_ContractualLifeOfStockOptionsAndOtherAwardsUnderSharedBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual life of stock options and other awards under the Shared-based compensation plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ContractualLifeOfStockOptionsAndOtherAwardsUnderSharedBasedCompensationPlans" xlink:href="dgx-20221231.xsd#dgx_ContractualLifeOfStockOptionsAndOtherAwardsUnderSharedBasedCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_ContractualLifeOfStockOptionsAndOtherAwardsUnderSharedBasedCompensationPlans" xlink:to="lab_dgx_ContractualLifeOfStockOptionsAndOtherAwardsUnderSharedBasedCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_1fa38986-a405-4c0a-9abc-b44d45b688a1_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions for tax positions of current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_9982764c-846e-4f92-9a1b-2e59c57cd5d4_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_b1506d70-1dc7-4a88-b166-3795dcfd2497_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Benefits</link:label>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Income Tax Contingencies [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_1042db9b-4240-44b5-9d6b-325b6bedfe44_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of leased assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_167ceeb9-1bfc-4737-ae6e-d7c4b13ba28c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_eefd24bb-dada-4677-8264-e95598706814_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ce9733fa-f170-43f5-b70d-c50c35db5516_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesDateDomain_36275b6d-97e4-4eb4-8ac4-199de4df6caa_terseLabel_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesDateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases, Date [Domain]</link:label>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesDateDomain_label_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesDateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases, Date [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcceleratedShareRepurchasesDateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesDateDomain" xlink:to="lab_us-gaap_AcceleratedShareRepurchasesDateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_CapitatedMember_109bc096-3923-48c1-86b3-961a0ba82250_terseLabel_en-US" xlink:label="lab_dgx_CapitatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitated</link:label>
    <link:label id="lab_dgx_CapitatedMember_label_en-US" xlink:label="lab_dgx_CapitatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitated [Member]</link:label>
    <link:label id="lab_dgx_CapitatedMember_documentation_en-US" xlink:label="lab_dgx_CapitatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitated [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_CapitatedMember" xlink:href="dgx-20221231.xsd#dgx_CapitatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_CapitatedMember" xlink:to="lab_dgx_CapitatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_e7ea412d-3c76-4d6e-8627-a6533d7c2404_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_14935564-0c97-41c0-bcd1-a8fc588bb903_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_8ce8c0a3-f83b-479d-87cd-c06def2e701a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_962deaaa-72fd-4517-8227-c8393f8aa3db_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, end of year weighted average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationTypeAxis_53774d5c-3c57-41b5-b6b5-83d0676ca435_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationTypeAxis_label_en-US" xlink:label="lab_us-gaap_ReclassificationTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationTypeAxis" xlink:to="lab_us-gaap_ReclassificationTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_ThreePointFourFivePercentSeniorNotesdueJune2026Member_0934c8f3-0899-417a-b509-4b22043a3b03_terseLabel_en-US" xlink:label="lab_dgx_ThreePointFourFivePercentSeniorNotesdueJune2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.45% Senior Notes due June 2026</link:label>
    <link:label id="lab_dgx_ThreePointFourFivePercentSeniorNotesdueJune2026Member_label_en-US" xlink:label="lab_dgx_ThreePointFourFivePercentSeniorNotesdueJune2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Four Five Percent Senior Notes due June 2026 [Member]</link:label>
    <link:label id="lab_dgx_ThreePointFourFivePercentSeniorNotesdueJune2026Member_documentation_en-US" xlink:label="lab_dgx_ThreePointFourFivePercentSeniorNotesdueJune2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Four Five Percent Senior Notes due June 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ThreePointFourFivePercentSeniorNotesdueJune2026Member" xlink:href="dgx-20221231.xsd#dgx_ThreePointFourFivePercentSeniorNotesdueJune2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_ThreePointFourFivePercentSeniorNotesdueJune2026Member" xlink:to="lab_dgx_ThreePointFourFivePercentSeniorNotesdueJune2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_b2e7ba94-be7b-48eb-9290-fd97280d71af_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_36d17afd-7914-483a-b38a-e6f58112cb37_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions for settlements</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_c2df3026-5110-43b1-8f5a-a487be81265c_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_9784b74a-e796-45ba-92ac-9e08a9326f2c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_942f0576-7781-43b0-b093-5f44472fe933_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_a0314557-f21a-4fd0-818c-aec6049fb7ef_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases:</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_e0f5c123-4ebe-4674-9b28-8a38c29cd678_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess tax benefits on stock-based compensation arrangements</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deduction, Other, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_ccf67c47-6b1c-4895-8264-ffc6108b5134_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_c2e96a40-6dba-4306-b82d-94059fc7c520_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt, net of current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BankOverdrafts_d56eb561-b002-4fd7-bb74-3f7b5bc75dd7_terseLabel_en-US" xlink:label="lab_us-gaap_BankOverdrafts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overdrafts</link:label>
    <link:label id="lab_us-gaap_BankOverdrafts_label_en-US" xlink:label="lab_us-gaap_BankOverdrafts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank Overdrafts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankOverdrafts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankOverdrafts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BankOverdrafts" xlink:to="lab_us-gaap_BankOverdrafts" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_SupplementalDeferredCompensationPlanMember_7b2b7edf-de34-41b8-a564-d9832ddfdf0d_terseLabel_en-US" xlink:label="lab_dgx_SupplementalDeferredCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Deferred Compensation Plan</link:label>
    <link:label id="lab_dgx_SupplementalDeferredCompensationPlanMember_label_en-US" xlink:label="lab_dgx_SupplementalDeferredCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Deferred Compensation Plan [Member]</link:label>
    <link:label id="lab_dgx_SupplementalDeferredCompensationPlanMember_documentation_en-US" xlink:label="lab_dgx_SupplementalDeferredCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Deferred Compensation Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_SupplementalDeferredCompensationPlanMember" xlink:href="dgx-20221231.xsd#dgx_SupplementalDeferredCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_SupplementalDeferredCompensationPlanMember" xlink:to="lab_dgx_SupplementalDeferredCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_456ace28-b5b5-4a9a-a429-4c67e01362a6_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term, Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b4ef26c-af9b-452e-bd0e-14582eb0e652_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_71a876f1-3ee8-4199-998c-296becc0665a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_0ba83d5f-0a66-40e4-8ec1-5bfba96a9428_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Bonus and Profit Sharing Plan, Type of Deferred Compensation [Axis]</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_96cb9331-bafc-4d68-8c7b-1c088b5fbf30_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_48573833-4335-4a0f-83d7-236279da5ffb_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_MeasurementInputComparableCompanyRevenueVolatilityMember_b02444fe-6443-4324-bc78-eb4c52dd99fa_terseLabel_en-US" xlink:label="lab_dgx_MeasurementInputComparableCompanyRevenueVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comparable Company Revenue Volatility</link:label>
    <link:label id="lab_dgx_MeasurementInputComparableCompanyRevenueVolatilityMember_label_en-US" xlink:label="lab_dgx_MeasurementInputComparableCompanyRevenueVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Comparable Company Revenue Volatility [Member]</link:label>
    <link:label id="lab_dgx_MeasurementInputComparableCompanyRevenueVolatilityMember_documentation_en-US" xlink:label="lab_dgx_MeasurementInputComparableCompanyRevenueVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Comparable Company Revenue Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_MeasurementInputComparableCompanyRevenueVolatilityMember" xlink:href="dgx-20221231.xsd#dgx_MeasurementInputComparableCompanyRevenueVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_MeasurementInputComparableCompanyRevenueVolatilityMember" xlink:to="lab_dgx_MeasurementInputComparableCompanyRevenueVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0937cc9-2f16-4d2e-ba36-2415c5c6f6a6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_04e21f25-61d6-4f3d-af31-1c1c04f69073_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Changes in Available-for-Sale Debt Securities</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_17deb27f-66fd-436b-b46c-efc9d364c5af_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_EquityMethodInvestmentOwnershipPercentDisposedOf_70163744-508f-474d-ac86-1a86c8d0161e_terseLabel_en-US" xlink:label="lab_dgx_EquityMethodInvestmentOwnershipPercentDisposedOf" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of ownership interest sold</link:label>
    <link:label id="lab_dgx_EquityMethodInvestmentOwnershipPercentDisposedOf_label_en-US" xlink:label="lab_dgx_EquityMethodInvestmentOwnershipPercentDisposedOf" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percent Disposed Of</link:label>
    <link:label id="lab_dgx_EquityMethodInvestmentOwnershipPercentDisposedOf_documentation_en-US" xlink:label="lab_dgx_EquityMethodInvestmentOwnershipPercentDisposedOf" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percent Disposed Of</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_EquityMethodInvestmentOwnershipPercentDisposedOf" xlink:href="dgx-20221231.xsd#dgx_EquityMethodInvestmentOwnershipPercentDisposedOf"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_EquityMethodInvestmentOwnershipPercentDisposedOf" xlink:to="lab_dgx_EquityMethodInvestmentOwnershipPercentDisposedOf" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0cf8dc88-d2b3-4320-9691-2cea100b6c4e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_c5600d4f-13b7-4e19-976a-4fdb1d5924ce_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_daa60ad4-0bca-4277-ba9c-00d3c79da385_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_30b0d96a-9ea4-4cfa-b61f-c2e39a4f2873_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited and cancelled</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_058623df-0a55-4213-9d0f-14b87196f1aa_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_9e29fdc4-2bfd-4f3c-8f26-d4575b8a35cb_verboseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee separation costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_47d24403-95fb-48b5-9c20-8e8ef7a9c12c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding, beginning of year weighted average grant date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9c339ed2-e728-4f93-b246-6f7027220d90_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding, end of year weighted average grant date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsAccountsReceivables_bdcf70b5-c755-41b4-a07a-12a0fc783526_terseLabel_en-US" xlink:label="lab_dgx_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsAccountsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable reserves</link:label>
    <link:label id="lab_dgx_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsAccountsReceivables_label_en-US" xlink:label="lab_dgx_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsAccountsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accounts Receivables</link:label>
    <link:label id="lab_dgx_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsAccountsReceivables_documentation_en-US" xlink:label="lab_dgx_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsAccountsReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accounts Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsAccountsReceivables" xlink:href="dgx-20221231.xsd#dgx_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsAccountsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsAccountsReceivables" xlink:to="lab_dgx_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsAccountsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenueAbstract_4de914a2-5d85-48dd-83a6-5f92f29f2f05_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating costs and expenses and other operating income:</link:label>
    <link:label id="lab_us-gaap_CostOfRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_CostOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenueAbstract" xlink:to="lab_us-gaap_CostOfRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_b192196d-0b43-49bc-afd0-f4eb2ee4bea2_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_Mergerconsiderationpaidpayablenet_1cc33dd3-b5f1-4c6c-8b0d-0bb02ce991bc_terseLabel_en-US" xlink:label="lab_dgx_Mergerconsiderationpaidpayablenet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger consideration payable</link:label>
    <link:label id="lab_dgx_Mergerconsiderationpaidpayablenet_label_en-US" xlink:label="lab_dgx_Mergerconsiderationpaidpayablenet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger consideration paid (payable), net</link:label>
    <link:label id="lab_dgx_Mergerconsiderationpaidpayablenet_documentation_en-US" xlink:label="lab_dgx_Mergerconsiderationpaidpayablenet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger consideration paid (payable), net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_Mergerconsiderationpaidpayablenet" xlink:href="dgx-20221231.xsd#dgx_Mergerconsiderationpaidpayablenet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_Mergerconsiderationpaidpayablenet" xlink:to="lab_dgx_Mergerconsiderationpaidpayablenet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_e0085d16-a512-4d72-8593-43418aee6eab_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax provision</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_e5b5e165-74d1-44ad-87c1-df8cd239c3b8_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_AccountsReceivableDisaggregationTableTextBlock_a0632121-309e-4d62-a424-ba922d816473_terseLabel_en-US" xlink:label="lab_dgx_AccountsReceivableDisaggregationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable Disaggregation</link:label>
    <link:label id="lab_dgx_AccountsReceivableDisaggregationTableTextBlock_label_en-US" xlink:label="lab_dgx_AccountsReceivableDisaggregationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable Disaggregation [Table Text Block]</link:label>
    <link:label id="lab_dgx_AccountsReceivableDisaggregationTableTextBlock_documentation_en-US" xlink:label="lab_dgx_AccountsReceivableDisaggregationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable Disaggregation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_AccountsReceivableDisaggregationTableTextBlock" xlink:href="dgx-20221231.xsd#dgx_AccountsReceivableDisaggregationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_AccountsReceivableDisaggregationTableTextBlock" xlink:to="lab_dgx_AccountsReceivableDisaggregationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_5927a9d7-44da-4a02-b348-c84c49158265_terseLabel_en-US" xlink:label="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_label_en-US" xlink:label="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Right-of-Use Assets</link:label>
    <link:label id="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Right-of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:href="dgx-20221231.xsd#dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:to="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_PercentageofNetAccountsReceivable_6a5eb362-81cb-4f8d-b9ec-944f832da17f_terseLabel_en-US" xlink:label="lab_dgx_PercentageofNetAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of net accounts receivable</link:label>
    <link:label id="lab_dgx_PercentageofNetAccountsReceivable_label_en-US" xlink:label="lab_dgx_PercentageofNetAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Net Accounts Receivable</link:label>
    <link:label id="lab_dgx_PercentageofNetAccountsReceivable_documentation_en-US" xlink:label="lab_dgx_PercentageofNetAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Net Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_PercentageofNetAccountsReceivable" xlink:href="dgx-20221231.xsd#dgx_PercentageofNetAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_PercentageofNetAccountsReceivable" xlink:to="lab_dgx_PercentageofNetAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_79deeaa7-cf33-4961-ba4d-7b6df5ae7621_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-offs of accounts receivable, net of recoveries</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_7c7afc49-4094-4b8f-931a-23f78e5061e2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_LaboratoryEquipmentAndFurnitureAndFixturesMember_b6a68c88-b021-44f4-9eed-d2bb0189470d_terseLabel_en-US" xlink:label="lab_dgx_LaboratoryEquipmentAndFurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment and Furniture and Fixtures</link:label>
    <link:label id="lab_dgx_LaboratoryEquipmentAndFurnitureAndFixturesMember_label_en-US" xlink:label="lab_dgx_LaboratoryEquipmentAndFurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment And Furniture And Fixtures [Member]</link:label>
    <link:label id="lab_dgx_LaboratoryEquipmentAndFurnitureAndFixturesMember_documentation_en-US" xlink:label="lab_dgx_LaboratoryEquipmentAndFurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment and furniture and fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LaboratoryEquipmentAndFurnitureAndFixturesMember" xlink:href="dgx-20221231.xsd#dgx_LaboratoryEquipmentAndFurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_LaboratoryEquipmentAndFurnitureAndFixturesMember" xlink:to="lab_dgx_LaboratoryEquipmentAndFurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_db9218aa-eece-4a74-b008-3f88620ab771_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_b45ac44e-cae5-4fa4-bd98-b3c5fc31e8bc_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_b3690dce-cc6f-47c8-ad5b-17e3d0fdb8f1_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_b1c7e587-48b3-4451-abad-0c3aa93663c7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_6de40943-039f-4f60-a757-d4c883729f4a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_252e0485-f1e5-48c4-a16c-45e3928f1b77_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quest Diagnostics stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d7b1d204-e501-465e-b0e0-c9fb80723520_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_26873dc8-cbba-41de-be3e-ce9ecbb80fa3_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_82ab19e3-990d-4a6c-a736-b697945802cf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assumptions Used in Valuing The Company's Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_c31d9e81-d611-4ee8-9f5f-65a3e10965de_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Income Tax Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_6a0d5759-2bcf-4ed9-9e9f-601131dc32ae_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowances associated with certain net operating losses</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_AccountsReceivableAndAllowanceForCreditLossesPolicyPolicyTextBlock_210d79d3-cc24-452e-9767-f764fb3b3dbb_terseLabel_en-US" xlink:label="lab_dgx_AccountsReceivableAndAllowanceForCreditLossesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable and Allowance for Credit Losses</link:label>
    <link:label id="lab_dgx_AccountsReceivableAndAllowanceForCreditLossesPolicyPolicyTextBlock_label_en-US" xlink:label="lab_dgx_AccountsReceivableAndAllowanceForCreditLossesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable and Allowance for Credit Losses Policy [Policy Text Block]</link:label>
    <link:label id="lab_dgx_AccountsReceivableAndAllowanceForCreditLossesPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_dgx_AccountsReceivableAndAllowanceForCreditLossesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable and Allowance for Credit Losses Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_AccountsReceivableAndAllowanceForCreditLossesPolicyPolicyTextBlock" xlink:href="dgx-20221231.xsd#dgx_AccountsReceivableAndAllowanceForCreditLossesPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_AccountsReceivableAndAllowanceForCreditLossesPolicyPolicyTextBlock" xlink:to="lab_dgx_AccountsReceivableAndAllowanceForCreditLossesPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_bf97439a-c7c2-4f1d-8c19-089d9edd7fc8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation cost weighted average period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_9e5665fe-d7c5-4317-a444-78ef4235ddd6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, end of year weighted average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_96bcca4b-0450-4ca1-9d6d-245cc50423e6_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_TwoPointEightZeroPercentSeniorNotesDueJune2031Member_0b9cdc15-c176-4f2b-b2a4-2895b3da4ecd_terseLabel_en-US" xlink:label="lab_dgx_TwoPointEightZeroPercentSeniorNotesDueJune2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.80% Senior Notes due June 2031</link:label>
    <link:label id="lab_dgx_TwoPointEightZeroPercentSeniorNotesDueJune2031Member_label_en-US" xlink:label="lab_dgx_TwoPointEightZeroPercentSeniorNotesDueJune2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Eight Zero Percent Senior Notes due June 2031 [Member]</link:label>
    <link:label id="lab_dgx_TwoPointEightZeroPercentSeniorNotesDueJune2031Member_documentation_en-US" xlink:label="lab_dgx_TwoPointEightZeroPercentSeniorNotesDueJune2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Eight Zero Percent Senior Notes due June 2031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_TwoPointEightZeroPercentSeniorNotesDueJune2031Member" xlink:href="dgx-20221231.xsd#dgx_TwoPointEightZeroPercentSeniorNotesDueJune2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_TwoPointEightZeroPercentSeniorNotesDueJune2031Member" xlink:to="lab_dgx_TwoPointEightZeroPercentSeniorNotesDueJune2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_191e9e56-3dca-4c39-ba67-a3efebfd9342_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income before reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_2253071c-68aa-46ac-ba11-49d216723247_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash consideration</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_a340581f-a83f-4983-a2c2-20b36e1ea63b_netLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for business acquisitions</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_DSBusinessesMember_0ec9c115-2e00-4122-be6b-48ff2382e7de_terseLabel_en-US" xlink:label="lab_dgx_DSBusinessesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DS</link:label>
    <link:label id="lab_dgx_DSBusinessesMember_label_en-US" xlink:label="lab_dgx_DSBusinessesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DS Businesses [Member]</link:label>
    <link:label id="lab_dgx_DSBusinessesMember_documentation_en-US" xlink:label="lab_dgx_DSBusinessesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DS Businesses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_DSBusinessesMember" xlink:href="dgx-20221231.xsd#dgx_DSBusinessesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_DSBusinessesMember" xlink:to="lab_dgx_DSBusinessesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_9755368d-2a4e-46a1-b245-deac30652260_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_98a4eb57-be12-4674-a3c8-f0af67f31aa3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_PeriodofBillingFullyReserve_b7d781cc-8026-45bf-8481-15f8fafcb429_terseLabel_en-US" xlink:label="lab_dgx_PeriodofBillingFullyReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of billing fully reserve</link:label>
    <link:label id="lab_dgx_PeriodofBillingFullyReserve_label_en-US" xlink:label="lab_dgx_PeriodofBillingFullyReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of Billing Fully Reserve</link:label>
    <link:label id="lab_dgx_PeriodofBillingFullyReserve_documentation_en-US" xlink:label="lab_dgx_PeriodofBillingFullyReserve" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of Billing Fully Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_PeriodofBillingFullyReserve" xlink:href="dgx-20221231.xsd#dgx_PeriodofBillingFullyReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_PeriodofBillingFullyReserve" xlink:to="lab_dgx_PeriodofBillingFullyReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e9fc33b6-94df-4652-94bc-a1ce8f11905a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_RestatedDirectorLongTermIncentivePlanDltipMember_a9d2e9f2-4557-45b9-89d2-2fa312010c24_terseLabel_en-US" xlink:label="lab_dgx_RestatedDirectorLongTermIncentivePlanDltipMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restated Director Long-Term Incentive Plan (DLTIP)</link:label>
    <link:label id="lab_dgx_RestatedDirectorLongTermIncentivePlanDltipMember_label_en-US" xlink:label="lab_dgx_RestatedDirectorLongTermIncentivePlanDltipMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restated Director Long Term Incentive Plan Dltip [Member]</link:label>
    <link:label id="lab_dgx_RestatedDirectorLongTermIncentivePlanDltipMember_documentation_en-US" xlink:label="lab_dgx_RestatedDirectorLongTermIncentivePlanDltipMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restated Director Long-Term Incentive Plan (DLTIP) (Member)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_RestatedDirectorLongTermIncentivePlanDltipMember" xlink:href="dgx-20221231.xsd#dgx_RestatedDirectorLongTermIncentivePlanDltipMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_RestatedDirectorLongTermIncentivePlanDltipMember" xlink:to="lab_dgx_RestatedDirectorLongTermIncentivePlanDltipMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_febc3a95-bdc1-44df-9d17-fe00adf56370_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsAxis_417a101a-189f-4832-b69a-29e584b5f8ab_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsAxis" xlink:to="lab_us-gaap_SubsegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8a640419-d5d5-4b37-9ba7-7c0f55875b2a_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b5365ba6-6acf-4ad7-8f94-f7258f82ef72_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, value</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b729a58b-01fa-46db-af0e-0469887a95b0_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, value</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_f69bab03-d198-43fd-831f-697824c51979_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_TreasuryStockPurchasedbutNotyetPaid_d280b794-5cea-41fa-9f80-e8efd4da9e17_terseLabel_en-US" xlink:label="lab_dgx_TreasuryStockPurchasedbutNotyetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable associated with purchases of treasury stock</link:label>
    <link:label id="lab_dgx_TreasuryStockPurchasedbutNotyetPaid_label_en-US" xlink:label="lab_dgx_TreasuryStockPurchasedbutNotyetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Purchased but Not yet Paid</link:label>
    <link:label id="lab_dgx_TreasuryStockPurchasedbutNotyetPaid_documentation_en-US" xlink:label="lab_dgx_TreasuryStockPurchasedbutNotyetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Purchased but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_TreasuryStockPurchasedbutNotyetPaid" xlink:href="dgx-20221231.xsd#dgx_TreasuryStockPurchasedbutNotyetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_TreasuryStockPurchasedbutNotyetPaid" xlink:to="lab_dgx_TreasuryStockPurchasedbutNotyetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_bd16504f-8d03-40bc-86c3-5f9974cc2249_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_8b094b63-9197-4c6a-a563-715349df82f6_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_369ad125-0670-411b-83b8-f37efb261dd7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_83a0f1e1-1269-42a4-aa7e-d05d4f89cd09_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f39d64d1-f79b-40af-877f-762cbe26a263_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_c9cefaf2-07b2-41e9-a28c-321d29fd2638_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsMinorityInterest_5ba16a06-d2cc-4a45-81eb-4db67d644c13_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsMinorityInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions to noncontrolling interest partners</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsMinorityInterest_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsMinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsMinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsMinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsMinorityInterest" xlink:to="lab_us-gaap_PaymentsOfDividendsMinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_f91716a6-21e2-4750-8c19-1860911ff058_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_3dfc25f2-d67c-49a7-9f11-0af9e556c727_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesMember_3dc9027c-0cfa-4adb-9fed-f4f7a002e624_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesMember" xlink:to="lab_us-gaap_OtherLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_6e2e89dc-7daf-4953-a272-8e6796d888e6_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Excluding Goodwill</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_229b9101-6c8f-44ae-888a-209bed8b1bcb_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_bfa45141-4a52-4fef-94c5-c55dbc20f4f5_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_4f0f5673-34c6-4df3-a10d-a18a456cf6b3_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Comprehensive income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_37dffbc5-df00-4f91-abe6-945e498d3965_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred foreign income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_7085d9ce-dfbb-4c94-945c-17fcd0c2a075_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_ClientPayersMember_d3d66d71-467c-4523-8917-238f0a5d3668_terseLabel_en-US" xlink:label="lab_dgx_ClientPayersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client payers</link:label>
    <link:label id="lab_dgx_ClientPayersMember_label_en-US" xlink:label="lab_dgx_ClientPayersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client Payers [Member]</link:label>
    <link:label id="lab_dgx_ClientPayersMember_documentation_en-US" xlink:label="lab_dgx_ClientPayersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client Payers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ClientPayersMember" xlink:href="dgx-20221231.xsd#dgx_ClientPayersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_ClientPayersMember" xlink:to="lab_dgx_ClientPayersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_36902b98-9a48-48ae-a119-0de18c3dd055_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_07292a1b-c042-4a30-8f1e-e236bea2717e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bf5ae894-9101-4676-b4f1-92fd1c1ddf7f_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_948f3ed8-ef58-4502-8f96-5795d1e54423_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_2f1bf959-c85f-4130-83ca-aebcfdc521e0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BUSINESS ACQUISITIONS</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_2b6c5d52-f250-4376-8bae-7a66c34ff979_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_37699edd-1905-45d8-a27c-b375d5be83e8_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0fc72ad5-0c71-4d96-8965-9be8dd8efd92_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_41c00435-6719-4b7b-9ed6-0256f5c14c27_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_0a27f79d-ab6c-47ca-a439-34798726e9fc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TAXES ON INCOME</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_526c637f-8b51-4083-ac02-dc5abeb81748_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_80134b43-2580-4968-b86e-e3e95d33514b_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, gross excluding goodwill</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFour_8e21bbee-5fcf-431a-9aa0-9d2c4a4b9079_totalLabel_en-US" xlink:label="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating and Finance Lease, Liability, Payments, Due Year Four</link:label>
    <link:label id="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFour_documentation_en-US" xlink:label="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating and Finance Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="dgx-20221231.xsd#dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_02c197a8-4c87-41e9-858f-a87154cf4413_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFiniteLivedIntangibles1_cafb182a-b020-44c6-bf9e-824ea48f7e20_terseLabel_en-US" xlink:label="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFiniteLivedIntangibles1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangibles</link:label>
    <link:label id="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFiniteLivedIntangibles1_label_en-US" xlink:label="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFiniteLivedIntangibles1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles1</link:label>
    <link:label id="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFiniteLivedIntangibles1_documentation_en-US" xlink:label="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFiniteLivedIntangibles1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFiniteLivedIntangibles1" xlink:href="dgx-20221231.xsd#dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFiniteLivedIntangibles1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFiniteLivedIntangibles1" xlink:to="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFiniteLivedIntangibles1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_e9db3a0f-da08-4499-b2db-a2d8ab30053e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of shares vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_ContingentConsiderationMember_0f245ab6-8ab4-4cc3-a936-19d161a13364_terseLabel_en-US" xlink:label="lab_dgx_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_dgx_ContingentConsiderationMember_label_en-US" xlink:label="lab_dgx_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration [Member]</link:label>
    <link:label id="lab_dgx_ContingentConsiderationMember_documentation_en-US" xlink:label="lab_dgx_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ContingentConsiderationMember" xlink:href="dgx-20221231.xsd#dgx_ContingentConsiderationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_ContingentConsiderationMember" xlink:to="lab_dgx_ContingentConsiderationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_b3bafdf2-72b6-4c37-89f2-73c35e701e73_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_55d29031-1ef3-450e-b6fb-3cce589f143c_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_53d0a182-9f01-4238-bc92-5d1d93dba106_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_6872fbdd-e5c7-44b4-b49d-f9b7786b3a11_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ad472bce-92f3-419e-8c52-7ba5f50d9960_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_91fc2820-55ed-44e2-901a-835181a90dac_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_b837bd7d-bbbb-403f-8ec0-e567617ae174_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_b809b531-c647-4622-867a-fff1db382990_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_cf2c2fef-0d63-4bd8-922f-b679e39caf8f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of maximum annual wages witheld for the ESPP</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_LeaseRemainingLeaseTerm_8ce1fe0d-bec3-4552-89dd-bfa182269c6f_terseLabel_en-US" xlink:label="lab_dgx_LeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease term</link:label>
    <link:label id="lab_dgx_LeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_dgx_LeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Remaining Lease Term</link:label>
    <link:label id="lab_dgx_LeaseRemainingLeaseTerm_documentation_en-US" xlink:label="lab_dgx_LeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LeaseRemainingLeaseTerm" xlink:href="dgx-20221231.xsd#dgx_LeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_LeaseRemainingLeaseTerm" xlink:to="lab_dgx_LeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_b8a66739-8908-419c-a5e9-3c37c60d191e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under benefit plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_825bf89e-f6d9-49c0-89d2-02e8629dd4e9_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_2bd12b34-34e3-48c7-b5ef-c727e3c58db3_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_10d7d71e-3960-4554-b541-9217b789edeb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes on Income</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_BlueprintGeneticsOyMember_068867d5-1aed-4bb1-ab7c-ba917fabaf55_terseLabel_en-US" xlink:label="lab_dgx_BlueprintGeneticsOyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blueprint Genetics Oy</link:label>
    <link:label id="lab_dgx_BlueprintGeneticsOyMember_label_en-US" xlink:label="lab_dgx_BlueprintGeneticsOyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blueprint Genetics Oy [Member]</link:label>
    <link:label id="lab_dgx_BlueprintGeneticsOyMember_documentation_en-US" xlink:label="lab_dgx_BlueprintGeneticsOyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blueprint Genetics Oy [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_BlueprintGeneticsOyMember" xlink:href="dgx-20221231.xsd#dgx_BlueprintGeneticsOyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_BlueprintGeneticsOyMember" xlink:to="lab_dgx_BlueprintGeneticsOyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_b25d4566-d508-43ef-86ed-af94bf4eff12_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_FairValueOfNetAssetsAcquired_ee9786f5-dcf3-474f-9d82-cb386a5ad152_totalLabel_en-US" xlink:label="lab_dgx_FairValueOfNetAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of net assets acquired</link:label>
    <link:label id="lab_dgx_FairValueOfNetAssetsAcquired_label_en-US" xlink:label="lab_dgx_FairValueOfNetAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of net assets acquired</link:label>
    <link:label id="lab_dgx_FairValueOfNetAssetsAcquired_documentation_en-US" xlink:label="lab_dgx_FairValueOfNetAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of net assets acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_FairValueOfNetAssetsAcquired" xlink:href="dgx-20221231.xsd#dgx_FairValueOfNetAssetsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_FairValueOfNetAssetsAcquired" xlink:to="lab_dgx_FairValueOfNetAssetsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0b8d0320-a419-44b1-b5af-5a420505213c_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_b81e690d-63ed-421a-8530-cb56b85446cb_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_7f0ad771-c6ef-4831-a4b2-e886890bff0a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2f64304b-cb30-44df-9aa6-e4886650c4ba_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, end of year weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueafterYearFive_c51f41ab-e37c-4b0b-888d-71aa90807b02_totalLabel_en-US" xlink:label="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueafterYearFive" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueafterYearFive_label_en-US" xlink:label="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueafterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating and Finance Lease, Liability, Payments, Due after Year Five</link:label>
    <link:label id="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueafterYearFive_documentation_en-US" xlink:label="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueafterYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating and Finance Lease, Liability, Payments, Due after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueafterYearFive" xlink:href="dgx-20221231.xsd#dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueafterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueafterYearFive" xlink:to="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueafterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_7861a9e4-1ef3-4ea1-8e30-e6b54c06d64a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_25558051-570a-4adf-becd-a614c8ac48be_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_ecf25bf0-71d4-45fe-a7e4-75d3ee3caab6_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing cash flows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfAssetsAcquired_ab1fa6e0-babd-405d-8e27-b9331b064a9f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets acquired</link:label>
    <link:label id="lab_us-gaap_FairValueOfAssetsAcquired_label_en-US" xlink:label="lab_us-gaap_FairValueOfAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfAssetsAcquired" xlink:to="lab_us-gaap_FairValueOfAssetsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_TerminationOfInterestRateSwapAgreements_45ae8231-737a-404d-82d7-8f7baa8e78da_terseLabel_en-US" xlink:label="lab_dgx_TerminationOfInterestRateSwapAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination of interest rate swap agreements</link:label>
    <link:label id="lab_dgx_TerminationOfInterestRateSwapAgreements_label_en-US" xlink:label="lab_dgx_TerminationOfInterestRateSwapAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination Of Interest Rate Swap Agreements</link:label>
    <link:label id="lab_dgx_TerminationOfInterestRateSwapAgreements_documentation_en-US" xlink:label="lab_dgx_TerminationOfInterestRateSwapAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination Of Interest Rate Swap Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_TerminationOfInterestRateSwapAgreements" xlink:href="dgx-20221231.xsd#dgx_TerminationOfInterestRateSwapAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_TerminationOfInterestRateSwapAgreements" xlink:to="lab_dgx_TerminationOfInterestRateSwapAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_292f2c4a-8178-498f-a690-25e9cf1ee51f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_4064ebb8-5cb9-4941-835c-5a76b15533f3_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes payable, current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_MidAmericaClinicalLaboratoriesLLCMACLMember_b2fcf92e-dd38-4521-ad2c-4d69522a509a_terseLabel_en-US" xlink:label="lab_dgx_MidAmericaClinicalLaboratoriesLLCMACLMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mid America Clinical Laboratories, LLC (MACL)</link:label>
    <link:label id="lab_dgx_MidAmericaClinicalLaboratoriesLLCMACLMember_label_en-US" xlink:label="lab_dgx_MidAmericaClinicalLaboratoriesLLCMACLMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mid America Clinical Laboratories, LLC (MACL) [Member]</link:label>
    <link:label id="lab_dgx_MidAmericaClinicalLaboratoriesLLCMACLMember_documentation_en-US" xlink:label="lab_dgx_MidAmericaClinicalLaboratoriesLLCMACLMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mid America Clinical Laboratories, LLC (MACL)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_MidAmericaClinicalLaboratoriesLLCMACLMember" xlink:href="dgx-20221231.xsd#dgx_MidAmericaClinicalLaboratoriesLLCMACLMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_MidAmericaClinicalLaboratoriesLLCMACLMember" xlink:to="lab_dgx_MidAmericaClinicalLaboratoriesLLCMACLMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_a64eb4f3-ebec-43e4-80ac-36ec12e9c8ea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, end of year weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_LaboratoryEquipmentFurnitureAndFixturesMember_7e3729ce-3f30-4d1b-a821-12f15745fc4b_terseLabel_en-US" xlink:label="lab_dgx_LaboratoryEquipmentFurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment, Furniture and Fixtures</link:label>
    <link:label id="lab_dgx_LaboratoryEquipmentFurnitureAndFixturesMember_label_en-US" xlink:label="lab_dgx_LaboratoryEquipmentFurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment, Furniture and Fixtures [Member]</link:label>
    <link:label id="lab_dgx_LaboratoryEquipmentFurnitureAndFixturesMember_documentation_en-US" xlink:label="lab_dgx_LaboratoryEquipmentFurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment, Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LaboratoryEquipmentFurnitureAndFixturesMember" xlink:href="dgx-20221231.xsd#dgx_LaboratoryEquipmentFurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_LaboratoryEquipmentFurnitureAndFixturesMember" xlink:to="lab_dgx_LaboratoryEquipmentFurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_SixPointNineFivePercentSeniorNotesDue2037Member_c83d9004-354b-49b2-a476-b21de5c5dd74_terseLabel_en-US" xlink:label="lab_dgx_SixPointNineFivePercentSeniorNotesDue2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.95% Senior Notes due July 2037</link:label>
    <link:label id="lab_dgx_SixPointNineFivePercentSeniorNotesDue2037Member_label_en-US" xlink:label="lab_dgx_SixPointNineFivePercentSeniorNotesDue2037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Nine Five Percent Senior Notes Due2037 [Member]</link:label>
    <link:label id="lab_dgx_SixPointNineFivePercentSeniorNotesDue2037Member_documentation_en-US" xlink:label="lab_dgx_SixPointNineFivePercentSeniorNotesDue2037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Nine Five Percent Senior Notes Due 2037 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_SixPointNineFivePercentSeniorNotesDue2037Member" xlink:href="dgx-20221231.xsd#dgx_SixPointNineFivePercentSeniorNotesDue2037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_SixPointNineFivePercentSeniorNotesDue2037Member" xlink:to="lab_dgx_SixPointNineFivePercentSeniorNotesDue2037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_ReductionsForChangesInJudgment_ef4ce991-aac2-4b0e-a511-9dd350676bb4_negatedTerseLabel_en-US" xlink:label="lab_dgx_ReductionsForChangesInJudgment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions for changes in judgment</link:label>
    <link:label id="lab_dgx_ReductionsForChangesInJudgment_label_en-US" xlink:label="lab_dgx_ReductionsForChangesInJudgment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions for changes in judgment</link:label>
    <link:label id="lab_dgx_ReductionsForChangesInJudgment_documentation_en-US" xlink:label="lab_dgx_ReductionsForChangesInJudgment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The gross amount of decreases in unrecognized tax benefits resulting from changes in judgment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ReductionsForChangesInJudgment" xlink:href="dgx-20221231.xsd#dgx_ReductionsForChangesInJudgment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_ReductionsForChangesInJudgment" xlink:to="lab_dgx_ReductionsForChangesInJudgment" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_AnatomicpathologytestingservicesMember_202a8935-024d-43e0-b944-43d3b13e19a8_terseLabel_en-US" xlink:label="lab_dgx_AnatomicpathologytestingservicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anatomic pathology testing services</link:label>
    <link:label id="lab_dgx_AnatomicpathologytestingservicesMember_label_en-US" xlink:label="lab_dgx_AnatomicpathologytestingservicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anatomic pathology testing services [Member]</link:label>
    <link:label id="lab_dgx_AnatomicpathologytestingservicesMember_documentation_en-US" xlink:label="lab_dgx_AnatomicpathologytestingservicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anatomic pathology testing services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_AnatomicpathologytestingservicesMember" xlink:href="dgx-20221231.xsd#dgx_AnatomicpathologytestingservicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_AnatomicpathologytestingservicesMember" xlink:to="lab_dgx_AnatomicpathologytestingservicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_817be20b-ec31-4419-9ebb-d88fdb9403b2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_a9889abd-ac19-44b6-b9ca-86c15d950d5c_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without readily determinable fair value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_567d9cbb-8724-46f7-8e7a-6798338da8d6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_c26b1760-3b29-45bc-b0bf-793cef33d911_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_3039b6ad-f862-4174-baca-dd18ca6d656b_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_5b84103d-10c5-47ec-82f1-34b09250a6a7_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_43b61211-400c-4057-8b94-c1b40d9fc3a1_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, balance at beginning of year</link:label>
    <link:label id="lab_us-gaap_Goodwill_f92da0e4-e503-4aae-8006-4a8aea0a536d_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, balance at end of year</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidTaxes_9b9ddade-209a-4ce5-ab73-c2a9a38abbdc_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid taxes</link:label>
    <link:label id="lab_us-gaap_PrepaidTaxes_label_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidTaxes" xlink:to="lab_us-gaap_PrepaidTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_9a49bd55-7419-4cc5-86b2-a9d6ea6a2db6_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_200916ae-7a17-444d-9698-a711978c0018_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_14e2f23d-5bfe-40da-9fec-a75d2a507ec7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_735bf169-15d9-4d45-ae2b-dd3857bafcdd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_32072a03-3bb2-404a-a535-c76440144862_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_17706a8b-5173-43a9-995a-59b29228ee91_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_cdccc2e7-cc6d-421b-8fe7-9029d65a25ec_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5b4c037a-8132-4e2a-93ef-ab7c67b2cb44_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_98e403d0-5503-4768-bf49-0b2d46068485_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_f37b3641-6bb8-4a18-a7ad-d5fd3ae653af_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_FourPointTwoZeroPercentSeniorNotesdueJune2029Member_10407fda-4481-48ee-a6f3-4fe5bfe14487_terseLabel_en-US" xlink:label="lab_dgx_FourPointTwoZeroPercentSeniorNotesdueJune2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.20% Senior Notes due June 2029</link:label>
    <link:label id="lab_dgx_FourPointTwoZeroPercentSeniorNotesdueJune2029Member_label_en-US" xlink:label="lab_dgx_FourPointTwoZeroPercentSeniorNotesdueJune2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Two Zero Percent Senior Notes due June 2029 [Member]</link:label>
    <link:label id="lab_dgx_FourPointTwoZeroPercentSeniorNotesdueJune2029Member_documentation_en-US" xlink:label="lab_dgx_FourPointTwoZeroPercentSeniorNotesdueJune2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Two Zero Percent Senior Notes due June 2029 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_FourPointTwoZeroPercentSeniorNotesdueJune2029Member" xlink:href="dgx-20221231.xsd#dgx_FourPointTwoZeroPercentSeniorNotesdueJune2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_FourPointTwoZeroPercentSeniorNotesdueJune2029Member" xlink:to="lab_dgx_FourPointTwoZeroPercentSeniorNotesdueJune2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4dfbea52-d08a-4087-b8af-73cc0595aa0f_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_18d73ac1-463e-4e08-b334-9604fe8f5399_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAssumed1_55714cc9-36eb-45f1-974d-c4337440b6b6_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of liabilities assumed</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAssumed1" xlink:to="lab_us-gaap_LiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_fbfc4971-9518-46cd-a039-57a3589b6b67_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_f34b6232-3c51-4f71-b132-70f94749ac38_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_68a0bfc1-fcbb-4447-83f3-df0ff2ac053f_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_SummaryOfSignificantAccountingPoliciesLineItems_385ff6cf-2755-4255-bcdd-1afc69662ad3_terseLabel_en-US" xlink:label="lab_dgx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_dgx_SummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_dgx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_dgx_SummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_dgx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of significant accounting policies Line Items</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:href="dgx-20221231.xsd#dgx_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_dgx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_4b7ba169-c4f4-4eba-bc5b-e581f044a202_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value $0.01 per share; 600 shares authorized as of both December&#160;31, 2022 and 2021; 162 shares issued as of both December&#160;31, 2022 and 2021</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesTable_c509dea6-301c-4748-9832-e28b75ab9905_terseLabel_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases [Table]</link:label>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesTable_label_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcceleratedShareRepurchasesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesTable" xlink:to="lab_us-gaap_AcceleratedShareRepurchasesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_49e5a62b-53d9-4f3a-a078-e144e38833a9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_cd1cd2f8-e4f7-474c-babd-7146243a6354_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_c361d8da-13b9-47b7-a4eb-274a28907bef_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_TotalAmortizingIntangibleAssetsMember_790afb78-8169-4922-a9cf-5322da8cf78a_terseLabel_en-US" xlink:label="lab_dgx_TotalAmortizingIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Amortizing Intangible Assets</link:label>
    <link:label id="lab_dgx_TotalAmortizingIntangibleAssetsMember_label_en-US" xlink:label="lab_dgx_TotalAmortizingIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Amortizing Intangible Assets [Member]</link:label>
    <link:label id="lab_dgx_TotalAmortizingIntangibleAssetsMember_documentation_en-US" xlink:label="lab_dgx_TotalAmortizingIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Amortizing Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_TotalAmortizingIntangibleAssetsMember" xlink:href="dgx-20221231.xsd#dgx_TotalAmortizingIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_TotalAmortizingIntangibleAssetsMember" xlink:to="lab_dgx_TotalAmortizingIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_2ef734e8-4144-4130-a4e1-2b439dbabbba_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating expense (income), net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_a3143e50-c53a-4e21-8369-3c64d36b86c8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_ShorttermLeaseandVariableLeaseCost_6bb0c3c0-c47a-4a12-b0b1-ab414d277913_terseLabel_en-US" xlink:label="lab_dgx_ShorttermLeaseandVariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term leases and variable lease costs</link:label>
    <link:label id="lab_dgx_ShorttermLeaseandVariableLeaseCost_label_en-US" xlink:label="lab_dgx_ShorttermLeaseandVariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease and Variable Lease, Cost</link:label>
    <link:label id="lab_dgx_ShorttermLeaseandVariableLeaseCost_documentation_en-US" xlink:label="lab_dgx_ShorttermLeaseandVariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease and Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ShorttermLeaseandVariableLeaseCost" xlink:href="dgx-20221231.xsd#dgx_ShorttermLeaseandVariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_ShorttermLeaseandVariableLeaseCost" xlink:to="lab_dgx_ShorttermLeaseandVariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6403c23b-c12f-4e94-9b13-00313039ecd4_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash, beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1247fa5f-a3b5-4cac-85c0-28896e8f4d05_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash, end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_f2541488-903d-40c0-a943-177f3d4bbc4f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_5b22b524-aa5e-4774-8059-f6eb879dd7c6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from continuing operations - foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_e6fc5d67-6c74-4a1f-982f-d7068245684a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_fdb7fa2d-5959-4c1e-8fc4-0bf9f1f8dcb1_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings available to Quest Diagnostics&#8217; common stockholders &#8211; basic and diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_150c09ee-0058-408a-94a2-85aa12735580_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, end of year weighted average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_PatientMember_b6e9f000-1ede-4b2e-b9fd-b2a26a6d13c8_terseLabel_en-US" xlink:label="lab_dgx_PatientMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patients (including coinsurance and deductible responsibilities)</link:label>
    <link:label id="lab_dgx_PatientMember_label_en-US" xlink:label="lab_dgx_PatientMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient [Member]</link:label>
    <link:label id="lab_dgx_PatientMember_documentation_en-US" xlink:label="lab_dgx_PatientMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_PatientMember" xlink:href="dgx-20221231.xsd#dgx_PatientMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_PatientMember" xlink:to="lab_dgx_PatientMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_91f8a833-883a-45e6-9b43-f6f8107d1b61_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_87d82d43-3391-471b-9651-52c5670f6a59_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended company match percentage of employee contributions</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_b7ae706a-6c24-4560-88a3-2dab8a1623f0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f1ffa95c-0c6a-424e-9c05-b1eda293b7c7_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e3b29510-252e-4a2f-9745-fac9a80ba318_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible asset, useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_427e116c-a1ba-4941-8b8b-ea9258b38d13_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average amortization period</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueHedgingMember_966c989f-494b-48cb-9311-763ee37eac3f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_OtherIncomeExpenseMember_30cbac10-3047-48cc-80ae-d3bd98a1a419_terseLabel_en-US" xlink:label="lab_dgx_OtherIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income (Expense)</link:label>
    <link:label id="lab_dgx_OtherIncomeExpenseMember_label_en-US" xlink:label="lab_dgx_OtherIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income (Expense) [Member]</link:label>
    <link:label id="lab_dgx_OtherIncomeExpenseMember_documentation_en-US" xlink:label="lab_dgx_OtherIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_OtherIncomeExpenseMember" xlink:href="dgx-20221231.xsd#dgx_OtherIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_OtherIncomeExpenseMember" xlink:to="lab_dgx_OtherIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_fc5431d7-0d13-47f4-8f3a-fd8aab88bf78_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e4c92532-b981-46ed-a683-274c1811f26a_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_77eb0338-ece6-486c-8590-86e618ceb10f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net current period other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeLongTermGrowthRateUsedToDetermineFairValue_fdcae7ef-f6d1-4a47-9673-34e0139dbf1e_terseLabel_en-US" xlink:label="lab_dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeLongTermGrowthRateUsedToDetermineFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity interest in acquiree, long-term growth rate used to determine fair value</link:label>
    <link:label id="lab_dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeLongTermGrowthRateUsedToDetermineFairValue_label_en-US" xlink:label="lab_dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeLongTermGrowthRateUsedToDetermineFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Long-term Growth Rate used to determine fair value</link:label>
    <link:label id="lab_dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeLongTermGrowthRateUsedToDetermineFairValue_documentation_en-US" xlink:label="lab_dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeLongTermGrowthRateUsedToDetermineFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Long-term Growth Rate used to determine fair value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeLongTermGrowthRateUsedToDetermineFairValue" xlink:href="dgx-20221231.xsd#dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeLongTermGrowthRateUsedToDetermineFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeLongTermGrowthRateUsedToDetermineFairValue" xlink:to="lab_dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeLongTermGrowthRateUsedToDetermineFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_037d5048-168a-46a6-8987-621fd6806482_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill acquired during the year</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_efee56f3-a7d0-4687-94d9-6ca714572282_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_187739de-2d8f-4df1-b85d-43ea7047ae4e_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_ee49365f-225f-432a-a5ca-ffca67b24b51_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MalpracticeLossContingencyAccrualUndiscounted_cfdd2c3f-c8ea-43fe-a491-80dbbb1e6a16_terseLabel_en-US" xlink:label="lab_us-gaap_MalpracticeLossContingencyAccrualUndiscounted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self-insurance reserves</link:label>
    <link:label id="lab_us-gaap_MalpracticeLossContingencyAccrualUndiscounted_label_en-US" xlink:label="lab_us-gaap_MalpracticeLossContingencyAccrualUndiscounted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Malpractice Loss Contingency, Accrual, Undiscounted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscounted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscounted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscounted" xlink:to="lab_us-gaap_MalpracticeLossContingencyAccrualUndiscounted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b8129aa8-18fb-41c5-993c-df80ecbe32bc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, end of year shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_20c2f621-e3f1-40dc-bd32-c717dde565ea_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_f9445b5e-2066-4bf9-9db1-7eb2bd85f8f2_totalLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_3a1b22ba-f217-4cf3-b29d-81aa208f1a2c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_52773995-9617-438d-8ad4-f89158b2465e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangibles</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_59b84b22-74bb-40dd-92a8-d96f8fe4c2bb_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_302c0a57-fb63-48f9-a2eb-70f79a5d6d3a_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUPPLEMENTAL CASH FLOW AND OTHER DATA</link:label>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Supplemental Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_788fadee-49e9-463e-a47b-ea334e5c7208_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_FinanceLeaseObligationsandOtherMember_638114b9-c2ee-49c0-b426-7ed57334b066_verboseLabel_en-US" xlink:label="lab_dgx_FinanceLeaseObligationsandOtherMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_dgx_FinanceLeaseObligationsandOtherMember_49ca5e3f-70ed-42f5-badd-d3759071bcba_terseLabel_en-US" xlink:label="lab_dgx_FinanceLeaseObligationsandOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_dgx_FinanceLeaseObligationsandOtherMember_label_en-US" xlink:label="lab_dgx_FinanceLeaseObligationsandOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease Obligations and Other [Member]</link:label>
    <link:label id="lab_dgx_FinanceLeaseObligationsandOtherMember_documentation_en-US" xlink:label="lab_dgx_FinanceLeaseObligationsandOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease Obligations and Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_FinanceLeaseObligationsandOtherMember" xlink:href="dgx-20221231.xsd#dgx_FinanceLeaseObligationsandOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_FinanceLeaseObligationsandOtherMember" xlink:to="lab_dgx_FinanceLeaseObligationsandOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_e129c61d-6400-4d8a-a543-04353a158e43_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost; 51 and 43 shares as of December&#160;31, 2022 and 2021, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMember_e6e84631-88dc-4905-9531-7611660095f2_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMember_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMember" xlink:to="lab_us-gaap_LongTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7e94c587-f208-46fc-8119-8d7642f3847c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_992c8616-b7f2-43e1-a683-5f3440105426_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_fdd8c788-a0dd-4da8-ba5f-db85e5159838_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options, value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_6773b5c1-f0f5-4558-a989-b423fdaacd93_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in available-for-sale debt securities, net of taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_EmployeeLongTermIncentivePlanEltipMember_cf8ed248-92d6-426c-b04b-13445382a796_terseLabel_en-US" xlink:label="lab_dgx_EmployeeLongTermIncentivePlanEltipMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Long Term Incentive Plan ELTIP</link:label>
    <link:label id="lab_dgx_EmployeeLongTermIncentivePlanEltipMember_label_en-US" xlink:label="lab_dgx_EmployeeLongTermIncentivePlanEltipMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Long Term Incentive Plan Eltip [Member]</link:label>
    <link:label id="lab_dgx_EmployeeLongTermIncentivePlanEltipMember_documentation_en-US" xlink:label="lab_dgx_EmployeeLongTermIncentivePlanEltipMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Long-Term Incentive Plan (ELTIP) (Member)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_EmployeeLongTermIncentivePlanEltipMember" xlink:href="dgx-20221231.xsd#dgx_EmployeeLongTermIncentivePlanEltipMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_EmployeeLongTermIncentivePlanEltipMember" xlink:to="lab_dgx_EmployeeLongTermIncentivePlanEltipMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_57acee5f-fd9d-49ca-931f-688ed48e325f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_5a6e1e57-a31f-4eb1-b173-f68ad5762df5_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_96b0482f-8888-4d02-9427-50eabcabe4da_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_096309a8-1227-4e5c-b92e-b12d7690b6b9_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_ProceedsFromSaleOfEquityMethodInvestmentsGross_d0717cf3-ed9f-4cb1-a236-d66abb9795b9_terseLabel_en-US" xlink:label="lab_dgx_ProceedsFromSaleOfEquityMethodInvestmentsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds from disposition of joint venture</link:label>
    <link:label id="lab_dgx_ProceedsFromSaleOfEquityMethodInvestmentsGross_label_en-US" xlink:label="lab_dgx_ProceedsFromSaleOfEquityMethodInvestmentsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Equity Method Investments, Gross</link:label>
    <link:label id="lab_dgx_ProceedsFromSaleOfEquityMethodInvestmentsGross_documentation_en-US" xlink:label="lab_dgx_ProceedsFromSaleOfEquityMethodInvestmentsGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Equity Method Investments, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ProceedsFromSaleOfEquityMethodInvestmentsGross" xlink:href="dgx-20221231.xsd#dgx_ProceedsFromSaleOfEquityMethodInvestmentsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_ProceedsFromSaleOfEquityMethodInvestmentsGross" xlink:to="lab_dgx_ProceedsFromSaleOfEquityMethodInvestmentsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_SeniorunsecuredrevolvingcreditfacilityMember_b9662341-58cf-49fa-b57d-a45f5ae583a3_terseLabel_en-US" xlink:label="lab_dgx_SeniorunsecuredrevolvingcreditfacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior unsecured revolving credit facility</link:label>
    <link:label id="lab_dgx_SeniorunsecuredrevolvingcreditfacilityMember_label_en-US" xlink:label="lab_dgx_SeniorunsecuredrevolvingcreditfacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior unsecured revolving credit facility [Member]</link:label>
    <link:label id="lab_dgx_SeniorunsecuredrevolvingcreditfacilityMember_documentation_en-US" xlink:label="lab_dgx_SeniorunsecuredrevolvingcreditfacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior unsecured revolving credit facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_SeniorunsecuredrevolvingcreditfacilityMember" xlink:href="dgx-20221231.xsd#dgx_SeniorunsecuredrevolvingcreditfacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_SeniorunsecuredrevolvingcreditfacilityMember" xlink:to="lab_dgx_SeniorunsecuredrevolvingcreditfacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4a7b4578-bd9b-44ce-9dc6-9274cdc1f9ac_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_a56164d9-482e-471b-86c3-111d2a1a51ec_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_f8eea859-b2eb-4583-a9c4-8854a767be84_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading equity securities gain or (loss)</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_93b3921e-3c53-4904-846c-945a07a9c79b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_155af320-f309-40d3-a1f9-ccf3a77d2202_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_97ac82fd-fa87-498d-80a7-eb1a3075ad0f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY AND REDEEMABLE NONCONTROLLING INTEREST</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_f62c8beb-c4e9-4c2c-8925-3c016aed5f7c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow and Other Data</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_39bf74d8-ffb4-468b-8649-b09c7b6b7797_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit related to stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLongTermDebt_c2d222f2-7048-459e-b3f8-a126367d49f8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherLongTermDebt_label_en-US" xlink:label="lab_us-gaap_OtherLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermDebt" xlink:to="lab_us-gaap_OtherLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_d56c3f69-c3d4-4eee-992f-98190e1dd468_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_597007f1-e2f5-4af0-9ca4-388c82671fe8_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_57ad84c1-53a2-4bc4-a473-e593de227e8d_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_1de8ca3b-19af-4284-95e2-0ae5a600a468_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage by noncontrolling owners</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_SupplementalDeferredCompensationPlanVariableIncentiveCompensationDeferral_ff41fba3-f340-4674-8a53-391d000652f8_terseLabel_en-US" xlink:label="lab_dgx_SupplementalDeferredCompensationPlanVariableIncentiveCompensationDeferral" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SDCP variable incentive compensation deferral</link:label>
    <link:label id="lab_dgx_SupplementalDeferredCompensationPlanVariableIncentiveCompensationDeferral_label_en-US" xlink:label="lab_dgx_SupplementalDeferredCompensationPlanVariableIncentiveCompensationDeferral" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Deferred Compensation Plan Variable Incentive Compensation Deferral</link:label>
    <link:label id="lab_dgx_SupplementalDeferredCompensationPlanVariableIncentiveCompensationDeferral_documentation_en-US" xlink:label="lab_dgx_SupplementalDeferredCompensationPlanVariableIncentiveCompensationDeferral" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferral percentage of the variable incentive compensation under the Supplemental Deferred Compensation Plan. The plan is an unfunded, non-qualified plan that provides for certain management and highly compensated eligible employees to defer up to this percentage of their variable incentive compensation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_SupplementalDeferredCompensationPlanVariableIncentiveCompensationDeferral" xlink:href="dgx-20221231.xsd#dgx_SupplementalDeferredCompensationPlanVariableIncentiveCompensationDeferral"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_SupplementalDeferredCompensationPlanVariableIncentiveCompensationDeferral" xlink:to="lab_dgx_SupplementalDeferredCompensationPlanVariableIncentiveCompensationDeferral" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_43779e92-7752-48db-a2b1-d85261fb0b5f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_e5f73b45-cad2-4bc4-a8a0-a55ffa0e2411_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_6622e388-161f-4bf4-90ca-cbbdb275044a_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BUSINESS SEGMENT INFORMATION</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_445a52b5-eb01-40a6-a5f6-93c3a3d5f84e_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_06593c9a-0d04-4482-ae03-8fd5662bf17c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_03478369-5294-48e1-9e47-1e64769fd17b_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligation</link:label>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_label_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:to="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_731c9f30-dbc5-426f-a8df-94dc0e205915_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_76a2cde5-9fb6-4a86-8b24-2da96a49ecb9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited and cancelled weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_DeferredTaxLiabilityInvestmentsInvestmentsinSubsidiariesandEquitymethodinvestments_b694324d-adb5-45fb-a5ae-3533614b53ed_negatedTerseLabel_en-US" xlink:label="lab_dgx_DeferredTaxLiabilityInvestmentsInvestmentsinSubsidiariesandEquitymethodinvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis differences in investments, joint ventures and subsidiaries</link:label>
    <link:label id="lab_dgx_DeferredTaxLiabilityInvestmentsInvestmentsinSubsidiariesandEquitymethodinvestments_label_en-US" xlink:label="lab_dgx_DeferredTaxLiabilityInvestmentsInvestmentsinSubsidiariesandEquitymethodinvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liability, Investments, Investments in Subsidiaries and Equity method investments</link:label>
    <link:label id="lab_dgx_DeferredTaxLiabilityInvestmentsInvestmentsinSubsidiariesandEquitymethodinvestments_documentation_en-US" xlink:label="lab_dgx_DeferredTaxLiabilityInvestmentsInvestmentsinSubsidiariesandEquitymethodinvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liability, Investments, Investments in Subsidiaries and Equity method investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_DeferredTaxLiabilityInvestmentsInvestmentsinSubsidiariesandEquitymethodinvestments" xlink:href="dgx-20221231.xsd#dgx_DeferredTaxLiabilityInvestmentsInvestmentsinSubsidiariesandEquitymethodinvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_DeferredTaxLiabilityInvestmentsInvestmentsinSubsidiariesandEquitymethodinvestments" xlink:to="lab_dgx_DeferredTaxLiabilityInvestmentsInvestmentsinSubsidiariesandEquitymethodinvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders_f785f7df-7135-47b1-95be-f563fb38871d_negatedTerseLabel_en-US" xlink:label="lab_dgx_TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions to noncontrolling interest partners</link:label>
    <link:label id="lab_dgx_TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders_label_en-US" xlink:label="lab_dgx_TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity, Noncontrolling interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:label id="lab_dgx_TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders_documentation_en-US" xlink:label="lab_dgx_TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity, Noncontrolling interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders" xlink:href="dgx-20221231.xsd#dgx_TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders" xlink:to="lab_dgx_TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_07303a21-6dae-487c-968a-88c121717506_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_CommercialPaperAndTermSecuredOvernightFinancingRateMember_cece269f-2c49-4465-bf03-58c0ba51acc2_terseLabel_en-US" xlink:label="lab_dgx_CommercialPaperAndTermSecuredOvernightFinancingRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper and Term Secured Overnight Financing Rate</link:label>
    <link:label id="lab_dgx_CommercialPaperAndTermSecuredOvernightFinancingRateMember_label_en-US" xlink:label="lab_dgx_CommercialPaperAndTermSecuredOvernightFinancingRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper and Term Secured Overnight Financing Rate [Member]</link:label>
    <link:label id="lab_dgx_CommercialPaperAndTermSecuredOvernightFinancingRateMember_documentation_en-US" xlink:label="lab_dgx_CommercialPaperAndTermSecuredOvernightFinancingRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper and Term Secured Overnight Financing Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_CommercialPaperAndTermSecuredOvernightFinancingRateMember" xlink:href="dgx-20221231.xsd#dgx_CommercialPaperAndTermSecuredOvernightFinancingRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_CommercialPaperAndTermSecuredOvernightFinancingRateMember" xlink:to="lab_dgx_CommercialPaperAndTermSecuredOvernightFinancingRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_FivePointSevenFivePercentSeniorNotesDue2040Member_097e676c-c2e8-4cc7-8d33-b31a150f22b3_terseLabel_en-US" xlink:label="lab_dgx_FivePointSevenFivePercentSeniorNotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.75% Senior Notes due January 2040</link:label>
    <link:label id="lab_dgx_FivePointSevenFivePercentSeniorNotesDue2040Member_label_en-US" xlink:label="lab_dgx_FivePointSevenFivePercentSeniorNotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Seven Five Percent Senior Notes Due2040 [Member]</link:label>
    <link:label id="lab_dgx_FivePointSevenFivePercentSeniorNotesDue2040Member_documentation_en-US" xlink:label="lab_dgx_FivePointSevenFivePercentSeniorNotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Seven Five Percent Senior Notes Due 2040 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_FivePointSevenFivePercentSeniorNotesDue2040Member" xlink:href="dgx-20221231.xsd#dgx_FivePointSevenFivePercentSeniorNotesDue2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_FivePointSevenFivePercentSeniorNotesDue2040Member" xlink:to="lab_dgx_FivePointSevenFivePercentSeniorNotesDue2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_4aef33a6-fac1-4d57-b96b-5807b52b22d1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_d633b302-ebe7-4fb3-9a92-504a7e1e474c_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_60df827f-60fd-48e6-b01c-1a812c1da194_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, end of year aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_LongTermDebtMaturitiesGross_e03255be-9585-42cf-86a5-d388c9fbd25c_totalLabel_en-US" xlink:label="lab_dgx_LongTermDebtMaturitiesGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total maturities of long-term debt</link:label>
    <link:label id="lab_dgx_LongTermDebtMaturitiesGross_label_en-US" xlink:label="lab_dgx_LongTermDebtMaturitiesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities Gross</link:label>
    <link:label id="lab_dgx_LongTermDebtMaturitiesGross_documentation_en-US" xlink:label="lab_dgx_LongTermDebtMaturitiesGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Including current and noncurrent portions, aggregate carrying amount of long-term borrowings as of the balance sheet date. May include notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, which had initial maturities beyond one year or beyond the normal operating cycle, if longer, and before deducting unamortized discount or premiums, if any.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LongTermDebtMaturitiesGross" xlink:href="dgx-20221231.xsd#dgx_LongTermDebtMaturitiesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_LongTermDebtMaturitiesGross" xlink:to="lab_dgx_LongTermDebtMaturitiesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fc7f3b12-9d98-4ba0-b72e-e6e04c72dd58_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding - basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_5cc91023-0728-49be-9061-0a19617429a4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_1e8011a3-090b-4baf-8404-1cb8107e63d3_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_SupplementalDeferredCompensationPlanSalaryDeferral_5840fb27-71d6-4165-955d-52448940b623_terseLabel_en-US" xlink:label="lab_dgx_SupplementalDeferredCompensationPlanSalaryDeferral" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SDCP salary deferral</link:label>
    <link:label id="lab_dgx_SupplementalDeferredCompensationPlanSalaryDeferral_label_en-US" xlink:label="lab_dgx_SupplementalDeferredCompensationPlanSalaryDeferral" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Deferred Compensation Plan Salary Deferral</link:label>
    <link:label id="lab_dgx_SupplementalDeferredCompensationPlanSalaryDeferral_documentation_en-US" xlink:label="lab_dgx_SupplementalDeferredCompensationPlanSalaryDeferral" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of salary deferral under the Supplemental Deferred Compensation Plan. This plans is an unfunded, non-qualified plan that provides for certain management and highly compensated employees to defer up to this percentage of their annual salary in excess of their defined contribution plan limits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_SupplementalDeferredCompensationPlanSalaryDeferral" xlink:href="dgx-20221231.xsd#dgx_SupplementalDeferredCompensationPlanSalaryDeferral"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_SupplementalDeferredCompensationPlanSalaryDeferral" xlink:to="lab_dgx_SupplementalDeferredCompensationPlanSalaryDeferral" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_ScheduleOfLeaseByAssetTypeTableTextBlock_6eeac49e-2c1a-45ea-880e-28d3c32866ab_terseLabel_en-US" xlink:label="lab_dgx_ScheduleOfLeaseByAssetTypeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Lease By Asset Type</link:label>
    <link:label id="lab_dgx_ScheduleOfLeaseByAssetTypeTableTextBlock_label_en-US" xlink:label="lab_dgx_ScheduleOfLeaseByAssetTypeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Lease By Asset Type [Table Text Block]</link:label>
    <link:label id="lab_dgx_ScheduleOfLeaseByAssetTypeTableTextBlock_documentation_en-US" xlink:label="lab_dgx_ScheduleOfLeaseByAssetTypeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Lease By Asset Type [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ScheduleOfLeaseByAssetTypeTableTextBlock" xlink:href="dgx-20221231.xsd#dgx_ScheduleOfLeaseByAssetTypeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_ScheduleOfLeaseByAssetTypeTableTextBlock" xlink:to="lab_dgx_ScheduleOfLeaseByAssetTypeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_46aaa421-9ef7-4ad1-9d57-8e97334dba1b_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Carrying Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesLineItems_e7727e7d-7a38-407e-8615-f614589c2560_terseLabel_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases [Line Items]</link:label>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesLineItems_label_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcceleratedShareRepurchasesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems" xlink:to="lab_us-gaap_AcceleratedShareRepurchasesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_ae7da0e4-adbe-4048-a824-3c09bfe0df44_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_FundsinatrustpertainingtoallparticipantdeferralsandcompanymatchingamountsrelatedtotheSDCP_837fa2a2-e276-45a6-85bc-a5a13c8038b1_terseLabel_en-US" xlink:label="lab_dgx_FundsinatrustpertainingtoallparticipantdeferralsandcompanymatchingamountsrelatedtotheSDCP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funds in a trust pertaining to all participant deferrals and company matching amounts related to the SDCP</link:label>
    <link:label id="lab_dgx_FundsinatrustpertainingtoallparticipantdeferralsandcompanymatchingamountsrelatedtotheSDCP_label_en-US" xlink:label="lab_dgx_FundsinatrustpertainingtoallparticipantdeferralsandcompanymatchingamountsrelatedtotheSDCP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funds in a trust pertaining to all participant deferrals and company matching amounts related to the SDCP</link:label>
    <link:label id="lab_dgx_FundsinatrustpertainingtoallparticipantdeferralsandcompanymatchingamountsrelatedtotheSDCP_documentation_en-US" xlink:label="lab_dgx_FundsinatrustpertainingtoallparticipantdeferralsandcompanymatchingamountsrelatedtotheSDCP" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funds in a trust pertaining to all participant deferrals and company matching amounts related to the Supplemental Deferred Compensation Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_FundsinatrustpertainingtoallparticipantdeferralsandcompanymatchingamountsrelatedtotheSDCP" xlink:href="dgx-20221231.xsd#dgx_FundsinatrustpertainingtoallparticipantdeferralsandcompanymatchingamountsrelatedtotheSDCP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_FundsinatrustpertainingtoallparticipantdeferralsandcompanymatchingamountsrelatedtotheSDCP" xlink:to="lab_dgx_FundsinatrustpertainingtoallparticipantdeferralsandcompanymatchingamountsrelatedtotheSDCP" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_4caf8fef-d389-4487-b701-f02ffa7cbd0c_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_47f6fcae-b3bc-4080-a04c-aeedabdf4d06_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_0a3e9592-41f6-4849-8a87-cfa53916742b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_8c14732c-12da-4d59-b556-28cea18abd98_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_b60bfe6f-2515-4e72-a7a1-9892b3811af7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3d623a05-b8a5-4682-a5b3-56549826b46d_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes and equity in earnings of equity method investees</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_92498a27-eb1c-48eb-a8aa-d9a138bea43b_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCK OWNERSHIP AND COMPENSATION PLANS</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_601a2ada-4a6c-4938-b060-647f4ac3d206_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_935f8e5a-5ff2-4673-a772-29920d3b5d8d_periodStartLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_17048942-0793-489d-a520-b0fe7255003a_periodEndLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_b62511a1-95d6-472d-8347-6686866b295c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_c81ea9ef-21f4-4fa1-bf32-46369aceff93_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_1204888b-9ebd-462d-aa0a-d44ba1bd666a_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_f8e2b7e7-ecae-4270-9b87-4d948da819f1_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_563da8d2-85d6-4678-9843-330fbdb6614e_totalLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_fdcdb845-c0ab-4d3a-b4b4-5aaf1da05954_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_0020b692-ed83-417d-bce4-d598d5cf9ab8_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged items (Long-term debt)</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_FinanceLeaseLiabilityRealEstate_028f8d69-0e24-470f-8249-7c5ccfc7d4c7_terseLabel_en-US" xlink:label="lab_dgx_FinanceLeaseLiabilityRealEstate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liability, real estate</link:label>
    <link:label id="lab_dgx_FinanceLeaseLiabilityRealEstate_label_en-US" xlink:label="lab_dgx_FinanceLeaseLiabilityRealEstate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Real Estate</link:label>
    <link:label id="lab_dgx_FinanceLeaseLiabilityRealEstate_documentation_en-US" xlink:label="lab_dgx_FinanceLeaseLiabilityRealEstate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Real Estate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_FinanceLeaseLiabilityRealEstate" xlink:href="dgx-20221231.xsd#dgx_FinanceLeaseLiabilityRealEstate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_FinanceLeaseLiabilityRealEstate" xlink:to="lab_dgx_FinanceLeaseLiabilityRealEstate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_1eddbc7e-04fa-4b3d-8875-5cf301800559_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_0747ed0f-4e75-4c67-8a9c-1563902acba4_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities_503819a4-846d-46bf-86c5-820dbdc8c5b7_terseLabel_en-US" xlink:label="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities_label_en-US" xlink:label="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</link:label>
    <link:label id="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities" xlink:href="dgx-20221231.xsd#dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities" xlink:to="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1763740a-6196-4dfe-8ee3-b592441cf130_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options and performance share units</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_519ebaf8-6e9a-4948-af8b-add923d93d4b_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_22ce482a-744b-49aa-83f1-4551e3346d57_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_f19c7d2d-c5de-4655-981c-5810db553d87_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisitions, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_60b78ab3-aea1-4707-ab74-6aeead4601c4_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisitions, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_3f38260d-003b-4ce0-874c-94e1e132e5c9_totalLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisitions, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_65c74ae7-5ced-4dfe-98f4-3427bfd0a91b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_9b55637b-d1d1-43f6-8161-cc70202813db_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill deductible for tax purposes</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Goodwill, Expected Tax Deductible Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:to="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_54b8c015-1de0-4b33-95ec-2027ee5f79c4_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_6a30ed84-b8c7-41ce-af53-fe1274cf00df_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_62138968-b962-4821-9e0d-5381b5d47b22_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearThree_0409957a-f8ae-4369-8fa9-e25ae75ca6a0_totalLabel_en-US" xlink:label="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating and Finance Lease, Liability, Payments, Due Year Three</link:label>
    <link:label id="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearThree_documentation_en-US" xlink:label="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating and Finance Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="dgx-20221231.xsd#dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_954c43a6-04a6-4a39-ade5-0fb18d992d9f_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax Benefits, interest on income taxes expense</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2d727fc6-8639-4965-98da-e98db00dc845_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_b17efcf9-83b0-4ac2-87bc-24ad5cf1cba2_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDue_75b1aa0a-1992-4a0d-b20d-7dcb265d07aa_totalLabel_en-US" xlink:label="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating and Finance Lease, Liability, Payments, Due</link:label>
    <link:label id="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDue_documentation_en-US" xlink:label="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating and Finance Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDue" xlink:href="dgx-20221231.xsd#dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDue" xlink:to="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_136ca948-2513-4eba-af6d-96c3691f1904_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_bf475f6b-733e-42ed-9784-ed05fffe0be1_netLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DISPOSITION</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_6a0904b9-3841-44c3-bf01-e153fb5c4001_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_528ec6fd-f5b5-44cf-937c-4bf8be9a07bb_terseLabel_en-US" xlink:label="lab_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Earnings allocated to participating securities</link:label>
    <link:label id="lab_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_label_en-US" xlink:label="lab_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Participating Securities, Distributed and Undistributed Earnings (Loss), Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xlink:to="lab_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_9e0047c9-52bb-4148-9f89-ae96b59018b4_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_4d7e240a-67f9-4863-9557-77d994367160_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_ForeignCurrencyTranslationMember_bbfdf007-d6b8-4a54-82e4-05f45a3cef27_terseLabel_en-US" xlink:label="lab_dgx_ForeignCurrencyTranslationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_dgx_ForeignCurrencyTranslationMember_label_en-US" xlink:label="lab_dgx_ForeignCurrencyTranslationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation [Member]</link:label>
    <link:label id="lab_dgx_ForeignCurrencyTranslationMember_documentation_en-US" xlink:label="lab_dgx_ForeignCurrencyTranslationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ForeignCurrencyTranslationMember" xlink:href="dgx-20221231.xsd#dgx_ForeignCurrencyTranslationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_ForeignCurrencyTranslationMember" xlink:to="lab_dgx_ForeignCurrencyTranslationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_27640183-289e-4232-a1cc-d89389a516bc_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of services</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_41c3f494-4178-407c-8c4d-0dd0a9fb1735_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other financing activities, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_548c5945-77d8-4c45-b11e-5dd1eb64cd08_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term,Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_a69eb31c-f8a6-4349-9484-db155ec522cb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_48d53139-e39b-4cf6-901a-c85d879ed543_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_8f49d27d-c9cc-44c2-bb69-8c08dd8c5c9e_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_ed86ecbe-a42c-442d-9126-a8ddccd81da7_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_GoodwillAcquiredDuringPeriodBeforeAdjustments_93cdb3da-f81e-4731-9afc-432db68b3b6a_terseLabel_en-US" xlink:label="lab_dgx_GoodwillAcquiredDuringPeriodBeforeAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill acquired, before adjustments</link:label>
    <link:label id="lab_dgx_GoodwillAcquiredDuringPeriodBeforeAdjustments_label_en-US" xlink:label="lab_dgx_GoodwillAcquiredDuringPeriodBeforeAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period, Before Adjustments</link:label>
    <link:label id="lab_dgx_GoodwillAcquiredDuringPeriodBeforeAdjustments_documentation_en-US" xlink:label="lab_dgx_GoodwillAcquiredDuringPeriodBeforeAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period, Before Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_GoodwillAcquiredDuringPeriodBeforeAdjustments" xlink:href="dgx-20221231.xsd#dgx_GoodwillAcquiredDuringPeriodBeforeAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_GoodwillAcquiredDuringPeriodBeforeAdjustments" xlink:to="lab_dgx_GoodwillAcquiredDuringPeriodBeforeAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_1bc2a764-d9b1-4d54-a427-f0a8adc0fcf4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_1fa462e2-557f-4e51-b668-664e52661c57_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ac55cc60-0188-43b2-bc48-53cc998cd028_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_1f566656-a110-4d40-aaf2-b9163fd4c07b_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_14b84236-221a-4221-8bc3-2e8da3f84d11_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_404822e2-1e07-41c4-b428-aa1b5fca328b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Transactions Under Stock Awards Other than Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Share Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityNetIncome_8476d446-30fd-4c2e-bcee-b4bfb51b9bcf_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityNetIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityNetIncome_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityNetIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Net Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityNetIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityNetIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityNetIncome" xlink:to="lab_us-gaap_TemporaryEquityNetIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_GainLossOnDispositionOfJointVenture_2c415a66-a235-4bea-a064-b8de74271b92_negatedTerseLabel_en-US" xlink:label="lab_dgx_GainLossOnDispositionOfJointVenture" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on disposition of joint venture</link:label>
    <link:label id="lab_dgx_GainLossOnDispositionOfJointVenture_label_en-US" xlink:label="lab_dgx_GainLossOnDispositionOfJointVenture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Joint Venture</link:label>
    <link:label id="lab_dgx_GainLossOnDispositionOfJointVenture_documentation_en-US" xlink:label="lab_dgx_GainLossOnDispositionOfJointVenture" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Joint Venture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_GainLossOnDispositionOfJointVenture" xlink:href="dgx-20221231.xsd#dgx_GainLossOnDispositionOfJointVenture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_GainLossOnDispositionOfJointVenture" xlink:to="lab_dgx_GainLossOnDispositionOfJointVenture" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_d76ffc00-8155-4952-95cf-46f6725a5b91_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of the Federal Statutory Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_4d8cff6b-d6c9-4e1e-80d1-52f8dc875b7f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Pre-Tax Restructuring Charges</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_6758c7ca-7803-4a22-bcff-93f766094a27_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement input</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_cc9984d6-bb21-41bd-b33a-fcf91af3899f_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_0da08b5c-acea-4921-b74f-687ad54bcc1d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future amortization expense</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c5803d54-3b8c-4ad0-9d49-c82ac59b1509_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_2bfbdabb-828e-4681-accf-364a9a4a28ab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares to cover employee payroll tax withholdings on stock issued under stock-based compensation plans</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_888bc3fa-4369-4244-b133-7b5d898e77a6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_b627c37a-b22c-48c6-88b3-807175afaa15_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock_9ee9dcbb-049e-44f7-b1f7-6085f85f64a0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_f089f661-23c9-487a-8c3c-38bcda6ea7f8_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Return to provision true-ups</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFive_a232b9d4-7376-4bf5-bb90-7ee25404a43c_totalLabel_en-US" xlink:label="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating and Finance Lease, Liability, Payments, Due Year Five</link:label>
    <link:label id="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFive_documentation_en-US" xlink:label="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating and Finance Lease, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFive" xlink:href="dgx-20221231.xsd#dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_78aa2760-d7fa-4c59-af5d-a108e753034d_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_7724c90e-a1a6-43da-9b98-41bd9d085193_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_LeaseLiability_c37489dd-1427-4595-85a1-e1f008af14cb_totalLabel_en-US" xlink:label="lab_dgx_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_dgx_LeaseLiability_label_en-US" xlink:label="lab_dgx_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:label id="lab_dgx_LeaseLiability_documentation_en-US" xlink:label="lab_dgx_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LeaseLiability" xlink:href="dgx-20221231.xsd#dgx_LeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_LeaseLiability" xlink:to="lab_dgx_LeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_d7d8bcf7-1a17-40e5-a6ef-17138dbae8db_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_69d3e5b8-1ff5-4517-b2c9-a54e2047593b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets and liabilities, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_StockAwardsMember_7b98e19e-94b4-4d4d-a109-1aa8bddf484e_terseLabel_en-US" xlink:label="lab_dgx_StockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Awards</link:label>
    <link:label id="lab_dgx_StockAwardsMember_label_en-US" xlink:label="lab_dgx_StockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Awards [Member]</link:label>
    <link:label id="lab_dgx_StockAwardsMember_documentation_en-US" xlink:label="lab_dgx_StockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement - Equity Instruments Other than Options.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_StockAwardsMember" xlink:href="dgx-20221231.xsd#dgx_StockAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_StockAwardsMember" xlink:to="lab_dgx_StockAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_EffectiveIncomeTaxRateReconciliationAdjustmentToStateDeferredTaxLiabilities_33aa844a-ca00-40de-b5ed-0d42720d8e2a_terseLabel_en-US" xlink:label="lab_dgx_EffectiveIncomeTaxRateReconciliationAdjustmentToStateDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to state deferred tax liabilities</link:label>
    <link:label id="lab_dgx_EffectiveIncomeTaxRateReconciliationAdjustmentToStateDeferredTaxLiabilities_label_en-US" xlink:label="lab_dgx_EffectiveIncomeTaxRateReconciliationAdjustmentToStateDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Adjustment To State Deferred Tax Liabilities</link:label>
    <link:label id="lab_dgx_EffectiveIncomeTaxRateReconciliationAdjustmentToStateDeferredTaxLiabilities_documentation_en-US" xlink:label="lab_dgx_EffectiveIncomeTaxRateReconciliationAdjustmentToStateDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Adjustment To State Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_EffectiveIncomeTaxRateReconciliationAdjustmentToStateDeferredTaxLiabilities" xlink:href="dgx-20221231.xsd#dgx_EffectiveIncomeTaxRateReconciliationAdjustmentToStateDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_EffectiveIncomeTaxRateReconciliationAdjustmentToStateDeferredTaxLiabilities" xlink:to="lab_dgx_EffectiveIncomeTaxRateReconciliationAdjustmentToStateDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_e4875a94-0e1e-4735-ba12-c8d0e1b155f9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_15954ef9-4a5d-483d-bc12-d1eb3c15910b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_21bae0d7-55ca-46eb-b1d7-309e0524f471_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1b20036a-21cf-489f-8186-a5e0a3b1c2cf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value at grant date (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_56c8d00a-d1bd-4cc2-9da3-747116555acd_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_4396182e-c1fc-4acb-989d-bbc4ab52b206_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_2d0b4308-d402-4ac6-8fb5-c112f133a4ce_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in earnings of equity method investees, net of taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_31d73731-267f-432e-b7ae-5a868b776fdd_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of equity earnings from investments in affiliates</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5e8d0695-acb6-4074-8932-54157a221628_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_745a66ef-1497-483a-a385-a5504101df77_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_089ebce8-1644-4da6-baa9-ced89579e62d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_fa64bf29-fc42-4381-b19c-10ff197ce4b0_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxes_377aae95-52ca-4db5-a0cf-3b5095f93001_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxes" xlink:to="lab_us-gaap_AccruedIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4e887512-e33d-4b89-8101-24f718c876c4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7c4c70a5-fb24-420f-af4c-898a86ead2db_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leased assets obtained in exchange for new operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_ccc09c53-93c5-41a0-a0c3-15eee87724d1_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts reclassified from accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_699b347c-581d-4f7b-aa09-8bad6e8fd00d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_52ce78a2-2509-4b4a-913c-49d3edb923f9_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_875fea1c-3e28-49d3-b434-dfa19f2e4566_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_3ba6aef5-061f-4451-84b4-319ab1b81ad7_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_28306d48-442f-48e2-bd10-50b55afd1804_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_5422bc22-5daa-4323-9dd9-09858c5d9062_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_055bb9e3-757d-424b-bdf2-5be45993ac77_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_402d20ce-f79f-4cb0-809d-723abc10f2fc_terseLabel_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All other operating segments</link:label>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_label_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllOtherSegmentsMember" xlink:to="lab_us-gaap_AllOtherSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_DebtInstrumentExtensionPeriod_67786ef8-4271-4760-9a9a-1f781b07214a_terseLabel_en-US" xlink:label="lab_dgx_DebtInstrumentExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extension period</link:label>
    <link:label id="lab_dgx_DebtInstrumentExtensionPeriod_label_en-US" xlink:label="lab_dgx_DebtInstrumentExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, Extension Period</link:label>
    <link:label id="lab_dgx_DebtInstrumentExtensionPeriod_documentation_en-US" xlink:label="lab_dgx_DebtInstrumentExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, Extension Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_DebtInstrumentExtensionPeriod" xlink:href="dgx-20221231.xsd#dgx_DebtInstrumentExtensionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_DebtInstrumentExtensionPeriod" xlink:to="lab_dgx_DebtInstrumentExtensionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_OperatingLeaseFixedAndVariableCost_1af507b8-568d-4022-8d92-c00498b01228_terseLabel_en-US" xlink:label="lab_dgx_OperatingLeaseFixedAndVariableCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_dgx_OperatingLeaseFixedAndVariableCost_label_en-US" xlink:label="lab_dgx_OperatingLeaseFixedAndVariableCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Fixed and Variable Cost</link:label>
    <link:label id="lab_dgx_OperatingLeaseFixedAndVariableCost_documentation_en-US" xlink:label="lab_dgx_OperatingLeaseFixedAndVariableCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Fixed and Variable Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_OperatingLeaseFixedAndVariableCost" xlink:href="dgx-20221231.xsd#dgx_OperatingLeaseFixedAndVariableCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_OperatingLeaseFixedAndVariableCost" xlink:to="lab_dgx_OperatingLeaseFixedAndVariableCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_fa5919e5-6e74-43c2-bf99-64605a8dfb1d_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_48b2244c-9a01-40d2-94a5-7b131ed14537_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesRetired_2be71515-f310-4566-8f30-b18d6d1227b1_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesRetired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares retired (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesRetired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesRetired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Retired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesRetired" xlink:to="lab_us-gaap_TreasuryStockSharesRetired" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_ScheduleOfShareholdersEquityLineItems_18ef4f96-c0a1-44d1-b80e-d54fa05c71b4_terseLabel_en-US" xlink:label="lab_dgx_ScheduleOfShareholdersEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; Equity and Redeemable Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_dgx_ScheduleOfShareholdersEquityLineItems_label_en-US" xlink:label="lab_dgx_ScheduleOfShareholdersEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Shareholders' Equity [Line Items]</link:label>
    <link:label id="lab_dgx_ScheduleOfShareholdersEquityLineItems_documentation_en-US" xlink:label="lab_dgx_ScheduleOfShareholdersEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Schedule of Shareholders' Equity [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ScheduleOfShareholdersEquityLineItems" xlink:href="dgx-20221231.xsd#dgx_ScheduleOfShareholdersEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems" xlink:to="lab_dgx_ScheduleOfShareholdersEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_b7281822-1dfa-4c14-aa7a-b645c908688d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current deferred tax liability - depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_6a1fb3cb-b308-445d-94fa-e847c313e41e_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of equity earnings</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Equity in Earnings (Losses) of Unconsolidated Subsidiary, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_7463d9d6-f0d7-4e15-8157-8ece36b7622f_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_1e32f0be-2a3e-4f4e-8d75-a9b005fb2167_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_7329bc75-2b8c-494e-ab77-867e77b42164_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_c1340dc5-6a0a-4e7c-a512-67a4b407da5c_verboseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Software Developed or Obtained for Internal Use</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_cfcd420f-9333-441f-b0fc-dd9baff17fd6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases, additions and issuances</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_09b2c0bb-69cd-4164-924a-b3f0e6447784_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (increase) in investments and other assets, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_5923c6c3-f2ff-4782-be25-cd45c6650665_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d8e9f12a-8477-4b09-8b8e-daeb6912341d_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_718fe3d7-6d85-45cc-80dc-abce3a754d9e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_94be968a-53d5-4971-baa4-267e33e618b9_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_8d4b2597-c80c-458d-92f7-7b6ebecc0f84_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions for expirations of statutes of limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_UMassJointVentureMember_b696e78e-64bc-446f-b09d-dcaeca3612de_terseLabel_en-US" xlink:label="lab_dgx_UMassJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UMass Joint Venture</link:label>
    <link:label id="lab_dgx_UMassJointVentureMember_label_en-US" xlink:label="lab_dgx_UMassJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UMass Joint Venture [Member]</link:label>
    <link:label id="lab_dgx_UMassJointVentureMember_documentation_en-US" xlink:label="lab_dgx_UMassJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UMass Joint Venture [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_UMassJointVentureMember" xlink:href="dgx-20221231.xsd#dgx_UMassJointVentureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_UMassJointVentureMember" xlink:to="lab_dgx_UMassJointVentureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_NetIncomeLossExcludingRedeemableNoncontrollingInterest_16735585-d7d9-44ad-a014-967c382774ff_terseLabel_en-US" xlink:label="lab_dgx_NetIncomeLossExcludingRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_dgx_NetIncomeLossExcludingRedeemableNoncontrollingInterest_label_en-US" xlink:label="lab_dgx_NetIncomeLossExcludingRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Excluding Redeemable Noncontrolling Interest</link:label>
    <link:label id="lab_dgx_NetIncomeLossExcludingRedeemableNoncontrollingInterest_documentation_en-US" xlink:label="lab_dgx_NetIncomeLossExcludingRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Excluding Redeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_NetIncomeLossExcludingRedeemableNoncontrollingInterest" xlink:href="dgx-20221231.xsd#dgx_NetIncomeLossExcludingRedeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_NetIncomeLossExcludingRedeemableNoncontrollingInterest" xlink:to="lab_dgx_NetIncomeLossExcludingRedeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_aaf512be-787c-4238-812b-00416c2b6266_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Country</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_d8577260-4d44-4f39-af6f-77a1c04d9850_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_a97f1a8f-1778-4981-b8bd-66958b3cac37_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_RemainingTermsofContingentLeaseObligationsMaximum_da5942bd-94a4-4929-a712-d19aa9c021be_terseLabel_en-US" xlink:label="lab_dgx_RemainingTermsofContingentLeaseObligationsMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining terms of lease obligations, maximum</link:label>
    <link:label id="lab_dgx_RemainingTermsofContingentLeaseObligationsMaximum_label_en-US" xlink:label="lab_dgx_RemainingTermsofContingentLeaseObligationsMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining Terms of Contingent Lease Obligations, Maximum</link:label>
    <link:label id="lab_dgx_RemainingTermsofContingentLeaseObligationsMaximum_documentation_en-US" xlink:label="lab_dgx_RemainingTermsofContingentLeaseObligationsMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining Terms of Contingent Lease Obligations, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_RemainingTermsofContingentLeaseObligationsMaximum" xlink:href="dgx-20221231.xsd#dgx_RemainingTermsofContingentLeaseObligationsMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_RemainingTermsofContingentLeaseObligationsMaximum" xlink:to="lab_dgx_RemainingTermsofContingentLeaseObligationsMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1_0b3da49c-6bbc-484f-8d3e-4d933155894f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SDCP II vesting period</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_d3a2d468-a685-4538-b788-0eda6c1eae69_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of treasury stock, value</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_54a7df0a-f7db-4eab-94a1-216704771d85_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock value acquired cost method</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_14dc597f-e0c2-4f39-ab84-1154f77bb3a7_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Quest Diagnostics</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_c74adba1-f98a-4b67-8040-a6c5f0434450_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Quest Diagnostics</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_dabccda4-729f-46a7-9129-34807f7866ba_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_bf1eaab4-27ff-4cf5-bcb4-4b3cb50a6e65_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets, Subject To Amortization</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_BusinessAcquisitionPostacquisitionRevenue_098fb8bd-8e2a-4d83-9978-916e993b0cc1_terseLabel_en-US" xlink:label="lab_dgx_BusinessAcquisitionPostacquisitionRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_dgx_BusinessAcquisitionPostacquisitionRevenue_label_en-US" xlink:label="lab_dgx_BusinessAcquisitionPostacquisitionRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Post-acquisition Revenue</link:label>
    <link:label id="lab_dgx_BusinessAcquisitionPostacquisitionRevenue_documentation_en-US" xlink:label="lab_dgx_BusinessAcquisitionPostacquisitionRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Post-acquisition Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_BusinessAcquisitionPostacquisitionRevenue" xlink:href="dgx-20221231.xsd#dgx_BusinessAcquisitionPostacquisitionRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_BusinessAcquisitionPostacquisitionRevenue" xlink:to="lab_dgx_BusinessAcquisitionPostacquisitionRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_5b6c0792-4f57-4492-9eaa-effb1ce02240_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_dbae6ae1-8346-4d83-a69c-c0061c636bab_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_a129fa7f-7b45-42ac-9de6-0169a31d9829_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_1441c2f5-43f7-499a-93cd-aeef50a65673_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_29224cc3-cb45-4c0d-8baa-0290356d9a48_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_FinanceandOperatingLeaseLiabilitiesPaymentsDueAbstract_bffb4fd8-f92d-4843-b40e-2a367d12d9cb_terseLabel_en-US" xlink:label="lab_dgx_FinanceandOperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_dgx_FinanceandOperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_dgx_FinanceandOperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance and Operating Lease Liabilities, Payments, Due [Abstract]</link:label>
    <link:label id="lab_dgx_FinanceandOperatingLeaseLiabilitiesPaymentsDueAbstract_documentation_en-US" xlink:label="lab_dgx_FinanceandOperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance and Operating Lease Liabilities, Payments, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_FinanceandOperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="dgx-20221231.xsd#dgx_FinanceandOperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_FinanceandOperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_dgx_FinanceandOperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseMember_e6927d9a-a7f2-429c-aa8e-f0b6e74160a4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense)</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_9332d705-a8c4-4034-86ea-4e12f2d77c30_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_PackHealthLLCMember_16a64c99-9ef4-4703-8f92-22a0b0e12629_terseLabel_en-US" xlink:label="lab_dgx_PackHealthLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pack Health, LLC</link:label>
    <link:label id="lab_dgx_PackHealthLLCMember_label_en-US" xlink:label="lab_dgx_PackHealthLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pack Health, LLC [Member]</link:label>
    <link:label id="lab_dgx_PackHealthLLCMember_documentation_en-US" xlink:label="lab_dgx_PackHealthLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pack Health, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_PackHealthLLCMember" xlink:href="dgx-20221231.xsd#dgx_PackHealthLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_PackHealthLLCMember" xlink:to="lab_dgx_PackHealthLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_db3b5be3-1c40-402d-804c-3a9ff227dff4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity interest in acquiree, percentage</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:to="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_PercentageofNetRevenues_85f815b6-8683-451f-8020-f61e28bc762c_terseLabel_en-US" xlink:label="lab_dgx_PercentageofNetRevenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of net revenues</link:label>
    <link:label id="lab_dgx_PercentageofNetRevenues_7a2e520e-dc25-4752-831a-ab9f0ea2570f_verboseLabel_en-US" xlink:label="lab_dgx_PercentageofNetRevenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of net revenues from the DIS business</link:label>
    <link:label id="lab_dgx_PercentageofNetRevenues_label_en-US" xlink:label="lab_dgx_PercentageofNetRevenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Net Revenues</link:label>
    <link:label id="lab_dgx_PercentageofNetRevenues_documentation_en-US" xlink:label="lab_dgx_PercentageofNetRevenues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Net Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_PercentageofNetRevenues" xlink:href="dgx-20221231.xsd#dgx_PercentageofNetRevenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_PercentageofNetRevenues" xlink:to="lab_dgx_PercentageofNetRevenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationTable_b5d8c24f-8df4-4b1d-b7ea-abff1d8cf425_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationTable" xlink:to="lab_us-gaap_ReclassificationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_e6461526-953a-4513-a9e9-e7b9f86f65cd_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashSurrenderValueFairValueDisclosure_258cc214-c48d-430a-a433-8889e034305b_terseLabel_en-US" xlink:label="lab_us-gaap_CashSurrenderValueFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash surrender value of life insurance policies</link:label>
    <link:label id="lab_us-gaap_CashSurrenderValueFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashSurrenderValueFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Surrender Value, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashSurrenderValueFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashSurrenderValueFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashSurrenderValueFairValueDisclosure" xlink:to="lab_us-gaap_CashSurrenderValueFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_00d7b12b-31f8-4791-8fcc-7c7a6addc4a9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_5358ec35-d335-460e-a7d6-5947d26818c5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_ba7232a7-6995-43b4-bbc5-103900534cbb_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationTypeDomain_54dcb51f-3ec2-4609-a5e1-107d617e0fc0_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReclassificationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationTypeDomain" xlink:to="lab_us-gaap_ReclassificationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_f5014746-2486-4d8e-949e-c68dfbee4165_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityUndiscountedExcessAmount_9f7c7c80-e9c0-45d3-b960-413cfb2f89ac_totalLabel_en-US" xlink:label="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Interest</link:label>
    <link:label id="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating and Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label id="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityUndiscountedExcessAmount_documentation_en-US" xlink:label="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating and Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="dgx-20221231.xsd#dgx_LesseeOperatingandFinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2593e20a-db61-406d-8d77-cdb28d666463_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_StockRepurchaseProgramAdditionalAmountAuthorized_fd3364a0-d5c2-4463-90ad-b46f22e0193c_terseLabel_en-US" xlink:label="lab_dgx_StockRepurchaseProgramAdditionalAmountAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional amount authorized</link:label>
    <link:label id="lab_dgx_StockRepurchaseProgramAdditionalAmountAuthorized_label_en-US" xlink:label="lab_dgx_StockRepurchaseProgramAdditionalAmountAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Additional Amount Authorized</link:label>
    <link:label id="lab_dgx_StockRepurchaseProgramAdditionalAmountAuthorized_documentation_en-US" xlink:label="lab_dgx_StockRepurchaseProgramAdditionalAmountAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Additional Amount Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_StockRepurchaseProgramAdditionalAmountAuthorized" xlink:href="dgx-20221231.xsd#dgx_StockRepurchaseProgramAdditionalAmountAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_StockRepurchaseProgramAdditionalAmountAuthorized" xlink:to="lab_dgx_StockRepurchaseProgramAdditionalAmountAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_SdcpIiMember_dfb814f3-0759-49f4-98c1-147d326e29e6_terseLabel_en-US" xlink:label="lab_dgx_SdcpIiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SDCP II [Member]</link:label>
    <link:label id="lab_dgx_SdcpIiMember_label_en-US" xlink:label="lab_dgx_SdcpIiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sdcp Ii [Member]</link:label>
    <link:label id="lab_dgx_SdcpIiMember_documentation_en-US" xlink:label="lab_dgx_SdcpIiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SDCP II [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_SdcpIiMember" xlink:href="dgx-20221231.xsd#dgx_SdcpIiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_SdcpIiMember" xlink:to="lab_dgx_SdcpIiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_DeferredTaxAssetsOperatingLeaseLiabilitiesNoncurrent_7d3bf1f3-5a90-4d65-b791-ed25ae334724_terseLabel_en-US" xlink:label="lab_dgx_DeferredTaxAssetsOperatingLeaseLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_dgx_DeferredTaxAssetsOperatingLeaseLiabilitiesNoncurrent_label_en-US" xlink:label="lab_dgx_DeferredTaxAssetsOperatingLeaseLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liabilities, Noncurrent</link:label>
    <link:label id="lab_dgx_DeferredTaxAssetsOperatingLeaseLiabilitiesNoncurrent_documentation_en-US" xlink:label="lab_dgx_DeferredTaxAssetsOperatingLeaseLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_DeferredTaxAssetsOperatingLeaseLiabilitiesNoncurrent" xlink:href="dgx-20221231.xsd#dgx_DeferredTaxAssetsOperatingLeaseLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_DeferredTaxAssetsOperatingLeaseLiabilitiesNoncurrent" xlink:to="lab_dgx_DeferredTaxAssetsOperatingLeaseLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_be2a95cd-8815-4f23-b0c6-ec234f271bbe_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_5dda1420-3ae2-4f2e-96af-39af6a387023_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_DebtInstrumentFairValueBasisAdjustmentAttributableToHedgedDebt_89e6e770-62db-48c2-9a34-455280f3b8d3_negatedTerseLabel_en-US" xlink:label="lab_dgx_DebtInstrumentFairValueBasisAdjustmentAttributableToHedgedDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value basis adjustments attributable to hedged debt</link:label>
    <link:label id="lab_dgx_DebtInstrumentFairValueBasisAdjustmentAttributableToHedgedDebt_label_en-US" xlink:label="lab_dgx_DebtInstrumentFairValueBasisAdjustmentAttributableToHedgedDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, fair value basis adjustment attributable to hedged debt</link:label>
    <link:label id="lab_dgx_DebtInstrumentFairValueBasisAdjustmentAttributableToHedgedDebt_documentation_en-US" xlink:label="lab_dgx_DebtInstrumentFairValueBasisAdjustmentAttributableToHedgedDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, fair value basis adjustment attributable to hedged debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_DebtInstrumentFairValueBasisAdjustmentAttributableToHedgedDebt" xlink:href="dgx-20221231.xsd#dgx_DebtInstrumentFairValueBasisAdjustmentAttributableToHedgedDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_DebtInstrumentFairValueBasisAdjustmentAttributableToHedgedDebt" xlink:to="lab_dgx_DebtInstrumentFairValueBasisAdjustmentAttributableToHedgedDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_46eddd89-7287-41b0-801e-a1abaf8078ae_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of voting interests acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_b6181043-d08b-4e2c-ab6c-a8adbdb2d735_terseLabel_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology-Based Intangible Assets</link:label>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_0c17524f-e200-4345-9438-25ea091af079_verboseLabel_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology</link:label>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology-Based Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedPropertyPlantandEquipmentandWorkingCapital_8f1d397f-23ed-4965-84ac-22530640fe24_terseLabel_en-US" xlink:label="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedPropertyPlantandEquipmentandWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant, and equipment and working capital</link:label>
    <link:label id="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedPropertyPlantandEquipmentandWorkingCapital_label_en-US" xlink:label="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedPropertyPlantandEquipmentandWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment and Working Capital</link:label>
    <link:label id="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedPropertyPlantandEquipmentandWorkingCapital_documentation_en-US" xlink:label="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedPropertyPlantandEquipmentandWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment and Working Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedPropertyPlantandEquipmentandWorkingCapital" xlink:href="dgx-20221231.xsd#dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedPropertyPlantandEquipmentandWorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedPropertyPlantandEquipmentandWorkingCapital" xlink:to="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedPropertyPlantandEquipmentandWorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentsAbstract_bd5c4d90-16a9-45aa-9a0a-40c6e4deba6a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instruments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentsAbstract_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instruments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentsAbstract" xlink:to="lab_us-gaap_DebtInstrumentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostsAndAssetImpairmentCharges_6ca5ddc3-1772-4fbd-a614-f30a57868fda_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairment charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCostsAndAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Costs and Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostsAndAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:to="lab_us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_ded11ef2-c9e9-4e4e-9839-2e730ec2ab8f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_bcc7adcd-36fa-41fa-b4c6-5b87412f3c4e_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, value</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_5de6fcb7-93f9-4c66-aefe-cd299fd97e15_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, value</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_350561f2-4a8e-4f19-8bbc-a04782e2ea5b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_33319eb8-a953-4469-8b9b-12627732ca75_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_cb562d87-26bf-440e-ac6e-af08f3062b91_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_06ca2d00-9f07-433e-a98d-59a3024ff660_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DEBT</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_f1c0fd2b-0349-475e-8891-4f9758ce6ff2_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_e7378209-40b4-4184-ac84-f0688c19aeb5_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherRestructuringCosts_3d84f168-a663-4442-8c46-1a5b83bc23ae_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility-related costs</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringCosts_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Restructuring Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringCosts" xlink:to="lab_us-gaap_OtherRestructuringCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ce7711f0-1712-4e38-a111-68fa2313bf30_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_6d609b04-6516-49e9-bf31-154104373398_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_dde324ca-f1b5-47f6-b061-fca401076d86_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_Q2SolutionsMember_4baf937e-e4bc-4fe9-8ad3-18fabc146fb4_terseLabel_en-US" xlink:label="lab_dgx_Q2SolutionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Q2 Solutions</link:label>
    <link:label id="lab_dgx_Q2SolutionsMember_label_en-US" xlink:label="lab_dgx_Q2SolutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Q2 Solutions [Member]</link:label>
    <link:label id="lab_dgx_Q2SolutionsMember_documentation_en-US" xlink:label="lab_dgx_Q2SolutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Q2 Solutions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_Q2SolutionsMember" xlink:href="dgx-20221231.xsd#dgx_Q2SolutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_Q2SolutionsMember" xlink:to="lab_dgx_Q2SolutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_81e00c6b-70e9-4566-ba92-0cd790bea894_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_281cea68-624b-430c-988d-fa2c4071038f_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities_5595675c-6a7f-4984-859e-8fdd3f0b3a14_terseLabel_en-US" xlink:label="lab_dgx_EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments</link:label>
    <link:label id="lab_dgx_EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities_label_en-US" xlink:label="lab_dgx_EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Excluding Deferred Compensation Trading Securities</link:label>
    <link:label id="lab_dgx_EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities_documentation_en-US" xlink:label="lab_dgx_EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Excluding Deferred Compensation Trading Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities" xlink:href="dgx-20221231.xsd#dgx_EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities" xlink:to="lab_dgx_EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_218c14d9-52c7-46b3-b944-b4cbb10898c7_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_AllotherservicesMember_5df9ab03-6140-407c-a028-c8c6a4539ec0_terseLabel_en-US" xlink:label="lab_dgx_AllotherservicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All other services</link:label>
    <link:label id="lab_dgx_AllotherservicesMember_label_en-US" xlink:label="lab_dgx_AllotherservicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All other services [Member]</link:label>
    <link:label id="lab_dgx_AllotherservicesMember_documentation_en-US" xlink:label="lab_dgx_AllotherservicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All other services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_AllotherservicesMember" xlink:href="dgx-20221231.xsd#dgx_AllotherservicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_AllotherservicesMember" xlink:to="lab_dgx_AllotherservicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_9709608e-7ff5-4dfa-afe7-bf4b93d56e09_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share attributable to Quest Diagnostics&#8217; common stockholders:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_37ac847c-0ab3-49bb-b12c-e1b9fa66491c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_67532818-4dca-46e3-86f3-7489d6d7453e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_e8f6ed51-b431-4c32-b974-8ecf6a10b168_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_a7fa79bf-26ca-4a75-9657-504073d24d2f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_803108a1-57bb-410a-8301-cd42c4d3a94f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued wages and benefits (including incentive compensation)</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_364c66fc-388c-4b0f-a1e0-3b3552b4f5df_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_dd152d52-c3e8-4aab-a6c5-a36ef1dcb194_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_acd6d751-f0a5-4964-985e-56e4074cd9a3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_MergerConsiderationPayableCurrent_c6185d2c-7015-4510-a736-e29d0ad32f36_terseLabel_en-US" xlink:label="lab_dgx_MergerConsiderationPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger consideration payable</link:label>
    <link:label id="lab_dgx_MergerConsiderationPayableCurrent_label_en-US" xlink:label="lab_dgx_MergerConsiderationPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Consideration Payable, Current</link:label>
    <link:label id="lab_dgx_MergerConsiderationPayableCurrent_documentation_en-US" xlink:label="lab_dgx_MergerConsiderationPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Consideration Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_MergerConsiderationPayableCurrent" xlink:href="dgx-20221231.xsd#dgx_MergerConsiderationPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_MergerConsiderationPayableCurrent" xlink:to="lab_dgx_MergerConsiderationPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_8156907b-1990-4fc0-b047-45bdca3ea8ef_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Liability, Classified, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_8da07b14-4ab8-4e10-bc3a-35ab8a9cb0dc_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposed of by Sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_b1002f20-629c-403c-9a32-3304486ba666_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ac52b5bf-1a2e-4945-8e96-4a959e24e1d7_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9fa0615d-1e2a-476d-b77f-060b6251a74b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_731fad19-2c09-42b8-b038-8023545aa0c3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_FourPointSevenZeroPercentSeniorNotesdueMarch2045Member_1497ef8a-8f40-49af-a7aa-c95cbb6b6a47_terseLabel_en-US" xlink:label="lab_dgx_FourPointSevenZeroPercentSeniorNotesdueMarch2045Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.70% Senior Notes due March 2045</link:label>
    <link:label id="lab_dgx_FourPointSevenZeroPercentSeniorNotesdueMarch2045Member_label_en-US" xlink:label="lab_dgx_FourPointSevenZeroPercentSeniorNotesdueMarch2045Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Seven Zero Percent Senior Notes due March 2045 [Member]</link:label>
    <link:label id="lab_dgx_FourPointSevenZeroPercentSeniorNotesdueMarch2045Member_documentation_en-US" xlink:label="lab_dgx_FourPointSevenZeroPercentSeniorNotesdueMarch2045Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Seven Zero Percent Senior Notes due March 2045 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_FourPointSevenZeroPercentSeniorNotesdueMarch2045Member" xlink:href="dgx-20221231.xsd#dgx_FourPointSevenZeroPercentSeniorNotesdueMarch2045Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_FourPointSevenZeroPercentSeniorNotesdueMarch2045Member" xlink:to="lab_dgx_FourPointSevenZeroPercentSeniorNotesdueMarch2045Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_7d5df973-b75c-4715-b39e-f622383609cb_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_6fa0dd6a-e87c-4945-8ad5-8b2a18ea8c8b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_2f98a92e-6a26-49b7-a255-b978a09b040e_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_b4200d12-0d59-4d60-bcb2-91c4072f4395_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_44e670f5-f0bc-4a67-9a66-44c94385ae91_verboseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer - related</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_2412d3c0-d37e-4324-a150-29a8335902e6_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_DiagnosticInformationServicesBusinessMember_815ec7f7-c624-4946-bfb7-1de4613b3683_terseLabel_en-US" xlink:label="lab_dgx_DiagnosticInformationServicesBusinessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DIS business</link:label>
    <link:label id="lab_dgx_DiagnosticInformationServicesBusinessMember_label_en-US" xlink:label="lab_dgx_DiagnosticInformationServicesBusinessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diagnostic Information Services Business [Member]</link:label>
    <link:label id="lab_dgx_DiagnosticInformationServicesBusinessMember_documentation_en-US" xlink:label="lab_dgx_DiagnosticInformationServicesBusinessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diagnostic Information Services Business [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_DiagnosticInformationServicesBusinessMember" xlink:href="dgx-20221231.xsd#dgx_DiagnosticInformationServicesBusinessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_DiagnosticInformationServicesBusinessMember" xlink:to="lab_dgx_DiagnosticInformationServicesBusinessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_bee4dbcc-9853-44ae-98ed-1117f6cd41ce_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_2dd6761d-8d12-4041-aba5-2b9741d96dae_terseLabel_en-US" xlink:label="lab_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived and Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived and Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_documentation_en-US" xlink:label="lab_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived and Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:href="dgx-20221231.xsd#dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:to="lab_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_924749b9-a232-4c18-9c81-cfe1677b5b8b_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_130de363-937d-40e6-bc3a-1eacb1b67642_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_LeaseRightofUseAsset_6d7496e2-bf90-4de5-a7f2-3a8fbd686ece_totalLabel_en-US" xlink:label="lab_dgx_LeaseRightofUseAsset" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease assets</link:label>
    <link:label id="lab_dgx_LeaseRightofUseAsset_label_en-US" xlink:label="lab_dgx_LeaseRightofUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Right-of-Use Asset</link:label>
    <link:label id="lab_dgx_LeaseRightofUseAsset_documentation_en-US" xlink:label="lab_dgx_LeaseRightofUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LeaseRightofUseAsset" xlink:href="dgx-20221231.xsd#dgx_LeaseRightofUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_LeaseRightofUseAsset" xlink:to="lab_dgx_LeaseRightofUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_1092d0cc-24fe-4b11-b159-b6e45a5987a9_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, interest on income taxes accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f8515e00-fd9b-493f-aacb-fd0ae1f4b046_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_a927a447-4245-4d88-8987-a8d57eeeb4db_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsTable_e4c8302a-9c39-47a9-9f59-cd26a7c9d972_terseLabel_en-US" xlink:label="lab_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived and Indefinite-lived Intangible Assets [Table]</link:label>
    <link:label id="lab_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived and Indefinite-lived Intangible Assets [Table]</link:label>
    <link:label id="lab_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsTable_documentation_en-US" xlink:label="lab_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived and Indefinite-lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsTable" xlink:href="dgx-20221231.xsd#dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_addbf4d0-ddd4-4d96-aee6-9efddff472f1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrent_6306c5dc-e5c9-4976-86d5-d1a9557891a1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Trade, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrent" xlink:to="lab_us-gaap_AccountsPayableTradeCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_85dbfc0e-fd70-4f80-a070-47f15b4ac049_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions for tax positions of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_bcec287f-439e-41fd-b4bb-54ebd80e23a3_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_d607f445-1d5f-4291-945a-a7fa421e3413_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, end of year shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedInsuranceCurrent_12006bc9-bbcf-4d27-8fd4-38b8eca043c7_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedInsuranceCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued insurance</link:label>
    <link:label id="lab_us-gaap_AccruedInsuranceCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedInsuranceCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Insurance, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedInsuranceCurrent" xlink:to="lab_us-gaap_AccruedInsuranceCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_RevenueFromContractWithCustomerExcludingAssessedTaxPercent_c93c6383-1a41-4514-af85-4d9c6f1b122b_terseLabel_en-US" xlink:label="lab_dgx_RevenueFromContractWithCustomerExcludingAssessedTaxPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net revenues, percent</link:label>
    <link:label id="lab_dgx_RevenueFromContractWithCustomerExcludingAssessedTaxPercent_label_en-US" xlink:label="lab_dgx_RevenueFromContractWithCustomerExcludingAssessedTaxPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax, Percent</link:label>
    <link:label id="lab_dgx_RevenueFromContractWithCustomerExcludingAssessedTaxPercent_documentation_en-US" xlink:label="lab_dgx_RevenueFromContractWithCustomerExcludingAssessedTaxPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_RevenueFromContractWithCustomerExcludingAssessedTaxPercent" xlink:href="dgx-20221231.xsd#dgx_RevenueFromContractWithCustomerExcludingAssessedTaxPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_RevenueFromContractWithCustomerExcludingAssessedTaxPercent" xlink:to="lab_dgx_RevenueFromContractWithCustomerExcludingAssessedTaxPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_3e81496f-3402-4cc4-985a-e8457a1e44b4_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedge Accounting Basis Adjustment</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:to="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_3a7eee3b-403d-4b1f-8ad8-943c6ed92007_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_06b92c3a-74ec-4b18-ad2e-fa67d18016d9_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_6debc5c1-143d-46a6-85e6-b79c0c17be2e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred gain on cash flow hedges, net of taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_07546f7d-1b29-450d-b5c2-9bd9e5f2cac2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred state and local income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_561b87c4-f2b2-4e46-9bd1-e0068f3d6171_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_ca426fc1-a8ea-4e00-9b58-5370c3dbd9d4_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_b3816152-19c2-4e23-9216-966cc0d0fa74_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_5bc9b5f1-ba05-4d15-be66-ce1ba252e623_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Goodwill, Net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4057dafb-843a-408c-b920-2ba82a76a95b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_PerformanceShareUnitsWithMarketBasedRelativeTSRGoalMember_9c2ff9bf-1b59-42ee-afbd-d7a47f616326_terseLabel_en-US" xlink:label="lab_dgx_PerformanceShareUnitsWithMarketBasedRelativeTSRGoalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance share units with market-based relative TSR goal</link:label>
    <link:label id="lab_dgx_PerformanceShareUnitsWithMarketBasedRelativeTSRGoalMember_label_en-US" xlink:label="lab_dgx_PerformanceShareUnitsWithMarketBasedRelativeTSRGoalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance share units with market-based relative TSR goal [Member]</link:label>
    <link:label id="lab_dgx_PerformanceShareUnitsWithMarketBasedRelativeTSRGoalMember_documentation_en-US" xlink:label="lab_dgx_PerformanceShareUnitsWithMarketBasedRelativeTSRGoalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance share units with market-based relative TSR goal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_PerformanceShareUnitsWithMarketBasedRelativeTSRGoalMember" xlink:href="dgx-20221231.xsd#dgx_PerformanceShareUnitsWithMarketBasedRelativeTSRGoalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_PerformanceShareUnitsWithMarketBasedRelativeTSRGoalMember" xlink:to="lab_dgx_PerformanceShareUnitsWithMarketBasedRelativeTSRGoalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_4191f06d-4acf-4a2a-ab39-8c49ad68a1c9_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_RevenueCollectionofConsiderationPeriod_eb2d21ca-9010-4148-bdd9-f6226949470e_terseLabel_en-US" xlink:label="lab_dgx_RevenueCollectionofConsiderationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collection of consideration</link:label>
    <link:label id="lab_dgx_RevenueCollectionofConsiderationPeriod_label_en-US" xlink:label="lab_dgx_RevenueCollectionofConsiderationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Collection of Consideration Period</link:label>
    <link:label id="lab_dgx_RevenueCollectionofConsiderationPeriod_documentation_en-US" xlink:label="lab_dgx_RevenueCollectionofConsiderationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Collection of Consideration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_RevenueCollectionofConsiderationPeriod" xlink:href="dgx-20221231.xsd#dgx_RevenueCollectionofConsiderationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_RevenueCollectionofConsiderationPeriod" xlink:to="lab_dgx_RevenueCollectionofConsiderationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_5b7fd7ff-2cea-4b21-86aa-0441c6796a2b_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, at Cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_be24936a-96c2-4e94-90a9-bd9c0985ee9c_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Quest Diagnostics stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_80b36c25-14d9-4b6e-a622-ba076a0cd36c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FINANCIAL INSTRUMENTS</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_8a772147-193d-48f4-84d4-b14f10cc04a4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain]</link:label>
    <link:label id="lab_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_label_en-US" xlink:label="lab_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:to="lab_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_dea13b17-5463-4042-9cd7-286945f29c1e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares forfeited and cancelled weighted average grant date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_ThreePointFiveZeroPercentSeniorNotesdueMarch2025Member_5d741bf2-acef-414b-938c-8825f1ee251a_terseLabel_en-US" xlink:label="lab_dgx_ThreePointFiveZeroPercentSeniorNotesdueMarch2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.50% Senior Notes due March 2025</link:label>
    <link:label id="lab_dgx_ThreePointFiveZeroPercentSeniorNotesdueMarch2025Member_label_en-US" xlink:label="lab_dgx_ThreePointFiveZeroPercentSeniorNotesdueMarch2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Five Zero Percent Senior Notes due March 2025 [Member]</link:label>
    <link:label id="lab_dgx_ThreePointFiveZeroPercentSeniorNotesdueMarch2025Member_documentation_en-US" xlink:label="lab_dgx_ThreePointFiveZeroPercentSeniorNotesdueMarch2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Five Zero Percent Senior Notes due March 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ThreePointFiveZeroPercentSeniorNotesdueMarch2025Member" xlink:href="dgx-20221231.xsd#dgx_ThreePointFiveZeroPercentSeniorNotesdueMarch2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_ThreePointFiveZeroPercentSeniorNotesdueMarch2025Member" xlink:to="lab_dgx_ThreePointFiveZeroPercentSeniorNotesdueMarch2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_InvigorateProgramMember_a128f5a2-fa76-406f-9aea-369c1ea44ae0_terseLabel_en-US" xlink:label="lab_dgx_InvigorateProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invigorate Program</link:label>
    <link:label id="lab_dgx_InvigorateProgramMember_label_en-US" xlink:label="lab_dgx_InvigorateProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invigorate Program [Member]</link:label>
    <link:label id="lab_dgx_InvigorateProgramMember_documentation_en-US" xlink:label="lab_dgx_InvigorateProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invigorate Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_InvigorateProgramMember" xlink:href="dgx-20221231.xsd#dgx_InvigorateProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_InvigorateProgramMember" xlink:to="lab_dgx_InvigorateProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_SummaryOfSignificantAccountingPoliciesTable_8b21cc90-d3d3-4ec6-b911-c5fb17aaa894_terseLabel_en-US" xlink:label="lab_dgx_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_dgx_SummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_dgx_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_dgx_SummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_dgx_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of significant accounting policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_SummaryOfSignificantAccountingPoliciesTable" xlink:href="dgx-20221231.xsd#dgx_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_dgx_SummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7b318a67-84d3-4c9e-b167-9cfb4e637df1_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated amortization, intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_cf29a440-9e49-4a69-b9a8-b6e01638a21b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_aba4ce76-e9c1-44c0-a1e2-667ef926d4ca_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Beginning and Ending Liability Balances Unobservable Inputs</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_076e4aaa-2ad8-4fd9-8e1b-ef9afae40c24_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_d61fcd07-21ad-4d81-8a65-662d125a253f_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_33d4b967-02dd-4dc9-ab6a-26231fa9a546_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation not yet recognized, stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_1115e35d-55d5-4b63-893c-542514dcdda8_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_d21131f6-1da5-4d2a-ae67-b37dff7f1caa_negatedLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_cd5321a0-08cc-4303-9100-5ff6bde9ab67_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_26029f35-1917-4f9a-a750-027106e3a6c3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_ScheduleofLeaseTermandDiscountRateTableTextBlock_bc34c917-7428-44b8-84cf-caeb48d19b9f_terseLabel_en-US" xlink:label="lab_dgx_ScheduleofLeaseTermandDiscountRateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Term and Discount Rate</link:label>
    <link:label id="lab_dgx_ScheduleofLeaseTermandDiscountRateTableTextBlock_label_en-US" xlink:label="lab_dgx_ScheduleofLeaseTermandDiscountRateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Term and Discount Rate [Table Text Block]</link:label>
    <link:label id="lab_dgx_ScheduleofLeaseTermandDiscountRateTableTextBlock_documentation_en-US" xlink:label="lab_dgx_ScheduleofLeaseTermandDiscountRateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Term and Discount Rate [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ScheduleofLeaseTermandDiscountRateTableTextBlock" xlink:href="dgx-20221231.xsd#dgx_ScheduleofLeaseTermandDiscountRateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_ScheduleofLeaseTermandDiscountRateTableTextBlock" xlink:to="lab_dgx_ScheduleofLeaseTermandDiscountRateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_62d4676f-d64e-418d-9eaa-973cb3523b56_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_4da5c103-fc77-4219-9369-c44ed6643441_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_5ee5f8d7-9634-4bb6-9f45-0f87562778bf_netLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_48f5cec9-1e26-42cc-ae2f-cc359d44fdfc_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_eecda27d-55ba-4766-bce7-1eb4fa1dbb87_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ad76dd34-9717-4b35-a449-0d2ce4d6f67c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares vested weighted average grant date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_9ea063a7-ed75-4569-985d-3066ff041f35_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of investment, before tax</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Realized Gain (Loss) on Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:to="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_e3ac18a1-2ff2-424f-bc2d-2c44de373ec6_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_39a135c7-e904-4511-b346-3045fe561e90_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_05e4dc9b-88f6-42e4-b10f-92bc1fbe11b1_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_1f1e5f2a-76d4-47ce-9fea-8e9360f6a725_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_df9f4f52-e1a7-43b2-a2c9-7411eb2edea9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company's expense for contributions to its defined contribution plans</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_95895fca-a9ab-4e7e-a3ce-ab1c95847c4e_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_192c4b2c-94b4-41af-b62b-6ebae4510455_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of treasury stock, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_7135d5a9-28c6-4498-946c-d4890b4a9af1_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of treasury stock, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_b0ae0f74-d2f7-4ba1-b7f9-cd743357f14e_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1d54d181-d751-4491-826c-1ded8f46cd98_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_851386fa-32ad-445f-9d1c-bd7199f99f0a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net of allowance for credit losses of $30 and $31 as of December&#160;31, 2022 and 2021, respectively</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_566d1d6e-d9b3-40bf-a034-61d9d00b01a3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_OtherEquityComponentsMember_2c141a9b-622f-4b74-bce9-3f9763825b4a_terseLabel_en-US" xlink:label="lab_dgx_OtherEquityComponentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_dgx_OtherEquityComponentsMember_label_en-US" xlink:label="lab_dgx_OtherEquityComponentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Equity Components [Member]</link:label>
    <link:label id="lab_dgx_OtherEquityComponentsMember_documentation_en-US" xlink:label="lab_dgx_OtherEquityComponentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Equity Components [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_OtherEquityComponentsMember" xlink:href="dgx-20221231.xsd#dgx_OtherEquityComponentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_OtherEquityComponentsMember" xlink:to="lab_dgx_OtherEquityComponentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_3ccab050-87f7-4162-937e-6bcd2197b66a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c0d8bd05-4388-4e93-915c-e2b8c2640ed3_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding, beginning of year</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dbf83937-5efe-4738-8eb4-2caa3e994193_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding, end of year</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPeriodIncreaseDecrease_4dd9e797-0471-4b9d-be34-de2ed16db274_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_5d90e165-2558-4fdf-b653-b396ceea11ff_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-operating (expense) income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_ec80dc22-92aa-40b5-bcb5-e0585e356c0c_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-operating expenses, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_8bbb982b-2bf5-487c-87fd-0f6252d80420_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_NetOperatingLossCarryfowardsNetOfValuationAllowance_217c0655-c261-41c9-9b75-fdc358d908f9_terseLabel_en-US" xlink:label="lab_dgx_NetOperatingLossCarryfowardsNetOfValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryfowards, net of valuation allowance</link:label>
    <link:label id="lab_dgx_NetOperatingLossCarryfowardsNetOfValuationAllowance_label_en-US" xlink:label="lab_dgx_NetOperatingLossCarryfowardsNetOfValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryfowards, net of valuation allowance</link:label>
    <link:label id="lab_dgx_NetOperatingLossCarryfowardsNetOfValuationAllowance_documentation_en-US" xlink:label="lab_dgx_NetOperatingLossCarryfowardsNetOfValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount after allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_NetOperatingLossCarryfowardsNetOfValuationAllowance" xlink:href="dgx-20221231.xsd#dgx_NetOperatingLossCarryfowardsNetOfValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_NetOperatingLossCarryfowardsNetOfValuationAllowance" xlink:to="lab_dgx_NetOperatingLossCarryfowardsNetOfValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_9eacc294-f748-4596-9c0b-9d2857d3a291_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_OperatingandFinanceLeaseLiability_0bbc9321-22d4-4f7b-ac3c-081b570ae467_totalLabel_en-US" xlink:label="lab_dgx_OperatingandFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_dgx_OperatingandFinanceLeaseLiability_label_en-US" xlink:label="lab_dgx_OperatingandFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and Finance Lease, Liability</link:label>
    <link:label id="lab_dgx_OperatingandFinanceLeaseLiability_documentation_en-US" xlink:label="lab_dgx_OperatingandFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lessee's discounted obligation for lease payments from operating and finance leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_OperatingandFinanceLeaseLiability" xlink:href="dgx-20221231.xsd#dgx_OperatingandFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_OperatingandFinanceLeaseLiability" xlink:to="lab_dgx_OperatingandFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_COVID19TestingServicesMember_07a0dfb6-0bc5-4d47-899c-1199acaefb6a_terseLabel_en-US" xlink:label="lab_dgx_COVID19TestingServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 testing services</link:label>
    <link:label id="lab_dgx_COVID19TestingServicesMember_label_en-US" xlink:label="lab_dgx_COVID19TestingServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Testing Services [Member]</link:label>
    <link:label id="lab_dgx_COVID19TestingServicesMember_documentation_en-US" xlink:label="lab_dgx_COVID19TestingServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Testing Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_COVID19TestingServicesMember" xlink:href="dgx-20221231.xsd#dgx_COVID19TestingServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_COVID19TestingServicesMember" xlink:to="lab_dgx_COVID19TestingServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_b8329c4c-c0bc-4369-8a3d-69dbcdd0d69e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_48811eec-d60f-412c-aa79-e18369323e55_netLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f993e8db-6c5a-48fd-b7f3-ad63797390f5_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e9823f7a-764e-40b7-b133-2877501f613e_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_PackHealthAndLabtechMember_1aa9db60-5332-4975-8daf-8ec421af3eb4_terseLabel_en-US" xlink:label="lab_dgx_PackHealthAndLabtechMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pack Health and Labtech</link:label>
    <link:label id="lab_dgx_PackHealthAndLabtechMember_label_en-US" xlink:label="lab_dgx_PackHealthAndLabtechMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pack Health and Labtech [Member]</link:label>
    <link:label id="lab_dgx_PackHealthAndLabtechMember_documentation_en-US" xlink:label="lab_dgx_PackHealthAndLabtechMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pack Health and Labtech</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_PackHealthAndLabtechMember" xlink:href="dgx-20221231.xsd#dgx_PackHealthAndLabtechMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_PackHealthAndLabtechMember" xlink:to="lab_dgx_PackHealthAndLabtechMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_6fdc1147-8a40-46f6-8bee-e30835a0e21f_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_af0b8d36-d683-4d15-b504-e187b9663185_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_d502609a-7862-497b-b655-c1056ea74acb_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_6d7f5541-e705-4195-977c-37ed7317cf5a_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_ScheduleOfShareholdersEquityTable_1ae85fa5-033d-45da-9251-a3aba26467d8_terseLabel_en-US" xlink:label="lab_dgx_ScheduleOfShareholdersEquityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Shareholders' Equity [Table]</link:label>
    <link:label id="lab_dgx_ScheduleOfShareholdersEquityTable_label_en-US" xlink:label="lab_dgx_ScheduleOfShareholdersEquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Shareholders' Equity [Table]</link:label>
    <link:label id="lab_dgx_ScheduleOfShareholdersEquityTable_documentation_en-US" xlink:label="lab_dgx_ScheduleOfShareholdersEquityTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Shareholders' Equity [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ScheduleOfShareholdersEquityTable" xlink:href="dgx-20221231.xsd#dgx_ScheduleOfShareholdersEquityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_ScheduleOfShareholdersEquityTable" xlink:to="lab_dgx_ScheduleOfShareholdersEquityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_3e387782-0123-4eac-86f5-d115bc1a7a6c_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Country</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_e41142ed-de03-4aa3-9d2a-5db3d0e068f1_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6f4ca337-f3af-4a13-a502-8c1bef4c66ca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Transactions Under The Company's Stock Option Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_6bd68b77-fc22-497e-9ee6-235f757c3ab6_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_67cbbc60-fd32-434c-b2ba-a0b0e9b8dbd5_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_678d8d0a-8948-4d34-9f04-5e2417dc4f92_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_08be670a-aead-428b-b964-9ea770b0ae3a_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_LoanCommitmentMember_311480e6-7bab-445e-95c1-ec65a34f74a3_terseLabel_en-US" xlink:label="lab_dgx_LoanCommitmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Commitment</link:label>
    <link:label id="lab_dgx_LoanCommitmentMember_label_en-US" xlink:label="lab_dgx_LoanCommitmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Commitment [Member]</link:label>
    <link:label id="lab_dgx_LoanCommitmentMember_documentation_en-US" xlink:label="lab_dgx_LoanCommitmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LoanCommitmentMember" xlink:href="dgx-20221231.xsd#dgx_LoanCommitmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_LoanCommitmentMember" xlink:to="lab_dgx_LoanCommitmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_02fdf95c-073d-4340-a70e-f45e8358dbc7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities not currently deductible</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_ab31963e-6913-4fad-8304-836438be167a_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_dd8310a9-1bb5-4f1b-8be3-1ae38042fd30_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_46646ef7-1717-4dc8-bf4b-dc65a7ccdc96_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GOODWILL AND INTANGIBLE ASSETS</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_Sharebasedcompensationexcesstaxbenefitamount_691b9293-9552-48fd-b87d-349299c3c4e2_terseLabel_en-US" xlink:label="lab_dgx_Sharebasedcompensationexcesstaxbenefitamount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation, excess tax benefit, amount</link:label>
    <link:label id="lab_dgx_Sharebasedcompensationexcesstaxbenefitamount_label_en-US" xlink:label="lab_dgx_Sharebasedcompensationexcesstaxbenefitamount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation, excess tax benefit, amount</link:label>
    <link:label id="lab_dgx_Sharebasedcompensationexcesstaxbenefitamount_documentation_en-US" xlink:label="lab_dgx_Sharebasedcompensationexcesstaxbenefitamount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation, excess tax benefit, amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_Sharebasedcompensationexcesstaxbenefitamount" xlink:href="dgx-20221231.xsd#dgx_Sharebasedcompensationexcesstaxbenefitamount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_Sharebasedcompensationexcesstaxbenefitamount" xlink:to="lab_dgx_Sharebasedcompensationexcesstaxbenefitamount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_94df826f-f4a1-4aee-ae86-c7197450f014_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_a5666f32-743c-4abf-aa28-c765e60c4919_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_c23d82c6-43f6-4c70-b2bd-17e20fb27686_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_SdcpIiGradedVestingPercentage_0d1bba55-6746-4afe-9325-995059f72b62_terseLabel_en-US" xlink:label="lab_dgx_SdcpIiGradedVestingPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SDCP II graded vesting percentage</link:label>
    <link:label id="lab_dgx_SdcpIiGradedVestingPercentage_label_en-US" xlink:label="lab_dgx_SdcpIiGradedVestingPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SDCP II graded vesting percentage</link:label>
    <link:label id="lab_dgx_SdcpIiGradedVestingPercentage_documentation_en-US" xlink:label="lab_dgx_SdcpIiGradedVestingPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SDCP II graded vesting percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_SdcpIiGradedVestingPercentage" xlink:href="dgx-20221231.xsd#dgx_SdcpIiGradedVestingPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_SdcpIiGradedVestingPercentage" xlink:to="lab_dgx_SdcpIiGradedVestingPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_20073425-9956-4714-89c5-f219519e334c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_f8fc0c6b-e718-4708-8f66-c61cc7abda9f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cb60fb21-8633-4039-9adc-e1b8de50ad59_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearTwo_08bce241-54e6-42e9-8f49-b7e83738d397_totalLabel_en-US" xlink:label="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating and Finance Lease, Liability, Payments, Due Year Two</link:label>
    <link:label id="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearTwo_documentation_en-US" xlink:label="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating and Finance Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="dgx-20221231.xsd#dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_8ed924e8-a33c-4cb0-b5e8-ad908e0321c6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defered federal income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_c3c008b5-5df0-4f0c-a8ca-3255fe954594_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_201d1689-0d71-47ab-bad2-753bed45ec0d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_91ccdd05-063f-480f-9676-154f025596d2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_RoutineclinicaltestingservicesMember_5a301a83-a75b-408e-a7d1-4747b8fd4dc9_terseLabel_en-US" xlink:label="lab_dgx_RoutineclinicaltestingservicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Routine clinical testing and other services</link:label>
    <link:label id="lab_dgx_RoutineclinicaltestingservicesMember_label_en-US" xlink:label="lab_dgx_RoutineclinicaltestingservicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Routine clinical testing services [Member]</link:label>
    <link:label id="lab_dgx_RoutineclinicaltestingservicesMember_documentation_en-US" xlink:label="lab_dgx_RoutineclinicaltestingservicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Routine clinical testing services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_RoutineclinicaltestingservicesMember" xlink:href="dgx-20221231.xsd#dgx_RoutineclinicaltestingservicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_RoutineclinicaltestingservicesMember" xlink:to="lab_dgx_RoutineclinicaltestingservicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_08e4540c-89a4-4c34-a796-9905a4d71fbc_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from disposition of joint venture</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_860ae8cc-5a11-4219-8481-6dbbffade3a9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c9fd5683-19ad-4852-bff6-d6b493cfff67_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding - diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_dbd49e54-b8ba-4a7a-9260-45d03337ea4a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_645491ef-7dff-4f0d-bd87-9615b7e1e50c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected holding period, in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_d3f631d9-320c-4329-a8df-080769156197_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Building Improvements</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_58fc31b2-60c0-4c3a-b8a3-5c2e62505f1d_verboseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Improvements</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_823fd289-274c-462b-a3fd-204f3b76392c_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedWorkingCapital_77920f5a-ec91-4ed9-922b-d78334e5444c_terseLabel_en-US" xlink:label="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working capital</link:label>
    <link:label id="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedWorkingCapital_label_en-US" xlink:label="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Working Capital</link:label>
    <link:label id="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedWorkingCapital_documentation_en-US" xlink:label="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Working Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedWorkingCapital" xlink:href="dgx-20221231.xsd#dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedWorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedWorkingCapital" xlink:to="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedWorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_de25657e-0f9e-4758-a846-0ce27bcb51c5_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value at grant date (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4cb8a8cf-866f-4f43-9172-b34b83fcb54e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares granted weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_77eff5e8-41e1-4752-bee2-85645bc0dd9c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation arrangement with individual, employer contribution</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Contributions by Employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_0f24a470-67a8-477b-8b51-6735716cc006_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_dd5fe2be-ecd6-4019-b274-28026d86d0ae_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, end of year aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_ea27bcc2-6da8-4056-aa9f-68edbe3718dd_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_05c93fcf-b9da-4485-8f0b-72ec54b3a30f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_646ae682-0ac9-4c22-b980-90e2c851ad94_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity interest in acquiree, remeasurement gain</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:to="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_43b4d679-a051-4668-955a-386679fcbb40_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant change in unrecognized tax benefits is reasonably possible, estimated range of change, upper bound</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_49e5eaeb-a294-45a0-90e7-b254c7255630_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7ba02a3c-66c3-4485-9e42-bc81f7406724_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_11a47c8a-d073-433e-9e44-c4166a521e77_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeMember_60a6d26d-31aa-49a8-8868-81f19ab236ad_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income</link:label>
    <link:label id="lab_us-gaap_OtherIncomeMember_label_en-US" xlink:label="lab_us-gaap_OtherIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeMember" xlink:to="lab_us-gaap_OtherIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_06ad0a2d-0bd8-4499-a035-cc1a390913a3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_4e482cb7-cf83-422e-84b4-64fc51ddb282_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in equity method investees</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_8592814b-d68a-4ece-974f-aa864d269791_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments carrying value</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_9928c993-d2ff-46db-9764-579cdbcbeb01_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Deferred Losses on Cash Flow Hedges, net of tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:to="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_dc45d905-b068-4d7a-b3f8-505df37f415d_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable associated with capital expenditures</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_57ebfb5c-e962-448e-a691-83f056a86f3a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FacilityClosingMember_2aa7eaaa-7494-470d-9538-24d87017a2e4_terseLabel_en-US" xlink:label="lab_us-gaap_FacilityClosingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility-Related Costs</link:label>
    <link:label id="lab_us-gaap_FacilityClosingMember_label_en-US" xlink:label="lab_us-gaap_FacilityClosingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Closing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FacilityClosingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FacilityClosingMember" xlink:to="lab_us-gaap_FacilityClosingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesDateAxis_f5f5e912-89e7-452c-bbf7-fd4b6d4b6270_terseLabel_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases, Date [Axis]</link:label>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesDateAxis_label_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases, Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcceleratedShareRepurchasesDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesDateAxis" xlink:to="lab_us-gaap_AcceleratedShareRepurchasesDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_d458dfe2-8edf-4462-9e8a-f73b68190983_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_bc124e0d-8597-4d81-b04e-1db11bdab48a_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_d46337dd-38f3-47d5-abcf-c85a7b9cb98d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_a7f63446-a0b9-4f64-b339-e5aeb638aa88_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity interest in acquiree, fair value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:to="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_90b88105-873f-4ede-93ae-b1d18f47c988_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income attributable to Quest Diagnostics</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_28cea5ed-92eb-40fa-98e6-4d0c43864cb2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_MercyHealthMember_77c7dd19-b93c-4612-a3db-a727cb5a48c8_terseLabel_en-US" xlink:label="lab_dgx_MercyHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mercy Health</link:label>
    <link:label id="lab_dgx_MercyHealthMember_label_en-US" xlink:label="lab_dgx_MercyHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mercy Health [Member]</link:label>
    <link:label id="lab_dgx_MercyHealthMember_documentation_en-US" xlink:label="lab_dgx_MercyHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mercy Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_MercyHealthMember" xlink:href="dgx-20221231.xsd#dgx_MercyHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_MercyHealthMember" xlink:to="lab_dgx_MercyHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_ef9e077a-2dc7-4e05-a5aa-ad4ed84702cc_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_2f74dc88-d002-4fdd-8950-f9013cbff8cc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinanceLeaseLiabilities_8cdc98bf-fa56-45a0-aabd-7f4cca6962e1_terseLabel_en-US" xlink:label="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinanceLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinanceLeaseLiabilities_label_en-US" xlink:label="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinanceLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finance Lease Liabilities</link:label>
    <link:label id="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinanceLeaseLiabilities_documentation_en-US" xlink:label="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinanceLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finance Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinanceLeaseLiabilities" xlink:href="dgx-20221231.xsd#dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinanceLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinanceLeaseLiabilities" xlink:to="lab_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinanceLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_b2156ce4-190d-461c-8b9c-ededafa5d598_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_eafbc1b3-0cca-48fb-a103-63eba0e005e5_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax provision at statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_809781be-02db-437f-92f0-e225be115c18_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Separation Costs</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestAndDividendIncomeOperating_cb5dfa7e-0e4e-4d55-9032-411248fe8335_terseLabel_en-US" xlink:label="lab_us-gaap_InterestAndDividendIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestAndDividendIncomeOperating_label_en-US" xlink:label="lab_us-gaap_InterestAndDividendIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and Dividend Income, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDividendIncomeOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDividendIncomeOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndDividendIncomeOperating" xlink:to="lab_us-gaap_InterestAndDividendIncomeOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a5e7822f-ce53-4e51-9c8c-78675815e952_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares purchased by eligible employees under ESPP</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_271f0630-0671-47e2-8d3b-1777dd50e228_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b8a14991-b6d7-41c1-ab2d-a8275fd354f9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, beginning of year</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7dbb4da8-c735-44f9-9461-941fcd714800_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, end of year</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_278b34be-42e4-4c77-aad1-a27a295dbf38_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local income taxes, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_ade78288-4b26-4015-8865-d2fe361693cb_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_d9114cf5-e699-491c-a979-6b1217424f5a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_be9c7c83-1a64-4111-97a3-f1f065b4e2dd_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_GovernmentPayersMember_a7d7608d-6f1e-44d6-b3a9-e97866d5cc85_terseLabel_en-US" xlink:label="lab_dgx_GovernmentPayersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government payers</link:label>
    <link:label id="lab_dgx_GovernmentPayersMember_label_en-US" xlink:label="lab_dgx_GovernmentPayersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Payers [Member]</link:label>
    <link:label id="lab_dgx_GovernmentPayersMember_documentation_en-US" xlink:label="lab_dgx_GovernmentPayersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Payers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_GovernmentPayersMember" xlink:href="dgx-20221231.xsd#dgx_GovernmentPayersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_GovernmentPayersMember" xlink:to="lab_dgx_GovernmentPayersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_42757c02-7e2e-4421-bd40-be0bcb3c2bb3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Amortization Expense Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary_36afcecf-2e7b-4926-adcf-f24dfdeade1a_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligation, 2022</link:label>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary_label_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary" xlink:to="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_57f88b2e-fa46-4990-b3f6-f1d4b613bb3b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total (gains)/losses included in earnings - realized/unrealized</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_04516e2e-15de-418c-b615-b8987f147a66_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value adjustments included in earnings - realized/unrealized</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_AgreementtoOutsourceBillingandCollectionFunction_46fc3d78-d801-4f9e-828d-ed2de8cf5ac6_terseLabel_en-US" xlink:label="lab_dgx_AgreementtoOutsourceBillingandCollectionFunction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement to outsource billing and collection function</link:label>
    <link:label id="lab_dgx_AgreementtoOutsourceBillingandCollectionFunction_label_en-US" xlink:label="lab_dgx_AgreementtoOutsourceBillingandCollectionFunction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement to Outsource Billing and Collection Function</link:label>
    <link:label id="lab_dgx_AgreementtoOutsourceBillingandCollectionFunction_documentation_en-US" xlink:label="lab_dgx_AgreementtoOutsourceBillingandCollectionFunction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement to Outsource Billing and Collection Function</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_AgreementtoOutsourceBillingandCollectionFunction" xlink:href="dgx-20221231.xsd#dgx_AgreementtoOutsourceBillingandCollectionFunction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_AgreementtoOutsourceBillingandCollectionFunction" xlink:to="lab_dgx_AgreementtoOutsourceBillingandCollectionFunction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_00e30893-fb86-43dd-a296-ea1e37395750_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration arrangements, range of outcomes, value, high</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_87bb0bb5-d1b4-48f5-b0a2-725ef17ef798_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b7fbe248-e57b-4481-ae2c-1e871f771f5d_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares forfeited and cancelled</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_f9bfacff-7494-4d31-8470-141549526e35_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_90815f31-fe7e-4d2b-a4dd-0786c9000ff8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_02bae621-ef5d-4d34-8396-b531ef4f1810_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_09ab5af5-89d6-4a35-a476-fea9b43eb911_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RESTRUCTURING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4f5d4f83-7a27-4c03-af6f-8f27a6f0a2a0_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8546a111-1008-4c97-bd9b-490ac2d5c923_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated net loss from designated or qualifying cash flow hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_34ee8f52-7160-4dea-a19c-9cf87a0bffad_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3d82755e-dcd4-48b5-9f40-c344c266de85_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeDicountRateUsedToDetermineFairValue_a39c0e9d-54fa-4b10-8941-d5b79ec24f5f_terseLabel_en-US" xlink:label="lab_dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeDicountRateUsedToDetermineFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity interest in acquiree, discount rate used to determine fair value</link:label>
    <link:label id="lab_dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeDicountRateUsedToDetermineFairValue_label_en-US" xlink:label="lab_dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeDicountRateUsedToDetermineFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Dicount Rate used to determine fair value</link:label>
    <link:label id="lab_dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeDicountRateUsedToDetermineFairValue_documentation_en-US" xlink:label="lab_dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeDicountRateUsedToDetermineFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Dicount Rate used to determine fair value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeDicountRateUsedToDetermineFairValue" xlink:href="dgx-20221231.xsd#dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeDicountRateUsedToDetermineFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeDicountRateUsedToDetermineFairValue" xlink:to="lab_dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeDicountRateUsedToDetermineFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_IncreaseDecreaseinCommonStockDividendsDeclaredasPercent_c715d025-cf5e-478c-a15a-db67accfe562_terseLabel_en-US" xlink:label="lab_dgx_IncreaseDecreaseinCommonStockDividendsDeclaredasPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in quarterly dividends as percent</link:label>
    <link:label id="lab_dgx_IncreaseDecreaseinCommonStockDividendsDeclaredasPercent_label_en-US" xlink:label="lab_dgx_IncreaseDecreaseinCommonStockDividendsDeclaredasPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Common Stock, Dividends, Declared as Percent</link:label>
    <link:label id="lab_dgx_IncreaseDecreaseinCommonStockDividendsDeclaredasPercent_documentation_en-US" xlink:label="lab_dgx_IncreaseDecreaseinCommonStockDividendsDeclaredasPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Common Stock, Dividends, Declared as Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_IncreaseDecreaseinCommonStockDividendsDeclaredasPercent" xlink:href="dgx-20221231.xsd#dgx_IncreaseDecreaseinCommonStockDividendsDeclaredasPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_IncreaseDecreaseinCommonStockDividendsDeclaredasPercent" xlink:to="lab_dgx_IncreaseDecreaseinCommonStockDividendsDeclaredasPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_7227dafc-e74d-4715-bd1e-084604645d9e_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_0062a2a9-c55c-4415-9f17-acac9b5aa8e6_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_9ff5890a-f942-45b3-be91-6b519d03c722_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends per common share</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_e82799b5-73e4-411e-a083-d0c958d1d8af_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_eeec74f3-e284-49fe-8dbf-645cf94fad16_negatedLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions to noncontrolling interest partners</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_be6a07d2-5a95-4c0a-b4da-ee097c9484ec_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6cc45faa-ebaa-4abe-8cb4-cd30be8d0cb0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bf80b4a1-d69f-4744-8a5a-6862c1a57ec5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_aa07f9c1-658d-4bcf-8f96-df0b4e7a4ea7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROPERTY, PLANT AND EQUIPMENT</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_UnrecordedUnconditionalPurchaseObligationDuewithinTwoandThreeYears_9f39847e-ee33-4a01-9930-0b773ef13515_terseLabel_en-US" xlink:label="lab_dgx_UnrecordedUnconditionalPurchaseObligationDuewithinTwoandThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligation, 2023 through 2024</link:label>
    <link:label id="lab_dgx_UnrecordedUnconditionalPurchaseObligationDuewithinTwoandThreeYears_label_en-US" xlink:label="lab_dgx_UnrecordedUnconditionalPurchaseObligationDuewithinTwoandThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation, Due within Two and Three Years</link:label>
    <link:label id="lab_dgx_UnrecordedUnconditionalPurchaseObligationDuewithinTwoandThreeYears_documentation_en-US" xlink:label="lab_dgx_UnrecordedUnconditionalPurchaseObligationDuewithinTwoandThreeYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation, Due within Two and Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_UnrecordedUnconditionalPurchaseObligationDuewithinTwoandThreeYears" xlink:href="dgx-20221231.xsd#dgx_UnrecordedUnconditionalPurchaseObligationDuewithinTwoandThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_UnrecordedUnconditionalPurchaseObligationDuewithinTwoandThreeYears" xlink:to="lab_dgx_UnrecordedUnconditionalPurchaseObligationDuewithinTwoandThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_HealthcareInsurersMember_03ba75f7-b944-4d58-ad3a-06662658ab0d_terseLabel_en-US" xlink:label="lab_dgx_HealthcareInsurersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare insurers:</link:label>
    <link:label id="lab_dgx_HealthcareInsurersMember_label_en-US" xlink:label="lab_dgx_HealthcareInsurersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare Insurers [Member]</link:label>
    <link:label id="lab_dgx_HealthcareInsurersMember_documentation_en-US" xlink:label="lab_dgx_HealthcareInsurersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare Insurers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_HealthcareInsurersMember" xlink:href="dgx-20221231.xsd#dgx_HealthcareInsurersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_HealthcareInsurersMember" xlink:to="lab_dgx_HealthcareInsurersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5ae79b58-f5dd-4142-ab1b-8e20a8acb316_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, end of year aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_31f79b08-b212-4379-84e7-b4899e743d72_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_3d805604-024f-4fe1-8df0-4d99414cc888_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset, accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_7ca32e37-b9f3-440b-aa07-29fab929c07c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends received from equity method investees</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:to="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_4d2843b7-bcd1-4b40-b5e2-fc7d1ac1c943_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating costs and expenses, net</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_bda96712-0a7f-466d-b114-bce9f66b1102_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_1f483b46-1159-422e-810e-fa6253edf71e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationLineItems_59ac83d6-6f01-45b5-b90c-6ec22c472fcb_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationLineItems" xlink:to="lab_us-gaap_ReclassificationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_778e7c3c-ed7e-407f-bd30-4da8373bec9b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under benefit plans, sharers</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_bf68e1cf-aa7f-492f-949a-e10e5944e44e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_1d5f45f2-8d2b-4837-8725-92232d9f8b05_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_741058aa-653f-4ac1-85bb-c79beef7e179_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Number of Shares, Par Value and Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_d66f8309-25c7-4f6e-b120-2afbd1269405_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_2866433e-60bd-4e0f-a973-6f3c358793fd_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_79d19535-ee8c-4c26-a311-882b131f2d45_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_3cd41b91-b0c2-44db-abb1-3f56fc67defb_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives designated as hedging instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_301a2ab4-8912-4e88-9a1b-1ba364907439_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a10663c0-64ea-449d-b017-6d1df35e1c07_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, granted weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsDomain_3796c8e7-38a4-4db7-b8fc-5c77dae64acb_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsDomain" xlink:to="lab_us-gaap_SubsegmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_2f6a2792-e237-4dcb-b93d-5532fc6a90b9_totalLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_066c633f-c72b-4d4d-b903-7786faa4c056_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income statement (income) expense</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_InvestmentwithoutReadilyDeterminableFairValueImpairment_a54a11b5-45bc-43f4-9d1f-7df57920d609_terseLabel_en-US" xlink:label="lab_dgx_InvestmentwithoutReadilyDeterminableFairValueImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment charges</link:label>
    <link:label id="lab_dgx_InvestmentwithoutReadilyDeterminableFairValueImpairment_label_en-US" xlink:label="lab_dgx_InvestmentwithoutReadilyDeterminableFairValueImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment without Readily Determinable Fair Value, Impairment</link:label>
    <link:label id="lab_dgx_InvestmentwithoutReadilyDeterminableFairValueImpairment_documentation_en-US" xlink:label="lab_dgx_InvestmentwithoutReadilyDeterminableFairValueImpairment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment without Readily Determinable Fair Value, Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_InvestmentwithoutReadilyDeterminableFairValueImpairment" xlink:href="dgx-20221231.xsd#dgx_InvestmentwithoutReadilyDeterminableFairValueImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_InvestmentwithoutReadilyDeterminableFairValueImpairment" xlink:to="lab_dgx_InvestmentwithoutReadilyDeterminableFairValueImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_d664a27f-46e7-44db-a577-eb0ef8333490_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_7999ae6b-2b2e-4f33-8809-9916e1f773ad_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_ea001eb6-25cb-4051-b827-f7056ea3bae6_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_3ff55f49-cd18-4a50-9daa-17a75003c61a_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DESCRIPTION OF BUSINESS</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_f272113d-a2d9-4633-9a65-ec78d6e4c2a1_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_ac819d4b-0903-406c-9fec-c8ce4010990a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_da0cba81-00d0-4ea4-a9d9-a2cdd31cd0b1_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current federal tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_ae69c6d3-4846-4abf-8491-11c1a49c13df_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_61dfa79b-c2e8-4789-8aa4-66387f341e85_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e8c76d09-f19a-4624-bf11-fa241be9643a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, beginning of year weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c295aaf9-2c9a-4510-a9a7-9b550fa1eba0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, end of year weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_802f0f89-b0b4-48c6-92a9-5184c050a157_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_bc29c808-9d50-4419-8d63-ae727b89d4a3_totalLabel_en-US" xlink:label="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating and Finance Lease, Liability, Payments, Due Next Twelve Months</link:label>
    <link:label id="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_documentation_en-US" xlink:label="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating and Finance Lease, Liability, Payments, Due Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="dgx-20221231.xsd#dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_b7f8ce06-e2f8-4ea9-a694-01e8a3a9b595_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of credit outstanding, amount</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_MemorialHermannMember_3ebcbfd1-7ef1-42af-9118-7402cc8962c5_terseLabel_en-US" xlink:label="lab_dgx_MemorialHermannMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Memorial Hermann</link:label>
    <link:label id="lab_dgx_MemorialHermannMember_label_en-US" xlink:label="lab_dgx_MemorialHermannMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Memorial Hermann [Member]</link:label>
    <link:label id="lab_dgx_MemorialHermannMember_documentation_en-US" xlink:label="lab_dgx_MemorialHermannMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Memorial Hermann [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_MemorialHermannMember" xlink:href="dgx-20221231.xsd#dgx_MemorialHermannMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_MemorialHermannMember" xlink:to="lab_dgx_MemorialHermannMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7dfe4a2d-1175-4c43-9a7b-de733a047946_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c53d0e95-f440-49b3-af4e-fbeefd3c66e2_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_91961971-0323-4431-8ad1-2b7d252ceada_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_0d39f4ea-4a93-41be-9723-00691e21a84f_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_be7db068-eed6-493d-affa-1c9e4c93df26_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_491f4266-f1f5-46df-854b-451566770815_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate, Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_b978df77-f9c8-4510-9e66-8b8232e36e76_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUE RECOGNITION</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_cc9885e5-2229-469b-8ec8-20106f1cb107_terseLabel_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash acquired from acquisition</link:label>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_d7f76bf8-bee5-4c10-9c32-086888ba68d1_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: cash acquired</link:label>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_label_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAcquiredFromAcquisition" xlink:to="lab_us-gaap_CashAcquiredFromAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_a1d0bcfe-5a5f-430a-b9ed-3ac52cd15edb_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateMember_dca5a4ec-f81b-4423-bc41-7e8d6c211252_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General corporate income (expenses), Net</link:label>
    <link:label id="lab_us-gaap_CorporateMember_label_en-US" xlink:label="lab_us-gaap_CorporateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateMember" xlink:to="lab_us-gaap_CorporateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_6455efc6-fba7-4736-a210-77ef7441da7a_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_ScheduleOfShareBasedPaymentAwardPerformanceShareUnitsValuationAssumptionsTableTextBlock_d6b30eb1-e674-464d-98c4-7ff2d1828762_terseLabel_en-US" xlink:label="lab_dgx_ScheduleOfShareBasedPaymentAwardPerformanceShareUnitsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assumptions Used in Valuing The Company's Performance Share Units</link:label>
    <link:label id="lab_dgx_ScheduleOfShareBasedPaymentAwardPerformanceShareUnitsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_dgx_ScheduleOfShareBasedPaymentAwardPerformanceShareUnitsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Performance Share Units, Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_dgx_ScheduleOfShareBasedPaymentAwardPerformanceShareUnitsValuationAssumptionsTableTextBlock_documentation_en-US" xlink:label="lab_dgx_ScheduleOfShareBasedPaymentAwardPerformanceShareUnitsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Performance Share Units, Valuation Assumptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ScheduleOfShareBasedPaymentAwardPerformanceShareUnitsValuationAssumptionsTableTextBlock" xlink:href="dgx-20221231.xsd#dgx_ScheduleOfShareBasedPaymentAwardPerformanceShareUnitsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_ScheduleOfShareBasedPaymentAwardPerformanceShareUnitsValuationAssumptionsTableTextBlock" xlink:to="lab_dgx_ScheduleOfShareBasedPaymentAwardPerformanceShareUnitsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f3b6d04e-48b9-4bb6-84aa-a6daea9f7fa2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_e90a66c9-edcc-4e30-abac-815c8bf9be75_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c8734e5c-70ab-463b-ab41-251f894f5a91_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee payroll tax withholdings on stock issued under stock-based compensation plans</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_dff9c429-1332-4eea-bc8b-9dc2aeaa22cc_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_FeeforserviceMember_e2570952-b042-4e67-b5a6-856b8f341e33_terseLabel_en-US" xlink:label="lab_dgx_FeeforserviceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fee-for-service</link:label>
    <link:label id="lab_dgx_FeeforserviceMember_label_en-US" xlink:label="lab_dgx_FeeforserviceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fee-for-service [Member]</link:label>
    <link:label id="lab_dgx_FeeforserviceMember_documentation_en-US" xlink:label="lab_dgx_FeeforserviceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fee-for-service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_FeeforserviceMember" xlink:href="dgx-20221231.xsd#dgx_FeeforserviceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_FeeforserviceMember" xlink:to="lab_dgx_FeeforserviceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_c14c4ad8-150c-458a-a7c1-a6e38978e51e_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_ce4554e7-e2d8-48aa-82b3-0ff04f77ee29_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, remaining authorized repurchase amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_2fbbfba5-bafa-4a7d-8120-b12302638813_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reissuance of shares for employee benefit plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Treasury Stock Reissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_0bc0c5e4-f5b5-41c8-a0ad-df8dc891feaa_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCOUNTS PAYABLE AND ACCRUED EXPENSES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_FourpointtwofivepercentSeniorNotesDue2024Member_2f05bec7-f87d-4e2a-80b2-2fd612cd9623_terseLabel_en-US" xlink:label="lab_dgx_FourpointtwofivepercentSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.25% Senior Notes due April 2024</link:label>
    <link:label id="lab_dgx_FourpointtwofivepercentSeniorNotesDue2024Member_label_en-US" xlink:label="lab_dgx_FourpointtwofivepercentSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four point two five percent Senior Notes Due 2024 [Member]</link:label>
    <link:label id="lab_dgx_FourpointtwofivepercentSeniorNotesDue2024Member_documentation_en-US" xlink:label="lab_dgx_FourpointtwofivepercentSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four point two five percent Senior Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_FourpointtwofivepercentSeniorNotesDue2024Member" xlink:href="dgx-20221231.xsd#dgx_FourpointtwofivepercentSeniorNotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_FourpointtwofivepercentSeniorNotesDue2024Member" xlink:to="lab_dgx_FourpointtwofivepercentSeniorNotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4aef6fa3-39a4-4bb4-86be-459e58ce36f1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_f5d1c98d-cf90-4baa-b335-811e4d42b1ef_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5ea5ccfd-9900-4daa-a708-02faac82b023_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_TwoPointNineFivePercentSeniorNotesdueJune2030Member_31e2ad4a-70c0-464b-8688-2c520b85bbc8_terseLabel_en-US" xlink:label="lab_dgx_TwoPointNineFivePercentSeniorNotesdueJune2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Senior Notes due June 2030</link:label>
    <link:label id="lab_dgx_TwoPointNineFivePercentSeniorNotesdueJune2030Member_label_en-US" xlink:label="lab_dgx_TwoPointNineFivePercentSeniorNotesdueJune2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Nine Five Percent Senior Notes due June 2030 [Member]</link:label>
    <link:label id="lab_dgx_TwoPointNineFivePercentSeniorNotesdueJune2030Member_documentation_en-US" xlink:label="lab_dgx_TwoPointNineFivePercentSeniorNotesdueJune2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Nine Five Percent Senior Notes due June 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_TwoPointNineFivePercentSeniorNotesdueJune2030Member" xlink:href="dgx-20221231.xsd#dgx_TwoPointNineFivePercentSeniorNotesdueJune2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_TwoPointNineFivePercentSeniorNotesdueJune2030Member" xlink:to="lab_dgx_TwoPointNineFivePercentSeniorNotesdueJune2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_MarketPriceOfCompanyStockIssuedAtDiscountUnderEspp_54bf54f5-c03b-4f8d-8ee4-6b9f82f2ef76_terseLabel_en-US" xlink:label="lab_dgx_MarketPriceOfCompanyStockIssuedAtDiscountUnderEspp" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market price of company stock issued at a discount under the ESPP</link:label>
    <link:label id="lab_dgx_MarketPriceOfCompanyStockIssuedAtDiscountUnderEspp_label_en-US" xlink:label="lab_dgx_MarketPriceOfCompanyStockIssuedAtDiscountUnderEspp" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market price of Company stock issued at a discount under the ESPP</link:label>
    <link:label id="lab_dgx_MarketPriceOfCompanyStockIssuedAtDiscountUnderEspp_documentation_en-US" xlink:label="lab_dgx_MarketPriceOfCompanyStockIssuedAtDiscountUnderEspp" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Element represents the discounted market value of the Company stock on offering date or purchase date that participants pay for shares. Typically, the participant's per share cost is the lower of the prices on the two dates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_MarketPriceOfCompanyStockIssuedAtDiscountUnderEspp" xlink:href="dgx-20221231.xsd#dgx_MarketPriceOfCompanyStockIssuedAtDiscountUnderEspp"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_MarketPriceOfCompanyStockIssuedAtDiscountUnderEspp" xlink:to="lab_dgx_MarketPriceOfCompanyStockIssuedAtDiscountUnderEspp" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_59880da4-4207-4dec-badf-ffb3183757b8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_02bd551d-77f2-4042-bb96-c88c83c4ce62_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_788dbf10-0033-4df8-be93-8bd6e8ef170c_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_ad8c2c9c-192f-4ca8-b6e9-7fc3e36743bf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from continuing operations - domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_349b8eb1-d8cc-451f-ad23-7c5e839d75a6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:to="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_LabtechDiagnosticsLLCMember_6ba68b68-00e1-4559-9131-b5ff71ea8c0e_terseLabel_en-US" xlink:label="lab_dgx_LabtechDiagnosticsLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Labtech Diagnostics, LLC</link:label>
    <link:label id="lab_dgx_LabtechDiagnosticsLLCMember_label_en-US" xlink:label="lab_dgx_LabtechDiagnosticsLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Labtech Diagnostics, LLC [Member]</link:label>
    <link:label id="lab_dgx_LabtechDiagnosticsLLCMember_documentation_en-US" xlink:label="lab_dgx_LabtechDiagnosticsLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Labtech Diagnostics, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LabtechDiagnosticsLLCMember" xlink:href="dgx-20221231.xsd#dgx_LabtechDiagnosticsLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_LabtechDiagnosticsLLCMember" xlink:to="lab_dgx_LabtechDiagnosticsLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_4f6174ab-a365-426e-92e3-faa2602fe332_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_2c54ef6a-a12d-42fe-8be7-769be1750601_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_9b0b5745-0887-4a10-8bb7-b3c761ab431f_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_9d933f1f-47ba-4b16-a089-842e4df0e0b7_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_198ec20e-2e73-4ad9-a8ca-33df674d7dcd_verboseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Not Subject to Amortization - Tradenames</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_6007cad3-8b69-4de0-83ae-4735a01cc8d6_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_DonationsContributionsAndOtherFinancialSupport_35834aa2-fce0-4771-80be-f83ac8e2a866_terseLabel_en-US" xlink:label="lab_dgx_DonationsContributionsAndOtherFinancialSupport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Donations, contributions, and other financial support</link:label>
    <link:label id="lab_dgx_DonationsContributionsAndOtherFinancialSupport_label_en-US" xlink:label="lab_dgx_DonationsContributionsAndOtherFinancialSupport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Donations, Contributions, and Other Financial Support</link:label>
    <link:label id="lab_dgx_DonationsContributionsAndOtherFinancialSupport_documentation_en-US" xlink:label="lab_dgx_DonationsContributionsAndOtherFinancialSupport" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Donations, Contributions, and Other Financial Support</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_DonationsContributionsAndOtherFinancialSupport" xlink:href="dgx-20221231.xsd#dgx_DonationsContributionsAndOtherFinancialSupport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_DonationsContributionsAndOtherFinancialSupport" xlink:to="lab_dgx_DonationsContributionsAndOtherFinancialSupport" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_AcceleratedShareRepurchaseAgreementsMember_69d3d9a6-cc52-4b15-a69c-ace1bfdf4deb_terseLabel_en-US" xlink:label="lab_dgx_AcceleratedShareRepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchase Agreements</link:label>
    <link:label id="lab_dgx_AcceleratedShareRepurchaseAgreementsMember_label_en-US" xlink:label="lab_dgx_AcceleratedShareRepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchase Agreements [Member]</link:label>
    <link:label id="lab_dgx_AcceleratedShareRepurchaseAgreementsMember_documentation_en-US" xlink:label="lab_dgx_AcceleratedShareRepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchase Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_AcceleratedShareRepurchaseAgreementsMember" xlink:href="dgx-20221231.xsd#dgx_AcceleratedShareRepurchaseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_AcceleratedShareRepurchaseAgreementsMember" xlink:to="lab_dgx_AcceleratedShareRepurchaseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_beee3586-f5d4-4cfc-bd5c-3230a0e3c9a6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_badd2cb9-8b23-4717-a2b3-b1fb6b63aaa6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_label_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized Debt Issuance Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_6154d931-8bac-456d-b950-593525b46371_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_2990f295-a4ae-40c5-9e1e-fabbb94b0d1c_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_068f96b7-db75-485b-bec6-805157d2e007_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising cost</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_541d616f-bbe6-404f-9062-e26d2b568fde_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_AuditInformationAbstract_c35b66f1-9c5b-42aa-a091-625f5c2cd793_terseLabel_en-US" xlink:label="lab_dgx_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_dgx_AuditInformationAbstract_label_en-US" xlink:label="lab_dgx_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_dgx_AuditInformationAbstract_documentation_en-US" xlink:label="lab_dgx_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_AuditInformationAbstract" xlink:href="dgx-20221231.xsd#dgx_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_AuditInformationAbstract" xlink:to="lab_dgx_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_39a37110-89f6-4c4a-8ca0-d0ecf4d575dc_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_6da12d73-cdd1-4053-b696-14d105869d01_terseLabel_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-compete Agreements</link:label>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_label_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompete Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncompeteAgreementsMember" xlink:to="lab_us-gaap_NoncompeteAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_d6840d46-b111-4c2e-a9b0-b242e666caa4_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrent" xlink:to="lab_us-gaap_DividendsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_5f1ad0d9-2227-4a8e-8c41-2e6ccf8c772e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bbc13657-252d-4912-8a5c-52431e75fd47_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_5083c7e7-7419-4c7e-87fb-8aa21da58856_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Activity of Restructuring Liability</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_AcceleratedShareRepurchasesPayment_6dd45858-263f-4d95-9ed5-d3b1d17fb43d_terseLabel_en-US" xlink:label="lab_dgx_AcceleratedShareRepurchasesPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated share repurchases, payment</link:label>
    <link:label id="lab_dgx_AcceleratedShareRepurchasesPayment_label_en-US" xlink:label="lab_dgx_AcceleratedShareRepurchasesPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases, Payment</link:label>
    <link:label id="lab_dgx_AcceleratedShareRepurchasesPayment_documentation_en-US" xlink:label="lab_dgx_AcceleratedShareRepurchasesPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases, Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_AcceleratedShareRepurchasesPayment" xlink:href="dgx-20221231.xsd#dgx_AcceleratedShareRepurchasesPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_AcceleratedShareRepurchasesPayment" xlink:to="lab_dgx_AcceleratedShareRepurchasesPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnclassifiedIndefinitelivedIntangibleAssetsMember_30e1c9c1-daf0-4d2e-83b4-3283d5e2362a_terseLabel_en-US" xlink:label="lab_us-gaap_UnclassifiedIndefinitelivedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Not Subject to Amortization - Other</link:label>
    <link:label id="lab_us-gaap_UnclassifiedIndefinitelivedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_UnclassifiedIndefinitelivedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unclassified Indefinite-Lived Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnclassifiedIndefinitelivedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnclassifiedIndefinitelivedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnclassifiedIndefinitelivedIntangibleAssetsMember" xlink:to="lab_us-gaap_UnclassifiedIndefinitelivedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_daece915-841d-4de1-b8bc-04915ae50a73_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_4ec94af5-f9cf-4c5c-a2e6-cea2731f927b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ec630abf-efdf-4c1a-9baa-9e93fd2953cf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserve_39eea8bb-852c-41b6-a21b-b483105c7faf_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation reserves</link:label>
    <link:label id="lab_us-gaap_LitigationReserve_label_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserve" xlink:to="lab_us-gaap_LitigationReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_0be84a39-38b3-4406-a043-26086ca56c5b_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_eacd8743-bb85-4fbc-94b3-1e8ab19afbe8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_bf6391cd-2028-4f19-98b3-f4d8c4b65be6_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7ba7bbac-a68f-4f1d-848b-f7412f7c310a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_ab9ec94f-fc41-4e0e-a76c-4d2c375c1237_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_EffectiveIncomeTaxRateReconciliationChangeForUncertainTaxPosition_2057f31a-861f-4f18-be7f-ba7c3c2cc9d3_terseLabel_en-US" xlink:label="lab_dgx_EffectiveIncomeTaxRateReconciliationChangeForUncertainTaxPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in reserves for uncertain tax positions</link:label>
    <link:label id="lab_dgx_EffectiveIncomeTaxRateReconciliationChangeForUncertainTaxPosition_label_en-US" xlink:label="lab_dgx_EffectiveIncomeTaxRateReconciliationChangeForUncertainTaxPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change for uncertain tax position</link:label>
    <link:label id="lab_dgx_EffectiveIncomeTaxRateReconciliationChangeForUncertainTaxPosition_documentation_en-US" xlink:label="lab_dgx_EffectiveIncomeTaxRateReconciliationChangeForUncertainTaxPosition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change for uncertain tax position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_EffectiveIncomeTaxRateReconciliationChangeForUncertainTaxPosition" xlink:href="dgx-20221231.xsd#dgx_EffectiveIncomeTaxRateReconciliationChangeForUncertainTaxPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_EffectiveIncomeTaxRateReconciliationChangeForUncertainTaxPosition" xlink:to="lab_dgx_EffectiveIncomeTaxRateReconciliationChangeForUncertainTaxPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_310b1ff8-1869-4052-af79-90699503f221_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_label_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Retired, Cost Method, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:to="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_700cc2ce-6f2d-4715-954d-47eda65d20bc_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_7d271763-6bcd-4a9f-8470-ef3415673fd1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_dgx_SubstantialOwnershipInterestMember_d1cbb93a-3a37-41fe-bbc0-f2cef26b6bf9_terseLabel_en-US" xlink:label="lab_dgx_SubstantialOwnershipInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Substantial Ownership Interest</link:label>
    <link:label id="lab_dgx_SubstantialOwnershipInterestMember_label_en-US" xlink:label="lab_dgx_SubstantialOwnershipInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Substantial Ownership Interest [Member]</link:label>
    <link:label id="lab_dgx_SubstantialOwnershipInterestMember_documentation_en-US" xlink:label="lab_dgx_SubstantialOwnershipInterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Substantial Ownership Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_SubstantialOwnershipInterestMember" xlink:href="dgx-20221231.xsd#dgx_SubstantialOwnershipInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dgx_SubstantialOwnershipInterestMember" xlink:to="lab_dgx_SubstantialOwnershipInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_6c42d493-16df-46ea-b021-ec14fa8a90c1_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>19
<FILENAME>dgx-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:069b4a79-e86e-41e0-954a-e49896ade77c,g:4f5772c6-ef68-44f6-b836-f5065845bef2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://questdiagnostics.com/role/CoverPage" xlink:type="simple" xlink:href="dgx-20221231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_2e9da919-c039-40df-b280-f1e938255b2b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_8fd8441c-b3b6-4a8e-a269-298c173c435b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e9da919-c039-40df-b280-f1e938255b2b" xlink:to="loc_dei_DocumentType_8fd8441c-b3b6-4a8e-a269-298c173c435b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_0ecf473b-0277-4f4e-be74-ca370cc52607" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e9da919-c039-40df-b280-f1e938255b2b" xlink:to="loc_dei_DocumentAnnualReport_0ecf473b-0277-4f4e-be74-ca370cc52607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_2ab78de8-f5c9-4bfc-aca5-58e1bbc29376" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e9da919-c039-40df-b280-f1e938255b2b" xlink:to="loc_dei_DocumentPeriodEndDate_2ab78de8-f5c9-4bfc-aca5-58e1bbc29376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_fafdd809-80f8-4628-858c-5c5f1297cfda" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e9da919-c039-40df-b280-f1e938255b2b" xlink:to="loc_dei_CurrentFiscalYearEndDate_fafdd809-80f8-4628-858c-5c5f1297cfda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_6faeb446-ea74-4bee-9261-b688a3563c9a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e9da919-c039-40df-b280-f1e938255b2b" xlink:to="loc_dei_DocumentTransitionReport_6faeb446-ea74-4bee-9261-b688a3563c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_71bbb515-ac54-48ed-b360-5c228df1995c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e9da919-c039-40df-b280-f1e938255b2b" xlink:to="loc_dei_EntityFileNumber_71bbb515-ac54-48ed-b360-5c228df1995c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_01a3002b-6500-4987-8dc0-c6f9217b31ae" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e9da919-c039-40df-b280-f1e938255b2b" xlink:to="loc_dei_EntityRegistrantName_01a3002b-6500-4987-8dc0-c6f9217b31ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_d23bbcdd-25d3-482c-8b61-150ffc35e91b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e9da919-c039-40df-b280-f1e938255b2b" xlink:to="loc_dei_EntityIncorporationStateCountryCode_d23bbcdd-25d3-482c-8b61-150ffc35e91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_f69d07f1-2d0c-470f-8cc7-3e4ea7e8d4e2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e9da919-c039-40df-b280-f1e938255b2b" xlink:to="loc_dei_EntityTaxIdentificationNumber_f69d07f1-2d0c-470f-8cc7-3e4ea7e8d4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_e60969c2-174e-4949-9f98-12be852029b0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e9da919-c039-40df-b280-f1e938255b2b" xlink:to="loc_dei_EntityAddressAddressLine1_e60969c2-174e-4949-9f98-12be852029b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_26c14efa-1e63-44bd-8266-45488a789575" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e9da919-c039-40df-b280-f1e938255b2b" xlink:to="loc_dei_EntityAddressCityOrTown_26c14efa-1e63-44bd-8266-45488a789575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_2ca98860-73d5-400f-8326-f3734faaf498" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e9da919-c039-40df-b280-f1e938255b2b" xlink:to="loc_dei_EntityAddressStateOrProvince_2ca98860-73d5-400f-8326-f3734faaf498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_d1f98e1a-7371-4918-ae22-9bdff6afe5b0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e9da919-c039-40df-b280-f1e938255b2b" xlink:to="loc_dei_EntityAddressPostalZipCode_d1f98e1a-7371-4918-ae22-9bdff6afe5b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_206e528b-2dc8-494f-97de-88181970cc83" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e9da919-c039-40df-b280-f1e938255b2b" xlink:to="loc_dei_CityAreaCode_206e528b-2dc8-494f-97de-88181970cc83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_e9005cd4-04d3-485e-b49e-d2ea272c00d8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e9da919-c039-40df-b280-f1e938255b2b" xlink:to="loc_dei_LocalPhoneNumber_e9005cd4-04d3-485e-b49e-d2ea272c00d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_853c5e73-6af4-48b5-b364-8d8cb138ad6f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e9da919-c039-40df-b280-f1e938255b2b" xlink:to="loc_dei_Security12bTitle_853c5e73-6af4-48b5-b364-8d8cb138ad6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_217e9b7e-f5c1-4266-b967-467fe10ddeeb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e9da919-c039-40df-b280-f1e938255b2b" xlink:to="loc_dei_TradingSymbol_217e9b7e-f5c1-4266-b967-467fe10ddeeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a86c301f-79ff-4a10-90e0-d08b95ec0351" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e9da919-c039-40df-b280-f1e938255b2b" xlink:to="loc_dei_SecurityExchangeName_a86c301f-79ff-4a10-90e0-d08b95ec0351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_227c7ec3-47af-4b43-961b-696f7d820eb6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e9da919-c039-40df-b280-f1e938255b2b" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_227c7ec3-47af-4b43-961b-696f7d820eb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_d7b36ccb-2664-41ab-b7e6-8d78c3a8c6ac" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e9da919-c039-40df-b280-f1e938255b2b" xlink:to="loc_dei_EntityVoluntaryFilers_d7b36ccb-2664-41ab-b7e6-8d78c3a8c6ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_6809d355-0a9f-4fc5-af59-626fdea7f752" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e9da919-c039-40df-b280-f1e938255b2b" xlink:to="loc_dei_EntityCurrentReportingStatus_6809d355-0a9f-4fc5-af59-626fdea7f752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_1d1cf270-0fe0-4a44-8327-262c3ea09ace" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e9da919-c039-40df-b280-f1e938255b2b" xlink:to="loc_dei_EntityInteractiveDataCurrent_1d1cf270-0fe0-4a44-8327-262c3ea09ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_9d46610b-3cce-4ed9-af8c-fb21c7b3342e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e9da919-c039-40df-b280-f1e938255b2b" xlink:to="loc_dei_EntityFilerCategory_9d46610b-3cce-4ed9-af8c-fb21c7b3342e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_320c25f5-2062-4607-a6ae-cc5300117158" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e9da919-c039-40df-b280-f1e938255b2b" xlink:to="loc_dei_EntitySmallBusiness_320c25f5-2062-4607-a6ae-cc5300117158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_63aff1aa-f743-486e-add6-5e13daf7fd91" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e9da919-c039-40df-b280-f1e938255b2b" xlink:to="loc_dei_EntityEmergingGrowthCompany_63aff1aa-f743-486e-add6-5e13daf7fd91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_46e0fded-8f6c-4fad-917a-77514946c70b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e9da919-c039-40df-b280-f1e938255b2b" xlink:to="loc_dei_EntityShellCompany_46e0fded-8f6c-4fad-917a-77514946c70b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_f5cbc6ea-aca1-4433-bc82-f65bfe8553b2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e9da919-c039-40df-b280-f1e938255b2b" xlink:to="loc_dei_EntityPublicFloat_f5cbc6ea-aca1-4433-bc82-f65bfe8553b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_ecbda2e0-1ec4-45e3-b5e6-05bb5ce70407" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e9da919-c039-40df-b280-f1e938255b2b" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_ecbda2e0-1ec4-45e3-b5e6-05bb5ce70407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_ba3e4dfc-4535-45a9-b403-f40914d6a8f5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e9da919-c039-40df-b280-f1e938255b2b" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_ba3e4dfc-4535-45a9-b403-f40914d6a8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_663a44c8-42f0-4cc2-9e31-fbcfce3a06dc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e9da919-c039-40df-b280-f1e938255b2b" xlink:to="loc_dei_EntityCentralIndexKey_663a44c8-42f0-4cc2-9e31-fbcfce3a06dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_8fa5b69f-1ae4-484a-8ea0-5877b69dac57" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e9da919-c039-40df-b280-f1e938255b2b" xlink:to="loc_dei_DocumentFiscalYearFocus_8fa5b69f-1ae4-484a-8ea0-5877b69dac57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_8adb90d6-0b92-41e8-b9e6-a7cb5532ca99" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e9da919-c039-40df-b280-f1e938255b2b" xlink:to="loc_dei_DocumentFiscalPeriodFocus_8adb90d6-0b92-41e8-b9e6-a7cb5532ca99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_99dd9c2a-314d-4e71-974b-e062706bb249" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e9da919-c039-40df-b280-f1e938255b2b" xlink:to="loc_dei_AmendmentFlag_99dd9c2a-314d-4e71-974b-e062706bb249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_0aa5c6d9-2563-4043-97c5-19fd8dff6e88" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e9da919-c039-40df-b280-f1e938255b2b" xlink:to="loc_dei_IcfrAuditorAttestationFlag_0aa5c6d9-2563-4043-97c5-19fd8dff6e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/AuditInformation" xlink:type="simple" xlink:href="dgx-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dgx_AuditInformationAbstract_763f6097-1148-401c-b5a2-0e84224aab9a" xlink:href="dgx-20221231.xsd#dgx_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_16919f07-721e-49a6-9071-4d134ffa3113" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_AuditInformationAbstract_763f6097-1148-401c-b5a2-0e84224aab9a" xlink:to="loc_dei_AuditorName_16919f07-721e-49a6-9071-4d134ffa3113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_32ebd70d-635f-4d0d-ac9e-62697d3b23ea" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_AuditInformationAbstract_763f6097-1148-401c-b5a2-0e84224aab9a" xlink:to="loc_dei_AuditorLocation_32ebd70d-635f-4d0d-ac9e-62697d3b23ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_66277862-f983-4500-a261-9f4e8bcd3423" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_AuditInformationAbstract_763f6097-1148-401c-b5a2-0e84224aab9a" xlink:to="loc_dei_AuditorFirmId_66277862-f983-4500-a261-9f4e8bcd3423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="dgx-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_dd73d0ae-419d-4dd6-859e-08b03f1e17d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_6811a54f-309f-4a71-b9b5-29d7aaebd32c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dd73d0ae-419d-4dd6-859e-08b03f1e17d9" xlink:to="loc_us-gaap_AssetsAbstract_6811a54f-309f-4a71-b9b5-29d7aaebd32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5f8c7168-f578-48bf-8394-ee4012004883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6811a54f-309f-4a71-b9b5-29d7aaebd32c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5f8c7168-f578-48bf-8394-ee4012004883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_277b6a4c-083c-4f66-94c2-345c3c58e108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6811a54f-309f-4a71-b9b5-29d7aaebd32c" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_277b6a4c-083c-4f66-94c2-345c3c58e108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_34e04c20-d11b-4b9e-a1c8-e5c98dfe1bca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6811a54f-309f-4a71-b9b5-29d7aaebd32c" xlink:to="loc_us-gaap_InventoryNet_34e04c20-d11b-4b9e-a1c8-e5c98dfe1bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_12187da9-e8d3-46d8-9802-d277527c2502" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6811a54f-309f-4a71-b9b5-29d7aaebd32c" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_12187da9-e8d3-46d8-9802-d277527c2502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2195bb81-798b-4bdc-bdf6-7b5a3ed5edae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6811a54f-309f-4a71-b9b5-29d7aaebd32c" xlink:to="loc_us-gaap_AssetsCurrent_2195bb81-798b-4bdc-bdf6-7b5a3ed5edae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c969da7c-b519-492b-9a91-54d74d0e783f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6811a54f-309f-4a71-b9b5-29d7aaebd32c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c969da7c-b519-492b-9a91-54d74d0e783f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f75a2285-0851-46ec-8128-01af48431a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6811a54f-309f-4a71-b9b5-29d7aaebd32c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f75a2285-0851-46ec-8128-01af48431a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8cc7b4e9-e54e-4926-8db7-7a5016a739f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6811a54f-309f-4a71-b9b5-29d7aaebd32c" xlink:to="loc_us-gaap_Goodwill_8cc7b4e9-e54e-4926-8db7-7a5016a739f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e4007f6b-91e3-4040-9f9f-2ca05c9aedfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6811a54f-309f-4a71-b9b5-29d7aaebd32c" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e4007f6b-91e3-4040-9f9f-2ca05c9aedfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_96f9ead8-6c16-47d8-8e3c-c041a32163ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6811a54f-309f-4a71-b9b5-29d7aaebd32c" xlink:to="loc_us-gaap_EquityMethodInvestments_96f9ead8-6c16-47d8-8e3c-c041a32163ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b5e05bf3-a28a-4603-9ab8-6997037475b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6811a54f-309f-4a71-b9b5-29d7aaebd32c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b5e05bf3-a28a-4603-9ab8-6997037475b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_8ac14952-f5f0-4f14-9ce6-14c927cdc603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6811a54f-309f-4a71-b9b5-29d7aaebd32c" xlink:to="loc_us-gaap_Assets_8ac14952-f5f0-4f14-9ce6-14c927cdc603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5017158c-ed82-445f-8895-2ab7e6e1a494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dd73d0ae-419d-4dd6-859e-08b03f1e17d9" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5017158c-ed82-445f-8895-2ab7e6e1a494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1164b9a1-c83b-43a3-bfab-182a8e49e5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5017158c-ed82-445f-8895-2ab7e6e1a494" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1164b9a1-c83b-43a3-bfab-182a8e49e5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_d5702375-0c7a-4915-ae20-b9b55048ebde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5017158c-ed82-445f-8895-2ab7e6e1a494" xlink:to="loc_us-gaap_LongTermDebtCurrent_d5702375-0c7a-4915-ae20-b9b55048ebde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_659f0a69-0ca0-4f32-b46a-6f70dbaaa356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5017158c-ed82-445f-8895-2ab7e6e1a494" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_659f0a69-0ca0-4f32-b46a-6f70dbaaa356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_42999799-ff6d-44a4-8171-e1e83eea92ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5017158c-ed82-445f-8895-2ab7e6e1a494" xlink:to="loc_us-gaap_LiabilitiesCurrent_42999799-ff6d-44a4-8171-e1e83eea92ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_6ac50743-8017-4d89-b3e5-e7bb00531505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5017158c-ed82-445f-8895-2ab7e6e1a494" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_6ac50743-8017-4d89-b3e5-e7bb00531505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e0f1853f-05d9-4f2a-ad8e-5742fe5bbde9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5017158c-ed82-445f-8895-2ab7e6e1a494" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e0f1853f-05d9-4f2a-ad8e-5742fe5bbde9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_c6124bc7-d725-4702-9ab8-3a620164acd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5017158c-ed82-445f-8895-2ab7e6e1a494" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_c6124bc7-d725-4702-9ab8-3a620164acd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_62cdba46-1e8b-40d0-8081-dd4b609995b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5017158c-ed82-445f-8895-2ab7e6e1a494" xlink:to="loc_us-gaap_CommitmentsAndContingencies_62cdba46-1e8b-40d0-8081-dd4b609995b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_48516a95-37a9-4f0e-84b2-c57ea191872c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5017158c-ed82-445f-8895-2ab7e6e1a494" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_48516a95-37a9-4f0e-84b2-c57ea191872c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_091773d4-614b-4016-b77d-990fd56e1b44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5017158c-ed82-445f-8895-2ab7e6e1a494" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_091773d4-614b-4016-b77d-990fd56e1b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_601af66a-1f20-43c8-afd0-e9eaf7251166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_091773d4-614b-4016-b77d-990fd56e1b44" xlink:to="loc_us-gaap_StockholdersEquityAbstract_601af66a-1f20-43c8-afd0-e9eaf7251166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_2e339bc2-3d6c-467f-84f7-6e4ffe38fc4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_601af66a-1f20-43c8-afd0-e9eaf7251166" xlink:to="loc_us-gaap_CommonStockValue_2e339bc2-3d6c-467f-84f7-6e4ffe38fc4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_25a920db-105f-4e5d-8360-39aa7a9240b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_601af66a-1f20-43c8-afd0-e9eaf7251166" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_25a920db-105f-4e5d-8360-39aa7a9240b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9e1e5d4c-bc2f-40e4-8090-9c0e59d9e73f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_601af66a-1f20-43c8-afd0-e9eaf7251166" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9e1e5d4c-bc2f-40e4-8090-9c0e59d9e73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9baf294a-036a-4ef3-b992-d2eddd7670bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_601af66a-1f20-43c8-afd0-e9eaf7251166" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9baf294a-036a-4ef3-b992-d2eddd7670bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_38974758-25cd-4a72-a662-245553632633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_601af66a-1f20-43c8-afd0-e9eaf7251166" xlink:to="loc_us-gaap_TreasuryStockValue_38974758-25cd-4a72-a662-245553632633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_63d438e6-dfa4-4ed3-9202-b164778e866e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_601af66a-1f20-43c8-afd0-e9eaf7251166" xlink:to="loc_us-gaap_StockholdersEquity_63d438e6-dfa4-4ed3-9202-b164778e866e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_955efe8b-8f4c-45db-903e-270a6e607f09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_091773d4-614b-4016-b77d-990fd56e1b44" xlink:to="loc_us-gaap_MinorityInterest_955efe8b-8f4c-45db-903e-270a6e607f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7866fa68-7fdd-4150-8261-da4fd80226cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_091773d4-614b-4016-b77d-990fd56e1b44" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7866fa68-7fdd-4150-8261-da4fd80226cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d6a39200-ef86-4b9b-b784-61484d7ae34f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5017158c-ed82-445f-8895-2ab7e6e1a494" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_d6a39200-ef86-4b9b-b784-61484d7ae34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_25484e04-0abc-4b9b-96df-482adadddbec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5017158c-ed82-445f-8895-2ab7e6e1a494" xlink:to="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_25484e04-0abc-4b9b-96df-482adadddbec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f2fbd789-02ec-48c9-8d6c-6ef57500f03d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_25484e04-0abc-4b9b-96df-482adadddbec" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f2fbd789-02ec-48c9-8d6c-6ef57500f03d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ec3dbcdd-dac4-4c73-adc0-a63acb9b6987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f2fbd789-02ec-48c9-8d6c-6ef57500f03d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ec3dbcdd-dac4-4c73-adc0-a63acb9b6987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="dgx-20221231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_66e377f5-ced0-4de9-b367-fed140873c38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_68a9cfa1-71c8-4789-b0a0-79a621153cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_66e377f5-ced0-4de9-b367-fed140873c38" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_68a9cfa1-71c8-4789-b0a0-79a621153cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_ba50b987-ae35-4403-bb4b-698a1af545b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_66e377f5-ced0-4de9-b367-fed140873c38" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_ba50b987-ae35-4403-bb4b-698a1af545b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_7513d0cb-ae65-40d7-a996-17733cef424e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_66e377f5-ced0-4de9-b367-fed140873c38" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_7513d0cb-ae65-40d7-a996-17733cef424e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_d8d07803-b782-453c-b1d8-b3d028944332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_66e377f5-ced0-4de9-b367-fed140873c38" xlink:to="loc_us-gaap_CommonStockSharesIssued_d8d07803-b782-453c-b1d8-b3d028944332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_ac27ac0d-5ffd-4a6b-88c3-3bc9d6360c80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_66e377f5-ced0-4de9-b367-fed140873c38" xlink:to="loc_us-gaap_TreasuryStockShares_ac27ac0d-5ffd-4a6b-88c3-3bc9d6360c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="dgx-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_3a8a20e5-96c1-4750-8827-2e6378e52d05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_42a201d0-c5d9-4c30-9810-3facec440541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3a8a20e5-96c1-4750-8827-2e6378e52d05" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_42a201d0-c5d9-4c30-9810-3facec440541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenueAbstract_6bde121c-3883-40e1-9f9f-4c624b35ba12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3a8a20e5-96c1-4750-8827-2e6378e52d05" xlink:to="loc_us-gaap_CostOfRevenueAbstract_6bde121c-3883-40e1-9f9f-4c624b35ba12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_b0ef0ad2-2bf3-484e-982a-ef0422834c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_6bde121c-3883-40e1-9f9f-4c624b35ba12" xlink:to="loc_us-gaap_CostOfRevenue_b0ef0ad2-2bf3-484e-982a-ef0422834c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b3f39d18-0e16-4650-9ce1-c68dfe943c93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_6bde121c-3883-40e1-9f9f-4c624b35ba12" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b3f39d18-0e16-4650-9ce1-c68dfe943c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_c6c67a81-5a8f-43ae-ae6b-5f2e7f19dd76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_6bde121c-3883-40e1-9f9f-4c624b35ba12" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_c6c67a81-5a8f-43ae-ae6b-5f2e7f19dd76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_fbe6ecd4-cefe-4c01-8359-0477380cd8db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_6bde121c-3883-40e1-9f9f-4c624b35ba12" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_fbe6ecd4-cefe-4c01-8359-0477380cd8db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_a661c98a-56f4-4d44-b50d-f9fc426926b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3a8a20e5-96c1-4750-8827-2e6378e52d05" xlink:to="loc_us-gaap_CostsAndExpenses_a661c98a-56f4-4d44-b50d-f9fc426926b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ca9b1ae5-914b-449b-a8f3-4aa3213a46cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3a8a20e5-96c1-4750-8827-2e6378e52d05" xlink:to="loc_us-gaap_OperatingIncomeLoss_ca9b1ae5-914b-449b-a8f3-4aa3213a46cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f7bcdebf-3f74-4aa1-80ee-466ef09ad0ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3a8a20e5-96c1-4750-8827-2e6378e52d05" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f7bcdebf-3f74-4aa1-80ee-466ef09ad0ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_4ee66525-3d8b-4052-afa6-ed23f3287d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f7bcdebf-3f74-4aa1-80ee-466ef09ad0ac" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_4ee66525-3d8b-4052-afa6-ed23f3287d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_27d1048b-329a-49ae-824d-17171c5de397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f7bcdebf-3f74-4aa1-80ee-466ef09ad0ac" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_27d1048b-329a-49ae-824d-17171c5de397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_ee785a8d-93da-4f2a-9c10-6667533ffd44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f7bcdebf-3f74-4aa1-80ee-466ef09ad0ac" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_ee785a8d-93da-4f2a-9c10-6667533ffd44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2b477d37-a77b-4de0-b6ac-561324aec1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3a8a20e5-96c1-4750-8827-2e6378e52d05" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2b477d37-a77b-4de0-b6ac-561324aec1ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_71d207ee-cda6-46b9-85f7-3aa2ab628994" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3a8a20e5-96c1-4750-8827-2e6378e52d05" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_71d207ee-cda6-46b9-85f7-3aa2ab628994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_66595c3b-a847-4098-9819-a34502b69d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3a8a20e5-96c1-4750-8827-2e6378e52d05" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_66595c3b-a847-4098-9819-a34502b69d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4f91ebb8-bec7-44d1-89c5-0542eb9b4e62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3a8a20e5-96c1-4750-8827-2e6378e52d05" xlink:to="loc_us-gaap_ProfitLoss_4f91ebb8-bec7-44d1-89c5-0542eb9b4e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9c149ec0-3325-472c-89c5-6de11ea7e29c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3a8a20e5-96c1-4750-8827-2e6378e52d05" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9c149ec0-3325-472c-89c5-6de11ea7e29c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b57743ab-424e-4ff6-87fd-dd884cc12a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3a8a20e5-96c1-4750-8827-2e6378e52d05" xlink:to="loc_us-gaap_NetIncomeLoss_b57743ab-424e-4ff6-87fd-dd884cc12a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9863264c-9151-4124-a78d-f3dc5055d4a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3a8a20e5-96c1-4750-8827-2e6378e52d05" xlink:to="loc_us-gaap_EarningsPerShareAbstract_9863264c-9151-4124-a78d-f3dc5055d4a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_75d7aba2-6212-4508-856f-55c125e15643" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9863264c-9151-4124-a78d-f3dc5055d4a2" xlink:to="loc_us-gaap_EarningsPerShareBasic_75d7aba2-6212-4508-856f-55c125e15643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_de713e4b-7546-454f-835c-ac463e240b46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9863264c-9151-4124-a78d-f3dc5055d4a2" xlink:to="loc_us-gaap_EarningsPerShareDiluted_de713e4b-7546-454f-835c-ac463e240b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="dgx-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b2786abd-5e69-4064-b931-5aa8d923b97c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d4f24369-f85c-470f-aa27-8a67342a3220" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b2786abd-5e69-4064-b931-5aa8d923b97c" xlink:to="loc_us-gaap_ProfitLoss_d4f24369-f85c-470f-aa27-8a67342a3220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_220a6965-29d7-4aef-860b-5b5329515cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b2786abd-5e69-4064-b931-5aa8d923b97c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_220a6965-29d7-4aef-860b-5b5329515cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_d74748ed-1928-488e-a303-2770d97634e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_220a6965-29d7-4aef-860b-5b5329515cf8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_d74748ed-1928-488e-a303-2770d97634e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_ab3dc129-3c68-477e-a4a4-a20b35138683" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_220a6965-29d7-4aef-860b-5b5329515cf8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_ab3dc129-3c68-477e-a4a4-a20b35138683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_5feb6ae1-cfab-4e98-9eb5-9bf1c1dc2c53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_220a6965-29d7-4aef-860b-5b5329515cf8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_5feb6ae1-cfab-4e98-9eb5-9bf1c1dc2c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_025c24e7-b636-414c-be1d-f1edc40599d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_220a6965-29d7-4aef-860b-5b5329515cf8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_025c24e7-b636-414c-be1d-f1edc40599d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_461b4c73-e6af-468d-834c-3502ecdde678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b2786abd-5e69-4064-b931-5aa8d923b97c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_461b4c73-e6af-468d-834c-3502ecdde678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_f5ce60c0-c925-414d-b01f-e6c75e22d693" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b2786abd-5e69-4064-b931-5aa8d923b97c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_f5ce60c0-c925-414d-b01f-e6c75e22d693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_3e68a464-2e65-4f5e-a073-c502e03e8906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b2786abd-5e69-4064-b931-5aa8d923b97c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_3e68a464-2e65-4f5e-a073-c502e03e8906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="dgx-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_aa66e9fc-721a-49cd-8384-2dcc8ea9c35e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_04a450c4-787f-4048-a305-5cbe685c1647" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aa66e9fc-721a-49cd-8384-2dcc8ea9c35e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_04a450c4-787f-4048-a305-5cbe685c1647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8c82e21b-efcb-41c1-806b-7aaae03ab216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_04a450c4-787f-4048-a305-5cbe685c1647" xlink:to="loc_us-gaap_ProfitLoss_8c82e21b-efcb-41c1-806b-7aaae03ab216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0fcaa2b3-7884-410c-9383-8d37f47e7248" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_04a450c4-787f-4048-a305-5cbe685c1647" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0fcaa2b3-7884-410c-9383-8d37f47e7248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_a6ca7cea-1208-4ae1-aae8-52a227ae868e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0fcaa2b3-7884-410c-9383-8d37f47e7248" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_a6ca7cea-1208-4ae1-aae8-52a227ae868e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_0915911c-0578-44f0-a346-60083d913b91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0fcaa2b3-7884-410c-9383-8d37f47e7248" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_0915911c-0578-44f0-a346-60083d913b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_aa2db770-af47-492b-8ddb-284cbd839441" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0fcaa2b3-7884-410c-9383-8d37f47e7248" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_aa2db770-af47-492b-8ddb-284cbd839441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a6d3c3bf-6a18-471d-9313-dce985db45cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0fcaa2b3-7884-410c-9383-8d37f47e7248" xlink:to="loc_us-gaap_ShareBasedCompensation_a6d3c3bf-6a18-471d-9313-dce985db45cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_GainLossOnDispositionOfJointVenture_606a995d-77d4-4875-85f5-cd7c67829ba3" xlink:href="dgx-20221231.xsd#dgx_GainLossOnDispositionOfJointVenture"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0fcaa2b3-7884-410c-9383-8d37f47e7248" xlink:to="loc_dgx_GainLossOnDispositionOfJointVenture_606a995d-77d4-4875-85f5-cd7c67829ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_b42c8433-dddc-4c3f-bb43-01d443084fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0fcaa2b3-7884-410c-9383-8d37f47e7248" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_b42c8433-dddc-4c3f-bb43-01d443084fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9fb924e6-e955-4258-bd18-4d920e16d9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0fcaa2b3-7884-410c-9383-8d37f47e7248" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9fb924e6-e955-4258-bd18-4d920e16d9eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_acd8c3d0-0f66-4a74-beae-03a6e8825265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9fb924e6-e955-4258-bd18-4d920e16d9eb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_acd8c3d0-0f66-4a74-beae-03a6e8825265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e830d561-36a9-4254-8588-649942b0c06e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9fb924e6-e955-4258-bd18-4d920e16d9eb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e830d561-36a9-4254-8588-649942b0c06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_d0dc850c-13fb-4bdf-bc6d-79a1831002cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9fb924e6-e955-4258-bd18-4d920e16d9eb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_d0dc850c-13fb-4bdf-bc6d-79a1831002cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_TerminationOfInterestRateSwapAgreements_058e81db-e916-4b51-8d73-2803c9449dc7" xlink:href="dgx-20221231.xsd#dgx_TerminationOfInterestRateSwapAgreements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9fb924e6-e955-4258-bd18-4d920e16d9eb" xlink:to="loc_dgx_TerminationOfInterestRateSwapAgreements_058e81db-e916-4b51-8d73-2803c9449dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_4bf8b279-d2fa-4dab-adb8-698ae48def31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9fb924e6-e955-4258-bd18-4d920e16d9eb" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_4bf8b279-d2fa-4dab-adb8-698ae48def31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6aaba782-04b0-454a-aaa1-0868d58eb6e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_04a450c4-787f-4048-a305-5cbe685c1647" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6aaba782-04b0-454a-aaa1-0868d58eb6e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0ebaefff-e9b1-4a33-947b-9eb84cd4560e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aa66e9fc-721a-49cd-8384-2dcc8ea9c35e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0ebaefff-e9b1-4a33-947b-9eb84cd4560e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_408c74b9-80df-465b-8100-3956de562667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0ebaefff-e9b1-4a33-947b-9eb84cd4560e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_408c74b9-80df-465b-8100-3956de562667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_2ce5243b-078f-462c-b16e-a0e6d3d0343a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0ebaefff-e9b1-4a33-947b-9eb84cd4560e" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_2ce5243b-078f-462c-b16e-a0e6d3d0343a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7125f140-4276-4051-b5b5-005899c56b69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0ebaefff-e9b1-4a33-947b-9eb84cd4560e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7125f140-4276-4051-b5b5-005899c56b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_8d65a566-2141-4805-8852-ec559823e850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0ebaefff-e9b1-4a33-947b-9eb84cd4560e" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_8d65a566-2141-4805-8852-ec559823e850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c76c7615-4337-4576-a607-2f3e6a747b10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0ebaefff-e9b1-4a33-947b-9eb84cd4560e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c76c7615-4337-4576-a607-2f3e6a747b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_626871bd-7d89-48fe-b79b-fb251a459667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aa66e9fc-721a-49cd-8384-2dcc8ea9c35e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_626871bd-7d89-48fe-b79b-fb251a459667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_0bc9f6e1-088a-4b5e-bc01-5997ca7de75c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_626871bd-7d89-48fe-b79b-fb251a459667" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_0bc9f6e1-088a-4b5e-bc01-5997ca7de75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_83835f7c-bde5-45d2-a7f2-df7896c6b43e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_626871bd-7d89-48fe-b79b-fb251a459667" xlink:to="loc_us-gaap_RepaymentsOfDebt_83835f7c-bde5-45d2-a7f2-df7896c6b43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_54baa22f-3786-4984-b5bb-0a44544372c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_626871bd-7d89-48fe-b79b-fb251a459667" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_54baa22f-3786-4984-b5bb-0a44544372c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_c6539740-5a19-4e6a-896e-62ccdb35b789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_626871bd-7d89-48fe-b79b-fb251a459667" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_c6539740-5a19-4e6a-896e-62ccdb35b789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_a0af77e4-38fb-4159-9068-00b0b86547bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_626871bd-7d89-48fe-b79b-fb251a459667" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_a0af77e4-38fb-4159-9068-00b0b86547bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_b3397e09-b2d2-4fe7-b11a-d33a15c5ae89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_626871bd-7d89-48fe-b79b-fb251a459667" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_b3397e09-b2d2-4fe7-b11a-d33a15c5ae89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsMinorityInterest_58f09e77-2756-454e-a253-27687e18efd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsMinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_626871bd-7d89-48fe-b79b-fb251a459667" xlink:to="loc_us-gaap_PaymentsOfDividendsMinorityInterest_58f09e77-2756-454e-a253-27687e18efd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_adc51716-dbe8-47ab-ae53-16584b9800ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_626871bd-7d89-48fe-b79b-fb251a459667" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_adc51716-dbe8-47ab-ae53-16584b9800ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d23c4eb2-a3b2-4171-9e46-e981a706ba04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_626871bd-7d89-48fe-b79b-fb251a459667" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d23c4eb2-a3b2-4171-9e46-e981a706ba04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_884fe798-1399-48f9-9ffa-1b021e847d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aa66e9fc-721a-49cd-8384-2dcc8ea9c35e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_884fe798-1399-48f9-9ffa-1b021e847d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3f25946c-2117-4609-b16a-73269dcfdd09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aa66e9fc-721a-49cd-8384-2dcc8ea9c35e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3f25946c-2117-4609-b16a-73269dcfdd09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8ceac728-8948-43a5-8c8f-5a565325af04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aa66e9fc-721a-49cd-8384-2dcc8ea9c35e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8ceac728-8948-43a5-8c8f-5a565325af04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="dgx-20221231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_74e8e063-08a9-46aa-95a7-21ebef88e22d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_08b62ac9-609d-42c2-9a43-c41ee4e7a9d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_74e8e063-08a9-46aa-95a7-21ebef88e22d" xlink:to="loc_us-gaap_StatementTable_08b62ac9-609d-42c2-9a43-c41ee4e7a9d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_89f40c50-4232-4757-a3fd-25c6285133cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_08b62ac9-609d-42c2-9a43-c41ee4e7a9d1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_89f40c50-4232-4757-a3fd-25c6285133cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3ae55769-fbae-46d1-b5de-7dc83b3cc329" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_89f40c50-4232-4757-a3fd-25c6285133cf" xlink:to="loc_us-gaap_EquityComponentDomain_3ae55769-fbae-46d1-b5de-7dc83b3cc329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f506ecae-e2d0-4823-8de8-197109ec14d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3ae55769-fbae-46d1-b5de-7dc83b3cc329" xlink:to="loc_us-gaap_CommonStockMember_f506ecae-e2d0-4823-8de8-197109ec14d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_41c8833d-3d28-4ec9-bfad-8e521c2d4387" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3ae55769-fbae-46d1-b5de-7dc83b3cc329" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_41c8833d-3d28-4ec9-bfad-8e521c2d4387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_813c722c-0c66-4375-8264-07445ad73321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3ae55769-fbae-46d1-b5de-7dc83b3cc329" xlink:to="loc_us-gaap_RetainedEarningsMember_813c722c-0c66-4375-8264-07445ad73321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ff8fa9c6-5f6c-4c95-9434-e9fd049be125" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3ae55769-fbae-46d1-b5de-7dc83b3cc329" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ff8fa9c6-5f6c-4c95-9434-e9fd049be125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_840b3578-45e7-47d8-b561-64945932385d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3ae55769-fbae-46d1-b5de-7dc83b3cc329" xlink:to="loc_us-gaap_TreasuryStockMember_840b3578-45e7-47d8-b561-64945932385d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_7da121c1-d3c6-4220-b268-f1fc5f043c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3ae55769-fbae-46d1-b5de-7dc83b3cc329" xlink:to="loc_us-gaap_NoncontrollingInterestMember_7da121c1-d3c6-4220-b268-f1fc5f043c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_60a8c085-5cf7-4ca0-9e7d-70f92c863657" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_08b62ac9-609d-42c2-9a43-c41ee4e7a9d1" xlink:to="loc_us-gaap_StatementLineItems_60a8c085-5cf7-4ca0-9e7d-70f92c863657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33dad717-beb3-452b-bb49-c60935671fad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_60a8c085-5cf7-4ca0-9e7d-70f92c863657" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33dad717-beb3-452b-bb49-c60935671fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_800ac6d6-69f2-45d5-9a5f-543a59792734" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33dad717-beb3-452b-bb49-c60935671fad" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_800ac6d6-69f2-45d5-9a5f-543a59792734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3ecc7b52-0b38-4b95-b8d7-1b78574d9978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33dad717-beb3-452b-bb49-c60935671fad" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3ecc7b52-0b38-4b95-b8d7-1b78574d9978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_NetIncomeLossExcludingRedeemableNoncontrollingInterest_439d4379-bf6b-4fdd-a161-1471647451dc" xlink:href="dgx-20221231.xsd#dgx_NetIncomeLossExcludingRedeemableNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33dad717-beb3-452b-bb49-c60935671fad" xlink:to="loc_dgx_NetIncomeLossExcludingRedeemableNoncontrollingInterest_439d4379-bf6b-4fdd-a161-1471647451dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_19ee3427-6642-42d5-90b3-4e4c199e994e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33dad717-beb3-452b-bb49-c60935671fad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_19ee3427-6642-42d5-90b3-4e4c199e994e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_04d24445-2e35-4109-a33e-85688ff67465" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33dad717-beb3-452b-bb49-c60935671fad" xlink:to="loc_us-gaap_DividendsCommonStockCash_04d24445-2e35-4109-a33e-85688ff67465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_6d005d63-f6cd-4ecb-8d85-b5532e4ede63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33dad717-beb3-452b-bb49-c60935671fad" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_6d005d63-f6cd-4ecb-8d85-b5532e4ede63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_97f04231-ebc6-4ab3-b612-8ccc4202593e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33dad717-beb3-452b-bb49-c60935671fad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_97f04231-ebc6-4ab3-b612-8ccc4202593e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_60d2ce5d-a3ff-4b85-a827-5e716d942c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33dad717-beb3-452b-bb49-c60935671fad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_60d2ce5d-a3ff-4b85-a827-5e716d942c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4d0fa9cf-40e5-4825-9fef-52a63101b2ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33dad717-beb3-452b-bb49-c60935671fad" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4d0fa9cf-40e5-4825-9fef-52a63101b2ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9bc90cb1-7afa-4ee0-bb61-88998c450dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33dad717-beb3-452b-bb49-c60935671fad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9bc90cb1-7afa-4ee0-bb61-88998c450dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_bcca0449-b09c-46e8-8d6c-f8c62c5dc053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33dad717-beb3-452b-bb49-c60935671fad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_bcca0449-b09c-46e8-8d6c-f8c62c5dc053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_288bd04c-5c3d-4ccd-8dd0-7e16a41a1306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33dad717-beb3-452b-bb49-c60935671fad" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_288bd04c-5c3d-4ccd-8dd0-7e16a41a1306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_1e9df0fd-b4b6-4191-9a36-10ac61e3827d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33dad717-beb3-452b-bb49-c60935671fad" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_1e9df0fd-b4b6-4191-9a36-10ac61e3827d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_91ee759d-f73d-4603-8ccc-fdb7f04be1e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33dad717-beb3-452b-bb49-c60935671fad" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_91ee759d-f73d-4603-8ccc-fdb7f04be1e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_c6de5bc6-1c41-45ef-a73f-2fff4e458f04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33dad717-beb3-452b-bb49-c60935671fad" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_c6de5bc6-1c41-45ef-a73f-2fff4e458f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7f8755bb-690b-4e54-9d1f-d9e3c0965107" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33dad717-beb3-452b-bb49-c60935671fad" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7f8755bb-690b-4e54-9d1f-d9e3c0965107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_204169ae-6633-486e-97ad-23ff97b6a407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_33dad717-beb3-452b-bb49-c60935671fad" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_204169ae-6633-486e-97ad-23ff97b6a407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5f59402a-9366-4f7a-abf4-6e25249b59e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_60a8c085-5cf7-4ca0-9e7d-70f92c863657" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5f59402a-9366-4f7a-abf4-6e25249b59e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_e585f7d9-9b6c-4faa-a530-b42a237dbbbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5f59402a-9366-4f7a-abf4-6e25249b59e1" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_e585f7d9-9b6c-4faa-a530-b42a237dbbbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityNetIncome_59af26a0-1d12-4e78-9e81-458922b150d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityNetIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5f59402a-9366-4f7a-abf4-6e25249b59e1" xlink:to="loc_us-gaap_TemporaryEquityNetIncome_59af26a0-1d12-4e78-9e81-458922b150d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders_be2ab2da-15dd-44b3-a549-62bfc21765f0" xlink:href="dgx-20221231.xsd#dgx_TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5f59402a-9366-4f7a-abf4-6e25249b59e1" xlink:to="loc_dgx_TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders_be2ab2da-15dd-44b3-a549-62bfc21765f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_e59f601e-7adc-47d7-94ab-85bc3b4903d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5f59402a-9366-4f7a-abf4-6e25249b59e1" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_e59f601e-7adc-47d7-94ab-85bc3b4903d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/DESCRIPTIONOFBUSINESS" xlink:type="simple" xlink:href="dgx-20221231.xsd#DESCRIPTIONOFBUSINESS"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/DESCRIPTIONOFBUSINESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f955ce1d-0677-433d-a1bd-eda14a0c2e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_b47861fd-fc4f-46a2-905c-1320f35227a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f955ce1d-0677-433d-a1bd-eda14a0c2e8a" xlink:to="loc_us-gaap_NatureOfOperations_b47861fd-fc4f-46a2-905c-1320f35227a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="dgx-20221231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7980bca6-d714-4436-a77e-9b5e819a8dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_9262056e-ba24-4f35-862c-39c8adc0903e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7980bca6-d714-4436-a77e-9b5e819a8dd4" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_9262056e-ba24-4f35-862c-39c8adc0903e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/REVENUERECOGNITION" xlink:type="simple" xlink:href="dgx-20221231.xsd#REVENUERECOGNITION"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/REVENUERECOGNITION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9f4f742c-b359-4fb3-b6f4-9c9c6d27dfc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_652edd61-3737-47cf-b0f8-56bb98845e55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9f4f742c-b359-4fb3-b6f4-9c9c6d27dfc2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_652edd61-3737-47cf-b0f8-56bb98845e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/EARNINGSPERSHARE" xlink:type="simple" xlink:href="dgx-20221231.xsd#EARNINGSPERSHARE"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/EARNINGSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_94bbe730-9f7e-4163-80c0-b44174c9d4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_84d603f2-ae88-4e40-950a-c52497653816" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_94bbe730-9f7e-4163-80c0-b44174c9d4cc" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_84d603f2-ae88-4e40-950a-c52497653816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIES" xlink:type="simple" xlink:href="dgx-20221231.xsd#RESTRUCTURINGACTIVITIES"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5bef508d-5a31-450f-804c-2f896db9266a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_9a55be29-bde1-4eef-8a8e-3c1f11b0e24b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5bef508d-5a31-450f-804c-2f896db9266a" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_9a55be29-bde1-4eef-8a8e-3c1f11b0e24b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/BUSINESSACQUISITIONS" xlink:type="simple" xlink:href="dgx-20221231.xsd#BUSINESSACQUISITIONS"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/BUSINESSACQUISITIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_be1a2872-1cfe-4523-bc17-a78ab5cac22a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_667fe256-7d65-48ee-a3f3-3a93beedd9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_be1a2872-1cfe-4523-bc17-a78ab5cac22a" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_667fe256-7d65-48ee-a3f3-3a93beedd9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/DISPOSITION" xlink:type="simple" xlink:href="dgx-20221231.xsd#DISPOSITION"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/DISPOSITION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_6e79809c-be17-49eb-a7b6-35606b7341a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_a7a3f5d9-9978-4ad8-892f-23df43495411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_6e79809c-be17-49eb-a7b6-35606b7341a7" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_a7a3f5d9-9978-4ad8-892f-23df43495411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="dgx-20221231.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f0c9b78b-b0f6-4afc-aa44-7b43cde9586d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_31979a4f-ba07-448c-9df6-2fe3b2a8471e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f0c9b78b-b0f6-4afc-aa44-7b43cde9586d" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_31979a4f-ba07-448c-9df6-2fe3b2a8471e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/TAXESONINCOME" xlink:type="simple" xlink:href="dgx-20221231.xsd#TAXESONINCOME"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/TAXESONINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ed29e173-ec70-47df-b94a-7cd628bce92d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1db3af4f-a344-461b-a53f-79e011018aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ed29e173-ec70-47df-b94a-7cd628bce92d" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1db3af4f-a344-461b-a53f-79e011018aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATA" xlink:type="simple" xlink:href="dgx-20221231.xsd#SUPPLEMENTALCASHFLOWANDOTHERDATA"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATA" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_c81225d2-6aa8-43d5-b887-e40ccf4b00f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_cdd86286-6d9b-4a53-a96b-94be0a58fe69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_c81225d2-6aa8-43d5-b887-e40ccf4b00f4" xlink:to="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_cdd86286-6d9b-4a53-a96b-94be0a58fe69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENT" xlink:type="simple" xlink:href="dgx-20221231.xsd#PROPERTYPLANTANDEQUIPMENT"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_84bd742b-0180-4d64-997a-40088f86976c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_92549f04-ef19-4c80-8317-8a989d61876e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_84bd742b-0180-4d64-997a-40088f86976c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_92549f04-ef19-4c80-8317-8a989d61876e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETS" xlink:type="simple" xlink:href="dgx-20221231.xsd#GOODWILLANDINTANGIBLEASSETS"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2dc59139-3509-4516-ab29-de875d566bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_772ea443-1762-4d94-beea-d80e995f18b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2dc59139-3509-4516-ab29-de875d566bd0" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_772ea443-1762-4d94-beea-d80e995f18b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSES" xlink:type="simple" xlink:href="dgx-20221231.xsd#ACCOUNTSPAYABLEANDACCRUEDEXPENSES"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_fc6fa07f-2a92-47d8-958d-1c85aadb683f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_66a1ff71-8b87-4cdb-9d5a-62f6c0bd4132" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_fc6fa07f-2a92-47d8-958d-1c85aadb683f" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_66a1ff71-8b87-4cdb-9d5a-62f6c0bd4132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/DEBT" xlink:type="simple" xlink:href="dgx-20221231.xsd#DEBT"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/DEBT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentsAbstract_8f43f635-f0f3-47e4-99be-cf4086cfc98d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_65abc507-900d-4afc-96ed-41fd98f02388" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_8f43f635-f0f3-47e4-99be-cf4086cfc98d" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_65abc507-900d-4afc-96ed-41fd98f02388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/LEASES" xlink:type="simple" xlink:href="dgx-20221231.xsd#LEASES"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/LEASES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ade1dd99-ded5-43c5-9043-6eabc49beb36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_b76d16d7-3e13-4f8a-81b0-d9882d6826f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ade1dd99-ded5-43c5-9043-6eabc49beb36" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_b76d16d7-3e13-4f8a-81b0-d9882d6826f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_d24c9384-96ee-459c-99f4-9072e5a97464" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ade1dd99-ded5-43c5-9043-6eabc49beb36" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_d24c9384-96ee-459c-99f4-9072e5a97464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/FINANCIALINSTRUMENTS" xlink:type="simple" xlink:href="dgx-20221231.xsd#FINANCIALINSTRUMENTS"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/FINANCIALINSTRUMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_acc1c9b8-7e3d-47b1-ac2c-0272f2fbd77e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_f42c04e2-9d84-49a4-8160-df8ce3187efc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_acc1c9b8-7e3d-47b1-ac2c-0272f2fbd77e" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_f42c04e2-9d84-49a4-8160-df8ce3187efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTEREST" xlink:type="simple" xlink:href="dgx-20221231.xsd#STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTEREST"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTEREST" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_756d765c-840d-4cda-a9f6-6581b519542b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_68ca6394-e26d-4fa3-8e24-a759d2eb1baa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_756d765c-840d-4cda-a9f6-6581b519542b" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_68ca6394-e26d-4fa3-8e24-a759d2eb1baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANS" xlink:type="simple" xlink:href="dgx-20221231.xsd#STOCKOWNERSHIPANDCOMPENSATIONPLANS"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f81fca1c-025b-4bb1-8a87-e2b5e56144c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_10a7cd4d-7a4d-4e32-829f-1a0f4c93f4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f81fca1c-025b-4bb1-8a87-e2b5e56144c9" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_10a7cd4d-7a4d-4e32-829f-1a0f4c93f4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="dgx-20221231.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4f91c598-03e4-4e1f-b96d-be8c2df9bedf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2a5fd076-1ee7-4e30-91ff-57e21198301d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4f91c598-03e4-4e1f-b96d-be8c2df9bedf" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2a5fd076-1ee7-4e30-91ff-57e21198301d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATION" xlink:type="simple" xlink:href="dgx-20221231.xsd#BUSINESSSEGMENTINFORMATION"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_ba556caa-6090-4563-9613-89129311e3d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_61e22298-596e-4b83-a102-0787b43ebb1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ba556caa-6090-4563-9613-89129311e3d6" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_61e22298-596e-4b83-a102-0787b43ebb1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="dgx-20221231.xsd#SUBSEQUENTEVENTS"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_23a29247-7543-455a-999e-f054ea33cf92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_c3f56078-731a-421a-9da5-37bec5b4596a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_23a29247-7543-455a-999e-f054ea33cf92" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_c3f56078-731a-421a-9da5-37bec5b4596a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="dgx-20221231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8e0fc4bf-f674-43be-a15f-8ec4e3e8efcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_cee3488d-d458-49cf-8782-5b883b2c3bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e0fc4bf-f674-43be-a15f-8ec4e3e8efcc" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_cee3488d-d458-49cf-8782-5b883b2c3bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_4d6e835c-0e59-4bb5-9a1c-db3d883bd2bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e0fc4bf-f674-43be-a15f-8ec4e3e8efcc" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_4d6e835c-0e59-4bb5-9a1c-db3d883bd2bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_e100fa50-d03c-4541-9621-ed1b99d356c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e0fc4bf-f674-43be-a15f-8ec4e3e8efcc" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_e100fa50-d03c-4541-9621-ed1b99d356c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_d98cd9ba-cc5f-41eb-84e6-33480ac1cafa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e0fc4bf-f674-43be-a15f-8ec4e3e8efcc" xlink:to="loc_us-gaap_UseOfEstimates_d98cd9ba-cc5f-41eb-84e6-33480ac1cafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_b5c7efb2-20e8-49ac-90c1-092283bd1e85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e0fc4bf-f674-43be-a15f-8ec4e3e8efcc" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_b5c7efb2-20e8-49ac-90c1-092283bd1e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_e0009f00-1a06-4350-aea4-f3d53a7e7976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e0fc4bf-f674-43be-a15f-8ec4e3e8efcc" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_e0009f00-1a06-4350-aea4-f3d53a7e7976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_c534d89c-ed6a-4cca-80da-a1048c258785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e0fc4bf-f674-43be-a15f-8ec4e3e8efcc" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_c534d89c-ed6a-4cca-80da-a1048c258785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_d4f33fce-369a-4ba3-baa6-98a71658035d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e0fc4bf-f674-43be-a15f-8ec4e3e8efcc" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_d4f33fce-369a-4ba3-baa6-98a71658035d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_f2dc2cfc-16f5-4237-b04b-b6d6bf505091" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e0fc4bf-f674-43be-a15f-8ec4e3e8efcc" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_f2dc2cfc-16f5-4237-b04b-b6d6bf505091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_d5c6d992-67a3-409d-9ba9-272b1392fbed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e0fc4bf-f674-43be-a15f-8ec4e3e8efcc" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_d5c6d992-67a3-409d-9ba9-272b1392fbed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_8aa7ae9b-f524-4b50-a336-b73040f7d53f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e0fc4bf-f674-43be-a15f-8ec4e3e8efcc" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_8aa7ae9b-f524-4b50-a336-b73040f7d53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_db6f49f8-4bd4-4b69-835c-348ea593b395" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e0fc4bf-f674-43be-a15f-8ec4e3e8efcc" xlink:to="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_db6f49f8-4bd4-4b69-835c-348ea593b395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_AccountsReceivableAndAllowanceForCreditLossesPolicyPolicyTextBlock_21706e4b-65a3-42b4-a598-28b4fd86bc68" xlink:href="dgx-20221231.xsd#dgx_AccountsReceivableAndAllowanceForCreditLossesPolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e0fc4bf-f674-43be-a15f-8ec4e3e8efcc" xlink:to="loc_dgx_AccountsReceivableAndAllowanceForCreditLossesPolicyPolicyTextBlock_21706e4b-65a3-42b4-a598-28b4fd86bc68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_74280e6b-73fd-41b2-8e5d-a85f82ece5a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e0fc4bf-f674-43be-a15f-8ec4e3e8efcc" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_74280e6b-73fd-41b2-8e5d-a85f82ece5a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_8bf708a0-9fb4-4570-943b-68c6acef5c94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e0fc4bf-f674-43be-a15f-8ec4e3e8efcc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_8bf708a0-9fb4-4570-943b-68c6acef5c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_a310b77b-b50e-4e1e-a10b-3e7b1949bdb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e0fc4bf-f674-43be-a15f-8ec4e3e8efcc" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_a310b77b-b50e-4e1e-a10b-3e7b1949bdb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_22c9ec7c-3497-4d71-a07e-a079cda05a69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e0fc4bf-f674-43be-a15f-8ec4e3e8efcc" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_22c9ec7c-3497-4d71-a07e-a079cda05a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_dc09a810-d2cb-4056-b5b7-879d98c26a53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e0fc4bf-f674-43be-a15f-8ec4e3e8efcc" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_dc09a810-d2cb-4056-b5b7-879d98c26a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_a169f3be-1035-484d-bb3b-2dc03a64254c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e0fc4bf-f674-43be-a15f-8ec4e3e8efcc" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_a169f3be-1035-484d-bb3b-2dc03a64254c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock_3896e9b9-d156-42fc-a1e8-2fcc6c829bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e0fc4bf-f674-43be-a15f-8ec4e3e8efcc" xlink:to="loc_us-gaap_StockholdersEquityPolicyTextBlock_3896e9b9-d156-42fc-a1e8-2fcc6c829bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_ffbaa7a7-2342-48e6-80e5-b15f4dca9351" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e0fc4bf-f674-43be-a15f-8ec4e3e8efcc" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_ffbaa7a7-2342-48e6-80e5-b15f4dca9351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c73897e6-3faa-45dc-aca4-9e6101ba9b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e0fc4bf-f674-43be-a15f-8ec4e3e8efcc" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c73897e6-3faa-45dc-aca4-9e6101ba9b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_a512860c-edc3-4ab9-a23b-4029ca73851d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e0fc4bf-f674-43be-a15f-8ec4e3e8efcc" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_a512860c-edc3-4ab9-a23b-4029ca73851d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/REVENUERECOGNITIONTables" xlink:type="simple" xlink:href="dgx-20221231.xsd#REVENUERECOGNITIONTables"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/REVENUERECOGNITIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_93de71e1-ee34-4994-a9ff-8cbb44134fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_9395faf1-f1ad-4267-b35e-e11e272ce938" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_93de71e1-ee34-4994-a9ff-8cbb44134fb5" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_9395faf1-f1ad-4267-b35e-e11e272ce938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_AccountsReceivableDisaggregationTableTextBlock_24df2854-5f40-4025-8744-00a44761d2e0" xlink:href="dgx-20221231.xsd#dgx_AccountsReceivableDisaggregationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_93de71e1-ee34-4994-a9ff-8cbb44134fb5" xlink:to="loc_dgx_AccountsReceivableDisaggregationTableTextBlock_24df2854-5f40-4025-8744-00a44761d2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_8c0576a9-34aa-4f10-8f82-0f5e9714c359" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_93de71e1-ee34-4994-a9ff-8cbb44134fb5" xlink:to="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_8c0576a9-34aa-4f10-8f82-0f5e9714c359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/EARNINGSLOSSPERSHARETables" xlink:type="simple" xlink:href="dgx-20221231.xsd#EARNINGSLOSSPERSHARETables"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/EARNINGSLOSSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_73025fb0-59b3-407a-8d08-a1275ba04e14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_345864cc-ddc6-4cf0-ace7-99f04396be68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_73025fb0-59b3-407a-8d08-a1275ba04e14" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_345864cc-ddc6-4cf0-ace7-99f04396be68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_95e27faa-d821-4cdb-b52b-6182afabe8f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_73025fb0-59b3-407a-8d08-a1275ba04e14" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_95e27faa-d821-4cdb-b52b-6182afabe8f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESTables" xlink:type="simple" xlink:href="dgx-20221231.xsd#RESTRUCTURINGACTIVITIESTables"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_ad2b04fc-8b77-423c-b1cf-9041305d76e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_68c17672-fd95-43df-8a88-8e5be40f599c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_ad2b04fc-8b77-423c-b1cf-9041305d76e5" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_68c17672-fd95-43df-8a88-8e5be40f599c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_75b25a21-909f-44db-b825-7deea3127100" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_ad2b04fc-8b77-423c-b1cf-9041305d76e5" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_75b25a21-909f-44db-b825-7deea3127100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="dgx-20221231.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f89944d5-72ba-400c-a7be-ed01ec5bba51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_d415d2b0-050d-4d7c-978a-4984be0dcb9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f89944d5-72ba-400c-a7be-ed01ec5bba51" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_d415d2b0-050d-4d7c-978a-4984be0dcb9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1fd2ced6-b318-4f7e-aa5e-ba5a78876737" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f89944d5-72ba-400c-a7be-ed01ec5bba51" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1fd2ced6-b318-4f7e-aa5e-ba5a78876737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/TAXESONINCOMETables" xlink:type="simple" xlink:href="dgx-20221231.xsd#TAXESONINCOMETables"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/TAXESONINCOMETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_77ec3015-9ed0-4272-bc82-89ae26390318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_a672ca61-9b4d-4a18-bed9-9a335c7e3c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_77ec3015-9ed0-4272-bc82-89ae26390318" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_a672ca61-9b4d-4a18-bed9-9a335c7e3c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_832dde1f-2f29-47a4-a7eb-6bc02ae7a5a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_77ec3015-9ed0-4272-bc82-89ae26390318" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_832dde1f-2f29-47a4-a7eb-6bc02ae7a5a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_61bcbd67-4136-43c2-b58b-9308b73e4abe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_77ec3015-9ed0-4272-bc82-89ae26390318" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_61bcbd67-4136-43c2-b58b-9308b73e4abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_d372fecc-b22a-4c3c-b918-ae580a98fc72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_77ec3015-9ed0-4272-bc82-89ae26390318" xlink:to="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_d372fecc-b22a-4c3c-b918-ae580a98fc72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATATables" xlink:type="simple" xlink:href="dgx-20221231.xsd#SUPPLEMENTALCASHFLOWANDOTHERDATATables"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATATables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_17ad884f-6524-4ed3-ae49-21dcbbc91500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_ca2c53f8-bcf0-4e85-bd20-3e63f60a39b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_17ad884f-6524-4ed3-ae49-21dcbbc91500" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_ca2c53f8-bcf0-4e85-bd20-3e63f60a39b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENTTables" xlink:type="simple" xlink:href="dgx-20221231.xsd#PROPERTYPLANTANDEQUIPMENTTables"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e990e394-4bc9-4165-bfc4-4c018a62c7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_f3a8702d-19e3-4539-9e8a-bd559bfbcc45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e990e394-4bc9-4165-bfc4-4c018a62c7ad" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_f3a8702d-19e3-4539-9e8a-bd559bfbcc45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSTables" xlink:type="simple" xlink:href="dgx-20221231.xsd#GOODWILLANDINTANGIBLEASSETSTables"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9ea9d253-41e7-41f6-8cc6-9bd210868bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_67a44cbd-8ba7-409c-b825-a938c74d3cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9ea9d253-41e7-41f6-8cc6-9bd210868bb6" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_67a44cbd-8ba7-409c-b825-a938c74d3cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_6eed1160-d736-4336-883d-c54b0ecbcfbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9ea9d253-41e7-41f6-8cc6-9bd210868bb6" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_6eed1160-d736-4336-883d-c54b0ecbcfbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_8b7d6cad-e9f6-425d-ae51-6a21710d8c84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9ea9d253-41e7-41f6-8cc6-9bd210868bb6" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_8b7d6cad-e9f6-425d-ae51-6a21710d8c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables" xlink:type="simple" xlink:href="dgx-20221231.xsd#ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_2ac81039-7afe-478d-af07-d81626835b85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_9ba6e393-96a7-4c45-b7cd-bfc3d6fdea07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_2ac81039-7afe-478d-af07-d81626835b85" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_9ba6e393-96a7-4c45-b7cd-bfc3d6fdea07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/DEBTTables" xlink:type="simple" xlink:href="dgx-20221231.xsd#DEBTTables"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/DEBTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentsAbstract_bc513250-d45e-4e5c-8d5a-d234c9c4c399" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock_a788f4b5-08df-4d33-b383-01942c612eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_bc513250-d45e-4e5c-8d5a-d234c9c4c399" xlink:to="loc_us-gaap_LongTermDebtTextBlock_a788f4b5-08df-4d33-b383-01942c612eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_a5d3179a-da9b-4775-a699-72542e6d2309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_bc513250-d45e-4e5c-8d5a-d234c9c4c399" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_a5d3179a-da9b-4775-a699-72542e6d2309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/LEASESTables" xlink:type="simple" xlink:href="dgx-20221231.xsd#LEASESTables"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/LEASESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a045d93a-b4da-44d5-ba6a-27a754ba13f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ScheduleOfLeaseByAssetTypeTableTextBlock_aa8be23e-dd51-4ca4-8dd3-ba01be4be421" xlink:href="dgx-20221231.xsd#dgx_ScheduleOfLeaseByAssetTypeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a045d93a-b4da-44d5-ba6a-27a754ba13f7" xlink:to="loc_dgx_ScheduleOfLeaseByAssetTypeTableTextBlock_aa8be23e-dd51-4ca4-8dd3-ba01be4be421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_f30828db-406f-4b10-8e04-f947f87ed6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a045d93a-b4da-44d5-ba6a-27a754ba13f7" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_f30828db-406f-4b10-8e04-f947f87ed6bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5e2e0dab-672d-45de-ad25-fefb2e4499e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a045d93a-b4da-44d5-ba6a-27a754ba13f7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5e2e0dab-672d-45de-ad25-fefb2e4499e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_325f53dd-c80a-4efd-9b04-8c186d85520d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a045d93a-b4da-44d5-ba6a-27a754ba13f7" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_325f53dd-c80a-4efd-9b04-8c186d85520d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ScheduleofLeaseTermandDiscountRateTableTextBlock_c4d2789d-6c09-441d-9693-f596667fd65f" xlink:href="dgx-20221231.xsd#dgx_ScheduleofLeaseTermandDiscountRateTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a045d93a-b4da-44d5-ba6a-27a754ba13f7" xlink:to="loc_dgx_ScheduleofLeaseTermandDiscountRateTableTextBlock_c4d2789d-6c09-441d-9693-f596667fd65f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/FINANCIALINSTRUMENTSTables" xlink:type="simple" xlink:href="dgx-20221231.xsd#FINANCIALINSTRUMENTSTables"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/FINANCIALINSTRUMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_4d0ff1b4-8cd6-40db-9e23-5b7fccca03dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_9b308fe7-2c7a-4c11-879d-f09ea307b8db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_4d0ff1b4-8cd6-40db-9e23-5b7fccca03dd" xlink:to="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_9b308fe7-2c7a-4c11-879d-f09ea307b8db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTTables" xlink:type="simple" xlink:href="dgx-20221231.xsd#STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTTables"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_32f07404-7ddf-4419-aefa-1ea02d46f814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock_f788fadf-6fc3-40b3-8b7d-ed2bdb052699" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_32f07404-7ddf-4419-aefa-1ea02d46f814" xlink:to="loc_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock_f788fadf-6fc3-40b3-8b7d-ed2bdb052699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTables" xlink:type="simple" xlink:href="dgx-20221231.xsd#STOCKOWNERSHIPANDCOMPENSATIONPLANSTables"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d0838a25-411f-4123-aa3c-ac76e944dd34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_e7aed084-58f6-46d1-8adc-9caaf8adf407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d0838a25-411f-4123-aa3c-ac76e944dd34" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_e7aed084-58f6-46d1-8adc-9caaf8adf407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_b5904673-45e6-44d2-9e7d-58e8e0005fee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d0838a25-411f-4123-aa3c-ac76e944dd34" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_b5904673-45e6-44d2-9e7d-58e8e0005fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ScheduleOfShareBasedPaymentAwardPerformanceShareUnitsValuationAssumptionsTableTextBlock_3a9d3203-a0e5-4c26-9a24-6538dfde8cfd" xlink:href="dgx-20221231.xsd#dgx_ScheduleOfShareBasedPaymentAwardPerformanceShareUnitsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d0838a25-411f-4123-aa3c-ac76e944dd34" xlink:to="loc_dgx_ScheduleOfShareBasedPaymentAwardPerformanceShareUnitsValuationAssumptionsTableTextBlock_3a9d3203-a0e5-4c26-9a24-6538dfde8cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_9958c053-7792-408f-b3a2-1c4289a90103" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d0838a25-411f-4123-aa3c-ac76e944dd34" xlink:to="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_9958c053-7792-408f-b3a2-1c4289a90103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONTables" xlink:type="simple" xlink:href="dgx-20221231.xsd#BUSINESSSEGMENTINFORMATIONTables"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_d9979085-f401-4c9d-a6c4-998fe195b8d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_92d636ba-8dd5-4a23-ad93-86b6d384b4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d9979085-f401-4c9d-a6c4-998fe195b8d8" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_92d636ba-8dd5-4a23-ad93-86b6d384b4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_13f1c1ca-634d-4283-9982-36451e51a90d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_90d6b8b9-ed1a-4a59-8085-7f666f152df2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_13f1c1ca-634d-4283-9982-36451e51a90d" xlink:to="loc_us-gaap_AdvertisingExpense_90d6b8b9-ed1a-4a59-8085-7f666f152df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_SummaryOfSignificantAccountingPoliciesTable_a13a4804-ce75-4b72-8635-8d23b4dc380d" xlink:href="dgx-20221231.xsd#dgx_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_13f1c1ca-634d-4283-9982-36451e51a90d" xlink:to="loc_dgx_SummaryOfSignificantAccountingPoliciesTable_a13a4804-ce75-4b72-8635-8d23b4dc380d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_22db4a58-9087-499b-a5fe-8294c7920709" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesTable_a13a4804-ce75-4b72-8635-8d23b4dc380d" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_22db4a58-9087-499b-a5fe-8294c7920709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_6ba0f8d6-04c4-4ad7-8f3a-469408b45e74" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_22db4a58-9087-499b-a5fe-8294c7920709" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_6ba0f8d6-04c4-4ad7-8f3a-469408b45e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_SubstantialOwnershipInterestMember_b7385898-a413-4cf7-a0a5-ee9f079af2c0" xlink:href="dgx-20221231.xsd#dgx_SubstantialOwnershipInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6ba0f8d6-04c4-4ad7-8f3a-469408b45e74" xlink:to="loc_dgx_SubstantialOwnershipInterestMember_b7385898-a413-4cf7-a0a5-ee9f079af2c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ed8cbb25-056f-4b2f-8035-ae43182b27bd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesTable_a13a4804-ce75-4b72-8635-8d23b4dc380d" xlink:to="loc_srt_RangeAxis_ed8cbb25-056f-4b2f-8035-ae43182b27bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d2fc69d6-b511-4267-9263-cadb5b98976c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ed8cbb25-056f-4b2f-8035-ae43182b27bd" xlink:to="loc_srt_RangeMember_d2fc69d6-b511-4267-9263-cadb5b98976c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_65368125-87e8-408d-8730-c316d22ca92a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d2fc69d6-b511-4267-9263-cadb5b98976c" xlink:to="loc_srt_MinimumMember_65368125-87e8-408d-8730-c316d22ca92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1b715aae-98d4-44d2-aedc-a60efe953508" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d2fc69d6-b511-4267-9263-cadb5b98976c" xlink:to="loc_srt_MaximumMember_1b715aae-98d4-44d2-aedc-a60efe953508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7b09e81e-dfe6-4348-94b9-34c134996a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesTable_a13a4804-ce75-4b72-8635-8d23b4dc380d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7b09e81e-dfe6-4348-94b9-34c134996a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_80b22776-6061-42d0-8488-c71b70fe2c74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7b09e81e-dfe6-4348-94b9-34c134996a7b" xlink:to="loc_us-gaap_SegmentDomain_80b22776-6061-42d0-8488-c71b70fe2c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_DiagnosticInformationServicesBusinessMember_5d99f610-5567-4e87-a73d-42246663da71" xlink:href="dgx-20221231.xsd#dgx_DiagnosticInformationServicesBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_80b22776-6061-42d0-8488-c71b70fe2c74" xlink:to="loc_dgx_DiagnosticInformationServicesBusinessMember_5d99f610-5567-4e87-a73d-42246663da71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_ab5f0aaf-a0a5-4361-a89a-f68e6ddb2566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesTable_a13a4804-ce75-4b72-8635-8d23b4dc380d" xlink:to="loc_us-gaap_SubsegmentsAxis_ab5f0aaf-a0a5-4361-a89a-f68e6ddb2566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_0e8c7ec3-1bd1-4e4c-8a0d-6dec095244cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_ab5f0aaf-a0a5-4361-a89a-f68e6ddb2566" xlink:to="loc_us-gaap_SubsegmentsDomain_0e8c7ec3-1bd1-4e4c-8a0d-6dec095244cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_GovernmentPayersMember_b7039572-025a-4cca-b388-80feba0c6705" xlink:href="dgx-20221231.xsd#dgx_GovernmentPayersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_0e8c7ec3-1bd1-4e4c-8a0d-6dec095244cc" xlink:to="loc_dgx_GovernmentPayersMember_b7039572-025a-4cca-b388-80feba0c6705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_PatientMember_ae569e9e-c01e-4fcd-a42c-d5537ac3eb51" xlink:href="dgx-20221231.xsd#dgx_PatientMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_0e8c7ec3-1bd1-4e4c-8a0d-6dec095244cc" xlink:to="loc_dgx_PatientMember_ae569e9e-c01e-4fcd-a42c-d5537ac3eb51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_238c63b1-58c1-4e9d-84af-9a62e9d3db63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesTable_a13a4804-ce75-4b72-8635-8d23b4dc380d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_238c63b1-58c1-4e9d-84af-9a62e9d3db63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9d5048fd-5269-4f05-86d9-a1acc8caabbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_238c63b1-58c1-4e9d-84af-9a62e9d3db63" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9d5048fd-5269-4f05-86d9-a1acc8caabbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_7037ddaa-7127-4454-827f-f8d02f9517e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9d5048fd-5269-4f05-86d9-a1acc8caabbc" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_7037ddaa-7127-4454-827f-f8d02f9517e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LaboratoryEquipmentAndFurnitureAndFixturesMember_fece0cbf-5ad1-4ce1-a481-2959f30a8e31" xlink:href="dgx-20221231.xsd#dgx_LaboratoryEquipmentAndFurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9d5048fd-5269-4f05-86d9-a1acc8caabbc" xlink:to="loc_dgx_LaboratoryEquipmentAndFurnitureAndFixturesMember_fece0cbf-5ad1-4ce1-a481-2959f30a8e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_f2319f21-23ed-47f7-87c7-146b73aa898b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9d5048fd-5269-4f05-86d9-a1acc8caabbc" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_f2319f21-23ed-47f7-87c7-146b73aa898b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_ddd1b98e-2692-4664-80d7-913d0b52081e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesTable_a13a4804-ce75-4b72-8635-8d23b4dc380d" xlink:to="loc_srt_StatementScenarioAxis_ddd1b98e-2692-4664-80d7-913d0b52081e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_5568c3be-373d-4448-b529-61e524e788cc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_ddd1b98e-2692-4664-80d7-913d0b52081e" xlink:to="loc_srt_ScenarioUnspecifiedDomain_5568c3be-373d-4448-b529-61e524e788cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_6cf97803-f6e0-4a39-b68f-29319fbbbfa1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_5568c3be-373d-4448-b529-61e524e788cc" xlink:to="loc_srt_ScenarioForecastMember_6cf97803-f6e0-4a39-b68f-29319fbbbfa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9e9a90cb-ab1b-4a7b-9758-d54c11f8138b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesTable_a13a4804-ce75-4b72-8635-8d23b4dc380d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9e9a90cb-ab1b-4a7b-9758-d54c11f8138b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_6dac276e-4e49-48c8-8589-6cb2caa20132" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9e9a90cb-ab1b-4a7b-9758-d54c11f8138b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_6dac276e-4e49-48c8-8589-6cb2caa20132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_34627fdf-b103-41ee-aacf-afc0d45228d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_6dac276e-4e49-48c8-8589-6cb2caa20132" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_34627fdf-b103-41ee-aacf-afc0d45228d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_SummaryOfSignificantAccountingPoliciesLineItems_4f36536c-fb46-4974-8902-d97e63716ea3" xlink:href="dgx-20221231.xsd#dgx_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesTable_a13a4804-ce75-4b72-8635-8d23b4dc380d" xlink:to="loc_dgx_SummaryOfSignificantAccountingPoliciesLineItems_4f36536c-fb46-4974-8902-d97e63716ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_9ba11a07-4ce4-4d6b-b52c-aae3c7084fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesLineItems_4f36536c-fb46-4974-8902-d97e63716ea3" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_9ba11a07-4ce4-4d6b-b52c-aae3c7084fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_6e729580-d9d1-4021-836a-c39bfb004135" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesLineItems_4f36536c-fb46-4974-8902-d97e63716ea3" xlink:to="loc_us-gaap_EquityMethodInvestments_6e729580-d9d1-4021-836a-c39bfb004135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_PercentageofNetRevenues_d806bc9f-bc3b-472f-b3fd-c3710d13d0e1" xlink:href="dgx-20221231.xsd#dgx_PercentageofNetRevenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesLineItems_4f36536c-fb46-4974-8902-d97e63716ea3" xlink:to="loc_dgx_PercentageofNetRevenues_d806bc9f-bc3b-472f-b3fd-c3710d13d0e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3ea35ae1-4e04-4d0b-a830-d35c223827e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesLineItems_4f36536c-fb46-4974-8902-d97e63716ea3" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3ea35ae1-4e04-4d0b-a830-d35c223827e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_PercentageofNetAccountsReceivable_569ea57c-f012-40e7-9250-6394f8bb6146" xlink:href="dgx-20221231.xsd#dgx_PercentageofNetAccountsReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesLineItems_4f36536c-fb46-4974-8902-d97e63716ea3" xlink:to="loc_dgx_PercentageofNetAccountsReceivable_569ea57c-f012-40e7-9250-6394f8bb6146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1ce4989f-e233-418a-867c-ea36e0398729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesLineItems_4f36536c-fb46-4974-8902-d97e63716ea3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1ce4989f-e233-418a-867c-ea36e0398729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1435c208-5dda-43ca-a93b-2e900ffc6893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesLineItems_4f36536c-fb46-4974-8902-d97e63716ea3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1435c208-5dda-43ca-a93b-2e900ffc6893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e4dbfed9-fa44-42d3-9cd6-0d01ad91f4f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesLineItems_4f36536c-fb46-4974-8902-d97e63716ea3" xlink:to="loc_us-gaap_OperatingIncomeLoss_e4dbfed9-fa44-42d3-9cd6-0d01ad91f4f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f4004684-700c-43a6-bef7-cbe9db7a96d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesLineItems_4f36536c-fb46-4974-8902-d97e63716ea3" xlink:to="loc_us-gaap_ProfitLoss_f4004684-700c-43a6-bef7-cbe9db7a96d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_62a23ca3-1d98-466e-92de-23f2b2e7b228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesLineItems_4f36536c-fb46-4974-8902-d97e63716ea3" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_62a23ca3-1d98-466e-92de-23f2b2e7b228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_InvestmentwithoutReadilyDeterminableFairValueImpairment_bbccf26a-325d-4d8a-a729-09b396670537" xlink:href="dgx-20221231.xsd#dgx_InvestmentwithoutReadilyDeterminableFairValueImpairment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesLineItems_4f36536c-fb46-4974-8902-d97e63716ea3" xlink:to="loc_dgx_InvestmentwithoutReadilyDeterminableFairValueImpairment_bbccf26a-325d-4d8a-a729-09b396670537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_321a09c9-3906-49d4-a1ac-6c6b961fbfb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesLineItems_4f36536c-fb46-4974-8902-d97e63716ea3" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_321a09c9-3906-49d4-a1ac-6c6b961fbfb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8098e9a2-be0e-47ff-8c80-92bbfee55773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesLineItems_4f36536c-fb46-4974-8902-d97e63716ea3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8098e9a2-be0e-47ff-8c80-92bbfee55773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9c7446e2-6ea7-4806-ba6b-29a29ba0ac3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesLineItems_4f36536c-fb46-4974-8902-d97e63716ea3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9c7446e2-6ea7-4806-ba6b-29a29ba0ac3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_252b880a-0972-4f04-96d3-e8903dc951b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesLineItems_4f36536c-fb46-4974-8902-d97e63716ea3" xlink:to="loc_us-gaap_OperatingLeaseLiability_252b880a-0972-4f04-96d3-e8903dc951b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities_c6446c3e-97a1-4c4d-8a41-d1dfed0f79e7" xlink:href="dgx-20221231.xsd#dgx_EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesLineItems_4f36536c-fb46-4974-8902-d97e63716ea3" xlink:to="loc_dgx_EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities_c6446c3e-97a1-4c4d-8a41-d1dfed0f79e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_8d193c1d-eb6b-4dbf-9226-cdac029cd0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecurities"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_SummaryOfSignificantAccountingPoliciesLineItems_4f36536c-fb46-4974-8902-d97e63716ea3" xlink:to="loc_us-gaap_TradingSecurities_8d193c1d-eb6b-4dbf-9226-cdac029cd0cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/REVENUERECOGNITIONDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#REVENUERECOGNITIONDetails"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/REVENUERECOGNITIONDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_71b061f5-c8f3-44b2-8d65-ba3aac771bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f2b0f46b-4956-495a-9538-75641ad33ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_71b061f5-c8f3-44b2-8d65-ba3aac771bc0" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f2b0f46b-4956-495a-9538-75641ad33ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_4c1b27dc-3e2f-48bf-9237-f34da6b93c64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f2b0f46b-4956-495a-9538-75641ad33ba1" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_4c1b27dc-3e2f-48bf-9237-f34da6b93c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_18c69788-e1ee-4034-9c5d-bb19158c0343" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4c1b27dc-3e2f-48bf-9237-f34da6b93c64" xlink:to="loc_us-gaap_SegmentDomain_18c69788-e1ee-4034-9c5d-bb19158c0343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_DiagnosticInformationServicesBusinessMember_376d25f5-2a55-4e3c-81c0-d07ae2e2c754" xlink:href="dgx-20221231.xsd#dgx_DiagnosticInformationServicesBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_18c69788-e1ee-4034-9c5d-bb19158c0343" xlink:to="loc_dgx_DiagnosticInformationServicesBusinessMember_376d25f5-2a55-4e3c-81c0-d07ae2e2c754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_79eeaca4-d362-425d-bdd4-5bee36d29d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_18c69788-e1ee-4034-9c5d-bb19158c0343" xlink:to="loc_us-gaap_AllOtherSegmentsMember_79eeaca4-d362-425d-bdd4-5bee36d29d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_81353cbd-e681-40bd-8167-873e75a13891" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f2b0f46b-4956-495a-9538-75641ad33ba1" xlink:to="loc_us-gaap_SubsegmentsAxis_81353cbd-e681-40bd-8167-873e75a13891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_3c8a2e3f-7254-42c4-ae37-fbb2accf3876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_81353cbd-e681-40bd-8167-873e75a13891" xlink:to="loc_us-gaap_SubsegmentsDomain_3c8a2e3f-7254-42c4-ae37-fbb2accf3876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_HealthcareInsurersMember_78dd9073-49d5-44fa-9f77-ba9b7a8f4b84" xlink:href="dgx-20221231.xsd#dgx_HealthcareInsurersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_3c8a2e3f-7254-42c4-ae37-fbb2accf3876" xlink:to="loc_dgx_HealthcareInsurersMember_78dd9073-49d5-44fa-9f77-ba9b7a8f4b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_GovernmentPayersMember_c54182b8-5475-4846-b44f-d36250bc4d9a" xlink:href="dgx-20221231.xsd#dgx_GovernmentPayersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_3c8a2e3f-7254-42c4-ae37-fbb2accf3876" xlink:to="loc_dgx_GovernmentPayersMember_c54182b8-5475-4846-b44f-d36250bc4d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ClientPayersMember_d8ec1cee-01b6-4807-a550-1b9129718f8e" xlink:href="dgx-20221231.xsd#dgx_ClientPayersMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_3c8a2e3f-7254-42c4-ae37-fbb2accf3876" xlink:to="loc_dgx_ClientPayersMember_d8ec1cee-01b6-4807-a550-1b9129718f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_PatientMember_c10eed35-3fd7-4f45-bc59-eb58a08da32a" xlink:href="dgx-20221231.xsd#dgx_PatientMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_3c8a2e3f-7254-42c4-ae37-fbb2accf3876" xlink:to="loc_dgx_PatientMember_c10eed35-3fd7-4f45-bc59-eb58a08da32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_DSBusinessesMember_5be42483-3849-4248-a380-ffc531252d43" xlink:href="dgx-20221231.xsd#dgx_DSBusinessesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_3c8a2e3f-7254-42c4-ae37-fbb2accf3876" xlink:to="loc_dgx_DSBusinessesMember_5be42483-3849-4248-a380-ffc531252d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_285036d8-b21d-433c-8876-eb2a26f0a5e8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f2b0f46b-4956-495a-9538-75641ad33ba1" xlink:to="loc_srt_ProductOrServiceAxis_285036d8-b21d-433c-8876-eb2a26f0a5e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c38afb2d-fed9-4ef1-b0f3-5d28fcd12e94" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_285036d8-b21d-433c-8876-eb2a26f0a5e8" xlink:to="loc_srt_ProductsAndServicesDomain_c38afb2d-fed9-4ef1-b0f3-5d28fcd12e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_FeeforserviceMember_04a42e3f-11ef-4b5e-a750-867c40b89a79" xlink:href="dgx-20221231.xsd#dgx_FeeforserviceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c38afb2d-fed9-4ef1-b0f3-5d28fcd12e94" xlink:to="loc_dgx_FeeforserviceMember_04a42e3f-11ef-4b5e-a750-867c40b89a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_CapitatedMember_9d8ca0b4-a3c4-4a84-a831-98f6b46e4ce4" xlink:href="dgx-20221231.xsd#dgx_CapitatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c38afb2d-fed9-4ef1-b0f3-5d28fcd12e94" xlink:to="loc_dgx_CapitatedMember_9d8ca0b4-a3c4-4a84-a831-98f6b46e4ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_546a587f-75b7-4c21-8a2a-32fd015a4060" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f2b0f46b-4956-495a-9538-75641ad33ba1" xlink:to="loc_srt_RangeAxis_546a587f-75b7-4c21-8a2a-32fd015a4060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_015460e1-b2c9-4a24-8af2-96c250d08a6d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_546a587f-75b7-4c21-8a2a-32fd015a4060" xlink:to="loc_srt_RangeMember_015460e1-b2c9-4a24-8af2-96c250d08a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_552d6bae-b639-4b21-9b53-89974fa51a79" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_015460e1-b2c9-4a24-8af2-96c250d08a6d" xlink:to="loc_srt_MinimumMember_552d6bae-b639-4b21-9b53-89974fa51a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b1f1a365-da8e-4701-9f81-94d0a62b0a54" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_015460e1-b2c9-4a24-8af2-96c250d08a6d" xlink:to="loc_srt_MaximumMember_b1f1a365-da8e-4701-9f81-94d0a62b0a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_d3c0d219-6664-44e9-8a51-1cc8bb936823" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f2b0f46b-4956-495a-9538-75641ad33ba1" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_d3c0d219-6664-44e9-8a51-1cc8bb936823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_PercentageofNetRevenues_fca78aea-879a-4c7c-b643-319e1da74fea" xlink:href="dgx-20221231.xsd#dgx_PercentageofNetRevenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d3c0d219-6664-44e9-8a51-1cc8bb936823" xlink:to="loc_dgx_PercentageofNetRevenues_fca78aea-879a-4c7c-b643-319e1da74fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_RevenueCollectionofConsiderationPeriod_7eb8f708-b120-406a-aca7-c12fb79a400a" xlink:href="dgx-20221231.xsd#dgx_RevenueCollectionofConsiderationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d3c0d219-6664-44e9-8a51-1cc8bb936823" xlink:to="loc_dgx_RevenueCollectionofConsiderationPeriod_7eb8f708-b120-406a-aca7-c12fb79a400a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_PeriodofBillingFullyReserve_79f88eeb-35f0-4d75-ba65-bfa6401fdd6a" xlink:href="dgx-20221231.xsd#dgx_PeriodofBillingFullyReserve"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d3c0d219-6664-44e9-8a51-1cc8bb936823" xlink:to="loc_dgx_PeriodofBillingFullyReserve_79f88eeb-35f0-4d75-ba65-bfa6401fdd6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_PercentageofNetAccountsReceivable_72a913b3-ebce-4c9d-bc0f-6b617dc6170b" xlink:href="dgx-20221231.xsd#dgx_PercentageofNetAccountsReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d3c0d219-6664-44e9-8a51-1cc8bb936823" xlink:to="loc_dgx_PercentageofNetAccountsReceivable_72a913b3-ebce-4c9d-bc0f-6b617dc6170b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_7f779ae4-6de0-4925-b010-64854488f562" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d3c0d219-6664-44e9-8a51-1cc8bb936823" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_7f779ae4-6de0-4925-b010-64854488f562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_65ac2114-d330-4e69-8e05-8c0b925b4aba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_7f779ae4-6de0-4925-b010-64854488f562" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_65ac2114-d330-4e69-8e05-8c0b925b4aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_bec9201d-b54b-427f-8eb2-ddf15d508e54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_7f779ae4-6de0-4925-b010-64854488f562" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_bec9201d-b54b-427f-8eb2-ddf15d508e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_426b51c0-cde2-4f8b-9625-dd608b781d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_7f779ae4-6de0-4925-b010-64854488f562" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_426b51c0-cde2-4f8b-9625-dd608b781d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_f7805de3-4305-4d3f-b999-5b043d89fe36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d3c0d219-6664-44e9-8a51-1cc8bb936823" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_f7805de3-4305-4d3f-b999-5b043d89fe36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#EARNINGSLOSSPERSHAREDetails"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_699e3778-8eff-4650-b865-cc08294aad0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_71b5b4dd-f6f2-4cbb-ad8d-e04a3ea65914" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_699e3778-8eff-4650-b865-cc08294aad0c" xlink:to="loc_us-gaap_NetIncomeLoss_71b5b4dd-f6f2-4cbb-ad8d-e04a3ea65914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_db7c4dee-5c37-4fbf-ba8c-bbee617e6f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_699e3778-8eff-4650-b865-cc08294aad0c" xlink:to="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_db7c4dee-5c37-4fbf-ba8c-bbee617e6f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_6352df12-951c-4e02-8695-428b1261b355" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_699e3778-8eff-4650-b865-cc08294aad0c" xlink:to="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_6352df12-951c-4e02-8695-428b1261b355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_546fce42-d8e9-493e-bf5c-7d52595b692a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_699e3778-8eff-4650-b865-cc08294aad0c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_546fce42-d8e9-493e-bf5c-7d52595b692a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_6dc56e0d-4cd9-42c1-87b4-be6ed224e189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_699e3778-8eff-4650-b865-cc08294aad0c" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_6dc56e0d-4cd9-42c1-87b4-be6ed224e189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b9f62faa-e0c4-421a-a6cb-ca69a46b5458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_699e3778-8eff-4650-b865-cc08294aad0c" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b9f62faa-e0c4-421a-a6cb-ca69a46b5458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ad03c475-e632-4893-8e9a-9cc910491655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_699e3778-8eff-4650-b865-cc08294aad0c" xlink:to="loc_us-gaap_EarningsPerShareBasic_ad03c475-e632-4893-8e9a-9cc910491655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2a691015-7d71-4571-8058-3e9f64489b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_699e3778-8eff-4650-b865-cc08294aad0c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2a691015-7d71-4571-8058-3e9f64489b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1e3ac5ac-54c3-4ba1-868b-fd809311aa92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_699e3778-8eff-4650-b865-cc08294aad0c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1e3ac5ac-54c3-4ba1-868b-fd809311aa92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesTable_e56bc3d8-d8c9-4696-80a3-e635d81a9fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcceleratedShareRepurchasesTable"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_699e3778-8eff-4650-b865-cc08294aad0c" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesTable_e56bc3d8-d8c9-4696-80a3-e635d81a9fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesDateAxis_c76867d9-7b7c-4a0d-b9d9-757c033d31c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcceleratedShareRepurchasesDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesTable_e56bc3d8-d8c9-4696-80a3-e635d81a9fb0" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesDateAxis_c76867d9-7b7c-4a0d-b9d9-757c033d31c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesDateDomain_b27881fc-6c0f-4f85-bc40-fe5bc72eba22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcceleratedShareRepurchasesDateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesDateAxis_c76867d9-7b7c-4a0d-b9d9-757c033d31c8" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesDateDomain_b27881fc-6c0f-4f85-bc40-fe5bc72eba22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_AcceleratedShareRepurchaseAgreementsMember_6d20d50a-30a7-43a3-9887-e29c7e6a1bcd" xlink:href="dgx-20221231.xsd#dgx_AcceleratedShareRepurchaseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesDateDomain_b27881fc-6c0f-4f85-bc40-fe5bc72eba22" xlink:to="loc_dgx_AcceleratedShareRepurchaseAgreementsMember_6d20d50a-30a7-43a3-9887-e29c7e6a1bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesLineItems_29599a53-26fb-4f26-9968-31d848535e78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcceleratedShareRepurchasesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesTable_e56bc3d8-d8c9-4696-80a3-e635d81a9fb0" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesLineItems_29599a53-26fb-4f26-9968-31d848535e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_AcceleratedShareRepurchasesPayment_67bb39d4-7c83-4072-b95e-27218159ead2" xlink:href="dgx-20221231.xsd#dgx_AcceleratedShareRepurchasesPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_29599a53-26fb-4f26-9968-31d848535e78" xlink:to="loc_dgx_AcceleratedShareRepurchasesPayment_67bb39d4-7c83-4072-b95e-27218159ead2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESPreTaxRestructuringchargesDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#RESTRUCTURINGACTIVITIESPreTaxRestructuringchargesDetails"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESPreTaxRestructuringchargesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_eac1dc98-62e2-435a-97e6-9d93f4949bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f5b89b4b-46c6-47d8-ac56-ce7805bcca5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_eac1dc98-62e2-435a-97e6-9d93f4949bfc" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f5b89b4b-46c6-47d8-ac56-ce7805bcca5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_a075adb6-a89f-4315-9ac1-1f7f61f99c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f5b89b4b-46c6-47d8-ac56-ce7805bcca5a" xlink:to="loc_us-gaap_RestructuringPlanAxis_a075adb6-a89f-4315-9ac1-1f7f61f99c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_3e37c516-b74c-492c-a1a3-1a289c25d962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_a075adb6-a89f-4315-9ac1-1f7f61f99c4a" xlink:to="loc_us-gaap_RestructuringPlanDomain_3e37c516-b74c-492c-a1a3-1a289c25d962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_InvigorateProgramMember_30b49b05-5750-46f3-ab65-0e3cbc19a409" xlink:href="dgx-20221231.xsd#dgx_InvigorateProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_3e37c516-b74c-492c-a1a3-1a289c25d962" xlink:to="loc_dgx_InvigorateProgramMember_30b49b05-5750-46f3-ab65-0e3cbc19a409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_f5a03810-3648-4e87-a434-8f900b71bea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f5b89b4b-46c6-47d8-ac56-ce7805bcca5a" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_f5a03810-3648-4e87-a434-8f900b71bea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_18695346-af0f-488e-8373-78d32074581f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f5a03810-3648-4e87-a434-8f900b71bea0" xlink:to="loc_us-gaap_SeveranceCosts1_18695346-af0f-488e-8373-78d32074581f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringCosts_e717cd25-2ad8-45b2-869a-ab6cd7549fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f5a03810-3648-4e87-a434-8f900b71bea0" xlink:to="loc_us-gaap_OtherRestructuringCosts_e717cd25-2ad8-45b2-869a-ab6cd7549fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_dabd9b80-709b-4e15-aacb-b863324d0690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostsAndAssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f5a03810-3648-4e87-a434-8f900b71bea0" xlink:to="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_dabd9b80-709b-4e15-aacb-b863324d0690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_c348c6c6-1590-42ec-b0ab-e7e06a2e8f01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f5a03810-3648-4e87-a434-8f900b71bea0" xlink:to="loc_us-gaap_RestructuringCharges_c348c6c6-1590-42ec-b0ab-e7e06a2e8f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESNarrativeDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#RESTRUCTURINGACTIVITIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_a598ce77-be75-4451-a098-bd3c55cceda8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ed218ac0-94e1-44bd-b89b-4f6b6af98406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_a598ce77-be75-4451-a098-bd3c55cceda8" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ed218ac0-94e1-44bd-b89b-4f6b6af98406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_53bdc940-f49b-4c04-9ccd-ab89cdfb1751" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ed218ac0-94e1-44bd-b89b-4f6b6af98406" xlink:to="loc_us-gaap_RestructuringPlanAxis_53bdc940-f49b-4c04-9ccd-ab89cdfb1751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_adf8b768-1220-417a-b9c3-8520028ad606" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_53bdc940-f49b-4c04-9ccd-ab89cdfb1751" xlink:to="loc_us-gaap_RestructuringPlanDomain_adf8b768-1220-417a-b9c3-8520028ad606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_InvigorateProgramMember_5c531ac0-60ba-423a-b616-0266fef872db" xlink:href="dgx-20221231.xsd#dgx_InvigorateProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_adf8b768-1220-417a-b9c3-8520028ad606" xlink:to="loc_dgx_InvigorateProgramMember_5c531ac0-60ba-423a-b616-0266fef872db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_ab20992c-df82-4646-93f6-477022f12912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ed218ac0-94e1-44bd-b89b-4f6b6af98406" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_ab20992c-df82-4646-93f6-477022f12912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_bbcaed38-6152-40db-8d79-aa227260fac2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_ab20992c-df82-4646-93f6-477022f12912" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_bbcaed38-6152-40db-8d79-aa227260fac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_6a52d3fe-5853-44de-9cb7-8667bbc0199f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_bbcaed38-6152-40db-8d79-aa227260fac2" xlink:to="loc_us-gaap_CostOfSalesMember_6a52d3fe-5853-44de-9cb7-8667bbc0199f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_226fb6c4-3b57-4df9-bc41-e12819fb99fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_bbcaed38-6152-40db-8d79-aa227260fac2" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_226fb6c4-3b57-4df9-bc41-e12819fb99fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_59b00437-b0b5-4a8a-9bac-f4aa2c73b699" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_bbcaed38-6152-40db-8d79-aa227260fac2" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_59b00437-b0b5-4a8a-9bac-f4aa2c73b699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_2297361b-38fa-41e9-a79d-2c9e9526bda5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ed218ac0-94e1-44bd-b89b-4f6b6af98406" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_2297361b-38fa-41e9-a79d-2c9e9526bda5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_2967740a-9a3a-40a3-8b12-738098598abd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2297361b-38fa-41e9-a79d-2c9e9526bda5" xlink:to="loc_us-gaap_RestructuringCharges_2967740a-9a3a-40a3-8b12-738098598abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESActivitiesofRestructuringLiabilitiesDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#RESTRUCTURINGACTIVITIESActivitiesofRestructuringLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESActivitiesofRestructuringLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_caf9303d-0d35-4bd0-981b-d316b092060b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5d70bccc-64aa-422b-8930-b8bf2266a9db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_caf9303d-0d35-4bd0-981b-d316b092060b" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5d70bccc-64aa-422b-8930-b8bf2266a9db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_25ce1591-0d86-42eb-b870-52ef1cfd9818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5d70bccc-64aa-422b-8930-b8bf2266a9db" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_25ce1591-0d86-42eb-b870-52ef1cfd9818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_482bfcc0-0b62-48fd-9936-f2b4e77c71b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_25ce1591-0d86-42eb-b870-52ef1cfd9818" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_482bfcc0-0b62-48fd-9936-f2b4e77c71b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_3c8d3482-b1d6-4cef-bfec-1e84601a4e64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_482bfcc0-0b62-48fd-9936-f2b4e77c71b9" xlink:to="loc_us-gaap_EmployeeSeveranceMember_3c8d3482-b1d6-4cef-bfec-1e84601a4e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_6664977d-8e4f-4128-9e84-196b9b6b840c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FacilityClosingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_482bfcc0-0b62-48fd-9936-f2b4e77c71b9" xlink:to="loc_us-gaap_FacilityClosingMember_6664977d-8e4f-4128-9e84-196b9b6b840c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_736aeb17-87c7-4218-9ff7-059bfede2f43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5d70bccc-64aa-422b-8930-b8bf2266a9db" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_736aeb17-87c7-4218-9ff7-059bfede2f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_e1a000f9-b3a8-4826-a012-97142734deb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_736aeb17-87c7-4218-9ff7-059bfede2f43" xlink:to="loc_us-gaap_RestructuringReserveRollForward_e1a000f9-b3a8-4826-a012-97142734deb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_42088e81-e187-42f8-bca1-7eae146f4176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_e1a000f9-b3a8-4826-a012-97142734deb8" xlink:to="loc_us-gaap_RestructuringReserve_42088e81-e187-42f8-bca1-7eae146f4176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_8592f4e9-d477-49be-9020-cd0411b7d0c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_e1a000f9-b3a8-4826-a012-97142734deb8" xlink:to="loc_us-gaap_RestructuringCharges_8592f4e9-d477-49be-9020-cd0411b7d0c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_6c988945-f6f7-4da5-94cc-4bd4e18bc464" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_e1a000f9-b3a8-4826-a012-97142734deb8" xlink:to="loc_us-gaap_PaymentsForRestructuring_6c988945-f6f7-4da5-94cc-4bd4e18bc464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_5c25f460-c2d5-4443-9705-c7b0fc0d1cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_e1a000f9-b3a8-4826-a012-97142734deb8" xlink:to="loc_us-gaap_RestructuringReserve_5c25f460-c2d5-4443-9705-c7b0fc0d1cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#BUSINESSACQUISITIONSDetails"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_e2579587-32da-48d2-a617-5811c59024fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_950f271c-61f9-4ad6-b148-6c2631c81e75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_e2579587-32da-48d2-a617-5811c59024fb" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_950f271c-61f9-4ad6-b148-6c2631c81e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_56b90a1e-f5d9-4832-b3de-80834c9f5e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_950f271c-61f9-4ad6-b148-6c2631c81e75" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_56b90a1e-f5d9-4832-b3de-80834c9f5e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0be2b74a-3834-44a6-9e92-c46f2a5b6b83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_56b90a1e-f5d9-4832-b3de-80834c9f5e8a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0be2b74a-3834-44a6-9e92-c46f2a5b6b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_PackHealthLLCMember_90c59336-3257-427e-b6c7-cdf191f1ddb3" xlink:href="dgx-20221231.xsd#dgx_PackHealthLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0be2b74a-3834-44a6-9e92-c46f2a5b6b83" xlink:to="loc_dgx_PackHealthLLCMember_90c59336-3257-427e-b6c7-cdf191f1ddb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_MercyHealthMember_b6548818-1d36-4bd0-a0b2-fd27b3076a64" xlink:href="dgx-20221231.xsd#dgx_MercyHealthMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0be2b74a-3834-44a6-9e92-c46f2a5b6b83" xlink:to="loc_dgx_MercyHealthMember_b6548818-1d36-4bd0-a0b2-fd27b3076a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LabtechDiagnosticsLLCMember_c3e7af88-2f90-401b-8d00-6c01e2c8bbbc" xlink:href="dgx-20221231.xsd#dgx_LabtechDiagnosticsLLCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0be2b74a-3834-44a6-9e92-c46f2a5b6b83" xlink:to="loc_dgx_LabtechDiagnosticsLLCMember_c3e7af88-2f90-401b-8d00-6c01e2c8bbbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_BlueprintGeneticsOyMember_fcdf9c41-5d39-44e0-a00d-362c90d07d35" xlink:href="dgx-20221231.xsd#dgx_BlueprintGeneticsOyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0be2b74a-3834-44a6-9e92-c46f2a5b6b83" xlink:to="loc_dgx_BlueprintGeneticsOyMember_fcdf9c41-5d39-44e0-a00d-362c90d07d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_MemorialHermannMember_808c07cc-6ee4-4fd8-bb83-2105c61bd8b6" xlink:href="dgx-20221231.xsd#dgx_MemorialHermannMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0be2b74a-3834-44a6-9e92-c46f2a5b6b83" xlink:to="loc_dgx_MemorialHermannMember_808c07cc-6ee4-4fd8-bb83-2105c61bd8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_MidAmericaClinicalLaboratoriesLLCMACLMember_e6e124ef-6e58-4f59-b70e-36e993cf97a0" xlink:href="dgx-20221231.xsd#dgx_MidAmericaClinicalLaboratoriesLLCMACLMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0be2b74a-3834-44a6-9e92-c46f2a5b6b83" xlink:to="loc_dgx_MidAmericaClinicalLaboratoriesLLCMACLMember_e6e124ef-6e58-4f59-b70e-36e993cf97a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_524c77d1-1741-4923-af62-194aa4adfd79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_950f271c-61f9-4ad6-b148-6c2631c81e75" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_524c77d1-1741-4923-af62-194aa4adfd79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_74d33698-284c-4f39-9f1c-92a0c41dc048" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_524c77d1-1741-4923-af62-194aa4adfd79" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_74d33698-284c-4f39-9f1c-92a0c41dc048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_6bc368a0-6f7c-4798-84bc-c5a1d81a8c61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_74d33698-284c-4f39-9f1c-92a0c41dc048" xlink:to="loc_us-gaap_CustomerRelationshipsMember_6bc368a0-6f7c-4798-84bc-c5a1d81a8c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_1a9c4636-5fbc-4880-80a3-7401e42dcea7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_74d33698-284c-4f39-9f1c-92a0c41dc048" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_1a9c4636-5fbc-4880-80a3-7401e42dcea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_63f0f099-6491-4785-82ca-ea92c4c04d07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_950f271c-61f9-4ad6-b148-6c2631c81e75" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_63f0f099-6491-4785-82ca-ea92c4c04d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_336e5947-ce4f-4dc5-9a06-1f779eacd6d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_63f0f099-6491-4785-82ca-ea92c4c04d07" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_336e5947-ce4f-4dc5-9a06-1f779eacd6d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_OtherIncomeExpenseMember_aab7cd64-e10d-4fc0-bd5a-de74b1a349b3" xlink:href="dgx-20221231.xsd#dgx_OtherIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_336e5947-ce4f-4dc5-9a06-1f779eacd6d0" xlink:to="loc_dgx_OtherIncomeExpenseMember_aab7cd64-e10d-4fc0-bd5a-de74b1a349b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_950f271c-61f9-4ad6-b148-6c2631c81e75" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_f02954b8-5c5b-4205-b7c5-d57525d41fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_f02954b8-5c5b-4205-b7c5-d57525d41fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_bc08a27a-694d-4baa-b978-dda8359098e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_bc08a27a-694d-4baa-b978-dda8359098e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_ebe7b2b1-dbca-4620-bc62-39d991035743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_ebe7b2b1-dbca-4620-bc62-39d991035743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFiniteLivedIntangibles1_beb8be6a-6179-4636-9508-0a7d3751a58f" xlink:href="dgx-20221231.xsd#dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFiniteLivedIntangibles1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFiniteLivedIntangibles1_beb8be6a-6179-4636-9508-0a7d3751a58f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_d441ba0f-59f9-40a4-a179-88435db7d105" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_d441ba0f-59f9-40a4-a179-88435db7d105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_3afa7f7e-b095-43f3-a6c2-12cc2ae01c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_3afa7f7e-b095-43f3-a6c2-12cc2ae01c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9e39526c-523d-4aaf-a04d-8fcd63e76697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9e39526c-523d-4aaf-a04d-8fcd63e76697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9f01c13d-6e9f-4459-934a-1dd4b97f1916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_us-gaap_Goodwill_9f01c13d-6e9f-4459-934a-1dd4b97f1916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_b82a598d-e625-48cd-b2ff-c14983fadc50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_b82a598d-e625-48cd-b2ff-c14983fadc50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_5a9e3c1e-8cae-4cbf-a7bb-47c7bd1cb206" xlink:href="dgx-20221231.xsd#dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_5a9e3c1e-8cae-4cbf-a7bb-47c7bd1cb206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities_591c7854-4e76-43d9-942f-26734ed27b42" xlink:href="dgx-20221231.xsd#dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities_591c7854-4e76-43d9-942f-26734ed27b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedWorkingCapital_02f35d6e-71de-4fb1-b7d8-716c337ec890" xlink:href="dgx-20221231.xsd#dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedWorkingCapital"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedWorkingCapital_02f35d6e-71de-4fb1-b7d8-716c337ec890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_10d002ad-363c-46fd-9354-83c794bf17ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_10d002ad-363c-46fd-9354-83c794bf17ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_GoodwillAcquiredDuringPeriodBeforeAdjustments_7cdcf457-5d3e-405b-8602-c04c3ee545d1" xlink:href="dgx-20221231.xsd#dgx_GoodwillAcquiredDuringPeriodBeforeAdjustments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_dgx_GoodwillAcquiredDuringPeriodBeforeAdjustments_7cdcf457-5d3e-405b-8602-c04c3ee545d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_46295f66-1952-4c0c-bbc4-2ac3a7cab692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_46295f66-1952-4c0c-bbc4-2ac3a7cab692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_e794f2d4-4060-4319-8d45-8853a8a79ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_e794f2d4-4060-4319-8d45-8853a8a79ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinanceLeaseLiabilities_472377f3-89a2-4cd9-8100-95008c2f526b" xlink:href="dgx-20221231.xsd#dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinanceLeaseLiabilities"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinanceLeaseLiabilities_472377f3-89a2-4cd9-8100-95008c2f526b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_86be959b-f25c-4be6-b738-92d3fac05609" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_86be959b-f25c-4be6-b738-92d3fac05609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_BusinessAcquisitionPostacquisitionRevenue_c86f2bf1-01ab-484e-8409-05b595031476" xlink:href="dgx-20221231.xsd#dgx_BusinessAcquisitionPostacquisitionRevenue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_dgx_BusinessAcquisitionPostacquisitionRevenue_c86f2bf1-01ab-484e-8409-05b595031476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedPropertyPlantandEquipmentandWorkingCapital_ce5d58db-dd80-4eec-8dc0-d1837ab1e872" xlink:href="dgx-20221231.xsd#dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedPropertyPlantandEquipmentandWorkingCapital"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedPropertyPlantandEquipmentandWorkingCapital_ce5d58db-dd80-4eec-8dc0-d1837ab1e872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_c43f42b4-e5a8-47c2-bf4b-e3967919f21a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_c43f42b4-e5a8-47c2-bf4b-e3967919f21a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_126665c6-2b22-4571-bc12-24484c482b92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_126665c6-2b22-4571-bc12-24484c482b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_d5c68044-a64f-429d-9d42-6627e7849c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_d5c68044-a64f-429d-9d42-6627e7849c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_65af1f5e-e2b5-4705-a616-54e8070d11e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_65af1f5e-e2b5-4705-a616-54e8070d11e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeLongTermGrowthRateUsedToDetermineFairValue_3f8b788b-4154-48ca-8d33-663443167d2e" xlink:href="dgx-20221231.xsd#dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeLongTermGrowthRateUsedToDetermineFairValue"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeLongTermGrowthRateUsedToDetermineFairValue_3f8b788b-4154-48ca-8d33-663443167d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeDicountRateUsedToDetermineFairValue_6398bb1a-eb98-4f6a-a247-d17cfe338e51" xlink:href="dgx-20221231.xsd#dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeDicountRateUsedToDetermineFairValue"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe552e44-b29c-4674-b39e-ffd94f46497d" xlink:to="loc_dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeDicountRateUsedToDetermineFairValue_6398bb1a-eb98-4f6a-a247-d17cfe338e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/DISPOSITIONDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#DISPOSITIONDetails"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/DISPOSITIONDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_68df2d28-f28d-45cb-b094-c17e29082d29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6e6f315c-4dea-4d4c-b820-dd6f3fe0f6b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_68df2d28-f28d-45cb-b094-c17e29082d29" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6e6f315c-4dea-4d4c-b820-dd6f3fe0f6b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0106303b-9c91-4132-83c0-3f64a3ead7e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6e6f315c-4dea-4d4c-b820-dd6f3fe0f6b2" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0106303b-9c91-4132-83c0-3f64a3ead7e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4237c6e4-7b5c-4695-94ae-33d583324ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0106303b-9c91-4132-83c0-3f64a3ead7e7" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4237c6e4-7b5c-4695-94ae-33d583324ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_Q2SolutionsMember_473203f0-beab-4929-8c33-2240db6a4a4c" xlink:href="dgx-20221231.xsd#dgx_Q2SolutionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4237c6e4-7b5c-4695-94ae-33d583324ea0" xlink:to="loc_dgx_Q2SolutionsMember_473203f0-beab-4929-8c33-2240db6a4a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_7d6894b7-6955-4fb1-aec8-b96e8021efcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6e6f315c-4dea-4d4c-b820-dd6f3fe0f6b2" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_7d6894b7-6955-4fb1-aec8-b96e8021efcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_0e8d838d-a8e1-49b3-9dad-8804fe6b82ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_7d6894b7-6955-4fb1-aec8-b96e8021efcb" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_0e8d838d-a8e1-49b3-9dad-8804fe6b82ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_ddede343-74f6-4e08-a262-8abc41be4e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_0e8d838d-a8e1-49b3-9dad-8804fe6b82ab" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_ddede343-74f6-4e08-a262-8abc41be4e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9c472741-9f78-4c68-9146-3590fefd6a82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6e6f315c-4dea-4d4c-b820-dd6f3fe0f6b2" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9c472741-9f78-4c68-9146-3590fefd6a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f03cfce9-187b-42eb-8f38-1cd079880b52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9c472741-9f78-4c68-9146-3590fefd6a82" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f03cfce9-187b-42eb-8f38-1cd079880b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeMember_cf7afe4b-ec3a-4797-9b50-404f40742032" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f03cfce9-187b-42eb-8f38-1cd079880b52" xlink:to="loc_us-gaap_OtherIncomeMember_cf7afe4b-ec3a-4797-9b50-404f40742032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_44bb0a6a-71f0-4b2f-b4e1-e11348f999de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6e6f315c-4dea-4d4c-b820-dd6f3fe0f6b2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_44bb0a6a-71f0-4b2f-b4e1-e11348f999de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5eb330e9-1365-42fb-8741-467d2d139919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_44bb0a6a-71f0-4b2f-b4e1-e11348f999de" xlink:to="loc_us-gaap_EquityComponentDomain_5eb330e9-1365-42fb-8741-467d2d139919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ForeignCurrencyTranslationMember_3b8446f4-76d2-4ca1-98fb-2d11cdaf7f83" xlink:href="dgx-20221231.xsd#dgx_ForeignCurrencyTranslationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5eb330e9-1365-42fb-8741-467d2d139919" xlink:to="loc_dgx_ForeignCurrencyTranslationMember_3b8446f4-76d2-4ca1-98fb-2d11cdaf7f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22db42be-1498-465b-8bae-a55397dbe465" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6e6f315c-4dea-4d4c-b820-dd6f3fe0f6b2" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22db42be-1498-465b-8bae-a55397dbe465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_EquityMethodInvestmentOwnershipPercentDisposedOf_4279e549-1d66-46b0-8cd4-48f3d94d132c" xlink:href="dgx-20221231.xsd#dgx_EquityMethodInvestmentOwnershipPercentDisposedOf"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22db42be-1498-465b-8bae-a55397dbe465" xlink:to="loc_dgx_EquityMethodInvestmentOwnershipPercentDisposedOf_4279e549-1d66-46b0-8cd4-48f3d94d132c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ProceedsFromSaleOfEquityMethodInvestmentsGross_d9a2509a-4e74-46bc-b878-5505025095ce" xlink:href="dgx-20221231.xsd#dgx_ProceedsFromSaleOfEquityMethodInvestmentsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22db42be-1498-465b-8bae-a55397dbe465" xlink:to="loc_dgx_ProceedsFromSaleOfEquityMethodInvestmentsGross_d9a2509a-4e74-46bc-b878-5505025095ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_79dea128-fad3-4b15-b86e-eac2a1b81199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22db42be-1498-465b-8bae-a55397dbe465" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_79dea128-fad3-4b15-b86e-eac2a1b81199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_1caa8b8f-752c-4515-843f-2ed588682f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22db42be-1498-465b-8bae-a55397dbe465" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_1caa8b8f-752c-4515-843f-2ed588682f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_254c21ee-cd62-43e3-b972-e1af25b03c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22db42be-1498-465b-8bae-a55397dbe465" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_254c21ee-cd62-43e3-b972-e1af25b03c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_0011844c-ce44-474d-879a-b2551bc05b31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22db42be-1498-465b-8bae-a55397dbe465" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_0011844c-ce44-474d-879a-b2551bc05b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5530db43-578b-42eb-bd7c-bbb43425d742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_22db42be-1498-465b-8bae-a55397dbe465" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5530db43-578b-42eb-bd7c-bbb43425d742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0a3ceaf0-d0e5-4b50-b2ff-9fb44f27d0ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_0a9743be-2d8d-4532-ad88-1fd8bac656cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0a3ceaf0-d0e5-4b50-b2ff-9fb44f27d0ff" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_0a9743be-2d8d-4532-ad88-1fd8bac656cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_64f3d8a0-b88e-4b9f-9c69-12b5ed31c948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_0a9743be-2d8d-4532-ad88-1fd8bac656cf" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_64f3d8a0-b88e-4b9f-9c69-12b5ed31c948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_cedf6232-e075-4552-8eea-344ede66bd98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_64f3d8a0-b88e-4b9f-9c69-12b5ed31c948" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_cedf6232-e075-4552-8eea-344ede66bd98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_e36c026b-ca28-4627-bcd6-545bccdef73b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_cedf6232-e075-4552-8eea-344ede66bd98" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_e36c026b-ca28-4627-bcd6-545bccdef73b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2fd03575-6feb-46ec-b81b-9aa70e00dacc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_0a9743be-2d8d-4532-ad88-1fd8bac656cf" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2fd03575-6feb-46ec-b81b-9aa70e00dacc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_67161526-1f43-4bef-97f2-b3f9f10e1cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2fd03575-6feb-46ec-b81b-9aa70e00dacc" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_67161526-1f43-4bef-97f2-b3f9f10e1cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_74caa1b6-a960-4ab3-8b2b-248161158b46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_67161526-1f43-4bef-97f2-b3f9f10e1cc6" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_74caa1b6-a960-4ab3-8b2b-248161158b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_3e3dc64a-3310-45ed-9870-9c1a25775df5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_67161526-1f43-4bef-97f2-b3f9f10e1cc6" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_3e3dc64a-3310-45ed-9870-9c1a25775df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_778a6d8a-6d06-4372-b24b-1ebe172b863c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_67161526-1f43-4bef-97f2-b3f9f10e1cc6" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_778a6d8a-6d06-4372-b24b-1ebe172b863c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cb6ec1f8-9f42-45b4-a04a-73033671e710" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_0a9743be-2d8d-4532-ad88-1fd8bac656cf" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cb6ec1f8-9f42-45b4-a04a-73033671e710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_3a6a8e4e-3d3a-4733-8eb6-388757e49919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cb6ec1f8-9f42-45b4-a04a-73033671e710" xlink:to="loc_us-gaap_TradingSecurities_3a6a8e4e-3d3a-4733-8eb6-388757e49919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashSurrenderValueFairValueDisclosure_716148bb-c54b-4a42-b983-610afe1af9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashSurrenderValueFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cb6ec1f8-9f42-45b4-a04a-73033671e710" xlink:to="loc_us-gaap_CashSurrenderValueFairValueDisclosure_716148bb-c54b-4a42-b983-610afe1af9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities_ce86b088-eca7-489f-98ad-00e045118ba9" xlink:href="dgx-20221231.xsd#dgx_EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cb6ec1f8-9f42-45b4-a04a-73033671e710" xlink:to="loc_dgx_EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities_ce86b088-eca7-489f-98ad-00e045118ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0aefcf67-2780-461e-998f-18d06a523a01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cb6ec1f8-9f42-45b4-a04a-73033671e710" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0aefcf67-2780-461e-998f-18d06a523a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_1fc9ef31-d3cd-4b23-a549-44be6d0bef02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cb6ec1f8-9f42-45b4-a04a-73033671e710" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_1fc9ef31-d3cd-4b23-a549-44be6d0bef02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_4ab68ada-9889-4d26-b1e6-2c3eb027ba47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cb6ec1f8-9f42-45b4-a04a-73033671e710" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_4ab68ada-9889-4d26-b1e6-2c3eb027ba47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3a4bad1e-7a5a-4a0f-9693-87c0a7d44924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cb6ec1f8-9f42-45b4-a04a-73033671e710" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3a4bad1e-7a5a-4a0f-9693-87c0a7d44924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_2b63b294-9898-453d-8eb9-0fab2c16c6df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cb6ec1f8-9f42-45b4-a04a-73033671e710" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_2b63b294-9898-453d-8eb9-0fab2c16c6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_fba1f25d-a2d1-4df6-9bed-46e994ab50b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cb6ec1f8-9f42-45b4-a04a-73033671e710" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_fba1f25d-a2d1-4df6-9bed-46e994ab50b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSBusinessAcquisitionDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#FAIRVALUEMEASUREMENTSBusinessAcquisitionDetails"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSBusinessAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a81851d9-42a6-4873-ac00-ab23c6078ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d832b39b-4c2f-4131-bc7a-4c5f165139b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a81851d9-42a6-4873-ac00-ab23c6078ab3" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d832b39b-4c2f-4131-bc7a-4c5f165139b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0b5ad58b-50bc-4dd7-8b3a-fee46ae025c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d832b39b-4c2f-4131-bc7a-4c5f165139b3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0b5ad58b-50bc-4dd7-8b3a-fee46ae025c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9cdfe696-abf1-4468-b658-9b2afc0833e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0b5ad58b-50bc-4dd7-8b3a-fee46ae025c9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9cdfe696-abf1-4468-b658-9b2afc0833e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_PackHealthAndLabtechMember_cf7546f8-1dfb-4e65-8109-1bc7f7f2f59a" xlink:href="dgx-20221231.xsd#dgx_PackHealthAndLabtechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9cdfe696-abf1-4468-b658-9b2afc0833e6" xlink:to="loc_dgx_PackHealthAndLabtechMember_cf7546f8-1dfb-4e65-8109-1bc7f7f2f59a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_c31d38d7-65d2-4c07-981d-9052e3c73768" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d832b39b-4c2f-4131-bc7a-4c5f165139b3" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_c31d38d7-65d2-4c07-981d-9052e3c73768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_35c32461-acdf-408d-acb9-0b670a426fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_c31d38d7-65d2-4c07-981d-9052e3c73768" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_35c32461-acdf-408d-acb9-0b670a426fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_MeasurementInputComparableCompanyRevenueVolatilityMember_202a644b-0f28-444c-9fc0-778344c4298b" xlink:href="dgx-20221231.xsd#dgx_MeasurementInputComparableCompanyRevenueVolatilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_35c32461-acdf-408d-acb9-0b670a426fd8" xlink:to="loc_dgx_MeasurementInputComparableCompanyRevenueVolatilityMember_202a644b-0f28-444c-9fc0-778344c4298b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_69fbfd08-a378-40db-bbf2-e4a6afc8b030" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_35c32461-acdf-408d-acb9-0b670a426fd8" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_69fbfd08-a378-40db-bbf2-e4a6afc8b030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_61721f21-119e-4436-ae7c-99ced9c6350c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d832b39b-4c2f-4131-bc7a-4c5f165139b3" xlink:to="loc_srt_RangeAxis_61721f21-119e-4436-ae7c-99ced9c6350c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5212f319-2901-4633-99ca-65a46b6ef790" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_61721f21-119e-4436-ae7c-99ced9c6350c" xlink:to="loc_srt_RangeMember_5212f319-2901-4633-99ca-65a46b6ef790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d9efb54a-7d54-40af-b072-146a3a9203da" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5212f319-2901-4633-99ca-65a46b6ef790" xlink:to="loc_srt_MinimumMember_d9efb54a-7d54-40af-b072-146a3a9203da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8cd26f6a-31d8-4edc-82fb-6696f7a68657" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5212f319-2901-4633-99ca-65a46b6ef790" xlink:to="loc_srt_MaximumMember_8cd26f6a-31d8-4edc-82fb-6696f7a68657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_59d864e7-8505-4547-9b09-81c2540d2eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d832b39b-4c2f-4131-bc7a-4c5f165139b3" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_59d864e7-8505-4547-9b09-81c2540d2eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_3ddaafcd-289d-4cfb-b0ff-7866580af317" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_59d864e7-8505-4547-9b09-81c2540d2eb5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_3ddaafcd-289d-4cfb-b0ff-7866580af317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_beb719a3-8ffc-479e-9bf0-dcf7715bbc40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_59d864e7-8505-4547-9b09-81c2540d2eb5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_beb719a3-8ffc-479e-9bf0-dcf7715bbc40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#FAIRVALUEMEASUREMENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_efe6747f-6326-458d-ab90-4d86db5568c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a7b19df4-6771-48c4-8522-6fc2af3187a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_efe6747f-6326-458d-ab90-4d86db5568c6" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a7b19df4-6771-48c4-8522-6fc2af3187a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9dd21029-3afb-4b3d-b7e8-511a4bb76579" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a7b19df4-6771-48c4-8522-6fc2af3187a8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9dd21029-3afb-4b3d-b7e8-511a4bb76579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b780aa7-38a5-4a88-8832-9607f80ec44a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9dd21029-3afb-4b3d-b7e8-511a4bb76579" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b780aa7-38a5-4a88-8832-9607f80ec44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_990c6f19-1a14-40e3-87e3-dd4c9ae51af2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b780aa7-38a5-4a88-8832-9607f80ec44a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_990c6f19-1a14-40e3-87e3-dd4c9ae51af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_8e405fd5-7249-43d9-87e9-d4c5d551e242" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a7b19df4-6771-48c4-8522-6fc2af3187a8" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_8e405fd5-7249-43d9-87e9-d4c5d551e242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_82bae8c1-f0d7-44d8-8993-ce377e93fdd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_8e405fd5-7249-43d9-87e9-d4c5d551e242" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_82bae8c1-f0d7-44d8-8993-ce377e93fdd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ContingentConsiderationMember_a46284c7-57b1-4b60-ac98-9840a739ef2a" xlink:href="dgx-20221231.xsd#dgx_ContingentConsiderationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_82bae8c1-f0d7-44d8-8993-ce377e93fdd7" xlink:to="loc_dgx_ContingentConsiderationMember_a46284c7-57b1-4b60-ac98-9840a739ef2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_77f83c7a-bd08-4546-be3d-038c2d04f86a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a7b19df4-6771-48c4-8522-6fc2af3187a8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_77f83c7a-bd08-4546-be3d-038c2d04f86a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_505c6c5d-782a-4aaa-b324-1c46c1297104" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_77f83c7a-bd08-4546-be3d-038c2d04f86a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_505c6c5d-782a-4aaa-b324-1c46c1297104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_22a2030a-92cb-4187-9d8b-8c27ccceb341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_505c6c5d-782a-4aaa-b324-1c46c1297104" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_22a2030a-92cb-4187-9d8b-8c27ccceb341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_3ec8e9ab-053f-4522-9bf7-7dc240fea4b8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a7b19df4-6771-48c4-8522-6fc2af3187a8" xlink:to="loc_srt_OwnershipAxis_3ec8e9ab-053f-4522-9bf7-7dc240fea4b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_81829d9c-6a72-4135-a454-c1d1b761bfbb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_3ec8e9ab-053f-4522-9bf7-7dc240fea4b8" xlink:to="loc_srt_OwnershipDomain_81829d9c-6a72-4135-a454-c1d1b761bfbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_UMassJointVentureMember_26104279-b597-4f52-8ec6-d301ebec5104" xlink:href="dgx-20221231.xsd#dgx_UMassJointVentureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_81829d9c-6a72-4135-a454-c1d1b761bfbb" xlink:to="loc_dgx_UMassJointVentureMember_26104279-b597-4f52-8ec6-d301ebec5104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9b9c5ebe-6980-4ef4-a377-6790af709c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a7b19df4-6771-48c4-8522-6fc2af3187a8" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9b9c5ebe-6980-4ef4-a377-6790af709c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_e1d1257c-e80a-4990-8a6d-7385a849e953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9b9c5ebe-6980-4ef4-a377-6790af709c5f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_e1d1257c-e80a-4990-8a6d-7385a849e953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0e79d33a-113f-4700-bc92-4a1c613a7a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9b9c5ebe-6980-4ef4-a377-6790af709c5f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0e79d33a-113f-4700-bc92-4a1c613a7a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_21e97f98-0a68-4014-bd60-f1bd87c61acf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9b9c5ebe-6980-4ef4-a377-6790af709c5f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_21e97f98-0a68-4014-bd60-f1bd87c61acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_52495282-f7f8-43af-b65d-7fc693ebe081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9b9c5ebe-6980-4ef4-a377-6790af709c5f" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_52495282-f7f8-43af-b65d-7fc693ebe081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_c882cd8d-58c5-4e6a-9cc5-f93a9fc54962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9b9c5ebe-6980-4ef4-a377-6790af709c5f" xlink:to="loc_us-gaap_AssetImpairmentCharges_c882cd8d-58c5-4e6a-9cc5-f93a9fc54962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_4b7079d0-d1e9-40b0-a98c-6a38e2b48cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9b9c5ebe-6980-4ef4-a377-6790af709c5f" xlink:to="loc_us-gaap_DebtInstrumentFairValue_4b7079d0-d1e9-40b0-a98c-6a38e2b48cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSReconciliationofBeginningandEndingBalancesofLiabilitiesUnobservableInputsDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#FAIRVALUEMEASUREMENTSReconciliationofBeginningandEndingBalancesofLiabilitiesUnobservableInputsDetails"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSReconciliationofBeginningandEndingBalancesofLiabilitiesUnobservableInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b0c2fade-c45d-447e-ae61-ef36336fdc4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_dcb4b40f-a32d-470f-8fef-32877620992e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b0c2fade-c45d-447e-ae61-ef36336fdc4c" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_dcb4b40f-a32d-470f-8fef-32877620992e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a9f35051-a19c-453c-8a5c-e7f849225716" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_dcb4b40f-a32d-470f-8fef-32877620992e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a9f35051-a19c-453c-8a5c-e7f849225716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b97e46ee-dda3-4ccb-9055-df10ac66fdac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a9f35051-a19c-453c-8a5c-e7f849225716" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b97e46ee-dda3-4ccb-9055-df10ac66fdac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_89e06b93-d61c-4bd6-82bf-b11cef675f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b97e46ee-dda3-4ccb-9055-df10ac66fdac" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_89e06b93-d61c-4bd6-82bf-b11cef675f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_92656b55-aed7-4c21-8cde-60a0b21f98b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_dcb4b40f-a32d-470f-8fef-32877620992e" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_92656b55-aed7-4c21-8cde-60a0b21f98b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_eb5ff7ef-5923-42f2-92a9-c8ea1d5f033f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_92656b55-aed7-4c21-8cde-60a0b21f98b3" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_eb5ff7ef-5923-42f2-92a9-c8ea1d5f033f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ContingentConsiderationMember_706c9082-f341-4726-87de-397aefd9733c" xlink:href="dgx-20221231.xsd#dgx_ContingentConsiderationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_eb5ff7ef-5923-42f2-92a9-c8ea1d5f033f" xlink:to="loc_dgx_ContingentConsiderationMember_706c9082-f341-4726-87de-397aefd9733c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_29ec4410-0ddf-4b9b-878f-5bb6da0e20a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_dcb4b40f-a32d-470f-8fef-32877620992e" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_29ec4410-0ddf-4b9b-878f-5bb6da0e20a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1c2cb51f-2706-422a-8e18-db782a029955" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_29ec4410-0ddf-4b9b-878f-5bb6da0e20a9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1c2cb51f-2706-422a-8e18-db782a029955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4ff99501-3de2-4292-93d2-24b6491838e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1c2cb51f-2706-422a-8e18-db782a029955" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4ff99501-3de2-4292-93d2-24b6491838e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_8e5e561d-b519-4969-a8d8-b51068c64d07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1c2cb51f-2706-422a-8e18-db782a029955" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_8e5e561d-b519-4969-a8d8-b51068c64d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_e633c634-b39c-49cd-ac96-d2cdca11c468" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1c2cb51f-2706-422a-8e18-db782a029955" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_e633c634-b39c-49cd-ac96-d2cdca11c468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_7fac58e6-d1ab-4eaa-af7b-cf90b841bb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1c2cb51f-2706-422a-8e18-db782a029955" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_7fac58e6-d1ab-4eaa-af7b-cf90b841bb3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_8d474f5e-3d79-4ade-a1de-1199bccb48ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1c2cb51f-2706-422a-8e18-db782a029955" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_8d474f5e-3d79-4ade-a1de-1199bccb48ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/TAXESONINCOMEDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#TAXESONINCOMEDetails"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/TAXESONINCOMEDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ec2e3e10-7787-405b-868f-cd223d3bfdfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_4db0bbbd-f5e1-4e4a-83c6-bb2e8589f6da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ec2e3e10-7787-405b-868f-cd223d3bfdfc" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_4db0bbbd-f5e1-4e4a-83c6-bb2e8589f6da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_747ba63a-77dc-4827-b18f-4daa62986fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_4db0bbbd-f5e1-4e4a-83c6-bb2e8589f6da" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_747ba63a-77dc-4827-b18f-4daa62986fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_214184d7-5454-44d4-8779-2bd4f2de66c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_747ba63a-77dc-4827-b18f-4daa62986fb9" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_214184d7-5454-44d4-8779-2bd4f2de66c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_Q2SolutionsMember_5df3b932-db1b-4438-ae41-12b64a2051e9" xlink:href="dgx-20221231.xsd#dgx_Q2SolutionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_214184d7-5454-44d4-8779-2bd4f2de66c3" xlink:to="loc_dgx_Q2SolutionsMember_5df3b932-db1b-4438-ae41-12b64a2051e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_e69f4150-13df-409b-9d34-d2854ef074b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_4db0bbbd-f5e1-4e4a-83c6-bb2e8589f6da" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_e69f4150-13df-409b-9d34-d2854ef074b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_baa7d414-5518-41a5-975d-74e429c6692d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_e69f4150-13df-409b-9d34-d2854ef074b6" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_baa7d414-5518-41a5-975d-74e429c6692d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_73c4a0e5-52ee-4d46-a520-4a619a82b363" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_baa7d414-5518-41a5-975d-74e429c6692d" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_73c4a0e5-52ee-4d46-a520-4a619a82b363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_094fff84-1d6a-4f5e-9a50-3e4a2443a4bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_4db0bbbd-f5e1-4e4a-83c6-bb2e8589f6da" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_094fff84-1d6a-4f5e-9a50-3e4a2443a4bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3345bb9a-5332-432b-af16-5229b8838bca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_094fff84-1d6a-4f5e-9a50-3e4a2443a4bf" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_3345bb9a-5332-432b-af16-5229b8838bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_2a2d1081-a3ca-456c-8524-44f7f4a734ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3345bb9a-5332-432b-af16-5229b8838bca" xlink:to="loc_us-gaap_DomesticCountryMember_2a2d1081-a3ca-456c-8524-44f7f4a734ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_f7d73fbb-775f-4cce-8041-a9d680ec30df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3345bb9a-5332-432b-af16-5229b8838bca" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_f7d73fbb-775f-4cce-8041-a9d680ec30df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_8c9b2977-f7d8-4dcc-b59e-6b9fa64bc619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3345bb9a-5332-432b-af16-5229b8838bca" xlink:to="loc_us-gaap_ForeignCountryMember_8c9b2977-f7d8-4dcc-b59e-6b9fa64bc619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_cc45094c-c3f6-4154-96f0-d366ed84e424" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_4db0bbbd-f5e1-4e4a-83c6-bb2e8589f6da" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_cc45094c-c3f6-4154-96f0-d366ed84e424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_886636ee-cd49-4a4b-afbc-8face3d6f878" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_cc45094c-c3f6-4154-96f0-d366ed84e424" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_886636ee-cd49-4a4b-afbc-8face3d6f878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember_b69fe624-84e0-4c02-88af-3d66bbfc3945" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_886636ee-cd49-4a4b-afbc-8face3d6f878" xlink:to="loc_us-gaap_OtherLiabilitiesMember_b69fe624-84e0-4c02-88af-3d66bbfc3945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_4db0bbbd-f5e1-4e4a-83c6-bb2e8589f6da" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_ccc8516a-4658-4e2e-8cd6-cc9cc0babc89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_ccc8516a-4658-4e2e-8cd6-cc9cc0babc89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_ecf98bfb-c3d1-42c4-b55f-d6ec1ff1a8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_ecf98bfb-c3d1-42c4-b55f-d6ec1ff1a8fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_EquityMethodInvestmentOwnershipPercentDisposedOf_1a3509d6-2d8f-4c56-9848-e7382876324b" xlink:href="dgx-20221231.xsd#dgx_EquityMethodInvestmentOwnershipPercentDisposedOf"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_dgx_EquityMethodInvestmentOwnershipPercentDisposedOf_1a3509d6-2d8f-4c56-9848-e7382876324b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_088fe09a-d7df-439c-8548-dc901a2f4962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_088fe09a-d7df-439c-8548-dc901a2f4962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_59c34211-0154-4914-9802-df2afecfa6f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_59c34211-0154-4914-9802-df2afecfa6f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_5138eb5f-4e30-4464-a1b3-e2b81f43dce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_5138eb5f-4e30-4464-a1b3-e2b81f43dce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_f2ba9e7c-9f3a-498d-a635-7c5dcc0f64be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_f2ba9e7c-9f3a-498d-a635-7c5dcc0f64be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_d7df827e-f111-4fbf-8307-6d9caec958ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_d7df827e-f111-4fbf-8307-6d9caec958ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_40f14a55-63da-46e1-9297-58b63b455cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_40f14a55-63da-46e1-9297-58b63b455cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_764352ab-3f4c-4242-b2d8-c92d84f4c901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_764352ab-3f4c-4242-b2d8-c92d84f4c901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_16771596-43d0-4ba9-913e-000e41c84527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_16771596-43d0-4ba9-913e-000e41c84527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_722e97ed-e4b7-4fa4-a926-d0125f661e03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_722e97ed-e4b7-4fa4-a926-d0125f661e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dc5b0d1b-f286-4eb7-a2bd-94a650051dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dc5b0d1b-f286-4eb7-a2bd-94a650051dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_3e786b8e-0740-44c0-90d2-e061d151e4de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_3e786b8e-0740-44c0-90d2-e061d151e4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_EffectiveIncomeTaxRateReconciliationAdjustmentToStateDeferredTaxLiabilities_6c0270e2-cbb8-4c25-ae50-07aa9c3ce274" xlink:href="dgx-20221231.xsd#dgx_EffectiveIncomeTaxRateReconciliationAdjustmentToStateDeferredTaxLiabilities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_dgx_EffectiveIncomeTaxRateReconciliationAdjustmentToStateDeferredTaxLiabilities_6c0270e2-cbb8-4c25-ae50-07aa9c3ce274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_033c2a86-7c47-40be-8e3c-d59498d0c33d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_033c2a86-7c47-40be-8e3c-d59498d0c33d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_d2b50515-b08c-43e3-a45c-652764fc18cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_d2b50515-b08c-43e3-a45c-652764fc18cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_d99f2524-0ac9-4839-b872-cd49ca242687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_d99f2524-0ac9-4839-b872-cd49ca242687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_EffectiveIncomeTaxRateReconciliationChangeForUncertainTaxPosition_f75a412c-0b68-4a83-a0e5-3b8201490d98" xlink:href="dgx-20221231.xsd#dgx_EffectiveIncomeTaxRateReconciliationChangeForUncertainTaxPosition"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_dgx_EffectiveIncomeTaxRateReconciliationChangeForUncertainTaxPosition_f75a412c-0b68-4a83-a0e5-3b8201490d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_4d41c133-3d35-4ddf-83f4-036813300f07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_4d41c133-3d35-4ddf-83f4-036813300f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_be033d88-ee9e-4aec-8ba2-64c16c6e47d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_be033d88-ee9e-4aec-8ba2-64c16c6e47d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1e5095f8-2428-4b59-9a67-f6be838f3226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1e5095f8-2428-4b59-9a67-f6be838f3226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsAccountsReceivables_e08f01b3-874b-4be0-8764-53419797884e" xlink:href="dgx-20221231.xsd#dgx_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsAccountsReceivables"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_dgx_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsAccountsReceivables_e08f01b3-874b-4be0-8764-53419797884e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_800d7182-3282-4966-b899-b100283bf866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_800d7182-3282-4966-b899-b100283bf866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_53806aba-1c66-4490-9605-b2f2a5cb71cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_53806aba-1c66-4490-9605-b2f2a5cb71cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_DeferredTaxLiabilityInvestmentsInvestmentsinSubsidiariesandEquitymethodinvestments_cdc00508-c3ee-4346-a7b3-ab81ab8be154" xlink:href="dgx-20221231.xsd#dgx_DeferredTaxLiabilityInvestmentsInvestmentsinSubsidiariesandEquitymethodinvestments"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_dgx_DeferredTaxLiabilityInvestmentsInvestmentsinSubsidiariesandEquitymethodinvestments_cdc00508-c3ee-4346-a7b3-ab81ab8be154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_NetOperatingLossCarryfowardsNetOfValuationAllowance_a8920b03-4cfb-4ac0-94ce-c22a3519a679" xlink:href="dgx-20221231.xsd#dgx_NetOperatingLossCarryfowardsNetOfValuationAllowance"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_dgx_NetOperatingLossCarryfowardsNetOfValuationAllowance_a8920b03-4cfb-4ac0-94ce-c22a3519a679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_3fd76a3b-552a-4089-bd57-1adee1efe339" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_3fd76a3b-552a-4089-bd57-1adee1efe339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_DeferredTaxAssetsOperatingLeaseLiabilitiesNoncurrent_d44e102e-b64f-433f-b536-f24add0dbb6f" xlink:href="dgx-20221231.xsd#dgx_DeferredTaxAssetsOperatingLeaseLiabilitiesNoncurrent"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_dgx_DeferredTaxAssetsOperatingLeaseLiabilitiesNoncurrent_d44e102e-b64f-433f-b536-f24add0dbb6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_45e2e4f8-7b18-43ea-8b71-f7c0ce27bd32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_45e2e4f8-7b18-43ea-8b71-f7c0ce27bd32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_a63cde55-81bf-43cb-bed9-fa489adbd721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_DeferredTaxLiabilities_a63cde55-81bf-43cb-bed9-fa489adbd721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_bee8461e-de7a-4fe1-9b9c-cec54a0489a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_OperatingLossCarryforwards_bee8461e-de7a-4fe1-9b9c-cec54a0489a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_b12ad15d-668a-4377-a269-25e514cce96a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_b12ad15d-668a-4377-a269-25e514cce96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_4437fa4a-4467-4f8e-9f48-5c2af015975c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_4437fa4a-4467-4f8e-9f48-5c2af015975c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxes_446ad168-1843-4747-90e9-e368bd6c409c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxes"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_AccruedIncomeTaxes_446ad168-1843-4747-90e9-e368bd6c409c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_70cec720-fd1c-4f40-bf1c-af9dbdd324f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidTaxes"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_PrepaidTaxes_70cec720-fd1c-4f40-bf1c-af9dbdd324f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3a8cd2b7-2672-431a-b76f-0f748803cd95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3a8cd2b7-2672-431a-b76f-0f748803cd95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_5f501a4c-63f7-4fed-ba41-9d8fad5340ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3a8cd2b7-2672-431a-b76f-0f748803cd95" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_5f501a4c-63f7-4fed-ba41-9d8fad5340ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_ba2fc996-5a15-445f-b536-6419ba117acd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3a8cd2b7-2672-431a-b76f-0f748803cd95" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_ba2fc996-5a15-445f-b536-6419ba117acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_d5be96f5-92ca-4c21-81de-c300f4a233cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3a8cd2b7-2672-431a-b76f-0f748803cd95" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_d5be96f5-92ca-4c21-81de-c300f4a233cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ReductionsForChangesInJudgment_987708b0-37f8-4ddd-b6ab-0afc93706274" xlink:href="dgx-20221231.xsd#dgx_ReductionsForChangesInJudgment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3a8cd2b7-2672-431a-b76f-0f748803cd95" xlink:to="loc_dgx_ReductionsForChangesInJudgment_987708b0-37f8-4ddd-b6ab-0afc93706274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_2a3c95b2-a2ad-4f9e-8e07-00433ad76187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3a8cd2b7-2672-431a-b76f-0f748803cd95" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_2a3c95b2-a2ad-4f9e-8e07-00433ad76187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_2bee5549-4b5c-4bd3-a2bf-c656f4ce87cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3a8cd2b7-2672-431a-b76f-0f748803cd95" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_2bee5549-4b5c-4bd3-a2bf-c656f4ce87cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_9ed51ad8-1c91-42f5-a58e-5bb96ec00b49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3a8cd2b7-2672-431a-b76f-0f748803cd95" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_9ed51ad8-1c91-42f5-a58e-5bb96ec00b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_29a7689d-45da-4641-b3c1-68e515c5a267" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_29a7689d-45da-4641-b3c1-68e515c5a267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_f6324b7e-fa6f-4ff3-a971-145d749676c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_f6324b7e-fa6f-4ff3-a971-145d749676c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_bb2e579c-f7b4-42e6-bd82-ccb16e7c0925" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_bb2e579c-f7b4-42e6-bd82-ccb16e7c0925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_34b59af2-f33d-48e9-b1bb-0c9c8e3d2ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_97d83b7e-1318-455c-8b98-b27c5df17217" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_34b59af2-f33d-48e9-b1bb-0c9c8e3d2ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#SUPPLEMENTALCASHFLOWANDOTHERDATADetails"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_a41b14b0-7a79-46d7-b260-e37bf5ea9a19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_7fc8bdf3-679a-4d07-9508-9a3f1acc7b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a41b14b0-7a79-46d7-b260-e37bf5ea9a19" xlink:to="loc_us-gaap_Depreciation_7fc8bdf3-679a-4d07-9508-9a3f1acc7b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_571cbaa7-5eb6-4975-8ee6-ed69c4bb7a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a41b14b0-7a79-46d7-b260-e37bf5ea9a19" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_571cbaa7-5eb6-4975-8ee6-ed69c4bb7a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_07a06739-2a04-4088-a74c-49c2fbbfd511" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a41b14b0-7a79-46d7-b260-e37bf5ea9a19" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_07a06739-2a04-4088-a74c-49c2fbbfd511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_9b76c47f-aafa-4f0b-b0cc-38799e31bda3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a41b14b0-7a79-46d7-b260-e37bf5ea9a19" xlink:to="loc_us-gaap_InterestExpense_9b76c47f-aafa-4f0b-b0cc-38799e31bda3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDividendIncomeOperating_03194274-dff6-4226-a597-58beac2e0290" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDividendIncomeOperating"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a41b14b0-7a79-46d7-b260-e37bf5ea9a19" xlink:to="loc_us-gaap_InterestAndDividendIncomeOperating_03194274-dff6-4226-a597-58beac2e0290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_39779d39-5024-4148-bac2-e9741e8eabbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a41b14b0-7a79-46d7-b260-e37bf5ea9a19" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_39779d39-5024-4148-bac2-e9741e8eabbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_9c20e4de-3344-4928-956e-f0611418f41b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a41b14b0-7a79-46d7-b260-e37bf5ea9a19" xlink:to="loc_us-gaap_InterestPaidNet_9c20e4de-3344-4928-956e-f0611418f41b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_04745f84-d69b-4bf1-a2d0-eea9d52bd3ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a41b14b0-7a79-46d7-b260-e37bf5ea9a19" xlink:to="loc_us-gaap_IncomeTaxesPaid_04745f84-d69b-4bf1-a2d0-eea9d52bd3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_6c545a85-8343-42ac-8bbf-22723fa7e529" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a41b14b0-7a79-46d7-b260-e37bf5ea9a19" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_6c545a85-8343-42ac-8bbf-22723fa7e529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_TreasuryStockPurchasedbutNotyetPaid_2f8740c7-b797-49f5-9b9c-5a4bad996b31" xlink:href="dgx-20221231.xsd#dgx_TreasuryStockPurchasedbutNotyetPaid"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a41b14b0-7a79-46d7-b260-e37bf5ea9a19" xlink:to="loc_dgx_TreasuryStockPurchasedbutNotyetPaid_2f8740c7-b797-49f5-9b9c-5a4bad996b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_28a1aeaf-96d1-4448-b635-eb8fc7e129fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a41b14b0-7a79-46d7-b260-e37bf5ea9a19" xlink:to="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_28a1aeaf-96d1-4448-b635-eb8fc7e129fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_58691b15-16ae-4b3c-a899-c834abebb14f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a41b14b0-7a79-46d7-b260-e37bf5ea9a19" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_58691b15-16ae-4b3c-a899-c834abebb14f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired_6290201d-a700-49d7-bb02-923e2a6137ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a41b14b0-7a79-46d7-b260-e37bf5ea9a19" xlink:to="loc_us-gaap_FairValueOfAssetsAcquired_6290201d-a700-49d7-bb02-923e2a6137ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAssumed1_25994633-1f0e-452c-8b0e-7faba315d712" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAssumed1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a41b14b0-7a79-46d7-b260-e37bf5ea9a19" xlink:to="loc_us-gaap_LiabilitiesAssumed1_25994633-1f0e-452c-8b0e-7faba315d712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_FairValueOfNetAssetsAcquired_b94e2904-2c10-4ae2-8852-3e080e8c9533" xlink:href="dgx-20221231.xsd#dgx_FairValueOfNetAssetsAcquired"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a41b14b0-7a79-46d7-b260-e37bf5ea9a19" xlink:to="loc_dgx_FairValueOfNetAssetsAcquired_b94e2904-2c10-4ae2-8852-3e080e8c9533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_Mergerconsiderationpaidpayablenet_81356e8c-4b58-4727-ae07-648fff2b0658" xlink:href="dgx-20221231.xsd#dgx_Mergerconsiderationpaidpayablenet"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a41b14b0-7a79-46d7-b260-e37bf5ea9a19" xlink:to="loc_dgx_Mergerconsiderationpaidpayablenet_81356e8c-4b58-4727-ae07-648fff2b0658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_eb1685bc-0c00-4025-aae7-7fc65cff11e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a41b14b0-7a79-46d7-b260-e37bf5ea9a19" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_eb1685bc-0c00-4025-aae7-7fc65cff11e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_9b11d594-8d66-45c3-86c7-6eb57e6828d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a41b14b0-7a79-46d7-b260-e37bf5ea9a19" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_9b11d594-8d66-45c3-86c7-6eb57e6828d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2f617faa-09b0-41fd-a021-9143bb3a90c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a41b14b0-7a79-46d7-b260-e37bf5ea9a19" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2f617faa-09b0-41fd-a021-9143bb3a90c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_1688a6df-2d73-4e14-a9d7-6696ebd7fa02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a41b14b0-7a79-46d7-b260-e37bf5ea9a19" xlink:to="loc_us-gaap_LeaseCostAbstract_1688a6df-2d73-4e14-a9d7-6696ebd7fa02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_415322f9-d040-4a22-b37b-a5f1c887856d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_1688a6df-2d73-4e14-a9d7-6696ebd7fa02" xlink:to="loc_us-gaap_OperatingLeasePayments_415322f9-d040-4a22-b37b-a5f1c887856d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_0c474a2b-ca06-4d34-979a-ce39a9443c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_1688a6df-2d73-4e14-a9d7-6696ebd7fa02" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_0c474a2b-ca06-4d34-979a-ce39a9443c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_648512fd-ab7d-4def-8e35-b1124fc3ceb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_1688a6df-2d73-4e14-a9d7-6696ebd7fa02" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_648512fd-ab7d-4def-8e35-b1124fc3ceb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_f0651899-0661-4334-95db-816e8140f8ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_1688a6df-2d73-4e14-a9d7-6696ebd7fa02" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_f0651899-0661-4334-95db-816e8140f8ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_DonationsContributionsAndOtherFinancialSupport_284b9692-42e1-4402-b2bb-c2cd1e536221" xlink:href="dgx-20221231.xsd#dgx_DonationsContributionsAndOtherFinancialSupport"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a41b14b0-7a79-46d7-b260-e37bf5ea9a19" xlink:to="loc_dgx_DonationsContributionsAndOtherFinancialSupport_284b9692-42e1-4402-b2bb-c2cd1e536221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationTable_4f3cadad-7742-456a-9aa3-c7c129751c12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTable"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a41b14b0-7a79-46d7-b260-e37bf5ea9a19" xlink:to="loc_us-gaap_ReclassificationTable_4f3cadad-7742-456a-9aa3-c7c129751c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationTypeAxis_716d0e0d-bd6a-4612-ba9e-c85134d408d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationTable_4f3cadad-7742-456a-9aa3-c7c129751c12" xlink:to="loc_us-gaap_ReclassificationTypeAxis_716d0e0d-bd6a-4612-ba9e-c85134d408d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationTypeDomain_3a9b64c0-5115-4091-837d-25a4d8312474" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationTypeAxis_716d0e0d-bd6a-4612-ba9e-c85134d408d9" xlink:to="loc_us-gaap_ReclassificationTypeDomain_3a9b64c0-5115-4091-837d-25a4d8312474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LeaseTypeChangeMember_7c3d568d-257e-4d07-a512-f3a33f84fad2" xlink:href="dgx-20221231.xsd#dgx_LeaseTypeChangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationTypeDomain_3a9b64c0-5115-4091-837d-25a4d8312474" xlink:to="loc_dgx_LeaseTypeChangeMember_7c3d568d-257e-4d07-a512-f3a33f84fad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationLineItems_293428f8-ce2f-48bf-a1ce-b892daa2eeb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationTable_4f3cadad-7742-456a-9aa3-c7c129751c12" xlink:to="loc_us-gaap_ReclassificationLineItems_293428f8-ce2f-48bf-a1ce-b892daa2eeb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c17c46b4-a2cd-4f4e-9cb3-617dd38e2173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationLineItems_293428f8-ce2f-48bf-a1ce-b892daa2eeb9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c17c46b4-a2cd-4f4e-9cb3-617dd38e2173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENTDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#PROPERTYPLANTANDEQUIPMENTDetails"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENTDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6902fe99-3aac-4a93-a4be-c1fb83712a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c5885da6-8a42-47ec-8c8e-00aee8cc571d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6902fe99-3aac-4a93-a4be-c1fb83712a7f" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c5885da6-8a42-47ec-8c8e-00aee8cc571d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_49098f5c-d939-41a0-954e-494cefb254d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c5885da6-8a42-47ec-8c8e-00aee8cc571d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_49098f5c-d939-41a0-954e-494cefb254d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_42a73cf1-7c11-4dcd-aadf-9ed3d4d98cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_49098f5c-d939-41a0-954e-494cefb254d4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_42a73cf1-7c11-4dcd-aadf-9ed3d4d98cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_1e9966b5-ea47-4157-a818-f7d52560e078" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_42a73cf1-7c11-4dcd-aadf-9ed3d4d98cbf" xlink:to="loc_us-gaap_LandMember_1e9966b5-ea47-4157-a818-f7d52560e078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_a0cf08c1-1f79-442b-96ab-b3f0ff18fb08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_42a73cf1-7c11-4dcd-aadf-9ed3d4d98cbf" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_a0cf08c1-1f79-442b-96ab-b3f0ff18fb08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LaboratoryEquipmentFurnitureAndFixturesMember_508eca23-3bc9-4f10-9691-4aed8cd3e280" xlink:href="dgx-20221231.xsd#dgx_LaboratoryEquipmentFurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_42a73cf1-7c11-4dcd-aadf-9ed3d4d98cbf" xlink:to="loc_dgx_LaboratoryEquipmentFurnitureAndFixturesMember_508eca23-3bc9-4f10-9691-4aed8cd3e280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_849094c0-c1b4-4617-9421-f9c7711bcd4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_42a73cf1-7c11-4dcd-aadf-9ed3d4d98cbf" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_849094c0-c1b4-4617-9421-f9c7711bcd4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_0cf1a5f7-66d2-48b8-a133-6af08edf422a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_42a73cf1-7c11-4dcd-aadf-9ed3d4d98cbf" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_0cf1a5f7-66d2-48b8-a133-6af08edf422a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_8e508cda-0b07-4b09-abf4-c7e398823289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_42a73cf1-7c11-4dcd-aadf-9ed3d4d98cbf" xlink:to="loc_us-gaap_ConstructionInProgressMember_8e508cda-0b07-4b09-abf4-c7e398823289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_94fb8405-47c7-4f35-8c46-3f9dd5470ace" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c5885da6-8a42-47ec-8c8e-00aee8cc571d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_94fb8405-47c7-4f35-8c46-3f9dd5470ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f1ba31c2-ad5a-4223-a5de-7a91ae931dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_94fb8405-47c7-4f35-8c46-3f9dd5470ace" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f1ba31c2-ad5a-4223-a5de-7a91ae931dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_8a4b7b1b-1898-4b63-980f-48424d6ff3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f1ba31c2-ad5a-4223-a5de-7a91ae931dc5" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_8a4b7b1b-1898-4b63-980f-48424d6ff3ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f5de4428-9bcc-44bf-964a-f7be9767fabf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c5885da6-8a42-47ec-8c8e-00aee8cc571d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f5de4428-9bcc-44bf-964a-f7be9767fabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1f3c9e0e-8493-4897-b62d-f406a9949cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f5de4428-9bcc-44bf-964a-f7be9767fabf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1f3c9e0e-8493-4897-b62d-f406a9949cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1b0e20a5-d890-425d-8c38-5cfc8ed878b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f5de4428-9bcc-44bf-964a-f7be9767fabf" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1b0e20a5-d890-425d-8c38-5cfc8ed878b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_59ebae22-977b-4da0-8dbd-654f04141c98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f5de4428-9bcc-44bf-964a-f7be9767fabf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_59ebae22-977b-4da0-8dbd-654f04141c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#GOODWILLANDINTANGIBLEASSETSDetails"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2a8255d5-1c93-4ca3-8046-779e221221e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_de12f4e3-a658-4724-86da-96590509ea76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2a8255d5-1c93-4ca3-8046-779e221221e2" xlink:to="loc_us-gaap_GoodwillRollForward_de12f4e3-a658-4724-86da-96590509ea76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a2770ecd-594d-46a8-9cea-f9e191eb3b52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_de12f4e3-a658-4724-86da-96590509ea76" xlink:to="loc_us-gaap_Goodwill_a2770ecd-594d-46a8-9cea-f9e191eb3b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_60b6f478-e6c1-4d22-a406-06e86e8427a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_de12f4e3-a658-4724-86da-96590509ea76" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_60b6f478-e6c1-4d22-a406-06e86e8427a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease_0f5bffc5-6f6e-44bd-99c5-aabddd56ab17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_de12f4e3-a658-4724-86da-96590509ea76" xlink:to="loc_us-gaap_GoodwillPeriodIncreaseDecrease_0f5bffc5-6f6e-44bd-99c5-aabddd56ab17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c7ac9330-8708-4bc1-98b2-8b5a6c4f216f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_de12f4e3-a658-4724-86da-96590509ea76" xlink:to="loc_us-gaap_Goodwill_c7ac9330-8708-4bc1-98b2-8b5a6c4f216f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsTable_7c5e7bf0-a096-49fe-a85e-88eacf6ca5b1" xlink:href="dgx-20221231.xsd#dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2a8255d5-1c93-4ca3-8046-779e221221e2" xlink:to="loc_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsTable_7c5e7bf0-a096-49fe-a85e-88eacf6ca5b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a8a2ff92-72a1-4c02-9779-18b9c0eb97f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsTable_7c5e7bf0-a096-49fe-a85e-88eacf6ca5b1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a8a2ff92-72a1-4c02-9779-18b9c0eb97f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_84e93108-1272-439d-a699-044c7807ee86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a8a2ff92-72a1-4c02-9779-18b9c0eb97f6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_84e93108-1272-439d-a699-044c7807ee86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_74bb3669-be58-4bcc-b07a-e642f28340b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_84e93108-1272-439d-a699-044c7807ee86" xlink:to="loc_us-gaap_CustomerRelationshipsMember_74bb3669-be58-4bcc-b07a-e642f28340b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_0c4eabc5-b8a2-46c1-8582-8e88f2a31767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_84e93108-1272-439d-a699-044c7807ee86" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_0c4eabc5-b8a2-46c1-8582-8e88f2a31767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_6c299759-0692-4b72-9521-24882510692c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_84e93108-1272-439d-a699-044c7807ee86" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_6c299759-0692-4b72-9521-24882510692c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_962090af-05b2-4eeb-8be8-e1b32fd3ab06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_84e93108-1272-439d-a699-044c7807ee86" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_962090af-05b2-4eeb-8be8-e1b32fd3ab06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_TotalAmortizingIntangibleAssetsMember_994ae83f-10d1-4d5d-a1d6-17056392c75c" xlink:href="dgx-20221231.xsd#dgx_TotalAmortizingIntangibleAssetsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_84e93108-1272-439d-a699-044c7807ee86" xlink:to="loc_dgx_TotalAmortizingIntangibleAssetsMember_994ae83f-10d1-4d5d-a1d6-17056392c75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4b9e97d7-1702-4181-9d8c-3c692e65d4e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsTable_7c5e7bf0-a096-49fe-a85e-88eacf6ca5b1" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4b9e97d7-1702-4181-9d8c-3c692e65d4e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_68acbff3-c3d2-4da0-ab3a-3024dcca89f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4b9e97d7-1702-4181-9d8c-3c692e65d4e9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_68acbff3-c3d2-4da0-ab3a-3024dcca89f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_6354bc0e-fb77-40bf-a5e0-6fc6b015ec06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_68acbff3-c3d2-4da0-ab3a-3024dcca89f9" xlink:to="loc_us-gaap_TradeNamesMember_6354bc0e-fb77-40bf-a5e0-6fc6b015ec06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnclassifiedIndefinitelivedIntangibleAssetsMember_84a1d5fb-6c9e-406b-9249-b7fa58380961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnclassifiedIndefinitelivedIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_68acbff3-c3d2-4da0-ab3a-3024dcca89f9" xlink:to="loc_us-gaap_UnclassifiedIndefinitelivedIntangibleAssetsMember_84a1d5fb-6c9e-406b-9249-b7fa58380961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_2392b4ad-a70f-4344-9c23-1db5996637dc" xlink:href="dgx-20221231.xsd#dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsTable_7c5e7bf0-a096-49fe-a85e-88eacf6ca5b1" xlink:to="loc_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_2392b4ad-a70f-4344-9c23-1db5996637dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_b5e84299-9f6f-4aa6-9810-8caec4f068c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_2392b4ad-a70f-4344-9c23-1db5996637dc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_b5e84299-9f6f-4aa6-9810-8caec4f068c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_aa38e6d8-43d3-449c-8a34-035dae4c057b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_2392b4ad-a70f-4344-9c23-1db5996637dc" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_aa38e6d8-43d3-449c-8a34-035dae4c057b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_acf5563b-1659-4715-a1f0-2333573eef9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_2392b4ad-a70f-4344-9c23-1db5996637dc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_acf5563b-1659-4715-a1f0-2333573eef9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c916f016-49f8-4dfb-978d-d23b7fb1a1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_2392b4ad-a70f-4344-9c23-1db5996637dc" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c916f016-49f8-4dfb-978d-d23b7fb1a1b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_707d8f83-1f5f-4c3f-8e27-ac9e2d14b956" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_2392b4ad-a70f-4344-9c23-1db5996637dc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_707d8f83-1f5f-4c3f-8e27-ac9e2d14b956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_ab4f7be3-344a-4ab9-a8e3-25f3950a65d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_707d8f83-1f5f-4c3f-8e27-ac9e2d14b956" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_ab4f7be3-344a-4ab9-a8e3-25f3950a65d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_a3491bcc-f4e0-48a0-8ecc-1bcf20c82067" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_707d8f83-1f5f-4c3f-8e27-ac9e2d14b956" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_a3491bcc-f4e0-48a0-8ecc-1bcf20c82067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_fda3eb94-e789-457d-b21a-7bddbb0edf7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_707d8f83-1f5f-4c3f-8e27-ac9e2d14b956" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_fda3eb94-e789-457d-b21a-7bddbb0edf7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ef0c1d75-a823-46e5-b125-910064fc122d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_707d8f83-1f5f-4c3f-8e27-ac9e2d14b956" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ef0c1d75-a823-46e5-b125-910064fc122d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_96a1ac53-f9a1-47a4-b29e-01c01ded9f08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_707d8f83-1f5f-4c3f-8e27-ac9e2d14b956" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_96a1ac53-f9a1-47a4-b29e-01c01ded9f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_6486e45e-f191-4809-85e3-4f36575fec9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_707d8f83-1f5f-4c3f-8e27-ac9e2d14b956" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_6486e45e-f191-4809-85e3-4f36575fec9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_FiniteLivedIntangibleAssetsEstimatedAmortizationExpenseTotal_c1d3578a-0d71-4ebd-ae74-8c2a9911326d" xlink:href="dgx-20221231.xsd#dgx_FiniteLivedIntangibleAssetsEstimatedAmortizationExpenseTotal"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_707d8f83-1f5f-4c3f-8e27-ac9e2d14b956" xlink:to="loc_dgx_FiniteLivedIntangibleAssetsEstimatedAmortizationExpenseTotal_c1d3578a-0d71-4ebd-ae74-8c2a9911326d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_4eaa7275-aea2-4bbe-b6bd-692c1d85eda0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2a5e9bd4-3ea3-4390-8515-c33954dbf28d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_4eaa7275-aea2-4bbe-b6bd-692c1d85eda0" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2a5e9bd4-3ea3-4390-8515-c33954dbf28d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8d57e15b-aea7-456c-a686-bff74241e261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_4eaa7275-aea2-4bbe-b6bd-692c1d85eda0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8d57e15b-aea7-456c-a686-bff74241e261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_991f8086-f946-482f-8026-8ba7be3d536b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_4eaa7275-aea2-4bbe-b6bd-692c1d85eda0" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_991f8086-f946-482f-8026-8ba7be3d536b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankOverdrafts_cd076b22-5989-4a07-bc5a-f96f3ac29e76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankOverdrafts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_4eaa7275-aea2-4bbe-b6bd-692c1d85eda0" xlink:to="loc_us-gaap_BankOverdrafts_cd076b22-5989-4a07-bc5a-f96f3ac29e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_da08ab38-1d26-4ccf-a34e-93499397e8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_4eaa7275-aea2-4bbe-b6bd-692c1d85eda0" xlink:to="loc_us-gaap_DividendsPayableCurrent_da08ab38-1d26-4ccf-a34e-93499397e8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent_6600a165-d970-4583-92ae-9c9c64ed5aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_4eaa7275-aea2-4bbe-b6bd-692c1d85eda0" xlink:to="loc_us-gaap_AccruedInsuranceCurrent_6600a165-d970-4583-92ae-9c9c64ed5aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_5e1045e0-4e3e-4fb9-93cd-3bcf7e49a682" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_4eaa7275-aea2-4bbe-b6bd-692c1d85eda0" xlink:to="loc_us-gaap_InterestPayableCurrent_5e1045e0-4e3e-4fb9-93cd-3bcf7e49a682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_MergerConsiderationPayableCurrent_c33856c1-d717-446f-b1a6-259fda4bad69" xlink:href="dgx-20221231.xsd#dgx_MergerConsiderationPayableCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_4eaa7275-aea2-4bbe-b6bd-692c1d85eda0" xlink:to="loc_dgx_MergerConsiderationPayableCurrent_c33856c1-d717-446f-b1a6-259fda4bad69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_ff185656-51f6-4451-9f39-ccf2b1093c97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_4eaa7275-aea2-4bbe-b6bd-692c1d85eda0" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_ff185656-51f6-4451-9f39-ccf2b1093c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cccbaad0-ad4a-40bb-a1bb-917dd7a66a55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_4eaa7275-aea2-4bbe-b6bd-692c1d85eda0" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cccbaad0-ad4a-40bb-a1bb-917dd7a66a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/DEBTLongTermDebtDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#DEBTLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/DEBTLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentsAbstract_72bbca8d-9eab-4e9d-b970-557007170c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0e413f35-a5bd-4dcb-80be-3134f953ba24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_72bbca8d-9eab-4e9d-b970-557007170c1c" xlink:to="loc_us-gaap_DebtInstrumentTable_0e413f35-a5bd-4dcb-80be-3134f953ba24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b19996d4-3ff7-4dd8-babc-644c259e36b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0e413f35-a5bd-4dcb-80be-3134f953ba24" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b19996d4-3ff7-4dd8-babc-644c259e36b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e3ad79fa-72b1-4b8d-b313-7a88e184b57d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b19996d4-3ff7-4dd8-babc-644c259e36b1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e3ad79fa-72b1-4b8d-b313-7a88e184b57d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_895023cf-22e1-40e2-b6a3-c0c1d2aae31b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e3ad79fa-72b1-4b8d-b313-7a88e184b57d" xlink:to="loc_us-gaap_SeniorNotesMember_895023cf-22e1-40e2-b6a3-c0c1d2aae31b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e08e5615-6e25-4d8b-a5f6-8ffd1b49c6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0e413f35-a5bd-4dcb-80be-3134f953ba24" xlink:to="loc_us-gaap_DebtInstrumentAxis_e08e5615-6e25-4d8b-a5f6-8ffd1b49c6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d9f4fe65-74b3-42f0-8112-4ddcd6347d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e08e5615-6e25-4d8b-a5f6-8ffd1b49c6b9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d9f4fe65-74b3-42f0-8112-4ddcd6347d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_FourpointtwofivepercentSeniorNotesDue2024Member_282b84d8-83e8-4165-b1f6-2f8481fce008" xlink:href="dgx-20221231.xsd#dgx_FourpointtwofivepercentSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d9f4fe65-74b3-42f0-8112-4ddcd6347d1d" xlink:to="loc_dgx_FourpointtwofivepercentSeniorNotesDue2024Member_282b84d8-83e8-4165-b1f6-2f8481fce008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ThreePointFiveZeroPercentSeniorNotesdueMarch2025Member_8b2e0a48-442f-48a8-b0df-106b0ea711ee" xlink:href="dgx-20221231.xsd#dgx_ThreePointFiveZeroPercentSeniorNotesdueMarch2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d9f4fe65-74b3-42f0-8112-4ddcd6347d1d" xlink:to="loc_dgx_ThreePointFiveZeroPercentSeniorNotesdueMarch2025Member_8b2e0a48-442f-48a8-b0df-106b0ea711ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ThreePointFourFivePercentSeniorNotesdueJune2026Member_f2cd32c8-56b2-49b2-8cc0-ee737383bb6a" xlink:href="dgx-20221231.xsd#dgx_ThreePointFourFivePercentSeniorNotesdueJune2026Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d9f4fe65-74b3-42f0-8112-4ddcd6347d1d" xlink:to="loc_dgx_ThreePointFourFivePercentSeniorNotesdueJune2026Member_f2cd32c8-56b2-49b2-8cc0-ee737383bb6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_FourPointTwoZeroPercentSeniorNotesdueJune2029Member_7a9b92ab-6f1b-434a-83c9-cdba68f52b9c" xlink:href="dgx-20221231.xsd#dgx_FourPointTwoZeroPercentSeniorNotesdueJune2029Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d9f4fe65-74b3-42f0-8112-4ddcd6347d1d" xlink:to="loc_dgx_FourPointTwoZeroPercentSeniorNotesdueJune2029Member_7a9b92ab-6f1b-434a-83c9-cdba68f52b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_TwoPointNineFivePercentSeniorNotesdueJune2030Member_7fe4e2c2-d177-4c3b-a3d7-df0b6216edf5" xlink:href="dgx-20221231.xsd#dgx_TwoPointNineFivePercentSeniorNotesdueJune2030Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d9f4fe65-74b3-42f0-8112-4ddcd6347d1d" xlink:to="loc_dgx_TwoPointNineFivePercentSeniorNotesdueJune2030Member_7fe4e2c2-d177-4c3b-a3d7-df0b6216edf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_TwoPointEightZeroPercentSeniorNotesDueJune2031Member_d1310806-0e7c-4756-a159-eef0be822b23" xlink:href="dgx-20221231.xsd#dgx_TwoPointEightZeroPercentSeniorNotesDueJune2031Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d9f4fe65-74b3-42f0-8112-4ddcd6347d1d" xlink:to="loc_dgx_TwoPointEightZeroPercentSeniorNotesDueJune2031Member_d1310806-0e7c-4756-a159-eef0be822b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_SixPointNineFivePercentSeniorNotesDue2037Member_830560ac-dda7-430d-8d90-37f20563c35b" xlink:href="dgx-20221231.xsd#dgx_SixPointNineFivePercentSeniorNotesDue2037Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d9f4fe65-74b3-42f0-8112-4ddcd6347d1d" xlink:to="loc_dgx_SixPointNineFivePercentSeniorNotesDue2037Member_830560ac-dda7-430d-8d90-37f20563c35b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_FivePointSevenFivePercentSeniorNotesDue2040Member_31b690e2-35a0-43ca-9401-dcf157c6cd52" xlink:href="dgx-20221231.xsd#dgx_FivePointSevenFivePercentSeniorNotesDue2040Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d9f4fe65-74b3-42f0-8112-4ddcd6347d1d" xlink:to="loc_dgx_FivePointSevenFivePercentSeniorNotesDue2040Member_31b690e2-35a0-43ca-9401-dcf157c6cd52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_FourPointSevenZeroPercentSeniorNotesdueMarch2045Member_301b36f2-b397-4935-aadb-d39895987604" xlink:href="dgx-20221231.xsd#dgx_FourPointSevenZeroPercentSeniorNotesdueMarch2045Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d9f4fe65-74b3-42f0-8112-4ddcd6347d1d" xlink:to="loc_dgx_FourPointSevenZeroPercentSeniorNotesdueMarch2045Member_301b36f2-b397-4935-aadb-d39895987604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_FinanceLeaseObligationsandOtherMember_cb30cbe4-297a-499a-aa62-2fa3cd6f2b28" xlink:href="dgx-20221231.xsd#dgx_FinanceLeaseObligationsandOtherMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d9f4fe65-74b3-42f0-8112-4ddcd6347d1d" xlink:to="loc_dgx_FinanceLeaseObligationsandOtherMember_cb30cbe4-297a-499a-aa62-2fa3cd6f2b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_33b902ff-5c32-4aff-b441-5117db77f6a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0e413f35-a5bd-4dcb-80be-3134f953ba24" xlink:to="loc_us-gaap_DebtInstrumentLineItems_33b902ff-5c32-4aff-b441-5117db77f6a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_b3bcf20a-11c5-4ccf-9685-bde8c22d89c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33b902ff-5c32-4aff-b441-5117db77f6a1" xlink:to="loc_us-gaap_LongTermDebt_b3bcf20a-11c5-4ccf-9685-bde8c22d89c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermDebt_7cccb61a-14f0-40f4-b7d2-32e26be8152c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33b902ff-5c32-4aff-b441-5117db77f6a1" xlink:to="loc_us-gaap_OtherLongTermDebt_7cccb61a-14f0-40f4-b7d2-32e26be8152c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_3b8b6869-41d9-4a60-927a-97c42560969c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33b902ff-5c32-4aff-b441-5117db77f6a1" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_3b8b6869-41d9-4a60-927a-97c42560969c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_ef5619e8-bee4-465e-9c07-22f0676e9446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33b902ff-5c32-4aff-b441-5117db77f6a1" xlink:to="loc_us-gaap_LongTermDebtCurrent_ef5619e8-bee4-465e-9c07-22f0676e9446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_67d6db3b-01dd-4838-aa90-07e951b8c3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33b902ff-5c32-4aff-b441-5117db77f6a1" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_67d6db3b-01dd-4838-aa90-07e951b8c3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a2178fca-0084-4cea-a1f9-fb4ca44f1d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33b902ff-5c32-4aff-b441-5117db77f6a1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a2178fca-0084-4cea-a1f9-fb4ca44f1d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/DEBTFinanceLeaseDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#DEBTFinanceLeaseDetails"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/DEBTFinanceLeaseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentsAbstract_e1109bfe-2441-4243-82ab-2aaa52074b44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8b426992-5018-48a8-9bb8-216f7dab3270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_e1109bfe-2441-4243-82ab-2aaa52074b44" xlink:to="loc_us-gaap_DebtInstrumentTable_8b426992-5018-48a8-9bb8-216f7dab3270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1146f002-254e-4885-9d49-16ab63752138" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8b426992-5018-48a8-9bb8-216f7dab3270" xlink:to="loc_us-gaap_DebtInstrumentAxis_1146f002-254e-4885-9d49-16ab63752138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bfbe247b-0347-4a0f-989e-4b7a3d878ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1146f002-254e-4885-9d49-16ab63752138" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bfbe247b-0347-4a0f-989e-4b7a3d878ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_FinanceLeaseObligationsandOtherMember_319e9aba-f6e1-4283-a7b3-a517cf8eb38e" xlink:href="dgx-20221231.xsd#dgx_FinanceLeaseObligationsandOtherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bfbe247b-0347-4a0f-989e-4b7a3d878ea2" xlink:to="loc_dgx_FinanceLeaseObligationsandOtherMember_319e9aba-f6e1-4283-a7b3-a517cf8eb38e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_39f33502-4b8b-4c93-a9db-99ea5fc684e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8b426992-5018-48a8-9bb8-216f7dab3270" xlink:to="loc_us-gaap_DebtInstrumentLineItems_39f33502-4b8b-4c93-a9db-99ea5fc684e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_FinanceLeaseLiabilityRealEstate_8f140fa1-7d94-4ca5-a478-b88b15138650" xlink:href="dgx-20221231.xsd#dgx_FinanceLeaseLiabilityRealEstate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_39f33502-4b8b-4c93-a9db-99ea5fc684e1" xlink:to="loc_dgx_FinanceLeaseLiabilityRealEstate_8f140fa1-7d94-4ca5-a478-b88b15138650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/DEBTSecuredReceivablesCreditFacilityNarrativeDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#DEBTSecuredReceivablesCreditFacilityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/DEBTSecuredReceivablesCreditFacilityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentsAbstract_8b35eca1-f38c-46bf-8c2e-70968c50089d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_61ace9fc-5beb-4385-9aa0-12e43771476c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_8b35eca1-f38c-46bf-8c2e-70968c50089d" xlink:to="loc_us-gaap_DebtInstrumentTable_61ace9fc-5beb-4385-9aa0-12e43771476c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5af54d39-f3ef-4cae-bbf5-5fef9d64d900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_61ace9fc-5beb-4385-9aa0-12e43771476c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5af54d39-f3ef-4cae-bbf5-5fef9d64d900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fe793b70-734e-42a8-975d-4015f52519ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5af54d39-f3ef-4cae-bbf5-5fef9d64d900" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fe793b70-734e-42a8-975d-4015f52519ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_807289d2-edc9-4b35-8040-ee512f75e732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_fe793b70-734e-42a8-975d-4015f52519ec" xlink:to="loc_us-gaap_SecuredDebtMember_807289d2-edc9-4b35-8040-ee512f75e732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_246a30f0-d16c-4b0b-8561-4aa928554c25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_61ace9fc-5beb-4385-9aa0-12e43771476c" xlink:to="loc_us-gaap_CreditFacilityAxis_246a30f0-d16c-4b0b-8561-4aa928554c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_8241da14-b03e-4cbf-967a-0de2cdb0fcb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_246a30f0-d16c-4b0b-8561-4aa928554c25" xlink:to="loc_us-gaap_CreditFacilityDomain_8241da14-b03e-4cbf-967a-0de2cdb0fcb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LoanCommitmentMember_f746c824-dd78-4dcd-80ee-db206a0b6260" xlink:href="dgx-20221231.xsd#dgx_LoanCommitmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_8241da14-b03e-4cbf-967a-0de2cdb0fcb3" xlink:to="loc_dgx_LoanCommitmentMember_f746c824-dd78-4dcd-80ee-db206a0b6260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_44d25b8b-05ac-46f5-8de0-db214605f653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_8241da14-b03e-4cbf-967a-0de2cdb0fcb3" xlink:to="loc_us-gaap_LetterOfCreditMember_44d25b8b-05ac-46f5-8de0-db214605f653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_d91aadc9-bdb3-4d5e-bbd5-9c3daea9ef78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_61ace9fc-5beb-4385-9aa0-12e43771476c" xlink:to="loc_us-gaap_VariableRateAxis_d91aadc9-bdb3-4d5e-bbd5-9c3daea9ef78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_cb4b0ee9-19f6-4088-9274-9ab35b3c65f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_d91aadc9-bdb3-4d5e-bbd5-9c3daea9ef78" xlink:to="loc_us-gaap_VariableRateDomain_cb4b0ee9-19f6-4088-9274-9ab35b3c65f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_CommercialPaperAndTermSecuredOvernightFinancingRateMember_1dab5944-7107-4e33-ae02-f8bc2a3f5a8b" xlink:href="dgx-20221231.xsd#dgx_CommercialPaperAndTermSecuredOvernightFinancingRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_cb4b0ee9-19f6-4088-9274-9ab35b3c65f4" xlink:to="loc_dgx_CommercialPaperAndTermSecuredOvernightFinancingRateMember_1dab5944-7107-4e33-ae02-f8bc2a3f5a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_80198da7-070c-42f6-852f-ef43bcd4c06d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_61ace9fc-5beb-4385-9aa0-12e43771476c" xlink:to="loc_srt_RangeAxis_80198da7-070c-42f6-852f-ef43bcd4c06d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e7c80c53-ca42-43f6-8133-fde6573ce60d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_80198da7-070c-42f6-852f-ef43bcd4c06d" xlink:to="loc_srt_RangeMember_e7c80c53-ca42-43f6-8133-fde6573ce60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a6013c5a-ad5c-4a59-82f7-cbecf69ee4b6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e7c80c53-ca42-43f6-8133-fde6573ce60d" xlink:to="loc_srt_MinimumMember_a6013c5a-ad5c-4a59-82f7-cbecf69ee4b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_35917f0f-a35d-4fcf-bc78-3b1c1bd6b160" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e7c80c53-ca42-43f6-8133-fde6573ce60d" xlink:to="loc_srt_MaximumMember_35917f0f-a35d-4fcf-bc78-3b1c1bd6b160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_835dcc63-38d4-4ba5-bbf2-513f9b82a1ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_61ace9fc-5beb-4385-9aa0-12e43771476c" xlink:to="loc_us-gaap_DebtInstrumentLineItems_835dcc63-38d4-4ba5-bbf2-513f9b82a1ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_DebtInstrumentExtensionPeriod_4cfc2a62-fec0-44d0-8cf9-fa3dfaf41c4f" xlink:href="dgx-20221231.xsd#dgx_DebtInstrumentExtensionPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_835dcc63-38d4-4ba5-bbf2-513f9b82a1ad" xlink:to="loc_dgx_DebtInstrumentExtensionPeriod_4cfc2a62-fec0-44d0-8cf9-fa3dfaf41c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_133e150c-224d-4961-bad7-89367bb10653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_835dcc63-38d4-4ba5-bbf2-513f9b82a1ad" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_133e150c-224d-4961-bad7-89367bb10653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a7b79d59-67d6-4e6d-bd72-e4d8b5ede10c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_835dcc63-38d4-4ba5-bbf2-513f9b82a1ad" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a7b79d59-67d6-4e6d-bd72-e4d8b5ede10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_75ce3333-5e0a-4cfc-a5a7-f55803322332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_835dcc63-38d4-4ba5-bbf2-513f9b82a1ad" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_75ce3333-5e0a-4cfc-a5a7-f55803322332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/DEBTSeniorUnsecuredRevolvingCreditFacilityNarrativeDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#DEBTSeniorUnsecuredRevolvingCreditFacilityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/DEBTSeniorUnsecuredRevolvingCreditFacilityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentsAbstract_1e13987f-0c8e-403a-b313-94aebe92de32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4e3c48da-bcc2-487a-92eb-9ad75fb94c58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_1e13987f-0c8e-403a-b313-94aebe92de32" xlink:to="loc_us-gaap_DebtInstrumentTable_4e3c48da-bcc2-487a-92eb-9ad75fb94c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7384e76c-bb0f-401e-a619-2cce4919d386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4e3c48da-bcc2-487a-92eb-9ad75fb94c58" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7384e76c-bb0f-401e-a619-2cce4919d386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_dfcfc5e9-0aaf-4d18-9f06-9e7a4fa551ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7384e76c-bb0f-401e-a619-2cce4919d386" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_dfcfc5e9-0aaf-4d18-9f06-9e7a4fa551ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_SeniorunsecuredrevolvingcreditfacilityMember_ea747cb2-e2c2-4a3f-8fde-765582bd3fc0" xlink:href="dgx-20221231.xsd#dgx_SeniorunsecuredrevolvingcreditfacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dfcfc5e9-0aaf-4d18-9f06-9e7a4fa551ad" xlink:to="loc_dgx_SeniorunsecuredrevolvingcreditfacilityMember_ea747cb2-e2c2-4a3f-8fde-765582bd3fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_981d8554-6e28-4891-90df-162366598d61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4e3c48da-bcc2-487a-92eb-9ad75fb94c58" xlink:to="loc_us-gaap_CreditFacilityAxis_981d8554-6e28-4891-90df-162366598d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_9810fe4c-f09c-4bda-9eb4-cf3477071003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_981d8554-6e28-4891-90df-162366598d61" xlink:to="loc_us-gaap_CreditFacilityDomain_9810fe4c-f09c-4bda-9eb4-cf3477071003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_c4771493-ebf3-40e5-a0ed-522af43f910f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_9810fe4c-f09c-4bda-9eb4-cf3477071003" xlink:to="loc_us-gaap_LetterOfCreditMember_c4771493-ebf3-40e5-a0ed-522af43f910f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_f353bfa8-1504-4f2d-8092-81ff68198b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4e3c48da-bcc2-487a-92eb-9ad75fb94c58" xlink:to="loc_us-gaap_VariableRateAxis_f353bfa8-1504-4f2d-8092-81ff68198b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_db541ede-5cb6-41b6-9a14-b93cac9752a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_f353bfa8-1504-4f2d-8092-81ff68198b0c" xlink:to="loc_us-gaap_VariableRateDomain_db541ede-5cb6-41b6-9a14-b93cac9752a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_c118f993-dc98-491c-b0f5-c33e0f1cbdbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_db541ede-5cb6-41b6-9a14-b93cac9752a6" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_c118f993-dc98-491c-b0f5-c33e0f1cbdbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_10a38c6c-2574-4e1f-94a2-4c84345620c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4e3c48da-bcc2-487a-92eb-9ad75fb94c58" xlink:to="loc_us-gaap_DebtInstrumentLineItems_10a38c6c-2574-4e1f-94a2-4c84345620c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_513064ce-01cd-4f4d-a330-0f1eee41024e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10a38c6c-2574-4e1f-94a2-4c84345620c7" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_513064ce-01cd-4f4d-a330-0f1eee41024e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_f89e39f2-90d2-4803-94a6-447927f0f97c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10a38c6c-2574-4e1f-94a2-4c84345620c7" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_f89e39f2-90d2-4803-94a6-447927f0f97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_d8de9f0d-8dde-492c-a94f-8f931a8cf781" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_10a38c6c-2574-4e1f-94a2-4c84345620c7" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_d8de9f0d-8dde-492c-a94f-8f931a8cf781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/DEBTMaturitiesofLongTermDebtDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#DEBTMaturitiesofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/DEBTMaturitiesofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentsAbstract_6c5189d6-1123-4f14-a6b0-7fe5908d92a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_05353b92-9f6a-41f8-91bc-3346b7ef21c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_6c5189d6-1123-4f14-a6b0-7fe5908d92a1" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_05353b92-9f6a-41f8-91bc-3346b7ef21c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_05199a29-0f42-4f1d-b10b-b34907c36c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_6c5189d6-1123-4f14-a6b0-7fe5908d92a1" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_05199a29-0f42-4f1d-b10b-b34907c36c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_2d338412-fea0-436e-b450-0b4af30ee07a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_6c5189d6-1123-4f14-a6b0-7fe5908d92a1" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_2d338412-fea0-436e-b450-0b4af30ee07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_87540459-d8d0-42c5-b09a-a891925352e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_6c5189d6-1123-4f14-a6b0-7fe5908d92a1" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_87540459-d8d0-42c5-b09a-a891925352e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_82321cc2-6e7c-4fbd-9558-3e1555aa39bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_6c5189d6-1123-4f14-a6b0-7fe5908d92a1" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_82321cc2-6e7c-4fbd-9558-3e1555aa39bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_e1d9283b-f26e-4f89-a8fa-caf523fcafd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_6c5189d6-1123-4f14-a6b0-7fe5908d92a1" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_e1d9283b-f26e-4f89-a8fa-caf523fcafd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LongTermDebtMaturitiesGross_0ad23aa8-b52c-43fe-9f52-7e16c5efcecc" xlink:href="dgx-20221231.xsd#dgx_LongTermDebtMaturitiesGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_6c5189d6-1123-4f14-a6b0-7fe5908d92a1" xlink:to="loc_dgx_LongTermDebtMaturitiesGross_0ad23aa8-b52c-43fe-9f52-7e16c5efcecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_35fd4ee3-faa1-4ca5-be33-e1d57b986d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_6c5189d6-1123-4f14-a6b0-7fe5908d92a1" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_35fd4ee3-faa1-4ca5-be33-e1d57b986d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_3b3bf1c3-c9b4-48e0-976b-47843b772c71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_6c5189d6-1123-4f14-a6b0-7fe5908d92a1" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_3b3bf1c3-c9b4-48e0-976b-47843b772c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_DebtInstrumentFairValueBasisAdjustmentAttributableToHedgedDebt_88de3880-7a78-4a15-865d-ddf4ce1bc066" xlink:href="dgx-20221231.xsd#dgx_DebtInstrumentFairValueBasisAdjustmentAttributableToHedgedDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_6c5189d6-1123-4f14-a6b0-7fe5908d92a1" xlink:to="loc_dgx_DebtInstrumentFairValueBasisAdjustmentAttributableToHedgedDebt_88de3880-7a78-4a15-865d-ddf4ce1bc066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_ca3f531c-858c-4529-b00c-8aef761e8f34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_6c5189d6-1123-4f14-a6b0-7fe5908d92a1" xlink:to="loc_us-gaap_LongTermDebt_ca3f531c-858c-4529-b00c-8aef761e8f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_75558815-53e6-4640-a99f-338b8e6e6fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_6c5189d6-1123-4f14-a6b0-7fe5908d92a1" xlink:to="loc_us-gaap_LongTermDebtCurrent_75558815-53e6-4640-a99f-338b8e6e6fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_2b0e9ffc-f80e-45c2-903d-5e62174fd8df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_6c5189d6-1123-4f14-a6b0-7fe5908d92a1" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_2b0e9ffc-f80e-45c2-903d-5e62174fd8df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/LEASESNarrativeDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#LEASESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/LEASESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_eecce499-5675-435a-b022-d49cf720f191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_5d308cfb-1c7d-475c-8e6a-adab1bfaf3f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_eecce499-5675-435a-b022-d49cf720f191" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_5d308cfb-1c7d-475c-8e6a-adab1bfaf3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d2309dd3-91d2-4c01-95d1-f4f6b25d9925" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_5d308cfb-1c7d-475c-8e6a-adab1bfaf3f0" xlink:to="loc_srt_RangeAxis_d2309dd3-91d2-4c01-95d1-f4f6b25d9925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b029f4cc-c169-44d9-ae75-21cca2fcf4e7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d2309dd3-91d2-4c01-95d1-f4f6b25d9925" xlink:to="loc_srt_RangeMember_b029f4cc-c169-44d9-ae75-21cca2fcf4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f701642b-b5cb-4128-a3b5-8589173f877c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b029f4cc-c169-44d9-ae75-21cca2fcf4e7" xlink:to="loc_srt_MinimumMember_f701642b-b5cb-4128-a3b5-8589173f877c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0e9cd9e4-2bef-4bb0-9e89-db18c3371c04" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b029f4cc-c169-44d9-ae75-21cca2fcf4e7" xlink:to="loc_srt_MaximumMember_0e9cd9e4-2bef-4bb0-9e89-db18c3371c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationTypeAxis_02794222-a8a9-4c45-acd1-6b46172d5047" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_5d308cfb-1c7d-475c-8e6a-adab1bfaf3f0" xlink:to="loc_us-gaap_ReclassificationTypeAxis_02794222-a8a9-4c45-acd1-6b46172d5047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationTypeDomain_df7c9b4e-27fa-4c47-92da-ab644dbf6865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationTypeAxis_02794222-a8a9-4c45-acd1-6b46172d5047" xlink:to="loc_us-gaap_ReclassificationTypeDomain_df7c9b4e-27fa-4c47-92da-ab644dbf6865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LeaseTypeChangeMember_875d354d-eb81-458d-a93f-738645aaabb7" xlink:href="dgx-20221231.xsd#dgx_LeaseTypeChangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationTypeDomain_df7c9b4e-27fa-4c47-92da-ab644dbf6865" xlink:to="loc_dgx_LeaseTypeChangeMember_875d354d-eb81-458d-a93f-738645aaabb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_42dad8d6-79e0-411c-b857-e4e02a0ab839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_5d308cfb-1c7d-475c-8e6a-adab1bfaf3f0" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_42dad8d6-79e0-411c-b857-e4e02a0ab839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LeaseRemainingLeaseTerm_1e801fb5-639d-4276-996e-942f10758374" xlink:href="dgx-20221231.xsd#dgx_LeaseRemainingLeaseTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_42dad8d6-79e0-411c-b857-e4e02a0ab839" xlink:to="loc_dgx_LeaseRemainingLeaseTerm_1e801fb5-639d-4276-996e-942f10758374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LeaseRenewalTerm_61045e34-4166-49bb-864f-f5762c65bb41" xlink:href="dgx-20221231.xsd#dgx_LeaseRenewalTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_42dad8d6-79e0-411c-b857-e4e02a0ab839" xlink:to="loc_dgx_LeaseRenewalTerm_61045e34-4166-49bb-864f-f5762c65bb41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8b81ec67-ecad-4bff-bc42-3e182f137d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_42dad8d6-79e0-411c-b857-e4e02a0ab839" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8b81ec67-ecad-4bff-bc42-3e182f137d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/LEASESLiabilitiesDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#LEASESLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/LEASESLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_93fa0dd0-67d7-44e4-ad11-eb609cafbb22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_58d79e1c-3fbd-4e42-aed9-63ddab41d1aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_93fa0dd0-67d7-44e4-ad11-eb609cafbb22" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_58d79e1c-3fbd-4e42-aed9-63ddab41d1aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_f49932f9-db08-4fd2-99cb-238bdfdea4af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_93fa0dd0-67d7-44e4-ad11-eb609cafbb22" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_f49932f9-db08-4fd2-99cb-238bdfdea4af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_4714fd1a-55ce-4fae-8ffc-83708afc7708" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_93fa0dd0-67d7-44e4-ad11-eb609cafbb22" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_4714fd1a-55ce-4fae-8ffc-83708afc7708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LeaseRightofUseAsset_d1b8606c-909d-407d-aa02-a813287b8cb2" xlink:href="dgx-20221231.xsd#dgx_LeaseRightofUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_93fa0dd0-67d7-44e4-ad11-eb609cafbb22" xlink:to="loc_dgx_LeaseRightofUseAsset_d1b8606c-909d-407d-aa02-a813287b8cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5f32d6cb-0d16-4a66-928b-0242611dfd07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_93fa0dd0-67d7-44e4-ad11-eb609cafbb22" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5f32d6cb-0d16-4a66-928b-0242611dfd07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_e722209a-0321-4756-9d0b-4c7fc5a61c85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_93fa0dd0-67d7-44e4-ad11-eb609cafbb22" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_e722209a-0321-4756-9d0b-4c7fc5a61c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_21a99a80-7a44-46c3-91fb-ac560ea8407d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_93fa0dd0-67d7-44e4-ad11-eb609cafbb22" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_21a99a80-7a44-46c3-91fb-ac560ea8407d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f4084a29-35ac-49cd-b2d1-67017a1f4d62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_93fa0dd0-67d7-44e4-ad11-eb609cafbb22" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f4084a29-35ac-49cd-b2d1-67017a1f4d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_33df4a64-8630-4a04-9db9-70569750f468" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_93fa0dd0-67d7-44e4-ad11-eb609cafbb22" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_33df4a64-8630-4a04-9db9-70569750f468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_141bf81e-3419-40cb-8b44-418092d503b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_93fa0dd0-67d7-44e4-ad11-eb609cafbb22" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_141bf81e-3419-40cb-8b44-418092d503b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LeaseLiability_b1eb80b3-f0fd-4aa9-b16b-75f590a3d4c8" xlink:href="dgx-20221231.xsd#dgx_LeaseLiability"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_93fa0dd0-67d7-44e4-ad11-eb609cafbb22" xlink:to="loc_dgx_LeaseLiability_b1eb80b3-f0fd-4aa9-b16b-75f590a3d4c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_3f2103ea-0386-4804-be9f-50e3503d112d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_93fa0dd0-67d7-44e4-ad11-eb609cafbb22" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_3f2103ea-0386-4804-be9f-50e3503d112d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/LEASESCostsDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#LEASESCostsDetails"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/LEASESCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ea780550-384c-4fef-83d0-2ad6432e5e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_OperatingLeaseFixedAndVariableCost_46d1c31d-8707-426e-b510-479a60ce3599" xlink:href="dgx-20221231.xsd#dgx_OperatingLeaseFixedAndVariableCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ea780550-384c-4fef-83d0-2ad6432e5e6a" xlink:to="loc_dgx_OperatingLeaseFixedAndVariableCost_46d1c31d-8707-426e-b510-479a60ce3599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_60a95d68-3168-4f3d-9669-1f263d436165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ea780550-384c-4fef-83d0-2ad6432e5e6a" xlink:to="loc_us-gaap_LeaseCostAbstract_60a95d68-3168-4f3d-9669-1f263d436165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_8558482d-c7ef-4adf-9019-797cb4e21ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_60a95d68-3168-4f3d-9669-1f263d436165" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_8558482d-c7ef-4adf-9019-797cb4e21ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_54e84f37-9d9a-4156-8d15-fa0c4130662f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_60a95d68-3168-4f3d-9669-1f263d436165" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_54e84f37-9d9a-4156-8d15-fa0c4130662f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_2fa75962-f5b5-452e-a553-f2ac70265f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ea780550-384c-4fef-83d0-2ad6432e5e6a" xlink:to="loc_us-gaap_LeaseCost_2fa75962-f5b5-452e-a553-f2ac70265f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ShorttermLeaseandVariableLeaseCost_300e3e77-52d5-4c72-a34f-4bdabf64429f" xlink:href="dgx-20221231.xsd#dgx_ShorttermLeaseandVariableLeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ea780550-384c-4fef-83d0-2ad6432e5e6a" xlink:to="loc_dgx_ShorttermLeaseandVariableLeaseCost_300e3e77-52d5-4c72-a34f-4bdabf64429f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/LEASESMaturityDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#LEASESMaturityDetails"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/LEASESMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a062de10-84fb-4dc3-85dc-762616a9bf7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ccd02078-5b00-4ad7-9411-26e2af40d880" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a062de10-84fb-4dc3-85dc-762616a9bf7a" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ccd02078-5b00-4ad7-9411-26e2af40d880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c23872f7-1065-418e-baa8-977ef7472d33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ccd02078-5b00-4ad7-9411-26e2af40d880" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c23872f7-1065-418e-baa8-977ef7472d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1832b50a-21d1-4cd9-bb13-3f4cf8aa8f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ccd02078-5b00-4ad7-9411-26e2af40d880" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1832b50a-21d1-4cd9-bb13-3f4cf8aa8f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_36bc2f8d-fbba-4d22-86a7-5850355dec81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ccd02078-5b00-4ad7-9411-26e2af40d880" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_36bc2f8d-fbba-4d22-86a7-5850355dec81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_7a10ca3e-10da-4e44-b6fb-229e34e4569f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ccd02078-5b00-4ad7-9411-26e2af40d880" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_7a10ca3e-10da-4e44-b6fb-229e34e4569f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7d6b0621-f708-454f-b426-aa5e66ed6671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ccd02078-5b00-4ad7-9411-26e2af40d880" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7d6b0621-f708-454f-b426-aa5e66ed6671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_06cab8af-2cbc-45e1-98bd-517f8fd982b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ccd02078-5b00-4ad7-9411-26e2af40d880" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_06cab8af-2cbc-45e1-98bd-517f8fd982b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f5c614a5-be6b-4417-b85f-9d5e07a892cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ccd02078-5b00-4ad7-9411-26e2af40d880" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f5c614a5-be6b-4417-b85f-9d5e07a892cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b437b483-bd88-4ab6-a04b-abc97f720373" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ccd02078-5b00-4ad7-9411-26e2af40d880" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b437b483-bd88-4ab6-a04b-abc97f720373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_96395081-bb28-4d2f-b0f5-4030ef77ca52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ccd02078-5b00-4ad7-9411-26e2af40d880" xlink:to="loc_us-gaap_OperatingLeaseLiability_96395081-bb28-4d2f-b0f5-4030ef77ca52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_37deb95b-2c41-4444-97c0-d7024b94e84f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a062de10-84fb-4dc3-85dc-762616a9bf7a" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_37deb95b-2c41-4444-97c0-d7024b94e84f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_3786104c-b4ce-45c3-baf3-97fdafef081d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_37deb95b-2c41-4444-97c0-d7024b94e84f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_3786104c-b4ce-45c3-baf3-97fdafef081d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_cfc8f646-87e1-47bf-8471-fcee1c8e00aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_37deb95b-2c41-4444-97c0-d7024b94e84f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_cfc8f646-87e1-47bf-8471-fcee1c8e00aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_55cdba7b-d26c-4de2-8e82-c285eda693ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_37deb95b-2c41-4444-97c0-d7024b94e84f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_55cdba7b-d26c-4de2-8e82-c285eda693ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_e49243ed-554c-4463-95a2-c99cc489a76e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_37deb95b-2c41-4444-97c0-d7024b94e84f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_e49243ed-554c-4463-95a2-c99cc489a76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_646932a6-4243-4eab-bfc1-5a2f6f47192a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_37deb95b-2c41-4444-97c0-d7024b94e84f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_646932a6-4243-4eab-bfc1-5a2f6f47192a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_b6c2abad-fd8a-465c-8f30-44dea7fb8c55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_37deb95b-2c41-4444-97c0-d7024b94e84f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_b6c2abad-fd8a-465c-8f30-44dea7fb8c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_11b9d4b2-e111-4730-a49e-8e6302e0a60a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_37deb95b-2c41-4444-97c0-d7024b94e84f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_11b9d4b2-e111-4730-a49e-8e6302e0a60a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_63b977fd-272b-4e73-b526-701c23d876a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_37deb95b-2c41-4444-97c0-d7024b94e84f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_63b977fd-272b-4e73-b526-701c23d876a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_d49a027b-7ac2-498e-bb8f-f6afa14cc434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_37deb95b-2c41-4444-97c0-d7024b94e84f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_d49a027b-7ac2-498e-bb8f-f6afa14cc434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_779e3abb-6536-4da3-8d0a-770e4c1e03ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_37deb95b-2c41-4444-97c0-d7024b94e84f" xlink:to="loc_us-gaap_FinanceLeaseLiability_779e3abb-6536-4da3-8d0a-770e4c1e03ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_FinanceandOperatingLeaseLiabilitiesPaymentsDueAbstract_cd407780-f6e9-45b8-8a5c-bc4d10bda267" xlink:href="dgx-20221231.xsd#dgx_FinanceandOperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a062de10-84fb-4dc3-85dc-762616a9bf7a" xlink:to="loc_dgx_FinanceandOperatingLeaseLiabilitiesPaymentsDueAbstract_cd407780-f6e9-45b8-8a5c-bc4d10bda267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_a1e6f002-ba69-49ae-a4aa-e5d725bb2e17" xlink:href="dgx-20221231.xsd#dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_FinanceandOperatingLeaseLiabilitiesPaymentsDueAbstract_cd407780-f6e9-45b8-8a5c-bc4d10bda267" xlink:to="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_a1e6f002-ba69-49ae-a4aa-e5d725bb2e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearTwo_ba3600dd-74ed-4b0e-a738-18615e45899c" xlink:href="dgx-20221231.xsd#dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_FinanceandOperatingLeaseLiabilitiesPaymentsDueAbstract_cd407780-f6e9-45b8-8a5c-bc4d10bda267" xlink:to="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearTwo_ba3600dd-74ed-4b0e-a738-18615e45899c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearThree_c4d076c7-3e36-40bf-8174-309c074772b5" xlink:href="dgx-20221231.xsd#dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_FinanceandOperatingLeaseLiabilitiesPaymentsDueAbstract_cd407780-f6e9-45b8-8a5c-bc4d10bda267" xlink:to="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearThree_c4d076c7-3e36-40bf-8174-309c074772b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFour_b3d8a363-175e-4318-adcf-c6f295a65c5a" xlink:href="dgx-20221231.xsd#dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_FinanceandOperatingLeaseLiabilitiesPaymentsDueAbstract_cd407780-f6e9-45b8-8a5c-bc4d10bda267" xlink:to="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFour_b3d8a363-175e-4318-adcf-c6f295a65c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFive_cd4e775c-61e9-4a33-b0e8-c709b5e71d96" xlink:href="dgx-20221231.xsd#dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_FinanceandOperatingLeaseLiabilitiesPaymentsDueAbstract_cd407780-f6e9-45b8-8a5c-bc4d10bda267" xlink:to="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFive_cd4e775c-61e9-4a33-b0e8-c709b5e71d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueafterYearFive_7d48dfbb-5a79-406d-aa50-830cf367abc5" xlink:href="dgx-20221231.xsd#dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueafterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_FinanceandOperatingLeaseLiabilitiesPaymentsDueAbstract_cd407780-f6e9-45b8-8a5c-bc4d10bda267" xlink:to="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueafterYearFive_7d48dfbb-5a79-406d-aa50-830cf367abc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDue_f67181f0-872e-438f-a1ba-10ba7a6569a5" xlink:href="dgx-20221231.xsd#dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_FinanceandOperatingLeaseLiabilitiesPaymentsDueAbstract_cd407780-f6e9-45b8-8a5c-bc4d10bda267" xlink:to="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDue_f67181f0-872e-438f-a1ba-10ba7a6569a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityUndiscountedExcessAmount_8e11480e-20bd-4a03-b343-fd9e875c16b4" xlink:href="dgx-20221231.xsd#dgx_LesseeOperatingandFinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_FinanceandOperatingLeaseLiabilitiesPaymentsDueAbstract_cd407780-f6e9-45b8-8a5c-bc4d10bda267" xlink:to="loc_dgx_LesseeOperatingandFinanceLeaseLiabilityUndiscountedExcessAmount_8e11480e-20bd-4a03-b343-fd9e875c16b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_OperatingandFinanceLeaseLiability_473a92b3-6e99-4825-82a6-7529f2f3562d" xlink:href="dgx-20221231.xsd#dgx_OperatingandFinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_FinanceandOperatingLeaseLiabilitiesPaymentsDueAbstract_cd407780-f6e9-45b8-8a5c-bc4d10bda267" xlink:to="loc_dgx_OperatingandFinanceLeaseLiability_473a92b3-6e99-4825-82a6-7529f2f3562d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/LEASESTermandRateDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#LEASESTermandRateDetails"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/LEASESTermandRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e7d1421d-eccf-472f-9b84-8f0dc6c3e26e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_497e28ac-e88e-4626-b02f-4c9843cac0b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e7d1421d-eccf-472f-9b84-8f0dc6c3e26e" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_497e28ac-e88e-4626-b02f-4c9843cac0b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_10ad5b86-cce2-423b-839b-3d1885001d86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e7d1421d-eccf-472f-9b84-8f0dc6c3e26e" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_10ad5b86-cce2-423b-839b-3d1885001d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_778ce887-34b9-4cb2-adb7-85ecf70c8313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e7d1421d-eccf-472f-9b84-8f0dc6c3e26e" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_778ce887-34b9-4cb2-adb7-85ecf70c8313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_89aa547e-3458-43c7-93d2-f95ab00673d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e7d1421d-eccf-472f-9b84-8f0dc6c3e26e" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_89aa547e-3458-43c7-93d2-f95ab00673d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#FINANCIALINSTRUMENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_926d9037-d35a-4325-b2e3-2c9dcc896463" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_a052bbb5-e015-4d6c-99e0-f12eceed0641" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_926d9037-d35a-4325-b2e3-2c9dcc896463" xlink:to="loc_us-gaap_DerivativeTable_a052bbb5-e015-4d6c-99e0-f12eceed0641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5a5495ac-cb22-4f57-a9fb-a2e200178e30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_a052bbb5-e015-4d6c-99e0-f12eceed0641" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5a5495ac-cb22-4f57-a9fb-a2e200178e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_315ce7f6-354d-478a-ad50-777644d5f6ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5a5495ac-cb22-4f57-a9fb-a2e200178e30" xlink:to="loc_us-gaap_HedgingRelationshipDomain_315ce7f6-354d-478a-ad50-777644d5f6ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_75205421-4de0-4cd5-97db-a7b31cc83a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_315ce7f6-354d-478a-ad50-777644d5f6ae" xlink:to="loc_us-gaap_FairValueHedgingMember_75205421-4de0-4cd5-97db-a7b31cc83a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_02018962-ff8f-453b-a473-149612978fd6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_a052bbb5-e015-4d6c-99e0-f12eceed0641" xlink:to="loc_srt_StatementScenarioAxis_02018962-ff8f-453b-a473-149612978fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_393425fd-1ad3-478e-8ee2-328de00ed52a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_02018962-ff8f-453b-a473-149612978fd6" xlink:to="loc_srt_ScenarioUnspecifiedDomain_393425fd-1ad3-478e-8ee2-328de00ed52a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_300c0deb-de99-40d0-bffc-ed85eb35c1f8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_393425fd-1ad3-478e-8ee2-328de00ed52a" xlink:to="loc_srt_ScenarioForecastMember_300c0deb-de99-40d0-bffc-ed85eb35c1f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_908c805a-c479-440d-87a2-815964f531ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_a052bbb5-e015-4d6c-99e0-f12eceed0641" xlink:to="loc_us-gaap_VariableRateAxis_908c805a-c479-440d-87a2-815964f531ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_8b3ddad2-fb28-401c-87a0-2aa8ff88f69f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_908c805a-c479-440d-87a2-815964f531ef" xlink:to="loc_us-gaap_VariableRateDomain_8b3ddad2-fb28-401c-87a0-2aa8ff88f69f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_9333d456-bf4f-4c4a-aaf7-9809bf621f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_8b3ddad2-fb28-401c-87a0-2aa8ff88f69f" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_9333d456-bf4f-4c4a-aaf7-9809bf621f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6f377dfd-74ff-441c-b284-8326e93a5c6b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_a052bbb5-e015-4d6c-99e0-f12eceed0641" xlink:to="loc_srt_RangeAxis_6f377dfd-74ff-441c-b284-8326e93a5c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4376ba65-34bd-40f5-979f-46e0cc65a785" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6f377dfd-74ff-441c-b284-8326e93a5c6b" xlink:to="loc_srt_RangeMember_4376ba65-34bd-40f5-979f-46e0cc65a785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_63f079c2-96c6-475b-8665-98448a277d17" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4376ba65-34bd-40f5-979f-46e0cc65a785" xlink:to="loc_srt_MinimumMember_63f079c2-96c6-475b-8665-98448a277d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e58e841f-c4ac-4d98-a533-1b5db7ccd5aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4376ba65-34bd-40f5-979f-46e0cc65a785" xlink:to="loc_srt_MaximumMember_e58e841f-c4ac-4d98-a533-1b5db7ccd5aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5cdce26f-b1db-41b8-ae97-8151337ee0db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_a052bbb5-e015-4d6c-99e0-f12eceed0641" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5cdce26f-b1db-41b8-ae97-8151337ee0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_12743295-b355-456a-a42f-3be1c1fa2afd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5cdce26f-b1db-41b8-ae97-8151337ee0db" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_12743295-b355-456a-a42f-3be1c1fa2afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_006e7771-dec0-4c0d-8aff-279ff57d9053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_12743295-b355-456a-a42f-3be1c1fa2afd" xlink:to="loc_us-gaap_LongTermDebtMember_006e7771-dec0-4c0d-8aff-279ff57d9053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_0fe0854a-3937-443e-8375-66bca82501e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_a052bbb5-e015-4d6c-99e0-f12eceed0641" xlink:to="loc_us-gaap_DerivativeLineItems_0fe0854a-3937-443e-8375-66bca82501e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_32ec11cd-127e-4edb-8461-c2d6c295c6f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_0fe0854a-3937-443e-8375-66bca82501e5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_32ec11cd-127e-4edb-8461-c2d6c295c6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/FINANCIALINSTRUMENTSBalanceSheetsDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#FINANCIALINSTRUMENTSBalanceSheetsDetails"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/FINANCIALINSTRUMENTSBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b03a12a8-51d3-4b13-8b0e-6275fc28e94f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_b654be16-9d50-4d4a-945e-993a203c721c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b03a12a8-51d3-4b13-8b0e-6275fc28e94f" xlink:to="loc_us-gaap_DerivativeTable_b654be16-9d50-4d4a-945e-993a203c721c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7e9f9744-a1af-4eb5-a646-dcf6db5175da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_b654be16-9d50-4d4a-945e-993a203c721c" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_7e9f9744-a1af-4eb5-a646-dcf6db5175da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3a7c4c91-c8cf-4289-80d2-b03decc30f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7e9f9744-a1af-4eb5-a646-dcf6db5175da" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3a7c4c91-c8cf-4289-80d2-b03decc30f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_0df5cb31-d5bc-403a-aa7d-52d622374e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3a7c4c91-c8cf-4289-80d2-b03decc30f8a" xlink:to="loc_us-gaap_LongTermDebtMember_0df5cb31-d5bc-403a-aa7d-52d622374e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_87525515-9617-4f18-ac6d-24e528bee721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_b654be16-9d50-4d4a-945e-993a203c721c" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_87525515-9617-4f18-ac6d-24e528bee721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_bf178be9-5f53-42b9-88d8-e042c29804e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_87525515-9617-4f18-ac6d-24e528bee721" xlink:to="loc_us-gaap_HedgingRelationshipDomain_bf178be9-5f53-42b9-88d8-e042c29804e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_0a24da4e-b827-42f6-a02e-4dbdcd326e79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_bf178be9-5f53-42b9-88d8-e042c29804e5" xlink:to="loc_us-gaap_FairValueHedgingMember_0a24da4e-b827-42f6-a02e-4dbdcd326e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_c307205a-0fd8-4ed5-83b5-23dd8a0470f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_b654be16-9d50-4d4a-945e-993a203c721c" xlink:to="loc_us-gaap_DerivativeLineItems_c307205a-0fd8-4ed5-83b5-23dd8a0470f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_3b74fcea-ac68-434e-b359-68e02cce4647" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c307205a-0fd8-4ed5-83b5-23dd8a0470f4" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_3b74fcea-ac68-434e-b359-68e02cce4647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/FINANCIALINSTRUMENTSIncomeStatementDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#FINANCIALINSTRUMENTSIncomeStatementDetails"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/FINANCIALINSTRUMENTSIncomeStatementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_fc3eda52-032e-42e4-8eb4-93fd62a550fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_d149a1fb-2c55-4614-9449-71d35753737b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_fc3eda52-032e-42e4-8eb4-93fd62a550fb" xlink:to="loc_us-gaap_DerivativeTable_d149a1fb-2c55-4614-9449-71d35753737b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_efee842a-f71c-43aa-ab2b-259848b048fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_d149a1fb-2c55-4614-9449-71d35753737b" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_efee842a-f71c-43aa-ab2b-259848b048fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_872e5f70-c0c8-4e4f-ae0f-3bbdbc598e74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_efee842a-f71c-43aa-ab2b-259848b048fb" xlink:to="loc_us-gaap_HedgingRelationshipDomain_872e5f70-c0c8-4e4f-ae0f-3bbdbc598e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_400cd60b-b9b4-49c5-b6fd-a4c908fde2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_872e5f70-c0c8-4e4f-ae0f-3bbdbc598e74" xlink:to="loc_us-gaap_FairValueHedgingMember_400cd60b-b9b4-49c5-b6fd-a4c908fde2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_bd32f80c-d27d-4254-b425-ba92e59b1c60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_d149a1fb-2c55-4614-9449-71d35753737b" xlink:to="loc_us-gaap_DerivativeLineItems_bd32f80c-d27d-4254-b425-ba92e59b1c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_8439070a-fb51-4af8-a6c3-7b811afdfb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_bd32f80c-d27d-4254-b425-ba92e59b1c60" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_8439070a-fb51-4af8-a6c3-7b811afdfb8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_e17ef5a1-4592-47a3-a27a-57efa8473071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_bd32f80c-d27d-4254-b425-ba92e59b1c60" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_e17ef5a1-4592-47a3-a27a-57efa8473071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_50ba7130-87ee-4df3-b499-1b994210e596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_bd32f80c-d27d-4254-b425-ba92e59b1c60" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_50ba7130-87ee-4df3-b499-1b994210e596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a72ac47d-db00-4cac-9f82-67ebbf687c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ScheduleOfShareholdersEquityTable_12cbb3e9-faaa-4d15-9a47-7018fcac7c6e" xlink:href="dgx-20221231.xsd#dgx_ScheduleOfShareholdersEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a72ac47d-db00-4cac-9f82-67ebbf687c6a" xlink:to="loc_dgx_ScheduleOfShareholdersEquityTable_12cbb3e9-faaa-4d15-9a47-7018fcac7c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_455f3aaf-ec08-4a1c-ab14-ae3e78d26c49" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_ScheduleOfShareholdersEquityTable_12cbb3e9-faaa-4d15-9a47-7018fcac7c6e" xlink:to="loc_srt_RangeAxis_455f3aaf-ec08-4a1c-ab14-ae3e78d26c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b02cec9c-e971-49b8-be19-a0c33807612e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_455f3aaf-ec08-4a1c-ab14-ae3e78d26c49" xlink:to="loc_srt_RangeMember_b02cec9c-e971-49b8-be19-a0c33807612e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_769e9059-5697-46d0-bc2b-b524c3845663" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b02cec9c-e971-49b8-be19-a0c33807612e" xlink:to="loc_srt_MaximumMember_769e9059-5697-46d0-bc2b-b524c3845663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_10718479-4d01-4b70-b63e-0b800984354e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_ScheduleOfShareholdersEquityTable_12cbb3e9-faaa-4d15-9a47-7018fcac7c6e" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_10718479-4d01-4b70-b63e-0b800984354e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_bc216c71-d6b4-4399-90e1-d2b4014469a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_10718479-4d01-4b70-b63e-0b800984354e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_bc216c71-d6b4-4399-90e1-d2b4014469a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_e7f36b3e-e9cd-418b-878d-f4867bc24e64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_bc216c71-d6b4-4399-90e1-d2b4014469a6" xlink:to="loc_us-gaap_SubsequentEventMember_e7f36b3e-e9cd-418b-878d-f4867bc24e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_67d84e99-e03d-4799-9c6c-066bdb21c833" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_ScheduleOfShareholdersEquityTable_12cbb3e9-faaa-4d15-9a47-7018fcac7c6e" xlink:to="loc_srt_StatementScenarioAxis_67d84e99-e03d-4799-9c6c-066bdb21c833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_7cff6f73-b5d8-40b8-9458-45c9a15bfb7b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_67d84e99-e03d-4799-9c6c-066bdb21c833" xlink:to="loc_srt_ScenarioUnspecifiedDomain_7cff6f73-b5d8-40b8-9458-45c9a15bfb7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_49b8e6a2-9910-4faa-a256-fd78189edb6d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_7cff6f73-b5d8-40b8-9458-45c9a15bfb7b" xlink:to="loc_srt_ScenarioForecastMember_49b8e6a2-9910-4faa-a256-fd78189edb6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ebd6483f-5ec2-45b7-aa12-7dbe9c71fff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_ScheduleOfShareholdersEquityTable_12cbb3e9-faaa-4d15-9a47-7018fcac7c6e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ebd6483f-5ec2-45b7-aa12-7dbe9c71fff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_595e785f-9628-4422-bbef-741dd46cdc94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ebd6483f-5ec2-45b7-aa12-7dbe9c71fff6" xlink:to="loc_us-gaap_EquityComponentDomain_595e785f-9628-4422-bbef-741dd46cdc94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_0b58a079-f33f-44b7-801e-6da66c74e38d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_595e785f-9628-4422-bbef-741dd46cdc94" xlink:to="loc_us-gaap_TreasuryStockMember_0b58a079-f33f-44b7-801e-6da66c74e38d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ForeignCurrencyTranslationMember_ff5949d3-b3ae-4bcd-9587-55441d8ba250" xlink:href="dgx-20221231.xsd#dgx_ForeignCurrencyTranslationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_595e785f-9628-4422-bbef-741dd46cdc94" xlink:to="loc_dgx_ForeignCurrencyTranslationMember_ff5949d3-b3ae-4bcd-9587-55441d8ba250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_fd127d05-e12b-4dc0-8269-a9990408ee88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_595e785f-9628-4422-bbef-741dd46cdc94" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_fd127d05-e12b-4dc0-8269-a9990408ee88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_2e93cef3-b5ef-4924-8d41-cf92ee7076c6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_ScheduleOfShareholdersEquityTable_12cbb3e9-faaa-4d15-9a47-7018fcac7c6e" xlink:to="loc_srt_OwnershipAxis_2e93cef3-b5ef-4924-8d41-cf92ee7076c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_1bb524ae-7c2e-4835-8d96-df65bf2d4b8d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_2e93cef3-b5ef-4924-8d41-cf92ee7076c6" xlink:to="loc_srt_OwnershipDomain_1bb524ae-7c2e-4835-8d96-df65bf2d4b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_UMassJointVentureMember_bdb4573c-c233-4b12-9951-ec708331b85e" xlink:href="dgx-20221231.xsd#dgx_UMassJointVentureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_1bb524ae-7c2e-4835-8d96-df65bf2d4b8d" xlink:to="loc_dgx_UMassJointVentureMember_bdb4573c-c233-4b12-9951-ec708331b85e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_a6cf59e6-59d8-48f6-9a2f-75b61fc45a92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_ScheduleOfShareholdersEquityTable_12cbb3e9-faaa-4d15-9a47-7018fcac7c6e" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_a6cf59e6-59d8-48f6-9a2f-75b61fc45a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_a0d9370b-409c-4214-869f-4b15dd0f2ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_a6cf59e6-59d8-48f6-9a2f-75b61fc45a92" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_a0d9370b-409c-4214-869f-4b15dd0f2ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_51dd7480-cace-4e4c-a890-8a2ef13158ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_a0d9370b-409c-4214-869f-4b15dd0f2ac8" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_51dd7480-cace-4e4c-a890-8a2ef13158ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a0516225-5a64-4850-8f85-8c8245e7bb9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_ScheduleOfShareholdersEquityTable_12cbb3e9-faaa-4d15-9a47-7018fcac7c6e" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a0516225-5a64-4850-8f85-8c8245e7bb9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b71b9623-8d84-4c0b-8cd4-a3b795807d22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a0516225-5a64-4850-8f85-8c8245e7bb9c" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b71b9623-8d84-4c0b-8cd4-a3b795807d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_Q2SolutionsMember_8c0c0f7d-2c43-48e5-9f79-41a3c9b5f3ea" xlink:href="dgx-20221231.xsd#dgx_Q2SolutionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b71b9623-8d84-4c0b-8cd4-a3b795807d22" xlink:to="loc_dgx_Q2SolutionsMember_8c0c0f7d-2c43-48e5-9f79-41a3c9b5f3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesDateAxis_248be143-0a47-497f-999e-cf0ab626aced" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcceleratedShareRepurchasesDateAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_ScheduleOfShareholdersEquityTable_12cbb3e9-faaa-4d15-9a47-7018fcac7c6e" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesDateAxis_248be143-0a47-497f-999e-cf0ab626aced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesDateDomain_6437f380-2516-4931-8796-3feb059e9771" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcceleratedShareRepurchasesDateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesDateAxis_248be143-0a47-497f-999e-cf0ab626aced" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesDateDomain_6437f380-2516-4931-8796-3feb059e9771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_AcceleratedShareRepurchaseAgreementsMember_3d2f535c-930a-4f86-a3d5-9f9363a7be77" xlink:href="dgx-20221231.xsd#dgx_AcceleratedShareRepurchaseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesDateDomain_6437f380-2516-4931-8796-3feb059e9771" xlink:to="loc_dgx_AcceleratedShareRepurchaseAgreementsMember_3d2f535c-930a-4f86-a3d5-9f9363a7be77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ScheduleOfShareholdersEquityLineItems_4b7a2982-00a6-41b1-a39a-1e2ef7162af0" xlink:href="dgx-20221231.xsd#dgx_ScheduleOfShareholdersEquityLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_ScheduleOfShareholdersEquityTable_12cbb3e9-faaa-4d15-9a47-7018fcac7c6e" xlink:to="loc_dgx_ScheduleOfShareholdersEquityLineItems_4b7a2982-00a6-41b1-a39a-1e2ef7162af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_483bfa41-31f1-4bd7-a0e5-dd338c663d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_4b7a2982-00a6-41b1-a39a-1e2ef7162af0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_483bfa41-31f1-4bd7-a0e5-dd338c663d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_be0c9e9c-c652-4f45-85cd-76796b13aa1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_4b7a2982-00a6-41b1-a39a-1e2ef7162af0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_be0c9e9c-c652-4f45-85cd-76796b13aa1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_46e42536-3b4c-4a00-bf12-387d9e29675b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_4b7a2982-00a6-41b1-a39a-1e2ef7162af0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_46e42536-3b4c-4a00-bf12-387d9e29675b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_76d8bde6-e8c1-4aff-9d3d-66bc3274141e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_4b7a2982-00a6-41b1-a39a-1e2ef7162af0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_76d8bde6-e8c1-4aff-9d3d-66bc3274141e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_ae7e5f68-86ee-45d8-b3e8-01c12b943299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_4b7a2982-00a6-41b1-a39a-1e2ef7162af0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_ae7e5f68-86ee-45d8-b3e8-01c12b943299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_EquityMethodInvestmentOwnershipPercentDisposedOf_d9dbace1-41d0-4906-96d7-5ba933943cd5" xlink:href="dgx-20221231.xsd#dgx_EquityMethodInvestmentOwnershipPercentDisposedOf"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_4b7a2982-00a6-41b1-a39a-1e2ef7162af0" xlink:to="loc_dgx_EquityMethodInvestmentOwnershipPercentDisposedOf_d9dbace1-41d0-4906-96d7-5ba933943cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_d91fa99f-2f0e-451d-830e-40bc60253fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_4b7a2982-00a6-41b1-a39a-1e2ef7162af0" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_d91fa99f-2f0e-451d-830e-40bc60253fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_17664e56-7392-48f6-8ef2-0b27447c58ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_4b7a2982-00a6-41b1-a39a-1e2ef7162af0" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_17664e56-7392-48f6-8ef2-0b27447c58ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_IncreaseDecreaseinCommonStockDividendsDeclaredasPercent_33547436-5931-4b01-b973-dde1a26a5749" xlink:href="dgx-20221231.xsd#dgx_IncreaseDecreaseinCommonStockDividendsDeclaredasPercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_4b7a2982-00a6-41b1-a39a-1e2ef7162af0" xlink:to="loc_dgx_IncreaseDecreaseinCommonStockDividendsDeclaredasPercent_33547436-5931-4b01-b973-dde1a26a5749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_StockRepurchaseProgramAdditionalAmountAuthorized_258530e3-304e-41b0-b200-c760acb8bd2f" xlink:href="dgx-20221231.xsd#dgx_StockRepurchaseProgramAdditionalAmountAuthorized"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_4b7a2982-00a6-41b1-a39a-1e2ef7162af0" xlink:to="loc_dgx_StockRepurchaseProgramAdditionalAmountAuthorized_258530e3-304e-41b0-b200-c760acb8bd2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_3d7eb57b-2176-4570-9f9c-eecb4cc2e9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_4b7a2982-00a6-41b1-a39a-1e2ef7162af0" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_3d7eb57b-2176-4570-9f9c-eecb4cc2e9f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_b2062c19-846e-414d-bcb4-ef2e627a16de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_4b7a2982-00a6-41b1-a39a-1e2ef7162af0" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_b2062c19-846e-414d-bcb4-ef2e627a16de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_ea5c3824-0398-4898-b594-08273597d92f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_4b7a2982-00a6-41b1-a39a-1e2ef7162af0" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_ea5c3824-0398-4898-b594-08273597d92f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_AcceleratedShareRepurchasesPayment_f2610bdd-a3d0-49dc-bef9-49a6526e063e" xlink:href="dgx-20221231.xsd#dgx_AcceleratedShareRepurchasesPayment"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_4b7a2982-00a6-41b1-a39a-1e2ef7162af0" xlink:to="loc_dgx_AcceleratedShareRepurchasesPayment_f2610bdd-a3d0-49dc-bef9-49a6526e063e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_c994e805-2686-480e-9dd5-df85dabeab3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_4b7a2982-00a6-41b1-a39a-1e2ef7162af0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_c994e805-2686-480e-9dd5-df85dabeab3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_6c6b69cd-9381-4fdc-bf12-592f0216e4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_4b7a2982-00a6-41b1-a39a-1e2ef7162af0" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_6c6b69cd-9381-4fdc-bf12-592f0216e4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_498a56a0-2f7c-4d35-b116-72de22debe5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_4b7a2982-00a6-41b1-a39a-1e2ef7162af0" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_498a56a0-2f7c-4d35-b116-72de22debe5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_0015e40c-248b-40b3-adc1-a86e18c1bdcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_4b7a2982-00a6-41b1-a39a-1e2ef7162af0" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_0015e40c-248b-40b3-adc1-a86e18c1bdcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTComponentsofAccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTComponentsofAccumulatedOtherComprehensiveLossIncomeDetails"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTComponentsofAccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e4931728-0536-4d1f-ab81-a3983f99ec6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ScheduleOfShareholdersEquityTable_a9c58455-653c-45f8-8f0c-756a7cf814a0" xlink:href="dgx-20221231.xsd#dgx_ScheduleOfShareholdersEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e4931728-0536-4d1f-ab81-a3983f99ec6b" xlink:to="loc_dgx_ScheduleOfShareholdersEquityTable_a9c58455-653c-45f8-8f0c-756a7cf814a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_51232ce5-6940-4f22-822d-00df6eb11dea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_ScheduleOfShareholdersEquityTable_a9c58455-653c-45f8-8f0c-756a7cf814a0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_51232ce5-6940-4f22-822d-00df6eb11dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ded714e2-cecb-4f25-88e9-8afa5094de43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_51232ce5-6940-4f22-822d-00df6eb11dea" xlink:to="loc_us-gaap_EquityComponentDomain_ded714e2-cecb-4f25-88e9-8afa5094de43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_2378c600-4839-448b-93ef-69c9a5ed89c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ded714e2-cecb-4f25-88e9-8afa5094de43" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_2378c600-4839-448b-93ef-69c9a5ed89c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_f6b9ffa3-faa9-4f71-bbf1-902ea495b7c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ded714e2-cecb-4f25-88e9-8afa5094de43" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_f6b9ffa3-faa9-4f71-bbf1-902ea495b7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_363d2226-fd55-48c5-8ede-779b0305c60f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ded714e2-cecb-4f25-88e9-8afa5094de43" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_363d2226-fd55-48c5-8ede-779b0305c60f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_OtherEquityComponentsMember_7712a9c5-cc82-4845-951c-77c5ccca9850" xlink:href="dgx-20221231.xsd#dgx_OtherEquityComponentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ded714e2-cecb-4f25-88e9-8afa5094de43" xlink:to="loc_dgx_OtherEquityComponentsMember_7712a9c5-cc82-4845-951c-77c5ccca9850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_861466e0-f259-448d-8507-fbc84d5e53c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ded714e2-cecb-4f25-88e9-8afa5094de43" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_861466e0-f259-448d-8507-fbc84d5e53c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ScheduleOfShareholdersEquityLineItems_9a85cfcc-abcf-44e0-9df8-8d25a42c2958" xlink:href="dgx-20221231.xsd#dgx_ScheduleOfShareholdersEquityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_ScheduleOfShareholdersEquityTable_a9c58455-653c-45f8-8f0c-756a7cf814a0" xlink:to="loc_dgx_ScheduleOfShareholdersEquityLineItems_9a85cfcc-abcf-44e0-9df8-8d25a42c2958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0c7a3bd7-5087-4d82-85c1-ec6beea27d43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_9a85cfcc-abcf-44e0-9df8-8d25a42c2958" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0c7a3bd7-5087-4d82-85c1-ec6beea27d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_87823d6e-b197-4898-bcb0-9c9bcec350f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_9a85cfcc-abcf-44e0-9df8-8d25a42c2958" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_87823d6e-b197-4898-bcb0-9c9bcec350f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_f0c6e5be-b2d3-4b6e-ba57-41cefaacb1b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_9a85cfcc-abcf-44e0-9df8-8d25a42c2958" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_f0c6e5be-b2d3-4b6e-ba57-41cefaacb1b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_622395fa-cb04-44bb-9438-4027adcd341f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_9a85cfcc-abcf-44e0-9df8-8d25a42c2958" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_622395fa-cb04-44bb-9438-4027adcd341f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e4a70b3d-2f13-44b7-a4a3-cfa8343e4021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dgx_ScheduleOfShareholdersEquityLineItems_9a85cfcc-abcf-44e0-9df8-8d25a42c2958" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e4a70b3d-2f13-44b7-a4a3-cfa8343e4021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeandNonemployeeDirectorsStockOwnershipProgramsDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeandNonemployeeDirectorsStockOwnershipProgramsDetails"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeandNonemployeeDirectorsStockOwnershipProgramsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9bd270e6-b5b2-47d3-aad3-7c542ebb9c79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3612cd74-65a3-45ac-a9f6-5dafeb35b632" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9bd270e6-b5b2-47d3-aad3-7c542ebb9c79" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3612cd74-65a3-45ac-a9f6-5dafeb35b632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5f08cfac-2f94-4a87-9705-f3c12c795b83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3612cd74-65a3-45ac-a9f6-5dafeb35b632" xlink:to="loc_us-gaap_AwardTypeAxis_5f08cfac-2f94-4a87-9705-f3c12c795b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1c6b7bbd-713b-4e95-8a43-b95642a855cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5f08cfac-2f94-4a87-9705-f3c12c795b83" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1c6b7bbd-713b-4e95-8a43-b95642a855cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_EmployeeLongTermIncentivePlanEltipMember_b878b8de-5224-4f10-8ea9-4e3f3f80e35a" xlink:href="dgx-20221231.xsd#dgx_EmployeeLongTermIncentivePlanEltipMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1c6b7bbd-713b-4e95-8a43-b95642a855cc" xlink:to="loc_dgx_EmployeeLongTermIncentivePlanEltipMember_b878b8de-5224-4f10-8ea9-4e3f3f80e35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_RestatedDirectorLongTermIncentivePlanDltipMember_d9619e72-cfc7-41bc-96a8-442c524da6eb" xlink:href="dgx-20221231.xsd#dgx_RestatedDirectorLongTermIncentivePlanDltipMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1c6b7bbd-713b-4e95-8a43-b95642a855cc" xlink:to="loc_dgx_RestatedDirectorLongTermIncentivePlanDltipMember_d9619e72-cfc7-41bc-96a8-442c524da6eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_fb2023fc-501f-4d2b-bae8-d4fbe9243a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1c6b7bbd-713b-4e95-8a43-b95642a855cc" xlink:to="loc_us-gaap_StockOptionMember_fb2023fc-501f-4d2b-bae8-d4fbe9243a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c20dd585-4554-4eaa-99fc-2588ae3c88ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3612cd74-65a3-45ac-a9f6-5dafeb35b632" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c20dd585-4554-4eaa-99fc-2588ae3c88ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_ContractualLifeOfStockOptionsAndOtherAwardsUnderSharedBasedCompensationPlans_3d02b9af-46e7-4fe7-8856-cac052010bf3" xlink:href="dgx-20221231.xsd#dgx_ContractualLifeOfStockOptionsAndOtherAwardsUnderSharedBasedCompensationPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c20dd585-4554-4eaa-99fc-2588ae3c88ab" xlink:to="loc_dgx_ContractualLifeOfStockOptionsAndOtherAwardsUnderSharedBasedCompensationPlans_3d02b9af-46e7-4fe7-8856-cac052010bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_22766445-d5d8-42a8-ba56-c00af95c2d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c20dd585-4554-4eaa-99fc-2588ae3c88ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_22766445-d5d8-42a8-ba56-c00af95c2d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_34b49782-b77a-4e31-8e48-392148f78e97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c20dd585-4554-4eaa-99fc-2588ae3c88ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_34b49782-b77a-4e31-8e48-392148f78e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3a1df6bd-b289-4884-bacb-3c651b63cbb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c20dd585-4554-4eaa-99fc-2588ae3c88ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3a1df6bd-b289-4884-bacb-3c651b63cbb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSWeightedAverageAssumptionsUsedinValuingOptionsGrantedDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#STOCKOWNERSHIPANDCOMPENSATIONPLANSWeightedAverageAssumptionsUsedinValuingOptionsGrantedDetails"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSWeightedAverageAssumptionsUsedinValuingOptionsGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c305c6e1-a35e-4416-a1c1-a19b09faa854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b0b82b68-6e41-4d7d-87b7-fcaaf7435ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c305c6e1-a35e-4416-a1c1-a19b09faa854" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b0b82b68-6e41-4d7d-87b7-fcaaf7435ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0c5992de-f200-4b85-8449-485cb8e77a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b0b82b68-6e41-4d7d-87b7-fcaaf7435ba1" xlink:to="loc_us-gaap_AwardTypeAxis_0c5992de-f200-4b85-8449-485cb8e77a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e3d6ea7-d938-47d7-bfb4-cfdb7bcdd332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0c5992de-f200-4b85-8449-485cb8e77a3d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e3d6ea7-d938-47d7-bfb4-cfdb7bcdd332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_PerformanceShareUnitsWithMarketBasedRelativeTSRGoalMember_6a43c024-b0df-4122-9d0b-87bf5243339c" xlink:href="dgx-20221231.xsd#dgx_PerformanceShareUnitsWithMarketBasedRelativeTSRGoalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e3d6ea7-d938-47d7-bfb4-cfdb7bcdd332" xlink:to="loc_dgx_PerformanceShareUnitsWithMarketBasedRelativeTSRGoalMember_6a43c024-b0df-4122-9d0b-87bf5243339c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2cfdb2cc-7219-4842-bf37-fdec4e954868" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b0b82b68-6e41-4d7d-87b7-fcaaf7435ba1" xlink:to="loc_srt_RangeAxis_2cfdb2cc-7219-4842-bf37-fdec4e954868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8697a789-f4a9-4134-af0b-d0822b03841f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2cfdb2cc-7219-4842-bf37-fdec4e954868" xlink:to="loc_srt_RangeMember_8697a789-f4a9-4134-af0b-d0822b03841f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ef9b33a3-07bb-4173-8b48-e388686bea06" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8697a789-f4a9-4134-af0b-d0822b03841f" xlink:to="loc_srt_MinimumMember_ef9b33a3-07bb-4173-8b48-e388686bea06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f2134b16-7923-468c-a079-88bf23b7ba87" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8697a789-f4a9-4134-af0b-d0822b03841f" xlink:to="loc_srt_MaximumMember_f2134b16-7923-468c-a079-88bf23b7ba87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93099684-3985-4618-9166-738ed3550867" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b0b82b68-6e41-4d7d-87b7-fcaaf7435ba1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93099684-3985-4618-9166-738ed3550867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_665d422d-7cd7-4885-9f34-ee1c7eed57c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93099684-3985-4618-9166-738ed3550867" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_665d422d-7cd7-4885-9f34-ee1c7eed57c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a9aa8957-ae03-4628-b0b8-4a6602b1b0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93099684-3985-4618-9166-738ed3550867" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a9aa8957-ae03-4628-b0b8-4a6602b1b0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3546c254-0539-400a-bf48-48f56b39d678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93099684-3985-4618-9166-738ed3550867" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3546c254-0539-400a-bf48-48f56b39d678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_22fc9c4e-36fa-45ea-bc02-0c0577898167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93099684-3985-4618-9166-738ed3550867" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_22fc9c4e-36fa-45ea-bc02-0c0577898167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4c00e09f-4c95-4b24-af23-a7060fd698cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93099684-3985-4618-9166-738ed3550867" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4c00e09f-4c95-4b24-af23-a7060fd698cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9fcae365-9458-41d9-95a1-0deae5757df8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93099684-3985-4618-9166-738ed3550867" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9fcae365-9458-41d9-95a1-0deae5757df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTransactionsUnderStockOptionPlansDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#STOCKOWNERSHIPANDCOMPENSATIONPLANSTransactionsUnderStockOptionPlansDetails"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTransactionsUnderStockOptionPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fa133c0b-e28b-4f40-a2bc-4ebcceb66982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1252dfa9-0ba8-401f-905f-b4099a84a1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fa133c0b-e28b-4f40-a2bc-4ebcceb66982" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1252dfa9-0ba8-401f-905f-b4099a84a1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_47d95c23-a864-4a04-8870-edee11695726" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1252dfa9-0ba8-401f-905f-b4099a84a1b8" xlink:to="loc_us-gaap_AwardTypeAxis_47d95c23-a864-4a04-8870-edee11695726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_303a9352-1153-49f8-be9a-57dc19d58683" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_47d95c23-a864-4a04-8870-edee11695726" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_303a9352-1153-49f8-be9a-57dc19d58683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_0fcd853c-dd16-43ce-ab27-e2d681604d68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_303a9352-1153-49f8-be9a-57dc19d58683" xlink:to="loc_us-gaap_StockOptionMember_0fcd853c-dd16-43ce-ab27-e2d681604d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0656569-8539-41d3-a0a1-fadb45ec9bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1252dfa9-0ba8-401f-905f-b4099a84a1b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0656569-8539-41d3-a0a1-fadb45ec9bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4af3f44f-b4a8-474d-9d48-53cdadb6dca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0656569-8539-41d3-a0a1-fadb45ec9bf4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4af3f44f-b4a8-474d-9d48-53cdadb6dca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_784ccbf3-e481-4d9e-b322-0ac24f74e013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4af3f44f-b4a8-474d-9d48-53cdadb6dca3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_784ccbf3-e481-4d9e-b322-0ac24f74e013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9a9b78db-8619-45c5-ada0-91c0dcd324f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4af3f44f-b4a8-474d-9d48-53cdadb6dca3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9a9b78db-8619-45c5-ada0-91c0dcd324f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_10617d7f-dc78-488a-a97b-8e32de9df8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4af3f44f-b4a8-474d-9d48-53cdadb6dca3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_10617d7f-dc78-488a-a97b-8e32de9df8a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_14c6b1e1-9f01-466b-b714-4a87ccd81485" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4af3f44f-b4a8-474d-9d48-53cdadb6dca3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_14c6b1e1-9f01-466b-b714-4a87ccd81485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7116d72e-9f41-4b57-b949-9293d39adddb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4af3f44f-b4a8-474d-9d48-53cdadb6dca3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7116d72e-9f41-4b57-b949-9293d39adddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d58baf33-341c-439e-81ac-9a23e147c4f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0656569-8539-41d3-a0a1-fadb45ec9bf4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d58baf33-341c-439e-81ac-9a23e147c4f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_36511d17-d8cc-4ef4-a597-de90672835bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d58baf33-341c-439e-81ac-9a23e147c4f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_36511d17-d8cc-4ef4-a597-de90672835bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_388c2d47-ed5c-46dd-bed0-0269633d0330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d58baf33-341c-439e-81ac-9a23e147c4f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_388c2d47-ed5c-46dd-bed0-0269633d0330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5d74b241-661c-49a0-85a6-25b8eae13a23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d58baf33-341c-439e-81ac-9a23e147c4f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5d74b241-661c-49a0-85a6-25b8eae13a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_88a66813-8306-42f4-a26c-811b8d0eb9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d58baf33-341c-439e-81ac-9a23e147c4f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_88a66813-8306-42f4-a26c-811b8d0eb9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_98cac151-f7da-4fef-b16e-194d48a0f46f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d58baf33-341c-439e-81ac-9a23e147c4f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_98cac151-f7da-4fef-b16e-194d48a0f46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_899071a5-3fc8-44fa-86ac-0780f37c79c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0656569-8539-41d3-a0a1-fadb45ec9bf4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_899071a5-3fc8-44fa-86ac-0780f37c79c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_538caeae-0afc-47f6-bc67-1b684938a6d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0656569-8539-41d3-a0a1-fadb45ec9bf4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_538caeae-0afc-47f6-bc67-1b684938a6d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9589ba11-fe9f-43da-9251-1434ae3d93bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0656569-8539-41d3-a0a1-fadb45ec9bf4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9589ba11-fe9f-43da-9251-1434ae3d93bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a02e41d6-fa50-46dd-8fa3-42f294543eca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0656569-8539-41d3-a0a1-fadb45ec9bf4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a02e41d6-fa50-46dd-8fa3-42f294543eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_adef63e7-ec4a-431a-9b38-8adf15045822" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0656569-8539-41d3-a0a1-fadb45ec9bf4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_adef63e7-ec4a-431a-9b38-8adf15045822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_00e2e84d-64e5-46bb-b348-2129e421f04b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0656569-8539-41d3-a0a1-fadb45ec9bf4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_00e2e84d-64e5-46bb-b348-2129e421f04b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_a835e92f-9720-458a-a178-6845cfb4230c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0656569-8539-41d3-a0a1-fadb45ec9bf4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_a835e92f-9720-458a-a178-6845cfb4230c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_8f37a4df-5e38-4543-b096-9233ad99e097" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0656569-8539-41d3-a0a1-fadb45ec9bf4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_8f37a4df-5e38-4543-b096-9233ad99e097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_b1bfacbd-2800-41dc-8fec-dd1c7ff5625c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0656569-8539-41d3-a0a1-fadb45ec9bf4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_b1bfacbd-2800-41dc-8fec-dd1c7ff5625c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_bdd4a565-e0dd-4e6c-852e-3cbc76f8ccf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0656569-8539-41d3-a0a1-fadb45ec9bf4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_bdd4a565-e0dd-4e6c-852e-3cbc76f8ccf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_4636ea19-ecb0-47a0-91c9-3cfa055aff48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0656569-8539-41d3-a0a1-fadb45ec9bf4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_4636ea19-ecb0-47a0-91c9-3cfa055aff48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_6ed4ef57-aeef-442f-b9fc-40fb3ad3a151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0656569-8539-41d3-a0a1-fadb45ec9bf4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_6ed4ef57-aeef-442f-b9fc-40fb3ad3a151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4c7a8468-9d33-4cf6-a181-b94b1f119f54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0656569-8539-41d3-a0a1-fadb45ec9bf4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4c7a8468-9d33-4cf6-a181-b94b1f119f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSActivitiesRelatedtoStockAwardsDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#STOCKOWNERSHIPANDCOMPENSATIONPLANSActivitiesRelatedtoStockAwardsDetails"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSActivitiesRelatedtoStockAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ca92cc48-ed75-41d4-953c-0ef65834a338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_074176c1-435b-4f9b-ab73-70fd92f97256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ca92cc48-ed75-41d4-953c-0ef65834a338" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_074176c1-435b-4f9b-ab73-70fd92f97256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f55cc7ed-e704-4f8b-adbf-16794d730936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_074176c1-435b-4f9b-ab73-70fd92f97256" xlink:to="loc_us-gaap_AwardTypeAxis_f55cc7ed-e704-4f8b-adbf-16794d730936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b625f74c-610e-4312-829f-14788d558047" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f55cc7ed-e704-4f8b-adbf-16794d730936" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b625f74c-610e-4312-829f-14788d558047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_StockAwardsMember_d3811e1a-37c4-47d7-9684-0505b04702df" xlink:href="dgx-20221231.xsd#dgx_StockAwardsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b625f74c-610e-4312-829f-14788d558047" xlink:to="loc_dgx_StockAwardsMember_d3811e1a-37c4-47d7-9684-0505b04702df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85be73fa-0e67-462f-949c-071f5c449813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_074176c1-435b-4f9b-ab73-70fd92f97256" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85be73fa-0e67-462f-949c-071f5c449813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4960e8a7-1814-4883-9777-d3ac1187b2a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85be73fa-0e67-462f-949c-071f5c449813" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4960e8a7-1814-4883-9777-d3ac1187b2a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_36b2e672-ff7f-4995-aa3b-246ce3cd5ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4960e8a7-1814-4883-9777-d3ac1187b2a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_36b2e672-ff7f-4995-aa3b-246ce3cd5ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3c3948c0-d99f-45cf-bb7e-88cb1949db9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4960e8a7-1814-4883-9777-d3ac1187b2a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3c3948c0-d99f-45cf-bb7e-88cb1949db9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7046dfc3-86ea-49c7-af26-bf2dedb3462a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4960e8a7-1814-4883-9777-d3ac1187b2a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7046dfc3-86ea-49c7-af26-bf2dedb3462a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_34038a5e-43bf-4c82-86d4-e7faa9363e96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4960e8a7-1814-4883-9777-d3ac1187b2a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_34038a5e-43bf-4c82-86d4-e7faa9363e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f045c0cc-c899-4833-aeaf-b96518fc9bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4960e8a7-1814-4883-9777-d3ac1187b2a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f045c0cc-c899-4833-aeaf-b96518fc9bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8d36044b-e68d-4f7d-8287-377b76224622" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85be73fa-0e67-462f-949c-071f5c449813" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8d36044b-e68d-4f7d-8287-377b76224622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ccd88587-f033-41c0-b6fa-63f217801ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8d36044b-e68d-4f7d-8287-377b76224622" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ccd88587-f033-41c0-b6fa-63f217801ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6916911c-979a-4b9a-8383-ff8fef09ed9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8d36044b-e68d-4f7d-8287-377b76224622" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6916911c-979a-4b9a-8383-ff8fef09ed9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_40e43517-c13c-4487-a7e9-a7400b040057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8d36044b-e68d-4f7d-8287-377b76224622" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_40e43517-c13c-4487-a7e9-a7400b040057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7395c990-be30-4137-803c-c722946cc466" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8d36044b-e68d-4f7d-8287-377b76224622" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7395c990-be30-4137-803c-c722946cc466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_52286e2e-103d-43d6-8f15-5369195c632c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8d36044b-e68d-4f7d-8287-377b76224622" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_52286e2e-103d-43d6-8f15-5369195c632c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6822ebae-3b13-462a-87e9-f4bddd4f2884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85be73fa-0e67-462f-949c-071f5c449813" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6822ebae-3b13-462a-87e9-f4bddd4f2884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d7323134-c084-473e-aa37-8ae7829cdbe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85be73fa-0e67-462f-949c-071f5c449813" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d7323134-c084-473e-aa37-8ae7829cdbe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_17029f4a-2aa6-4fa2-9223-6647dd070311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85be73fa-0e67-462f-949c-071f5c449813" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_17029f4a-2aa6-4fa2-9223-6647dd070311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_ddcad9e8-6105-45cb-94e0-2507c2863226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85be73fa-0e67-462f-949c-071f5c449813" xlink:to="loc_us-gaap_ShareBasedCompensation_ddcad9e8-6105-45cb-94e0-2507c2863226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_40ff1e4e-fc25-49b7-883d-88bcddea229e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85be73fa-0e67-462f-949c-071f5c449813" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_40ff1e4e-fc25-49b7-883d-88bcddea229e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_Sharebasedcompensationexcesstaxbenefitamount_d92900c5-a2a1-40cc-8ce6-5511f3074a33" xlink:href="dgx-20221231.xsd#dgx_Sharebasedcompensationexcesstaxbenefitamount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85be73fa-0e67-462f-949c-071f5c449813" xlink:to="loc_dgx_Sharebasedcompensationexcesstaxbenefitamount_d92900c5-a2a1-40cc-8ce6-5511f3074a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeStockPurchasePlanandDefinedContributionPlansDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeStockPurchasePlanandDefinedContributionPlansDetails"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeStockPurchasePlanandDefinedContributionPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_44fec73b-39c5-4431-abc9-579392d1cd77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ee6d89d6-6a20-4046-90b0-5addcddbc954" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_44fec73b-39c5-4431-abc9-579392d1cd77" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ee6d89d6-6a20-4046-90b0-5addcddbc954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_416b3ab5-ebb8-4537-b795-fc8307ecc84c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ee6d89d6-6a20-4046-90b0-5addcddbc954" xlink:to="loc_us-gaap_AwardTypeAxis_416b3ab5-ebb8-4537-b795-fc8307ecc84c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f7743c79-9fff-47c0-aaf5-e467b7131a65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_416b3ab5-ebb8-4537-b795-fc8307ecc84c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f7743c79-9fff-47c0-aaf5-e467b7131a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_da8ea110-3c17-4778-ab0d-0a147a1c623d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f7743c79-9fff-47c0-aaf5-e467b7131a65" xlink:to="loc_us-gaap_EmployeeStockMember_da8ea110-3c17-4778-ab0d-0a147a1c623d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_050feb49-9ec6-4268-913e-041af94394e7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ee6d89d6-6a20-4046-90b0-5addcddbc954" xlink:to="loc_srt_RangeAxis_050feb49-9ec6-4268-913e-041af94394e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b1152f46-3093-4ffd-861f-4fd3ec9493fe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_050feb49-9ec6-4268-913e-041af94394e7" xlink:to="loc_srt_RangeMember_b1152f46-3093-4ffd-861f-4fd3ec9493fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b7727d0a-b6fd-447f-95dc-56bc60c4b70f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b1152f46-3093-4ffd-861f-4fd3ec9493fe" xlink:to="loc_srt_MaximumMember_b7727d0a-b6fd-447f-95dc-56bc60c4b70f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c05c811-e6d5-4b66-a0e5-7eb042777bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ee6d89d6-6a20-4046-90b0-5addcddbc954" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c05c811-e6d5-4b66-a0e5-7eb042777bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_61bf3094-b26b-4fcd-97d0-b2150830db50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c05c811-e6d5-4b66-a0e5-7eb042777bb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_61bf3094-b26b-4fcd-97d0-b2150830db50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_MarketPriceOfCompanyStockIssuedAtDiscountUnderEspp_7b87b97d-ea55-4ec8-8e3f-93e81e0bc6a6" xlink:href="dgx-20221231.xsd#dgx_MarketPriceOfCompanyStockIssuedAtDiscountUnderEspp"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c05c811-e6d5-4b66-a0e5-7eb042777bb4" xlink:to="loc_dgx_MarketPriceOfCompanyStockIssuedAtDiscountUnderEspp_7b87b97d-ea55-4ec8-8e3f-93e81e0bc6a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_848fca2b-8a28-489a-9287-0edc755f4f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c05c811-e6d5-4b66-a0e5-7eb042777bb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_848fca2b-8a28-489a-9287-0edc755f4f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a67e4b36-df4c-4e7f-974c-67fd4a7ca2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c05c811-e6d5-4b66-a0e5-7eb042777bb4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a67e4b36-df4c-4e7f-974c-67fd4a7ca2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_993e9b97-3d24-4731-9dad-78144ae540de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c05c811-e6d5-4b66-a0e5-7eb042777bb4" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_993e9b97-3d24-4731-9dad-78144ae540de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_33889ec4-7038-40e0-b5e8-e30bf4a9f2f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c05c811-e6d5-4b66-a0e5-7eb042777bb4" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_33889ec4-7038-40e0-b5e8-e30bf4a9f2f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSSupplementalDeferredCompensationPlansDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#STOCKOWNERSHIPANDCOMPENSATIONPLANSSupplementalDeferredCompensationPlansDetails"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSSupplementalDeferredCompensationPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7fb711dd-e945-459b-b7de-4cdb04ff4ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_ba742a73-aeb4-4f24-8613-2bff6e56ce69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7fb711dd-e945-459b-b7de-4cdb04ff4ed5" xlink:to="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_ba742a73-aeb4-4f24-8613-2bff6e56ce69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_83d4957e-ffb0-4279-a774-6541baf3146e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_ba742a73-aeb4-4f24-8613-2bff6e56ce69" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_83d4957e-ffb0-4279-a774-6541baf3146e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_b8bfbcd5-4868-4b57-bd15-fe51ff4d5656" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_83d4957e-ffb0-4279-a774-6541baf3146e" xlink:to="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_b8bfbcd5-4868-4b57-bd15-fe51ff4d5656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_SupplementalDeferredCompensationPlanMember_1884f8e9-9b07-43cb-afc4-d93ab8c68441" xlink:href="dgx-20221231.xsd#dgx_SupplementalDeferredCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_b8bfbcd5-4868-4b57-bd15-fe51ff4d5656" xlink:to="loc_dgx_SupplementalDeferredCompensationPlanMember_1884f8e9-9b07-43cb-afc4-d93ab8c68441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_SdcpIiMember_0b0a4eea-cfed-4045-80c8-a4544dd8aeeb" xlink:href="dgx-20221231.xsd#dgx_SdcpIiMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_b8bfbcd5-4868-4b57-bd15-fe51ff4d5656" xlink:to="loc_dgx_SdcpIiMember_0b0a4eea-cfed-4045-80c8-a4544dd8aeeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_15a2de6f-d9dc-4ad5-8fef-44323bc2bfbc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_ba742a73-aeb4-4f24-8613-2bff6e56ce69" xlink:to="loc_srt_RangeAxis_15a2de6f-d9dc-4ad5-8fef-44323bc2bfbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9df15ef2-2117-425f-8da1-29024631de75" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_15a2de6f-d9dc-4ad5-8fef-44323bc2bfbc" xlink:to="loc_srt_RangeMember_9df15ef2-2117-425f-8da1-29024631de75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cbe46403-b1f0-4164-914f-a45cd46cb6a2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9df15ef2-2117-425f-8da1-29024631de75" xlink:to="loc_srt_MaximumMember_cbe46403-b1f0-4164-914f-a45cd46cb6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_25fb0b53-8b09-4a8c-8f50-3330baf4dcd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_ba742a73-aeb4-4f24-8613-2bff6e56ce69" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_25fb0b53-8b09-4a8c-8f50-3330baf4dcd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_SupplementalDeferredCompensationPlanSalaryDeferral_a084373f-e369-4f1e-8f10-97875f55f3aa" xlink:href="dgx-20221231.xsd#dgx_SupplementalDeferredCompensationPlanSalaryDeferral"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_25fb0b53-8b09-4a8c-8f50-3330baf4dcd1" xlink:to="loc_dgx_SupplementalDeferredCompensationPlanSalaryDeferral_a084373f-e369-4f1e-8f10-97875f55f3aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_SupplementalDeferredCompensationPlanVariableIncentiveCompensationDeferral_b4936054-a46a-49bf-a043-3221cc568aef" xlink:href="dgx-20221231.xsd#dgx_SupplementalDeferredCompensationPlanVariableIncentiveCompensationDeferral"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_25fb0b53-8b09-4a8c-8f50-3330baf4dcd1" xlink:to="loc_dgx_SupplementalDeferredCompensationPlanVariableIncentiveCompensationDeferral_b4936054-a46a-49bf-a043-3221cc568aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_107c2f15-9ece-47e1-bb7a-ec3c6adc70c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_25fb0b53-8b09-4a8c-8f50-3330baf4dcd1" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_107c2f15-9ece-47e1-bb7a-ec3c6adc70c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability_1bdd9410-b21f-477c-88b2-7677f40301e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_25fb0b53-8b09-4a8c-8f50-3330baf4dcd1" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability_1bdd9410-b21f-477c-88b2-7677f40301e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_FundsinatrustpertainingtoallparticipantdeferralsandcompanymatchingamountsrelatedtotheSDCP_b09e8b09-9fb5-4377-a651-82fe400ceea0" xlink:href="dgx-20221231.xsd#dgx_FundsinatrustpertainingtoallparticipantdeferralsandcompanymatchingamountsrelatedtotheSDCP"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_25fb0b53-8b09-4a8c-8f50-3330baf4dcd1" xlink:to="loc_dgx_FundsinatrustpertainingtoallparticipantdeferralsandcompanymatchingamountsrelatedtotheSDCP_b09e8b09-9fb5-4377-a651-82fe400ceea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_5e85d3ff-797b-4b40-a080-9490a0b38f73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_25fb0b53-8b09-4a8c-8f50-3330baf4dcd1" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_5e85d3ff-797b-4b40-a080-9490a0b38f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1_90b86588-5edf-4e43-a56a-e2918ed89be7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_25fb0b53-8b09-4a8c-8f50-3330baf4dcd1" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1_90b86588-5edf-4e43-a56a-e2918ed89be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_SdcpIiGradedVestingPercentage_38b5774a-4dd9-4987-8fea-d4f6ade0ca17" xlink:href="dgx-20221231.xsd#dgx_SdcpIiGradedVestingPercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_25fb0b53-8b09-4a8c-8f50-3330baf4dcd1" xlink:to="loc_dgx_SdcpIiGradedVestingPercentage_38b5774a-4dd9-4987-8fea-d4f6ade0ca17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashSurrenderValueFairValueDisclosure_c77f0364-2904-4473-9036-f0b3bf3279aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashSurrenderValueFairValueDisclosure"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_25fb0b53-8b09-4a8c-8f50-3330baf4dcd1" xlink:to="loc_us-gaap_CashSurrenderValueFairValueDisclosure_c77f0364-2904-4473-9036-f0b3bf3279aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6c59e304-9dbe-4f2d-ab33-9c7486b6740a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d4adc829-231b-45d3-96f9-5cf32cedc79f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6c59e304-9dbe-4f2d-ab33-9c7486b6740a" xlink:to="loc_us-gaap_DebtInstrumentTable_d4adc829-231b-45d3-96f9-5cf32cedc79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_df48838c-d80f-47c7-8748-2be5f37deeb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d4adc829-231b-45d3-96f9-5cf32cedc79f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_df48838c-d80f-47c7-8748-2be5f37deeb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_92afde79-9e86-467c-82e4-07e487fb7baa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_df48838c-d80f-47c7-8748-2be5f37deeb0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_92afde79-9e86-467c-82e4-07e487fb7baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_f400d5c6-4072-410c-90de-27079b456901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_92afde79-9e86-467c-82e4-07e487fb7baa" xlink:to="loc_us-gaap_SecuredDebtMember_f400d5c6-4072-410c-90de-27079b456901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_247578af-74de-4581-97ee-856fd7dd847b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d4adc829-231b-45d3-96f9-5cf32cedc79f" xlink:to="loc_us-gaap_CreditFacilityAxis_247578af-74de-4581-97ee-856fd7dd847b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_1d43d6d2-efc9-471c-bc88-af08e2687961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_247578af-74de-4581-97ee-856fd7dd847b" xlink:to="loc_us-gaap_CreditFacilityDomain_1d43d6d2-efc9-471c-bc88-af08e2687961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_28ed6d30-f3dc-488f-854e-6d31fde929e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_1d43d6d2-efc9-471c-bc88-af08e2687961" xlink:to="loc_us-gaap_LetterOfCreditMember_28ed6d30-f3dc-488f-854e-6d31fde929e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_50afece9-279a-4e08-8cc0-12acc38883b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d4adc829-231b-45d3-96f9-5cf32cedc79f" xlink:to="loc_us-gaap_DebtInstrumentAxis_50afece9-279a-4e08-8cc0-12acc38883b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ad127e4c-4572-4173-b4c6-10b792c9b46f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_50afece9-279a-4e08-8cc0-12acc38883b8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ad127e4c-4572-4173-b4c6-10b792c9b46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_48fc5211-9aed-4f42-8f3c-de27b197e426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ad127e4c-4572-4173-b4c6-10b792c9b46f" xlink:to="loc_us-gaap_LetterOfCreditMember_48fc5211-9aed-4f42-8f3c-de27b197e426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e99c8010-5eec-4fc9-83c0-b6187a6baada" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d4adc829-231b-45d3-96f9-5cf32cedc79f" xlink:to="loc_us-gaap_DebtInstrumentLineItems_e99c8010-5eec-4fc9-83c0-b6187a6baada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_01c078b8-1c51-4e10-ae33-b2c584a7f1c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e99c8010-5eec-4fc9-83c0-b6187a6baada" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_01c078b8-1c51-4e10-ae33-b2c584a7f1c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_eb3e77bf-a816-4be3-982c-c941c55b440a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e99c8010-5eec-4fc9-83c0-b6187a6baada" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_eb3e77bf-a816-4be3-982c-c941c55b440a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_0c74c8e2-c452-4e41-b2e3-aa03f2bc830a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e99c8010-5eec-4fc9-83c0-b6187a6baada" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_0c74c8e2-c452-4e41-b2e3-aa03f2bc830a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary_da4ad286-fd0c-430c-9aae-6cfc3c898643" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e99c8010-5eec-4fc9-83c0-b6187a6baada" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary_da4ad286-fd0c-430c-9aae-6cfc3c898643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_UnrecordedUnconditionalPurchaseObligationDuewithinTwoandThreeYears_98519090-66fb-41fa-822c-7d7d56e3fcb3" xlink:href="dgx-20221231.xsd#dgx_UnrecordedUnconditionalPurchaseObligationDuewithinTwoandThreeYears"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e99c8010-5eec-4fc9-83c0-b6187a6baada" xlink:to="loc_dgx_UnrecordedUnconditionalPurchaseObligationDuewithinTwoandThreeYears_98519090-66fb-41fa-822c-7d7d56e3fcb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_AgreementtoOutsourceBillingandCollectionFunction_a444984f-1a91-45ff-a1cc-bd635198cba5" xlink:href="dgx-20221231.xsd#dgx_AgreementtoOutsourceBillingandCollectionFunction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e99c8010-5eec-4fc9-83c0-b6187a6baada" xlink:to="loc_dgx_AgreementtoOutsourceBillingandCollectionFunction_a444984f-1a91-45ff-a1cc-bd635198cba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_RemainingTermsofContingentLeaseObligationsMaximum_3ee9f294-5d2f-4d74-9b7d-f2560ceab1d8" xlink:href="dgx-20221231.xsd#dgx_RemainingTermsofContingentLeaseObligationsMaximum"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e99c8010-5eec-4fc9-83c0-b6187a6baada" xlink:to="loc_dgx_RemainingTermsofContingentLeaseObligationsMaximum_3ee9f294-5d2f-4d74-9b7d-f2560ceab1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_b605e710-fe5f-468a-ba16-105eec28197f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e99c8010-5eec-4fc9-83c0-b6187a6baada" xlink:to="loc_us-gaap_LitigationReserve_b605e710-fe5f-468a-ba16-105eec28197f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscounted_b7007775-5ab4-4f95-b262-22d9bae59bac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscounted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e99c8010-5eec-4fc9-83c0-b6187a6baada" xlink:to="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscounted_b7007775-5ab4-4f95-b262-22d9bae59bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#BUSINESSSEGMENTINFORMATIONDetails"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_9830f55a-e73f-4de2-883d-d81b8b56b108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2b1b31f8-17df-48d0-877e-81342c9d41e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_9830f55a-e73f-4de2-883d-d81b8b56b108" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2b1b31f8-17df-48d0-877e-81342c9d41e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b7166346-0891-47ce-8056-18be2cfa29cb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2b1b31f8-17df-48d0-877e-81342c9d41e1" xlink:to="loc_srt_RangeAxis_b7166346-0891-47ce-8056-18be2cfa29cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_db82f674-0c6f-4cb8-ad9d-ef0819fe1693" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b7166346-0891-47ce-8056-18be2cfa29cb" xlink:to="loc_srt_RangeMember_db82f674-0c6f-4cb8-ad9d-ef0819fe1693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_876e2f9c-2412-460b-9b53-8ca089df634b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_db82f674-0c6f-4cb8-ad9d-ef0819fe1693" xlink:to="loc_srt_MinimumMember_876e2f9c-2412-460b-9b53-8ca089df634b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a4e7a1e6-44de-4205-9f9a-dab080f4d01e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2b1b31f8-17df-48d0-877e-81342c9d41e1" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a4e7a1e6-44de-4205-9f9a-dab080f4d01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2b3f6d79-5b67-4210-9be2-25e9a990df46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a4e7a1e6-44de-4205-9f9a-dab080f4d01e" xlink:to="loc_us-gaap_SegmentDomain_2b3f6d79-5b67-4210-9be2-25e9a990df46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_DiagnosticInformationServicesBusinessMember_e9a9dc8a-a9ad-4c58-b3df-ffd8db640e6d" xlink:href="dgx-20221231.xsd#dgx_DiagnosticInformationServicesBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2b3f6d79-5b67-4210-9be2-25e9a990df46" xlink:to="loc_dgx_DiagnosticInformationServicesBusinessMember_e9a9dc8a-a9ad-4c58-b3df-ffd8db640e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_de33b576-613e-48e2-835d-73103bfe80bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2b3f6d79-5b67-4210-9be2-25e9a990df46" xlink:to="loc_us-gaap_AllOtherSegmentsMember_de33b576-613e-48e2-835d-73103bfe80bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateMember_b198a912-ae59-4c34-bb58-15935a131005" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2b3f6d79-5b67-4210-9be2-25e9a990df46" xlink:to="loc_us-gaap_CorporateMember_b198a912-ae59-4c34-bb58-15935a131005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c0430620-50e6-4586-b931-12447778be1f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2b1b31f8-17df-48d0-877e-81342c9d41e1" xlink:to="loc_srt_ProductOrServiceAxis_c0430620-50e6-4586-b931-12447778be1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2fa800f3-6614-4eea-bab4-cd432550bebb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c0430620-50e6-4586-b931-12447778be1f" xlink:to="loc_srt_ProductsAndServicesDomain_2fa800f3-6614-4eea-bab4-cd432550bebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_RoutineclinicaltestingservicesMember_c034c9d7-e95b-457f-9d1f-ea081bfc60f3" xlink:href="dgx-20221231.xsd#dgx_RoutineclinicaltestingservicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2fa800f3-6614-4eea-bab4-cd432550bebb" xlink:to="loc_dgx_RoutineclinicaltestingservicesMember_c034c9d7-e95b-457f-9d1f-ea081bfc60f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_COVID19TestingServicesMember_506fc2bf-2bf6-43ff-a2f1-f4257969ea07" xlink:href="dgx-20221231.xsd#dgx_COVID19TestingServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2fa800f3-6614-4eea-bab4-cd432550bebb" xlink:to="loc_dgx_COVID19TestingServicesMember_506fc2bf-2bf6-43ff-a2f1-f4257969ea07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_GenebasedandesoterictestingservicesMember_8d9ac005-219e-4eeb-85c7-7021b573904c" xlink:href="dgx-20221231.xsd#dgx_GenebasedandesoterictestingservicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2fa800f3-6614-4eea-bab4-cd432550bebb" xlink:to="loc_dgx_GenebasedandesoterictestingservicesMember_8d9ac005-219e-4eeb-85c7-7021b573904c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_AnatomicpathologytestingservicesMember_21825ff2-2ee1-437a-9b45-7aa44134929c" xlink:href="dgx-20221231.xsd#dgx_AnatomicpathologytestingservicesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2fa800f3-6614-4eea-bab4-cd432550bebb" xlink:to="loc_dgx_AnatomicpathologytestingservicesMember_21825ff2-2ee1-437a-9b45-7aa44134929c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_AllotherservicesMember_e73bc3a9-8001-4486-bbda-33c0459fd908" xlink:href="dgx-20221231.xsd#dgx_AllotherservicesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2fa800f3-6614-4eea-bab4-cd432550bebb" xlink:to="loc_dgx_AllotherservicesMember_e73bc3a9-8001-4486-bbda-33c0459fd908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_80fe6118-45f5-4e6b-9bef-903df5bfd2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2b1b31f8-17df-48d0-877e-81342c9d41e1" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_80fe6118-45f5-4e6b-9bef-903df5bfd2a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_PercentageofNetRevenues_50a6a52d-90f8-4183-a7e8-a9a1822da384" xlink:href="dgx-20221231.xsd#dgx_PercentageofNetRevenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_80fe6118-45f5-4e6b-9bef-903df5bfd2a8" xlink:to="loc_dgx_PercentageofNetRevenues_50a6a52d-90f8-4183-a7e8-a9a1822da384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0db5db45-3c64-44a0-9160-0a6fc5ca413d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_80fe6118-45f5-4e6b-9bef-903df5bfd2a8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0db5db45-3c64-44a0-9160-0a6fc5ca413d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_08eab82f-ce60-4c36-badb-735f0982e75c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_80fe6118-45f5-4e6b-9bef-903df5bfd2a8" xlink:to="loc_us-gaap_OperatingIncomeLoss_08eab82f-ce60-4c36-badb-735f0982e75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_ed511ee4-6cef-43c6-9b86-85ed6ca4d14b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_80fe6118-45f5-4e6b-9bef-903df5bfd2a8" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_ed511ee4-6cef-43c6-9b86-85ed6ca4d14b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_976ba800-2e40-41f6-a696-71398d6032a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_80fe6118-45f5-4e6b-9bef-903df5bfd2a8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_976ba800-2e40-41f6-a696-71398d6032a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_82d5e290-1251-4eb4-bde8-3c306e9144ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_80fe6118-45f5-4e6b-9bef-903df5bfd2a8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_82d5e290-1251-4eb4-bde8-3c306e9144ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c1940c03-0fa7-4f68-a2be-5a839d165986" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_80fe6118-45f5-4e6b-9bef-903df5bfd2a8" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c1940c03-0fa7-4f68-a2be-5a839d165986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2a8d54d5-bcb7-424f-86e5-77b20c31c743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_80fe6118-45f5-4e6b-9bef-903df5bfd2a8" xlink:to="loc_us-gaap_ProfitLoss_2a8d54d5-bcb7-424f-86e5-77b20c31c743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4e532e22-948c-4da0-abce-02da5972cfb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_80fe6118-45f5-4e6b-9bef-903df5bfd2a8" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4e532e22-948c-4da0-abce-02da5972cfb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cf8141e2-346c-4c2e-98ae-f9966ca84fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_80fe6118-45f5-4e6b-9bef-903df5bfd2a8" xlink:to="loc_us-gaap_NetIncomeLoss_cf8141e2-346c-4c2e-98ae-f9966ca84fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_a2edf721-d532-4389-aec6-62669a77262f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_80fe6118-45f5-4e6b-9bef-903df5bfd2a8" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_a2edf721-d532-4389-aec6-62669a77262f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a2c6202f-36c8-47da-9a81-a33811af2038" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_80fe6118-45f5-4e6b-9bef-903df5bfd2a8" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a2c6202f-36c8-47da-9a81-a33811af2038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_RevenueFromContractWithCustomerExcludingAssessedTaxPercent_1a4502e6-20bc-420f-83c1-8243b398231f" xlink:href="dgx-20221231.xsd#dgx_RevenueFromContractWithCustomerExcludingAssessedTaxPercent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_80fe6118-45f5-4e6b-9bef-903df5bfd2a8" xlink:to="loc_dgx_RevenueFromContractWithCustomerExcludingAssessedTaxPercent_1a4502e6-20bc-420f-83c1-8243b398231f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://questdiagnostics.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="dgx-20221231.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:presentationLink xlink:role="http://questdiagnostics.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_814a8660-3791-4479-bb5a-44c4d414653c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_8cea6b30-fd72-4a02-895a-f86a9393b262" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_814a8660-3791-4479-bb5a-44c4d414653c" xlink:to="loc_us-gaap_SubsequentEventTable_8cea6b30-fd72-4a02-895a-f86a9393b262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_e7629627-63d6-454a-b50b-dfae62bc6654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_8cea6b30-fd72-4a02-895a-f86a9393b262" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_e7629627-63d6-454a-b50b-dfae62bc6654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_423e1226-a1d2-4e61-98ea-41d91c0c099d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e7629627-63d6-454a-b50b-dfae62bc6654" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_423e1226-a1d2-4e61-98ea-41d91c0c099d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_2c48a627-ef76-4e4d-8a60-9cfea359700f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_423e1226-a1d2-4e61-98ea-41d91c0c099d" xlink:to="loc_us-gaap_SubsequentEventMember_2c48a627-ef76-4e4d-8a60-9cfea359700f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8be6eca9-5723-4499-bc57-e92da698789d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_8cea6b30-fd72-4a02-895a-f86a9393b262" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8be6eca9-5723-4499-bc57-e92da698789d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5a20e5c4-641e-4323-b54f-bd633a97d9da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8be6eca9-5723-4499-bc57-e92da698789d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5a20e5c4-641e-4323-b54f-bd633a97d9da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dgx_PackHealthLLCMember_01a05de0-6839-4132-a063-4169727eefcf" xlink:href="dgx-20221231.xsd#dgx_PackHealthLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5a20e5c4-641e-4323-b54f-bd633a97d9da" xlink:to="loc_dgx_PackHealthLLCMember_01a05de0-6839-4132-a063-4169727eefcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_bf24cb14-8289-44f6-a3ee-784faae642b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_8cea6b30-fd72-4a02-895a-f86a9393b262" xlink:to="loc_us-gaap_SubsequentEventLineItems_bf24cb14-8289-44f6-a3ee-784faae642b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_c24a8c32-be51-4784-88fc-526ecb6f08ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_bf24cb14-8289-44f6-a3ee-784faae642b6" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_c24a8c32-be51-4784-88fc-526ecb6f08ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_7199c1a0-4e1a-4b42-b029-d36565ff45e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_bf24cb14-8289-44f6-a3ee-784faae642b6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_7199c1a0-4e1a-4b42-b029-d36565ff45e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>dgx-20221231_g1.jpg
<TEXT>
begin 644 dgx-20221231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1$&17AI9@  34T *@    @ ! $[  (
M   4   (2H=I  0    !   (7IR=  $    H   0UNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $YI8VAO;',L
M(%!A=')I8VEA($<   60 P "    %   $*R0!  "    %   $,"2D0 "
M S$S  "2D@ "     S$S  #J'  '   (#   "*      '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MZ'KUCX@T];O3Y-R]'1OO(?0BM*@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "HKFYAL[62XNI%BBC4L[L< "I2<#)X%>,^/_&+:W>MI^GR?\2^
M!N2I_P!<P[_0=OS], %7QIXTG\271@MBT6G1GY(\\R'^\W]!VKE:** "BBB@
M J>SLKG4+A8+*WDN)6Z)&I)^OTKL/"WPWO-7V76K[[.S/(3&))![#^$>Y_+O
M7JNE:-8:+:BWTVV2!.Y Y8^I/4F@#S31OA1?7(636;E;1#R8HOG?Z$]!^M=M
MIO@'P[IH!6P6XD Y>Y/F9_ \?D*Z.B@!D<4<,:I$BHBC 51@"GT44 %%%%
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MA44 ?30(901R#R**YGX?ZO\ VMX1MM[9EMOW$G_ >G_CN*Z:@ HHHH ****
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M\U48C 9HP.1G -<?I_P]\9W\WAI?$\TLTBZ)J-G>WKW*2R6QG!$2,V09&52
M6 (R#R1@F6Z\*>+-;^$-A\-[O0'LW4PVEWJYNH6M1!#(&$L8#F5F81IA6C7E
M^< 9H [6P^)NA:AXRUKPS&EW'?Z/&TDAEC4).% +",[N2-RY! ZUO>'==MO$
MWANPUJP26.VOH5FB28 .%/3(!(S]":\HU;X:Z_-+XFUC2[18=9M]9-]HC-,F
M+F%H$CEB)W?*LB@J=V#P.G6O1/AUI-[H7PWT'2]5A\B]M+)(IHMZML8#D94D
M'\#0!TM%%% !1110 4444 <O\0=&&K^$[AD7,]I^_C/?C[P_+/'KBO#:^F2
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MC1D"1!$J%]ZD\J5W##9'RG$;>.M)M(Y&U2=8B=0DL($MXYIWED1=VW:(P=^
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MDZ9!H^E06-HNV*%=H]SW/U)YKF_A_P"$O[!TW[7>QXU"Y7Y@?^6:]E^O<_\
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M>FW=K Q>*"XM(Y$C8]2JD8!.3R*T+:V@L[6*ULX8X+>%!'%%$@5(U P%4#@
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M.*5E1[BX3<$D7.&V1H2,YP6]\USWPW\;W#^)/L^H>*%U63Q/I4NI);+?B?\
MLVY5WD-NJY)C B=?EXYC/'' ![O17A-]X@UL?L=+K,>K7XU;R(F-\MR_G_\
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M'Y3;=O&TC(P<%3D'TK5HH YC2_AWX:T?3)-,L[.Y;3I8&MVL;G4+BXM]C')
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M'^=>CUY6"001P1TKU"WE$]K%*.CH&_,4 24444 %%%% !1110 4444 %%%%
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M-OI4DV+VYADGBBVGYDC*!SG&!@R)P3GGCH:D-[:B_6Q-S"+MHC,MN9!YAC!
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MHTK8_0?XUR=% &C>:]J%]D23E$/\$?RC_$_C6=110 4444 %%*JEF"J"S$X
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IHHH T$C2)0L:A5'0 8Q3J** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>dgx-20221231_g2.jpg
<TEXT>
begin 644 dgx-20221231_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1$&17AI9@  34T *@    @ ! $[  (
M   4   (2H=I  0    !   (7IR=  $    H   0UNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $YI8VAO;',L
M(%!A=')I8VEA($<   60 P "    %   $*R0!  "    %   $,"2D0 "
M S$P  "2D@ "     S$P  #J'  '   (#   "*      '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                               R,#(P.C Q.C(R(# X.C4T.C0W #(P
M,C Z,#$Z,C(@,#@Z-30Z-#<   !. &D 8P!H &\ ; !S "P ( !0 &$ = !R
M &D 8P!I &$ ( !'    _^$+)FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"\ /#]X<&%C:V5T(&)E9VEN/2?ON[\G(&ED/2=7-4TP37!#96AI2'IR95-Z
M3E1C>FMC.60G/SX-"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T
M82\B/CQR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY
M.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ,61A+6%D,S$M9#,S9#<U,3@R
M9C%B(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N
M,2\B+SX\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB=75I9#IF868U8F1D
M-2UB83-D+3$Q9&$M860S,2UD,S-D-S4Q.#)F,6(B('AM;&YS.GAM<#TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(^/'AM<#I#<F5A=&5$871E/C(P
M,C M,#$M,C)4,#@Z-30Z-#<N,#DV/"]X;7 Z0W)E871E1&%T93X\+W)D9CI$
M97-C<FEP=&EO;CX\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB=75I9#IF
M868U8F1D-2UB83-D+3$Q9&$M860S,2UD,S-D-S4Q.#)F,6(B('AM;&YS.F1C
M/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^/&1C.F-R96%T
M;W(^/')D9CI397$@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY
M+S R+S(R+7)D9BUS>6YT87@M;G,C(CX\<F1F.FQI/DYI8VAO;',L(%!A=')I
M8VEA($<\+W)D9CIL:3X\+W)D9CI397$^#0H)"0D\+V1C.F-R96%T;W(^/"]R
M9&8Z1&5S8W)I<'1I;VX^/"]R9&8Z4D1&/CPO>#IX;7!M971A/@T*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" \/WAP86-K970@96YD/2=W)S\^_]L 0P '!04&
M!00'!@4&" <'" H1"PH)"0H5#Q ,$1@5&AD8%1@7&QXG(1L=)1T7&"(N(B4H
M*2LL*QH@+S,O*C(G*BLJ_]L 0P$'" @*"0H4"PL4*AP8'"HJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ_\  $0@!
M,0(& P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ ^D:*** "BBB@ HHHH **J7FI060PYW/V1>O_ -:L*ZU>ZN"0
MK>4G]U/\: .HHJ"QN/M5G'+W(PWU[U/0 4444 %%%% !1110 4444 %%%0WE
MR+.QGN6Y$4;/CUP,T 345PO_  G]U_SY0_\ ?1H_X3^Z_P"?*'_OHT =U17*
M:)XPEU/5HK2>WCB$@.&5CU S_2NKH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ Z=:Q-1UK!,5D?K)_A_C46K:J9F,
M%LW[L<,P_B_^M610 I)9B6))/))[U+;VLUT^V!"WJ>P_&M#3]&:?$MUE(^R]
MV_PK?CB2&,)$H11T % %33+%[&%DDD#;CG ' -7:** "BBB@ HHHH **** "
MBBB@ K!\977V?PY(@.&G=8Q_,_H*WJXGQ_=9GM+4'[JF1A]>!_(T <=1110!
M9T^Y^QZE;W'_ #RD5C],\UZ\#D9%>,5ZOH5U]LT&SFSDF(*Q]QP?U% &A111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH ]%\$7'G>'_ "B>8967'L>?ZFNBKCOA^^8;Y/1D/YY_PKL: "BBB@ HHHH
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M-OY;2=E:2,@$H21R,]_K5:N^N?LNIZ_JFG36%OE+?S!<;?WA;"\Y_$?E7 T
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M)%X/1E]#7*W%N]K<-%(/F4_G[U/IMZ;*Z#$_NVX<>WK0!U=% ((!!R#T(HH
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M:>=;$AEXDC;JAJ_6=H6E+I&E1VXP9#\TK>K'K_A^%:- !1110 4444 %%%%
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MA[U7KV5XTE0I(JNIZJPR#7DVKVOV+6+JW PJ2D*/;.1^F* *=%%% !1178^
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M^>-1_$P'ZU=UN3?J; ?P*%_K_6H=,C\S4X!Z-N_+F@#K**** "BBB@ HHHH
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M0 4444 %%%% !1110 5Q_B/Q=Y3/9:4WSC*R3C^'V7W]Z["O/O&>C_8M0%[
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M(R#6)?\ A'2K[++";:0_Q0G _+I6Y10!5TVPBTS3XK6#[L8Y8CECW)JU110
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MP5#;3ZVR7,*R$1%H]PSA@1V^E>BUY?X7G^S^);1L\,Q0_B"/YFO4* "BBB@
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M](JJBA44*HZ # %+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>dgx-20221231_g3.jpg
<TEXT>
begin 644 dgx-20221231_g3.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  <%!08%! <&!08(!P<("A$+"@D)
M"A4/$ P1&!4:&1@5&!<;'B<A&QTE'1<8(BXB)2@I*RPK&B O,R\J,B<J*RK_
MVP!# 0<(" H)"A0+"Q0J'!@<*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" '(!24# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#Z1HHKRG2_
MA[/XJ&HZO=>._&ED\VK:A&+:QU@QPQ+'>2QJJ*5. %0<9H ]6HKS;_A3?_51
M_B!_X//_ +"C_A3?_51_B!_X//\ ["@#TFBO-O\ A3?_ %4?X@?^#S_["C_A
M3?\ U4?X@?\ @\_^PH ])HKS;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\
M["@#TFBO-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PH ])HKS;_A3
M?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["@#TFBO-O\ A3?_ %4?X@?^#S_[
M"C_A3?\ U4?X@?\ @\_^PH ])HKS;_A3?_51_B!_X//_ +"C_A3?_51_B!_X
M//\ ["@#TFBO-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PH ])HKS
M;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["@#TFBO-O\ A3?_ %4?X@?^
M#S_["C_A3?\ U4?X@?\ @\_^PH ])HKS;_A3?_51_B!_X//_ +"C_A3?_51_
MB!_X//\ ["@#TFBO-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PH ]
M)HKS;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["@#TFBO-O\ A3?_ %4?
MX@?^#S_["C_A3?\ U4?X@?\ @\_^PH ])HKS;_A3?_51_B!_X//_ +"C_A3?
M_51_B!_X//\ ["@#TFBO-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^
MPH ])HKS;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["@#TFBO-O\ A3?_
M %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PH ])HKS;_A3?_51_B!_X//_ +"C
M_A3?_51_B!_X//\ ["@#TFBO-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\
M@\_^PH ])HKS;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["@#TFBO-O\
MA3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PH ])HKS;_A3?_51_B!_X//_
M +"C_A3?_51_B!_X//\ ["@#TFBO-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X
M@?\ @\_^PH ])HKS;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["@#TFBO
M-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PH ])HKS;_A3?_51_B!_
MX//_ +"C_A3?_51_B!_X//\ ["@#TFBO-O\ A3?_ %4?X@?^#S_["C_A3?\
MU4?X@?\ @\_^PH ])HKS;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["@#
MTFBO-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PH ])HKS;_A3?_51
M_B!_X//_ +"C_A3?_51_B!_X//\ ["@#TFBO-O\ A3?_ %4?X@?^#S_["C_A
M3?\ U4?X@?\ @\_^PH ])HKS;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\
M["@#TFBO-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PH ])HKS;_A3
M?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["@#TFBO-O\ A3?_ %4?X@?^#S_[
M"C_A3?\ U4?X@?\ @\_^PH ])HKS;_A3?_51_B!_X//_ +"C_A3?_51_B!_X
M//\ ["@#TFBO-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PH ])HKS
M;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["@#TFBO-O\ A3?_ %4?X@?^
M#S_["C_A3?\ U4?X@?\ @\_^PH ])HKS;_A3?_51_B!_X//_ +"C_A3?_51_
MB!_X//\ ["@#TFBO-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PH ]
M)HKS;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["@#TFBO-O\ A3?_ %4?
MX@?^#S_["C_A3?\ U4?X@?\ @\_^PH ])HKS;_A3?_51_B!_X//_ +"C_A3?
M_51_B!_X//\ ["@#TFBO-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^
MPH ])HKS;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["@#TFBO-O\ A3?_
M %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PH ])HKS;_A3?_51_B!_X//_ +"C
M_A3?_51_B!_X//\ ["@#TFBO-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\
M@\_^PH ])HKS;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["@#TFBO-O\
MA3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PH ])HKS;_A3?_51_B!_X//_
M +"C_A3?_51_B!_X//\ ["@#TFBO-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X
M@?\ @\_^PH ])HKS;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["@#TFBO
M-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PH ])HKS;_A3?_51_B!_
MX//_ +"C_A3?_51_B!_X//\ ["@#TFBO-O\ A3?_ %4?X@?^#S_["C_A3?\
MU4?X@?\ @\_^PH ])HKS;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["@#
MTFBO-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PH ])HKS;_A3?_51
M_B!_X//_ +"C_A3?_51_B!_X//\ ["@#TFBO-O\ A3?_ %4?X@?^#S_["C_A
M3?\ U4?X@?\ @\_^PH ])HKS;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\
M["@#TFBO-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PH ])HKS;_A3
M?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["@#TFBO-O\ A3?_ %4?X@?^#S_[
M"C_A3?\ U4?X@?\ @\_^PH ])HKS;_A3?_51_B!_X//_ +"C_A3?_51_B!_X
M//\ ["@#TFBO-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PH ])HKS
M;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["@#TFBO-O\ A3?_ %4?X@?^
M#S_["C_A3?\ U4?X@?\ @\_^PH ])HKS;_A3?_51_B!_X//_ +"C_A3?_51_
MB!_X//\ ["@#TFBO-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PH ]
M)HKS;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["@#TFBO-O\ A3?_ %4?
MX@?^#S_["C_A3?\ U4?X@?\ @\_^PH ])HKS;_A3?_51_B!_X//_ +"C_A3?
M_51_B!_X//\ ["@#TFBO-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^
MPH ])HKS;_A3?_51_B!_X//_ +"C_A3?_51_B!_X//\ ["@#TFBO-O\ A3?_
M %4?X@?^#S_["C_A3?\ U4?X@?\ @\_^PH ])HKS;_A3?_51_B!_X//_ +"C
M_A3?_51_B!_X//\ ["@#TFBO-O\ A3?_ %4?X@?^#S_["C_A3?\ U4?X@?\
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M7!C12P+<$*,@$_3<^(7BYO!GA-M0MX5GO9YX[2SCD)"--(<+N(_A')/TQWH
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MYOP'_P B[=?]AK5?_3A<5TE<WX#_ .1=NO\ L-:K_P"G"XH Z2BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "O/-$^'#:5\:M;\5*^--O((YH8 PVB[8,DC[>Q"@\]_.;\/0Z*
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MMRNI<@$9X(SFO0Z* /-M&TGQ9I/Q,\3>);O18+FUU&SM52*UO%\PO&A^1 ^
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MSJ%/'4YX].M '):C8>)?''PSL?"DNA-IR7D%M'>ZFUU$T(A7:S-$H8R,Q"X
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M],?^RHM>:X>4ZO9PS1HJ*P^58C*0#MX&#@-R3@GC+\$^$K[P[KOB;6-+T?\
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M$@8\-U.>OJ >J45X5X.\":5XQ\0>/K'79M0FMK37_P#1T6]D!C91PV[.6.,
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MK;4;^RD:(36\S2XCX9%9F53N /ITVUUM !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<WXH_Y&+P9_
MV&I/_3?>5TE<WXH_Y&+P9_V&I/\ TWWE '24444 %<WX#_Y%VZ_[#6J_^G"X
MKI*\)M/V@/"O@BZU;P]JMAK$UW9ZUJ/F/;0Q-&=]Y,XP6D!Z,.W6@#W:BO$O
M^&J_!'_0*\0?^ \'_P >H_X:K\$?] KQ!_X#P?\ QZ@#VVBO$O\ AJOP1_T"
MO$'_ (#P?_'J/^&J_!'_ $"O$'_@/!_\>H ]MHKQ+_AJOP1_T"O$'_@/!_\
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M@#VVBO$O^&J_!'_0*\0?^ \'_P >H_X:K\$?] KQ!_X#P?\ QZ@#VVBO$O\
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M:[=ZI:?$Z.TDNL#8GAZ%Q&@Z(I>1B%'7&>223R:YW_AJOP1_T"O$'_@/!_\
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MGA^U93;Z7);1H<+]U))AEW08'RC:#C!&.*Y;_AJOP1_T"O$'_@/!_P#'J/\
MAJOP1_T"O$'_ (#P?_'J .]F\*>(TU/6)--\4P16&JR%VM+K3//-OE%0^6XE
M7!.W/S!AD].N=SPSX>L_"GAFPT/3-_V6QB$:&0Y9NY8GU))/XUY-_P -5^"/
M^@5X@_\  >#_ ./4?\-5^"/^@5X@_P# >#_X]0!Z=XU\(VGC?PO-HM]+);J\
MD<J3Q??B='#!E/8\$9]S53Q'\/M'\1-X<\Y!!'X?NDGMHXUX**N/*]E.$)]=
MN*\\_P"&J_!'_0*\0?\ @/!_\>H_X:K\$?\ 0*\0?^ \'_QZ@#T[QIX.TWQS
MX;DTC5C+&N]9H)X6VR6\J_==3ZC)_ FLGPWX)U_3)XYO$?C6Z\0M:JWV*.:S
M2&.)BI4.X4[I6 )Y9NY[X(X?_AJOP1_T"O$'_@/!_P#'J/\ AJOP1_T"O$'_
M (#P?_'J .S\$> ]9\)>(M:U*\\16NHPZU<F[N;=-,,)24]T;S6P.>A!Z#D=
MZVK?"^]7QA=>(_!7BNZ\,W6H%3J$*6J7,-P1_%L<X5O?GUQR<\K_ ,-5^"/^
M@5X@_P# >#_X]1_PU7X(_P"@5X@_\!X/_CU 'KNB:2FBZ7':+<3W<@)>:YN&
MW23N3EG8],GT& !@   "N%\>VUYXD^(&BZ/X7\3MH6O:7:S7Y=H$GC,<F(A^
M[;[S<, ?X5+9^\*YS_AJOP1_T"O$'_@/!_\ 'JP/$GQR^$GBYH7\0^%M;NIK
M?_4SB&.*6,>@D2<,![9H ]%TBW^(7AWQ-I4'B+Q78>(K*^E>&2'^SUMYD 1F
M\Q=G! *J#GCYO7%,B^$^H:-KMY<>"_&E_P"']*U"9IKK38[6.=0[?>,3/GR\
M_0_D!7!Z#\?OA9X:#G1O#FOPR2#:\TD<<TK#L#(\Y8CVSBMG_AJOP1_T"O$'
M_@/!_P#'J .M\4_#?4-:O?#KZ1KUOIMMX>F6YMHI]/:Y>64=6DD,R[@>_ .2
M22<\3:EX&U^_^(^F^+(_$ME"=/@:W2S_ +*9E=''S[F\\')/((Z<<'!SQG_#
M5?@C_H%>(/\ P'@_^/4?\-5^"/\ H%>(/_ >#_X]0!TUQ\*[^Q\4WVK^"?&%
MYX;BU.;S[^R2UCN(Y)#]YT#\(Q]<'\L"I/&'PQOO$>DZ'IFF>(ET^VTB[2_6
M2XL3<S3W*ECYCOYBCDNQ(V\DGG'%<K_PU7X(_P"@5X@_\!X/_CU'_#5?@C_H
M%>(/_ >#_P"/4 =[XR\#W?C#0M*BDUO^S]8TN[BO8-0MK;Y!,@(SY3.?E.3\
MN[TY/(-5/AYJ+>.M.\4W7BJXFO+>S:TNE%JBB="X?"<XC7(QT9B#][/-<9_P
MU7X(_P"@5X@_\!X/_CU'_#5?@C_H%>(/_ >#_P"/4 =WHG@&;0O&FMZO:ZU)
M_9VL7 NI]-^SK_K=I!)DR25.<[0!T'.,@XFG?"/4?#][/;^%?'&I:/X>N)&D
M?2H[>.0Q[CDB*5\F,?09]\\US_\ PU7X(_Z!7B#_ ,!X/_CU'_#5?@C_ *!7
MB#_P'@_^/4 =IXL^&5OK=YHVJ>']3E\/:UHB"&RO88A*!%C'ENC$;UP3P3W/
M7-,L?AS?Q_$6V\8:GXIN+N]BT\63Q1V<422+O9R!][:I)''WN#\W.!QW_#5?
M@C_H%>(/_ >#_P"/4?\ #5?@C_H%>(/_  '@_P#CU 'L]W;)>V4]K-GRYXVC
M?:<'##!Q^=<-IOPXU.Q\*+X2E\4--X=5/)\M;$1W;0D\Q&8/MVD$@D1AL$\C
MK7(_\-5^"/\ H%>(/_ >#_X]1_PU7X(_Z!7B#_P'@_\ CU 'K<HT;2='&G3F
MTM+"&U*""1E5%@1<$8/\(7K[5R_P@\*6WA7P%$MM'*G]H2O>A9CF1(W/[I&/
MJL80$>N:\LUWXX?"'Q-K-CJNO>$]9O[RP&+=YH(B%&<X*^?M89Y^8&N@_P"&
MJ_!'_0*\0?\ @/!_\>H ]KD198VCD&58%6'J#7FVF?"K5=&^'-]X.L/%@-C<
M13VT!GTX-Y$$Q8N,"12S_,<,3@9/R\\<[_PU7X(_Z!7B#_P'@_\ CU'_  U7
MX(_Z!7B#_P !X/\ X]0!O:E\*]<U/X36_@.;Q59+9Q*D3W*Z0WF/%&R-&N//
MP"&0Y/<$# P2VEXF^&UQXF@TC4'\02:=XITI"L.LV%OL# ]5:)G.5/INZY[$
MBN/_ .&J_!'_ $"O$'_@/!_\>H_X:K\$?] KQ!_X#P?_ !Z@#TWPOX<OM&66
MYU[7KC7]4F4(]W-"D*H@_A2)/E09Y/4DXR3@8K^/O!?_  F^AVMI%J4NEWEA
M?17]G>1QB3RIH\[25)&X?,>,CM7G7_#5?@C_ *!7B#_P'@_^/4?\-5^"/^@5
MX@_\!X/_ (]0!V+?#O4Y_&.D>)+SQ9<2WUE;R6]QMLT19D?!VH,XC''7YF.>
MHXQ3F^%%_8>+-0UCP9XQO?#MOJLOG:A91VD<Z2.?O,F_B,G).<$Y/I@5S7_#
M5?@C_H%>(/\ P'@_^/4?\-5^"/\ H%>(/_ >#_X]0!W?BOX=6WB+P+!X=M+^
M:Q>UGCN;>]=?.<3*Q8R."1O+$L3R,EB:H^+?A]KWBBVT.,^+(H'TF^CU+S9-
M,\QI;E"=IXE4*@#8V@9]6)KDO^&J_!'_ $"O$'_@/!_\>H_X:K\$?] KQ!_X
M#P?_ !Z@#UG6M#B\1>%;O1-8*2I>VQ@G>--HR5QN523C!Y R<8')J/PWX>B\
M+^$K+1-.EW?8X/+$TJ9\R0Y+2, 1DLQ+'GN>:\J_X:K\$?\ 0*\0?^ \'_QZ
MC_AJOP1_T"O$'_@/!_\ 'J .U\$>!-5\+:GKT^J:_;:M;ZY<O=SPIIQMRDS8
M!VMYK?+MXVD9Z'/7,/A;X=ZMX0\%7/AW2_%'F1!9([!KC3PRVJ2.7;<H<&1N
M6P=P )^Z1Q7(?\-5^"/^@5X@_P# >#_X]1_PU7X(_P"@5X@_\!X/_CU '5:/
M\*(HOA4_@/Q+J:ZM8*"+>>&U-M+#\Y<'.]P2&/!XXX(/-6O#'@+7-*N+<>(_
M&U]X@LK-@UI:2VR0A2/NF1QEI2O49.,@'&0*XO\ X:K\$?\ 0*\0?^ \'_QZ
MC_AJOP1_T"O$'_@/!_\ 'J .QN/ >O7&FZUHTGBN*31M8GN7DADTS=/;QSNS
M-'%+YN!]\@%D;';' '9:9IUOI&DV>FV*%+6S@2WA4G.U$4*HS] *\<_X:K\$
M?] KQ!_X#P?_ !ZC_AJOP1_T"O$'_@/!_P#'J .U_P"$&UK_ (6U_P )K_PD
M5KL^Q_V?]@_LP_\ 'MYGF;?,\[[^[G=C'^SCBJUM\,;W0_%NHZKX/\43:-8Z
MM(9K[3C9I.AE/5XBQ_=GKV8>V  .3_X:K\$?] KQ!_X#P?\ QZC_ (:K\$?]
M KQ!_P" \'_QZ@#J=&^#^GV/@?6/"VL:I=:M8ZK<27#AXTC,3LP8,I )W JI
MR21D=.<5/X:^'NMZ3<6T>N^.-0UW3+)U>UL9;:.+!7[ADD&7DVD C) R <5Q
M_P#PU7X(_P"@5X@_\!X/_CU'_#5?@C_H%>(/_ >#_P"/4 =?H?@+7M'\?ZYX
MI;Q)83RZU&B3V_\ 9+JJ&./9$5/GD\<$YSN&1\N01'X9^&FH:/I_BC3M8\00
M:G8>)I;FXNHXM/-N\<TXVN5;S6&W&?EQGISQ@\I_PU7X(_Z!7B#_ ,!X/_CU
M'_#5?@C_ *!7B#_P'@_^/4 =9;?#G6K7X7S^#U\5K();0V"W,NF@K%;%64JL
M8D'SD-C>6/0<4Z?X?Z]-\*8O!(\36:HMK]A>]_LIBS6X0*JA?.P&P,%LG([
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M3S.SSQD[26\U?EP3\N/QKA_^&J_!'_0*\0?^ \'_ ,>H_P"&J_!'_0*\0?\
M@/!_\>H [#4O >OZC\1=)\6'Q)812:7 T$=L-)<JZN,29/GYR23C'3CK@DRZ
M?X'URR^)][XND\1VDL=]"MM+8C2V4"%3E '\X_./[Q!!R?E'&.*_X:K\$?\
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M%>(/_ >#_P"/4?\ #5?@C_H%>(/_  '@_P#CU 'MM%>)?\-5^"/^@5X@_P#
M>#_X]1_PU7X(_P"@5X@_\!X/_CU 'MM%>)?\-5^"/^@5X@_\!X/_ (]1_P -
M5^"/^@5X@_\  >#_ ./4 >VT5XE_PU7X(_Z!7B#_ ,!X/_CU'_#5?@C_ *!7
MB#_P'@_^/4 >VT5XE_PU7X(_Z!7B#_P'@_\ CU'_  U7X(_Z!7B#_P !X/\
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MH *])_9\_P"2[>'O^WG_ -)I:\VKTG]GS_DNWA[_ +>?_2:6@#[:HHHH *^
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M#_P5S_\ Q- '-T5TG_"N/&__ $)OB#_P5S__ !-'_"N/&_\ T)OB#_P5S_\
MQ- '-T5TG_"N/&__ $)OB#_P5S__ !-'_"N/&_\ T)OB#_P5S_\ Q- '-T5T
MG_"N/&__ $)OB#_P5S__ !-'_"N/&_\ T)OB#_P5S_\ Q- '-T5TG_"N/&__
M $)OB#_P5S__ !-'_"N/&_\ T)OB#_P5S_\ Q- '-T5TG_"N/&__ $)OB#_P
M5S__ !-'_"N/&_\ T)OB#_P5S_\ Q- '-T5TG_"N/&__ $)OB#_P5S__ !-'
M_"N/&_\ T)OB#_P5S_\ Q- '-T5TG_"N/&__ $)OB#_P5S__ !-'_"N/&_\
MT)OB#_P5S_\ Q- '-T5TG_"N/&__ $)OB#_P5S__ !-'_"N/&_\ T)OB#_P5
MS_\ Q- '-T5TG_"N/&__ $)OB#_P5S__ !-'_"N/&_\ T)OB#_P5S_\ Q- '
M-T5TG_"N/&__ $)OB#_P5S__ !-'_"N/&_\ T)OB#_P5S_\ Q- '-T5TG_"N
M/&__ $)OB#_P5S__ !-'_"N/&_\ T)OB#_P5S_\ Q- '-T5TG_"N/&__ $)O
MB#_P5S__ !-'_"N/&_\ T)OB#_P5S_\ Q- '-T5TG_"N/&__ $)OB#_P5S__
M !-'_"N/&_\ T)OB#_P5S_\ Q- '-T5TG_"N/&__ $)OB#_P5S__ !-'_"N/
M&_\ T)OB#_P5S_\ Q- '-T5TG_"N/&__ $)OB#_P5S__ !-'_"N/&_\ T)OB
M#_P5S_\ Q- '-T5TG_"N/&__ $)OB#_P5S__ !-'_"N/&_\ T)OB#_P5S_\
MQ- '-T5TG_"N/&__ $)OB#_P5S__ !-'_"N/&_\ T)OB#_P5S_\ Q- '-T5T
MG_"N/&__ $)OB#_P5S__ !-'_"N/&_\ T)OB#_P5S_\ Q- '-T5TG_"N/&__
M $)OB#_P5S__ !-'_"N/&_\ T)OB#_P5S_\ Q- '-T5TG_"N/&__ $)OB#_P
M5S__ !-'_"N/&_\ T)OB#_P5S_\ Q- '-T5TG_"N/&__ $)OB#_P5S__ !-'
M_"N/&_\ T)OB#_P5S_\ Q- '-T5TG_"N/&__ $)OB#_P5S__ !-'_"N/&_\
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MG#Y*\*/PSQ__  KCQO\ ]";X@_\ !7/_ /$T?\*X\;_]";X@_P#!7/\ _$T
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M^(/_  5S_P#Q- '-T5TG_"N/&_\ T)OB#_P5S_\ Q-'_  KCQO\ ]";X@_\
M!7/_ /$T <W172?\*X\;_P#0F^(/_!7/_P#$T?\ "N/&_P#T)OB#_P %<_\
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MX\;_ /0F^(/_  5S_P#Q- '-T5TG_"N/&_\ T)OB#_P5S_\ Q-'_  KCQO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5S?BC_ )&+P9_V&I/_ $WW
ME=)7-^*/^1B\&?\ 8:D_]-]Y0!TE%%% !7-^ _\ D7;K_L-:K_Z<+BNDKF_
M?_(NW7_8:U7_ -.%Q0!TE%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5S?BC_D8O!G_8:D_]-]Y725S?BC_D8O!G
M_8:D_P#3?>4 =)1110 5S?@/_D7;K_L-:K_Z<+BNDKF_ ?\ R+MU_P!AK5?_
M $X7% '24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1136D5/O''X4 .HJE
M+K%C <2S[?\ @#?X57/B?1E.&U"('T.1_2@#5HK)_P"$HT3_ *",/ZT?\)1H
MG_01A_6@#6HK)_X2C1/^@C#^M'_"4:)_T$8?UH UJ*R?^$HT3_H(P_K1_P )
M1HG_ $$8?UH UJ*R?^$HT3_H(P_K1_PE&B?]!&']: -:BLG_ (2C1/\ H(P_
MK1_PE&B?]!&']: -:BLG_A*-$_Z",/ZT^+Q'I$\R10W\3R.<*HSDF@#3HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ2#$J02COE"#_.K<'BW3Y&_T_2H\]W15;]"/ZUR5% 'HMGJ7A^](6)+97/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7-^*/^1B\&?\ 8:D_]-]Y725S?BC_ )&+P9_V&I/_ $WW
ME '24444 %<WX#_Y%VZ_[#6J_P#IPN*Z2N;\!_\ (NW7_8:U7_TX7% '2444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 445CZ[X@@TB$JN)+EA\D?I[F@"YJ6JVNE6YENGQ_=0?>;Z"N"U?Q+>:
MHQ0-Y%OGB-#U^I[UG7EY/?W+3W3EW8_@/85!0 4444 %%%% !1110 4444 %
M%%% !1110 5HZ7KEYI,G^CONC)^:)N0?\*SJ* /3M(UVUU>+]TWES ?-$QY'
MT]16G7D,4LD$JRPNR.IR&4\BN\\.^)TU$+;7I"70'![2?_7H Z*BBB@ HHHH
M **** //O$__ ",=S_P#_P!!%9-:WB?_ )&.Y_X!_P"@BLF@ HHHH **** "
MBBB@ HHHH **** "O1/#G_(NVG^X?YFO.Z]$\.?\B[:?[A_F: -.BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "N;\4?\C%X,_[#4G_ *;[RNDKF_%'_(Q>#/\ L-2?^F^\H Z2BBB@ KF_
M ?\ R+MU_P!AK5?_ $X7%=)7-^ _^1=NO^PUJO\ Z<+B@#I**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJIJ>HQ:7
M8/<S?P\*O]X]A0!3U_78]'M<*0US(/W:>GN?:O.)II+B9I9G+NYRS'O4E[>2
MW]Y)<W#9=SGZ#TJ"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"E!*L&4D$'(([4E% '?>&/$(U",6EXP%R@^5C_RT'^-='7D,4KP3++$Q1T.5
M8=C7I6@ZPFKV <D"=.)4]#ZT :E%%% !1110!Y]XG_Y&.Y_X!_Z"*R:UO$__
M ",=S_P#_P!!%9- !1110 4444 %%%% !1110 4444 %>B>'/^1=M/\ </\
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M_IUEJME)9ZI:07EK(,/#<1B1&^JG@U):VEO8VL=K901V]O$NV.*) JH/0 <
M4 2UY7\8C9S>(/ UI>7CVRR:R S0W!AD4&-QD.I!7D@9'K7JE8NI^#/#&M7K
M7FL>'=*O[E@%,US91R.0.@W,": /,?#OV/X9_%*YL/%K?:1K&3I/B*\<R2$=
M[9Y&Y!].>:VM.OH4_:!UF#7"NZXTR+^R7F(*-%_RT6,GC.>2!7>7_AS1-4T^
M*PU/2+&\LX2#%;SVR/''@8&%(P.*CN_"OA^_TVWTZ^T/3KFRM0!!;36B-'$!
MP JD8'X4 >(:KIGV?X9?$Z/34WZ$-0:2P51F-""#+L]%#9Z5U'B/5=-NOB+\
M.)+6\MY@IDW.C@@ Q#'->JI86D=A]A2UA6TV>7Y C 3;TV[>F/:J=IX7T"PC
MMTL=$T^V2V8O L-JB"(GJ5P."?:@#@? MQ:0^-/B':7<L4<TNJ;EBD(!93 G
M.#VKA7:VD_9CF^:)@FLR@<CY<W;?TKWN;P[HMS=W-U<:38RW%W%Y-Q,]NA>:
M/^XQ(RP]CQ6?_P *^\&_9?LW_"*:)Y&_?Y7]GQ;=V,9QMQG '- '(:W#IEA\
M6/ #6*VUN\]K>H?+PN\;8BH..O)8_G7%Z596GB7PSKVC>)_&LNFW*ZC,;[37
ML[<3;Q)F-D9EWL2H0*0?85[*? ?A%I893X7T8R6X A<V$68P#D;3MXP>>*O3
M^'=%NM6CU2YTFQFU"+_5W<ENC2I]'(R* 'Z7"]OH-K"KR.\=NJ*\^-[87 +>
M_K7D?A"]\)ZO\,]2T/QBRC45OG.I6LLA2XEG$F4(QALG"@8Z]*]JK.?P_HTF
MLKJ\FDV3:D@PMXUNAF ] ^,_K0!P5Y-"G[0WAV+<L;?V'.HC9OF'*X'UP*R?
M"AM3J?Q;CS#Y8O"VW(QCR3S^=>F3^$?#EUK":M<Z!IDVHHZR+>26D;2JRG*L
M'(SD$<'/%01> _",*3I#X7T:-;A=LRK81 2C.<-\O(SSS0!X])!I<'[.?A*^
M5+:.X2[T]O/& P;S5#<]>F<UUVK21+^TMH_DO&)'\/38P1EF\QL5V)^'_@YK
M9;=O"FBF!6+K$=/BVACWQMQFI8O!7A:"^@O8?#>DQW=L$$,ZV48>+8 %VMC(
MP  ,=,4 >9^$+SPEK'PWU#1/&DL2ZDFH3G5+>679.\_G,P8$88YR,$?2I]:O
M;"^\5^++&P^S:3=P:3#'J-S?-YLDBF(NB1QL=N!NPQQR3[5Z@_A_1I=975Y-
M)LGU)1A;QK=#,!Z!\9_6EGT#1[G55U.XTJREOU0QK=/;JTH7^[N(SCVH \/U
MR]MY?V:O!I6>-MM]8*WSYP0_(_ 5[^K!E!4@@\@CO6+<^"_"]Y8V]G=^'-*G
MM;4L;>"6RC9(=WWMJD87.!G'6M:UM;>QM8[:R@CM[>)=L<42!50>@ X H \%
MTJ[G@^#GC^STZ;9J8UJZD," &40[X?,(3N-F[ZUOZ#I>DZYK7A?7;;QN^KW%
MEQ9VUM:V\3!&3#J^Q00H7.0?2O4[;1M,L[ZYO;33[6"ZN\?:)XX55YL?WF R
MWXU'IWA[1M(NI[G2M)L;*>X_UTMO;I&TG^\0,G\: /+A/:>'X+&:W:QU_P -
M7.LQ&$9V7EE</* N/[P5NH^]C/:M/P;<6MM\7?'=O>RQ1R3S6Y2.0@%P4(X!
MZBNWMO"/ARRU0:E9Z!ID%\"2+J*SC63GK\P&:L3Z!I%S?R7UQI=E+=RPF"2=
M[=2[QD8*%B,E2.W2@#P^Q:VD_9R\;A6B8)>7Y49'RGS#C%=!K<.E6<WPOGME
MMH'>\C"R1X4ONC&>1UR:] 7P%X02TDM4\+:,MO(P9XA81!6(Z$C;@FD?X?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=L<?\]T_G0!ZI1110!P_B+QPFCZ]<6+:1%<&+;^]:3!;*@]-I]:S/^%EQ_\
M0 @_[_?_ &%8OCW_ )':^^D?_HM:YV@#O/\ A9<?_0 @_P"_W_V%'_"RX_\
MH 0?]_O_ +"N#HH [S_A9<?_ $ (/^_W_P!A1_PLN/\ Z $'_?[_ .PK@Z*
M.\_X67'_ - "#_O]_P#84?\ "RX_^@!!_P!_O_L*X.B@#O/^%EQ_] "#_O\
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M$V,B-&8_E0!Z+1110!XUX]_Y':^^D?\ Z+6N=KHO'O\ R.U]](__ $6M<[0
M4444 %%%% !1110 4444 %%%% !7M/@G_D2]._ZYG_T(UXM7M/@G_D2]._ZY
MG_T(T ;U%%% !1110 45C:_K\NCJD=CI5WJ]XX+"VM=H(4=268A1^)YJIX?\
M<Z5K_ABXUI?-LX[-Y([R"Y7;);.APR,/44 =)17"6?Q2MV\2V6D:UH&KZ)_:
M3;+"XOH=J7#?W>.5..S8/-6-8^)-CI&KW5LVGW=Q9:?-%!J&H1;?+M7D *@@
MG<W#+G:#C(S0!V=%4-5U:+2[:.1D::6:0100QXW2L>P_#)^@J^"2H)&#Z>E
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8>,O$7P[UJWGT:"+4-2M39Q:=#=IMB#<&5W)P3ST';'>O2** //-0T[Q->?
MTZ&-! UE[!; VOVR/:N%V>9OSC'&<=>:R&\)^,+;0_!^M:/8P0>(/#UD+"XT
MZ>Y5H[J':JG$@X!.S</K7K5% &-X>.N7$4MYXCBAM)I=HCLH9-ZPJ/5NA8DG
M.., 5S7BC3GT_P"*_ACQ.$_T9XIM,N9,?ZLOAXR3V&589]2/6N]9U7&Y@,G
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MF&.9-N02,\^M;/A+QCH.M>/H-8U[66DU9;8V-F@TJ6SC"DECG>S%G.?7'H*
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MMP'E*\BLJX&3@@D]J /1J*P-"MM>L]5OHM7OUOM/5$^Q3&,(Y&/FWXX)SW
M]J2V\=^&KO6TTF#58S>2'$2LCJLI]$<C:_\ P$F@#H**YJY^(GA2TEFBN-9A
M62"X%M*H5R4D(R%.![]>E.T+Q]X:\3?;/[#U%KO[$";C%M*OEXZ@[E'/'3K[
M4 ='17%:IXA\)^)M)TF[;7KFUMI+]3:R0&2 SRJ2/+(*Y*YSD8[5N:YXMT3P
MXRKK%\(7*[MB1/*RK_>*H"0/<\<4 ;-%9<OB71X=#CUAM0B:PF ,4T9+^9GL
MH7)8\'@#/!JOI_C/P]JFD7.IV6J1-:6AQ<.X9&A/HRL P)[ CGM0!N45BZ)X
MOT/Q'<2V^D7IFFA0/)&\,D;*I. <.H.*J^-O$C^'],M(;+!U+5;N.PL@PR%D
M<X+D=PJ[F([[<=Z .DHK@_$FJW>FZYX=\&Z9?2VUQK+2M-J+X>1$C0NVW(V[
MV(P,C STJ/2-;UC1OB#=^#=1OFU42V/VW3;NZ"K*<'#)(44 X/0A1QVH ] H
MKR;Q3H/C/0M#%S%\1-2GU"XFCM[>!;.W6-YG; &-A(7\?QI?%_B+78-8\0PV
M6MRZ>GAK3(+J-1'&1>.V26DW#[O&,+MYSSVH ]8HKFIM>N[_ $K3+?356+5-
M3MDG((R+5&4%G(]LX /4_0UJ:GITUSH_DVUW*EW"@,-P3\V\#@L!@'/<8QR>
ME &B1D8/(KSCQ-HYTO42\0_T>8ED/H>XKJ/!7B9/%GAB'40H2=9'M[F,?P2Q
ML58?3(R/8BM/5-.BU2P>VF'7E6_NGL: /*J*GO;.:PO'MKA=KH?S'K4% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5_1M,?5=2CMUX3
M[TC>B]ZI1QO-*L<2EG<X51W->EZ!HR:/8!#AIWYD;W]/I0!I11)#$L<2A408
M4#L*=110 4444 >/^.K2YD\9WSQ6TSJ1'AEC8@_NU[@5S_V&\_Y\[C_ORW^%
M3?$GXV>)_"'Q!U'0]+MM,>UM1%L:>%V<[HE8Y(<#JQ[5RW_#2/C3_GST;_P'
MD_\ CE '1_8;S_GSN/\ ORW^%'V&\_Y\[C_ORW^%<Y_PTCXT_P"?/1O_  'D
M_P#CE'_#2/C3_GST;_P'D_\ CE '1_8;S_GSN/\ ORW^%'V&\_Y\[C_ORW^%
M<Y_PTCXT_P"?/1O_  'D_P#CE'_#2/C3_GST;_P'D_\ CE '1_8;S_GSN/\
MORW^%'V&\_Y\[C_ORW^%<Y_PTCXT_P"?/1O_  'D_P#CE'_#2/C3_GST;_P'
MD_\ CE '1_8;S_GSN/\ ORW^%'V&\_Y\[C_ORW^%<Y_PTCXT_P"?/1O_  'D
M_P#CE'_#2/C3_GST;_P'D_\ CE '1_8;S_GSN/\ ORW^%'V&\_Y\[C_ORW^%
M<Y_PTCXT_P"?/1O_  'D_P#CE'_#2/C3_GST;_P'D_\ CE '1_8;S_GSN/\
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MKIJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?O@#C YYZ5Z<=$TH[<Z99G:,+FW7@>W%33Z=974B/<V=O,\?W&DB5BOTR.*
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M@(!VMU'%=10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M444 %%%% !1110 4444 %<WXH_Y&+P9_V&I/_3?>5TE<WXH_Y&+P9_V&I/\
MTWWE '24444 %<WX#_Y%VZ_[#6J_^G"XKI*YOP'_ ,B[=?\ 8:U7_P!.%Q0!
MTE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MWR:Z2B@#F_LEQ_SPD_[Y-;E@K)8Q*ZE6 Y!'3FK%% !1110 4444 %<=\5M
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M-^ _^1=NO^PUJO\ Z<+B@#I**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ KF_%'_ ",7@S_L-2?^F^\KI*YOQ1_R
M,7@S_L-2?^F^\H Z2BBB@ KF_ ?_ "+MU_V&M5_].%Q725S?@/\ Y%VZ_P"P
MUJO_ *<+B@#I**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ KF_%'_(Q>#/\ L-2?^F^\KI*YOQ1_R,7@S_L-2?\
MIOO* .DHHHH *YOP'_R+MU_V&M5_].%Q725S?@/_ )%VZ_[#6J_^G"XH Z2B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'_A1ZA_\?HHH /\ A ](_P"?SQ!_X4>H?_'Z/^$#TC_G\\0?^%'J'_Q^BB@
M_P"$#TC_ )_/$'_A1ZA_\?H_X0/2/^?SQ!_X4>H?_'Z** #_ (0/2/\ G\\0
M?^%'J'_Q^C_A ](_Y_/$'_A1ZA_\?HHH /\ A ](_P"?SQ!_X4>H?_'Z/^$#
MTC_G\\0?^%'J'_Q^BB@ _P"$#TC_ )_/$'_A1ZA_\?H_X0/2/^?SQ!_X4>H?
M_'Z** #_ (0/2/\ G\\0?^%'J'_Q^C_A ](_Y_/$'_A1ZA_\?HHH /\ A ](
M_P"?SQ!_X4>H?_'Z/^$#TC_G\\0?^%'J'_Q^BB@ _P"$#TC_ )_/$'_A1ZA_
M\?H_X0/2/^?SQ!_X4>H?_'Z** #_ (0/2/\ G\\0?^%'J'_Q^C_A ](_Y_/$
M'_A1ZA_\?HHH /\ A ](_P"?SQ!_X4>H?_'Z/^$#TC_G\\0?^%'J'_Q^BB@
M_P"$#TC_ )_/$'_A1ZA_\?H_X0/2/^?SQ!_X4>H?_'Z** #_ (0/2/\ G\\0
M?^%'J'_Q^C_A ](_Y_/$'_A1ZA_\?HHH /\ A ](_P"?SQ!_X4>H?_'Z/^$#
MTC_G\\0?^%'J'_Q^BB@ _P"$#TC_ )_/$'_A1ZA_\?H_X0/2/^?SQ!_X4>H?
M_'Z** #_ (0/2/\ G\\0?^%'J'_Q^C_A ](_Y_/$'_A1ZA_\?HHH /\ A ](
M_P"?SQ!_X4>H?_'Z/^$#TC_G\\0?^%'J'_Q^BB@ _P"$#TC_ )_/$'_A1ZA_
M\?H_X0/2/^?SQ!_X4>H?_'Z** #_ (0/2/\ G\\0?^%'J'_Q^C_A ](_Y_/$
M'_A1ZA_\?HHH /\ A ](_P"?SQ!_X4>H?_'Z/^$#TC_G\\0?^%'J'_Q^BB@
M_P"$#TC_ )_/$'_A1ZA_\?H_X0/2/^?SQ!_X4>H?_'Z** #_ (0/2/\ G\\0
M?^%'J'_Q^C_A ](_Y_/$'_A1ZA_\?HHH /\ A ](_P"?SQ!_X4>H?_'Z/^$#
MTC_G\\0?^%'J'_Q^BB@ _P"$#TC_ )_/$'_A1ZA_\?H_X0/2/^?SQ!_X4>H?
M_'Z** #_ (0/2/\ G\\0?^%'J'_Q^C_A ](_Y_/$'_A1ZA_\?HHH /\ A ](
M_P"?SQ!_X4>H?_'Z/^$#TC_G\\0?^%'J'_Q^BB@ _P"$#TC_ )_/$'_A1ZA_
M\?H_X0/2/^?SQ!_X4>H?_'Z** #_ (0/2/\ G\\0?^%'J'_Q^C_A ](_Y_/$
M'_A1ZA_\?HHH /\ A ](_P"?SQ!_X4>H?_'Z/^$#TC_G\\0?^%'J'_Q^BB@
M_P"$#TC_ )_/$'_A1ZA_\?H_X0/2/^?SQ!_X4>H?_'Z** #_ (0/2/\ G\\0
M?^%'J'_Q^C_A ](_Y_/$'_A1ZA_\?HHH /\ A ](_P"?SQ!_X4>H?_'Z/^$#
MTC_G\\0?^%'J'_Q^BB@ _P"$#TC_ )_/$'_A1ZA_\?H_X0/2/^?SQ!_X4>H?
M_'Z** #_ (0/2/\ G\\0?^%'J'_Q^C_A ](_Y_/$'_A1ZA_\?HHH /\ A ](
M_P"?SQ!_X4>H?_'Z/^$#TC_G\\0?^%'J'_Q^BB@ _P"$#TC_ )_/$'_A1ZA_
M\?H_X0/2/^?SQ!_X4>H?_'Z** #_ (0/2/\ G\\0?^%'J'_Q^C_A ](_Y_/$
M'_A1ZA_\?HHH /\ A ](_P"?SQ!_X4>H?_'Z/^$#TC_G\\0?^%'J'_Q^BB@
M_P"$#TC_ )_/$'_A1ZA_\?H_X0/2/^?SQ!_X4>H?_'Z** #_ (0/2/\ G\\0
M?^%'J'_Q^C_A ](_Y_/$'_A1ZA_\?HHH /\ A ](_P"?SQ!_X4>H?_'Z/^$#
MTC_G\\0?^%'J'_Q^BB@ _P"$#TC_ )_/$'_A1ZA_\?H_X0/2/^?SQ!_X4>H?
M_'Z** #_ (0/2/\ G\\0?^%'J'_Q^C_A ](_Y_/$'_A1ZA_\?HHH /\ A ](
M_P"?SQ!_X4>H?_'Z/^$#TC_G\\0?^%'J'_Q^BB@ _P"$#TC_ )_/$'_A1ZA_
M\?H_X0/2/^?SQ!_X4>H?_'Z** #_ (0/2/\ G\\0?^%'J'_Q^C_A ](_Y_/$
M'_A1ZA_\?HHH /\ A ](_P"?SQ!_X4>H?_'Z/^$#TC_G\\0?^%'J'_Q^BB@
M_P"$#TC_ )_/$'_A1ZA_\?H_X0/2/^?SQ!_X4>H?_'Z** #_ (0/2/\ G\\0
M?^%'J'_Q^C_A ](_Y_/$'_A1ZA_\?HHH /\ A ](_P"?SQ!_X4>H?_'Z/^$#
MTC_G\\0?^%'J'_Q^BB@ _P"$#TC_ )_/$'_A1ZA_\?H_X0/2/^?SQ!_X4>H?
M_'Z** #_ (0/2/\ G\\0?^%'J'_Q^C_A ](_Y_/$'_A1ZA_\?HHH /\ A ](
M_P"?SQ!_X4>H?_'Z/^$#TC_G\\0?^%'J'_Q^BB@ _P"$#TC_ )_/$'_A1ZA_
M\?H_X0/2/^?SQ!_X4>H?_'Z** #_ (0/2/\ G\\0?^%'J'_Q^C_A ](_Y_/$
M'_A1ZA_\?HHH /\ A ](_P"?SQ!_X4>H?_'Z/^$#TC_G\\0?^%'J'_Q^BB@
M_P"$#TC_ )_/$'_A1ZA_\?H_X0/2/^?SQ!_X4>H?_'Z** #_ (0/2/\ G\\0
M?^%'J'_Q^C_A ](_Y_/$'_A1ZA_\?HHH /\ A ](_P"?SQ!_X4>H?_'Z/^$#
MTC_G\\0?^%'J'_Q^BB@ _P"$#TC_ )_/$'_A1ZA_\?H_X0/2/^?SQ!_X4>H?
M_'Z** #_ (0/2/\ G\\0?^%'J'_Q^C_A ](_Y_/$'_A1ZA_\?HHH /\ A ](
M_P"?SQ!_X4>H?_'Z/^$#TC_G\\0?^%'J'_Q^BB@ _P"$#TC_ )_/$'_A1ZA_
M\?H_X0/2/^?SQ!_X4>H?_'Z** #_ (0/2/\ G\\0?^%'J'_Q^C_A ](_Y_/$
M'_A1ZA_\?HHH /\ A ](_P"?SQ!_X4>H?_'Z/^$#TC_G\\0?^%'J'_Q^BB@
M_P"$#TC_ )_/$'_A1ZA_\?H_X0/2/^?SQ!_X4>H?_'Z** #_ (0/2/\ G\\0
M?^%'J'_Q^C_A ](_Y_/$'_A1ZA_\?HHH /\ A ](_P"?SQ!_X4>H?_'Z/^$#
MTC_G\\0?^%'J'_Q^BB@ _P"$#TC_ )_/$'_A1ZA_\?H_X0/2/^?SQ!_X4>H?
M_'Z** #_ (0/2/\ G\\0?^%'J'_Q^C_A ](_Y_/$'_A1ZA_\?HHH /\ A ](
M_P"?SQ!_X4>H?_'Z/^$#TC_G\\0?^%'J'_Q^BB@ _P"$#TC_ )_/$'_A1ZA_
M\?H_X0/2/^?SQ!_X4>H?_'Z** #_ (0/2/\ G\\0?^%'J'_Q^C_A ](_Y_/$
M'_A1ZA_\?HHH /\ A ](_P"?SQ!_X4>H?_'Z/^$#TC_G\\0?^%'J'_Q^BB@
M_P"$#TC_ )_/$'_A1ZA_\?H_X0/2/^?SQ!_X4>H?_'Z** #_ (0/2/\ G\\0
M?^%'J'_Q^I+3P3H]GJ=K?JVJ3W%F[20?;-8N[E(V*,A8))*RYVNPSC^(T44
(=!1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>dgx-20221231_g4.jpg
<TEXT>
begin 644 dgx-20221231_g4.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1$&17AI9@  34T *@    @ ! $[  (
M   4   (2H=I  0    !   (7IR=  $    H   0UNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $YI8VAO;',L
M(%!A=')I8VEA($<   60 P "    %   $*R0!  "    %   $,"2D0 "
M S@P  "2D@ "     S@P  #J'  '   (#   "*      '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M $,W_DA<_P#QNC_AH/X8_P#0S?\ DA<__&Z /2:*\V_X:#^&/_0S?^2%S_\
M&Z/^&@_AC_T,W_DA<_\ QN@#TFBO-O\ AH/X8_\ 0S?^2%S_ /&Z/^&@_AC_
M -#-_P"2%S_\;H ])HKS;_AH/X8_]#-_Y(7/_P ;H_X:#^&/_0S?^2%S_P#&
MZ /2:*\V_P"&@_AC_P!#-_Y(7/\ \;H_X:#^&/\ T,W_ )(7/_QN@#TFBO-O
M^&@_AC_T,W_DA<__ !NC_AH/X8_]#-_Y(7/_ ,;H ])HKS;_ (:#^&/_ $,W
M_DA<_P#QNC_AH/X8_P#0S?\ DA<__&Z /2:*\V_X:#^&/_0S?^2%S_\ &Z/^
M&@_AC_T,W_DA<_\ QN@#TFBO-O\ AH/X8_\ 0S?^2%S_ /&Z/^&@_AC_ -#-
M_P"2%S_\;H ])HKS;_AH/X8_]#-_Y(7/_P ;H_X:#^&/_0S?^2%S_P#&Z /2
M:*\V_P"&@_AC_P!#-_Y(7/\ \;H_X:#^&/\ T,W_ )(7/_QN@#TFBO-O^&@_
MAC_T,W_DA<__ !NC_AH/X8_]#-_Y(7/_ ,;H ])HKS;_ (:#^&/_ $,W_DA<
M_P#QNC_AH/X8_P#0S?\ DA<__&Z /2:*\V_X:#^&/_0S?^2%S_\ &Z/^&@_A
MC_T,W_DA<_\ QN@#TFBO-O\ AH/X8_\ 0S?^2%S_ /&Z/^&@_AC_ -#-_P"2
M%S_\;H ])HKS;_AH/X8_]#-_Y(7/_P ;H_X:#^&/_0S?^2%S_P#&Z /2:*\V
M_P"&@_AC_P!#-_Y(7/\ \;H_X:#^&/\ T,W_ )(7/_QN@#TFBO-O^&@_AC_T
M,W_DA<__ !NC_AH/X8_]#-_Y(7/_ ,;H ])HKS;_ (:#^&/_ $,W_DA<_P#Q
MNC_AH/X8_P#0S?\ DA<__&Z /2:*\V_X:#^&/_0S?^2%S_\ &Z/^&@_AC_T,
MW_DA<_\ QN@#TFBO-O\ AH/X8_\ 0S?^2%S_ /&Z/^&@_AC_ -#-_P"2%S_\
M;H ])HKS;_AH/X8_]#-_Y(7/_P ;H_X:#^&/_0S?^2%S_P#&Z /2:*\V_P"&
M@_AC_P!#-_Y(7/\ \;H_X:#^&/\ T,W_ )(7/_QN@#TFBO-O^&@_AC_T,W_D
MA<__ !NC_AH/X8_]#-_Y(7/_ ,;H ])HKS;_ (:#^&/_ $,W_DA<_P#QNC_A
MH/X8_P#0S?\ DA<__&Z /2:*\V_X:#^&/_0S?^2%S_\ &Z/^&@_AC_T,W_DA
M<_\ QN@#TFBO-O\ AH/X8_\ 0S?^2%S_ /&Z/^&@_AC_ -#-_P"2%S_\;H ]
M)HKS;_AH/X8_]#-_Y(7/_P ;H_X:#^&/_0S?^2%S_P#&Z /2:*\V_P"&@_AC
M_P!#-_Y(7/\ \;H_X:#^&/\ T,W_ )(7/_QN@#TFBO-O^&@_AC_T,W_DA<__
M !NC_AH/X8_]#-_Y(7/_ ,;H ])HKS;_ (:#^&/_ $,W_DA<_P#QNC_AH/X8
M_P#0S?\ DA<__&Z /2:*\V_X:#^&/_0S?^2%S_\ &Z/^&@_AC_T,W_DA<_\
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MX8_]#-_Y(7/_ ,;H ])HKS;_ (:#^&/_ $,W_DA<_P#QNC_AH/X8_P#0S?\
MDA<__&Z /2:*\V_X:#^&/_0S?^2%S_\ &Z/^&@_AC_T,W_DA<_\ QN@#TFBO
M-O\ AH/X8_\ 0S?^2%S_ /&Z/^&@_AC_ -#-_P"2%S_\;H ])HKS;_AH/X8_
M]#-_Y(7/_P ;H_X:#^&/_0S?^2%S_P#&Z /2:*\V_P"&@_AC_P!#-_Y(7/\
M\;H_X:#^&/\ T,W_ )(7/_QN@#TFBO-O^&@_AC_T,W_DA<__ !NC_AH/X8_]
M#-_Y(7/_ ,;H ])HKS;_ (:#^&/_ $,W_DA<_P#QNC_AH/X8_P#0S?\ DA<_
M_&Z /2:*\V_X:#^&/_0S?^2%S_\ &Z/^&@_AC_T,W_DA<_\ QN@#TFBO-O\
MAH/X8_\ 0S?^2%S_ /&Z/^&@_AC_ -#-_P"2%S_\;H ])HKS;_AH/X8_]#-_
MY(7/_P ;H_X:#^&/_0S?^2%S_P#&Z /2:*\V_P"&@_AC_P!#-_Y(7/\ \;H_
MX:#^&/\ T,W_ )(7/_QN@#TFBO-O^&@_AC_T,W_DA<__ !NC_AH/X8_]#-_Y
M(7/_ ,;H ])HKS;_ (:#^&/_ $,W_DA<_P#QNC_AH/X8_P#0S?\ DA<__&Z
M/2:*\V_X:#^&/_0S?^2%S_\ &Z/^&@_AC_T,W_DA<_\ QN@#TFBO-O\ AH/X
M8_\ 0S?^2%S_ /&Z/^&@_AC_ -#-_P"2%S_\;H ])HKS;_AH/X8_]#-_Y(7/
M_P ;H_X:#^&/_0S?^2%S_P#&Z /2:*\V_P"&@_AC_P!#-_Y(7/\ \;H_X:#^
M&/\ T,W_ )(7/_QN@#TFBO-O^&@_AC_T,W_DA<__ !NC_AH/X8_]#-_Y(7/_
M ,;H ])HKS;_ (:#^&/_ $,W_DA<_P#QNC_AH/X8_P#0S?\ DA<__&Z /2:*
M\V_X:#^&/_0S?^2%S_\ &Z/^&@_AC_T,W_DA<_\ QN@#TFBO-O\ AH/X8_\
M0S?^2%S_ /&Z/^&@_AC_ -#-_P"2%S_\;H ])HKS;_AH/X8_]#-_Y(7/_P ;
MH_X:#^&/_0S?^2%S_P#&Z /2:*\V_P"&@_AC_P!#-_Y(7/\ \;H_X:#^&/\
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M2!=Q] .I/L.: -*BJVFZA:ZOI5IJ6GR^=:7D*3P2;2N]'4,IP0",@C@C-6:
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M=)7-WW_)4]"_[ NI?^C[&@#I**** "N;OO\ DJ>A?]@74O\ T?8UTE<W??\
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M;X,ZLRZ%K$%C?Q1BTU"XMD$4G[Q&4E0YD0''!=%!X]16/\4-)\/:'\']>A\
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MGT.UBOHFAM#>"\N+?R[:6($!F1R?F )^]C:<'!-<_P#M&?\ )$=5_P"NUO\
M^CEK8^(UK=S_  .UFWTJ,F8Z5A8XUY*!1N  _P!D$8H ?JGQ1TS1].BU>^TG
M6%T&5E"ZPMNA@"L<*Y7?YH0Y&&V8.1C.14>O_%6PT#Q%IFCOH6LWSZOM_LVZ
MM%MS!>9"GY':9<8W ?-CUZ$$\[X;M?AUXS^&T%[?:K>RV!M4%_:W?B.\"0LH
M&Y7C:?  (XXQP".U7O'O@^WUWX,V8\(V\UI/HL,.H:*C[O,C\I057YB6R4R
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M_L]DGPOXG!)POB:["CT&R*@#T3Q'H,/B723I=[-(EE,X^U1Q,5,\8Y,>X$$
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MX"YP9"Q&U0@;)XI=&^)FBZYX:AUBVM]0B,]V]E!8S6^VYEF7JBH"0< $DYP
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M_P!*9:=X"U33M1_9YL9-/DC,=OHA@G ;[DB1%9 WH=P)_'/2F_L^'/P)\/\
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M79(A#K^!%0Z?X+T'3=2348K.2YOHP5CN[^ZENY8P>H5YF9E_ BH/^%C^"/\
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MOCIEV)8@9. 3QFH?^%C^"/\ H<O#_P#X-(/_ (JC_A8_@C_H<O#_ /X-(/\
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ME@3DDYR:D_X6/X(_Z'+P_P#^#2#_ .*H_P"%C^"/^AR\/_\ @T@_^*H ?<^
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M3;7UM=WZ,MU,NK79:;<""6)EY;YB0W4$Y!!YJS_PL?P1_P!#EX?_ /!I!_\
M%4?\+'\$?]#EX?\ _!I!_P#%4 5]%^&7A?PZUXVAVU]9&]#"X,6K78\PMU8_
MO?O<\-]X=B*31?ACX6\.I>)H=K?62WP(N!#JUV/,)ZM_K>&X^\/FZ\\FK/\
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M'_0Y>'__  :0?_%4 4]0^%7A#5-9AU6[T^Y^VV_%O+%J5S%]G'I&$D C'LH
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M,9-/B\*:1'X:N/#[PSW.F7$;120W=W-<$HPVE0\C,P&.@!&.V*I_\+'\$?\
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M+FGD\-6EQ9_:,F6,W\\L;DXRQ1W*[N!\V,XXS@FC_A8_@C_H<O#_ /X-(/\
MXJC_ (6/X(_Z'+P__P"#2#_XJ@"WXG\)Z-XRTL:;XBMI+JSWAS"ES+"&(Z;O
M+9=P]CD9YKC_ /AGSX8_]"S_ .3]S_\ '*Z7_A8_@C_H<O#_ /X-(/\ XJC_
M (6/X(_Z'+P__P"#2#_XJ@#7O]&T[5-'?2M1LH;BPD01M;R+E2HZ#'M@8],5
M3T?PEHVA7DEW86TC7<D8B:ZNKF6YF\L<A!)*S,%S_"#CVJI_PL?P1_T.7A__
M ,&D'_Q5'_"Q_!'_ $.7A_\ \&D'_P 50!E:Y\&? GB36)]5US19+V]N&W22
MR:A<\^P DP .P  ':K?ACX6^#O!MU<W/AG2#83W4!MY95NIF8H2"0"SDKR <
MC!X%6O\ A8_@C_H<O#__ (-(/_BJ/^%C^"/^AR\/_P#@T@_^*H YV7X _#2>
M9Y9O#C222,6=WU&Z)8GDDGS.375^%?!N@^"=+DT_POIXL;664S.@E>0LY &<
MN2>BCC.*K?\ "Q_!'_0Y>'__  :0?_%4?\+'\$?]#EX?_P#!I!_\50!J:YH.
MF>)='FTK7;..]LIP/,ADS@X.001R"#W'-<[_ ,*D\"_V1;:8?#MN;6UG$\0,
MDA;>!@$ONW, .,,2,=JO?\+'\$?]#EX?_P#!I!_\51_PL?P1_P!#EX?_ /!I
M!_\ %4 4[WX5>$-0UR+6+BPNQJ$(Q!/%JEU$8%YPL860"-1DX5< 9X%=#K>A
M:7XCTN33==L8;ZSDY:&9<C(Z$>A'J.:RO^%C^"/^AR\/_P#@T@_^*H_X6/X(
M_P"AR\/_ /@T@_\ BJ &^%/AUX4\$/+)X8T:&QEF&UY=[R2$>FYR3CCIG%='
M-$MQ;R0N7"R*58QN48 C'#*00?<$$5SW_"Q_!'_0Y>'_ /P:0?\ Q5'_  L?
MP1_T.7A__P &D'_Q5 #/#OPZ\->%-5N-2T&TN;:ZNB3<.VH7$HF)YW.KR$,>
M3R03R:9+\,?!TWB"76VT*$7TQ)F='=$FSR=\88(^3R<@YJ;_ (6/X(_Z'+P_
M_P"#2#_XJC_A8_@C_H<O#_\ X-(/_BJ )]!\$^&_#-I/;:'HUK:QW&X3X3>T
MH/4,S9+#V)Q63IGPB\!Z-KPUG3?#5K#?*^]'W.RQMV*H6*J1VP!BK_\ PL?P
M1_T.7A__ ,&D'_Q5'_"Q_!'_ $.7A_\ \&D'_P 50!!JGPS\+ZSXB37M1M;Z
M35(_]5=)JMU&T/LFV0!!R>%P.31??#/POJ/B=?$5W:WKZNA/EW:ZK=(T8Y^5
M-L@"KR?E&!R>.:G_ .%C^"/^AR\/_P#@T@_^*H_X6/X(_P"AR\/_ /@T@_\
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M\$?]#EX?_P#!I!_\51_PL?P1_P!#EX?_ /!I!_\ %4 7+SPEH-_X3;PS<Z7
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M*/\ V^_^T*^DJ^;?VN?^91_[??\ VA0!\W4444 %%%% !1110 4444 %%%%
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M,H]2%!.* *-%?3>E^'M.OOV8]7U;7?"^DP:];VMTC3?V1#;S1LC$*?E0%6
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MM%J%KIMF(4:;S"%8 * =RX/?&<5B7O@WQ/IVGM?:AX<U:TLU&6N)[&5(P/\
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M:7V_<+M!'\3_ )]'J'_)G2?]@*+^:UX!XY^)UQ\0[[07\1V<AMM*M1!+';W
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M;"*%.$Q).Z.-O3#*H4CT JO^UA*\.O\ A>6%VCD2&=D=#@J0R8(/8USNK_M
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M<7$ADD<@#<Q.3P.!]!Q0![?\*TO-2^!WB?2K_1[6R\/-YDUUK\C-O&U5.$B
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M'7I0![%K/A/0_&'P>\7:S%I&GZ7JGAO5[N&">QM4MP\4;*P1E0 -\C[02,Y
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M@/XK:YX&\47VKQA-075"3J%O,=HN"23NR!\K LW('<\5H6_Q9B\/>#=5\/\
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M2664( ,DG^#I@'.,T 2ZG\0?"-Q\#F\$!M9U*_MY_/L+Z[L8HEA/F!BN!.Y
MVEUR,_>Z5Y-7:>,/'.DZY'<P^&/"-EX:BO6#7AAF:9YL$,%!( 1-P!VJ "0,
M]*XV,H)%,JLR9&Y5;!([@'!Q^1H ^G_V?/\ DWSQ5_U]WG_I+%7@/@7QM?\
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M2Y&U74K^X8;8]N6#NQXR7Q[]3VH VOVG;."U^+PEAC"/=:=#+*0/O,"Z9/\
MP%%'X5X]78?%/QF/'GQ%U'6H=PLRPAM%88(A084_CRV#TW8KCZ "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *]M_94_P"2IZE_V!9?_1\%>)5[
M;^RI_P E3U+_ + LO_H^"@#ZVHHHH *\D^,?PZ_X6;XJ\-:-_:G]F>197]WY
MWV?SMVU[5-NW<O\ ?SG/:O6ZYN^_Y*GH7_8%U+_T?8T >(_\,C?]3M_Y2?\
M[=1_PR-_U.W_ )2?_MU?25% 'S;_ ,,C?]3M_P"4G_[=1_PR-_U.W_E)_P#M
MU?25% 'S;_PR-_U.W_E)_P#MU'_#(W_4[?\ E)_^W5])44 ?-O\ PR-_U.W_
M )2?_MU'_#(W_4[?^4G_ .W5])44 ?-O_#(W_4[?^4G_ .W4?\,C?]3M_P"4
MG_[=7TE10!\V_P##(W_4[?\ E)_^W4?\,C?]3M_Y2?\ [=7TE10!\V_\,C?]
M3M_Y2?\ [=1_PR-_U.W_ )2?_MU?25% 'S;_ ,,C?]3M_P"4G_[=1_PR-_U.
MW_E)_P#MU?25% 'S;_PR-_U.W_E)_P#MU'_#(W_4[?\ E)_^W5])44 ?-O\
MPR-_U.W_ )2?_MU'_#(W_4[?^4G_ .W5])44 ?-O_#(W_4[?^4G_ .W4?\,C
M?]3M_P"4G_[=7TE10!\V_P##(W_4[?\ E)_^W4?\,C?]3M_Y2?\ [=7TE10!
M\V_\,C?]3M_Y2?\ [=1_PR-_U.W_ )2?_MU?25% 'S;_ ,,C?]3M_P"4G_[=
M1_PR-_U.W_E)_P#MU?25% 'S;_PR-_U.W_E)_P#MU'_#(W_4[?\ E)_^W5])
M44 ?-O\ PR-_U.W_ )2?_MU'_#(W_4[?^4G_ .W5])44 ?-O_#(W_4[?^4G_
M .W4?\,C?]3M_P"4G_[=7TE10!\V_P##(W_4[?\ E)_^W4?\,C?]3M_Y2?\
M[=7TE10!\V_\,C?]3M_Y2?\ [=1_PR-_U.W_ )2?_MU?25% 'S;_ ,,C?]3M
M_P"4G_[=1_PR-_U.W_E)_P#MU?25% 'S;_PR-_U.W_E)_P#MU'_#(W_4[?\
ME)_^W5])44 ?-O\ PR-_U.W_ )2?_MU'_#(W_4[?^4G_ .W5])44 ?-O_#(W
M_4[?^4G_ .W4?\,C?]3M_P"4G_[=7TE10!\V_P##(W_4[?\ E)_^W4?\,C?]
M3M_Y2?\ [=7TE10!\V_\,C?]3M_Y2?\ [=1_PR-_U.W_ )2?_MU?25% 'S;_
M ,,C?]3M_P"4G_[=1_PR-_U.W_E)_P#MU?25% 'S;_PR-_U.W_E)_P#MU'_#
M(W_4[?\ E)_^W5])44 ?-O\ PR-_U.W_ )2?_MU'_#(W_4[?^4G_ .W5])44
M ?-O_#(W_4[?^4G_ .W4?\,C?]3M_P"4G_[=7TE10!\V_P##(W_4[?\ E)_^
MW4?\,C?]3M_Y2?\ [=7TE10!\V_\,C?]3M_Y2?\ [=1_PR-_U.W_ )2?_MU?
M25% 'S;_ ,,C?]3M_P"4G_[=1_PR-_U.W_E)_P#MU?25% 'S;_PR-_U.W_E)
M_P#MU'_#(W_4[?\ E)_^W5])44 ?-O\ PR-_U.W_ )2?_MU'_#(W_4[?^4G_
M .W5])44 ?-O_#(W_4[?^4G_ .W4?\,C?]3M_P"4G_[=7TE10!\V_P##(W_4
M[?\ E)_^W4?\,C?]3M_Y2?\ [=7TE10!\V_\,C?]3M_Y2?\ [=1_PR-_U.W_
M )2?_MU?25% 'S;_ ,,C?]3M_P"4G_[=1_PR-_U.W_E)_P#MU?25% 'S;_PR
M-_U.W_E)_P#MU'_#(W_4[?\ E)_^W5])44 ?-O\ PR-_U.W_ )2?_MU'_#(W
M_4[?^4G_ .W5])44 ?-O_#(W_4[?^4G_ .W4?\,C?]3M_P"4G_[=7TE10!\V
M_P##(W_4[?\ E)_^W4?\,C?]3M_Y2?\ [=7TE10!\V_\,C?]3M_Y2?\ [=1_
MPR-_U.W_ )2?_MU?25% 'S;_ ,,C?]3M_P"4G_[=1_PR-_U.W_E)_P#MU?25
M% 'S;_PR-_U.W_E)_P#MU'_#(W_4[?\ E)_^W5])44 ?-O\ PR-_U.W_ )2?
M_MU'_#(W_4[?^4G_ .W5])44 ?-O_#(W_4[?^4G_ .W4?\,C?]3M_P"4G_[=
M7TE10!\V_P##(W_4[?\ E)_^W4?\,C?]3M_Y2?\ [=7TE10!\V_\,C?]3M_Y
M2?\ [=1_PR-_U.W_ )2?_MU?25% 'S;_ ,,C?]3M_P"4G_[=1_PR-_U.W_E)
M_P#MU?25% 'S;_PR-_U.W_E)_P#MU'_#(W_4[?\ E)_^W5])44 ?-O\ PR-_
MU.W_ )2?_MU'_#(W_4[?^4G_ .W5])44 ?-O_#(W_4[?^4G_ .W4?\,C?]3M
M_P"4G_[=7TE10!\V_P##(W_4[?\ E)_^W4?\,C?]3M_Y2?\ [=7TE10!\V_\
M,C?]3M_Y2?\ [=1_PR-_U.W_ )2?_MU?25% 'S;_ ,,C?]3M_P"4G_[=1_PR
M-_U.W_E)_P#MU?25% 'S;_PR-_U.W_E)_P#MU'_#(W_4[?\ E)_^W5])44 ?
M-O\ PR-_U.W_ )2?_MU'_#(W_4[?^4G_ .W5])44 ?-O_#(W_4[?^4G_ .W4
M?\,C?]3M_P"4G_[=7TE10!\V_P##(W_4[?\ E)_^W4?\,C?]3M_Y2?\ [=7T
ME10!\V_\,C?]3M_Y2?\ [=1_PR-_U.W_ )2?_MU?25% 'S;_ ,,C?]3M_P"4
MG_[=1_PR-_U.W_E)_P#MU?25% 'S;_PR-_U.W_E)_P#MU'_#(W_4[?\ E)_^
MW5])44 ?-O\ PR-_U.W_ )2?_MU'_#(W_4[?^4G_ .W5])44 ?-O_#(W_4[?
M^4G_ .W4?\,C?]3M_P"4G_[=7TE10!\V_P##(W_4[?\ E)_^W4?\,C?]3M_Y
M2?\ [=7TE10!\V_\,C?]3M_Y2?\ [=5_1_V8=2\/ZG'J&B_$.:RNH^!)%I>"
M1W!'G8(/<'(/>OH.B@#YRN?V3I+N[FN9_&R^9,[2/LT8(N2<G"K* ![  "HO
M^&1O^IV_\I/_ -NKZ2HH ^;?^&1O^IV_\I/_ -NH_P"&1O\ J=O_ "D__;J^
MDJ* /FW_ (9&_P"IV_\ *3_]NH_X9&_ZG;_RD_\ VZOI*B@#YM_X9&_ZG;_R
MD_\ VZC_ (9&_P"IV_\ *3_]NKZ2HH ^;?\ AD;_ *G;_P I/_VZC_AD;_J=
MO_*3_P#;J^DJ* /FW_AD;_J=O_*3_P#;J/\ AD;_ *G;_P I/_VZOI*B@#YM
M_P"&1O\ J=O_ "D__;JU#^S5JY\-KH"_$22/2A(96M8]("+(Y.=SXE!<C QN
MSC'&*]^HH ^;?^&1O^IV_P#*3_\ ;J/^&1O^IV_\I/\ ]NKZ2HH ^;?^&1O^
MIV_\I/\ ]NH_X9&_ZG;_ ,I/_P!NKZ2HH ^;?^&1O^IV_P#*3_\ ;J/^&1O^
MIV_\I/\ ]NKZ2HH ^;?^&1O^IV_\I/\ ]NH_X9&_ZG;_ ,I/_P!NKZ2HH ^;
M?^&1O^IV_P#*3_\ ;J/^&1O^IV_\I/\ ]NKZ2HH ^;?^&1O^IV_\I/\ ]NH_
MX9&_ZG;_ ,I/_P!NKZ2HH ^;?^&1O^IV_P#*3_\ ;J/^&1O^IV_\I/\ ]NKZ
M2HH ^;?^&1O^IV_\I/\ ]NH_X9&_ZG;_ ,I/_P!NKZ2HH ^;?^&1O^IV_P#*
M3_\ ;J/^&1O^IV_\I/\ ]NKZ2HH ^;?^&1O^IV_\I/\ ]NKI?AC\(_\ A5?Q
M3B_XG?\ :O\ :6BW?_+IY'E^7/:_[;9SYGMC'O7MM<W??\E3T+_L"ZE_Z/L:
M .DHHHH *YN^_P"2IZ%_V!=2_P#1]C725S=]_P E3T+_ + NI?\ H^QH Z2B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *YN^_Y*GH7_ &!=2_\ 1]C725S=]_R5/0O^P+J7
M_H^QH Z2BBB@ KF[[_DJ>A?]@74O_1]C725S=]_R5/0O^P+J7_H^QH Z2BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ KF[[_DJ>A?]@74O_1]C725S=]_R5/0O^P+J7_H^QH Z2BBB@ K
MF[[_ )*GH7_8%U+_ -'V-=)7-WW_ "5/0O\ L"ZE_P"C[&@#I**** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N;OO\ DJ>A?]@74O\
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M@ JW;:C-;X#'>GH:J44 =);W<5RN8SSW!ZBIJY=':-@R,5([BM>SU19,)/\
M*W9NQH T:*.M% !1110 4444 %%%% !1110 4444 %0O:6\O^L@C;ZJ#4U%
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M;=?.3_?A9?YB@#2HJFNK6#?\O<2_[[A?YU,EW;2?<N(F^C@T 344 Y&1S10
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7-WW_ "5/
M0O\ L"ZE_P"C[&NDKF[[_DJ>A?\ 8%U+_P!'V- '24444 %<W??\E3T+_L"Z
ME_Z/L:Z2N;OO^2IZ%_V!=2_]'V- '24444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 !( )/ %8>H7QN&\N,_NQ^M3:I>Y/D1'I]XC^59= !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=0-Y+'>6,K01J%W$+M,B%L;<=#7IVG_"#POIFO1ZS:G5?M\;J_G/JD[%]IR
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MZW?9/>P7< $9'7Y"X<X]@:VM4\?Z38Z18WMFZ7TFH()+2!)TC:8>Q<A1^)H
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MZ%_V!=2_]'V-=)7-WW_)4]"_[ NI?^C[&@#I**** "N;OO\ DJ>A?]@74O\
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M1110 4444 ?"GB7_ )&[6?\ L(3_ /HQJS*T_$O_ "-VL_\ 80G_ /1C5F4
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MZJJMUI\5R"<;7_O"@#GZ*FN+66V;$@X[,.AJ&@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ !PP([&NGAD\V!''\0
MS7,5N:3+OL]IZJ<?A0!>HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#X4\2_P#(W:S_ -A"?_T8
MU9E:?B7_ )&[6?\ L(3_ /HQJS* "BBB@ HHHH **** "BBB@ HHHH ****
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M%:U% '+,I5BK @CJ#25T5S917*_,,-V85BW-E+;-\PW)V84 5Z*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K3T5\22)Z@$5
MF5<TM]M\H[$$4 ;U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 ?"GB7_D;M9_["$_\ Z,:LRM/Q
M+_R-VL_]A"?_ -&-690 4444 %%%% !1110 4444 %%%% !1110 5]0?LV?\
MDTN_^PG+_P"@I7R_7U!^S9_R32[_ .PG+_Z"E 'KU%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2?7+#BO-/B[=Z=JUYX?U#1O$/VDV^I1VT]I:7:O%UW9=5Y#=._2@#V>BBB@
MHHHH **** "BBB@ HHHH *^>_BO/Y_Q N?1(D3\LU]"5\X?$9M_CW4?9\?SH
M Y>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH [?PE\3=4\/,EO?,
MU]8#C8YRZ?0_TKVO0?$NF>([,7&F7"R<?-&3\R>Q%?+M6M.U*\TF\6ZTZX>W
MF7HR&@#ZMHKS+PA\6[:_V6?B(+;7'07 ^X_U]*]+CD2:-9(G5T895E.010 Z
MD(####(/8TM% &9=Z4&R]OP?[M93HT;E74JPZ@UU%0W%K%<KB1>>Q'44 <W1
M5NZT^6WRP&]/4=JJ4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %6+$XO8_KBJ]2VQQ=Q'_;% '2T444 %%%<EXEG\8S>)+73_";V%I;&
MV::>[OK9Y5#!L! %9><'- '6T5Y'X?U[XF>(=9U[3H-6\.Q2:-/Y!9M.E(F/
M/(_><?=]Z]$\)WVIZEX5L;O7;<6VHR(?/B52H5@Q' /(X /XT ;%%%8NB>)[
M37M4U2SL1O739?)DE5@5+\Y'X8H VJ**\L^(&N^(M)^+'@NRL]4$.DZE>B.6
MVC3#/CJ&;N#GIQ0!ZG1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\*>)?^1NUG_L(3_^C&K,K3\2_P#(W:S_ -A"?_T8U9E !1110 4444 %%%%
M!1110 4444 %%%% !7U!^S9_R32[_P"PG+_Z"E?+]?4'[-G_ "32[_["<O\
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MA0G@:WT6_/B-8/LABEMG$*GH7,I&PCZ&K%YX:U/X<^(/"6M6UI+JFF:7IO\
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M&V"[G\EFC_W@.* /F2BE(*DJ>H.#24 %%%% !1110 4444 %%%% !13D1Y9
MD2L[MT51DG\*])\(?"6ZU#R[SQ$3;6Q&1;@_._U]!^M '$Z#X<U/Q'>"WTNV
M:3GYI#PB?4U[5X1^&.F>'@ES? 7M\!G>X^5#[#^M=;INEV>D6:6NG6Z00H,!
M5%6Z "BBB@ HILDB1*6D8*!ZUDW>JL^4M_E7^]W- %ZZOXK8$$[G_NBL:YO)
M;EOG.%[*.E0$DG).3ZFB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ K6T6/Y9)/7@5DUOZ;'Y=BG^U\U %NBBB@
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M4* )9[F2X?=(V?0=A45%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MFG_"30E;=XH-)B92R\;RYY XR3BOH98HU.510?4"CRT#;@BY]<4 >0P:Q%X
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M*I\B>@[T 7[O5$ARD/SOZ]A6/+-).Y:5B33** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5OZ?;?9[<;A\[<FL[3+7SI_,<?(GZFMR@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ^%/$O\ R-VL_P#80G_]&-696GXE_P"1NUG_ +"$_P#Z,:LR@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KZ@_9L_P"2:7?_ &$Y?_04KY?KZ@_9L_Y)
MI=_]A.7_ -!2@#UZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *YN^_Y*GH7_8%U+_T?8UTE<W??\E3T+_L"ZE_Z/L:
M.DHHHH *YN^_Y*GH7_8%U+_T?8UTE<W??\E3T+_L"ZE_Z/L: .DHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "HYX5N(6C?H?TJ2B@#F9X6@F:-^H_6HZWM0L_M,
M6Y/]8O3WK"(*L0PP1U% "4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5)!"UQ,L:=^I]*8JEF"
MJ,D]!6]868M8LM_K&ZGTH L0PK!"L:=!^M/HHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** /A3Q+_R-VL_]A"?_ -&-696GXE_Y&[6?^PA/_P"C&K,H **** "BBB@
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M]@74O_1]C725S=]_R5/0O^P+J7_H^QH Z2BBB@ HHHH **** "BBB@ HHHH
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M'V- '24444 %<W??\E3T+_L"ZE_Z/L:Z2N;OO^2IZ%_V!=2_]'V- '24444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !7-WW_)4]"_[ NI?^C[&NDKF[[_ )*GH7_8%U+_ -'V
M- '24444 %<W??\ )4]"_P"P+J7_ */L:Z2N;OO^2IZ%_P!@74O_ $?8T =)
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %<W??\E3T+_L"ZE_Z/L:Z2N;OO^2IZ%_V!=2_]
M'V- '24444 %<W??\E3T+_L"ZE_Z/L:Z2N;OO^2IZ%_V!=2_]'V- '24444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !7-WW_)4]"_[ NI?^C[&NDKF[[_ )*GH7_8%U+_ -'V
M- '24444 %<WKVGZY_PE6EZSH-KI]W]ELKJTEAO;Q[;_ %KV[AE98I,X\@@@
M@=17244 <W]N\;_]"]X?_P#!]/\ _(='V[QO_P!"]X?_ /!]/_\ (==)10!S
M?V[QO_T+WA__ ,'T_P#\AT?;O&__ $+WA_\ \'T__P AUTE% '-_;O&__0O>
M'_\ P?3_ /R'1]N\;_\ 0O>'_P#P?3__ "'7244 <W]N\;_]"]X?_P#!]/\
M_(='V[QO_P!"]X?_ /!]/_\ (==)10!S?V[QO_T+WA__ ,'T_P#\AT?;O&__
M $+WA_\ \'T__P AUTE% '-_;O&__0O>'_\ P?3_ /R'1]N\;_\ 0O>'_P#P
M?3__ "'7244 <W]N\;_]"]X?_P#!]/\ _(='V[QO_P!"]X?_ /!]/_\ (==)
M10!S?V[QO_T+WA__ ,'T_P#\AT?;O&__ $+WA_\ \'T__P AUTE% '-_;O&_
M_0O>'_\ P?3_ /R'1]N\;_\ 0O>'_P#P?3__ "'7244 <W]N\;_]"]X?_P#!
M]/\ _(='V[QO_P!"]X?_ /!]/_\ (==)10!S?V[QO_T+WA__ ,'T_P#\AT?;
MO&__ $+WA_\ \'T__P AUTE% '-_;O&__0O>'_\ P?3_ /R'1]N\;_\ 0O>'
M_P#P?3__ "'7244 <W]N\;_]"]X?_P#!]/\ _(='V[QO_P!"]X?_ /!]/_\
M(==)10!S?V[QO_T+WA__ ,'T_P#\AT?;O&__ $+WA_\ \'T__P AUTE% '-_
M;O&__0O>'_\ P?3_ /R'1]N\;_\ 0O>'_P#P?3__ "'7244 <W]N\;_]"]X?
M_P#!]/\ _(='V[QO_P!"]X?_ /!]/_\ (==)10!S?V[QO_T+WA__ ,'T_P#\
MAT?;O&__ $+WA_\ \'T__P AUTE% '-_;O&__0O>'_\ P?3_ /R'1]N\;_\
M0O>'_P#P?3__ "'7244 <W]N\;_]"]X?_P#!]/\ _(='V[QO_P!"]X?_ /!]
M/_\ (==)10!S?V[QO_T+WA__ ,'T_P#\AT?;O&__ $+WA_\ \'T__P AUTE%
M '-_;O&__0O>'_\ P?3_ /R'1]N\;_\ 0O>'_P#P?3__ "'7244 <W]N\;_]
M"]X?_P#!]/\ _(='V[QO_P!"]X?_ /!]/_\ (==)10!S?V[QO_T+WA__ ,'T
M_P#\AT?;O&__ $+WA_\ \'T__P AUTE% '-_;O&__0O>'_\ P?3_ /R'1]N\
M;_\ 0O>'_P#P?3__ "'7244 <W]N\;_]"]X?_P#!]/\ _(='V[QO_P!"]X?_
M /!]/_\ (==)10!S?V[QO_T+WA__ ,'T_P#\AT?;O&__ $+WA_\ \'T__P A
MUTE% '-_;O&__0O>'_\ P?3_ /R'1]N\;_\ 0O>'_P#P?3__ "'7244 <W]N
M\;_]"]X?_P#!]/\ _(='V[QO_P!"]X?_ /!]/_\ (==)10!S?V[QO_T+WA__
M ,'T_P#\AT?;O&__ $+WA_\ \'T__P AUTE% '-_;O&__0O>'_\ P?3_ /R'
M1]N\;_\ 0O>'_P#P?3__ "'7244 <W]N\;_]"]X?_P#!]/\ _(='V[QO_P!"
M]X?_ /!]/_\ (==)10!S?V[QO_T+WA__ ,'T_P#\AT?;O&__ $+WA_\ \'T_
M_P AUTE% '-_;O&__0O>'_\ P?3_ /R'1]N\;_\ 0O>'_P#P?3__ "'7244
M<W]N\;_]"]X?_P#!]/\ _(='V[QO_P!"]X?_ /!]/_\ (==)10!S?V[QO_T+
MWA__ ,'T_P#\AT?;O&__ $+WA_\ \'T__P AUTE% '-_;O&__0O>'_\ P?3_
M /R'1]N\;_\ 0O>'_P#P?3__ "'7244 <W]N\;_]"]X?_P#!]/\ _(='V[QO
M_P!"]X?_ /!]/_\ (==)10!S?V[QO_T+WA__ ,'T_P#\AT?;O&__ $+WA_\
M\'T__P AUTE% '-_;O&__0O>'_\ P?3_ /R'1]N\;_\ 0O>'_P#P?3__ "'7
M244 <W]N\;_]"]X?_P#!]/\ _(='V[QO_P!"]X?_ /!]/_\ (==)10!S?V[Q
MO_T+WA__ ,'T_P#\AT?;O&__ $+WA_\ \'T__P AUTE% '-_;O&__0O>'_\
MP?3_ /R'1]N\;_\ 0O>'_P#P?3__ "'7244 <W]N\;_]"]X?_P#!]/\ _(='
MV[QO_P!"]X?_ /!]/_\ (==)10!S?V[QO_T+WA__ ,'T_P#\AT?;O&__ $+W
MA_\ \'T__P AUTE% '-_;O&__0O>'_\ P?3_ /R'1]N\;_\ 0O>'_P#P?3__
M "'7244 <W]N\;_]"]X?_P#!]/\ _(='V[QO_P!"]X?_ /!]/_\ (==)10!S
M?V[QO_T+WA__ ,'T_P#\AT?;O&__ $+WA_\ \'T__P AUTE% '-_;O&__0O>
M'_\ P?3_ /R'1]N\;_\ 0O>'_P#P?3__ "'7244 <W]N\;_]"]X?_P#!]/\
M_(='V[QO_P!"]X?_ /!]/_\ (==)10!S?V[QO_T+WA__ ,'T_P#\AT?;O&__
M $+WA_\ \'T__P AUTE% '-_;O&__0O>'_\ P?3_ /R'1]N\;_\ 0O>'_P#P
M?3__ "'7244 <W]N\;_]"]X?_P#!]/\ _(='V[QO_P!"]X?_ /!]/_\ (==)
M10!S?V[QO_T+WA__ ,'T_P#\AT?;O&__ $+WA_\ \'T__P AUTE% '-_;O&_
M_0O>'_\ P?3_ /R'1]N\;_\ 0O>'_P#P?3__ "'7244 <W]N\;_]"]X?_P#!
M]/\ _(='V[QO_P!"]X?_ /!]/_\ (==)10!S?V[QO_T+WA__ ,'T_P#\AT?;
MO&__ $+WA_\ \'T__P AUTE% '-_;O&__0O>'_\ P?3_ /R'1]N\;_\ 0O>'
M_P#P?3__ "'7244 <W]N\;_]"]X?_P#!]/\ _(='V[QO_P!"]X?_ /!]/_\
M(==)10!S?V[QO_T+WA__ ,'T_P#\AT?;O&__ $+WA_\ \'T__P AUTE% '-_
M;O&__0O>'_\ P?3_ /R'1]N\;_\ 0O>'_P#P?3__ "'7244 <W]N\;_]"]X?
M_P#!]/\ _(='V[QO_P!"]X?_ /!]/_\ (==)10!S?V[QO_T+WA__ ,'T_P#\
MAT?;O&__ $+WA_\ \'T__P AUTE% '-_;O&__0O>'_\ P?3_ /R'1]N\;_\
M0O>'_P#P?3__ "'7244 <W]N\;_]"]X?_P#!]/\ _(='V[QO_P!"]X?_ /!]
M/_\ (==)10!S?V[QO_T+WA__ ,'T_P#\AT?;O&__ $+WA_\ \'T__P AUTE%
M '-_;O&__0O>'_\ P?3_ /R'1]N\;_\ 0O>'_P#P?3__ "'7244 <W]N\;_]
M"]X?_P#!]/\ _(='V[QO_P!"]X?_ /!]/_\ (==)10!S?V[QO_T+WA__ ,'T
M_P#\AT?;O&__ $+WA_\ \'T__P AUTE% '-_;O&__0O>'_\ P?3_ /R'1]N\
M;_\ 0O>'_P#P?3__ "'7244 <W]N\;_]"]X?_P#!]/\ _(='V[QO_P!"]X?_
M /!]/_\ (==)10!S?V[QO_T+WA__ ,'T_P#\AT?;O&__ $+WA_\ \'T__P A
MUTE% '-_;O&__0O>'_\ P?3_ /R'1]N\;_\ 0O>'_P#P?3__ "'7244 <W]N
M\;_]"]X?_P#!]/\ _(='V[QO_P!"]X?_ /!]/_\ (==)10!S?V[QO_T+WA__
M ,'T_P#\AT?;O&__ $+WA_\ \'T__P AUTE% '-_;O&__0O>'_\ P?3_ /R'
M1]N\;_\ 0O>'_P#P?3__ "'7244 <W]N\;_]"]X?_P#!]/\ _(='V[QO_P!"
M]X?_ /!]/_\ (==)10!S?V[QO_T+WA__ ,'T_P#\AT?;O&__ $+WA_\ \'T_
M_P AUTE% '-_;O&__0O>'_\ P?3_ /R'1]N\;_\ 0O>'_P#P?3__ "'7244
M<W]N\;_]"]X?_P#!]/\ _(='V[QO_P!"]X?_ /!]/_\ (==)10!S?V[QO_T+
MWA__ ,'T_P#\AT?;O&__ $+WA_\ \'T__P AUTE% '-_;O&__0O>'_\ P?3_
M /R'1]N\;_\ 0O>'_P#P?3__ "'7244 <W]N\;_]"]X?_P#!]/\ _(='V[QO
M_P!"]X?_ /!]/_\ (==)10!S?V[QO_T+WA__ ,'T_P#\AT?;O&__ $+WA_\
M\'T__P AUTE% '-_;O&__0O>'_\ P?3_ /R'45C8^([SQI9ZOKECI=C;V>GW
M-JJV>H27+R--);L"0T$8  @/<_>%=310 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
/ 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>dgx-20221231_g5.jpg
<TEXT>
begin 644 dgx-20221231_g5.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\
M27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV
M_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'R!_P7X_Y0V?M"?]D_
MF_\ 1T5?QA5_9[_P7X_Y0V?M"?\ 9/YO_1T5?QA4 ?O]_P &FW_*4S]KO_MX
M_P#3Y/7[_5^ /_!IM_RE,_:[_P"WC_T^3U^_U !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% 'R!_P7X_Y0V?M"?]D_F_\ 1T5?QA5_9[_P7X_Y0V?M
M"?\ 9/YO_1T5?QA4 ?O]_P &FW_*4S]KO_MX_P#3Y/7[_5^ /_!IM_RE,_:[
M_P"WC_T^3U^_U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'R!_P7
MX_Y0V?M"?]D_F_\ 1T5?QA5_9[_P7X_Y0V?M"?\ 9/YO_1T5?QA4 ?O]_P &
MFW_*4S]KO_MX_P#3Y/7[_5^ /_!IM_RE,_:[_P"WC_T^3U^_U !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%?,W_  63
M_:;\6?L=_P#!+WXU?M#> ;U[37M%\&26^A7T1P]G>WDL=E!<+_M1R7*2#W04
M ?$?_!2C_@Y,\:>&?VL;;_@FS_P27^#FF_%+XO7NNC0[OQ#JCM)I5CJ.2LEM
M!'&Z?:'APYEF>1(8?+;=Y@5]OT-\'OV-O^"Z4GAB#Q?\;?\ @LMX?M?%$\(E
MF\):-\ =&O-"LI#R8?/;[/=W* \;P\)QGCO7XV_\&9/PKT#Q]_P4^\7?%'Q+
M MU>>#OA5?76D23?,\5Y=7EI;-,"><^1)<H3Z3&OZ@: /S>^"?\ P4(_X*B:
M?_P5K\ _\$W?VT?@UX&\/Z?=^%=;U]O'?@(W$FG>-K:"WQ UO'=AY+(Q29,L
M/F-('V<^6RF7](:Y'QA\#OAQXZ^*W@[XU>(M$\WQ'X#&HKX;U!7VM;I?0+#<
MQG^\CJD9(_O1H>U?E=_P4O\ ^"V'[1WC7_@J[X&_X(T?\$\OB!8>"]1U'Q18
M:3\1OBF^C0:E=Z?+.%FGM[&&X5H,P6Q+.[JS&4^6#%Y;,X!^O]%?C)^W5_P5
M:_;"_P""#'_!0SX?_"/]H7]H'5_CK\!_B%H,5]>W?C#0M.M_$>@$7+P73P7&
MFVUM'<^7B.8))&=ZN8AL($I^CO\ @X@_;._:D_8I_8$TW]M/]BC]H)-#N+;Q
M!IUI-9/X?T[4K#5[*]#;)@;B!Y$=2$*LCA"K-E22K* ?H;17X<?L5?MK?\%\
M/^"F?_!*GQK^TWX&_:B\$_#F3P,=;N%\7?\ "&6=UJOBV6TMQ.=/BA$8M]-M
MXT^7[08Y9I)'. BIEL+_ ((7_P#!:#_@K]_P4Z\*^+/V--'\5>#IO'FDP1:G
M_P +U\5:+"PT#1V)BD5M,M1%'J%YYIA$&?+3#2M,S;%5P#]Y**_ O_@G!_P6
M3_X*=?!C_@N5>_\ !+O]NW]H:R^*V@7WC74?"LNJMX;L[%[6\CCEDM;VV^S0
MQE5D9(U:%RZJLIV_,N3[?_P<]?\ !2W_ (*#_P#!+#Q9\+/&_P"R3^TB+#1O
MB.NKPZAX9UGP?I5[#ITU@EAM>WEDMO.*R_:G9UD=\,ORD*0B@'["T5^*'QB^
M-G_!P-\7_P#@D+HO_!5GP'^VMX;^'Y\/_#RT\23_  VT'X?V%U<Z_I\42M=:
MQ=7TZ/'%+(@EN5LHH!"L.Q&8R!J^I/\ @W9_X+'^(O\ @K5^S'KO_"YM+T^R
M^*'PYO[:R\6G2HO*MM3MKA':TOTBR?*:3R9T>,94/"67:KJB@'Z%T5^-O[#G
M_!7O]H7_ (+8?\% OBY^R=\/?VC?$_[/OAGP=HMS>> [7P9X0TV\U76(+>\%
MK/<ZC=ZG;W"V[AI;=Q;PQ1\2,GFYBW2<E_P0O_X+=?MQ_$#_ (*@>+?^"57[
M;GQ%L_B4MIJWB'3/#GC@Z);:??07>DO.7$BVR)'+#+%;RL-RF16V_.RY  /V
M_HK\=?\ @Y]_X*:_\%"/^"5_CCX4^+/V2OVCUL-&^)5OK,=_X:UCP?I5[%IT
MVG#3P'MY9+;S2LHO"661GPR':0I"+YC\:/V_/^#DK]LG]B3X-_M+_P#!.GX;
M36OAB\\/:;:^)_$.BZ-ID^O>)]=2!$U"]%C<QLEMIBWJSPQ^6@+>4TC8AD0
M ^H?^#EK]N/_ (*B_L3?"?X9:S_P3A\*:@(->UV]A\:^*M*\'1:W/I[1K;_8
M[3R9H9HXTN#)<YD,9),"JK*3\WW#^PQ\0OCW\6?V.OAI\2_VH_ 8\,?$/7/!
MMC>>+]"%LT!M+YX@9%,3$M"Q^\8F^:,L4/*FORN_X.&/^"F/_!4__@EUX)^
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MG')K%WKVD:##<,H+P6T,,UPZJ>P=YT+>ODIZ4 ?H-X4_9!_X+9> _#0\2O\
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M7&O>.],\6RZ->:98^'],L(]"M_LZ26US"D-L#(TOF2$O,9$+6VU4&UR_I?\
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M+IOCCQEH&H"/P3IME/?+I5CJC02F2"%6C)EM(G(4@'D="14O_!PI_P %0O\
M@L__ ,$EOVL]-T/X4?M,V5]\,/'^FRZGX*N=5^'^D2364D4@2ZTYY1;#S3"7
MA97(R8[B,,68,Q /WBHKXL_:#_:?^(.F?\$51^V1\#OVJ-;N?%4GPUL_$'A+
MQ>OAW2)YO$.K7D2K8Z=-9FU,"K/>7,%MY<2)*AVC>6#[Z'[6'[>7Q._X(Z?\
M$JX?VD/VX/B'_P +0^*CQ6EC%9Q6-IIMMJ'B*ZB+"P@%K$BI:P^7/(9&#2-'
M#(V261  ?<5%?B]XS_:K_P""NOAO_@BQ:?\ !;NY_;>FC\9O/:^(W^$$?@K2
M/^$2_P"$=N=32SCL@AMOMQE\N1+@SF[W[2T8YQ)7Z2?\$POV[_"?_!2C]B+P
M1^U[X6T0:3)XCLI(M;T3SO,_LW4K>5H+J ,<%D$B,R,0"T;HQ )Q0!Z7\>_"
M/QC\;?#*_P!#^ GQ=@\$>*60OI6O7F@1:G;I(%;:DUO(5WQEBN[:RM@<$5_.
MS'_P<F?\%B/@K^W?:_L@?MN?$WP7X&L]%^(EOX>^(>KV7P^@E?2K7[4L4]Y%
MO<+)&(F\Y'P0R%6 8$ _TL5^!W_!Y'_P3 _M'2M#_P""I'PE\.YFLA;^'OBL
MEM%]Z$D1Z?J3X_NL1:.QR2'M0.%)H _>#PK:ZA9^%M/L]3\3MK-S'91K/K#0
MQQF]?:,S;8@$7<?FPH"\\#%? WP,^(7_  5!^-?_  4S^(_P(\&_MB^']1^"
M'PC_ +/MO%'BF3X968U"\UV>%+B30H9$D$3/%"Z/-.%S%YJ1F/<=P^1_^"+_
M /P7D\3^./\ @E!!^S7ILL/B/]I7PEJ=C\/OA7X>OI=S^(&O5=-*OI<\FWLX
MHIVNGZ+#8!F8-,N?UK_8G_94\-?L9?LY:%\#-$UJ?6=0MO.O_%?BB^'^E>(=
M;NI&GO\ 4[AN2TD]P\C\D[5*H#A!0!ZO17Y9_P#!2C_@L/\ '74O^"HWP[_X
M(N?L">*+#PSXP\1ZO91_$CXFW6EPZA-X?MY8?MCP65M.K0/<)9*9B\JNN9$0
M*#N9<'QK_P %-_VF/^"5O_!:?P/_ ,$Z?VH/C_JGQ:^$7QBT72[CPIXI\7:7
MI]OKOAJ]OKNXL8DEGT^VMH;F W=N0^^(%(YT8-^Z82 'ZU45^4?_  64_P""
MYGQ+_90_X*(?"O\ X)K_  AU)_ ]OXOGTF;QU\5#X;CU:]TRVO[I[>)-.M)_
MW+LNS<\LB3 ;]JQLR$-\W?\ !5#_ (*L?\%)O^"$O_!2SPA\/=3_ &O-7^.G
MPP\2>$[+Q%JGAKQ]X9TBVN_)DO+JUN(([G3[6W\N4"V:2.10J R*KQ.$RP!^
M]M%?(_\ P6<^._Q[^ '_  34\<_M;_LJ?&BX\)>(O!6C0:U8,VA6-_;:E"\T
M*-#/'=PR$#9(Q5HV1@V,[AE3^7'_  37_P""U7_!=+_@H[^RE\5_AQ^S1I.@
M^-OC/HEW%>P^+-1T;3M-L?#>D& [(HDV)#=:A=3K(L"2@QJ()FDP N0#]_Z^
M>_\ @JQ^T!\9?V6?^">_Q.^/G[/,,$OC?P[HL,OAJ&XT_P"UI)=27<$*IY/_
M "T)\P@+W)%>6_\ !!OQ5_P5#\8?L67VJ_\ !6'2]0MO'R^-[V/03K>F6MG?
MRZ.(;?RVGBME5%/V@W2J2H8HJD@KM8_8WBGPEX8\;Z,WA[QAH%IJ=@]Q!.UG
M>P"2-I(94FB8JW!*21HX]&4'M0!^8G[1/BC_ (+Z?LF_\$Z/%G[;GQW_ &Z?
MA39>)O"'A+^VM1^'.C_!5+N-7RF;5M1-]& Z[\,RP.NY3M+C#'YP_P""(/\
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M]7T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&>S07-OM[<C%?T._LA_L%? K]C5-:U_P/+KWB7QIXKD27QI\2_'>L-JGB'Q
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M^NIGLG)9=+OKR"POA;N< !VC<@=V^S/_ ':_3SXX?\$,?%G[8P\#_#;]O/\
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M[FUN;AD0 EW1% RPK\WO^#)O]JWPCX4^)WQ@_8S\5:S#:ZIXKL[#Q'X3MIY
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M2 <?_P 'F=O-/_P2:T"2*,LL/QIT=Y"!]U?[/U1<G\6 _&O)?^">&I:=8?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKXJ?LI_$/5OAS;:UJJAG\13B]6RT?4;E5QO9FE7SL8,@M9'R"Y(W?VJOAO\
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M (%M1_P@^D?\_-[_ .!;4 ;%%8__  @^D?\ /S>_^!;4?\(/I'_/S>_^!;4
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M6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\
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M^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\WO\
MX%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U
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M_7Q<Z#X=O49F@EAB\L33B NQ@BNIIXK?Y3$D91"OTE10 4444 %%%% '@O\
MP3J_Y(?J_P#V/>L?^CZ]ZKP7_@G5_P D/U?_ +'O6/\ T?7O5 !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8_B7_D+Z/_
M -?I_P#036Q6/XE_Y"^C_P#7Z?\ T$T ;%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 9OC'_D6+W_K@:N:=_R#X/\
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M'ZO_ -CWK'_H^O>J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQAF.+J5I1]DXJI4E-I?O.9Q4F[?9O;ROT-.BBBOYS/Z2"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K'LO\ D=[W_KRB_F:V*Q[+
M_D=[W_KRB_F: -BBBB@ HHHH **** /D#_@OQ_RAL_:$_P"R?S?^CHJ_C"K^
MSW_@OQ_RAL_:$_[)_-_Z.BK^,*@#]_O^#3;_ )2F?M=_]O'_ *?)Z_?ZOP!_
MX--O^4IG[7?_ &\?^GR>OW^H **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#P7_@G5_R0_5_^Q[UC_T?7O5>"_\ !.K_ )(?J_\ V/>L?^CZ]ZH
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M9ZE (;D ?W)(MJL/]HJQ]<5]*_#[_@IG\$_$FRV\<Z-JGAR=L;Y&C^UVZ_\
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M;/?"#P_SZ\JF#5.;^U2_=OULO<?SBS]-Q&1Y9BE>5/E?EI^6GX'ZGM9?M?\
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MQ Q_YYM^[.1@Q@8/P)\-?A3^SW^S9\2KSPI^T#_P3W^%_B>WBN1'KOAWQ?\
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \%_X)U?\D/U?_L>]8_\
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M'U[U7@O_  3J_P"2'ZO_ -CWK'_H^O>J "BBB@ HHHH **** "BBB@ HHHH
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M*S=65L G)R,X/BO@S_@GI^T+XC\3G0/$6FV&A11A7N+NZU"*;:A/55A9BQ]
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8_B7_ )"^C_\
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MHR?U>@_AG).RG-?:Y>K=TY7BO=4D_FL%#$9WB/K6(TI1?NQ[ON^]OSTV+0
MP!1117]%GU04444 %%%% !6/XE_Y"^C_ /7Z?_036Q6/XE_Y"^C_ /7Z?_03
M0!L4444 %%%% !1110 4444 %%%% !1110 4444 9'COP!X*^)_A6[\#_$/P
MO9:QI-_'LNK"_@$D;CL<'HP/(88((!!!&:_-']MG_@CEXO\ AU]K^)/[+*76
MOZ&NZ6Y\+2,9+^R7J?(/6Y0?W?\ 6C@?O.2/U%HK['A#CKB#@O%^UP%2\&_>
MIRUA+U71_P!Y6?RT/C.,> ^'N-L)[+'T[32]VI'2<?1]5WB[KYZGY,?L6_\
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M;8RI_$JRU=WJU&^J5]W\4GK+HE]X_P#!9?\ X.%?V7O^"5>AW?PS\-O:>/\
MXRW%KG3_  -87G[G2BRY2?4YDSY"8(80C]]("N B-YJ_SV^!/AI_P57_ .#D
MK]L^XUV[O[WQ7JBNJZIX@U+?:^'/!FGNY*Q+M!2VB&"5AC#33%6;$C;WKVC_
M ((X?\&Y'[4'_!4WQ)!^U%^UAK6O>#/A/J=Z;^Z\1ZF6?7/&#.^]VLQ.&.QR
M26O90RDME%F.[;_3'^S_ /LZ?LP_L!_L_6WPH^!'@'2/ _@?PW:M,\%HA&XA
M1ON)Y6S)<3-@;I'+.QP,G@5^;5*E.E3<YM**5VWHDENV^B1^CMJ*NSY2_P""
M=O\ P20_8<_X(6? JZ^)=M;+XI^(D]B(-=^(>K6B"_OY6&?L5C&2PLX&8?<4
MEF W2NX0%>-M;?XL?MQ?'TM(^;J^?,CX)M]*LE/;T50>!U=F]6S5W]H/XV>.
MOVP?C!::#X2TVYDL!<FU\,Z,GWCN/,K]@[ 98GA%&,X4D_:W[+W[.>@?LZ?#
M]-#M_+N=9O0LNMZDJ_ZZ7'"*3R(TR0H[Y+8RQK^9<97QGCCQ7]3P[<<GPDKS
MDKKVLO+S>T?Y8-R?O243Y&I*IQ%C?9PTH0>K_F?];=EKU.H^%/PN\)_!OP-9
M> ?!MEY5I9I\\C8\RXE/WY7/=F/)]. ,  #HZ**_I7"87#8'#0P^'@H4X)1C
M%:)):))=DCZV$(4X*$59+8****Z"@HHHH **** "L?Q+_P A?1_^OT_^@FMB
ML?Q+_P A?1_^OT_^@F@#8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "N>^*'PH^'7QI\&W7@#XI>$+/6M(NQ^]M+V/(#8.'1AAHW&3AU(8=B*Z&
MBM:->MAJT:M*3C*+NFG9IK9IK5,RKT*.)HRI5HJ49*S32::>Z:>C1^4?[:W_
M  2'^)'P2DNOB5^SHU[XH\,Q$S3:8HW:GIBCG("@?:$']Y!O ZJ0"]7/V)_^
M"POCOX4&T^&_[3)O/$GAY,16^OK\^HZ>O0>9G_CY0>Y\P#/+X"U^J%?*G[;'
M_!*WX1_M-K=^._AX+;PEXUD#2/?00XL]2?K_ *3&HX8G_EJ@W<DL'X _=,D\
M3,GXFP$<FXUI>TAM&NE[\'WE;7UE'?:49:L_!L\\,,YX7Q\LZX(JNG/>=!OW
M)KM&^EO[LMMXRB[(^C_AU\2O 7Q<\(VGCSX:>+++6M(O4W6]]8S!T/JI[HPZ
M%6 93P0#6Y7XE^'_ !=^V1_P3"^,<FF2P7>AW#N&N=+O09M+UJ%3@.,';*O8
M2(0Z9(RIR*_2K]C'_@I)\$_VN+2#PXUPGAOQD(_W_AO4+@?Z00,EK60X$R]3
MMP'&#E<#<?F^,_"W,N'J']I9=/ZU@I*ZJ0LW%?WDM+?WU[O?EV/IN"O%;+.(
MJ_\ 9N90^JXZ+LZ<[I2E_<;L[_W)>]VYMSZ*HHHK\J/U@*Q[+_D=[W_KRB_F
M:V*Q[+_D=[W_ *\HOYF@#8HHHH **** "BBB@#Y _P""_'_*&S]H3_LG\W_H
MZ*OXPJ_L]_X+\?\ *&S]H3_LG\W_ *.BK^,*@#]_O^#3;_E*9^UW_P!O'_I\
MGK]_J_ '_@TV_P"4IG[7?_;Q_P"GR>OW^H **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#P7_@G5_P D/U?_ +'O6/\ T?7O5>"_\$ZO^2'ZO_V/
M>L?^CZ]ZH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ K'\2_\ (7T?_K]/_H)K8K'\2_\ (7T?_K]/_H)H V**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S?&/\
MR+%[_P!<#5S3O^0?!_UQ7^0JGXQ_Y%B]_P"N!JYIW_(/@_ZXK_(4 34444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!CV
M7_([WO\ UY1?S-;%8]E_R.][_P!>47\S6Q0 4444 %%%<G\:OC=\,OV?/ %W
M\2_BOXGATS2[08#.<R7$A!*PQ(.9)&P<*/0DX )&V'P^(Q=>-"A!RG)I))7;
M;V22W9CB<3A\'AY5Z\U"$4VY-V22W;;T2-[Q-XF\/>#/#]YXK\6ZW:Z;IFGP
M-/>W][,(XH(U&2S,W %?EC_P4&_X*H^)OC]-=_!C]GJYN]+\'.Q@OM316CN]
M<!."H'WHH#_<^\X^]@$I7!_M=?MO_'3_ (*!?$2U^&O@70M1M_#LM\(_#W@[
M309)KV7/RRW&S_6R=P/N1CI_$[?:/_!/?_@EEX8_9WCL_BY\<;6UUGQSA9;.
MRXDM=$/4;.TLX[R=%/W.F]OZ#RGACAWPKR^&<\36JXV2O2PZ:?*^C>ZNNLG>
M,?L\TK'\[YOQ3Q'XKYA/)>&&Z6"CI6Q#37,NJ6S2?2*M*?VN6-SRC_@GE_P2
M0>[^P_&W]K'0BL7RSZ-X)N4P7[K+>@]!W$'?^/NA^POVR/VVOV7/^">GP-NO
MCE^T]\2;#POX>L4\FPML!KG49PN4M+.W7YIY2!PBC"@%F*HK,/E__@LA_P '
M G[+'_!*3P[<^ +*:W\=_&&ZM-VE> --O %T_<N4N-2E7/V:+!#"/F60$;5"
MDR+_ #P>'_"W_!5K_@Y-_;2EU":YO/%NKHP%WJ5UOM/#?@K3W?(08#):Q#!Q
M&H>>8H3B5]S5^/\ %G&&=<99D\7CY[?#!?#!=HK\V]7U>Q^R<(\&Y)P7EBP>
M7PU?Q3?Q3?>3_)+1=%N>C?\ !6+_ (+S?MI?\%G?B3#^S/\  +PGKWASX:ZI
MJJ6GAWX9>&U>XU/Q-,7_ '37Y@RUS(6PRVR9B0[>)&02G]$/^")/_!J!X1^$
M/]D?M0?\%/\ 0[#Q#XI79=:'\)2Z7&FZ2W#*^I,I*7DP./W"DP+@[C-G"?<W
M_!(/_@A)^R9_P29\'1ZYX9L8_&/Q3O[/RO$'Q*U>S59\,/GM[&,EA9VY[JI+
MR?\ +1V 55^WZ^6/JB.""UL;5+:VACAAAC"QQHH544#   X  KX,_;G_ &L)
MOC#XA/PH^'=\S^'-/N0MQ/;DG^U+D' (Q]Z-3]T=&/S<_+CT/_@H#^UM_8UO
M<_ ;X;ZG_I<R;/$E_ _^IC(_X]5(_B8??/8';U+;<[_@G[^R3YK6OQ]^)&F?
M*")/#.GSIU/:[8'_ ,AY_P!_^Z:_G7Q XBS/CW/_ /4GAV5H_P#,356T8I^]
M&ZZ+:2^U*T-%S7^5S/%5LSQ/]GX5Z?;EV7;_ #[O3N>B?L.?LG1_!;PX/B#X
MXT]3XIU6 8BD7)TV!N?*'I(W!<]N%'0EOH&BBOVWAOAW+.%<FI9;@(\M."^<
MGUE)]9-ZO[E9)(^APF%HX*A&C26B_'S84445[ITA1110 4444 %%%% !6/XE
M_P"0OH__ %^G_P!!-;%8_B7_ )"^C_\ 7Z?_ $$T ;%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% ')_&;X'?"O]H+P5/\/_BYX.M=
M8TV;)1)UQ);OC DBD&&B<?WE(/4="17Y<_MG?\$J/B_^S+=S?$_X)W5_XG\*
M6DGV@3VJD:EI 4[@TJQXWJN,^=&!C!+*@&3^N5%?=<&>(7$'!5?_ &67/1;]
MZE+6+[M?RR\U\TUH?!<:^'7#W&]#_:H\E=+W:L=)KLG_ #1\G\FGJ?F/^Q-_
MP64\1>#OL?PV_:Q>XU?2EVQ6OC"&,O>6HZ#[2@YN%'=U_>#!)$A/'Z2^#?&G
MA+XA^&;3QEX%\1V>K:5?Q"2SU"PN%EBE7V9>X/!'4$$'!%?)_P"VS_P22^&'
MQ]^U_$+X(_9/"7B^3=)-;I'MT[4WZGS$4?N9"?\ EH@P3DLK$[A\)?#7XU?M
M@?\ !,WXM7'A2]T^\THB8/JGA;65,EAJ,><>:FT[3D#"S1-GC&2 5K]-Q?"?
M!OB?AI8[AB:PV,2O/#RLDWU<4MO\4;QVYHP;;/S#"<7<9^%F)C@.*(/$X)NT
M,1&[:712;U?^&5I[\LII)'[85CV7_([WO_7E%_,U^?X_X+]G W?LG G')'CO
M_P"X:IP?\%Y?)UN?6?\ AE7/G0K'Y?\ PG/3'?/V&OA_^(->)/\ T _^5:/_
M ,L/NO\ B-/AG_T'_P#E*M_\K/TDHKYS_8!_;^_X;F_X2W_BTW_"+_\ "+_8
M/^8]]N^T_:?M'_3"+9M^S_[6=_;'/T97PF<Y-F7#^95,OS"GR5H6YHWC*W-%
M26L6T[IIZ/\ $^]R7.LLXBRRGF&7U.>C._+*THWY9.+TDDU9IK5?@%%%%>6>
MJ%%%% 'R!_P7X_Y0V?M"?]D_F_\ 1T5?QA5_9[_P7X_Y0V?M"?\ 9/YO_1T5
M?QA4 ?O]_P &FW_*4S]KO_MX_P#3Y/7[_5^ /_!IM_RE,_:[_P"WC_T^3U^_
MU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >"_\$ZO^2'ZO_V/
M>L?^CZ]ZKP7_ ()U?\D/U?\ ['O6/_1]>]4 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5C^)?^0OH_P#U^G_T$UL5C^)?
M^0OH_P#U^G_T$T ;%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 9OC'_D6+W_K@:N:=_P @^#_KBO\ (53\8_\ (L7O
M_7 U<T[_ )!\'_7%?Y"@":BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** ,>R_P"1WO?^O*+^9K8K'LO^1WO?^O*+^9K8
MH ***^9OV]/^"D7P\_9$TF7P=X9^S:]X\N(,VNCB3,.GAA\LUT5.5'<1@AWX
M^ZIW5ZV2Y'FG$68PP.7TG4J2Z+HNK;V275O0\G/,]RKAS+9X[,*JITX]7U?1
M);MOHEJ=_P#M;_ME?"+]CWP,?$WQ U#[3JETC#1/#MI(/M6H2#T'_+.,'[TA
M&!VW,0I_*;QAXW_:M_X*A_'^#2[2QEU&Z9F_LW2+5F33M#M2PW.Q.0BCC=(V
M6<X')VK4_P %/@%^T]_P4S^-][XKUK7+FY22X4^(O%^IH3;6$?411J, L%X2
M!, <9VKEA^BGBGQ;^P?_ ,$7OV5+SX@?%+QK8>%/#UH!]NU?4")=3\07H4E8
MHT4;[F9L-MAC&U!N.%4,U?O4ZG#/@K@^2ERXK-YK5_9I77WI>6DY]>6+2/Y_
MA2XG\;L:IU>;"Y1"6B^U5L_N;\]80Z<TDV:?[&?["7P;_8;\$3^*-2O[.^\2
MFQ:3Q#XPU#;$EO"J[I$B+G$$"@$L2<MC<QP J_DW_P %MO\ @[(T[P[_ &O^
MRY_P2O\ $$-[??/::]\91&'@MSRKQZ2C B5NH^UL-@P3$KY29?AW_@KC_P %
M_P#]L3_@L/X]7]F/]G/POK_A?X8:IJ:6>B?#S0%>?5O%4I<"(WY@R9V9L%;2
M/,2MC/FLJR5][_\ !$G_ (-._#OPZ_LC]J+_ (*D:#9ZSKPV7>A?!\R+-8Z>
MW#*^J,I*W4H.#]F4F%<?O#+N*)^ YMF^99[CYXW'U'4JSW;_ "71)=$K)+8_
MH/*,GRS(<OA@<!25.E#9+\V]VWU;NV]SX6_X(^?\&[W[5_\ P5F\71_M0?M0
M>(->\(?"K5+]K[4?&.L,TNM>+Y&<M(;(3[BX<D[KV7*9)VB9@RK_ $Z?LH?L
MB?LZ?L0_!C3?@#^S!\+M.\*>&=,7*VEE&3)=3$ -<7$K9>XF; W22%F. ,X
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M$.NWF9+S[=J/V6:);>VB6UAC\S8BRO=[G&U<@'Z]T5\/?M(?$+P]_P $/_\
M@CQXZ^+_ ( ^-'CGXJW?AK3'N_#/BGXK>+VU[4=5U/4KF.WLC+<!462WC>>$
MA(U1?)B)^\S.?'OVJOAO\8/V$O\ @DUHG_!2#P#\5?%>K?'OP'H^@^+_ ![K
MVN^)[R>'QB+B:V_M;3+VV:0P"R,=S-Y,21K]F\B'R?+*DD _4*BN:^#'Q3\-
M_'/X/>%/C9X-9SH_C'PU8:YI1DQN-M=VZ3Q9QQG9(M=+0 4444 >"_\ !.K_
M )(?J_\ V/>L?^CZ]ZKP7_@G5_R0_5_^Q[UC_P!'U[U0 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6/XE_P"0OH__ %^G
M_P!!-;%8_B7_ )"^C_\ 7Z?_ $$T ;%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 9OC'_D6+W_ *X&KFG?\@^#_KBO
M\A5/QC_R+%[_ -<#5S3O^0?!_P!<5_D* )J*** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHK\Y_^'_G_ %:;_P"7Y_\ <-?4
M<-\&<2\7>U_LFA[7V7+S>]"-N:_+\<HWORO:]K:]#Y;B7C7AG@_V7]KU_9>U
MYN7W9RORVYO@C*UN9;VO?3J?H!9?\CO>_P#7E%_,UL5^;<'_  7E\G6Y]9_X
M95SYT*Q^7_PG/3'?/V&O.OVJO^"Q_P 7?C[X";X=_#7P3_P@5I>JR:S=VNN&
M[NKJ(C'E)((8O)0\[L LPXW ;@WV6 \$O$'%8R%*OAE2@WK-U*<E%=[1G*3\
MDEOV6I\5F'CCX>87!SJX?$NK-+2$:=2+D^UYPC%>;;V[O0^@?^"AO_!6+2/A
M7]N^"W[,^J6^H>)EW0:MXECVR6^E-T:.'JLLX[GE$/'S-D+\Q?L._P#!.SXJ
M?MJ>)V^+/Q6U/4M.\'37C3:AKUVY:\UJ7<2ZP&3)8ELAIFR <XW,"!Z'^P#_
M ,$II/%MC;_'[]K6T.E>&;>+[98>&[U_(>\B4;O/NB2##  ,[3AF')VK]_Y@
M_P""T?\ P=9>$/A5IVH?LB_\$F[_ $Z[OK2$Z?JGQ7M;9&T_3$4;##I$6-D[
M+C:+D@PJ!^Z63*R)]7G?%_#_ (;9=/(N%+3Q+TJXAV;OU47LVNB7NP_O2NU\
MGD?!W$/B9F4,^XMO##+6CAE=*W1R6Z3ZM^_/^[&R?VG_ ,%//^"TO["O_!#S
MX10? OX>:#I_B#XB1:>/^$;^%V@W04VNY<K=:E,-QMXVR&RVZ:8G*J06D7^?
M*&#_ (*M_P#!R?\ MIER;SQ;K"'YG;?:>&O!&G._3^)+6$;>GSSSE/\ EM)U
M]4_X)$_\&^W[7W_!7WQS_P -._M)>)M?\*_"[5-2>]UCQ]KK//K'BR5G+2_8
M1/DS%FR&O)<QJQ./.960?T[_ +(?[&G[-O["7P6T_P" /[+?PNL/"_ARP&YX
MK5=T]].0 US<S-E[B9L#,CDG "C"JH'\_5JU7$595:LG*4FVVW=MO=MO5M]S
M^AJ-&CAZ,:5**C&*222LDELDEHDNB/F3_@CU_P $$_V4/^"3OA2'Q7IMK%XU
M^+5[9^7KGQ&U6R4/ &7#V^GQ$M]C@Z@D$R2?QN1M1?NNBBLS0*Q/B-\0O"WP
MK\&7WCOQEJ(MK"PAWR-U9VZ+&@_B=C@ >IK5U'4;#2-/GU75;R*WMK:%I;BX
MF<*D:*,LS$\   DFOSP_:P_:.\1_M1?$>V\'>!K>ZET*UO!!H6G0H=]].QV^
M>R]2S9PH/W5/8LU?G7B1Q]A>!<F]I%<^*J^[2I[WE_,TM>6-U?N[16]UY6;9
MG#+:%]YO2*\_\E_P#'\7^)_BK^V]\>8K?3K-C->2&'3+'>3#IMH#DLQQP /F
M=L98G@?=6OOWX&?!7PG\!OA_:^!/"T6[9^\O[UD DO)R!NE;\L =E ':N1_9
M#_9ATO\ 9W\$>;J<<4_B75(U?6+Q<$1#J+>,_P!Q>Y_B;GH% ]>KPO"W@'%9
M'"IGN=OGS'$^])RU=-2UY?\ $_M6T5E%:+7FR;+)X=/$XC6K/?R\O\_N"BBB
MOV(]X**** "BBB@ HHHH **** "BBB@ K'\2_P#(7T?_ *_3_P"@FMBL?Q+_
M ,A?1_\ K]/_ *": -BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "L>R_Y'>]_Z\HOYFMBL>R_Y'>]_P"O*+^9H V*
M*** "BBB@ HHHH ^0/\ @OQ_RAL_:$_[)_-_Z.BK^,*O[/?^"_'_ "AL_:$_
M[)_-_P"CHJ_C"H _?[_@TV_Y2F?M=_\ ;Q_Z?)Z_?ZOP!_X--O\ E*9^UW_V
M\?\ I\GK]_J "BBB@ HHHH *QO'?C;P9X T&/6O'NKP66GW>J6&E)+<H622Z
MOKN&RM8< 'F2XN(8AGC,@R0,FMFN%_:4_9R^%/[6GP5UK]G_ .->DWMYX;UT
MVSWD>FZM<6%Q'+;7,5U;S17%LZ2Q21SP0R*RL.8QG(R" ?D-^W7^Q[XZ_P""
M6_[0OQS_ ."E_P#P2I\9V?PWB^&6G^'=9^(7P>,;?\(UXOL+QI_M2F#<%MY%
M*AD6,*%#/Y7E.?G_ %MO_'B_%/\ 9)G^)RZ+/IH\1_#EM4&G77^MM?M%@9?*
M?@?,N_:>!R#7@]I_P2,\$^+OB/K]_P#M)_M _$+XI^"-2;0YK?P1XQUJW:UO
M9M-\UH?[3-K;02:E''(R.D5P\B,RYE64A2/ICXN_#.'XN_#K4OAI<>,=:T&T
MU:T>UO;SP[-#%=&W="CQI)+%)Y>Y6(W( XZJRGF@#XX_X-G?^4'GP'_[!NM?
M^GW4:^KOVEOV6OV?OVPOA/J?P1_:3^%6C^+?#>JV[Q36.K6BR&%F7 FAD^_!
M,O598RKJ0"""*YO]A_\ 8B^%G_!/[X)V7[.GP)\3^)YO!>DM(="T3Q%J<=XN
MF>;/+/,(9?*67:\LSL5=W /W0N3GS#PC_P $=?V=? _Q*\8^-?#7QL^-MIH/
MCW7KK6/$_P .;;XM:A#X?NKNY<R3L((F655D9CO03!74[&!3"4 ?FY\=_P!F
MGXW:O_P:E?%+X,VVOZCXJTWX7_$75V^'VJ7),DVJ>$-'\3F..Z!'6);>*YF0
M_=\F)-OR!:^S/^"S_P 8/"NM_P#!NYX[^)F@W27%AXP^%>@)H(M_G-T=2GL(
M[=8P.7+>>I ';GM7WII_@3P1I/@B'X9Z7X/TNV\.6^EKIEOH$%A&EE'9+'Y0
MMEA V"(1_)Y8&W;QC%>!>"O^"6/[-/@U?"7AB75_%^M>!?A[K:ZQ\/?AAK^O
MBYT'P[>HS-!+#%Y8FG$!=C!%=33Q6_RF)(RB%0#N?V"OA1XD^ _[#/P8^!_C
M&%H]7\&_"CP[H>JQN>4N;33;>"5?P>-A7K-%% &3XZL_&-_X1O[/X?ZQ::?K
M4D!&G7M];F6&&3(PSH/O#&>*\A_X0'_@H)_T7_P)_P"$I)_\57NE% 'S7_P3
MGL?'(^!.IB37+(N/&FJ"4BU.&<2 .1SP"V2!V!KWS[%XW_Z#=E_X#'_&O'?^
M"=7_ "0_5_\ L>]8_P#1]>]4 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !
MC_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0
M;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\
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M!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\
M8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B
M\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%%
M&/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\
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M &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\ ]!NR_P#
M8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\
MP&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\
M]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_
M /0;LO\ P&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44
M8_V+QO\ ]!NR_P# 8_XU!H,=_%XLO$U.XCEF^QQ[GC3:#R<<5OUCV7_([WO_
M %Y1?S- &Q1110 4444 %%%% 'R!_P %^/\ E#9^T)_V3^;_ -'15_&%7]GO
M_!?C_E#9^T)_V3^;_P!'15_&%0!^_P!_P:;?\I3/VN_^WC_T^3U^_P!7X _\
M&FW_ "E,_:[_ .WC_P!/D]?O]0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% '@O_!.K_DA^K_\ 8]ZQ_P"CZ]ZKP7_@G5_R0_5_^Q[UC_T?7O5
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M* "BBB@ HHHH *Q[+_D=[W_KRB_F:V*Q[+_D=[W_ *\HOYF@#8HHHH ****
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MS_P4._8U_88\./X@_:;^/>@>&W\LO;Z5<7R->W/&0$@!W<]B<+[U^.W[=?\
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M<  <DD <FOSI^,GQ4^(W[:'QKM=*\.:9.\4LYM?#FC!N((B<F1\<!B!O=N@
MQG"BND_;6_:FOOCWXO3X;_#R>67PW8782W6W!+:K<YVB3 Y*@G"+WSNZD!?H
M_P#8I_93MO@/X4_X2OQ;:(_BO5H!]J)PWV"$X(MU/KT+D=2 !D*"?YGXBS+'
M>,G%/^KV53<<MP[3KU5M-I[)[-734%LVG4=U%'R.*JU,^QGU6B[4H_$^_P#7
M3[^AVG[-_P"S_P"&OV>/A]#X4TD)<:A/MEUG4]F&NI\=NX1<D*O8<]22?0**
M*_HK+,MP.3Y?3P6#@H4J:48Q71+\WU;>K=V]3ZJC1IT*2ITU9+8****[C0**
M** "BBB@ HHHH **** "BBB@ HHHH **** "L?Q+_P A?1_^OT_^@FMBL?Q+
M_P A?1_^OT_^@F@#8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ K'LO^1WO?\ KRB_F:V*Q[+_ )'>]_Z\HOYF@#8H
MHHH **** "BBB@#Y _X+\?\ *&S]H3_LG\W_ *.BK^,*O[/?^"_'_*&S]H3_
M +)_-_Z.BK^,*@#]_O\ @TV_Y2F?M=_]O'_I\GK]_J_ '_@TV_Y2F?M=_P#;
MQ_Z?)Z_?Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /!?^"=7
M_)#]7_['O6/_ $?7O5>"_P#!.K_DA^K_ /8]ZQ_Z/KWJ@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L?Q+_R%]'_Z_3_Z
M":V*Q_$O_(7T?_K]/_H)H V**** "BBB@ HHHH **** "BBB@ HHHH ****
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M  4O_P""BWQ-A\2>*M,\=>-/$.KN%CUOQOJ-U=74X)R-@F+SR+SD>6C "N_
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M .@FMBL?Q+_R%]'_ .OT_P#H)H V**** "BBB@ HHHH **** "BBB@ HHHH
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MKS,WSG*L@P$L;F-:-*E'>4G]R75M]$DV^B,:^(HX:FZE65DNK._LO^1WO?\
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MJ_Y(?J__ &/>L?\ H^O>J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *Q_$O\ R%]'_P"OT_\ H)K8K'\2_P#(7T?_ *_3
M_P"@F@#8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M ***S/&?C;P9\.?"][XW^(7B[3-!T738#-J.KZS?QVMK:QCJ\DLK*B*/5B!0
M!IT5^3G[?_\ P=V?\$^_V8OMO@O]E?3;[XV^*X-T:W.CS&QT&"0<?-?2(6GQ
MP1]GBD1AD>:O6OQ0_;=_X+O?\%7_ /@IU/JOA+6_B;J>@^#S;237G@/X96LU
MCI\=ID!C=NC-/<1<KN-Q*T8."%7-5&,IR48J[>R)E*,(N4G9+=GZS?\ !UA_
MP69^"_A+]D^__8!_9B^->B^(/&WCJ_%E\0/^$;U-+G^PM'B(>:VFDB)6.>XD
M$<1B)W"(3;E7<F?R_P#@%_P<Y?\ !3#]E[]B/PM^Q3\#]9\+:9;^$K::STOQ
MQ?Z)]OU>*S,C/#;(+AVM@D(8QJ6A<A%C48V\_G?7J7[%G[3/B']C_P#::\*?
MM!^&K+3;B?0;_,J:IH=KJ*+#(ICD=8;J.2/S51V9&VY5U4@@C-70IJM6C3<E
M%-I7=[*[W=DW9;NR;MLF17JNC0E447)Q3?*K7=E>RNTKO97:5]VCZ7\%_L7_
M /!=W_@M?XGM?'VL^$?BI\1K&YD\RS\6>/\ 4Y+/0[9&^\UM+>M';A #GR[8
M$\\*<\_:/PM_X-._@A^SEH]KXY_X*L?M_:;HA>,2_P#""_"^W,U[<CKA+FYC
M+MS\IVVA4$_ZP#FOK#4O^"R/[7WQ!^$&D>%?#OCFQAFN;1GNO%^FV$*WNII*
M[/&4V(L4"B)XT!C0,=N[=DT_X%_\$R?VQOVK-8_X3OQS;77A_3]0D$MUXD\9
MRRFZN@>KI"V9I21@AGVJPZ/7[E@_!K#Y13>,XIS"GAZ";MR2O*:76+:6ZU24
M92MO%,_",9XTXC.*BP7"F7U,17:5W.-HP;Z22;V>C;E&-]I-'F7@S5_^">_[
M&>S3_P#@G-^PIX8T'5+;'E?$[XAVBZ[X@WC_ );0&Z,J6;'&<(=I_N+79?#;
M]E+]N3]OSQ./'NH6NKZE;W3?/XN\7WDD5HJ$](F<$NH_NPJP'H*_1#]FW_@E
M'^RQ\ /L^M:UX?/C37XL-_:GB2)7AC<=XK;F-.<$%M[ ]&KZ9CC2)!%$@55
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M_//AG"UYY@JR7NQ3N_56MZGJU%%%?W$?H@4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %8_B7_D+Z/_U^G_T$UL5C^)?^0OH__7Z?
M_030!L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5CV7_([WO_ %Y1?S-;%8]E_P CO>_]>47\S0!L4444 %%%% !1
M110!\@?\%^/^4-G[0G_9/YO_ $=%7\85?V>_\%^/^4-G[0G_ &3^;_T=%7\8
M5 '[_?\ !IM_RE,_:[_[>/\ T^3U^_U?@#_P:;?\I3/VN_\ MX_]/D]?O]0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '@O_!.K_DA^K_]CWK'
M_H^O>J\%_P""=7_)#]7_ .Q[UC_T?7O5 !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %8_B7_D+Z/\ ]?I_]!-;%8_B7_D+
MZ/\ ]?I_]!- &Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%?
M+?[>7_!9K_@G5_P3CL[BT_:1_:%TU/$D,6Z+P+X<(U'6YCC*J;:(_N PZ/.T
M49Q]Z@#ZDKS7]IW]L;]EK]B_P(WQ*_:H^._AOP-H^&\B;7=16.6[91DI;PC,
MMR^.=D2.WM7\]7[?_P#P>2_M9_&3[=X'_8-^&5C\*M!DW1IXIUQ8M3UZ9.FY
M$8&UM"0>5VSL" 5E!KYE_9B_X(O_ /!9K_@LAX[7XZ>-=#\2G3M:*O<_%7XS
M:M<PPSPDY#0>>'N;J/!.WR(VB&-NY!0!^C'[?_\ P>C^!M ^V^!/^"<'P(DU
MZY&Z-/'WQ#B>WLP>F^WT^)A-*"#E6FDA((^:)A7YAA?^"WG_  <"_$_/_%P/
MBQ%;WO4[;#PQH;G_ +]6%HP4^TK@?QFOV[_8 _X-%/\ @GS^S#]B\:?M3:C?
M?&WQ7!MD:WUF$V6@P2#GY+&-RTX'(/VB61&&#Y:]*_3Z"#X2_L__  W2TLK3
MP_X,\):!:!8;>VAAL-/T^$=%1%"QQKSP  ,GBJA"=6:A!7;T26K;[(F<X4H.
M<W9+5MZ)+NS\0_V /^#+GP)X?^Q>._\ @H_\=I-?NEVR2> ?AY*]O9 ]=EQJ
M$BB:4$'!6&.$@CY96%?;W_!1O]D3]@#]EK_@E[XU_9#^$7PD\(>!],\80Z;;
MIX;T)C9WNMK%J-K+(TLT;"YN2(XVW2R.QP-I8YP:?[7O_!:^RLOM7@;]D?3%
MN91F.3QEJML?+4^MM;N,M[/* ./]6PP:^4O _P"RA^W!^VU_:?QFTGPCK'B9
MY2&?6]=U*.#[<V\+Y<$ERZ*X4$G"G8H0KP=JG]VX+\*<1@ZU#.^)JL,+AX3C
M)0J.*<VFFHS4FHQC+9J7O-77*MS\$XV\6<-C:-?(^&*4\7B*D)Q<Z2DU!--.
M4'%.4I1O=.-HIV?,]CX7_P"';'[%7_1%_P#RX]2_^2*/^';'[%7_ $1?_P N
M/4O_ )(K[ZO/^"4G[?6GVKWMW\!=D4:Y=O\ A*=*.!]!=5)'_P $G/\ @H!+
M&LL?P"RK*"I_X2K2N0?^WJOW7_C3'_4O_P#+8_!O^-U_]3#_ ,N3[*_X(I_L
M:?LS_"O]BWP)\0?!_P *+%=;>.^CAU349I;V>VCAU"YAC2%[AW,05(U7Y2#@
M8SCBOMNO%O\ @GE\)?B#\#/V/?"'PL^*?A_^R]>TO^T/M]A]KBG\KS=0N9D^
M>%W1LQR(W#'&<'!!%>TU_'/&>-6-XIQDJ=3GI1JU(T[.\534VH*%M%!1LHJ/
MNI6MH?V=P5@G@>%,%&I3Y*LJ5.51-6DZC@G-SOJYN5W)R]YRO?4****^8/J
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M1WF/9?\ ([WO_7E%_,UL5CV7_([WO_7E%_,UL4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5C^)?^0OH__7Z?_036Q6/X
ME_Y"^C_]?I_]!- &Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !6/9?\CO>_\ 7E%_,UL5CV7_ ".][_UY1?S- &Q1
M110 4444 %%%% 'R!_P7X_Y0V?M"?]D_F_\ 1T5?QA5_9[_P7X_Y0V?M"?\
M9/YO_1T5?QA4 ?O]_P &FW_*4S]KO_MX_P#3Y/7[_5^ /_!IM_RE,_:[_P"W
MC_T^3U^_U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >"_\$ZO
M^2'ZO_V/>L?^CZ]ZKP7_ ()U?\D/U?\ ['O6/_1]>]4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5C^)?^0OH_P#U^G_T
M$UL5C^)?^0OH_P#U^G_T$T ;%%%% !1110 4444 %%%% !1110 4444 %%<Q
M\7_C7\'_ -GWP)=_$_XZ?%'0/!_AVP&;O6_$NK0V5K&<$A3)*RKN.#A0<D\
M$U^1?[?_ /P>1_LD?!C[;X'_ &$/AK??%?7H]T:>*-9673-!A?IN16475V 0
M<J$A4C!64B@#]E[R\M-/M);^_NHX(((VDFFF<*D:*,EF)X  !))Z5^<W[?\
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MVYMO&&O)B1-&13_9=HWHRL UT1ZN G.-AP#7VK:6EI86L5C8VT<$$,82&&%
MJ1J!@*H'  '  J2BOQ?B'BC/>*<9]9S.LZDNBVC%=HQ6B7HKOJVS]LX=X6R'
MA3!?5LLH*G'J]Y2?>4GJWZNRZ)(S?&/_ "+%[_UP-7-._P"0?!_UQ7^0JGXQ
M_P"18O?^N!JYIW_(/@_ZXK_(5X!] 34444 %%%% !1110 45'=WEII]L][?W
M4<$,2[I)9G"J@]23P!7DWQ%_;E_9O^'/F6\WCE=9NDS_ *)H$?VDD^GF B(?
M0O7DYMGN2Y%1]KF.(A1CWG)1OZ7=WZ*[,*^)P^&CS59J*\W8]=H)"@LQ  ')
M-?$_Q%_X*D>,=1\RS^%WP_L]-C/"WNK2FXE(]0B[54^Q+BO*I_$G[7?[4]RU
MK'=>)O$-O(V)(+2-HK%#_M! L*_5L5^19KX]<,4J_P!6R:A5QM5[*$7&+^;7
M-]T&CPZW$N#4N3#Q=27DK?\ !_ ^Y?B-^UQ^SW\+_,@\1?$BRGNX\@V&EL;J
M;=_=(CR$/^^5KP3XC?\ !4TGS+3X3?#7'7R[_7YO_:,1_P#:GX5S7PY_X)A?
M%37?+N_B/XKT[0(3@M;6P^UW ]0=I6,?4.WTKWKX<_\ !/O]G/P'Y=SJ7AZX
M\0W:8/G:Y/O3/_7) J$>S!OK7E_7?'?C'^!1IY;1?67QV^:G-/\ [<AZF/M.
M),?\,52CY[_J_P $?(VL?'K]KG]HW4'T33-=U_4%D.&TSPY:M%$JGLX@ RON
MY/UKJOAU_P $V?COXN*7GC.ZT[PU;/RXNIOM%Q@]Q'$2OX,ZFOO/1]$T7P[I
MZ:3X?TBUL;6(8CMK.W6*-/HJ@ 5:KKP/@/E^+Q"Q7$F/K8VKYR<8^EVY3MZ2
MCZ&E/ANE.7/BZLJC];+]7^*/GSX<_P#!-SX"^$/+NO%\FH>);E<%A>3F"#/J
M(XB#^#,PKV_PIX(\&^!-/&D^"_"NGZ5;<9AT^S2%3[G:!D^YYK4HK]:R/A+A
MGAN'+EF$A2\U%<S]9.\G\VSV\/@<)A%:C!1^6OW[A1117T1U!1110 4444 %
M%%% &/9?\CO>_P#7E%_,UL5CV7_([WO_ %Y1?S-;% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %8_B7_D+Z/_ -?I_P#0
M36Q6/XE_Y"^C_P#7Z?\ T$T ;%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %8]E_R.][_UY1?S-;%8]E_R.][_ ->4
M7\S0!L4444 %%%% !1110!\@?\%^/^4-G[0G_9/YO_1T5?QA5_9[_P %^/\
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M5JH^NLN\F%%%%?G!^E!1110!F^,?^18O?^N!JYIW_(/@_P"N*_R%?.O[0/\
MP4'^%G@>[OO GA+2+CQ'>Q$PW5Q;7"Q6L;@\J)"&+D'KM7;[FI_@=_P42^%?
MQ&U>T\'>+=$N/#-[<%8K6:YN5FM9'Z!3* I0D]-R[?>OA/\ B)W 7]K_ -F?
M7X>VORV][EOM;GMR7OI;FWT/-_M?+?;^Q]JN;;R^_;\3Z)HK(\7>/O!'@"P_
MM3QOXMT[28,';)J%XD0;V7<1N/L,FO#_ (C?\%*?@5X3\RU\%VFH^);E<A6M
MHOL]OGT,DHW?B$85[&><7\,<-0OF>+A2?9R]Y^D%>3^29OB,=@\(OWTTOGK]
MVY]#U3USQ!H/AC3GU?Q)K=II]I'_ *RYOKE8HU^K,0!7P5\0_P#@I!\??&3/
M9>#TT_PW;N<(+&W\^X(/8R2Y&?=54US>A_L[?M;_ +1&HIKNJZ!KEXLG(U7Q
M-=M$@4]U,QW,O^X#7Y+C?'?!8VN\+PUE];&5.ZBXQ];)2G;UC'U/$J<24ZDN
M3"4I5'Z67ZO\$?6?Q&_X*%?LZ^!?,M='UJZ\17:9'E:-;YC!]Y9-J$>ZEJ\$
M^(W_  4Z^+GB'S+3X=^&M-\/0-D)<2C[7<#W!<",?0H?K77?#G_@EE;IY=W\
M6/B4SGCS+'0(,#_O]*.?^_8^M>]_#G]E#]G_ .%WES^&/AM8/=1X(O\ 44-U
M/N_O!I=VP_[N*Y?[/\=N,?\ >:]/+J+Z0^.WERN4D_\ N)#T(]EQ)C_CDJ4?
M+?\ 5_BCX6M/!7[7?[4=TE]/8^)=?@D;='=:A*T5DGNC2%8E^B_E7K/PY_X)
M:^*+[R[SXJ?$.UL$."UEHT)GD(]#(^U5/T5Q7VH  , 45ZN4^ O"M&M]9SBM
M5QM5[N<G&+?HGS??-HWH\-8*,N>O)U)>;_I_B>3?#G]B+]G#X;^7/:> HM6N
MX\?Z9KS_ &IB?78P\L'W""O5K:VM[.!+6TMTBBC4+''&@55 Z  < 4^BOUW*
MLCR;(Z'L<OP\*,>T(J-_6RU?F[L]RCA\/AH\M**BO)6"BBBO5-@HHHH ****
M "BBB@ HHHH **** "BBB@#'LO\ D=[W_KRB_F:V*Q[+_D=[W_KRB_F:V* "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q
M_$O_ "%]'_Z_3_Z":V*Q_$O_ "%]'_Z_3_Z": -BBBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L>R_Y'>]_P"O*+^9
MK8K'LO\ D=[W_KRB_F: -BBBB@ HHHH **** /D#_@OQ_P H;/VA/^R?S?\
MHZ*OXPJ_L]_X+\?\H;/VA/\ LG\W_HZ*OXPJ /W^_P"#3;_E*9^UW_V\?^GR
M>OW^K\ ?^#3;_E*9^UW_ -O'_I\GK]_J "BBB@ HHHH **** "BBB@ HHHH
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M%^/^4-G[0G_9/YO_ $=%7\85?V>_\%^/^4-G[0G_ &3^;_T=%7\85 '[_?\
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MH Q[+_D=[W_KRB_F:V*Q[+_D=[W_ *\HOYFMB@ HHHH **** "BBB@ HHHH
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MGU,HAWL?<L37LNG:;IVCV4>FZ3806MM"NV*WMH@B(/0*H  ^E '\@7_#,O\
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MO.?R0_;K_8]\=?\ !+?]H7XY_P#!2_\ X)4^,[/X;Q?#+3_#NL_$+X/&-O\
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M=Q)/"S ^X.:^I_A9_P %:OC-\'K(:7X%^!GPITFU"!3%HGA V&1Z8MY57'_
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MEW'CGXA?"+PE"<>;%?\ B:\NKA?HMM9O&3_VT'UKZ#^&O_!CKXEG\NY^,/\
MP4/L;7&/-LO#7P[>?=])I[V/'_?HU^D&C?\ !<3X$WN$UCPUXOLG(Y8:+:RH
M/Q%T#_X[77Z+_P %@?V3M5(^W?%2\TW)Y^V^$KEL?]^0]>)B/#CCO#?'EU5_
MX8N7_I-SW,/XE<!8GX,RI+_%)1_]*L?&?PU_X,KO^"<'ASR[GXF?M ?%[Q+.
MF-T5KJ6G:?;/ZY1;.20?A(*^@OAI_P &M_\ P1+^''ESW'[)=QXCNH\8NO$O
MC;5I\_6)+E(3^,=>\Z)_P4F_9+\0;?L'[4OAR/=C'VW2KNVZ^OG1+BNNT3]K
M7X#>(L#1_P!J_P"'$K-TB/B&U1_^^6D#?I7BXCAKB/"_Q\%5A_BIS7YH]O#\
M3\-XO^!C:,_\-2#_ "D<W\-?^"3/_!,+X0^7)\/?^"?WP@L9XL>7>R> +"XN
M5_[;S1/)_P"/5[GX9\(>$_!6FKHW@WPOIVD6:_=M-,LH[>(?14 'Z5@:+XUM
M_$A \._%/PW?[ON_8KJ.7/\ WRQK8^Q>-_\ H-V7_@,?\:\>I2J4I<LXM/S5
MCV*=6E6CS4Y)KR=S8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\:@T-
MBBL?[%XW_P"@W9?^ Q_QH^Q>-_\ H-V7_@,?\: -BBL?[%XW_P"@W9?^ Q_Q
MH^Q>-_\ H-V7_@,?\: -BBL?[%XW_P"@W9?^ Q_QH^Q>-_\ H-V7_@,?\: -
MBBL?[%XW_P"@W9?^ Q_QH^Q>-_\ H-V7_@,?\: -BL?Q+_R%]'_Z_3_Z":/L
M7C?_ *#=E_X#'_&LS7+7Q2NHZ:MUJEL[M<D0,L! 5MO4^M '5T5C_8O&_P#T
M&[+_ ,!C_C7G_P"T!^TEX(_9B\+GQ3\8OBEI6G+(I-EIZ6QDN[UA_##"IW/S
M@%N%7(W$#FNG!X/%YAB8X?#4W.I)V48IMM^26IS8S&X3+\-+$8JHJ=.*NY2:
M22\V]#UBOG']KK_@IM^S[^RNMSX:BU >*?%L0*CP[I%PI%N_I<S<K![KAI.G
MR8.:^%_VH_\ @K5^T)\?9)O 'PAENO"N@W3^2JZ<,:G?AC@*TB9,>[CY(CGD
M@LP-:_[*/_!&_P",WQ=CM_&_Q\NY?!VBRD2)IDJYU2[4\\H01;@^KY?_ &!G
M-?M^5>%F3\-X..:<:XE48;QHQ=YR\FU=^JA>V[G'4_"\U\5LXXEQLLJX(PSK
M3VE7DK0CYI2LO1SM?90EH>8_%3]HS]LO_@H_\0HO UC::AJ<4LV^P\'>'(F2
MRME!XDD!.#MSS-,Q"Y."H.*^N?V0O^"+'@[P?]E\<?M4ZC#K^I+B2+PM82L+
M& ]0)I!AIV'&5&U,@@^8#7U5\$_V<_"W[.WA)?!?P=T#1M%LN#.T%F6FN7 Q
MOFE8EY6]V)QT&!Q79?8O&_\ T&[+_P !C_C7F\2>+N+JX3^R^&Z*P6$6BY;*
MI)=VU\-^O*W)O>;N>GPSX/82CC/[4XFK/&XMZOFNZ<7V2?QVZ<R44MH*Q?T;
M1=&\.:5;Z#X>TFVL+&TB$5K9V<"Q10H.BHB@!0/0#%6:Q_L7C?\ Z#=E_P"
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MN!7XS+BOQ-\3VZ?#E!X'!/1UYZ3DO[K_ /E:=GO41X'UW.,XTPD?9T_YGO\
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M (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\
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M\3K*FD^ZT_+3\#\Q/%/[.'[2?P?D>?5OAQJT-NC%I)[&$7=LP]7,6],'T?\
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M86" I8Q-Z$'#3?\  L*>Z5]%:%H&A^%]*AT+PWH]K865NNV"TLX%CCC'H%4
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M* "BBB@ K'\2_P#(7T?_ *_3_P"@FMBL?Q+_ ,A?1_\ K]/_ *": -BBBB@
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M[M?GV<9YE'#^">+S*O&E3763M?R2W;\DFWV/J*^)H86GSU9**\SV D*"S$
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M .@FMBL?Q+_R%]'_ .OT_P#H)H V**** "BBB@ HHHH **** "BBB@ HHHH
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M^Z8/!8/+L-'#X6G&G3CHHQ2BDO)+1'T=.G"E!1@K)=$%%%%=)84444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% &;XQ_P"18O?^N!JYIW_(/@_ZXK_(
M53\8_P#(L7O_ %P-7-._Y!\'_7%?Y"@":BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** ,>R_Y'>]_P"O*+^9K8K'LO\
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M@^H((/<&OFO5/^"7WAG3O$5G&/B[?/87=SL,!TE!,JXS_K/,VD^^S\*_COQ
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M'_D6+W_K@:N:=_R#X/\ KBO\A5/QC_R+%[_UP-7-._Y!\'_7%?Y"@":BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,>
MR_Y'>]_Z\HOYFMBL>R_Y'>]_Z\HOYFMB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "L?Q+_R%]'_Z_3_Z":V*Q_$O_(7T
M?_K]/_H)H V**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *Q[+_ )'>]_Z\HOYFMBL>R_Y'>]_Z\HOYF@#8HHHH ***
M* "BBB@#Y _X+\?\H;/VA/\ LG\W_HZ*OXPJ_L]_X+\?\H;/VA/^R?S?^CHJ
M_C"H _?[_@TV_P"4IG[7?_;Q_P"GR>OW^K\ ?^#3;_E*9^UW_P!O'_I\GK]_
MJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \%_X)U?\D/U?_L>
M]8_]'U[U7@O_  3J_P"2'ZO_ -CWK'_H^O>J "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q_$O_(7T?\ Z_3_ .@FMBL?
MQ+_R%]'_ .OT_P#H)H V**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH S?&/_(L7O_7 U<T[_D'P?]<5_D*I^,?^18O?
M^N!JYIW_ "#X/^N*_P A0!-1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% &/9?\ ([WO_7E%_,UL5CV7_([WO_7E%_,U
ML4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5C^)?^0OH__7Z?_036Q6/XE_Y"^C_]?I_]!- &Q1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6/9?\CO>_\ 7E%_
M,UL5CV7_ ".][_UY1?S- &Q1110 4444 %%%% 'R!_P7X_Y0V?M"?]D_F_\
M1T5?QA5_9[_P7X_Y0V?M"?\ 9/YO_1T5?QA4 ?O]_P &FW_*4S]KO_MX_P#3
MY/7[_5^ /_!IM_RE,_:[_P"WC_T^3U^_U !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 >"_\$ZO^2'ZO_V/>L?^CZ]ZKP7_ ()U?\D/U?\ ['O6
M/_1]>]4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5C^)?^0OH_P#U^G_T$UL5C^)?^0OH_P#U^G_T$T ;%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9OC'_D6+
MW_K@:N:=_P @^#_KBO\ (53\8_\ (L7O_7 U<T[_ )!\'_7%?Y"@":BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,>R
M_P"1WO?^O*+^9K8K'LO^1WO?^O*+^9K8H **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ K'\2_\ (7T?_K]/_H)K8K'\2_\
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MHH **** "BBB@ HHHH **** ,WQC_P BQ>_]<#5S3O\ D'P?]<5_D*I^,?\
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M\CO>_P#7E%_,UL5CV7_([WO_ %Y1?S- &Q1110 4444 %%%% 'R!_P %^/\
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M!L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!F^,?\ D6+W_K@:N:=_R#X/^N*_R%4_&/\ R+%[_P!<#5S3O^0?!_UQ
M7^0H FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#'LO^1WO?\ KRB_F:V*Q[+_ )'>]_Z\HOYFMB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L?Q+_ ,A?1_\
MK]/_ *":V*Q_$O\ R%]'_P"OT_\ H)H V**** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!CV7_([WO\
MUY1?S-;%8]E_R.][_P!>47\S6Q0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !6/XE_Y"^C_P#7Z?\ T$UL5C^)?^0OH_\
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M* "BBB@#-\8_\BQ>_P#7 U<T[_D'P?\ 7%?Y"J?C'_D6+W_K@:N:=_R#X/\
MKBO\A0!-1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% &/9?\CO>_]>47\S6Q6/9?\CO>_P#7E%_,UL4 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5C^)?^0OH_P#U
M^G_T$UL5C^)?^0OH_P#U^G_T$T ;%%%% !1110 4444 %%%% !1110 4444
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ML)?\$FM$_P""D'@'XJ^*]6^/?@/1]!\7^/=>UWQ/>3P^,1<36W]K:9>VS2&
M61CN9O)B2-?LWD0^3Y94D@'ZA45S7P8^*?AOXY_![PI\;/!K.='\8^&K#7-*
M,F-QMKNW2>+..,[)%KI: "BBB@#P7_@G5_R0_5_^Q[UC_P!'U[U7@O\ P3J_
MY(?J_P#V/>L?^CZ]ZH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ K'\2_\A?1_^OT_^@FMBL?Q+_R%]'_Z_3_Z": -BBBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M,WQC_P BQ>_]<#5S3O\ D'P?]<5_D*I^,?\ D6+W_K@:N:=_R#X/^N*_R% $
MU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 8]E_R.][_P!>47\S6Q6/9?\ ([WO_7E%_,UL4 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5C^)?\ D+Z/_P!?I_\
M036Q6/XE_P"0OH__ %^G_P!!- &Q1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !6/9?\CO>_P#7E%_,UL5CV7_([WO_
M %Y1?S- &Q1110 4444 %%%% 'R!_P %^/\ E#9^T)_V3^;_ -'15_&%7]GO
M_!?C_E#9^T)_V3^;_P!'15_&%0!^_P!_P:;?\I3/VN_^WC_T^3U^_P!7X _\
M&FW_ "E,_:[_ .WC_P!/D]?O]0 4444 %%%% !1110 5Y1^TM\$_V3_VU/#&
MN_L;?M*>"='\7V5SH]OJNH^&M3A<20P2R3PP7D,J[6BD$D,RK+$XDC(ZJ'&[
MU>O&OCM^Q%\.OC=\9-#_ &C-/^(GCGP/\0/#VBRZ/I_BSP-XB^SR/ITDHF>T
MGM;B.:SNHO- DQ- ^& (/ P ?F?_ ,$;]=_:U_X)R_M"?LT_L2>)OC/>?$KX
M)?M,_!9O%O@:UUL;M1\!:E:Z/#J-Y:)("<V+&0(B\+NF3:J,DAF_5;]I;]EK
M]G[]L+X3ZG\$?VD_A5H_BWPWJMN\4UCJUHLAA9EP)H9/OP3+U66,JZD @@BO
M*OV&/^";7PW_ &1M&\)>,O%_B;5?'?Q-T#X::7X-;QKXAO?.%AIUK!$K6.FP
M*B165J9(]^$C$LF$,TDK*#6#X1_X(Z_LZ^!_B5XQ\:^&OC9\;;30?'NO76L>
M)_AS;?%K4(?#]U=W+F2=A!$RRJLC,=Z"8*ZG8P*82@#\W/CO^S3\;M7_ .#4
MKXI?!FVU_4?%6F_"_P"(NKM\/M4N29)M4\(:/XG,<=T".L2V\5S,A^[Y,2;?
MD"U]F?\ !9_XP>%=;_X-W/'?Q,T&Z2XL/&'PKT!-!%O\YNCJ4]A';K&!RY;S
MU( [<]J^]-/\">"-)\$0_#/2_!^EVWARWTM=,M] @L(TLH[)8_*%LL(&P1"/
MY/+ V[>,8KP+P5_P2Q_9I\&KX2\,2ZOXOUKP+\/=;76/A[\,-?U\7.@^';U&
M9H)88O+$TX@+L8(KJ:>*W^4Q)&40J =S^P5\*/$GP'_89^#'P/\ &,+1ZOX-
M^%'AW0]5C<\I<VFFV\$J_@\;"O6:** ,GQU9^,;_ ,(W]G\/]8M-/UJ2 C3K
MV^MS+##)D89T'WAC/%>0_P#" _\ !03_ *+_ .!/_"4D_P#BJ]THH ^,/V/_
M  ;^V'J/POOY_A5\7/">DZ>OBG4DN;?4-">9WN5G(ED!YPK$ A>U>J_\*^_X
M*'_]'!>!/_"7>MO]BGP+XN^'WPGU+1/&F@SZ==S>,-4NHX+@ ,T,DY9'X/0C
MD5Z_0!X+_P *^_X*'_\ 1P7@3_PEWH_X5]_P4/\ ^C@O G_A+O7O5% '@O\
MPK[_ (*'_P#1P7@3_P )=Z/^%??\%#_^C@O G_A+O7O5% '@O_"OO^"A_P#T
M<%X$_P#"7>C_ (5]_P %#_\ HX+P)_X2[U[U10!X+_PK[_@H?_T<%X$_\)=Z
M/^%??\%#_P#HX+P)_P"$N]>]44 >"_\ "OO^"A__ $<%X$_\)=Z/^%??\%#_
M /HX+P)_X2[U[U10!X+_ ,*^_P""A_\ T<%X$_\ "7>C_A7W_!0__HX+P)_X
M2[U[U10!X+_PK[_@H?\ ]'!>!/\ PEWH_P"%??\ !0__ *."\"?^$N]>]44
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M_"OO^"A__1P7@3_PEWKWJB@#P7_A7W_!0_\ Z."\"?\ A+O1_P *^_X*'_\
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M_"OO^"A__1P7@3_PEWH_X5]_P4/_ .C@O G_ (2[U[U10!X+_P *^_X*'_\
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MZ7\+_@YXP_:>_:<_X+,?MEK=Z%H>I>)_&]SX-^,*Z3I2&*.2ZN?L5DUM,;6
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M6MU.S276G17_ )T=M*6==H=$<I&H7[(H **** "BBB@ HHHH **** "BBB@
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MQWT-QJUSY?G7P9H1*DKB)00KA#R2A."-CXD_L3?#3QM\>8_VI?!/B_Q-\/\
MXC-H:Z+J7BSP5=VR2:MIR.7CMKRVO(+BUNA&Q)CDDA,L>XA'4$B@#YE_X(A_
M%;]KKP5XC^,G_!,']L_7[?Q5XB_9LO="L_#GQ#M(/+&O^'M2M9I=.\Y><3QP
MV^&));#JK%VC:1_OVN"^!?[.'PV_9^CUZ_\ "$=]?:YXMU8:IXP\5:Y=_:=2
MUR\$20K+<2X PD4:1QQ1JD,2($CC1>*[V@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "J^JZKI>A:7<ZYKFI6]G96=N\]Y>7<RQQ01(I9Y'=B
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M&U/_  3_ -'MVM-(^)_QXM8GGEG>*V^,^I(K2RR-)(Y"L 6=V9V/5F8DY)-
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MXZ\0?$SX,WWC75]?\1Z5!IMYJWCGQC<ZQ/!:1R-+Y,#3DF)&<JS@?>,:?W:
M/#/^#;?Q[H?A'_@AO\/5\79TN?X=MXHL/&-I=+LDTRXM=:U":9)5."C")D<@
MX(W5D?\ !JA\+O%_P]_X) ^&O%/C'39;.3QYXQUOQ+86TRD,MK-<"")L'HKB
MV\Q3W616'!KZ5\=_\$Q?V>O&NL>.18>)/&?AKPU\4]0:_P#BGX#\*^(OL6C^
M*[IXUBGFN$6,S0/<1JJ7!M);?[0J_OO,R2??/"WA?PWX'\,Z=X+\&Z#9Z5I&
MD6,5EI6F:?;K#!:6T2!(X8T4!4145550    * +]%%% !1110 4444 %%%%
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M-_Z.BK^,*O[/?^"_'_*&S]H3_LG\W_HZ*OXPJ /W^_X--O\ E*9^UW_V\?\
MI\GK]_J_ '_@TV_Y2F?M=_\ ;Q_Z?)Z_?Z@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#Y _X+\?\H;/VA/\ LG\W_HZ*OXPJ_L]_X+\?\H;/VA/^
MR?S?^CHJ_C"H _?[_@TV_P"4IG[7?_;Q_P"GR>OW^K\ ?^#3;_E*9^UW_P!O
M'_I\GK]_J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUU;.>^M5BT^Z0^;>6DTMO/;;R0JR)/#)"VX@*Z,#C!KB?V//C-\8?V@OV>-
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M\,K3P+K?C?XB_$S5+BP^'WP^\,F!;S57MX?.NKAY;B2.&VM;>(AYIY' 0,N
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MA3:-J*1FV6-O-,TUT6AC!A6/""1R[H8PC@'WO\0/^1#UO_L$7/\ Z*:OSO\
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MVN5/1Z7/C/#VIQ!2XOPT\CA&>*7/R*?PO]W/FO=Q^SS-:K6Q]Q_\/GOV(O\
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MC>+5?&O@&2&#^WX'*E[?5+.:.2UOXW*J69XQ-E5*RHR(RS_$;]ON['[2.O\
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MT:&RAD=A!;PF663+($/G& KNR%<=?IV@ HHKYBTC_@I7IGQP^*?B?X4?L._
M;7?B^?!&J/I?C'QI9:K::7X9TS44 +V"W]PY:\N4!7>EK#,D>X;W4D @'T[1
M7SEX8_X*%PM^U3X._8Q^+?[-GCCP/XX\9:=J>H:9+JHM+G2+JTL81)++;7]K
M-(DYRR*8F$<R;MSQJI0O]&T %%%% !1110 45YS)^T7H>M?'^X_9S^&VC-K^
MM:#:6U[X[NTNA%:>&[>X#-;QS2;6+W<RJTD=LHSY:^9(T2O"9?+;G_@H;XA^
M(WQ?\;_"3]CW]EKQ#\5E^&6LG1?'GB:V\0Z?I.EV>L+&LDFE6\MW(&N[N)'0
MRJJK%$756E#$@ '/_&K_ ()\?';XG_\ !3WX;_\ !0_0OCYX4TVR^&OA?4M
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MW_H=?B!_X0DW_P 71_Q%X_\ !&W_ *'7X@?^$)-_\77S_P#\00W[+'_1\'Q
M_P#">L?\:/\ B"&_98_Z/@^('_A/6/\ C0!] ?\ $7C_ ,$;?^AU^('_ (0D
MW_Q=?I5X(\7Z-\0?!>D>/?#CR-I^N:7;ZA8--'L<PS1K(A9>QVL,CM7XJ_\
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MK-]X$\$:?H^H:I%N\NXN(8565HPW(CW[M@/(0*#7AG_!3C_@GQ^W%^U7\6/
M_P"T)^Q;_P % T^$/B3X:Z/?1>'-%O?!$.I65]>7943RW$LDC! \4<,0_P!'
ME**)< ^:PK[/KYJ^-_[>OQB^!/[4O_"CM1_X)V_&#Q=X/O-$@NM&^)OP[L+?
M5;2:[8L)+6Y@,D;6>S  D=SN+9VJOST >%?L/_\ !3;]JSXE? ?]HOX#_MF?
M#'3_  M^T9^S=X<N)_$(T,9T[7H)+"XN-/U2U!SA9?()91E?FC8!/,\J-_\
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M'-K\.O$'P,L/"&C^-KKPO<1V5QJMO?0SO'ROF)'M$@$SHL9,9PV&0L >W_\
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MPSXV\0Z*D^J>#]2GOO#]YG#VTLUI/:2\CJK0W$@*G@D(V,HI'YS?M=_MJ_\
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M<\#_ !5T/7(8/"6HZ7 /*L[B]O74BVCB@" [0\S)&!Y*RY4@'TC>_MX?%O\
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M_P $T(?B?X^T6;3-3^-'Q UGXBG3;E<206VH/%':EO\ KI;6T$P_V9E[YK]
MJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#\LZ^_Z* /@#_B%Q_X(4?]&,_^9-\3_P#RSK[/^ /P&^%O[,'P:\/?L_\
MP2\/W&D^$O"FGBQT#2[G5[J_:TME)*Q">[EEF=5SA0SG:H55PJ@#L** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH ^0/\ @OQ_RAL_:$_[)_-_Z.BK^,*O
M[/?^"_'_ "AL_:$_[)_-_P"CHJ_C"H _?[_@TV_Y2F?M=_\ ;Q_Z?)Z_?ZOP
M!_X--O\ E*9^UW_V\?\ I\GK]_J "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** /D#_ (+\?\H;/VA/^R?S?^CHJ_C"K^SW_@OQ_P H;/VA/^R?S?\
MHZ*OXPJ /W^_X--O^4IG[7?_ &\?^GR>OW^K\ ?^#3;_ )2F?M=_]O'_ *?)
MZ_?Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOB!_X45C_A0!^WU%?B#_ ,1O/[+/_1CWQ _\**Q_PH_XC>?V6?\ HQ[X@?\
MA16/^% '[?45^(/_ !&\_LL_]&/?$#_PHK'_  H_XC>?V6?^C'OB!_X45C_A
M0!^WU%?B#_Q&\_LL_P#1CWQ _P#"BL?\*/\ B-Y_99_Z,>^('_A16/\ A0!^
MWU%?B#_Q&\_LL_\ 1CWQ _\ "BL?\*/^(WG]EG_HQ[X@?^%%8_X4 ?M]17X@
M_P#$;S^RS_T8]\0/_"BL?\*/^(WG]EG_ *,>^('_ (45C_A0!^WU%?B#_P 1
MO/[+/_1CWQ _\**Q_P */^(WG]EG_HQ[X@?^%%8_X4 ?M]17X@_\1O/[+/\
MT8]\0/\ PHK'_"C_ (C>?V6?^C'OB!_X45C_ (4 ?M]17X@_\1O/[+/_ $8]
M\0/_  HK'_"C_B-Y_99_Z,>^('_A16/^% '[?45^(/\ Q&\_LL_]&/?$#_PH
MK'_"C_B-Y_99_P"C'OB!_P"%%8_X4 ?M]17X@_\ $;S^RS_T8]\0/_"BL?\
M"C_B-Y_99_Z,>^('_A16/^% '[?45^(/_$;S^RS_ -&/?$#_ ,**Q_PH_P"(
MWG]EG_HQ[X@?^%%8_P"% '[?45^(/_$;S^RS_P!&/?$#_P **Q_PH_XC>?V6
M?^C'OB!_X45C_A0!^WU%?B#_ ,1O/[+/_1CWQ _\**Q_PH_XC>?V6?\ HQ[X
M@?\ A16/^% '[?45^(/_ !&\_LL_]&/?$#_PHK'_  H_XC>?V6?^C'OB!_X4
M5C_A0!^WU%?B#_Q&\_LL_P#1CWQ _P#"BL?\*/\ B-Y_99_Z,>^('_A16/\
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M>?V6?^C'OB!_X45C_A0!^WU%?B#_ ,1O/[+/_1CWQ _\**Q_PH_XC>?V6?\
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M7X@_\1O/[+/_ $8]\0/_  HK'_"C_B-Y_99_Z,>^('_A16/^% '[?45^(/\
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MX4 ?M]17X@_\1O/[+/\ T8]\0/\ PHK'_"C_ (C>?V6?^C'OB!_X45C_ (4
M?M]17X@_\1O/[+/_ $8]\0/_  HK'_"C_B-Y_99_Z,>^('_A16/^% '[?45^
M(/\ Q&\_LL_]&/?$#_PHK'_"C_B-Y_99_P"C'OB!_P"%%8_X4 ?M]17X@_\
M$;S^RS_T8]\0/_"BL?\ "C_B-Y_99_Z,>^('_A16/^% '[?45^(/_$;S^RS_
M -&/?$#_ ,**Q_PH_P"(WG]EG_HQ[X@?^%%8_P"% 'W_ /\ !?C_ )0V?M"?
M]D_F_P#1T5?QA5^Z7_!1S_@[2_9X_;<_8=^)7[)_A;]DCQIH>H>.O#;Z;::M
7J&N6DD-J[.C;W5!N(^7H/6OPMH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596525294560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-12215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Quest Diagnostics Inc<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">16-1387862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">500 Plaza Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Secaucus,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(973)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">520-2700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $.01 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DGX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,323,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the registrant's Proxy Statement to be filed by April&#160;30, 2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001022079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596524163248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Florham Park, New Jersey<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">238<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596524696736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 315<span></span>
</td>
<td class="nump">$ 872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowance for credit losses of $30 and $31 as of December&#160;31, 2022 and 2021, respectively</a></td>
<td class="nump">1,195<span></span>
</td>
<td class="nump">1,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">192<span></span>
</td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,898<span></span>
</td>
<td class="nump">2,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">1,766<span></span>
</td>
<td class="nump">1,707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">585<span></span>
</td>
<td class="nump">597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">7,220<span></span>
</td>
<td class="nump">7,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">1,092<span></span>
</td>
<td class="nump">1,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in equity method investees</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">12,837<span></span>
</td>
<td class="nump">13,611<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">1,396<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Current portion of long-term debt</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of long-term operating lease liabilities</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,551<span></span>
</td>
<td class="nump">1,753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt</a></td>
<td class="nump">3,978<span></span>
</td>
<td class="nump">4,010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">489<span></span>
</td>
<td class="nump">494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">812<span></span>
</td>
<td class="nump">792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Redeemable noncontrolling interest</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Quest Diagnostics stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.01 per share; 600 shares authorized as of both December&#160;31, 2022 and 2021; 162 shares issued as of both December&#160;31, 2022 and 2021</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">2,295<span></span>
</td>
<td class="nump">2,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">8,290<span></span>
</td>
<td class="nump">7,649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss) income</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost; 51 and 43 shares as of December&#160;31, 2022 and 2021, respectively</a></td>
<td class="num">(4,673)<span></span>
</td>
<td class="num">(3,453)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Quest Diagnostics stockholders' equity</a></td>
<td class="nump">5,893<span></span>
</td>
<td class="nump">6,444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders' equity</a></td>
<td class="nump">5,930<span></span>
</td>
<td class="nump">6,483<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 12,837<span></span>
</td>
<td class="nump">$ 13,611<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596525251536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596525126496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">$ 9,883<span></span>
</td>
<td class="nump">$ 10,788<span></span>
</td>
<td class="nump">$ 9,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Operating costs and expenses and other operating income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of services</a></td>
<td class="nump">6,450<span></span>
</td>
<td class="nump">6,579<span></span>
</td>
<td class="nump">5,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">1,874<span></span>
</td>
<td class="nump">1,727<span></span>
</td>
<td class="nump">1,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other operating expense (income), net</a></td>
<td class="nump">11<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating costs and expenses, net</a></td>
<td class="nump">8,455<span></span>
</td>
<td class="nump">8,407<span></span>
</td>
<td class="nump">7,466<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">1,428<span></span>
</td>
<td class="nump">2,381<span></span>
</td>
<td class="nump">1,971<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense, net</a></td>
<td class="num">(138)<span></span>
</td>
<td class="num">(151)<span></span>
</td>
<td class="num">(163)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(55)<span></span>
</td>
<td class="nump">369<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total non-operating (expense) income, net</a></td>
<td class="num">(193)<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="num">(87)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes and equity in earnings of equity method investees</a></td>
<td class="nump">1,235<span></span>
</td>
<td class="nump">2,599<span></span>
</td>
<td class="nump">1,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(264)<span></span>
</td>
<td class="num">(597)<span></span>
</td>
<td class="num">(460)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in earnings of equity method investees, net of taxes</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,015<span></span>
</td>
<td class="nump">2,080<span></span>
</td>
<td class="nump">1,499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net income attributable to noncontrolling interests</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Quest Diagnostics</a></td>
<td class="nump">$ 946<span></span>
</td>
<td class="nump">$ 1,995<span></span>
</td>
<td class="nump">$ 1,431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings per share attributable to Quest Diagnostics&#8217; common stockholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 8.10<span></span>
</td>
<td class="nump">$ 15.85<span></span>
</td>
<td class="nump">$ 10.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 7.97<span></span>
</td>
<td class="nump">$ 15.55<span></span>
</td>
<td class="nump">$ 10.47<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596525181888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 1,015<span></span>
</td>
<td class="nump">$ 2,080<span></span>
</td>
<td class="nump">$ 1,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net change in available-for-sale debt securities, net of taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Net deferred gain on cash flow hedges, net of taxes</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) income</a></td>
<td class="num">(7)<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income</a></td>
<td class="nump">1,008<span></span>
</td>
<td class="nump">2,087<span></span>
</td>
<td class="nump">1,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Less: Comprehensive income attributable to noncontrolling interests</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to Quest Diagnostics</a></td>
<td class="nump">$ 939<span></span>
</td>
<td class="nump">$ 2,002<span></span>
</td>
<td class="nump">$ 1,449<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596525361632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 1,015<span></span>
</td>
<td class="nump">$ 2,080<span></span>
</td>
<td class="nump">$ 1,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">437<span></span>
</td>
<td class="nump">408<span></span>
</td>
<td class="nump">361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for credit losses</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax provision</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(57)<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_GainLossOnDispositionOfJointVenture', window );">Gain on disposition of joint venture</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(314)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other, net</a></td>
<td class="nump">66<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">246<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="num">(455)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(149)<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="num">(31)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_TerminationOfInterestRateSwapAgreements', window );">Termination of interest rate swap agreements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other assets and liabilities, net</a></td>
<td class="nump">53<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">1,718<span></span>
</td>
<td class="nump">2,233<span></span>
</td>
<td class="nump">2,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Business acquisitions, net of cash acquired</a></td>
<td class="num">(144)<span></span>
</td>
<td class="num">(331)<span></span>
</td>
<td class="num">(330)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from disposition of joint venture</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">755<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="num">(404)<span></span>
</td>
<td class="num">(403)<span></span>
</td>
<td class="num">(418)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Decrease (increase) in investments and other assets, net</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(543)<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="num">(772)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(1,554)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of treasury stock</a></td>
<td class="num">(1,408)<span></span>
</td>
<td class="num">(2,199)<span></span>
</td>
<td class="num">(325)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="nump">189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Employee payroll tax withholdings on stock issued under stock-based compensation plans</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Dividends paid</a></td>
<td class="num">(305)<span></span>
</td>
<td class="num">(309)<span></span>
</td>
<td class="num">(297)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsMinorityInterest', window );">Distributions to noncontrolling interest partners</a></td>
<td class="num">(73)<span></span>
</td>
<td class="num">(99)<span></span>
</td>
<td class="num">(58)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other financing activities, net</a></td>
<td class="num">(39)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(1,732)<span></span>
</td>
<td class="num">(2,540)<span></span>
</td>
<td class="num">(1,267)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net change in cash and cash equivalents and restricted cash</a></td>
<td class="num">(557)<span></span>
</td>
<td class="num">(286)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash, beginning of year</a></td>
<td class="nump">872<span></span>
</td>
<td class="nump">1,158<span></span>
</td>
<td class="nump">1,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash, end of year</a></td>
<td class="nump">$ 315<span></span>
</td>
<td class="nump">$ 872<span></span>
</td>
<td class="nump">$ 1,158<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_GainLossOnDispositionOfJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on Disposition of Joint Venture</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_GainLossOnDispositionOfJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_TerminationOfInterestRateSwapAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Termination Of Interest Rate Swap Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_TerminationOfInterestRateSwapAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsMinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends provided by the non-wholly owned subsidiary to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsMinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596526694416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Treasury Stock, at Cost</div></th>
<th class="th"><div>Non-controlling Interests</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Dec. 31, 2019</a></td>
<td class="nump">$ 5,687<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 2,722<span></span>
</td>
<td class="nump">$ 8,174<span></span>
</td>
<td class="num">$ (39)<span></span>
</td>
<td class="num">$ (5,218)<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_NetIncomeLossExcludingRedeemableNoncontrollingInterest', window );">Net income</a></td>
<td class="nump">1,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends declared</a></td>
<td class="num">(302)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(302)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions to noncontrolling interest partners</a></td>
<td class="num">(49)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under benefit plans, sharers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under benefit plans</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options, value</a></td>
<td class="nump">189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares to cover employee payroll tax withholdings on stock issued under stock-based compensation plans</a></td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchases of treasury stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchases of treasury stock, value</a></td>
<td class="num">(325)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (325)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Dec. 31, 2020</a></td>
<td class="nump">6,809<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">2,841<span></span>
</td>
<td class="nump">9,303<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="num">(5,366)<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Balance, value at Dec. 31, 2019</a></td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityNetIncome', window );">Net income</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders', window );">Distributions to noncontrolling interest partners</a></td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Balance, value at Dec. 31, 2020</a></td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_NetIncomeLossExcludingRedeemableNoncontrollingInterest', window );">Net income</a></td>
<td class="nump">2,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends declared</a></td>
<td class="num">(307)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(307)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions to noncontrolling interest partners</a></td>
<td class="num">(83)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(83)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under benefit plans, sharers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under benefit plans</a></td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options, value</a></td>
<td class="nump">129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares to cover employee payroll tax withholdings on stock issued under stock-based compensation plans</a></td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchases of treasury stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchases of treasury stock, value</a></td>
<td class="num">(2,222)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,222)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of treasury stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(649)<span></span>
</td>
<td class="num">(3,342)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Dec. 31, 2021</a></td>
<td class="nump">6,483<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">2,260<span></span>
</td>
<td class="nump">7,649<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="num">(3,453)<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityNetIncome', window );">Net income</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders', window );">Distributions to noncontrolling interest partners</a></td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_NetIncomeLossExcludingRedeemableNoncontrollingInterest', window );">Net income</a></td>
<td class="nump">1,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends declared</a></td>
<td class="num">(305)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(305)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions to noncontrolling interest partners</a></td>
<td class="num">(64)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under benefit plans, sharers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under benefit plans</a></td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options, value</a></td>
<td class="nump">123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares to cover employee payroll tax withholdings on stock issued under stock-based compensation plans</a></td>
<td class="num">(28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchases of treasury stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchases of treasury stock, value</a></td>
<td class="num">(1,385)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,385)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Dec. 31, 2022</a></td>
<td class="nump">5,930<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 2,295<span></span>
</td>
<td class="nump">$ 8,290<span></span>
</td>
<td class="num">$ (21)<span></span>
</td>
<td class="num">$ (4,673)<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityNetIncome', window );">Net income</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders', window );">Distributions to noncontrolling interest partners</a></td>
<td class="num">$ (9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_NetIncomeLossExcludingRedeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Income (Loss), Excluding Redeemable Noncontrolling Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_NetIncomeLossExcludingRedeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity, Noncontrolling interest, Decrease from Distributions to Noncontrolling Interest Holders</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityNetIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of net income or loss attributable to temporary equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityNetIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredCostMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredCostMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596526082128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">DESCRIPTION OF BUSINESS</a></td>
<td class="text">DESCRIPTION OF BUSINESS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Background</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Quest Diagnostics Incorporated and its subsidiaries ("Quest Diagnostics" or the "Company") empower people to take action to improve health outcomes.&#160; The Company uses its extensive database of clinical lab results to derive diagnostic insights that reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management.&#160; The Company's diagnostic information services business ("DIS") provides information and insights based on an industry-leading menu of routine, non-routine and advanced clinical testing and anatomic pathology testing, and other diagnostic information services.  The Company provides services to a broad range of customers, including patients, clinicians, hospitals, independent delivery networks ("IDNs"), health plans, employers, consumers, and accountable care organizations ("ACOs").  The Company offers the broadest access in the United States to diagnostic information services through its nationwide network of laboratories, patient service centers and phlebotomists in physician offices and the Company's connectivity resources, including call centers and mobile paramedics, nurses and other health and wellness professionals.  The Company is the world's leading provider of diagnostic information services.  The Company provides interpretive consultation with one of the largest medical and scientific staffs in the industry. The Company's Diagnostic Solutions businesses ("DS") are the leading provider of risk assessment services for the life insurance industry and offer healthcare organizations and clinicians robust information technology solutions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596525278544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The consolidated financial statements include the accounts of all entities controlled by the Company through its direct or indirect ownership of a majority voting interest.  Additionally, the consolidated financial statements include the accounts of variable interest entities (&#8220;VIEs&#8221;) in which the Company has a variable interest and for which the Company is the &#8220;primary beneficiary&#8221; as it has both: (1) the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and (2) the obligation to absorb losses of the VIE that potentially could be significant to the VIE or the right to receive benefits from the VIE that potentially could be significant to the VIE.  All significant intercompany accounts and transactions are eliminated in consolidation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Income attributable to the minority interest in the Company's majority owned and controlled consolidated subsidiaries is recorded as net income attributable to noncontrolling interests in the consolidated statements of operations and the noncontrolling interest is reflected as a separate component of consolidated stockholders' equity in the consolidated balance sheet.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Reclassifications</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Method Investments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Investments in entities which the Company does not control, but in which it has a substantial ownership interest (generally between 20% and 49%) and can exercise significant influence, are accounted for using the equity method of accounting.  These investments are classified as investments in equity method investees in the consolidated balance sheet.  The Company records its pro rata share of the earnings, adjusted for accretion of basis difference, of these investments in equity in earnings of equity method investees, net of taxes in the consolidated statements of operations.  The Company reviews its investments in equity method investees for impairment whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The preparation of financial statements in conformity with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes as revenue the amount that reflects the consideration to which it expects to be entitled in exchange for goods sold or services rendered primarily upon completion of the testing process (when results are reported) or when services have been rendered (see Note 3).  Net revenues from Medicare and Medicaid programs were approximately 11%, 10% and 11% of the Company's consolidated net revenues for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Taxes on Income</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the year.  Current and deferred income taxes are measured based on the tax laws that are enacted as of the balance sheet date of the relevant reporting period.  Deferred tax assets and liabilities are recognized for the expected future tax consequences of differences between the carrying amounts of assets and liabilities and their respective tax bases using tax rates in effect for the year in which the differences are expected to reverse.  A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period when the change is enacted.  Tax benefits from uncertain tax positions are recognized only if the tax position is more likely than not to be sustained upon examination by taxing authorities based on the technical merits of the position. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings Per Share</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company's unvested restricted stock units that contain non-forfeitable rights to dividends are participating securities and, therefore, are included in the earnings allocation in computing earnings per share using the two-class method.  Basic earnings per common share is calculated by dividing net income attributable to Quest Diagnostics, adjusted for earnings allocated to participating securities, by the weighted average number of common shares outstanding.  Diluted earnings per common share is calculated by dividing net income attributable to Quest Diagnostics, adjusted for earnings allocated to participating securities, by the weighted average number of common shares outstanding after giving effect to all potentially dilutive common shares outstanding during the period.  Potentially dilutive common shares include the dilutive effect of outstanding stock options and performance share units granted under the Company's Amended and Restated Employee Long-Term Incentive Plan (&#8220;ELTIP&#8221;) and its Amended and Restated Non-Employee Director Long-Term Incentive Plan (&#8220;DLTIP&#8221;), as well as the dilutive effect of accelerated share repurchase agreements ("ASRs"), if applicable.  Earnings allocable to participating securities include the portion of dividends declared as well as the portion of undistributed earnings during the period allocable to participating securities.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company measures stock-based compensation for equity awards at fair value on the date of grant and records stock-based compensation as a charge to earnings net of the estimated impact of forfeited awards.  As such, the Company recognizes stock-based compensation cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">only for those stock-based awards that are estimated to ultimately vest over their requisite service period, based on the vesting provisions of the individual grants.  The cumulative effect on current and prior periods of a change in the estimated forfeiture rate is recognized as compensation cost in earnings in the period of the change.  The terms of the Company's performance share units allow the recipients of such awards to earn a variable number of shares based on the achievement of the performance goals, which are based on the financial performance of the Company and the total shareholder return of the Company relative to an index of peer companies ("relative TSR"), specified in the awards.  For performance share units with a goal based on the financial performance of the Company, stock-based compensation expense is recognized based on management's best estimates of the achievement of the performance goals specified in such awards and the resulting number of shares that will be earned.  The cumulative effect on current and prior periods of a change in the estimated number of performance share units expected to be earned for these awards is recognized as compensation cost in earnings in the period of the change.  For performance share units with a market-based relative TSR goal, stock-based compensation expense is recognized based on the estimated fair value of the award regardless of the actual number of shares earned.  For further details regarding stock-based compensation, see Note&#160;18.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company determines fair value measurements used in its consolidated financial statements based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants exclusive of any transaction costs, as determined by either the principal market or the most advantageous market.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Inputs used in the valuation techniques to derive fair values are classified based on a three-level hierarchy.  The basis for fair value measurements for each level within the hierarchy is described below with Level 1 having the highest priority and Level 3 having the lowest.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1: Quoted prices in active markets for identical assets or liabilities.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3: Valuations derived from valuation techniques in which one or more significant inputs are unobservable.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company predominately uses the U.S. dollar as its functional currency.  The functional currency of the Company's foreign operating subsidiaries generally is the applicable local currency.  Assets and liabilities denominated in non-U.S. dollars are translated into U.S. dollars at exchange rates as of the end of the reporting period.  Income and expense items are translated at the average monthly exchange rates during the year.  Resulting translation adjustments are recorded as a component of accumulated other comprehensive loss within stockholders' equity.  Gains and losses from foreign currency transactions, which are denominated in a currency other than the functional currency, are included within other operating expense (income), net in the consolidated statements of operations.  Foreign currency transaction gains and losses have historically not been material.  The Company may be exposed to market risk for changes in foreign exchange rates primarily under certain intercompany receivables and payables.  From time to time, the Company uses foreign exchange forward contracts to mitigate the exposure of the eventual net cash inflows or outflows resulting from these intercompany transactions.  The Company's foreign exchange exposure is not material to the Company's consolidated financial condition.  The Company does not hedge its net investment in non-U.S. subsidiaries because it views those investments as long-term in nature.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Cash and cash equivalents include all highly-liquid investments with original maturities, at the time acquired by the Company, of three months or less.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Financial instruments that potentially subject the Company to concentrations of credit risk are principally cash, cash equivalents, short-term investments, accounts receivable and derivative financial instruments.  The Company's policy is to place its cash, cash equivalents and short-term investments in highly-rated financial instruments and institutions.  Concentration of credit risk with respect to accounts receivable is mitigated by the diversity of the Company's payers and their dispersion across many different geographic regions, and credit risk is concentrated among certain payers who are large buyers of the Company's services.  To reduce risk, the Company routinely assesses the financial strength of these payers and, consequently, believes that its accounts receivable credit risk exposure, with respect to these payers, is limited.  While the Company has receivables due from federal and state governmental agencies, the Company does not believe that such receivables represent a credit risk since the related healthcare programs are funded by federal and state governments, and payment is primarily dependent on submitting appropriate documentation timely.  As of both December&#160;31, 2022 and 2021, receivables due from government payers under the Medicare and Medicaid programs represented approximately 6% of the Company's consolidated net accounts receivable.  The portion of the Company's accounts receivable due from patients comprises the largest portion of credit risk.  As of December&#160;31, 2022 and 2021, receivables due from patients represented approximately 18% and 21%, respectively, of the Company's consolidated net accounts receivable.  The Company applies assumptions and judgments including historical collection experience (including the period of time that the receivables have been outstanding) for assessing collectability and determining net revenues and accounts receivable from patients.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Credit Losses</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Accounts receivable are reported net of allowances for credit losses.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;When estimating its allowance for credit losses, the Company pools its trade receivables based on the following customer types: healthcare insurers, government payers, client payers and patients, which are described in Note 3.&#160; The Company principally estimates the allowance for credit losses by pool based on historical collection experience, the current credit worthiness of the customers, current economic conditions, expectations of future economic conditions and the period of time that the receivables have been outstanding.&#160; To the extent that any individual payers are identified that have deteriorated in credit quality, the Company removes the customers from their respective pools and establishes allowances based on the individual risk characteristics of such customers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Inventories, which consist principally of finished goods testing supplies and reagents, are valued at the lower of cost (first in, first out method) or net realizable value.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Property, plant and equipment is recorded at cost.  Major renewals and improvements are capitalized, while maintenance and repairs are expensed as incurred.  Costs incurred for computer software developed or obtained for internal use are capitalized for application development activities and expensed as incurred for preliminary project activities and post-implementation activities.  Capitalized costs include external direct costs of materials and services consumed in developing or obtaining internal-use software, payroll and payroll-related costs for employees who are directly associated with the internal-use software project, and interest costs incurred, when material, while developing internal-use software.  Capitalization of such costs ceases when the project is substantially complete and ready for its intended purpose.  Costs for maintenance and training are expensed as incurred.  The Company capitalizes interest on borrowings during the active construction period of major capital projects.  Capitalized interest is added to the cost of the underlying assets and is amortized over the expected useful lives of the assets.  Depreciation and amortization are provided on the straight-line method over expected useful asset lives as of December&#160;31, 2022 as follows: </span></div><div><span><br/></span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">buildings and improvements, ranging up to thirty-one and a half years; </span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">laboratory equipment and furniture and fixtures, ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzE1MDA1_cf798870-e9ec-4915-8333-6fffdab241e2">five</span> to twelve years; </span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">leasehold improvements, the lesser of the useful life of the improvement or the remaining life of the building or lease, as applicable; and </span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">computer software developed or obtained for internal use, principally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzE1MjE1_15232aa9-a205-41d3-834e-46d37c844c97">five</span> to ten years.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Goodwill represents the excess of the fair value of the acquiree (including the fair value of non-controlling interests) over the recognized bases of the net identifiable assets acquired and includes the future economic benefits from other assets that could not be individually identified and separately recognized.  Goodwill is not amortized, but instead is periodically reviewed for impairment and an impairment charge is recorded in the periods in which the recorded carrying value of goodwill exceeds its fair value.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On a quarterly basis, the Company performs a review of its business to determine if events or changes in circumstances have occurred which could have a material adverse effect on the fair value of the Company and its goodwill.  If such events or changes in circumstances were deemed to have occurred, the Company would perform an impairment test of goodwill as of the end of the quarter and record any noted impairment loss.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The goodwill test is performed at least annually, or more frequently if events or changes in circumstances indicate that the asset might be impaired.  The annual impairment test includes an option to perform a qualitative assessment of whether it is more likely than not that a reporting unit's fair value is less than its carrying value; the qualitative test may be performed prior to, or as an alternative to, performing a quantitative goodwill impairment test.  If, after assessing the totality of events or circumstances, the Company determines that it is more likely than not that the fair value of a reporting unit is less than its carrying value, then the Company is required to perform the quantitative goodwill impairment test.  Otherwise, no further analysis is required.  Additionally, the Company's policy is to update the fair value calculation of its reporting units and perform the quantitative goodwill impairment test on a periodic basis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The quantitative impairment test involves the comparison of the fair value of the reporting unit to its carrying value.  The Company calculates the fair value of each reporting unit using either (i) a discounted cash flows analysis that converts future cash flow amounts into a single discounted present value amount or (ii) a market approach.  The Company assesses the valuation methodology based upon the relevance and availability of the data at the time that the valuation is performed.  The Company compares the estimate of fair value for the reporting unit to the carrying value of the reporting unit.  If the carrying value is greater than the estimate of fair value, an impairment loss will be recognized in the amount of the excess. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company performs its annual impairment test during the fourth quarter of the fiscal year.  For the years ended December&#160;31, 2022 and 2021, the Company performed a qualitative impairment test for its DIS reporting unit and, based on the totality of information available, the Company concluded that it was more-likely-than-not that the estimated fair value of its DIS reporting unit was greater than the carrying value of the reporting unit and, as such, no further analysis was required.  For the year ended December&#160;31, 2022, the Company updated the fair value calculation of its risk assessment services reporting unit, performed the quantitative impairment test and concluded that goodwill for the reporting unit was not impaired.  For the year ended December 31, 2021, the Company performed a qualitative impairment test for its risk assessment reporting unit and, based on the totality of information available, the Company concluded that it was more-likely-than-not that the estimated fair value of the reporting unit was greater than the carrying value of the reporting unit and, as such, no further analysis was required.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Intangible assets are recognized at fair value, as an asset apart from goodwill if the asset (i) arises from contractual or other legal rights, or (ii) is separable.  Intangible assets, principally representing the cost of customer-related intangibles, non-competition agreements and technology acquired, are capitalized and amortized on the straight-line method over their expected useful lives, which generally range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzE5MDc3_e109cd52-340f-452f-8421-53cd708ea892">five</span> to twenty years.  Intangible assets with indefinite useful lives, consisting principally of acquired tradenames, are not amortized, but instead are periodically reviewed for impairment.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company reviews indefinite-lived intangible assets periodically for impairment and an impairment charge is recorded in the periods in which the recorded carrying value of an indefinite-lived intangible asset is more than its estimated fair value.  The indefinite-lived intangible asset impairment test is performed at least annually, or more frequently in the case of other events that indicate a potential impairment.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Based upon the Company&#8217;s most recent annual impairment tests completed during the fourth quarters of the years ended December&#160;31, 2022 and 2021, the Company concluded that indefinite-lived intangible assets were not impaired.</span></div><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company reviews the recoverability of its long-lived assets (including amortizable intangible assets), other than goodwill and indefinite-lived intangible assets, when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable.  Evaluation of possible impairment is based on the Company's ability to recover the asset from the expected future pre-tax cash flows (undiscounted and without interest charges) of the related operations.  If these cash flows are less than the carrying amount of such asset, an impairment loss is recognized for the difference between the estimated fair value and carrying amount of the asset.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company's investments (except for those accounted for under the equity method of accounting) include:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Equity investments with readily determinable fair values, including investments comprised mostly of strategic holdings in companies concentrated in the life sciences and healthcare industries (such investments, which previously did not have readily determinable fair values, became publicly-traded during the year ended December 31, 2021); as well as participant-directed investments of deferred employee compensation and related Company matching contributions held in trusts pursuant to the Company's supplemental deferred compensation plans (see Note 18).  These investments are measured at fair value with both realized and unrealized gains and losses recorded in current earnings within other (expense) income, net in the consolidated statements of operations.  For the years ended December&#160;31, 2022, 2021 and 2020, (losses)/gains from all equity investments with readily determinable fair values totaled $(55) million, $56 million, and $8 million, respectively.  See Note 8 for a discussion of the fair value of such investments. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Equity investments that do not have readily determinable fair values, which consist of investments in preferred and common shares of privately held companies.  These investments are measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes.  The Company regularly evaluates these equity investments to determine if there are any indicators that the investment is impaired; no impairment charges were recognized related to these investments for the years ended December&#160;31, 2022, 2021 and 2020.  The carrying value of these investments was $4&#160;million at both December&#160;31, 2022 and 2021.  Such amounts were included in other assets in the consolidated balance sheet.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Available-for-sale debt securities of privately-held companies.  These investments are measured at fair value with unrealized gains and losses presented in other comprehensive (loss) income.  The carrying amount of these investments was $2 million and $1 million at December&#160;31, 2022 and 2021, respectively.  See Note 8 for a discussion of the fair value of such investments. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Financial Instruments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company uses derivative financial instruments, from time to time, to manage its exposure to market risks for changes in interest rates and foreign currencies.  This strategy includes the use of interest rate swap agreements, forward-starting interest rate swap agreements, interest rate lock agreements and foreign currency forward contracts to manage its exposure to movements in interest and currency rates.  The Company has established policies and procedures for risk assessment and the approval, reporting and monitoring of derivative financial instrument activities.  These policies prohibit holding or issuing derivative financial instruments for speculative purposes.  The Company does not enter into derivative financial instruments that contain credit risk-related contingent features or requirements to post collateral.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company is exposed to interest rate risk on its cash and cash equivalents and its debt obligations.  Interest income earned on cash and cash equivalents may fluctuate as interest rates change; however, due to their relatively short maturities, the Company does not hedge these assets or their investment cash flows and the impact of interest rate risk is not material.  The Company's debt obligations consist of fixed-rate and, from time to time, variable-rate debt instruments.  The Company's primary objective is to achieve the lowest overall cost of funding while managing the variability in cash outflows within an acceptable range.  In order to achieve this objective, the Company has historically entered into interest rate swap agreements.  Interest rate swap agreements involve the periodic exchange of payments without the exchange of underlying principal or notional amounts.  Net settlements between the counterparties are recognized as an adjustment to interest expense, net.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company accounts for these derivatives as either an asset or liability measured at its fair value.  The fair value is based upon model-derived valuations in which all significant inputs are observable in active markets including certain financial </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">information and certain assumptions regarding past, present and future market conditions.  For a derivative instrument that has been formally designated as a fair value hedge, fair value gains or losses on the derivative instrument along with offsetting fair value gains or losses on the hedged item that are attributable to the risk being hedged are reported in other (expense) income, net in the consolidated statements of operations.  For derivatives that have been formally designated as a cash flow hedge, the change in the fair value of the derivatives is recorded in accumulated other comprehensive loss.  Upon maturity or early termination of an effective interest rate swap agreement designated as a cash flow hedge, unrealized gains or losses are deferred in stockholders' equity, as a component of accumulated other comprehensive loss, and are amortized as an adjustment to interest expense over the period during which the hedged forecasted transaction affects earnings, which is when the Company recognizes interest expense on the hedged cash flows.  At inception and quarterly thereafter, the Company formally assesses whether the derivatives that are used in hedging transactions are highly effective in offsetting changes in the fair value or cash flows of the hedged item.  After the initial quantitative assessment, this analysis is initially performed on a qualitative basis and, if it is determined that the hedging relationship was and continues to be highly effective, no further analysis is required.  All components of each derivative financial instrument's gain or loss are included in the assessment of hedge effectiveness.  If it is determined that a derivative ceases to be a highly effective hedge, the Company discontinues hedge accounting and any deferred gains or losses related to a discontinued cash flow hedge shall continue to be reported in accumulated other comprehensive loss, unless it is probable that the forecasted transaction will not occur.  If it is probable that the forecasted transaction will not occur by the originally specified time period, the Company discontinues hedge accounting and any deferred gains or losses reported in accumulated other comprehensive loss are classified into earnings immediately.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Comprehensive income (loss) encompasses all changes in stockholders' equity (except those arising from transactions with stockholders) and includes:</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Foreign currency translation adjustments; </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net deferred gains (losses) on cash flow hedges, which represent deferred gains (losses), net of tax, on interest rate-related derivative financial instruments designated as cash flow hedges, net of amounts reclassified to interest expense (see Notes 16 and 17); and</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net changes in available-for-sale debt securities, which represent unrealized holding gains (losses), net of tax, on available-for-sale debt securities.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Costs&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Advertising costs are expensed as incurred.  For the years ended December&#160;31, 2022, 2021 and 2020, advertising costs were $74&#160;million, $78&#160;million and $38&#160;million, respectively.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Standards </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;New Accounting Standards To Be Adopted</span></div>&#160;&#160;&#160;&#160;In March 2020, the Financial Accounting Standards Board ("FASB") issued a new accounting standard which provides temporary optional guidance to ease the potential burden in accounting for reference rate reform due to the risk of cessation of the London Interbank Offered Rate ("LIBOR").  The amendments apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform.  The pronouncement was effective immediately and, due to an accounting standards update which the FASB issued in December 2022, can be applied to contract modifications through December 31, 2024.  To the extent that, prior to December 31, 2024, the Company enters into any contract modifications for which the optional expedients are applied, the adoption of this standard is not expected to have a material impact on the Company&#8217;s consolidated results of operations, financial position or cash flows.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596614072160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUE RECOGNITION</a></td>
<td class="text">REVENUE RECOGNITION<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DIS</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Net revenues in the Company&#8217;s DIS business accounted for greater than 95% of the Company&#8217;s consolidated net revenues for the years ended December&#160;31, 2022, 2021 and 2020 and are primarily comprised of a high volume of relatively low-dollar transactions.  The DIS business, which provides clinical testing services and other services, satisfies its performance obligation and recognizes revenues primarily upon completion of the testing process (when results are reported) or when services have been rendered.  The Company estimates the amount of consideration it expects to be entitled to receive from customer groups in exchange for providing services using the portfolio approach. These estimates include the impact of contractual allowances (including payer denials), and patient price concessions, as discussed below. The portfolios determined using the portfolio approach consist of the following groups of customers: healthcare insurers, government payers (Medicare and Medicaid programs), client payers and patients.  Contracts with customers in the DIS business do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation.  The Company follows a standard process, which considers historical denial and collection experience and other factors (including the period of time that the receivables have been outstanding), to estimate contractual allowances and implicit price concessions, recording adjustments in the current period as changes in estimates.  Further adjustments to the allowances, based on actual receipts, may be recorded upon settlement.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following are descriptions of the DIS business&#8217; portfolios:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healthcare Insurers </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Reimbursements from healthcare insurers are based on negotiated fee-for-service schedules and on capitated payment rates.  Under fee-for-service arrangements, healthcare insurers are billed at the Company's list price.  Net revenues recognized consist of amounts billed net of contractual allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payers, which considers historical denial and collection experience and the terms of the Company&#8217;s contractual arrangements. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Collection of the Company's net revenues from healthcare insurers is normally a function of providing complete and correct billing information to the healthcare insurers within the various filing deadlines and generally occurs within 30 to 60 days of billing.  Provided the Company has billed healthcare insurers accurately with complete information prior to the established filing deadline, there has historically been little to no credit risk.  If there has been a delay in billing, the Company determines if the amounts in question will likely go past the filing deadline, and if so, it will reserve accordingly for the billing.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Under capitated arrangements with healthcare insurers, the Company recognizes revenue based on a predetermined monthly reimbursement rate for each member of an insurer's health plan regardless of the number or cost of services provided by the Company.  Healthcare insurers typically reimburse the Company under capitated arrangements in the same month services are performed, essentially giving rise to no outstanding accounts receivable at the end of a reporting period.  If any capitated payments are not received on a timely basis, the Company determines the cause and makes a separate determination as to whether or not the collection of the amount from the healthcare insurer is at risk and, if so, would reserve accordingly.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Payers</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Reimbursements from government payers are based on fee-for-service schedules set by governmental authorities, including traditional Medicare and Medicaid.  Net revenues recognized consist of amounts billed net of contractual allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payers, which considers historical denial and collection experience and other factors. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Collection of the Company's net revenues from government payers is normally a function of providing the complete and correct billing information within the various filing deadlines and generally occurs within 30 days of billing.  Provided the Company has billed government payers accurately with complete information prior to the established filing deadline, there has historically been little to no credit risk.  If there has been a delay in billing, the Company determines if the amounts in question will likely go past the filing deadline, and, if so, it will reserve for the billing accordingly.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Client Payers </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Client payers include physicians, hospitals, ACOs, IDNs, employers, other commercial laboratories and institutions for which services are performed on a wholesale basis, and are billed based on negotiated fee schedules.  Credit risk and ability to pay are more of a consideration for these payers than healthcare insurers and government payers.  Collection of consideration the Company expects to receive generally occurs within 60 to 90 days of billing.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company principally estimates the allowance for credit losses for client payers based on historical collection experience, the current credit worthiness of the customers, current economic conditions, expectations of future economic conditions and the period of time that the receivables have been outstanding. To the extent that any individual client payers are identified that have deteriorated in credit quality, the Company establishes allowances based on the individual risk characteristics of such customers.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patients</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Uninsured patients are billed based on established patient fee schedules or fees negotiated with physicians on behalf of their patients.  Insured patients (includes coinsurance and deductible responsibilities) are billed based on fees negotiated with healthcare insurers.  Collection of billings from patients is subject to credit risk and ability of the patients to pay.  Net revenues consist of amounts billed net of discounts provided to uninsured patients in accordance with the Company&#8217;s policies and implicit price concessions.  Implicit price concessions represent differences between amounts billed and the estimated consideration the Company expects to receive from patients, which considers historical collection experience (including the period of time that the receivables have been outstanding) and other factors including current market conditions. Patient billings are generally fully reserved for when the related service reaches 210 days outstanding.  Balances are automatically written off when they are sent to collection agencies.  Allowances are further adjusted for estimated recoveries of amounts sent to collection agencies based on historical collection experience, which is regularly monitored.  Collection of consideration the Company expects to receive generally occurs within 30 to 60 days of billing.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DS</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company&#8217;s DS businesses primarily satisfy their performance obligations and recognize revenues when delivery has occurred or services have been rendered.  Collection of consideration the Company expects to receive generally occurs within 30 to 60 days of billing.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The approximate percentage of net revenues by type of customer was as follows:</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:62.026%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.699%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.699%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.702%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare insurers:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fee-for-service</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitated</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total healthcare insurers</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government payers</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Client payers</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients (including coinsurance and deductible responsibilities)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total DIS</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DS</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the years ended December&#160;31, 2022, 2021 and 2020, substantially all of the Company&#8217;s services were provided within the United States, see Note 20.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The approximate percentage of net accounts receivable by type of customer as of December&#160;31, 2022 and 2021 was as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:74.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.838%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.771%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare insurers</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government payers</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Client payers</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients (including coinsurance and deductible responsibilities)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total DIS</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DS</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net accounts receivable</span></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following table summarizes the activity for the Company's allowance for credit losses during the years ended December&#160;31, 2022 and 2021, which principally relates to client payers:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Allowance for Credit Losses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for credit losses</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs of accounts receivable, net of recoveries</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for credit losses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs of accounts receivable, net of recoveries</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, December&#160;31, 2022</span></div></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596613991200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS PER SHARE</a></td>
<td class="text">EARNINGS PER SHARE<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The computation of basic and diluted earnings per common share is as follows (in millions, except per share data):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts attributable to Quest Diagnostics&#8217; common stockholders:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Quest Diagnostics</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,995&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,431&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Earnings allocated to participating securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings available to Quest Diagnostics&#8217; common stockholders &#8211; basic and diluted</span></div></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,988&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,425&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding &#8211; basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and performance share units</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding &#8211; diluted</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings per share attributable to Quest Diagnostics&#8217; common stockholders:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.62&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.97&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.55&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.47&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following securities were not included in the calculation of diluted earnings per share due to their antidilutive effect:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and performance share units</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596613987680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING ACTIVITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">RESTRUCTURING ACTIVITIES</a></td>
<td class="text">RESTRUCTURING ACTIVITIES <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Invigorate Program</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company is committed to a program called Invigorate which is designed to reduce its cost structure and improve performance.  Invigorate consists of several flagship programs, with structured plans in each, to drive savings and improve performance across the customer value chain.  These flagship programs include: organization excellence; information technology excellence; procurement excellence; field and customer service excellence; lab excellence; and revenue services excellence.  In addition to these programs, the Company identified key themes to change how it operates including reducing denials and patient price concessions; further digitizing the business; standardization; automation; optimization and selecting and retaining talent. The Invigorate program is intended to offset reimbursement pressures and labor and benefit cost increases; free up additional resources to invest in innovation and other growth initiatives; and enable the Company to improve service quality and operating profitability. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Restructuring Charges</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the Company's pre-tax restructuring charges for the years ended December&#160;31, 2022, 2021 and 2020: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee separation costs</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility-related costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment charges</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restructuring charges</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The restructuring charges incurred for the years ended December&#160;31, 2022, 2021 and 2020 were primarily associated with various workforce reduction initiatives as the Company continued to restructure its organization. Additionally, during the year ended December 31, 2022, the Company fully impaired certain property, plant and equipment (see Note 8).  Of the total restructuring charges incurred during the year ended December&#160;31, 2022, $19&#160;million,  $36&#160;million and $14&#160;million were recorded in cost of services, selling, general and administrative expenses and other operating expense (income), net, respectively.  Of the total restructuring charges incurred during the year ended December&#160;31, 2021, $8&#160;million and $4&#160;million were recorded in cost of services and selling, general and administrative expenses, respectively.  Of the total restructuring charges incurred during the year ended December&#160;31, 2020, $9&#160;million and $5&#160;million were recorded in cost of services and selling, general and administrative expenses, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The employee separation costs for all periods presented were primarily recorded in the Company's DIS business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity of the restructuring liability during 2022 and 2021, which is included in accrued expenses in Note 13:  </span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"/><td style="width:62.049%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.396%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.711%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Employee Separation Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Facility-Related Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, December&#160;31, 2020</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income statement expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, December&#160;31, 2021</span></div></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income statement expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, December&#160;31, 2022</span></div></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI https://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596614048224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS ACQUISITIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">BUSINESS ACQUISITIONS</a></td>
<td class="text">BUSINESS ACQUISITIONS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;2022 Acquisitions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, the Company completed acquisitions for an aggregate purchase price of $162&#160;million, net of cash acquired, including the acquisition discussed below.  The 2022 acquisitions resulted in goodwill of $121&#160;million, of which $103&#160;million is deductible for tax purposes.  These acquisitions also resulted in $45&#160;million of intangible assets, principally comprised of customer-related intangible assets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Pack Health, LLC</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2022, the Company acquired Pack Health, LLC ("Pack Health"), a patient engagement company that helps individuals adopt healthier behaviors to improve outcomes, in an all cash transaction for $123&#160;million, net of $4&#160;million cash acquired, which consisted of cash consideration of $105&#160;million and contingent consideration initially estimated at $18&#160;million.  The contingent consideration arrangement was dependent upon the achievement of certain revenue benchmarks.  Based on the purchase price allocation, the assets acquired and liabilities assumed consist of $96&#160;million of goodwill (of which $78&#160;million was tax-deductible on the acquisition date), $30&#160;million of intangible assets, $5&#160;million of operating lease right-of-use assets, $5&#160;million of operating lease liabilities and $(3)&#160;million of working capital. The intangible assets consist primarily of customer-related assets which are being amortized over a useful life of 15 years.  For further details regarding the fair value of the contingent consideration, see Note 8.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;2021 Acquisitions</span></div><div style="padding-left:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the Company completed acquisitions for an aggregate purchase price of $346&#160;million, net of cash acquired, including the acquisitions discussed below.  The 2021 acquisitions resulted in goodwill of $236&#160;million, of which $221&#160;million is deductible for tax purposes. These acquisitions also resulted in $107&#160;million of intangible assets, principally comprised of customer-related intangible assets.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of the outreach laboratory services business of Mercy Health</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2021, the Company completed the acquisition of the outreach laboratory services business of Mercy Health ("Mercy Health"), which serves providers and patients in Arkansas, Kansas, Missouri and Oklahoma, in an all-cash transaction for $225&#160;million.  Based on the purchase price allocation, the assets acquired primarily consist of $171&#160;million of tax-deductible goodwill and $54&#160;million of customer-related intangible assets.  The intangible assets are being amortized over a useful life of 15 years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of assets of Labtech Diagnostics, LLC</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 13, 2021, the Company completed the acquisition of assets of Labtech Diagnostics, LLC ("Labtech"), an independent clinical diagnostic laboratory provider serving physicians and patients primarily in South Carolina, North Carolina, Florida and Georgia, in an all cash transaction for $95&#160;million, which consisted of cash consideration of $80&#160;million and contingent consideration estimated at $15&#160;million. The contingent consideration arrangement was dependent upon the achievement of certain testing volume benchmarks.  Based on the purchase price allocation, which was finalized during the three months ended March 31, 2022, the assets acquired and liabilities assumed consist of $48&#160;million of goodwill (of which $33&#160;million was tax deductible on the acquisition date), $44&#160;million of intangible assets, $11&#160;million of property, plant and equipment, $9&#160;million of finance lease liabilities, $6&#160;million of operating lease right-of-use assets, $6&#160;million of operating lease liabilities, and $1&#160;million of inventories. The intangible assets consist primarily of customer-related assets which are being amortized over a useful life of 15 years.  For further details regarding the fair value of the contingent consideration, see Note 8.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;2020 Acquisitions</span></div><div style="padding-left:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, the Company completed acquisitions for an aggregate purchase price of $330&#160;million, net of cash acquired, including the acquisitions discussed below.  The 2020 acquisitions resulted in goodwill of $247&#160;million, of which $210&#160;million is deductible for tax purposes.  These acquisitions also resulted in $146&#160;million of intangible assets, principally comprised of customer-related and technology intangible assets.  Net revenues attributable to the 2020 acquisitions were $127&#160;million for the year ended December 31, 2020.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Blueprint Genetics Oy</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 21, 2020, the Company completed the acquisition of Blueprint Genetics Oy ("Blueprint Genetics"), in an all cash transaction for $108&#160;million, net of $3&#160;million cash acquired.  Blueprint Genetics is a leading specialty genetic testing company with expertise in gene variant interpretation based on next generation sequencing and proprietary bioinformatics.  Through the acquisition, the Company acquired all of Blueprint Genetics' operations.  Based on the purchase price allocation, the assets acquired and liabilities assumed primarily consist of $66&#160;million of tax-deductible goodwill, $43&#160;million of intangible assets, and $2&#160;million of property, plant and equipment and working capital.  The intangible assets primarily consist of technology and customer-related assets which are being amortized over a useful life of 10 years and 15 years, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of the Outreach Laboratory Services Business of Memorial Hermann Health System</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 6, 2020, the Company completed the acquisition of select assets which constitute substantially all of the operations of Memorial Hermann Diagnostic Laboratories, the outreach laboratory division of Memorial Hermann Health System ("Memorial Hermann"), in an all cash transaction for $120&#160;million.  Memorial Hermann is a not-for-profit health system in Southeast Texas.  Based on the purchase price allocation, the assets acquired primarily consist of $93&#160;million of tax-deductible goodwill and $27&#160;million of customer-related intangible assets.  The intangible assets are being amortized over a useful life of 15 years.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of the Remaining 56% Interest in Mid America Clinical Laboratories, LLC</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On August 1, 2020, the Company completed the acquisition of the remaining 56% interest in Mid America Clinical Laboratories, LLC ("MACL") from its joint venture partners in an all cash transaction for $93&#160;million, net of $18&#160;million cash acquired.  MACL was the largest independent clinical laboratory provider in Indiana.  Prior to the acquisition, the Company accounted for its 44% interest in MACL as an equity method investment, which was remeasured to its fair value of $87&#160;million on the acquisition date, resulting in a gain of $70&#160;million that was recognized in other (expense) income, net in the consolidated statements of operations.  The fair value of the previously held equity interest was determined using a discounted cash flow analysis that took into account, among other items, MACL's expected future cash flows, long-term growth rate (1.5%), and a discount rate commensurate with economic risk (7.5%).  Based on the purchase price allocation, the assets acquired and liabilities assumed consist of $84&#160;million of goodwill (of which $47&#160;million is tax-deductible), $74&#160;million of intangible assets, $11&#160;million of working capital and $11&#160;million of property, plant and equipment.  The intangible assets consist of customer-related assets which are being amortized over a useful life of 15 years.  As a result of the acquisition, MACL became a wholly owned subsidiary of the Company.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;General Information</span></div>&#160;&#160;&#160;&#160;The acquisitions described above were accounted for under the acquisition method of accounting.  As such, the assets acquired and liabilities assumed are recorded based on their estimated fair values as of the closing date.  Supplemental pro forma combined financial information has not been presented as the impact of the acquisitions is not material to the Company's consolidated financial statements.  The goodwill recorded primarily includes the expected synergies resulting from combining the operations of the acquired entities with those of the Company and the value associated with an&#160;assembled workforce and other intangible assets that do not qualify for separate recognition.  All of the goodwill acquired in connection with these acquisitions has been allocated to the Company's DIS business.  For further details regarding business segment information, see Note 20.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596526266080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISPOSITION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">DISPOSITION</a></td>
<td class="text">DISPOSITION<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On April 1, 2021, the Company sold its 40% ownership interest in Q</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Solutions&#174; ("Q</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Solutions"), its clinical trials central laboratory services joint venture, to IQVIA Holdings, Inc. ("IQVIA"), its joint venture partner, for $760&#160;million in an all-cash transaction.  Prior to the transaction, the Company accounted for its minority interest as an equity method investment.  As a result of the transaction, during the year ended December 31, 2021, the Company recorded a $314&#160;million pre-tax gain in other (expense) income, net in the consolidated statement of operations based on the difference between the net sales proceeds and the carrying value of the investment, including $20&#160;million of cumulative translation losses which were previously recorded in accumulated other comprehensive loss.  During the year ended December 31, 2021, the Company also recorded $55&#160;million </span>of income tax expense related to the gain, consisting of $127&#160;million of current income tax expense, partially offset by $72&#160;million of deferred income tax benefit.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596530677696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following table provides a summary of the recognized assets and liabilities that are measured at fair value on a recurring basis:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of Fair Value Measurements</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation trading securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash surrender value of life insurance policies</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liabilities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redeemable noncontrolling interest</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation trading securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash surrender value of life insurance policies</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liabilities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redeemable noncontrolling interest</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company offers certain employees the opportunity to participate in a non-qualified supplemental deferred compensation plan.  A participant's deferrals, together with Company matching credits, are invested in a variety of participant-directed stock and bond mutual funds that are classified as trading securities.  The trading securities are classified within Level 1 of the fair value hierarchy because the changes in the fair value of these securities, which are recorded in other assets in the Company's consolidated balance sheet, are measured using quoted prices in active markets based on the market price per unit multiplied by the number of units held, exclusive of any transaction costs.  A corresponding adjustment for changes in fair value of the trading securities is also reflected in the changes in fair value of the deferred compensation obligation.  The deferred compensation liabilities are classified within Level 2 of the fair value hierarchy because their inputs are derived principally from observable market data by correlation to the trading securities.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company offers certain employees the opportunity to participate in a non-qualified deferred compensation program.  A participant's deferrals, together with Company matching credits, are &#8220;invested&#8221; at the direction of the employee in a hypothetical portfolio of investments which are tracked by an administrator.  The Company purchases life insurance policies, with the Company named as beneficiary of the policies, for the purpose of funding the program's liability.  Changes in the cash surrender value of the life insurance policies are based upon earnings and changes in the value of the underlying investments.  Changes in the fair value of the deferred compensation obligation are derived using quoted prices in active markets based on the market price per unit multiplied by the number of units.  The cash surrender value, which is recorded in other assets in the Company's consolidated balance sheet, and the deferred compensation obligation are classified within Level 2 of the fair value hierarchy because their inputs are derived principally from observable market data by correlation to the hypothetical investments. Deferrals under the plan currently may only be made by participants who made deferrals under the plan in 2017. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company's investment portfolio primarily includes equity investments comprised mostly of strategic holdings in companies concentrated in the life sciences and healthcare industries.  Equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) with readily determinable fair values are measured at fair value in prepaid expenses and other current assets in the Company's consolidated balance sheet.  Such equity investments are classified within Level 1 of the fair value hierarchy because the changes in the fair values of the securities are measured using quoted prices in active markets based on the market price per share multiplied by the number of shares held, exclusive of any transaction costs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company's available-for-sale debt securities are measured at fair value using discounted cash flows.  These fair value measurements are classified within Level 3 of the fair value hierarchy as the fair value is based on significant inputs that are not observable.  Significant inputs include cash flows projections and a discount rate.  The investments are recorded in other assets in the Company's consolidated balance sheet.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In connection with the acquisitions of Pack Health and Labtech (see Note 6), the Company has contingent consideration obligations, with a potential maximum aggregate payment of $40&#160;million, that are to be paid based on the achievement of certain testing volume or revenue benchmarks.  Contingent consideration accruals are measured at fair value using either an option-pricing method or a Monte Carlo method and are classified within Level 3 of the fair value hierarchy as the fair value is determined based on significant inputs that are not observable.  Significant inputs include management&#8217;s estimate of volume or revenue and other market inputs, including comparable company revenue volatility (7.5%) and a discount rate (ranging from 2.5% to 3.0%).</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following table provides a reconciliation of the beginning and ending balances of liabilities using significant unobservable inputs (Level 3):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.912%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent Consideration</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases, additions and issuances</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases, additions and issuances</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value adjustments included in earnings - realized/unrealized</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The $5 million net loss included in earnings associated with the change in the fair value of contingent consideration for the year ended December&#160;31, 2022 is reported in other operating expense (income), net.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In connection with the sale of an 18.9% noncontrolling interest in a subsidiary to UMass Memorial Medical Center ("UMass") on July 1, 2015, the Company granted UMass the right to require the Company to purchase all of its interest in the subsidiary at fair value commencing July 1, 2020.  As of December&#160;31, 2022, the redeemable noncontrolling interest was presented at its fair value.  The fair value measurement of the redeemable noncontrolling interest is classified within Level 3 of the fair value hierarchy because the fair value is based on a discounted cash flow analysis that takes into account, among other items, the joint venture's expected future cash flows, long-term growth rates, and a discount rate commensurate with economic risk.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the year ended December 31, 2022, the Company recorded a $14&#160;million impairment charge, which is included in other operating expense (income), net, in order to fully impair certain property, plant and equipment.  The fair value measurement was classified within Level 3 of the fair value hierarchy as it was based on significant inputs that are not observable, including cash flow projections.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The carrying amounts of cash and cash equivalents, accounts receivable and accounts payable and accrued expenses approximate fair value based on the short maturities of these instruments.  As of December&#160;31, 2022 and 2021, the fair value of the Company&#8217;s debt was estimated at $3.7 billion and $4.4 billion, respectively.  Principally all of the Company's debt is classified within Level 1 of the fair value hierarchy because the fair value of the debt is estimated based on rates currently offered to the Company with identical terms and maturities, using quoted active market prices and yields, taking into account the underlying terms of the debt instruments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596613795904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">TAXES ON INCOME</a></td>
<td class="text">TAXES ON INCOME<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company's pre-tax income before equity in earnings of equity method investees consisted of approximately $1.2 billion, $2.5 billion and $1.9 billion from U.S. operations and pre-tax income (loss) of $2 million, $148 million and $(7) million from foreign operations for the years ended December&#160;31, 2022, 2021 and 2020, respectively. &#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The components of income tax expense (benefit) for 2022, 2021 and 2020 were as follows: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:42.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;A reconciliation of the federal statutory income tax rate to the Company's effective income tax rate for 2022, 2021 and 2020 was as follows: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax provision at statutory rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local income taxes, net of federal benefit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of noncontrolling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment to state deferred tax liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess tax benefits on stock-based compensation arrangements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return to provision true-ups </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of equity earnings</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in reserves for uncertain tax positions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowances associated with certain net operating losses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.4&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The tax effects of temporary differences that give rise to significant portions of the deferred tax assets (liabilities) as of December&#160;31, 2022 and 2021 were as follows: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current deferred tax assets (liabilities):</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable reserves</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities not currently deductible</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basis differences in investments, joint ventures and subsidiaries </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards, net of valuation allowance</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(568)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(633)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current deferred tax liabilities, net</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(295)</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(290)</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of December&#160;31, 2022 and 2021, non-current deferred tax liabilities of $295 million and $290 million, respectively, are included in other liabilities in the consolidated balance sheet. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of December&#160;31, 2022, the Company had estimated net operating loss carryforwards for federal and state income tax purposes of $12 million and $732 million, respectively, which expire at various dates through 2042.  Estimated net operating loss carryforwards for foreign income tax purposes are $73 million as of December&#160;31, 2022, some of which can be carried forward indefinitely while others expire at various dates through 2032.  As of December&#160;31, 2022 and 2021, deferred tax assets associated with net operating loss carryforwards of $77 million and $71 million, respectively, have each been reduced by valuation allowances of $28 million and $29 million, respectively.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Income taxes payable, including those classified as long-term in other liabilities in the consolidated balance sheet as of December&#160;31, 2022 and 2021, were $81 million and $106 million, respectively.  Prepaid income taxes were $26 million and $36 million as of December&#160;31, 2022 and 2021, respectively, and were recorded in prepaid expenses and other current assets in the consolidated balance sheet. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The total amount of unrecognized tax benefits as of and for the years ended December&#160;31, 2022, 2021 and 2020 consisted of the following:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For tax positions of current year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For tax positions of prior years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in judgment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expirations of statutes of limitations</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The contingent liabilities for tax positions primarily relate to uncertainties associated with the realization of tax benefits derived from the allocation of income and expense among state jurisdictions, the characterization and timing of certain tax deductions associated with business combinations, certain tax credits and the deductibility of certain expenses and settlement payments.   </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The total amount of unrecognized tax benefits as of December&#160;31, 2022, that, if recognized, would affect the effective income tax rate is $78 million.  Based upon the expiration of statutes of limitations, settlements and/or the conclusion of tax examinations, the Company believes it is reasonably possible that the total amount of unrecognized tax benefits may decrease by up to $13 million within the next twelve months.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Accruals for interest expense on contingent tax liabilities are classified in income tax expense in the consolidated statements of operations.  Accruals for penalties have historically been immaterial.  Interest expense (income) included in income tax expense in each of the years ended December&#160;31, 2022, 2021 and 2020 was approximately $3 million, $(2) million and $6 million, respectively.  As of December&#160;31, 2022 and 2021, the Company had approximately $16 million and $20 million, respectively, accrued, net of the benefit of a federal and state deduction, for the payment of interest on uncertain tax positions.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The recognition and measurement of certain tax benefits includes estimates and judgment by management and inherently involves subjectivity.  Changes in estimates may create volatility in the Company's effective tax rate in future periods and may be due to settlements with various tax authorities (either favorable or unfavorable), the expiration of the statute of limitations on certain tax positions and obtaining new information about particular tax positions that may cause management to change its estimates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In the regular course of business, various federal, state, local and foreign tax authorities conduct examinations of the Company's income tax filings and the Company generally remains subject to examination until the statute of limitations expires for the respective jurisdiction.  The Internal Revenue Service has either completed its examinations of the Company's consolidated federal income tax returns or the statute of limitations has expired up through and including the 2018 tax year.  At this time, the Company does not believe that there will be any material additional payments beyond its recorded contingent liability reserves that may be required as a result of these tax audits.  As of December&#160;31, 2022, a summary of the tax years that remain subject to examination, awaiting approval, are under appeal, or are otherwise unresolved for the Company's major jurisdictions are:</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;United States - federal&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2019 - 2021 </span></div>&#160;&#160;&#160;&#160;United States - various states&#160;&#160;&#160;&#160;2007 - 2021<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596614048224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL CASH FLOW AND OTHER DATA<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">SUPPLEMENTAL CASH FLOW AND OTHER DATA</a></td>
<td class="text">SUPPLEMENTAL CASH FLOW AND OTHER DATA <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Supplemental cash flow and other data for the years ended December&#160;31, 2022, 2021 and 2020 was as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(151)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">709&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable associated with capital expenditures</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable associated with purchases of treasury stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend payable</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends received from equity method investees</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Businesses acquired:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of liabilities assumed</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of net assets acquired</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merger consideration payable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for business acquisitions</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Cash acquired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business acquisitions, net of cash acquired</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Leases:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased assets obtained in exchange for new operating lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the year ended December 31, 2022, the Company amended a real estate lease and, based on the updated terms, the classification of the lease changed from a finance lease to an operating lease. As a result, the Company recorded a $31&#160;million operating lease right-of-use asset.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the years ended December 31, 2022, 2021 and 2020, costs associated with donations, contributions, and other financial support through Quest for Health Equity, the Company's initiative with the Quest Diagnostics Foundation to reduce health disparities in underserved communities, were $93&#160;million, $16&#160;million and $2&#160;million, respectively.  Such amounts are included in selling, general and administrative expenses in the Company's consolidated statement of operations.  Costs incurred during the year ended December 31, 2022 will be donated and contributed over several years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -URI https://asc.fasb.org/topic&amp;trid=2134446<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596530706016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY, PLANT AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY, PLANT AND EQUIPMENT</a></td>
<td class="text">PROPERTY, PLANT AND EQUIPMENT<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Property, plant and equipment as of December&#160;31, 2022 and 2021 consisted of the following: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment and furniture and fixtures</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,140&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,009&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software developed or obtained for internal use</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,103&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,795&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,337)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,088)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,766&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,707&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596526291920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">GOODWILL AND INTANGIBLE ASSETS</a></td>
<td class="text">GOODWILL AND INTANGIBLE ASSETS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The changes in goodwill for the years ended December&#160;31, 2022 and 2021 were as follows:</span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,095&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,873&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired during the year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to goodwill</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,220&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,095&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Principally all of the Company&#8217;s goodwill as of December&#160;31, 2022 and 2021 was associated with its DIS business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the year ended December&#160;31, 2022, goodwill acquired was principally associated with the acquisition of Pack Health (see Note 6).  For the year ended December&#160;31, 2022, adjustments to goodwill related to an adjustment of the purchase price allocation for Labtech, partially offset by foreign currency translation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the year ended December&#160;31, 2021, goodwill acquired was principally associated with the acquisitions of the assets of the outreach laboratory business of Mercy Health and the assets of Labtech (see Note 6). For the year ended December&#160;31, 2021, adjustments to goodwill related to foreign currency translation. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Intangible assets as of December&#160;31, 2022 and 2021 consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.436%"/><td style="width:0.1%"/></tr><tr style="height:39pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Amortization<br/>Period (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizing intangible assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer-related</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,623&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(832)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,581&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(726)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-compete agreements</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,878&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,022)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,834&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(903)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets not subject to amortization:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,114&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,022)</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,070&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(903)</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,167&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The estimated amortization expense related to amortizable intangible assets for each of the five succeeding fiscal years and thereafter as of December&#160;31, 2022 is as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:41.959%"><tr><td style="width:1.0%"/><td style="width:71.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.775%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596530677696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accounts Payable and Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCOUNTS PAYABLE AND ACCRUED EXPENSES</a></td>
<td class="text">ACCOUNTS PAYABLE AND ACCRUED EXPENSES <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Accounts payable and accrued expenses as of December&#160;31, 2022 and 2021 consisted of the following: </span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.105%"><tr><td style="width:1.0%"/><td style="width:72.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued wages and benefits (including incentive compensation)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">518&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Overdrafts</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend payable</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued insurance</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merger consideration payable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,396&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596526130016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Debt Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text">DEBT<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Long-term debt (including finance lease obligations) as of December&#160;31, 2022 and 2021 consisted of the following: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:77.962%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.004%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25% Senior Notes due April 2024</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50% Senior Notes due March 2025</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.45% Senior Notes due June 2026</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.20% Senior Notes due June 2029</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95% Senior Notes due June 2030</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80% Senior Notes due June 2031</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.95% Senior Notes due July 2037</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% Senior Notes due January 2040</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.70% Senior Notes due March 2045</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,980&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,012&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, net of current portion</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,978&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,010&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Finance Lease</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the year ended December 31, 2022, the Company amended a real estate lease and, based on the updated terms, the classification of the lease changed from a finance lease to an operating lease.  As of December 31, 2021, the $25&#160;million carrying value of the finance lease was included in "other" in the table above.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Secured Receivables Credit Facility </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During October 2022, the Company amended its secured receivables credit facility (the &#8220;Secured Receivables Credit Facility&#8221;), previously amended in October 2021, to extend the maturity dates for each underlying commitment by one year, while decreasing the aggregate borrowing capacity under the facility from $600&#160;million to $525&#160;million. Under the Secured Receivables Credit Facility, the Company can borrow against a $425&#160;million loan commitment, half of which matures in October 2023 and half of which matures in October 2024. Additionally, the Company can issue up to $100&#160;million of letters of credit (see Note 19) through October 2024.  Borrowings under the Secured Receivables Credit Facility are collateralized by certain domestic receivables.  Interest on borrowings under the facility is based on either commercial paper rates for highly-rated issuers or the Term Secured Overnight Financing Rate, plus a spread of 0.725% to 0.80%.  The Secured Receivables Credit Facility is subject to customary affirmative and negative covenants and certain financial covenants with respect to the receivables that comprise the borrowing base and secure the borrowings under the facility. As of both December&#160;31, 2022 and 2021, there were no outstanding borrowings under the Secured Receivables Credit Facility.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Unsecured Revolving Credit Facility</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company is party to a $750&#160;million senior unsecured revolving credit facility (the &#8220;Credit Facility&#8221; or "Senior Unsecured Revolving Credit Facility") which matures in November 2026.  Under the Credit Facility, the Company can issue letters of credit totaling $150&#160;million (see Note 19).  Issued letters of credit reduce the available borrowing capacity under the Credit Facility.  Interest on the Credit Facility is based on certain published rates plus an applicable margin based on changes in the Company's public debt ratings.  At the option of the Company, it may elect to lock into LIBOR-based interest rates for periods up to six months.  Interest on any outstanding amounts not covered under LIBOR-based interest rate contracts is based on an alternate base rate, which is calculated by reference to the prime rate, the federal funds rate or an adjusted LIBOR rate.  As of December&#160;31, 2022, the Company's borrowing rate for LIBOR-based loans under the Credit Facility was LIBOR plus 1.00%.  The Credit Facility contains various covenants, including the maintenance of a financial leverage ratio, which could impact the Company's ability to, among other things, incur additional indebtedness.  As of both December&#160;31, 2022 and 2021, there were no outstanding borrowings under the Senior Unsecured Revolving Credit Facility.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Notes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;All of the senior notes are unsecured obligations of the Company and rank equally with the Company's other senior unsecured obligations.  None of the Company's senior notes have a sinking fund requirement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company may redeem its outstanding senior notes prior to scheduled maturity, as a whole or in part, at a redemption price equal to the present value of the remaining scheduled payments of principal and interest, except for certain notes for which the Company also has an option to redeem such instruments at par value on or after dates specified in the indentures governing the notes ("the par value redemption option"). &#160;For notes with the par value redemption option, if such notes are redeemed prior to the specified dates, the redemption price calculations exclude any interest that would have been due after such dates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Maturities of Long-Term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of December&#160;31, 2022, long-term debt matures as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:297.00pt"><tr><td style="width:1.0pt"/><td style="width:235.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,576&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturities of long-term debt</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,985&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized discount</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value basis adjustments attributable to hedged debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,980&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, net of current portion</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,978&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596526132704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company determines if an arrangement is or contains a lease at contract inception. The Company leases office space, patient service centers, clinical laboratories, warehouses, logistic hubs and equipment primarily through operating leases, with a limited number of finance leases. A <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NDc_562c010d-bbaa-4f52-a8ac-de2660c01cb7"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NDc_da6e8994-01f0-4a9a-83e2-083574a1b91f">right-of-use asset</span></span>, representing the underlying asset during the lease term, and a lease <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTQ_323fe1c8-01d7-47a9-afae-473da3defda0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTQ_4bd99473-36cb-4abf-841b-9d98e467569f">liability</span></span>, representing the payment obligation arising from the lease, are recognized on the balance sheet at lease commencement based on the present value of the payment obligation. For operating leases, expense is recognized on a straight-line basis over the lease term. For finance leases, interest expense on the lease <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTU_6f606824-b677-4250-a7ed-24f9f3915ac5"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTU_8ee62599-1731-4db2-b098-6e0dac4293f9">liability</span></span> is recognized using the effective interest method and amortization of the right-of-use asset is recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term.  Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet; the Company recognizes lease expense for these leases on a straight-line basis over the lease term.  For the years ended December&#160;31, 2022, 2021, and 2020, lease expense associated with short-term leases was not material.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company primarily uses its collateralized incremental borrowing rate in determining the present value of lease payments as the Company's leases generally do not provide an implicit rate.  Such incremental borrowing rates, which take into account interest rates offered to companies that have similar credit ratings to the Company, are determined using a portfolio approach which groups the Company&#8217;s leases based on tenor.</span></div><div style="padding-left:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company has lease agreements with (i) right-of-use asset payments and (ii) non-lease components (i.e., payments related to maintenance fees, utilities, etc.) which have been combined and accounted for as a single lease component. </span></div><div style="padding-left:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company's leases have remaining terms of less than 1 year to 15 years, some of which include options to extend the leases for up to 15 years. The Company's lease terms may include renewal options that are reasonably certain to be exercised and termination options that are reasonably certain not to be exercised. Certain leases also include options to purchase the leased property.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Certain of the Company's lease agreements include rental payments adjusted periodically for inflation or a market rate which are included in the lease liabilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the year ended December 31, 2022, the Company amended a real estate lease and, based on the updated terms, the classification of the lease changed from a finance lease to an operating lease. As a result, the Company recorded a $31&#160;million operating lease right-of-use asset.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company's assets and liabilities for its lease agreements as of December&#160;31, 2022 and 2021 were as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:21.634%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.672%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.571%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.573%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net (a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">626&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzEyLTItMS0xLTc4MjE1_1c2a9643-64b7-48eb-992f-a3efa9e86f06"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzEyLTItMS0xLTc4MjE1_5bf1d7b4-f29c-4002-9627-e2075dfadeb9">Long-term debt</span></span></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679&#160;</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Finance lease assets as of December&#160;31, 2022 and 2021 were recorded net of accumulated amortization of $3&#160;million and $8&#160;million, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Components of lease cost for the years ended December&#160;31, 2022, 2021 and 2020 were as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:468.75pt"><tr><td style="width:1.0pt"/><td style="width:247.75pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td style="width:1.0pt"/><td style="width:70.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.00pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost (a)</span></td><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of leased assets</span></td><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net lease cost</span></td><td colspan="3" style="display:none"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Includes short-term leases and variable lease costs (primarily usage-based maintenance fees and utilities related to real estate leases and certain equipment-related and vehicle-related costs) of $160&#160;million, $140&#160;million and $120&#160;million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The maturity of the Company's lease liabilities as of December&#160;31, 2022 is as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:365.25pt"><tr><td style="width:1.0pt"/><td style="width:163.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:29pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Lease term and discount rate as of December&#160;31, 2022 and 2021 were as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:363.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.00pt"/><td style="width:1.0pt"/></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Lease term and discount rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years):</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company's discount rates for its operating leases were primarily determined using the Company's incremental borrowing rate.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;See Note 10 for cash flow information on cash paid for amounts included in the measurement of lease liabilities and leased assets obtained in exchange for new operating lease liabilities for the years ended December&#160;31, 2022, 2021 and 2020.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company determines if an arrangement is or contains a lease at contract inception. The Company leases office space, patient service centers, clinical laboratories, warehouses, logistic hubs and equipment primarily through operating leases, with a limited number of finance leases. A <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NDc_562c010d-bbaa-4f52-a8ac-de2660c01cb7"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NDc_da6e8994-01f0-4a9a-83e2-083574a1b91f">right-of-use asset</span></span>, representing the underlying asset during the lease term, and a lease <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTQ_323fe1c8-01d7-47a9-afae-473da3defda0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTQ_4bd99473-36cb-4abf-841b-9d98e467569f">liability</span></span>, representing the payment obligation arising from the lease, are recognized on the balance sheet at lease commencement based on the present value of the payment obligation. For operating leases, expense is recognized on a straight-line basis over the lease term. For finance leases, interest expense on the lease <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTU_6f606824-b677-4250-a7ed-24f9f3915ac5"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTU_8ee62599-1731-4db2-b098-6e0dac4293f9">liability</span></span> is recognized using the effective interest method and amortization of the right-of-use asset is recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term.  Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet; the Company recognizes lease expense for these leases on a straight-line basis over the lease term.  For the years ended December&#160;31, 2022, 2021, and 2020, lease expense associated with short-term leases was not material.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company primarily uses its collateralized incremental borrowing rate in determining the present value of lease payments as the Company's leases generally do not provide an implicit rate.  Such incremental borrowing rates, which take into account interest rates offered to companies that have similar credit ratings to the Company, are determined using a portfolio approach which groups the Company&#8217;s leases based on tenor.</span></div><div style="padding-left:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company has lease agreements with (i) right-of-use asset payments and (ii) non-lease components (i.e., payments related to maintenance fees, utilities, etc.) which have been combined and accounted for as a single lease component. </span></div><div style="padding-left:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company's leases have remaining terms of less than 1 year to 15 years, some of which include options to extend the leases for up to 15 years. The Company's lease terms may include renewal options that are reasonably certain to be exercised and termination options that are reasonably certain not to be exercised. Certain leases also include options to purchase the leased property.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Certain of the Company's lease agreements include rental payments adjusted periodically for inflation or a market rate which are included in the lease liabilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the year ended December 31, 2022, the Company amended a real estate lease and, based on the updated terms, the classification of the lease changed from a finance lease to an operating lease. As a result, the Company recorded a $31&#160;million operating lease right-of-use asset.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company's assets and liabilities for its lease agreements as of December&#160;31, 2022 and 2021 were as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:21.634%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.672%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.571%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.573%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net (a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">626&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzEyLTItMS0xLTc4MjE1_1c2a9643-64b7-48eb-992f-a3efa9e86f06"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzEyLTItMS0xLTc4MjE1_5bf1d7b4-f29c-4002-9627-e2075dfadeb9">Long-term debt</span></span></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679&#160;</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Finance lease assets as of December&#160;31, 2022 and 2021 were recorded net of accumulated amortization of $3&#160;million and $8&#160;million, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Components of lease cost for the years ended December&#160;31, 2022, 2021 and 2020 were as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:468.75pt"><tr><td style="width:1.0pt"/><td style="width:247.75pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td style="width:1.0pt"/><td style="width:70.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.00pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost (a)</span></td><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of leased assets</span></td><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net lease cost</span></td><td colspan="3" style="display:none"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Includes short-term leases and variable lease costs (primarily usage-based maintenance fees and utilities related to real estate leases and certain equipment-related and vehicle-related costs) of $160&#160;million, $140&#160;million and $120&#160;million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The maturity of the Company's lease liabilities as of December&#160;31, 2022 is as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:365.25pt"><tr><td style="width:1.0pt"/><td style="width:163.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:29pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Lease term and discount rate as of December&#160;31, 2022 and 2021 were as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:363.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.00pt"/><td style="width:1.0pt"/></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Lease term and discount rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years):</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company's discount rates for its operating leases were primarily determined using the Company's incremental borrowing rate.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;See Note 10 for cash flow information on cash paid for amounts included in the measurement of lease liabilities and leased assets obtained in exchange for new operating lease liabilities for the years ended December&#160;31, 2022, 2021 and 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596525046384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">FINANCIAL INSTRUMENTS</a></td>
<td class="text">FINANCIAL INSTRUMENTS <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Interest Rate Derivatives &#8211; Cash Flow Hedges</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;From time to time, the Company has entered into various interest rate lock agreements and forward-starting interest rate swap agreements to hedge part of the Company's interest rate exposure associated with the variability in future cash flows attributable to changes in interest rates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Derivatives &#8211; Fair Value Hedges </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Historically, the Company has entered into various fixed-to-variable interest rate swap agreements in order to convert a portion of the Company's long-term debt into variable interest rate debt. All such fixed-to-variable interest rate swap agreements have been terminated and proceeds from the terminations have been reflected as basis adjustments to the hedged debt instruments and are being amortized as a reduction of interest expense, net over the remaining terms of such debt instruments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of December&#160;31, 2022 and 2021, the following amounts were recorded on the consolidated balance sheets related to cumulative basis adjustments for fair value hedges included in the carrying amount of long-term debt:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hedge Accounting Basis Adjustment (a)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) As of both December&#160;31, 2022 and 2021, the entire balance is associated with remaining unamortized hedging adjustments on discontinued relationships. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following table presents the effect of fair value hedge accounting on the consolidated statements of operations for the years ended December&#160;31, 2022, 2021 and 2020, respectively:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:14.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.275%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.246%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other (expense) income, net</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total for line item in which the effects of fair value hedges are recorded</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gain (loss) on fair value hedging relationships:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items (Long-term debt)</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI https://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596526131248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY AND REDEEMABLE NONCONTROLLING INTEREST<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY AND REDEEMABLE NONCONTROLLING INTEREST</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY AND REDEEMABLE NONCONTROLLING INTEREST<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Stockholders' Equity</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Series Preferred Stock </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Quest Diagnostics is authorized to issue up to 10 million shares of Series Preferred Stock, par value $1.00 per share.  The Company's Board of Directors has the authority to issue such shares without stockholder approval and to determine the designations, preferences, rights and restrictions of such shares.  No shares are currently outstanding.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Common Stock</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Under the Company's Restated Certificate of Incorporation the number of authorized shares of common stock, par value $0.01 per share, is 600 million shares.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Changes in Accumulated Other Comprehensive Loss by Component</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Comprehensive income (loss) includes:</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Foreign currency translation adjustments; </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net deferred gains (losses) on cash flow hedges, which represent deferred gains (losses), net of tax, on interest rate-related derivative financial instruments designated as cash flow hedges, net of amounts reclassified to interest expense (see Note 16); and</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net changes in available-for-sale debt securities, which represent unrealized holding gains (losses), net of tax, on available-for-sale debt securities.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the years ended December&#160;31, 2022, 2021, and 2020, the tax effects related to the deferred gains (losses) on cash flow hedges and net changes in available-for-sale debt securities were not material.  Foreign currency translation adjustments related to indefinite investments in non-U.S. subsidiaries are not adjusted for income taxes. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The changes in accumulated other comprehensive loss by component for 2022, 2021 and 2020 were as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.379%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Changes in Available-for-Sale Debt Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Deferred Losses on Cash Flow Hedges, net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income before reclassifications</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss before reclassifications</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss before reclassifications</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive (loss) income</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On April 1, 2021, the Company sold its 40% ownership interest in Q</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Solutions, its clinical trials central laboratory services joint venture, to IQVIA, its joint venture partner.  As a result of the transaction, during the year ended December 31, 2021, $20&#160;million of cumulative translation losses were reclassified from accumulated other comprehensive loss to other (expense) income, net.  See Note 7 for further details. &#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Additionally, for the year ended December 31, 2020, $3&#160;million of cumulative translation losses were reclassified from accumulated other comprehensive loss to other operating expense (income), net as a result of the sale of foreign subsidiaries.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the years ended December&#160;31, 2022, 2021 and 2020, the gross deferred losses on cash flow hedges were reclassified from accumulated other comprehensive loss to interest expense, net.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividend Program</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During each of the four quarters of 2022, the Company's Board of Directors declared a quarterly cash dividend of $0.66 per common share.  During each of the four quarters of 2021, the Company's Board of Directors declared a quarterly cash dividend of $0.62 per common share.  During each of the four quarters of 2020, the Company's Board of Directors declared a quarterly cash dividend of $0.56 per common share.  In February 2023, the Company announced that its Board of Directors authorized a 7.6% increase in its quarterly cash dividend from $0.66 to $0.71 per share, or $2.84 per share annually, commencing with the dividend payable in April 2023.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Repurchase Program</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In February 2022, the Company's Board of Directors increased the size of its share repurchase program by $1&#160;billion.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of December&#160;31, 2022, $0.3 billion remained available under the Company's share repurchase authorization.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In February 2023, the Company announced that its Board of Directors authorized the Company to repurchase an additional $1&#160;billion of the Company's common stock.  The share repurchase authorization has no set expiration or termination date.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Repurchases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the year ended December&#160;31, 2022, the Company repurchased 10.1 million shares of its common stock for $1.4 billion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021, the Company repurchased 16.0 million shares of its common stock for $2.2 billion, including shares repurchased under ASRs. The repurchases during the year included an accrual of $23&#160;million recorded in accounts payable and accrued expenses in the consolidated balance sheet for share repurchases not settled until after December 31, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In April 2021, the Company entered into ASRs with several financial institutions to repurchase its common stock as part of a share repurchase program.  Each of the ASRs was structured to permit the Company to purchase shares immediately with the final purchase price of those shares determined by the volume-weighted average price of the Company's common stock during the repurchase period, less a fixed discount, and was accounted for as two transactions: (1) a treasury stock repurchase and (2) a forward contract.  During the year ended December&#160;31, 2021, the Company paid $1.5&#160;billion to the financial institutions and received 10.7&#160;million shares of its common stock under the ASRs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the year ended December&#160;31, 2020, the Company repurchased 2.7 million shares of its common stock for $325 million.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;  &#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Shares Reissued from Treasury Stock</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the years ended December&#160;31, 2022, 2021 and 2020, the Company reissued 2 million shares, 2 million shares and 3 million shares, respectively, from treasury stock for shares issued under the Employee Stock Purchase Plan ("ESPP") and stock-based compensation program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Treasury Stock Retirement &#160;&#160;&#160;&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the year ended December&#160;31, 2021, the Company retired 55&#160;million shares of treasury stock.  In accordance with the Company's policy, the amount paid to repurchase the shares in excess of par value was allocated between retained earnings and additional paid-in capital based on a pro-rata allocation of additional paid-in capital at the time of the share retirement.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redeemable Noncontrolling Interest</span></div>&#160;&#160;&#160;&#160;In connection with the sale of an 18.9% noncontrolling interest in a subsidiary to UMass on July 1, 2015, the Company granted UMass the right to require the Company to purchase all of its interest in the subsidiary at fair value commencing July 1, 2020.  The subsidiary performs diagnostic information services in a defined territory within the state of Massachusetts.  Since the redemption of the noncontrolling interest is outside of the Company's control, it has been presented outside of stockholders' equity at the greater of its carrying amount or its fair value.  The Company records changes in the fair value of the noncontrolling interest immediately as they occur.  As of December&#160;31, 2022 and 2021, the redeemable noncontrolling interest was $77 million and $79 million, respectively, and was presented at its fair value.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596526139424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OWNERSHIP AND COMPENSATION PLANS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK OWNERSHIP AND COMPENSATION PLANS</a></td>
<td class="text">STOCK OWNERSHIP AND COMPENSATION PLANS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee and Non-employee Directors Stock Ownership Programs</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The ELTIP provides for three types of awards: (a) stock options, (b) stock appreciation rights and (c) stock awards.  The ELTIP provides for the grant to eligible employees of either non-qualified or incentive stock options, or both, to purchase shares of Company common stock at an exercise price no less than the fair market value of the Company's common stock on the date of grant.  Grants of stock appreciation rights allow eligible employees to receive a payment based on the appreciation of Company common stock in cash, shares of Company common stock or a combination thereof.  The stock appreciation rights are granted at an exercise price no less than the fair market value of the Company's common stock on the date of grant.  Stock options and stock appreciation rights granted under the ELTIP expire on the date designated by the Board of Directors but in no event more than ten years from date of grant.  No stock appreciation rights have been granted under the ELTIP.  Under the ELTIP, awards are subject to forfeiture if employment terminates prior to the end of the vesting period prescribed by the Board of Directors.  For all award types, the vesting period is generally over three years from the date of grant.  For performance share units, the actual amount of shares earned is based on the achievement of the performance goals specified in the awards.  The performance goals for awards granted in 2020, 2021 and 2022 were based on the financial performance of the Company, as well as relative TSR.  The maximum number of shares of Company common stock in respect of which awards may be granted under the ELTIP is approximately 79 million shares.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The DLTIP provides for the grant to non-employee directors of non-qualified stock options to purchase shares of Company common stock at an exercise price no less than the fair market value of the Company's common stock on the date of grant.  The DLTIP also permits awards of restricted stock and restricted stock units to non-employee directors.  Stock options granted under the DLTIP expire on the date designated by the Board of Directors but in no event more than ten years from date of grant.  For all award types, the vesting period is generally over three years from the date of grant, regardless of whether the award recipient remains a director of the Company.  The maximum number of shares that may be issued under the DLTIP is 2.4 million shares.  For the years ended December&#160;31, 2022, 2021 and 2020, grants under the DLTIP totaled 10 thousand shares, 12 thousand shares and 14 thousand shares, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company's practice had been to issue shares related to its stock-based compensation program from shares of its common stock held in treasury or by issuing new shares of its common stock.  In January 2021, the Company began to issue shares related to its ESPP and stock-based compensation program solely from common stock held in treasury.  See Note 17 for further information regarding the Company's share repurchase program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The fair value of each stock option award granted was estimated on the date of grant using a Black-Scholes option-valuation model.  The expected volatility under the Black-Scholes option-valuation model was based on historical volatilities of the Company's common stock.  The dividend yield was based on the approved annual dividend rate in effect and current market price of the underlying common stock at the time of grant.  The risk-free interest rate was based on the U.S. Treasury yield curve in effect at the time of grant for bonds with maturities consistent with the expected holding period of the related award.  The expected holding period was estimated using the historical stock option exercise behavior of employees. The Black-Scholes option-valuation model also incorporates the average market price of the Company's common stock at the date of grant.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The weighted average assumptions used in valuing stock options granted in the periods presented were:  </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:61.216%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.219%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at grant date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$26.80</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$21.82</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$17.25</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.4%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.6%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.3%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected holding period, in years</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following summarizes the activity relative to stock option awards for 2022: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:54.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.457%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.457%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.457%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.459%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, beginning of year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.44&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.51&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited and canceled</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, end of year</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.78&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable, end of year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.36&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, end of year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.61&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value (the difference between the Company's closing common stock price on the last trading day of 2022 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on December&#160;31, 2022.  This amount changes based on the fair market value of the Company's common stock.  Total intrinsic value of options exercised in 2022, 2021 and 2020 was $70 million, $83 million and $113 million, respectively. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of December&#160;31, 2022, there was $5 million of unrecognized stock-based compensation cost related to nonvested stock options which is expected to be recognized over a weighted average period of 1.5 years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The fair value of restricted stock awards and restricted stock units is the average market price of the Company's common stock at the date of grant.  For performance share units with a goal based on the financial performance of the Company, the fair value is based on the average market price of the Company's common stock at the date of grant, adjusted for the present value of dividends expected to be paid on the Company's common stock during the vesting period.  For performance share units with a market-based relative TSR goal, the fair value is estimated on the date of grant using a Monte Carlo valuation model.  The expected volatility under the Monte Carlo valuation model is based on the historical volatility of the common stock of the Company and the common stock of the companies in the peer index.  The dividend yield is based on the approved annual dividend rate in effect and current market price of the underlying common stock at the time of grant.  The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for bonds with maturities consistent with the performance period of the related award. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The weighted average assumptions used in valuing performance share units with a market-based relative TSR goal in the periods presented were:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.289%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.385%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at grant date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$130.00</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$150.15</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$144.03</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.9%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.2%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following summarizes the activity relative to stock awards, including restricted stock units and performance share units, for 2022, 2021 and 2020: </span></div><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:31.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.478%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares outstanding, beginning of year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.46&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.36&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares forfeited and canceled</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares outstanding, end of year</span></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.45&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.46&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.12&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of December&#160;31, 2022, there was $40 million of unrecognized stock-based compensation cost related to nonvested stock awards, which is expected to be recognized over a weighted average period of 1.8 years.  Total fair value of shares vested was $72 million, $59 million and $37 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.  For performance share units with a goal based on financial performance of the Company, the amount of unrecognized stock-based compensation cost is subject to change based on changes, if any, to management's best estimates of the achievement of the performance goals specified in such awards and the resulting number of shares that will be earned at the end of the performance periods.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the years ended December&#160;31, 2022, 2021 and 2020, stock-based compensation expense totaled $77 million, $79 million and $97 million, respectively.  Income tax benefits recognized in the consolidated statements of operations related to stock-based compensation expense totaled $27 million, $32 million and $39 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively, which includes excess tax benefits associated with stock-based compensation arrangements of $14 million, $19 million and $23 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Under the Company's ESPP, substantially all employees can elect to have up to 10% of their annual wages withheld to purchase Quest Diagnostics common stock.  The purchase price of the stock is 95% of the market price of the Company's common stock on the last business day of each calendar month.  Under the ESPP, the maximum number of shares of Quest Diagnostics common stock which may be purchased by eligible employees is 9 million.  Approximately 216 thousand shares, 200 thousand shares and 225 thousand shares of common stock were purchased by eligible employees in 2022, 2021 and 2020, respectively.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defined Contribution Plans </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company maintains qualified defined contribution plans covering substantially all of its employees.  The maximum Company matching contribution is 5% of eligible employee compensation.  During 2020, the Company temporarily suspended matching contributions for certain qualified defined contribution plans; matching contributions were reinstated in the third quarter of 2020.  The Company's expense for contributions to its defined contribution plans aggregated $95 million, $93 million and $64 million for 2022, 2021 and 2020, respectively. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Supplemental Deferred Compensation Plans</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company has a supplemental deferred compensation plan that is an unfunded, non-qualified plan that provides for certain management and highly compensated employees to defer up to 50% of their salary in excess of their defined contribution plan limits and for certain eligible employees, up to 95% of their variable incentive compensation.  The maximum Company matching contribution is 5% of eligible employee compensation.  The compensation deferred under this plan, together with Company matching amounts, are credited with earnings or losses measured by the mirrored rate of return on investments elected by plan participants.  Each plan participant is fully vested in all deferred compensation, Company match and earnings credited to their account.  The amounts accrued under the Company's deferred compensation plans were $68 million and $77 million as of December&#160;31, 2022 and 2021, respectively.  Although the Company is currently contributing all participant deferrals and matching amounts to a trust, the funds in this trust, totaling $68 million and $77 million as of December&#160;31, 2022 and 2021, respectively, are general assets of the Company and are subject to any claims of the Company's creditors. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company also offers certain employees the opportunity to participate in a non-qualified deferred compensation program.  The Company matches employee contributions equal to 25%, up to a maximum of $5 thousand per plan year.  A participant's deferrals, together with Company matching credits, are &#8220;invested&#8221; at the direction of the employee in a hypothetical portfolio of investments which are tracked by an administrator.  Each participant is fully vested in their deferred compensation and vests in Company matching contributions over a period of four years at 25% per year.  This plan was amended effective January 1, 2018 so that future deferrals under the plan may only be made by participants who made deferrals under the plan in 2017.  The amounts accrued under this plan were $52 million and $66 million as of December&#160;31, 2022 and 2021, respectively.  The Company purchases life insurance policies, with the Company named as beneficiary of the policies, for the purpose of funding the program's liability.  The cash surrender value of such life insurance policies was $46 million and $57 million as of December&#160;31, 2022 and 2021, respectively.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;  For each of the years ended December&#160;31, 2022, 2021 and 2020, the Company's expense for matching contributions to these plans was not material.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596526305072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Letters of Credit and Contractual Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company can issue letters of credit under its Secured Receivables Credit Facility and Senior Unsecured Revolving Credit Facility (see Note 14).  In support of its risk management program, to ensure the Company&#8217;s performance or payment to third parties, $70 million in letters of credit under the Secured Receivables Credit Facility were outstanding as of December&#160;31, 2022.  The letters of credit primarily represent collateral for current and future automobile liability and workers&#8217; compensation loss payments.</span></div><div style="padding-right:13.5pt"><span><br/></span></div><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company has certain noncancelable commitments, primarily under take-or-pay arrangements, to purchase products or services from various suppliers, mainly for consulting and other service agreements, and standing orders to purchase reagents and other laboratory supplies.  As of December&#160;31, 2022, the approximate total future purchase commitments are $384 million, of which $125 million are expected to be incurred in 2023, $166 million are expected to be incurred in 2024 through 2025 and the balance thereafter. </span></div><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Billing and Collection Agreement</span></div><div style="padding-right:13.5pt"><span><br/></span></div><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In September 2016, the Company entered into a ten-year agreement with a third party to outsource its billing and  related operations for the majority of the Company&#8217;s revenues.  Services under the agreement commenced during the fourth quarter of 2016.  The agreement includes an annual fee, which is subject to adjustment based on certain changes in the Company's requisition volume and the achievement of various performance metrics.</span></div><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Lease Obligations</span></div><div style="padding-right:13.5pt"><span><br/></span></div><div style="padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company remains subject to contingent obligations under certain real estate leases, including real estate leases that were entered into by certain predecessor companies of a subsidiary prior to the Company's acquisition of the subsidiary.  While over the course of many years, the title to certain properties and interest in the subject leases have been transferred to third parties and the subject leases have been amended several times by such third parties, the lessors have not formally released the subsidiary predecessor companies from their original obligations under the leases and therefore remain contingently liable in the event of default.  The remaining terms of the lease obligations and the Company's corresponding indemnifications range up to 25 years.  The lease payments under certain leases are subject to market value adjustments and contingent rental payments and therefore, the total contingent obligations under the leases cannot be precisely determined but are likely to total several hundred million dollars.  A claim against the Company would be made only upon the current lessee's default and, in certain cases, after a series of claims and corresponding defaults by third parties that precede the Company in the order of liability.  The Company also has certain indemnification rights from other parties to recover losses in the event of default on the lease obligations.  The Company believes that the likelihood of its performance under these contingent obligations is remote and no liability has been recorded for any potential payments under the contingent lease obligations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain Legal Matters</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;The Company may incur losses associated with these proceedings and investigations, but it is not possible to estimate the amount of loss or range of loss, if any, that might result from adverse judgments, settlements, fines, penalties, or other resolution of these proceedings and investigations based on the stage of these proceedings and investigations, the absence of specific allegations as to alleged damages, the uncertainty as to the certification of a class or classes and the size of any certified class, if applicable, and/or the lack of resolution of significant factual and legal issues.  The Company has insurance coverage rights in place (limited in amount; subject to deductible) for certain potential costs and liabilities related to these proceedings and investigations.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">401(k) Plan Lawsuit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;In 2020, two putative class action lawsuits were filed in the U.S. District Court for New Jersey against the Company and other defendants with respect to the Company&#8217;s 401(k) plan. The complaint alleges, among other things, that the fiduciaries of the 401(k) plan breached their duties by failing to disclose the expenses and risks of plan investment options, allowing unreasonable administration expenses to be charged to plan participants, and selecting and retaining high cost and poor performing investments.  In October 2020, the court consolidated the two lawsuits under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">In re: Quest Diagnostics ERISA Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and plaintiffs filed a consolidated amended complaint.  In May 2021, the court denied the Company's motion to dismiss the complaint.  Discovery is proceeding.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">AMCA Data Security Incident</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  </span></div><div style="padding-left:36pt;text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;On June 3, 2019, the Company reported that Retrieval-Masters Creditors Bureau, Inc./American Medical Collection Agency (&#8220;AMCA&#8221;) had informed the Company and Optum360 LLC that an unauthorized user had access to AMCA&#8217;s system between August 1, 2018 and March 30, 2019 (the &#8220;AMCA Data Security Incident&#8221;).  Optum360 provides revenue management services to the Company, and AMCA provided debt collection services to Optum360.  AMCA first informed the Company of the AMCA Data Security Incident on May 14, 2019.  AMCA&#8217;s affected system included financial information (e.g., credit card numbers and bank account information), medical information and other personal information (e.g., social security numbers). Test results were not included.  Neither Optum360&#8217;s nor the Company&#8217;s systems or databases were involved in the incident. AMCA also informed the Company that information pertaining to other laboratories&#8217; customers was also affected.  Following announcement of the AMCA Data Security Incident, AMCA sought protection under the U.S. bankruptcy laws.  The bankruptcy proceeding has been dismissed.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Numerous putative class action lawsuits were filed against the Company related to the AMCA Data Security Incident.  The U.S. Judicial Panel on Multidistrict Litigation transferred the cases that were then still pending to, and consolidated them for pre-trial proceedings in, the U.S. District Court for New Jersey.  In November 2019, the plaintiffs in the multidistrict proceeding filed a consolidated putative class action complaint against the Company and Optum360 that named additional individuals as plaintiffs and that asserted a variety of common law and statutory claims in connection with the AMCA Data Security Incident.  In January 2020, the Company moved to dismiss the consolidated complaint; the motion to dismiss was granted in part and denied in part.  Discovery is proceeding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In addition, the Company has been notified that numerous state attorney general offices were investigating or otherwise seeking information and/or documents, and that certain U.S. senators were seeking information, from the Company related to the AMCA Data Security Incident.  </span></div><div><span><br/></span></div><div style="text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ReproSource Fertility Diagnostics, Inc.</span></div><div style="text-indent:72pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;ReproSource Fertility Diagnostics, Inc. (&#8220;ReproSource&#8221;), a subsidiary of the Company, is subject to two putative class action lawsuits in the U.S. District Court for Massachusetts: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Bickham v. ReproSource Fertility Diagnostics, Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Gordon v. ReproSource Fertility Diagnostics, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> The class actions are related to a data security incident that occurred in August 2021 in which an unauthorized party may have accessed or acquired protected health information and personally identifiable information of ReproSource patients. The complaints generally allege that ReproSource, among other claims, failed to adequately safeguard customers&#8217; private information. ReproSource has moved to dismiss both complaints.  A third putative class action pertaining to the same data security incident, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Trouville v. ReproSource Fertility Diagnostics, Inc.,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> was filed in California state court.  The Company removed the case to federal court and moved to dismiss and/or transfer it to U.S. District Court for Massachusetts.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                       </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cole, et. al v. Quest Diagnostics Incorporated</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;The Company is</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">subject to a putative class action entitled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Cole, et al. v Quest Diagnostics Incorporated</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, which was filed in the U. S. District Court for the Eastern District of California, for allegedly conspiring with Facebook to track customers&#8217; internet communications on Company web platforms without authorization, in violation of the California Invasion of Privacy Act and the California Confidentiality of Medical Information Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  The complaint alleged that the Company&#8217;s actions were an invasion of privacy and contributed to a loss of value in plaintiffs&#8217; personally identifiable information.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company moved to dismiss the case or, in the alternative, transfer venue to the U.S. District Court for New Jersey.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Subsequently, plaintiffs filed an amended complaint.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Other Legal Matters</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In the normal course of business, the Company has been named, from time to time, as a defendant in various legal actions, including arbitrations, class actions and other litigation, arising in connection with the Company's activities as a provider of diagnostic testing, information and services.  These actions could involve claims for substantial compensatory and/or punitive damages or claims for indeterminate amounts of damages, and could have an adverse impact on the Company's client base and reputation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company is also involved, from time to time, in other reviews, investigations and proceedings by governmental agencies regarding the Company's business which may result in adverse judgments, settlements, fines, penalties, injunctions or other relief. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In addition, certain federal and state statutes, including the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> provisions of the federal False Claims Act, allow private individuals to bring lawsuits against healthcare companies on behalf of the government or private payers.  The Company is aware of lawsuits, and from time to time has received subpoenas, related to billing or other practices based on the False Claims Act or other federal and state statutes, regulations or other laws.  The Company understands that there may be other pending qui tam claims brought by former employees or other "whistle blowers" as to which the Company cannot determine the extent of any potential liability.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Management cannot predict the outcome of such matters.  Although management does not anticipate that the ultimate outcome of such matters will have a material adverse effect on the Company's financial condition, given the high degree of judgment involved in establishing loss estimates related to these types of matters, the outcome of such matters may be material to the Company's consolidated results of operations or cash flows in the period in which the impact of such matters is determined or paid.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;These matters are in different stages.  Some of these matters are in their early stages.  Matters may involve responding to and cooperating with various government investigations and related subpoenas.  As of December&#160;31, 2022, the Company does not believe that material losses related to legal matters are probable.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Reserves for legal matters totaled $2 million and $4&#160;million as of December&#160;31, 2022 and December&#160;31, 2021, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reserves for General and Professional Liability Claims</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div>&#160;&#160;&#160;&#160;As a general matter, providers of clinical testing services may be subject to lawsuits alleging negligence or other similar legal claims.  These suits could involve claims for substantial damages.  Any professional liability litigation could also have an adverse impact on the Company's client base and reputation.  The Company maintains various liability insurance coverages for, among other things, claims that could result from providing, or failing to provide, clinical testing services, including inaccurate testing results, and other exposures.  The Company's insurance coverage limits its maximum exposure on individual claims; however, the Company is essentially self-insured for a significant portion of these claims.  Reserves for such matters, including those associated with both asserted and incurred but not reported claims, are established on an undiscounted basis by considering actuarially determined losses based upon the Company's historical and projected loss experience.  Such reserves totaled $169 million and $159 million as of December&#160;31, 2022 and December&#160;31, 2021, respectively.  Management believes that established reserves and present insurance coverage are sufficient to cover currently estimated exposures.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596526503280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS SEGMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">BUSINESS SEGMENT INFORMATION</a></td>
<td class="text">BUSINESS SEGMENT INFORMATION<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company's DIS business is the only reportable segment based on the manner in which the Chief Executive Officer, who is the Company's chief operating decision maker ("CODM"), assesses performance and allocates resources across the organization.  The DIS business provides diagnostic information services to a broad range of customers, including patients, clinicians, hospitals, IDNs, health plans, employers, consumers, and ACOs.  The Company is the world's leading provider of diagnostic information services, which includes providing information and insights based on an industry-leading menu of routine, non-routine and advanced clinical testing and anatomic pathology testing, and other diagnostic information services.  The DIS business accounted for greater than 95% of net revenues in 2022, 2021 and 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other operating segments include the Company's DS businesses, which consist of its risk assessment services and healthcare information technology businesses.  The Company's DS businesses are the leading provider of risk assessment services for the life insurance industry and offer healthcare organizations and clinicians robust information technology solutions.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of December&#160;31, 2022, substantially all of the Company&#8217;s services were provided within the United States, and substantially all of the Company&#8217;s assets were located within the United States.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following table is a summary of segment information for the years ended December&#160;31, 2022, 2021 and 2020. Segment asset information is not presented since it is not used by the CODM at the operating segment level.  Operating earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income (loss) for the segment.  General corporate activities included in the table below are comprised of general management and administrative corporate expenses, amortization and impairment of intangibles assets and other operating income and expenses, net of certain general corporate activity costs that are allocated to the DIS and DS businesses.  The accounting policies of the segments are the same as those of the Company as set forth in Note 2.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net revenues:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DIS business</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,609&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,494&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,139&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other operating segments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,883&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,788&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,437&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating earnings (loss):</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DIS business</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,704&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,646&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,201&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other operating segments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(296)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(294)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(269)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating income</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,428&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,381&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,971&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-operating (expense) income, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(193)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before income taxes and equity in earnings of equity method investees</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,235&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,599&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income tax expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(264)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(597)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(460)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity in earnings of equity method investees, net of taxes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,015&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,080&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less: Net income attributable to noncontrolling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to Quest Diagnostics</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,995&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,431&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Depreciation and amortization expense for the years ended December&#160;31, 2022, 2021 and 2020 were as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DIS business</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other operating segments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total depreciation and amortization</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Capital expenditures for the years ended December&#160;31, 2022, 2021 and 2020 were as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DIS business</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other operating segments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total capital expenditures</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The approximate percentage of net revenues by major service for the years ended December&#160;31, 2022, 2021 and 2020 was as follows: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Routine clinical testing and other services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19 testing services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gene-based and esoteric (including advanced diagnostics) testing services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anatomic pathology testing services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596530706016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">SUBSEQUENT EVENTS&#160;&#160;&#160;&#160; During February 2023, the Company announced that it had entered into a definitive agreement to acquire select assets of the laboratory services business of New York-Presbyterian, which serves providers and patients in New York, as well as the Tri-State Area and beyond. The transaction, which is expected to close during the three months ended June 30, 2023, remains subject to customary closing conditions.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596525350432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Principles of Consolidation and Basis of Presentation</a></td>
<td class="text">The consolidated financial statements include the accounts of all entities controlled by the Company through its direct or indirect ownership of a majority voting interest.  Additionally, the consolidated financial statements include the accounts of variable interest entities (&#8220;VIEs&#8221;) in which the Company has a variable interest and for which the Company is the &#8220;primary beneficiary&#8221; as it has both: (1) the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and (2) the obligation to absorb losses of the VIE that potentially could be significant to the VIE or the right to receive benefits from the VIE that potentially could be significant to the VIE.  All significant intercompany accounts and transactions are eliminated in consolidation.&#160;&#160;&#160;&#160;Income attributable to the minority interest in the Company's majority owned and controlled consolidated subsidiaries is recorded as net income attributable to noncontrolling interests in the consolidated statements of operations and the noncontrolling interest is reflected as a separate component of consolidated stockholders' equity in the consolidated balance sheet.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text">Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Method Investments</a></td>
<td class="text">Investments in entities which the Company does not control, but in which it has a substantial ownership interest (generally between 20% and 49%) and can exercise significant influence, are accounted for using the equity method of accounting.  These investments are classified as investments in equity method investees in the consolidated balance sheet.  The Company records its pro rata share of the earnings, adjusted for accretion of basis difference, of these investments in equity in earnings of equity method investees, net of taxes in the consolidated statements of operations.  The Company reviews its investments in equity method investees for impairment whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">The preparation of financial statements in conformity with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">The Company recognizes as revenue the amount that reflects the consideration to which it expects to be entitled in exchange for goods sold or services rendered primarily upon completion of the testing process (when results are reported) or when services have been rendered (see Note 3).  Net revenues from Medicare and Medicaid programs were approximately 11%, 10% and 11% of the Company's consolidated net revenues for the years ended December&#160;31, 2022, 2021 and 2020, respectively.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Taxes on Income</a></td>
<td class="text">The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the year.  Current and deferred income taxes are measured based on the tax laws that are enacted as of the balance sheet date of the relevant reporting period.  Deferred tax assets and liabilities are recognized for the expected future tax consequences of differences between the carrying amounts of assets and liabilities and their respective tax bases using tax rates in effect for the year in which the differences are expected to reverse.  A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period when the change is enacted.  Tax benefits from uncertain tax positions are recognized only if the tax position is more likely than not to be sustained upon examination by taxing authorities based on the technical merits of the position.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share</a></td>
<td class="text">The Company's unvested restricted stock units that contain non-forfeitable rights to dividends are participating securities and, therefore, are included in the earnings allocation in computing earnings per share using the two-class method.  Basic earnings per common share is calculated by dividing net income attributable to Quest Diagnostics, adjusted for earnings allocated to participating securities, by the weighted average number of common shares outstanding.  Diluted earnings per common share is calculated by dividing net income attributable to Quest Diagnostics, adjusted for earnings allocated to participating securities, by the weighted average number of common shares outstanding after giving effect to all potentially dilutive common shares outstanding during the period.  Potentially dilutive common shares include the dilutive effect of outstanding stock options and performance share units granted under the Company's Amended and Restated Employee Long-Term Incentive Plan (&#8220;ELTIP&#8221;) and its Amended and Restated Non-Employee Director Long-Term Incentive Plan (&#8220;DLTIP&#8221;), as well as the dilutive effect of accelerated share repurchase agreements ("ASRs"), if applicable.  Earnings allocable to participating securities include the portion of dividends declared as well as the portion of undistributed earnings during the period allocable to participating securities.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">The Company measures stock-based compensation for equity awards at fair value on the date of grant and records stock-based compensation as a charge to earnings net of the estimated impact of forfeited awards.  As such, the Company recognizes stock-based compensation cost only for those stock-based awards that are estimated to ultimately vest over their requisite service period, based on the vesting provisions of the individual grants.  The cumulative effect on current and prior periods of a change in the estimated forfeiture rate is recognized as compensation cost in earnings in the period of the change.  The terms of the Company's performance share units allow the recipients of such awards to earn a variable number of shares based on the achievement of the performance goals, which are based on the financial performance of the Company and the total shareholder return of the Company relative to an index of peer companies ("relative TSR"), specified in the awards.  For performance share units with a goal based on the financial performance of the Company, stock-based compensation expense is recognized based on management's best estimates of the achievement of the performance goals specified in such awards and the resulting number of shares that will be earned.  The cumulative effect on current and prior periods of a change in the estimated number of performance share units expected to be earned for these awards is recognized as compensation cost in earnings in the period of the change.  For performance share units with a market-based relative TSR goal, stock-based compensation expense is recognized based on the estimated fair value of the award regardless of the actual number of shares earned.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">The Company determines fair value measurements used in its consolidated financial statements based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants exclusive of any transaction costs, as determined by either the principal market or the most advantageous market.<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Inputs used in the valuation techniques to derive fair values are classified based on a three-level hierarchy.  The basis for fair value measurements for each level within the hierarchy is described below with Level 1 having the highest priority and Level 3 having the lowest.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1: Quoted prices in active markets for identical assets or liabilities.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3: Valuations derived from valuation techniques in which one or more significant inputs are unobservable.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text">The Company predominately uses the U.S. dollar as its functional currency.  The functional currency of the Company's foreign operating subsidiaries generally is the applicable local currency.  Assets and liabilities denominated in non-U.S. dollars are translated into U.S. dollars at exchange rates as of the end of the reporting period.  Income and expense items are translated at the average monthly exchange rates during the year.  Resulting translation adjustments are recorded as a component of accumulated other comprehensive loss within stockholders' equity.  Gains and losses from foreign currency transactions, which are denominated in a currency other than the functional currency, are included within other operating expense (income), net in the consolidated statements of operations.  Foreign currency transaction gains and losses have historically not been material.  The Company may be exposed to market risk for changes in foreign exchange rates primarily under certain intercompany receivables and payables.  From time to time, the Company uses foreign exchange forward contracts to mitigate the exposure of the eventual net cash inflows or outflows resulting from these intercompany transactions.  The Company's foreign exchange exposure is not material to the Company's consolidated financial condition.  The Company does not hedge its net investment in non-U.S. subsidiaries because it views those investments as long-term in nature.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">Cash and cash equivalents include all highly-liquid investments with original maturities, at the time acquired by the Company, of three months or less.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">Concentration of Credit Risk</a></td>
<td class="text">Financial instruments that potentially subject the Company to concentrations of credit risk are principally cash, cash equivalents, short-term investments, accounts receivable and derivative financial instruments.  The Company's policy is to place its cash, cash equivalents and short-term investments in highly-rated financial instruments and institutions.  Concentration of credit risk with respect to accounts receivable is mitigated by the diversity of the Company's payers and their dispersion across many different geographic regions, and credit risk is concentrated among certain payers who are large buyers of the Company's services.  To reduce risk, the Company routinely assesses the financial strength of these payers and, consequently, believes that its accounts receivable credit risk exposure, with respect to these payers, is limited.  While the Company has receivables due from federal and state governmental agencies, the Company does not believe that such receivables represent a credit risk since the related healthcare programs are funded by federal and state governments, and payment is primarily dependent on submitting appropriate documentation timely.  As of both December&#160;31, 2022 and 2021, receivables due from government payers under the Medicare and Medicaid programs represented approximately 6% of the Company's consolidated net accounts receivable.  The portion of the Company's accounts receivable due from patients comprises the largest portion of credit risk.  As of December&#160;31, 2022 and 2021, receivables due from patients represented approximately 18% and 21%, respectively, of the Company's consolidated net accounts receivable.  The Company applies assumptions and judgments including historical collection experience (including the period of time that the receivables have been outstanding) for assessing collectability and determining net revenues and accounts receivable from patients.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_AccountsReceivableAndAllowanceForCreditLossesPolicyPolicyTextBlock', window );">Accounts Receivable and Allowance for Credit Losses</a></td>
<td class="text">Accounts receivable are reported net of allowances for credit losses.  <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;When estimating its allowance for credit losses, the Company pools its trade receivables based on the following customer types: healthcare insurers, government payers, client payers and patients, which are described in Note 3.&#160; The Company principally estimates the allowance for credit losses by pool based on historical collection experience, the current credit worthiness of the customers, current economic conditions, expectations of future economic conditions and the period of time that the receivables have been outstanding.&#160; To the extent that any individual payers are identified that have deteriorated in credit quality, the Company removes the customers from their respective pools and establishes allowances based on the individual risk characteristics of such customers.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text">Inventories, which consist principally of finished goods testing supplies and reagents, are valued at the lower of cost (first in, first out method) or net realizable value.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text">Property, plant and equipment is recorded at cost.  Major renewals and improvements are capitalized, while maintenance and repairs are expensed as incurred.  Costs incurred for computer software developed or obtained for internal use are capitalized for application development activities and expensed as incurred for preliminary project activities and post-implementation activities.  Capitalized costs include external direct costs of materials and services consumed in developing or obtaining internal-use software, payroll and payroll-related costs for employees who are directly associated with the internal-use software project, and interest costs incurred, when material, while developing internal-use software.  Capitalization of such costs ceases when the project is substantially complete and ready for its intended purpose.  Costs for maintenance and training are expensed as incurred.  The Company capitalizes interest on borrowings during the active construction period of major capital projects.  Capitalized interest is added to the cost of the underlying assets and is amortized over the expected useful lives of the assets.  Depreciation and amortization are provided on the straight-line method over expected useful asset lives as of December&#160;31, 2022 as follows: <div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">buildings and improvements, ranging up to thirty-one and a half years; </span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">laboratory equipment and furniture and fixtures, ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzE1MDA1_cf798870-e9ec-4915-8333-6fffdab241e2">five</span> to twelve years; </span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">leasehold improvements, the lesser of the useful life of the improvement or the remaining life of the building or lease, as applicable; and </span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">computer software developed or obtained for internal use, principally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzE1MjE1_15232aa9-a205-41d3-834e-46d37c844c97">five</span> to ten years.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text">Goodwill represents the excess of the fair value of the acquiree (including the fair value of non-controlling interests) over the recognized bases of the net identifiable assets acquired and includes the future economic benefits from other assets that could not be individually identified and separately recognized.  Goodwill is not amortized, but instead is periodically reviewed for impairment and an impairment charge is recorded in the periods in which the recorded carrying value of goodwill exceeds its fair value.  <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On a quarterly basis, the Company performs a review of its business to determine if events or changes in circumstances have occurred which could have a material adverse effect on the fair value of the Company and its goodwill.  If such events or changes in circumstances were deemed to have occurred, the Company would perform an impairment test of goodwill as of the end of the quarter and record any noted impairment loss.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The goodwill test is performed at least annually, or more frequently if events or changes in circumstances indicate that the asset might be impaired.  The annual impairment test includes an option to perform a qualitative assessment of whether it is more likely than not that a reporting unit's fair value is less than its carrying value; the qualitative test may be performed prior to, or as an alternative to, performing a quantitative goodwill impairment test.  If, after assessing the totality of events or circumstances, the Company determines that it is more likely than not that the fair value of a reporting unit is less than its carrying value, then the Company is required to perform the quantitative goodwill impairment test.  Otherwise, no further analysis is required.  Additionally, the Company's policy is to update the fair value calculation of its reporting units and perform the quantitative goodwill impairment test on a periodic basis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The quantitative impairment test involves the comparison of the fair value of the reporting unit to its carrying value.  The Company calculates the fair value of each reporting unit using either (i) a discounted cash flows analysis that converts future cash flow amounts into a single discounted present value amount or (ii) a market approach.  The Company assesses the valuation methodology based upon the relevance and availability of the data at the time that the valuation is performed.  The Company compares the estimate of fair value for the reporting unit to the carrying value of the reporting unit.  If the carrying value is greater than the estimate of fair value, an impairment loss will be recognized in the amount of the excess. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company performs its annual impairment test during the fourth quarter of the fiscal year.  For the years ended December&#160;31, 2022 and 2021, the Company performed a qualitative impairment test for its DIS reporting unit and, based on the totality of information available, the Company concluded that it was more-likely-than-not that the estimated fair value of its DIS reporting unit was greater than the carrying value of the reporting unit and, as such, no further analysis was required.  For the year ended December&#160;31, 2022, the Company updated the fair value calculation of its risk assessment services reporting unit, performed the quantitative impairment test and concluded that goodwill for the reporting unit was not impaired.  For the year ended December 31, 2021, the Company performed a qualitative impairment test for its risk assessment reporting unit and, based on the totality of information available, the Company concluded that it was more-likely-than-not that the estimated fair value of the reporting unit was greater than the carrying value of the reporting unit and, as such, no further analysis was required.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets</a></td>
<td class="text">Intangible assets are recognized at fair value, as an asset apart from goodwill if the asset (i) arises from contractual or other legal rights, or (ii) is separable.  Intangible assets, principally representing the cost of customer-related intangibles, non-competition agreements and technology acquired, are capitalized and amortized on the straight-line method over their expected useful lives, which generally range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzE5MDc3_e109cd52-340f-452f-8421-53cd708ea892">five</span> to twenty years.  Intangible assets with indefinite useful lives, consisting principally of acquired tradenames, are not amortized, but instead are periodically reviewed for impairment.  <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company reviews indefinite-lived intangible assets periodically for impairment and an impairment charge is recorded in the periods in which the recorded carrying value of an indefinite-lived intangible asset is more than its estimated fair value.  The indefinite-lived intangible asset impairment test is performed at least annually, or more frequently in the case of other events that indicate a potential impairment.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Based upon the Company&#8217;s most recent annual impairment tests completed during the fourth quarters of the years ended December&#160;31, 2022 and 2021, the Company concluded that indefinite-lived intangible assets were not impaired.</span></div>&#160;&#160;&#160;&#160;The Company reviews the recoverability of its long-lived assets (including amortizable intangible assets), other than goodwill and indefinite-lived intangible assets, when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable.  Evaluation of possible impairment is based on the Company's ability to recover the asset from the expected future pre-tax cash flows (undiscounted and without interest charges) of the related operations.  If these cash flows are less than the carrying amount of such asset, an impairment loss is recognized for the difference between the estimated fair value and carrying amount of the asset.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text">The Company's investments (except for those accounted for under the equity method of accounting) include:<div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Equity investments with readily determinable fair values, including investments comprised mostly of strategic holdings in companies concentrated in the life sciences and healthcare industries (such investments, which previously did not have readily determinable fair values, became publicly-traded during the year ended December 31, 2021); as well as participant-directed investments of deferred employee compensation and related Company matching contributions held in trusts pursuant to the Company's supplemental deferred compensation plans (see Note 18).  These investments are measured at fair value with both realized and unrealized gains and losses recorded in current earnings within other (expense) income, net in the consolidated statements of operations.  For the years ended December&#160;31, 2022, 2021 and 2020, (losses)/gains from all equity investments with readily determinable fair values totaled $(55) million, $56 million, and $8 million, respectively.  See Note 8 for a discussion of the fair value of such investments. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Equity investments that do not have readily determinable fair values, which consist of investments in preferred and common shares of privately held companies.  These investments are measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes.  The Company regularly evaluates these equity investments to determine if there are any indicators that the investment is impaired; no impairment charges were recognized related to these investments for the years ended December&#160;31, 2022, 2021 and 2020.  The carrying value of these investments was $4&#160;million at both December&#160;31, 2022 and 2021.  Such amounts were included in other assets in the consolidated balance sheet.</span></div>&#8226;Available-for-sale debt securities of privately-held companies.  These investments are measured at fair value with unrealized gains and losses presented in other comprehensive (loss) income.  The carrying amount of these investments was $2 million and $1 million at December&#160;31, 2022 and 2021, respectively.  See Note 8 for a discussion of the fair value of such investments.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text">The Company uses derivative financial instruments, from time to time, to manage its exposure to market risks for changes in interest rates and foreign currencies.  This strategy includes the use of interest rate swap agreements, forward-starting interest rate swap agreements, interest rate lock agreements and foreign currency forward contracts to manage its exposure to movements in interest and currency rates.  The Company has established policies and procedures for risk assessment and the approval, reporting and monitoring of derivative financial instrument activities.  These policies prohibit holding or issuing derivative financial instruments for speculative purposes.  The Company does not enter into derivative financial instruments that contain credit risk-related contingent features or requirements to post collateral.<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company is exposed to interest rate risk on its cash and cash equivalents and its debt obligations.  Interest income earned on cash and cash equivalents may fluctuate as interest rates change; however, due to their relatively short maturities, the Company does not hedge these assets or their investment cash flows and the impact of interest rate risk is not material.  The Company's debt obligations consist of fixed-rate and, from time to time, variable-rate debt instruments.  The Company's primary objective is to achieve the lowest overall cost of funding while managing the variability in cash outflows within an acceptable range.  In order to achieve this objective, the Company has historically entered into interest rate swap agreements.  Interest rate swap agreements involve the periodic exchange of payments without the exchange of underlying principal or notional amounts.  Net settlements between the counterparties are recognized as an adjustment to interest expense, net.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company accounts for these derivatives as either an asset or liability measured at its fair value.  The fair value is based upon model-derived valuations in which all significant inputs are observable in active markets including certain financial </span></div>information and certain assumptions regarding past, present and future market conditions.  For a derivative instrument that has been formally designated as a fair value hedge, fair value gains or losses on the derivative instrument along with offsetting fair value gains or losses on the hedged item that are attributable to the risk being hedged are reported in other (expense) income, net in the consolidated statements of operations.  For derivatives that have been formally designated as a cash flow hedge, the change in the fair value of the derivatives is recorded in accumulated other comprehensive loss.  Upon maturity or early termination of an effective interest rate swap agreement designated as a cash flow hedge, unrealized gains or losses are deferred in stockholders' equity, as a component of accumulated other comprehensive loss, and are amortized as an adjustment to interest expense over the period during which the hedged forecasted transaction affects earnings, which is when the Company recognizes interest expense on the hedged cash flows.  At inception and quarterly thereafter, the Company formally assesses whether the derivatives that are used in hedging transactions are highly effective in offsetting changes in the fair value or cash flows of the hedged item.  After the initial quantitative assessment, this analysis is initially performed on a qualitative basis and, if it is determined that the hedging relationship was and continues to be highly effective, no further analysis is required.  All components of each derivative financial instrument's gain or loss are included in the assessment of hedge effectiveness.  If it is determined that a derivative ceases to be a highly effective hedge, the Company discontinues hedge accounting and any deferred gains or losses related to a discontinued cash flow hedge shall continue to be reported in accumulated other comprehensive loss, unless it is probable that the forecasted transaction will not occur.  If it is probable that the forecasted transaction will not occur by the originally specified time period, the Company discontinues hedge accounting and any deferred gains or losses reported in accumulated other comprehensive loss are classified into earnings immediately.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text">Comprehensive income (loss) encompasses all changes in stockholders' equity (except those arising from transactions with stockholders) and includes:<div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Foreign currency translation adjustments; </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net deferred gains (losses) on cash flow hedges, which represent deferred gains (losses), net of tax, on interest rate-related derivative financial instruments designated as cash flow hedges, net of amounts reclassified to interest expense (see Notes 16 and 17); and</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net changes in available-for-sale debt securities, which represent unrealized holding gains (losses), net of tax, on available-for-sale debt securities.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Costs</a></td>
<td class="text">Advertising costs are expensed as incurred.  For the years ended December&#160;31, 2022, 2021 and 2020, advertising costs were $74&#160;million, $78&#160;million and $38&#160;million, respectively.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Standards</a></td>
<td class="text">New Accounting Standards To Be Adopted&#160;&#160;&#160;&#160;In March 2020, the Financial Accounting Standards Board ("FASB") issued a new accounting standard which provides temporary optional guidance to ease the potential burden in accounting for reference rate reform due to the risk of cessation of the London Interbank Offered Rate ("LIBOR").  The amendments apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform.  The pronouncement was effective immediately and, due to an accounting standards update which the FASB issued in December 2022, can be applied to contract modifications through December 31, 2024.  To the extent that, prior to December 31, 2024, the Company enters into any contract modifications for which the optional expedients are applied, the adoption of this standard is not expected to have a material impact on the Company&#8217;s consolidated results of operations, financial position or cash flows.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">The Company determines if an arrangement is or contains a lease at contract inception. The Company leases office space, patient service centers, clinical laboratories, warehouses, logistic hubs and equipment primarily through operating leases, with a limited number of finance leases. A <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NDc_562c010d-bbaa-4f52-a8ac-de2660c01cb7"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NDc_da6e8994-01f0-4a9a-83e2-083574a1b91f">right-of-use asset</span></span>, representing the underlying asset during the lease term, and a lease <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTQ_323fe1c8-01d7-47a9-afae-473da3defda0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTQ_4bd99473-36cb-4abf-841b-9d98e467569f">liability</span></span>, representing the payment obligation arising from the lease, are recognized on the balance sheet at lease commencement based on the present value of the payment obligation. For operating leases, expense is recognized on a straight-line basis over the lease term. For finance leases, interest expense on the lease <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTU_6f606824-b677-4250-a7ed-24f9f3915ac5"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTU_8ee62599-1731-4db2-b098-6e0dac4293f9">liability</span></span> is recognized using the effective interest method and amortization of the right-of-use asset is recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term.  Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet; the Company recognizes lease expense for these leases on a straight-line basis over the lease term.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_AccountsReceivableAndAllowanceForCreditLossesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable and Allowance for Credit Losses Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_AccountsReceivableAndAllowanceForCreditLossesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144439<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21459-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596526597232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text">The approximate percentage of net revenues by type of customer was as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:62.026%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.699%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.699%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.702%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare insurers:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fee-for-service</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitated</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total healthcare insurers</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government payers</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Client payers</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients (including coinsurance and deductible responsibilities)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total DIS</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DS</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_AccountsReceivableDisaggregationTableTextBlock', window );">Accounts Receivable Disaggregation</a></td>
<td class="text">The approximate percentage of net accounts receivable by type of customer as of December&#160;31, 2022 and 2021 was as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:74.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.838%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.771%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare insurers</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government payers</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Client payers</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients (including coinsurance and deductible responsibilities)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total DIS</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DS</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net accounts receivable</span></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock', window );">Accounts Receivable, Allowance for Credit Loss</a></td>
<td class="text">The following table summarizes the activity for the Company's allowance for credit losses during the years ended December&#160;31, 2022 and 2021, which principally relates to client payers:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Allowance for Credit Losses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for credit losses</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs of accounts receivable, net of recoveries</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for credit losses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs of accounts receivable, net of recoveries</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, December&#160;31, 2022</span></div></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_AccountsReceivableDisaggregationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable Disaggregation [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_AccountsReceivableDisaggregationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596526147088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text">The computation of basic and diluted earnings per common share is as follows (in millions, except per share data):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts attributable to Quest Diagnostics&#8217; common stockholders:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Quest Diagnostics</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,995&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,431&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Earnings allocated to participating securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings available to Quest Diagnostics&#8217; common stockholders &#8211; basic and diluted</span></div></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,988&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,425&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding &#8211; basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and performance share units</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding &#8211; diluted</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings per share attributable to Quest Diagnostics&#8217; common stockholders:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.62&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.97&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.55&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.47&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text">The following securities were not included in the calculation of diluted earnings per share due to their antidilutive effect:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and performance share units</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596525179440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING ACTIVITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Schedule of Pre-Tax Restructuring Charges</a></td>
<td class="text">The following table provides a summary of the Company's pre-tax restructuring charges for the years ended December&#160;31, 2022, 2021 and 2020: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee separation costs</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility-related costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment charges</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restructuring charges</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Activity of Restructuring Liability</a></td>
<td class="text">The following table summarizes the activity of the restructuring liability during 2022 and 2021, which is included in accrued expenses in Note 13:  <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"/><td style="width:62.049%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.396%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.711%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Employee Separation Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Facility-Related Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, December&#160;31, 2020</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income statement expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, December&#160;31, 2021</span></div></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income statement expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, December&#160;31, 2022</span></div></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596526492976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text">The following table provides a summary of the recognized assets and liabilities that are measured at fair value on a recurring basis:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of Fair Value Measurements</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation trading securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash surrender value of life insurance policies</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liabilities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redeemable noncontrolling interest</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation trading securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash surrender value of life insurance policies</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liabilities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redeemable noncontrolling interest</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of Beginning and Ending Liability Balances Unobservable Inputs</a></td>
<td class="text">The following table provides a reconciliation of the beginning and ending balances of liabilities using significant unobservable inputs (Level 3):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.912%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent Consideration</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases, additions and issuances</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases, additions and issuances</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value adjustments included in earnings - realized/unrealized</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596530729936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Components of Income Tax Expense</a></td>
<td class="text">The components of income tax expense (benefit) for 2022, 2021 and 2020 were as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of the Federal Statutory Rate</a></td>
<td class="text">A reconciliation of the federal statutory income tax rate to the Company's effective income tax rate for 2022, 2021 and 2020 was as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax provision at statutory rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local income taxes, net of federal benefit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of noncontrolling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment to state deferred tax liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess tax benefits on stock-based compensation arrangements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return to provision true-ups </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of equity earnings</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in reserves for uncertain tax positions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowances associated with certain net operating losses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.4&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text">The tax effects of temporary differences that give rise to significant portions of the deferred tax assets (liabilities) as of December&#160;31, 2022 and 2021 were as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current deferred tax assets (liabilities):</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable reserves</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities not currently deductible</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basis differences in investments, joint ventures and subsidiaries </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards, net of valuation allowance</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(568)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(633)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current deferred tax liabilities, net</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(295)</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(290)</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Schedule of Unrecognized Benefits</a></td>
<td class="text">The total amount of unrecognized tax benefits as of and for the years ended December&#160;31, 2022, 2021 and 2020 consisted of the following:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For tax positions of current year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For tax positions of prior years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in judgment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expirations of statutes of limitations</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596526287696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL CASH FLOW AND OTHER DATA (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Supplemental Cash Flow and Other Data</a></td>
<td class="text">Supplemental cash flow and other data for the years ended December&#160;31, 2022, 2021 and 2020 was as follows:<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(151)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">709&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable associated with capital expenditures</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable associated with purchases of treasury stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend payable</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends received from equity method investees</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Businesses acquired:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of liabilities assumed</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of net assets acquired</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merger consideration payable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for business acquisitions</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Cash acquired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business acquisitions, net of cash acquired</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Leases:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased assets obtained in exchange for new operating lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596526271504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY, PLANT AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text">Property, plant and equipment as of December&#160;31, 2022 and 2021 consisted of the following: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment and furniture and fixtures</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,140&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,009&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software developed or obtained for internal use</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,103&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,795&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,337)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,088)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,766&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,707&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596525166192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Changes in Goodwill, Net</a></td>
<td class="text">The changes in goodwill for the years ended December&#160;31, 2022 and 2021 were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,095&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,873&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired during the year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to goodwill</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,220&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,095&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets Excluding Goodwill</a></td>
<td class="text">Intangible assets as of December&#160;31, 2022 and 2021 consisted of the following:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.436%"/><td style="width:0.1%"/></tr><tr style="height:39pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Amortization<br/>Period (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizing intangible assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer-related</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,623&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(832)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,581&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(726)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-compete agreements</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,878&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,022)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,834&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(903)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets not subject to amortization:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,114&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,022)</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,070&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(903)</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,167&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Future Amortization Expense Intangible Assets</a></td>
<td class="text">The estimated amortization expense related to amortizable intangible assets for each of the five succeeding fiscal years and thereafter as of December&#160;31, 2022 is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:41.959%"><tr><td style="width:1.0%"/><td style="width:71.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.775%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596526307776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accounts Payable and Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Liabilities</a></td>
<td class="text">Accounts payable and accrued expenses as of December&#160;31, 2022 and 2021 consisted of the following: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.105%"><tr><td style="width:1.0%"/><td style="width:72.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued wages and benefits (including incentive compensation)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">518&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Overdrafts</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend payable</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued insurance</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merger consideration payable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,396&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596525242928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Debt Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Long-term Debt</a></td>
<td class="text">Long-term debt (including finance lease obligations) as of December&#160;31, 2022 and 2021 consisted of the following: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:77.962%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.004%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25% Senior Notes due April 2024</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50% Senior Notes due March 2025</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.45% Senior Notes due June 2026</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.20% Senior Notes due June 2029</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95% Senior Notes due June 2030</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80% Senior Notes due June 2031</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.95% Senior Notes due July 2037</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% Senior Notes due January 2040</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.70% Senior Notes due March 2045</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,980&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,012&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, net of current portion</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,978&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,010&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-term Debt</a></td>
<td class="text">As of December&#160;31, 2022, long-term debt matures as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:297.00pt"><tr><td style="width:1.0pt"/><td style="width:235.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,576&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturities of long-term debt</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,985&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized discount</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value basis adjustments attributable to hedged debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,980&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, net of current portion</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,978&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596525264688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_ScheduleOfLeaseByAssetTypeTableTextBlock', window );">Schedule Of Lease By Asset Type</a></td>
<td class="text">The Company's assets and liabilities for its lease agreements as of December&#160;31, 2022 and 2021 were as follows:<div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:21.634%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.672%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.571%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.573%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net (a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">626&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzEyLTItMS0xLTc4MjE1_1c2a9643-64b7-48eb-992f-a3efa9e86f06"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzEyLTItMS0xLTc4MjE1_5bf1d7b4-f29c-4002-9627-e2075dfadeb9">Long-term debt</span></span></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679&#160;</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Finance lease assets as of December&#160;31, 2022 and 2021 were recorded net of accumulated amortization of $3&#160;million and $8&#160;million, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease, Cost</a></td>
<td class="text">Components of lease cost for the years ended December&#160;31, 2022, 2021 and 2020 were as follows:<div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:468.75pt"><tr><td style="width:1.0pt"/><td style="width:247.75pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td style="width:1.0pt"/><td style="width:70.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.00pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost (a)</span></td><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of leased assets</span></td><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net lease cost</span></td><td colspan="3" style="display:none"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Includes short-term leases and variable lease costs (primarily usage-based maintenance fees and utilities related to real estate leases and certain equipment-related and vehicle-related costs) of $160&#160;million, $140&#160;million and $120&#160;million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Operating Lease, Liability, Maturity</a></td>
<td class="text">The maturity of the Company's lease liabilities as of December&#160;31, 2022 is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:365.25pt"><tr><td style="width:1.0pt"/><td style="width:163.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:29pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Finance Lease, Liability, Maturity</a></td>
<td class="text">The maturity of the Company's lease liabilities as of December&#160;31, 2022 is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:365.25pt"><tr><td style="width:1.0pt"/><td style="width:163.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:29pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_ScheduleofLeaseTermandDiscountRateTableTextBlock', window );">Schedule of Lease Term and Discount Rate</a></td>
<td class="text">Lease term and discount rate as of December&#160;31, 2022 and 2021 were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:363.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.00pt"/><td style="width:1.0pt"/></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Lease term and discount rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years):</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_ScheduleOfLeaseByAssetTypeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Lease By Asset Type [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_ScheduleOfLeaseByAssetTypeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_ScheduleofLeaseTermandDiscountRateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Lease Term and Discount Rate [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_ScheduleofLeaseTermandDiscountRateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596530636224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location</a></td>
<td class="text">As of December&#160;31, 2022 and 2021, the following amounts were recorded on the consolidated balance sheets related to cumulative basis adjustments for fair value hedges included in the carrying amount of long-term debt:<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hedge Accounting Basis Adjustment (a)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) As of both December&#160;31, 2022 and 2021, the entire balance is associated with remaining unamortized hedging adjustments on discontinued relationships. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following table presents the effect of fair value hedge accounting on the consolidated statements of operations for the years ended December&#160;31, 2022, 2021 and 2020, respectively:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:14.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.275%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.246%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other (expense) income, net</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total for line item in which the effects of fair value hedges are recorded</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gain (loss) on fair value hedging relationships:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items (Long-term debt)</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596522023584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock', window );">Components of Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text">The changes in accumulated other comprehensive loss by component for 2022, 2021 and 2020 were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.379%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Changes in Available-for-Sale Debt Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Deferred Losses on Cash Flow Hedges, net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income before reclassifications</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss before reclassifications</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss before reclassifications</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive (loss) income</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of comprehensive income (loss). Includes, but is not limited to, foreign currency translation adjustments, foreign currency transactions designated as economic hedges of a net investment in foreign entity, gain (loss) and prior service cost (credit) for pension plans and other postretirement benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e526-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596525026176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OWNERSHIP AND COMPENSATION PLANS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used in Valuing The Company's Stock Options</a></td>
<td class="text">The weighted average assumptions used in valuing stock options granted in the periods presented were:  <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:61.216%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.219%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at grant date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$26.80</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$21.82</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$17.25</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.4%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.6%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.3%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected holding period, in years</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Transactions Under The Company's Stock Option Plans</a></td>
<td class="text">The following summarizes the activity relative to stock option awards for 2022: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:54.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.457%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.457%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.457%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.459%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, beginning of year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.44&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.51&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited and canceled</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, end of year</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.78&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable, end of year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.36&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, end of year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.61&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_ScheduleOfShareBasedPaymentAwardPerformanceShareUnitsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used in Valuing The Company's Performance Share Units</a></td>
<td class="text">The weighted average assumptions used in valuing performance share units with a market-based relative TSR goal in the periods presented were:  <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.289%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.385%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at grant date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$130.00</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$150.15</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$144.03</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.9%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.2%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Summary of Transactions Under Stock Awards Other than Options</a></td>
<td class="text">The following summarizes the activity relative to stock awards, including restricted stock units and performance share units, for 2022, 2021 and 2020: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:31.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.478%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares outstanding, beginning of year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.46&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.36&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares forfeited and canceled</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares outstanding, end of year</span></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.45&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.46&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.12&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_ScheduleOfShareBasedPaymentAwardPerformanceShareUnitsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Share-based Payment Award, Performance Share Units, Valuation Assumptions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_ScheduleOfShareBasedPaymentAwardPerformanceShareUnitsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596526299712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS SEGMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment</a></td>
<td class="text">The following table is a summary of segment information for the years ended December&#160;31, 2022, 2021 and 2020. Segment asset information is not presented since it is not used by the CODM at the operating segment level.  Operating earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income (loss) for the segment.  General corporate activities included in the table below are comprised of general management and administrative corporate expenses, amortization and impairment of intangibles assets and other operating income and expenses, net of certain general corporate activity costs that are allocated to the DIS and DS businesses.  The accounting policies of the segments are the same as those of the Company as set forth in Note 2.<div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net revenues:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DIS business</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,609&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,494&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,139&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other operating segments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,883&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,788&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,437&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating earnings (loss):</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DIS business</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,704&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,646&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,201&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other operating segments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(296)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(294)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(269)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating income</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,428&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,381&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,971&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-operating (expense) income, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(193)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before income taxes and equity in earnings of equity method investees</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,235&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,599&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income tax expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(264)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(597)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(460)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity in earnings of equity method investees, net of taxes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,015&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,080&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less: Net income attributable to noncontrolling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to Quest Diagnostics</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,995&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,431&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Depreciation and amortization expense for the years ended December&#160;31, 2022, 2021 and 2020 were as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DIS business</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other operating segments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total depreciation and amortization</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Capital expenditures for the years ended December&#160;31, 2022, 2021 and 2020 were as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DIS business</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other operating segments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total capital expenditures</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The approximate percentage of net revenues by major service for the years ended December&#160;31, 2022, 2021 and 2020 was as follows: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Routine clinical testing and other services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19 testing services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gene-based and esoteric (including advanced diagnostics) testing services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anatomic pathology testing services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596520990160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising cost</a></td>
<td class="nump">$ 74,000,000<span></span>
</td>
<td class="nump">$ 78,000,000<span></span>
</td>
<td class="nump">$ 38,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investments carrying value</a></td>
<td class="nump">$ 132,000,000<span></span>
</td>
<td class="nump">$ 141,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_PercentageofNetRevenues', window );">Percentage of net revenues</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of equity earnings from investments in affiliates</a></td>
<td class="nump">$ 44,000,000<span></span>
</td>
<td class="nump">$ 78,000,000<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_PercentageofNetAccountsReceivable', window );">Percentage of net accounts receivable</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="nump">$ 1,428,000,000<span></span>
</td>
<td class="nump">$ 2,381,000,000<span></span>
</td>
<td class="nump">1,971,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,015,000,000<span></span>
</td>
<td class="nump">2,080,000,000<span></span>
</td>
<td class="nump">1,499,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Trading equity securities gain or (loss)</a></td>
<td class="num">(55,000,000)<span></span>
</td>
<td class="nump">56,000,000<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_InvestmentwithoutReadilyDeterminableFairValueImpairment', window );">Impairment charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity Securities without readily determinable fair value</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">585,000,000<span></span>
</td>
<td class="nump">597,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="nump">642,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities', window );">Equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Deferred compensation trading securities</a></td>
<td class="nump">$ 68,000,000<span></span>
</td>
<td class="nump">$ 77,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dgx_DiagnosticInformationServicesBusinessMember', window );">DIS business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_PercentageofNetRevenues', window );">Percentage of net revenues</a></td>
<td class="nump">97.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_PercentageofNetAccountsReceivable', window );">Percentage of net accounts receivable</a></td>
<td class="nump">96.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="nump">$ 1,704,000,000<span></span>
</td>
<td class="nump">$ 2,646,000,000<span></span>
</td>
<td class="nump">$ 2,201,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dgx_DiagnosticInformationServicesBusinessMember', window );">DIS business | Government payers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_PercentageofNetRevenues', window );">Percentage of net revenues</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_PercentageofNetAccountsReceivable', window );">Percentage of net accounts receivable</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dgx_DiagnosticInformationServicesBusinessMember', window );">DIS business | Patients (including coinsurance and deductible responsibilities)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_PercentageofNetRevenues', window );">Percentage of net revenues</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_PercentageofNetAccountsReceivable', window );">Percentage of net accounts receivable</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Laboratory Equipment and Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Software and Software Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | DIS business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_PercentageofNetRevenues', window );">Percentage of net revenues</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Building and Building Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">31 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Laboratory Equipment and Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Software and Software Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dgx_SubstantialOwnershipInterestMember', window );">Substantial Ownership Interest | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dgx_SubstantialOwnershipInterestMember', window );">Substantial Ownership Interest | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Excluding Deferred Compensation Trading Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_InvestmentwithoutReadilyDeterminableFairValueImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment without Readily Determinable Fair Value, Impairment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_InvestmentwithoutReadilyDeterminableFairValueImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_PercentageofNetAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Net Accounts Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_PercentageofNetAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_PercentageofNetRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Net Revenues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_PercentageofNetRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies Line Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=dgx_DiagnosticInformationServicesBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=dgx_DiagnosticInformationServicesBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=dgx_GovernmentPayersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=dgx_GovernmentPayersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=dgx_PatientMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=dgx_PatientMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dgx_LaboratoryEquipmentAndFurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=dgx_LaboratoryEquipmentAndFurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dgx_SubstantialOwnershipInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dgx_SubstantialOwnershipInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596521248480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_PercentageofNetRevenues', window );">Percentage of net revenues</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_PercentageofNetAccountsReceivable', window );">Percentage of net accounts receivable</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Accounts Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Beginning balance</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Write-offs of accounts receivable, net of recoveries</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Ending balance</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for credit losses</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=dgx_HealthcareInsurersMember', window );">Healthcare insurers: | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_RevenueCollectionofConsiderationPeriod', window );">Collection of consideration</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=dgx_HealthcareInsurersMember', window );">Healthcare insurers: | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_RevenueCollectionofConsiderationPeriod', window );">Collection of consideration</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=dgx_GovernmentPayersMember', window );">Government payers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_RevenueCollectionofConsiderationPeriod', window );">Collection of consideration</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=dgx_ClientPayersMember', window );">Client payers | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_RevenueCollectionofConsiderationPeriod', window );">Collection of consideration</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=dgx_ClientPayersMember', window );">Client payers | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_RevenueCollectionofConsiderationPeriod', window );">Collection of consideration</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=dgx_PatientMember', window );">Patients (including coinsurance and deductible responsibilities) | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_RevenueCollectionofConsiderationPeriod', window );">Collection of consideration</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=dgx_PatientMember', window );">Patients (including coinsurance and deductible responsibilities) | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_RevenueCollectionofConsiderationPeriod', window );">Collection of consideration</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=dgx_DSBusinessesMember', window );">DS | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_RevenueCollectionofConsiderationPeriod', window );">Collection of consideration</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=dgx_DSBusinessesMember', window );">DS | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_RevenueCollectionofConsiderationPeriod', window );">Collection of consideration</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dgx_DiagnosticInformationServicesBusinessMember', window );">DIS business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_PercentageofNetRevenues', window );">Percentage of net revenues</a></td>
<td class="nump">97.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_PercentageofNetAccountsReceivable', window );">Percentage of net accounts receivable</a></td>
<td class="nump">96.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dgx_DiagnosticInformationServicesBusinessMember', window );">DIS business | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_PercentageofNetRevenues', window );">Percentage of net revenues</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dgx_DiagnosticInformationServicesBusinessMember', window );">DIS business | Healthcare insurers:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_PercentageofNetRevenues', window );">Percentage of net revenues</a></td>
<td class="nump">41.00%<span></span>
</td>
<td class="nump">42.00%<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_PercentageofNetAccountsReceivable', window );">Percentage of net accounts receivable</a></td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dgx_DiagnosticInformationServicesBusinessMember', window );">DIS business | Healthcare insurers: | Fee-for-service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_PercentageofNetRevenues', window );">Percentage of net revenues</a></td>
<td class="nump">38.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dgx_DiagnosticInformationServicesBusinessMember', window );">DIS business | Healthcare insurers: | Capitated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_PercentageofNetRevenues', window );">Percentage of net revenues</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dgx_DiagnosticInformationServicesBusinessMember', window );">DIS business | Government payers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_PercentageofNetRevenues', window );">Percentage of net revenues</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_PercentageofNetAccountsReceivable', window );">Percentage of net accounts receivable</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dgx_DiagnosticInformationServicesBusinessMember', window );">DIS business | Client payers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_PercentageofNetRevenues', window );">Percentage of net revenues</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_PercentageofNetAccountsReceivable', window );">Percentage of net accounts receivable</a></td>
<td class="nump">44.00%<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dgx_DiagnosticInformationServicesBusinessMember', window );">DIS business | Patients (including coinsurance and deductible responsibilities)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_PercentageofNetRevenues', window );">Percentage of net revenues</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_PeriodofBillingFullyReserve', window );">Period of billing fully reserve</a></td>
<td class="text">210 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_PercentageofNetAccountsReceivable', window );">Percentage of net accounts receivable</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">All other operating segments | DS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_PercentageofNetRevenues', window );">Percentage of net revenues</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_PercentageofNetAccountsReceivable', window );">Percentage of net accounts receivable</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_PercentageofNetAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Net Accounts Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_PercentageofNetAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_PercentageofNetRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Net Revenues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_PercentageofNetRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_PeriodofBillingFullyReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of Billing Fully Reserve</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_PeriodofBillingFullyReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_RevenueCollectionofConsiderationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Collection of Consideration Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_RevenueCollectionofConsiderationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=dgx_HealthcareInsurersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=dgx_HealthcareInsurersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=dgx_GovernmentPayersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=dgx_GovernmentPayersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=dgx_ClientPayersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=dgx_ClientPayersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=dgx_PatientMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=dgx_PatientMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=dgx_DSBusinessesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=dgx_DSBusinessesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=dgx_DiagnosticInformationServicesBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=dgx_DiagnosticInformationServicesBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dgx_FeeforserviceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dgx_FeeforserviceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dgx_CapitatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dgx_CapitatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596521408784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Quest Diagnostics</a></td>
<td class="nump">$ 946<span></span>
</td>
<td class="nump">$ 1,995<span></span>
</td>
<td class="nump">$ 1,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic', window );">Less: Earnings allocated to participating securities</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic', window );">Earnings available to Quest Diagnostics&#8217; common stockholders &#8211; basic and diluted</a></td>
<td class="nump">$ 942<span></span>
</td>
<td class="nump">$ 1,988<span></span>
</td>
<td class="nump">$ 1,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding - basic</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock options and performance share units</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding - diluted</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 8.10<span></span>
</td>
<td class="nump">$ 15.85<span></span>
</td>
<td class="nump">$ 10.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 7.97<span></span>
</td>
<td class="nump">$ 15.55<span></span>
</td>
<td class="nump">$ 10.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Stock options and performance share units not included due to their antidilutive effect</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesDateAxis=dgx_AcceleratedShareRepurchaseAgreementsMember', window );">Accelerated Share Repurchase Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesLineItems', window );"><strong>Accelerated Share Repurchases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_AcceleratedShareRepurchasesPayment', window );">Accelerated share repurchases, payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_AcceleratedShareRepurchasesPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accelerated Share Repurchases, Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_AcceleratedShareRepurchasesPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchasesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchasesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126962052&amp;loc=d3e4991-113900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1500-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from continuing operations available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2740-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchasesDateAxis=dgx_AcceleratedShareRepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchasesDateAxis=dgx_AcceleratedShareRepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596525072624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING ACTIVITIES (Pre-Tax Restructuring charges) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total restructuring charges</a></td>
<td class="nump">$ 55<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=dgx_InvigorateProgramMember', window );">Invigorate Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Employee separation costs</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Facility-related costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostsAndAssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total restructuring charges</a></td>
<td class="nump">$ 69<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherRestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherRestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=dgx_InvigorateProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=dgx_InvigorateProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596520895248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING ACTIVITIES (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Income statement (income) expense</a></td>
<td class="nump">$ 55<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=dgx_InvigorateProgramMember', window );">Invigorate Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Income statement (income) expense</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=dgx_InvigorateProgramMember', window );">Invigorate Program | Cost of Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Income statement (income) expense</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=dgx_InvigorateProgramMember', window );">Invigorate Program | Selling, General and Administrative Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Income statement (income) expense</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=dgx_InvigorateProgramMember', window );">Invigorate Program | Other Operating Income (Expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Income statement (income) expense</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=dgx_InvigorateProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=dgx_InvigorateProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherOperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherOperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596524988848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING ACTIVITIES (Activities of Restructuring Liabilities) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Income statement (income) expense</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Separation Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Income statement (income) expense</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember', window );">Facility-Related Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Income statement (income) expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596517478672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS ACQUISITIONS (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 01, 2022</div></th>
<th class="th"><div>Dec. 13, 2021</div></th>
<th class="th"><div>Jun. 01, 2021</div></th>
<th class="th"><div>Aug. 01, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Apr. 06, 2020</div></th>
<th class="th"><div>Jan. 21, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 162<span></span>
</td>
<td class="nump">$ 346<span></span>
</td>
<td class="nump">$ 330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired during the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill deductible for tax purposes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="nump">221<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFiniteLivedIntangibles1', window );">Finite-lived intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired from acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Business acquisitions, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="nump">331<span></span>
</td>
<td class="nump">330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,220<span></span>
</td>
<td class="nump">7,095<span></span>
</td>
<td class="nump">6,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_GoodwillAcquiredDuringPeriodBeforeAdjustments', window );">Goodwill acquired, before adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 148<span></span>
</td>
<td class="nump">$ 331<span></span>
</td>
<td class="nump">351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_BusinessAcquisitionPostacquisitionRevenue', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer - related</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">17 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember', window );">Technology-Based Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dgx_PackHealthLLCMember', window );">Pack Health, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration</a></td>
<td class="nump">$ 123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill deductible for tax purposes</a></td>
<td class="nump">78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired from acquisition</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Business acquisitions, net of cash acquired</a></td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangibles</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedWorkingCapital', window );">Working capital</a></td>
<td class="num">$ (3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dgx_PackHealthLLCMember', window );">Pack Health, LLC | Customer - related</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dgx_MercyHealthMember', window );">Mercy Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill deductible for tax purposes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dgx_MercyHealthMember', window );">Mercy Health | Customer - related</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dgx_LabtechDiagnosticsLLCMember', window );">Labtech Diagnostics, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill deductible for tax purposes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property, plant and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinanceLeaseLiabilities', window );">Finance lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dgx_LabtechDiagnosticsLLCMember', window );">Labtech Diagnostics, LLC | Customer - related</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dgx_BlueprintGeneticsOyMember', window );">Blueprint Genetics Oy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill deductible for tax purposes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired from acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Business acquisitions, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedPropertyPlantandEquipmentandWorkingCapital', window );">Property, plant, and equipment and working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dgx_BlueprintGeneticsOyMember', window );">Blueprint Genetics Oy | Customer - related</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dgx_BlueprintGeneticsOyMember', window );">Blueprint Genetics Oy | Technology-Based Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dgx_MemorialHermannMember', window );">Memorial Hermann</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill deductible for tax purposes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dgx_MemorialHermannMember', window );">Memorial Hermann | Customer - related</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dgx_MidAmericaClinicalLaboratoriesLLCMACLMember', window );">Mid America Clinical Laboratories, LLC (MACL)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill deductible for tax purposes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired from acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Business acquisitions, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedWorkingCapital', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property, plant and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of voting interests acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage', window );">Equity interest in acquiree, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1', window );">Equity interest in acquiree, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeLongTermGrowthRateUsedToDetermineFairValue', window );">Equity interest in acquiree, long-term growth rate used to determine fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeDicountRateUsedToDetermineFairValue', window );">Equity interest in acquiree, discount rate used to determine fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dgx_MidAmericaClinicalLaboratoriesLLCMACLMember', window );">Mid America Clinical Laboratories, LLC (MACL) | Other Income (Expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain', window );">Equity interest in acquiree, remeasurement gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dgx_MidAmericaClinicalLaboratoriesLLCMACLMember', window );">Mid America Clinical Laboratories, LLC (MACL) | Customer - related</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_BusinessAcquisitionPostacquisitionRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Post-acquisition Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_BusinessAcquisitionPostacquisitionRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinanceLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finance Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinanceLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Right-of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFiniteLivedIntangibles1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFiniteLivedIntangibles1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedPropertyPlantandEquipmentandWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment and Working Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedPropertyPlantandEquipmentandWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Working Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeDicountRateUsedToDetermineFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Step Acquisition, Equity Interest in Acquiree, Dicount Rate used to determine fair value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeDicountRateUsedToDetermineFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeLongTermGrowthRateUsedToDetermineFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Step Acquisition, Equity Interest in Acquiree, Long-term Growth Rate used to determine fair value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeLongTermGrowthRateUsedToDetermineFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_GoodwillAcquiredDuringPeriodBeforeAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill, Acquired During Period, Before Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_GoodwillAcquiredDuringPeriodBeforeAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=dgx_PackHealthLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=dgx_PackHealthLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=dgx_MercyHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=dgx_MercyHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=dgx_LabtechDiagnosticsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=dgx_LabtechDiagnosticsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=dgx_BlueprintGeneticsOyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=dgx_BlueprintGeneticsOyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=dgx_MemorialHermannMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=dgx_MemorialHermannMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=dgx_MidAmericaClinicalLaboratoriesLLCMACLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=dgx_MidAmericaClinicalLaboratoriesLLCMACLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=dgx_OtherIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=dgx_OtherIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596521237600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISPOSITION (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 264<span></span>
</td>
<td class="nump">$ 597<span></span>
</td>
<td class="nump">$ 460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(57)<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=dgx_Q2SolutionsMember', window );">Q2 Solutions | Disposed of by Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_EquityMethodInvestmentOwnershipPercentDisposedOf', window );">Percent of ownership interest sold</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_ProceedsFromSaleOfEquityMethodInvestmentsGross', window );">Gross proceeds from disposition of joint venture</a></td>
<td class="nump">$ 760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Taxes payable, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=dgx_Q2SolutionsMember', window );">Q2 Solutions | Disposed of by Sale | Foreign Currency Translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=dgx_Q2SolutionsMember', window );">Q2 Solutions | Disposed of by Sale | Other Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Gain on sale of investment, before tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (314)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_EquityMethodInvestmentOwnershipPercentDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percent Disposed Of</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_EquityMethodInvestmentOwnershipPercentDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_ProceedsFromSaleOfEquityMethodInvestmentsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Sale of Equity Method Investments, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_ProceedsFromSaleOfEquityMethodInvestmentsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of an equity method investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=dgx_Q2SolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=dgx_Q2SolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=dgx_ForeignCurrencyTranslationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=dgx_ForeignCurrencyTranslationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596521264656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Recognized Assets and Liabilities at Fair Value) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Deferred compensation trading securities</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashSurrenderValueFairValueDisclosure', window );">Cash surrender value of life insurance policies</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities', window );">Equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent', window );">Deferred compensation liabilities</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue', window );">Redeemable noncontrolling interest</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Deferred compensation trading securities</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashSurrenderValueFairValueDisclosure', window );">Cash surrender value of life insurance policies</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities', window );">Equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent', window );">Deferred compensation liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue', window );">Redeemable noncontrolling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Deferred compensation trading securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashSurrenderValueFairValueDisclosure', window );">Cash surrender value of life insurance policies</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities', window );">Equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent', window );">Deferred compensation liabilities</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Deferred compensation trading securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashSurrenderValueFairValueDisclosure', window );">Cash surrender value of life insurance policies</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities', window );">Equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent', window );">Deferred compensation liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue', window );">Redeemable noncontrolling interest</a></td>
<td class="nump">$ 77<span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Excluding Deferred Compensation Trading Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashSurrenderValueFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of the amount that could be realized under a life insurance contract or contracts owned by the entity, commonly known as corporate-owned life insurance (COLI) or bank-owned life insurance (BOLI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashSurrenderValueFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value as of the reporting date of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596525071344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Business Acquisition) (Details) - Pack Health and Labtech<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Contingent consideration arrangements, range of outcomes, value, high</a></td>
<td class="nump">$ 40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dgx_PackHealthAndLabtechMember', window );">Comparable Company Revenue Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.075<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dgx_PackHealthAndLabtechMember', window );">Discount rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dgx_PackHealthAndLabtechMember', window );">Discount rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.030<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=dgx_PackHealthAndLabtechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=dgx_PackHealthAndLabtechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=dgx_MeasurementInputComparableCompanyRevenueVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=dgx_MeasurementInputComparableCompanyRevenueVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596524667744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jul. 01, 2015</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Trading equity securities gain or (loss)</a></td>
<td class="num">$ (55)<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">3,700<span></span>
</td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=dgx_UMassJointVentureMember', window );">UMass Joint Venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership percentage by noncontrolling owners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember', window );">Other Operating Income (Expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Total (gains)/losses included in earnings - realized/unrealized</a></td>
<td class="num">$ (5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=dgx_UMassJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=dgx_UMassJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=dgx_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=dgx_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596532010544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Reconciliation of Beginning and Ending Balances of Liabilities Unobservable Inputs) (Details) - Level 3 - Contingent Consideration - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements', window );">Purchases, additions and issuances</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Settlements</a></td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Total fair value adjustments included in earnings - realized/unrealized</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases, (sales), issuances and (settlements) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=dgx_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=dgx_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596516111008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Apr. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Income (loss) from continuing operations - domestic</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Income (loss) from continuing operations - foreign</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">148<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax expense (benefit)</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(57)<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Current federal tax expense (benefit)</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">528<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Current state and local income tax expense</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Current foreign income tax expense</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Defered federal income tax expense (benefit)</a></td>
<td class="nump">29<span></span>
</td>
<td class="num">(61)<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">Deferred state and local income tax expense (benefit)</a></td>
<td class="num">(27)<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Deferred foreign income tax expense (benefit)</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="num">$ (264)<span></span>
</td>
<td class="num">$ (597)<span></span>
</td>
<td class="num">$ (460)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax provision at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State and local income taxes, net of federal benefit</a></td>
<td class="nump">4.70%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense', window );">Impact of noncontrolling interests</a></td>
<td class="num">(1.40%)<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
<td class="num">(0.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_EffectiveIncomeTaxRateReconciliationAdjustmentToStateDeferredTaxLiabilities', window );">Adjustment to state deferred tax liabilities</a></td>
<td class="num">(1.50%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther', window );">Excess tax benefits on stock-based compensation arrangements</a></td>
<td class="num">(1.10%)<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes', window );">Return to provision true-ups</a></td>
<td class="num">(1.10%)<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary', window );">Impact of equity earnings</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_EffectiveIncomeTaxRateReconciliationChangeForUncertainTaxPosition', window );">Changes in reserves for uncertain tax positions</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowances associated with certain net operating losses</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other, net</a></td>
<td class="num">(0.60%)<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">21.40%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">24.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsAccountsReceivables', window );">Accounts receivable reserves</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Liabilities not currently deductible</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_DeferredTaxLiabilityInvestmentsInvestmentsinSubsidiariesandEquitymethodinvestments', window );">Basis differences in investments, joint ventures and subsidiaries</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_NetOperatingLossCarryfowardsNetOfValuationAllowance', window );">Net operating loss carryfowards, net of valuation allowance</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Operating lease right-of-use assets</a></td>
<td class="num">(147)<span></span>
</td>
<td class="num">(150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_DeferredTaxAssetsOperatingLeaseLiabilitiesNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">161<span></span>
</td>
<td class="nump">162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Non-current deferred tax liability - depreciation and amortization</a></td>
<td class="num">(568)<span></span>
</td>
<td class="num">(633)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total non-current deferred tax liabilities</a></td>
<td class="num">(295)<span></span>
</td>
<td class="num">(290)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, valuation allowance</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxes', window );">Income taxes payable</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Prepaid taxes</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits, beginning balance</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="nump">$ 88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions for tax positions of current year</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions for tax positions of prior years</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_ReductionsForChangesInJudgment', window );">Reductions for changes in judgment</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Reductions for expirations of statutes of limitations</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Reductions for settlements</a></td>
<td class="num">(24)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits, ending balance</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Significant change in unrecognized tax benefits is reasonably possible, estimated range of change, upper bound</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense', window );">Unrecognized tax Benefits, interest on income taxes expense</a></td>
<td class="nump">3<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued', window );">Unrecognized tax benefits, interest on income taxes accrued</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember', window );">Other Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total non-current deferred tax liabilities</a></td>
<td class="num">(295)<span></span>
</td>
<td class="num">(290)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Country</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Country</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=dgx_Q2SolutionsMember', window );">Q2 Solutions | Disposed of by Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_EquityMethodInvestmentOwnershipPercentDisposedOf', window );">Percent of ownership interest sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (55)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_DeferredTaxAssetsOperatingLeaseLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease Liabilities, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_DeferredTaxAssetsOperatingLeaseLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsAccountsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accounts Receivables</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsAccountsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_DeferredTaxLiabilityInvestmentsInvestmentsinSubsidiariesandEquitymethodinvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liability, Investments, Investments in Subsidiaries and Equity method investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_DeferredTaxLiabilityInvestmentsInvestmentsinSubsidiariesandEquitymethodinvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_EffectiveIncomeTaxRateReconciliationAdjustmentToStateDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Adjustment To State Deferred Tax Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_EffectiveIncomeTaxRateReconciliationAdjustmentToStateDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_EffectiveIncomeTaxRateReconciliationChangeForUncertainTaxPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Change for uncertain tax position</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_EffectiveIncomeTaxRateReconciliationChangeForUncertainTaxPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_EquityMethodInvestmentOwnershipPercentDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percent Disposed Of</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_EquityMethodInvestmentOwnershipPercentDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_NetOperatingLossCarryfowardsNetOfValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_NetOperatingLossCarryfowardsNetOfValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_ReductionsForChangesInJudgment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross amount of decreases in unrecognized tax benefits resulting from changes in judgment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_ReductionsForChangesInJudgment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due. This amount is the total of current and noncurrent accrued income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity in earnings (loss) of unconsolidated subsidiaries exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to noncontrolling interest income (loss) exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense accrued for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=dgx_Q2SolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=dgx_Q2SolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596517399328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL CASH FLOW AND OTHER DATA (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 317<span></span>
</td>
<td class="nump">$ 305<span></span>
</td>
<td class="nump">$ 258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">437<span></span>
</td>
<td class="nump">408<span></span>
</td>
<td class="nump">361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(148)<span></span>
</td>
<td class="num">(152)<span></span>
</td>
<td class="num">(166)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDividendIncomeOperating', window );">Interest income</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense, net</a></td>
<td class="num">(138)<span></span>
</td>
<td class="num">(151)<span></span>
</td>
<td class="num">(163)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">159<span></span>
</td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="nump">283<span></span>
</td>
<td class="nump">709<span></span>
</td>
<td class="nump">360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Accounts payable associated with capital expenditures</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_TreasuryStockPurchasedbutNotyetPaid', window );">Accounts payable associated with purchases of treasury stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrentAndNoncurrent', window );">Dividend payable</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Dividends received from equity method investees</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Fair value of assets acquired</a></td>
<td class="nump">182<span></span>
</td>
<td class="nump">364<span></span>
</td>
<td class="nump">368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Fair value of liabilities assumed</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_FairValueOfNetAssetsAcquired', window );">Fair value of net assets acquired</a></td>
<td class="nump">166<span></span>
</td>
<td class="nump">346<span></span>
</td>
<td class="nump">351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_Mergerconsiderationpaidpayablenet', window );">Merger consideration payable</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for business acquisitions</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">331<span></span>
</td>
<td class="nump">351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Less: cash acquired</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Business acquisitions, net of cash acquired</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">331<span></span>
</td>
<td class="nump">330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">185<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flows from finance leases</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flows from finance leases</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Leased assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_DonationsContributionsAndOtherFinancialSupport', window );">Donations, contributions, and other financial support</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationLineItems', window );"><strong>Reclassification [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">585<span></span>
</td>
<td class="nump">$ 597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationTypeAxis=dgx_LeaseTypeChangeMember', window );">Lease Type Change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationLineItems', window );"><strong>Reclassification [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_DonationsContributionsAndOtherFinancialSupport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Donations, Contributions, and Other Financial Support</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_DonationsContributionsAndOtherFinancialSupport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_FairValueOfNetAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of net assets acquired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_FairValueOfNetAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_Mergerconsiderationpaidpayablenet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Merger consideration paid (payable), net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_Mergerconsiderationpaidpayablenet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_TreasuryStockPurchasedbutNotyetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury Stock Purchased but Not yet Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_TreasuryStockPurchasedbutNotyetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of assets acquired in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDividendIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.1-5)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDividendIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of liabilities assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationTypeAxis=dgx_LeaseTypeChangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationTypeAxis=dgx_LeaseTypeChangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596525448960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 5,103<span></span>
</td>
<td class="nump">$ 4,795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(3,337)<span></span>
</td>
<td class="num">(3,088)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">1,766<span></span>
</td>
<td class="nump">1,707<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Building and Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">520<span></span>
</td>
<td class="nump">532<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dgx_LaboratoryEquipmentFurnitureAndFixturesMember', window );">Laboratory Equipment, Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">2,140<span></span>
</td>
<td class="nump">2,009<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">760<span></span>
</td>
<td class="nump">705<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer Software Developed or Obtained for Internal Use</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">1,363<span></span>
</td>
<td class="nump">1,292<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 277<span></span>
</td>
<td class="nump">$ 214<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dgx_LaboratoryEquipmentFurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=dgx_LaboratoryEquipmentFurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596519538016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, balance at beginning of year</a></td>
<td class="nump">$ 7,095<span></span>
</td>
<td class="nump">$ 6,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired during the year</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="nump">$ 247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPeriodIncreaseDecrease', window );">Adjustments to goodwill</a></td>
<td class="nump">4<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, balance at end of year</a></td>
<td class="nump">7,220<span></span>
</td>
<td class="nump">7,095<span></span>
</td>
<td class="nump">$ 6,873<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived and Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible assets, gross excluding goodwill</a></td>
<td class="nump">2,114<span></span>
</td>
<td class="nump">2,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization, intangible assets</a></td>
<td class="num">(1,022)<span></span>
</td>
<td class="num">(903)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total intangible assets, net</a></td>
<td class="nump">1,092<span></span>
</td>
<td class="nump">1,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Future amortization expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2027</a></td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_FiniteLivedIntangibleAssetsEstimatedAmortizationExpenseTotal', window );">Total</a></td>
<td class="nump">856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Intangible Assets Not Subject to Amortization - Tradenames</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived and Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible assets, gross excluding goodwill</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total intangible assets, net</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_UnclassifiedIndefinitelivedIntangibleAssetsMember', window );">Intangible Assets Not Subject to Amortization - Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived and Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible assets, gross excluding goodwill</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total intangible assets, net</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived and Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted average amortization period</a></td>
<td class="text">17 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible assets, gross excluding goodwill</a></td>
<td class="nump">$ 1,623<span></span>
</td>
<td class="nump">1,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization, intangible assets</a></td>
<td class="num">(832)<span></span>
</td>
<td class="num">(726)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total intangible assets, net</a></td>
<td class="nump">$ 791<span></span>
</td>
<td class="nump">855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Non-compete Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived and Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted average amortization period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible assets, gross excluding goodwill</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization, intangible assets</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total intangible assets, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember', window );">Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived and Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted average amortization period</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible assets, gross excluding goodwill</a></td>
<td class="nump">$ 138<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization, intangible assets</a></td>
<td class="num">(81)<span></span>
</td>
<td class="num">(74)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total intangible assets, net</a></td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other Intangible Assets, Subject To Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived and Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted average amortization period</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible assets, gross excluding goodwill</a></td>
<td class="nump">$ 114<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization, intangible assets</a></td>
<td class="num">(106)<span></span>
</td>
<td class="num">(101)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total intangible assets, net</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=dgx_TotalAmortizingIntangibleAssetsMember', window );">Total Amortizing Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived and Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted average amortization period</a></td>
<td class="text">17 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible assets, gross excluding goodwill</a></td>
<td class="nump">$ 1,878<span></span>
</td>
<td class="nump">1,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization, intangible assets</a></td>
<td class="num">(1,022)<span></span>
</td>
<td class="num">(903)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total intangible assets, net</a></td>
<td class="nump">$ 856<span></span>
</td>
<td class="nump">$ 931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived and Indefinite-lived Intangible Assets [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_FiniteLivedIntangibleAssetsEstimatedAmortizationExpenseTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-lived intangible assets, estimated amortization expense, total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_FiniteLivedIntangibleAssetsEstimatedAmortizationExpenseTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_UnclassifiedIndefinitelivedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_UnclassifiedIndefinitelivedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=dgx_TotalAmortizingIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=dgx_TotalAmortizingIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596531742896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accounts Payable and Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued wages and benefits (including incentive compensation)</a></td>
<td class="nump">$ 428<span></span>
</td>
<td class="nump">$ 518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">392<span></span>
</td>
<td class="nump">460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade accounts payable</a></td>
<td class="nump">324<span></span>
</td>
<td class="nump">357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BankOverdrafts', window );">Overdrafts</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividend payable</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedInsuranceCurrent', window );">Accrued insurance</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_MergerConsiderationPayableCurrent', window );">Merger consideration payable</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 1,396<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_MergerConsiderationPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Merger Consideration Payable, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_MergerConsiderationPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedInsuranceCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedInsuranceCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BankOverdrafts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of payments made in excess of existing cash balances, which will be honored by the bank but reflected as a loan to the entity. Overdrafts generally have a very short time frame for correction or repayment and are therefore more similar to short-term bank financing than trade financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1243-112600<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BankOverdrafts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596515980256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT (Long-Term Debt) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 3,980<span></span>
</td>
<td class="nump">$ 4,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Debt issuance costs</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: current portion of long-term debt</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt, net of current portion</a></td>
<td class="nump">3,978<span></span>
</td>
<td class="nump">4,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dgx_FinanceLeaseObligationsandOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermDebt', window );">Other</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.25% Senior Notes due April 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 306<span></span>
</td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate</a></td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.50% Senior Notes due March 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 612<span></span>
</td>
<td class="nump">616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.45% Senior Notes due June 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 508<span></span>
</td>
<td class="nump">510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate</a></td>
<td class="nump">3.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.20% Senior Notes due June 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 499<span></span>
</td>
<td class="nump">499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.95% Senior Notes due June 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 799<span></span>
</td>
<td class="nump">798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate</a></td>
<td class="nump">2.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.80% Senior Notes due June 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 549<span></span>
</td>
<td class="nump">549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 6.95% Senior Notes due July 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 175<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate</a></td>
<td class="nump">6.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.75% Senior Notes due January 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 245<span></span>
</td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.70% Senior Notes due March 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate</a></td>
<td class="nump">4.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dgx_FinanceLeaseObligationsandOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dgx_FinanceLeaseObligationsandOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dgx_FourpointtwofivepercentSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dgx_FourpointtwofivepercentSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dgx_ThreePointFiveZeroPercentSeniorNotesdueMarch2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dgx_ThreePointFiveZeroPercentSeniorNotesdueMarch2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dgx_ThreePointFourFivePercentSeniorNotesdueJune2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dgx_ThreePointFourFivePercentSeniorNotesdueJune2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dgx_FourPointTwoZeroPercentSeniorNotesdueJune2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dgx_FourPointTwoZeroPercentSeniorNotesdueJune2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dgx_TwoPointNineFivePercentSeniorNotesdueJune2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dgx_TwoPointNineFivePercentSeniorNotesdueJune2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dgx_TwoPointEightZeroPercentSeniorNotesDueJune2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dgx_TwoPointEightZeroPercentSeniorNotesDueJune2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dgx_SixPointNineFivePercentSeniorNotesDue2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dgx_SixPointNineFivePercentSeniorNotesDue2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dgx_FivePointSevenFivePercentSeniorNotesDue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dgx_FivePointSevenFivePercentSeniorNotesDue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dgx_FourPointSevenZeroPercentSeniorNotesdueMarch2045Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dgx_FourPointSevenZeroPercentSeniorNotesdueMarch2045Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596528140640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT (Finance Lease) (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dgx_FinanceLeaseObligationsandOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_FinanceLeaseLiabilityRealEstate', window );">Finance lease liability, real estate</a></td>
<td class="nump">$ 25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_FinanceLeaseLiabilityRealEstate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Liability, Real Estate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_FinanceLeaseLiabilityRealEstate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dgx_FinanceLeaseObligationsandOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dgx_FinanceLeaseObligationsandOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596524833088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Secured Receivables Credit Facility) (Narrative) (Details) - Secured Receivables Credit Facility - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Oct. 21, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_DebtInstrumentExtensionPeriod', window );">Extension period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility capacity</a></td>
<td class="nump">$ 525,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 525,000,000<span></span>
</td>
<td class="nump">$ 600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Commercial Paper and Term Secured Overnight Financing Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate in excess of LIBOR</a></td>
<td class="nump">0.725%<span></span>
</td>
<td class="nump">0.725%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Commercial Paper and Term Secured Overnight Financing Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate in excess of LIBOR</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Loan Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility capacity</a></td>
<td class="nump">$ 425,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility capacity</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_DebtInstrumentExtensionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, Extension Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_DebtInstrumentExtensionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=dgx_CommercialPaperAndTermSecuredOvernightFinancingRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=dgx_CommercialPaperAndTermSecuredOvernightFinancingRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=dgx_LoanCommitmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=dgx_LoanCommitmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596517371424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Senior Unsecured Revolving Credit Facility) (Narrative) (Details) - Senior unsecured revolving credit facility - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Amount outstanding</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dgx_SeniorunsecuredrevolvingcreditfacilityMember', window );">LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate in excess of LIBOR</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dgx_SeniorunsecuredrevolvingcreditfacilityMember', window );">Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=dgx_SeniorunsecuredrevolvingcreditfacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=dgx_SeniorunsecuredrevolvingcreditfacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596516094432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT (Maturities of Long-Term Debt) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Debt Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2027</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">2,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_LongTermDebtMaturitiesGross', window );">Total maturities of long-term debt</a></td>
<td class="nump">3,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized discount</a></td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Debt issuance costs</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">$ (25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_DebtInstrumentFairValueBasisAdjustmentAttributableToHedgedDebt', window );">Fair value basis adjustments attributable to hedged debt</a></td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">3,980<span></span>
</td>
<td class="nump">4,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Current portion of long-term debt</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt, net of current portion</a></td>
<td class="nump">$ 3,978<span></span>
</td>
<td class="nump">$ 4,010<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_DebtInstrumentFairValueBasisAdjustmentAttributableToHedgedDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, fair value basis adjustment attributable to hedged debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_DebtInstrumentFairValueBasisAdjustmentAttributableToHedgedDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_LongTermDebtMaturitiesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including current and noncurrent portions, aggregate carrying amount of long-term borrowings as of the balance sheet date. May include notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, which had initial maturities beyond one year or beyond the normal operating cycle, if longer, and before deducting unamortized discount or premiums, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_LongTermDebtMaturitiesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596526719520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 585<span></span>
</td>
<td class="nump">$ 597<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationTypeAxis=dgx_LeaseTypeChangeMember', window );">Lease Type Change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_LeaseRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_LeaseRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_LeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_LeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Remaining Lease Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_LeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_LeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Renewal Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_LeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationTypeAxis=dgx_LeaseTypeChangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationTypeAxis=dgx_LeaseTypeChangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596526722208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES (Liabilities) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">$ 585<span></span>
</td>
<td class="nump">$ 597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Operating lease assets<span></span>
</td>
<td class="text">Operating lease assets<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease assets</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_LeaseRightofUseAsset', window );">Total lease assets</a></td>
<td class="nump">594<span></span>
</td>
<td class="nump">626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">$ 153<span></span>
</td>
<td class="nump">$ 151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Accounts payable and accrued expenses<span></span>
</td>
<td class="text">Accounts payable and accrued expenses<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current finance lease liabilities</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent operating lease liabilities</a></td>
<td class="nump">$ 489<span></span>
</td>
<td class="nump">$ 494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Long-Term Debt and Lease Obligation<span></span>
</td>
<td class="text">Long-Term Debt and Lease Obligation<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Noncurrent finance lease liabilities</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_LeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">651<span></span>
</td>
<td class="nump">679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization', window );">Right-of-use asset, accumulated amortization</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_LeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_LeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_LeaseRightofUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Right-of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_LeaseRightofUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596531906416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Costs) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_OperatingLeaseFixedAndVariableCost', window );">Operating lease cost</a></td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">$ 321<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of leased assets</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Net lease cost</a></td>
<td class="nump">348<span></span>
</td>
<td class="nump">325<span></span>
</td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_ShorttermLeaseandVariableLeaseCost', window );">Short-term leases and variable lease costs</a></td>
<td class="nump">$ 160<span></span>
</td>
<td class="nump">$ 140<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_OperatingLeaseFixedAndVariableCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Fixed and Variable Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_OperatingLeaseFixedAndVariableCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_ShorttermLeaseandVariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-term Lease and Variable Lease, Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_ShorttermLeaseandVariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596521222896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES (Maturity) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other liabilities<span></span>
</td>
<td class="text">Other liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_FinanceandOperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueafterYearFive', window );">Thereafter</a></td>
<td class="nump">174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_LesseeOperatingandFinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_OperatingandFinanceLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_FinanceandOperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance and Operating Lease Liabilities, Payments, Due [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_FinanceandOperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating and Finance Lease, Liability, Payments, Due</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating and Finance Lease, Liability, Payments, Due Next Twelve Months</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating and Finance Lease, Liability, Payments, Due Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating and Finance Lease, Liability, Payments, Due Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating and Finance Lease, Liability, Payments, Due Year Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating and Finance Lease, Liability, Payments, Due Year Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueafterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating and Finance Lease, Liability, Payments, Due after Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueafterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_LesseeOperatingandFinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating and Finance Lease, Liability, Undiscounted Excess Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_LesseeOperatingandFinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_OperatingandFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating and finance leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_OperatingandFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596525200320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES (Term and Rate) (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term, Operating leases</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term,Finance leases</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">11 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate, Operating leases</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate, Finance leases</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">6.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596524292704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated net loss from designated or qualifying cash flow hedges</a></td>
<td class="num">$ (21)<span></span>
</td>
<td class="num">$ (14)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596525165392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS (Balance Sheets) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember', window );">Long-term Debt | Fair Value Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease', window );">Hedge Accounting Basis Adjustment</a></td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596532062032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS (Income Statement) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">$ (55)<span></span>
</td>
<td class="nump">$ 369<span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1', window );">Hedged items (Long-term debt)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(68)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivatives designated as hedging instruments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596516429200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="12">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 02, 2023</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Apr. 01, 2021</div></th>
<th class="th"><div>Jul. 01, 2015</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_ScheduleOfShareholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity and Redeemable Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividends per common share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.66<span></span>
</td>
<td class="nump">$ 0.66<span></span>
</td>
<td class="nump">$ 0.66<span></span>
</td>
<td class="nump">$ 0.66<span></span>
</td>
<td class="nump">$ 0.62<span></span>
</td>
<td class="nump">$ 0.62<span></span>
</td>
<td class="nump">$ 0.62<span></span>
</td>
<td class="nump">$ 0.62<span></span>
</td>
<td class="nump">$ 0.56<span></span>
</td>
<td class="nump">$ 0.56<span></span>
</td>
<td class="nump">$ 0.56<span></span>
</td>
<td class="nump">$ 0.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_StockRepurchaseProgramAdditionalAmountAuthorized', window );">Additional amount authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Stock repurchase program, remaining authorized repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury stock value acquired cost method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,385,000,000<span></span>
</td>
<td class="nump">$ 2,222,000,000<span></span>
</td>
<td class="nump">$ 325,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Reissuance of shares for employee benefit plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Shares retired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Redeemable noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,000,000<span></span>
</td>
<td class="nump">$ 79,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesDateAxis=dgx_AcceleratedShareRepurchaseAgreementsMember', window );">Accelerated Share Repurchase Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_ScheduleOfShareholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity and Redeemable Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_AcceleratedShareRepurchasesPayment', window );">Accelerated share repurchases, payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposed of by Sale | Q2 Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_ScheduleOfShareholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity and Redeemable Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_EquityMethodInvestmentOwnershipPercentDisposedOf', window );">Percent of ownership interest sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=dgx_UMassJointVentureMember', window );">UMass Joint Venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_ScheduleOfShareholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity and Redeemable Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership percentage by noncontrolling owners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember', window );">Treasury Stock, at Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_ScheduleOfShareholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity and Redeemable Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchases of treasury stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,100,000<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury stock value acquired cost method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,385,000,000<span></span>
</td>
<td class="nump">$ 2,222,000,000<span></span>
</td>
<td class="nump">$ 325,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember', window );">Treasury Stock, at Cost | Accelerated Share Repurchase Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_ScheduleOfShareholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity and Redeemable Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchases of treasury stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=dgx_ForeignCurrencyTranslationMember', window );">Foreign Currency Translation | Disposed of by Sale | Q2 Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_ScheduleOfShareholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity and Redeemable Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign Currency Translation Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_ScheduleOfShareholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity and Redeemable Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_ScheduleOfShareholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity and Redeemable Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividends per common share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_ScheduleOfShareholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity and Redeemable Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividends per common share</a></td>
<td class="nump">$ 0.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_IncreaseDecreaseinCommonStockDividendsDeclaredasPercent', window );">Increase in quarterly dividends as percent</a></td>
<td class="nump">7.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_StockRepurchaseProgramAdditionalAmountAuthorized', window );">Additional amount authorized</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_ScheduleOfShareholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity and Redeemable Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_AcceleratedShareRepurchasesPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accelerated Share Repurchases, Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_AcceleratedShareRepurchasesPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_EquityMethodInvestmentOwnershipPercentDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percent Disposed Of</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_EquityMethodInvestmentOwnershipPercentDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_IncreaseDecreaseinCommonStockDividendsDeclaredasPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Common Stock, Dividends, Declared as Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_IncreaseDecreaseinCommonStockDividendsDeclaredasPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_ScheduleOfShareholdersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Schedule of Shareholders' Equity [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_ScheduleOfShareholdersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_StockRepurchaseProgramAdditionalAmountAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Repurchase Program, Additional Amount Authorized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_StockRepurchaseProgramAdditionalAmountAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesRetired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common and preferred stock retired from treasury during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesRetired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchasesDateAxis=dgx_AcceleratedShareRepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchasesDateAxis=dgx_AcceleratedShareRepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=dgx_Q2SolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=dgx_Q2SolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=dgx_UMassJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=dgx_UMassJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=dgx_ForeignCurrencyTranslationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=dgx_ForeignCurrencyTranslationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596520814000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Components of Accumulated Other Comprehensive (Loss) Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_ScheduleOfShareholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity and Redeemable Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Beginning Balance</a></td>
<td class="num">$ (14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income (loss)</a></td>
<td class="num">(7)<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Ending Balance</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign Currency Translation Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_ScheduleOfShareholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity and Redeemable Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Beginning Balance</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive (loss) income before reclassifications</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income (loss)</a></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Ending Balance</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Net Changes in Available-for-Sale Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_ScheduleOfShareholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity and Redeemable Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Beginning Balance</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive (loss) income before reclassifications</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income (loss)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Ending Balance</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember', window );">Net Deferred Losses on Cash Flow Hedges, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_ScheduleOfShareholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity and Redeemable Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Beginning Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive (loss) income before reclassifications</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income (loss)</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Ending Balance</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=dgx_OtherEquityComponentsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_ScheduleOfShareholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity and Redeemable Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Beginning Balance</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive (loss) income before reclassifications</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income (loss)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Ending Balance</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_ScheduleOfShareholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity and Redeemable Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Beginning Balance</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive (loss) income before reclassifications</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income (loss)</a></td>
<td class="num">(7)<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Ending Balance</a></td>
<td class="num">$ (21)<span></span>
</td>
<td class="num">$ (14)<span></span>
</td>
<td class="num">$ (21)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_ScheduleOfShareholdersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Schedule of Shareholders' Equity [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_ScheduleOfShareholdersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=dgx_OtherEquityComponentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=dgx_OtherEquityComponentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596519524336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OWNERSHIP AND COMPENSATION PLANS (Employee and Non-employee Directors Stock Ownership Programs) (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dgx_EmployeeLongTermIncentivePlanEltipMember', window );">Employee Long Term Incentive Plan ELTIP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_ContractualLifeOfStockOptionsAndOtherAwardsUnderSharedBasedCompensationPlans', window );">Contractual life of stock options and other awards under the shared-based compensation plans</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares available for award</a></td>
<td class="nump">79,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dgx_RestatedDirectorLongTermIncentivePlanDltipMember', window );">Restated Director Long-Term Incentive Plan (DLTIP)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_ContractualLifeOfStockOptionsAndOtherAwardsUnderSharedBasedCompensationPlans', window );">Contractual life of stock options and other awards under the shared-based compensation plans</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares available for award</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares granted</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_ContractualLifeOfStockOptionsAndOtherAwardsUnderSharedBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual life of stock options and other awards under the Shared-based compensation plans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_ContractualLifeOfStockOptionsAndOtherAwardsUnderSharedBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dgx_EmployeeLongTermIncentivePlanEltipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dgx_EmployeeLongTermIncentivePlanEltipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dgx_RestatedDirectorLongTermIncentivePlanDltipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dgx_RestatedDirectorLongTermIncentivePlanDltipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596519526000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OWNERSHIP AND COMPENSATION PLANS (Weighted Average Assumptions Used in Valuing Options Granted) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value at grant date (in dollars per share)</a></td>
<td class="nump">$ 26.80<span></span>
</td>
<td class="nump">$ 21.82<span></span>
</td>
<td class="nump">$ 17.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">26.40%<span></span>
</td>
<td class="nump">25.60%<span></span>
</td>
<td class="nump">20.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected holding period, in years</a></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dgx_PerformanceShareUnitsWithMarketBasedRelativeTSRGoalMember', window );">Performance share units with market-based relative TSR goal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value at grant date (in dollars per share)</a></td>
<td class="nump">$ 130.00<span></span>
</td>
<td class="nump">$ 150.15<span></span>
</td>
<td class="nump">$ 144.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">29.90%<span></span>
</td>
<td class="nump">30.20%<span></span>
</td>
<td class="nump">20.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dgx_PerformanceShareUnitsWithMarketBasedRelativeTSRGoalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dgx_PerformanceShareUnitsWithMarketBasedRelativeTSRGoalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596521300048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OWNERSHIP AND COMPENSATION PLANS (Transactions Under Stock Option Plans) (Details) - Equity Option - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning of year</a></td>
<td class="nump">5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="num">(1,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options forfeited and cancelled</a></td>
<td class="num">(100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, end of year</a></td>
<td class="nump">4,700<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, beginning of year weighted average exercise price</a></td>
<td class="nump">$ 96.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options, granted weighted average exercise price</a></td>
<td class="nump">128.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised weighted average exercise price</a></td>
<td class="nump">89.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Options forfeited and cancelled weighted average exercise price</a></td>
<td class="nump">120.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, end of year weighted average exercise price</a></td>
<td class="nump">$ 101.78<span></span>
</td>
<td class="nump">$ 96.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, end of year weighted average remaining contractual term</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, end of year aggregate intrinsic value</a></td>
<td class="nump">$ 257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, end of year shares</a></td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, end of year weighted average exercise price</a></td>
<td class="nump">$ 94.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, end of year weighted average remaining contractual term</a></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, end of year aggregate intrinsic value</a></td>
<td class="nump">$ 215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest, end of year shares</a></td>
<td class="nump">4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest, end of year weighted average exercise price</a></td>
<td class="nump">$ 101.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest, end of year weighted average remaining contractual term</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest, end of year aggregate intrinsic value</a></td>
<td class="nump">$ 256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">$ 83<span></span>
</td>
<td class="nump">$ 113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Compensation not yet recognized, stock options</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation cost weighted average period</a></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596531732608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OWNERSHIP AND COMPENSATION PLANS (Activities Related to Stock Awards) (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 77<span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
<td class="nump">$ 97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Income tax benefit related to stock-based compensation expense</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_Sharebasedcompensationexcesstaxbenefitamount', window );">Share-based compensation, excess tax benefit, amount</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dgx_StockAwardsMember', window );">Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Shares outstanding, beginning of year</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares granted</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares vested</a></td>
<td class="num">(0.6)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares forfeited and cancelled</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Shares outstanding, end of year</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Shares outstanding, beginning of year weighted average grant date fair value</a></td>
<td class="nump">$ 107.46<span></span>
</td>
<td class="nump">$ 100.12<span></span>
</td>
<td class="nump">$ 93.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Shares granted weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">128.49<span></span>
</td>
<td class="nump">122.78<span></span>
</td>
<td class="nump">112.43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Shares vested weighted average grant date fair value</a></td>
<td class="nump">92.45<span></span>
</td>
<td class="nump">103.41<span></span>
</td>
<td class="nump">96.36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Shares forfeited and cancelled weighted average grant date fair value</a></td>
<td class="nump">122.38<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Shares outstanding, end of year weighted average grant date fair value</a></td>
<td class="nump">$ 122.45<span></span>
</td>
<td class="nump">$ 107.46<span></span>
</td>
<td class="nump">$ 100.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation cost</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation cost weighted average period</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of shares vested</a></td>
<td class="nump">$ 72<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_Sharebasedcompensationexcesstaxbenefitamount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation, excess tax benefit, amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_Sharebasedcompensationexcesstaxbenefitamount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dgx_StockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dgx_StockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596521172080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OWNERSHIP AND COMPENSATION PLANS (Employee Stock Purchase Plan and Defined Contribution Plans) (Details) - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Company's expense for contributions to its defined contribution plans</a></td>
<td class="nump">$ 95<span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">$ 64<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Amended company match percentage of employee contributions</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Percentage of maximum annual wages witheld for the ESPP</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_MarketPriceOfCompanyStockIssuedAtDiscountUnderEspp', window );">Market price of company stock issued at a discount under the ESPP</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares available for award</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares purchased by eligible employees under ESPP</a></td>
<td class="nump">216<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_MarketPriceOfCompanyStockIssuedAtDiscountUnderEspp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Element represents the discounted market value of the Company stock on offering date or purchase date that participants pay for shares. Typically, the participant's per share cost is the lower of the prices on the two dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_MarketPriceOfCompanyStockIssuedAtDiscountUnderEspp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596526697184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OWNERSHIP AND COMPENSATION PLANS (Supplemental Deferred Compensation Plans) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Amended company match percentage of employee contributions</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis=dgx_SupplementalDeferredCompensationPlanMember', window );">Supplemental Deferred Compensation Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_SupplementalDeferredCompensationPlanSalaryDeferral', window );">SDCP salary deferral</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_SupplementalDeferredCompensationPlanVariableIncentiveCompensationDeferral', window );">SDCP variable incentive compensation deferral</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability', window );">SDCP accrual</a></td>
<td class="nump">$ 68,000<span></span>
</td>
<td class="nump">$ 77,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_FundsinatrustpertainingtoallparticipantdeferralsandcompanymatchingamountsrelatedtotheSDCP', window );">Funds in a trust pertaining to all participant deferrals and company matching amounts related to the SDCP</a></td>
<td class="nump">$ 68,000<span></span>
</td>
<td class="nump">77,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis=dgx_SupplementalDeferredCompensationPlanMember', window );">Supplemental Deferred Compensation Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Amended company match percentage of employee contributions</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis=dgx_SdcpIiMember', window );">SDCP II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Amended company match percentage of employee contributions</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability', window );">SDCP accrual</a></td>
<td class="nump">$ 52,000<span></span>
</td>
<td class="nump">66,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1', window );">SDCP II vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_SdcpIiGradedVestingPercentage', window );">SDCP II graded vesting percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashSurrenderValueFairValueDisclosure', window );">Cash surrender value of life insurance policies</a></td>
<td class="nump">$ 46,000<span></span>
</td>
<td class="nump">$ 57,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis=dgx_SdcpIiMember', window );">SDCP II [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer', window );">Deferred compensation arrangement with individual, employer contribution</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_FundsinatrustpertainingtoallparticipantdeferralsandcompanymatchingamountsrelatedtotheSDCP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funds in a trust pertaining to all participant deferrals and company matching amounts related to the Supplemental Deferred Compensation Plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_FundsinatrustpertainingtoallparticipantdeferralsandcompanymatchingamountsrelatedtotheSDCP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_SdcpIiGradedVestingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>SDCP II graded vesting percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_SdcpIiGradedVestingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_SupplementalDeferredCompensationPlanSalaryDeferral">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of salary deferral under the Supplemental Deferred Compensation Plan. This plans is an unfunded, non-qualified plan that provides for certain management and highly compensated employees to defer up to this percentage of their annual salary in excess of their defined contribution plan limits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_SupplementalDeferredCompensationPlanSalaryDeferral</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_SupplementalDeferredCompensationPlanVariableIncentiveCompensationDeferral">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferral percentage of the variable incentive compensation under the Supplemental Deferred Compensation Plan. The plan is an unfunded, non-qualified plan that provides for certain management and highly compensated eligible employees to defer up to this percentage of their variable incentive compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_SupplementalDeferredCompensationPlanVariableIncentiveCompensationDeferral</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashSurrenderValueFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of the amount that could be realized under a life insurance contract or contracts owned by the entity, commonly known as corporate-owned life insurance (COLI) or bank-owned life insurance (BOLI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashSurrenderValueFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contributions made by employer into fund established for purposes of making future disbursement to individual in accordance with deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the liability as of the balance sheet date to an individual under a deferred compensation arrangement. This amount may be the result of periodic accruals made over the period of active employment, or reflect termination benefits resulting contractual terms or a death benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6409875&amp;loc=d3e20015-108363<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum period the individual is required to perform services to be fully vested under the deferred compensation arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=6409961&amp;loc=d3e20487-108367<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis=dgx_SupplementalDeferredCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis=dgx_SupplementalDeferredCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis=dgx_SdcpIiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis=dgx_SdcpIiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596520968272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Oct. 21, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount', window );">Purchase obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 384,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary', window );">Purchase obligation, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_UnrecordedUnconditionalPurchaseObligationDuewithinTwoandThreeYears', window );">Purchase obligation, 2023 through 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_AgreementtoOutsourceBillingandCollectionFunction', window );">Agreement to outsource billing and collection function</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_RemainingTermsofContingentLeaseObligationsMaximum', window );">Remaining terms of lease obligations, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">Litigation reserves</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MalpracticeLossContingencyAccrualUndiscounted', window );">Self-insurance reserves</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 159,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of credit outstanding, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Receivables Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 525,000,000<span></span>
</td>
<td class="nump">$ 525,000,000<span></span>
</td>
<td class="nump">$ 600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Receivables Credit Facility | Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_AgreementtoOutsourceBillingandCollectionFunction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement to Outsource Billing and Collection Function</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_AgreementtoOutsourceBillingandCollectionFunction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_RemainingTermsofContingentLeaseObligationsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining Terms of Contingent Lease Obligations, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_RemainingTermsofContingentLeaseObligationsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_UnrecordedUnconditionalPurchaseObligationDuewithinTwoandThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecorded Unconditional Purchase Obligation, Due within Two and Three Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_UnrecordedUnconditionalPurchaseObligationDuewithinTwoandThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MalpracticeLossContingencyAccrualUndiscounted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability) at the end of the accounting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MalpracticeLossContingencyAccrualUndiscounted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the unrecorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596521042112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS SEGMENT INFORMATION (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_PercentageofNetRevenues', window );">Percentage of net revenues from the DIS business</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenues</a></td>
<td class="nump">$ 9,883<span></span>
</td>
<td class="nump">$ 10,788<span></span>
</td>
<td class="nump">$ 9,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating income</a></td>
<td class="nump">1,428<span></span>
</td>
<td class="nump">2,381<span></span>
</td>
<td class="nump">1,971<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Non-operating expenses, net</a></td>
<td class="num">(193)<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="num">(87)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes and equity in earnings of equity method investees</a></td>
<td class="nump">1,235<span></span>
</td>
<td class="nump">2,599<span></span>
</td>
<td class="nump">1,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(264)<span></span>
</td>
<td class="num">(597)<span></span>
</td>
<td class="num">(460)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in earnings of equity method investees, net of taxes</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,015<span></span>
</td>
<td class="nump">2,080<span></span>
</td>
<td class="nump">1,499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: net income attributable to noncontrolling interests</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Quest Diagnostics</a></td>
<td class="nump">946<span></span>
</td>
<td class="nump">1,995<span></span>
</td>
<td class="nump">1,431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">437<span></span>
</td>
<td class="nump">408<span></span>
</td>
<td class="nump">361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Total capital expenditures</a></td>
<td class="nump">$ 404<span></span>
</td>
<td class="nump">$ 403<span></span>
</td>
<td class="nump">$ 418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_RevenueFromContractWithCustomerExcludingAssessedTaxPercent', window );">Total net revenues, percent</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dgx_RoutineclinicaltestingservicesMember', window );">Routine clinical testing and other services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_RevenueFromContractWithCustomerExcludingAssessedTaxPercent', window );">Total net revenues, percent</a></td>
<td class="nump">44.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">41.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dgx_COVID19TestingServicesMember', window );">COVID-19 testing services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_RevenueFromContractWithCustomerExcludingAssessedTaxPercent', window );">Total net revenues, percent</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dgx_GenebasedandesoterictestingservicesMember', window );">Gene-based and esoteric (including advanced diagnostics) testing services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_RevenueFromContractWithCustomerExcludingAssessedTaxPercent', window );">Total net revenues, percent</a></td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dgx_AnatomicpathologytestingservicesMember', window );">Anatomic pathology testing services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_RevenueFromContractWithCustomerExcludingAssessedTaxPercent', window );">Total net revenues, percent</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dgx_AllotherservicesMember', window );">All other services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_RevenueFromContractWithCustomerExcludingAssessedTaxPercent', window );">Total net revenues, percent</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dgx_DiagnosticInformationServicesBusinessMember', window );">DIS business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_PercentageofNetRevenues', window );">Percentage of net revenues from the DIS business</a></td>
<td class="nump">97.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenues</a></td>
<td class="nump">$ 9,609<span></span>
</td>
<td class="nump">$ 10,494<span></span>
</td>
<td class="nump">$ 9,139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating income</a></td>
<td class="nump">1,704<span></span>
</td>
<td class="nump">2,646<span></span>
</td>
<td class="nump">2,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">305<span></span>
</td>
<td class="nump">294<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Total capital expenditures</a></td>
<td class="nump">384<span></span>
</td>
<td class="nump">379<span></span>
</td>
<td class="nump">394<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">All other operating segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenues</a></td>
<td class="nump">274<span></span>
</td>
<td class="nump">294<span></span>
</td>
<td class="nump">298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating income</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Total capital expenditures</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember', window );">General corporate income (expenses), Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating income</a></td>
<td class="num">(296)<span></span>
</td>
<td class="num">(294)<span></span>
</td>
<td class="num">(269)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Total capital expenditures</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | DIS business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dgx_PercentageofNetRevenues', window );">Percentage of net revenues from the DIS business</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_PercentageofNetRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Net Revenues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_PercentageofNetRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dgx_RevenueFromContractWithCustomerExcludingAssessedTaxPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue from Contract with Customer, Excluding Assessed Tax, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dgx_RevenueFromContractWithCustomerExcludingAssessedTaxPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dgx_RoutineclinicaltestingservicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dgx_RoutineclinicaltestingservicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dgx_COVID19TestingServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dgx_COVID19TestingServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dgx_GenebasedandesoterictestingservicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dgx_GenebasedandesoterictestingservicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dgx_AnatomicpathologytestingservicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dgx_AnatomicpathologytestingservicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dgx_AllotherservicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dgx_AllotherservicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=dgx_DiagnosticInformationServicesBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=dgx_DiagnosticInformationServicesBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140596528166288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash consideration</a></td>
<td class="nump">$ 148<span></span>
</td>
<td class="nump">$ 331<span></span>
</td>
<td class="nump">$ 351<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>dgx-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:dgx="http://questdiagnostics.com/20221231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="dgx-20221231.xsd" xlink:type="simple"/>
    <context id="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1477f11899e948a2a39ffb87d82e1e57_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i39a01f81398e4a8bb499e63010bd00dc_I20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="i2255f9500efa4f9fbb33148f349cbf15_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6f31e868418c42c5abbd3bb28b8a4277_D20230202-20230202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-02</startDate>
            <endDate>2023-02-02</endDate>
        </period>
    </context>
    <context id="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icb3e78d19c4a46b8a67dec2f47339bab_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">dgx:CommercialPaperAndTermSecuredOvernightFinancingRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i56456ee32fec497ca7d092cc9d8721eb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">dgx:CommercialPaperAndTermSecuredOvernightFinancingRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iec0fa8127aa846ccb173e5c0dac001e5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dgx:SeniorunsecuredrevolvingcreditfacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iddbc623b9422462099ee73f0b8dd8181_I20221021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-21</instant>
        </period>
    </context>
    <context id="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7037d88cebe7461283abb9164475ebce_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i872b3ea2e369403f8c0129ff07e0b538_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1240b052d8214432b601d5bcbb753f11_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i60096e15242147fba12636c6498e0696_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ide8bb1978e06466ca724c39081cca9e9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i288558364eaf483197b8585096922212_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i472db09b826445d8914756bb3c893218_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5cb753814e7c442992f309372e45e63f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9986f08efdbe402bbac2c867d4d5b49a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4a99166a414743a488765966d2720acc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i10198ce773244072a76824474330a1cf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7c187eb3582c4c4a85507116a2a9051a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i65ea28f7aede4d8cb4a1add480265c52_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i35ba9cb930d94eb9a0e61b9e0381a8d8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2998701e47ab4c2da75bc84322736ac6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id1339fcf6a344dd38e3445336c362756_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3df6ca3ffce342b4877024296cfa0551_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib876f54cbcd740bbaa56a7f098ffd2ac_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic144ab8f0cf34804be4018d616f6d4ac_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifb272b75d2c44e3689c068a802c47179_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icb2b0c92f23149e9923b4ac5d5a66fc9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3b1b2d14ccd04831986cecdccfec9b2d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9b667d9c2eff4eebb2ac4e52f720ef07_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i095b5e9afd734c41af3e81c20d90f712_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibf09d963d3644445a1026aa035d87436_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6bf24e1056814b529c1aaa4c1d657c4a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic4718e0f26e04ae097941f11f8d84f52_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibf9d22d584794a70962f2aa7e63d53ed_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i46c3bce145ea4fa5aa062add4078cdfe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ide97930b20624098ba7878ad5bcd0d94_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id3c04cff9ac445b78c60050390c6354a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4a13b74a4feb49a384914744e3913d6d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9fa9e0c121174bc7b51c26277e515b9b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3cc12e58d5654ed5b8115cae8aed17f6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie63ea040842e454a8a302897c8462f6f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic7dd85f38ce14e469eb57e11ba9cfd32_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2e6f2503a5bd421392c0a3810d1d34b3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i08ee5ae92da64f5088e4f441aadc7efd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7840e393be1c4cfaafc766cd6a649f57_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i87e8a4e1a2e74540b572c7f19b5a4c4d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia1e66f8b2302475fb1c8bca2f57488d3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4abbc656bb9d4006bae9f455034d8851_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib4848abb5a7147028c83ac30e5fcf981_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3448ddb537854f44a9c15ae5f60d4048_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7fcf55e48b7c44a8aa6c6dce683057f7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iedbe1fc06b5345c38cc97c62d3b664a3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dgx:SubstantialOwnershipInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4b416adaeaac49cfb869af6c8e627c39_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dgx:SubstantialOwnershipInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib62f2d7bef64474dbe05584de6966e18_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:GovernmentPayersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i316b4c39b6be48408e5109495bc92124_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:GovernmentPayersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i27098106112f421c94055f0cdae93371_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:GovernmentPayersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iba76f6181ce848fcbd7af0ece345152c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:GovernmentPayersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i81be56c5955845f49525165bab74c70f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:PatientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i915edbec2fea42159bcc1ba9f3179a51_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:PatientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i47d0ec07fa9b492b8d1144a50f6eb621_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dgx:LaboratoryEquipmentAndFurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i05ea7f33f7e549de90d8144e632a0571_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dgx:LaboratoryEquipmentAndFurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2d8ec938f1c4401ea9c7bd969cee4119_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifa192df489ca4b7eb7ca0059b95703b2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4a8532c66ad64ac990f07caabad868b2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4c9530356f3242cdb77f114a2aa32961_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i97cb2aca70ed4416839a2cd2c733918e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i73714e6410064c5eac002e398216cb2c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id9ea9ce1f68f4cde8b57ba97522e9899_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifbf8633ce3e245ac94d164f390ff90af_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7d71e5c8af24471ca79d701791aa2094_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:HealthcareInsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1d2e4bb54e5b41c9be7d8748b8f55367_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:HealthcareInsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic16acd3f5abe4057b2ded728e43030c9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:GovernmentPayersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifa2bee4df39349539bed4c4b3462277a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:ClientPayersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i94893ea869b54dd78d6d051a6bad548d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:ClientPayersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icf5f880be7d24d7a8c69fe4843654a88_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:PatientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib881549de5d14c42a72abbd13bb6179b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:PatientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i25375b7fc67348ac91275e0d3f7a1f4b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:PatientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4f428209a39d4b7b8a174be53283b875_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:DSBusinessesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9fd62e07b13c458892bd229457bbe1b5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:DSBusinessesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i01555413d91d42e3b436c505bbc70a67_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:FeeforserviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:HealthcareInsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i82dfa27313e34853973b9607939068a5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:FeeforserviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:HealthcareInsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i391fa00d0a7e46b0bc4a34ff6434ba24_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:FeeforserviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:HealthcareInsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idd41f50ca74e49ffadac56ef4c8022aa_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:CapitatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:HealthcareInsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0be3de26f2574a208f21fd35944e0cad_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:CapitatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:HealthcareInsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4ee750c8e58548218454f6b303208917_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:CapitatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:HealthcareInsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5a3f190b89e94247905769314473af12_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:HealthcareInsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i509d8b446ac14984bc658ece06fea971_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:HealthcareInsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i18a0eea57b5d4a778b3c4fc7048a92d0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:HealthcareInsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i99d6e0655d0f4b178b998f09b7ac1aa5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:ClientPayersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if95a07a0521045d7aa3fd6eca9554b97_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:ClientPayersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i397e6f4394d44cd0bbe7d033eb4fb637_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:ClientPayersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibcdd11aeccf94ec496587c6ccc6a4281_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:PatientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8f3ad29ae1e34df5b6995f7ffaeaa6cf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:PatientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i74ad488f1dfb40baa83701a002b6d98f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i680bf76bfe8647638c33f242f0ef1980_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic662fc7ebbb744a885416e3447893d64_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie0468d2fc9ab47638da16013b1893683_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:DSBusinessesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idd3a7338f2d040dda1e6639ac9f7d70f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:DSBusinessesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic76d3eea03004ba5aed3d7cc7917604b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:DSBusinessesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia6826b0f73ee4f00ab77a97be130c154_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:HealthcareInsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic12c618fa4d74532b772090eef552ce5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:HealthcareInsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i34f778b2b04c48679029b462c5367cb2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:GovernmentPayersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibaf0eafb0e0a4b05aa543fafe1dafb0a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:ClientPayersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3e02c394b9084450982de162d83141b3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:ClientPayersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6a770caf14c1492f8e3fbcaf507b29ae_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i762548338af343bcbc7df9361e2ba54e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dgx:DiagnosticInformationServicesBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia340b53589ac4a729154593b434a8b5b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:DSBusinessesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i69908b0e9ded44c68e9a26989fdf9843_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">dgx:DSBusinessesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2188840dc2a3430ebc240517ab668786_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">dgx:InvigorateProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iac2da26b5ef14b8f8e69ce008fd54d9b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">dgx:InvigorateProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7f2e4d03479a4236a60beb9b0835a79f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">dgx:InvigorateProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic2dc2704459f476aa2a7a5bdd5d24a31_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">dgx:InvigorateProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5c94d4fa6b2c4f048fbd732ba22d94f5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">dgx:InvigorateProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6c9c73f96c044bfe81dabb5b4fad4570_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">dgx:InvigorateProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i390853c339b546a497c9c3581d6c33ec_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">dgx:InvigorateProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9dfd2596231f42d583a3e66c7908bd62_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">dgx:InvigorateProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i17932ddd3fbd4fa39599486002e2399c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">dgx:InvigorateProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7641ac8ab06549359c0d7224c74f7f8b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">dgx:InvigorateProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2d8eee27a6fd4fbe801850524c5786c5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iebd99150341c4b0c873203afdafdd710_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i475d92c712f048aa906901cd998f7a38_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib738456c29b743669e686681cc7a5304_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id6084444236f40aca1b0c8796c27af45_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i50168a95b652435bb092f9dfbde9c76a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic24828d839184f6fa08a929719d4b23f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i57fc38f4b96048cbb2a8e0410884049d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i74144fa02d0949e18fcfdec627d2b59e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6fe6929b64864257bf0e3c4054d32428_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib3022bb32f9b457dac0b1400e74fad49_D20220201-20220201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:PackHealthLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-01</endDate>
        </period>
    </context>
    <context id="idc2a90ebfed1402e9780a6ef5de70976_I20220201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:PackHealthLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-01</instant>
        </period>
    </context>
    <context id="i0a5b8ece9a5340aa9b88329c3be13301_D20220201-20220201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:PackHealthLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-01</endDate>
        </period>
    </context>
    <context id="i48a2f820f01a423fa5d8fb263ceee2c0_D20210601-20210601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:MercyHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-01</endDate>
        </period>
    </context>
    <context id="i7c718b40c7aa46b79dd5ad4b49064a03_I20210601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:MercyHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-01</instant>
        </period>
    </context>
    <context id="i5e9e75dc29624f80957117764e6a8712_I20210601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:MercyHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-01</instant>
        </period>
    </context>
    <context id="ib254cb5566f04ccb957b18919eed9f8d_D20210601-20210601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:MercyHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-01</endDate>
        </period>
    </context>
    <context id="i1b56aef5907945b3abd0ec2ca54428c0_D20211213-20211213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:LabtechDiagnosticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-13</startDate>
            <endDate>2021-12-13</endDate>
        </period>
    </context>
    <context id="i52f75c68a74542ba8c151adcd5b7c6c1_I20211213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:LabtechDiagnosticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-13</instant>
        </period>
    </context>
    <context id="if8ace4c429434da1b559d5ea5059ac8a_I20211213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:LabtechDiagnosticsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-13</instant>
        </period>
    </context>
    <context id="i16f34a8359cd44c7a2ed3560a9171968_D20211213-20211213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:LabtechDiagnosticsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-13</startDate>
            <endDate>2021-12-13</endDate>
        </period>
    </context>
    <context id="i7198b30a0f3543f8b7624f5a08626715_D20200121-20200121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:BlueprintGeneticsOyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-21</startDate>
            <endDate>2020-01-21</endDate>
        </period>
    </context>
    <context id="i5c6b2d78cc5544cea4ff096768c26e2f_I20200121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:BlueprintGeneticsOyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-21</instant>
        </period>
    </context>
    <context id="ia0752516755c42d4b6bd8c225ce45827_D20200121-20200121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:BlueprintGeneticsOyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-21</startDate>
            <endDate>2020-01-21</endDate>
        </period>
    </context>
    <context id="iffd12e5591e7425f9d86856d3c9e755a_D20200121-20200121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:BlueprintGeneticsOyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-21</startDate>
            <endDate>2020-01-21</endDate>
        </period>
    </context>
    <context id="ibbfa5abb43c94c9b95f08bbd21c21a95_D20200406-20200406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:MemorialHermannMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-06</startDate>
            <endDate>2020-04-06</endDate>
        </period>
    </context>
    <context id="i97014f982e65418d980efc0a485ac0d0_I20200406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:MemorialHermannMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-06</instant>
        </period>
    </context>
    <context id="ib0b5a278261f4aeaa3c8450f4ab8f98b_I20200406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:MemorialHermannMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-06</instant>
        </period>
    </context>
    <context id="idc562163c50f4774ba7552b47b943aa8_D20200406-20200406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:MemorialHermannMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-06</startDate>
            <endDate>2020-04-06</endDate>
        </period>
    </context>
    <context id="i318abc26c57d45e199c441d6a27fb59b_I20200801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:MidAmericaClinicalLaboratoriesLLCMACLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-01</instant>
        </period>
    </context>
    <context id="i8e330046544a4466b899b21db4a44981_D20200801-20200801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:MidAmericaClinicalLaboratoriesLLCMACLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-01</endDate>
        </period>
    </context>
    <context id="ia4132aab88954f808a22077ce48c7778_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:MidAmericaClinicalLaboratoriesLLCMACLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="if02f69bfea444e448def3a82a65cb96b_D20200731-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:MidAmericaClinicalLaboratoriesLLCMACLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-31</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="i56f4083aa1ed47fbbfc4bd4e9a05cc0f_D20200801-20200801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:MidAmericaClinicalLaboratoriesLLCMACLMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">dgx:OtherIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-01</endDate>
        </period>
    </context>
    <context id="ibd44c8b9d5c649278afdc75ade9c679b_I20200801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:MidAmericaClinicalLaboratoriesLLCMACLMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-01</instant>
        </period>
    </context>
    <context id="if6cc04f23f064d64bc9599f898569338_D20200801-20200801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:MidAmericaClinicalLaboratoriesLLCMACLMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-01</endDate>
        </period>
    </context>
    <context id="i0c20173d8dc64ebdb79161256ab69f0d_I20210401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dgx:Q2SolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-01</instant>
        </period>
    </context>
    <context id="i5953c712e4234176ac0378246142fc74_D20210401-20210401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dgx:Q2SolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-01</endDate>
        </period>
    </context>
    <context id="i8a3a680061ef49fcac90a1aabb89821b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dgx:Q2SolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idcd7cd9e61214881b085d41e21b23992_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dgx:Q2SolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dgx:ForeignCurrencyTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i309534767ce0403ba44362e2a393aa76_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dgx:Q2SolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2a46256065f64a1f83735b542ac8cd05_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifacb18823a32464e8277a40cd0e40141_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i939ef35c1b364fccb6c395109ba883a8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i806fc0b55bb0418c955d42a8e1e2a9d5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iec46d6b614174b4a84f77d9cff2de05f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0e74f4a4c6c44d98bda7c8be9f02a6b2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i454f20bc7ea343f5a803483a6773d323_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i08e7768575cf494bab1f563baab11bdc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iec1e53779a1a46e382c71420c86a8e65_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:PackHealthAndLabtechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia070c0d807ae41f189d8789aa235216b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:PackHealthAndLabtechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">dgx:MeasurementInputComparableCompanyRevenueVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i23329615d047484080f7bc81509ea79e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:PackHealthAndLabtechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i435823dcec83485dbadc7a18b519986a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dgx:PackHealthAndLabtechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie2740945331a4803b48ca4d039b3724f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">dgx:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifd12294595f84e56a311bfb11080c96c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">dgx:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1029a7e4535b4243bba665741dbd11de_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">dgx:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i38a23e14d23244c8a2e550a645bbdcd1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">dgx:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i341269c4649443fbbe35b79f45362759_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">dgx:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia809ec8fd18c4ad48fc0dd81f2cdd760_I20150701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dgx:UMassJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-07-01</instant>
        </period>
    </context>
    <context id="i1880b74088be4b518518151d49b3c3d9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i71e02c56049a42c4a6be7ec8bf9a657b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia3f1c4f0d1ab416eb53e5a18510fd0dd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i585fd94209a4454c885f38e54a3ac3d2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if150c31900d447178580723791094470_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3d1d68fb080a45eaa9d48446425aaa2a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0cc8a896b5014eec950deeb2b23e329e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationTypeAxis">dgx:LeaseTypeChangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id8c3207c09bd46528b441166ed00ce51_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9a0fe7e6792a43c6948edd202dfa3610_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i67120ecad309432da683bc8101a2349a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i16c4c9b2568544898fd08b624fe50b66_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i98ddc5b3f9b247d7aff2886d77af5203_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dgx:LaboratoryEquipmentFurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib3b24be39ce649f0b555d02d17abd4b5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dgx:LaboratoryEquipmentFurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i556301e56725415db5e0e99af8881ab2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2941ae72a36c43deb9d71ecae5604733_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1cd92532b444421cbbef1840ffb1e964_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i26ad136d73174bb492bfb4eb3f70e8ac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie438daf2fc794813a4a9dc699c36d20a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id5cf2176ed3c4e77a2914da13e51e940_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie457eb795c6c447ab93368b3aed4f823_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib9f9ea06f7194197817bb2efd0215f53_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7c904f919f5841dab0cc8a467bfece73_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie5d6933739c34b618deb542c4712132c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i91553244d95f431f99ff6af124bfc732_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icb82f3cff9fb4367b9527abfc041ea6d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icfe0b2f1d56541548f5ba20eedeeffdf_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ieb995e58236640a2bebf429f0ef15cf6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icae1953df1b64580906887b236811607_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i309a355e12ca4ac8aebec7a6a293b7f1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i34d5911f3c604626be8defe10191d842_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i73c028f5ff27446fa49dcddeadcef5ff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if532e9c222b34f83ac093a3483e120ea_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">dgx:TotalAmortizingIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibdf0044ebfdf413bac60a2d162bc3800_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">dgx:TotalAmortizingIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia02c4586208e4e3ba284b0ed0d180568_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">dgx:TotalAmortizingIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i12811850249e482399304d53d433f814_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i16c67c4eb43e4026aebad131b1687d4c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i607e1bfaecc64044abfb3030ef16268d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:UnclassifiedIndefinitelivedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2e42f87022b0417485ee3c3cae380452_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:UnclassifiedIndefinitelivedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i73f9034273a34d5687d848b3ebe178b2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dgx:FourpointtwofivepercentSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iafc4f10dcb30465792e3db376f9db383_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dgx:FourpointtwofivepercentSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i36d2de3414984080b11b7ed1f9472589_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dgx:ThreePointFiveZeroPercentSeniorNotesdueMarch2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i35159921eda04fbdb92fa45ac28509d5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dgx:ThreePointFiveZeroPercentSeniorNotesdueMarch2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i744959a3bc17412a9e5af1fd1d359295_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dgx:ThreePointFourFivePercentSeniorNotesdueJune2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2d5ca1c0cd5d40019d0db21e80203f2c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dgx:ThreePointFourFivePercentSeniorNotesdueJune2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6e6f9e7f0256442db64c6fa43a0ced20_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dgx:FourPointTwoZeroPercentSeniorNotesdueJune2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie3b4fa91393e4b0e8d2f092086ab0bdf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dgx:FourPointTwoZeroPercentSeniorNotesdueJune2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7e13bac0fccd4f16898a65173f8a921b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dgx:TwoPointNineFivePercentSeniorNotesdueJune2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib1c4a18ddf92439da82f42ca78db7257_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dgx:TwoPointNineFivePercentSeniorNotesdueJune2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3bb1349879f5435fa9e912e4cf525b01_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dgx:TwoPointEightZeroPercentSeniorNotesDueJune2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i42e6dc0040114c70b13940e177bb3b1f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dgx:TwoPointEightZeroPercentSeniorNotesDueJune2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iae49dd1a44e743bdb49b617b9cfbaed7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dgx:SixPointNineFivePercentSeniorNotesDue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6b3b2a9d05bf465db9db7f32f4c7f461_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dgx:SixPointNineFivePercentSeniorNotesDue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2eb4e252832c4cd59e4e6274194a0627_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dgx:FivePointSevenFivePercentSeniorNotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8c8de336b3a044bfa41bbd2480192421_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dgx:FivePointSevenFivePercentSeniorNotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifaf7d8fd470f4603bcbefc2804dc479c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dgx:FourPointSevenZeroPercentSeniorNotesdueMarch2045Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i04b933ae20f7405ea1d07a3a04b5d06a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dgx:FourPointSevenZeroPercentSeniorNotesdueMarch2045Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3e9c816b535f468b832f1fb4f7578811_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dgx:FinanceLeaseObligationsandOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3f456f42e2b64e4cb74fbc8ba3ba7668_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dgx:FinanceLeaseObligationsandOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie3e292d5aced49a991453002828a13bf_D20221001-20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="i2473c6e1cff643f4807fa97482f2514c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7ee94c3ad75540f2895fbc6c74806807_I20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="id3f22fe062a74e759fbf551f8c1b5809_I20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">dgx:LoanCommitmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="ia223c678f59d4b39a7af63150694192c_I20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="i03277559f860449c9b5e26471a9ae119_D20221001-20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">dgx:CommercialPaperAndTermSecuredOvernightFinancingRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="i71d143709b514b99a2a4f28f2a601632_D20221001-20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">dgx:CommercialPaperAndTermSecuredOvernightFinancingRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="ibf24b8c7cb904d33aca6b6f9275180b7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8e3820f04333496f8fc57291a5c51523_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ied9b303df1ae4f6daa7db9f2e1d5d9f0_I20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dgx:SeniorunsecuredrevolvingcreditfacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="iba1e578b1a6c4c79882ebb5fa88eae23_I20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dgx:SeniorunsecuredrevolvingcreditfacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="if73e958db14b401a8087839f76ce387c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dgx:SeniorunsecuredrevolvingcreditfacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if79143d725024a98b36d4ee85edf5cee_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dgx:SeniorunsecuredrevolvingcreditfacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i723c452601804300bcd7029176377b7a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0b93c42f53bc4c24b90b5c3989b66730_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i04612297cd0342579339c26a21934632_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i60fd27e051b74dd08de8773691041dd4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4fe1409e54674ca0be0e82d1932f97ca_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6f4546cb1b9c4a1693b7d8224d2b29b1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icb6d00d91a6d489898ca322307bd7551_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib7a65c0363624e68becc030a94a0ab77_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4c59c3612c6041ba80e0a3204b427ce3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i78646261649e4ab5b1d6101a7499cb08_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dgx:OtherEquityComponentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i78b2c70c8a144740bff9b6549c2df838_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i339059f763014b84a165529202925717_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i35e31e8eeed44389aab551248c319740_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if8a22be73b2240fe97a3e930cdf33583_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dgx:OtherEquityComponentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id1a47bc1d3184e49a881195d814db2bc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2e971db364844d9d9d8d92ab27c1ed37_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i90b395d6ce534de0bc8b53e2fca569ff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iafd3f192541f4ebabada939564433870_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dgx:OtherEquityComponentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i06cf1391d00e4b208aa2ec8b206f2b32_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia1a523db0fd148b6b27ba256f8d6079a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i580c408beba54cb7a6726b2b9bdd3f50_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2c1a794ae52b4383b4bd9c5a8df17404_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dgx:OtherEquityComponentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4ebd65fb3e6947f2a405a8aeaf512a19_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id7541d2de1e4457b8836169fd42ffe28_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0788f175bb734eec93e8a4d7abcbb8e0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i38b5a632e224465fb4d85fbc4eff5dd8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dgx:OtherEquityComponentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i66bf6627917044748f98d7c18e1307e2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i109b68d4a89d48ec97b242717a341fdf_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i933dedd678a149a484d0a02f4c2d33e0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7a52a88c88684f908d9a67c0b1361c4e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dgx:OtherEquityComponentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i71a45e6a745e4ddf8252c87f04dd758e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1423840c822742dc9fdf987c08a9badf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib4cc611bd437409a9457b4e8ca870211_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i920e105da0ab40dcba086a031fe03430_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dgx:OtherEquityComponentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6e808f2e2e6543d1a2b3a31c4bb749dc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia40f541edc5a4e009d95c57cd1bcb927_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie092f7c613574f36ac6303f206cea249_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7f7bde7107be4688966df19bafdeea10_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib70de56c8cc94b818521ce47775ed911_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5bb911fffd174a0aa2ac5f0facc0999e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic46672a2c9fc4d0e990f241632df20c6_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib82daccc7a0640b288f5167661d2539c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ida73f1775008469a8c0cf852ee5a1c29_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id98e1b95cd5d4adf98b2c4cb2f733c61_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i145904e8a701484d92f0e52d1adeca1f_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8aae4e22f3264196b0bfa35291c77a16_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i62fbbac4e0dc4fa697878a348ac0758e_I20230202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-02</instant>
        </period>
    </context>
    <context id="ia76a036d7fa340e7b4834c31bf563b49_D20230101-20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="ie4d8aae1ad91426ab8c1e84816ea8730_D20220201-20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="ic235750c5b474440bd8465c5df75988a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">dgx:AcceleratedShareRepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i47113d1bbe9f4fea9bec3bbe1f7f5d91_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">dgx:AcceleratedShareRepurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i73f261b4c48d49e994b979548d66b542_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dgx:EmployeeLongTermIncentivePlanEltipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idca3214cc24d4df2accb5f1aee19ee63_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dgx:EmployeeLongTermIncentivePlanEltipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8ad2a8b3713f4742b9996055520adc29_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dgx:RestatedDirectorLongTermIncentivePlanDltipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic372c83c8186472099c6d4d6461f9670_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dgx:RestatedDirectorLongTermIncentivePlanDltipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2e67e2f9ed6e486593285a490abea14a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dgx:RestatedDirectorLongTermIncentivePlanDltipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9a2a79f2f8da4bf5859f277ed9314d52_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dgx:RestatedDirectorLongTermIncentivePlanDltipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie7fd18a6db5a4c6bb7e209edcc7ba998_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iecaf266ba15d4c5da2f6be8c3e8e76bd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0c80ac26791d4a08826451cfe6ab22a4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if4c31ce97f0b4d679967210dea5d4ce8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i50195984ca72444b94471a4f11e6b415_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0800ecbb791747f4ad71925d6e8c45e7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dgx:PerformanceShareUnitsWithMarketBasedRelativeTSRGoalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i94c763d3175548ab80e291e8d327ea98_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dgx:PerformanceShareUnitsWithMarketBasedRelativeTSRGoalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i066c181da1cc4104bc13332037ebc51c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dgx:PerformanceShareUnitsWithMarketBasedRelativeTSRGoalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia3870621ff0c4e94a8c0db30f0a94950_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dgx:StockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2a773294c9f247f4b61dc287d74d2f4a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dgx:StockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0f2ed080770b4b799d26a7b0773c6afa_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dgx:StockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i532fc9e0076b4da684698168d99ecf57_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dgx:StockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0859d2d438a749bd85c7c9580402ecc9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dgx:StockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3510a40b3f92452ca5683687a18ac5b5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dgx:StockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i173f1992d3144e31a2d74876e89770d5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dgx:StockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9cf6871cc3fb4fc7964b07d9e8dd6df6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0d352bd28a45443e80612ac16c512e54_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i061fddd15a744d87ae3c69a6d735a09b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9bef679f049f4a7589e81ff16e6faf39_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3984e240129249f2b9f78c9c4f3a1818_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">dgx:SupplementalDeferredCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6bf42c10d101437f98e7eac589472f72_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">dgx:SupplementalDeferredCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i70242db0befe4ca299c35c570e02ae70_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">dgx:SupplementalDeferredCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id56d32d3a5174c0f9f67b3b882cf8826_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">dgx:SupplementalDeferredCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icf5e6c8d02cb4230b46883164090ae6c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">dgx:SdcpIiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idd8f2aef04fc44bc86451fb4062847cc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">dgx:SdcpIiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie1765ce7329f47f2a55b699f67f431bf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">dgx:SdcpIiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1b69605427b24c3290b808836c99ad60_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">dgx:SdcpIiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie85140ba27db46a5a05080eae640b00a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibb34a0a60bd547a58f8634a55d3ea6e9_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="i665754908631467fb2b6eca930750884_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic5336086104449ec9ccb20ce787e8fa9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib687289786894660a55bf2477787ca9e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie4aca837d0034736866ba4562ecf3fff_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3ea9a777ccce400dadb97bbedd6fb6f4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i810fd9c44b7c42e0aef7f96144b246dd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie440446d54134ae79c1720e049889ebd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:RoutineclinicaltestingservicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibd0d2af9458945a7ab9a6eb6470b7961_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:RoutineclinicaltestingservicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8b73fe03ff7442f4bd575024a507e151_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:RoutineclinicaltestingservicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i641939e760e747a197a3088d7c7a54e4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:COVID19TestingServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i89453a368ad04b51b87732034e68487c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:COVID19TestingServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0c23351df28247d08a300337a2d833f5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:COVID19TestingServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3eee41bc2ea54b62a9ae3435b8b4aaa4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:GenebasedandesoterictestingservicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i57003099795448e795abfddd003aa4e2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:GenebasedandesoterictestingservicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7aec35972bb74cfb959afd84e8d0cffb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:GenebasedandesoterictestingservicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i726866d00c5c49f1bfa820096ee409a8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:AnatomicpathologytestingservicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i12a2b45922a846d39e944bbd98829c1c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:AnatomicpathologytestingservicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i258b629fbed9441ea0961341779923f0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:AnatomicpathologytestingservicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i862341280d314ae3b1668f3553ff24f3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:AllotherservicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iba77f4a14ac549e4ad21be96084cdd06_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:AllotherservicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7d5572f43c3845b0af34754ce6041d2b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dgx:AllotherservicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV80L2ZyYWc6YWY1ZjAyODE4MjgzNDgyM2E5MWU2MTExMzI3YjMxODgvdGFibGU6MmQ1MjgyZjI0ZDQ4NGYwNGIyMTM5YWRmMzM1MzU1ZTEvdGFibGVyYW5nZToyZDUyODJmMjRkNDg0ZjA0YjIxMzlhZGYzMzUzNTVlMV8yLTEtMS0xLTc4MjE1_91585d3e-54db-4841-abc3-210c9ad43b0e">0001022079</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV80L2ZyYWc6YWY1ZjAyODE4MjgzNDgyM2E5MWU2MTExMzI3YjMxODgvdGFibGU6MmQ1MjgyZjI0ZDQ4NGYwNGIyMTM5YWRmMzM1MzU1ZTEvdGFibGVyYW5nZToyZDUyODJmMjRkNDg0ZjA0YjIxMzlhZGYzMzUzNTVlMV80LTEtMS0xLTc4MjE1_f4be097a-db01-4239-bf65-ba40cede5c3a">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV80L2ZyYWc6YWY1ZjAyODE4MjgzNDgyM2E5MWU2MTExMzI3YjMxODgvdGFibGU6MmQ1MjgyZjI0ZDQ4NGYwNGIyMTM5YWRmMzM1MzU1ZTEvdGFibGVyYW5nZToyZDUyODJmMjRkNDg0ZjA0YjIxMzlhZGYzMzUzNTVlMV81LTEtMS0xLTc4MjE1_7cb635d1-1f4f-4d64-a84e-43fc29c85113">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV80L2ZyYWc6YWY1ZjAyODE4MjgzNDgyM2E5MWU2MTExMzI3YjMxODgvdGFibGU6MmQ1MjgyZjI0ZDQ4NGYwNGIyMTM5YWRmMzM1MzU1ZTEvdGFibGVyYW5nZToyZDUyODJmMjRkNDg0ZjA0YjIxMzlhZGYzMzUzNTVlMV82LTEtMS0xLTc4MjE1_9dd7a89c-4481-47b8-94f6-4686d30e7ff9">false</dei:AmendmentFlag>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i47d0ec07fa9b492b8d1144a50f6eb621_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzE1MDA1_cf798870-e9ec-4915-8333-6fffdab241e2">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i2d8ec938f1c4401ea9c7bd969cee4119_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzE1MjE1_15232aa9-a205-41d3-834e-46d37c844c97">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i4a8532c66ad64ac990f07caabad868b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzE5MDc3_e109cd52-340f-452f-8421-53cd708ea892">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i97cb2aca70ed4416839a2cd2c733918e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODEvZnJhZzoxZjJiYjBkMDExZWQ0ZjA4YWM5MmI5Y2FlOWJlNzY5ZS90YWJsZTpkZGFhYmJjNjQ2MTU0M2ZjYTlhOWY3OWU2YTcwOWUzMy90YWJsZXJhbmdlOmRkYWFiYmM2NDYxNTQzZmNhOWE5Zjc5ZTZhNzA5ZTMzXzEtMS0xLTEtNzgyMTU_37b4c223-e872-4eb6-a8c3-d223241460ff">P31Y6M</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NDc_562c010d-bbaa-4f52-a8ac-de2660c01cb7">http://fasb.org/us-gaap/2022#OperatingLeaseRightOfUseAsset</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NDc_da6e8994-01f0-4a9a-83e2-083574a1b91f">http://fasb.org/us-gaap/2022#OperatingLeaseRightOfUseAsset</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTQ_323fe1c8-01d7-47a9-afae-473da3defda0">http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTQ_4bd99473-36cb-4abf-841b-9d98e467569f">http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTU_6f606824-b677-4250-a7ed-24f9f3915ac5">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTU_8ee62599-1731-4db2-b098-6e0dac4293f9">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzEyLTItMS0xLTc4MjE1_1c2a9643-64b7-48eb-992f-a3efa9e86f06">http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligations</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzEyLTItMS0xLTc4MjE1_5bf1d7b4-f29c-4002-9627-e2075dfadeb9">http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligations</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGV4dHJlZ2lvbjpmNDI4MzBjYWUyYTc0NTQzOWYyOTc2YjkzOWEyOGE0ZF8zMTMy_c5cf6507-eb8f-42f2-a811-ae34dd81d848">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGV4dHJlZ2lvbjpmNDI4MzBjYWUyYTc0NTQzOWYyOTc2YjkzOWEyOGE0ZF8zMTMz_90e87ded-471f-4ad6-bb35-89f8b0f72cfa">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGV4dHJlZ2lvbjpmNDI4MzBjYWUyYTc0NTQzOWYyOTc2YjkzOWEyOGE0ZF8yMTM_7fd8955e-88b1-49ad-8728-f5253fdaded5">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGV4dHJlZ2lvbjpmNDI4MzBjYWUyYTc0NTQzOWYyOTc2YjkzOWEyOGE0ZF8yMTM_b17903c8-ce99-4874-a9b9-3d18daec9147">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGV4dHJlZ2lvbjpmNDI4MzBjYWUyYTc0NTQzOWYyOTc2YjkzOWEyOGE0ZF8zMTI4_097a5f81-1fdd-4617-88a4-51f4543ab614">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGV4dHJlZ2lvbjpmNDI4MzBjYWUyYTc0NTQzOWYyOTc2YjkzOWEyOGE0ZF8zMTM0_b3906759-1f08-49f6-ad4a-b2648aad4d86">001-12215</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGV4dHJlZ2lvbjpmNDI4MzBjYWUyYTc0NTQzOWYyOTc2YjkzOWEyOGE0ZF8zMTI5_4400ffb2-149e-4682-a878-6d5283880aa8">Quest Diagnostics Inc</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGFibGU6ZjJkNjA4NjJhYWExNDkwZmE4ZDE2N2QyZmU5YWIwMTcvdGFibGVyYW5nZTpmMmQ2MDg2MmFhYTE0OTBmYThkMTY3ZDJmZTlhYjAxN18wLTAtMS0xLTc4MjE1_1d2b8469-99d2-4736-81e2-d09cd9a61985">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGFibGU6ZjJkNjA4NjJhYWExNDkwZmE4ZDE2N2QyZmU5YWIwMTcvdGFibGVyYW5nZTpmMmQ2MDg2MmFhYTE0OTBmYThkMTY3ZDJmZTlhYjAxN18wLTUtMS0xLTc4MjE1_555f75bb-7579-47c5-a6c2-085526a43558">16-1387862</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGFibGU6ZjJkNjA4NjJhYWExNDkwZmE4ZDE2N2QyZmU5YWIwMTcvdGFibGVyYW5nZTpmMmQ2MDg2MmFhYTE0OTBmYThkMTY3ZDJmZTlhYjAxN18yLTAtMS0xLTc4MjE1_a31569f3-812b-4e42-ab31-0418a3d06519">500 Plaza Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGFibGU6ZjJkNjA4NjJhYWExNDkwZmE4ZDE2N2QyZmU5YWIwMTcvdGFibGVyYW5nZTpmMmQ2MDg2MmFhYTE0OTBmYThkMTY3ZDJmZTlhYjAxN18zLTAtMS0xLTc4MjE1_16e998d1-b669-4246-a99f-3ceb47d70a80">Secaucus,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGFibGU6ZjJkNjA4NjJhYWExNDkwZmE4ZDE2N2QyZmU5YWIwMTcvdGFibGVyYW5nZTpmMmQ2MDg2MmFhYTE0OTBmYThkMTY3ZDJmZTlhYjAxN18zLTEtMS0xLTc4MjE1_7563b9b1-6d81-4460-b5bc-4612295d4c40">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGFibGU6ZjJkNjA4NjJhYWExNDkwZmE4ZDE2N2QyZmU5YWIwMTcvdGFibGVyYW5nZTpmMmQ2MDg2MmFhYTE0OTBmYThkMTY3ZDJmZTlhYjAxN18zLTItMS0xLTc4MjE1_13c7e0ad-a2bc-4596-88f1-a5384a3593de">07094</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGFibGU6ZjJkNjA4NjJhYWExNDkwZmE4ZDE2N2QyZmU5YWIwMTcvdGFibGVyYW5nZTpmMmQ2MDg2MmFhYTE0OTBmYThkMTY3ZDJmZTlhYjAxN180LTAtMS0xLTc4MjE1_ba3bb5ca-6983-4f57-b65c-bcb7a446c6df">(973)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGFibGU6ZjJkNjA4NjJhYWExNDkwZmE4ZDE2N2QyZmU5YWIwMTcvdGFibGVyYW5nZTpmMmQ2MDg2MmFhYTE0OTBmYThkMTY3ZDJmZTlhYjAxN180LTEtMS0xLTc4MjE1_cb5c9ff5-3fdf-481c-a9a9-9ba6ed11e9fd">520-2700</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGFibGU6ZDg0Y2RjY2RhMTU2NDFhY2I5NjE4ZmI2MmIxNDhhZWYvdGFibGVyYW5nZTpkODRjZGNjZGExNTY0MWFjYjk2MThmYjYyYjE0OGFlZl8yLTAtMS0xLTc4MjE1_1001dc50-d053-4648-b453-6d38d5e9745f">Common Stock, $.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGFibGU6ZDg0Y2RjY2RhMTU2NDFhY2I5NjE4ZmI2MmIxNDhhZWYvdGFibGVyYW5nZTpkODRjZGNjZGExNTY0MWFjYjk2MThmYjYyYjE0OGFlZl8yLTEtMS0xLTc4MjE1_59879241-71aa-4ef8-8e46-c33df4c494c4">DGX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGFibGU6ZDg0Y2RjY2RhMTU2NDFhY2I5NjE4ZmI2MmIxNDhhZWYvdGFibGVyYW5nZTpkODRjZGNjZGExNTY0MWFjYjk2MThmYjYyYjE0OGFlZl8yLTItMS0xLTc4MjE1_a85e2454-777b-480a-885f-b64c43e7a8fa">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGV4dHJlZ2lvbjpmNDI4MzBjYWUyYTc0NTQzOWYyOTc2YjkzOWEyOGE0ZF8zMTMw_d7980b85-930f-4222-b199-74da75ed9a12">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGV4dHJlZ2lvbjpmNDI4MzBjYWUyYTc0NTQzOWYyOTc2YjkzOWEyOGE0ZF8zMTMx_60893030-becd-4488-b00a-9def618df16e">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGV4dHJlZ2lvbjpmNDI4MzBjYWUyYTc0NTQzOWYyOTc2YjkzOWEyOGE0ZF8zMTM1_840d73d1-c653-4260-b09e-3e32c6de7dd3">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGV4dHJlZ2lvbjpmNDI4MzBjYWUyYTc0NTQzOWYyOTc2YjkzOWEyOGE0ZF8zMTM2_ad83f22f-53cc-4a5a-846a-a68b95f78899">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGFibGU6Y2Y5YTU2Y2E1ZmI0NDYzYzk5NDlkNzI1Y2VhMzUyZGQvdGFibGVyYW5nZTpjZjlhNTZjYTVmYjQ0NjNjOTk0OWQ3MjVjZWEzNTJkZF8wLTAtMS0xLTc4MjE1_d2664f5a-70b8-4aa2-9ec3-8a36fb2a840d">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGFibGU6Y2Y5YTU2Y2E1ZmI0NDYzYzk5NDlkNzI1Y2VhMzUyZGQvdGFibGVyYW5nZTpjZjlhNTZjYTVmYjQ0NjNjOTk0OWQ3MjVjZWEzNTJkZF8xLTMtMS0xLTc4MjE1_e12f43e4-d81c-4604-894f-27cbe49e33c5">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGFibGU6Y2Y5YTU2Y2E1ZmI0NDYzYzk5NDlkNzI1Y2VhMzUyZGQvdGFibGVyYW5nZTpjZjlhNTZjYTVmYjQ0NjNjOTk0OWQ3MjVjZWEzNTJkZF8yLTMtMS0xLTc4MjE1_aa22cb16-b670-497e-a768-9565fbddeb96">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGV4dHJlZ2lvbjpmNDI4MzBjYWUyYTc0NTQzOWYyOTc2YjkzOWEyOGE0ZF8zMTM3_150a2cde-6597-4316-9b1a-b7fd8bf46fe5">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGV4dHJlZ2lvbjpmNDI4MzBjYWUyYTc0NTQzOWYyOTc2YjkzOWEyOGE0ZF8zMTM4_7337230f-cf48-49c5-b47b-ea9f153f5403">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i1477f11899e948a2a39ffb87d82e1e57_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGV4dHJlZ2lvbjpmNDI4MzBjYWUyYTc0NTQzOWYyOTc2YjkzOWEyOGE0ZF8yNzUx_b726cc5a-fb75-4788-b884-ab5c0d730f16"
      unitRef="usd">15400000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i39a01f81398e4a8bb499e63010bd00dc_I20230131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGV4dHJlZ2lvbjpmNDI4MzBjYWUyYTc0NTQzOWYyOTc2YjkzOWEyOGE0ZF8yODkz_7d91676a-35cb-40e4-b751-02ef480dad8a"
      unitRef="shares">111323003</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xL2ZyYWc6ZjQyODMwY2FlMmE3NDU0MzlmMjk3NmI5MzlhMjhhNGQvdGFibGU6OGEwMjA2ZWViMmM2NDc4MWJhOWQxNTEzOTk0MzE0YTYvdGFibGVyYW5nZTo4YTAyMDZlZWIyYzY0NzgxYmE5ZDE1MTM5OTQzMTRhNl8yLTAtMS0xLTc4MjE1_787fdce9-0494-4a9b-ac7b-6e01fd253869">Portions of the registrant's Proxy Statement to be filed by April&#160;30, 2023</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV83Ni9mcmFnOjY3ZWM2OWRlYjY5ZjQyYTQ4NjViOTAzN2QwMmIwOGQyL3RleHRyZWdpb246NjdlYzY5ZGViNjlmNDJhNDg2NWI5MDM3ZDAyYjA4ZDJfMTA5OTUxMTYzMjUxNw_293e45b4-5299-4374-a527-94d1b6f55e1c"
      unitRef="usd">300000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <dgx:StockRepurchaseProgramAdditionalAmountAuthorized
      contextRef="i6f31e868418c42c5abbd3bb28b8a4277_D20230202-20230202"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV83Ni9mcmFnOjY3ZWM2OWRlYjY5ZjQyYTQ4NjViOTAzN2QwMmIwOGQyL3RleHRyZWdpb246NjdlYzY5ZGViNjlmNDJhNDg2NWI5MDM3ZDAyYjA4ZDJfMTA5OTUxMTYzMjY4NA_67132518-25f7-4e9d-ad3c-8ea05c8a28e2"
      unitRef="usd">1000000000</dgx:StockRepurchaseProgramAdditionalAmountAuthorized>
    <dei:AuditorFirmId
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xMjQvZnJhZzo0MzNjOWRhZDU3MTQ0NzM1OWJkNTI3NDViZWJlZDM5Ny90YWJsZTowNGIyMGRjMDFiNDM0YTE3OTM2N2M3NTUxYmEyMmQ4Ni90YWJsZXJhbmdlOjA0YjIwZGMwMWI0MzRhMTc5MzY3Yzc1NTFiYTIyZDg2XzItMC0xLTEtNzgyMTUvdGV4dHJlZ2lvbjpmMmU2N2Y3NzI5MTE0OTRmOWJkODViM2VjZDIwODI2Nl83MA_6d5bbdcf-5a98-402d-8a31-e4887c718544">238</dei:AuditorFirmId>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xMzkvZnJhZzpjZGQzYWY5YmY0YmY0ZWIwOTEwNWFkOTA2NWMyNTQ3MC90ZXh0cmVnaW9uOmNkZDNhZjliZjRiZjRlYjA5MTA1YWQ5MDY1YzI1NDcwXzEyNzk_2bc3b26c-e382-4a0b-bef0-4ed6237cd75b"
      unitRef="usd">3700000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xMzkvZnJhZzpjZGQzYWY5YmY0YmY0ZWIwOTEwNWFkOTA2NWMyNTQ3MC90ZXh0cmVnaW9uOmNkZDNhZjliZjRiZjRlYjA5MTA1YWQ5MDY1YzI1NDcwXzEyODY_9bdf270d-3ffc-4bae-b633-93740f8d7ce8"
      unitRef="usd">4400000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="icb3e78d19c4a46b8a67dec2f47339bab_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xMzkvZnJhZzpjZGQzYWY5YmY0YmY0ZWIwOTEwNWFkOTA2NWMyNTQ3MC90ZXh0cmVnaW9uOmNkZDNhZjliZjRiZjRlYjA5MTA1YWQ5MDY1YzI1NDcwXzU0OTc1NTgyMTg3Mw_9d68e870-1bbd-4dc2-ab20-244ae1b75149"
      unitRef="number">0.00725</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i56456ee32fec497ca7d092cc9d8721eb_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xMzkvZnJhZzpjZGQzYWY5YmY0YmY0ZWIwOTEwNWFkOTA2NWMyNTQ3MC90ZXh0cmVnaW9uOmNkZDNhZjliZjRiZjRlYjA5MTA1YWQ5MDY1YzI1NDcwXzU0OTc1NTgyMTg4MQ_d6ba1c2c-bfa2-4cbd-bfd7-ff2d4fa62b82"
      unitRef="number">0.0080</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="iec0fa8127aa846ccb173e5c0dac001e5_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xMzkvZnJhZzpjZGQzYWY5YmY0YmY0ZWIwOTEwNWFkOTA2NWMyNTQ3MC90ZXh0cmVnaW9uOmNkZDNhZjliZjRiZjRlYjA5MTA1YWQ5MDY1YzI1NDcwXzI3MzY_8c5d2d00-c19d-48ec-b417-afdbfd124f59"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="iddbc623b9422462099ee73f0b8dd8181_I20221021"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xMzkvZnJhZzpjZGQzYWY5YmY0YmY0ZWIwOTEwNWFkOTA2NWMyNTQ3MC90ZXh0cmVnaW9uOmNkZDNhZjliZjRiZjRlYjA5MTA1YWQ5MDY1YzI1NDcwXzI4MDU_c0286930-2613-4925-b9ff-937a812ab798"
      unitRef="usd">525000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <dei:AuditorName
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTEvZnJhZzpiYzJlOTdkYzAxOWY0MmUyOGMwZmQ0YmM5NmE1M2Y1Ni90YWJsZTpjMWEwYWY5YjFkZWI0ODA4ODEyZWI5NDllOTVkYTQwYi90YWJsZXJhbmdlOmMxYTBhZjliMWRlYjQ4MDg4MTJlYjk0OWU5NWRhNDBiXzAtMS0xLTEtNzgyMTU_111e0d85-f858-4afb-9319-543c6d3aff81">PricewaterhouseCoopers LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTEvZnJhZzpiYzJlOTdkYzAxOWY0MmUyOGMwZmQ0YmM5NmE1M2Y1Ni90YWJsZTpjMWEwYWY5YjFkZWI0ODA4ODEyZWI5NDllOTVkYTQwYi90YWJsZXJhbmdlOmMxYTBhZjliMWRlYjQ4MDg4MTJlYjk0OWU5NWRhNDBiXzItMS0xLTEtNzgyMTU_227518e1-1223-403c-a849-eba35b35324a">Florham Park, New Jersey</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzMtMS0xLTEtNzgyMTU_d44d30f3-7f12-43e8-ba0d-ddfa8c9a7a01"
      unitRef="usd">315000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzMtMy0xLTEtNzgyMTU_4ba70290-7550-44fc-9df6-2fc95a5b1097"
      unitRef="usd">872000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzQtMC0xLTEtNzgyMTUvdGV4dHJlZ2lvbjphNWQ4MmMwYzE3Zjk0YWQwYmFhNmQ1ZTJhN2ZmMWVjYl82NA_6b4b212f-9c0f-453b-9a0b-49cc5844852a"
      unitRef="usd">30000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzQtMC0xLTEtNzgyMTUvdGV4dHJlZ2lvbjphNWQ4MmMwYzE3Zjk0YWQwYmFhNmQ1ZTJhN2ZmMWVjYl83MQ_dcc85d5f-5b36-4ad8-a8ac-03370711b610"
      unitRef="usd">31000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzQtMS0xLTEtNzgyMTU_02ac65d8-3cf5-4d6b-b594-df120f53acfc"
      unitRef="usd">1195000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzQtMy0xLTEtNzgyMTU_f55b9f7e-3dc5-4451-9ace-1e3a428eb084"
      unitRef="usd">1438000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzUtMS0xLTEtNzgyMTU_db9cf3eb-2b71-486b-abbb-8a776512f31b"
      unitRef="usd">192000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzUtMy0xLTEtNzgyMTU_d5a29e58-fbc2-4815-958d-48e9d01cc5f8"
      unitRef="usd">208000000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzYtMS0xLTEtNzgyMTU_48ca8822-1884-4ae9-92e2-1fa7c745c1f7"
      unitRef="usd">196000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzYtMy0xLTEtNzgyMTU_303bc50f-8b50-411d-be46-826c0b3be023"
      unitRef="usd">223000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzgtMS0xLTEtNzgyMTU_4c6642ca-4dce-4e25-81f9-4084a9eab3a4"
      unitRef="usd">1898000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzgtMy0xLTEtNzgyMTU_486eea32-f9b7-46d5-a7ea-f5afdcf8f63e"
      unitRef="usd">2741000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzktMS0xLTEtNzgyMTU_4f2be92f-f923-440a-8f88-5fee867306c4"
      unitRef="usd">1766000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzktMy0xLTEtNzgyMTU_3934127b-21ce-4e16-bd57-1e15c9fc441e"
      unitRef="usd">1707000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzEwLTEtMS0xLTc4MjE1_2a23607f-5be3-47e1-9cae-bca10fc2296d"
      unitRef="usd">585000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzEwLTMtMS0xLTc4MjE1_cb359a95-9e69-4431-88d0-090d0e0bf8a8"
      unitRef="usd">597000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzExLTEtMS0xLTc4MjE1_6ad963f7-ddcf-4e08-bfc1-7046d4d32533"
      unitRef="usd">7220000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzExLTMtMS0xLTc4MjE1_0f232e8e-8817-4043-8b6b-dd897e0e704a"
      unitRef="usd">7095000000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzEyLTEtMS0xLTc4MjE1_69a14998-ecdd-4a4c-905e-175c5e480826"
      unitRef="usd">1092000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzEyLTMtMS0xLTc4MjE1_fb3070fa-6419-40af-8149-b23862ffe7ed"
      unitRef="usd">1167000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:EquityMethodInvestments
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzEzLTEtMS0xLTc4MjE1_3f2e0f2a-5a70-4b48-8ffe-32d0d9f74709"
      unitRef="usd">132000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzEzLTMtMS0xLTc4MjE1_ac73b6f4-cef9-41c1-845c-57bc0fabdfca"
      unitRef="usd">141000000</us-gaap:EquityMethodInvestments>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzE0LTEtMS0xLTc4MjE1_5bd68357-20e6-4c53-b305-69e5c65ec49c"
      unitRef="usd">144000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzE0LTMtMS0xLTc4MjE1_c09eba8d-26f0-4b5e-82df-a8f0763b3fbd"
      unitRef="usd">163000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzE2LTEtMS0xLTc4MjE1_4b84a61d-cf27-4d4b-baaa-a67c183e444a"
      unitRef="usd">12837000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzE2LTMtMS0xLTc4MjE1_70e93a04-f780-4cad-929d-8fe6c779483c"
      unitRef="usd">13611000000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzIwLTEtMS0xLTc4MjE1_4dcc085d-dbee-4123-94dd-ced950550f8d"
      unitRef="usd">1396000000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzIwLTMtMS0xLTc4MjE1_173ca221-4d64-4a01-b049-570e57593d06"
      unitRef="usd">1600000000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzIxLTEtMS0xLTc4MjE1_5f49b4b6-9c69-45cf-a195-cdf1fe6f0d80"
      unitRef="usd">2000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzIxLTMtMS0xLTc4MjE1_af45c9a6-ea43-4003-b788-8a492ef8e7f1"
      unitRef="usd">2000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzIyLTEtMS0xLTc4MjE1_a3d89de6-36cf-40a1-9c93-6d6c0d00227a"
      unitRef="usd">153000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzIyLTMtMS0xLTc4MjE1_8cf94bb0-81a8-4478-b077-1ecd3298d268"
      unitRef="usd">151000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzIzLTEtMS0xLTc4MjE1_e5da209b-f017-4be1-ab7e-efbf99b8c0d6"
      unitRef="usd">1551000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzIzLTMtMS0xLTc4MjE1_12984ae9-9ed7-4881-aa43-970957ed62fb"
      unitRef="usd">1753000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzI0LTEtMS0xLTc4MjE1_4422fb2b-2593-4cbe-b6bc-0a664e2498fc"
      unitRef="usd">3978000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzI0LTMtMS0xLTc4MjE1_1837d8db-0eac-4240-bd15-3a149de33ebf"
      unitRef="usd">4010000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzI1LTEtMS0xLTc4MjE1_6432681c-e191-457e-bce8-501f8ce635a0"
      unitRef="usd">489000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzI1LTMtMS0xLTc4MjE1_00012651-b80e-4dd7-b499-134880ebf476"
      unitRef="usd">494000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzI2LTEtMS0xLTc4MjE1_7cd7d49d-cfff-4393-8f81-08add98f3085"
      unitRef="usd">812000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzI2LTMtMS0xLTc4MjE1_2fb07fc7-7c5b-4dea-8c81-85ada096c758"
      unitRef="usd">792000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzI4LTEtMS0xLTc4MjE1_d3dad885-6fbd-406a-be6a-d036cc7298de"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzI4LTMtMS0xLTc4MjE1_48d9dc67-752c-48d4-8bfe-968ad5f31b04"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzI5LTEtMS0xLTc4MjE1_eb3f1175-a5a5-4f16-8e16-ace03c4abf69"
      unitRef="usd">77000000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzI5LTMtMS0xLTc4MjE1_0aebb405-8cb4-4908-afb6-5854b9af29ef"
      unitRef="usd">79000000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzMyLTAtMS0xLTc4MjE1L3RleHRyZWdpb246NWI2ZGQ4ZjNjZTNkNGQ5ZDkyZGY4ZmY0MWFjMDNiNWRfMjg_82793bdf-7bc9-4a91-aed3-a5a1011c7214"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzMyLTAtMS0xLTc4MjE1L3RleHRyZWdpb246NWI2ZGQ4ZjNjZTNkNGQ5ZDkyZGY4ZmY0MWFjMDNiNWRfMjg_f4a71998-71c6-4557-a7c5-ae6a28fd6e2b"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzMyLTAtMS0xLTc4MjE1L3RleHRyZWdpb246NWI2ZGQ4ZjNjZTNkNGQ5ZDkyZGY4ZmY0MWFjMDNiNWRfNDI_09105e3b-1455-4ab8-ad01-71ee3d9c32a9"
      unitRef="shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzMyLTAtMS0xLTc4MjE1L3RleHRyZWdpb246NWI2ZGQ4ZjNjZTNkNGQ5ZDkyZGY4ZmY0MWFjMDNiNWRfNDI_9e793718-382f-46a0-8e76-a0c7e767821f"
      unitRef="shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzMyLTAtMS0xLTc4MjE1L3RleHRyZWdpb246NWI2ZGQ4ZjNjZTNkNGQ5ZDkyZGY4ZmY0MWFjMDNiNWRfMTA5_516fd8b7-3b26-4db5-b104-7da491f12012"
      unitRef="shares">162000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzMyLTEtMS0xLTc4MjE1_10de332d-65a4-402c-8357-9669929ffe08"
      unitRef="usd">2000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzMyLTMtMS0xLTc4MjE1_95536f01-5843-4b3e-8d95-fe91d0950492"
      unitRef="usd">2000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzMzLTEtMS0xLTc4MjE1_b584e495-6b10-4c79-9407-6663c21ed130"
      unitRef="usd">2295000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzMzLTMtMS0xLTc4MjE1_7442a6d8-0b6c-46b3-865a-7680d8fa779c"
      unitRef="usd">2260000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzM0LTEtMS0xLTc4MjE1_320dbf79-95aa-47fe-86ae-6d3929809441"
      unitRef="usd">8290000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzM0LTMtMS0xLTc4MjE1_c3fbb909-7d89-47c4-b838-978f112c7f4c"
      unitRef="usd">7649000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzM1LTEtMS0xLTc4MjE1_7add56e3-e204-44ef-a880-e6121f5dda1c"
      unitRef="usd">-21000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzM1LTMtMS0xLTc4MjE1_cd937d83-662c-4160-8464-1745f2ebe0e3"
      unitRef="usd">-14000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockShares
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzM2LTAtMS0xLTc4MjE1L3RleHRyZWdpb246NjhmMDY4ZjA3MDg1NGQ1ZmJkNThjZDY4NWVlYzRhZDNfMjk_97fb7526-2fd6-47a2-8db5-96f63b8ecb4f"
      unitRef="shares">51000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzM2LTAtMS0xLTc4MjE1L3RleHRyZWdpb246NjhmMDY4ZjA3MDg1NGQ1ZmJkNThjZDY4NWVlYzRhZDNfMzY_0aadbbdc-2d3c-472e-9ba7-4637f9582b3f"
      unitRef="shares">43000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzM2LTEtMS0xLTc4MjE1_5573647b-8a67-4bef-878b-c3f509622b2d"
      unitRef="usd">4673000000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzM2LTMtMS0xLTc4MjE1_d0a944bb-9c50-4c9d-be35-66d728f99739"
      unitRef="usd">3453000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzM3LTEtMS0xLTc4MjE1_739ef55d-dfaa-4f50-a283-c56079ce1e50"
      unitRef="usd">5893000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzM3LTMtMS0xLTc4MjE1_9ebd8697-77c2-4ce0-8b47-b2de33b7f255"
      unitRef="usd">6444000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzM4LTEtMS0xLTc4MjE1_66bbd0dd-1570-4df3-a308-4dab0dece8b3"
      unitRef="usd">37000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzM4LTMtMS0xLTc4MjE1_e1700b7f-11d7-4081-86f6-ba226bc1e6d3"
      unitRef="usd">39000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzM5LTEtMS0xLTc4MjE1_28d0504a-aa59-4aa1-b610-6c815a38382f"
      unitRef="usd">5930000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzM5LTMtMS0xLTc4MjE1_b7333bfc-3cc0-4584-a90e-fa48e5d9d2a8"
      unitRef="usd">6483000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzQwLTEtMS0xLTc4MjE1_655cabc0-d0cc-4278-ad14-8afc0d50508a"
      unitRef="usd">12837000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNTcvZnJhZzo1OWZhZWJlY2JiY2I0OWVlOTdkOTk0YjU0ZGU1MTIyMC90YWJsZTpkNDdhZDljNGY3NDI0NmVhOGE1MzFmYWEwMzJkODcxMC90YWJsZXJhbmdlOmQ0N2FkOWM0Zjc0MjQ2ZWE4YTUzMWZhYTAzMmQ4NzEwXzQwLTMtMS0xLTc4MjE1_c9b26607-3081-4869-8880-92f71c965c1b"
      unitRef="usd">13611000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzItMS0xLTEtNzgyMTU_efe8c69a-1447-48f9-843d-1aa2636890fd"
      unitRef="usd">9883000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzItMy0xLTEtNzgyMTU_91c407c7-6e63-47b0-ad58-fa5bfac4985b"
      unitRef="usd">10788000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzItNS0xLTEtNzgyMTU_54618871-584a-4fe1-82dd-f851ee2f2e06"
      unitRef="usd">9437000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzUtMS0xLTEtNzgyMTU_8620b7c1-24cd-4eaf-b350-ddb07a240e59"
      unitRef="usd">6450000000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzUtMy0xLTEtNzgyMTU_a96f69df-178c-4a44-a1dd-c386162dcb8b"
      unitRef="usd">6579000000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzUtNS0xLTEtNzgyMTU_6150efae-ee34-4da9-931e-d0b736c9f67e"
      unitRef="usd">5804000000</us-gaap:CostOfRevenue>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzYtMS0xLTEtNzgyMTU_a4d44fe9-4ecb-42a4-b19b-06d29d9898fb"
      unitRef="usd">1874000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzYtMy0xLTEtNzgyMTU_fb23e626-ab37-4205-9dc5-c4343d6042b1"
      unitRef="usd">1727000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzYtNS0xLTEtNzgyMTU_ce5fbf3c-9a2e-4a82-810c-1eab455b1807"
      unitRef="usd">1550000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzctMS0xLTEtNzgyMTU_e2fd5e9d-c40a-45ce-85b1-263a08026e06"
      unitRef="usd">120000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzctMy0xLTEtNzgyMTU_b824a99b-8850-4f0a-8a09-ea28e2ff3266"
      unitRef="usd">103000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzctNS0xLTEtNzgyMTU_91d5387f-8ade-4fcb-b60c-c939a42ba426"
      unitRef="usd">103000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzgtMS0xLTEtNzgyMTU_22b7c066-00bb-412d-a1e4-409ce0d82207"
      unitRef="usd">-11000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzgtMy0xLTEtNzgyMTU_da6a0a9f-182b-4afe-98db-56a6b6ef0327"
      unitRef="usd">2000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzgtNS0xLTEtNzgyMTU_722d3721-e783-4e47-ba59-8b3b328fc1dd"
      unitRef="usd">-9000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:CostsAndExpenses
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzktMS0xLTEtNzgyMTU_3101c8d1-4496-492d-85cf-8957ef878227"
      unitRef="usd">8455000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzktMy0xLTEtNzgyMTU_8e38ad44-3344-424a-9229-d1a13491accd"
      unitRef="usd">8407000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzktNS0xLTEtNzgyMTU_7b90a2f7-5f7c-4ead-9140-747b60f4ee8c"
      unitRef="usd">7466000000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzExLTEtMS0xLTc4MjE1_a396dd97-b9e0-4098-8221-d3cb487403d9"
      unitRef="usd">1428000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzExLTMtMS0xLTc4MjE1_9a3bca9f-e53e-4a19-9d4c-896de72c5d12"
      unitRef="usd">2381000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzExLTUtMS0xLTc4MjE1_e1e59cb2-caf7-4a1b-83cf-716f561d8d04"
      unitRef="usd">1971000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzE0LTEtMS0xLTc4MjE1_2484c687-6c6e-41d1-bdb7-51f05bae697a"
      unitRef="usd">-138000000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzE0LTMtMS0xLTc4MjE1_94b3e03a-fbf5-434c-8690-27d742942b93"
      unitRef="usd">-151000000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzE0LTUtMS0xLTc4MjE1_69b448b3-926a-44f9-b6ab-1d35e831bf94"
      unitRef="usd">-163000000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzE1LTEtMS0xLTc4MjE1_569f10c8-c009-43fd-9ebe-01728aa2d7b5"
      unitRef="usd">-55000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzE1LTMtMS0xLTc4MjE1_3f3ce883-02db-4662-9ec7-a2e93333f45a"
      unitRef="usd">369000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzE1LTUtMS0xLTc4MjE1_3fc93c78-4ffa-4752-9ca0-59dbf666ca08"
      unitRef="usd">76000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzE2LTEtMS0xLTc4MjE1_762e50aa-5e91-46b5-8d8c-f90c9c5d7bbf"
      unitRef="usd">-193000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzE2LTMtMS0xLTc4MjE1_829ce789-86b1-42a2-8508-509d2164afa0"
      unitRef="usd">218000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzE2LTUtMS0xLTc4MjE1_1d9cb710-c878-4bdf-866d-3612f7d8b954"
      unitRef="usd">-87000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzE4LTEtMS0xLTc4MjE1_f1d66541-6b7c-4a5d-8b95-44b567947104"
      unitRef="usd">1235000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzE4LTMtMS0xLTc4MjE1_2a2c7185-f222-47c7-9fb3-c89596ba2d11"
      unitRef="usd">2599000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzE4LTUtMS0xLTc4MjE1_2e662f83-1696-45b8-a545-054a5b07060c"
      unitRef="usd">1884000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzE5LTEtMS0xLTc4MjE1_d1fed1b9-9f1c-46a1-94f2-8f1fb0030980"
      unitRef="usd">264000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzE5LTMtMS0xLTc4MjE1_30c470a1-4439-4ba8-983f-275f9dbc402a"
      unitRef="usd">597000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzE5LTUtMS0xLTc4MjE1_5af5097d-f91b-4173-8fe9-b8576fe99f5b"
      unitRef="usd">460000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzIwLTEtMS0xLTc4MjE1_62327402-df7b-4e5b-b138-68dad07e93a1"
      unitRef="usd">44000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzIwLTMtMS0xLTc4MjE1_94d14ea2-60d9-49a9-9784-463a6182044b"
      unitRef="usd">78000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzIwLTUtMS0xLTc4MjE1_aeb36c21-d39a-408a-b66f-9677a2fd4ff4"
      unitRef="usd">75000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ProfitLoss
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzI1LTEtMS0xLTc4MjE1_a14360b7-f42e-4bf5-9563-f371ae9455db"
      unitRef="usd">1015000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzI1LTMtMS0xLTc4MjE1_31f29a98-a921-4f98-ab22-39f78bb9d52e"
      unitRef="usd">2080000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzI1LTUtMS0xLTc4MjE1_ecf66436-59b1-48ab-af3b-9aed111909e6"
      unitRef="usd">1499000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzI2LTEtMS0xLTc4MjE1_437619ce-8e8f-40a8-be51-8226bb3f9783"
      unitRef="usd">69000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzI2LTMtMS0xLTc4MjE1_42927960-86e6-496b-9d20-bc5ed521fb06"
      unitRef="usd">85000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzI2LTUtMS0xLTc4MjE1_fec8336a-9098-4e10-bfba-31a2dce5cf80"
      unitRef="usd">68000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzI3LTEtMS0xLTc4MjE1_266fbf2f-805c-4d79-bdcb-89d29da2625e"
      unitRef="usd">946000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzI3LTMtMS0xLTc4MjE1_da3aa183-af1b-4e86-bae8-96892871a86c"
      unitRef="usd">1995000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzI3LTUtMS0xLTc4MjE1_cda909b7-3f63-47a0-ae2f-c91755d7ac18"
      unitRef="usd">1431000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzM1LTEtMS0xLTc4MjE1_1217a075-4845-4761-82d9-18973d17e30d"
      unitRef="usdPerShare">8.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzM1LTMtMS0xLTc4MjE1_7842517a-4c4a-46ef-aa35-f3a8ab523c43"
      unitRef="usdPerShare">15.85</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzM1LTUtMS0xLTc4MjE1_450a1225-bbfa-4047-a130-804a63759f28"
      unitRef="usdPerShare">10.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzQwLTEtMS0xLTc4MjE1_3908523d-46cb-4184-bc7d-4257c2fd183b"
      unitRef="usdPerShare">7.97</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzQwLTMtMS0xLTc4MjE1_1de0acf7-a9ee-437f-a674-775da169bd4a"
      unitRef="usdPerShare">15.55</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjAvZnJhZzowYTJiZTA1MDI3NGI0ZTUwYTg4ODdiNzdkNmVkZTQ5MC90YWJsZToyNzRiOThjZTU3NjQ0NGEzYjY4YWU4N2Q2OTI1ZGQ1YS90YWJsZXJhbmdlOjI3NGI5OGNlNTc2NDQ0YTNiNjhhZTg3ZDY5MjVkZDVhXzQwLTUtMS0xLTc4MjE1_612983cc-cc57-408f-ba9d-eb29276a0254"
      unitRef="usdPerShare">10.47</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ProfitLoss
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzItMS0xLTEtNzgyMTU_a14360b7-f42e-4bf5-9563-f371ae9455db"
      unitRef="usd">1015000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzItMy0xLTEtNzgyMTU_107bfa50-dc1e-4f9c-9e89-e4b232c2d7ce"
      unitRef="usd">2080000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzItNS0xLTEtNzgyMTU_de454d06-b23f-4020-a7b6-51c9c0bb782f"
      unitRef="usd">1499000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzUtMS0xLTEtNzgyMTU_f5a6ded0-a4db-44e6-822f-261e66bb8bef"
      unitRef="usd">-8000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzUtMy0xLTEtNzgyMTU_46bb6296-3bbb-496a-8415-5ca8a7217193"
      unitRef="usd">13000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzUtNS0xLTEtNzgyMTU_f46eb879-6fec-42b6-ad8f-b2fb4d5567f4"
      unitRef="usd">15000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzYtMS0xLTEtNzgyMTU_83936c06-2a09-4c9a-8938-9958708b4376"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzYtMy0xLTEtNzgyMTU_381e7ab3-8554-496a-9e3e-b4a71d9a93c2"
      unitRef="usd">-7000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzYtNS0xLTEtNzgyMTU_1699cabc-0d8e-4230-bf70-3d3f508b4a32"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzctMS0xLTEtNzgyMTU_bced750f-cd49-4d6d-9124-ccdb86279437"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzctMy0xLTEtNzgyMTU_75d5ef97-ab42-427c-ae61-193483252db8"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzctNS0xLTEtNzgyMTU_bc705f09-f3ff-4df1-892e-a37856ce6d1f"
      unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzktMS0xLTEtNzgyMTU_41cf06a9-bbc8-4683-9fc0-8d4360925adc"
      unitRef="usd">-7000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzktMy0xLTEtNzgyMTU_ad545ae2-5a14-493b-8429-0ceb7c98386e"
      unitRef="usd">7000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzktNS0xLTEtNzgyMTU_1df25a9d-7d83-4481-8d2c-3f556ceb9d59"
      unitRef="usd">18000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzExLTEtMS0xLTc4MjE1_6046e592-2ec9-4630-9e9c-1eccad4e5d90"
      unitRef="usd">1008000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzExLTMtMS0xLTc4MjE1_dcd7b681-2702-47eb-a59b-abd3abc24403"
      unitRef="usd">2087000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzExLTUtMS0xLTc4MjE1_64256c53-66c0-46e0-828d-72d703108975"
      unitRef="usd">1517000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzEyLTEtMS0xLTc4MjE1_53e3aa4e-7cc3-4328-83b7-f79d9540a6ea"
      unitRef="usd">69000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzEyLTMtMS0xLTc4MjE1_6b7e651b-d1ee-4b2d-8d7f-f6272fc918c6"
      unitRef="usd">85000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzEyLTUtMS0xLTc4MjE1_93cdbba2-7014-492a-8c0b-8ee473fd5c12"
      unitRef="usd">68000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzEzLTEtMS0xLTc4MjE1_84d8f353-8d63-4f2b-9e9d-9d4df8c7e5dd"
      unitRef="usd">939000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzEzLTMtMS0xLTc4MjE1_83ff8fac-a670-43b5-b528-66525e247d10"
      unitRef="usd">2002000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjMvZnJhZzpjMGIzYjE2ZTc3ZjE0MzkwYjgxNmQxOGQ5YTgzODk4ZS90YWJsZTo1ODA0ZjAyZGFhZTc0YTc4OWMwODBiNjhiYTZhYjk0My90YWJsZXJhbmdlOjU4MDRmMDJkYWFlNzRhNzg5YzA4MGI2OGJhNmFiOTQzXzEzLTUtMS0xLTc4MjE1_5980f48e-1f00-4d1b-9658-f64dcc72cdc5"
      unitRef="usd">1449000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzItMS0xLTEtNzgyMTU_207ca5a1-b8a1-4760-a6af-4232340fe8b9"
      unitRef="usd">1015000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzItMy0xLTEtNzgyMTU_7be68600-dd92-4b41-9756-046fa6643241"
      unitRef="usd">2080000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzItNS0xLTEtNzgyMTU_513c016e-3357-418a-8b56-34db3f5025ce"
      unitRef="usd">1499000000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzQtMS0xLTEtNzgyMTU_9ead1b44-886b-4a2a-9389-ab22023cb312"
      unitRef="usd">437000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzQtMy0xLTEtNzgyMTU_ec9f2afb-67ad-42d3-8983-0d4096e217b8"
      unitRef="usd">408000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzQtNS0xLTEtNzgyMTU_4223328e-2529-45b6-a870-1f799d828ada"
      unitRef="usd">361000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzUtMS0xLTEtNzgyMTU_58b52080-ed67-4986-b0b7-beb49cfb4695"
      unitRef="usd">3000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzUtMy0xLTEtNzgyMTU_78ea10f7-69ce-435d-afe3-b5557650c77a"
      unitRef="usd">4000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzUtNS0xLTEtNzgyMTU_e2941e31-86d4-4a58-89f6-b63ab838086e"
      unitRef="usd">19000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzYtMS0xLTEtNzgyMTU_2c71b19a-de06-438c-afa3-2e379bfdea94"
      unitRef="usd">1000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzYtMy0xLTEtNzgyMTU_0a9335e9-29b0-447b-8a87-cd60836dd84c"
      unitRef="usd">-57000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzYtNS0xLTEtNzgyMTU_8654e475-7967-4a7a-8885-5767ece6776d"
      unitRef="usd">85000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzctMS0xLTEtNzgyMTU_72a540ba-48d6-4c08-843b-b8565f3453d3"
      unitRef="usd">77000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzctMy0xLTEtNzgyMTU_fd1d6a03-9d40-433d-bc05-805c0af8e51f"
      unitRef="usd">79000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzctNS0xLTEtNzgyMTU_ff83b681-c4fd-4983-9399-6199f7d18309"
      unitRef="usd">97000000</us-gaap:ShareBasedCompensation>
    <dgx:GainLossOnDispositionOfJointVenture
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzgtMS0xLTEtNzgyMTU_7cf6c774-51d2-4de6-8742-1c9240753c0d"
      unitRef="usd">0</dgx:GainLossOnDispositionOfJointVenture>
    <dgx:GainLossOnDispositionOfJointVenture
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzgtMy0xLTEtNzgyMTU_0438c0ad-265b-4cf6-a683-58ac1c888a7b"
      unitRef="usd">314000000</dgx:GainLossOnDispositionOfJointVenture>
    <dgx:GainLossOnDispositionOfJointVenture
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzgtNS0xLTEtNzgyMTU_94f58a50-a0b5-4a89-a8a8-263fd1b2e2de"
      unitRef="usd">0</dgx:GainLossOnDispositionOfJointVenture>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzE0LTEtMS0xLTc4MjE1_be66b43b-f0de-4eae-ab74-a44d39863d53"
      unitRef="usd">-66000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzE0LTMtMS0xLTc4MjE1_1bba35d4-12a8-44a9-b4e7-0f6afbcd31d6"
      unitRef="usd">54000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzE0LTUtMS0xLTc4MjE1_fcc24eec-9c2e-41ea-91d3-6413735ff88c"
      unitRef="usd">78000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzE2LTEtMS0xLTc4MjE1_f3e7dfb0-d49a-46cf-9833-a83705b6b84c"
      unitRef="usd">-246000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzE2LTMtMS0xLTc4MjE1_935a4550-be18-41c9-9a55-3255b0042bda"
      unitRef="usd">-81000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzE2LTUtMS0xLTc4MjE1_2f22026e-0287-46c2-a5a2-d3bde71b9bb4"
      unitRef="usd">455000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzE3LTEtMS0xLTc4MjE1_4be4768f-2f1c-4e6a-8c7e-a059e9333504"
      unitRef="usd">-149000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzE3LTMtMS0xLTc4MjE1_ad47871b-b082-47ff-a2c3-11d7ac4160fc"
      unitRef="usd">35000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzE3LTUtMS0xLTc4MjE1_ea377096-e9ec-48a1-ad93-fcb8ecfca49c"
      unitRef="usd">452000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzE5LTEtMS0xLTc4MjE1_d64e5b54-1c6f-4f63-90ab-110511147c11"
      unitRef="usd">-31000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzE5LTMtMS0xLTc4MjE1_ec337199-06e5-424c-aecc-ba8e14436900"
      unitRef="usd">-20000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzE5LTUtMS0xLTc4MjE1_6247798f-4158-414c-a09d-269c6a7a6fb4"
      unitRef="usd">22000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <dgx:TerminationOfInterestRateSwapAgreements
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzIwLTEtMS0xLTc4MjE1_60b01faf-7a48-429d-9e68-d1beded8274b"
      unitRef="usd">0</dgx:TerminationOfInterestRateSwapAgreements>
    <dgx:TerminationOfInterestRateSwapAgreements
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzIwLTMtMS0xLTc4MjE1_9f002fce-686b-4615-9493-1b852556e8ea"
      unitRef="usd">0</dgx:TerminationOfInterestRateSwapAgreements>
    <dgx:TerminationOfInterestRateSwapAgreements
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzIwLTUtMS0xLTc4MjE1_7899069e-f250-46fa-8ff6-1dca60089e46"
      unitRef="usd">40000000</dgx:TerminationOfInterestRateSwapAgreements>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzIxLTEtMS0xLTc4MjE1_b55dc194-0e03-4c4e-9006-c7b88e8fa388"
      unitRef="usd">-53000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzIxLTMtMS0xLTc4MjE1_32e0f29b-ab0e-4ac4-bf6b-ebef4636ff17"
      unitRef="usd">9000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzIxLTUtMS0xLTc4MjE1_38a4f99d-a547-45bb-912b-cda2370614ef"
      unitRef="usd">37000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzIyLTEtMS0xLTc4MjE1_4088e37b-9748-4195-a361-6841d5e4df04"
      unitRef="usd">1718000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzIyLTMtMS0xLTc4MjE1_fcc30b68-e3da-4aab-af0c-1cdf4dd2cb42"
      unitRef="usd">2233000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzIyLTUtMS0xLTc4MjE1_ff66707f-4b43-4899-b7e9-c316aea1420a"
      unitRef="usd">2005000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzI1LTEtMS0xLTc4MjE1_327cd0cf-7d97-4c7d-9d8e-d5783cd6539c"
      unitRef="usd">144000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzI1LTMtMS0xLTc4MjE1_b83c0a63-65fc-42ed-8b49-597fe63b7b67"
      unitRef="usd">331000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzI1LTUtMS0xLTc4MjE1_3a5daf0f-e343-4e9f-8b61-78665865093c"
      unitRef="usd">330000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzI2LTEtMS0xLTc4MjE1_872a1162-5606-47a1-824a-d07326292631"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzI2LTMtMS0xLTc4MjE1_7edfc383-8779-47b6-9122-85b7cb2443ad"
      unitRef="usd">755000000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzI2LTUtMS0xLTc4MjE1_8fb88f93-d8b9-4bc9-8a57-adf1988d6144"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzI5LTEtMS0xLTc4MjE1_aa066287-5903-43d1-a10c-071f67cb6949"
      unitRef="usd">404000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzI5LTMtMS0xLTc4MjE1_43956624-8a3b-4abc-b9ac-a2c46ad9aeb2"
      unitRef="usd">403000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzI5LTUtMS0xLTc4MjE1_66e5f88c-de5e-4d78-ba31-140fda03ac62"
      unitRef="usd">418000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzMxLTEtMS0xLTc4MjE1_814ba3cd-b4a4-40a9-85dc-b50bfba440d4"
      unitRef="usd">-5000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzMxLTMtMS0xLTc4MjE1_e2f50db7-3ec6-4b9b-b29e-9527ed4df109"
      unitRef="usd">0</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzMxLTUtMS0xLTc4MjE1_95980216-c536-4427-bf30-8b77ac4a3301"
      unitRef="usd">24000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzMyLTEtMS0xLTc4MjE1_a04c9a51-26dc-49fc-bc73-c71ab2b42a37"
      unitRef="usd">-543000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzMyLTMtMS0xLTc4MjE1_624f7587-06d1-41dc-8e6c-ea189d2912e2"
      unitRef="usd">21000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzMyLTUtMS0xLTc4MjE1_f74a6a61-e9ee-4e76-84b9-dd777d158cdc"
      unitRef="usd">-772000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzM1LTEtMS0xLTc4MjE1_8a02061e-66a6-462d-9752-cd0c7c92229a"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzM1LTMtMS0xLTc4MjE1_7f888003-b691-408d-bbc6-0d029b5518e7"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzM1LTUtMS0xLTc4MjE1_5c585bb6-4a02-46bd-9302-dfcc164bc1aa"
      unitRef="usd">749000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzM2LTEtMS0xLTc4MjE1_65eece06-8d3c-4558-a4a1-e49a7a62537a"
      unitRef="usd">2000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzM2LTMtMS0xLTc4MjE1_cb7e67bf-d8e0-4f18-abbf-c554f4141ae0"
      unitRef="usd">2000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzM2LTUtMS0xLTc4MjE1_e40c9b0c-f547-441b-a6eb-da8542034882"
      unitRef="usd">1554000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzM3LTEtMS0xLTc4MjE1_027cfc17-eb38-495d-a794-f743292761d5"
      unitRef="usd">1408000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzM3LTMtMS0xLTc4MjE1_fd37f5ea-e4ad-4f0d-af0e-3a4446cab683"
      unitRef="usd">2199000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzM3LTUtMS0xLTc4MjE1_deaab6ec-e4b8-44fc-b5ae-86f9ffa186d4"
      unitRef="usd">325000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzM4LTEtMS0xLTc4MjE1_7853bb8a-0ee9-429b-b7ca-564c80663116"
      unitRef="usd">123000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzM4LTMtMS0xLTc4MjE1_dc2ba048-df4d-46ea-828d-5b8d5cdaeca7"
      unitRef="usd">129000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzM4LTUtMS0xLTc4MjE1_70221699-82f5-4f72-b387-ada415d275ee"
      unitRef="usd">189000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzM5LTEtMS0xLTc4MjE1_cbbe4679-feca-4a9c-8464-bff06dee7ca5"
      unitRef="usd">28000000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzM5LTMtMS0xLTc4MjE1_a81a0ab3-3c35-477c-aa52-a7eaebb11d3a"
      unitRef="usd">22000000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzM5LTUtMS0xLTc4MjE1_15d9e0d1-598c-4de4-9095-43d1f940db1f"
      unitRef="usd">15000000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzQwLTEtMS0xLTc4MjE1_76d76b97-a430-4452-b31b-6d512e60a422"
      unitRef="usd">305000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzQwLTMtMS0xLTc4MjE1_5b5c125f-3da5-4aa8-8d79-a115fcefaa0f"
      unitRef="usd">309000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzQwLTUtMS0xLTc4MjE1_70de473c-e408-48a7-99ff-36161b49c0ea"
      unitRef="usd">297000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsMinorityInterest
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzQxLTEtMS0xLTc4MjE1_98062ee7-5457-4f23-844d-a8bb9fd56c90"
      unitRef="usd">73000000</us-gaap:PaymentsOfDividendsMinorityInterest>
    <us-gaap:PaymentsOfDividendsMinorityInterest
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzQxLTMtMS0xLTc4MjE1_8e0d312f-31b6-44b7-9a64-a3f5dda91a5b"
      unitRef="usd">99000000</us-gaap:PaymentsOfDividendsMinorityInterest>
    <us-gaap:PaymentsOfDividendsMinorityInterest
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzQxLTUtMS0xLTc4MjE1_03dc7f68-1035-4bbb-b6f9-e61be73536a5"
      unitRef="usd">58000000</us-gaap:PaymentsOfDividendsMinorityInterest>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzQ1LTEtMS0xLTc4MjE1_6b936252-ef99-42c1-9c43-06864e42d3a9"
      unitRef="usd">-39000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzQ1LTMtMS0xLTc4MjE1_ee449128-6638-4ed8-8bf6-c415ef28778e"
      unitRef="usd">-38000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzQ1LTUtMS0xLTc4MjE1_da8e430b-8719-49fe-9de8-f11d76c76a61"
      unitRef="usd">44000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzQ2LTEtMS0xLTc4MjE1_07913910-eb6e-4967-a00c-b757cdabb091"
      unitRef="usd">-1732000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzQ2LTMtMS0xLTc4MjE1_f4c9fd6e-f8df-4725-a5e3-13f4d232acdc"
      unitRef="usd">-2540000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzQ2LTUtMS0xLTc4MjE1_7d741074-76e9-4449-9243-1fce7ddf8071"
      unitRef="usd">-1267000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzQ4LTEtMS0xLTc4MjE1_bdc3e6de-1a6c-4f36-a34c-385f1fc19cba"
      unitRef="usd">-557000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzQ4LTMtMS0xLTc4MjE1_f716f041-4cde-4851-990d-7ef4887a0a2d"
      unitRef="usd">-286000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzQ4LTUtMS0xLTc4MjE1_79e569c5-3d8f-46fb-9485-1c8d34540847"
      unitRef="usd">-34000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzUwLTEtMS0xLTc4MjE1_af9bdc9f-5c33-463e-be97-4b5ab99c66c4"
      unitRef="usd">872000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i872b3ea2e369403f8c0129ff07e0b538_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzUwLTMtMS0xLTc4MjE1_65415025-2c7f-4b94-b92f-0f5d758aa25a"
      unitRef="usd">1158000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1240b052d8214432b601d5bcbb753f11_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzUwLTUtMS0xLTc4MjE1_461c14c2-f790-4c90-8860-3275c745cd44"
      unitRef="usd">1192000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzUxLTEtMS0xLTc4MjE1_191e5469-4bc4-4dea-a3ec-e506fecba9fc"
      unitRef="usd">315000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzUxLTMtMS0xLTc4MjE1_646aade5-2385-4c58-b2e0-5c912b4ce44a"
      unitRef="usd">872000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i872b3ea2e369403f8c0129ff07e0b538_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjYvZnJhZzpjZTMyOWQxZTg1ZDI0MmY2OWFlNTcyZjkwOTkzMjVhNS90YWJsZTpjNmYwNWQ2OGVhNGQ0ZmVjOTBhOGZlMTUzMmMzOTQzMi90YWJsZXJhbmdlOmM2ZjA1ZDY4ZWE0ZDRmZWM5MGE4ZmUxNTMyYzM5NDMyXzUxLTUtMS0xLTc4MjE1_b7a71ef7-ce33-4d9d-866b-74102098746c"
      unitRef="usd">1158000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i60096e15242147fba12636c6498e0696_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzItMS0xLTEtNzgyMTU_3a933e4e-a0fe-49f4-8678-0b869f98c639"
      unitRef="shares">133000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i60096e15242147fba12636c6498e0696_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzItMi0xLTEtNzgyMTU_43bfa16e-ae55-4ef9-823f-d1bb780c46b6"
      unitRef="usd">2000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ide8bb1978e06466ca724c39081cca9e9_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzItMy0xLTEtNzgyMTU_e147f640-82f7-4380-8cba-a66932a522ed"
      unitRef="usd">2722000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i288558364eaf483197b8585096922212_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzItNC0xLTEtNzgyMTU_f9ba5bc8-7013-42e9-974a-d861c69d3b9d"
      unitRef="usd">8174000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i472db09b826445d8914756bb3c893218_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzItNS0xLTEtNzgyMTU_74539b47-a8c6-4132-86d1-bae17f12e874"
      unitRef="usd">-39000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5cb753814e7c442992f309372e45e63f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzItNi0xLTEtNzgyMTU_24c9fbc2-10d2-44a2-bb34-4078a8e301a9"
      unitRef="usd">-5218000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9986f08efdbe402bbac2c867d4d5b49a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzItNy0xLTEtNzgyMTU_732ce549-4901-4738-b05d-b9615b5efa01"
      unitRef="usd">46000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1240b052d8214432b601d5bcbb753f11_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzItOC0xLTEtNzgyMTU_e2c527f2-d9ac-4062-87db-34416907fa38"
      unitRef="usd">5687000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i1240b052d8214432b601d5bcbb753f11_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzItMTEtMS0xLTc4MjE1_4016539b-38cf-4c09-b1e8-cf35ace33a36"
      unitRef="usd">76000000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <dgx:NetIncomeLossExcludingRedeemableNoncontrollingInterest
      contextRef="i4a99166a414743a488765966d2720acc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMtNC0xLTEtNzgyMTU_4842779d-59c1-420b-9187-68a68cd8405b"
      unitRef="usd">1431000000</dgx:NetIncomeLossExcludingRedeemableNoncontrollingInterest>
    <dgx:NetIncomeLossExcludingRedeemableNoncontrollingInterest
      contextRef="i10198ce773244072a76824474330a1cf_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMtNy0xLTEtNzgyMTU_e96fb1c5-61ce-4620-bcbe-ef6076e9d86a"
      unitRef="usd">53000000</dgx:NetIncomeLossExcludingRedeemableNoncontrollingInterest>
    <dgx:NetIncomeLossExcludingRedeemableNoncontrollingInterest
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMtOC0xLTEtNzgyMTU_88da13aa-2c95-42a6-9992-1ddb2931f09c"
      unitRef="usd">1484000000</dgx:NetIncomeLossExcludingRedeemableNoncontrollingInterest>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMtMTEtMS0xLTc4MjE1_813b79e9-7897-40a1-b7af-d8ce95c2c859"
      unitRef="usd">15000000</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7c187eb3582c4c4a85507116a2a9051a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzQtNS0xLTEtNzgyMTU_1a7287a0-c28a-4a86-84b5-8b32faafbe12"
      unitRef="usd">18000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzQtOC0xLTEtNzgyMTU_2ee45e71-32f1-43e7-a7a8-b5b50637dffe"
      unitRef="usd">18000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="i4a99166a414743a488765966d2720acc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzUtNC0xLTEtNzgyMTU_c535ae46-5b82-4b24-948b-6082fbe384f0"
      unitRef="usd">302000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzUtOC0xLTEtNzgyMTU_ebd36475-b380-4cb2-9c86-96d7d6004844"
      unitRef="usd">302000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i10198ce773244072a76824474330a1cf_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzYtNy0xLTEtNzgyMTU_db13a9ab-f37f-4018-8300-a624aa9ef56d"
      unitRef="usd">49000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzYtOC0xLTEtNzgyMTU_45307b36-5a88-48ee-b321-af935e68f89a"
      unitRef="usd">49000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <dgx:TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzYtMTEtMS0xLTc4MjE1_557a8435-e72c-4d92-95bc-71cec2c3760b"
      unitRef="usd">9000000</dgx:TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i65ea28f7aede4d8cb4a1add480265c52_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzctMS0xLTEtNzgyMTU_850798ca-8e4a-4dec-bb60-36af1122c613"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i35ba9cb930d94eb9a0e61b9e0381a8d8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzctMy0xLTEtNzgyMTU_8663a381-c9db-49f1-a22c-522ac933b73d"
      unitRef="usd">11000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i2998701e47ab4c2da75bc84322736ac6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzctNi0xLTEtNzgyMTU_e084672d-fefd-4413-9eaf-1a2101be73f0"
      unitRef="usd">14000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzctOC0xLTEtNzgyMTU_0e000b6c-1360-4620-8356-ff7625dd4a2b"
      unitRef="usd">25000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i35ba9cb930d94eb9a0e61b9e0381a8d8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzgtMy0xLTEtNzgyMTU_f2be223d-2792-44b2-9120-eb24c3b91e02"
      unitRef="usd">97000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzgtOC0xLTEtNzgyMTU_68fa374a-18b3-4f09-a0b7-17d6c72b7245"
      unitRef="usd">97000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i65ea28f7aede4d8cb4a1add480265c52_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzktMS0xLTEtNzgyMTU_f7c7b1fa-be88-467b-ae1f-0f70e172bb8e"
      unitRef="shares">2000000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i35ba9cb930d94eb9a0e61b9e0381a8d8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzktMy0xLTEtNzgyMTU_d910d1c9-1bde-4d7e-9f35-4e31aa46adc5"
      unitRef="usd">26000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2998701e47ab4c2da75bc84322736ac6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzktNi0xLTEtNzgyMTU_9eaa812e-eadb-4d6f-adb0-74a7e4d52ae5"
      unitRef="usd">163000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzktOC0xLTEtNzgyMTU_b460fd66-9b64-4189-b063-e8186a9df283"
      unitRef="usd">189000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i35ba9cb930d94eb9a0e61b9e0381a8d8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzEwLTMtMS0xLTc4MjE1_753f0859-e871-4674-8bb1-f7718f90ac9c"
      unitRef="usd">15000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzEwLTgtMS0xLTc4MjE1_a5520f41-8b6f-4a6a-a156-2ea5dac62697"
      unitRef="usd">15000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i65ea28f7aede4d8cb4a1add480265c52_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzEyLTEtMS0xLTc4MjE1_6847f4b9-fa31-46df-a1c3-54ead8d997ea"
      unitRef="shares">3000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i2998701e47ab4c2da75bc84322736ac6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzEyLTYtMS0xLTc4MjE1_68c75ea3-eee6-4fbe-b206-dc13225586bc"
      unitRef="usd">325000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzEyLTgtMS0xLTc4MjE1_4e5a3128-5f17-4133-9e08-e385e6f947ac"
      unitRef="usd">325000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id1339fcf6a344dd38e3445336c362756_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzE2LTEtMS0xLTc4MjE1_4f66ce0f-187d-47f0-9513-9267d25731b9"
      unitRef="shares">133000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id1339fcf6a344dd38e3445336c362756_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzE2LTItMS0xLTc4MjE1_9652ee6f-4aaa-4671-b302-cdf5c33154f5"
      unitRef="usd">2000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3df6ca3ffce342b4877024296cfa0551_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzE2LTMtMS0xLTc4MjE1_91067350-a7aa-42fc-b436-3a43ae4da3c5"
      unitRef="usd">2841000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib876f54cbcd740bbaa56a7f098ffd2ac_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzE2LTQtMS0xLTc4MjE1_44ab0ed0-fd2c-4801-88a2-e0780b0349b3"
      unitRef="usd">9303000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic144ab8f0cf34804be4018d616f6d4ac_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzE2LTUtMS0xLTc4MjE1_666b88b3-4ddf-480c-9598-0e9c63dcb3f3"
      unitRef="usd">-21000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifb272b75d2c44e3689c068a802c47179_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzE2LTYtMS0xLTc4MjE1_eb5176e7-5f97-4f45-ad71-673e6e4cdfa8"
      unitRef="usd">-5366000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icb2b0c92f23149e9923b4ac5d5a66fc9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzE2LTctMS0xLTc4MjE1_c1f6daba-3d9e-4323-ad4e-cca2f8fd1834"
      unitRef="usd">50000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i872b3ea2e369403f8c0129ff07e0b538_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzE2LTgtMS0xLTc4MjE1_8cbe26f2-cf76-4005-8249-12de81f7dee1"
      unitRef="usd">6809000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i872b3ea2e369403f8c0129ff07e0b538_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzE2LTExLTEtMS03ODIxNQ_c25eb189-48b5-47bf-8ae6-aa53e30cb9d7"
      unitRef="usd">82000000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <dgx:NetIncomeLossExcludingRedeemableNoncontrollingInterest
      contextRef="i3b1b2d14ccd04831986cecdccfec9b2d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzE3LTQtMS0xLTc4MjE1_6ab45574-1e79-44b6-88b3-2f969bc49d0d"
      unitRef="usd">1995000000</dgx:NetIncomeLossExcludingRedeemableNoncontrollingInterest>
    <dgx:NetIncomeLossExcludingRedeemableNoncontrollingInterest
      contextRef="i9b667d9c2eff4eebb2ac4e52f720ef07_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzE3LTctMS0xLTc4MjE1_be54df66-d084-4cd2-ba36-87fb01fb5187"
      unitRef="usd">72000000</dgx:NetIncomeLossExcludingRedeemableNoncontrollingInterest>
    <dgx:NetIncomeLossExcludingRedeemableNoncontrollingInterest
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzE3LTgtMS0xLTc4MjE1_e4a392ca-9c48-4cc9-94fe-f5b7bdfd2dff"
      unitRef="usd">2067000000</dgx:NetIncomeLossExcludingRedeemableNoncontrollingInterest>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzE3LTExLTEtMS03ODIxNQ_667f2966-815b-40e0-970f-24d9b596f713"
      unitRef="usd">13000000</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i095b5e9afd734c41af3e81c20d90f712_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzE4LTUtMS0xLTc4MjE1_57b2a225-eedb-4770-83a7-98ab9c00c391"
      unitRef="usd">7000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzE4LTgtMS0xLTc4MjE1_4bb4dfa3-68bb-4fca-b94a-e869879bb1f7"
      unitRef="usd">7000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="i3b1b2d14ccd04831986cecdccfec9b2d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzE5LTQtMS0xLTc4MjE1_cf7b6a63-ec15-4bd7-b017-66f30ea9ab7e"
      unitRef="usd">307000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzE5LTgtMS0xLTc4MjE1_e9daf5f2-7350-4c75-9ace-d261c949fcbe"
      unitRef="usd">307000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i9b667d9c2eff4eebb2ac4e52f720ef07_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzIwLTctMS0xLTc4MjE1_91c06cba-a2c8-4013-88b5-5942950a6e57"
      unitRef="usd">83000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzIwLTgtMS0xLTc4MjE1_49a88358-230b-4dfc-badf-3df544bd76d5"
      unitRef="usd">83000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <dgx:TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzIwLTExLTEtMS03ODIxNQ_98876322-2c18-4b35-bddd-ec8a2f6ab797"
      unitRef="usd">16000000</dgx:TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ibf09d963d3644445a1026aa035d87436_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzIxLTEtMS0xLTc4MjE1_8e1dc421-d45c-4a94-8d31-5db5fd58397b"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6bf24e1056814b529c1aaa4c1d657c4a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzIxLTMtMS0xLTc4MjE1_5089180a-1b36-4188-8884-ee96d07aac88"
      unitRef="usd">-21000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic4718e0f26e04ae097941f11f8d84f52_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzIxLTYtMS0xLTc4MjE1_85641155-70ec-4584-9908-598237c69de9"
      unitRef="usd">47000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzIxLTgtMS0xLTc4MjE1_647e1606-36b0-4c03-ba2a-4546d4a5579f"
      unitRef="usd">26000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6bf24e1056814b529c1aaa4c1d657c4a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzIyLTMtMS0xLTc4MjE1_f3b73b44-e4d6-494a-b5dc-e5691f081f55"
      unitRef="usd">79000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzIyLTgtMS0xLTc4MjE1_36d97033-40e5-41e9-bd49-f9e4a75fccad"
      unitRef="usd">79000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ibf09d963d3644445a1026aa035d87436_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzIzLTEtMS0xLTc4MjE1_0e486155-be8a-45ac-ab6b-8ff63a6da792"
      unitRef="shares">2000000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6bf24e1056814b529c1aaa4c1d657c4a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzIzLTMtMS0xLTc4MjE1_6ce5f062-9cb8-480b-86f3-d58270ebb47f"
      unitRef="usd">20000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic4718e0f26e04ae097941f11f8d84f52_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzIzLTYtMS0xLTc4MjE1_d94bcebb-9a75-4117-8b10-9acf70588239"
      unitRef="usd">109000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzIzLTgtMS0xLTc4MjE1_05c97390-c5ea-41d1-90ab-9af48436e15c"
      unitRef="usd">129000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i6bf24e1056814b529c1aaa4c1d657c4a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzI0LTMtMS0xLTc4MjE1_34933df9-8d05-4aea-ad97-b8e8e47fea27"
      unitRef="usd">10000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ic4718e0f26e04ae097941f11f8d84f52_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzI0LTYtMS0xLTc4MjE1_7f1a2065-f913-424d-af72-90cf8ea78dce"
      unitRef="usd">12000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzI0LTgtMS0xLTc4MjE1_3b91645d-5822-46b5-965d-f065aa6bdf16"
      unitRef="usd">22000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ibf09d963d3644445a1026aa035d87436_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzI2LTEtMS0xLTc4MjE1_2bcf1159-fc8a-418a-a9d2-fef4b9aff7ed"
      unitRef="shares">16000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ic4718e0f26e04ae097941f11f8d84f52_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzI2LTYtMS0xLTc4MjE1_ff5df8ba-d853-4235-a4ca-5157953749a9"
      unitRef="usd">2222000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzI2LTgtMS0xLTc4MjE1_8bddc66e-8b10-4359-b7f0-e3dccb9e130a"
      unitRef="usd">2222000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i6bf24e1056814b529c1aaa4c1d657c4a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzI5LTMtMS0xLTc4MjE1_efcb956a-2323-49ad-be4d-9c42e272902d"
      unitRef="usd">649000000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i3b1b2d14ccd04831986cecdccfec9b2d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzI5LTQtMS0xLTc4MjE1_3673ee8c-71f1-450c-9bd1-e0941f485487"
      unitRef="usd">3342000000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ic4718e0f26e04ae097941f11f8d84f52_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzI5LTYtMS0xLTc4MjE1_5c7c085d-9510-448d-818c-98b0e63c0f2a"
      unitRef="usd">-3991000000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzI5LTgtMS0xLTc4MjE1_15aa7510-4bea-4b82-9dd8-83972b154a7e"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ibf9d22d584794a70962f2aa7e63d53ed_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMwLTEtMS0xLTc4MjE1_6a1c80f5-9411-4c3d-9e25-44d984708c0b"
      unitRef="shares">119000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibf9d22d584794a70962f2aa7e63d53ed_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMwLTItMS0xLTc4MjE1_48183045-1bdc-4670-802a-40ad040d6a3e"
      unitRef="usd">2000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i46c3bce145ea4fa5aa062add4078cdfe_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMwLTMtMS0xLTc4MjE1_f2f9413d-7fe1-4b65-8786-9ecc0511c344"
      unitRef="usd">2260000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ide97930b20624098ba7878ad5bcd0d94_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMwLTQtMS0xLTc4MjE1_02e95fb7-8527-49d4-8c3e-0ab2227b7267"
      unitRef="usd">7649000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id3c04cff9ac445b78c60050390c6354a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMwLTUtMS0xLTc4MjE1_09761ac2-fdc7-4942-898f-f3095abbb0bb"
      unitRef="usd">-14000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4a13b74a4feb49a384914744e3913d6d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMwLTYtMS0xLTc4MjE1_0d864412-f1a7-48c3-8bef-4b478f96c74c"
      unitRef="usd">-3453000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9fa9e0c121174bc7b51c26277e515b9b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMwLTctMS0xLTc4MjE1_e8f53e11-7902-47ac-8df0-c31b6a8b0e8e"
      unitRef="usd">39000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMwLTgtMS0xLTc4MjE1_22a580de-ec93-49c0-84ba-5d800387e6e0"
      unitRef="usd">6483000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMwLTExLTEtMS03ODIxNQ_3b950d97-2563-4fbb-bbf2-3b0408357a66"
      unitRef="usd">79000000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <dgx:NetIncomeLossExcludingRedeemableNoncontrollingInterest
      contextRef="i3cc12e58d5654ed5b8115cae8aed17f6_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMxLTQtMS0xLTc4MjE1_351f7635-4a7a-4082-8a71-045cb7aa7d5a"
      unitRef="usd">946000000</dgx:NetIncomeLossExcludingRedeemableNoncontrollingInterest>
    <dgx:NetIncomeLossExcludingRedeemableNoncontrollingInterest
      contextRef="ie63ea040842e454a8a302897c8462f6f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMxLTctMS0xLTc4MjE1_ee6fc63a-348e-4f4e-a12d-ef70b04a0337"
      unitRef="usd">62000000</dgx:NetIncomeLossExcludingRedeemableNoncontrollingInterest>
    <dgx:NetIncomeLossExcludingRedeemableNoncontrollingInterest
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMxLTgtMS0xLTc4MjE1_42bcb1ed-b53b-4144-a2b0-06f5f8d0836f"
      unitRef="usd">1008000000</dgx:NetIncomeLossExcludingRedeemableNoncontrollingInterest>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMxLTExLTEtMS03ODIxNQ_53c203f1-82ae-4c5f-aa93-9867dab10a44"
      unitRef="usd">7000000</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic7dd85f38ce14e469eb57e11ba9cfd32_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMyLTUtMS0xLTc4MjE1_2ba6bd77-77a4-4ae9-bd89-b352cb020ad3"
      unitRef="usd">-7000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMyLTgtMS0xLTc4MjE1_6b02b928-73c2-4521-983e-aa365a519b5b"
      unitRef="usd">-7000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="i3cc12e58d5654ed5b8115cae8aed17f6_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMzLTQtMS0xLTc4MjE1_b4e55739-4ee9-4a22-982b-c16fcc54e3f1"
      unitRef="usd">305000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzMzLTgtMS0xLTc4MjE1_7fa7566b-e2a6-4110-853c-7b96b33c8dfd"
      unitRef="usd">305000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ie63ea040842e454a8a302897c8462f6f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzM0LTctMS0xLTc4MjE1_1f322a1e-f6be-4035-a183-eb16df2a3bb3"
      unitRef="usd">64000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzM0LTgtMS0xLTc4MjE1_3f1031fc-18e0-4e15-9621-378be5e58529"
      unitRef="usd">64000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <dgx:TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzM0LTExLTEtMS03ODIxNQ_5e12879d-a4b0-4601-af2c-b8df22fefb1e"
      unitRef="usd">9000000</dgx:TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i2e6f2503a5bd421392c0a3810d1d34b3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzM1LTEtMS0xLTc4MjE1_6e62177b-c111-4689-b39b-2c7430561aa5"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i08ee5ae92da64f5088e4f441aadc7efd_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzM1LTMtMS0xLTc4MjE1_523f5feb-2aec-492a-80e3-7e68077b78c3"
      unitRef="usd">-36000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7840e393be1c4cfaafc766cd6a649f57_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzM1LTYtMS0xLTc4MjE1_f7674d73-5e43-4217-ad01-a2902251fbf9"
      unitRef="usd">64000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzM1LTgtMS0xLTc4MjE1_6325b752-f2f4-4a90-8733-0acfb2f77a01"
      unitRef="usd">28000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i08ee5ae92da64f5088e4f441aadc7efd_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzM2LTMtMS0xLTc4MjE1_68b81e76-f970-4e3d-a224-d1f1f0b58084"
      unitRef="usd">77000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzM2LTgtMS0xLTc4MjE1_cf47bd6f-ca65-451d-97e2-e8823c2e4b62"
      unitRef="usd">77000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i2e6f2503a5bd421392c0a3810d1d34b3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzM3LTEtMS0xLTc4MjE1_f747cfa9-1ad5-4b3b-876e-f1cd97a3ebb3"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i08ee5ae92da64f5088e4f441aadc7efd_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzM3LTMtMS0xLTc4MjE1_4a76c57a-5176-4ba2-9222-b51ddcbf40a6"
      unitRef="usd">4000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i7840e393be1c4cfaafc766cd6a649f57_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzM3LTYtMS0xLTc4MjE1_ed2fbb74-d439-4f77-ac7d-53eebb41b279"
      unitRef="usd">119000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzM3LTgtMS0xLTc4MjE1_97455b17-9eef-4ab5-9d2c-fe03adc33539"
      unitRef="usd">123000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i08ee5ae92da64f5088e4f441aadc7efd_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzM4LTMtMS0xLTc4MjE1_b7ee20e1-6ea8-4d9b-a0a1-4d5a5fba31b9"
      unitRef="usd">10000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i7840e393be1c4cfaafc766cd6a649f57_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzM4LTYtMS0xLTc4MjE1_65fdd565-6128-41e6-9a84-19971e85f891"
      unitRef="usd">18000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzM4LTgtMS0xLTc4MjE1_9645970c-aff5-4a15-9a10-f1fc650f4f52"
      unitRef="usd">28000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i2e6f2503a5bd421392c0a3810d1d34b3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzM5LTEtMS0xLTc4MjE1_5f7cadb3-badd-43da-87bb-340a1858ab79"
      unitRef="shares">10000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i7840e393be1c4cfaafc766cd6a649f57_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzM5LTYtMS0xLTc4MjE1_f4394762-e68a-4ff0-89ca-5ed61431e0a3"
      unitRef="usd">1385000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzM5LTgtMS0xLTc4MjE1_4d1f0b26-e758-4b11-ab29-ecfe62d415d4"
      unitRef="usd">1385000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i87e8a4e1a2e74540b572c7f19b5a4c4d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzQzLTEtMS0xLTc4MjE1_07dee6cf-409b-4889-b18d-c70bfce6d391"
      unitRef="shares">111000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i87e8a4e1a2e74540b572c7f19b5a4c4d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzQzLTItMS0xLTc4MjE1_3c850d19-470e-471d-af25-0df550da8776"
      unitRef="usd">2000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia1e66f8b2302475fb1c8bca2f57488d3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzQzLTMtMS0xLTc4MjE1_534ad7df-25da-4f39-b760-526a27942af9"
      unitRef="usd">2295000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4abbc656bb9d4006bae9f455034d8851_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzQzLTQtMS0xLTc4MjE1_d9aaac0b-0e76-49b9-8cba-7e7e34461769"
      unitRef="usd">8290000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib4848abb5a7147028c83ac30e5fcf981_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzQzLTUtMS0xLTc4MjE1_4cd942f3-98e3-45ba-868d-86fe89f0edf1"
      unitRef="usd">-21000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3448ddb537854f44a9c15ae5f60d4048_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzQzLTYtMS0xLTc4MjE1_7ac676c9-0737-40be-8bad-8095412add51"
      unitRef="usd">-4673000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7fcf55e48b7c44a8aa6c6dce683057f7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzQzLTctMS0xLTc4MjE1_531dff2b-9ec3-4d3a-9b86-ce4313a75b74"
      unitRef="usd">37000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzQzLTgtMS0xLTc4MjE1_e3e24576-c479-4723-83af-8cb0e34a0f9d"
      unitRef="usd">5930000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNjkvZnJhZzo1NmZmZjExZDE4MDA0ZDAyOTY3MDEyODJiNWQwODlhMS90YWJsZToyZTFjYzAzZDQwMzU0M2RkYjZjYmY3MWE0MDQ3M2Q5Mi90YWJsZXJhbmdlOjJlMWNjMDNkNDAzNTQzZGRiNmNiZjcxYTQwNDczZDkyXzQzLTExLTEtMS03ODIxNQ_6d29d152-8827-4074-89c9-58d604ad918c"
      unitRef="usd">77000000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:NatureOfOperations
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzUvZnJhZzozOGY0NjI0MGEzNWI0NGI1YmI5NTk5MmE4MTIyYzgzMC90ZXh0cmVnaW9uOjM4ZjQ2MjQwYTM1YjQ0YjViYjk1OTkyYTgxMjJjODMwXzE3MDI_4d1320a4-a15c-444e-b5b7-3e45cee7bdfc">DESCRIPTION OF BUSINESS&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Background&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Quest Diagnostics Incorporated and its subsidiaries ("Quest Diagnostics" or the "Company") empower people to take action to improve health outcomes.&#160; The Company uses its extensive database of clinical lab results to derive diagnostic insights that reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management.&#160; The Company's diagnostic information services business ("DIS") provides information and insights based on an industry-leading menu of routine, non-routine and advanced clinical testing and anatomic pathology testing, and other diagnostic information services.  The Company provides services to a broad range of customers, including patients, clinicians, hospitals, independent delivery networks ("IDNs"), health plans, employers, consumers, and accountable care organizations ("ACOs").  The Company offers the broadest access in the United States to diagnostic information services through its nationwide network of laboratories, patient service centers and phlebotomists in physician offices and the Company's connectivity resources, including call centers and mobile paramedics, nurses and other health and wellness professionals.  The Company is the world's leading provider of diagnostic information services.  The Company provides interpretive consultation with one of the largest medical and scientific staffs in the industry. The Company's Diagnostic Solutions businesses ("DS") are the leading provider of risk assessment services for the life insurance industry and offer healthcare organizations and clinicians robust information technology solutions.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MTI0_23b82634-541a-49b7-b767-39ab73e54ab7">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The consolidated financial statements include the accounts of all entities controlled by the Company through its direct or indirect ownership of a majority voting interest.  Additionally, the consolidated financial statements include the accounts of variable interest entities (&#x201c;VIEs&#x201d;) in which the Company has a variable interest and for which the Company is the &#x201c;primary beneficiary&#x201d; as it has both: (1) the power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and (2) the obligation to absorb losses of the VIE that potentially could be significant to the VIE or the right to receive benefits from the VIE that potentially could be significant to the VIE.  All significant intercompany accounts and transactions are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Income attributable to the minority interest in the Company's majority owned and controlled consolidated subsidiaries is recorded as net income attributable to noncontrolling interests in the consolidated statements of operations and the noncontrolling interest is reflected as a separate component of consolidated stockholders' equity in the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Method Investments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Investments in entities which the Company does not control, but in which it has a substantial ownership interest (generally between 20% and 49%) and can exercise significant influence, are accounted for using the equity method of accounting.  These investments are classified as investments in equity method investees in the consolidated balance sheet.  The Company records its pro rata share of the earnings, adjusted for accretion of basis difference, of these investments in equity in earnings of equity method investees, net of taxes in the consolidated statements of operations.  The Company reviews its investments in equity method investees for impairment whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The preparation of financial statements in conformity with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes as revenue the amount that reflects the consideration to which it expects to be entitled in exchange for goods sold or services rendered primarily upon completion of the testing process (when results are reported) or when services have been rendered (see Note 3).  Net revenues from Medicare and Medicaid programs were approximately 11%, 10% and 11% of the Company's consolidated net revenues for the years ended December&#160;31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Taxes on Income&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the year.  Current and deferred income taxes are measured based on the tax laws that are enacted as of the balance sheet date of the relevant reporting period.  Deferred tax assets and liabilities are recognized for the expected future tax consequences of differences between the carrying amounts of assets and liabilities and their respective tax bases using tax rates in effect for the year in which the differences are expected to reverse.  A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period when the change is enacted.  Tax benefits from uncertain tax positions are recognized only if the tax position is more likely than not to be sustained upon examination by taxing authorities based on the technical merits of the position. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Earnings Per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company's unvested restricted stock units that contain non-forfeitable rights to dividends are participating securities and, therefore, are included in the earnings allocation in computing earnings per share using the two-class method.  Basic earnings per common share is calculated by dividing net income attributable to Quest Diagnostics, adjusted for earnings allocated to participating securities, by the weighted average number of common shares outstanding.  Diluted earnings per common share is calculated by dividing net income attributable to Quest Diagnostics, adjusted for earnings allocated to participating securities, by the weighted average number of common shares outstanding after giving effect to all potentially dilutive common shares outstanding during the period.  Potentially dilutive common shares include the dilutive effect of outstanding stock options and performance share units granted under the Company's Amended and Restated Employee Long-Term Incentive Plan (&#x201c;ELTIP&#x201d;) and its Amended and Restated Non-Employee Director Long-Term Incentive Plan (&#x201c;DLTIP&#x201d;), as well as the dilutive effect of accelerated share repurchase agreements ("ASRs"), if applicable.  Earnings allocable to participating securities include the portion of dividends declared as well as the portion of undistributed earnings during the period allocable to participating securities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company measures stock-based compensation for equity awards at fair value on the date of grant and records stock-based compensation as a charge to earnings net of the estimated impact of forfeited awards.  As such, the Company recognizes stock-based compensation cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;only for those stock-based awards that are estimated to ultimately vest over their requisite service period, based on the vesting provisions of the individual grants.  The cumulative effect on current and prior periods of a change in the estimated forfeiture rate is recognized as compensation cost in earnings in the period of the change.  The terms of the Company's performance share units allow the recipients of such awards to earn a variable number of shares based on the achievement of the performance goals, which are based on the financial performance of the Company and the total shareholder return of the Company relative to an index of peer companies ("relative TSR"), specified in the awards.  For performance share units with a goal based on the financial performance of the Company, stock-based compensation expense is recognized based on management's best estimates of the achievement of the performance goals specified in such awards and the resulting number of shares that will be earned.  The cumulative effect on current and prior periods of a change in the estimated number of performance share units expected to be earned for these awards is recognized as compensation cost in earnings in the period of the change.  For performance share units with a market-based relative TSR goal, stock-based compensation expense is recognized based on the estimated fair value of the award regardless of the actual number of shares earned.  For further details regarding stock-based compensation, see Note&#160;18.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company determines fair value measurements used in its consolidated financial statements based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants exclusive of any transaction costs, as determined by either the principal market or the most advantageous market.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Inputs used in the valuation techniques to derive fair values are classified based on a three-level hierarchy.  The basis for fair value measurements for each level within the hierarchy is described below with Level 1 having the highest priority and Level 3 having the lowest.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1: Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3: Valuations derived from valuation techniques in which one or more significant inputs are unobservable.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company predominately uses the U.S. dollar as its functional currency.  The functional currency of the Company's foreign operating subsidiaries generally is the applicable local currency.  Assets and liabilities denominated in non-U.S. dollars are translated into U.S. dollars at exchange rates as of the end of the reporting period.  Income and expense items are translated at the average monthly exchange rates during the year.  Resulting translation adjustments are recorded as a component of accumulated other comprehensive loss within stockholders' equity.  Gains and losses from foreign currency transactions, which are denominated in a currency other than the functional currency, are included within other operating expense (income), net in the consolidated statements of operations.  Foreign currency transaction gains and losses have historically not been material.  The Company may be exposed to market risk for changes in foreign exchange rates primarily under certain intercompany receivables and payables.  From time to time, the Company uses foreign exchange forward contracts to mitigate the exposure of the eventual net cash inflows or outflows resulting from these intercompany transactions.  The Company's foreign exchange exposure is not material to the Company's consolidated financial condition.  The Company does not hedge its net investment in non-U.S. subsidiaries because it views those investments as long-term in nature.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Cash and cash equivalents include all highly-liquid investments with original maturities, at the time acquired by the Company, of three months or less.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk   &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Financial instruments that potentially subject the Company to concentrations of credit risk are principally cash, cash equivalents, short-term investments, accounts receivable and derivative financial instruments.  The Company's policy is to place its cash, cash equivalents and short-term investments in highly-rated financial instruments and institutions.  Concentration of credit risk with respect to accounts receivable is mitigated by the diversity of the Company's payers and their dispersion across many different geographic regions, and credit risk is concentrated among certain payers who are large buyers of the Company's services.  To reduce risk, the Company routinely assesses the financial strength of these payers and, consequently, believes that its accounts receivable credit risk exposure, with respect to these payers, is limited.  While the Company has receivables due from federal and state governmental agencies, the Company does not believe that such receivables represent a credit risk since the related healthcare programs are funded by federal and state governments, and payment is primarily dependent on submitting appropriate documentation timely.  As of both December&#160;31, 2022 and 2021, receivables due from government payers under the Medicare and Medicaid programs represented approximately 6% of the Company's consolidated net accounts receivable.  The portion of the Company's accounts receivable due from patients comprises the largest portion of credit risk.  As of December&#160;31, 2022 and 2021, receivables due from patients represented approximately 18% and 21%, respectively, of the Company's consolidated net accounts receivable.  The Company applies assumptions and judgments including historical collection experience (including the period of time that the receivables have been outstanding) for assessing collectability and determining net revenues and accounts receivable from patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable and Allowance for Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Accounts receivable are reported net of allowances for credit losses.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;When estimating its allowance for credit losses, the Company pools its trade receivables based on the following customer types: healthcare insurers, government payers, client payers and patients, which are described in Note 3.&#160; The Company principally estimates the allowance for credit losses by pool based on historical collection experience, the current credit worthiness of the customers, current economic conditions, expectations of future economic conditions and the period of time that the receivables have been outstanding.&#160; To the extent that any individual payers are identified that have deteriorated in credit quality, the Company removes the customers from their respective pools and establishes allowances based on the individual risk characteristics of such customers.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Inventories, which consist principally of finished goods testing supplies and reagents, are valued at the lower of cost (first in, first out method) or net realizable value.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment   &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Property, plant and equipment is recorded at cost.  Major renewals and improvements are capitalized, while maintenance and repairs are expensed as incurred.  Costs incurred for computer software developed or obtained for internal use are capitalized for application development activities and expensed as incurred for preliminary project activities and post-implementation activities.  Capitalized costs include external direct costs of materials and services consumed in developing or obtaining internal-use software, payroll and payroll-related costs for employees who are directly associated with the internal-use software project, and interest costs incurred, when material, while developing internal-use software.  Capitalization of such costs ceases when the project is substantially complete and ready for its intended purpose.  Costs for maintenance and training are expensed as incurred.  The Company capitalizes interest on borrowings during the active construction period of major capital projects.  Capitalized interest is added to the cost of the underlying assets and is amortized over the expected useful lives of the assets.  Depreciation and amortization are provided on the straight-line method over expected useful asset lives as of December&#160;31, 2022 as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:63pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;buildings and improvements, ranging up to thirty-one and a half years; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:63pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;laboratory equipment and furniture and fixtures, ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzE1MDA1_cf798870-e9ec-4915-8333-6fffdab241e2"&gt;five&lt;/span&gt; to twelve years; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:63pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;leasehold improvements, the lesser of the useful life of the improvement or the remaining life of the building or lease, as applicable; and &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:63pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;computer software developed or obtained for internal use, principally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzE1MjE1_15232aa9-a205-41d3-834e-46d37c844c97"&gt;five&lt;/span&gt; to ten years.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Goodwill represents the excess of the fair value of the acquiree (including the fair value of non-controlling interests) over the recognized bases of the net identifiable assets acquired and includes the future economic benefits from other assets that could not be individually identified and separately recognized.  Goodwill is not amortized, but instead is periodically reviewed for impairment and an impairment charge is recorded in the periods in which the recorded carrying value of goodwill exceeds its fair value.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;On a quarterly basis, the Company performs a review of its business to determine if events or changes in circumstances have occurred which could have a material adverse effect on the fair value of the Company and its goodwill.  If such events or changes in circumstances were deemed to have occurred, the Company would perform an impairment test of goodwill as of the end of the quarter and record any noted impairment loss.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The goodwill test is performed at least annually, or more frequently if events or changes in circumstances indicate that the asset might be impaired.  The annual impairment test includes an option to perform a qualitative assessment of whether it is more likely than not that a reporting unit's fair value is less than its carrying value; the qualitative test may be performed prior to, or as an alternative to, performing a quantitative goodwill impairment test.  If, after assessing the totality of events or circumstances, the Company determines that it is more likely than not that the fair value of a reporting unit is less than its carrying value, then the Company is required to perform the quantitative goodwill impairment test.  Otherwise, no further analysis is required.  Additionally, the Company's policy is to update the fair value calculation of its reporting units and perform the quantitative goodwill impairment test on a periodic basis.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The quantitative impairment test involves the comparison of the fair value of the reporting unit to its carrying value.  The Company calculates the fair value of each reporting unit using either (i) a discounted cash flows analysis that converts future cash flow amounts into a single discounted present value amount or (ii) a market approach.  The Company assesses the valuation methodology based upon the relevance and availability of the data at the time that the valuation is performed.  The Company compares the estimate of fair value for the reporting unit to the carrying value of the reporting unit.  If the carrying value is greater than the estimate of fair value, an impairment loss will be recognized in the amount of the excess. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company performs its annual impairment test during the fourth quarter of the fiscal year.  For the years ended December&#160;31, 2022 and 2021, the Company performed a qualitative impairment test for its DIS reporting unit and, based on the totality of information available, the Company concluded that it was more-likely-than-not that the estimated fair value of its DIS reporting unit was greater than the carrying value of the reporting unit and, as such, no further analysis was required.  For the year ended December&#160;31, 2022, the Company updated the fair value calculation of its risk assessment services reporting unit, performed the quantitative impairment test and concluded that goodwill for the reporting unit was not impaired.  For the year ended December 31, 2021, the Company performed a qualitative impairment test for its risk assessment reporting unit and, based on the totality of information available, the Company concluded that it was more-likely-than-not that the estimated fair value of the reporting unit was greater than the carrying value of the reporting unit and, as such, no further analysis was required.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Intangible assets are recognized at fair value, as an asset apart from goodwill if the asset (i) arises from contractual or other legal rights, or (ii) is separable.  Intangible assets, principally representing the cost of customer-related intangibles, non-competition agreements and technology acquired, are capitalized and amortized on the straight-line method over their expected useful lives, which generally range from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzE5MDc3_e109cd52-340f-452f-8421-53cd708ea892"&gt;five&lt;/span&gt; to twenty years.  Intangible assets with indefinite useful lives, consisting principally of acquired tradenames, are not amortized, but instead are periodically reviewed for impairment.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company reviews indefinite-lived intangible assets periodically for impairment and an impairment charge is recorded in the periods in which the recorded carrying value of an indefinite-lived intangible asset is more than its estimated fair value.  The indefinite-lived intangible asset impairment test is performed at least annually, or more frequently in the case of other events that indicate a potential impairment.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Based upon the Company&#x2019;s most recent annual impairment tests completed during the fourth quarters of the years ended December&#160;31, 2022 and 2021, the Company concluded that indefinite-lived intangible assets were not impaired.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company reviews the recoverability of its long-lived assets (including amortizable intangible assets), other than goodwill and indefinite-lived intangible assets, when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable.  Evaluation of possible impairment is based on the Company's ability to recover the asset from the expected future pre-tax cash flows (undiscounted and without interest charges) of the related operations.  If these cash flows are less than the carrying amount of such asset, an impairment loss is recognized for the difference between the estimated fair value and carrying amount of the asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company's investments (except for those accounted for under the equity method of accounting) include:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Equity investments with readily determinable fair values, including investments comprised mostly of strategic holdings in companies concentrated in the life sciences and healthcare industries (such investments, which previously did not have readily determinable fair values, became publicly-traded during the year ended December 31, 2021); as well as participant-directed investments of deferred employee compensation and related Company matching contributions held in trusts pursuant to the Company's supplemental deferred compensation plans (see Note 18).  These investments are measured at fair value with both realized and unrealized gains and losses recorded in current earnings within other (expense) income, net in the consolidated statements of operations.  For the years ended December&#160;31, 2022, 2021 and 2020, (losses)/gains from all equity investments with readily determinable fair values totaled $(55) million, $56 million, and $8 million, respectively.  See Note 8 for a discussion of the fair value of such investments. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Equity investments that do not have readily determinable fair values, which consist of investments in preferred and common shares of privately held companies.  These investments are measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes.  The Company regularly evaluates these equity investments to determine if there are any indicators that the investment is impaired; no impairment charges were recognized related to these investments for the years ended December&#160;31, 2022, 2021 and 2020.  The carrying value of these investments was $4&#160;million at both December&#160;31, 2022 and 2021.  Such amounts were included in other assets in the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Available-for-sale debt securities of privately-held companies.  These investments are measured at fair value with unrealized gains and losses presented in other comprehensive (loss) income.  The carrying amount of these investments was $2 million and $1 million at December&#160;31, 2022 and 2021, respectively.  See Note 8 for a discussion of the fair value of such investments. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company uses derivative financial instruments, from time to time, to manage its exposure to market risks for changes in interest rates and foreign currencies.  This strategy includes the use of interest rate swap agreements, forward-starting interest rate swap agreements, interest rate lock agreements and foreign currency forward contracts to manage its exposure to movements in interest and currency rates.  The Company has established policies and procedures for risk assessment and the approval, reporting and monitoring of derivative financial instrument activities.  These policies prohibit holding or issuing derivative financial instruments for speculative purposes.  The Company does not enter into derivative financial instruments that contain credit risk-related contingent features or requirements to post collateral.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest Rate Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company is exposed to interest rate risk on its cash and cash equivalents and its debt obligations.  Interest income earned on cash and cash equivalents may fluctuate as interest rates change; however, due to their relatively short maturities, the Company does not hedge these assets or their investment cash flows and the impact of interest rate risk is not material.  The Company's debt obligations consist of fixed-rate and, from time to time, variable-rate debt instruments.  The Company's primary objective is to achieve the lowest overall cost of funding while managing the variability in cash outflows within an acceptable range.  In order to achieve this objective, the Company has historically entered into interest rate swap agreements.  Interest rate swap agreements involve the periodic exchange of payments without the exchange of underlying principal or notional amounts.  Net settlements between the counterparties are recognized as an adjustment to interest expense, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company accounts for these derivatives as either an asset or liability measured at its fair value.  The fair value is based upon model-derived valuations in which all significant inputs are observable in active markets including certain financial &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;information and certain assumptions regarding past, present and future market conditions.  For a derivative instrument that has been formally designated as a fair value hedge, fair value gains or losses on the derivative instrument along with offsetting fair value gains or losses on the hedged item that are attributable to the risk being hedged are reported in other (expense) income, net in the consolidated statements of operations.  For derivatives that have been formally designated as a cash flow hedge, the change in the fair value of the derivatives is recorded in accumulated other comprehensive loss.  Upon maturity or early termination of an effective interest rate swap agreement designated as a cash flow hedge, unrealized gains or losses are deferred in stockholders' equity, as a component of accumulated other comprehensive loss, and are amortized as an adjustment to interest expense over the period during which the hedged forecasted transaction affects earnings, which is when the Company recognizes interest expense on the hedged cash flows.  At inception and quarterly thereafter, the Company formally assesses whether the derivatives that are used in hedging transactions are highly effective in offsetting changes in the fair value or cash flows of the hedged item.  After the initial quantitative assessment, this analysis is initially performed on a qualitative basis and, if it is determined that the hedging relationship was and continues to be highly effective, no further analysis is required.  All components of each derivative financial instrument's gain or loss are included in the assessment of hedge effectiveness.  If it is determined that a derivative ceases to be a highly effective hedge, the Company discontinues hedge accounting and any deferred gains or losses related to a discontinued cash flow hedge shall continue to be reported in accumulated other comprehensive loss, unless it is probable that the forecasted transaction will not occur.  If it is probable that the forecasted transaction will not occur by the originally specified time period, the Company discontinues hedge accounting and any deferred gains or losses reported in accumulated other comprehensive loss are classified into earnings immediately.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Comprehensive income (loss) encompasses all changes in stockholders' equity (except those arising from transactions with stockholders) and includes:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Foreign currency translation adjustments; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Net deferred gains (losses) on cash flow hedges, which represent deferred gains (losses), net of tax, on interest rate-related derivative financial instruments designated as cash flow hedges, net of amounts reclassified to interest expense (see Notes 16 and 17); and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Net changes in available-for-sale debt securities, which represent unrealized holding gains (losses), net of tax, on available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising Costs&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Advertising costs are expensed as incurred.  For the years ended December&#160;31, 2022, 2021 and 2020, advertising costs were $74&#160;million, $78&#160;million and $38&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;New Accounting Standards &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;New Accounting Standards To Be Adopted&lt;/span&gt;&lt;/div&gt;&#160;&#160;&#160;&#160;In March 2020, the Financial Accounting Standards Board ("FASB") issued a new accounting standard which provides temporary optional guidance to ease the potential burden in accounting for reference rate reform due to the risk of cessation of the London Interbank Offered Rate ("LIBOR").  The amendments apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform.  The pronouncement was effective immediately and, due to an accounting standards update which the FASB issued in December 2022, can be applied to contract modifications through December 31, 2024.  To the extent that, prior to December 31, 2024, the Company enters into any contract modifications for which the optional expedients are applied, the adoption of this standard is not expected to have a material impact on the Company&#x2019;s consolidated results of operations, financial position or cash flows.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MDQ2_c56374e1-897a-4ad5-b74b-af70aa94a7aa">The consolidated financial statements include the accounts of all entities controlled by the Company through its direct or indirect ownership of a majority voting interest.  Additionally, the consolidated financial statements include the accounts of variable interest entities (&#x201c;VIEs&#x201d;) in which the Company has a variable interest and for which the Company is the &#x201c;primary beneficiary&#x201d; as it has both: (1) the power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and (2) the obligation to absorb losses of the VIE that potentially could be significant to the VIE or the right to receive benefits from the VIE that potentially could be significant to the VIE.  All significant intercompany accounts and transactions are eliminated in consolidation.&#160;&#160;&#160;&#160;Income attributable to the minority interest in the Company's majority owned and controlled consolidated subsidiaries is recorded as net income attributable to noncontrolling interests in the consolidated statements of operations and the noncontrolling interest is reflected as a separate component of consolidated stockholders' equity in the consolidated balance sheet.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI3NDg3NzkxMDM3NDQ_75c8848c-72f9-465c-aeaa-07b58d0628f9">Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements.</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MDMy_ff61deec-3b67-4832-a3aa-3e0111003e78">Investments in entities which the Company does not control, but in which it has a substantial ownership interest (generally between 20% and 49%) and can exercise significant influence, are accounted for using the equity method of accounting.  These investments are classified as investments in equity method investees in the consolidated balance sheet.  The Company records its pro rata share of the earnings, adjusted for accretion of basis difference, of these investments in equity in earnings of equity method investees, net of taxes in the consolidated statements of operations.  The Company reviews its investments in equity method investees for impairment whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable.</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="iedbe1fc06b5345c38cc97c62d3b664a3_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzE4ODc_76a63277-0249-4d40-a72d-2c34366d5cf0"
      unitRef="number">0.20</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i4b416adaeaac49cfb869af6c8e627c39_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzE4OTQ_891d6c36-33ef-4833-a0c1-96ac1e707969"
      unitRef="number">0.49</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:UseOfEstimates
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MTE4_24138090-76d1-4e8d-94e6-3f4687fbae5b">The preparation of financial statements in conformity with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.</us-gaap:UseOfEstimates>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MDg4_baaa60e1-02f2-4a91-b107-874a7a9fa7fe">The Company recognizes as revenue the amount that reflects the consideration to which it expects to be entitled in exchange for goods sold or services rendered primarily upon completion of the testing process (when results are reported) or when services have been rendered (see Note 3).  Net revenues from Medicare and Medicaid programs were approximately 11%, 10% and 11% of the Company's consolidated net revenues for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</us-gaap:RevenueRecognitionPolicyTextBlock>
    <dgx:PercentageofNetRevenues
      contextRef="ib62f2d7bef64474dbe05584de6966e18_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzMzOTA_ca41b615-264d-43e5-a406-fba07bba850f"
      unitRef="number">0.11</dgx:PercentageofNetRevenues>
    <dgx:PercentageofNetRevenues
      contextRef="i316b4c39b6be48408e5109495bc92124_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzMzOTQ_e6b31b3d-ccd6-4808-b71b-4faa236421a2"
      unitRef="number">0.10</dgx:PercentageofNetRevenues>
    <dgx:PercentageofNetRevenues
      contextRef="i27098106112f421c94055f0cdae93371_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzM0MDE_718b3ffd-82c6-4dd8-80cb-d91a8cdf70b8"
      unitRef="number">0.11</dgx:PercentageofNetRevenues>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MTM3_f6fca248-1fe7-4454-91a5-1e795dd3484c">The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the year.  Current and deferred income taxes are measured based on the tax laws that are enacted as of the balance sheet date of the relevant reporting period.  Deferred tax assets and liabilities are recognized for the expected future tax consequences of differences between the carrying amounts of assets and liabilities and their respective tax bases using tax rates in effect for the year in which the differences are expected to reverse.  A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period when the change is enacted.  Tax benefits from uncertain tax positions are recognized only if the tax position is more likely than not to be sustained upon examination by taxing authorities based on the technical merits of the position.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MDY3_d74ebf33-a620-45dc-a404-77aee393d1d0">The Company's unvested restricted stock units that contain non-forfeitable rights to dividends are participating securities and, therefore, are included in the earnings allocation in computing earnings per share using the two-class method.  Basic earnings per common share is calculated by dividing net income attributable to Quest Diagnostics, adjusted for earnings allocated to participating securities, by the weighted average number of common shares outstanding.  Diluted earnings per common share is calculated by dividing net income attributable to Quest Diagnostics, adjusted for earnings allocated to participating securities, by the weighted average number of common shares outstanding after giving effect to all potentially dilutive common shares outstanding during the period.  Potentially dilutive common shares include the dilutive effect of outstanding stock options and performance share units granted under the Company's Amended and Restated Employee Long-Term Incentive Plan (&#x201c;ELTIP&#x201d;) and its Amended and Restated Non-Employee Director Long-Term Incentive Plan (&#x201c;DLTIP&#x201d;), as well as the dilutive effect of accelerated share repurchase agreements ("ASRs"), if applicable.  Earnings allocable to participating securities include the portion of dividends declared as well as the portion of undistributed earnings during the period allocable to participating securities.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MTM5_36c13a2b-0db3-48b1-9cc1-407e50535914">The Company measures stock-based compensation for equity awards at fair value on the date of grant and records stock-based compensation as a charge to earnings net of the estimated impact of forfeited awards.  As such, the Company recognizes stock-based compensation cost only for those stock-based awards that are estimated to ultimately vest over their requisite service period, based on the vesting provisions of the individual grants.  The cumulative effect on current and prior periods of a change in the estimated forfeiture rate is recognized as compensation cost in earnings in the period of the change.  The terms of the Company's performance share units allow the recipients of such awards to earn a variable number of shares based on the achievement of the performance goals, which are based on the financial performance of the Company and the total shareholder return of the Company relative to an index of peer companies ("relative TSR"), specified in the awards.  For performance share units with a goal based on the financial performance of the Company, stock-based compensation expense is recognized based on management's best estimates of the achievement of the performance goals specified in such awards and the resulting number of shares that will be earned.  The cumulative effect on current and prior periods of a change in the estimated number of performance share units expected to be earned for these awards is recognized as compensation cost in earnings in the period of the change.  For performance share units with a market-based relative TSR goal, stock-based compensation expense is recognized based on the estimated fair value of the award regardless of the actual number of shares earned.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MTA0_1436ab5c-4837-4fea-b3cb-81f8115d1ec8">The Company determines fair value measurements used in its consolidated financial statements based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants exclusive of any transaction costs, as determined by either the principal market or the most advantageous market.&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Inputs used in the valuation techniques to derive fair values are classified based on a three-level hierarchy.  The basis for fair value measurements for each level within the hierarchy is described below with Level 1 having the highest priority and Level 3 having the lowest.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1: Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3: Valuations derived from valuation techniques in which one or more significant inputs are unobservable.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MDM1_df599ac8-a8ad-423f-948a-7ca2eb94a0d7">The Company predominately uses the U.S. dollar as its functional currency.  The functional currency of the Company's foreign operating subsidiaries generally is the applicable local currency.  Assets and liabilities denominated in non-U.S. dollars are translated into U.S. dollars at exchange rates as of the end of the reporting period.  Income and expense items are translated at the average monthly exchange rates during the year.  Resulting translation adjustments are recorded as a component of accumulated other comprehensive loss within stockholders' equity.  Gains and losses from foreign currency transactions, which are denominated in a currency other than the functional currency, are included within other operating expense (income), net in the consolidated statements of operations.  Foreign currency transaction gains and losses have historically not been material.  The Company may be exposed to market risk for changes in foreign exchange rates primarily under certain intercompany receivables and payables.  From time to time, the Company uses foreign exchange forward contracts to mitigate the exposure of the eventual net cash inflows or outflows resulting from these intercompany transactions.  The Company's foreign exchange exposure is not material to the Company's consolidated financial condition.  The Company does not hedge its net investment in non-U.S. subsidiaries because it views those investments as long-term in nature.</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MDAx_d188d1f2-cc41-43b1-87b9-288f3df31691">Cash and cash equivalents include all highly-liquid investments with original maturities, at the time acquired by the Company, of three months or less.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskDisclosureTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MDcz_00f14b55-6b05-47e3-bf82-341cc40e53a6">Financial instruments that potentially subject the Company to concentrations of credit risk are principally cash, cash equivalents, short-term investments, accounts receivable and derivative financial instruments.  The Company's policy is to place its cash, cash equivalents and short-term investments in highly-rated financial instruments and institutions.  Concentration of credit risk with respect to accounts receivable is mitigated by the diversity of the Company's payers and their dispersion across many different geographic regions, and credit risk is concentrated among certain payers who are large buyers of the Company's services.  To reduce risk, the Company routinely assesses the financial strength of these payers and, consequently, believes that its accounts receivable credit risk exposure, with respect to these payers, is limited.  While the Company has receivables due from federal and state governmental agencies, the Company does not believe that such receivables represent a credit risk since the related healthcare programs are funded by federal and state governments, and payment is primarily dependent on submitting appropriate documentation timely.  As of both December&#160;31, 2022 and 2021, receivables due from government payers under the Medicare and Medicaid programs represented approximately 6% of the Company's consolidated net accounts receivable.  The portion of the Company's accounts receivable due from patients comprises the largest portion of credit risk.  As of December&#160;31, 2022 and 2021, receivables due from patients represented approximately 18% and 21%, respectively, of the Company's consolidated net accounts receivable.  The Company applies assumptions and judgments including historical collection experience (including the period of time that the receivables have been outstanding) for assessing collectability and determining net revenues and accounts receivable from patients.</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <dgx:PercentageofNetAccountsReceivable
      contextRef="iba76f6181ce848fcbd7af0ece345152c_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzExODg5_936350dc-beac-4561-aea8-42eadb5f0cf5"
      unitRef="number">0.06</dgx:PercentageofNetAccountsReceivable>
    <dgx:PercentageofNetAccountsReceivable
      contextRef="i81be56c5955845f49525165bab74c70f_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzEyMTM1_837db2ce-c5d8-4624-9713-8dcc26271237"
      unitRef="number">0.18</dgx:PercentageofNetAccountsReceivable>
    <dgx:PercentageofNetAccountsReceivable
      contextRef="i915edbec2fea42159bcc1ba9f3179a51_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzEyMTQy_8701ee87-ae54-4b52-b0b3-e85111b765a1"
      unitRef="number">0.21</dgx:PercentageofNetAccountsReceivable>
    <dgx:AccountsReceivableAndAllowanceForCreditLossesPolicyPolicyTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MTQw_3340de95-a6b8-4145-87b1-1e3c9cb66fd7">Accounts receivable are reported net of allowances for credit losses.  &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;When estimating its allowance for credit losses, the Company pools its trade receivables based on the following customer types: healthcare insurers, government payers, client payers and patients, which are described in Note 3.&#160; The Company principally estimates the allowance for credit losses by pool based on historical collection experience, the current credit worthiness of the customers, current economic conditions, expectations of future economic conditions and the period of time that the receivables have been outstanding.&#160; To the extent that any individual payers are identified that have deteriorated in credit quality, the Company removes the customers from their respective pools and establishes allowances based on the individual risk characteristics of such customers.&lt;/span&gt;&lt;/div&gt;</dgx:AccountsReceivableAndAllowanceForCreditLossesPolicyPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MDk5_382bd057-c2ac-48ed-8b6a-2bf8d60ccaf7">Inventories, which consist principally of finished goods testing supplies and reagents, are valued at the lower of cost (first in, first out method) or net realizable value.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MDQ5_25db0b4c-b69c-481a-92f1-c4fe37f52d3d">Property, plant and equipment is recorded at cost.  Major renewals and improvements are capitalized, while maintenance and repairs are expensed as incurred.  Costs incurred for computer software developed or obtained for internal use are capitalized for application development activities and expensed as incurred for preliminary project activities and post-implementation activities.  Capitalized costs include external direct costs of materials and services consumed in developing or obtaining internal-use software, payroll and payroll-related costs for employees who are directly associated with the internal-use software project, and interest costs incurred, when material, while developing internal-use software.  Capitalization of such costs ceases when the project is substantially complete and ready for its intended purpose.  Costs for maintenance and training are expensed as incurred.  The Company capitalizes interest on borrowings during the active construction period of major capital projects.  Capitalized interest is added to the cost of the underlying assets and is amortized over the expected useful lives of the assets.  Depreciation and amortization are provided on the straight-line method over expected useful asset lives as of December&#160;31, 2022 as follows: &lt;div style="padding-left:63pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;buildings and improvements, ranging up to thirty-one and a half years; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:63pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;laboratory equipment and furniture and fixtures, ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzE1MDA1_cf798870-e9ec-4915-8333-6fffdab241e2"&gt;five&lt;/span&gt; to twelve years; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:63pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;leasehold improvements, the lesser of the useful life of the improvement or the remaining life of the building or lease, as applicable; and &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:63pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;computer software developed or obtained for internal use, principally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzE1MjE1_15232aa9-a205-41d3-834e-46d37c844c97"&gt;five&lt;/span&gt; to ten years.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i05ea7f33f7e549de90d8144e632a0571_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzE1MDEx_e5c74e81-babe-45e1-8478-7eb6d4b741c7">P12Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ifa192df489ca4b7eb7ca0059b95703b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzE1MjIx_247ef8e2-ddcb-4b77-8804-70d3522fea99">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MDQy_d7b789b3-018a-4725-a6b0-eeb5d3a48651">Goodwill represents the excess of the fair value of the acquiree (including the fair value of non-controlling interests) over the recognized bases of the net identifiable assets acquired and includes the future economic benefits from other assets that could not be individually identified and separately recognized.  Goodwill is not amortized, but instead is periodically reviewed for impairment and an impairment charge is recorded in the periods in which the recorded carrying value of goodwill exceeds its fair value.  &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;On a quarterly basis, the Company performs a review of its business to determine if events or changes in circumstances have occurred which could have a material adverse effect on the fair value of the Company and its goodwill.  If such events or changes in circumstances were deemed to have occurred, the Company would perform an impairment test of goodwill as of the end of the quarter and record any noted impairment loss.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The goodwill test is performed at least annually, or more frequently if events or changes in circumstances indicate that the asset might be impaired.  The annual impairment test includes an option to perform a qualitative assessment of whether it is more likely than not that a reporting unit's fair value is less than its carrying value; the qualitative test may be performed prior to, or as an alternative to, performing a quantitative goodwill impairment test.  If, after assessing the totality of events or circumstances, the Company determines that it is more likely than not that the fair value of a reporting unit is less than its carrying value, then the Company is required to perform the quantitative goodwill impairment test.  Otherwise, no further analysis is required.  Additionally, the Company's policy is to update the fair value calculation of its reporting units and perform the quantitative goodwill impairment test on a periodic basis.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The quantitative impairment test involves the comparison of the fair value of the reporting unit to its carrying value.  The Company calculates the fair value of each reporting unit using either (i) a discounted cash flows analysis that converts future cash flow amounts into a single discounted present value amount or (ii) a market approach.  The Company assesses the valuation methodology based upon the relevance and availability of the data at the time that the valuation is performed.  The Company compares the estimate of fair value for the reporting unit to the carrying value of the reporting unit.  If the carrying value is greater than the estimate of fair value, an impairment loss will be recognized in the amount of the excess. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company performs its annual impairment test during the fourth quarter of the fiscal year.  For the years ended December&#160;31, 2022 and 2021, the Company performed a qualitative impairment test for its DIS reporting unit and, based on the totality of information available, the Company concluded that it was more-likely-than-not that the estimated fair value of its DIS reporting unit was greater than the carrying value of the reporting unit and, as such, no further analysis was required.  For the year ended December&#160;31, 2022, the Company updated the fair value calculation of its risk assessment services reporting unit, performed the quantitative impairment test and concluded that goodwill for the reporting unit was not impaired.  For the year ended December 31, 2021, the Company performed a qualitative impairment test for its risk assessment reporting unit and, based on the totality of information available, the Company concluded that it was more-likely-than-not that the estimated fair value of the reporting unit was greater than the carrying value of the reporting unit and, as such, no further analysis was required.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MDY0_298380e3-4361-4e89-a2c3-cf540457586c">Intangible assets are recognized at fair value, as an asset apart from goodwill if the asset (i) arises from contractual or other legal rights, or (ii) is separable.  Intangible assets, principally representing the cost of customer-related intangibles, non-competition agreements and technology acquired, are capitalized and amortized on the straight-line method over their expected useful lives, which generally range from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzE5MDc3_e109cd52-340f-452f-8421-53cd708ea892"&gt;five&lt;/span&gt; to twenty years.  Intangible assets with indefinite useful lives, consisting principally of acquired tradenames, are not amortized, but instead are periodically reviewed for impairment.  &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company reviews indefinite-lived intangible assets periodically for impairment and an impairment charge is recorded in the periods in which the recorded carrying value of an indefinite-lived intangible asset is more than its estimated fair value.  The indefinite-lived intangible asset impairment test is performed at least annually, or more frequently in the case of other events that indicate a potential impairment.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Based upon the Company&#x2019;s most recent annual impairment tests completed during the fourth quarters of the years ended December&#160;31, 2022 and 2021, the Company concluded that indefinite-lived intangible assets were not impaired.&lt;/span&gt;&lt;/div&gt;&#160;&#160;&#160;&#160;The Company reviews the recoverability of its long-lived assets (including amortizable intangible assets), other than goodwill and indefinite-lived intangible assets, when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable.  Evaluation of possible impairment is based on the Company's ability to recover the asset from the expected future pre-tax cash flows (undiscounted and without interest charges) of the related operations.  If these cash flows are less than the carrying amount of such asset, an impairment loss is recognized for the difference between the estimated fair value and carrying amount of the asset.</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i4c9530356f3242cdb77f114a2aa32961_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzE5MDgz_6e37a90a-194f-41dd-8faf-f055479df330">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MDgz_c48bb8b4-0fba-4a8b-8685-2ead6d230cb7">The Company's investments (except for those accounted for under the equity method of accounting) include:&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Equity investments with readily determinable fair values, including investments comprised mostly of strategic holdings in companies concentrated in the life sciences and healthcare industries (such investments, which previously did not have readily determinable fair values, became publicly-traded during the year ended December 31, 2021); as well as participant-directed investments of deferred employee compensation and related Company matching contributions held in trusts pursuant to the Company's supplemental deferred compensation plans (see Note 18).  These investments are measured at fair value with both realized and unrealized gains and losses recorded in current earnings within other (expense) income, net in the consolidated statements of operations.  For the years ended December&#160;31, 2022, 2021 and 2020, (losses)/gains from all equity investments with readily determinable fair values totaled $(55) million, $56 million, and $8 million, respectively.  See Note 8 for a discussion of the fair value of such investments. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Equity investments that do not have readily determinable fair values, which consist of investments in preferred and common shares of privately held companies.  These investments are measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes.  The Company regularly evaluates these equity investments to determine if there are any indicators that the investment is impaired; no impairment charges were recognized related to these investments for the years ended December&#160;31, 2022, 2021 and 2020.  The carrying value of these investments was $4&#160;million at both December&#160;31, 2022 and 2021.  Such amounts were included in other assets in the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&#x2022;Available-for-sale debt securities of privately-held companies.  These investments are measured at fair value with unrealized gains and losses presented in other comprehensive (loss) income.  The carrying amount of these investments was $2 million and $1 million at December&#160;31, 2022 and 2021, respectively.  See Note 8 for a discussion of the fair value of such investments.</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzIxNTYx_307dcf12-4d47-4b92-99ee-3bd6465ab3d3"
      unitRef="usd">-55000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzIxNTY1_c5cc29d6-7bf6-4d5c-9fe4-61212e17b00c"
      unitRef="usd">56000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzIxNTcz_168681cd-b25d-418d-a7ab-f349a5577634"
      unitRef="usd">8000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <dgx:InvestmentwithoutReadilyDeterminableFairValueImpairment
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzIyMzY0_25013ac6-8b15-488c-b139-b2759345a359"
      unitRef="usd">0</dgx:InvestmentwithoutReadilyDeterminableFairValueImpairment>
    <dgx:InvestmentwithoutReadilyDeterminableFairValueImpairment
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzIyMzY0_250f160d-cd2e-48a3-8214-56bccc1228e4"
      unitRef="usd">0</dgx:InvestmentwithoutReadilyDeterminableFairValueImpairment>
    <dgx:InvestmentwithoutReadilyDeterminableFairValueImpairment
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzIyMzY0_97749a40-7e87-4ecc-897c-f65947a9952b"
      unitRef="usd">0</dgx:InvestmentwithoutReadilyDeterminableFairValueImpairment>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzEwOTk1MTE2NjY5OTY_6bb1c5ca-adf1-4c05-aa6a-8c81e2e99bd9"
      unitRef="usd">4000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzEwOTk1MTE2NjY5OTY_829e1408-8528-40d9-b58c-17c09d6e60c3"
      unitRef="usd">4000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzIyODY1_287083d9-b80f-46cd-a7a9-2364c4b74243"
      unitRef="usd">2000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzIyODcy_7df8db56-5b2e-4395-8cbd-0580d08e824b"
      unitRef="usd">1000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MDA5_f842d9ce-4b72-4504-b769-991ecf9abba6">The Company uses derivative financial instruments, from time to time, to manage its exposure to market risks for changes in interest rates and foreign currencies.  This strategy includes the use of interest rate swap agreements, forward-starting interest rate swap agreements, interest rate lock agreements and foreign currency forward contracts to manage its exposure to movements in interest and currency rates.  The Company has established policies and procedures for risk assessment and the approval, reporting and monitoring of derivative financial instrument activities.  These policies prohibit holding or issuing derivative financial instruments for speculative purposes.  The Company does not enter into derivative financial instruments that contain credit risk-related contingent features or requirements to post collateral.&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest Rate Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company is exposed to interest rate risk on its cash and cash equivalents and its debt obligations.  Interest income earned on cash and cash equivalents may fluctuate as interest rates change; however, due to their relatively short maturities, the Company does not hedge these assets or their investment cash flows and the impact of interest rate risk is not material.  The Company's debt obligations consist of fixed-rate and, from time to time, variable-rate debt instruments.  The Company's primary objective is to achieve the lowest overall cost of funding while managing the variability in cash outflows within an acceptable range.  In order to achieve this objective, the Company has historically entered into interest rate swap agreements.  Interest rate swap agreements involve the periodic exchange of payments without the exchange of underlying principal or notional amounts.  Net settlements between the counterparties are recognized as an adjustment to interest expense, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company accounts for these derivatives as either an asset or liability measured at its fair value.  The fair value is based upon model-derived valuations in which all significant inputs are observable in active markets including certain financial &lt;/span&gt;&lt;/div&gt;information and certain assumptions regarding past, present and future market conditions.  For a derivative instrument that has been formally designated as a fair value hedge, fair value gains or losses on the derivative instrument along with offsetting fair value gains or losses on the hedged item that are attributable to the risk being hedged are reported in other (expense) income, net in the consolidated statements of operations.  For derivatives that have been formally designated as a cash flow hedge, the change in the fair value of the derivatives is recorded in accumulated other comprehensive loss.  Upon maturity or early termination of an effective interest rate swap agreement designated as a cash flow hedge, unrealized gains or losses are deferred in stockholders' equity, as a component of accumulated other comprehensive loss, and are amortized as an adjustment to interest expense over the period during which the hedged forecasted transaction affects earnings, which is when the Company recognizes interest expense on the hedged cash flows.  At inception and quarterly thereafter, the Company formally assesses whether the derivatives that are used in hedging transactions are highly effective in offsetting changes in the fair value or cash flows of the hedged item.  After the initial quantitative assessment, this analysis is initially performed on a qualitative basis and, if it is determined that the hedging relationship was and continues to be highly effective, no further analysis is required.  All components of each derivative financial instrument's gain or loss are included in the assessment of hedge effectiveness.  If it is determined that a derivative ceases to be a highly effective hedge, the Company discontinues hedge accounting and any deferred gains or losses related to a discontinued cash flow hedge shall continue to be reported in accumulated other comprehensive loss, unless it is probable that the forecasted transaction will not occur.  If it is probable that the forecasted transaction will not occur by the originally specified time period, the Company discontinues hedge accounting and any deferred gains or losses reported in accumulated other comprehensive loss are classified into earnings immediately.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:StockholdersEquityPolicyTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MTMy_5f33774e-c3f8-47c7-9787-6ce2dbaf76fb">Comprehensive income (loss) encompasses all changes in stockholders' equity (except those arising from transactions with stockholders) and includes:&lt;div style="padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Foreign currency translation adjustments; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Net deferred gains (losses) on cash flow hedges, which represent deferred gains (losses), net of tax, on interest rate-related derivative financial instruments designated as cash flow hedges, net of amounts reclassified to interest expense (see Notes 16 and 17); and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Net changes in available-for-sale debt securities, which represent unrealized holding gains (losses), net of tax, on available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI5MDA3_e9ff3b83-9cb7-4732-8050-9bf97241ebe2">Advertising costs are expensed as incurred.  For the years ended December&#160;31, 2022, 2021 and 2020, advertising costs were $74&#160;million, $78&#160;million and $38&#160;million, respectively.</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI4MTY5_59618dbb-915e-4a51-835c-014361317dd0"
      unitRef="usd">74000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI4MTcz_e1fde760-001b-4609-b365-dd2e24ca0429"
      unitRef="usd">78000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI4MTgw_49e30dfc-504b-47af-b36b-b851d8649ba9"
      unitRef="usd">38000000</us-gaap:AdvertisingExpense>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xNzgvZnJhZzozNGNiNjc1ZDI4OGQ0NTg1OWMwODJkY2QxMzVmMzk4OC90ZXh0cmVnaW9uOjM0Y2I2NzVkMjg4ZDQ1ODU5YzA4MmRjZDEzNWYzOTg4XzI4OTk5_eb7e6f7b-45a2-4148-a9df-cae140f63214">New Accounting Standards To Be Adopted&#160;&#160;&#160;&#160;In March 2020, the Financial Accounting Standards Board ("FASB") issued a new accounting standard which provides temporary optional guidance to ease the potential burden in accounting for reference rate reform due to the risk of cessation of the London Interbank Offered Rate ("LIBOR").  The amendments apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform.  The pronouncement was effective immediately and, due to an accounting standards update which the FASB issued in December 2022, can be applied to contract modifications through December 31, 2024.  To the extent that, prior to December 31, 2024, the Company enters into any contract modifications for which the optional expedients are applied, the adoption of this standard is not expected to have a material impact on the Company&#x2019;s consolidated results of operations, financial position or cash flows.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90ZXh0cmVnaW9uOmQxNDYxNDJhODllZTQ3NGFiYzI2MTkyNDIyNWU1MjE1Xzc5NzM_a42b11a6-df6e-4e43-866e-e5a3cbde61f8">REVENUE RECOGNITION&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;DIS&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Net revenues in the Company&#x2019;s DIS business accounted for greater than 95% of the Company&#x2019;s consolidated net revenues for the years ended December&#160;31, 2022, 2021 and 2020 and are primarily comprised of a high volume of relatively low-dollar transactions.  The DIS business, which provides clinical testing services and other services, satisfies its performance obligation and recognizes revenues primarily upon completion of the testing process (when results are reported) or when services have been rendered.  The Company estimates the amount of consideration it expects to be entitled to receive from customer groups in exchange for providing services using the portfolio approach. These estimates include the impact of contractual allowances (including payer denials), and patient price concessions, as discussed below. The portfolios determined using the portfolio approach consist of the following groups of customers: healthcare insurers, government payers (Medicare and Medicaid programs), client payers and patients.  Contracts with customers in the DIS business do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation.  The Company follows a standard process, which considers historical denial and collection experience and other factors (including the period of time that the receivables have been outstanding), to estimate contractual allowances and implicit price concessions, recording adjustments in the current period as changes in estimates.  Further adjustments to the allowances, based on actual receipts, may be recorded upon settlement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The following are descriptions of the DIS business&#x2019; portfolios:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Healthcare Insurers &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Reimbursements from healthcare insurers are based on negotiated fee-for-service schedules and on capitated payment rates.  Under fee-for-service arrangements, healthcare insurers are billed at the Company's list price.  Net revenues recognized consist of amounts billed net of contractual allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payers, which considers historical denial and collection experience and the terms of the Company&#x2019;s contractual arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Collection of the Company's net revenues from healthcare insurers is normally a function of providing complete and correct billing information to the healthcare insurers within the various filing deadlines and generally occurs within 30 to 60 days of billing.  Provided the Company has billed healthcare insurers accurately with complete information prior to the established filing deadline, there has historically been little to no credit risk.  If there has been a delay in billing, the Company determines if the amounts in question will likely go past the filing deadline, and if so, it will reserve accordingly for the billing.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Under capitated arrangements with healthcare insurers, the Company recognizes revenue based on a predetermined monthly reimbursement rate for each member of an insurer's health plan regardless of the number or cost of services provided by the Company.  Healthcare insurers typically reimburse the Company under capitated arrangements in the same month services are performed, essentially giving rise to no outstanding accounts receivable at the end of a reporting period.  If any capitated payments are not received on a timely basis, the Company determines the cause and makes a separate determination as to whether or not the collection of the amount from the healthcare insurer is at risk and, if so, would reserve accordingly.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Payers&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Reimbursements from government payers are based on fee-for-service schedules set by governmental authorities, including traditional Medicare and Medicaid.  Net revenues recognized consist of amounts billed net of contractual allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payers, which considers historical denial and collection experience and other factors. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Collection of the Company's net revenues from government payers is normally a function of providing the complete and correct billing information within the various filing deadlines and generally occurs within 30 days of billing.  Provided the Company has billed government payers accurately with complete information prior to the established filing deadline, there has historically been little to no credit risk.  If there has been a delay in billing, the Company determines if the amounts in question will likely go past the filing deadline, and, if so, it will reserve for the billing accordingly.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Client Payers &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Client payers include physicians, hospitals, ACOs, IDNs, employers, other commercial laboratories and institutions for which services are performed on a wholesale basis, and are billed based on negotiated fee schedules.  Credit risk and ability to pay are more of a consideration for these payers than healthcare insurers and government payers.  Collection of consideration the Company expects to receive generally occurs within 60 to 90 days of billing.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company principally estimates the allowance for credit losses for client payers based on historical collection experience, the current credit worthiness of the customers, current economic conditions, expectations of future economic conditions and the period of time that the receivables have been outstanding. To the extent that any individual client payers are identified that have deteriorated in credit quality, the Company establishes allowances based on the individual risk characteristics of such customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Patients&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Uninsured patients are billed based on established patient fee schedules or fees negotiated with physicians on behalf of their patients.  Insured patients (includes coinsurance and deductible responsibilities) are billed based on fees negotiated with healthcare insurers.  Collection of billings from patients is subject to credit risk and ability of the patients to pay.  Net revenues consist of amounts billed net of discounts provided to uninsured patients in accordance with the Company&#x2019;s policies and implicit price concessions.  Implicit price concessions represent differences between amounts billed and the estimated consideration the Company expects to receive from patients, which considers historical collection experience (including the period of time that the receivables have been outstanding) and other factors including current market conditions. Patient billings are generally fully reserved for when the related service reaches 210 days outstanding.  Balances are automatically written off when they are sent to collection agencies.  Allowances are further adjusted for estimated recoveries of amounts sent to collection agencies based on historical collection experience, which is regularly monitored.  Collection of consideration the Company expects to receive generally occurs within 30 to 60 days of billing.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;DS&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company&#x2019;s DS businesses primarily satisfy their performance obligations and recognize revenues when delivery has occurred or services have been rendered.  Collection of consideration the Company expects to receive generally occurs within 30 to 60 days of billing.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The approximate percentage of net revenues by type of customer was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.699%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.699%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.702%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Healthcare insurers:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fee-for-service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total healthcare insurers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government payers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Client payers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patients (including coinsurance and deductible responsibilities)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total DIS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;DS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;For the years ended December&#160;31, 2022, 2021 and 2020, substantially all of the Company&#x2019;s services were provided within the United States, see Note 20.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The approximate percentage of net accounts receivable by type of customer as of December&#160;31, 2022 and 2021 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.838%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Healthcare insurers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government payers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Client payers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patients (including coinsurance and deductible responsibilities)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total DIS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;DS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The following table summarizes the activity for the Company's allowance for credit losses during the years ended December&#160;31, 2022 and 2021, which principally relates to client payers:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Allowance for Credit Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Write-offs of accounts receivable, net of recoveries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Write-offs of accounts receivable, net of recoveries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance, December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <dgx:PercentageofNetRevenues
      contextRef="i73714e6410064c5eac002e398216cb2c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90ZXh0cmVnaW9uOmQxNDYxNDJhODllZTQ3NGFiYzI2MTkyNDIyNWU1MjE1XzEwNw_993afb16-bb09-437b-93ae-7376bdae3b00"
      unitRef="number">0.95</dgx:PercentageofNetRevenues>
    <dgx:PercentageofNetRevenues
      contextRef="id9ea9ce1f68f4cde8b57ba97522e9899_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90ZXh0cmVnaW9uOmQxNDYxNDJhODllZTQ3NGFiYzI2MTkyNDIyNWU1MjE1XzEwNw_b32b3c7f-34ab-463d-92cd-cd9117a85934"
      unitRef="number">0.95</dgx:PercentageofNetRevenues>
    <dgx:PercentageofNetRevenues
      contextRef="ifbf8633ce3e245ac94d164f390ff90af_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90ZXh0cmVnaW9uOmQxNDYxNDJhODllZTQ3NGFiYzI2MTkyNDIyNWU1MjE1XzEwNw_dad166fc-e478-46e9-bac5-c0984ba1f529"
      unitRef="number">0.95</dgx:PercentageofNetRevenues>
    <dgx:RevenueCollectionofConsiderationPeriod
      contextRef="i7d71e5c8af24471ca79d701791aa2094_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90ZXh0cmVnaW9uOmQxNDYxNDJhODllZTQ3NGFiYzI2MTkyNDIyNWU1MjE1XzI2NjU_def9d786-e706-4aa5-ad55-43ac39739920">P30D</dgx:RevenueCollectionofConsiderationPeriod>
    <dgx:RevenueCollectionofConsiderationPeriod
      contextRef="i1d2e4bb54e5b41c9be7d8748b8f55367_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90ZXh0cmVnaW9uOmQxNDYxNDJhODllZTQ3NGFiYzI2MTkyNDIyNWU1MjE1XzI2NzE_e7ce2004-731d-4fb8-85c2-70be7791a00d">P60D</dgx:RevenueCollectionofConsiderationPeriod>
    <dgx:RevenueCollectionofConsiderationPeriod
      contextRef="ic16acd3f5abe4057b2ded728e43030c9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90ZXh0cmVnaW9uOmQxNDYxNDJhODllZTQ3NGFiYzI2MTkyNDIyNWU1MjE1XzQ0NjU_6483b2ac-2577-47d9-8764-fd40146d7d68">P30D</dgx:RevenueCollectionofConsiderationPeriod>
    <dgx:RevenueCollectionofConsiderationPeriod
      contextRef="ifa2bee4df39349539bed4c4b3462277a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90ZXh0cmVnaW9uOmQxNDYxNDJhODllZTQ3NGFiYzI2MTkyNDIyNWU1MjE1XzUzMTA_53b6161f-a0f5-4935-9cf1-f373e210d776">P60D</dgx:RevenueCollectionofConsiderationPeriod>
    <dgx:RevenueCollectionofConsiderationPeriod
      contextRef="i94893ea869b54dd78d6d051a6bad548d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90ZXh0cmVnaW9uOmQxNDYxNDJhODllZTQ3NGFiYzI2MTkyNDIyNWU1MjE1XzUzMTY_a7f19d31-ec56-4586-9eb8-c52432a61495">P90D</dgx:RevenueCollectionofConsiderationPeriod>
    <dgx:PeriodofBillingFullyReserve
      contextRef="icf5f880be7d24d7a8c69fe4843654a88_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90ZXh0cmVnaW9uOmQxNDYxNDJhODllZTQ3NGFiYzI2MTkyNDIyNWU1MjE1XzY4MTc_ce5257ee-bd02-4b2c-838a-d11435476c98">P210D</dgx:PeriodofBillingFullyReserve>
    <dgx:RevenueCollectionofConsiderationPeriod
      contextRef="ib881549de5d14c42a72abbd13bb6179b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90ZXh0cmVnaW9uOmQxNDYxNDJhODllZTQ3NGFiYzI2MTkyNDIyNWU1MjE1XzcxNzU_47306fce-1196-4801-a6dc-2ddfd6969447">P30D</dgx:RevenueCollectionofConsiderationPeriod>
    <dgx:RevenueCollectionofConsiderationPeriod
      contextRef="i25375b7fc67348ac91275e0d3f7a1f4b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90ZXh0cmVnaW9uOmQxNDYxNDJhODllZTQ3NGFiYzI2MTkyNDIyNWU1MjE1XzcxODE_5dbc759f-c915-411b-9fdf-f4246f92aed6">P60D</dgx:RevenueCollectionofConsiderationPeriod>
    <dgx:RevenueCollectionofConsiderationPeriod
      contextRef="i4f428209a39d4b7b8a174be53283b875_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90ZXh0cmVnaW9uOmQxNDYxNDJhODllZTQ3NGFiYzI2MTkyNDIyNWU1MjE1Xzc0NTA_34327fbd-e894-493e-aaba-508f23487fd3">P30D</dgx:RevenueCollectionofConsiderationPeriod>
    <dgx:RevenueCollectionofConsiderationPeriod
      contextRef="i9fd62e07b13c458892bd229457bbe1b5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90ZXh0cmVnaW9uOmQxNDYxNDJhODllZTQ3NGFiYzI2MTkyNDIyNWU1MjE1Xzc0NTY_fab5c063-a0e2-4223-bff1-0f07dfc3c737">P60D</dgx:RevenueCollectionofConsiderationPeriod>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90ZXh0cmVnaW9uOmQxNDYxNDJhODllZTQ3NGFiYzI2MTkyNDIyNWU1MjE1Xzc5Nzg_844160dc-3698-4827-8355-25cad1f446c5">The approximate percentage of net revenues by type of customer was as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.699%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.699%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.702%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Healthcare insurers:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fee-for-service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total healthcare insurers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government payers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Client payers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patients (including coinsurance and deductible responsibilities)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total DIS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;DS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <dgx:PercentageofNetRevenues
      contextRef="i01555413d91d42e3b436c505bbc70a67_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzMtMS0xLTEtNzgyMTU_775fe213-8eeb-49f0-8763-f4dedf7418b3"
      unitRef="number">0.38</dgx:PercentageofNetRevenues>
    <dgx:PercentageofNetRevenues
      contextRef="i82dfa27313e34853973b9607939068a5_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzMtMy0xLTEtNzgyMTU_9690ab6e-1bcc-4feb-bbd8-bd2c82331b79"
      unitRef="number">0.39</dgx:PercentageofNetRevenues>
    <dgx:PercentageofNetRevenues
      contextRef="i391fa00d0a7e46b0bc4a34ff6434ba24_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzMtNS0xLTEtNzgyMTU_959d3213-0f6c-4253-b8b1-432902a5c838"
      unitRef="number">0.34</dgx:PercentageofNetRevenues>
    <dgx:PercentageofNetRevenues
      contextRef="idd41f50ca74e49ffadac56ef4c8022aa_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzQtMS0xLTEtNzgyMTU_0165f04b-8458-4a57-a4a9-e1258e5024a1"
      unitRef="number">0.03</dgx:PercentageofNetRevenues>
    <dgx:PercentageofNetRevenues
      contextRef="i0be3de26f2574a208f21fd35944e0cad_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzQtMy0xLTEtNzgyMTU_abcb0422-1f69-4dee-85c3-2785019b0667"
      unitRef="number">0.03</dgx:PercentageofNetRevenues>
    <dgx:PercentageofNetRevenues
      contextRef="i4ee750c8e58548218454f6b303208917_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzQtNS0xLTEtNzgyMTU_55ea4db7-81ad-4594-97ee-05c0f5ff61b2"
      unitRef="number">0.03</dgx:PercentageofNetRevenues>
    <dgx:PercentageofNetRevenues
      contextRef="i5a3f190b89e94247905769314473af12_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzUtMS0xLTEtNzgyMTU_88f099a4-0525-4057-a194-f71d1da45fd5"
      unitRef="number">0.41</dgx:PercentageofNetRevenues>
    <dgx:PercentageofNetRevenues
      contextRef="i509d8b446ac14984bc658ece06fea971_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzUtMy0xLTEtNzgyMTU_fc009f75-f626-44f1-bda4-0588672bbfb5"
      unitRef="number">0.42</dgx:PercentageofNetRevenues>
    <dgx:PercentageofNetRevenues
      contextRef="i18a0eea57b5d4a778b3c4fc7048a92d0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzUtNS0xLTEtNzgyMTU_77b819c4-52c3-44b1-abe3-ecf46ab185d9"
      unitRef="number">0.37</dgx:PercentageofNetRevenues>
    <dgx:PercentageofNetRevenues
      contextRef="ib62f2d7bef64474dbe05584de6966e18_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzYtMS0xLTEtNzgyMTU_ca41b615-264d-43e5-a406-fba07bba850f"
      unitRef="number">0.11</dgx:PercentageofNetRevenues>
    <dgx:PercentageofNetRevenues
      contextRef="i316b4c39b6be48408e5109495bc92124_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzYtMy0xLTEtNzgyMTU_e6b31b3d-ccd6-4808-b71b-4faa236421a2"
      unitRef="number">0.10</dgx:PercentageofNetRevenues>
    <dgx:PercentageofNetRevenues
      contextRef="i27098106112f421c94055f0cdae93371_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzYtNS0xLTEtNzgyMTU_718b3ffd-82c6-4dd8-80cb-d91a8cdf70b8"
      unitRef="number">0.11</dgx:PercentageofNetRevenues>
    <dgx:PercentageofNetRevenues
      contextRef="i99d6e0655d0f4b178b998f09b7ac1aa5_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzctMS0xLTEtNzgyMTU_47114b64-4c0e-4703-8c21-5ca0826bc98d"
      unitRef="number">0.33</dgx:PercentageofNetRevenues>
    <dgx:PercentageofNetRevenues
      contextRef="if95a07a0521045d7aa3fd6eca9554b97_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzctMy0xLTEtNzgyMTU_ad318e1f-794a-49ec-acc5-1183a56cf2d7"
      unitRef="number">0.33</dgx:PercentageofNetRevenues>
    <dgx:PercentageofNetRevenues
      contextRef="i397e6f4394d44cd0bbe7d033eb4fb637_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzctNS0xLTEtNzgyMTU_01bfb8a6-3807-43db-ad7d-357c295201c0"
      unitRef="number">0.38</dgx:PercentageofNetRevenues>
    <dgx:PercentageofNetRevenues
      contextRef="icf5f880be7d24d7a8c69fe4843654a88_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzgtMS0xLTEtNzgyMTU_a7bfc11d-5a5d-498f-989b-72f119f84ea6"
      unitRef="number">0.12</dgx:PercentageofNetRevenues>
    <dgx:PercentageofNetRevenues
      contextRef="ibcdd11aeccf94ec496587c6ccc6a4281_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzgtMy0xLTEtNzgyMTU_23ac0175-a8c2-4c06-9449-601f5de355c4"
      unitRef="number">0.12</dgx:PercentageofNetRevenues>
    <dgx:PercentageofNetRevenues
      contextRef="i8f3ad29ae1e34df5b6995f7ffaeaa6cf_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzgtNS0xLTEtNzgyMTU_fe3973f8-83da-42f5-b393-04614eb0dcaa"
      unitRef="number">0.11</dgx:PercentageofNetRevenues>
    <dgx:PercentageofNetRevenues
      contextRef="i74ad488f1dfb40baa83701a002b6d98f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzktMS0xLTEtNzgyMTU_fb3675ab-82af-45a5-89e7-daf6a4482b57"
      unitRef="number">0.97</dgx:PercentageofNetRevenues>
    <dgx:PercentageofNetRevenues
      contextRef="i680bf76bfe8647638c33f242f0ef1980_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzktMy0xLTEtNzgyMTU_8c185403-6304-4f53-8b1c-cd0f26580dc5"
      unitRef="number">0.97</dgx:PercentageofNetRevenues>
    <dgx:PercentageofNetRevenues
      contextRef="ic662fc7ebbb744a885416e3447893d64_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzktNS0xLTEtNzgyMTU_407ace74-7622-44a6-9d67-6c52e06b90b9"
      unitRef="number">0.97</dgx:PercentageofNetRevenues>
    <dgx:PercentageofNetRevenues
      contextRef="ie0468d2fc9ab47638da16013b1893683_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzEwLTEtMS0xLTc4MjE1_6ef9eff3-a68a-4974-aa16-8a9ed09bc4dd"
      unitRef="number">0.03</dgx:PercentageofNetRevenues>
    <dgx:PercentageofNetRevenues
      contextRef="idd3a7338f2d040dda1e6639ac9f7d70f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzEwLTMtMS0xLTc4MjE1_30f56d15-bc91-44eb-9a0d-622659ecac67"
      unitRef="number">0.03</dgx:PercentageofNetRevenues>
    <dgx:PercentageofNetRevenues
      contextRef="ic76d3eea03004ba5aed3d7cc7917604b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzEwLTUtMS0xLTc4MjE1_4d737021-f484-46b9-af96-73569ca5e26c"
      unitRef="number">0.03</dgx:PercentageofNetRevenues>
    <dgx:PercentageofNetRevenues
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzExLTEtMS0xLTc4MjE1_a89a8009-4e38-4e47-b74b-7c17c3c8295c"
      unitRef="number">1</dgx:PercentageofNetRevenues>
    <dgx:PercentageofNetRevenues
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzExLTMtMS0xLTc4MjE1_34b70b1d-2df4-4425-9489-6bfb1c61f642"
      unitRef="number">1</dgx:PercentageofNetRevenues>
    <dgx:PercentageofNetRevenues
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTpiMjViNTg3MGRkNGY0ZjQyYmZmNTEzMjI0YWQwZmQ5OC90YWJsZXJhbmdlOmIyNWI1ODcwZGQ0ZjRmNDJiZmY1MTMyMjRhZDBmZDk4XzExLTUtMS0xLTc4MjE1_3386dfb6-5c3a-4f7d-b60f-354535490d9d"
      unitRef="number">1</dgx:PercentageofNetRevenues>
    <dgx:AccountsReceivableDisaggregationTableTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90ZXh0cmVnaW9uOmQxNDYxNDJhODllZTQ3NGFiYzI2MTkyNDIyNWU1MjE1Xzc5Nzc_a3bc694f-6a4c-4400-b47b-4f4140754db3">The approximate percentage of net accounts receivable by type of customer as of December&#160;31, 2022 and 2021 was as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.838%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Healthcare insurers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government payers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Client payers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patients (including coinsurance and deductible responsibilities)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total DIS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;DS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</dgx:AccountsReceivableDisaggregationTableTextBlock>
    <dgx:PercentageofNetAccountsReceivable
      contextRef="ia6826b0f73ee4f00ab77a97be130c154_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTo0MjI4NGM1N2JjNDg0MGQ3YTkwYmQ5ZjU2OWVlZTYzZC90YWJsZXJhbmdlOjQyMjg0YzU3YmM0ODQwZDdhOTBiZDlmNTY5ZWVlNjNkXzItMS0xLTEtNzgyMTU_1ba4cf20-5cf1-442d-91f7-09406ca1c700"
      unitRef="number">0.28</dgx:PercentageofNetAccountsReceivable>
    <dgx:PercentageofNetAccountsReceivable
      contextRef="ic12c618fa4d74532b772090eef552ce5_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTo0MjI4NGM1N2JjNDg0MGQ3YTkwYmQ5ZjU2OWVlZTYzZC90YWJsZXJhbmdlOjQyMjg0YzU3YmM0ODQwZDdhOTBiZDlmNTY5ZWVlNjNkXzItMy0xLTEtNzgyMTU_60efe44d-8f2d-416a-9ec0-616295b8559e"
      unitRef="number">0.32</dgx:PercentageofNetAccountsReceivable>
    <dgx:PercentageofNetAccountsReceivable
      contextRef="iba76f6181ce848fcbd7af0ece345152c_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTo0MjI4NGM1N2JjNDg0MGQ3YTkwYmQ5ZjU2OWVlZTYzZC90YWJsZXJhbmdlOjQyMjg0YzU3YmM0ODQwZDdhOTBiZDlmNTY5ZWVlNjNkXzMtMS0xLTEtNzgyMTU_936350dc-beac-4561-aea8-42eadb5f0cf5"
      unitRef="number">0.06</dgx:PercentageofNetAccountsReceivable>
    <dgx:PercentageofNetAccountsReceivable
      contextRef="i34f778b2b04c48679029b462c5367cb2_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTo0MjI4NGM1N2JjNDg0MGQ3YTkwYmQ5ZjU2OWVlZTYzZC90YWJsZXJhbmdlOjQyMjg0YzU3YmM0ODQwZDdhOTBiZDlmNTY5ZWVlNjNkXzMtMy0xLTEtNzgyMTU_8a87f053-fa56-4ae2-a965-2147bcc6fcac"
      unitRef="number">0.06</dgx:PercentageofNetAccountsReceivable>
    <dgx:PercentageofNetAccountsReceivable
      contextRef="ibaf0eafb0e0a4b05aa543fafe1dafb0a_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTo0MjI4NGM1N2JjNDg0MGQ3YTkwYmQ5ZjU2OWVlZTYzZC90YWJsZXJhbmdlOjQyMjg0YzU3YmM0ODQwZDdhOTBiZDlmNTY5ZWVlNjNkXzQtMS0xLTEtNzgyMTU_f5cffab1-59d3-4772-a09e-c33616ef1bac"
      unitRef="number">0.44</dgx:PercentageofNetAccountsReceivable>
    <dgx:PercentageofNetAccountsReceivable
      contextRef="i3e02c394b9084450982de162d83141b3_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTo0MjI4NGM1N2JjNDg0MGQ3YTkwYmQ5ZjU2OWVlZTYzZC90YWJsZXJhbmdlOjQyMjg0YzU3YmM0ODQwZDdhOTBiZDlmNTY5ZWVlNjNkXzQtMy0xLTEtNzgyMTU_f76a2b99-0c36-4452-a1b6-d8a59983f249"
      unitRef="number">0.38</dgx:PercentageofNetAccountsReceivable>
    <dgx:PercentageofNetAccountsReceivable
      contextRef="i81be56c5955845f49525165bab74c70f_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTo0MjI4NGM1N2JjNDg0MGQ3YTkwYmQ5ZjU2OWVlZTYzZC90YWJsZXJhbmdlOjQyMjg0YzU3YmM0ODQwZDdhOTBiZDlmNTY5ZWVlNjNkXzUtMS0xLTEtNzgyMTU_837db2ce-c5d8-4624-9713-8dcc26271237"
      unitRef="number">0.18</dgx:PercentageofNetAccountsReceivable>
    <dgx:PercentageofNetAccountsReceivable
      contextRef="i915edbec2fea42159bcc1ba9f3179a51_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTo0MjI4NGM1N2JjNDg0MGQ3YTkwYmQ5ZjU2OWVlZTYzZC90YWJsZXJhbmdlOjQyMjg0YzU3YmM0ODQwZDdhOTBiZDlmNTY5ZWVlNjNkXzUtMy0xLTEtNzgyMTU_8701ee87-ae54-4b52-b0b3-e85111b765a1"
      unitRef="number">0.21</dgx:PercentageofNetAccountsReceivable>
    <dgx:PercentageofNetAccountsReceivable
      contextRef="i6a770caf14c1492f8e3fbcaf507b29ae_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTo0MjI4NGM1N2JjNDg0MGQ3YTkwYmQ5ZjU2OWVlZTYzZC90YWJsZXJhbmdlOjQyMjg0YzU3YmM0ODQwZDdhOTBiZDlmNTY5ZWVlNjNkXzYtMS0xLTEtNzgyMTU_bb9cfbdb-4b45-4e36-ae34-2232fc6bdd85"
      unitRef="number">0.96</dgx:PercentageofNetAccountsReceivable>
    <dgx:PercentageofNetAccountsReceivable
      contextRef="i762548338af343bcbc7df9361e2ba54e_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTo0MjI4NGM1N2JjNDg0MGQ3YTkwYmQ5ZjU2OWVlZTYzZC90YWJsZXJhbmdlOjQyMjg0YzU3YmM0ODQwZDdhOTBiZDlmNTY5ZWVlNjNkXzYtMy0xLTEtNzgyMTU_74f24464-f9b4-40d4-8bbb-e7ffa53eb433"
      unitRef="number">0.97</dgx:PercentageofNetAccountsReceivable>
    <dgx:PercentageofNetAccountsReceivable
      contextRef="ia340b53589ac4a729154593b434a8b5b_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTo0MjI4NGM1N2JjNDg0MGQ3YTkwYmQ5ZjU2OWVlZTYzZC90YWJsZXJhbmdlOjQyMjg0YzU3YmM0ODQwZDdhOTBiZDlmNTY5ZWVlNjNkXzctMS0xLTEtNzgyMTU_01eddaa4-8821-4ac8-ae65-722f58d1b0f3"
      unitRef="number">0.04</dgx:PercentageofNetAccountsReceivable>
    <dgx:PercentageofNetAccountsReceivable
      contextRef="i69908b0e9ded44c68e9a26989fdf9843_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTo0MjI4NGM1N2JjNDg0MGQ3YTkwYmQ5ZjU2OWVlZTYzZC90YWJsZXJhbmdlOjQyMjg0YzU3YmM0ODQwZDdhOTBiZDlmNTY5ZWVlNjNkXzctMy0xLTEtNzgyMTU_7b06eec7-57c2-4e68-a8b6-f95f7fc141c5"
      unitRef="number">0.03</dgx:PercentageofNetAccountsReceivable>
    <dgx:PercentageofNetAccountsReceivable
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTo0MjI4NGM1N2JjNDg0MGQ3YTkwYmQ5ZjU2OWVlZTYzZC90YWJsZXJhbmdlOjQyMjg0YzU3YmM0ODQwZDdhOTBiZDlmNTY5ZWVlNjNkXzgtMS0xLTEtNzgyMTU_20b3e52e-93ff-4247-b782-4492c67e5414"
      unitRef="number">1</dgx:PercentageofNetAccountsReceivable>
    <dgx:PercentageofNetAccountsReceivable
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTo0MjI4NGM1N2JjNDg0MGQ3YTkwYmQ5ZjU2OWVlZTYzZC90YWJsZXJhbmdlOjQyMjg0YzU3YmM0ODQwZDdhOTBiZDlmNTY5ZWVlNjNkXzgtMy0xLTEtNzgyMTU_67e5941c-fd5b-4fed-827c-4821a72900b1"
      unitRef="number">1</dgx:PercentageofNetAccountsReceivable>
    <us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90ZXh0cmVnaW9uOmQxNDYxNDJhODllZTQ3NGFiYzI2MTkyNDIyNWU1MjE1Xzc5ODA_ecc4024f-6e5c-4044-af35-c542dac28a3f">The following table summarizes the activity for the Company's allowance for credit losses during the years ended December&#160;31, 2022 and 2021, which principally relates to client payers:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Allowance for Credit Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Write-offs of accounts receivable, net of recoveries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Write-offs of accounts receivable, net of recoveries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance, December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i872b3ea2e369403f8c0129ff07e0b538_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTplZWVhZTY0OGEyMTc0ODQzYmYzNWIzMGE1NmUyNjUzNi90YWJsZXJhbmdlOmVlZWFlNjQ4YTIxNzQ4NDNiZjM1YjMwYTU2ZTI2NTM2XzItMS0xLTEtNzgyMTU_15e091eb-5d55-4595-926d-539f05bee841"
      unitRef="usd">28000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTplZWVhZTY0OGEyMTc0ODQzYmYzNWIzMGE1NmUyNjUzNi90YWJsZXJhbmdlOmVlZWFlNjQ4YTIxNzQ4NDNiZjM1YjMwYTU2ZTI2NTM2XzMtMS0xLTEtNzgyMTU_57346205-a772-4ab6-ba35-39864e02e45e"
      unitRef="usd">4000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTplZWVhZTY0OGEyMTc0ODQzYmYzNWIzMGE1NmUyNjUzNi90YWJsZXJhbmdlOmVlZWFlNjQ4YTIxNzQ4NDNiZjM1YjMwYTU2ZTI2NTM2XzQtMS0xLTEtNzgyMTU_18b9718b-55c8-456f-942b-ee47b0c2863e"
      unitRef="usd">1000000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTplZWVhZTY0OGEyMTc0ODQzYmYzNWIzMGE1NmUyNjUzNi90YWJsZXJhbmdlOmVlZWFlNjQ4YTIxNzQ4NDNiZjM1YjMwYTU2ZTI2NTM2XzUtMS0xLTEtNzgyMTU_84160d8a-eeee-4475-b333-35300f5901d8"
      unitRef="usd">31000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTplZWVhZTY0OGEyMTc0ODQzYmYzNWIzMGE1NmUyNjUzNi90YWJsZXJhbmdlOmVlZWFlNjQ4YTIxNzQ4NDNiZjM1YjMwYTU2ZTI2NTM2XzYtMS0xLTEtNzgyMTU_58b52080-ed67-4986-b0b7-beb49cfb4695"
      unitRef="usd">3000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTplZWVhZTY0OGEyMTc0ODQzYmYzNWIzMGE1NmUyNjUzNi90YWJsZXJhbmdlOmVlZWFlNjQ4YTIxNzQ4NDNiZjM1YjMwYTU2ZTI2NTM2XzctMS0xLTEtNzgyMTU_9cda3ad6-e76e-4060-a5ea-08a7982ec736"
      unitRef="usd">4000000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODQvZnJhZzpkMTQ2MTQyYTg5ZWU0NzRhYmMyNjE5MjQyMjVlNTIxNS90YWJsZTplZWVhZTY0OGEyMTc0ODQzYmYzNWIzMGE1NmUyNjUzNi90YWJsZXJhbmdlOmVlZWFlNjQ4YTIxNzQ4NDNiZjM1YjMwYTU2ZTI2NTM2XzgtMS0xLTEtNzgyMTU_5161d36f-6415-4bea-88fb-65405061b222"
      unitRef="usd">30000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90ZXh0cmVnaW9uOjNhMGFmYWU5NWY2OTQyYjRhMmM4NTNhNGIxMWJiODYzXzUwNg_710bcc44-0df7-452a-959c-79d8c439fba6">EARNINGS PER SHARE&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The computation of basic and diluted earnings per common share is as follows (in millions, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amounts attributable to Quest Diagnostics&#x2019; common stockholders:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Quest Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Earnings allocated to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings available to Quest Diagnostics&#x2019; common stockholders &#x2013; basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options and performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Earnings per share attributable to Quest Diagnostics&#x2019; common stockholders:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following securities were not included in the calculation of diluted earnings per share due to their antidilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options and performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90ZXh0cmVnaW9uOjNhMGFmYWU5NWY2OTQyYjRhMmM4NTNhNGIxMWJiODYzXzQ5OA_d8be5321-e2d9-42d4-bd85-11cdd5887ac5">The computation of basic and diluted earnings per common share is as follows (in millions, except per share data):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amounts attributable to Quest Diagnostics&#x2019; common stockholders:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Quest Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Earnings allocated to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings available to Quest Diagnostics&#x2019; common stockholders &#x2013; basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options and performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Earnings per share attributable to Quest Diagnostics&#x2019; common stockholders:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzQtMS0xLTEtNzgyMTU_7118c3b8-096c-4d38-80af-423140b9db32"
      unitRef="usd">946000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzQtMy0xLTEtNzgyMTU_64d76494-204b-439d-b6ce-19b3ad78b074"
      unitRef="usd">1995000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzQtNS0xLTEtNzgyMTU_cea17a75-c081-486d-a7a4-2fe6236a5081"
      unitRef="usd">1431000000</us-gaap:NetIncomeLoss>
    <us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzctMS0xLTEtNzgyMTU_03a5c938-8440-4488-90f3-2cf0208a9c01"
      unitRef="usd">4000000</us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic>
    <us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzctMy0xLTEtNzgyMTU_fdf346ea-5f3b-473f-bb87-ec1aeca41fda"
      unitRef="usd">7000000</us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic>
    <us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzctNS0xLTEtNzgyMTU_b048efb1-c3c7-4b70-ba7c-071474568138"
      unitRef="usd">6000000</us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic>
    <us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzgtMS0xLTEtNzgyMTU_8c8cba7b-947e-4304-babb-b42bb5d3b57b"
      unitRef="usd">942000000</us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic>
    <us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzgtMy0xLTEtNzgyMTU_592da970-f9b6-4add-a0f4-83f239d65bac"
      unitRef="usd">1988000000</us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic>
    <us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzgtNS0xLTEtNzgyMTU_6daa96cd-6bda-4a9f-92ce-e47a362f06d2"
      unitRef="usd">1425000000</us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzEwLTEtMS0xLTc4MjE1_e2f2ca7d-0f16-427f-81a0-487845ee5f03"
      unitRef="shares">116000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzEwLTMtMS0xLTc4MjE1_1ea447f1-29ab-413f-8754-133e6b207aa2"
      unitRef="shares">125000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzEwLTUtMS0xLTc4MjE1_307dbbb2-c0a0-49d0-b8fa-9b1c639ad8fd"
      unitRef="shares">134000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzEyLTEtMS0xLTc4MjE1_0a368a69-f8fd-42a3-a64e-9edd54ca1098"
      unitRef="shares">2000000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzEyLTMtMS0xLTc4MjE1_6140b8e4-64e0-4571-8ae0-bfa4a5d841fa"
      unitRef="shares">3000000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzEyLTUtMS0xLTc4MjE1_4d3ad67c-c36d-49f3-b313-6cc795112e26"
      unitRef="shares">2000000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzEzLTEtMS0xLTc4MjE1_7a759291-ca09-44f1-afbf-6db81d032846"
      unitRef="shares">118000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzEzLTMtMS0xLTc4MjE1_d05ed9c4-9e54-4e82-9ecb-927c595a32d0"
      unitRef="shares">128000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzEzLTUtMS0xLTc4MjE1_a5f992bd-0ee7-4a06-adb9-4c59ea111e80"
      unitRef="shares">136000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzE4LTEtMS0xLTc4MjE1_8bf09634-c2ad-4311-a117-f3c9afa68c55"
      unitRef="usdPerShare">8.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzE4LTMtMS0xLTc4MjE1_adbaf1b2-9a7a-4541-9162-b328ebab959a"
      unitRef="usdPerShare">15.85</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzE4LTUtMS0xLTc4MjE1_94c82c26-64f8-4a52-bb35-300c62640f12"
      unitRef="usdPerShare">10.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzIzLTEtMS0xLTc4MjE1_5d894d25-df6a-4e5a-aad8-bf516183a276"
      unitRef="usdPerShare">7.97</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzIzLTMtMS0xLTc4MjE1_cffe72d2-9106-4c58-9908-7c97f44bf96a"
      unitRef="usdPerShare">15.55</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTplNGE0ZjVjMDBiZjE0NWE2OTRlNmIyZTI3MWZjNjI3My90YWJsZXJhbmdlOmU0YTRmNWMwMGJmMTQ1YTY5NGU2YjJlMjcxZmM2MjczXzIzLTUtMS0xLTc4MjE1_691fcd0a-b659-4664-83fc-06e696d7dec9"
      unitRef="usdPerShare">10.47</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90ZXh0cmVnaW9uOjNhMGFmYWU5NWY2OTQyYjRhMmM4NTNhNGIxMWJiODYzXzUxMA_b08940d3-94ad-4e60-a441-51cec38c2253">The following securities were not included in the calculation of diluted earnings per share due to their antidilutive effect:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options and performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTo0ZGQ2MWU4MGI0ZjE0ZTgyOGQzZjRiYWE0ZmJmMmZlNC90YWJsZXJhbmdlOjRkZDYxZTgwYjRmMTRlODI4ZDNmNGJhYTRmYmYyZmU0XzItMS0xLTEtNzgyMTU_1b53dc19-bc52-46d8-9c50-f2247297f12d"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTo0ZGQ2MWU4MGI0ZjE0ZTgyOGQzZjRiYWE0ZmJmMmZlNC90YWJsZXJhbmdlOjRkZDYxZTgwYjRmMTRlODI4ZDNmNGJhYTRmYmYyZmU0XzItMy0xLTEtNzgyMTU_3e50c207-ec81-456a-928d-7f026307c8ba"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xODcvZnJhZzozYTBhZmFlOTVmNjk0MmI0YTJjODUzYTRiMTFiYjg2My90YWJsZTo0ZGQ2MWU4MGI0ZjE0ZTgyOGQzZjRiYWE0ZmJmMmZlNC90YWJsZXJhbmdlOjRkZDYxZTgwYjRmMTRlODI4ZDNmNGJhYTRmYmYyZmU0XzItNS0xLTEtNzgyMTU_e475b355-dc04-4d6d-9fd4-efb2eb0938a6"
      unitRef="shares">1000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGV4dHJlZ2lvbjpjN2EzMmYzNzk0YjU0NGE2YmM1YTIxMzhiZTM0MjE3NF8yNzQ4Nzc5MDcyOTk3_38bef7b7-fe38-4341-8ed2-82d658b84207">RESTRUCTURING ACTIVITIES &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Invigorate Program&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company is committed to a program called Invigorate which is designed to reduce its cost structure and improve performance.  Invigorate consists of several flagship programs, with structured plans in each, to drive savings and improve performance across the customer value chain.  These flagship programs include: organization excellence; information technology excellence; procurement excellence; field and customer service excellence; lab excellence; and revenue services excellence.  In addition to these programs, the Company identified key themes to change how it operates including reducing denials and patient price concessions; further digitizing the business; standardization; automation; optimization and selecting and retaining talent. The Invigorate program is intended to offset reimbursement pressures and labor and benefit cost increases; free up additional resources to invest in innovation and other growth initiatives; and enable the Company to improve service quality and operating profitability. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;Restructuring Charges&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary of the Company's pre-tax restructuring charges for the years ended December&#160;31, 2022, 2021 and 2020: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee separation costs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Facility-related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The restructuring charges incurred for the years ended December&#160;31, 2022, 2021 and 2020 were primarily associated with various workforce reduction initiatives as the Company continued to restructure its organization. Additionally, during the year ended December 31, 2022, the Company fully impaired certain property, plant and equipment (see Note 8).  Of the total restructuring charges incurred during the year ended December&#160;31, 2022, $19&#160;million,  $36&#160;million and $14&#160;million were recorded in cost of services, selling, general and administrative expenses and other operating expense (income), net, respectively.  Of the total restructuring charges incurred during the year ended December&#160;31, 2021, $8&#160;million and $4&#160;million were recorded in cost of services and selling, general and administrative expenses, respectively.  Of the total restructuring charges incurred during the year ended December&#160;31, 2020, $9&#160;million and $5&#160;million were recorded in cost of services and selling, general and administrative expenses, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The employee separation costs for all periods presented were primarily recorded in the Company's DIS business.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity of the restructuring liability during 2022 and 2021, which is included in accrued expenses in Note 13:  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.049%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.711%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Employee Separation Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Facility-Related Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance, December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income statement expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance, December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income statement expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance, December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGV4dHJlZ2lvbjpjN2EzMmYzNzk0YjU0NGE2YmM1YTIxMzhiZTM0MjE3NF8yNzQ4Nzc5MDcyOTk4_d6c6b631-b9ae-4202-8a43-bc0a7adb516d">The following table provides a summary of the Company's pre-tax restructuring charges for the years ended December&#160;31, 2022, 2021 and 2020: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee separation costs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Facility-related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:SeveranceCosts1
      contextRef="i2188840dc2a3430ebc240517ab668786_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6NTgzNzkxMWRhOTMyNDFmMmE2OTg1ZjEwMjM1NmE3YzAvdGFibGVyYW5nZTo1ODM3OTExZGE5MzI0MWYyYTY5ODVmMTAyMzU2YTdjMF8yLTEtMS0xLTc4MzY3_0c842e23-81d1-4c78-958a-82967fdeb7e3"
      unitRef="usd">55000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="iac2da26b5ef14b8f8e69ce008fd54d9b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6NTgzNzkxMWRhOTMyNDFmMmE2OTg1ZjEwMjM1NmE3YzAvdGFibGVyYW5nZTo1ODM3OTExZGE5MzI0MWYyYTY5ODVmMTAyMzU2YTdjMF8yLTMtMS0xLTc4MzY3_7c3e96e1-5f29-4ef7-9ee5-85f55a441b1b"
      unitRef="usd">11000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i7f2e4d03479a4236a60beb9b0835a79f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6NTgzNzkxMWRhOTMyNDFmMmE2OTg1ZjEwMjM1NmE3YzAvdGFibGVyYW5nZTo1ODM3OTExZGE5MzI0MWYyYTY5ODVmMTAyMzU2YTdjMF8yLTUtMS0xLTc4MzY3_71b7724a-10a5-425c-b8df-fb5dcc057e95"
      unitRef="usd">14000000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts
      contextRef="i2188840dc2a3430ebc240517ab668786_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6NTgzNzkxMWRhOTMyNDFmMmE2OTg1ZjEwMjM1NmE3YzAvdGFibGVyYW5nZTo1ODM3OTExZGE5MzI0MWYyYTY5ODVmMTAyMzU2YTdjMF8zLTEtMS0xLTc4MzY3_806831b4-5715-42b4-aaec-10883a2cd33c"
      unitRef="usd">0</us-gaap:OtherRestructuringCosts>
    <us-gaap:OtherRestructuringCosts
      contextRef="iac2da26b5ef14b8f8e69ce008fd54d9b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6NTgzNzkxMWRhOTMyNDFmMmE2OTg1ZjEwMjM1NmE3YzAvdGFibGVyYW5nZTo1ODM3OTExZGE5MzI0MWYyYTY5ODVmMTAyMzU2YTdjMF8zLTMtMS0xLTc4MzY3_17fda193-3cb2-49fb-a254-7177b3aaee2b"
      unitRef="usd">1000000</us-gaap:OtherRestructuringCosts>
    <us-gaap:OtherRestructuringCosts
      contextRef="i7f2e4d03479a4236a60beb9b0835a79f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6NTgzNzkxMWRhOTMyNDFmMmE2OTg1ZjEwMjM1NmE3YzAvdGFibGVyYW5nZTo1ODM3OTExZGE5MzI0MWYyYTY5ODVmMTAyMzU2YTdjMF8zLTUtMS0xLTc4MzY3_bca41fef-1966-4c76-a195-fc5f2ac1fa86"
      unitRef="usd">0</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCostsAndAssetImpairmentCharges
      contextRef="i2188840dc2a3430ebc240517ab668786_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6NTgzNzkxMWRhOTMyNDFmMmE2OTg1ZjEwMjM1NmE3YzAvdGFibGVyYW5nZTo1ODM3OTExZGE5MzI0MWYyYTY5ODVmMTAyMzU2YTdjMF80LTEtMS0xLTc4MzY3_0772f272-1edb-4eb8-954b-69b756b3a7d2"
      unitRef="usd">14000000</us-gaap:RestructuringCostsAndAssetImpairmentCharges>
    <us-gaap:RestructuringCostsAndAssetImpairmentCharges
      contextRef="iac2da26b5ef14b8f8e69ce008fd54d9b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6NTgzNzkxMWRhOTMyNDFmMmE2OTg1ZjEwMjM1NmE3YzAvdGFibGVyYW5nZTo1ODM3OTExZGE5MzI0MWYyYTY5ODVmMTAyMzU2YTdjMF80LTMtMS0xLTc4MzY3_8cb36ed6-cc36-4a6c-8650-72ad0510cce2"
      unitRef="usd">0</us-gaap:RestructuringCostsAndAssetImpairmentCharges>
    <us-gaap:RestructuringCostsAndAssetImpairmentCharges
      contextRef="i7f2e4d03479a4236a60beb9b0835a79f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6NTgzNzkxMWRhOTMyNDFmMmE2OTg1ZjEwMjM1NmE3YzAvdGFibGVyYW5nZTo1ODM3OTExZGE5MzI0MWYyYTY5ODVmMTAyMzU2YTdjMF80LTUtMS0xLTc4MzY3_633e495f-e0a4-4756-a898-6a53c80fd059"
      unitRef="usd">0</us-gaap:RestructuringCostsAndAssetImpairmentCharges>
    <us-gaap:RestructuringCharges
      contextRef="i2188840dc2a3430ebc240517ab668786_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6NTgzNzkxMWRhOTMyNDFmMmE2OTg1ZjEwMjM1NmE3YzAvdGFibGVyYW5nZTo1ODM3OTExZGE5MzI0MWYyYTY5ODVmMTAyMzU2YTdjMF82LTEtMS0xLTc4MzY3_9a3f7085-ace4-4ba9-85c8-e8fa805c6755"
      unitRef="usd">69000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="iac2da26b5ef14b8f8e69ce008fd54d9b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6NTgzNzkxMWRhOTMyNDFmMmE2OTg1ZjEwMjM1NmE3YzAvdGFibGVyYW5nZTo1ODM3OTExZGE5MzI0MWYyYTY5ODVmMTAyMzU2YTdjMF82LTMtMS0xLTc4MzY3_b7cbeadc-c621-422d-942c-bb85e7247c18"
      unitRef="usd">12000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i7f2e4d03479a4236a60beb9b0835a79f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6NTgzNzkxMWRhOTMyNDFmMmE2OTg1ZjEwMjM1NmE3YzAvdGFibGVyYW5nZTo1ODM3OTExZGE5MzI0MWYyYTY5ODVmMTAyMzU2YTdjMF82LTUtMS0xLTc4MzY3_9aafbba3-71e5-4bd3-af06-d5485fbac767"
      unitRef="usd">14000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ic2dc2704459f476aa2a7a5bdd5d24a31_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGV4dHJlZ2lvbjpjN2EzMmYzNzk0YjU0NGE2YmM1YTIxMzhiZTM0MjE3NF8yNzQ4Nzc5MDczMDAx_06780716-5921-4e01-be58-4339cd3ab77a"
      unitRef="usd">19000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i5c94d4fa6b2c4f048fbd732ba22d94f5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGV4dHJlZ2lvbjpjN2EzMmYzNzk0YjU0NGE2YmM1YTIxMzhiZTM0MjE3NF8yNzQ4Nzc5MDczMDEz_053ac3f8-6d53-4edb-9f01-1d7c8090994d"
      unitRef="usd">36000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i6c9c73f96c044bfe81dabb5b4fad4570_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGV4dHJlZ2lvbjpjN2EzMmYzNzk0YjU0NGE2YmM1YTIxMzhiZTM0MjE3NF8xNjQ5MjY3NDQ1Njk1_26d48109-1fe3-4981-9dca-4495ccc797f7"
      unitRef="usd">14000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i390853c339b546a497c9c3581d6c33ec_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGV4dHJlZ2lvbjpjN2EzMmYzNzk0YjU0NGE2YmM1YTIxMzhiZTM0MjE3NF8xNjQ5MjY3NDQ1NjYw_6540208a-9824-4c96-acea-604c89d9f0a9"
      unitRef="usd">8000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i9dfd2596231f42d583a3e66c7908bd62_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGV4dHJlZ2lvbjpjN2EzMmYzNzk0YjU0NGE2YmM1YTIxMzhiZTM0MjE3NF8xNjQ5MjY3NDQ1NjQ4_f0bb74b4-4289-43d4-b4e6-cea4bc627e17"
      unitRef="usd">4000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i17932ddd3fbd4fa39599486002e2399c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGV4dHJlZ2lvbjpjN2EzMmYzNzk0YjU0NGE2YmM1YTIxMzhiZTM0MjE3NF8yNzQ4Nzc5MDczMDM3_99e0f336-67eb-4864-9eb0-fbc80fb5d626"
      unitRef="usd">9000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i7641ac8ab06549359c0d7224c74f7f8b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGV4dHJlZ2lvbjpjN2EzMmYzNzk0YjU0NGE2YmM1YTIxMzhiZTM0MjE3NF8yNzQ4Nzc5MDczMDQ5_5986ee80-2368-4fc6-a552-e23a08acdb5d"
      unitRef="usd">5000000</us-gaap:RestructuringCharges>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGV4dHJlZ2lvbjpjN2EzMmYzNzk0YjU0NGE2YmM1YTIxMzhiZTM0MjE3NF8yNzQ4Nzc5MDcyOTk5_db943892-2593-422e-8c28-cbe457ed74d7">The following table summarizes the activity of the restructuring liability during 2022 and 2021, which is included in accrued expenses in Note 13:  &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.049%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.711%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Employee Separation Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Facility-Related Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance, December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income statement expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance, December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income statement expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance, December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="i2d8eee27a6fd4fbe801850524c5786c5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M18yLTEtMS0xLTc4MzY3_be47e8f0-2fc0-4cb0-8e76-901fdaadf93c"
      unitRef="usd">7000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="iebd99150341c4b0c873203afdafdd710_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M18yLTMtMS0xLTc4MzY3_972b3e14-8e86-497a-ac26-e4bcedeafcdf"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i872b3ea2e369403f8c0129ff07e0b538_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M18yLTUtMS0xLTc4MzY3_e50525bd-0331-4a0f-9d7a-b2080e62867a"
      unitRef="usd">7000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="i475d92c712f048aa906901cd998f7a38_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M18zLTEtMS0xLTc4MzY3_7015fce1-a809-4f9a-aaca-a80c69537f6a"
      unitRef="usd">12000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ib738456c29b743669e686681cc7a5304_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M18zLTMtMS0xLTc4MzY3_30a8f9d9-5ea9-48e2-9319-8a1b17169725"
      unitRef="usd">1000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M18zLTUtMS0xLTc4MzY3_10d98b7c-3e85-4a64-9dea-d77d51d28a29"
      unitRef="usd">13000000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="i475d92c712f048aa906901cd998f7a38_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M180LTEtMS0xLTc4MzY3_cb144c24-68ff-480d-8791-e16a5a1e9ba1"
      unitRef="usd">12000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="ib738456c29b743669e686681cc7a5304_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M180LTMtMS0xLTc4MzY3_d32237be-18cf-47a7-bbe7-360a288e14df"
      unitRef="usd">1000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M180LTUtMS0xLTc4MzY3_6000d47a-db59-4862-833f-524f462cd84b"
      unitRef="usd">13000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="id6084444236f40aca1b0c8796c27af45_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M182LTEtMS0xLTc4MzY3_99ba86a0-e3d3-428b-86aa-e268d56df986"
      unitRef="usd">7000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i50168a95b652435bb092f9dfbde9c76a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M182LTMtMS0xLTc4MzY3_9eaa795d-2b63-41e9-bb0c-3c9106d39ab9"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M182LTUtMS0xLTc4MzY3_17b4049b-30da-4654-bb51-014d06cabe87"
      unitRef="usd">7000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="ic24828d839184f6fa08a929719d4b23f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M183LTEtMS0xLTc4MzY3_d60da5ce-4571-46cb-a272-6d4d0ada5045"
      unitRef="usd">55000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i57fc38f4b96048cbb2a8e0410884049d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M183LTMtMS0xLTc4MzY3_50b6815b-a1af-457d-8aeb-3fe97102f0a7"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M183LTUtMS0xLTc4MzY3_4720d902-8f98-4aac-829b-d08d0807d1c3"
      unitRef="usd">55000000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="ic24828d839184f6fa08a929719d4b23f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M184LTEtMS0xLTc4MzY3_50ab866c-29be-4e9a-8247-9a47b12dba93"
      unitRef="usd">18000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i57fc38f4b96048cbb2a8e0410884049d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M184LTMtMS0xLTc4MzY3_1113bd6e-248c-486e-aebe-fca5e4ec75fa"
      unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M184LTUtMS0xLTc4MzY3_2964a976-2dfc-4538-bdfa-6830e70eac17"
      unitRef="usd">18000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="i74144fa02d0949e18fcfdec627d2b59e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M18xMC0xLTEtMS04NTU4MQ_fa462339-4186-48a9-832c-c73921db4365"
      unitRef="usd">44000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i6fe6929b64864257bf0e3c4054d32428_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M18xMC0zLTEtMS04NTU4MQ_6df36e0c-258d-418b-af34-8cc05f5cc6d3"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTk0L2ZyYWc6YzdhMzJmMzc5NGI1NDRhNmJjNWEyMTM4YmUzNDIxNzQvdGFibGU6ODVjNzhhMTMyODQ1NDlmYzg3NGUyZjI5YmFlNjkwNTMvdGFibGVyYW5nZTo4NWM3OGExMzI4NDU0OWZjODc0ZTJmMjliYWU2OTA1M18xMC01LTEtMS04NTU4MQ_54ca0b9c-24c8-4e57-90f1-303605f1d1e7"
      unitRef="usd">44000000</us-gaap:RestructuringReserve>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5Xzc5Mjc_0fc69918-0fee-4712-9105-598b0aea6099">BUSINESS ACQUISITIONS&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;2022 Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2022, the Company completed acquisitions for an aggregate purchase price of $162&#160;million, net of cash acquired, including the acquisition discussed below.  The 2022 acquisitions resulted in goodwill of $121&#160;million, of which $103&#160;million is deductible for tax purposes.  These acquisitions also resulted in $45&#160;million of intangible assets, principally comprised of customer-related intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisition of Pack Health, LLC&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 1, 2022, the Company acquired Pack Health, LLC ("Pack Health"), a patient engagement company that helps individuals adopt healthier behaviors to improve outcomes, in an all cash transaction for $123&#160;million, net of $4&#160;million cash acquired, which consisted of cash consideration of $105&#160;million and contingent consideration initially estimated at $18&#160;million.  The contingent consideration arrangement was dependent upon the achievement of certain revenue benchmarks.  Based on the purchase price allocation, the assets acquired and liabilities assumed consist of $96&#160;million of goodwill (of which $78&#160;million was tax-deductible on the acquisition date), $30&#160;million of intangible assets, $5&#160;million of operating lease right-of-use assets, $5&#160;million of operating lease liabilities and $(3)&#160;million of working capital. The intangible assets consist primarily of customer-related assets which are being amortized over a useful life of 15 years.  For further details regarding the fair value of the contingent consideration, see Note 8.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;2021 Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2021, the Company completed acquisitions for an aggregate purchase price of $346&#160;million, net of cash acquired, including the acquisitions discussed below.  The 2021 acquisitions resulted in goodwill of $236&#160;million, of which $221&#160;million is deductible for tax purposes. These acquisitions also resulted in $107&#160;million of intangible assets, principally comprised of customer-related intangible assets.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisition of the outreach laboratory services business of Mercy Health&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 1, 2021, the Company completed the acquisition of the outreach laboratory services business of Mercy Health ("Mercy Health"), which serves providers and patients in Arkansas, Kansas, Missouri and Oklahoma, in an all-cash transaction for $225&#160;million.  Based on the purchase price allocation, the assets acquired primarily consist of $171&#160;million of tax-deductible goodwill and $54&#160;million of customer-related intangible assets.  The intangible assets are being amortized over a useful life of 15 years.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisition of assets of Labtech Diagnostics, LLC&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 13, 2021, the Company completed the acquisition of assets of Labtech Diagnostics, LLC ("Labtech"), an independent clinical diagnostic laboratory provider serving physicians and patients primarily in South Carolina, North Carolina, Florida and Georgia, in an all cash transaction for $95&#160;million, which consisted of cash consideration of $80&#160;million and contingent consideration estimated at $15&#160;million. The contingent consideration arrangement was dependent upon the achievement of certain testing volume benchmarks.  Based on the purchase price allocation, which was finalized during the three months ended March 31, 2022, the assets acquired and liabilities assumed consist of $48&#160;million of goodwill (of which $33&#160;million was tax deductible on the acquisition date), $44&#160;million of intangible assets, $11&#160;million of property, plant and equipment, $9&#160;million of finance lease liabilities, $6&#160;million of operating lease right-of-use assets, $6&#160;million of operating lease liabilities, and $1&#160;million of inventories. The intangible assets consist primarily of customer-related assets which are being amortized over a useful life of 15 years.  For further details regarding the fair value of the contingent consideration, see Note 8.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;2020 Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2020, the Company completed acquisitions for an aggregate purchase price of $330&#160;million, net of cash acquired, including the acquisitions discussed below.  The 2020 acquisitions resulted in goodwill of $247&#160;million, of which $210&#160;million is deductible for tax purposes.  These acquisitions also resulted in $146&#160;million of intangible assets, principally comprised of customer-related and technology intangible assets.  Net revenues attributable to the 2020 acquisitions were $127&#160;million for the year ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisition of Blueprint Genetics Oy&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 21, 2020, the Company completed the acquisition of Blueprint Genetics Oy ("Blueprint Genetics"), in an all cash transaction for $108&#160;million, net of $3&#160;million cash acquired.  Blueprint Genetics is a leading specialty genetic testing company with expertise in gene variant interpretation based on next generation sequencing and proprietary bioinformatics.  Through the acquisition, the Company acquired all of Blueprint Genetics' operations.  Based on the purchase price allocation, the assets acquired and liabilities assumed primarily consist of $66&#160;million of tax-deductible goodwill, $43&#160;million of intangible assets, and $2&#160;million of property, plant and equipment and working capital.  The intangible assets primarily consist of technology and customer-related assets which are being amortized over a useful life of 10 years and 15 years, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisition of the Outreach Laboratory Services Business of Memorial Hermann Health System&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 6, 2020, the Company completed the acquisition of select assets which constitute substantially all of the operations of Memorial Hermann Diagnostic Laboratories, the outreach laboratory division of Memorial Hermann Health System ("Memorial Hermann"), in an all cash transaction for $120&#160;million.  Memorial Hermann is a not-for-profit health system in Southeast Texas.  Based on the purchase price allocation, the assets acquired primarily consist of $93&#160;million of tax-deductible goodwill and $27&#160;million of customer-related intangible assets.  The intangible assets are being amortized over a useful life of 15 years.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisition of the Remaining 56% Interest in Mid America Clinical Laboratories, LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;On August 1, 2020, the Company completed the acquisition of the remaining 56% interest in Mid America Clinical Laboratories, LLC ("MACL") from its joint venture partners in an all cash transaction for $93&#160;million, net of $18&#160;million cash acquired.  MACL was the largest independent clinical laboratory provider in Indiana.  Prior to the acquisition, the Company accounted for its 44% interest in MACL as an equity method investment, which was remeasured to its fair value of $87&#160;million on the acquisition date, resulting in a gain of $70&#160;million that was recognized in other (expense) income, net in the consolidated statements of operations.  The fair value of the previously held equity interest was determined using a discounted cash flow analysis that took into account, among other items, MACL's expected future cash flows, long-term growth rate (1.5%), and a discount rate commensurate with economic risk (7.5%).  Based on the purchase price allocation, the assets acquired and liabilities assumed consist of $84&#160;million of goodwill (of which $47&#160;million is tax-deductible), $74&#160;million of intangible assets, $11&#160;million of working capital and $11&#160;million of property, plant and equipment.  The intangible assets consist of customer-related assets which are being amortized over a useful life of 15 years.  As a result of the acquisition, MACL became a wholly owned subsidiary of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;General Information&lt;/span&gt;&lt;/div&gt;&#160;&#160;&#160;&#160;The acquisitions described above were accounted for under the acquisition method of accounting.  As such, the assets acquired and liabilities assumed are recorded based on their estimated fair values as of the closing date.  Supplemental pro forma combined financial information has not been presented as the impact of the acquisitions is not material to the Company's consolidated financial statements.  The goodwill recorded primarily includes the expected synergies resulting from combining the operations of the acquired entities with those of the Company and the value associated with an&#160;assembled workforce and other intangible assets that do not qualify for separate recognition.  All of the goodwill acquired in connection with these acquisitions has been allocated to the Company's DIS business.  For further details regarding business segment information, see Note 20.</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzI3NDg3NzkwODA4OTc_a13c6180-b701-4173-abb5-6d1d0bc8e37c"
      unitRef="usd">162000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzI3NDg3NzkwODA5MjE_7a2c3f0a-3462-45b9-ac47-05490c09cdeb"
      unitRef="usd">121000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzI3NDg3NzkwODA5MDk_f42aa90e-e6ed-4cc0-9b58-a8aef895883f"
      unitRef="usd">103000000</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <dgx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFiniteLivedIntangibles1
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzI3NDg3NzkwODA5MzM_b69f9d08-6a42-4784-a196-85e776934ee1"
      unitRef="usd">45000000</dgx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFiniteLivedIntangibles1>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="ib3022bb32f9b457dac0b1400e74fad49_D20220201-20220201"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzIxOTkwMjMyNjY4Njg_d32b596d-96ab-4e4b-b0dd-4cbcfcb73044"
      unitRef="usd">123000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="ib3022bb32f9b457dac0b1400e74fad49_D20220201-20220201"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzIxOTkwMjMyNjY4ODI_d2161907-3ab6-46a8-9af7-b2ffe74c914b"
      unitRef="usd">4000000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ib3022bb32f9b457dac0b1400e74fad49_D20220201-20220201"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzIxOTkwMjMyNjY4OTQ_6a046da6-b068-453d-9227-856a561752e5"
      unitRef="usd">105000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="idc2a90ebfed1402e9780a6ef5de70976_I20220201"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzIxOTkwMjMyNjY5MDg_3dc10478-cccd-42a1-81a5-8c4fb2ce0c26"
      unitRef="usd">18000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:Goodwill
      contextRef="idc2a90ebfed1402e9780a6ef5de70976_I20220201"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzIxOTkwMjMyNjY5MjE_8fee0117-78f5-413f-a20c-5f39590805de"
      unitRef="usd">96000000</us-gaap:Goodwill>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="idc2a90ebfed1402e9780a6ef5de70976_I20220201"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzIxOTkwMjMyNjY5MzQ_d2f4acce-63f2-4edc-a840-29ad776b4311"
      unitRef="usd">78000000</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="idc2a90ebfed1402e9780a6ef5de70976_I20220201"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzIxOTkwMjMyNjY5NDc_d58a2556-b2ea-4e4c-9753-ece8d108de11"
      unitRef="usd">30000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <dgx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets
      contextRef="idc2a90ebfed1402e9780a6ef5de70976_I20220201"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzIxOTkwMjMyNjY5NjA_5ab619c7-8dbe-4bcf-9ff0-6daa5c8a6a79"
      unitRef="usd">5000000</dgx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets>
    <dgx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities
      contextRef="idc2a90ebfed1402e9780a6ef5de70976_I20220201"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzIxOTkwMjMyNjY5NzI_1073cc33-ee6d-4152-b64f-b65225b75f0a"
      unitRef="usd">5000000</dgx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities>
    <dgx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedWorkingCapital
      contextRef="idc2a90ebfed1402e9780a6ef5de70976_I20220201"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzIxOTkwMjMyNjY5ODQ_b269b6d4-e4a4-4e8b-83e3-fe80b23386e2"
      unitRef="usd">-3000000</dgx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedWorkingCapital>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i0a5b8ece9a5340aa9b88329c3be13301_D20220201-20220201"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzIxOTkwMjMyNjY5OTY_516515d3-a970-486c-9f7d-2e012c5a08ee">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzEzNg_6e49ff3e-d089-4b99-858f-f648301fe1d6"
      unitRef="usd">346000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <dgx:GoodwillAcquiredDuringPeriodBeforeAdjustments
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzI1Mw_cd3a2da9-3955-4332-aaa8-8304a582b3af"
      unitRef="usd">236000000</dgx:GoodwillAcquiredDuringPeriodBeforeAdjustments>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzI2Ng_26d8323e-53be-41aa-beb0-357b0200a8a5"
      unitRef="usd">221000000</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <dgx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFiniteLivedIntangibles1
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzMzOA_7b69007d-4fbe-4dca-a3aa-6de691194c30"
      unitRef="usd">107000000</dgx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFiniteLivedIntangibles1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i48a2f820f01a423fa5d8fb263ceee2c0_D20210601-20210601"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5Xzc0OA_e46149e8-def8-40a5-8c11-5c5792b351f1"
      unitRef="usd">225000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="i7c718b40c7aa46b79dd5ad4b49064a03_I20210601"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzEyNDQ1_f760043a-d182-471d-91bd-7bcad56141ed"
      unitRef="usd">171000000</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i5e9e75dc29624f80957117764e6a8712_I20210601"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5Xzk0Mg_cf6e1c97-9957-4411-af7a-3799f44f259e"
      unitRef="usd">54000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ib254cb5566f04ccb957b18919eed9f8d_D20210601-20210601"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzEwODM_074467e6-dab3-4be6-91d5-fd3caea83bbe">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i1b56aef5907945b3abd0ec2ca54428c0_D20211213-20211213"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzE0MTk_991f8697-d422-4269-8c5a-83776186d993"
      unitRef="usd">95000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i1b56aef5907945b3abd0ec2ca54428c0_D20211213-20211213"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzE0NjQ_8b9da566-c3da-4d0b-b4ae-8cbaae315062"
      unitRef="usd">80000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i52f75c68a74542ba8c151adcd5b7c6c1_I20211213"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzE1MTk_1cb11e90-9c61-45e0-a343-256bcce7bc1f"
      unitRef="usd">15000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:Goodwill
      contextRef="i52f75c68a74542ba8c151adcd5b7c6c1_I20211213"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzE4NjU_5f6a66fd-6bd1-4e9a-8daa-78e0907a9896"
      unitRef="usd">48000000</us-gaap:Goodwill>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="i52f75c68a74542ba8c151adcd5b7c6c1_I20211213"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzE4OTA_78534cd1-e9ed-4fe8-801a-1a8325d1ae02"
      unitRef="usd">33000000</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="if8ace4c429434da1b559d5ea5059ac8a_I20211213"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzEyNDk4_d80d48db-f7a7-42ed-ae7c-bdc33ac1091d"
      unitRef="usd">44000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i52f75c68a74542ba8c151adcd5b7c6c1_I20211213"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzE5MTM_18155ca2-17dd-439b-b981-8d8a25caa89a"
      unitRef="usd">11000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <dgx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinanceLeaseLiabilities
      contextRef="i52f75c68a74542ba8c151adcd5b7c6c1_I20211213"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzE5NTA_bf92b010-1cfe-4ea3-b360-fdde53c37029"
      unitRef="usd">9000000</dgx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinanceLeaseLiabilities>
    <dgx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets
      contextRef="i52f75c68a74542ba8c151adcd5b7c6c1_I20211213"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzE5ODM_99191d1c-28a8-4fad-a6b8-3dccdcd5333b"
      unitRef="usd">6000000</dgx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets>
    <dgx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities
      contextRef="i52f75c68a74542ba8c151adcd5b7c6c1_I20211213"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzIwMjY_1471a2ec-029c-4aec-9b25-227a1c083914"
      unitRef="usd">6000000</dgx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="i52f75c68a74542ba8c151adcd5b7c6c1_I20211213"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzIwNjU_26978981-d367-4f0e-a637-84ccec87da28"
      unitRef="usd">1000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i16f34a8359cd44c7a2ed3560a9171968_D20211213-20211213"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzIxOTk_298317a7-9d9c-491b-99cb-b29047bc86e0">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzIzMDg_87c0ea90-4d71-4d3e-895e-1c42ba4b6e77"
      unitRef="usd">330000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzI0MjU_83589e47-af93-455e-9fc1-782e11c7eb92"
      unitRef="usd">247000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="i872b3ea2e369403f8c0129ff07e0b538_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzI0Mzg_9d2ec457-3127-41dd-be5e-d4faa97a545f"
      unitRef="usd">210000000</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <dgx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFiniteLivedIntangibles1
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzI1MTA_fc535f3a-a6fc-4720-8b1e-4b569e4eb026"
      unitRef="usd">146000000</dgx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFiniteLivedIntangibles1>
    <dgx:BusinessAcquisitionPostacquisitionRevenue
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzI2Njg_24a4f73e-043f-44bb-900d-9aa55e8561ec"
      unitRef="usd">127000000</dgx:BusinessAcquisitionPostacquisitionRevenue>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i7198b30a0f3543f8b7624f5a08626715_D20200121-20200121"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzI4ODk_e6149a4b-f303-40b8-a6c2-b3b3a84060f3"
      unitRef="usd">108000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="i7198b30a0f3543f8b7624f5a08626715_D20200121-20200121"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzI5MDA_fb5b0c9a-9d4c-43e9-a2c0-58bb39c0ee73"
      unitRef="usd">3000000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="i5c6b2d78cc5544cea4ff096768c26e2f_I20200121"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzMyOTE_07f651fd-26d2-454c-9284-4c21ad2c5173"
      unitRef="usd">66000000</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:Goodwill
      contextRef="i5c6b2d78cc5544cea4ff096768c26e2f_I20200121"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzMyOTE_74a53d34-b23a-4f4b-a533-ac6d9ece6a28"
      unitRef="usd">66000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i5c6b2d78cc5544cea4ff096768c26e2f_I20200121"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzMzMjI_9d291029-ebd2-46f4-a110-0c5af8d41b8c"
      unitRef="usd">43000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <dgx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedPropertyPlantandEquipmentandWorkingCapital
      contextRef="i5c6b2d78cc5544cea4ff096768c26e2f_I20200121"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzMzNTE_89101ed6-19f6-4848-9fbc-ee395131404e"
      unitRef="usd">2000000</dgx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedPropertyPlantandEquipmentandWorkingCapital>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ia0752516755c42d4b6bd8c225ce45827_D20200121-20200121"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzM1Mzk_e98dd22c-3377-4049-88cb-0866efc68585">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="iffd12e5591e7425f9d86856d3c9e755a_D20200121-20200121"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzM1NDY_c0417501-1127-4f69-989d-beffb669b171">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ibbfa5abb43c94c9b95f08bbd21c21a95_D20200406-20200406"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzM5NTA_9880cab6-dbe8-48f2-b394-7a71bf333cc7"
      unitRef="usd">120000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="i97014f982e65418d980efc0a485ac0d0_I20200406"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzEyNTcz_1dcae439-09b1-43f3-900a-03aa2fcb1b89"
      unitRef="usd">93000000</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ib0b5a278261f4aeaa3c8450f4ab8f98b_I20200406"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzQxMDg_e8d86e4a-5b95-433d-bf2d-8218def08791"
      unitRef="usd">27000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="idc562163c50f4774ba7552b47b943aa8_D20200406-20200406"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzQyNDk_cfe0d7b8-5bb7-4686-94f7-343a1c926fa8">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i318abc26c57d45e199c441d6a27fb59b_I20200801"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzQyODY_cf7f9911-5029-43ab-9752-db8d78aeccf8"
      unitRef="number">0.56</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i318abc26c57d45e199c441d6a27fb59b_I20200801"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzQ0MTY_8236b0f3-54ac-4db8-92fe-e2ca72cbdcd3"
      unitRef="number">0.56</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i8e330046544a4466b899b21db4a44981_D20200801-20200801"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzQ1NDI_4f5617b6-78a8-4e99-894b-da922a313477"
      unitRef="usd">93000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="i8e330046544a4466b899b21db4a44981_D20200801-20200801"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzQ1NTM_2bb7bfa8-2e16-4f23-b63d-a5c72faf919c"
      unitRef="usd">18000000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage
      contextRef="ia4132aab88954f808a22077ce48c7778_I20200731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzQ3MDI_268aa092-45ec-41a2-8799-250178ea086d"
      unitRef="number">0.44</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1
      contextRef="if02f69bfea444e448def3a82a65cb96b_D20200731-20200731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzQ3OTY_aebe1715-e5e9-4e75-ae18-89a72a59edd5"
      unitRef="usd">87000000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
      contextRef="i56f4083aa1ed47fbbfc4bd4e9a05cc0f_D20200801-20200801"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzQ4NDc_a999aab6-fe8c-4d75-9c4f-9c14687f63b2"
      unitRef="usd">70000000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <dgx:BusinessCombinationStepAcquisitionEquityInterestInAcquireeLongTermGrowthRateUsedToDetermineFairValue
      contextRef="i318abc26c57d45e199c441d6a27fb59b_I20200801"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzUxMzE_5f1df13f-61fc-4307-bde1-633da719bf85"
      unitRef="number">0.015</dgx:BusinessCombinationStepAcquisitionEquityInterestInAcquireeLongTermGrowthRateUsedToDetermineFairValue>
    <dgx:BusinessCombinationStepAcquisitionEquityInterestInAcquireeDicountRateUsedToDetermineFairValue
      contextRef="i318abc26c57d45e199c441d6a27fb59b_I20200801"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzUxODk_0d731389-430e-400d-9ffe-6e4a239e2c5d"
      unitRef="number">0.075</dgx:BusinessCombinationStepAcquisitionEquityInterestInAcquireeDicountRateUsedToDetermineFairValue>
    <us-gaap:Goodwill
      contextRef="i318abc26c57d45e199c441d6a27fb59b_I20200801"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzUyOTA_dc830fda-aa6f-4129-9984-e607ab4ab1dc"
      unitRef="usd">84000000</us-gaap:Goodwill>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="i318abc26c57d45e199c441d6a27fb59b_I20200801"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzUzMTU_496b54ef-aa0f-4df0-abde-8dfa274b97dd"
      unitRef="usd">47000000</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ibd44c8b9d5c649278afdc75ade9c679b_I20200801"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzUzMzg_e5c08b1f-e878-493b-b18b-789d37d3b7cc"
      unitRef="usd">74000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <dgx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedWorkingCapital
      contextRef="i318abc26c57d45e199c441d6a27fb59b_I20200801"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzUzNjM_3e94b2d5-efed-4871-be99-da4b9dbb016b"
      unitRef="usd">11000000</dgx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedWorkingCapital>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i318abc26c57d45e199c441d6a27fb59b_I20200801"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzUzODk_cf2dea3d-76f1-4f6a-8b82-a3a62655d5de"
      unitRef="usd">11000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="if6cc04f23f064d64bc9599f898569338_D20200801-20200801"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTAvZnJhZzphMDEzZWFlYjNlOGU0NWE1YjlhZjExNGJjYWI5MDU3OS90ZXh0cmVnaW9uOmEwMTNlYWViM2U4ZTQ1YTViOWFmMTE0YmNhYjkwNTc5XzU1MzI_a419199f-e1b7-48b2-b56f-f571e26c6db2">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTMvZnJhZzoyMjQ3YjJkZWM1ZWM0M2U1YTFjY2I3YTAwODgwZDI1ZS90ZXh0cmVnaW9uOjIyNDdiMmRlYzVlYzQzZTVhMWNjYjdhMDA4ODBkMjVlXzEyODA_602efe99-f9b9-4a4e-b2a5-8c741eaad6d5">DISPOSITION&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;On April 1, 2021, the Company sold its 40% ownership interest in Q&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Solutions&#xae; ("Q&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Solutions"), its clinical trials central laboratory services joint venture, to IQVIA Holdings, Inc. ("IQVIA"), its joint venture partner, for $760&#160;million in an all-cash transaction.  Prior to the transaction, the Company accounted for its minority interest as an equity method investment.  As a result of the transaction, during the year ended December 31, 2021, the Company recorded a $314&#160;million pre-tax gain in other (expense) income, net in the consolidated statement of operations based on the difference between the net sales proceeds and the carrying value of the investment, including $20&#160;million of cumulative translation losses which were previously recorded in accumulated other comprehensive loss.  During the year ended December 31, 2021, the Company also recorded $55&#160;million &lt;/span&gt;of income tax expense related to the gain, consisting of $127&#160;million of current income tax expense, partially offset by $72&#160;million of deferred income tax benefit.</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <dgx:EquityMethodInvestmentOwnershipPercentDisposedOf
      contextRef="i0c20173d8dc64ebdb79161256ab69f0d_I20210401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTMvZnJhZzoyMjQ3YjJkZWM1ZWM0M2U1YTFjY2I3YTAwODgwZDI1ZS90ZXh0cmVnaW9uOjIyNDdiMmRlYzVlYzQzZTVhMWNjYjdhMDA4ODBkMjVlXzYx_439a551c-3366-410e-a137-1e036afe5a23"
      unitRef="number">0.40</dgx:EquityMethodInvestmentOwnershipPercentDisposedOf>
    <dgx:ProceedsFromSaleOfEquityMethodInvestmentsGross
      contextRef="i5953c712e4234176ac0378246142fc74_D20210401-20210401"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTMvZnJhZzoyMjQ3YjJkZWM1ZWM0M2U1YTFjY2I3YTAwODgwZDI1ZS90ZXh0cmVnaW9uOjIyNDdiMmRlYzVlYzQzZTVhMWNjYjdhMDA4ODBkMjVlXzI0Nw_5ff3128c-2424-495f-8cf2-90d99448efe8"
      unitRef="usd">760000000</dgx:ProceedsFromSaleOfEquityMethodInvestmentsGross>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="i8a3a680061ef49fcac90a1aabb89821b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTMvZnJhZzoyMjQ3YjJkZWM1ZWM0M2U1YTFjY2I3YTAwODgwZDI1ZS90ZXh0cmVnaW9uOjIyNDdiMmRlYzVlYzQzZTVhMWNjYjdhMDA4ODBkMjVlXzUzNA_7b53549c-00f3-4579-b5cb-11cb0f865e1f"
      unitRef="usd">-314000000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="idcd7cd9e61214881b085d41e21b23992_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTMvZnJhZzoyMjQ3YjJkZWM1ZWM0M2U1YTFjY2I3YTAwODgwZDI1ZS90ZXh0cmVnaW9uOjIyNDdiMmRlYzVlYzQzZTVhMWNjYjdhMDA4ODBkMjVlXzcwNw_97e13888-1af6-4943-87d8-0b6842bc61ad"
      unitRef="usd">20000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i309534767ce0403ba44362e2a393aa76_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTMvZnJhZzoyMjQ3YjJkZWM1ZWM0M2U1YTFjY2I3YTAwODgwZDI1ZS90ZXh0cmVnaW9uOjIyNDdiMmRlYzVlYzQzZTVhMWNjYjdhMDA4ODBkMjVlXzg2OA_6556572b-8115-4684-b43d-d852df057416"
      unitRef="usd">55000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i309534767ce0403ba44362e2a393aa76_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTMvZnJhZzoyMjQ3YjJkZWM1ZWM0M2U1YTFjY2I3YTAwODgwZDI1ZS90ZXh0cmVnaW9uOjIyNDdiMmRlYzVlYzQzZTVhMWNjYjdhMDA4ODBkMjVlXzkyOA_55612f3b-37ea-4451-a1e3-f6e55b750e60"
      unitRef="usd">127000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i309534767ce0403ba44362e2a393aa76_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTMvZnJhZzoyMjQ3YjJkZWM1ZWM0M2U1YTFjY2I3YTAwODgwZDI1ZS90ZXh0cmVnaW9uOjIyNDdiMmRlYzVlYzQzZTVhMWNjYjdhMDA4ODBkMjVlXzk4Mg_353efe59-d3ce-4f60-88b0-66bd69043ba4"
      unitRef="usd">72000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90ZXh0cmVnaW9uOjBlMmU5NWZhNmI2ZjQ2NjU5NmI1Y2Q1MDgyNmI1MTI5XzY3OTk_80be8f10-123d-4530-94ea-5d09f9fc9dce">FAIR VALUE MEASUREMENTS &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The following table provides a summary of the recognized assets and liabilities that are measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basis of Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation trading securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash surrender value of life insurance policies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Redeemable noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation trading securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash surrender value of life insurance policies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Redeemable noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company offers certain employees the opportunity to participate in a non-qualified supplemental deferred compensation plan.  A participant's deferrals, together with Company matching credits, are invested in a variety of participant-directed stock and bond mutual funds that are classified as trading securities.  The trading securities are classified within Level 1 of the fair value hierarchy because the changes in the fair value of these securities, which are recorded in other assets in the Company's consolidated balance sheet, are measured using quoted prices in active markets based on the market price per unit multiplied by the number of units held, exclusive of any transaction costs.  A corresponding adjustment for changes in fair value of the trading securities is also reflected in the changes in fair value of the deferred compensation obligation.  The deferred compensation liabilities are classified within Level 2 of the fair value hierarchy because their inputs are derived principally from observable market data by correlation to the trading securities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company offers certain employees the opportunity to participate in a non-qualified deferred compensation program.  A participant's deferrals, together with Company matching credits, are &#x201c;invested&#x201d; at the direction of the employee in a hypothetical portfolio of investments which are tracked by an administrator.  The Company purchases life insurance policies, with the Company named as beneficiary of the policies, for the purpose of funding the program's liability.  Changes in the cash surrender value of the life insurance policies are based upon earnings and changes in the value of the underlying investments.  Changes in the fair value of the deferred compensation obligation are derived using quoted prices in active markets based on the market price per unit multiplied by the number of units.  The cash surrender value, which is recorded in other assets in the Company's consolidated balance sheet, and the deferred compensation obligation are classified within Level 2 of the fair value hierarchy because their inputs are derived principally from observable market data by correlation to the hypothetical investments. Deferrals under the plan currently may only be made by participants who made deferrals under the plan in 2017. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company's investment portfolio primarily includes equity investments comprised mostly of strategic holdings in companies concentrated in the life sciences and healthcare industries.  Equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) with readily determinable fair values are measured at fair value in prepaid expenses and other current assets in the Company's consolidated balance sheet.  Such equity investments are classified within Level 1 of the fair value hierarchy because the changes in the fair values of the securities are measured using quoted prices in active markets based on the market price per share multiplied by the number of shares held, exclusive of any transaction costs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company's available-for-sale debt securities are measured at fair value using discounted cash flows.  These fair value measurements are classified within Level 3 of the fair value hierarchy as the fair value is based on significant inputs that are not observable.  Significant inputs include cash flows projections and a discount rate.  The investments are recorded in other assets in the Company's consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;In connection with the acquisitions of Pack Health and Labtech (see Note 6), the Company has contingent consideration obligations, with a potential maximum aggregate payment of $40&#160;million, that are to be paid based on the achievement of certain testing volume or revenue benchmarks.  Contingent consideration accruals are measured at fair value using either an option-pricing method or a Monte Carlo method and are classified within Level 3 of the fair value hierarchy as the fair value is determined based on significant inputs that are not observable.  Significant inputs include management&#x2019;s estimate of volume or revenue and other market inputs, including comparable company revenue volatility (7.5%) and a discount rate (ranging from 2.5% to 3.0%).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The following table provides a reconciliation of the beginning and ending balances of liabilities using significant unobservable inputs (Level 3):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.912%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contingent Consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases, additions and issuances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases, additions and issuances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value adjustments included in earnings - realized/unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The $5 million net loss included in earnings associated with the change in the fair value of contingent consideration for the year ended December&#160;31, 2022 is reported in other operating expense (income), net.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;In connection with the sale of an 18.9% noncontrolling interest in a subsidiary to UMass Memorial Medical Center ("UMass") on July 1, 2015, the Company granted UMass the right to require the Company to purchase all of its interest in the subsidiary at fair value commencing July 1, 2020.  As of December&#160;31, 2022, the redeemable noncontrolling interest was presented at its fair value.  The fair value measurement of the redeemable noncontrolling interest is classified within Level 3 of the fair value hierarchy because the fair value is based on a discounted cash flow analysis that takes into account, among other items, the joint venture's expected future cash flows, long-term growth rates, and a discount rate commensurate with economic risk.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;During the year ended December 31, 2022, the Company recorded a $14&#160;million impairment charge, which is included in other operating expense (income), net, in order to fully impair certain property, plant and equipment.  The fair value measurement was classified within Level 3 of the fair value hierarchy as it was based on significant inputs that are not observable, including cash flow projections.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The carrying amounts of cash and cash equivalents, accounts receivable and accounts payable and accrued expenses approximate fair value based on the short maturities of these instruments.  As of December&#160;31, 2022 and 2021, the fair value of the Company&#x2019;s debt was estimated at $3.7 billion and $4.4 billion, respectively.  Principally all of the Company's debt is classified within Level 1 of the fair value hierarchy because the fair value of the debt is estimated based on rates currently offered to the Company with identical terms and maturities, using quoted active market prices and yields, taking into account the underlying terms of the debt instruments.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90ZXh0cmVnaW9uOjBlMmU5NWZhNmI2ZjQ2NjU5NmI1Y2Q1MDgyNmI1MTI5XzY4MDA_346c1513-1070-4ca9-bfe6-3158067e444d">The following table provides a summary of the recognized assets and liabilities that are measured at fair value on a recurring basis:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basis of Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation trading securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash surrender value of life insurance policies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Redeemable noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation trading securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash surrender value of life insurance policies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Redeemable noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:TradingSecurities
      contextRef="i2a46256065f64a1f83735b542ac8cd05_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzUtMS0xLTEtNzgyMTU_040c8411-2d1b-45c4-b041-f95ec6d68755"
      unitRef="usd">68000000</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="ifacb18823a32464e8277a40cd0e40141_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzUtMy0xLTEtNzgyMTU_dc8cb6b2-99a5-41a3-9d7c-bddd41b37d58"
      unitRef="usd">68000000</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i939ef35c1b364fccb6c395109ba883a8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzUtNS0xLTEtNzgyMTU_cc478dd9-92a7-46ce-93d4-b21c4ac70633"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i806fc0b55bb0418c955d42a8e1e2a9d5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzUtNy0xLTEtNzgyMTU_c6b60bd5-0625-494b-9117-bca65c6e51d8"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:CashSurrenderValueFairValueDisclosure
      contextRef="i2a46256065f64a1f83735b542ac8cd05_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzYtMS0xLTEtNzgyMTU_5f209a0a-e98a-40ed-a2d3-b08055b5fe5b"
      unitRef="usd">46000000</us-gaap:CashSurrenderValueFairValueDisclosure>
    <us-gaap:CashSurrenderValueFairValueDisclosure
      contextRef="ifacb18823a32464e8277a40cd0e40141_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzYtMy0xLTEtNzgyMTU_d11e94cb-840b-44b0-b3dd-b8cc464a720b"
      unitRef="usd">0</us-gaap:CashSurrenderValueFairValueDisclosure>
    <us-gaap:CashSurrenderValueFairValueDisclosure
      contextRef="i939ef35c1b364fccb6c395109ba883a8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzYtNS0xLTEtNzgyMTU_91ed14f3-d1f0-4925-9bb1-b1cd49723208"
      unitRef="usd">46000000</us-gaap:CashSurrenderValueFairValueDisclosure>
    <us-gaap:CashSurrenderValueFairValueDisclosure
      contextRef="i806fc0b55bb0418c955d42a8e1e2a9d5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzYtNy0xLTEtNzgyMTU_1aa75c16-81ea-4511-a795-5d6da70e5aa9"
      unitRef="usd">0</us-gaap:CashSurrenderValueFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2a46256065f64a1f83735b542ac8cd05_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzktMS0xLTEtNzgyMTU_6877498b-2e5b-47c4-9b40-336b715e958d"
      unitRef="usd">2000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifacb18823a32464e8277a40cd0e40141_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzktMy0xLTEtNzgyMTU_3d84cc5f-03a0-4f2f-b7e6-6b113f121186"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i939ef35c1b364fccb6c395109ba883a8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzktNS0xLTEtNzgyMTU_f85bb497-a082-45a6-9b1b-e52afc4ea77d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i806fc0b55bb0418c955d42a8e1e2a9d5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzktNy0xLTEtNzgyMTU_01883d87-ccd5-484c-811b-2a7c1bad6568"
      unitRef="usd">2000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2a46256065f64a1f83735b542ac8cd05_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzEyLTEtMS0xLTc4MjE1_5175ba1d-35d5-44e8-b2c8-0dfbc1cc5215"
      unitRef="usd">116000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifacb18823a32464e8277a40cd0e40141_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzEyLTMtMS0xLTc4MjE1_a06e20e6-1a79-495c-82ee-3eede61f53ea"
      unitRef="usd">68000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i939ef35c1b364fccb6c395109ba883a8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzEyLTUtMS0xLTc4MjE1_607bf6f8-8111-457b-8f12-89ab2c320acf"
      unitRef="usd">46000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i806fc0b55bb0418c955d42a8e1e2a9d5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzEyLTctMS0xLTc4MjE1_76547a8f-cf9c-4d64-a3d2-eb92fc21a35f"
      unitRef="usd">2000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent
      contextRef="i2a46256065f64a1f83735b542ac8cd05_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzE1LTEtMS0xLTc4MjE1_636bd8cd-165c-44a5-b99d-e6008793fb6d"
      unitRef="usd">120000000</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
    <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent
      contextRef="ifacb18823a32464e8277a40cd0e40141_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzE1LTMtMS0xLTc4MjE1_ebdfb51a-b4db-4032-9918-8c6913922f10"
      unitRef="usd">0</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
    <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent
      contextRef="i939ef35c1b364fccb6c395109ba883a8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzE1LTUtMS0xLTc4MjE1_2b3e8c6f-0089-4bb7-be88-f51ac127a283"
      unitRef="usd">120000000</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
    <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent
      contextRef="i806fc0b55bb0418c955d42a8e1e2a9d5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzE1LTctMS0xLTc4MjE1_54e1ea61-6343-460c-ba83-799648fc64e9"
      unitRef="usd">0</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2a46256065f64a1f83735b542ac8cd05_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzE3LTEtMS0xLTc4MjE1_f8b4101e-ecb0-4289-b47b-c2d7c668e300"
      unitRef="usd">23000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ifacb18823a32464e8277a40cd0e40141_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzE3LTMtMS0xLTc4MjE1_774a8714-b1ea-4886-ad48-c1c68159b165"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i939ef35c1b364fccb6c395109ba883a8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzE3LTUtMS0xLTc4MjE1_23261b9b-c09f-4d3d-83a3-3fc00224745c"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i806fc0b55bb0418c955d42a8e1e2a9d5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzE3LTctMS0xLTc4MjE1_db859fe9-7e23-4369-b861-54dabc259804"
      unitRef="usd">23000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i2a46256065f64a1f83735b542ac8cd05_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzIwLTEtMS0xLTc4MjE1_3767b151-3aa2-4583-a4ea-88f0a03a2e55"
      unitRef="usd">143000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ifacb18823a32464e8277a40cd0e40141_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzIwLTMtMS0xLTc4MjE1_684cc193-800d-488b-8178-dcbac242c596"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i939ef35c1b364fccb6c395109ba883a8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzIwLTUtMS0xLTc4MjE1_3df65495-4472-4e59-ad25-e7fcacbc31cf"
      unitRef="usd">120000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i806fc0b55bb0418c955d42a8e1e2a9d5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzIwLTctMS0xLTc4MjE1_9b4256dd-748c-4440-b846-9d07d9563a5d"
      unitRef="usd">23000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="i2a46256065f64a1f83735b542ac8cd05_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzIyLTEtMS0xLTc4MjE1_5afd0ed2-1eab-4ead-af4b-c406d7e905cd"
      unitRef="usd">77000000</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="ifacb18823a32464e8277a40cd0e40141_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzIyLTMtMS0xLTc4MjE1_b6eb2125-5eb3-4269-a8bc-3a66b54cb073"
      unitRef="usd">0</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="i806fc0b55bb0418c955d42a8e1e2a9d5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzIyLTctMS0xLTc4MjE1_5da5e59b-0db6-4e7e-b4ab-5125155f11b5"
      unitRef="usd">77000000</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:TradingSecurities
      contextRef="iec46d6b614174b4a84f77d9cff2de05f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzI2LTEtMS0xLTc4MjE1_0a255b1f-c627-40bc-af6d-7a9660d4abe8"
      unitRef="usd">77000000</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i0e74f4a4c6c44d98bda7c8be9f02a6b2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzI2LTMtMS0xLTc4MjE1_f8c62d71-e153-40ba-900d-01a9ae4c4327"
      unitRef="usd">77000000</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i454f20bc7ea343f5a803483a6773d323_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzI2LTUtMS0xLTc4MjE1_82cfb7c6-dd1e-4a74-b1b4-337da53ca752"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i08e7768575cf494bab1f563baab11bdc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzI2LTctMS0xLTc4MjE1_c67c473f-ac0e-4bbb-aec8-96fa833ef66b"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:CashSurrenderValueFairValueDisclosure
      contextRef="iec46d6b614174b4a84f77d9cff2de05f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzI3LTEtMS0xLTc4MjE1_eda8ebd2-d715-4214-81d0-3ec5c6bd6a39"
      unitRef="usd">57000000</us-gaap:CashSurrenderValueFairValueDisclosure>
    <us-gaap:CashSurrenderValueFairValueDisclosure
      contextRef="i0e74f4a4c6c44d98bda7c8be9f02a6b2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzI3LTMtMS0xLTc4MjE1_b6997fa5-e3ef-470c-9679-9714c0b1d239"
      unitRef="usd">0</us-gaap:CashSurrenderValueFairValueDisclosure>
    <us-gaap:CashSurrenderValueFairValueDisclosure
      contextRef="i454f20bc7ea343f5a803483a6773d323_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzI3LTUtMS0xLTc4MjE1_e694fba3-725a-46ec-9618-7e10df34b4bc"
      unitRef="usd">57000000</us-gaap:CashSurrenderValueFairValueDisclosure>
    <us-gaap:CashSurrenderValueFairValueDisclosure
      contextRef="i08e7768575cf494bab1f563baab11bdc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzI3LTctMS0xLTc4MjE1_46b550ec-2509-49dc-8629-1712dcd45645"
      unitRef="usd">0</us-gaap:CashSurrenderValueFairValueDisclosure>
    <dgx:EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities
      contextRef="iec46d6b614174b4a84f77d9cff2de05f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzI4LTEtMS0xLTc4MjE1_51a969a3-e15c-458b-988c-1df8fec179be"
      unitRef="usd">44000000</dgx:EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities>
    <dgx:EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities
      contextRef="i0e74f4a4c6c44d98bda7c8be9f02a6b2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzI4LTMtMS0xLTc4MjE1_c152d82a-1fa8-473f-a0fc-093c21ccaa77"
      unitRef="usd">44000000</dgx:EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities>
    <dgx:EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities
      contextRef="i454f20bc7ea343f5a803483a6773d323_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzI4LTUtMS0xLTc4MjE1_8b963335-7bf9-4dd7-99e0-280618cf6573"
      unitRef="usd">0</dgx:EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities>
    <dgx:EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities
      contextRef="i08e7768575cf494bab1f563baab11bdc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzI4LTctMS0xLTc4MjE1_79947eed-e7e6-4457-b9e5-57758533d962"
      unitRef="usd">0</dgx:EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iec46d6b614174b4a84f77d9cff2de05f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzMwLTEtMS0xLTc4MjE1_342134ca-634f-4fab-9403-0b53d4c91bbe"
      unitRef="usd">1000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0e74f4a4c6c44d98bda7c8be9f02a6b2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzMwLTMtMS0xLTc4MjE1_17b19021-fee1-4470-a0cf-4fd86efed65f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i454f20bc7ea343f5a803483a6773d323_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzMwLTUtMS0xLTc4MjE1_0474e06d-722a-4445-bcd4-0ade1e543fe3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i08e7768575cf494bab1f563baab11bdc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzMwLTctMS0xLTc4MjE1_c3382274-9cd6-4078-83a9-57e11f2f1a6b"
      unitRef="usd">1000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iec46d6b614174b4a84f77d9cff2de05f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzMyLTEtMS0xLTc4MjE1_9b8c48e9-a4f3-4d5c-97a7-d0019255f871"
      unitRef="usd">179000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0e74f4a4c6c44d98bda7c8be9f02a6b2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzMyLTMtMS0xLTc4MjE1_acbbf77a-69ad-43ff-bdc8-4d87ec3f261d"
      unitRef="usd">121000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i454f20bc7ea343f5a803483a6773d323_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzMyLTUtMS0xLTc4MjE1_6d90e25c-1349-4b2c-90bb-d1e1a8e033ec"
      unitRef="usd">57000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i08e7768575cf494bab1f563baab11bdc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzMyLTctMS0xLTc4MjE1_09166055-4bf2-4d32-a763-d2964d6a0f4b"
      unitRef="usd">1000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent
      contextRef="iec46d6b614174b4a84f77d9cff2de05f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzM1LTEtMS0xLTc4MjE1_e42e2d2b-6baf-41aa-af17-1fb4ef01d14b"
      unitRef="usd">143000000</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
    <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent
      contextRef="i0e74f4a4c6c44d98bda7c8be9f02a6b2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzM1LTMtMS0xLTc4MjE1_0c3dbab8-cdfa-4efa-93f2-ad5e0ef718f2"
      unitRef="usd">0</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
    <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent
      contextRef="i454f20bc7ea343f5a803483a6773d323_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzM1LTUtMS0xLTc4MjE1_a7059350-9165-4760-a29f-dbf7830eb983"
      unitRef="usd">143000000</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
    <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent
      contextRef="i08e7768575cf494bab1f563baab11bdc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzM1LTctMS0xLTc4MjE1_0b730083-4749-4beb-b5b0-f91c867be3ff"
      unitRef="usd">0</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iec46d6b614174b4a84f77d9cff2de05f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzM3LTEtMS0xLTc4MjE1_04912852-b20e-44f3-b125-ed683b4109c2"
      unitRef="usd">5000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i0e74f4a4c6c44d98bda7c8be9f02a6b2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzM3LTMtMS0xLTc4MjE1_986123ec-fbb6-4c2c-b38d-0dcf0608f792"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i454f20bc7ea343f5a803483a6773d323_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzM3LTUtMS0xLTc4MjE1_bad18442-3faa-4e99-a660-30e8649d5e3e"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i08e7768575cf494bab1f563baab11bdc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzM3LTctMS0xLTc4MjE1_52c1db5f-4634-4174-99df-9baf81c714e3"
      unitRef="usd">5000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="iec46d6b614174b4a84f77d9cff2de05f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzQwLTEtMS0xLTc4MjE1_8a8e05d4-3eaa-4b04-acc6-ef7dc4deef25"
      unitRef="usd">148000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i0e74f4a4c6c44d98bda7c8be9f02a6b2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzQwLTMtMS0xLTc4MjE1_b7374b0d-61d6-4c5b-828f-41aeaf2a4d78"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i454f20bc7ea343f5a803483a6773d323_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzQwLTUtMS0xLTc4MjE1_9014c631-b9d0-463a-be96-d6d8e505d4b3"
      unitRef="usd">143000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i08e7768575cf494bab1f563baab11bdc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzQwLTctMS0xLTc4MjE1_914fc1c6-a9dc-4270-ad8c-2ff924a14879"
      unitRef="usd">5000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="iec46d6b614174b4a84f77d9cff2de05f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzQyLTEtMS0xLTc4MjE1_539fecf5-fa0d-44a4-8737-25fd56f0febf"
      unitRef="usd">79000000</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="i0e74f4a4c6c44d98bda7c8be9f02a6b2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzQyLTMtMS0xLTc4MjE1_4d5d87e5-4b83-4198-aca5-07d992567dbf"
      unitRef="usd">0</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="i08e7768575cf494bab1f563baab11bdc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTpjOTIyNzRkMGM4NTk0NmIzYWQwMWQ1YzUxN2U1YzI4YS90YWJsZXJhbmdlOmM5MjI3NGQwYzg1OTQ2YjNhZDAxZDVjNTE3ZTVjMjhhXzQyLTctMS0xLTc4MjE1_58f1ad02-1ef0-411b-8794-75df69467ce5"
      unitRef="usd">79000000</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="iec1e53779a1a46e382c71420c86a8e65_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90ZXh0cmVnaW9uOjBlMmU5NWZhNmI2ZjQ2NjU5NmI1Y2Q1MDgyNmI1MTI5XzQwNDQ_a2b3cf6b-e69f-42fb-899a-1cd01cffde91"
      unitRef="usd">40000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ia070c0d807ae41f189d8789aa235216b_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90ZXh0cmVnaW9uOjBlMmU5NWZhNmI2ZjQ2NjU5NmI1Y2Q1MDgyNmI1MTI5XzQ1NTE_66ab5341-065a-499e-9643-128e9e118ddc"
      unitRef="number">0.075</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i23329615d047484080f7bc81509ea79e_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90ZXh0cmVnaW9uOjBlMmU5NWZhNmI2ZjQ2NjU5NmI1Y2Q1MDgyNmI1MTI5XzQ1NzY_e66dfe4e-818b-4b12-8744-0041b5e182a7"
      unitRef="number">0.025</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i435823dcec83485dbadc7a18b519986a_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90ZXh0cmVnaW9uOjBlMmU5NWZhNmI2ZjQ2NjU5NmI1Y2Q1MDgyNmI1MTI5XzIxOTkwMjMyNjY4ODE_7ede8b73-28f5-406b-be0d-25896e24b8a0"
      unitRef="number">0.030</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90ZXh0cmVnaW9uOjBlMmU5NWZhNmI2ZjQ2NjU5NmI1Y2Q1MDgyNmI1MTI5XzY3ODY_d3f5e4c1-3f16-4849-999a-8f2a033fa6dd">The following table provides a reconciliation of the beginning and ending balances of liabilities using significant unobservable inputs (Level 3):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.912%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contingent Consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases, additions and issuances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases, additions and issuances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value adjustments included in earnings - realized/unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ie2740945331a4803b48ca4d039b3724f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTo3NjNhZWFhMTk0Yjg0ZDMyOTM2YWZlZDUyNzdhMDk0My90YWJsZXJhbmdlOjc2M2FlYWExOTRiODRkMzI5MzZhZmVkNTI3N2EwOTQzXzItMS0xLTEtNzgyMTU_2f11e525-22c6-436a-9977-0d32602eced0"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements
      contextRef="ifd12294595f84e56a311bfb11080c96c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTo3NjNhZWFhMTk0Yjg0ZDMyOTM2YWZlZDUyNzdhMDk0My90YWJsZXJhbmdlOjc2M2FlYWExOTRiODRkMzI5MzZhZmVkNTI3N2EwOTQzXzMtMS0xLTEtNzgyMTU_43de4c1f-d5fe-4552-9ab6-9d5139d9d2d3"
      unitRef="usd">5000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i1029a7e4535b4243bba665741dbd11de_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTo3NjNhZWFhMTk0Yjg0ZDMyOTM2YWZlZDUyNzdhMDk0My90YWJsZXJhbmdlOjc2M2FlYWExOTRiODRkMzI5MzZhZmVkNTI3N2EwOTQzXzktMS0xLTEtNzgyMTU_d8b79a45-70d9-4285-81dc-3c060ac16eda"
      unitRef="usd">5000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements
      contextRef="i38a23e14d23244c8a2e550a645bbdcd1_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTo3NjNhZWFhMTk0Yjg0ZDMyOTM2YWZlZDUyNzdhMDk0My90YWJsZXJhbmdlOjc2M2FlYWExOTRiODRkMzI5MzZhZmVkNTI3N2EwOTQzXzExLTEtMS0xLTc4MjE1_36d0cfe9-15cb-4a4a-bd16-abaf85f43ac2"
      unitRef="usd">28000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i38a23e14d23244c8a2e550a645bbdcd1_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTo3NjNhZWFhMTk0Yjg0ZDMyOTM2YWZlZDUyNzdhMDk0My90YWJsZXJhbmdlOjc2M2FlYWExOTRiODRkMzI5MzZhZmVkNTI3N2EwOTQzXzEyLTEtMS0xLTc4MjE1_0c42f959-a8a9-4729-943b-f17cc9cabe25"
      unitRef="usd">15000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i38a23e14d23244c8a2e550a645bbdcd1_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTo3NjNhZWFhMTk0Yjg0ZDMyOTM2YWZlZDUyNzdhMDk0My90YWJsZXJhbmdlOjc2M2FlYWExOTRiODRkMzI5MzZhZmVkNTI3N2EwOTQzXzEzLTEtMS0xLTc4MjE1_62bec608-7d0f-483c-b2d7-c40cc3eea005"
      unitRef="usd">-5000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i341269c4649443fbbe35b79f45362759_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90YWJsZTo3NjNhZWFhMTk0Yjg0ZDMyOTM2YWZlZDUyNzdhMDk0My90YWJsZXJhbmdlOjc2M2FlYWExOTRiODRkMzI5MzZhZmVkNTI3N2EwOTQzXzE0LTEtMS0xLTc4MjE1_2a07cb66-1627-47dc-b711-701c1bcb7710"
      unitRef="usd">23000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i38a23e14d23244c8a2e550a645bbdcd1_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90ZXh0cmVnaW9uOjBlMmU5NWZhNmI2ZjQ2NjU5NmI1Y2Q1MDgyNmI1MTI5XzIxOTkwMjMyNjY5MDM_4fe43e86-ec06-4c60-926f-f58b80191d0c"
      unitRef="usd">-5000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="ia809ec8fd18c4ad48fc0dd81f2cdd760_I20150701"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90ZXh0cmVnaW9uOjBlMmU5NWZhNmI2ZjQ2NjU5NmI1Y2Q1MDgyNmI1MTI5XzQ5MjM_3f379efb-619d-45e1-aaa6-b89e8053d9af"
      unitRef="number">0.189</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:AssetImpairmentCharges
      contextRef="i1880b74088be4b518518151d49b3c3d9_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90ZXh0cmVnaW9uOjBlMmU5NWZhNmI2ZjQ2NjU5NmI1Y2Q1MDgyNmI1MTI5XzEwOTk1MTE2NDIwMTg_7ed0f8b1-76e3-4734-b394-0896e43935ea"
      unitRef="usd">14000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90ZXh0cmVnaW9uOjBlMmU5NWZhNmI2ZjQ2NjU5NmI1Y2Q1MDgyNmI1MTI5XzY0MTc_2bc3b26c-e382-4a0b-bef0-4ed6237cd75b"
      unitRef="usd">3700000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTYvZnJhZzowZTJlOTVmYTZiNmY0NjY1OTZiNWNkNTA4MjZiNTEyOS90ZXh0cmVnaW9uOjBlMmU5NWZhNmI2ZjQ2NjU5NmI1Y2Q1MDgyNmI1MTI5XzY0MjQ_9bdf270d-3ffc-4bae-b633-93740f8d7ce8"
      unitRef="usd">4400000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzUzMjE_722a6394-30fd-4d7a-9cc8-82f54b53fd65">TAXES ON INCOME&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company's pre-tax income before equity in earnings of equity method investees consisted of approximately $1.2 billion, $2.5 billion and $1.9 billion from U.S. operations and pre-tax income (loss) of $2 million, $148 million and $(7) million from foreign operations for the years ended December&#160;31, 2022, 2021 and 2020, respectively. &#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The components of income tax expense (benefit) for 2022, 2021 and 2020 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:42.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;A reconciliation of the federal statutory income tax rate to the Company's effective income tax rate for 2022, 2021 and 2020 was as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax provision at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and local income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustment to state deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Excess tax benefits on stock-based compensation arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Return to provision true-ups &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of equity earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in reserves for uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowances associated with certain net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The tax effects of temporary differences that give rise to significant portions of the deferred tax assets (liabilities) as of December&#160;31, 2022 and 2021 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-current deferred tax assets (liabilities):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable reserves&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities not currently deductible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basis differences in investments, joint ventures and subsidiaries &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards, net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(147)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(568)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(633)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total non-current deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(295)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(290)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;As of December&#160;31, 2022 and 2021, non-current deferred tax liabilities of $295 million and $290 million, respectively, are included in other liabilities in the consolidated balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;As of December&#160;31, 2022, the Company had estimated net operating loss carryforwards for federal and state income tax purposes of $12 million and $732 million, respectively, which expire at various dates through 2042.  Estimated net operating loss carryforwards for foreign income tax purposes are $73 million as of December&#160;31, 2022, some of which can be carried forward indefinitely while others expire at various dates through 2032.  As of December&#160;31, 2022 and 2021, deferred tax assets associated with net operating loss carryforwards of $77 million and $71 million, respectively, have each been reduced by valuation allowances of $28 million and $29 million, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Income taxes payable, including those classified as long-term in other liabilities in the consolidated balance sheet as of December&#160;31, 2022 and 2021, were $81 million and $106 million, respectively.  Prepaid income taxes were $26 million and $36 million as of December&#160;31, 2022 and 2021, respectively, and were recorded in prepaid expenses and other current assets in the consolidated balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The total amount of unrecognized tax benefits as of and for the years ended December&#160;31, 2022, 2021 and 2020 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;For tax positions of current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;For tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in judgment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expirations of statutes of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The contingent liabilities for tax positions primarily relate to uncertainties associated with the realization of tax benefits derived from the allocation of income and expense among state jurisdictions, the characterization and timing of certain tax deductions associated with business combinations, certain tax credits and the deductibility of certain expenses and settlement payments.   &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The total amount of unrecognized tax benefits as of December&#160;31, 2022, that, if recognized, would affect the effective income tax rate is $78 million.  Based upon the expiration of statutes of limitations, settlements and/or the conclusion of tax examinations, the Company believes it is reasonably possible that the total amount of unrecognized tax benefits may decrease by up to $13 million within the next twelve months.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Accruals for interest expense on contingent tax liabilities are classified in income tax expense in the consolidated statements of operations.  Accruals for penalties have historically been immaterial.  Interest expense (income) included in income tax expense in each of the years ended December&#160;31, 2022, 2021 and 2020 was approximately $3 million, $(2) million and $6 million, respectively.  As of December&#160;31, 2022 and 2021, the Company had approximately $16 million and $20 million, respectively, accrued, net of the benefit of a federal and state deduction, for the payment of interest on uncertain tax positions.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The recognition and measurement of certain tax benefits includes estimates and judgment by management and inherently involves subjectivity.  Changes in estimates may create volatility in the Company's effective tax rate in future periods and may be due to settlements with various tax authorities (either favorable or unfavorable), the expiration of the statute of limitations on certain tax positions and obtaining new information about particular tax positions that may cause management to change its estimates.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;In the regular course of business, various federal, state, local and foreign tax authorities conduct examinations of the Company's income tax filings and the Company generally remains subject to examination until the statute of limitations expires for the respective jurisdiction.  The Internal Revenue Service has either completed its examinations of the Company's consolidated federal income tax returns or the statute of limitations has expired up through and including the 2018 tax year.  At this time, the Company does not believe that there will be any material additional payments beyond its recorded contingent liability reserves that may be required as a result of these tax audits.  As of December&#160;31, 2022, a summary of the tax years that remain subject to examination, awaiting approval, are under appeal, or are otherwise unresolved for the Company's major jurisdictions are:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;United States - federal&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2019 - 2021 &lt;/span&gt;&lt;/div&gt;&#160;&#160;&#160;&#160;United States - various states&#160;&#160;&#160;&#160;2007 - 2021</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzE2Mw_f5906071-c7db-4367-988e-ea57df514040"
      unitRef="usd">1200000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzE2Nw_14e4d72c-bfd3-48cf-9f7c-b684c6e3cb59"
      unitRef="usd">2500000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzE3NA_4550ea47-0e84-482b-a31f-78a012867c0c"
      unitRef="usd">1900000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzIyNw_e6252223-ba5c-4547-a329-3418cce82eea"
      unitRef="usd">2000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzIzMQ_8b1834e4-7990-4c73-8427-1a1e65952ca9"
      unitRef="usd">148000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzIzOA_01dbe790-dfc3-49ec-be2c-66c96175e3b2"
      unitRef="usd">-7000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzUzMjg_d42c2fd3-8ff5-49ca-af20-734856d166ce">The components of income tax expense (benefit) for 2022, 2021 and 2020 were as follows: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzItMS0xLTEtNzgyMTU_eec42518-61f4-4e06-9ffd-349da95dba28"
      unitRef="usd">200000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzItMy0xLTEtNzgyMTU_763a5867-1c5a-46ac-a706-a627a115495b"
      unitRef="usd">528000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzItNS0xLTEtNzgyMTU_b27e9a46-fc93-4cfc-98b0-0faed324c542"
      unitRef="usd">300000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzMtMS0xLTEtNzgyMTU_0d9a9e1a-c645-4811-9d2b-740143078450"
      unitRef="usd">62000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzMtMy0xLTEtNzgyMTU_90765054-26a4-42c8-a5eb-8a45be3e3144"
      unitRef="usd">123000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzMtNS0xLTEtNzgyMTU_586803bc-a317-4ade-8366-1c7545b38f6e"
      unitRef="usd">74000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzQtMS0xLTEtNzgyMTU_b147bdac-6924-453c-8b8c-d713a06368ed"
      unitRef="usd">1000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzQtMy0xLTEtNzgyMTU_9fdd0194-363f-414f-8268-0ca0344a0577"
      unitRef="usd">3000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzQtNS0xLTEtNzgyMTU_9963bd84-d8ac-413e-8d32-3be1e4c5624f"
      unitRef="usd">1000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzYtMS0xLTEtNzgyMTU_da66c5e8-8bf5-4389-8266-f08c6cbb2fe7"
      unitRef="usd">29000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzYtMy0xLTEtNzgyMTU_fd59c077-eb1e-40cf-bc97-0c394ca73b8b"
      unitRef="usd">-61000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzYtNS0xLTEtNzgyMTU_35876fde-ff28-4e13-a3e8-6180617e50f0"
      unitRef="usd">55000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzctMS0xLTEtNzgyMTU_75398ac0-a203-4a74-8f85-9ea7efde793f"
      unitRef="usd">-27000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzctMy0xLTEtNzgyMTU_cc66e0d0-0330-4041-b138-d677c7da3a22"
      unitRef="usd">5000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzctNS0xLTEtNzgyMTU_916e6042-a3f2-4732-894a-e6a207e2130c"
      unitRef="usd">29000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzgtMS0xLTEtNzgyMTU_2d19fe41-3585-4ce2-af9a-18650528f1eb"
      unitRef="usd">-1000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzgtMy0xLTEtNzgyMTU_d1883c3f-af64-4b17-8c15-208a94e07ea5"
      unitRef="usd">-1000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzgtNS0xLTEtNzgyMTU_fd8810a8-5aa3-4b1d-906f-f444f27ac209"
      unitRef="usd">1000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzktMS0xLTEtNzgyMTU_704164ae-6fe6-42c3-9a11-b3aa25864461"
      unitRef="usd">264000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzktMy0xLTEtNzgyMTU_bec8fd98-84f4-4102-8e46-8ec972506a84"
      unitRef="usd">597000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZToyMjMwZGNhYThiNmU0NTdkOGIzMWY2ZjM1OTU0MTRhMy90YWJsZXJhbmdlOjIyMzBkY2FhOGI2ZTQ1N2Q4YjMxZjZmMzU5NTQxNGEzXzktNS0xLTEtNzgyMTU_0c1cdbeb-9945-4c81-aeb5-c4ee1e1bdb01"
      unitRef="usd">460000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzUzMjM_a0fbe8ca-744b-4e9f-9e65-cdf495be5edb">A reconciliation of the federal statutory income tax rate to the Company's effective income tax rate for 2022, 2021 and 2020 was as follows: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax provision at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and local income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustment to state deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Excess tax benefits on stock-based compensation arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Return to provision true-ups &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of equity earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in reserves for uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowances associated with certain net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzItMS0xLTEtNzgyMTU_b9da69cb-04c2-4beb-8cbb-01ce6cc19f4d"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzItMy0xLTEtNzgyMTU_7585421b-e41d-4d58-8934-c817aa36b386"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzItNS0xLTEtNzgyMTU_5519e7d4-d098-4c59-ba5a-9bdcadf7cbb7"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzMtMS0xLTEtNzgyMTU_36439cee-c9a2-4da1-8b41-b1d766284afb"
      unitRef="number">0.047</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzMtMy0xLTEtNzgyMTU_7d42b74a-d22a-469b-a32e-be6e0f60b3e3"
      unitRef="number">0.041</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzMtNS0xLTEtNzgyMTU_4532e655-bdbc-4cdf-89cf-e9136766d859"
      unitRef="number">0.045</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzgtMS0xLTEtNzgyMTU_d480a333-605c-419a-b226-125858e84388"
      unitRef="number">-0.014</us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzgtMy0xLTEtNzgyMTU_5ad2deaa-0504-4b91-89b9-753a81837241"
      unitRef="number">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzgtNS0xLTEtNzgyMTU_71364748-a0a3-486f-8cac-9516603cb006"
      unitRef="number">-0.009</us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense>
    <dgx:EffectiveIncomeTaxRateReconciliationAdjustmentToStateDeferredTaxLiabilities
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzktMS0xLTEtNzgyMTU_5a3a8f34-a6a5-4624-8a85-05ab50b4a641"
      unitRef="number">-0.015</dgx:EffectiveIncomeTaxRateReconciliationAdjustmentToStateDeferredTaxLiabilities>
    <dgx:EffectiveIncomeTaxRateReconciliationAdjustmentToStateDeferredTaxLiabilities
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzktMy0xLTEtNzgyMTU_6da41182-96fd-4b0f-bd95-61c3b04c48af"
      unitRef="number">0</dgx:EffectiveIncomeTaxRateReconciliationAdjustmentToStateDeferredTaxLiabilities>
    <dgx:EffectiveIncomeTaxRateReconciliationAdjustmentToStateDeferredTaxLiabilities
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzktNS0xLTEtNzgyMTU_56f1c03a-7ba3-4b18-b80e-cd46745e8c76"
      unitRef="number">0</dgx:EffectiveIncomeTaxRateReconciliationAdjustmentToStateDeferredTaxLiabilities>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzEwLTEtMS0xLTc4MjE1_25e4cf1c-c136-415b-b04b-fea6efcbd8f8"
      unitRef="number">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzEwLTMtMS0xLTc4MjE1_95df9435-7354-412f-83e2-4da160c08efe"
      unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzEwLTUtMS0xLTc4MjE1_17b4a902-abe7-4722-ae10-2ff08708b7d1"
      unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzExLTEtMS0xLTc4MjE1_5a615742-cbd2-4398-9ac2-4a89dcfadc27"
      unitRef="number">-0.011</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzExLTMtMS0xLTc4MjE1_5a2b5b24-0c6d-4f2d-9b94-0186746559cb"
      unitRef="number">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzExLTUtMS0xLTc4MjE1_50180417-adcb-4817-aa7c-60b37a27ee41"
      unitRef="number">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzE0LTEtMS0xLTc4MjE1_c6af7ae4-23fa-4340-a9b6-acc2e93fe882"
      unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary>
    <us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzE0LTMtMS0xLTc4MjE1_1df14cd6-ba70-44dd-8f92-91cac52ba077"
      unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary>
    <us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzE0LTUtMS0xLTc4MjE1_4e1ca6cc-71ae-4c25-b27e-8099c1cd7f5e"
      unitRef="number">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary>
    <dgx:EffectiveIncomeTaxRateReconciliationChangeForUncertainTaxPosition
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzE1LTEtMS0xLTc4MjE1_f9f8bfb5-bd34-4e19-87d7-d98d3f320f6a"
      unitRef="number">0.007</dgx:EffectiveIncomeTaxRateReconciliationChangeForUncertainTaxPosition>
    <dgx:EffectiveIncomeTaxRateReconciliationChangeForUncertainTaxPosition
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzE1LTMtMS0xLTc4MjE1_921464eb-c15f-44ec-96f8-a9dd785d4e4a"
      unitRef="number">0.004</dgx:EffectiveIncomeTaxRateReconciliationChangeForUncertainTaxPosition>
    <dgx:EffectiveIncomeTaxRateReconciliationChangeForUncertainTaxPosition
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzE1LTUtMS0xLTc4MjE1_4274a97f-8040-42e2-877f-95d8da674f28"
      unitRef="number">0.009</dgx:EffectiveIncomeTaxRateReconciliationChangeForUncertainTaxPosition>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzE2LTEtMS0xLTc4MjE1_a4076b62-6b51-43d4-a33d-9e4eb143470a"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzE2LTMtMS0xLTc4MjE1_e2851244-d7d9-4b0e-9211-b9acddb36b25"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzE2LTUtMS0xLTc4MjE1_c60a3bdf-08b0-414d-a58a-ea108446e0fe"
      unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzE3LTEtMS0xLTc4MjE1_0188fac3-e1c5-48a8-a54a-fb4329ce67ca"
      unitRef="number">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzE3LTMtMS0xLTc4MjE1_1c9a91a3-f275-4c9d-92b5-1573bbd538d3"
      unitRef="number">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzE3LTUtMS0xLTc4MjE1_2f59b8ab-0e81-41a1-9f86-50001bbb0ba5"
      unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzE4LTEtMS0xLTc4MjE1_a6e995a6-5356-4868-b559-ce95963e2164"
      unitRef="number">0.214</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzE4LTMtMS0xLTc4MjE1_d95593b8-1fb6-49b1-b2cb-e86dccd808ab"
      unitRef="number">0.230</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpkZTE0YWJlMTMzNDM0YWU4OGNhNjIxZjg0YmExMDY3NC90YWJsZXJhbmdlOmRlMTRhYmUxMzM0MzRhZTg4Y2E2MjFmODRiYTEwNjc0XzE4LTUtMS0xLTc4MjE1_4aef52da-da80-47e4-bebd-964ae8d57c79"
      unitRef="number">0.245</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzUzNTE_029614c0-b85e-4252-b140-1279054ac83f">The tax effects of temporary differences that give rise to significant portions of the deferred tax assets (liabilities) as of December&#160;31, 2022 and 2021 were as follows: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-current deferred tax assets (liabilities):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable reserves&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities not currently deductible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basis differences in investments, joint ventures and subsidiaries &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards, net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(147)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(568)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(633)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total non-current deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(295)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(290)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <dgx:DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsAccountsReceivables
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpiZTJkYzVkNThlN2U0Yzk4YTZiMTc5YjY0YjlkOTE0OS90YWJsZXJhbmdlOmJlMmRjNWQ1OGU3ZTRjOThhNmIxNzliNjRiOWQ5MTQ5XzItMS0xLTEtNzgyMTU_3ed0b1cc-8296-4d59-81d1-6d091fe0603d"
      unitRef="usd">15000000</dgx:DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsAccountsReceivables>
    <dgx:DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsAccountsReceivables
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpiZTJkYzVkNThlN2U0Yzk4YTZiMTc5YjY0YjlkOTE0OS90YWJsZXJhbmdlOmJlMmRjNWQ1OGU3ZTRjOThhNmIxNzliNjRiOWQ5MTQ5XzItMy0xLTEtNzgyMTU_d03fb56a-bbe4-4464-993d-035a9382f111"
      unitRef="usd">89000000</dgx:DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsAccountsReceivables>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpiZTJkYzVkNThlN2U0Yzk4YTZiMTc5YjY0YjlkOTE0OS90YWJsZXJhbmdlOmJlMmRjNWQ1OGU3ZTRjOThhNmIxNzliNjRiOWQ5MTQ5XzMtMS0xLTEtNzgyMTU_5a3c3728-29cb-4603-a758-63d76ba178bc"
      unitRef="usd">174000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpiZTJkYzVkNThlN2U0Yzk4YTZiMTc5YjY0YjlkOTE0OS90YWJsZXJhbmdlOmJlMmRjNWQ1OGU3ZTRjOThhNmIxNzliNjRiOWQ5MTQ5XzMtMy0xLTEtNzgyMTU_d579b7c2-bdbd-4225-a891-aa6fb2262837"
      unitRef="usd">180000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpiZTJkYzVkNThlN2U0Yzk4YTZiMTc5YjY0YjlkOTE0OS90YWJsZXJhbmdlOmJlMmRjNWQ1OGU3ZTRjOThhNmIxNzliNjRiOWQ5MTQ5XzQtMS0xLTEtNzgyMTU_ff093905-a4d2-4d8a-83be-57a44c561591"
      unitRef="usd">32000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpiZTJkYzVkNThlN2U0Yzk4YTZiMTc5YjY0YjlkOTE0OS90YWJsZXJhbmdlOmJlMmRjNWQ1OGU3ZTRjOThhNmIxNzliNjRiOWQ5MTQ5XzQtMy0xLTEtNzgyMTU_a3982e49-1f3f-41b6-b19b-1682dfc7e4d2"
      unitRef="usd">32000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <dgx:DeferredTaxLiabilityInvestmentsInvestmentsinSubsidiariesandEquitymethodinvestments
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpiZTJkYzVkNThlN2U0Yzk4YTZiMTc5YjY0YjlkOTE0OS90YWJsZXJhbmdlOmJlMmRjNWQ1OGU3ZTRjOThhNmIxNzliNjRiOWQ5MTQ5XzYtMS0xLTEtNzgyMTU_670b237b-76a5-442b-8fc0-4696a3e37c9f"
      unitRef="usd">11000000</dgx:DeferredTaxLiabilityInvestmentsInvestmentsinSubsidiariesandEquitymethodinvestments>
    <dgx:DeferredTaxLiabilityInvestmentsInvestmentsinSubsidiariesandEquitymethodinvestments
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpiZTJkYzVkNThlN2U0Yzk4YTZiMTc5YjY0YjlkOTE0OS90YWJsZXJhbmdlOmJlMmRjNWQ1OGU3ZTRjOThhNmIxNzliNjRiOWQ5MTQ5XzYtMy0xLTEtNzgyMTU_40686d3f-33e1-456e-9b80-24523e50937f"
      unitRef="usd">12000000</dgx:DeferredTaxLiabilityInvestmentsInvestmentsinSubsidiariesandEquitymethodinvestments>
    <dgx:NetOperatingLossCarryfowardsNetOfValuationAllowance
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpiZTJkYzVkNThlN2U0Yzk4YTZiMTc5YjY0YjlkOTE0OS90YWJsZXJhbmdlOmJlMmRjNWQ1OGU3ZTRjOThhNmIxNzliNjRiOWQ5MTQ5XzctMS0xLTEtNzgyMTU_10acfe83-d951-46dc-b0df-05bfc512fc86"
      unitRef="usd">49000000</dgx:NetOperatingLossCarryfowardsNetOfValuationAllowance>
    <dgx:NetOperatingLossCarryfowardsNetOfValuationAllowance
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpiZTJkYzVkNThlN2U0Yzk4YTZiMTc5YjY0YjlkOTE0OS90YWJsZXJhbmdlOmJlMmRjNWQ1OGU3ZTRjOThhNmIxNzliNjRiOWQ5MTQ5XzctMy0xLTEtNzgyMTU_8d1c95fc-c094-41d1-87b8-cc480bc92083"
      unitRef="usd">42000000</dgx:NetOperatingLossCarryfowardsNetOfValuationAllowance>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpiZTJkYzVkNThlN2U0Yzk4YTZiMTc5YjY0YjlkOTE0OS90YWJsZXJhbmdlOmJlMmRjNWQ1OGU3ZTRjOThhNmIxNzliNjRiOWQ5MTQ5XzgtMS0xLTEtNzgyMTU_425adb9f-749b-4972-8812-22d431ff313a"
      unitRef="usd">147000000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpiZTJkYzVkNThlN2U0Yzk4YTZiMTc5YjY0YjlkOTE0OS90YWJsZXJhbmdlOmJlMmRjNWQ1OGU3ZTRjOThhNmIxNzliNjRiOWQ5MTQ5XzgtMy0xLTEtNzgyMTU_5bce6e7b-bcf5-4951-981f-795609d2e6ce"
      unitRef="usd">150000000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <dgx:DeferredTaxAssetsOperatingLeaseLiabilitiesNoncurrent
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpiZTJkYzVkNThlN2U0Yzk4YTZiMTc5YjY0YjlkOTE0OS90YWJsZXJhbmdlOmJlMmRjNWQ1OGU3ZTRjOThhNmIxNzliNjRiOWQ5MTQ5XzktMS0xLTEtNzgyMTU_93a09dfe-3398-4a68-815a-1a5a03cde10b"
      unitRef="usd">161000000</dgx:DeferredTaxAssetsOperatingLeaseLiabilitiesNoncurrent>
    <dgx:DeferredTaxAssetsOperatingLeaseLiabilitiesNoncurrent
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpiZTJkYzVkNThlN2U0Yzk4YTZiMTc5YjY0YjlkOTE0OS90YWJsZXJhbmdlOmJlMmRjNWQ1OGU3ZTRjOThhNmIxNzliNjRiOWQ5MTQ5XzktMy0xLTEtNzgyMTU_12f3bf1d-0fb3-4ed1-b961-d6a62a1ca72c"
      unitRef="usd">162000000</dgx:DeferredTaxAssetsOperatingLeaseLiabilitiesNoncurrent>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpiZTJkYzVkNThlN2U0Yzk4YTZiMTc5YjY0YjlkOTE0OS90YWJsZXJhbmdlOmJlMmRjNWQ1OGU3ZTRjOThhNmIxNzliNjRiOWQ5MTQ5XzEwLTEtMS0xLTc4MjE1_f87701dd-3c6d-4aca-8efe-ba7d0547de07"
      unitRef="usd">568000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpiZTJkYzVkNThlN2U0Yzk4YTZiMTc5YjY0YjlkOTE0OS90YWJsZXJhbmdlOmJlMmRjNWQ1OGU3ZTRjOThhNmIxNzliNjRiOWQ5MTQ5XzEwLTMtMS0xLTc4MjE1_486e1bf6-f7b7-484f-b968-ebec6d0c7328"
      unitRef="usd">633000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpiZTJkYzVkNThlN2U0Yzk4YTZiMTc5YjY0YjlkOTE0OS90YWJsZXJhbmdlOmJlMmRjNWQ1OGU3ZTRjOThhNmIxNzliNjRiOWQ5MTQ5XzExLTEtMS0xLTc4MjE1_9c2dc1ec-824c-416b-bf66-c1449e4b02d4"
      unitRef="usd">295000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTpiZTJkYzVkNThlN2U0Yzk4YTZiMTc5YjY0YjlkOTE0OS90YWJsZXJhbmdlOmJlMmRjNWQ1OGU3ZTRjOThhNmIxNzliNjRiOWQ5MTQ5XzExLTMtMS0xLTc4MjE1_bd19c83c-6389-4ebe-9365-5a8304987ad1"
      unitRef="usd">290000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i71e02c56049a42c4a6be7ec8bf9a657b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzE0MDc_e9090af4-1cac-4373-af5c-e19966c77d1b"
      unitRef="usd">295000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="ia3f1c4f0d1ab416eb53e5a18510fd0dd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzE0MTQ_47318c1d-ca95-41e4-94b9-17f62933d14d"
      unitRef="usd">290000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i585fd94209a4454c885f38e54a3ac3d2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzE2MTg_6c6c1e56-3c4f-4b99-bfb3-6188aeefb3e9"
      unitRef="usd">12000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="if150c31900d447178580723791094470_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzE2MjU_76d7579b-28be-48c2-a20d-ecdc60f42669"
      unitRef="usd">732000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i3d1d68fb080a45eaa9d48446425aaa2a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzE3NjU_8d11cc39-e059-44ed-b3a7-cf55ba06fde2"
      unitRef="usd">73000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzE5Njc_da8371ad-4bee-4d8a-8424-9d16a3777e65"
      unitRef="usd">77000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzE5NzQ_8a8cb407-9553-418a-a923-a3c1702cf22c"
      unitRef="usd">71000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzIwNDI_01480b0e-ee24-4c2b-a45b-bfb00f8dc749"
      unitRef="usd">28000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzIwNDk_13159291-094c-4709-9bec-0c878fb7fdc9"
      unitRef="usd">29000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:AccruedIncomeTaxes
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzIyMTE_121d076e-ab68-4c42-807d-e58ddd57c067"
      unitRef="usd">81000000</us-gaap:AccruedIncomeTaxes>
    <us-gaap:AccruedIncomeTaxes
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzIyMTg_ece31126-8cb3-4500-8bc6-8c2986906301"
      unitRef="usd">106000000</us-gaap:AccruedIncomeTaxes>
    <us-gaap:PrepaidTaxes
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzIyNjM_49719096-e505-4dd0-bf32-bd7b9a780047"
      unitRef="usd">26000000</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidTaxes
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzIyNzA_c168d3cf-8c68-4fa4-acef-8b34b64b9bff"
      unitRef="usd">36000000</us-gaap:PrepaidTaxes>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzUzMjY_e99a8df1-481a-41ee-8605-cc38d94dddd4">The total amount of unrecognized tax benefits as of and for the years ended December&#160;31, 2022, 2021 and 2020 consisted of the following:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;For tax positions of current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;For tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in judgment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expirations of statutes of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzItMS0xLTEtNzgyMTU_77f38d0a-11ef-4ce0-89ee-7a03f6c76abf"
      unitRef="usd">110000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i872b3ea2e369403f8c0129ff07e0b538_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzItMy0xLTEtNzgyMTU_d7ff478e-2754-4b08-aec4-f759dcd28775"
      unitRef="usd">93000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i1240b052d8214432b601d5bcbb753f11_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzItNS0xLTEtNzgyMTU_9f2293c4-35ed-497d-87a6-f7aab08547a7"
      unitRef="usd">88000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzQtMS0xLTEtNzgyMTU_2cb5242e-4522-4170-a47b-df351dbcf1c0"
      unitRef="usd">1000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzQtMy0xLTEtNzgyMTU_9142f3ce-6e5e-4849-9f19-ed47645ebe3f"
      unitRef="usd">1000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzQtNS0xLTEtNzgyMTU_d3c2e317-cfe8-44dd-8b48-7a63ad11d25b"
      unitRef="usd">2000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzUtMS0xLTEtNzgyMTU_9cdc50e3-e899-49c4-8dff-e0a52a20b88d"
      unitRef="usd">18000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzUtMy0xLTEtNzgyMTU_c3622434-98cd-4094-95c3-11e3301e07bc"
      unitRef="usd">30000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzUtNS0xLTEtNzgyMTU_5a93b020-a111-4e0b-a137-f2de7118dba1"
      unitRef="usd">25000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <dgx:ReductionsForChangesInJudgment
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzctMS0xLTEtNzgyMTU_720574b9-25da-4758-86ef-73c1c7c595cd"
      unitRef="usd">7000000</dgx:ReductionsForChangesInJudgment>
    <dgx:ReductionsForChangesInJudgment
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzctMy0xLTEtNzgyMTU_2eb13588-de63-42bb-b301-5568300cc2a5"
      unitRef="usd">6000000</dgx:ReductionsForChangesInJudgment>
    <dgx:ReductionsForChangesInJudgment
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzctNS0xLTEtNzgyMTU_a112bace-cb2f-48f1-880a-e3fd04994890"
      unitRef="usd">9000000</dgx:ReductionsForChangesInJudgment>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzgtMS0xLTEtNzgyMTU_cb6f85e3-2dfc-48c8-b156-db410e8812c9"
      unitRef="usd">4000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzgtMy0xLTEtNzgyMTU_39abaa5f-4405-4c83-91ed-7f1133c8f8fc"
      unitRef="usd">8000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzgtNS0xLTEtNzgyMTU_920c745d-9e0b-472c-acfe-dc69512c2511"
      unitRef="usd">4000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzktMS0xLTEtNzgyMTU_e39b4e3c-4be1-4df1-a209-312ebe02d0b6"
      unitRef="usd">24000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzktMy0xLTEtNzgyMTU_4713ae34-f245-4c25-926b-17d25da3283b"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzktNS0xLTEtNzgyMTU_918c8c9e-e91c-473a-9a99-51cbe9978c54"
      unitRef="usd">9000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzEwLTEtMS0xLTc4MjE1_1ee24f80-5668-4d41-b73f-19a9e9d995c3"
      unitRef="usd">94000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzEwLTMtMS0xLTc4MjE1_47a503be-0db7-46d0-ae1d-71728f9bb0d8"
      unitRef="usd">110000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i872b3ea2e369403f8c0129ff07e0b538_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90YWJsZTozY2I4YTBjYTIwOTU0MzdmOWIzMTFlNDA4NDQyNjkwNS90YWJsZXJhbmdlOjNjYjhhMGNhMjA5NTQzN2Y5YjMxMWU0MDg0NDI2OTA1XzEwLTUtMS0xLTc4MjE1_eb126211-60e1-4992-a090-2b9fb623abcd"
      unitRef="usd">93000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzMwNDM_4f343fc5-02bc-40da-810b-4cd769f1ae00"
      unitRef="usd">78000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzMyNzc_f41f50f2-ad75-4392-b772-69e4a860b61c"
      unitRef="usd">13000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzM2MzI_df6fc15f-dfe6-443a-a634-1ae8a264c770"
      unitRef="usd">3000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzM2MzY_5af9c1ee-c0bb-4202-8d20-8c3e1ee3afee"
      unitRef="usd">-2000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzM2NDM_cd99df63-ace7-4e95-8543-771e539c0ed7"
      unitRef="usd">6000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzM3MDk_e2629b92-f675-4d77-9669-481c0194a76e"
      unitRef="usd">16000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8xOTkvZnJhZzpkYjFmNTkxOWQ2MGM0MDgzOTQyNTkxODkzNWQzOTkyMy90ZXh0cmVnaW9uOmRiMWY1OTE5ZDYwYzQwODM5NDI1OTE4OTM1ZDM5OTIzXzM3MTY_01231e6a-6880-46d0-82c0-dd73c936d765"
      unitRef="usd">20000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90ZXh0cmVnaW9uOjc5OTUxNmE0MzQ3NTQ5Njg4NThkYTgyYWI2Yzc1ZjZhXzE1Nw_f1e31031-fc02-434f-a5a7-4051acb00ac4">SUPPLEMENTAL CASH FLOW AND OTHER DATA &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Supplemental cash flow and other data for the years ended December&#160;31, 2022, 2021 and 2020 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(148)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(152)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(166)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(151)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(163)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest paid&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes paid&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable associated with capital expenditures&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable associated with purchases of treasury stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend payable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividends received from equity method investees&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Businesses acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Merger consideration payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for business acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Business acquisitions, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leased assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;During the year ended December 31, 2022, the Company amended a real estate lease and, based on the updated terms, the classification of the lease changed from a finance lease to an operating lease. As a result, the Company recorded a $31&#160;million operating lease right-of-use asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;During the years ended December 31, 2022, 2021 and 2020, costs associated with donations, contributions, and other financial support through Quest for Health Equity, the Company's initiative with the Quest Diagnostics Foundation to reduce health disparities in underserved communities, were $93&#160;million, $16&#160;million and $2&#160;million, respectively.  Such amounts are included in selling, general and administrative expenses in the Company's consolidated statement of operations.  Costs incurred during the year ended December 31, 2022 will be donated and contributed over several years.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90ZXh0cmVnaW9uOjc5OTUxNmE0MzQ3NTQ5Njg4NThkYTgyYWI2Yzc1ZjZhXzE2MA_0a01e125-1ea2-42bb-b6b7-60a9026b47f0">Supplemental cash flow and other data for the years ended December&#160;31, 2022, 2021 and 2020 was as follows:&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(148)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(152)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(166)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(151)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(163)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest paid&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes paid&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable associated with capital expenditures&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable associated with purchases of treasury stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend payable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividends received from equity method investees&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Businesses acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Merger consideration payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for business acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Business acquisitions, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leased assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:Depreciation
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzItMS0xLTEtNzgyMTU_4db0d78c-dad5-48f0-a33d-86c33d49b7a8"
      unitRef="usd">317000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzItMy0xLTEtNzgyMTU_27d599bc-d207-442b-b1d3-f5b2230f8b7e"
      unitRef="usd">305000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzItNS0xLTEtNzgyMTU_58fa8c06-c261-4611-88da-59abb8ad7997"
      unitRef="usd">258000000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzMtMS0xLTEtNzgyMTU_24ab52bd-efac-4b69-9dba-6cee21d00e21"
      unitRef="usd">120000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzMtMy0xLTEtNzgyMTU_f6f9a3e4-f52a-46fe-9ecd-73cd35d16419"
      unitRef="usd">103000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzMtNS0xLTEtNzgyMTU_ff83543c-7719-415b-bd30-19be2be12610"
      unitRef="usd">103000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzQtMS0xLTEtNzgyMTU_52d16c17-675d-47ac-804e-ea84e2b95071"
      unitRef="usd">437000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzQtMy0xLTEtNzgyMTU_712310ce-075a-4436-b3ae-e20d286ec057"
      unitRef="usd">408000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzQtNS0xLTEtNzgyMTU_ef9c34fa-0001-4399-b177-eb2bc13d4bd3"
      unitRef="usd">361000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:InterestExpense
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzYtMS0xLTEtNzgyMTU_d59f002c-c71a-40bc-846e-ae6871957fab"
      unitRef="usd">148000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzYtMy0xLTEtNzgyMTU_0cce88d9-5ed6-4987-a248-7c6acbcf118c"
      unitRef="usd">152000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzYtNS0xLTEtNzgyMTU_1313ddc5-ab13-4456-b034-0abaf89a592a"
      unitRef="usd">166000000</us-gaap:InterestExpense>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzctMS0xLTEtNzgyMTU_7a6181ae-1a83-44ca-8caf-361725a63a65"
      unitRef="usd">10000000</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzctMy0xLTEtNzgyMTU_863c921e-319d-4093-a39d-24545ddd1b7c"
      unitRef="usd">1000000</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzctNS0xLTEtNzgyMTU_49bfbc83-f8c5-46bc-9279-4c8643b968e5"
      unitRef="usd">3000000</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzgtMS0xLTEtNzgyMTU_3e1271ab-6a73-4fd3-b529-8371abbca911"
      unitRef="usd">-138000000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzgtMy0xLTEtNzgyMTU_22622d87-4cc5-4538-98cc-05783c038eb4"
      unitRef="usd">-151000000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzgtNS0xLTEtNzgyMTU_cd68a95b-7e18-417c-8687-68bb78b616d9"
      unitRef="usd">-163000000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestPaidNet
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzEwLTEtMS0xLTc4MjE1_dfea8138-e264-4f32-8d88-ee7540f1aac5"
      unitRef="usd">156000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzEwLTMtMS0xLTc4MjE1_682e29f4-55af-4324-ac1b-4ea92e6c2b04"
      unitRef="usd">159000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzEwLTUtMS0xLTc4MjE1_e4259023-a7d8-41a3-8f70-44132ec817ef"
      unitRef="usd">201000000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzExLTEtMS0xLTc4MjE1_a47ef209-b60f-4f6a-965f-d8802ddf0a8b"
      unitRef="usd">283000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzExLTMtMS0xLTc4MjE1_140a15b8-ca9c-4957-b942-2f7c9c365e49"
      unitRef="usd">709000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzExLTUtMS0xLTc4MjE1_4db9bb6e-7af7-41a0-837e-f1e6dfc1f082"
      unitRef="usd">360000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzEzLTEtMS0xLTc4MjE1_414081ee-70d3-43a6-b1b5-64f905f2e80a"
      unitRef="usd">38000000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzEzLTMtMS0xLTc4MjE1_b0ed045e-57b9-46b3-9063-e60e653f3219"
      unitRef="usd">26000000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzEzLTUtMS0xLTc4MjE1_3cf296ce-1c5d-433e-a5fc-e05ab6b8dd0a"
      unitRef="usd">46000000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <dgx:TreasuryStockPurchasedbutNotyetPaid
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzE0LTEtMS0xLTc4MjE1_d09123ac-d1f0-4fee-920e-c380c288f10c"
      unitRef="usd">0</dgx:TreasuryStockPurchasedbutNotyetPaid>
    <dgx:TreasuryStockPurchasedbutNotyetPaid
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzE0LTMtMS0xLTc4MjE1_99d701b1-e8d3-4510-9dea-5963d61b73c6"
      unitRef="usd">23000000</dgx:TreasuryStockPurchasedbutNotyetPaid>
    <dgx:TreasuryStockPurchasedbutNotyetPaid
      contextRef="i872b3ea2e369403f8c0129ff07e0b538_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzE0LTUtMS0xLTc4MjE1_8988b5ce-8026-4242-b372-de73f0e7f854"
      unitRef="usd">0</dgx:TreasuryStockPurchasedbutNotyetPaid>
    <us-gaap:DividendsPayableCurrentAndNoncurrent
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzE1LTEtMS0xLTc4MjE1_62d950d6-890c-41bf-86cf-11ea0da4288b"
      unitRef="usd">74000000</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <us-gaap:DividendsPayableCurrentAndNoncurrent
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzE1LTMtMS0xLTc4MjE1_fe9a89a1-3b23-4d51-9e2c-f160425ed94e"
      unitRef="usd">74000000</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <us-gaap:DividendsPayableCurrentAndNoncurrent
      contextRef="i872b3ea2e369403f8c0129ff07e0b538_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzE1LTUtMS0xLTc4MjE1_cd25d315-c1a6-45d3-b860-9ef0b1290803"
      unitRef="usd">76000000</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzE3LTEtMS0xLTc4MjE1_d4e5f538-2334-4187-8189-5ac7844c88fe"
      unitRef="usd">61000000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzE3LTMtMS0xLTc4MjE1_204678cf-3bff-4db3-be97-47f7ffcf2670"
      unitRef="usd">60000000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzE3LTUtMS0xLTc4MjE1_d5334a99-2a61-42f6-9b13-17a0366c77bc"
      unitRef="usd">54000000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:FairValueOfAssetsAcquired
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzIwLTEtMS0xLTc4MjE1_2ade47d8-5b82-4f2c-a841-8c7ffa3aa46c"
      unitRef="usd">182000000</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:FairValueOfAssetsAcquired
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzIwLTMtMS0xLTc4MjE1_03f2ad8b-51ef-43a8-b1dc-b7fdb79ef59a"
      unitRef="usd">364000000</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:FairValueOfAssetsAcquired
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzIwLTUtMS0xLTc4MjE1_98ab0d56-d524-45ab-8d57-93114567fc5e"
      unitRef="usd">368000000</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:LiabilitiesAssumed1
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzIxLTEtMS0xLTc4MjE1_f27103cf-157f-4a73-9485-de3d9d0ce66f"
      unitRef="usd">16000000</us-gaap:LiabilitiesAssumed1>
    <us-gaap:LiabilitiesAssumed1
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzIxLTMtMS0xLTc4MjE1_98f50ba9-59f7-461e-b707-0addf937962e"
      unitRef="usd">18000000</us-gaap:LiabilitiesAssumed1>
    <us-gaap:LiabilitiesAssumed1
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzIxLTUtMS0xLTc4MjE1_35912ede-7048-44d7-b53f-c5db37d21616"
      unitRef="usd">17000000</us-gaap:LiabilitiesAssumed1>
    <dgx:FairValueOfNetAssetsAcquired
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzIyLTEtMS0xLTc4MjE1_07f3848d-079c-409b-a86a-6d626b400e5d"
      unitRef="usd">166000000</dgx:FairValueOfNetAssetsAcquired>
    <dgx:FairValueOfNetAssetsAcquired
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzIyLTMtMS0xLTc4MjE1_b3f60fb1-1704-48fe-ad8c-05410704f4cc"
      unitRef="usd">346000000</dgx:FairValueOfNetAssetsAcquired>
    <dgx:FairValueOfNetAssetsAcquired
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzIyLTUtMS0xLTc4MjE1_fa9f9e9b-5669-40c3-bb3d-96efb03fe3b9"
      unitRef="usd">351000000</dgx:FairValueOfNetAssetsAcquired>
    <dgx:Mergerconsiderationpaidpayablenet
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzIzLTEtMS0xLTc4MjE1_3538dfd3-e0c9-4115-8ab9-65fc6e18dc9b"
      unitRef="usd">-18000000</dgx:Mergerconsiderationpaidpayablenet>
    <dgx:Mergerconsiderationpaidpayablenet
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzIzLTMtMS0xLTc4MjE1_747088ea-8ed1-4d87-b195-c31e4ce24dc5"
      unitRef="usd">-15000000</dgx:Mergerconsiderationpaidpayablenet>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzI0LTEtMS0xLTc4MjE1_a662faa3-166c-46fd-83a0-41f72c53872d"
      unitRef="usd">148000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzI0LTMtMS0xLTc4MjE1_da1175d6-32b2-48e0-b919-c72dc9bd442d"
      unitRef="usd">331000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzI0LTUtMS0xLTc4MjE1_311e22ac-01bb-4560-a10b-aafd24b4ca67"
      unitRef="usd">351000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzI1LTEtMS0xLTc4MjE1_18cd5d0d-7c23-4cdd-b676-3aa247477857"
      unitRef="usd">4000000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzI1LTMtMS0xLTc4MjE1_ce573ff5-072a-4060-9bd9-38e3d0bb96c3"
      unitRef="usd">0</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzI1LTUtMS0xLTc4MjE1_54675ebf-ebdc-4423-9e87-10260184ad6b"
      unitRef="usd">21000000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzI2LTEtMS0xLTc4MjE1_a6b04955-3191-44e6-be2e-c20eb55f6aad"
      unitRef="usd">144000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzI2LTMtMS0xLTc4MjE1_3a92e5aa-aa72-4e3d-b655-dafb2d4fe5b3"
      unitRef="usd">331000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTphYjYxOWEzZWNkZmI0ZDQzOTdjMmYyOTZjOGVjYzdjNy90YWJsZXJhbmdlOmFiNjE5YTNlY2RmYjRkNDM5N2MyZjI5NmM4ZWNjN2M3XzI2LTUtMS0xLTc4MjE1_f9345ebe-9c93-46fa-b7f2-569c42ce2ee2"
      unitRef="usd">330000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:OperatingLeasePayments
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTowYzYxOTRmMjExYmM0MzYzOTZkNzA2OWM2NmY0N2Q2Ny90YWJsZXJhbmdlOjBjNjE5NGYyMTFiYzQzNjM5NmQ3MDY5YzY2ZjQ3ZDY3XzMtNC0xLTEtNzgyMTU_1bfc5d04-be5c-453d-b4bf-f7911a2e6fb3"
      unitRef="usd">185000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTowYzYxOTRmMjExYmM0MzYzOTZkNzA2OWM2NmY0N2Q2Ny90YWJsZXJhbmdlOjBjNjE5NGYyMTFiYzQzNjM5NmQ3MDY5YzY2ZjQ3ZDY3XzMtNi0xLTEtNzgyMTU_936a744b-f7ff-4e48-9514-7711dbf49b6a"
      unitRef="usd">185000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTowYzYxOTRmMjExYmM0MzYzOTZkNzA2OWM2NmY0N2Q2Ny90YWJsZXJhbmdlOjBjNjE5NGYyMTFiYzQzNjM5NmQ3MDY5YzY2ZjQ3ZDY3XzMtOC0xLTEtNzgyMTU_40901750-ae17-4702-94c2-7606baf5d5ec"
      unitRef="usd">185000000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTowYzYxOTRmMjExYmM0MzYzOTZkNzA2OWM2NmY0N2Q2Ny90YWJsZXJhbmdlOjBjNjE5NGYyMTFiYzQzNjM5NmQ3MDY5YzY2ZjQ3ZDY3XzQtNC0xLTEtNzgyMTU_92a25201-dd83-4eac-9288-61531bd16732"
      unitRef="usd">1000000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTowYzYxOTRmMjExYmM0MzYzOTZkNzA2OWM2NmY0N2Q2Ny90YWJsZXJhbmdlOjBjNjE5NGYyMTFiYzQzNjM5NmQ3MDY5YzY2ZjQ3ZDY3XzQtNi0xLTEtNzgyMTU_b91ba8bf-d118-4c1e-9eee-fb91f5096bcb"
      unitRef="usd">2000000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTowYzYxOTRmMjExYmM0MzYzOTZkNzA2OWM2NmY0N2Q2Ny90YWJsZXJhbmdlOjBjNjE5NGYyMTFiYzQzNjM5NmQ3MDY5YzY2ZjQ3ZDY3XzQtOC0xLTEtNzgyMTU_6ad9c841-437c-4b80-ab2a-18b9eb8e0f51"
      unitRef="usd">3000000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTowYzYxOTRmMjExYmM0MzYzOTZkNzA2OWM2NmY0N2Q2Ny90YWJsZXJhbmdlOjBjNjE5NGYyMTFiYzQzNjM5NmQ3MDY5YzY2ZjQ3ZDY3XzUtNC0xLTEtNzgyMTU_0fd9b714-9b3b-4ed2-816b-28efa148c0ea"
      unitRef="usd">1000000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTowYzYxOTRmMjExYmM0MzYzOTZkNzA2OWM2NmY0N2Q2Ny90YWJsZXJhbmdlOjBjNjE5NGYyMTFiYzQzNjM5NmQ3MDY5YzY2ZjQ3ZDY3XzUtNi0xLTEtNzgyMTU_a92d2061-9d2f-42a2-b1dd-ccbe1a55c097"
      unitRef="usd">2000000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTowYzYxOTRmMjExYmM0MzYzOTZkNzA2OWM2NmY0N2Q2Ny90YWJsZXJhbmdlOjBjNjE5NGYyMTFiYzQzNjM5NmQ3MDY5YzY2ZjQ3ZDY3XzUtOC0xLTEtNzgyMTU_361f3765-51df-460d-a7bb-d8b249ae4ea8"
      unitRef="usd">3000000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTowYzYxOTRmMjExYmM0MzYzOTZkNzA2OWM2NmY0N2Q2Ny90YWJsZXJhbmdlOjBjNjE5NGYyMTFiYzQzNjM5NmQ3MDY5YzY2ZjQ3ZDY3XzYtNC0xLTEtNzgyMTU_70d130a7-3097-45a9-9d70-211ebcc81ebd"
      unitRef="usd">154000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTowYzYxOTRmMjExYmM0MzYzOTZkNzA2OWM2NmY0N2Q2Ny90YWJsZXJhbmdlOjBjNjE5NGYyMTFiYzQzNjM5NmQ3MDY5YzY2ZjQ3ZDY3XzYtNi0xLTEtNzgyMTU_78896e58-0618-4ae6-8f5c-5e33cdbd6a19"
      unitRef="usd">150000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90YWJsZTowYzYxOTRmMjExYmM0MzYzOTZkNzA2OWM2NmY0N2Q2Ny90YWJsZXJhbmdlOjBjNjE5NGYyMTFiYzQzNjM5NmQ3MDY5YzY2ZjQ3ZDY3XzYtOC0xLTEtNzgyMTU_e8562513-7054-4098-9d11-22caa1b41d90"
      unitRef="usd">219000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i0cc8a896b5014eec950deeb2b23e329e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90ZXh0cmVnaW9uOjc5OTUxNmE0MzQ3NTQ5Njg4NThkYTgyYWI2Yzc1ZjZhXzEwOTk1MTE2MjgyNzI_a06b29e3-b81c-41df-be2f-cea31c076984"
      unitRef="usd">31000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <dgx:DonationsContributionsAndOtherFinancialSupport
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90ZXh0cmVnaW9uOjc5OTUxNmE0MzQ3NTQ5Njg4NThkYTgyYWI2Yzc1ZjZhXzE2NDkyNjc0NDI3NjE_e6eacb94-e6a3-43f0-96bd-b620a3cca059"
      unitRef="usd">93000000</dgx:DonationsContributionsAndOtherFinancialSupport>
    <dgx:DonationsContributionsAndOtherFinancialSupport
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90ZXh0cmVnaW9uOjc5OTUxNmE0MzQ3NTQ5Njg4NThkYTgyYWI2Yzc1ZjZhXzE2NDkyNjc0NDI3NzQ_74f860d4-361b-4010-a04a-7f7d83e64904"
      unitRef="usd">16000000</dgx:DonationsContributionsAndOtherFinancialSupport>
    <dgx:DonationsContributionsAndOtherFinancialSupport
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDIvZnJhZzo3OTk1MTZhNDM0NzU0OTY4ODU4ZGE4MmFiNmM3NWY2YS90ZXh0cmVnaW9uOjc5OTUxNmE0MzQ3NTQ5Njg4NThkYTgyYWI2Yzc1ZjZhXzE2NDkyNjc0NDI3ODc_07e0bfe1-5aba-4d0a-bf9f-3136a7d12f49"
      unitRef="usd">2000000</dgx:DonationsContributionsAndOtherFinancialSupport>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDUvZnJhZzo2Y2Q3OWQzYjU0YzM0Nzc3Yjc4NTM0ZDQzZjFjNjljMi90ZXh0cmVnaW9uOjZjZDc5ZDNiNTRjMzQ3NzdiNzg1MzRkNDNmMWM2OWMyXzI0NQ_64e06dd8-80b0-453e-98c4-b1b321e3b5c6">PROPERTY, PLANT AND EQUIPMENT&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Property, plant and equipment as of December&#160;31, 2022 and 2021 consisted of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment and furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software developed or obtained for internal use&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,337)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,088)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDUvZnJhZzo2Y2Q3OWQzYjU0YzM0Nzc3Yjc4NTM0ZDQzZjFjNjljMi90ZXh0cmVnaW9uOjZjZDc5ZDNiNTRjMzQ3NzdiNzg1MzRkNDNmMWM2OWMyXzI0Mg_41b2f616-fecf-4006-a015-72ef48331a69">Property, plant and equipment as of December&#160;31, 2022 and 2021 consisted of the following: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment and furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software developed or obtained for internal use&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,337)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,088)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id8c3207c09bd46528b441166ed00ce51_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDUvZnJhZzo2Y2Q3OWQzYjU0YzM0Nzc3Yjc4NTM0ZDQzZjFjNjljMi90YWJsZTo4MDQ0ZTcwYTY0ODY0NzVmYWE1NzMxYjY4ZmRjNGM5Zi90YWJsZXJhbmdlOjgwNDRlNzBhNjQ4NjQ3NWZhYTU3MzFiNjhmZGM0YzlmXzItMS0xLTEtNzgyMTU_2950cf7d-e380-4149-bb73-6b41d6e919b2"
      unitRef="usd">43000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9a0fe7e6792a43c6948edd202dfa3610_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDUvZnJhZzo2Y2Q3OWQzYjU0YzM0Nzc3Yjc4NTM0ZDQzZjFjNjljMi90YWJsZTo4MDQ0ZTcwYTY0ODY0NzVmYWE1NzMxYjY4ZmRjNGM5Zi90YWJsZXJhbmdlOjgwNDRlNzBhNjQ4NjQ3NWZhYTU3MzFiNjhmZGM0YzlmXzItMy0xLTEtNzgyMTU_2ed99bb8-b888-444e-adee-f4e5a36f0c95"
      unitRef="usd">43000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i67120ecad309432da683bc8101a2349a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDUvZnJhZzo2Y2Q3OWQzYjU0YzM0Nzc3Yjc4NTM0ZDQzZjFjNjljMi90YWJsZTo4MDQ0ZTcwYTY0ODY0NzVmYWE1NzMxYjY4ZmRjNGM5Zi90YWJsZXJhbmdlOjgwNDRlNzBhNjQ4NjQ3NWZhYTU3MzFiNjhmZGM0YzlmXzMtMS0xLTEtNzgyMTU_deb45686-ff37-44d7-9934-581b6838a143"
      unitRef="usd">520000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i16c4c9b2568544898fd08b624fe50b66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDUvZnJhZzo2Y2Q3OWQzYjU0YzM0Nzc3Yjc4NTM0ZDQzZjFjNjljMi90YWJsZTo4MDQ0ZTcwYTY0ODY0NzVmYWE1NzMxYjY4ZmRjNGM5Zi90YWJsZXJhbmdlOjgwNDRlNzBhNjQ4NjQ3NWZhYTU3MzFiNjhmZGM0YzlmXzMtMy0xLTEtNzgyMTU_11a78fc5-9e2c-4f58-a4f4-3651b098afec"
      unitRef="usd">532000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i98ddc5b3f9b247d7aff2886d77af5203_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDUvZnJhZzo2Y2Q3OWQzYjU0YzM0Nzc3Yjc4NTM0ZDQzZjFjNjljMi90YWJsZTo4MDQ0ZTcwYTY0ODY0NzVmYWE1NzMxYjY4ZmRjNGM5Zi90YWJsZXJhbmdlOjgwNDRlNzBhNjQ4NjQ3NWZhYTU3MzFiNjhmZGM0YzlmXzQtMS0xLTEtNzgyMTU_773be802-819e-43f1-81cc-1dd1b7ec74c9"
      unitRef="usd">2140000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib3b24be39ce649f0b555d02d17abd4b5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDUvZnJhZzo2Y2Q3OWQzYjU0YzM0Nzc3Yjc4NTM0ZDQzZjFjNjljMi90YWJsZTo4MDQ0ZTcwYTY0ODY0NzVmYWE1NzMxYjY4ZmRjNGM5Zi90YWJsZXJhbmdlOjgwNDRlNzBhNjQ4NjQ3NWZhYTU3MzFiNjhmZGM0YzlmXzQtMy0xLTEtNzgyMTU_919be72a-f8c1-4d99-9969-aefdcfefef7e"
      unitRef="usd">2009000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i556301e56725415db5e0e99af8881ab2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDUvZnJhZzo2Y2Q3OWQzYjU0YzM0Nzc3Yjc4NTM0ZDQzZjFjNjljMi90YWJsZTo4MDQ0ZTcwYTY0ODY0NzVmYWE1NzMxYjY4ZmRjNGM5Zi90YWJsZXJhbmdlOjgwNDRlNzBhNjQ4NjQ3NWZhYTU3MzFiNjhmZGM0YzlmXzUtMS0xLTEtNzgyMTU_5ee12b0c-3221-45d6-92d5-e1e668f25c99"
      unitRef="usd">760000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2941ae72a36c43deb9d71ecae5604733_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDUvZnJhZzo2Y2Q3OWQzYjU0YzM0Nzc3Yjc4NTM0ZDQzZjFjNjljMi90YWJsZTo4MDQ0ZTcwYTY0ODY0NzVmYWE1NzMxYjY4ZmRjNGM5Zi90YWJsZXJhbmdlOjgwNDRlNzBhNjQ4NjQ3NWZhYTU3MzFiNjhmZGM0YzlmXzUtMy0xLTEtNzgyMTU_d36f1de4-020c-4d25-adf5-131b2a404459"
      unitRef="usd">705000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1cd92532b444421cbbef1840ffb1e964_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDUvZnJhZzo2Y2Q3OWQzYjU0YzM0Nzc3Yjc4NTM0ZDQzZjFjNjljMi90YWJsZTo4MDQ0ZTcwYTY0ODY0NzVmYWE1NzMxYjY4ZmRjNGM5Zi90YWJsZXJhbmdlOjgwNDRlNzBhNjQ4NjQ3NWZhYTU3MzFiNjhmZGM0YzlmXzYtMS0xLTEtNzgyMTU_599c35ad-a95d-446a-891f-45dd5ffbdfd0"
      unitRef="usd">1363000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i26ad136d73174bb492bfb4eb3f70e8ac_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDUvZnJhZzo2Y2Q3OWQzYjU0YzM0Nzc3Yjc4NTM0ZDQzZjFjNjljMi90YWJsZTo4MDQ0ZTcwYTY0ODY0NzVmYWE1NzMxYjY4ZmRjNGM5Zi90YWJsZXJhbmdlOjgwNDRlNzBhNjQ4NjQ3NWZhYTU3MzFiNjhmZGM0YzlmXzYtMy0xLTEtNzgyMTU_e001dc0a-b9d2-40c3-8b8d-f09797cec679"
      unitRef="usd">1292000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie438daf2fc794813a4a9dc699c36d20a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDUvZnJhZzo2Y2Q3OWQzYjU0YzM0Nzc3Yjc4NTM0ZDQzZjFjNjljMi90YWJsZTo4MDQ0ZTcwYTY0ODY0NzVmYWE1NzMxYjY4ZmRjNGM5Zi90YWJsZXJhbmdlOjgwNDRlNzBhNjQ4NjQ3NWZhYTU3MzFiNjhmZGM0YzlmXzctMS0xLTEtNzgyMTU_ee1ac02c-08ce-43cd-8793-95bc2a3808e4"
      unitRef="usd">277000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id5cf2176ed3c4e77a2914da13e51e940_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDUvZnJhZzo2Y2Q3OWQzYjU0YzM0Nzc3Yjc4NTM0ZDQzZjFjNjljMi90YWJsZTo4MDQ0ZTcwYTY0ODY0NzVmYWE1NzMxYjY4ZmRjNGM5Zi90YWJsZXJhbmdlOjgwNDRlNzBhNjQ4NjQ3NWZhYTU3MzFiNjhmZGM0YzlmXzctMy0xLTEtNzgyMTU_0e95abef-cc1e-406d-b3b4-fd31238e03d8"
      unitRef="usd">214000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDUvZnJhZzo2Y2Q3OWQzYjU0YzM0Nzc3Yjc4NTM0ZDQzZjFjNjljMi90YWJsZTo4MDQ0ZTcwYTY0ODY0NzVmYWE1NzMxYjY4ZmRjNGM5Zi90YWJsZXJhbmdlOjgwNDRlNzBhNjQ4NjQ3NWZhYTU3MzFiNjhmZGM0YzlmXzgtMS0xLTEtNzgyMTU_bfaab681-d635-42db-b8e4-ad185ba38792"
      unitRef="usd">5103000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDUvZnJhZzo2Y2Q3OWQzYjU0YzM0Nzc3Yjc4NTM0ZDQzZjFjNjljMi90YWJsZTo4MDQ0ZTcwYTY0ODY0NzVmYWE1NzMxYjY4ZmRjNGM5Zi90YWJsZXJhbmdlOjgwNDRlNzBhNjQ4NjQ3NWZhYTU3MzFiNjhmZGM0YzlmXzgtMy0xLTEtNzgyMTU_5c99a722-02f0-47be-89aa-1ac316c048c1"
      unitRef="usd">4795000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDUvZnJhZzo2Y2Q3OWQzYjU0YzM0Nzc3Yjc4NTM0ZDQzZjFjNjljMi90YWJsZTo4MDQ0ZTcwYTY0ODY0NzVmYWE1NzMxYjY4ZmRjNGM5Zi90YWJsZXJhbmdlOjgwNDRlNzBhNjQ4NjQ3NWZhYTU3MzFiNjhmZGM0YzlmXzktMS0xLTEtNzgyMTU_d53490e2-2809-44da-af56-66eaa21c3a0f"
      unitRef="usd">3337000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDUvZnJhZzo2Y2Q3OWQzYjU0YzM0Nzc3Yjc4NTM0ZDQzZjFjNjljMi90YWJsZTo4MDQ0ZTcwYTY0ODY0NzVmYWE1NzMxYjY4ZmRjNGM5Zi90YWJsZXJhbmdlOjgwNDRlNzBhNjQ4NjQ3NWZhYTU3MzFiNjhmZGM0YzlmXzktMy0xLTEtNzgyMTU_b41fb5e7-5f3c-48b6-8e56-8c9c65f9bcf5"
      unitRef="usd">3088000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDUvZnJhZzo2Y2Q3OWQzYjU0YzM0Nzc3Yjc4NTM0ZDQzZjFjNjljMi90YWJsZTo4MDQ0ZTcwYTY0ODY0NzVmYWE1NzMxYjY4ZmRjNGM5Zi90YWJsZXJhbmdlOjgwNDRlNzBhNjQ4NjQ3NWZhYTU3MzFiNjhmZGM0YzlmXzEwLTEtMS0xLTc4MjE1_a949a152-d473-476c-b2b7-a8e94b92b0ea"
      unitRef="usd">1766000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDUvZnJhZzo2Y2Q3OWQzYjU0YzM0Nzc3Yjc4NTM0ZDQzZjFjNjljMi90YWJsZTo4MDQ0ZTcwYTY0ODY0NzVmYWE1NzMxYjY4ZmRjNGM5Zi90YWJsZXJhbmdlOjgwNDRlNzBhNjQ4NjQ3NWZhYTU3MzFiNjhmZGM0YzlmXzEwLTMtMS0xLTc4MjE1_6c6e0bf9-b196-4957-a032-ce24db034f31"
      unitRef="usd">1707000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90ZXh0cmVnaW9uOmI3MDNlNWE3YTk1ZjRlMjM4ZjU4NjhkZTMzOWQ5ZjEyXzk4OA_833d756e-9e7e-4a08-9ad3-4fbe82abd726">GOODWILL AND INTANGIBLE ASSETS&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The changes in goodwill for the years ended December&#160;31, 2022 and 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill acquired during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments to goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Principally all of the Company&#x2019;s goodwill as of December&#160;31, 2022 and 2021 was associated with its DIS business.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;For the year ended December&#160;31, 2022, goodwill acquired was principally associated with the acquisition of Pack Health (see Note 6).  For the year ended December&#160;31, 2022, adjustments to goodwill related to an adjustment of the purchase price allocation for Labtech, partially offset by foreign currency translation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;For the year ended December&#160;31, 2021, goodwill acquired was principally associated with the acquisitions of the assets of the outreach laboratory business of Mercy Health and the assets of Labtech (see Note 6). For the year ended December&#160;31, 2021, adjustments to goodwill related to foreign currency translation. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Intangible assets as of December&#160;31, 2022 and 2021 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:39pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Amortization&lt;br/&gt;Period (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortizing intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer-related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(832)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(726)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-compete agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,022)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(903)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible assets not subject to amortization:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade names&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,022)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(903)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The estimated amortization expense related to amortizable intangible assets for each of the five succeeding fiscal years and thereafter as of December&#160;31, 2022 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:41.959%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90ZXh0cmVnaW9uOmI3MDNlNWE3YTk1ZjRlMjM4ZjU4NjhkZTMzOWQ5ZjEyXzk5NA_311d2f35-7bd9-49d3-9e04-ec62adeb03e9">The changes in goodwill for the years ended December&#160;31, 2022 and 2021 were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill acquired during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments to goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpiN2NkYzQyMzRjOGE0MTExOGE2NDI2NzM2M2FiNjk1NS90YWJsZXJhbmdlOmI3Y2RjNDIzNGM4YTQxMTE4YTY0MjY3MzYzYWI2OTU1XzItMS0xLTEtNzgyMTU_1a22ed72-ec90-4fd9-8299-78ca61da442e"
      unitRef="usd">7095000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i872b3ea2e369403f8c0129ff07e0b538_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpiN2NkYzQyMzRjOGE0MTExOGE2NDI2NzM2M2FiNjk1NS90YWJsZXJhbmdlOmI3Y2RjNDIzNGM4YTQxMTE4YTY0MjY3MzYzYWI2OTU1XzItMy0xLTEtNzgyMTU_dda13cb4-d7ca-4cdb-ba3e-9f3a0df8e317"
      unitRef="usd">6873000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpiN2NkYzQyMzRjOGE0MTExOGE2NDI2NzM2M2FiNjk1NS90YWJsZXJhbmdlOmI3Y2RjNDIzNGM4YTQxMTE4YTY0MjY3MzYzYWI2OTU1XzMtMS0xLTEtNzgyMTU_f1933609-e081-4276-aeda-04613547055c"
      unitRef="usd">121000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpiN2NkYzQyMzRjOGE0MTExOGE2NDI2NzM2M2FiNjk1NS90YWJsZXJhbmdlOmI3Y2RjNDIzNGM4YTQxMTE4YTY0MjY3MzYzYWI2OTU1XzMtMy0xLTEtNzgyMTU_d0e7e469-2059-4276-a99f-0c172dea2ae9"
      unitRef="usd">228000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpiN2NkYzQyMzRjOGE0MTExOGE2NDI2NzM2M2FiNjk1NS90YWJsZXJhbmdlOmI3Y2RjNDIzNGM4YTQxMTE4YTY0MjY3MzYzYWI2OTU1XzQtMS0xLTEtNzgyMTU_e88a5dce-4035-4fb4-aa3c-42333cbd4fec"
      unitRef="usd">4000000</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpiN2NkYzQyMzRjOGE0MTExOGE2NDI2NzM2M2FiNjk1NS90YWJsZXJhbmdlOmI3Y2RjNDIzNGM4YTQxMTE4YTY0MjY3MzYzYWI2OTU1XzQtMy0xLTEtNzgyMTU_615d19f6-ed39-4f0f-badf-17ba9f594613"
      unitRef="usd">-6000000</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpiN2NkYzQyMzRjOGE0MTExOGE2NDI2NzM2M2FiNjk1NS90YWJsZXJhbmdlOmI3Y2RjNDIzNGM4YTQxMTE4YTY0MjY3MzYzYWI2OTU1XzUtMS0xLTEtNzgyMTU_8232bd9e-4f9a-4da6-b454-1f80caf9de99"
      unitRef="usd">7220000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpiN2NkYzQyMzRjOGE0MTExOGE2NDI2NzM2M2FiNjk1NS90YWJsZXJhbmdlOmI3Y2RjNDIzNGM4YTQxMTE4YTY0MjY3MzYzYWI2OTU1XzUtMy0xLTEtNzgyMTU_b5b40d8f-b214-46da-9ce0-58e2537010a0"
      unitRef="usd">7095000000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90ZXh0cmVnaW9uOmI3MDNlNWE3YTk1ZjRlMjM4ZjU4NjhkZTMzOWQ5ZjEyXzEwMDQ_dfdd8ab1-bfab-482d-ad53-41e36a1449a6">Intangible assets as of December&#160;31, 2022 and 2021 consisted of the following:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:39pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Amortization&lt;br/&gt;Period (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortizing intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer-related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(832)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(726)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-compete agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,022)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(903)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible assets not subject to amortization:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade names&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,022)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(903)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ie457eb795c6c447ab93368b3aed4f823_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzMtMS0xLTEtNzgyMTU_dcc51485-caef-4b73-bc1c-f8d14b73a79d">P17Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="ib9f9ea06f7194197817bb2efd0215f53_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzMtMy0xLTEtNzgyMTU_6f589e54-30e6-40b0-a133-23df98366d6a"
      unitRef="usd">1623000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib9f9ea06f7194197817bb2efd0215f53_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzMtNS0xLTEtNzgyMTU_f50d8e29-938d-4e71-9a0e-c54a93e01704"
      unitRef="usd">832000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ib9f9ea06f7194197817bb2efd0215f53_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzMtNy0xLTEtNzgyMTU_c2e1f260-6c42-4f71-a254-e376c94b0fa7"
      unitRef="usd">791000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i7c904f919f5841dab0cc8a467bfece73_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzMtOS0xLTEtNzgyMTU_624571da-4772-4ce1-9b37-68b9d7b31d88"
      unitRef="usd">1581000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i7c904f919f5841dab0cc8a467bfece73_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzMtMTEtMS0xLTc4MjE1_3b180432-ef4d-4438-ab40-110be48977f8"
      unitRef="usd">726000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i7c904f919f5841dab0cc8a467bfece73_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzMtMTMtMS0xLTc4MjE1_dd5f0f54-704c-48da-9a56-c10a2c727f56"
      unitRef="usd">855000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ie5d6933739c34b618deb542c4712132c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzQtMS0xLTEtNzgyMTU_4683526e-3059-4920-bc74-62e0a640d25e">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i91553244d95f431f99ff6af124bfc732_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzQtMy0xLTEtNzgyMTU_2aaf4543-5b66-4447-a4ae-44f3790b9f15"
      unitRef="usd">3000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i91553244d95f431f99ff6af124bfc732_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzQtNS0xLTEtNzgyMTU_452bdd9b-4159-4934-9850-15597f9fa414"
      unitRef="usd">3000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i91553244d95f431f99ff6af124bfc732_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzQtNy0xLTEtNzgyMTU_5ed00104-9d17-462a-9cd3-8e0d77e0e58c"
      unitRef="usd">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="icb82f3cff9fb4367b9527abfc041ea6d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzQtOS0xLTEtNzgyMTU_cfe88fe7-e76f-4c5e-966a-2feade54679a"
      unitRef="usd">3000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="icb82f3cff9fb4367b9527abfc041ea6d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzQtMTEtMS0xLTc4MjE1_33099d3e-2b4e-41c6-b433-3ef9b36ec617"
      unitRef="usd">2000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="icb82f3cff9fb4367b9527abfc041ea6d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzQtMTMtMS0xLTc4MjE1_c3558295-c71f-4dff-9ade-cf601f3aeb88"
      unitRef="usd">1000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="icfe0b2f1d56541548f5ba20eedeeffdf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzUtMS0xLTEtNzgyMTU_288fc58a-a562-4a27-95b5-7391194a12cf">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="ieb995e58236640a2bebf429f0ef15cf6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzUtMy0xLTEtNzgyMTU_2d42831c-6d73-46d7-8ebd-44f34dc513d4"
      unitRef="usd">138000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ieb995e58236640a2bebf429f0ef15cf6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzUtNS0xLTEtNzgyMTU_26506fc9-cd1d-4a6b-9ab1-28ebe0570169"
      unitRef="usd">81000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ieb995e58236640a2bebf429f0ef15cf6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzUtNy0xLTEtNzgyMTU_75baee0c-e986-471c-9646-c51511f8a56e"
      unitRef="usd">57000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="icae1953df1b64580906887b236811607_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzUtOS0xLTEtNzgyMTU_666ef1a0-8e67-42d9-877d-522d23c58a7b"
      unitRef="usd">141000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="icae1953df1b64580906887b236811607_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzUtMTEtMS0xLTc4MjE1_0398d142-fc45-44a0-b195-fd7f7f05d9c4"
      unitRef="usd">74000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="icae1953df1b64580906887b236811607_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzUtMTMtMS0xLTc4MjE1_2dbc4b8b-0859-4022-b0f4-942bd171d6d5"
      unitRef="usd">67000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i309a355e12ca4ac8aebec7a6a293b7f1_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzYtMS0xLTEtNzgyMTU_2e1d9b4f-5f70-481e-b6d5-b7bdb9a17f39">P6Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i34d5911f3c604626be8defe10191d842_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzYtMy0xLTEtNzgyMTU_64ba0901-8879-4bc0-a207-bbcab68f88e0"
      unitRef="usd">114000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i34d5911f3c604626be8defe10191d842_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzYtNS0xLTEtNzgyMTU_d85ce958-8577-4884-b3a3-8d50c28f3094"
      unitRef="usd">106000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i34d5911f3c604626be8defe10191d842_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzYtNy0xLTEtNzgyMTU_c3310d11-7edd-4e2d-aba2-34a96a46e7e8"
      unitRef="usd">8000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i73c028f5ff27446fa49dcddeadcef5ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzYtOS0xLTEtNzgyMTU_7c3e1c94-1eed-423b-ab12-81936796f778"
      unitRef="usd">109000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i73c028f5ff27446fa49dcddeadcef5ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzYtMTEtMS0xLTc4MjE1_f665d4b4-86d6-4668-9d21-1b88598d6618"
      unitRef="usd">101000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i73c028f5ff27446fa49dcddeadcef5ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzYtMTMtMS0xLTc4MjE1_403b5d6d-d504-4bca-8957-022800e354a4"
      unitRef="usd">8000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="if532e9c222b34f83ac093a3483e120ea_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzctMS0xLTEtNzgyMTU_f75683f4-2bf8-4c77-a494-c58eb6c2e057">P17Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="ibdf0044ebfdf413bac60a2d162bc3800_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzctMy0xLTEtNzgyMTU_ee9faed1-51c2-4103-bf28-b06d62b77b23"
      unitRef="usd">1878000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ibdf0044ebfdf413bac60a2d162bc3800_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzctNS0xLTEtNzgyMTU_08848d22-9d5b-4742-8c48-152d2ac0104a"
      unitRef="usd">1022000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ibdf0044ebfdf413bac60a2d162bc3800_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzctNy0xLTEtNzgyMTU_fbdee4a7-4634-4a2e-a4ee-ef85934c7805"
      unitRef="usd">856000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="ia02c4586208e4e3ba284b0ed0d180568_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzctOS0xLTEtNzgyMTU_23517489-af6f-485d-904b-754dc3b5060b"
      unitRef="usd">1834000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia02c4586208e4e3ba284b0ed0d180568_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzctMTEtMS0xLTc4MjE1_ba46a7f6-3365-4dba-ac89-e3b7dec1fe3a"
      unitRef="usd">903000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ia02c4586208e4e3ba284b0ed0d180568_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzctMTMtMS0xLTc4MjE1_116ef9e9-6806-421e-9a8c-28ea61094ffd"
      unitRef="usd">931000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i12811850249e482399304d53d433f814_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzEwLTMtMS0xLTc4MjE1_30e61462-28f9-4b32-a42c-e527689b89d8"
      unitRef="usd">235000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i12811850249e482399304d53d433f814_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzEwLTctMS0xLTc4MjE1_51734fea-7eae-401f-826c-e158ad45d61d"
      unitRef="usd">235000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i16c67c4eb43e4026aebad131b1687d4c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzEwLTktMS0xLTc4MjE1_1cc60eec-f5a2-4705-9d74-335e811cb8c8"
      unitRef="usd">235000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i16c67c4eb43e4026aebad131b1687d4c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzEwLTEzLTEtMS03ODIxNQ_d8b22fbe-d6c8-4f31-8cd7-9ba183e62fc5"
      unitRef="usd">235000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i607e1bfaecc64044abfb3030ef16268d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzExLTMtMS0xLTc4MjE1_38f669b7-5609-41da-9572-240188075367"
      unitRef="usd">1000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i607e1bfaecc64044abfb3030ef16268d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzExLTctMS0xLTc4MjE1_3ed463e5-4829-4bf1-870b-2ec22e0c8c53"
      unitRef="usd">1000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i2e42f87022b0417485ee3c3cae380452_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzExLTktMS0xLTc4MjE1_73739aff-bde9-4634-b2a5-acd9a0583295"
      unitRef="usd">1000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i2e42f87022b0417485ee3c3cae380452_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzExLTEzLTEtMS03ODIxNQ_1968cb74-affd-48e3-9baf-693aeef2a462"
      unitRef="usd">1000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzEyLTMtMS0xLTc4MjE1_1a393fea-d885-4416-95a3-5537b7688461"
      unitRef="usd">2114000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzEyLTUtMS0xLTc4MjE1_c05714bc-735c-48ab-8e48-812f60ad78dc"
      unitRef="usd">1022000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzEyLTctMS0xLTc4MjE1_63f74890-176e-488a-976f-f03331409ae2"
      unitRef="usd">1092000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzEyLTktMS0xLTc4MjE1_443a396c-a432-470f-a52d-47419d4e2833"
      unitRef="usd">2070000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzEyLTExLTEtMS03ODIxNQ_744c02fb-0437-47b9-a870-6f1de7c78d3b"
      unitRef="usd">903000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZTpjNDhhOTM2M2U0N2M0OTY2ODE1YmYyNjI0NjBlNzkzMi90YWJsZXJhbmdlOmM0OGE5MzYzZTQ3YzQ5NjY4MTViZjI2MjQ2MGU3OTMyXzEyLTEzLTEtMS03ODIxNQ_793e8a80-a408-4826-8f53-0924b0f3b73c"
      unitRef="usd">1167000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90ZXh0cmVnaW9uOmI3MDNlNWE3YTk1ZjRlMjM4ZjU4NjhkZTMzOWQ5ZjEyXzEwMDU_8da6f22b-0b78-4b77-a52d-079312c87172">The estimated amortization expense related to amortizable intangible assets for each of the five succeeding fiscal years and thereafter as of December&#160;31, 2022 is as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:41.959%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZToxNzNlOTgyZjZmNjE0NzkxOTc1MjBlN2UwODhhMjM4NS90YWJsZXJhbmdlOjE3M2U5ODJmNmY2MTQ3OTE5NzUyMGU3ZTA4OGEyMzg1XzEtMS0xLTEtNzgyMTU_551853f6-d642-46f4-b60e-f7bcc94a2f78"
      unitRef="usd">106000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZToxNzNlOTgyZjZmNjE0NzkxOTc1MjBlN2UwODhhMjM4NS90YWJsZXJhbmdlOjE3M2U5ODJmNmY2MTQ3OTE5NzUyMGU3ZTA4OGEyMzg1XzItMS0xLTEtNzgyMTU_e5ba5d42-ea26-42db-8a47-b858e7501303"
      unitRef="usd">103000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZToxNzNlOTgyZjZmNjE0NzkxOTc1MjBlN2UwODhhMjM4NS90YWJsZXJhbmdlOjE3M2U5ODJmNmY2MTQ3OTE5NzUyMGU3ZTA4OGEyMzg1XzMtMS0xLTEtNzgyMTU_238daa79-808e-459d-98a3-344227e7f5e5"
      unitRef="usd">102000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZToxNzNlOTgyZjZmNjE0NzkxOTc1MjBlN2UwODhhMjM4NS90YWJsZXJhbmdlOjE3M2U5ODJmNmY2MTQ3OTE5NzUyMGU3ZTA4OGEyMzg1XzQtMS0xLTEtNzgyMTU_2ea35101-3076-4b8d-85c2-ffa4ac1a55bb"
      unitRef="usd">96000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZToxNzNlOTgyZjZmNjE0NzkxOTc1MjBlN2UwODhhMjM4NS90YWJsZXJhbmdlOjE3M2U5ODJmNmY2MTQ3OTE5NzUyMGU3ZTA4OGEyMzg1XzUtMS0xLTEtNzgyMTU_3b71d2de-e73d-4a2d-96d1-326c3a706bbc"
      unitRef="usd">85000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZToxNzNlOTgyZjZmNjE0NzkxOTc1MjBlN2UwODhhMjM4NS90YWJsZXJhbmdlOjE3M2U5ODJmNmY2MTQ3OTE5NzUyMGU3ZTA4OGEyMzg1XzYtMS0xLTEtNzgyMTU_489331ad-9d43-447c-b302-0a8c79893eff"
      unitRef="usd">364000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <dgx:FiniteLivedIntangibleAssetsEstimatedAmortizationExpenseTotal
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMDgvZnJhZzpiNzAzZTVhN2E5NWY0ZTIzOGY1ODY4ZGUzMzlkOWYxMi90YWJsZToxNzNlOTgyZjZmNjE0NzkxOTc1MjBlN2UwODhhMjM4NS90YWJsZXJhbmdlOjE3M2U5ODJmNmY2MTQ3OTE5NzUyMGU3ZTA4OGEyMzg1XzctMS0xLTEtNzgyMTU_d0f78f45-ca01-43cd-88c4-87890520d925"
      unitRef="usd">856000000</dgx:FiniteLivedIntangibleAssetsEstimatedAmortizationExpenseTotal>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90ZXh0cmVnaW9uOjI5N2YyZTE0ZDI1ZDQyOWRhYmU0NDc0MWQ3ZWRhMzRiXzE0NA_0f7640cd-ab3d-4473-b094-0814d43580df">ACCOUNTS PAYABLE AND ACCRUED EXPENSES &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Accounts payable and accrued expenses as of December&#160;31, 2022 and 2021 consisted of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.105%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued wages and benefits (including incentive compensation)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Overdrafts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Merger consideration payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90ZXh0cmVnaW9uOjI5N2YyZTE0ZDI1ZDQyOWRhYmU0NDc0MWQ3ZWRhMzRiXzE0Mw_8b6c45a2-638f-4de0-9391-aa4e49a2e5cf">Accounts payable and accrued expenses as of December&#160;31, 2022 and 2021 consisted of the following: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.105%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued wages and benefits (including incentive compensation)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Overdrafts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Merger consideration payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90YWJsZTpmYWYwZThkM2Y0MzE0NjZiYjhhZTlkYWUxYzNjMzg3ZC90YWJsZXJhbmdlOmZhZjBlOGQzZjQzMTQ2NmJiOGFlOWRhZTFjM2MzODdkXzItMS0xLTEtNzgyMTU_0e897c94-33df-4d28-9421-abefe086102f"
      unitRef="usd">428000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90YWJsZTpmYWYwZThkM2Y0MzE0NjZiYjhhZTlkYWUxYzNjMzg3ZC90YWJsZXJhbmdlOmZhZjBlOGQzZjQzMTQ2NmJiOGFlOWRhZTFjM2MzODdkXzItMy0xLTEtNzgyMTU_07c88aa5-d186-4250-b868-605a800e7fd5"
      unitRef="usd">518000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90YWJsZTpmYWYwZThkM2Y0MzE0NjZiYjhhZTlkYWUxYzNjMzg3ZC90YWJsZXJhbmdlOmZhZjBlOGQzZjQzMTQ2NmJiOGFlOWRhZTFjM2MzODdkXzMtMS0xLTEtNzgyMTU_433c9e7b-3acb-43cd-8f28-797a8aed55c1"
      unitRef="usd">392000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90YWJsZTpmYWYwZThkM2Y0MzE0NjZiYjhhZTlkYWUxYzNjMzg3ZC90YWJsZXJhbmdlOmZhZjBlOGQzZjQzMTQ2NmJiOGFlOWRhZTFjM2MzODdkXzMtMy0xLTEtNzgyMTU_034993b3-2056-4079-8f64-475e6b7669e7"
      unitRef="usd">460000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90YWJsZTpmYWYwZThkM2Y0MzE0NjZiYjhhZTlkYWUxYzNjMzg3ZC90YWJsZXJhbmdlOmZhZjBlOGQzZjQzMTQ2NmJiOGFlOWRhZTFjM2MzODdkXzQtMS0xLTEtNzgyMTU_7f4f8ee1-94fd-45b3-9533-a269a0e79b7a"
      unitRef="usd">324000000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90YWJsZTpmYWYwZThkM2Y0MzE0NjZiYjhhZTlkYWUxYzNjMzg3ZC90YWJsZXJhbmdlOmZhZjBlOGQzZjQzMTQ2NmJiOGFlOWRhZTFjM2MzODdkXzQtMy0xLTEtNzgyMTU_b95e6beb-9f3c-4b5f-b46e-37d20fed8b01"
      unitRef="usd">357000000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:BankOverdrafts
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90YWJsZTpmYWYwZThkM2Y0MzE0NjZiYjhhZTlkYWUxYzNjMzg3ZC90YWJsZXJhbmdlOmZhZjBlOGQzZjQzMTQ2NmJiOGFlOWRhZTFjM2MzODdkXzUtMS0xLTEtNzgyMTU_d953d8ba-f954-442e-bb82-743e5a79b8ba"
      unitRef="usd">92000000</us-gaap:BankOverdrafts>
    <us-gaap:BankOverdrafts
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90YWJsZTpmYWYwZThkM2Y0MzE0NjZiYjhhZTlkYWUxYzNjMzg3ZC90YWJsZXJhbmdlOmZhZjBlOGQzZjQzMTQ2NmJiOGFlOWRhZTFjM2MzODdkXzUtMy0xLTEtNzgyMTU_42f65901-54ac-4720-bf1b-2ecd9c69dcb5"
      unitRef="usd">116000000</us-gaap:BankOverdrafts>
    <us-gaap:DividendsPayableCurrent
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90YWJsZTpmYWYwZThkM2Y0MzE0NjZiYjhhZTlkYWUxYzNjMzg3ZC90YWJsZXJhbmdlOmZhZjBlOGQzZjQzMTQ2NmJiOGFlOWRhZTFjM2MzODdkXzYtMS0xLTEtNzgyMTU_832ec74c-58cb-4671-941c-177f9fd1e40e"
      unitRef="usd">74000000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90YWJsZTpmYWYwZThkM2Y0MzE0NjZiYjhhZTlkYWUxYzNjMzg3ZC90YWJsZXJhbmdlOmZhZjBlOGQzZjQzMTQ2NmJiOGFlOWRhZTFjM2MzODdkXzYtMy0xLTEtNzgyMTU_9d8e2519-3190-4e0b-8995-4a1255d3adb5"
      unitRef="usd">74000000</us-gaap:DividendsPayableCurrent>
    <us-gaap:AccruedInsuranceCurrent
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90YWJsZTpmYWYwZThkM2Y0MzE0NjZiYjhhZTlkYWUxYzNjMzg3ZC90YWJsZXJhbmdlOmZhZjBlOGQzZjQzMTQ2NmJiOGFlOWRhZTFjM2MzODdkXzctMS0xLTEtNzgyMTU_81ef21cf-8311-4634-b12f-53f5c81280ae"
      unitRef="usd">35000000</us-gaap:AccruedInsuranceCurrent>
    <us-gaap:AccruedInsuranceCurrent
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90YWJsZTpmYWYwZThkM2Y0MzE0NjZiYjhhZTlkYWUxYzNjMzg3ZC90YWJsZXJhbmdlOmZhZjBlOGQzZjQzMTQ2NmJiOGFlOWRhZTFjM2MzODdkXzctMy0xLTEtNzgyMTU_8df7a6f8-c934-4c36-8986-eda82ef5ad96"
      unitRef="usd">34000000</us-gaap:AccruedInsuranceCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90YWJsZTpmYWYwZThkM2Y0MzE0NjZiYjhhZTlkYWUxYzNjMzg3ZC90YWJsZXJhbmdlOmZhZjBlOGQzZjQzMTQ2NmJiOGFlOWRhZTFjM2MzODdkXzgtMS0xLTEtNzgyMTU_74f796c8-b3c5-4bbf-bdde-09666eb3a966"
      unitRef="usd">26000000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90YWJsZTpmYWYwZThkM2Y0MzE0NjZiYjhhZTlkYWUxYzNjMzg3ZC90YWJsZXJhbmdlOmZhZjBlOGQzZjQzMTQ2NmJiOGFlOWRhZTFjM2MzODdkXzgtMy0xLTEtNzgyMTU_bef4989a-0bc7-487f-9e60-9692cfff9089"
      unitRef="usd">26000000</us-gaap:InterestPayableCurrent>
    <dgx:MergerConsiderationPayableCurrent
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90YWJsZTpmYWYwZThkM2Y0MzE0NjZiYjhhZTlkYWUxYzNjMzg3ZC90YWJsZXJhbmdlOmZhZjBlOGQzZjQzMTQ2NmJiOGFlOWRhZTFjM2MzODdkXzktMS0xLTEtOTMwOTA_30a00388-d6f3-49d6-8f42-a5c972ed2b33"
      unitRef="usd">23000000</dgx:MergerConsiderationPayableCurrent>
    <dgx:MergerConsiderationPayableCurrent
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90YWJsZTpmYWYwZThkM2Y0MzE0NjZiYjhhZTlkYWUxYzNjMzg3ZC90YWJsZXJhbmdlOmZhZjBlOGQzZjQzMTQ2NmJiOGFlOWRhZTFjM2MzODdkXzktMy0xLTEtOTMwOTQ_b18b7303-d5ab-4dd9-a1a3-4be8f84043f6"
      unitRef="usd">5000000</dgx:MergerConsiderationPayableCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90YWJsZTpmYWYwZThkM2Y0MzE0NjZiYjhhZTlkYWUxYzNjMzg3ZC90YWJsZXJhbmdlOmZhZjBlOGQzZjQzMTQ2NmJiOGFlOWRhZTFjM2MzODdkXzktMS0xLTEtNzgyMTU_9b86eb8b-d9c4-4237-a741-634c7c96dae0"
      unitRef="usd">2000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90YWJsZTpmYWYwZThkM2Y0MzE0NjZiYjhhZTlkYWUxYzNjMzg3ZC90YWJsZXJhbmdlOmZhZjBlOGQzZjQzMTQ2NmJiOGFlOWRhZTFjM2MzODdkXzktMy0xLTEtNzgyMTU_d46ce0e9-686c-47ad-a560-8c247a297629"
      unitRef="usd">10000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90YWJsZTpmYWYwZThkM2Y0MzE0NjZiYjhhZTlkYWUxYzNjMzg3ZC90YWJsZXJhbmdlOmZhZjBlOGQzZjQzMTQ2NmJiOGFlOWRhZTFjM2MzODdkXzExLTEtMS0xLTc4MjE1_c8fd1146-bdfb-4be0-a36e-0d07403e0dce"
      unitRef="usd">1396000000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTEvZnJhZzoyOTdmMmUxNGQyNWQ0MjlkYWJlNDQ3NDFkN2VkYTM0Yi90YWJsZTpmYWYwZThkM2Y0MzE0NjZiYjhhZTlkYWUxYzNjMzg3ZC90YWJsZXJhbmdlOmZhZjBlOGQzZjQzMTQ2NmJiOGFlOWRhZTFjM2MzODdkXzExLTMtMS0xLTc4MjE1_6136702d-3df8-4c11-894b-4721e18e6ace"
      unitRef="usd">1600000000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90ZXh0cmVnaW9uOjRmYzg0NDliZjgzOTQ2ZWY4N2E1YTA1NjdmOGNlZWQwXzQ3NzM_764d296f-785b-4438-8a04-8c61e2e5dcf4">DEBT&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Long-term debt (including finance lease obligations) as of December&#160;31, 2022 and 2021 consisted of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.962%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.004%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.25% Senior Notes due April 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.50% Senior Notes due March 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.45% Senior Notes due June 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.20% Senior Notes due June 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.95% Senior Notes due June 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80% Senior Notes due June 2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.95% Senior Notes due July 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75% Senior Notes due January 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.70% Senior Notes due March 2045&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Finance Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;During the year ended December 31, 2022, the Company amended a real estate lease and, based on the updated terms, the classification of the lease changed from a finance lease to an operating lease.  As of December 31, 2021, the $25&#160;million carrying value of the finance lease was included in "other" in the table above.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Secured Receivables Credit Facility &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;During October 2022, the Company amended its secured receivables credit facility (the &#x201c;Secured Receivables Credit Facility&#x201d;), previously amended in October 2021, to extend the maturity dates for each underlying commitment by one year, while decreasing the aggregate borrowing capacity under the facility from $600&#160;million to $525&#160;million. Under the Secured Receivables Credit Facility, the Company can borrow against a $425&#160;million loan commitment, half of which matures in October 2023 and half of which matures in October 2024. Additionally, the Company can issue up to $100&#160;million of letters of credit (see Note 19) through October 2024.  Borrowings under the Secured Receivables Credit Facility are collateralized by certain domestic receivables.  Interest on borrowings under the facility is based on either commercial paper rates for highly-rated issuers or the Term Secured Overnight Financing Rate, plus a spread of 0.725% to 0.80%.  The Secured Receivables Credit Facility is subject to customary affirmative and negative covenants and certain financial covenants with respect to the receivables that comprise the borrowing base and secure the borrowings under the facility. As of both December&#160;31, 2022 and 2021, there were no outstanding borrowings under the Secured Receivables Credit Facility.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Senior Unsecured Revolving Credit Facility&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company is party to a $750&#160;million senior unsecured revolving credit facility (the &#x201c;Credit Facility&#x201d; or "Senior Unsecured Revolving Credit Facility") which matures in November 2026.  Under the Credit Facility, the Company can issue letters of credit totaling $150&#160;million (see Note 19).  Issued letters of credit reduce the available borrowing capacity under the Credit Facility.  Interest on the Credit Facility is based on certain published rates plus an applicable margin based on changes in the Company's public debt ratings.  At the option of the Company, it may elect to lock into LIBOR-based interest rates for periods up to six months.  Interest on any outstanding amounts not covered under LIBOR-based interest rate contracts is based on an alternate base rate, which is calculated by reference to the prime rate, the federal funds rate or an adjusted LIBOR rate.  As of December&#160;31, 2022, the Company's borrowing rate for LIBOR-based loans under the Credit Facility was LIBOR plus 1.00%.  The Credit Facility contains various covenants, including the maintenance of a financial leverage ratio, which could impact the Company's ability to, among other things, incur additional indebtedness.  As of both December&#160;31, 2022 and 2021, there were no outstanding borrowings under the Senior Unsecured Revolving Credit Facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;All of the senior notes are unsecured obligations of the Company and rank equally with the Company's other senior unsecured obligations.  None of the Company's senior notes have a sinking fund requirement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company may redeem its outstanding senior notes prior to scheduled maturity, as a whole or in part, at a redemption price equal to the present value of the remaining scheduled payments of principal and interest, except for certain notes for which the Company also has an option to redeem such instruments at par value on or after dates specified in the indentures governing the notes ("the par value redemption option"). &#160;For notes with the par value redemption option, if such notes are redeemed prior to the specified dates, the redemption price calculations exclude any interest that would have been due after such dates.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Maturities of Long-Term Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;As of December&#160;31, 2022, long-term debt matures as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:297.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:235.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total maturities of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value basis adjustments attributable to hedged debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LongTermDebtTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90ZXh0cmVnaW9uOjRmYzg0NDliZjgzOTQ2ZWY4N2E1YTA1NjdmOGNlZWQwXzQ3NjU_ce24927b-bd16-4a36-9c88-1ee73994c18e">Long-term debt (including finance lease obligations) as of December&#160;31, 2022 and 2021 consisted of the following: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.962%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.004%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.25% Senior Notes due April 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.50% Senior Notes due March 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.45% Senior Notes due June 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.20% Senior Notes due June 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.95% Senior Notes due June 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80% Senior Notes due June 2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.95% Senior Notes due July 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75% Senior Notes due January 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.70% Senior Notes due March 2045&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i73f9034273a34d5687d848b3ebe178b2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzItMC0xLTEtNzgyMTUvdGV4dHJlZ2lvbjozZDJmN2ZmYjM5MDc0ZDgzYWMwMTRlYzgzNGUxMWE3Zl80_d374bcc2-8c02-4fed-a91c-489d46d02251"
      unitRef="number">0.0425</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i73f9034273a34d5687d848b3ebe178b2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzItMS0xLTEtNzgyMTU_0808812f-6b21-4e40-913f-b600d93c550b"
      unitRef="usd">306000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="iafc4f10dcb30465792e3db376f9db383_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzItMy0xLTEtNzgyMTU_6c697744-2a42-492f-b933-08ae5fb05bcc"
      unitRef="usd">311000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i36d2de3414984080b11b7ed1f9472589_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzMtMC0xLTEtNzgyMTUvdGV4dHJlZ2lvbjo3ODk4MDk2NWUwMGQ0NmExYWUxZjZhNDEwNmZlN2E4NV80_1db90da3-7cf7-46b4-9831-5ddb3ec2c7f1"
      unitRef="number">0.0350</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i36d2de3414984080b11b7ed1f9472589_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzMtMS0xLTEtNzgyMTU_2620f226-be63-4244-9542-b14e63b74441"
      unitRef="usd">612000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i35159921eda04fbdb92fa45ac28509d5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzMtMy0xLTEtNzgyMTU_0466094d-b837-41df-a65c-31333e34d23e"
      unitRef="usd">616000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i744959a3bc17412a9e5af1fd1d359295_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzQtMC0xLTEtNzgyMTUvdGV4dHJlZ2lvbjoxOGNlM2RmOTg2M2Y0MzgxYWZlYzI3YjY4MmQ3MmIxMV80_beee190c-4d72-4af5-8caa-3e7840c85226"
      unitRef="number">0.0345</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i744959a3bc17412a9e5af1fd1d359295_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzQtMS0xLTEtNzgyMTU_66e8fa40-afa9-495e-8007-4fc9590dd413"
      unitRef="usd">508000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i2d5ca1c0cd5d40019d0db21e80203f2c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzQtMy0xLTEtNzgyMTU_c07f8111-6962-456a-8d59-168e3d02b182"
      unitRef="usd">510000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6e6f9e7f0256442db64c6fa43a0ced20_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzUtMC0xLTEtNzgyMTUvdGV4dHJlZ2lvbjo3NTZjZWJlMjE0N2U0MzAzYjYzYWFmY2YxYTM2NzcyM180_0ea3676b-a9d1-4557-a2ff-236c5987f282"
      unitRef="number">0.0420</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i6e6f9e7f0256442db64c6fa43a0ced20_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzUtMS0xLTEtNzgyMTU_b0625036-6d25-4d52-90e4-83e298254e3a"
      unitRef="usd">499000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ie3b4fa91393e4b0e8d2f092086ab0bdf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzUtMy0xLTEtNzgyMTU_0be94618-6659-4423-b7e5-561c5ca81530"
      unitRef="usd">499000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7e13bac0fccd4f16898a65173f8a921b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzYtMC0xLTEtNzgyMTUvdGV4dHJlZ2lvbjo2NzVlOGM1NDkxZGQ0ZTg2OTMxODcxYjJmMDIxOWFiM180_033afbf2-2700-46b2-a2af-e939c2a3d815"
      unitRef="number">0.0295</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i7e13bac0fccd4f16898a65173f8a921b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzYtMS0xLTEtNzgyMTU_1696248b-bc31-445a-bb51-6dc1caf1dd46"
      unitRef="usd">799000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ib1c4a18ddf92439da82f42ca78db7257_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzYtMy0xLTEtNzgyMTU_04145a77-43b0-4cb4-ac7e-28f4ca86afc3"
      unitRef="usd">798000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3bb1349879f5435fa9e912e4cf525b01_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzctMC0xLTEtNzgyMTUvdGV4dHJlZ2lvbjo1MmFhY2VlYjE1OTY0MTgzODI3NWM0NDAwODUwMjg2OV80_756c74a2-6112-4c53-91c7-9239a2180485"
      unitRef="number">0.0280</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i3bb1349879f5435fa9e912e4cf525b01_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzctMS0xLTEtNzgyMTU_e0ff252e-54d4-440b-8b88-d9c05aa0a573"
      unitRef="usd">549000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i42e6dc0040114c70b13940e177bb3b1f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzctMy0xLTEtNzgyMTU_45536b53-48ec-4159-b20f-21e62b2ffebf"
      unitRef="usd">549000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iae49dd1a44e743bdb49b617b9cfbaed7_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzgtMC0xLTEtNzgyMTUvdGV4dHJlZ2lvbjowNmUzNGU2YWUxYjA0NDUwYWUyZTg0YTZkMGYyNTkzOV80_ebf5650b-d9c9-4b9f-ac33-212fa112f218"
      unitRef="number">0.0695</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="iae49dd1a44e743bdb49b617b9cfbaed7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzgtMS0xLTEtNzgyMTU_b9560ce1-04c7-42f4-a3d6-53d4f75b445c"
      unitRef="usd">175000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i6b3b2a9d05bf465db9db7f32f4c7f461_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzgtMy0xLTEtNzgyMTU_a03db56a-db25-4423-99d0-cc563d8b47b8"
      unitRef="usd">175000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2eb4e252832c4cd59e4e6274194a0627_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzktMC0xLTEtNzgyMTUvdGV4dHJlZ2lvbjoyZWU5MTZhMGRlZDI0MWZlOGVlZWNmMGQ1ZDc5MTk2ZV80_64c49270-3f12-4174-b0c8-9c8146bcaada"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i2eb4e252832c4cd59e4e6274194a0627_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzktMS0xLTEtNzgyMTU_34c4dac3-2971-4e70-8537-d2bc5a98dbad"
      unitRef="usd">245000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i8c8de336b3a044bfa41bbd2480192421_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzktMy0xLTEtNzgyMTU_4eb717d4-60d2-40aa-b044-5c2a06a8dfd3"
      unitRef="usd">245000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ifaf7d8fd470f4603bcbefc2804dc479c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzEwLTAtMS0xLTc4MjE1L3RleHRyZWdpb246MDFlYTQ5N2VjZjc5NGY3ZWE3NDAwM2QwNWE5ODdkZDlfNA_9370b61b-8ba8-4aba-8a53-01b2bf088b7d"
      unitRef="number">0.0470</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ifaf7d8fd470f4603bcbefc2804dc479c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzEwLTEtMS0xLTc4MjE1_cfbfdcf5-83e4-4855-9122-871bd1a642b9"
      unitRef="usd">300000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i04b933ae20f7405ea1d07a3a04b5d06a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzEwLTMtMS0xLTc4MjE1_0cab734d-e16e-47e3-b773-7f00b7d799e1"
      unitRef="usd">300000000</us-gaap:LongTermDebt>
    <us-gaap:OtherLongTermDebt
      contextRef="i3e9c816b535f468b832f1fb4f7578811_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzExLTEtMS0xLTc4MjE1_9fb9bf0b-3fa5-41ed-bb26-800938729ca2"
      unitRef="usd">9000000</us-gaap:OtherLongTermDebt>
    <us-gaap:OtherLongTermDebt
      contextRef="i3f456f42e2b64e4cb74fbc8ba3ba7668_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzExLTMtMS0xLTc4MjE1_7d8088b3-290b-4c7a-98cd-ccb76c9dc00f"
      unitRef="usd">34000000</us-gaap:OtherLongTermDebt>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzEyLTEtMS0xLTc4MjE1_1f2fdae1-ab0d-4a85-951b-107f886a2b0f"
      unitRef="usd">22000000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzEyLTMtMS0xLTc4MjE1_cee5c588-ac8a-497d-bac5-ba658bf350e3"
      unitRef="usd">25000000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:LongTermDebt
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzEzLTEtMS0xLTc4MjE1_78c787e8-ad10-4d82-afc5-6076e6ba7b39"
      unitRef="usd">3980000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzEzLTMtMS0xLTc4MjE1_48718d91-d60e-45c9-869d-56b3b3422a8d"
      unitRef="usd">4012000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzE0LTEtMS0xLTc4MjE1_5f49b4b6-9c69-45cf-a195-cdf1fe6f0d80"
      unitRef="usd">2000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzE0LTMtMS0xLTc4MjE1_26ae1b11-865a-4941-b647-a5e2134d1153"
      unitRef="usd">2000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzE1LTEtMS0xLTc4MjE1_1180e3be-dfc9-4216-8694-4ae8fbf1aa3a"
      unitRef="usd">3978000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTpjZjczY2E2NDJhMjI0MmQxODkyY2E2NzViMzNhNzkyNi90YWJsZXJhbmdlOmNmNzNjYTY0MmEyMjQyZDE4OTJjYTY3NWIzM2E3OTI2XzE1LTMtMS0xLTc4MjE1_7338bcc1-f2ac-4fce-a877-c66490741b42"
      unitRef="usd">4010000000</us-gaap:LongTermDebtNoncurrent>
    <dgx:FinanceLeaseLiabilityRealEstate
      contextRef="i3f456f42e2b64e4cb74fbc8ba3ba7668_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90ZXh0cmVnaW9uOjRmYzg0NDliZjgzOTQ2ZWY4N2E1YTA1NjdmOGNlZWQwXzEwOTk1MTE2NDkwNDg_edb91d3e-40ee-4b54-a1f5-7da6ae065f38"
      unitRef="usd">25000000</dgx:FinanceLeaseLiabilityRealEstate>
    <dgx:DebtInstrumentExtensionPeriod
      contextRef="ie3e292d5aced49a991453002828a13bf_D20221001-20221031"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90ZXh0cmVnaW9uOjRmYzg0NDliZjgzOTQ2ZWY4N2E1YTA1NjdmOGNlZWQwXzI3NDg3NzkwOTA3Mzc_0431ef1c-fb9b-4731-81f0-fe356406ee89">P1Y</dgx:DebtInstrumentExtensionPeriod>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i2473c6e1cff643f4807fa97482f2514c_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90ZXh0cmVnaW9uOjRmYzg0NDliZjgzOTQ2ZWY4N2E1YTA1NjdmOGNlZWQwXzEwOTk1MTE2NDU1NDA_6d18f7a5-3bb4-482f-b7c5-e37b4da45d12"
      unitRef="usd">600000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i7ee94c3ad75540f2895fbc6c74806807_I20221031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90ZXh0cmVnaW9uOjRmYzg0NDliZjgzOTQ2ZWY4N2E1YTA1NjdmOGNlZWQwXzEwOTk1MTE2NDU1NTQ_ea2d0f70-5fff-4344-bc6c-cec922f49a9e"
      unitRef="usd">525000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="id3f22fe062a74e759fbf551f8c1b5809_I20221031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90ZXh0cmVnaW9uOjRmYzg0NDliZjgzOTQ2ZWY4N2E1YTA1NjdmOGNlZWQwXzEwOTk1MTE2NDU4OTU_04d91a2c-d5d9-464b-b328-cfbfc422b315"
      unitRef="usd">425000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ia223c678f59d4b39a7af63150694192c_I20221031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90ZXh0cmVnaW9uOjRmYzg0NDliZjgzOTQ2ZWY4N2E1YTA1NjdmOGNlZWQwXzEwOTk1MTE2NDU5MDk_d1516519-a82c-4ea2-a8bb-08e1028aea23"
      unitRef="usd">100000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i03277559f860449c9b5e26471a9ae119_D20221001-20221031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90ZXh0cmVnaW9uOjRmYzg0NDliZjgzOTQ2ZWY4N2E1YTA1NjdmOGNlZWQwXzEwOTk1MTE2NDc0NjQ_81569a53-aaf4-4809-b0c5-4ccb863837ff"
      unitRef="number">0.00725</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i71d143709b514b99a2a4f28f2a601632_D20221001-20221031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90ZXh0cmVnaW9uOjRmYzg0NDliZjgzOTQ2ZWY4N2E1YTA1NjdmOGNlZWQwXzEwOTk1MTE2NDc0NzI_b3be111b-60a5-4070-89ad-bc4c9d125b1c"
      unitRef="number">0.0080</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ibf24b8c7cb904d33aca6b6f9275180b7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90ZXh0cmVnaW9uOjRmYzg0NDliZjgzOTQ2ZWY4N2E1YTA1NjdmOGNlZWQwXzEwOTk1MTE2NDc1ODM_417d71aa-e689-4ed7-87f9-60a2b5fe778c"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i8e3820f04333496f8fc57291a5c51523_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90ZXh0cmVnaW9uOjRmYzg0NDliZjgzOTQ2ZWY4N2E1YTA1NjdmOGNlZWQwXzEwOTk1MTE2NDc1ODM_678a2830-fdcc-4f07-a88a-4ec4dabe19d0"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ied9b303df1ae4f6daa7db9f2e1d5d9f0_I20211130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90ZXh0cmVnaW9uOjRmYzg0NDliZjgzOTQ2ZWY4N2E1YTA1NjdmOGNlZWQwXzU0OTc1NTgyNzYzNQ_fbbeabeb-6837-4dd7-a987-9d97ac2376f8"
      unitRef="usd">750000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="iba1e578b1a6c4c79882ebb5fa88eae23_I20211130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90ZXh0cmVnaW9uOjRmYzg0NDliZjgzOTQ2ZWY4N2E1YTA1NjdmOGNlZWQwXzE3NDg_74a6f037-2f8e-4083-95f7-c2c77045724c"
      unitRef="usd">150000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="iec0fa8127aa846ccb173e5c0dac001e5_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90ZXh0cmVnaW9uOjRmYzg0NDliZjgzOTQ2ZWY4N2E1YTA1NjdmOGNlZWQwXzI0NDc_8c5d2d00-c19d-48ec-b417-afdbfd124f59"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if73e958db14b401a8087839f76ce387c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90ZXh0cmVnaW9uOjRmYzg0NDliZjgzOTQ2ZWY4N2E1YTA1NjdmOGNlZWQwXzI2ODc_2d139e73-0aa7-416d-a3a7-9cc7ef8fdae8"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if79143d725024a98b36d4ee85edf5cee_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90ZXh0cmVnaW9uOjRmYzg0NDliZjgzOTQ2ZWY4N2E1YTA1NjdmOGNlZWQwXzI2ODc_bd8d2f18-a56c-4b86-b58f-03b3e08efc5d"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90ZXh0cmVnaW9uOjRmYzg0NDliZjgzOTQ2ZWY4N2E1YTA1NjdmOGNlZWQwXzQ3Njc_4db341d0-2e4c-4df2-9306-2dee39ee8887">As of December&#160;31, 2022, long-term debt matures as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:297.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:235.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total maturities of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value basis adjustments attributable to hedged debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTo1ODMwOTdhMDdmMWU0OGJhYjU4MjdhMzZjN2JiZTI0OS90YWJsZXJhbmdlOjU4MzA5N2EwN2YxZTQ4YmFiNTgyN2EzNmM3YmJlMjQ5XzEtMS0xLTEtNzgyMTU_9dafe759-a16e-4879-aebb-e56a9db6042c"
      unitRef="usd">2000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTo1ODMwOTdhMDdmMWU0OGJhYjU4MjdhMzZjN2JiZTI0OS90YWJsZXJhbmdlOjU4MzA5N2EwN2YxZTQ4YmFiNTgyN2EzNmM3YmJlMjQ5XzItMS0xLTEtNzgyMTU_9c049728-3174-4930-b256-64dbd42a5997"
      unitRef="usd">302000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTo1ODMwOTdhMDdmMWU0OGJhYjU4MjdhMzZjN2JiZTI0OS90YWJsZXJhbmdlOjU4MzA5N2EwN2YxZTQ4YmFiNTgyN2EzNmM3YmJlMjQ5XzMtMS0xLTEtNzgyMTU_1a5af5a5-d6a2-4c8a-b328-d1b1aa1932c3"
      unitRef="usd">601000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTo1ODMwOTdhMDdmMWU0OGJhYjU4MjdhMzZjN2JiZTI0OS90YWJsZXJhbmdlOjU4MzA5N2EwN2YxZTQ4YmFiNTgyN2EzNmM3YmJlMjQ5XzQtMS0xLTEtNzgyMTU_49fd90eb-3596-4870-81fb-e06dd51bedbe"
      unitRef="usd">502000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTo1ODMwOTdhMDdmMWU0OGJhYjU4MjdhMzZjN2JiZTI0OS90YWJsZXJhbmdlOjU4MzA5N2EwN2YxZTQ4YmFiNTgyN2EzNmM3YmJlMjQ5XzUtMS0xLTEtNzgyMTU_07f19f53-87ad-4746-827a-be07f59cefc8"
      unitRef="usd">2000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTo1ODMwOTdhMDdmMWU0OGJhYjU4MjdhMzZjN2JiZTI0OS90YWJsZXJhbmdlOjU4MzA5N2EwN2YxZTQ4YmFiNTgyN2EzNmM3YmJlMjQ5XzYtMS0xLTEtNzgyMTU_ecf59738-5488-4801-9ac7-726b197cb1f4"
      unitRef="usd">2576000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <dgx:LongTermDebtMaturitiesGross
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTo1ODMwOTdhMDdmMWU0OGJhYjU4MjdhMzZjN2JiZTI0OS90YWJsZXJhbmdlOjU4MzA5N2EwN2YxZTQ4YmFiNTgyN2EzNmM3YmJlMjQ5XzctMS0xLTEtNzgyMTU_26313902-214a-4b55-b17c-ce473803054f"
      unitRef="usd">3985000000</dgx:LongTermDebtMaturitiesGross>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTo1ODMwOTdhMDdmMWU0OGJhYjU4MjdhMzZjN2JiZTI0OS90YWJsZXJhbmdlOjU4MzA5N2EwN2YxZTQ4YmFiNTgyN2EzNmM3YmJlMjQ5XzgtMS0xLTEtNzgyMTU_5fe7bcc3-2aad-4ad4-aed9-cc8895ff42be"
      unitRef="usd">9000000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTo1ODMwOTdhMDdmMWU0OGJhYjU4MjdhMzZjN2JiZTI0OS90YWJsZXJhbmdlOjU4MzA5N2EwN2YxZTQ4YmFiNTgyN2EzNmM3YmJlMjQ5XzktMS0xLTEtNzgyMTU_1f2fdae1-ab0d-4a85-951b-107f886a2b0f"
      unitRef="usd">22000000</us-gaap:UnamortizedDebtIssuanceExpense>
    <dgx:DebtInstrumentFairValueBasisAdjustmentAttributableToHedgedDebt
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTo1ODMwOTdhMDdmMWU0OGJhYjU4MjdhMzZjN2JiZTI0OS90YWJsZXJhbmdlOjU4MzA5N2EwN2YxZTQ4YmFiNTgyN2EzNmM3YmJlMjQ5XzEwLTEtMS0xLTc4MjE1_2a2b9300-bb95-45ea-af2f-1611602ace14"
      unitRef="usd">-26000000</dgx:DebtInstrumentFairValueBasisAdjustmentAttributableToHedgedDebt>
    <us-gaap:LongTermDebt
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTo1ODMwOTdhMDdmMWU0OGJhYjU4MjdhMzZjN2JiZTI0OS90YWJsZXJhbmdlOjU4MzA5N2EwN2YxZTQ4YmFiNTgyN2EzNmM3YmJlMjQ5XzExLTEtMS0xLTc4MjE1_ac5b3885-b809-4a27-ad17-6c3effc9cbc8"
      unitRef="usd">3980000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTo1ODMwOTdhMDdmMWU0OGJhYjU4MjdhMzZjN2JiZTI0OS90YWJsZXJhbmdlOjU4MzA5N2EwN2YxZTQ4YmFiNTgyN2EzNmM3YmJlMjQ5XzEyLTEtMS0xLTc4MjE1_1abec6c6-95cd-44d3-8e59-305b23b7fbbd"
      unitRef="usd">2000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTQvZnJhZzo0ZmM4NDQ5YmY4Mzk0NmVmODdhNWEwNTY3ZjhjZWVkMC90YWJsZTo1ODMwOTdhMDdmMWU0OGJhYjU4MjdhMzZjN2JiZTI0OS90YWJsZXJhbmdlOjU4MzA5N2EwN2YxZTQ4YmFiNTgyN2EzNmM3YmJlMjQ5XzEzLTEtMS0xLTc4MjE1_01d63b68-99e5-4652-861a-68391933cee7"
      unitRef="usd">3978000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTE_801a284d-90fc-484c-abe6-6c5abc50b76c">LEASES&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company determines if an arrangement is or contains a lease at contract inception. The Company leases office space, patient service centers, clinical laboratories, warehouses, logistic hubs and equipment primarily through operating leases, with a limited number of finance leases. A &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NDc_562c010d-bbaa-4f52-a8ac-de2660c01cb7"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NDc_da6e8994-01f0-4a9a-83e2-083574a1b91f"&gt;right-of-use asset&lt;/span&gt;&lt;/span&gt;, representing the underlying asset during the lease term, and a lease &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTQ_323fe1c8-01d7-47a9-afae-473da3defda0"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTQ_4bd99473-36cb-4abf-841b-9d98e467569f"&gt;liability&lt;/span&gt;&lt;/span&gt;, representing the payment obligation arising from the lease, are recognized on the balance sheet at lease commencement based on the present value of the payment obligation. For operating leases, expense is recognized on a straight-line basis over the lease term. For finance leases, interest expense on the lease &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTU_6f606824-b677-4250-a7ed-24f9f3915ac5"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTU_8ee62599-1731-4db2-b098-6e0dac4293f9"&gt;liability&lt;/span&gt;&lt;/span&gt; is recognized using the effective interest method and amortization of the right-of-use asset is recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term.  Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet; the Company recognizes lease expense for these leases on a straight-line basis over the lease term.  For the years ended December&#160;31, 2022, 2021, and 2020, lease expense associated with short-term leases was not material.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company primarily uses its collateralized incremental borrowing rate in determining the present value of lease payments as the Company's leases generally do not provide an implicit rate.  Such incremental borrowing rates, which take into account interest rates offered to companies that have similar credit ratings to the Company, are determined using a portfolio approach which groups the Company&#x2019;s leases based on tenor.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company has lease agreements with (i) right-of-use asset payments and (ii) non-lease components (i.e., payments related to maintenance fees, utilities, etc.) which have been combined and accounted for as a single lease component. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company's leases have remaining terms of less than 1 year to 15 years, some of which include options to extend the leases for up to 15 years. The Company's lease terms may include renewal options that are reasonably certain to be exercised and termination options that are reasonably certain not to be exercised. Certain leases also include options to purchase the leased property.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Certain of the Company's lease agreements include rental payments adjusted periodically for inflation or a market rate which are included in the lease liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;During the year ended December 31, 2022, the Company amended a real estate lease and, based on the updated terms, the classification of the lease changed from a finance lease to an operating lease. As a result, the Company recorded a $31&#160;million operating lease right-of-use asset.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company's assets and liabilities for its lease agreements as of December&#160;31, 2022 and 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzEyLTItMS0xLTc4MjE1_1c2a9643-64b7-48eb-992f-a3efa9e86f06"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzEyLTItMS0xLTc4MjE1_5bf1d7b4-f29c-4002-9627-e2075dfadeb9"&gt;Long-term debt&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Finance lease assets as of December&#160;31, 2022 and 2021 were recorded net of accumulated amortization of $3&#160;million and $8&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Components of lease cost for the years ended December&#160;31, 2022, 2021 and 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:468.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:247.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of leased assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Includes short-term leases and variable lease costs (primarily usage-based maintenance fees and utilities related to real estate leases and certain equipment-related and vehicle-related costs) of $160&#160;million, $140&#160;million and $120&#160;million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The maturity of the Company's lease liabilities as of December&#160;31, 2022 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:365.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:163.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:29pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Maturity of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Lease term and discount rate as of December&#160;31, 2022 and 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:363.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Lease term and discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company's discount rates for its operating leases were primarily determined using the Company's incremental borrowing rate.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;See Note 10 for cash flow information on cash paid for amounts included in the measurement of lease liabilities and leased assets obtained in exchange for new operating lease liabilities for the years ended December&#160;31, 2022, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTI_5a71e417-db60-4584-9cb9-bb92bf1cf18e">LEASES&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company determines if an arrangement is or contains a lease at contract inception. The Company leases office space, patient service centers, clinical laboratories, warehouses, logistic hubs and equipment primarily through operating leases, with a limited number of finance leases. A &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NDc_562c010d-bbaa-4f52-a8ac-de2660c01cb7"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NDc_da6e8994-01f0-4a9a-83e2-083574a1b91f"&gt;right-of-use asset&lt;/span&gt;&lt;/span&gt;, representing the underlying asset during the lease term, and a lease &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTQ_323fe1c8-01d7-47a9-afae-473da3defda0"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTQ_4bd99473-36cb-4abf-841b-9d98e467569f"&gt;liability&lt;/span&gt;&lt;/span&gt;, representing the payment obligation arising from the lease, are recognized on the balance sheet at lease commencement based on the present value of the payment obligation. For operating leases, expense is recognized on a straight-line basis over the lease term. For finance leases, interest expense on the lease &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTU_6f606824-b677-4250-a7ed-24f9f3915ac5"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTU_8ee62599-1731-4db2-b098-6e0dac4293f9"&gt;liability&lt;/span&gt;&lt;/span&gt; is recognized using the effective interest method and amortization of the right-of-use asset is recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term.  Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet; the Company recognizes lease expense for these leases on a straight-line basis over the lease term.  For the years ended December&#160;31, 2022, 2021, and 2020, lease expense associated with short-term leases was not material.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company primarily uses its collateralized incremental borrowing rate in determining the present value of lease payments as the Company's leases generally do not provide an implicit rate.  Such incremental borrowing rates, which take into account interest rates offered to companies that have similar credit ratings to the Company, are determined using a portfolio approach which groups the Company&#x2019;s leases based on tenor.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company has lease agreements with (i) right-of-use asset payments and (ii) non-lease components (i.e., payments related to maintenance fees, utilities, etc.) which have been combined and accounted for as a single lease component. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company's leases have remaining terms of less than 1 year to 15 years, some of which include options to extend the leases for up to 15 years. The Company's lease terms may include renewal options that are reasonably certain to be exercised and termination options that are reasonably certain not to be exercised. Certain leases also include options to purchase the leased property.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Certain of the Company's lease agreements include rental payments adjusted periodically for inflation or a market rate which are included in the lease liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;During the year ended December 31, 2022, the Company amended a real estate lease and, based on the updated terms, the classification of the lease changed from a finance lease to an operating lease. As a result, the Company recorded a $31&#160;million operating lease right-of-use asset.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company's assets and liabilities for its lease agreements as of December&#160;31, 2022 and 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzEyLTItMS0xLTc4MjE1_1c2a9643-64b7-48eb-992f-a3efa9e86f06"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzEyLTItMS0xLTc4MjE1_5bf1d7b4-f29c-4002-9627-e2075dfadeb9"&gt;Long-term debt&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Finance lease assets as of December&#160;31, 2022 and 2021 were recorded net of accumulated amortization of $3&#160;million and $8&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Components of lease cost for the years ended December&#160;31, 2022, 2021 and 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:468.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:247.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of leased assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Includes short-term leases and variable lease costs (primarily usage-based maintenance fees and utilities related to real estate leases and certain equipment-related and vehicle-related costs) of $160&#160;million, $140&#160;million and $120&#160;million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The maturity of the Company's lease liabilities as of December&#160;31, 2022 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:365.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:163.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:29pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Maturity of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Lease term and discount rate as of December&#160;31, 2022 and 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:363.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Lease term and discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company's discount rates for its operating leases were primarily determined using the Company's incremental borrowing rate.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;See Note 10 for cash flow information on cash paid for amounts included in the measurement of lease liabilities and leased assets obtained in exchange for new operating lease liabilities for the years ended December&#160;31, 2022, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTM_981c240f-e9c1-4e35-a1aa-563f844cad72">The Company determines if an arrangement is or contains a lease at contract inception. The Company leases office space, patient service centers, clinical laboratories, warehouses, logistic hubs and equipment primarily through operating leases, with a limited number of finance leases. A &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NDc_562c010d-bbaa-4f52-a8ac-de2660c01cb7"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NDc_da6e8994-01f0-4a9a-83e2-083574a1b91f"&gt;right-of-use asset&lt;/span&gt;&lt;/span&gt;, representing the underlying asset during the lease term, and a lease &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTQ_323fe1c8-01d7-47a9-afae-473da3defda0"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTQ_4bd99473-36cb-4abf-841b-9d98e467569f"&gt;liability&lt;/span&gt;&lt;/span&gt;, representing the payment obligation arising from the lease, are recognized on the balance sheet at lease commencement based on the present value of the payment obligation. For operating leases, expense is recognized on a straight-line basis over the lease term. For finance leases, interest expense on the lease &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTU_6f606824-b677-4250-a7ed-24f9f3915ac5"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTU_8ee62599-1731-4db2-b098-6e0dac4293f9"&gt;liability&lt;/span&gt;&lt;/span&gt; is recognized using the effective interest method and amortization of the right-of-use asset is recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term.  Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet; the Company recognizes lease expense for these leases on a straight-line basis over the lease term.</us-gaap:LesseeLeasesPolicyTextBlock>
    <dgx:LeaseRemainingLeaseTerm
      contextRef="i4a8532c66ad64ac990f07caabad868b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzE5NjU_56fb4871-d1b2-4ad5-9ec9-8b0189e7b7af">P1Y</dgx:LeaseRemainingLeaseTerm>
    <dgx:LeaseRemainingLeaseTerm
      contextRef="i4c9530356f3242cdb77f114a2aa32961_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzE5NzE_d2e9d8a4-575f-443b-9423-64b74d1c3bfa">P15Y</dgx:LeaseRemainingLeaseTerm>
    <dgx:LeaseRenewalTerm
      contextRef="i4c9530356f3242cdb77f114a2aa32961_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzIwMzY_bf46933e-b47a-4ff7-874e-2e8793edbdc4">P15Y</dgx:LeaseRenewalTerm>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i0cc8a896b5014eec950deeb2b23e329e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzEwOTk1MTE2MzIwNzQ_a06b29e3-b81c-41df-be2f-cea31c076984"
      unitRef="usd">31000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <dgx:ScheduleOfLeaseByAssetTypeTableTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTY_5dddc570-d12f-4355-9252-611accadf959">The Company's assets and liabilities for its lease agreements as of December&#160;31, 2022 and 2021 were as follows:&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzEyLTItMS0xLTc4MjE1_1c2a9643-64b7-48eb-992f-a3efa9e86f06"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzEyLTItMS0xLTc4MjE1_5bf1d7b4-f29c-4002-9627-e2075dfadeb9"&gt;Long-term debt&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Finance lease assets as of December&#160;31, 2022 and 2021 were recorded net of accumulated amortization of $3&#160;million and $8&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;</dgx:ScheduleOfLeaseByAssetTypeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzItNC0xLTEtNzgyMTU_2a23607f-5be3-47e1-9cae-bca10fc2296d"
      unitRef="usd">585000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzItNi0xLTEtNzgyMTU_cb359a95-9e69-4431-88d0-090d0e0bf8a8"
      unitRef="usd">597000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzMtNC0xLTEtNzgyMTU_3b3f9292-8664-4665-ae71-231bb0e95c24"
      unitRef="usd">9000000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzMtNi0xLTEtNzgyMTU_151bc0c3-ab96-4409-bcfe-1c3f243e8e66"
      unitRef="usd">29000000</us-gaap:FinanceLeaseRightOfUseAsset>
    <dgx:LeaseRightofUseAsset
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzQtNC0xLTEtNzgyMTU_6125d843-583d-46b1-9daf-36ec97f9f21c"
      unitRef="usd">594000000</dgx:LeaseRightofUseAsset>
    <dgx:LeaseRightofUseAsset
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzQtNi0xLTEtNzgyMTU_b8ad5106-0503-4946-b7d3-b76c1b5d6904"
      unitRef="usd">626000000</dgx:LeaseRightofUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzgtNC0xLTEtNzgyMTU_a3d89de6-36cf-40a1-9c93-6d6c0d00227a"
      unitRef="usd">153000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzgtNi0xLTEtNzgyMTU_8cf94bb0-81a8-4478-b077-1ecd3298d268"
      unitRef="usd">151000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzktNC0xLTEtNzgyMTU_2eaf8cd9-c1a9-44f1-a32f-fe8c5b1d4683"
      unitRef="usd">2000000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzktNi0xLTEtNzgyMTU_cb26f99c-8260-4541-a6da-17a5e36b6163"
      unitRef="usd">2000000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzExLTQtMS0xLTc4MjE1_6432681c-e191-457e-bce8-501f8ce635a0"
      unitRef="usd">489000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzExLTYtMS0xLTc4MjE1_00012651-b80e-4dd7-b499-134880ebf476"
      unitRef="usd">494000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzEyLTQtMS0xLTc4MjE1_0ce654df-abc1-4fce-a715-c8dd373d888f"
      unitRef="usd">7000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzEyLTYtMS0xLTc4MjE1_741b085d-837d-4b6e-a2cf-6c4d63c6ef85"
      unitRef="usd">32000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <dgx:LeaseLiability
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzEzLTQtMS0xLTc4MjE1_7436fbd4-3d90-42fd-8bad-156232a68f3c"
      unitRef="usd">651000000</dgx:LeaseLiability>
    <dgx:LeaseLiability
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpmNWE0ZTQxMTIyNGY0ZWZlYjRkZDc1NGNhYjJlNGE2OC90YWJsZXJhbmdlOmY1YTRlNDExMjI0ZjRlZmViNGRkNzU0Y2FiMmU0YTY4XzEzLTYtMS0xLTc4MjE1_ba7a189c-d4ac-4931-baa2-4f7310b7ccb7"
      unitRef="usd">679000000</dgx:LeaseLiability>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzI2MzU_a5163b0a-0dab-431a-9351-bfe3f90aabab"
      unitRef="usd">3000000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzI2NDI_8fc9629f-cce1-4659-b40e-7436ae9c7ac6"
      unitRef="usd">8000000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NDg_75cb7b5d-05b1-4f9b-aad7-0959b4974fa1">Components of lease cost for the years ended December&#160;31, 2022, 2021 and 2020 were as follows:&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:468.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:247.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of leased assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Includes short-term leases and variable lease costs (primarily usage-based maintenance fees and utilities related to real estate leases and certain equipment-related and vehicle-related costs) of $160&#160;million, $140&#160;million and $120&#160;million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <dgx:OperatingLeaseFixedAndVariableCost
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTo0N2EyZDE5Y2NmNjU0NmIzYjQ3ZGY5NDdkNTIyZWVjNC90YWJsZXJhbmdlOjQ3YTJkMTljY2Y2NTQ2YjNiNDdkZjk0N2Q1MjJlZWM0XzItMi0xLTEtNzgyMTU_dc75282d-1c78-4ce9-b279-4cc9262a7348"
      unitRef="usd">345000000</dgx:OperatingLeaseFixedAndVariableCost>
    <dgx:OperatingLeaseFixedAndVariableCost
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTo0N2EyZDE5Y2NmNjU0NmIzYjQ3ZGY5NDdkNTIyZWVjNC90YWJsZXJhbmdlOjQ3YTJkMTljY2Y2NTQ2YjNiNDdkZjk0N2Q1MjJlZWM0XzItNC0xLTEtNzgyMTU_27195652-aaf4-4403-a4b6-5ab545b3dc5c"
      unitRef="usd">321000000</dgx:OperatingLeaseFixedAndVariableCost>
    <dgx:OperatingLeaseFixedAndVariableCost
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTo0N2EyZDE5Y2NmNjU0NmIzYjQ3ZGY5NDdkNTIyZWVjNC90YWJsZXJhbmdlOjQ3YTJkMTljY2Y2NTQ2YjNiNDdkZjk0N2Q1MjJlZWM0XzItNS0xLTEtNzgyMTU_00183c4b-97a3-43ac-9e8c-3a2983e628a0"
      unitRef="usd">300000000</dgx:OperatingLeaseFixedAndVariableCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTo0N2EyZDE5Y2NmNjU0NmIzYjQ3ZGY5NDdkNTIyZWVjNC90YWJsZXJhbmdlOjQ3YTJkMTljY2Y2NTQ2YjNiNDdkZjk0N2Q1MjJlZWM0XzUtMi0xLTEtNzgyMTU_dc37ce96-f678-48ef-8d4b-cd9af7563c0b"
      unitRef="usd">2000000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTo0N2EyZDE5Y2NmNjU0NmIzYjQ3ZGY5NDdkNTIyZWVjNC90YWJsZXJhbmdlOjQ3YTJkMTljY2Y2NTQ2YjNiNDdkZjk0N2Q1MjJlZWM0XzUtNC0xLTEtNzgyMTU_70e36d47-62b2-4d97-a589-f35d742c3aaf"
      unitRef="usd">2000000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTo0N2EyZDE5Y2NmNjU0NmIzYjQ3ZGY5NDdkNTIyZWVjNC90YWJsZXJhbmdlOjQ3YTJkMTljY2Y2NTQ2YjNiNDdkZjk0N2Q1MjJlZWM0XzUtNS0xLTEtNzgyMTU_2555273b-9094-4527-a39b-e7d1b1629cf3"
      unitRef="usd">6000000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTo0N2EyZDE5Y2NmNjU0NmIzYjQ3ZGY5NDdkNTIyZWVjNC90YWJsZXJhbmdlOjQ3YTJkMTljY2Y2NTQ2YjNiNDdkZjk0N2Q1MjJlZWM0XzYtMi0xLTEtNzgyMTU_0cf20c10-1891-4706-89eb-17933d430e0e"
      unitRef="usd">1000000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTo0N2EyZDE5Y2NmNjU0NmIzYjQ3ZGY5NDdkNTIyZWVjNC90YWJsZXJhbmdlOjQ3YTJkMTljY2Y2NTQ2YjNiNDdkZjk0N2Q1MjJlZWM0XzYtNC0xLTEtNzgyMTU_76018635-78d3-4946-a595-b0ecd39191c8"
      unitRef="usd">2000000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTo0N2EyZDE5Y2NmNjU0NmIzYjQ3ZGY5NDdkNTIyZWVjNC90YWJsZXJhbmdlOjQ3YTJkMTljY2Y2NTQ2YjNiNDdkZjk0N2Q1MjJlZWM0XzYtNS0xLTEtNzgyMTU_e536e15d-f6fa-4a83-8662-9fc43925d7d7"
      unitRef="usd">3000000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:LeaseCost
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTo0N2EyZDE5Y2NmNjU0NmIzYjQ3ZGY5NDdkNTIyZWVjNC90YWJsZXJhbmdlOjQ3YTJkMTljY2Y2NTQ2YjNiNDdkZjk0N2Q1MjJlZWM0XzctMi0xLTEtNzgyMTU_3f6524cf-3505-4c1b-855d-a8aa6cf3dbb6"
      unitRef="usd">348000000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTo0N2EyZDE5Y2NmNjU0NmIzYjQ3ZGY5NDdkNTIyZWVjNC90YWJsZXJhbmdlOjQ3YTJkMTljY2Y2NTQ2YjNiNDdkZjk0N2Q1MjJlZWM0XzctNC0xLTEtNzgyMTU_9ac4c9a1-f506-4188-b3a2-85ae3d3d3e29"
      unitRef="usd">325000000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTo0N2EyZDE5Y2NmNjU0NmIzYjQ3ZGY5NDdkNTIyZWVjNC90YWJsZXJhbmdlOjQ3YTJkMTljY2Y2NTQ2YjNiNDdkZjk0N2Q1MjJlZWM0XzctNS0xLTEtNzgyMTU_df0ab8a5-0df1-4815-8831-091e2d2094ac"
      unitRef="usd">309000000</us-gaap:LeaseCost>
    <dgx:ShorttermLeaseandVariableLeaseCost
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzU0OTc1NTgxNzY3Ng_22637482-7f63-4efa-85d9-b247f773b271"
      unitRef="usd">160000000</dgx:ShorttermLeaseandVariableLeaseCost>
    <dgx:ShorttermLeaseandVariableLeaseCost
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzI5NDY_710bdff9-79e8-4d24-9fea-779e0aeaa23f"
      unitRef="usd">140000000</dgx:ShorttermLeaseandVariableLeaseCost>
    <dgx:ShorttermLeaseandVariableLeaseCost
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzI5NTM_61f53b6c-413f-499f-a19a-236bdde32783"
      unitRef="usd">120000000</dgx:ShorttermLeaseandVariableLeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NDk_f93bcd7f-9bdc-42cf-83c9-91fe6943728a">The maturity of the Company's lease liabilities as of December&#160;31, 2022 is as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:365.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:163.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:29pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Maturity of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTc_6a5e95a5-366a-4059-9fdc-1654eeeb258e">The maturity of the Company's lease liabilities as of December&#160;31, 2022 is as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:365.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:163.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:29pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Maturity of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzEtMi0xLTEtNzgyMTU_7ab4e6cf-27c5-4481-ad95-d3cc3ec6939c"
      unitRef="usd">167000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzEtNC0xLTEtNzgyMTU_a55ebb5a-8f6f-4199-9d82-7b673b8b9da5"
      unitRef="usd">2000000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <dgx:LesseeOperatingandFinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzEtNi0xLTEtNzgyMTU_d92736e7-86f7-4088-9113-a90577cdf32e"
      unitRef="usd">169000000</dgx:LesseeOperatingandFinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzItMi0xLTEtNzgyMTU_8eab6117-dc70-48bd-b8d0-1527eb3ff03a"
      unitRef="usd">137000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzItNC0xLTEtNzgyMTU_a14abf6e-3bf6-4797-b101-c51be9f5d04c"
      unitRef="usd">2000000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <dgx:LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzItNi0xLTEtNzgyMTU_b8cdb49c-aef8-487e-bb54-40c2b114d1e5"
      unitRef="usd">139000000</dgx:LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzMtMi0xLTEtNzgyMTU_833d614d-15e9-4fa9-9f8e-ce88380c3171"
      unitRef="usd">104000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzMtNC0xLTEtNzgyMTU_5e4df9fa-af1c-47b4-8b82-f619a51ef0c2"
      unitRef="usd">2000000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <dgx:LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzMtNi0xLTEtNzgyMTU_cf2723b8-1607-46dd-9849-69fb6c70a459"
      unitRef="usd">106000000</dgx:LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzQtMi0xLTEtNzgyMTU_c04a1a9e-f791-4393-b847-078a3b560d0c"
      unitRef="usd">75000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzQtNC0xLTEtNzgyMTU_51f24a9b-b666-46b6-97e3-c7bada620fac"
      unitRef="usd">2000000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <dgx:LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzQtNi0xLTEtNzgyMTU_3cb847eb-fa38-43af-a9ec-02f025aa3c0f"
      unitRef="usd">77000000</dgx:LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzUtMi0xLTEtNzgyMTU_4cb540db-0e37-4cad-a80f-cd8a8f6c78c9"
      unitRef="usd">59000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzUtNC0xLTEtNzgyMTU_c3776e46-697e-46fa-86d0-1fc6c5559bc8"
      unitRef="usd">1000000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <dgx:LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzUtNi0xLTEtNzgyMTU_14802f77-7bdb-4f19-8049-67b95e07ee29"
      unitRef="usd">60000000</dgx:LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzYtMi0xLTEtNzgyMTU_074ff12a-024f-4c93-9899-181791b8b2ab"
      unitRef="usd">173000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzYtNC0xLTEtNzgyMTU_9702105f-2252-4cb0-b174-75d23f6fb955"
      unitRef="usd">1000000</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <dgx:LesseeOperatingandFinanceLeaseLiabilityPaymentsDueafterYearFive
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzYtNi0xLTEtNzgyMTU_22c0e827-03d1-4079-8c02-20e0157ee55b"
      unitRef="usd">174000000</dgx:LesseeOperatingandFinanceLeaseLiabilityPaymentsDueafterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzctMi0xLTEtNzgyMTU_25030233-4c57-434b-a1bb-8c481cb1e9c5"
      unitRef="usd">715000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzctNC0xLTEtNzgyMTU_0ae08370-458b-4411-b3dd-63b5558f0cc5"
      unitRef="usd">10000000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <dgx:LesseeOperatingandFinanceLeaseLiabilityPaymentsDue
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzctNi0xLTEtNzgyMTU_a6aff095-0fe6-4da9-9944-11446674ed79"
      unitRef="usd">725000000</dgx:LesseeOperatingandFinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzgtMi0xLTEtNzgyMTU_8cf11e0a-57bc-4099-8f34-8363078cf0eb"
      unitRef="usd">73000000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzgtNC0xLTEtNzgyMTU_57ea5660-ee42-4442-b989-2e10b4197bc9"
      unitRef="usd">1000000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <dgx:LesseeOperatingandFinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzgtNi0xLTEtNzgyMTU_92afcd43-a8f9-4723-a54c-3971286053eb"
      unitRef="usd">74000000</dgx:LesseeOperatingandFinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzktMi0xLTEtNzgyMTU_fbbca144-1327-4d12-97db-acf8547f43dc"
      unitRef="usd">642000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzktNC0xLTEtNzgyMTU_6e0f9449-fca0-486c-9907-1619ec85b1af"
      unitRef="usd">9000000</us-gaap:FinanceLeaseLiability>
    <dgx:OperatingandFinanceLeaseLiability
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTpkMzVmZDdlZTA4ZGQ0NzA4YTk0OTFjMDBlOWIxMTVkZC90YWJsZXJhbmdlOmQzNWZkN2VlMDhkZDQ3MDhhOTQ5MWMwMGU5YjExNWRkXzktNi0xLTEtNzgyMTU_3f17ab16-c07f-4ec9-bf9d-d1eb464b488d"
      unitRef="usd">651000000</dgx:OperatingandFinanceLeaseLiability>
    <dgx:ScheduleofLeaseTermandDiscountRateTableTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90ZXh0cmVnaW9uOmI4MzUwYjcyYjMwZDQwZDhhZGM3MjAxZjY1NzY2ZmUxXzM3NTA_f5c2ef36-f83e-4385-b6d3-7dc463f07d5f">Lease term and discount rate as of December&#160;31, 2022 and 2021 were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:363.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Lease term and discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</dgx:ScheduleofLeaseTermandDiscountRateTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTphMDMyNTc4MjMyMzE0YjMxYjc4MmJiZTRkYTkzYjUyMi90YWJsZXJhbmdlOmEwMzI1NzgyMzIzMTRiMzFiNzgyYmJlNGRhOTNiNTIyXzItMS0xLTEtNzgyMTU_9c6410d8-19e7-4e24-b5f5-0b1f22efc4ab">P6Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTphMDMyNTc4MjMyMzE0YjMxYjc4MmJiZTRkYTkzYjUyMi90YWJsZXJhbmdlOmEwMzI1NzgyMzIzMTRiMzFiNzgyYmJlNGRhOTNiNTIyXzItMy0xLTEtNzgyMTU_1ec69b49-28a2-418a-ad8e-b4591c2fbfc1">P6Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTphMDMyNTc4MjMyMzE0YjMxYjc4MmJiZTRkYTkzYjUyMi90YWJsZXJhbmdlOmEwMzI1NzgyMzIzMTRiMzFiNzgyYmJlNGRhOTNiNTIyXzMtMS0xLTEtNzgyMTU_000c3337-b1a4-4004-ae42-fb90f09f5251">P6Y</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTphMDMyNTc4MjMyMzE0YjMxYjc4MmJiZTRkYTkzYjUyMi90YWJsZXJhbmdlOmEwMzI1NzgyMzIzMTRiMzFiNzgyYmJlNGRhOTNiNTIyXzMtMy0xLTEtNzgyMTU_60a39f96-da96-4739-9a7b-07c6e3e95c32">P11Y</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTphMDMyNTc4MjMyMzE0YjMxYjc4MmJiZTRkYTkzYjUyMi90YWJsZXJhbmdlOmEwMzI1NzgyMzIzMTRiMzFiNzgyYmJlNGRhOTNiNTIyXzYtMS0xLTEtNzgyMTU_6d811526-840e-4067-a374-a127b9651584"
      unitRef="number">0.030</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTphMDMyNTc4MjMyMzE0YjMxYjc4MmJiZTRkYTkzYjUyMi90YWJsZXJhbmdlOmEwMzI1NzgyMzIzMTRiMzFiNzgyYmJlNGRhOTNiNTIyXzYtMy0xLTEtNzgyMTU_bab52c2b-6c1b-426a-9cae-75972661997a"
      unitRef="number">0.030</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTphMDMyNTc4MjMyMzE0YjMxYjc4MmJiZTRkYTkzYjUyMi90YWJsZXJhbmdlOmEwMzI1NzgyMzIzMTRiMzFiNzgyYmJlNGRhOTNiNTIyXzctMS0xLTEtNzgyMTU_88e675b6-1a59-4b58-8705-1f5e0cf9cb97"
      unitRef="number">0.024</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMTcvZnJhZzpiODM1MGI3MmIzMGQ0MGQ4YWRjNzIwMWY2NTc2NmZlMS90YWJsZTphMDMyNTc4MjMyMzE0YjMxYjc4MmJiZTRkYTkzYjUyMi90YWJsZXJhbmdlOmEwMzI1NzgyMzIzMTRiMzFiNzgyYmJlNGRhOTNiNTIyXzctMy0xLTEtNzgyMTU_219c562e-13d0-407b-8126-9354b297fa7a"
      unitRef="number">0.069</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjAvZnJhZzo2ZjIxMGQ2OGJiMDU0YmNkYmE3N2ZhZTAzNjQxNjMxMS90ZXh0cmVnaW9uOjZmMjEwZDY4YmIwNTRiY2RiYTc3ZmFlMDM2NDE2MzExXzE0Mzg_aa059164-05ea-485e-8195-aa4bb15b00ea">FINANCIAL INSTRUMENTS &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;Interest Rate Derivatives &#x2013; Cash Flow Hedges&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;From time to time, the Company has entered into various interest rate lock agreements and forward-starting interest rate swap agreements to hedge part of the Company's interest rate exposure associated with the variability in future cash flows attributable to changes in interest rates. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest Rate Derivatives &#x2013; Fair Value Hedges &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Historically, the Company has entered into various fixed-to-variable interest rate swap agreements in order to convert a portion of the Company's long-term debt into variable interest rate debt. All such fixed-to-variable interest rate swap agreements have been terminated and proceeds from the terminations have been reflected as basis adjustments to the hedged debt instruments and are being amortized as a reduction of interest expense, net over the remaining terms of such debt instruments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;As of December&#160;31, 2022 and 2021, the following amounts were recorded on the consolidated balance sheets related to cumulative basis adjustments for fair value hedges included in the carrying amount of long-term debt:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Hedge Accounting Basis Adjustment (a)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) As of both December&#160;31, 2022 and 2021, the entire balance is associated with remaining unamortized hedging adjustments on discontinued relationships. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The following table presents the effect of fair value hedge accounting on the consolidated statements of operations for the years ended December&#160;31, 2022, 2021 and 2020, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.275%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total for line item in which the effects of fair value hedges are recorded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="6" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gain (loss) on fair value hedging relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedged items (Long-term debt)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjAvZnJhZzo2ZjIxMGQ2OGJiMDU0YmNkYmE3N2ZhZTAzNjQxNjMxMS90ZXh0cmVnaW9uOjZmMjEwZDY4YmIwNTRiY2RiYTc3ZmFlMDM2NDE2MzExXzE0MzU_63447359-6611-49f7-97d4-973d3f820a18">As of December&#160;31, 2022 and 2021, the following amounts were recorded on the consolidated balance sheets related to cumulative basis adjustments for fair value hedges included in the carrying amount of long-term debt:&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Hedge Accounting Basis Adjustment (a)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) As of both December&#160;31, 2022 and 2021, the entire balance is associated with remaining unamortized hedging adjustments on discontinued relationships. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The following table presents the effect of fair value hedge accounting on the consolidated statements of operations for the years ended December&#160;31, 2022, 2021 and 2020, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.275%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total for line item in which the effects of fair value hedges are recorded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="6" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gain (loss) on fair value hedging relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedged items (Long-term debt)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i723c452601804300bcd7029176377b7a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjAvZnJhZzo2ZjIxMGQ2OGJiMDU0YmNkYmE3N2ZhZTAzNjQxNjMxMS90YWJsZTo5Nzk2ZTFhZTEwNGY0MDRjOWRiODc5NTVjZjBlZGFkMi90YWJsZXJhbmdlOjk3OTZlMWFlMTA0ZjQwNGM5ZGI4Nzk1NWNmMGVkYWQyXzItNS0xLTEtNzgyMTU_8fe2d1dc-e2bb-4cf3-8c9b-e8bb2bacbc5a"
      unitRef="usd">26000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i0b93c42f53bc4c24b90b5c3989b66730_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjAvZnJhZzo2ZjIxMGQ2OGJiMDU0YmNkYmE3N2ZhZTAzNjQxNjMxMS90YWJsZTo5Nzk2ZTFhZTEwNGY0MDRjOWRiODc5NTVjZjBlZGFkMi90YWJsZXJhbmdlOjk3OTZlMWFlMTA0ZjQwNGM5ZGI4Nzk1NWNmMGVkYWQyXzItOS0xLTEtNzgyMTU_e3b88d27-92e8-414a-b19a-89e2a54b14ea"
      unitRef="usd">38000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjAvZnJhZzo2ZjIxMGQ2OGJiMDU0YmNkYmE3N2ZhZTAzNjQxNjMxMS90YWJsZTo0MTQwMzFmNDljMDk0OWE5YmE0YTc1ZmY0MTI5OTI1YS90YWJsZXJhbmdlOjQxNDAzMWY0OWMwOTQ5YTliYTRhNzVmZjQxMjk5MjVhXzMtMy0xLTEtNzgyMTU_569f10c8-c009-43fd-9ebe-01728aa2d7b5"
      unitRef="usd">-55000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjAvZnJhZzo2ZjIxMGQ2OGJiMDU0YmNkYmE3N2ZhZTAzNjQxNjMxMS90YWJsZTo0MTQwMzFmNDljMDk0OWE5YmE0YTc1ZmY0MTI5OTI1YS90YWJsZXJhbmdlOjQxNDAzMWY0OWMwOTQ5YTliYTRhNzVmZjQxMjk5MjVhXzMtNS0xLTEtNzgyMTU_3f3ce883-02db-4662-9ec7-a2e93333f45a"
      unitRef="usd">369000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjAvZnJhZzo2ZjIxMGQ2OGJiMDU0YmNkYmE3N2ZhZTAzNjQxNjMxMS90YWJsZTo0MTQwMzFmNDljMDk0OWE5YmE0YTc1ZmY0MTI5OTI1YS90YWJsZXJhbmdlOjQxNDAzMWY0OWMwOTQ5YTliYTRhNzVmZjQxMjk5MjVhXzMtNy0xLTEtNzgyMTU_3fc93c78-4ffa-4752-9ca0-59dbf666ca08"
      unitRef="usd">76000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjAvZnJhZzo2ZjIxMGQ2OGJiMDU0YmNkYmE3N2ZhZTAzNjQxNjMxMS90YWJsZTo0MTQwMzFmNDljMDk0OWE5YmE0YTc1ZmY0MTI5OTI1YS90YWJsZXJhbmdlOjQxNDAzMWY0OWMwOTQ5YTliYTRhNzVmZjQxMjk5MjVhXzYtMy0xLTEtNzgyMTU_8c357099-cf07-44ba-ab60-1b94429a05cc"
      unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjAvZnJhZzo2ZjIxMGQ2OGJiMDU0YmNkYmE3N2ZhZTAzNjQxNjMxMS90YWJsZTo0MTQwMzFmNDljMDk0OWE5YmE0YTc1ZmY0MTI5OTI1YS90YWJsZXJhbmdlOjQxNDAzMWY0OWMwOTQ5YTliYTRhNzVmZjQxMjk5MjVhXzYtNS0xLTEtNzgyMTU_668d8416-6a39-45ee-8336-17222310af92"
      unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjAvZnJhZzo2ZjIxMGQ2OGJiMDU0YmNkYmE3N2ZhZTAzNjQxNjMxMS90YWJsZTo0MTQwMzFmNDljMDk0OWE5YmE0YTc1ZmY0MTI5OTI1YS90YWJsZXJhbmdlOjQxNDAzMWY0OWMwOTQ5YTliYTRhNzVmZjQxMjk5MjVhXzYtNy0xLTEtNzgyMTU_1e07962f-6cdc-488e-bd1d-33f28543c1d2"
      unitRef="usd">-68000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i04612297cd0342579339c26a21934632_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjAvZnJhZzo2ZjIxMGQ2OGJiMDU0YmNkYmE3N2ZhZTAzNjQxNjMxMS90YWJsZTo0MTQwMzFmNDljMDk0OWE5YmE0YTc1ZmY0MTI5OTI1YS90YWJsZXJhbmdlOjQxNDAzMWY0OWMwOTQ5YTliYTRhNzVmZjQxMjk5MjVhXzctMy0xLTEtNzgyMTU_b4a159b1-5d18-45f6-ac0e-d4c7fd447a9a"
      unitRef="usd">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i60fd27e051b74dd08de8773691041dd4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjAvZnJhZzo2ZjIxMGQ2OGJiMDU0YmNkYmE3N2ZhZTAzNjQxNjMxMS90YWJsZTo0MTQwMzFmNDljMDk0OWE5YmE0YTc1ZmY0MTI5OTI1YS90YWJsZXJhbmdlOjQxNDAzMWY0OWMwOTQ5YTliYTRhNzVmZjQxMjk5MjVhXzctNS0xLTEtNzgyMTU_afa88cac-263d-4633-bac4-79066a19c8d0"
      unitRef="usd">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i4fe1409e54674ca0be0e82d1932f97ca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjAvZnJhZzo2ZjIxMGQ2OGJiMDU0YmNkYmE3N2ZhZTAzNjQxNjMxMS90YWJsZTo0MTQwMzFmNDljMDk0OWE5YmE0YTc1ZmY0MTI5OTI1YS90YWJsZXJhbmdlOjQxNDAzMWY0OWMwOTQ5YTliYTRhNzVmZjQxMjk5MjVhXzctNy0xLTEtNzgyMTU_b324da05-9404-4fc5-a0aa-dc55e7c936ab"
      unitRef="usd">68000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzYxNDM_1a6f85f1-ce45-4f8d-bdd5-0cb86af18226">STOCKHOLDERS&#x2019; EQUITY AND REDEEMABLE NONCONTROLLING INTEREST&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;Stockholders' Equity&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Series Preferred Stock &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Quest Diagnostics is authorized to issue up to 10 million shares of Series Preferred Stock, par value $1.00 per share.  The Company's Board of Directors has the authority to issue such shares without stockholder approval and to determine the designations, preferences, rights and restrictions of such shares.  No shares are currently outstanding.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Under the Company's Restated Certificate of Incorporation the number of authorized shares of common stock, par value $0.01 per share, is 600 million shares.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Changes in Accumulated Other Comprehensive Loss by Component&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Comprehensive income (loss) includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Foreign currency translation adjustments; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Net deferred gains (losses) on cash flow hedges, which represent deferred gains (losses), net of tax, on interest rate-related derivative financial instruments designated as cash flow hedges, net of amounts reclassified to interest expense (see Note 16); and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Net changes in available-for-sale debt securities, which represent unrealized holding gains (losses), net of tax, on available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;For the years ended December&#160;31, 2022, 2021, and 2020, the tax effects related to the deferred gains (losses) on cash flow hedges and net changes in available-for-sale debt securities were not material.  Foreign currency translation adjustments related to indefinite investments in non-U.S. subsidiaries are not adjusted for income taxes. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The changes in accumulated other comprehensive loss by component for 2022, 2021 and 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Foreign&lt;br/&gt;Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Changes in Available-for-Sale Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Deferred Losses on Cash Flow Hedges, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;On April 1, 2021, the Company sold its 40% ownership interest in Q&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Solutions, its clinical trials central laboratory services joint venture, to IQVIA, its joint venture partner.  As a result of the transaction, during the year ended December 31, 2021, $20&#160;million of cumulative translation losses were reclassified from accumulated other comprehensive loss to other (expense) income, net.  See Note 7 for further details. &#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Additionally, for the year ended December 31, 2020, $3&#160;million of cumulative translation losses were reclassified from accumulated other comprehensive loss to other operating expense (income), net as a result of the sale of foreign subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;For the years ended December&#160;31, 2022, 2021 and 2020, the gross deferred losses on cash flow hedges were reclassified from accumulated other comprehensive loss to interest expense, net.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dividend Program&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;During each of the four quarters of 2022, the Company's Board of Directors declared a quarterly cash dividend of $0.66 per common share.  During each of the four quarters of 2021, the Company's Board of Directors declared a quarterly cash dividend of $0.62 per common share.  During each of the four quarters of 2020, the Company's Board of Directors declared a quarterly cash dividend of $0.56 per common share.  In February 2023, the Company announced that its Board of Directors authorized a 7.6% increase in its quarterly cash dividend from $0.66 to $0.71 per share, or $2.84 per share annually, commencing with the dividend payable in April 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share Repurchase Program&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;In February 2022, the Company's Board of Directors increased the size of its share repurchase program by $1&#160;billion.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of December&#160;31, 2022, $0.3 billion remained available under the Company's share repurchase authorization.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;In February 2023, the Company announced that its Board of Directors authorized the Company to repurchase an additional $1&#160;billion of the Company's common stock.  The share repurchase authorization has no set expiration or termination date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share Repurchases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;For the year ended December&#160;31, 2022, the Company repurchased 10.1 million shares of its common stock for $1.4 billion.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;For the year ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2021, the Company repurchased 16.0 million shares of its common stock for $2.2 billion, including shares repurchased under ASRs. The repurchases during the year included an accrual of $23&#160;million recorded in accounts payable and accrued expenses in the consolidated balance sheet for share repurchases not settled until after December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;In April 2021, the Company entered into ASRs with several financial institutions to repurchase its common stock as part of a share repurchase program.  Each of the ASRs was structured to permit the Company to purchase shares immediately with the final purchase price of those shares determined by the volume-weighted average price of the Company's common stock during the repurchase period, less a fixed discount, and was accounted for as two transactions: (1) a treasury stock repurchase and (2) a forward contract.  During the year ended December&#160;31, 2021, the Company paid $1.5&#160;billion to the financial institutions and received 10.7&#160;million shares of its common stock under the ASRs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;For the year ended December&#160;31, 2020, the Company repurchased 2.7 million shares of its common stock for $325 million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;  &#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Shares Reissued from Treasury Stock&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;For the years ended December&#160;31, 2022, 2021 and 2020, the Company reissued 2 million shares, 2 million shares and 3 million shares, respectively, from treasury stock for shares issued under the Employee Stock Purchase Plan ("ESPP") and stock-based compensation program.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Treasury Stock Retirement &#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;During the year ended December&#160;31, 2021, the Company retired 55&#160;million shares of treasury stock.  In accordance with the Company's policy, the amount paid to repurchase the shares in excess of par value was allocated between retained earnings and additional paid-in capital based on a pro-rata allocation of additional paid-in capital at the time of the share retirement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Redeemable Noncontrolling Interest&lt;/span&gt;&lt;/div&gt;&#160;&#160;&#160;&#160;In connection with the sale of an 18.9% noncontrolling interest in a subsidiary to UMass on July 1, 2015, the Company granted UMass the right to require the Company to purchase all of its interest in the subsidiary at fair value commencing July 1, 2020.  The subsidiary performs diagnostic information services in a defined territory within the state of Massachusetts.  Since the redemption of the noncontrolling interest is outside of the Company's control, it has been presented outside of stockholders' equity at the greater of its carrying amount or its fair value.  The Company records changes in the fair value of the noncontrolling interest immediately as they occur.  As of December&#160;31, 2022 and 2021, the redeemable noncontrolling interest was $77 million and $79 million, respectively, and was presented at its fair value.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i6f4546cb1b9c4a1693b7d8224d2b29b1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzE2OQ_aa819c62-d713-4587-a062-bc77b7348ba7"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzIxNg_ac6d35e5-1638-464b-aa57-315b2bc7ffce"
      unitRef="usdPerShare">1.00</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzQyMQ_1d1c40de-18d1-4a5b-a5f2-c5cebedc7c34"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzU5NQ_e07786ab-744a-4d8e-8ece-28d80fb52d9c"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzYxMg_a4ce3829-edb1-49bf-8d5b-1677b2316a26"
      unitRef="shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzYxNDg_ec1f0d20-a41d-46b8-99a5-53d5833b04ed">The changes in accumulated other comprehensive loss by component for 2022, 2021 and 2020 were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Foreign&lt;br/&gt;Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Changes in Available-for-Sale Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Deferred Losses on Cash Flow Hedges, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="icb6d00d91a6d489898ca322307bd7551_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzItMS0xLTEtNzgyMTU_bc29047e-16a9-42dd-93d5-e378f0e2373c"
      unitRef="usd">-42000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib7a65c0363624e68becc030a94a0ab77_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzItMy0xLTEtNzgyMTU_fa1c5779-3cf1-4613-9157-e2a3dc7067f7"
      unitRef="usd">8000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i4c59c3612c6041ba80e0a3204b427ce3_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzItNS0xLTEtNzgyMTU_6d484891-9ad8-4711-a873-9d7bcc903c1b"
      unitRef="usd">-4000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i78646261649e4ab5b1d6101a7499cb08_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzItNy0xLTEtNzgyMTU_4b6bdead-025c-4620-a169-665fdcf01359"
      unitRef="usd">-1000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i472db09b826445d8914756bb3c893218_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzItOS0xLTEtNzgyMTU_6eb70165-eaa0-4ed3-977a-0447abd9e714"
      unitRef="usd">-39000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i78b2c70c8a144740bff9b6549c2df838_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzMtMS0xLTEtNzgyMTU_7051703d-17e6-4a61-9724-d947a3452a9f"
      unitRef="usd">12000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i339059f763014b84a165529202925717_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzMtMy0xLTEtNzgyMTU_4139b6c5-ec4f-43bd-a855-7fe8a1b89dc8"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i35e31e8eeed44389aab551248c319740_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzMtNS0xLTEtNzgyMTU_a942bb48-2b21-40e3-9706-6871fce54328"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="if8a22be73b2240fe97a3e930cdf33583_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzMtNy0xLTEtNzgyMTU_7d6986c0-3c9e-4ac4-b2ec-5fd5c11d139d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i7c187eb3582c4c4a85507116a2a9051a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzMtOS0xLTEtNzgyMTU_5dd22a8c-e289-4237-ac61-bbd0ff9fcc6d"
      unitRef="usd">13000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i78b2c70c8a144740bff9b6549c2df838_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzQtMS0xLTEtNzgyMTU_d8e66ed0-9730-41b7-b67b-4ea22a22032d"
      unitRef="usd">3000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i339059f763014b84a165529202925717_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzQtMy0xLTEtNzgyMTU_87595815-6345-48eb-8d5d-ec5c2c5ee0e6"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i35e31e8eeed44389aab551248c319740_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzQtNS0xLTEtNzgyMTU_f4f8f7eb-80be-4577-aff0-5d456fd8842d"
      unitRef="usd">2000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="if8a22be73b2240fe97a3e930cdf33583_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzQtNy0xLTEtNzgyMTU_5d0985d4-9499-41fc-af2e-cad1229946ae"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i7c187eb3582c4c4a85507116a2a9051a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzQtOS0xLTEtNzgyMTU_e52c857c-c2b4-43a6-ab41-8371ef28003a"
      unitRef="usd">5000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i78b2c70c8a144740bff9b6549c2df838_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzUtMS0xLTEtNzgyMTU_1de0c262-9c37-486e-bed7-c1db86ae6bf8"
      unitRef="usd">15000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i339059f763014b84a165529202925717_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzUtMy0xLTEtNzgyMTU_12a8a914-98a4-4af4-b4af-26eae6363978"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i35e31e8eeed44389aab551248c319740_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzUtNS0xLTEtNzgyMTU_ec8688e5-e0d6-4ba1-8f9a-8f71e44c1a21"
      unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if8a22be73b2240fe97a3e930cdf33583_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzUtNy0xLTEtNzgyMTU_51d5e4d0-38d3-4dcd-ae4f-9114474b73f0"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7c187eb3582c4c4a85507116a2a9051a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzUtOS0xLTEtNzgyMTU_e78a41de-7039-4746-9284-4f93aaff1822"
      unitRef="usd">18000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id1a47bc1d3184e49a881195d814db2bc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzctMS0xLTEtNzgyMTU_6e40b304-140f-4056-b749-225947183a52"
      unitRef="usd">-27000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i2e971db364844d9d9d8d92ab27c1ed37_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzctMy0xLTEtNzgyMTU_1d1053ed-58e2-479f-b528-759e289a3244"
      unitRef="usd">8000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i90b395d6ce534de0bc8b53e2fca569ff_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzctNS0xLTEtNzgyMTU_cba31c4f-ebb6-4829-a967-bbcf79dd7b1f"
      unitRef="usd">-1000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="iafd3f192541f4ebabada939564433870_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzctNy0xLTEtNzgyMTU_9328138c-f1ae-4b67-9625-61bbc6562653"
      unitRef="usd">-1000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ic144ab8f0cf34804be4018d616f6d4ac_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzctOS0xLTEtNzgyMTU_8b56525e-0630-4793-b610-82ff6fcfa8a8"
      unitRef="usd">-21000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i06cf1391d00e4b208aa2ec8b206f2b32_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzgtMS0xLTEtNzgyMTU_42b83f99-d324-4da6-a9fd-367cd2a6c492"
      unitRef="usd">-7000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ia1a523db0fd148b6b27ba256f8d6079a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzgtMy0xLTEtNzgyMTU_5fb7b9eb-3aff-4c2d-8864-67a43a604765"
      unitRef="usd">-7000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i580c408beba54cb7a6726b2b9bdd3f50_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzgtNS0xLTEtNzgyMTU_806ac5a3-7576-49c0-b8cb-6f6659e76c65"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i2c1a794ae52b4383b4bd9c5a8df17404_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzgtNy0xLTEtNzgyMTU_40806b4c-861c-4868-9906-42988cb1c82e"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i095b5e9afd734c41af3e81c20d90f712_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzgtOS0xLTEtNzgyMTU_cafcacce-6846-4316-bd78-925728d22f85"
      unitRef="usd">-14000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i06cf1391d00e4b208aa2ec8b206f2b32_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzktMS0xLTEtNzgyMTU_5ffda830-9835-43df-8e21-0d8c35957903"
      unitRef="usd">20000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ia1a523db0fd148b6b27ba256f8d6079a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzktMy0xLTEtNzgyMTU_8d1988f7-6244-46c2-a612-4e74f0cd313d"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i580c408beba54cb7a6726b2b9bdd3f50_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzktNS0xLTEtNzgyMTU_be383cc2-3de0-4849-b15b-2fdd9a4d4d65"
      unitRef="usd">1000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i2c1a794ae52b4383b4bd9c5a8df17404_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzktNy0xLTEtNzgyMTU_d0ffee28-e3b0-4e84-9ac9-99da0e061aeb"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i095b5e9afd734c41af3e81c20d90f712_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzktOS0xLTEtNzgyMTU_c70c59d9-e8b1-4dc1-8220-c6222abde70b"
      unitRef="usd">21000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i06cf1391d00e4b208aa2ec8b206f2b32_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzEwLTEtMS0xLTc4MjE1_99a6c2b5-1b34-4858-8392-0926eca9ac8c"
      unitRef="usd">13000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia1a523db0fd148b6b27ba256f8d6079a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzEwLTMtMS0xLTc4MjE1_76a8cbed-8f20-4e52-9019-82b0ab0ba42c"
      unitRef="usd">-7000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i580c408beba54cb7a6726b2b9bdd3f50_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzEwLTUtMS0xLTc4MjE1_f585359d-4264-4942-a045-446871948885"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i2c1a794ae52b4383b4bd9c5a8df17404_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzEwLTctMS0xLTc4MjE1_fe764f61-599d-4d13-a195-387323e48c60"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i095b5e9afd734c41af3e81c20d90f712_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzEwLTktMS0xLTc4MjE1_00486fb7-1ef1-4ce2-aa31-649ad1931498"
      unitRef="usd">7000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i4ebd65fb3e6947f2a405a8aeaf512a19_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzEyLTEtMS0xLTc4MjE1_903ada0d-216c-46b2-a6f3-155817559ed6"
      unitRef="usd">-14000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id7541d2de1e4457b8836169fd42ffe28_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzEyLTMtMS0xLTc4MjE1_b604470f-23c6-4a8b-887c-4f96e7e31357"
      unitRef="usd">1000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i0788f175bb734eec93e8a4d7abcbb8e0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzEyLTUtMS0xLTc4MjE1_71cd948d-1aec-435e-93e0-6721776b4953"
      unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i38b5a632e224465fb4d85fbc4eff5dd8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzEyLTctMS0xLTc4MjE1_f921ae90-dce8-4901-850a-c029b6eb68e2"
      unitRef="usd">-1000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id3c04cff9ac445b78c60050390c6354a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzEyLTktMS0xLTc4MjE1_6c7195d2-1563-410f-8da4-edf601aea1e8"
      unitRef="usd">-14000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i66bf6627917044748f98d7c18e1307e2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzEzLTEtMS0xLTc4MjE1_bbfd2528-1d56-4c98-82d4-ce19a88e37a1"
      unitRef="usd">-8000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i109b68d4a89d48ec97b242717a341fdf_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzEzLTMtMS0xLTc4MjE1_bae0b8ee-865f-4851-bf57-93da16482a35"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i933dedd678a149a484d0a02f4c2d33e0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzEzLTUtMS0xLTc4MjE1_dd0f7182-f823-485d-8332-b13c8eaaf596"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i7a52a88c88684f908d9a67c0b1361c4e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzEzLTctMS0xLTc4MjE1_1315f8bb-1372-4ba8-b5be-8e62e64db02d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ic7dd85f38ce14e469eb57e11ba9cfd32_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzEzLTktMS0xLTc4MjE1_d8fde155-080c-45f9-8ea1-fa2c5b3b0ebd"
      unitRef="usd">-8000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i66bf6627917044748f98d7c18e1307e2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzE0LTEtMS0xLTc4MjE1_f7a54fea-3cc6-4441-b32b-7a0724aeee0c"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i109b68d4a89d48ec97b242717a341fdf_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzE0LTMtMS0xLTc4MjE1_263aa890-fec2-40fb-90d5-deaf88c62ec5"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i933dedd678a149a484d0a02f4c2d33e0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzE0LTUtMS0xLTc4MjE1_d3316e12-1ca2-4ca7-bed4-da328504bff3"
      unitRef="usd">1000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i7a52a88c88684f908d9a67c0b1361c4e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzE0LTctMS0xLTc4MjE1_995d5e38-ad4a-40c6-8fa3-71640b72e40a"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ic7dd85f38ce14e469eb57e11ba9cfd32_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzE0LTktMS0xLTc4MjE1_86a3def1-5026-423c-8f74-81fb780fe497"
      unitRef="usd">1000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i66bf6627917044748f98d7c18e1307e2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzE1LTEtMS0xLTc4MjE1_70eb8c71-d661-464f-8ff6-5c18073640ea"
      unitRef="usd">-8000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i109b68d4a89d48ec97b242717a341fdf_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzE1LTMtMS0xLTc4MjE1_b782e0f4-4f94-4b00-a6e3-4293ad442c9a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i933dedd678a149a484d0a02f4c2d33e0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzE1LTUtMS0xLTc4MjE1_a74cdead-ba11-4f70-82f7-5d4e588b7c80"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7a52a88c88684f908d9a67c0b1361c4e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzE1LTctMS0xLTc4MjE1_dd38becd-b123-455c-928c-c20f3b9198d3"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic7dd85f38ce14e469eb57e11ba9cfd32_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzE1LTktMS0xLTc4MjE1_dd24e198-314b-4416-ad73-e1934c7fbc48"
      unitRef="usd">-7000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i71a45e6a745e4ddf8252c87f04dd758e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzE3LTEtMS0xLTc4MjE1_aac851cc-853a-4ce8-9d65-86638cb5c44d"
      unitRef="usd">-22000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i1423840c822742dc9fdf987c08a9badf_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzE3LTMtMS0xLTc4MjE1_fc453c77-bbe4-4c4d-879e-52b1a7e9fe9d"
      unitRef="usd">1000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib4cc611bd437409a9457b4e8ca870211_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzE3LTUtMS0xLTc4MjE1_2c4980ae-93ce-477b-ae75-42245dcd1e50"
      unitRef="usd">1000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i920e105da0ab40dcba086a031fe03430_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzE3LTctMS0xLTc4MjE1_af5d3fa4-fc9b-446a-bbf7-5dd87e2441b2"
      unitRef="usd">-1000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib4848abb5a7147028c83ac30e5fcf981_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90YWJsZToyMGMzMzhjMTBjMmI0OTdjOTZkMjJiMWMyMzQ4ZjA1ZC90YWJsZXJhbmdlOjIwYzMzOGMxMGMyYjQ5N2M5NmQyMmIxYzIzNDhmMDVkXzE3LTktMS0xLTc4MjE1_819e6683-53aa-40d0-877a-a2a7eec8f3e6"
      unitRef="usd">-21000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <dgx:EquityMethodInvestmentOwnershipPercentDisposedOf
      contextRef="i0c20173d8dc64ebdb79161256ab69f0d_I20210401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzE2NTU_439a551c-3366-410e-a137-1e036afe5a23"
      unitRef="number">0.40</dgx:EquityMethodInvestmentOwnershipPercentDisposedOf>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="idcd7cd9e61214881b085d41e21b23992_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzE4NTM_45fa4115-b802-4672-ae0d-f9c1767dd0d3"
      unitRef="usd">20000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i78b2c70c8a144740bff9b6549c2df838_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzIwNDY_9124231a-ec26-4b64-856e-95d8f553062b"
      unitRef="usd">3000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i6e808f2e2e6543d1a2b3a31c4bb749dc_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzI0OTk_58fdc8ad-9774-4004-905e-e000134bf434"
      unitRef="usdPerShare">0.66</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ia40f541edc5a4e009d95c57cd1bcb927_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzI0OTk_74c28383-56c1-4783-9915-7f9785cb550c"
      unitRef="usdPerShare">0.66</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ie092f7c613574f36ac6303f206cea249_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzI0OTk_954d8690-a876-4571-a47a-0f9209285188"
      unitRef="usdPerShare">0.66</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i7f7bde7107be4688966df19bafdeea10_D20221001-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzI0OTk_f739f6da-34f5-4674-9487-b6ef81ef841f"
      unitRef="usdPerShare">0.66</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ib70de56c8cc94b818521ce47775ed911_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzI2MzI_133c58ed-e1cb-43b9-af2e-4bcc523f3323"
      unitRef="usdPerShare">0.62</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i5bb911fffd174a0aa2ac5f0facc0999e_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzI2MzI_51fbd632-34cb-4ce7-9d86-856c60277d17"
      unitRef="usdPerShare">0.62</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ic46672a2c9fc4d0e990f241632df20c6_D20211001-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzI2MzI_5ec430ab-cebc-4040-9b29-7918e5220705"
      unitRef="usdPerShare">0.62</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ib82daccc7a0640b288f5167661d2539c_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzI2MzI_a4604203-64cf-48af-ad58-fb182884c345"
      unitRef="usdPerShare">0.62</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ida73f1775008469a8c0cf852ee5a1c29_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzI3NjU_52439cb6-0522-4aae-a594-6b56802f6f03"
      unitRef="usdPerShare">0.56</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="id98e1b95cd5d4adf98b2c4cb2f733c61_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzI3NjU_78224b75-5af8-4007-8550-b9b8a9f84a13"
      unitRef="usdPerShare">0.56</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i145904e8a701484d92f0e52d1adeca1f_D20201001-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzI3NjU_79518c3d-31bb-49b4-8680-95f5b40908ea"
      unitRef="usdPerShare">0.56</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i8aae4e22f3264196b0bfa35291c77a16_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzI3NjU_f5c6ed25-7376-42d9-b9a5-95e1a126b80c"
      unitRef="usdPerShare">0.56</us-gaap:CommonStockDividendsPerShareDeclared>
    <dgx:IncreaseDecreaseinCommonStockDividendsDeclaredasPercent
      contextRef="i62fbbac4e0dc4fa697878a348ac0758e_I20230202"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzI4NTc_2ecf22bc-e5fa-48c1-b0b1-00c1528b02e8"
      unitRef="number">0.076</dgx:IncreaseDecreaseinCommonStockDividendsDeclaredasPercent>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i6e808f2e2e6543d1a2b3a31c4bb749dc_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzU0OTc1NTgyMDA4NQ_58fdc8ad-9774-4004-905e-e000134bf434"
      unitRef="usdPerShare">0.66</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ia40f541edc5a4e009d95c57cd1bcb927_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzU0OTc1NTgyMDA4NQ_74c28383-56c1-4783-9915-7f9785cb550c"
      unitRef="usdPerShare">0.66</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ie092f7c613574f36ac6303f206cea249_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzU0OTc1NTgyMDA4NQ_954d8690-a876-4571-a47a-0f9209285188"
      unitRef="usdPerShare">0.66</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i7f7bde7107be4688966df19bafdeea10_D20221001-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzU0OTc1NTgyMDA4NQ_f739f6da-34f5-4674-9487-b6ef81ef841f"
      unitRef="usdPerShare">0.66</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i6f31e868418c42c5abbd3bb28b8a4277_D20230202-20230202"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzI5MTE_a18f0c56-d7fc-4c80-8ad4-00edfba53686"
      unitRef="usdPerShare">0.71</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ia76a036d7fa340e7b4834c31bf563b49_D20230101-20231231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzI5Mjg_ca799468-ecff-4357-b1d9-71643c79d528"
      unitRef="usdPerShare">2.84</us-gaap:CommonStockDividendsPerShareDeclared>
    <dgx:StockRepurchaseProgramAdditionalAmountAuthorized
      contextRef="ie4d8aae1ad91426ab8c1e84816ea8730_D20220201-20220228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzI3NDg3NzkwODA3Mzg_3359ff75-2eaa-42c5-bc98-6830c8fee9df"
      unitRef="usd">1000000000</dgx:StockRepurchaseProgramAdditionalAmountAuthorized>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzU0OTc1NTgyMDIwMw_293e45b4-5299-4374-a527-94d1b6f55e1c"
      unitRef="usd">300000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <dgx:StockRepurchaseProgramAdditionalAmountAuthorized
      contextRef="i6f31e868418c42c5abbd3bb28b8a4277_D20230202-20230202"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzEwOTk1MTE2NDA2NDA_67132518-25f7-4e9d-ad3c-8ea05c8a28e2"
      unitRef="usd">1000000000</dgx:StockRepurchaseProgramAdditionalAmountAuthorized>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i7840e393be1c4cfaafc766cd6a649f57_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzM1MzE_a7857b2c-b1a2-4d4a-abf1-4dcbf816282a"
      unitRef="shares">10100000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i7840e393be1c4cfaafc766cd6a649f57_D20220101-20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzM1NjU_aa7dd19d-4228-4c29-8269-e623de6d002f"
      unitRef="usd">1400000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ic4718e0f26e04ae097941f11f8d84f52_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzQ1MjI_97231abb-d051-4dfb-89da-63c9489e7b2e"
      unitRef="shares">16000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ic4718e0f26e04ae097941f11f8d84f52_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzQ1NTY_47d60d46-eadf-4b8b-bfe4-0f7b595fbbed"
      unitRef="usd">2200000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <dgx:TreasuryStockPurchasedbutNotyetPaid
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzEwOTk1MTE2Mzk1OTI_7d0bade1-6b22-4c15-a443-43ded83aabdf"
      unitRef="usd">23000000</dgx:TreasuryStockPurchasedbutNotyetPaid>
    <dgx:AcceleratedShareRepurchasesPayment
      contextRef="ic235750c5b474440bd8465c5df75988a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzU0OTc1NTgyNDcyMA_d5053bc4-41a5-4553-abce-41770939fa89"
      unitRef="usd">1500000000</dgx:AcceleratedShareRepurchasesPayment>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i47113d1bbe9f4fea9bec3bbe1f7f5d91_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzU0OTc1NTgyNDc0Nw_bb55c613-194f-4c05-986f-4d17ff256f97"
      unitRef="shares">10700000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i2998701e47ab4c2da75bc84322736ac6_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzQ2MDk_a78ab44d-b9d0-4c60-a799-68a259fd0ebc"
      unitRef="shares">2700000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i2998701e47ab4c2da75bc84322736ac6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzQ2NDM_a0ea7f53-9728-441e-9b37-862b9ddd05c4"
      unitRef="usd">325000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzQ3NDc_e5f0e35e-7ce5-4991-b583-bb28ed99c874"
      unitRef="shares">2000000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzQ3NTg_b62c8b3e-5ce2-463a-bd10-8a2aead261ee"
      unitRef="shares">2000000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzQ3NzI_20991392-84dc-4e46-97c8-d2b0d2c19f8b"
      unitRef="shares">3000000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzU0OTc1NTgyNTE2MQ_8af7c742-44f2-4229-8581-5e7f414cc13d"
      unitRef="shares">55000000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="ia809ec8fd18c4ad48fc0dd81f2cdd760_I20150701"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzUzNzY_664d8456-d7ad-4c1e-87e9-ca98229c8454"
      unitRef="number">0.189</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzYwNzU_6d29d152-8827-4074-89c9-58d604ad918c"
      unitRef="usd">77000000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjMvZnJhZzpkNTAzOWMxNDk2NDU0YjViYTcxZTM2ZTY0NWEzZmNiNi90ZXh0cmVnaW9uOmQ1MDM5YzE0OTY0NTRiNWJhNzFlMzZlNjQ1YTNmY2I2XzYwODI_3b950d97-2563-4fbb-bbf2-3b0408357a66"
      unitRef="usd">79000000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzExMTgw_fd803b61-fbe3-4c67-8400-e9c7a97fd40e">STOCK OWNERSHIP AND COMPENSATION PLANS&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee and Non-employee Directors Stock Ownership Programs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The ELTIP provides for three types of awards: (a) stock options, (b) stock appreciation rights and (c) stock awards.  The ELTIP provides for the grant to eligible employees of either non-qualified or incentive stock options, or both, to purchase shares of Company common stock at an exercise price no less than the fair market value of the Company's common stock on the date of grant.  Grants of stock appreciation rights allow eligible employees to receive a payment based on the appreciation of Company common stock in cash, shares of Company common stock or a combination thereof.  The stock appreciation rights are granted at an exercise price no less than the fair market value of the Company's common stock on the date of grant.  Stock options and stock appreciation rights granted under the ELTIP expire on the date designated by the Board of Directors but in no event more than ten years from date of grant.  No stock appreciation rights have been granted under the ELTIP.  Under the ELTIP, awards are subject to forfeiture if employment terminates prior to the end of the vesting period prescribed by the Board of Directors.  For all award types, the vesting period is generally over three years from the date of grant.  For performance share units, the actual amount of shares earned is based on the achievement of the performance goals specified in the awards.  The performance goals for awards granted in 2020, 2021 and 2022 were based on the financial performance of the Company, as well as relative TSR.  The maximum number of shares of Company common stock in respect of which awards may be granted under the ELTIP is approximately 79 million shares.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The DLTIP provides for the grant to non-employee directors of non-qualified stock options to purchase shares of Company common stock at an exercise price no less than the fair market value of the Company's common stock on the date of grant.  The DLTIP also permits awards of restricted stock and restricted stock units to non-employee directors.  Stock options granted under the DLTIP expire on the date designated by the Board of Directors but in no event more than ten years from date of grant.  For all award types, the vesting period is generally over three years from the date of grant, regardless of whether the award recipient remains a director of the Company.  The maximum number of shares that may be issued under the DLTIP is 2.4 million shares.  For the years ended December&#160;31, 2022, 2021 and 2020, grants under the DLTIP totaled 10 thousand shares, 12 thousand shares and 14 thousand shares, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company's practice had been to issue shares related to its stock-based compensation program from shares of its common stock held in treasury or by issuing new shares of its common stock.  In January 2021, the Company began to issue shares related to its ESPP and stock-based compensation program solely from common stock held in treasury.  See Note 17 for further information regarding the Company's share repurchase program.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The fair value of each stock option award granted was estimated on the date of grant using a Black-Scholes option-valuation model.  The expected volatility under the Black-Scholes option-valuation model was based on historical volatilities of the Company's common stock.  The dividend yield was based on the approved annual dividend rate in effect and current market price of the underlying common stock at the time of grant.  The risk-free interest rate was based on the U.S. Treasury yield curve in effect at the time of grant for bonds with maturities consistent with the expected holding period of the related award.  The expected holding period was estimated using the historical stock option exercise behavior of employees. The Black-Scholes option-valuation model also incorporates the average market price of the Company's common stock at the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The weighted average assumptions used in valuing stock options granted in the periods presented were:  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.219%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value at grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$26.80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$21.82&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$17.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.3%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected holding period, in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The following summarizes the activity relative to stock option awards for 2022: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.457%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.457%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.457%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.459%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options forfeited and canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value (the difference between the Company's closing common stock price on the last trading day of 2022 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on December&#160;31, 2022.  This amount changes based on the fair market value of the Company's common stock.  Total intrinsic value of options exercised in 2022, 2021 and 2020 was $70 million, $83 million and $113 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;As of December&#160;31, 2022, there was $5 million of unrecognized stock-based compensation cost related to nonvested stock options which is expected to be recognized over a weighted average period of 1.5 years.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The fair value of restricted stock awards and restricted stock units is the average market price of the Company's common stock at the date of grant.  For performance share units with a goal based on the financial performance of the Company, the fair value is based on the average market price of the Company's common stock at the date of grant, adjusted for the present value of dividends expected to be paid on the Company's common stock during the vesting period.  For performance share units with a market-based relative TSR goal, the fair value is estimated on the date of grant using a Monte Carlo valuation model.  The expected volatility under the Monte Carlo valuation model is based on the historical volatility of the common stock of the Company and the common stock of the companies in the peer index.  The dividend yield is based on the approved annual dividend rate in effect and current market price of the underlying common stock at the time of grant.  The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for bonds with maturities consistent with the performance period of the related award. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The weighted average assumptions used in valuing performance share units with a market-based relative TSR goal in the periods presented were:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.289%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value at grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$130.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$150.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$144.03&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.1%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The following summarizes the activity relative to stock awards, including restricted stock units and performance share units, for 2022, 2021 and 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center;text-indent:31.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares outstanding, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares forfeited and canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares outstanding, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;As of December&#160;31, 2022, there was $40 million of unrecognized stock-based compensation cost related to nonvested stock awards, which is expected to be recognized over a weighted average period of 1.8 years.  Total fair value of shares vested was $72 million, $59 million and $37 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.  For performance share units with a goal based on financial performance of the Company, the amount of unrecognized stock-based compensation cost is subject to change based on changes, if any, to management's best estimates of the achievement of the performance goals specified in such awards and the resulting number of shares that will be earned at the end of the performance periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;For the years ended December&#160;31, 2022, 2021 and 2020, stock-based compensation expense totaled $77 million, $79 million and $97 million, respectively.  Income tax benefits recognized in the consolidated statements of operations related to stock-based compensation expense totaled $27 million, $32 million and $39 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively, which includes excess tax benefits associated with stock-based compensation arrangements of $14 million, $19 million and $23 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Under the Company's ESPP, substantially all employees can elect to have up to 10% of their annual wages withheld to purchase Quest Diagnostics common stock.  The purchase price of the stock is 95% of the market price of the Company's common stock on the last business day of each calendar month.  Under the ESPP, the maximum number of shares of Quest Diagnostics common stock which may be purchased by eligible employees is 9 million.  Approximately 216 thousand shares, 200 thousand shares and 225 thousand shares of common stock were purchased by eligible employees in 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Defined Contribution Plans &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company maintains qualified defined contribution plans covering substantially all of its employees.  The maximum Company matching contribution is 5% of eligible employee compensation.  During 2020, the Company temporarily suspended matching contributions for certain qualified defined contribution plans; matching contributions were reinstated in the third quarter of 2020.  The Company's expense for contributions to its defined contribution plans aggregated $95 million, $93 million and $64 million for 2022, 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Supplemental Deferred Compensation Plans&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company has a supplemental deferred compensation plan that is an unfunded, non-qualified plan that provides for certain management and highly compensated employees to defer up to 50% of their salary in excess of their defined contribution plan limits and for certain eligible employees, up to 95% of their variable incentive compensation.  The maximum Company matching contribution is 5% of eligible employee compensation.  The compensation deferred under this plan, together with Company matching amounts, are credited with earnings or losses measured by the mirrored rate of return on investments elected by plan participants.  Each plan participant is fully vested in all deferred compensation, Company match and earnings credited to their account.  The amounts accrued under the Company's deferred compensation plans were $68 million and $77 million as of December&#160;31, 2022 and 2021, respectively.  Although the Company is currently contributing all participant deferrals and matching amounts to a trust, the funds in this trust, totaling $68 million and $77 million as of December&#160;31, 2022 and 2021, respectively, are general assets of the Company and are subject to any claims of the Company's creditors. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company also offers certain employees the opportunity to participate in a non-qualified deferred compensation program.  The Company matches employee contributions equal to 25%, up to a maximum of $5 thousand per plan year.  A participant's deferrals, together with Company matching credits, are &#x201c;invested&#x201d; at the direction of the employee in a hypothetical portfolio of investments which are tracked by an administrator.  Each participant is fully vested in their deferred compensation and vests in Company matching contributions over a period of four years at 25% per year.  This plan was amended effective January 1, 2018 so that future deferrals under the plan may only be made by participants who made deferrals under the plan in 2017.  The amounts accrued under this plan were $52 million and $66 million as of December&#160;31, 2022 and 2021, respectively.  The Company purchases life insurance policies, with the Company named as beneficiary of the policies, for the purpose of funding the program's liability.  The cash surrender value of such life insurance policies was $46 million and $57 million as of December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;  For each of the years ended December&#160;31, 2022, 2021 and 2020, the Company's expense for matching contributions to these plans was not material.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <dgx:ContractualLifeOfStockOptionsAndOtherAwardsUnderSharedBasedCompensationPlans
      contextRef="i73f261b4c48d49e994b979548d66b542_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzEwMDE_15872580-fe82-4d76-ab1a-abfbe31c55eb">P10Y</dgx:ContractualLifeOfStockOptionsAndOtherAwardsUnderSharedBasedCompensationPlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzEzMDE_e119f39b-38eb-4135-a0bc-58767e028492">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="idca3214cc24d4df2accb5f1aee19ee63_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzE4NDc_195bf044-4c2b-4409-8335-29e8b815e2d1"
      unitRef="shares">79000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <dgx:ContractualLifeOfStockOptionsAndOtherAwardsUnderSharedBasedCompensationPlans
      contextRef="i8ad2a8b3713f4742b9996055520adc29_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzIzMjk_9839098f-5eb1-40b1-9e51-a7c14556f5ff">P10Y</dgx:ContractualLifeOfStockOptionsAndOtherAwardsUnderSharedBasedCompensationPlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i8ad2a8b3713f4742b9996055520adc29_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzI0MTE_059492df-946a-4b3b-8df0-667621c7b038">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ic372c83c8186472099c6d4d6461f9670_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzI1ODM_89be6491-b336-473e-9563-cd51b1b89847"
      unitRef="shares">2400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i8ad2a8b3713f4742b9996055520adc29_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzI2NjE_c2f5ca36-5e89-41b7-a1bf-1328ddb5e2ea"
      unitRef="shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i2e67e2f9ed6e486593285a490abea14a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzI2NzI_74dc2b46-636a-4208-b9ce-6994a23aedad"
      unitRef="shares">12000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i9a2a79f2f8da4bf5859f277ed9314d52_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzI2ODY_1c4b96c0-443f-49c1-b960-3a162490c99f"
      unitRef="shares">14000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzExMTgx_9c7232cd-c86e-4c79-9993-3729ec2f4a29">The weighted average assumptions used in valuing stock options granted in the periods presented were:  &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.219%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value at grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$26.80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$21.82&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$17.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.3%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected holding period, in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3MDBkOTYxOTZjNjE0Zjk3YTMwMTNiODc2YzQ1OTc5NS90YWJsZXJhbmdlOjcwMGQ5NjE5NmM2MTRmOTdhMzAxM2I4NzZjNDU5Nzk1XzItMS0xLTEtNzgyMTU_c800782a-4fbf-46b7-9ccc-d8902b778a68"
      unitRef="usdPerShare">26.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3MDBkOTYxOTZjNjE0Zjk3YTMwMTNiODc2YzQ1OTc5NS90YWJsZXJhbmdlOjcwMGQ5NjE5NmM2MTRmOTdhMzAxM2I4NzZjNDU5Nzk1XzItMy0xLTEtNzgyMTU_46278225-ecbc-4b40-9a65-579abf69915f"
      unitRef="usdPerShare">21.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3MDBkOTYxOTZjNjE0Zjk3YTMwMTNiODc2YzQ1OTc5NS90YWJsZXJhbmdlOjcwMGQ5NjE5NmM2MTRmOTdhMzAxM2I4NzZjNDU5Nzk1XzItNS0xLTEtNzgyMTU_a485929b-3c97-4ce3-96e5-3dea2414ca8e"
      unitRef="usdPerShare">17.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3MDBkOTYxOTZjNjE0Zjk3YTMwMTNiODc2YzQ1OTc5NS90YWJsZXJhbmdlOjcwMGQ5NjE5NmM2MTRmOTdhMzAxM2I4NzZjNDU5Nzk1XzMtMS0xLTEtNzgyMTU_d8df9e97-fb0f-489f-96f8-d1b2d9981e1e"
      unitRef="number">0.264</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3MDBkOTYxOTZjNjE0Zjk3YTMwMTNiODc2YzQ1OTc5NS90YWJsZXJhbmdlOjcwMGQ5NjE5NmM2MTRmOTdhMzAxM2I4NzZjNDU5Nzk1XzMtMy0xLTEtNzgyMTU_1627dc60-7665-46c6-85d3-703ae0c1a731"
      unitRef="number">0.256</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3MDBkOTYxOTZjNjE0Zjk3YTMwMTNiODc2YzQ1OTc5NS90YWJsZXJhbmdlOjcwMGQ5NjE5NmM2MTRmOTdhMzAxM2I4NzZjNDU5Nzk1XzMtNS0xLTEtNzgyMTU_2687908c-f63a-406f-a624-204ae4fb9a64"
      unitRef="number">0.203</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3MDBkOTYxOTZjNjE0Zjk3YTMwMTNiODc2YzQ1OTc5NS90YWJsZXJhbmdlOjcwMGQ5NjE5NmM2MTRmOTdhMzAxM2I4NzZjNDU5Nzk1XzQtMS0xLTEtNzgyMTU_54d2222d-9094-4f07-904a-53f8522ced6f"
      unitRef="number">0.020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3MDBkOTYxOTZjNjE0Zjk3YTMwMTNiODc2YzQ1OTc5NS90YWJsZXJhbmdlOjcwMGQ5NjE5NmM2MTRmOTdhMzAxM2I4NzZjNDU5Nzk1XzQtMy0xLTEtNzgyMTU_18263ed0-bc88-44e2-b2a0-5df395a4f03f"
      unitRef="number">0.020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3MDBkOTYxOTZjNjE0Zjk3YTMwMTNiODc2YzQ1OTc5NS90YWJsZXJhbmdlOjcwMGQ5NjE5NmM2MTRmOTdhMzAxM2I4NzZjNDU5Nzk1XzQtNS0xLTEtNzgyMTU_49ab281a-f20a-4f58-aa78-bfeb396c01e7"
      unitRef="number">0.020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3MDBkOTYxOTZjNjE0Zjk3YTMwMTNiODc2YzQ1OTc5NS90YWJsZXJhbmdlOjcwMGQ5NjE5NmM2MTRmOTdhMzAxM2I4NzZjNDU5Nzk1XzUtMS0xLTEtNzgyMTU_3638fff3-6a3d-4c9d-ab11-f01290816d8c"
      unitRef="number">0.020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3MDBkOTYxOTZjNjE0Zjk3YTMwMTNiODc2YzQ1OTc5NS90YWJsZXJhbmdlOjcwMGQ5NjE5NmM2MTRmOTdhMzAxM2I4NzZjNDU5Nzk1XzUtMy0xLTEtNzgyMTU_2beb1b49-6a46-4b48-a9f2-d8ea3fbc163e"
      unitRef="number">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3MDBkOTYxOTZjNjE0Zjk3YTMwMTNiODc2YzQ1OTc5NS90YWJsZXJhbmdlOjcwMGQ5NjE5NmM2MTRmOTdhMzAxM2I4NzZjNDU5Nzk1XzUtNS0xLTEtNzgyMTU_2eefc65a-ba05-4972-9b38-22b6f0ecfae2"
      unitRef="number">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3MDBkOTYxOTZjNjE0Zjk3YTMwMTNiODc2YzQ1OTc5NS90YWJsZXJhbmdlOjcwMGQ5NjE5NmM2MTRmOTdhMzAxM2I4NzZjNDU5Nzk1XzYtMS0xLTEtNzgyMTU_64628d22-74a3-4a1a-a0e8-e6329fb2d35b">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3MDBkOTYxOTZjNjE0Zjk3YTMwMTNiODc2YzQ1OTc5NS90YWJsZXJhbmdlOjcwMGQ5NjE5NmM2MTRmOTdhMzAxM2I4NzZjNDU5Nzk1XzYtMy0xLTEtNzgyMTU_c4c6dd59-ad35-4fc5-8a0a-d04dbb037733">P4Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3MDBkOTYxOTZjNjE0Zjk3YTMwMTNiODc2YzQ1OTc5NS90YWJsZXJhbmdlOjcwMGQ5NjE5NmM2MTRmOTdhMzAxM2I4NzZjNDU5Nzk1XzYtNS0xLTEtNzgyMTU_1255db4e-9976-4a92-83e4-908c45bedf66">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzExMjAx_b1e576c5-1dea-46c6-b42d-627f5ffc287f">The following summarizes the activity relative to stock option awards for 2022: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.457%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.457%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.457%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.459%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options forfeited and canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ie7fd18a6db5a4c6bb7e209edcc7ba998_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTpmZjcyZjUwOGE0OWM0OTM5OGUwN2Y4YjI0YmJiOWIxOS90YWJsZXJhbmdlOmZmNzJmNTA4YTQ5YzQ5Mzk4ZTA3ZjhiMjRiYmI5YjE5XzItMS0xLTEtNzgyMTU_cdc0c329-a924-4d1d-ba30-d2199f7a41bd"
      unitRef="shares">5700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ie7fd18a6db5a4c6bb7e209edcc7ba998_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTpmZjcyZjUwOGE0OWM0OTM5OGUwN2Y4YjI0YmJiOWIxOS90YWJsZXJhbmdlOmZmNzJmNTA4YTQ5YzQ5Mzk4ZTA3ZjhiMjRiYmI5YjE5XzItMy0xLTEtNzgyMTU_13f3c5ff-a4f8-4f20-92d7-b0017cb03ba5"
      unitRef="usdPerShare">96.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="iecaf266ba15d4c5da2f6be8c3e8e76bd_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTpmZjcyZjUwOGE0OWM0OTM5OGUwN2Y4YjI0YmJiOWIxOS90YWJsZXJhbmdlOmZmNzJmNTA4YTQ5YzQ5Mzk4ZTA3ZjhiMjRiYmI5YjE5XzMtMS0xLTEtNzgyMTU_d6babb25-2c05-4dbb-8cbc-6d0b08dd0cfa"
      unitRef="shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="iecaf266ba15d4c5da2f6be8c3e8e76bd_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTpmZjcyZjUwOGE0OWM0OTM5OGUwN2Y4YjI0YmJiOWIxOS90YWJsZXJhbmdlOmZmNzJmNTA4YTQ5YzQ5Mzk4ZTA3ZjhiMjRiYmI5YjE5XzMtMy0xLTEtNzgyMTU_b9cd396b-9aa0-4c29-aeec-b0c0770a973b"
      unitRef="usdPerShare">128.51</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iecaf266ba15d4c5da2f6be8c3e8e76bd_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTpmZjcyZjUwOGE0OWM0OTM5OGUwN2Y4YjI0YmJiOWIxOS90YWJsZXJhbmdlOmZmNzJmNTA4YTQ5YzQ5Mzk4ZTA3ZjhiMjRiYmI5YjE5XzQtMS0xLTEtNzgyMTU_1dfee15e-3b7d-4dd9-8946-a9dda72525ca"
      unitRef="shares">1400000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="iecaf266ba15d4c5da2f6be8c3e8e76bd_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTpmZjcyZjUwOGE0OWM0OTM5OGUwN2Y4YjI0YmJiOWIxOS90YWJsZXJhbmdlOmZmNzJmNTA4YTQ5YzQ5Mzk4ZTA3ZjhiMjRiYmI5YjE5XzQtMy0xLTEtNzgyMTU_7e11bfb4-5de4-4bfa-b8bb-dbbcc3a5d7f7"
      unitRef="usdPerShare">89.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="iecaf266ba15d4c5da2f6be8c3e8e76bd_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTpmZjcyZjUwOGE0OWM0OTM5OGUwN2Y4YjI0YmJiOWIxOS90YWJsZXJhbmdlOmZmNzJmNTA4YTQ5YzQ5Mzk4ZTA3ZjhiMjRiYmI5YjE5XzUtMS0xLTEtNzgyMTU_98684b93-e6d9-448b-b571-8d8783dd5495"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="iecaf266ba15d4c5da2f6be8c3e8e76bd_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTpmZjcyZjUwOGE0OWM0OTM5OGUwN2Y4YjI0YmJiOWIxOS90YWJsZXJhbmdlOmZmNzJmNTA4YTQ5YzQ5Mzk4ZTA3ZjhiMjRiYmI5YjE5XzUtMy0xLTEtNzgyMTU_37f18aa0-e1db-4c31-a7e0-c1a85e894f22"
      unitRef="usdPerShare">120.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i0c80ac26791d4a08826451cfe6ab22a4_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTpmZjcyZjUwOGE0OWM0OTM5OGUwN2Y4YjI0YmJiOWIxOS90YWJsZXJhbmdlOmZmNzJmNTA4YTQ5YzQ5Mzk4ZTA3ZjhiMjRiYmI5YjE5XzYtMS0xLTEtNzgyMTU_84c82d7e-13e5-48f2-9ee9-65855c394709"
      unitRef="shares">4700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i0c80ac26791d4a08826451cfe6ab22a4_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTpmZjcyZjUwOGE0OWM0OTM5OGUwN2Y4YjI0YmJiOWIxOS90YWJsZXJhbmdlOmZmNzJmNTA4YTQ5YzQ5Mzk4ZTA3ZjhiMjRiYmI5YjE5XzYtMy0xLTEtNzgyMTU_f0c85893-a7ad-411e-90a7-1a0d49bf29e4"
      unitRef="usdPerShare">101.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="iecaf266ba15d4c5da2f6be8c3e8e76bd_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTpmZjcyZjUwOGE0OWM0OTM5OGUwN2Y4YjI0YmJiOWIxOS90YWJsZXJhbmdlOmZmNzJmNTA4YTQ5YzQ5Mzk4ZTA3ZjhiMjRiYmI5YjE5XzYtNS0xLTEtNzgyMTU_ee03b3a4-0340-4236-a4c2-eea6803a29f0">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i0c80ac26791d4a08826451cfe6ab22a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTpmZjcyZjUwOGE0OWM0OTM5OGUwN2Y4YjI0YmJiOWIxOS90YWJsZXJhbmdlOmZmNzJmNTA4YTQ5YzQ5Mzk4ZTA3ZjhiMjRiYmI5YjE5XzYtNy0xLTEtNzgyMTU_f769d790-e394-4924-a4b5-0e0e1b749170"
      unitRef="usd">257000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i0c80ac26791d4a08826451cfe6ab22a4_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTpmZjcyZjUwOGE0OWM0OTM5OGUwN2Y4YjI0YmJiOWIxOS90YWJsZXJhbmdlOmZmNzJmNTA4YTQ5YzQ5Mzk4ZTA3ZjhiMjRiYmI5YjE5XzgtMS0xLTEtNzgyMTU_971feb37-1a11-47c6-9b11-90d0613e81a1"
      unitRef="shares">3500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i0c80ac26791d4a08826451cfe6ab22a4_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTpmZjcyZjUwOGE0OWM0OTM5OGUwN2Y4YjI0YmJiOWIxOS90YWJsZXJhbmdlOmZmNzJmNTA4YTQ5YzQ5Mzk4ZTA3ZjhiMjRiYmI5YjE5XzgtMy0xLTEtNzgyMTU_0f0412e5-3941-4661-8c31-cd9383332efa"
      unitRef="usdPerShare">94.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="iecaf266ba15d4c5da2f6be8c3e8e76bd_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTpmZjcyZjUwOGE0OWM0OTM5OGUwN2Y4YjI0YmJiOWIxOS90YWJsZXJhbmdlOmZmNzJmNTA4YTQ5YzQ5Mzk4ZTA3ZjhiMjRiYmI5YjE5XzgtNS0xLTEtNzgyMTU_7b1ffcbc-453b-4efc-9159-47256b0402c6">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i0c80ac26791d4a08826451cfe6ab22a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTpmZjcyZjUwOGE0OWM0OTM5OGUwN2Y4YjI0YmJiOWIxOS90YWJsZXJhbmdlOmZmNzJmNTA4YTQ5YzQ5Mzk4ZTA3ZjhiMjRiYmI5YjE5XzgtNy0xLTEtNzgyMTU_2ed57b4b-2502-4f2f-85cc-10f75f7a46ca"
      unitRef="usd">215000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i0c80ac26791d4a08826451cfe6ab22a4_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTpmZjcyZjUwOGE0OWM0OTM5OGUwN2Y4YjI0YmJiOWIxOS90YWJsZXJhbmdlOmZmNzJmNTA4YTQ5YzQ5Mzk4ZTA3ZjhiMjRiYmI5YjE5XzktMS0xLTEtNzgyMTU_e1e72e24-795b-4ada-ae27-bfdb567f9fec"
      unitRef="shares">4700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i0c80ac26791d4a08826451cfe6ab22a4_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTpmZjcyZjUwOGE0OWM0OTM5OGUwN2Y4YjI0YmJiOWIxOS90YWJsZXJhbmdlOmZmNzJmNTA4YTQ5YzQ5Mzk4ZTA3ZjhiMjRiYmI5YjE5XzktMy0xLTEtNzgyMTU_1ee7fe97-5342-4099-9d82-d503f277330e"
      unitRef="usdPerShare">101.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="iecaf266ba15d4c5da2f6be8c3e8e76bd_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTpmZjcyZjUwOGE0OWM0OTM5OGUwN2Y4YjI0YmJiOWIxOS90YWJsZXJhbmdlOmZmNzJmNTA4YTQ5YzQ5Mzk4ZTA3ZjhiMjRiYmI5YjE5XzktNS0xLTEtNzgyMTU_7f4246d9-e3b5-4742-8f37-b2bf9dc69d14">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i0c80ac26791d4a08826451cfe6ab22a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTpmZjcyZjUwOGE0OWM0OTM5OGUwN2Y4YjI0YmJiOWIxOS90YWJsZXJhbmdlOmZmNzJmNTA4YTQ5YzQ5Mzk4ZTA3ZjhiMjRiYmI5YjE5XzktNy0xLTEtNzgyMTU_ef7a5b06-058e-430c-a549-8b5e1c98458a"
      unitRef="usd">256000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="iecaf266ba15d4c5da2f6be8c3e8e76bd_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzQ3MjU_cce99557-7f5c-4074-aa03-b2ee9a8a6a14"
      unitRef="usd">70000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="if4c31ce97f0b4d679967210dea5d4ce8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzQ3Mjk_d8188320-eed7-4ac6-9d31-275d921f08e3"
      unitRef="usd">83000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i50195984ca72444b94471a4f11e6b415_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzQ3MzY_5cf6ec87-d641-47f3-aac9-996b46753ef4"
      unitRef="usd">113000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i0c80ac26791d4a08826451cfe6ab22a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzQ3Nzg_93f1d694-8c36-456d-aec3-c2f15b654683"
      unitRef="usd">5000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="iecaf266ba15d4c5da2f6be8c3e8e76bd_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzQ5MzE_c75e6204-fdcc-4f55-b186-0afe31c038d6">P1Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <dgx:ScheduleOfShareBasedPaymentAwardPerformanceShareUnitsValuationAssumptionsTableTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzExMTk0_f486bf42-f681-46ec-bd22-30864dbc46e7">The weighted average assumptions used in valuing performance share units with a market-based relative TSR goal in the periods presented were:  &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.289%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value at grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$130.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$150.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$144.03&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.1%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</dgx:ScheduleOfShareBasedPaymentAwardPerformanceShareUnitsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0800ecbb791747f4ad71925d6e8c45e7_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo5OTA5ODM4M2RiNGM0OWYxYWZhOGU5YzI0Mjg2Njk1OC90YWJsZXJhbmdlOjk5MDk4MzgzZGI0YzQ5ZjFhZmE4ZTljMjQyODY2OTU4XzItMS0xLTEtNzgyMTU_564f51ef-ab25-41bf-96ef-0c7791ffdf55"
      unitRef="usdPerShare">130.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i94c763d3175548ab80e291e8d327ea98_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo5OTA5ODM4M2RiNGM0OWYxYWZhOGU5YzI0Mjg2Njk1OC90YWJsZXJhbmdlOjk5MDk4MzgzZGI0YzQ5ZjFhZmE4ZTljMjQyODY2OTU4XzItMy0xLTEtNzgyMTU_3136cb4c-e567-4757-a007-8396035a7d88"
      unitRef="usdPerShare">150.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i066c181da1cc4104bc13332037ebc51c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo5OTA5ODM4M2RiNGM0OWYxYWZhOGU5YzI0Mjg2Njk1OC90YWJsZXJhbmdlOjk5MDk4MzgzZGI0YzQ5ZjFhZmE4ZTljMjQyODY2OTU4XzItNS0xLTEtODc3NDM_d3423e9c-75eb-4255-9bba-a4a81950f176"
      unitRef="usdPerShare">144.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i0800ecbb791747f4ad71925d6e8c45e7_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo5OTA5ODM4M2RiNGM0OWYxYWZhOGU5YzI0Mjg2Njk1OC90YWJsZXJhbmdlOjk5MDk4MzgzZGI0YzQ5ZjFhZmE4ZTljMjQyODY2OTU4XzMtMS0xLTEtNzgyMTU_0258d55d-39f2-49d1-a99e-55d09ae220b3"
      unitRef="number">0.299</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i94c763d3175548ab80e291e8d327ea98_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo5OTA5ODM4M2RiNGM0OWYxYWZhOGU5YzI0Mjg2Njk1OC90YWJsZXJhbmdlOjk5MDk4MzgzZGI0YzQ5ZjFhZmE4ZTljMjQyODY2OTU4XzMtMy0xLTEtNzgyMTU_71867c5d-8e47-4139-8bbb-4c6ab2b17b16"
      unitRef="number">0.302</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i066c181da1cc4104bc13332037ebc51c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo5OTA5ODM4M2RiNGM0OWYxYWZhOGU5YzI0Mjg2Njk1OC90YWJsZXJhbmdlOjk5MDk4MzgzZGI0YzQ5ZjFhZmE4ZTljMjQyODY2OTU4XzMtNS0xLTEtODc3NTg_79f003e1-1a4c-4e2d-b79b-c4369dc71ded"
      unitRef="number">0.201</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i0800ecbb791747f4ad71925d6e8c45e7_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo5OTA5ODM4M2RiNGM0OWYxYWZhOGU5YzI0Mjg2Njk1OC90YWJsZXJhbmdlOjk5MDk4MzgzZGI0YzQ5ZjFhZmE4ZTljMjQyODY2OTU4XzQtMS0xLTEtNzgyMTU_f148e0bb-d866-41ac-aa90-bc4030c8c73d"
      unitRef="number">0.020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i94c763d3175548ab80e291e8d327ea98_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo5OTA5ODM4M2RiNGM0OWYxYWZhOGU5YzI0Mjg2Njk1OC90YWJsZXJhbmdlOjk5MDk4MzgzZGI0YzQ5ZjFhZmE4ZTljMjQyODY2OTU4XzQtMy0xLTEtNzgyMTU_46d14c7d-427a-46bd-94b7-263db0045ed0"
      unitRef="number">0.020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i066c181da1cc4104bc13332037ebc51c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo5OTA5ODM4M2RiNGM0OWYxYWZhOGU5YzI0Mjg2Njk1OC90YWJsZXJhbmdlOjk5MDk4MzgzZGI0YzQ5ZjFhZmE4ZTljMjQyODY2OTU4XzQtNS0xLTEtODc3NjY_9693a782-f90f-4d6e-a2f6-836e6eac5920"
      unitRef="number">0.020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i0800ecbb791747f4ad71925d6e8c45e7_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo5OTA5ODM4M2RiNGM0OWYxYWZhOGU5YzI0Mjg2Njk1OC90YWJsZXJhbmdlOjk5MDk4MzgzZGI0YzQ5ZjFhZmE4ZTljMjQyODY2OTU4XzUtMS0xLTEtNzgyMTU_9aa0d117-6170-4292-82b8-9c4fe48efe87"
      unitRef="number">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i94c763d3175548ab80e291e8d327ea98_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo5OTA5ODM4M2RiNGM0OWYxYWZhOGU5YzI0Mjg2Njk1OC90YWJsZXJhbmdlOjk5MDk4MzgzZGI0YzQ5ZjFhZmE4ZTljMjQyODY2OTU4XzUtMy0xLTEtNzgyMTU_ade613b7-f32e-4042-94cc-823ccb80dab7"
      unitRef="number">0.002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i066c181da1cc4104bc13332037ebc51c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo5OTA5ODM4M2RiNGM0OWYxYWZhOGU5YzI0Mjg2Njk1OC90YWJsZXJhbmdlOjk5MDk4MzgzZGI0YzQ5ZjFhZmE4ZTljMjQyODY2OTU4XzUtNS0xLTEtODc3NzQ_218f458c-c0d9-41ea-8ce7-cc3165d43566"
      unitRef="number">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzExMTg0_ffb8e215-9fe9-4631-9d6e-ecb258d31c5f">The following summarizes the activity relative to stock awards, including restricted stock units and performance share units, for 2022, 2021 and 2020: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares outstanding, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares forfeited and canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares outstanding, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ia3870621ff0c4e94a8c0db30f0a94950_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzMtMS0xLTEtNzgyMTU_5710bbde-3fa3-4a73-be04-a43bf0aa06f8"
      unitRef="shares">1000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ia3870621ff0c4e94a8c0db30f0a94950_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzMtMy0xLTEtNzgyMTU_ff5a8a3d-c839-4aee-a867-60d3268ddcae"
      unitRef="usdPerShare">107.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i2a773294c9f247f4b61dc287d74d2f4a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzMtNS0xLTEtNzgyMTU_17d81d3b-8c8e-4cae-b781-8bd09743caec"
      unitRef="shares">1000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i2a773294c9f247f4b61dc287d74d2f4a_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzMtNy0xLTEtNzgyMTU_7b1785a7-5f2b-41c5-bbf1-81f96b0c11da"
      unitRef="usdPerShare">100.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i0f2ed080770b4b799d26a7b0773c6afa_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzMtOS0xLTEtNzgyMTU_2fc38904-b105-4dbf-9349-62cc7a7263f9"
      unitRef="shares">1000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i0f2ed080770b4b799d26a7b0773c6afa_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzMtMTEtMS0xLTc4MjE1_a35a56cf-a390-49ab-a54d-3120e9eff442"
      unitRef="usdPerShare">93.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i532fc9e0076b4da684698168d99ecf57_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzQtMS0xLTEtNzgyMTU_76e243f6-c048-44ee-a453-813ae89d7a1c"
      unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i532fc9e0076b4da684698168d99ecf57_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzQtMy0xLTEtNzgyMTU_e9dbe980-3417-4e10-a460-a0660fd9d0e7"
      unitRef="usdPerShare">128.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i0859d2d438a749bd85c7c9580402ecc9_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzQtNS0xLTEtNzgyMTU_a6c4ad70-60a8-4301-ab21-a54ad8d3aaf3"
      unitRef="shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0859d2d438a749bd85c7c9580402ecc9_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzQtNy0xLTEtNzgyMTU_81e7711c-4127-4193-a3ef-bffbdb1ce43d"
      unitRef="usdPerShare">122.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i3510a40b3f92452ca5683687a18ac5b5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzQtOS0xLTEtNzgyMTU_6c52bd37-b8e0-43a5-9c16-39ffd5641404"
      unitRef="shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3510a40b3f92452ca5683687a18ac5b5_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzQtMTEtMS0xLTc4MjE1_9f549c0a-7aeb-4f29-9bc4-4b94fd4aa607"
      unitRef="usdPerShare">112.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i532fc9e0076b4da684698168d99ecf57_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzUtMS0xLTEtNzgyMTU_9e13cb85-6870-49e0-8013-2a54eafd881c"
      unitRef="shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i532fc9e0076b4da684698168d99ecf57_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzUtMy0xLTEtNzgyMTU_402e74f5-986d-4b94-98d6-3ddac9c2b0b6"
      unitRef="usdPerShare">92.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i0859d2d438a749bd85c7c9580402ecc9_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzUtNS0xLTEtNzgyMTU_4e68b4ac-749b-43f5-a207-9ef48fec5eeb"
      unitRef="shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0859d2d438a749bd85c7c9580402ecc9_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzUtNy0xLTEtNzgyMTU_5536e51a-7f2d-4cf1-9abc-03776df54bf0"
      unitRef="usdPerShare">103.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i3510a40b3f92452ca5683687a18ac5b5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzUtOS0xLTEtNzgyMTU_7d791cee-abbd-4464-ad8d-ebb1e8b0a65d"
      unitRef="shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3510a40b3f92452ca5683687a18ac5b5_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzUtMTEtMS0xLTc4MjE1_41e06773-770d-434f-8e25-101b3733bd62"
      unitRef="usdPerShare">96.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i532fc9e0076b4da684698168d99ecf57_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzYtMS0xLTEtNzgyMTU_37a3531f-faf0-4dac-88b9-ea4abb5b369c"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i532fc9e0076b4da684698168d99ecf57_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzYtMy0xLTEtNzgyMTU_0c4899ef-fd9d-45d8-acd9-18b882168cb4"
      unitRef="usdPerShare">122.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i0859d2d438a749bd85c7c9580402ecc9_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzYtNS0xLTEtNzgyMTU_c0e5a618-f8b7-41da-98a5-73c669c2b561"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i0859d2d438a749bd85c7c9580402ecc9_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzYtNy0xLTEtNzgyMTU_e23fb7dc-95df-4add-838c-9c1c2ea8de9d"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i3510a40b3f92452ca5683687a18ac5b5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzYtOS0xLTEtNzgyMTU_d7233420-4f50-415f-8b79-b60f4dc70001"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i3510a40b3f92452ca5683687a18ac5b5_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzYtMTEtMS0xLTc4MjE1_eab99d09-9d9c-470a-8f6b-d009235f0fc7"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i173f1992d3144e31a2d74876e89770d5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzgtMS0xLTEtNzgyMTU_e3ae4c97-9adb-4323-b5b5-a8d30a82e94d"
      unitRef="shares">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i173f1992d3144e31a2d74876e89770d5_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzgtMy0xLTEtNzgyMTU_c892d5c7-c794-4261-aab0-1172bd9ff9f7"
      unitRef="usdPerShare">122.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ia3870621ff0c4e94a8c0db30f0a94950_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzgtNS0xLTEtNzgyMTU_0d2f6109-bca1-4f2a-872e-c157b63a0292"
      unitRef="shares">1000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ia3870621ff0c4e94a8c0db30f0a94950_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzgtNy0xLTEtNzgyMTU_0b409f6a-3aca-4d02-b51a-73ebcd61d99d"
      unitRef="usdPerShare">107.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i2a773294c9f247f4b61dc287d74d2f4a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzgtOS0xLTEtNzgyMTU_0e21aeda-1e2f-4501-91f9-2ac346c9f56d"
      unitRef="shares">1000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i2a773294c9f247f4b61dc287d74d2f4a_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90YWJsZTo3ODZhNzUwNGMxZjc0OGY1YjAzMDE5YmY5OGMwZmE3OC90YWJsZXJhbmdlOjc4NmE3NTA0YzFmNzQ4ZjViMDMwMTliZjk4YzBmYTc4XzgtMTEtMS0xLTc4MjE1_33188ee4-e9d1-4c26-9522-273c55119f0c"
      unitRef="usdPerShare">100.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i173f1992d3144e31a2d74876e89770d5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzY0MTY_c4a7dde0-878c-4ef5-8015-f479b9d26e6a"
      unitRef="usd">40000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i532fc9e0076b4da684698168d99ecf57_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzY1Njk_0a7e22c4-48f3-4e3a-a539-e37ec413c9b7">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i532fc9e0076b4da684698168d99ecf57_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzY2MTI_921cada2-4b14-4813-aa01-20dcc95b427c"
      unitRef="usd">72000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i0859d2d438a749bd85c7c9580402ecc9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzY2MTY_79cfb5e4-c80e-4b87-acdc-44adb910c3dc"
      unitRef="usd">59000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i3510a40b3f92452ca5683687a18ac5b5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzY2MjM_40896c10-c16d-4a0d-83d4-fd0661c6ef82"
      unitRef="usd">37000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensation
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzcxMzk_404a4ca8-f7fa-4d9f-bace-860a045e2ac6"
      unitRef="usd">77000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzcxNDM_ac9d1257-17e4-4391-a47a-1bbe238d3749"
      unitRef="usd">79000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzcxNTA_16ee9b94-02bd-4041-931d-920e2c1d942e"
      unitRef="usd">97000000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzcyOTc_cd5f9a74-83bc-48f1-9887-c305fb5d6da6"
      unitRef="usd">27000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzczMDE_29468238-ad3c-42cd-9fe4-e38c1b0523e9"
      unitRef="usd">32000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzczMDg_b2f2fd95-4462-4bbd-bf3e-e8e3fac07e78"
      unitRef="usd">39000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <dgx:Sharebasedcompensationexcesstaxbenefitamount
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzc0NTI_de995712-801a-4bb3-999c-2d88a2992589"
      unitRef="usd">14000000</dgx:Sharebasedcompensationexcesstaxbenefitamount>
    <dgx:Sharebasedcompensationexcesstaxbenefitamount
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzc0NTY_02d1ce49-42d1-4d2a-94ac-ede01dc4cbd8"
      unitRef="usd">19000000</dgx:Sharebasedcompensationexcesstaxbenefitamount>
    <dgx:Sharebasedcompensationexcesstaxbenefitamount
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzc0NjM_658f5f6c-15ef-45fa-b253-57b7995bb7f2"
      unitRef="usd">23000000</dgx:Sharebasedcompensationexcesstaxbenefitamount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="i9cf6871cc3fb4fc7964b07d9e8dd6df6_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzc2Mjc_4d6d6ee4-f59b-42c7-bcf3-6888d70fc456"
      unitRef="number">0.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <dgx:MarketPriceOfCompanyStockIssuedAtDiscountUnderEspp
      contextRef="i0d352bd28a45443e80612ac16c512e54_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzc3NDE_f2174d9c-ec83-4a70-9b6e-7dd2bb516564"
      unitRef="number">0.95</dgx:MarketPriceOfCompanyStockIssuedAtDiscountUnderEspp>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i9cf6871cc3fb4fc7964b07d9e8dd6df6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzc5NzE_f4a343c1-d48a-4a40-aaa5-e75d086077e2"
      unitRef="shares">9000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i0d352bd28a45443e80612ac16c512e54_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzc5OTA_c4240bff-03a6-4805-940d-6ea649f8d222"
      unitRef="shares">216000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i061fddd15a744d87ae3c69a6d735a09b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzgwMDE_21426887-9aae-48f2-9335-830f636cc694"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i9bef679f049f4a7589e81ff16e6faf39_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzgwMTU_b3e16ad5-b6b4-4045-b63c-9b5d405c84f0"
      unitRef="shares">225000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="i4c9530356f3242cdb77f114a2aa32961_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzgyOTI_c31a3134-2669-45ad-826a-0283ace33fc9"
      unitRef="number">0.05</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzg2MDY_c154c01b-a0e0-44b4-b901-81b6a339fcec"
      unitRef="usd">95000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzg2MTA_d1fc1d05-44e5-4004-bbb3-78d935ebd3af"
      unitRef="usd">93000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzg2MTc_5c3a63e5-089e-42dd-817e-cd8860097187"
      unitRef="usd">64000000</us-gaap:DefinedContributionPlanCostRecognized>
    <dgx:SupplementalDeferredCompensationPlanSalaryDeferral
      contextRef="i3984e240129249f2b9f78c9c4f3a1818_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzg4ODI_ebb4c9ac-6041-4e00-93e3-73b16a44f4e5"
      unitRef="number">0.50</dgx:SupplementalDeferredCompensationPlanSalaryDeferral>
    <dgx:SupplementalDeferredCompensationPlanVariableIncentiveCompensationDeferral
      contextRef="i3984e240129249f2b9f78c9c4f3a1818_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzg5OTU_988d7b04-cd0e-481e-b603-0231729190d6"
      unitRef="number">0.95</dgx:SupplementalDeferredCompensationPlanVariableIncentiveCompensationDeferral>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="i6bf42c10d101437f98e7eac589472f72_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzkwODY_87a2c622-eb42-4847-bacd-863ba652aed9"
      unitRef="number">0.05</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DeferredCompensationArrangementWithIndividualRecordedLiability
      contextRef="i70242db0befe4ca299c35c570e02ae70_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzk2Njg_5d95606d-09e2-4ced-b842-666a13926c5f"
      unitRef="usd">68000000</us-gaap:DeferredCompensationArrangementWithIndividualRecordedLiability>
    <us-gaap:DeferredCompensationArrangementWithIndividualRecordedLiability
      contextRef="id56d32d3a5174c0f9f67b3b882cf8826_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzk2NzU_1ea7129f-bd66-492d-8658-29d93907cd37"
      unitRef="usd">77000000</us-gaap:DeferredCompensationArrangementWithIndividualRecordedLiability>
    <dgx:FundsinatrustpertainingtoallparticipantdeferralsandcompanymatchingamountsrelatedtotheSDCP
      contextRef="i70242db0befe4ca299c35c570e02ae70_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzk4NTA_218d08a5-6dcc-4604-86bb-fd065aefc0de"
      unitRef="usd">68000000</dgx:FundsinatrustpertainingtoallparticipantdeferralsandcompanymatchingamountsrelatedtotheSDCP>
    <dgx:FundsinatrustpertainingtoallparticipantdeferralsandcompanymatchingamountsrelatedtotheSDCP
      contextRef="id56d32d3a5174c0f9f67b3b882cf8826_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzk4NTc_4dbea03b-78cc-45cd-9f02-24c5c20c4f84"
      unitRef="usd">77000000</dgx:FundsinatrustpertainingtoallparticipantdeferralsandcompanymatchingamountsrelatedtotheSDCP>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="icf5e6c8d02cb4230b46883164090ae6c_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzEwMTYy_bc804c10-2a12-4251-b49a-45554771dcef"
      unitRef="number">0.25</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer
      contextRef="idd8f2aef04fc44bc86451fb4062847cc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzEwMTg1_cedc7909-4a14-4bc2-ab3c-a197124bc726"
      unitRef="usd">5000</us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer>
    <us-gaap:DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1
      contextRef="icf5e6c8d02cb4230b46883164090ae6c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzEwNTI3_57c0a2a9-2c34-4b49-9532-55c834f79050">P4Y</us-gaap:DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1>
    <dgx:SdcpIiGradedVestingPercentage
      contextRef="icf5e6c8d02cb4230b46883164090ae6c_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzEwNTMz_c92d2672-84a6-4704-a4a2-771cee74bfea"
      unitRef="number">0.25</dgx:SdcpIiGradedVestingPercentage>
    <us-gaap:DeferredCompensationArrangementWithIndividualRecordedLiability
      contextRef="ie1765ce7329f47f2a55b699f67f431bf_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzEwNzUz_e85c8398-fdb5-4aa3-97d9-1accf0c9e678"
      unitRef="usd">52000000</us-gaap:DeferredCompensationArrangementWithIndividualRecordedLiability>
    <us-gaap:DeferredCompensationArrangementWithIndividualRecordedLiability
      contextRef="i1b69605427b24c3290b808836c99ad60_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzEwNzYw_ea4d482f-2d46-4173-9ce1-fce285395dac"
      unitRef="usd">66000000</us-gaap:DeferredCompensationArrangementWithIndividualRecordedLiability>
    <us-gaap:CashSurrenderValueFairValueDisclosure
      contextRef="ie1765ce7329f47f2a55b699f67f431bf_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzExMDEx_01d76ff7-cffe-4066-a5fb-66e014a03e86"
      unitRef="usd">46000000</us-gaap:CashSurrenderValueFairValueDisclosure>
    <us-gaap:CashSurrenderValueFairValueDisclosure
      contextRef="i1b69605427b24c3290b808836c99ad60_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjYvZnJhZzozZTE4ZmJkZTg3OGY0MTYyYWQ0MzVmZTU1ZTVkOWNjZC90ZXh0cmVnaW9uOjNlMThmYmRlODc4ZjQxNjJhZDQzNWZlNTVlNWQ5Y2NkXzExMDE4_1e92db5c-99ae-48d5-b1f7-acca755c3451"
      unitRef="usd">57000000</us-gaap:CashSurrenderValueFairValueDisclosure>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjkvZnJhZzoxMjE0Y2U5MTA2NmE0ZjdhODFiMWQ1ZDU3MDliOTUxYy90ZXh0cmVnaW9uOjEyMTRjZTkxMDY2YTRmN2E4MWIxZDVkNTcwOWI5NTFjXzEwNjMw_1f524227-9f4e-4a77-a530-565bfce76da4">COMMITMENTS AND CONTINGENCIES &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Letters of Credit and Contractual Obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company can issue letters of credit under its Secured Receivables Credit Facility and Senior Unsecured Revolving Credit Facility (see Note 14).  In support of its risk management program, to ensure the Company&#x2019;s performance or payment to third parties, $70 million in letters of credit under the Secured Receivables Credit Facility were outstanding as of December&#160;31, 2022.  The letters of credit primarily represent collateral for current and future automobile liability and workers&#x2019; compensation loss payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company has certain noncancelable commitments, primarily under take-or-pay arrangements, to purchase products or services from various suppliers, mainly for consulting and other service agreements, and standing orders to purchase reagents and other laboratory supplies.  As of December&#160;31, 2022, the approximate total future purchase commitments are $384 million, of which $125 million are expected to be incurred in 2023, $166 million are expected to be incurred in 2024 through 2025 and the balance thereafter. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Billing and Collection Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;In September 2016, the Company entered into a ten-year agreement with a third party to outsource its billing and  related operations for the majority of the Company&#x2019;s revenues.  Services under the agreement commenced during the fourth quarter of 2016.  The agreement includes an annual fee, which is subject to adjustment based on certain changes in the Company's requisition volume and the achievement of various performance metrics.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Lease Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company remains subject to contingent obligations under certain real estate leases, including real estate leases that were entered into by certain predecessor companies of a subsidiary prior to the Company's acquisition of the subsidiary.  While over the course of many years, the title to certain properties and interest in the subject leases have been transferred to third parties and the subject leases have been amended several times by such third parties, the lessors have not formally released the subsidiary predecessor companies from their original obligations under the leases and therefore remain contingently liable in the event of default.  The remaining terms of the lease obligations and the Company's corresponding indemnifications range up to 25 years.  The lease payments under certain leases are subject to market value adjustments and contingent rental payments and therefore, the total contingent obligations under the leases cannot be precisely determined but are likely to total several hundred million dollars.  A claim against the Company would be made only upon the current lessee's default and, in certain cases, after a series of claims and corresponding defaults by third parties that precede the Company in the order of liability.  The Company also has certain indemnification rights from other parties to recover losses in the event of default on the lease obligations.  The Company believes that the likelihood of its performance under these contingent obligations is remote and no liability has been recorded for any potential payments under the contingent lease obligations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Certain Legal Matters&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;&#160;The Company may incur losses associated with these proceedings and investigations, but it is not possible to estimate the amount of loss or range of loss, if any, that might result from adverse judgments, settlements, fines, penalties, or other resolution of these proceedings and investigations based on the stage of these proceedings and investigations, the absence of specific allegations as to alleged damages, the uncertainty as to the certification of a class or classes and the size of any certified class, if applicable, and/or the lack of resolution of significant factual and legal issues.  The Company has insurance coverage rights in place (limited in amount; subject to deductible) for certain potential costs and liabilities related to these proceedings and investigations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;401(k) Plan Lawsuit&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;&#160;In 2020, two putative class action lawsuits were filed in the U.S. District Court for New Jersey against the Company and other defendants with respect to the Company&#x2019;s 401(k) plan. The complaint alleges, among other things, that the fiduciaries of the 401(k) plan breached their duties by failing to disclose the expenses and risks of plan investment options, allowing unreasonable administration expenses to be charged to plan participants, and selecting and retaining high cost and poor performing investments.  In October 2020, the court consolidated the two lawsuits under the caption &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;In re: Quest Diagnostics ERISA Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; and plaintiffs filed a consolidated amended complaint.  In May 2021, the court denied the Company's motion to dismiss the complaint.  Discovery is proceeding.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;AMCA Data Security Incident&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;&#160;On June 3, 2019, the Company reported that Retrieval-Masters Creditors Bureau, Inc./American Medical Collection Agency (&#x201c;AMCA&#x201d;) had informed the Company and Optum360 LLC that an unauthorized user had access to AMCA&#x2019;s system between August 1, 2018 and March 30, 2019 (the &#x201c;AMCA Data Security Incident&#x201d;).  Optum360 provides revenue management services to the Company, and AMCA provided debt collection services to Optum360.  AMCA first informed the Company of the AMCA Data Security Incident on May 14, 2019.  AMCA&#x2019;s affected system included financial information (e.g., credit card numbers and bank account information), medical information and other personal information (e.g., social security numbers). Test results were not included.  Neither Optum360&#x2019;s nor the Company&#x2019;s systems or databases were involved in the incident. AMCA also informed the Company that information pertaining to other laboratories&#x2019; customers was also affected.  Following announcement of the AMCA Data Security Incident, AMCA sought protection under the U.S. bankruptcy laws.  The bankruptcy proceeding has been dismissed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Numerous putative class action lawsuits were filed against the Company related to the AMCA Data Security Incident.  The U.S. Judicial Panel on Multidistrict Litigation transferred the cases that were then still pending to, and consolidated them for pre-trial proceedings in, the U.S. District Court for New Jersey.  In November 2019, the plaintiffs in the multidistrict proceeding filed a consolidated putative class action complaint against the Company and Optum360 that named additional individuals as plaintiffs and that asserted a variety of common law and statutory claims in connection with the AMCA Data Security Incident.  In January 2020, the Company moved to dismiss the consolidated complaint; the motion to dismiss was granted in part and denied in part.  Discovery is proceeding.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;In addition, the Company has been notified that numerous state attorney general offices were investigating or otherwise seeking information and/or documents, and that certain U.S. senators were seeking information, from the Company related to the AMCA Data Security Incident.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ReproSource Fertility Diagnostics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:72pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&#160;&#160;&#160;ReproSource Fertility Diagnostics, Inc. (&#x201c;ReproSource&#x201d;), a subsidiary of the Company, is subject to two putative class action lawsuits in the U.S. District Court for Massachusetts: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Bickham v. ReproSource Fertility Diagnostics, Inc. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Gordon v. ReproSource Fertility Diagnostics, Inc.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; The class actions are related to a data security incident that occurred in August 2021 in which an unauthorized party may have accessed or acquired protected health information and personally identifiable information of ReproSource patients. The complaints generally allege that ReproSource, among other claims, failed to adequately safeguard customers&#x2019; private information. ReproSource has moved to dismiss both complaints.  A third putative class action pertaining to the same data security incident, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Trouville v. ReproSource Fertility Diagnostics, Inc.,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; was filed in California state court.  The Company removed the case to federal court and moved to dismiss and/or transfer it to U.S. District Court for Massachusetts.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;                       &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cole, et. al v. Quest Diagnostics Incorporated&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#160;&#160;&#160;&#160;The Company is&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;subject to a putative class action entitled &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Cole, et al. v Quest Diagnostics Incorporated&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, which was filed in the U. S. District Court for the Eastern District of California, for allegedly conspiring with Facebook to track customers&#x2019; internet communications on Company web platforms without authorization, in violation of the California Invasion of Privacy Act and the California Confidentiality of Medical Information Act&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;  The complaint alleged that the Company&#x2019;s actions were an invasion of privacy and contributed to a loss of value in plaintiffs&#x2019; personally identifiable information.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company moved to dismiss the case or, in the alternative, transfer venue to the U.S. District Court for New Jersey.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Subsequently, plaintiffs filed an amended complaint.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;Other Legal Matters&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;In the normal course of business, the Company has been named, from time to time, as a defendant in various legal actions, including arbitrations, class actions and other litigation, arising in connection with the Company's activities as a provider of diagnostic testing, information and services.  These actions could involve claims for substantial compensatory and/or punitive damages or claims for indeterminate amounts of damages, and could have an adverse impact on the Company's client base and reputation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company is also involved, from time to time, in other reviews, investigations and proceedings by governmental agencies regarding the Company's business which may result in adverse judgments, settlements, fines, penalties, injunctions or other relief. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;In addition, certain federal and state statutes, including the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; provisions of the federal False Claims Act, allow private individuals to bring lawsuits against healthcare companies on behalf of the government or private payers.  The Company is aware of lawsuits, and from time to time has received subpoenas, related to billing or other practices based on the False Claims Act or other federal and state statutes, regulations or other laws.  The Company understands that there may be other pending qui tam claims brought by former employees or other "whistle blowers" as to which the Company cannot determine the extent of any potential liability.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Management cannot predict the outcome of such matters.  Although management does not anticipate that the ultimate outcome of such matters will have a material adverse effect on the Company's financial condition, given the high degree of judgment involved in establishing loss estimates related to these types of matters, the outcome of such matters may be material to the Company's consolidated results of operations or cash flows in the period in which the impact of such matters is determined or paid.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;These matters are in different stages.  Some of these matters are in their early stages.  Matters may involve responding to and cooperating with various government investigations and related subpoenas.  As of December&#160;31, 2022, the Company does not believe that material losses related to legal matters are probable.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Reserves for legal matters totaled $2 million and $4&#160;million as of December&#160;31, 2022 and December&#160;31, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reserves for General and Professional Liability Claims&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&#160;&#160;&#160;&#160;As a general matter, providers of clinical testing services may be subject to lawsuits alleging negligence or other similar legal claims.  These suits could involve claims for substantial damages.  Any professional liability litigation could also have an adverse impact on the Company's client base and reputation.  The Company maintains various liability insurance coverages for, among other things, claims that could result from providing, or failing to provide, clinical testing services, including inaccurate testing results, and other exposures.  The Company's insurance coverage limits its maximum exposure on individual claims; however, the Company is essentially self-insured for a significant portion of these claims.  Reserves for such matters, including those associated with both asserted and incurred but not reported claims, are established on an undiscounted basis by considering actuarially determined losses based upon the Company's historical and projected loss experience.  Such reserves totaled $169 million and $159 million as of December&#160;31, 2022 and December&#160;31, 2021, respectively.  Management believes that established reserves and present insurance coverage are sufficient to cover currently estimated exposures.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="ie85140ba27db46a5a05080eae640b00a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjkvZnJhZzoxMjE0Y2U5MTA2NmE0ZjdhODFiMWQ1ZDU3MDliOTUxYy90ZXh0cmVnaW9uOjEyMTRjZTkxMDY2YTRmN2E4MWIxZDVkNTcwOWI5NTFjXzM0OQ_43d6b829-4132-471a-92e1-c61d1f7adcf7"
      unitRef="usd">70000000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjkvZnJhZzoxMjE0Y2U5MTA2NmE0ZjdhODFiMWQ1ZDU3MDliOTUxYy90ZXh0cmVnaW9uOjEyMTRjZTkxMDY2YTRmN2E4MWIxZDVkNTcwOWI5NTFjXzkyNg_94ad311a-460e-4f82-8949-1d9f97436e4c"
      unitRef="usd">384000000</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjkvZnJhZzoxMjE0Y2U5MTA2NmE0ZjdhODFiMWQ1ZDU3MDliOTUxYy90ZXh0cmVnaW9uOjEyMTRjZTkxMDY2YTRmN2E4MWIxZDVkNTcwOWI5NTFjXzkzOQ_bf0b2e03-9a0f-4d4b-88ea-c962046aaac4"
      unitRef="usd">125000000</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary>
    <dgx:UnrecordedUnconditionalPurchaseObligationDuewithinTwoandThreeYears
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjkvZnJhZzoxMjE0Y2U5MTA2NmE0ZjdhODFiMWQ1ZDU3MDliOTUxYy90ZXh0cmVnaW9uOjEyMTRjZTkxMDY2YTRmN2E4MWIxZDVkNTcwOWI5NTFjXzk3Nw_8f2d1a76-885a-456e-9aa1-4db1dc42f8a0"
      unitRef="usd">166000000</dgx:UnrecordedUnconditionalPurchaseObligationDuewithinTwoandThreeYears>
    <dgx:AgreementtoOutsourceBillingandCollectionFunction
      contextRef="ibb34a0a60bd547a58f8634a55d3ea6e9_D20160901-20160930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjkvZnJhZzoxMjE0Y2U5MTA2NmE0ZjdhODFiMWQ1ZDU3MDliOTUxYy90ZXh0cmVnaW9uOjEyMTRjZTkxMDY2YTRmN2E4MWIxZDVkNTcwOWI5NTFjXzI3NDg3NzkwOTE0Nzc_a2a47e31-8a00-4662-ab45-50416b571d4d">P10Y</dgx:AgreementtoOutsourceBillingandCollectionFunction>
    <dgx:RemainingTermsofContingentLeaseObligationsMaximum
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjkvZnJhZzoxMjE0Y2U5MTA2NmE0ZjdhODFiMWQ1ZDU3MDliOTUxYy90ZXh0cmVnaW9uOjEyMTRjZTkxMDY2YTRmN2E4MWIxZDVkNTcwOWI5NTFjXzIzMjI_66bee583-07bd-4283-9b81-ed89ef325f6f">P25Y</dgx:RemainingTermsofContingentLeaseObligationsMaximum>
    <us-gaap:LitigationReserve
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjkvZnJhZzoxMjE0Y2U5MTA2NmE0ZjdhODFiMWQ1ZDU3MDliOTUxYy90ZXh0cmVnaW9uOjEyMTRjZTkxMDY2YTRmN2E4MWIxZDVkNTcwOWI5NTFjXzkzMzU_1b95a33f-67f7-4c7a-a9f8-e411abeb5eb1"
      unitRef="usd">2000000</us-gaap:LitigationReserve>
    <us-gaap:LitigationReserve
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjkvZnJhZzoxMjE0Y2U5MTA2NmE0ZjdhODFiMWQ1ZDU3MDliOTUxYy90ZXh0cmVnaW9uOjEyMTRjZTkxMDY2YTRmN2E4MWIxZDVkNTcwOWI5NTFjXzkzNDI_45e6ee5b-b065-4896-84d8-97a7b6c31f37"
      unitRef="usd">4000000</us-gaap:LitigationReserve>
    <us-gaap:MalpracticeLossContingencyAccrualUndiscounted
      contextRef="i2255f9500efa4f9fbb33148f349cbf15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjkvZnJhZzoxMjE0Y2U5MTA2NmE0ZjdhODFiMWQ1ZDU3MDliOTUxYy90ZXh0cmVnaW9uOjEyMTRjZTkxMDY2YTRmN2E4MWIxZDVkNTcwOWI5NTFjXzEwNDUx_e713e46d-5c3c-445c-8144-72af5b2bcc0a"
      unitRef="usd">169000000</us-gaap:MalpracticeLossContingencyAccrualUndiscounted>
    <us-gaap:MalpracticeLossContingencyAccrualUndiscounted
      contextRef="i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMjkvZnJhZzoxMjE0Y2U5MTA2NmE0ZjdhODFiMWQ1ZDU3MDliOTUxYy90ZXh0cmVnaW9uOjEyMTRjZTkxMDY2YTRmN2E4MWIxZDVkNTcwOWI5NTFjXzEwNDU4_1ae24318-732c-46ab-a919-ea164c8d592e"
      unitRef="usd">159000000</us-gaap:MalpracticeLossContingencyAccrualUndiscounted>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90ZXh0cmVnaW9uOjc2ZjJiMDRmMjA1ZjRiZmFhNGMxNTQ1MTM3MTZmMTA0XzI0NTI_9c444a3b-cc79-4372-b09e-f84eae71f8d0">BUSINESS SEGMENT INFORMATION&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The Company's DIS business is the only reportable segment based on the manner in which the Chief Executive Officer, who is the Company's chief operating decision maker ("CODM"), assesses performance and allocates resources across the organization.  The DIS business provides diagnostic information services to a broad range of customers, including patients, clinicians, hospitals, IDNs, health plans, employers, consumers, and ACOs.  The Company is the world's leading provider of diagnostic information services, which includes providing information and insights based on an industry-leading menu of routine, non-routine and advanced clinical testing and anatomic pathology testing, and other diagnostic information services.  The DIS business accounted for greater than 95% of net revenues in 2022, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All other operating segments include the Company's DS businesses, which consist of its risk assessment services and healthcare information technology businesses.  The Company's DS businesses are the leading provider of risk assessment services for the life insurance industry and offer healthcare organizations and clinicians robust information technology solutions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;As of December&#160;31, 2022, substantially all of the Company&#x2019;s services were provided within the United States, and substantially all of the Company&#x2019;s assets were located within the United States.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The following table is a summary of segment information for the years ended December&#160;31, 2022, 2021 and 2020. Segment asset information is not presented since it is not used by the CODM at the operating segment level.  Operating earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income (loss) for the segment.  General corporate activities included in the table below are comprised of general management and administrative corporate expenses, amortization and impairment of intangibles assets and other operating income and expenses, net of certain general corporate activity costs that are allocated to the DIS and DS businesses.  The accounting policies of the segments are the same as those of the Company as set forth in Note 2.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;DIS business&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other operating segments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating earnings (loss):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;DIS business&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other operating segments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General corporate activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(296)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(294)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(269)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-operating (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(193)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income before income taxes and equity in earnings of equity method investees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(264)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(597)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(460)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Equity in earnings of equity method investees, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Less: Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income attributable to Quest Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Depreciation and amortization expense for the years ended December&#160;31, 2022, 2021 and 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;DIS business&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other operating segments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Capital expenditures for the years ended December&#160;31, 2022, 2021 and 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;DIS business&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other operating segments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total capital expenditures&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The approximate percentage of net revenues by major service for the years ended December&#160;31, 2022, 2021 and 2020 was as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Routine clinical testing and other services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;COVID-19 testing services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gene-based and esoteric (including advanced diagnostics) testing services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anatomic pathology testing services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <dgx:PercentageofNetRevenues
      contextRef="i73714e6410064c5eac002e398216cb2c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90ZXh0cmVnaW9uOjc2ZjJiMDRmMjA1ZjRiZmFhNGMxNTQ1MTM3MTZmMTA0XzgwOQ_993afb16-bb09-437b-93ae-7376bdae3b00"
      unitRef="number">0.95</dgx:PercentageofNetRevenues>
    <dgx:PercentageofNetRevenues
      contextRef="id9ea9ce1f68f4cde8b57ba97522e9899_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90ZXh0cmVnaW9uOjc2ZjJiMDRmMjA1ZjRiZmFhNGMxNTQ1MTM3MTZmMTA0XzgwOQ_b32b3c7f-34ab-463d-92cd-cd9117a85934"
      unitRef="number">0.95</dgx:PercentageofNetRevenues>
    <dgx:PercentageofNetRevenues
      contextRef="ifbf8633ce3e245ac94d164f390ff90af_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90ZXh0cmVnaW9uOjc2ZjJiMDRmMjA1ZjRiZmFhNGMxNTQ1MTM3MTZmMTA0XzgwOQ_dad166fc-e478-46e9-bac5-c0984ba1f529"
      unitRef="number">0.95</dgx:PercentageofNetRevenues>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90ZXh0cmVnaW9uOjc2ZjJiMDRmMjA1ZjRiZmFhNGMxNTQ1MTM3MTZmMTA0XzI0NDQ_a6de8a3e-b563-4e0f-a535-9f2cadf401f3">The following table is a summary of segment information for the years ended December&#160;31, 2022, 2021 and 2020. Segment asset information is not presented since it is not used by the CODM at the operating segment level.  Operating earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income (loss) for the segment.  General corporate activities included in the table below are comprised of general management and administrative corporate expenses, amortization and impairment of intangibles assets and other operating income and expenses, net of certain general corporate activity costs that are allocated to the DIS and DS businesses.  The accounting policies of the segments are the same as those of the Company as set forth in Note 2.&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;DIS business&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other operating segments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating earnings (loss):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;DIS business&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other operating segments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General corporate activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(296)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(294)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(269)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-operating (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(193)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income before income taxes and equity in earnings of equity method investees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(264)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(597)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(460)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Equity in earnings of equity method investees, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Less: Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income attributable to Quest Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Depreciation and amortization expense for the years ended December&#160;31, 2022, 2021 and 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;DIS business&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other operating segments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Capital expenditures for the years ended December&#160;31, 2022, 2021 and 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;DIS business&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other operating segments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total capital expenditures&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The approximate percentage of net revenues by major service for the years ended December&#160;31, 2022, 2021 and 2020 was as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Routine clinical testing and other services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;COVID-19 testing services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gene-based and esoteric (including advanced diagnostics) testing services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anatomic pathology testing services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i74ad488f1dfb40baa83701a002b6d98f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzItMS0xLTEtNzgyMTU_c50a6ed6-abef-4c32-ae3a-f32a21421a12"
      unitRef="usd">9609000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i680bf76bfe8647638c33f242f0ef1980_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzItMy0xLTEtNzgyMTU_fc753f79-72ce-467c-8ac4-f38890e10ee3"
      unitRef="usd">10494000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic662fc7ebbb744a885416e3447893d64_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzItNS0xLTEtNzgyMTU_c7dc33a7-00fb-4d39-a76e-77a2a5bf5d60"
      unitRef="usd">9139000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i665754908631467fb2b6eca930750884_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzMtMS0xLTEtNzgyMTU_7bfeb489-a4c4-46ba-9e78-7222f6158a0f"
      unitRef="usd">274000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic5336086104449ec9ccb20ce787e8fa9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzMtMy0xLTEtNzgyMTU_02dffd3a-b04d-48de-9610-ac22441dd7df"
      unitRef="usd">294000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib687289786894660a55bf2477787ca9e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzMtNS0xLTEtNzgyMTU_62081148-3585-4619-bcbc-d70b54f9cc9c"
      unitRef="usd">298000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzQtMS0xLTEtNzgyMTU_8804c162-f37e-44f5-9fdc-fb3b164c7301"
      unitRef="usd">9883000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzQtMy0xLTEtNzgyMTU_feaf82d4-7394-4502-89d0-e06446ec6c6d"
      unitRef="usd">10788000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzQtNS0xLTEtNzgyMTU_d733144b-9042-430f-b453-837521b8e7e4"
      unitRef="usd">9437000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="i74ad488f1dfb40baa83701a002b6d98f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzctMS0xLTEtNzgyMTU_d5f08743-8917-4719-9b97-53f82d3c9d2e"
      unitRef="usd">1704000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i680bf76bfe8647638c33f242f0ef1980_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzctMy0xLTEtNzgyMTU_2e931179-8f0b-4fe1-9879-b2ce0f7e2911"
      unitRef="usd">2646000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic662fc7ebbb744a885416e3447893d64_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzctNS0xLTEtNzgyMTU_8ad539de-6199-4630-99dd-b5d7752513f5"
      unitRef="usd">2201000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i665754908631467fb2b6eca930750884_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzgtMS0xLTEtNzgyMTU_88377d85-56e9-4d24-852b-667cca075947"
      unitRef="usd">20000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic5336086104449ec9ccb20ce787e8fa9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzgtMy0xLTEtNzgyMTU_3558e8e4-69b3-4ff7-89cc-0c8281f7c3d6"
      unitRef="usd">29000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib687289786894660a55bf2477787ca9e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzgtNS0xLTEtNzgyMTU_7b2297d1-20dc-4ef0-906b-7c5ea980e3e2"
      unitRef="usd">39000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie4aca837d0034736866ba4562ecf3fff_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzktMS0xLTEtNzgyMTU_e2dc3b37-f2ae-4bcb-b03d-da88188aff01"
      unitRef="usd">-296000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3ea9a777ccce400dadb97bbedd6fb6f4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzktMy0xLTEtNzgyMTU_38b490fd-aad8-4dde-bc29-4b9dd1a24f02"
      unitRef="usd">-294000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i810fd9c44b7c42e0aef7f96144b246dd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzktNS0xLTEtNzgyMTU_9310c1e3-6dc3-49bd-9712-3b7cad98b17b"
      unitRef="usd">-269000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzEwLTEtMS0xLTc4MjE1_563f1244-e36f-41fa-b5d4-1e908435b45c"
      unitRef="usd">1428000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzEwLTMtMS0xLTc4MjE1_5595cd00-a45f-48f9-a80b-191ef7aab0a5"
      unitRef="usd">2381000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzEwLTUtMS0xLTc4MjE1_934a7113-29d1-4a0e-ba5b-1881873e08e8"
      unitRef="usd">1971000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzExLTEtMS0xLTc4MjE1_762e50aa-5e91-46b5-8d8c-f90c9c5d7bbf"
      unitRef="usd">-193000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzExLTMtMS0xLTc4MjE1_829ce789-86b1-42a2-8508-509d2164afa0"
      unitRef="usd">218000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzExLTUtMS0xLTc4MjE1_1d9cb710-c878-4bdf-866d-3612f7d8b954"
      unitRef="usd">-87000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzEyLTEtMS0xLTc4MjE1_f1d66541-6b7c-4a5d-8b95-44b567947104"
      unitRef="usd">1235000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzEyLTMtMS0xLTc4MjE1_2a2c7185-f222-47c7-9fb3-c89596ba2d11"
      unitRef="usd">2599000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzEyLTUtMS0xLTc4MjE1_2e662f83-1696-45b8-a545-054a5b07060c"
      unitRef="usd">1884000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzEzLTEtMS0xLTc4MjE1_d1fed1b9-9f1c-46a1-94f2-8f1fb0030980"
      unitRef="usd">264000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzEzLTMtMS0xLTc4MjE1_30c470a1-4439-4ba8-983f-275f9dbc402a"
      unitRef="usd">597000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzEzLTUtMS0xLTc4MjE1_5af5097d-f91b-4173-8fe9-b8576fe99f5b"
      unitRef="usd">460000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzE0LTEtMS0xLTc4MjE1_62327402-df7b-4e5b-b138-68dad07e93a1"
      unitRef="usd">44000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzE0LTMtMS0xLTc4MjE1_94d14ea2-60d9-49a9-9784-463a6182044b"
      unitRef="usd">78000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzE0LTUtMS0xLTc4MjE1_aeb36c21-d39a-408a-b66f-9677a2fd4ff4"
      unitRef="usd">75000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ProfitLoss
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzE3LTEtMS0xLTc4MjE1_a14360b7-f42e-4bf5-9563-f371ae9455db"
      unitRef="usd">1015000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzE3LTMtMS0xLTc4MjE1_31f29a98-a921-4f98-ab22-39f78bb9d52e"
      unitRef="usd">2080000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzE3LTUtMS0xLTc4MjE1_ecf66436-59b1-48ab-af3b-9aed111909e6"
      unitRef="usd">1499000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzE4LTEtMS0xLTc4MjE1_437619ce-8e8f-40a8-be51-8226bb3f9783"
      unitRef="usd">69000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzE4LTMtMS0xLTc4MjE1_42927960-86e6-496b-9d20-bc5ed521fb06"
      unitRef="usd">85000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzE4LTUtMS0xLTc4MjE1_fec8336a-9098-4e10-bfba-31a2dce5cf80"
      unitRef="usd">68000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzE5LTEtMS0xLTc4MjE1_266fbf2f-805c-4d79-bdcb-89d29da2625e"
      unitRef="usd">946000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzE5LTMtMS0xLTc4MjE1_da3aa183-af1b-4e86-bae8-96892871a86c"
      unitRef="usd">1995000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTowMWIzZjI2NzJkN2I0NDNiYWEzYjZkY2RlOGVkOWIzZC90YWJsZXJhbmdlOjAxYjNmMjY3MmQ3YjQ0M2JhYTNiNmRjZGU4ZWQ5YjNkXzE5LTUtMS0xLTc4MjE1_cda909b7-3f63-47a0-ae2f-c91755d7ac18"
      unitRef="usd">1431000000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i74ad488f1dfb40baa83701a002b6d98f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphZjg5MTY2ZWY5ZWQ0YTIwYWY1ZTYzMDBkNDQ3NzVmNi90YWJsZXJhbmdlOmFmODkxNjZlZjllZDRhMjBhZjVlNjMwMGQ0NDc3NWY2XzItMS0xLTEtNzgyMTU_d9946e0b-72a0-40a9-9d11-f157c8937c7c"
      unitRef="usd">305000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i680bf76bfe8647638c33f242f0ef1980_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphZjg5MTY2ZWY5ZWQ0YTIwYWY1ZTYzMDBkNDQ3NzVmNi90YWJsZXJhbmdlOmFmODkxNjZlZjllZDRhMjBhZjVlNjMwMGQ0NDc3NWY2XzItMy0xLTEtNzgyMTU_0f220cae-30a2-441b-a4f1-89b6d5ee5421"
      unitRef="usd">294000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ic662fc7ebbb744a885416e3447893d64_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphZjg5MTY2ZWY5ZWQ0YTIwYWY1ZTYzMDBkNDQ3NzVmNi90YWJsZXJhbmdlOmFmODkxNjZlZjllZDRhMjBhZjVlNjMwMGQ0NDc3NWY2XzItNS0xLTEtNzgyMTU_283f2865-98e2-43c9-a412-2084279c6c0e"
      unitRef="usd">249000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i665754908631467fb2b6eca930750884_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphZjg5MTY2ZWY5ZWQ0YTIwYWY1ZTYzMDBkNDQ3NzVmNi90YWJsZXJhbmdlOmFmODkxNjZlZjllZDRhMjBhZjVlNjMwMGQ0NDc3NWY2XzMtMS0xLTEtNzgyMTU_1046b58f-d43f-4e74-b37e-60a183ed5667"
      unitRef="usd">12000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ic5336086104449ec9ccb20ce787e8fa9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphZjg5MTY2ZWY5ZWQ0YTIwYWY1ZTYzMDBkNDQ3NzVmNi90YWJsZXJhbmdlOmFmODkxNjZlZjllZDRhMjBhZjVlNjMwMGQ0NDc3NWY2XzMtMy0xLTEtNzgyMTU_f4f15808-3a5b-4821-a2d4-2e50f932e469"
      unitRef="usd">10000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ib687289786894660a55bf2477787ca9e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphZjg5MTY2ZWY5ZWQ0YTIwYWY1ZTYzMDBkNDQ3NzVmNi90YWJsZXJhbmdlOmFmODkxNjZlZjllZDRhMjBhZjVlNjMwMGQ0NDc3NWY2XzMtNS0xLTEtNzgyMTU_7070a5f5-83cd-405a-aa70-753986cdbc85"
      unitRef="usd">8000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie4aca837d0034736866ba4562ecf3fff_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphZjg5MTY2ZWY5ZWQ0YTIwYWY1ZTYzMDBkNDQ3NzVmNi90YWJsZXJhbmdlOmFmODkxNjZlZjllZDRhMjBhZjVlNjMwMGQ0NDc3NWY2XzQtMS0xLTEtNzgyMTU_b3a7f871-438d-4905-a9a5-fa66f1661d96"
      unitRef="usd">120000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i3ea9a777ccce400dadb97bbedd6fb6f4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphZjg5MTY2ZWY5ZWQ0YTIwYWY1ZTYzMDBkNDQ3NzVmNi90YWJsZXJhbmdlOmFmODkxNjZlZjllZDRhMjBhZjVlNjMwMGQ0NDc3NWY2XzQtMy0xLTEtNzgyMTU_480ff057-dd3f-4ea2-b047-695aabe0166e"
      unitRef="usd">104000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i810fd9c44b7c42e0aef7f96144b246dd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphZjg5MTY2ZWY5ZWQ0YTIwYWY1ZTYzMDBkNDQ3NzVmNi90YWJsZXJhbmdlOmFmODkxNjZlZjllZDRhMjBhZjVlNjMwMGQ0NDc3NWY2XzQtNS0xLTEtNzgyMTU_52029da5-f4f9-40e1-b7d3-5c3330d48dee"
      unitRef="usd">104000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphZjg5MTY2ZWY5ZWQ0YTIwYWY1ZTYzMDBkNDQ3NzVmNi90YWJsZXJhbmdlOmFmODkxNjZlZjllZDRhMjBhZjVlNjMwMGQ0NDc3NWY2XzgtMS0xLTEtNzgyMTU_74602c56-fa9a-4940-9156-5823b8c009ce"
      unitRef="usd">437000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphZjg5MTY2ZWY5ZWQ0YTIwYWY1ZTYzMDBkNDQ3NzVmNi90YWJsZXJhbmdlOmFmODkxNjZlZjllZDRhMjBhZjVlNjMwMGQ0NDc3NWY2XzgtMy0xLTEtNzgyMTU_d10b2551-10dd-40e9-a6d7-923a16880eba"
      unitRef="usd">408000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphZjg5MTY2ZWY5ZWQ0YTIwYWY1ZTYzMDBkNDQ3NzVmNi90YWJsZXJhbmdlOmFmODkxNjZlZjllZDRhMjBhZjVlNjMwMGQ0NDc3NWY2XzgtNS0xLTEtNzgyMTU_362e4cb8-a65e-4405-9353-638e339022d6"
      unitRef="usd">361000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i74ad488f1dfb40baa83701a002b6d98f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphYzM4NmU3ZmY2Y2E0OTdhODJjZmRlNjViMGUxMDc5Mi90YWJsZXJhbmdlOmFjMzg2ZTdmZjZjYTQ5N2E4MmNmZGU2NWIwZTEwNzkyXzItMS0xLTEtNzgyMTU_8df286e3-2860-4677-bb0f-0969e0a098ca"
      unitRef="usd">384000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i680bf76bfe8647638c33f242f0ef1980_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphYzM4NmU3ZmY2Y2E0OTdhODJjZmRlNjViMGUxMDc5Mi90YWJsZXJhbmdlOmFjMzg2ZTdmZjZjYTQ5N2E4MmNmZGU2NWIwZTEwNzkyXzItMy0xLTEtNzgyMTU_8ac441e5-138f-49d9-a37c-e7c36026aa21"
      unitRef="usd">379000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ic662fc7ebbb744a885416e3447893d64_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphYzM4NmU3ZmY2Y2E0OTdhODJjZmRlNjViMGUxMDc5Mi90YWJsZXJhbmdlOmFjMzg2ZTdmZjZjYTQ5N2E4MmNmZGU2NWIwZTEwNzkyXzItNS0xLTEtNzgyMTU_2af35af9-6ba6-41ca-946c-7b311f86bec7"
      unitRef="usd">394000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i665754908631467fb2b6eca930750884_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphYzM4NmU3ZmY2Y2E0OTdhODJjZmRlNjViMGUxMDc5Mi90YWJsZXJhbmdlOmFjMzg2ZTdmZjZjYTQ5N2E4MmNmZGU2NWIwZTEwNzkyXzMtMS0xLTEtNzgyMTU_a5c42201-4580-4633-969b-fc859ef40953"
      unitRef="usd">19000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ic5336086104449ec9ccb20ce787e8fa9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphYzM4NmU3ZmY2Y2E0OTdhODJjZmRlNjViMGUxMDc5Mi90YWJsZXJhbmdlOmFjMzg2ZTdmZjZjYTQ5N2E4MmNmZGU2NWIwZTEwNzkyXzMtMy0xLTEtNzgyMTU_a872220b-83e9-43f5-a0c0-cc82e380c578"
      unitRef="usd">14000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ib687289786894660a55bf2477787ca9e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphYzM4NmU3ZmY2Y2E0OTdhODJjZmRlNjViMGUxMDc5Mi90YWJsZXJhbmdlOmFjMzg2ZTdmZjZjYTQ5N2E4MmNmZGU2NWIwZTEwNzkyXzMtNS0xLTEtNzgyMTU_829cf28f-57e9-456f-bbb5-1ca82cda8469"
      unitRef="usd">15000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie4aca837d0034736866ba4562ecf3fff_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphYzM4NmU3ZmY2Y2E0OTdhODJjZmRlNjViMGUxMDc5Mi90YWJsZXJhbmdlOmFjMzg2ZTdmZjZjYTQ5N2E4MmNmZGU2NWIwZTEwNzkyXzQtMS0xLTEtNzgyMTU_c845c8b0-54c6-4984-a39e-42c2bc8b703e"
      unitRef="usd">1000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i3ea9a777ccce400dadb97bbedd6fb6f4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphYzM4NmU3ZmY2Y2E0OTdhODJjZmRlNjViMGUxMDc5Mi90YWJsZXJhbmdlOmFjMzg2ZTdmZjZjYTQ5N2E4MmNmZGU2NWIwZTEwNzkyXzQtMy0xLTEtNzgyMTU_ea60578b-713f-447c-ab43-b58e63418fce"
      unitRef="usd">10000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i810fd9c44b7c42e0aef7f96144b246dd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphYzM4NmU3ZmY2Y2E0OTdhODJjZmRlNjViMGUxMDc5Mi90YWJsZXJhbmdlOmFjMzg2ZTdmZjZjYTQ5N2E4MmNmZGU2NWIwZTEwNzkyXzQtNS0xLTEtNzgyMTU_3e417b6d-62c2-47f9-980b-786662f71888"
      unitRef="usd">9000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphYzM4NmU3ZmY2Y2E0OTdhODJjZmRlNjViMGUxMDc5Mi90YWJsZXJhbmdlOmFjMzg2ZTdmZjZjYTQ5N2E4MmNmZGU2NWIwZTEwNzkyXzgtMS0xLTEtNzgyMTU_0ba6a1f7-9fdb-4af8-bb87-a1493e5423e7"
      unitRef="usd">404000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphYzM4NmU3ZmY2Y2E0OTdhODJjZmRlNjViMGUxMDc5Mi90YWJsZXJhbmdlOmFjMzg2ZTdmZjZjYTQ5N2E4MmNmZGU2NWIwZTEwNzkyXzgtMy0xLTEtNzgyMTU_ce5dcc6e-9761-426a-bf0e-8efe80b79be5"
      unitRef="usd">403000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZTphYzM4NmU3ZmY2Y2E0OTdhODJjZmRlNjViMGUxMDc5Mi90YWJsZXJhbmdlOmFjMzg2ZTdmZjZjYTQ5N2E4MmNmZGU2NWIwZTEwNzkyXzgtNS0xLTEtNzgyMTU_477beb04-69a6-4e36-8342-6c0a2bdf8346"
      unitRef="usd">418000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent
      contextRef="ie440446d54134ae79c1720e049889ebd_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZToyYTI2ZDIzNGUzMzk0YWFiOTExNTkzYTc1NzQyNWZkOC90YWJsZXJhbmdlOjJhMjZkMjM0ZTMzOTRhYWI5MTE1OTNhNzU3NDI1ZmQ4XzItMS0xLTEtNzgyMTU_629010b6-6405-40bd-8792-81ea68acad37"
      unitRef="number">0.44</dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent>
    <dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent
      contextRef="ibd0d2af9458945a7ab9a6eb6470b7961_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZToyYTI2ZDIzNGUzMzk0YWFiOTExNTkzYTc1NzQyNWZkOC90YWJsZXJhbmdlOjJhMjZkMjM0ZTMzOTRhYWI5MTE1OTNhNzU3NDI1ZmQ4XzItMy0xLTEtNzgyMTU_8a32178c-5587-4af2-b662-550e5c81d035"
      unitRef="number">0.40</dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent>
    <dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent
      contextRef="i8b73fe03ff7442f4bd575024a507e151_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZToyYTI2ZDIzNGUzMzk0YWFiOTExNTkzYTc1NzQyNWZkOC90YWJsZXJhbmdlOjJhMjZkMjM0ZTMzOTRhYWI5MTE1OTNhNzU3NDI1ZmQ4XzItNS0xLTEtNzgyMTU_0609cbd4-790c-4efd-9603-6652fe008db3"
      unitRef="number">0.41</dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent>
    <dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent
      contextRef="i641939e760e747a197a3088d7c7a54e4_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZToyYTI2ZDIzNGUzMzk0YWFiOTExNTkzYTc1NzQyNWZkOC90YWJsZXJhbmdlOjJhMjZkMjM0ZTMzOTRhYWI5MTE1OTNhNzU3NDI1ZmQ4XzMtMS0xLTEtNzgyMTU_fe308b9d-bf59-4c2b-bc36-ac6050fa61c7"
      unitRef="number">0.15</dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent>
    <dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent
      contextRef="i89453a368ad04b51b87732034e68487c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZToyYTI2ZDIzNGUzMzk0YWFiOTExNTkzYTc1NzQyNWZkOC90YWJsZXJhbmdlOjJhMjZkMjM0ZTMzOTRhYWI5MTE1OTNhNzU3NDI1ZmQ4XzMtMy0xLTEtNzgyMTU_8eec5573-ddf7-42ae-9d90-bb5b5b4189a4"
      unitRef="number">0.26</dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent>
    <dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent
      contextRef="i0c23351df28247d08a300337a2d833f5_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZToyYTI2ZDIzNGUzMzk0YWFiOTExNTkzYTc1NzQyNWZkOC90YWJsZXJhbmdlOjJhMjZkMjM0ZTMzOTRhYWI5MTE1OTNhNzU3NDI1ZmQ4XzMtNS0xLTEtNzgyMTU_0f61b2d7-aead-43f9-9ffb-cd22d007bbae"
      unitRef="number">0.29</dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent>
    <dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent
      contextRef="i3eee41bc2ea54b62a9ae3435b8b4aaa4_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZToyYTI2ZDIzNGUzMzk0YWFiOTExNTkzYTc1NzQyNWZkOC90YWJsZXJhbmdlOjJhMjZkMjM0ZTMzOTRhYWI5MTE1OTNhNzU3NDI1ZmQ4XzQtMS0xLTEtNzgyMTU_9ef7e19f-dcf5-404f-841b-b0fd45297620"
      unitRef="number">0.32</dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent>
    <dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent
      contextRef="i57003099795448e795abfddd003aa4e2_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZToyYTI2ZDIzNGUzMzk0YWFiOTExNTkzYTc1NzQyNWZkOC90YWJsZXJhbmdlOjJhMjZkMjM0ZTMzOTRhYWI5MTE1OTNhNzU3NDI1ZmQ4XzQtMy0xLTEtNzgyMTU_d68d1a22-0f95-4387-88ce-dcae63a5545d"
      unitRef="number">0.26</dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent>
    <dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent
      contextRef="i7aec35972bb74cfb959afd84e8d0cffb_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZToyYTI2ZDIzNGUzMzk0YWFiOTExNTkzYTc1NzQyNWZkOC90YWJsZXJhbmdlOjJhMjZkMjM0ZTMzOTRhYWI5MTE1OTNhNzU3NDI1ZmQ4XzQtNS0xLTEtNzgyMTU_4e6cdf7c-310c-4373-8306-53602da50708"
      unitRef="number">0.22</dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent>
    <dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent
      contextRef="i726866d00c5c49f1bfa820096ee409a8_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZToyYTI2ZDIzNGUzMzk0YWFiOTExNTkzYTc1NzQyNWZkOC90YWJsZXJhbmdlOjJhMjZkMjM0ZTMzOTRhYWI5MTE1OTNhNzU3NDI1ZmQ4XzUtMS0xLTEtNzgyMTU_3858df94-d83e-4e8c-8073-10e6c3cd4f63"
      unitRef="number">0.06</dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent>
    <dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent
      contextRef="i12a2b45922a846d39e944bbd98829c1c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZToyYTI2ZDIzNGUzMzk0YWFiOTExNTkzYTc1NzQyNWZkOC90YWJsZXJhbmdlOjJhMjZkMjM0ZTMzOTRhYWI5MTE1OTNhNzU3NDI1ZmQ4XzUtMy0xLTEtNzgyMTU_e5a514b4-6055-4dd9-9a11-970838b93454"
      unitRef="number">0.05</dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent>
    <dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent
      contextRef="i258b629fbed9441ea0961341779923f0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZToyYTI2ZDIzNGUzMzk0YWFiOTExNTkzYTc1NzQyNWZkOC90YWJsZXJhbmdlOjJhMjZkMjM0ZTMzOTRhYWI5MTE1OTNhNzU3NDI1ZmQ4XzUtNS0xLTEtNzgyMTU_7808d0d3-e159-47dd-8846-7faa545750ae"
      unitRef="number">0.05</dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent>
    <dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent
      contextRef="i862341280d314ae3b1668f3553ff24f3_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZToyYTI2ZDIzNGUzMzk0YWFiOTExNTkzYTc1NzQyNWZkOC90YWJsZXJhbmdlOjJhMjZkMjM0ZTMzOTRhYWI5MTE1OTNhNzU3NDI1ZmQ4XzYtMS0xLTEtNzgyMTU_96cbdad5-10f8-42c8-ae5a-51fefc921c82"
      unitRef="number">0.03</dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent>
    <dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent
      contextRef="iba77f4a14ac549e4ad21be96084cdd06_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZToyYTI2ZDIzNGUzMzk0YWFiOTExNTkzYTc1NzQyNWZkOC90YWJsZXJhbmdlOjJhMjZkMjM0ZTMzOTRhYWI5MTE1OTNhNzU3NDI1ZmQ4XzYtMy0xLTEtNzgyMTU_cf5c5613-ea26-48d8-b0c3-513410643dde"
      unitRef="number">0.03</dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent>
    <dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent
      contextRef="i7d5572f43c3845b0af34754ce6041d2b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZToyYTI2ZDIzNGUzMzk0YWFiOTExNTkzYTc1NzQyNWZkOC90YWJsZXJhbmdlOjJhMjZkMjM0ZTMzOTRhYWI5MTE1OTNhNzU3NDI1ZmQ4XzYtNS0xLTEtNzgyMTU_acabf938-e0e0-4e2f-a1ba-ef89fb982e55"
      unitRef="number">0.03</dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent>
    <dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZToyYTI2ZDIzNGUzMzk0YWFiOTExNTkzYTc1NzQyNWZkOC90YWJsZXJhbmdlOjJhMjZkMjM0ZTMzOTRhYWI5MTE1OTNhNzU3NDI1ZmQ4XzctMS0xLTEtNzgyMTU_eb6aed98-6cb7-4db7-a35c-6eb8e87c34a8"
      unitRef="number">1</dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent>
    <dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent
      contextRef="ibe23d649ab93415f89f9ab85b2c07445_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZToyYTI2ZDIzNGUzMzk0YWFiOTExNTkzYTc1NzQyNWZkOC90YWJsZXJhbmdlOjJhMjZkMjM0ZTMzOTRhYWI5MTE1OTNhNzU3NDI1ZmQ4XzctMy0xLTEtNzgyMTU_0353dbaa-53e7-4a0e-aeb9-2a224814e5e9"
      unitRef="number">1</dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent>
    <dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent
      contextRef="i7037d88cebe7461283abb9164475ebce_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzIvZnJhZzo3NmYyYjA0ZjIwNWY0YmZhYTRjMTU0NTEzNzE2ZjEwNC90YWJsZToyYTI2ZDIzNGUzMzk0YWFiOTExNTkzYTc1NzQyNWZkOC90YWJsZXJhbmdlOjJhMjZkMjM0ZTMzOTRhYWI5MTE1OTNhNzU3NDI1ZmQ4XzctNS0xLTEtNzgyMTU_610d1c30-6feb-4d65-ada2-7781b8ba7961"
      unitRef="number">1</dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NzBlNTc1MGQ5ZTQ1NThiYmNiNWNiMGRjOGVhMGE1L3NlYzplOTcwZTU3NTBkOWU0NTU4YmJjYjVjYjBkYzhlYTBhNV8yMzgvZnJhZzo3OGFlNWNlNzZhYzg0MzQ4OWI1YTg3NGY4YTUyZGE1Yy90ZXh0cmVnaW9uOjc4YWU1Y2U3NmFjODQzNDg5YjVhODc0ZjhhNTJkYTVjXzcyMQ_09eaf2b5-128e-4e84-9b36-025ebef47af1">SUBSEQUENT EVENTS&#160;&#160;&#160;&#160; During February 2023, the Company announced that it had entered into a definitive agreement to acquire select assets of the laboratory services business of New York-Presbyterian, which serves providers and patients in New York, as well as the Tri-State Area and beyond. The transaction, which is expected to close during the three months ended June 30, 2023, remains subject to customary closing conditions.</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>112
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" #NA556*!8S;$H'  "3+@  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;+6:;7/B-A2%_XJ&[K2[,TFP90C)-F&&0++-OF1IR.XV[?2#L 5X8EM4DO/2
M7]\K S;.R,+NB"\)-K['UH,LGV/I[(GQ![&@5*+G.$K$>6LAY?)]NRW\!8V)
M.&)+FL W,\9C(F&3S]MBR2D)LJ(X:F/'.6[')$Q:_;-LWYCWSU@JHS"A8XY$
M&L>$OUS0B#V=M]S69L=M.%](M:/=/UN2.9U0^6TYYK#5SE6",*:)"%F".)V=
MMP;N^Y'74P79$=]#^B2V/B/5E"EC#VKC.CAO.>J*:$1]J20(_'ND0QI%2@FN
MXY^U:"L_IRK<_KQ1O\H:#XV9$D&'+/H1!G)QWCIIH8#.2!K)6_;T&UTWJ*OT
M?!:)["]Z6AW;Z;20GPK)XG4Q7$$<)JO_Y'D-8JN@UZTHP.L"_*K K3J#MR[P
MZA9TU@6=C,RJ*1F'$9&D?\;9$^+J:%!3'S*8634T/TS4[SZ1'+X-H4[VA^R1
M<C2&GQ@=HF^3$7K[YAUZ@\($7811!+^,.&M+.(\ZNNVO-2]6FKA"T\7H"TOD
M0J#+)*!!6: -%YA?)=Y<Y04V*HZH?X0\]P!A!V/-!0W-Y1])DI=[FO+1CO)4
ME3NZLY=:X^7,O4S/,S+_:S 5DD.__UM'>*70T2NHP>"]6!*?GK?@;A>4/])6
M_^>?W&/G5QT=FV(C2V(E<IV<7,>DWA\Q/X5!1Z*[ER7583.7N\[A)QT?8U53
M/I;$2GRZ.9]N/3Z#)$E)A&[IDG&I V76D3S5X1T:JYJ"LB16 G6<@SJN!VI,
M><@"-5 A&#^U?6J'TF9HJAR;C/5-H5D2*T'KY=!ZQJ8.4\X5LZM0^-"Y[BGA
M1G!FM<-#%Q]ZKHZ8L; I,4MB)6(G.;&3FN,5)V"5,J=3?4^:M68D$MJ;TEC6
ME)8EL1*MTYS6J;&%EXD,Y0MTKXBBFS2>4JZC9-9P'!?Z%7:[.E+&TJ:D+(F5
M2+E.8=N<.JQNZ3Q4+@*ZV V)M7?A#J'?4RHD&H5DGC A0U^@Z\37P3/K-*5G
M2ZV,;\OUNG7P05,9A]N1J#OS $TDC&2(<31D:2+Y"_P/]$S-ZJ-++4!C46.
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M2FWJWDUSTV@!K8/9WTFICX8]H&O=\5]02P,$%     @ [H555I2//!N:!@
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MZR/[<@B@C'#DR(LIA*)NF$MA5,=")ZV$(F$)9?8<.6.+O<^\51T27QFY$0R
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M*6_@_O(I'XA'G!&FH.KP*#$4L<@-F1;ZAS?KLF*;-QL!JZBZ8MB!Q0K^H(0
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MD?EH("O0R=E3R3'%MB'=59-D=57OI<5M3OZR\Y?>DJIYSQ[:AT1K#>*[E&!
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MQ:<T -)IS3[V^<XS8JZ))4A,:42"!@D\A^[RPXFXSJ*)/%9"9@ZJ@;W!O.G
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ME..OX$L4$QJ ^YE!5H<?M$#WEMSE?P%02P,$%     @ [H555O4VIYN, P
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M.4(H,+4.@='C =^@$ Z(:'PY8 ;M)YWAZ?J(_KOWG7S9,H-OE/C,,UM,@U$
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MAYTP^5<73N?^Z_N)=G"A_XB."Z"C!7@^U9A\RPLZH/X]Q]E_ %!+ P04
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MDQV=8DOGJG@5\09U#TX')U#TB^(5O--=>*<)[_0E/!,T,S2NQ1)N&_1*[D(
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MRXJ?<_2BP.<+HKC=B(/=/PB3OP%02P,$%     @ [H555B%'1"I0"P  ^",
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M$%^!<<!=^,ZTX^POG/^(L^#!,QS*NT%UHL2\A&$JM72)8LD"\^ 395>#WT7
MS10F"1.R!=D%06G\1)'![**H2[]U2$M<%W1PE*PI/:0#M*<UO^S20;S90V@J
MZ0?B_+&-2SU=-"4K@+-=MIB@,2K,#VDN2P0I#W=FAEE4\8#D?5M=:79=YAL"
MN,GI7(6$\VFYKOU5R+'?AKP-S:(VW'2RGZL!4)KG-)4AE)Q39;:))>?[/:2M
MO/=F^YQI/S5_=;;&YX)[,_](8-/!1YBDF[?-[Y!Q&+\WXN%'S(TP<X5^G,L9
M5+OM-_U6R.7U@].5'\:GVF&T]U\1:,24!; _T]JM'_B YM?9Z=]02P,$%
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M@EI[M"Q ^S-#Y::>L('FS\+X;U!+ P04    " #NA556T"A/0?4"  "@!@
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;+59;6_CN!'^*X0OO4L
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M15!ALC,<R=3FN0[$]V+^A)Q'('7%>J41ITS!>^D;C,GETJDEH65NG6,F0T[
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MRP9-#5]$C$@+ -]AEW7>ZM./P[ ON_?Y6_EDQI3/ZLQRUVR>?"029<.NW&\
MOK/VO 37KN __!F%3(ZQBS00=V<GV>[FZ-#KY]WY\[#,\;<5FCE%.W![!'8
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M&DQU'O[+SZ4?6@2GFPCBDB!FO8,@UO)*>GGVRIJYL+0:W.B"365J**=S"LK
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M"ZW"]C @9:+V(!ZX<Q2$7U$J@#X,JA]-T9-H-#BE8TS'P>BT,N"+O C;<91
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M5!?6C[!N;./W :2U=;K<.A.#4JIF%L_;.NPYG$6O.,1;A]CS;@)YEI?"B='
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M2.FX])NMV!^F?$[R:%T9VHYNV=9L@G]*OHFU[#5Y:%4MB@:_EY4IR'?IY1A
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MGB4IO2@4/+B$ C4+=A_$KT. &S]L=QP<9+\>6C!%9RX\@D7-D'GQ3B51C/P
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MTF5DWZ@46CWF!:ZL4+1E@.Q>"BN_46U<12XK&KXUTAS2PI!N6%_8FG!'S@W
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M/4-E%]#\7$JS[5@'NSOK^"]02P,$%     @ [H555J0@G5/, P  FPD  !D
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M6V6I=7FSIG\%:@>@[Y52]M5Q"8:_S^)?4$L#!!0    ( .Z%559<+65@; 0
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M37G.18(MF.,R$R(32Y +APLGT&WY_8C^XU:O&\(^7LFO,E.D,BV5%=@Q 4:
M0="#2?J#*H=:!X71R#WM#IS&9WN5Q/N%LB#P:Z4-L8GJV$2-L7F;4E=/25ZF
MEO+.EF-Q:D0]'J<#5;Q21=XFTQIBDDAJK-J@<X'U8!4<(C> 1]?+,#V(TX74
M!B9)4A9ESNT5)=GQPTDAE<G^LU9FKVD-X,*U-%2?%%8BK$L^9ZTX".G_M!<&
M9S8&?>9.HY[]/^T&L3WM11'<2O$ID<4:#6$N%6(59>9#"*?A&7S\T M8\-GN
M"(G!#).5D+E</@.+@(4]TL'.(.H"ZS!"[IQ!W(4[<H""&!BC%&$^:>L19-^N
MF5W/I.&YI<HH$PF"M<@Q=!'%]B0DH;Y/ROLA@[>A$-+0-V_^@[Y#-AMYY1]N
M/TH#F"F>(@A>4(4%853SM^O7^XHEJ\_8BW7%\8W+R6]!R]IU4M.VGO7[@;OQ
MNS;G*_KVG)$W&G(_KG,_;LS]+Z6QC7-R8"ME/TT2&M^VVF-%T C_?K-";;+"
MY=6AFP&WJG=)=Q &2^.MTVR#0YZLZN*@T8&"F"2(KGX7]'$@;U?]S]:4#0WR
MA:$ O5=ZF7[1 _^V;8>^C1;N]6-;"Y2&=MFA16@7E+V^*\88^NZF2_D'L[W>
M,.YLD^#$9>:Q,+8/)@6JPJ6;AS0U@U*8:FBH3^N1:U)-&OOGU;SVC2OJV!IR
M7)"H?]ZEOJ6J&:C:&+EV<\=<&BIYMUS1V(C*/J#[A91FM[$*ZD%T_#]02P,$
M%     @ [H555MK.BKH! P  D@8  !D   !X;"]W;W)K<VAE971S+W-H965T
M,SDN>&ULC55I;]I $/TK([>J4BF*+R"$ A)7U4@Y4$AZJ.J'Q1[#*O8NW5T#
M^?>=78-#)((J6?8>\]Z\-_:.NQNIGO42T<"VR(7N>4MC5AW?U\D2"Z8OY H%
M[612%<S05"U\O5+(4@<J<C\*@I9?,"Z\?M>M356_*TN3<X%3!;HL"J9>AIC+
M3<\+O?W" U\LC5WP^]T56^ ,S=-JJFCFURPI+U!H+@4HS'K>(.P,&S;>!7SG
MN-$'8[!.YE(^V\EUVO,"*PAS3(QE8/18XPCSW!*1C+\[3J].:8&'XSW[5^>=
MO,R9QI',?_#4+'M>VX,4,U;FYD%NON'.3]/R)3+7[@Z;*K89>Y"4VLAB!R8%
M!1?5DVUW=3@ M(-W -$.$#G=52*G<LP,ZW>5W("RT<1F!\ZJ0Y,X+NQ+F1E%
MNYQPIC\8C>Z?[AYG,!W\&@QO)C"X&P,M/CQ-QC#Y.9W<S28S.'MD\QSUYZYO
M**=%^LF.?UCQ1^_PAQ'<2F&6&B8BQ?0M@4]B:\717O$P.LDXQN0"XO <HB"*
M3O#%=05BQQ>_5X$DD:4P&J;LQ;H$)E*@155B"C><S7G.#4<-OP=S;11]1G^.
ME:%*TCB>Q!ZMCEZQ!'L>G1V-:HU>_].'L!5\.6&A45MHG&+OS^BHIB5)EQG\
MKYUC'DYF.>ZA3K<Z2,=VZ7!+O4-3Z9BVTNC-83%'5;\]%TR#$!))QUP;PE"<
M62)D,J=^P<6B4T6ZJ+V-#;4+[<!S%)AQ2G_&19*7*0& 1BCL62?6P@I@]OQ_
MAH_0B-IT;X;MFJE6&%]%T&@%\*A8BM; 6U=QU("X>0GW:U2I8AEM$2 ,6S#F
M:YXB2=F'7C;LM4_ A2X5(T4$A_APW2 5T4#4LM<MJ@45QI4A1>44UXQ1#$VX
M%N0&P; MOLHB"219&I:3K_ \OFJY9RL(X-AGY1_TB<)FM-U0@_-:M8QZM6ZX
M@ZK/O(97W?J6J05Y@QPS@@87ETT/5-4!JXF1*]=UYM)0#W/#)?TT4-D VL^D
M-/N)35#_AOK_ %!+ P04    " #NA556H68??,\#  "8"0  &0   'AL+W=O
M<FMS:&5E=',O<VAE970T,"YX;6R=5FUOVS80_BL'K1MBP+/>_3;;@)VT6(=F
M"YITPS#L RV=;:X4Z9)4W.[7[TC9;A+(VK /DDCJN8?'NWM(S@Y*?S0[1 N?
M*R'-/-A9NY^&H2EV6#$S4'N4]&>C=,4L=?4V-'N-K/1&E0B3*!J&%>,R6,S\
MV)U>S%1M!9=XI\'45<7TEQ4*=9@'<7 :>,^W.^L&PL5LS[9XC_;#_DY3+SRS
ME+Q":;B2H'$S#Y;Q=)4[O ?\RO%@GK3!K62MU$?7>5O.@\@YA (+ZQ@8?1[Q
M&H5P1.3&IR-G<)[2&3YMG]C?^+736M;,X+42O_'2[N;!.( 2-ZP6]KTZ_(C'
M]7@'"R6,?\.AP68T8U$;JZJC,?4K+ILO^WR,PQ.#<73!(#D:)-[O9B+OY0VS
M;#'3Z@#:H8G--?Q2O34YQZ5+RKW5])>3G5W<O%X]P-4#6PLTO5EHB=+]"(NC
M^:HQ3RZ8QPG<*FEW!E[+$LOG!"'Y<G8H.3FT2CH9;[ 80!KW(8F2I(,O/2\P
M]7SI1;ZUA;?26%U3+5D#?RS7U*%J^+-MN0U9UD[F%#(U>U;@/" )&-2/&"R^
M^R8>1C]TN)J=7<VZV!?OE-Q^;U%7X)QN\Z[3OMV[KZ2EB\05EX6H2RZWL.&2
MR0)!(%4UJ+7@6^:48GK #*@->5%@M49]3@<P6;I&# 7!N+%8.IS=(6R4('T3
M[;1!>E0V2/)OX1XE5QI^5A8-E#7"<J^Y<(@,7D$:#=T[CB$=Y%$+^I;I8N?0
M.0RIW(;QD)!9&^]/M40''$(>C2&/(^= &^4).(%LTCS)8-+!F$8P(M!H,B;@
MN(,QC2'/)OX97F(47QQP!/$H]T\^&+4"F:QIER1L%D&2Y?[)!J.N$!$BC2+_
M_$))T3"!-//%!-R8VF>[4(9$<)4D/7KE/7A0E@D0SZLD[4_&%+U^1 %_A\9,
MX;K6FN0#>Z7];DII?V%#.6\EZX.DLX7PQ0N*5VZ:T9B^;J((.A24GQ64=RKH
MGLZLLA;HIKMEMM;<<O2U_._:ZF1NU]:R72;]EZ&IG"OD!\FJT0D%]'=DVFV:
M3HDO&5**2=(()(V28^U'\:FV_<C(A9MRC&Q#$T'2ST?#8_RK9RMO26T.'R2K
M7!K^)@67W!2JIL1<37J7B^4-XQH>F:!RHU.0TV+*O^AX:O949JWFZ]JZ8P2L
M LK"UC'[NAAVU=A_KZ[_55MM-14^.2TKU%M_)S#@8] <G.?1\[5CV9RV7^'-
MG86$M^72T!:Z(=.(E!R ;NX!3<>JO3][U\K22>Z;.[HZH78 ^K]1).)CQTUP
MOHPM_@%02P,$%     @ [H555FEY_BQ3!0  +!   !D   !X;"]W;W)K<VAE
M971S+W-H965T-#$N>&UL[5A;;]LV%/XK!UZZ)4!LZV;)]A(#2=IB!9(V:++U
M8=@#+1W;0BE1):FXWJ_?(77Q)8Z0]6D/0P":I,B/WSG\SB&9B[607]4*4</W
MC.?JLK?2NI@.ARI>8<;40!28TY>%D!G3U)3+H2HDLL1.ROC0<YQPF+$T[\TN
M;-^]G%V(4O,TQWL)JLPR)C?7R,7ZLN?VFH[/Z7*E3<=P=E&P)3Z@_KVXE]0:
MMBA)FF&N4I&#Q,5E[\J=7H_->#O@CQ37:J<.QI*Y$%]-XT-RV7,,(>08:X/
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M'Y' >0$+N1V0,)*BDAY52[ZCBSX+>O#Z5<_G_KN#__LRW]4QSKA-TW<!'2[
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M#X3QF$Z*8DNQEEPT2B@:\S^E.^T@T(OL8XPTC6O049KZ@20>?3NQMUB%O5'
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M>S7]\O[S]=_77SZ3UY3E?AAE;\@1^7I'R>M7;\@K$L;D4QA%_&)E9\.<G[H
M& ;U:2ZKTU@MIS$M\BF)\V5&KN(YF\L 0][F;<.MYX9?6B B9<$QL<VWQ#(L
M2]&@Z?[NIL*=[N]N -'8V\M@EWAV"]X=N^?)E)-;MD[2/(SOR75<)761'#\^
M<G-RG;-5]H^*^PK;46,7(\=IMO8#=C[@0T/&T@<VF/SYA^D9?ZEXPP2C2& 2
MI\Z64P="G]RP-."<\M&+) L2\S$T90\LWC!E_ZVP3*,$*T;+APGO%P^[S'2;
M4-!$BL+=1N%J1N$'0;*)\XR'$[#PP9]%3!60VQU0MPD%&W?@!?2VH7M@4EP\
M!WJ[#?0MN8CX5.7' 2,\/\@T9?,P)Q^3+",_;I,H(GPV>/33N3)//,P\P02C
M2& 2S:,MS2.PAUVR^S".BS%GYD<%LRKJ*HC13D^QF[WII8EUTNA-8$,.#/-D
M&^8)&.;W-,S94;)89$4B*9+H;9E=_#=^*'E@::@>**JS>#MA'CD-)A0FS;P"
MVWH@$^,M$V.0"3X%=USM\8L ;*,1H\*D&>,8ZA!2RTU#R!4#'@[3Y"$L16>1
M_D&5_A%/?_7%JM&D?ML(1&'2N)Y486*.6R+9$5XF&,D'YD?Y,O!3QJ55MDE9
MFIV2_[C&BL/59J4,!@34';]0T2@6FDRF)<BT>M1/-3@6L9AH% M-)E;H4A.4
M:!->3SV7:'QD#+CX#^<L+6E5,@FCV0:9^T^J3)W"GMJL]2$\3:$\35AZMN6V
M_ZLUMT% [2Z(B4:QT&0RA0 VW3YS&TG!UL1BHE$L-)E8(:]-4%9JYS:,Y@&Y
MC:J5L=!DUH1:-F&Y_+[0AG'9(]?^$\]L)5=(2K?F#Q.-8J')_ D9;I[TF<Y(
MPKDF%A.-8J')Q I5;\*R7C>=831HJ@8]M5E#0I/O(HJ"PH(+BFD4BE2&]3>,
MI-OW4-$H%IK,HBAF++/'I+90"QM4-(J%)A,K"AL+U/>Z2=V!!LS1L*<V:WU4
M+9:H6JR.JJ69U.W"&T;2[GNH50P6FLRBJ&(LI\^D1JUH4-$H%II,K*AH+/B>
MOFY2PVAC(*E1RQ4L-)DU4:Y8<(%QPPEBQ2W;UV$<1)OR'F:0E/5U^3S C^=D
MSN8;3NPL8H0W85TP.PNCD#MF;SHF=]2' ZAH% M-)EY4/-:HSW$ M11"1:-8
M:#*QHA2RX$<2NN, C 8H=MA3F[4^ZAQ+U#D67)E@C . 'L L;J:H:!0+35ZB
M($HEV^ASD0)J]82*1K'09&)%]63#CX(TQX$.-$#DPY[:K/51&MFB-++A8H;>
MP3,Z[*[=X5#K(RPTF;J=U4:]+C?"76^$N^"HCY+)%B63#3_XT<UD& V8T6%/
M;=;ZJ(=L40_9< 5397+[G R[:W<XU*(("TVF3A1%-KQ&ZC<S&;7H046C6&@R
ML:+HL>''/+J9#*-!<S)J18.%)K,F*AH;KD'H]1V9;3)^-%,^%X/=M3L<:EF#
MA293)\H:>]QG)J.6+:AH% M-7@4LRA:G8\F8WCK@"DQ:%&L<CT?-M<![F=%.
M,SDF43$XL,8_>%5PC=MLD-<,3VWV(KP^*@!'5 !.1P6P,]K M0 ,I)L>J&@4
M"TTF4=0"3I^U@(-:"Z"B42PTF=B=UP]@]:XY[CC*C'.;B;F7&>TTDV,22MWI
M4.IRQJG6N2F#0Q7PJ&@4"TUF5 AXIT\![Z *>%0TBH4F$RL$O -+;LWT&ZD2
MQGGQ"I#:S&JFG]+,;IOVA;QV8'E]^+1_HFI0\_V,J=K,?A%>'TK9$4K9@1\
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MJR]YLBYWZYPE>9ZLRH]+YL]96ACPWQ=)DC]_*4ZPW2%V\C]02P,$%     @
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M =W! P-Z^P&]0P?T]P/ZAPX8[ <,#ATPW \8'CI@M!\P.G3 >#]@?.B R7[
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M )K.&^_:&SS:=29IGG.8X[OV_D1JJ,6Z0W;' <[_/0_ TH?,'WG4-OK Z/F
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M,->'4NJW@_1[G?S[K.[_4$L#!!0    ( .Z%558TP7,2!0,  !$*   9
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MA5[\Z4-X''S>0;C3$.[L0H\OE+1<+E%:2"B3?(Z:52=9:T;K5!O6'$ Y!K4
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M#L&U7;?FA2[?'^[4A'OO#[=KPOWF\"]9= QV'N[T&L3HE*YV<E[G+5<)$_!
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M O%ER>.>,I-;1(:8R,BRGLOPU:U^DXW&L27AT7%\"AGC21GCP3+FB^07<Z^
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M+W=O<FMS:&5E=',O<VAE970U.2YX;6RM6MMNVS@0_17"6RRZ0%-+E"W;V22
M$R5H@:0)DG3[4.P#+=,Q44E412I.]NN7E!3+)D>T6_@ET>5P-&=(SAR2/EGQ
MXH=84BK12YIDXK2WE#(_[O=%O*0I$1]Y3C/U9L&+E$AU6SSU15Y0,J\:I4D?
M>U[83PG+>F<GU;.[XNR$ES)A&;TKD"C3E!2OYS3AJ].>WWM[<,^>EE(_Z)^=
MY.2)/E#Y-;\KU%U_;67.4IH)QC-4T,5I;^H?1T&@&U2(?QA=B8UKI*G,./^A
M;S[/3WN>]H@F-);:!%'_GND%31)M2?GQLS':6W]3-]R\?K-^59%79&9$T N>
M?&-SN3SMC7MH3A>D3.0]7WVB#:&AMA?S1%1_T:K&CG /Q:60/&T:*P]2EM7_
MR4L3B(T&?MC1 #<-L-E@T-$@:!H$^S88- T&561J*E4<(B+)V4G!5ZC0:&5-
M7U3!K%HK^BS3_?X@"_66J7;R[.'KW=WUY<WEE\?I-;J8/GQ"5]>WW]#T2X1N
M'S]=WJ-H^CA%[R,J"4O$7^@(?7V(T/MW?Z%WB&7HAB6)ZCYQTI?*&6VR'S<?
M/J\_C#L^[&-TPS.Y%.@RF]/YMH&^8K&F@M^HG&.GQ8C&'U'@?T#8PQAPZ&+_
MYC[0/-J_N>=@$ZP[)JCL!5T=4^9Y0M4,DR1!%T0LT96:H^BR?B;0]^E,R$)-
MFW^AV->V![!MG4N.14YB>MI3R4+0XIGVSO[\PP^]OZ&X'=)8="!C6S$=K&,Z
M<%E7?:2,QHQ4&8>^J-PI*!2]VLJHLJ(3Y_-9X(].^L^;00$PWG ;$]D8/!RO
M,5L4AFL*0R>%:<H+R?[;2:&V$FY\VM?#<HL"@/$"@X(;LT4A7%,(]^\%DLT1
MV9-3:/DR",QN 3#>V.!D8X+0ASF-UIQ&3DZ?,TG5>)4N]T?69X_\@>';!00:
M8H, ! I#F,%XS6"\'P.6Q3P%"8R!L6"X#T ,WVU$QW":K!V?_%+H/Z",2LC]
M"1"UP(P_!!J:'"!0V$'#]]I*[.U')"=L#A94SX[N,#0(@*")00  8:]C"O@;
M4L+?04"/'"3)"Q7=)'S[T^/ )&&#1IY%P@8%H==! K<DL#O!QC$O=8'-R2N9
M)101(;C.5G2NI)E<HICD3-?D:KC-F2Q5GX%$L>V>.=H # Y-FC9FT#'7_59<
M^,XZNYME7A;Q4NEI@?@"2;6B$&7QBI0<C7^ 9 /+23,U !!L5ANGF6VJ;<WW
M=Q1]]LSFJJ?>J(+N#^SQ-C#]WXV)($Q77[45WW>7_#<"0JVS8JI627.T*'B*
MZ,^2R5>44KGD<Y6VGU7NH!UCT2[CH6_R S">R<_&# <=_%HYX+OUP!5A!7HF
M24GU6%,#D:IQ26+%KC#7!0T;NX#[8VS2@:J\U5\0J$.A^:T6\-UB8)M0PLB,
M)4PR-9<4N3+M(&47==_*[0#&%#<09M3!J-4&OEL<;#-2]76O;@+$0&A1 O3
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MF6@+K9Z*BG:!G=1K#ENMQCZR]BI69V0C?<W"4F[ QM>X.DJ?&,>2\9=RT\[
M3<Q#*F-.TA!NZ',RUE-O57*TA59/1BDZH-UE*3=*FI-3T1):/16EG('->N;-
MI7RH3Q#L'=2RQLJRAD>*N50QL%G&W!+U ;5A_G^?O\U )^]52VCUL$LU!)TN
MR[95U=066CT5I6Z"C7KD[67K'A2DZQQ4K<;(.O+= $N- YM%SI0%42P)!P]L
M)7=8G;DSLB6^BL,#C(//3^J+-U3CE9K,0V488A\\"J(-HW&ID_>R);1Z8DH]
M!8==EG6K$JLMM'I/H-18J%&XO+FL<]C:UY?M[&MAG14:'I$6J%1#J%D-35DH
M)(^S]A@-@0IBK9*C)]H(=7+GHB6T>N"5%DZG/9QVFSA=*"I4*BK431\''?9H
MD+O?"M$9P=Y>V9J57F32"+[#?$U# 7RR4E[6N:O>W3SKK683R:*T/?G$I&1!
M.MP0[!&>&*C[*\;DZR3I>!8=[LD/4$L#!!0    ( .Z%559$7%7\<P@   9#
M   9    >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;+V<77.;.!2&_XK&V]EI
M9Y(:!!B[FW@F,6TW,VG::=+M16<OB%%L6D NR$F[OWX%)I;UD9,8R[E);"R]
MZ+S T2,A.+JCY8]J3@A#O_*LJ(Y[<\86;_K]:CHG>5R]I@M2\%]N:)G'C'\M
M9_UJ49(X:2KE61\[SJ"?QVG1&Q\UVSZ5XR.Z9%E:D$\EJI9Y'I>_3TE&[XY[
M;N]^P^=T-F?UAO[X:!'/R"5A7Q:?2OZMOU9)TIP454H+5)*;X]Z)^R8*PKI"
M4^*?E-Q5&Y]1'<HUI3_J+V?)<<^I6T0R,F6U1,S_W9()R;):B;?C9RO:6^^S
MKKCY^5[]71,\#^8ZKLB$9E_3A,V/>\,>2LA-O,S89WKW-VD#"FJ]*<VJYB^Z
M6Y4=!#TT75:,YFUEWH(\+5;_XU^M$1L5W,$#%7!; :L5_ <J>&T%[ZD5_+:"
MWSBS"J7Q(8I9/#XJZ1TJZ])<K?[0F-G4YN&G17W<+UG)?TUY/39^__%C]/7L
M_!R=7$3H[.+JY.+]V>GY6W1R>?GVZA*]C B+TZQZA0[1E\L(O7SQ"KU :8$^
MI%G&CUMUU&>\%;56?]KN\72U1_S 'EV,/M""S2OTMDA((@OT>?/7,>#[&$XQ
MJ!B1Z6ODN0<(.Q@;&C1Y>G774#UZ>G4'B,9;'Q&OT?,>.B*4)G?<7?3M,^5_
M^=E]%Y?)OR:C5T*^6:C.&&^J13PEQSV>$BI2WI+>^,\_W('SE\DDFV*1)3')
M0']MH ^IKPT\X DABXLI03%#UV26%D5:S!"]0;])7)K\7.F&C6Z=,&_'H3,*
MCOJWFS[IA0;#T),+16 +.\8?K.,/GA0_SZD_EVE)$I0LRSIR-B</AKZ2'&Q$
MY=87@Q2Y7@;CH1)XH+F#_7!=1HIGL(YG ,9SDGSG>9#W-:Q"C*)9&YXIBH'6
M0E^)02]Q.%!" %O3\=B%ZUC#[<]=4B3061MJ(86XSD12W(9"VJD=A?"I+44T
M7$<T!-/9N[1(&3D\Y[U[@F(>R1G/^C>KC5FS\:Q@<3%+KS."3JJ*\*/\[9R+
MH#-&\LJ8]X8V\YY-L<B2F.3T:.WT"#QW-GR,&Q\/T*RD587(KVFV3.H, %T[
M(_WJ=EWU\C$4<D+E7(O 9G8TP74$T#APNIA.E_DRBUE]ON6T9.E_<8V8!QQ;
M%(.,\.+H&<)MN$(RPE1LY*C= -S4KE9LL)T+6G%%69SI81^@@C!C[*[>"S@C
M+71#*7<0JJ&#3>L:.A:A8SCM+-FR)-()P*\#/EJJB#%R;#.E6%6+;*G)3@H<
M=4%8XQ<X]HR6>8:39:">*U:ITI::[(3@2A<&2^Z$;W3"-SCAJ4Y80L+6B7T
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M!/3[%>?JN#"S3#6[QO\!4$L#!!0    ( .Z%55:" NZGYP4  %4I   9
M>&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;+5:6V_;-AC]*X36#0G0VN)%DI4Y
M!MIDPS*D6]&DV\.P!\5F8J&Z>!2=M,!^_"A9%461YBR#[D/C"WGX'8K'W_&Q
MYB\E^URM*>7@2YX5U:6WYGQS,9U6RS7-DVI2;F@AWGDL69YP\90]3:L-H\FJ
MF91G4^3[X31/TL);S)O7/K#%O-SR+"WH!P:J;9XG[.L[FI4OEQ[TOKWP,7U:
M\_J%Z6*^29[H'>6?-A^8>#;M4%9I3HLJ+0O Z..E]Q9>7)&@GM",^".E+U7O
M,:BI/)3EY_K)S>K2\^N*:$:7O(9(Q)]G>D6SK$82=?S3@GK=FO7$_N-OZ#\W
MY 69AZ2B5V7V9[KBZTMOYH$5?4RV&?]8OOQ"6T)-@<LRJYK_P<MN;!!Z8+FM
M>)FWDT4%>5KL_B9?VHWH38!DSP343D"'3L#M!-P0W576T+I.>+*8L_(%L'JT
M0*L?-'O3S!9LTJ*^C'><B7=3,8\OKG]Z=P_.;LOBZ<T]93FXI@_\')Q=4YZD
M674.WH!/=]?@[-4Y> 72 KQ/LTSL?C6?<K%X#3%=M@N]VRV$]BU$EQ. X6N
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M9D'/"Q@70/MKK?'@N)9O'ZSL'5!+ P04    " #NA556O-QQ+;($  !I(@
M&0   'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6RUFFUOJS84Q[^*Q::I5]K*
M0QYOET1J"NA6:M>JO7=[,>V%2TX2ZP+.;"=II7WXV4!)2(F72&=]T0+Q_^?#
M^9L#/6&TY>*[7 (H\IJEN1P[2Z565ZXKDR5D5%[R%>3ZDSD7&55Z5RQ<N1)
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M^:(MV5;&N76P_R$Q!PD),:>+,&&Q+?9&_@=U_@?V)<^S#$3":$H>J2Y:1)M
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M9H#^?,ZY>M\Q$]1OETS^!5!+ P04    " #NA556,N5FHE4#   U#P  &0
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MH;$&RIMSK&M!F@%X?RJ$?NZ8":I*.?P#4$L#!!0    ( .Z%559#\TI^G ,
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MSQ9J@)4_LK1R,M*6(=4?G678:#>Z[G)75LF:3BM?4XBVD4?;L$9K,H6^/Z>
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M>!1(IDF"Q>L=4+X>.+ZS??"5+);*/'"C_@HO8 +J:?4H])V;H\Q( DP2SI"
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M, ;Z_9QSM;TQ)X+\!!C]!U!+ P04    " #NA556;FG+U"4#  ##"@  &0
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MN MQHYFMS/B"Y&8BB,9UOB)?2^S53:MJFY/C T7D":AL$X[^0;C'VFU8NR_
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M>CIP_M[A)\6=WMN#4[*1\LD9\VP<]%U"R# UCH'898M39,P1V32>6\Z@"^F
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MRQ2@FK35VK=NZIH%E-%V%51344U#-1W5#%0S4<U"-1O5'%1S4<U#-7_P-SI
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M[CZD2_+P">>"SCF?1\(T^PL><FRG!;Q]2DF4-V8]B(+X\-_]G@?BJ('5K6D
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M@%U?$T(?#_@-BNW$PW\ 4$L#!!0    ( .Z%559B[I'_- 0  #X4   9
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M[QYGHY?[IT<P_7OT. .?7QCV.0[&BH-7WR8,S 2U?H*G=3!^4U>^_P(^3XC
MCBNO+L#=KXTCWO<%+L#K; (^?_H"/H$VX"O," >.+WTY@C=3#UY6=,.Q;\N'
MG]3]@^.ZJM;KMI#]5:UN6U'?;L.^H0-]@P@\4%^L.+B3#;:S#MH25$P+[6G=
M(JW'";%:H .; !D(E31H?+PY+#&?'&]N:'K3B<>^$_CK'!I[Q?Q"S1H;C*DG
M4PG'P5B-F!SM)9'36X#Y.TB7F^+WX/%HAYG=C 97#M731G A1\WQE^#',W5=
M(*>E*O-/V;B%[3++VZ52W15?8XO<-&0NXX1M26/X^V^P9_Q1QKQ.9Y.:G&7&
MPXS'P]1Y'T8P 4U8-L&<+!W?5UCI KP3S,IXAGY[@5^5Z;?#;M^0(;)-<])6
M7I533<XRG+HQI^Y1G)8R2D5^7H= ND4@!1[:2JKRJ,E9AD<OYM'3\KA[(\QR
M.%$1PH.D3/?3,DRK981Z!4(7T"PPTE9<E5%-SC*,^C&C_E$Q(W=*"^+(J %R
M@@$+^Y;<<I3'4+^$4 &0MM:J@&IRE@$TB $-JB<?(AEITLZ@0,@LIIUBH6)N
MFFC;=F+/+^.>7_X?RV 3? \VG;+T:$N8W$2#>*).F6,1\&,TYX+)357I&GE9
MYQI9I[-)3<XR@P6-9,-JU+!*@MT>/H[@DSW\M8)?NIL,*QZD0O6RUS+-7$#K
MVU<59EW>LC13VW]X#,WF?C$]B5LD,<P4.(@&K2[,D].VI3*YFKQER:&$'#HJ
M#O=\3D.'"MEQ<)FGIFU'96HU><M22R0'U.Z@/UJ'3V+8*0L_H]4IA%^M2J$N
M;UF0B5: )XB%U'I]$DFSD "A 5O]01YDL5Q)HISH>W JH40EP.-DPO&$&%%?
MRM0J8E$_6)DWV 6",*^4EK[Z;E )!Y? "S]"P &P\7O99GRL=U4Y,L\A1F"B
M1J!>CGS('2^7C"RQ(,"1E!V?.Q;88G=3'I-A9?U4K*%N/Q^0M>J4NKQE^25*
M!>JE2K1+Q'.79+D=%G.PJ%4Z1<&KK[<RI7.H%9C(%:C7*P<IG9+W!L5\9K8Z
MO3R_FE1*Q.\<F@<FH@=JM^D5^%7,BOIJS2@K0F.?%I%Y."W6*EOJ\I;]<ISH
M%J37+0>!5TJ'4269= B[N4#5MZ0JM[J\9;DE"@7I%<HWPO?;1/*V)I:Z$11L
MY>-CTV-4PP<?*O3MJ$SM'.H$)>H$Z=7)T=1.2)=1U?EM8B^_W]8WL3+0<P@7
ME @7I!<NIP.MEC\_:$:57:7>567^Y] [*-$[2*]WCN9?+9V:);O+_+JO;UEE
MCN=012A114@O2UZHD-&70Z/@T?SWC%)>Q1]6^H4\VBTP'71RTK"D#(1)H6S?
M$N6!],HC\_76IT(&A)#3SZ)+W_F7V,WLKR.E_2NJC<+B6JO6J,M;EEBB-9!>
M:[SZ"9Z03O2!VTJCM"@7Q;RV)LRAY5&BKQ2&$[47I;#2U%6K5*G+6PBYG3IM
MX1&V#$ZM< EIXXOP*$'\-#X9,PK.@^2>W\*K27B^)7$3'K=YP&PIIR=PR4*Z
M-%I].5U8>((EO!%T'9SIF%,AJ!=<K@BV"5,%Y/L%I6)_HRJ(SQ$-_P-02P,$
M%     @ [H555L,#_@B_!0  :1H  !D   !X;"]W;W)K<VAE971S+W-H965T
M.#$N>&ULS5E=<]HX%/TK=]C.3CI#P3(.'UG"#,'I-K,;PH2F?>CL@[ %>&I;
M5!*0[*]?R7;\*0S9\M 7L.5[CW3NE:Z.Y>&>LN]\38B Y\ /^75C+<3FJMWF
MSIH$F+?HAH3RR9*R  MYRU9MOF$$NY%3X+=-P^BV ^R%C=$P:INQT9!NA>^%
M9,: ;X, LY<;XM/]=0,U7AL>O=5:J(;V:+C!*S(GXFDS8_*NG:*X7D!"[M$0
M&%E>-\;HRC9-Y1!9?/'(GN>N05%94/I=W=RYUPU#C8CXQ!$* LN_'9D0WU=(
M<AP_$M!&VJ=RS%^_HG^,R$LR"\S)A/I?/5>LKQO]!KADB;>^>*3[3R0A=*GP
M'.KSZ!?VB:W1 &?+!0T29SF"P OC?_R<!"+G8%H'',S$P2PYH$,.G<2A<ZJ#
ME3A8461B*E$<;"SP:,CH'IBREFCJ(@IFY"WI>Z'*^UPP^=23?F(T__PP^0L>
MODYO'^>?[F8PGMHP>;B?W4[GX\]W#U.8_3V>SN%BK/+C"8]P>"0^%L0%06$N
MJ/,=QGO,7/X>+FPBL.?+JP_P-+?AXMU[> =MX&O,I)\7PE/H"=[,-=Q[OB_3
M+]O>Y6^';2&YJ1&VG83'3<S#/, #F7!/0['F<!NZQ"T"M&50TLB8KY&Y,6L1
M;>*TH(.:8!JFJ1G0Y'1WI'&W3W<W:MATTCQW(KS.H3RKD']0*\2%"0UDV> X
M6GACQG"X(G(I"UB\0-YNAE^BYBB_3;C]L?7$"]R%7+"M>L#A0:P) ['&(3QL
M1)S(*0UWA,L)TH2OT:J32.,=8;**P)^R+P%RHA+XB#T&7["_)?!MO)"0L@+\
MH\M[S,O2\U)E\8IOL$.N&[+N<<)VI#'Z_3?4-?[0Y>R<8/:9P KYM-)\6G7H
MHVCE)7ER\ODDS^J:Z"(9(_8B1+4?[$:]WK"]R\='8S(HFMA5DT&&4N!RF7*Y
MK.5R%TH&! 1^A@4)R=(3<D=):PS_'TSC_KJY,9IEIE63CEEBJC$9Z)EV4Z;=
M^JSE5E>>2U.2<0CG^1@T 0=T&PH=OVXE!\@J\=.8E#-9-3$[>GZ]E%_O^*Q,
M]@/=N&N]W[J6SPEFGPFL$+5^&K7^KU>;I]M@(9_390S+X=LC]7V08DHA:BMQ
M_YS9.R>8?2:P0O8&:?8&Q]<T!ZFIN<"AZX6KIES"*R\,Y:6*[PO!3!?.0:6\
MH-(:/FIAUUD4V" C$X3&*7Q6:JLN"ZE$B<4 @URO1JM?&KO6Z+(T?*V1=8!!
M3M*B4QC$,UU+ %6Z_6"TNF4&6JL*!:W5(0YFQL$\A8-\L5L23^V$<FJ!@T-'
MOB$=(&7J!E*>4HE5?L88949U)D4ZF?I$M6)(NTB(9%2S/!+$/!]4I=,YND1J
M38IT,O&%K%^O8I]%3:-:6?G6(GY6-/M<:,6D9BH4U<O0DPHY[%^S@),L1(42
M7)6%I<K"3F5!&_JX^WY^(AJ]EE6I.SH[N9++\E1C-^BT#B@XE$E4=()&3>O_
MB7SA0KZ]NU) 8,9A(V=Q](K_7AN&N'MDY?F9_98U*,=!:VBV>OUR('2&R&Q9
MAV*1R5ET1,_F=Y*?27VO.L*!'.!EF;+&#AF=EE4I:CK ;JO3/< XDZ*H5BL=
MV7=^)@1]?38[%>'0/[Y#U9D4B6<J#KU=QN5VJ)]A/JBN9U.7?(V=IC[86KM"
M?2B>=V7*SZQ7?D\A(PY=A=Z_DN;!UVZ'<NT[:0*>?YVT2HF;U _@K?O%N="*
MX<IDIEDO,T\/5W7RR!+I4:V,.](IBF?C (+XM!/UY11\T;UL3^J1WASL,Z$5
M@YWI8;->#W^F OOY#4>N2WY,YR>8A>,LLSPEJS:7Y8,2C4VG?.;5SIW!!X2M
MHF\97*9_&XKXT#EM3;^7C*.O!*7V&W1EQU\],ICX(\P]9E*-</#)4D(:K9X4
M "S^KA'?"+J)3OH75 @:1)=K@EW"E(%\OJ14O-ZH#M*O2Z/_ %!+ P04
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M/91:8O/Y87.B>)*]P;_C2O$H.PP VZ;0 _#^@G/U>*(G*#X"#?\'4$L#!!0
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MN27*-A-717$"U+(GQH8[@,)CO6["(!3V6O;'B'*LQ+Y-W;LB0LR:-M$=TPT
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M;@O]?P!A O3YDG.U-4R"[H^3_ -02P,$%     @ [H555BV8MXE- P  CA4
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M 4?^MOV=IFR9)\U3US 1]JEM^QL,+XR;8[_.Q41*5S2=V*Z<3^NFIQLZJ[V
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MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " #NA5564G4RLHL&  !S.   #P
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M8R%K!\;454SPC#+V 31P+;C7FI!Y+.S:!\3LM2:D'@O[. &(:2B8-F0@&]E
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M<' N>&UL4$L! A0#%     @ [H555E;M@R[O    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ [H555IE<G",0
M!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    " #NA556*!8S;$H'  "3+@  &               @($."
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ [H555JG&6(-!
M @  Q@4  !@              ("!C@\  'AL+W=O<FMS:&5E=',O<VAE970R
M+GAM;%!+ 0(4 Q0    ( .Z%55:4CSP;F@8  -T;   8              "
M@042  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " #NA556
M#^&]F,T"  #O!P  &               @('5&   >&PO=V]R:W-H965T<R]S
M:&5E=#0N>&UL4$L! A0#%     @ [H555F$[R(K,!0  [Q@  !@
M     ("!V!L  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (
M .Z%55:5*:.&"00  /T-   8              " @=HA  !X;"]W;W)K<VAE
M971S+W-H965T-BYX;6Q02P$"% ,4    " #NA556I<TWN,P'  !W)   &
M            @($9)@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#
M%     @ [H555F!@'82-#   A(8  !@              ("!&RX  'AL+W=O
M<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( .Z%559CE@$PY00  #\+
M   8              " @=XZ  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q0
M2P$"% ,4    " #NA556O(5.QP,B  "+<@  &0              @('Y/P
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( .Z%558&=VLM
M$0P  #$G   9              " @3-B  !X;"]W;W)K<VAE971S+W-H965T
M,3$N>&UL4$L! A0#%     @ [H555O4VIYN, P  H@@  !D
M ("!>VX  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " #N
MA556GHG5X5$&  "*$   &0              @($^<@  >&PO=V]R:W-H965T
M<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( .Z%5590?]E$PPD  -LA   9
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M970Q."YX;6Q02P$"% ,4    " #NA556R4:M#QD#  ">!@  &0
M    @(&@HP  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (
M .Z%55;#V%^: P4  #@,   9              " @?"F  !X;"]W;W)K<VAE
M971S+W-H965T,C N>&UL4$L! A0#%     @ [H555M H3T'U @  H 8  !D
M             ("!*JP  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"
M% ,4    " #NA5561G#3R!H)   _&   &0              @(%6KP  >&PO
M=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( .Z%55:TT.2Z$@@
M )LE   9              " @:>X  !X;"]W;W)K<VAE971S+W-H965T,C,N
M>&UL4$L! A0#%     @ [H555A_GX7X)!0  >0P  !D              ("!
M\,   'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " #NA556
M;9C .5P*  !P'P  &0              @($PQ@  >&PO=V]R:W-H965T<R]S
M:&5E=#(U+GAM;%!+ 0(4 Q0    ( .Z%558H'Y.C]@\  $(V   9
M      " @</0  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%
M  @ [H555M(\PW3[$0  =3$  !D              ("!\.   'AL+W=O<FMS
M:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " #NA556&PG!?;D'  #:$P
M&0              @($B\P  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+
M 0(4 Q0    ( .Z%558?-5R][P(  $X&   9              " @1+[  !X
M;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ [H555LI5DOE7
M(@  ]W0  !D              ("!./X  'AL+W=O<FMS:&5E=',O<VAE970S
M,"YX;6Q02P$"% ,4    " #NA556)4N0X!L$  "_"@  &0
M@('&( $ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( .Z%
M55:D()U3S ,  )L)   9              " @1@E 0!X;"]W;W)K<VAE971S
M+W-H965T,S(N>&UL4$L! A0#%     @ [H555MQ"D2". P  JP@  !D
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M=#,W+GAM;%!+ 0(4 Q0    ( .Z%559<+65@; 0  )0*   9
M  " @=<_ 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @
M[H555MK.BKH! P  D@8  !D              ("!>D0! 'AL+W=O<FMS:&5E
M=',O<VAE970S.2YX;6Q02P$"% ,4    " #NA556H68??,\#  "8"0  &0
M            @(&R1P$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4
M Q0    ( .Z%559I>?XL4P4  "P0   9              " @;A+ 0!X;"]W
M;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ [H555G0(SP@&!
M4@D  !D              ("!0E$! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX
M;6Q02P$"% ,4    " #NA556U@C\]KH#  "*"0  &0              @(%_
M50$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( .Z%559B
M2WX:+ 4  ,(-   9              " @7!9 0!X;"]W;W)K<VAE971S+W-H
M965T-#0N>&UL4$L! A0#%     @ [H555O8*\'#K!0  =@X  !D
M     ("!TUX! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4
M" #NA556XX#/#O$)  !B3P  &0              @('U9 $ >&PO=V]R:W-H
M965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( .Z%55:A_W,C* D  "U6   9
M              " @1UO 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L!
M A0#%     @ [H555MJL"&*N!   UQ$  !D              ("!?'@! 'AL
M+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " #NA556Y:/G*U4#
M  "&#   &0              @(%A?0$ >&PO=V]R:W-H965T<R]S:&5E=#0Y
M+GAM;%!+ 0(4 Q0    ( .Z%55:=[.Q9Z@,  "(5   9              "
M@>V  0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ [H55
M5L;*N\/, P  E1   !D              ("!#H4! 'AL+W=O<FMS:&5E=',O
M<VAE970U,2YX;6Q02P$"% ,4    " #NA556_S=:W6L4  !$3 $ &0
M        @($1B0$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0
M   ( .Z%55;#GS)Y'04  #,>   9              " @;.= 0!X;"]W;W)K
M<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ [H555HY*B2T(!@  JR4
M !D              ("!!Z,! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q0
M2P$"% ,4    " #NA556-,%S$@4#   1"@  &0              @(%&J0$
M>&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( .Z%55;I5:RC
M? 0  *,7   9              " @8*L 0!X;"]W;W)K<VAE971S+W-H965T
M-38N>&UL4$L! A0#%     @ [H555CS!G"IC P  9 D  !D
M ("!-;$! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    " #N
MA556;5#<8*T,  #B6@  &0              @('/M $ >&PO=V]R:W-H965T
M<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( .Z%55;&)\AKN08  /H@   9
M          " @;/! 0!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#
M%     @ [H555ET7&E1.!   [18  !D              ("!H\@! 'AL+W=O
M<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    " #NA5561%Q5_',(   &
M0P  &0              @($HS0$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM
M;%!+ 0(4 Q0    ( .Z%55;5Q[L.9P,  ,<*   9              " @=+5
M 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ [H555H("
M[J?G!0  52D  !D              ("!<-D! 'AL+W=O<FMS:&5E=',O<VAE
M970V,RYX;6Q02P$"% ,4    " #NA556='1)-1\"  "\!   &0
M    @(&.WP$ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    (
M .Z%55:\W'$ML@0  &DB   9              " @>3A 0!X;"]W;W)K<VAE
M971S+W-H965T-C4N>&UL4$L! A0#%     @ [H555C+E9J)5 P  -0\  !D
M             ("!S>8! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"
M% ,4    " #NA5560_-*?IP#   %#@  &0              @(%9Z@$ >&PO
M=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( .Z%55;?8YC@00,
M -T.   9              " @2SN 0!X;"]W;W)K<VAE971S+W-H965T-C@N
M>&UL4$L! A0#%     @ [H555N(,I<2V P  #0X  !D              ("!
MI/$! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4    " #NA556
M;FG+U"4#  ##"@  &0              @(&1]0$ >&PO=V]R:W-H965T<R]S
M:&5E=#<P+GAM;%!+ 0(4 Q0    ( .Z%558@X#8GEP0  )T;   9
M      " @>WX 0!X;"]W;W)K<VAE971S+W-H965T-S$N>&UL4$L! A0#%
M  @ [H555@K5A'9X @  G0<  !D              ("!N_T! 'AL+W=O<FMS
M:&5E=',O<VAE970W,BYX;6Q02P$"% ,4    " #NA5560((*:$X"   R!0
M&0              @(%J  ( >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+
M 0(4 Q0    ( .Z%55;8#.B]: (  !,&   9              " @>\" @!X
M;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @ [H555A+H<P<>
M P  L@H  !D              ("!C@4" 'AL+W=O<FMS:&5E=',O<VAE970W
M-2YX;6Q02P$"% ,4    " #NA5566P5%KGX1   _*@$ &0
M@('C" ( >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0    ( .Z%
M559<E.S-X 8  %HL   9              " @9@: @!X;"]W;W)K<VAE971S
M+W-H965T-S<N>&UL4$L! A0#%     @ [H555F+ND?\T!   /A0  !D
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M=#@R+GAM;%!+ 0(4 Q0    ( .Z%558Y!_-5%04  ! :   9
M  " @9@[ @!X;"]W;W)K<VAE971S+W-H965T.#,N>&UL4$L! A0#%     @
M[H555C&J_AA$!0  FRD  !D              ("!Y$ " 'AL+W=O<FMS:&5E
M=',O<VAE970X-"YX;6Q02P$"% ,4    " #NA556.0Z/'$0(  !=-P  &0
M            @(%?1@( >&PO=V]R:W-H965T<R]S:&5E=#@U+GAM;%!+ 0(4
M Q0    ( .Z%559V0F1%<P(  'T&   9              " @=I. @!X;"]W
M;W)K<VAE971S+W-H965T.#8N>&UL4$L! A0#%     @ [H555BV8MXE- P
MCA4   T              ( !A%$" 'AL+W-T>6QE<RYX;6Q02P$"% ,4
M" #NA556EXJ[',     3 @  "P              @ '\5 ( 7W)E;',O+G)E
M;'-02P$"% ,4    " #NA5564G4RLHL&  !S.   #P              @ 'E
M50( >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ [H555E(UQJ.* @  N3(
M !H              ( !G5P" 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ [H555H/1K $N @  1#$  !,              ( !7U\"
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     %X 7@#)&0  OF$"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>360</ContextCount>
  <ElementCount>513</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>105</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/DESCRIPTIONOFBUSINESS</Role>
      <ShortName>DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - REVENUE RECOGNITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/REVENUERECOGNITION</Role>
      <ShortName>REVENUE RECOGNITION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - EARNINGS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/EARNINGSPERSHARE</Role>
      <ShortName>EARNINGS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - RESTRUCTURING ACTIVITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIES</Role>
      <ShortName>RESTRUCTURING ACTIVITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - BUSINESS ACQUISITIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/BUSINESSACQUISITIONS</Role>
      <ShortName>BUSINESS ACQUISITIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - DISPOSITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/DISPOSITION</Role>
      <ShortName>DISPOSITION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - TAXES ON INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/TAXESONINCOME</Role>
      <ShortName>TAXES ON INCOME</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - SUPPLEMENTAL CASH FLOW AND OTHER DATA</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATA</Role>
      <ShortName>SUPPLEMENTAL CASH FLOW AND OTHER DATA</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - PROPERTY, PLANT AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENT</Role>
      <ShortName>PROPERTY, PLANT AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - GOODWILL AND INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETS</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSES</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/DEBT</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/FINANCIALINSTRUMENTS</Role>
      <ShortName>FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - STOCKHOLDERS??? EQUITY AND REDEEMABLE NONCONTROLLING INTEREST</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTEREST</Role>
      <ShortName>STOCKHOLDERS??? EQUITY AND REDEEMABLE NONCONTROLLING INTEREST</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - STOCK OWNERSHIP AND COMPENSATION PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANS</Role>
      <ShortName>STOCK OWNERSHIP AND COMPENSATION PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - BUSINESS SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATION</Role>
      <ShortName>BUSINESS SEGMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - REVENUE RECOGNITION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/REVENUERECOGNITIONTables</Role>
      <ShortName>REVENUE RECOGNITION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/REVENUERECOGNITION</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/EARNINGSLOSSPERSHARETables</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/EARNINGSPERSHARE</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - RESTRUCTURING ACTIVITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESTables</Role>
      <ShortName>RESTRUCTURING ACTIVITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIES</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTS</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - TAXES ON INCOME (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/TAXESONINCOMETables</Role>
      <ShortName>TAXES ON INCOME (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/TAXESONINCOME</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - SUPPLEMENTAL CASH FLOW AND OTHER DATA (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATATables</Role>
      <ShortName>SUPPLEMENTAL CASH FLOW AND OTHER DATA (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATA</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENTTables</Role>
      <ShortName>PROPERTY, PLANT AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENT</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSTables</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETS</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSES</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/DEBTTables</Role>
      <ShortName>DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/DEBT</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/LEASESTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/LEASES</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - FINANCIAL INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/FINANCIALINSTRUMENTSTables</Role>
      <ShortName>FINANCIAL INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/FINANCIALINSTRUMENTS</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - STOCKHOLDERS??? EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTTables</Role>
      <ShortName>STOCKHOLDERS??? EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTEREST</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - STOCK OWNERSHIP AND COMPENSATION PLANS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTables</Role>
      <ShortName>STOCK OWNERSHIP AND COMPENSATION PLANS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANS</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - BUSINESS SEGMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONTables</Role>
      <ShortName>BUSINESS SEGMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATION</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - REVENUE RECOGNITION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/REVENUERECOGNITIONDetails</Role>
      <ShortName>REVENUE RECOGNITION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/REVENUERECOGNITIONTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/EARNINGSLOSSPERSHAREDetails</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/EARNINGSLOSSPERSHARETables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - RESTRUCTURING ACTIVITIES (Pre-Tax Restructuring charges) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESPreTaxRestructuringchargesDetails</Role>
      <ShortName>RESTRUCTURING ACTIVITIES (Pre-Tax Restructuring charges) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - RESTRUCTURING ACTIVITIES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESNarrativeDetails</Role>
      <ShortName>RESTRUCTURING ACTIVITIES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - RESTRUCTURING ACTIVITIES (Activities of Restructuring Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESActivitiesofRestructuringLiabilitiesDetails</Role>
      <ShortName>RESTRUCTURING ACTIVITIES (Activities of Restructuring Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - BUSINESS ACQUISITIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails</Role>
      <ShortName>BUSINESS ACQUISITIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/BUSINESSACQUISITIONS</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - DISPOSITION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/DISPOSITIONDetails</Role>
      <ShortName>DISPOSITION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/DISPOSITION</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - FAIR VALUE MEASUREMENTS (Recognized Assets and Liabilities at Fair Value) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Recognized Assets and Liabilities at Fair Value) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - FAIR VALUE MEASUREMENTS (Business Acquisition) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSBusinessAcquisitionDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Business Acquisition) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - FAIR VALUE MEASUREMENTS (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - FAIR VALUE MEASUREMENTS (Reconciliation of Beginning and Ending Balances of Liabilities Unobservable Inputs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSReconciliationofBeginningandEndingBalancesofLiabilitiesUnobservableInputsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Reconciliation of Beginning and Ending Balances of Liabilities Unobservable Inputs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - TAXES ON INCOME (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/TAXESONINCOMEDetails</Role>
      <ShortName>TAXES ON INCOME (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/TAXESONINCOMETables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - SUPPLEMENTAL CASH FLOW AND OTHER DATA (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails</Role>
      <ShortName>SUPPLEMENTAL CASH FLOW AND OTHER DATA (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATATables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENTDetails</Role>
      <ShortName>PROPERTY, PLANT AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENTTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - DEBT (Long-Term Debt) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/DEBTLongTermDebtDetails</Role>
      <ShortName>DEBT (Long-Term Debt) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/DEBTTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - DEBT (Finance Lease) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/DEBTFinanceLeaseDetails</Role>
      <ShortName>DEBT (Finance Lease) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/DEBTTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - DEBT (Secured Receivables Credit Facility) (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/DEBTSecuredReceivablesCreditFacilityNarrativeDetails</Role>
      <ShortName>DEBT (Secured Receivables Credit Facility) (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/DEBTTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - DEBT (Senior Unsecured Revolving Credit Facility) (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/DEBTSeniorUnsecuredRevolvingCreditFacilityNarrativeDetails</Role>
      <ShortName>DEBT (Senior Unsecured Revolving Credit Facility) (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/DEBTTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - DEBT (Maturities of Long-Term Debt) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/DEBTMaturitiesofLongTermDebtDetails</Role>
      <ShortName>DEBT (Maturities of Long-Term Debt) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/DEBTTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - LEASES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/LEASESNarrativeDetails</Role>
      <ShortName>LEASES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/LEASESTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - LEASES (Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/LEASESLiabilitiesDetails</Role>
      <ShortName>LEASES (Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/LEASESTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - LEASES (Costs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/LEASESCostsDetails</Role>
      <ShortName>LEASES (Costs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/LEASESTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - LEASES (Maturity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/LEASESMaturityDetails</Role>
      <ShortName>LEASES (Maturity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/LEASESTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - LEASES (Term and Rate) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/LEASESTermandRateDetails</Role>
      <ShortName>LEASES (Term and Rate) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/LEASESTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - FINANCIAL INSTRUMENTS (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/FINANCIALINSTRUMENTSTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>0000074 - Disclosure - FINANCIAL INSTRUMENTS (Balance Sheets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/FINANCIALINSTRUMENTSBalanceSheetsDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS (Balance Sheets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/FINANCIALINSTRUMENTSTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>0000075 - Disclosure - FINANCIAL INSTRUMENTS (Income Statement) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/FINANCIALINSTRUMENTSIncomeStatementDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS (Income Statement) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/FINANCIALINSTRUMENTSTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>0000076 - Disclosure - STOCKHOLDERS??? EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>0000077 - Disclosure - STOCKHOLDERS??? EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Components of Accumulated Other Comprehensive (Loss) Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTComponentsofAccumulatedOtherComprehensiveLossIncomeDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Components of Accumulated Other Comprehensive (Loss) Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>0000078 - Disclosure - STOCK OWNERSHIP AND COMPENSATION PLANS (Employee and Non-employee Directors Stock Ownership Programs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeandNonemployeeDirectorsStockOwnershipProgramsDetails</Role>
      <ShortName>STOCK OWNERSHIP AND COMPENSATION PLANS (Employee and Non-employee Directors Stock Ownership Programs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>0000079 - Disclosure - STOCK OWNERSHIP AND COMPENSATION PLANS (Weighted Average Assumptions Used in Valuing Options Granted) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSWeightedAverageAssumptionsUsedinValuingOptionsGrantedDetails</Role>
      <ShortName>STOCK OWNERSHIP AND COMPENSATION PLANS (Weighted Average Assumptions Used in Valuing Options Granted) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>0000080 - Disclosure - STOCK OWNERSHIP AND COMPENSATION PLANS (Transactions Under Stock Option Plans) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTransactionsUnderStockOptionPlansDetails</Role>
      <ShortName>STOCK OWNERSHIP AND COMPENSATION PLANS (Transactions Under Stock Option Plans) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>0000081 - Disclosure - STOCK OWNERSHIP AND COMPENSATION PLANS (Activities Related to Stock Awards) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSActivitiesRelatedtoStockAwardsDetails</Role>
      <ShortName>STOCK OWNERSHIP AND COMPENSATION PLANS (Activities Related to Stock Awards) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>0000082 - Disclosure - STOCK OWNERSHIP AND COMPENSATION PLANS (Employee Stock Purchase Plan and Defined Contribution Plans) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeStockPurchasePlanandDefinedContributionPlansDetails</Role>
      <ShortName>STOCK OWNERSHIP AND COMPENSATION PLANS (Employee Stock Purchase Plan and Defined Contribution Plans) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>0000083 - Disclosure - STOCK OWNERSHIP AND COMPENSATION PLANS (Supplemental Deferred Compensation Plans) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSSupplementalDeferredCompensationPlansDetails</Role>
      <ShortName>STOCK OWNERSHIP AND COMPENSATION PLANS (Supplemental Deferred Compensation Plans) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>0000084 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>0000085 - Disclosure - BUSINESS SEGMENT INFORMATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails</Role>
      <ShortName>BUSINESS SEGMENT INFORMATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="dgx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>0000086 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://questdiagnostics.com/role/SUBSEQUENTEVENTSDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://questdiagnostics.com/role/SUBSEQUENTEVENTS</ParentRole>
      <Position>86</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 4 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:FiniteLivedIntangibleAssetUsefulLife, us-gaap:PropertyPlantAndEquipmentUsefulLife -  dgx-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="dgx-20221231.htm">dgx-20221231.htm</File>
    <File>dgx-20221231.xsd</File>
    <File>dgx-20221231_cal.xml</File>
    <File>dgx-20221231_def.xml</File>
    <File>dgx-20221231_lab.xml</File>
    <File>dgx-20221231_pre.xml</File>
    <File>dgx12312022ex1010.htm</File>
    <File>dgx12312022ex1020.htm</File>
    <File>dgx12312022ex105.htm</File>
    <File>dgx12312022ex211.htm</File>
    <File>dgx12312022ex22.htm</File>
    <File>dgx12312022ex231.htm</File>
    <File>dgx12312022ex311.htm</File>
    <File>dgx12312022ex312.htm</File>
    <File>dgx12312022ex321.htm</File>
    <File>dgx12312022ex322.htm</File>
    <File>dgx12312022ex432.htm</File>
    <File>dgx12312022ex9910.htm</File>
    <File>dgx12312022ex9912.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>dgx-20221231_g1.jpg</File>
    <File>dgx-20221231_g2.jpg</File>
    <File>dgx-20221231_g3.jpg</File>
    <File>dgx-20221231_g4.jpg</File>
    <File>dgx-20221231_g5.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1336">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>118
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "dgx-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 33,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 1336,
    "http://xbrl.sec.gov/dei/2022": 37
   },
   "contextCount": 360,
   "dts": {
    "calculationLink": {
     "local": [
      "dgx-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "dgx-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "dgx-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "dgx-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "dgx-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "dgx-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 780,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 12,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 16
   },
   "keyCustom": 73,
   "keyStandard": 440,
   "memberCustom": 53,
   "memberStandard": 50,
   "nsprefix": "dgx",
   "nsuri": "http://questdiagnostics.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://questdiagnostics.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - REVENUE RECOGNITION",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://questdiagnostics.com/role/REVENUERECOGNITION",
     "shortName": "REVENUE RECOGNITION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - EARNINGS PER SHARE",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://questdiagnostics.com/role/EARNINGSPERSHARE",
     "shortName": "EARNINGS PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - RESTRUCTURING ACTIVITIES",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIES",
     "shortName": "RESTRUCTURING ACTIVITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - BUSINESS ACQUISITIONS",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://questdiagnostics.com/role/BUSINESSACQUISITIONS",
     "shortName": "BUSINESS ACQUISITIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - DISPOSITION",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://questdiagnostics.com/role/DISPOSITION",
     "shortName": "DISPOSITION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - FAIR VALUE MEASUREMENTS",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - TAXES ON INCOME",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://questdiagnostics.com/role/TAXESONINCOME",
     "shortName": "TAXES ON INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - SUPPLEMENTAL CASH FLOW AND OTHER DATA",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATA",
     "shortName": "SUPPLEMENTAL CASH FLOW AND OTHER DATA",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - PROPERTY, PLANT AND EQUIPMENT",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENT",
     "shortName": "PROPERTY, PLANT AND EQUIPMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://questdiagnostics.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - GOODWILL AND INTANGIBLE ASSETS",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETS",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://questdiagnostics.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSES",
     "shortName": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - DEBT",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://questdiagnostics.com/role/DEBT",
     "shortName": "DEBT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - LEASES",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://questdiagnostics.com/role/LEASES",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - FINANCIAL INSTRUMENTS",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://questdiagnostics.com/role/FINANCIALINSTRUMENTS",
     "shortName": "FINANCIAL INSTRUMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - STOCKHOLDERS\u2019 EQUITY AND REDEEMABLE NONCONTROLLING INTEREST",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTEREST",
     "shortName": "STOCKHOLDERS\u2019 EQUITY AND REDEEMABLE NONCONTROLLING INTEREST",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - STOCK OWNERSHIP AND COMPENSATION PLANS",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANS",
     "shortName": "STOCK OWNERSHIP AND COMPENSATION PLANS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "menuCat": "Notes",
     "order": "27",
     "role": "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - BUSINESS SEGMENT INFORMATION",
     "menuCat": "Notes",
     "order": "28",
     "role": "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATION",
     "shortName": "BUSINESS SEGMENT INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - SUBSEQUENT EVENTS",
     "menuCat": "Notes",
     "order": "29",
     "role": "http://questdiagnostics.com/role/SUBSEQUENTEVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i2255f9500efa4f9fbb33148f349cbf15_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i2255f9500efa4f9fbb33148f349cbf15_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "menuCat": "Policies",
     "order": "30",
     "role": "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - REVENUE RECOGNITION (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://questdiagnostics.com/role/REVENUERECOGNITIONTables",
     "shortName": "REVENUE RECOGNITION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://questdiagnostics.com/role/EARNINGSLOSSPERSHARETables",
     "shortName": "EARNINGS (LOSS) PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - RESTRUCTURING ACTIVITIES (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESTables",
     "shortName": "RESTRUCTURING ACTIVITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSTables",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - TAXES ON INCOME (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://questdiagnostics.com/role/TAXESONINCOMETables",
     "shortName": "TAXES ON INCOME (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - SUPPLEMENTAL CASH FLOW AND OTHER DATA (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATATables",
     "shortName": "SUPPLEMENTAL CASH FLOW AND OTHER DATA (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENTTables",
     "shortName": "PROPERTY, PLANT AND EQUIPMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSTables",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://questdiagnostics.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables",
     "shortName": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i2255f9500efa4f9fbb33148f349cbf15_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i2255f9500efa4f9fbb33148f349cbf15_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - DEBT (Tables)",
     "menuCat": "Tables",
     "order": "40",
     "role": "http://questdiagnostics.com/role/DEBTTables",
     "shortName": "DEBT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dgx:ScheduleOfLeaseByAssetTypeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - LEASES (Tables)",
     "menuCat": "Tables",
     "order": "41",
     "role": "http://questdiagnostics.com/role/LEASESTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dgx:ScheduleOfLeaseByAssetTypeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - FINANCIAL INSTRUMENTS (Tables)",
     "menuCat": "Tables",
     "order": "42",
     "role": "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSTables",
     "shortName": "FINANCIAL INSTRUMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - STOCKHOLDERS\u2019 EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Tables)",
     "menuCat": "Tables",
     "order": "43",
     "role": "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTTables",
     "shortName": "STOCKHOLDERS\u2019 EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - STOCK OWNERSHIP AND COMPENSATION PLANS (Tables)",
     "menuCat": "Tables",
     "order": "44",
     "role": "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTables",
     "shortName": "STOCK OWNERSHIP AND COMPENSATION PLANS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - BUSINESS SEGMENT INFORMATION (Tables)",
     "menuCat": "Tables",
     "order": "45",
     "role": "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONTables",
     "shortName": "BUSINESS SEGMENT INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AdvertisingCostsPolicyTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdvertisingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AdvertisingCostsPolicyTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdvertisingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "dgx:PercentageofNetRevenues",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - REVENUE RECOGNITION (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails",
     "shortName": "REVENUE RECOGNITION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://questdiagnostics.com/role/EARNINGSLOSSPERSHAREDetails",
     "shortName": "EARNINGS (LOSS) PER SHARE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - RESTRUCTURING ACTIVITIES (Pre-Tax Restructuring charges) (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESPreTaxRestructuringchargesDetails",
     "shortName": "RESTRUCTURING ACTIVITIES (Pre-Tax Restructuring charges) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i2188840dc2a3430ebc240517ab668786_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - RESTRUCTURING ACTIVITIES (Narrative) (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESNarrativeDetails",
     "shortName": "RESTRUCTURING ACTIVITIES (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "ic2dc2704459f476aa2a7a5bdd5d24a31_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - RESTRUCTURING ACTIVITIES (Activities of Restructuring Liabilities) (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESActivitiesofRestructuringLiabilitiesDetails",
     "shortName": "RESTRUCTURING ACTIVITIES (Activities of Restructuring Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i872b3ea2e369403f8c0129ff07e0b538_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - BUSINESS ACQUISITIONS (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails",
     "shortName": "BUSINESS ACQUISITIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - DISPOSITION (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://questdiagnostics.com/role/DISPOSITIONDetails",
     "shortName": "DISPOSITION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i5953c712e4234176ac0378246142fc74_D20210401-20210401",
      "decimals": "-6",
      "lang": "en-US",
      "name": "dgx:ProceedsFromSaleOfEquityMethodInvestmentsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i2255f9500efa4f9fbb33148f349cbf15_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - FAIR VALUE MEASUREMENTS (Recognized Assets and Liabilities at Fair Value) (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails",
     "shortName": "FAIR VALUE MEASUREMENTS (Recognized Assets and Liabilities at Fair Value) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i2a46256065f64a1f83735b542ac8cd05_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CashSurrenderValueFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "iec1e53779a1a46e382c71420c86a8e65_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - FAIR VALUE MEASUREMENTS (Business Acquisition) (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSBusinessAcquisitionDetails",
     "shortName": "FAIR VALUE MEASUREMENTS (Business Acquisition) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "iec1e53779a1a46e382c71420c86a8e65_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiGainLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - FAIR VALUE MEASUREMENTS (Narrative) (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENTS (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i2255f9500efa4f9fbb33148f349cbf15_I20221231",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i1029a7e4535b4243bba665741dbd11de_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - FAIR VALUE MEASUREMENTS (Reconciliation of Beginning and Ending Balances of Liabilities Unobservable Inputs) (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSReconciliationofBeginningandEndingBalancesofLiabilitiesUnobservableInputsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS (Reconciliation of Beginning and Ending Balances of Liabilities Unobservable Inputs) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "ie2740945331a4803b48ca4d039b3724f_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - TAXES ON INCOME (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://questdiagnostics.com/role/TAXESONINCOMEDetails",
     "shortName": "TAXES ON INCOME (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - SUPPLEMENTAL CASH FLOW AND OTHER DATA (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails",
     "shortName": "SUPPLEMENTAL CASH FLOW AND OTHER DATA (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i2255f9500efa4f9fbb33148f349cbf15_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENTDetails",
     "shortName": "PROPERTY, PLANT AND EQUIPMENT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i2255f9500efa4f9fbb33148f349cbf15_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillPeriodIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i2255f9500efa4f9fbb33148f349cbf15_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://questdiagnostics.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails",
     "shortName": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i2255f9500efa4f9fbb33148f349cbf15_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i2255f9500efa4f9fbb33148f349cbf15_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - DEBT (Long-Term Debt) (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://questdiagnostics.com/role/DEBTLongTermDebtDetails",
     "shortName": "DEBT (Long-Term Debt) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i3e9c816b535f468b832f1fb4f7578811_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherLongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i3f456f42e2b64e4cb74fbc8ba3ba7668_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "dgx:FinanceLeaseLiabilityRealEstate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - DEBT (Finance Lease) (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://questdiagnostics.com/role/DEBTFinanceLeaseDetails",
     "shortName": "DEBT (Finance Lease) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i3f456f42e2b64e4cb74fbc8ba3ba7668_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "dgx:FinanceLeaseLiabilityRealEstate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "ie3e292d5aced49a991453002828a13bf_D20221001-20221031",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dgx:DebtInstrumentExtensionPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - DEBT (Secured Receivables Credit Facility) (Narrative) (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://questdiagnostics.com/role/DEBTSecuredReceivablesCreditFacilityNarrativeDetails",
     "shortName": "DEBT (Secured Receivables Credit Facility) (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "ie3e292d5aced49a991453002828a13bf_D20221001-20221031",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dgx:DebtInstrumentExtensionPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "ied9b303df1ae4f6daa7db9f2e1d5d9f0_I20211130",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - DEBT (Senior Unsecured Revolving Credit Facility) (Narrative) (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://questdiagnostics.com/role/DEBTSeniorUnsecuredRevolvingCreditFacilityNarrativeDetails",
     "shortName": "DEBT (Senior Unsecured Revolving Credit Facility) (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "ied9b303df1ae4f6daa7db9f2e1d5d9f0_I20211130",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i2255f9500efa4f9fbb33148f349cbf15_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - DEBT (Maturities of Long-Term Debt) (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://questdiagnostics.com/role/DEBTMaturitiesofLongTermDebtDetails",
     "shortName": "DEBT (Maturities of Long-Term Debt) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i2255f9500efa4f9fbb33148f349cbf15_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i2255f9500efa4f9fbb33148f349cbf15_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - LEASES (Narrative) (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://questdiagnostics.com/role/LEASESNarrativeDetails",
     "shortName": "LEASES (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i4a8532c66ad64ac990f07caabad868b2_D20220101-20221231",
      "decimals": null,
      "lang": "en-US",
      "name": "dgx:LeaseRemainingLeaseTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i2255f9500efa4f9fbb33148f349cbf15_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - LEASES (Liabilities) (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://questdiagnostics.com/role/LEASESLiabilitiesDetails",
     "shortName": "LEASES (Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i2255f9500efa4f9fbb33148f349cbf15_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "dgx:GainLossOnDispositionOfJointVenture",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "dgx:OperatingLeaseFixedAndVariableCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - LEASES (Costs) (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://questdiagnostics.com/role/LEASESCostsDetails",
     "shortName": "LEASES (Costs) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "dgx:OperatingLeaseFixedAndVariableCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i2255f9500efa4f9fbb33148f349cbf15_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - LEASES (Maturity) (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://questdiagnostics.com/role/LEASESMaturityDetails",
     "shortName": "LEASES (Maturity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i2255f9500efa4f9fbb33148f349cbf15_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i2255f9500efa4f9fbb33148f349cbf15_I20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - LEASES (Term and Rate) (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://questdiagnostics.com/role/LEASESTermandRateDetails",
     "shortName": "LEASES (Term and Rate) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i2255f9500efa4f9fbb33148f349cbf15_I20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i2255f9500efa4f9fbb33148f349cbf15_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - FINANCIAL INSTRUMENTS (Narrative) (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
     "shortName": "FINANCIAL INSTRUMENTS (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i723c452601804300bcd7029176377b7a_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000074 - Disclosure - FINANCIAL INSTRUMENTS (Balance Sheets) (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSBalanceSheetsDetails",
     "shortName": "FINANCIAL INSTRUMENTS (Balance Sheets) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i723c452601804300bcd7029176377b7a_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherNonoperatingIncomeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000075 - Disclosure - FINANCIAL INSTRUMENTS (Income Statement) (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSIncomeStatementDetails",
     "shortName": "FINANCIAL INSTRUMENTS (Income Statement) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i2255f9500efa4f9fbb33148f349cbf15_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000076 - Disclosure - STOCKHOLDERS\u2019 EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Narrative) (Details)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails",
     "shortName": "STOCKHOLDERS\u2019 EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockDividendsPerShareDeclared",
       "us-gaap:CommonStockDividendsPerShareDeclared",
       "us-gaap:CommonStockDividendsPerShareDeclared",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i7f7bde7107be4688966df19bafdeea10_D20221001-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i34d39af68edd4e0aaa2c32fc41a6ba66_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000077 - Disclosure - STOCKHOLDERS\u2019 EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Components of Accumulated Other Comprehensive (Loss) Income (Details)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTComponentsofAccumulatedOtherComprehensiveLossIncomeDetails",
     "shortName": "STOCKHOLDERS\u2019 EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Components of Accumulated Other Comprehensive (Loss) Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "icb6d00d91a6d489898ca322307bd7551_I20191231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000078 - Disclosure - STOCK OWNERSHIP AND COMPENSATION PLANS (Employee and Non-employee Directors Stock Ownership Programs) (Details)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeandNonemployeeDirectorsStockOwnershipProgramsDetails",
     "shortName": "STOCK OWNERSHIP AND COMPENSATION PLANS (Employee and Non-employee Directors Stock Ownership Programs) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000079 - Disclosure - STOCK OWNERSHIP AND COMPENSATION PLANS (Weighted Average Assumptions Used in Valuing Options Granted) (Details)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSWeightedAverageAssumptionsUsedinValuingOptionsGrantedDetails",
     "shortName": "STOCK OWNERSHIP AND COMPENSATION PLANS (Weighted Average Assumptions Used in Valuing Options Granted) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i60096e15242147fba12636c6498e0696_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i60096e15242147fba12636c6498e0696_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "ie7fd18a6db5a4c6bb7e209edcc7ba998_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000080 - Disclosure - STOCK OWNERSHIP AND COMPENSATION PLANS (Transactions Under Stock Option Plans) (Details)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTransactionsUnderStockOptionPlansDetails",
     "shortName": "STOCK OWNERSHIP AND COMPENSATION PLANS (Transactions Under Stock Option Plans) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "iecaf266ba15d4c5da2f6be8c3e8e76bd_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000081 - Disclosure - STOCK OWNERSHIP AND COMPENSATION PLANS (Activities Related to Stock Awards) (Details)",
     "menuCat": "Details",
     "order": "81",
     "role": "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSActivitiesRelatedtoStockAwardsDetails",
     "shortName": "STOCK OWNERSHIP AND COMPENSATION PLANS (Activities Related to Stock Awards) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000082 - Disclosure - STOCK OWNERSHIP AND COMPENSATION PLANS (Employee Stock Purchase Plan and Defined Contribution Plans) (Details)",
     "menuCat": "Details",
     "order": "82",
     "role": "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeStockPurchasePlanandDefinedContributionPlansDetails",
     "shortName": "STOCK OWNERSHIP AND COMPENSATION PLANS (Employee Stock Purchase Plan and Defined Contribution Plans) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i4c9530356f3242cdb77f114a2aa32961_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000083 - Disclosure - STOCK OWNERSHIP AND COMPENSATION PLANS (Supplemental Deferred Compensation Plans) (Details)",
     "menuCat": "Details",
     "order": "83",
     "role": "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSSupplementalDeferredCompensationPlansDetails",
     "shortName": "STOCK OWNERSHIP AND COMPENSATION PLANS (Supplemental Deferred Compensation Plans) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i3984e240129249f2b9f78c9c4f3a1818_D20220101-20221231",
      "decimals": "2",
      "lang": "en-US",
      "name": "dgx:SupplementalDeferredCompensationPlanSalaryDeferral",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i2255f9500efa4f9fbb33148f349cbf15_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000084 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "menuCat": "Details",
     "order": "84",
     "role": "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i2255f9500efa4f9fbb33148f349cbf15_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "dgx:PercentageofNetRevenues",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000085 - Disclosure - BUSINESS SEGMENT INFORMATION (Details)",
     "menuCat": "Details",
     "order": "85",
     "role": "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails",
     "shortName": "BUSINESS SEGMENT INFORMATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "dgx:RevenueFromContractWithCustomerExcludingAssessedTaxPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000086 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "menuCat": "Details",
     "order": "86",
     "role": "http://questdiagnostics.com/role/SUBSEQUENTEVENTSDetails",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - DESCRIPTION OF BUSINESS",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://questdiagnostics.com/role/DESCRIPTIONOFBUSINESS",
     "shortName": "DESCRIPTION OF BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dgx-20221231.htm",
      "contextRef": "i33480409a35f4cc9b09ab3a1c921bfe2_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 105,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r736",
      "r737",
      "r738"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://questdiagnostics.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r736",
      "r737",
      "r738"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://questdiagnostics.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r736",
      "r737",
      "r738"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://questdiagnostics.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r736",
      "r737",
      "r738"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r736",
      "r737",
      "r738"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dgx_AcceleratedShareRepurchaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accelerated Share Repurchase Agreements",
        "label": "Accelerated Share Repurchase Agreements [Member]",
        "terseLabel": "Accelerated Share Repurchase Agreements"
       }
      }
     },
     "localname": "AcceleratedShareRepurchaseAgreementsMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/EARNINGSLOSSPERSHAREDetails",
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_AcceleratedShareRepurchasesPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accelerated Share Repurchases, Payment",
        "label": "Accelerated Share Repurchases, Payment",
        "terseLabel": "Accelerated share repurchases, payment"
       }
      }
     },
     "localname": "AcceleratedShareRepurchasesPayment",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/EARNINGSLOSSPERSHAREDetails",
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_AccountsReceivableAndAllowanceForCreditLossesPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable and Allowance for Credit Losses Policy",
        "label": "Accounts Receivable and Allowance for Credit Losses Policy [Policy Text Block]",
        "terseLabel": "Accounts Receivable and Allowance for Credit Losses"
       }
      }
     },
     "localname": "AccountsReceivableAndAllowanceForCreditLossesPolicyPolicyTextBlock",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dgx_AccountsReceivableDisaggregationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable Disaggregation [Table Text Block]",
        "label": "Accounts Receivable Disaggregation [Table Text Block]",
        "terseLabel": "Accounts Receivable Disaggregation"
       }
      }
     },
     "localname": "AccountsReceivableDisaggregationTableTextBlock",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/REVENUERECOGNITIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dgx_AgreementtoOutsourceBillingandCollectionFunction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement to Outsource Billing and Collection Function",
        "label": "Agreement to Outsource Billing and Collection Function",
        "terseLabel": "Agreement to outsource billing and collection function"
       }
      }
     },
     "localname": "AgreementtoOutsourceBillingandCollectionFunction",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dgx_AllotherservicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All other services [Member]",
        "label": "All other services [Member]",
        "terseLabel": "All other services"
       }
      }
     },
     "localname": "AllotherservicesMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_AnatomicpathologytestingservicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Anatomic pathology testing services [Member]",
        "label": "Anatomic pathology testing services [Member]",
        "terseLabel": "Anatomic pathology testing services"
       }
      }
     },
     "localname": "AnatomicpathologytestingservicesMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]",
        "terseLabel": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://questdiagnostics.com/20221231",
     "xbrltype": "stringItemType"
    },
    "dgx_BlueprintGeneticsOyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Blueprint Genetics Oy [Member]",
        "label": "Blueprint Genetics Oy [Member]",
        "terseLabel": "Blueprint Genetics Oy"
       }
      }
     },
     "localname": "BlueprintGeneticsOyMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_BusinessAcquisitionPostacquisitionRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Post-acquisition Revenue",
        "label": "Business Acquisition, Post-acquisition Revenue",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "BusinessAcquisitionPostacquisitionRevenue",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinanceLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finance Lease Liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finance Lease Liabilities",
        "terseLabel": "Finance lease liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinanceLeaseLiabilities",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Right-of-Use Assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Right-of-Use Assets",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFiniteLivedIntangibles1": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles1",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles1",
        "terseLabel": "Finite-lived intangibles"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFiniteLivedIntangibles1",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedPropertyPlantandEquipmentandWorkingCapital": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment and Working Capital",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment and Working Capital",
        "terseLabel": "Property, plant, and equipment and working capital"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedPropertyPlantandEquipmentandWorkingCapital",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedWorkingCapital": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Working Capital",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Working Capital",
        "terseLabel": "Working capital"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedWorkingCapital",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeDicountRateUsedToDetermineFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Dicount Rate used to determine fair value",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Dicount Rate used to determine fair value",
        "terseLabel": "Equity interest in acquiree, discount rate used to determine fair value"
       }
      }
     },
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeDicountRateUsedToDetermineFairValue",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dgx_BusinessCombinationStepAcquisitionEquityInterestInAcquireeLongTermGrowthRateUsedToDetermineFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Long-term Growth Rate used to determine fair value",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Long-term Growth Rate used to determine fair value",
        "terseLabel": "Equity interest in acquiree, long-term growth rate used to determine fair value"
       }
      }
     },
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeLongTermGrowthRateUsedToDetermineFairValue",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dgx_COVID19TestingServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19 Testing Services",
        "label": "COVID-19 Testing Services [Member]",
        "terseLabel": "COVID-19 testing services"
       }
      }
     },
     "localname": "COVID19TestingServicesMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_CapitatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitated [Member]",
        "label": "Capitated [Member]",
        "terseLabel": "Capitated"
       }
      }
     },
     "localname": "CapitatedMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_ClientPayersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Client Payers [Member]",
        "label": "Client Payers [Member]",
        "terseLabel": "Client payers"
       }
      }
     },
     "localname": "ClientPayersMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_CommercialPaperAndTermSecuredOvernightFinancingRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Paper and Term Secured Overnight Financing Rate",
        "label": "Commercial Paper and Term Secured Overnight Financing Rate [Member]",
        "terseLabel": "Commercial Paper and Term Secured Overnight Financing Rate"
       }
      }
     },
     "localname": "CommercialPaperAndTermSecuredOvernightFinancingRateMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/DEBTSecuredReceivablesCreditFacilityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_ContingentConsiderationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration [Member]",
        "label": "Contingent Consideration [Member]",
        "terseLabel": "Contingent Consideration"
       }
      }
     },
     "localname": "ContingentConsiderationMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails",
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSReconciliationofBeginningandEndingBalancesofLiabilitiesUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_ContractualLifeOfStockOptionsAndOtherAwardsUnderSharedBasedCompensationPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual life of stock options and other awards under the Shared-based compensation plans",
        "label": "Contractual life of stock options and other awards under the Shared-based compensation plans",
        "terseLabel": "Contractual life of stock options and other awards under the shared-based compensation plans"
       }
      }
     },
     "localname": "ContractualLifeOfStockOptionsAndOtherAwardsUnderSharedBasedCompensationPlans",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeandNonemployeeDirectorsStockOwnershipProgramsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dgx_DSBusinessesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DS Businesses [Member]",
        "label": "DS Businesses [Member]",
        "terseLabel": "DS"
       }
      }
     },
     "localname": "DSBusinessesMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_DebtInstrumentExtensionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument, Extension Period",
        "label": "Debt instrument, Extension Period",
        "terseLabel": "Extension period"
       }
      }
     },
     "localname": "DebtInstrumentExtensionPeriod",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/DEBTSecuredReceivablesCreditFacilityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dgx_DebtInstrumentFairValueBasisAdjustmentAttributableToHedgedDebt": {
     "auth_ref": [],
     "calculation": {
      "http://questdiagnostics.com/role/DEBTMaturitiesofLongTermDebtDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, fair value basis adjustment attributable to hedged debt",
        "label": "Debt Instrument, fair value basis adjustment attributable to hedged debt",
        "negatedTerseLabel": "Fair value basis adjustments attributable to hedged debt"
       }
      }
     },
     "localname": "DebtInstrumentFairValueBasisAdjustmentAttributableToHedgedDebt",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/DEBTMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_DeferredTaxAssetsOperatingLeaseLiabilitiesNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Operating Lease Liabilities, Noncurrent",
        "label": "Deferred Tax Assets, Operating Lease Liabilities, Noncurrent",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilitiesNoncurrent",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsAccountsReceivables": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accounts Receivables",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accounts Receivables",
        "terseLabel": "Accounts receivable reserves"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsAccountsReceivables",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_DeferredTaxLiabilityInvestmentsInvestmentsinSubsidiariesandEquitymethodinvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liability, Investments, Investments in Subsidiaries and Equity method investments",
        "label": "Deferred Tax Liability, Investments, Investments in Subsidiaries and Equity method investments",
        "negatedTerseLabel": "Basis differences in investments, joint ventures and subsidiaries"
       }
      }
     },
     "localname": "DeferredTaxLiabilityInvestmentsInvestmentsinSubsidiariesandEquitymethodinvestments",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_DiagnosticInformationServicesBusinessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Diagnostic Information Services Business [Member]",
        "label": "Diagnostic Information Services Business [Member]",
        "terseLabel": "DIS business"
       }
      }
     },
     "localname": "DiagnosticInformationServicesBusinessMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails",
      "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails",
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_DonationsContributionsAndOtherFinancialSupport": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Donations, Contributions, and Other Financial Support",
        "label": "Donations, Contributions, and Other Financial Support",
        "terseLabel": "Donations, contributions, and other financial support"
       }
      }
     },
     "localname": "DonationsContributionsAndOtherFinancialSupport",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_EffectiveIncomeTaxRateReconciliationAdjustmentToStateDeferredTaxLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Adjustment To State Deferred Tax Liabilities",
        "label": "Effective Income Tax Rate Reconciliation, Adjustment To State Deferred Tax Liabilities",
        "terseLabel": "Adjustment to state deferred tax liabilities"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAdjustmentToStateDeferredTaxLiabilities",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dgx_EffectiveIncomeTaxRateReconciliationChangeForUncertainTaxPosition": {
     "auth_ref": [],
     "calculation": {
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Change for uncertain tax position",
        "label": "Effective Income Tax Rate Reconciliation, Change for uncertain tax position",
        "terseLabel": "Changes in reserves for uncertain tax positions"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeForUncertainTaxPosition",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dgx_EmployeeLongTermIncentivePlanEltipMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Long-Term Incentive Plan (ELTIP) (Member)",
        "label": "Employee Long Term Incentive Plan Eltip [Member]",
        "terseLabel": "Employee Long Term Incentive Plan ELTIP"
       }
      }
     },
     "localname": "EmployeeLongTermIncentivePlanEltipMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeandNonemployeeDirectorsStockOwnershipProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_EquityMethodInvestmentOwnershipPercentDisposedOf": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Ownership Percent Disposed Of",
        "label": "Equity Method Investment, Ownership Percent Disposed Of",
        "terseLabel": "Percent of ownership interest sold"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentDisposedOf",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/DISPOSITIONDetails",
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails",
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dgx_EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Excluding Deferred Compensation Trading Securities",
        "label": "Equity Securities, FV-NI, Excluding Deferred Compensation Trading Securities",
        "terseLabel": "Equity investments"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIExcludingDeferredCompensationTradingSecurities",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails",
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_FairValueOfNetAssetsAcquired": {
     "auth_ref": [],
     "calculation": {
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of net assets acquired",
        "label": "Fair value of net assets acquired",
        "totalLabel": "Fair value of net assets acquired"
       }
      }
     },
     "localname": "FairValueOfNetAssetsAcquired",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_FeeforserviceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fee-for-service [Member]",
        "label": "Fee-for-service [Member]",
        "terseLabel": "Fee-for-service"
       }
      }
     },
     "localname": "FeeforserviceMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_FinanceLeaseLiabilityRealEstate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Liability, Real Estate",
        "label": "Finance Lease, Liability, Real Estate",
        "terseLabel": "Finance lease liability, real estate"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityRealEstate",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/DEBTFinanceLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_FinanceLeaseObligationsandOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease Obligations and Other [Member]",
        "label": "Finance Lease Obligations and Other [Member]",
        "terseLabel": "Other",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "FinanceLeaseObligationsandOtherMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/DEBTFinanceLeaseDetails",
      "http://questdiagnostics.com/role/DEBTLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_FinanceandOperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance and Operating Lease Liabilities, Payments, Due [Abstract]",
        "label": "Finance and Operating Lease Liabilities, Payments, Due [Abstract]",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "FinanceandOperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived and Indefinite-lived Intangible Assets [Line Items]",
        "label": "Finite-Lived and Indefinite-lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived and Indefinite-lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived and Indefinite-lived Intangible Assets [Table]",
        "label": "Finite-Lived and Indefinite-lived Intangible Assets [Table]",
        "terseLabel": "Finite-Lived and Indefinite-lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsTable",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dgx_FiniteLivedIntangibleAssetsEstimatedAmortizationExpenseTotal": {
     "auth_ref": [],
     "calculation": {
      "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-lived intangible assets, estimated amortization expense, total.",
        "label": "Finite-lived intangible assets, Estimated amortization expense, total",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsEstimatedAmortizationExpenseTotal",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_FivePointSevenFivePercentSeniorNotesDue2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Point Seven Five Percent Senior Notes Due 2040 [Member]",
        "label": "Five Point Seven Five Percent Senior Notes Due2040 [Member]",
        "terseLabel": "5.75% Senior Notes due January 2040"
       }
      }
     },
     "localname": "FivePointSevenFivePercentSeniorNotesDue2040Member",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/DEBTLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_ForeignCurrencyTranslationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Currency Translation",
        "label": "Foreign Currency Translation [Member]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTranslationMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/DISPOSITIONDetails",
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_FourPointSevenZeroPercentSeniorNotesdueMarch2045Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point Seven Zero Percent Senior Notes due March 2045 [Member]",
        "label": "Four Point Seven Zero Percent Senior Notes due March 2045 [Member]",
        "terseLabel": "4.70% Senior Notes due March 2045"
       }
      }
     },
     "localname": "FourPointSevenZeroPercentSeniorNotesdueMarch2045Member",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/DEBTLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_FourPointTwoZeroPercentSeniorNotesdueJune2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point Two Zero Percent Senior Notes due June 2029 [Member]",
        "label": "Four Point Two Zero Percent Senior Notes due June 2029 [Member]",
        "terseLabel": "4.20% Senior Notes due June 2029"
       }
      }
     },
     "localname": "FourPointTwoZeroPercentSeniorNotesdueJune2029Member",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/DEBTLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_FourpointtwofivepercentSeniorNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four point two five percent Senior Notes Due 2024 [Member]",
        "label": "Four point two five percent Senior Notes Due 2024 [Member]",
        "terseLabel": "4.25% Senior Notes due April 2024"
       }
      }
     },
     "localname": "FourpointtwofivepercentSeniorNotesDue2024Member",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/DEBTLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_FundsinatrustpertainingtoallparticipantdeferralsandcompanymatchingamountsrelatedtotheSDCP": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funds in a trust pertaining to all participant deferrals and company matching amounts related to the Supplemental Deferred Compensation Plan.",
        "label": "Funds in a trust pertaining to all participant deferrals and company matching amounts related to the SDCP",
        "terseLabel": "Funds in a trust pertaining to all participant deferrals and company matching amounts related to the SDCP"
       }
      }
     },
     "localname": "FundsinatrustpertainingtoallparticipantdeferralsandcompanymatchingamountsrelatedtotheSDCP",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSSupplementalDeferredCompensationPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_GainLossOnDispositionOfJointVenture": {
     "auth_ref": [],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) on Disposition of Joint Venture",
        "label": "Gain (Loss) on Disposition of Joint Venture",
        "negatedTerseLabel": "Gain on disposition of joint venture"
       }
      }
     },
     "localname": "GainLossOnDispositionOfJointVenture",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_GenebasedandesoterictestingservicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gene-based and esoteric testing services [Member]",
        "label": "Gene-based and esoteric testing services [Member]",
        "terseLabel": "Gene-based and esoteric (including advanced diagnostics) testing services"
       }
      }
     },
     "localname": "GenebasedandesoterictestingservicesMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_GoodwillAcquiredDuringPeriodBeforeAdjustments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill, Acquired During Period, Before Adjustments",
        "label": "Goodwill, Acquired During Period, Before Adjustments",
        "terseLabel": "Goodwill acquired, before adjustments"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriodBeforeAdjustments",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_GovernmentPayersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Payers [Member]",
        "label": "Government Payers [Member]",
        "terseLabel": "Government payers"
       }
      }
     },
     "localname": "GovernmentPayersMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails",
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_HealthcareInsurersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Healthcare Insurers [Member]",
        "label": "Healthcare Insurers [Member]",
        "terseLabel": "Healthcare insurers:"
       }
      }
     },
     "localname": "HealthcareInsurersMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_IncreaseDecreaseinCommonStockDividendsDeclaredasPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Common Stock, Dividends, Declared as Percent",
        "label": "Increase (Decrease) in Common Stock, Dividends, Declared as Percent",
        "terseLabel": "Increase in quarterly dividends as percent"
       }
      }
     },
     "localname": "IncreaseDecreaseinCommonStockDividendsDeclaredasPercent",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dgx_InvestmentwithoutReadilyDeterminableFairValueImpairment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment without Readily Determinable Fair Value, Impairment",
        "label": "Investment without Readily Determinable Fair Value, Impairment",
        "terseLabel": "Impairment charges"
       }
      }
     },
     "localname": "InvestmentwithoutReadilyDeterminableFairValueImpairment",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_InvigorateProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Invigorate Program [Member]",
        "label": "Invigorate Program [Member]",
        "terseLabel": "Invigorate Program"
       }
      }
     },
     "localname": "InvigorateProgramMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESNarrativeDetails",
      "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESPreTaxRestructuringchargesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_LaboratoryEquipmentAndFurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment and furniture and fixtures [Member]",
        "label": "Laboratory Equipment And Furniture And Fixtures [Member]",
        "terseLabel": "Laboratory Equipment and Furniture and Fixtures"
       }
      }
     },
     "localname": "LaboratoryEquipmentAndFurnitureAndFixturesMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_LaboratoryEquipmentFurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment, Furniture and Fixtures [Member]",
        "label": "Laboratory Equipment, Furniture and Fixtures [Member]",
        "terseLabel": "Laboratory Equipment, Furniture and Fixtures"
       }
      }
     },
     "localname": "LaboratoryEquipmentFurnitureAndFixturesMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_LabtechDiagnosticsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Labtech Diagnostics, LLC",
        "label": "Labtech Diagnostics, LLC [Member]",
        "terseLabel": "Labtech Diagnostics, LLC"
       }
      }
     },
     "localname": "LabtechDiagnosticsLLCMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_LeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://questdiagnostics.com/role/LEASESLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Liability",
        "label": "Lease, Liability",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "LeaseLiability",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_LeaseRemainingLeaseTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Remaining Lease Term",
        "label": "Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease term"
       }
      }
     },
     "localname": "LeaseRemainingLeaseTerm",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dgx_LeaseRenewalTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Renewal Term",
        "label": "Lease, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "LeaseRenewalTerm",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dgx_LeaseRightofUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://questdiagnostics.com/role/LEASESLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Right-of-Use Asset",
        "label": "Lease, Right-of-Use Asset",
        "totalLabel": "Total lease assets"
       }
      }
     },
     "localname": "LeaseRightofUseAsset",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_LeaseTypeChangeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Type Change",
        "label": "Lease Type Change [Member]",
        "terseLabel": "Lease Type Change"
       }
      }
     },
     "localname": "LeaseTypeChangeMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESNarrativeDetails",
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [],
     "calculation": {
      "http://questdiagnostics.com/role/LEASESMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating and Finance Lease, Liability, Payments, Due",
        "label": "Lessee, Operating and Finance Lease, Liability, Payments, Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingandFinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [],
     "calculation": {
      "http://questdiagnostics.com/role/LEASESMaturityDetails": {
       "order": 1.0,
       "parentTag": "dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating and Finance Lease, Liability, Payments, Due Next Twelve Months",
        "label": "Lessee, Operating and Finance Lease, Liability, Payments, Due Next Twelve Months",
        "totalLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingandFinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://questdiagnostics.com/role/LEASESMaturityDetails": {
       "order": 5.0,
       "parentTag": "dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating and Finance Lease, Liability, Payments, Due Year Five",
        "label": "Lessee, Operating and Finance Lease, Liability, Payments, Due Year Five",
        "totalLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://questdiagnostics.com/role/LEASESMaturityDetails": {
       "order": 4.0,
       "parentTag": "dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating and Finance Lease, Liability, Payments, Due Year Four",
        "label": "Lessee, Operating and Finance Lease, Liability, Payments, Due Year Four",
        "totalLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://questdiagnostics.com/role/LEASESMaturityDetails": {
       "order": 3.0,
       "parentTag": "dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating and Finance Lease, Liability, Payments, Due Year Three",
        "label": "Lessee, Operating and Finance Lease, Liability, Payments, Due Year Three",
        "totalLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://questdiagnostics.com/role/LEASESMaturityDetails": {
       "order": 2.0,
       "parentTag": "dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating and Finance Lease, Liability, Payments, Due Year Two",
        "label": "Lessee, Operating and Finance Lease, Liability, Payments, Due Year Two",
        "totalLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueafterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://questdiagnostics.com/role/LEASESMaturityDetails": {
       "order": 6.0,
       "parentTag": "dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating and Finance Lease, Liability, Payments, Due after Year Five",
        "label": "Lessee, Operating and Finance Lease, Liability, Payments, Due after Year Five",
        "totalLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingandFinanceLeaseLiabilityPaymentsDueafterYearFive",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_LesseeOperatingandFinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [],
     "calculation": {
      "http://questdiagnostics.com/role/LEASESMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating and Finance Lease, Liability, Undiscounted Excess Amount",
        "label": "Lessee, Operating and Finance Lease, Liability, Undiscounted Excess Amount",
        "totalLabel": "Less: Interest"
       }
      }
     },
     "localname": "LesseeOperatingandFinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_LoanCommitmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Commitment",
        "label": "Loan Commitment [Member]",
        "terseLabel": "Loan Commitment"
       }
      }
     },
     "localname": "LoanCommitmentMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/DEBTSecuredReceivablesCreditFacilityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_LongTermDebtMaturitiesGross": {
     "auth_ref": [],
     "calculation": {
      "http://questdiagnostics.com/role/DEBTMaturitiesofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including current and noncurrent portions, aggregate carrying amount of long-term borrowings as of the balance sheet date. May include notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, which had initial maturities beyond one year or beyond the normal operating cycle, if longer, and before deducting unamortized discount or premiums, if any.",
        "label": "Long-term Debt, Maturities Gross",
        "totalLabel": "Total maturities of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesGross",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/DEBTMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_MarketPriceOfCompanyStockIssuedAtDiscountUnderEspp": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Element represents the discounted market value of the Company stock on offering date or purchase date that participants pay for shares. Typically, the participant's per share cost is the lower of the prices on the two dates.",
        "label": "Market price of Company stock issued at a discount under the ESPP",
        "terseLabel": "Market price of company stock issued at a discount under the ESPP"
       }
      }
     },
     "localname": "MarketPriceOfCompanyStockIssuedAtDiscountUnderEspp",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeStockPurchasePlanandDefinedContributionPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dgx_MeasurementInputComparableCompanyRevenueVolatilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Comparable Company Revenue Volatility [Member]",
        "label": "Measurement Input, Comparable Company Revenue Volatility [Member]",
        "terseLabel": "Comparable Company Revenue Volatility"
       }
      }
     },
     "localname": "MeasurementInputComparableCompanyRevenueVolatilityMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSBusinessAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_MemorialHermannMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Memorial Hermann [Member]",
        "label": "Memorial Hermann [Member]",
        "terseLabel": "Memorial Hermann"
       }
      }
     },
     "localname": "MemorialHermannMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_MercyHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mercy Health",
        "label": "Mercy Health [Member]",
        "terseLabel": "Mercy Health"
       }
      }
     },
     "localname": "MercyHealthMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_MergerConsiderationPayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://questdiagnostics.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merger Consideration Payable, Current",
        "label": "Merger Consideration Payable, Current",
        "terseLabel": "Merger consideration payable"
       }
      }
     },
     "localname": "MergerConsiderationPayableCurrent",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_Mergerconsiderationpaidpayablenet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merger consideration paid (payable), net",
        "label": "Merger consideration paid (payable), net",
        "terseLabel": "Merger consideration payable"
       }
      }
     },
     "localname": "Mergerconsiderationpaidpayablenet",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_MidAmericaClinicalLaboratoriesLLCMACLMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mid America Clinical Laboratories, LLC (MACL)",
        "label": "Mid America Clinical Laboratories, LLC (MACL) [Member]",
        "terseLabel": "Mid America Clinical Laboratories, LLC (MACL)"
       }
      }
     },
     "localname": "MidAmericaClinicalLaboratoriesLLCMACLMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_NetIncomeLossExcludingRedeemableNoncontrollingInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Income (Loss), Excluding Redeemable Noncontrolling Interest",
        "label": "Net Income (Loss), Excluding Redeemable Noncontrolling Interest",
        "terseLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLossExcludingRedeemableNoncontrollingInterest",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_NetOperatingLossCarryfowardsNetOfValuationAllowance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Net operating loss carryfowards, net of valuation allowance",
        "terseLabel": "Net operating loss carryfowards, net of valuation allowance"
       }
      }
     },
     "localname": "NetOperatingLossCarryfowardsNetOfValuationAllowance",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_OperatingLeaseFixedAndVariableCost": {
     "auth_ref": [],
     "calculation": {
      "http://questdiagnostics.com/role/LEASESCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Fixed and Variable Cost",
        "label": "Operating Lease, Fixed and Variable Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseFixedAndVariableCost",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_OperatingandFinanceLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://questdiagnostics.com/role/LEASESMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating and finance leases.",
        "label": "Operating and Finance Lease, Liability",
        "totalLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingandFinanceLeaseLiability",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_OtherEquityComponentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Equity Components [Member]",
        "label": "Other Equity Components [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherEquityComponentsMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTComponentsofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_OtherIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Income (Expense)",
        "label": "Other Income (Expense) [Member]",
        "terseLabel": "Other Income (Expense)"
       }
      }
     },
     "localname": "OtherIncomeExpenseMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_PackHealthAndLabtechMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pack Health and Labtech",
        "label": "Pack Health and Labtech [Member]",
        "terseLabel": "Pack Health and Labtech"
       }
      }
     },
     "localname": "PackHealthAndLabtechMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSBusinessAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_PackHealthLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pack Health, LLC",
        "label": "Pack Health, LLC [Member]",
        "terseLabel": "Pack Health, LLC"
       }
      }
     },
     "localname": "PackHealthLLCMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails",
      "http://questdiagnostics.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_PatientMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patient [Member]",
        "label": "Patient [Member]",
        "terseLabel": "Patients (including coinsurance and deductible responsibilities)"
       }
      }
     },
     "localname": "PatientMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails",
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_PercentageofNetAccountsReceivable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Net Accounts Receivable",
        "label": "Percentage of Net Accounts Receivable",
        "terseLabel": "Percentage of net accounts receivable"
       }
      }
     },
     "localname": "PercentageofNetAccountsReceivable",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails",
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dgx_PercentageofNetRevenues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Net Revenues",
        "label": "Percentage of Net Revenues",
        "terseLabel": "Percentage of net revenues",
        "verboseLabel": "Percentage of net revenues from the DIS business"
       }
      }
     },
     "localname": "PercentageofNetRevenues",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails",
      "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails",
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dgx_PerformanceShareUnitsWithMarketBasedRelativeTSRGoalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance share units with market-based relative TSR goal",
        "label": "Performance share units with market-based relative TSR goal [Member]",
        "terseLabel": "Performance share units with market-based relative TSR goal"
       }
      }
     },
     "localname": "PerformanceShareUnitsWithMarketBasedRelativeTSRGoalMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSWeightedAverageAssumptionsUsedinValuingOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_PeriodofBillingFullyReserve": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of Billing Fully Reserve",
        "label": "Period of Billing Fully Reserve",
        "terseLabel": "Period of billing fully reserve"
       }
      }
     },
     "localname": "PeriodofBillingFullyReserve",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dgx_ProceedsFromSaleOfEquityMethodInvestmentsGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Sale of Equity Method Investments, Gross",
        "label": "Proceeds from Sale of Equity Method Investments, Gross",
        "terseLabel": "Gross proceeds from disposition of joint venture"
       }
      }
     },
     "localname": "ProceedsFromSaleOfEquityMethodInvestmentsGross",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/DISPOSITIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_Q2SolutionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Q2 Solutions",
        "label": "Q2 Solutions [Member]",
        "terseLabel": "Q2 Solutions"
       }
      }
     },
     "localname": "Q2SolutionsMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/DISPOSITIONDetails",
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails",
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_ReductionsForChangesInJudgment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross amount of decreases in unrecognized tax benefits resulting from changes in judgment.",
        "label": "Reductions for changes in judgment",
        "negatedTerseLabel": "Reductions for changes in judgment"
       }
      }
     },
     "localname": "ReductionsForChangesInJudgment",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_RemainingTermsofContingentLeaseObligationsMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining Terms of Contingent Lease Obligations, Maximum",
        "label": "Remaining Terms of Contingent Lease Obligations, Maximum",
        "terseLabel": "Remaining terms of lease obligations, maximum"
       }
      }
     },
     "localname": "RemainingTermsofContingentLeaseObligationsMaximum",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dgx_RestatedDirectorLongTermIncentivePlanDltipMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restated Director Long-Term Incentive Plan (DLTIP) (Member)",
        "label": "Restated Director Long Term Incentive Plan Dltip [Member]",
        "terseLabel": "Restated Director Long-Term Incentive Plan (DLTIP)"
       }
      }
     },
     "localname": "RestatedDirectorLongTermIncentivePlanDltipMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeandNonemployeeDirectorsStockOwnershipProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_RevenueCollectionofConsiderationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Collection of Consideration Period",
        "label": "Revenue, Collection of Consideration Period",
        "terseLabel": "Collection of consideration"
       }
      }
     },
     "localname": "RevenueCollectionofConsiderationPeriod",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dgx_RevenueFromContractWithCustomerExcludingAssessedTaxPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from Contract with Customer, Excluding Assessed Tax, Percent",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax, Percent",
        "terseLabel": "Total net revenues, percent"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTaxPercent",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dgx_RoutineclinicaltestingservicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Routine clinical testing services",
        "label": "Routine clinical testing services [Member]",
        "terseLabel": "Routine clinical testing and other services"
       }
      }
     },
     "localname": "RoutineclinicaltestingservicesMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_ScheduleOfLeaseByAssetTypeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Lease By Asset Type [Table Text Block]",
        "label": "Schedule Of Lease By Asset Type [Table Text Block]",
        "terseLabel": "Schedule Of Lease By Asset Type"
       }
      }
     },
     "localname": "ScheduleOfLeaseByAssetTypeTableTextBlock",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dgx_ScheduleOfShareBasedPaymentAwardPerformanceShareUnitsValuationAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Share-based Payment Award, Performance Share Units, Valuation Assumptions",
        "label": "Schedule of Share-based Payment Award, Performance Share Units, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Assumptions Used in Valuing The Company's Performance Share Units"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardPerformanceShareUnitsValuationAssumptionsTableTextBlock",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dgx_ScheduleOfShareholdersEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Schedule of Shareholders' Equity [Table]",
        "label": "Schedule of Shareholders' Equity [Line Items]",
        "terseLabel": "Stockholders\u2019 Equity and Redeemable Noncontrolling Interest [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfShareholdersEquityLineItems",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTComponentsofAccumulatedOtherComprehensiveLossIncomeDetails",
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dgx_ScheduleOfShareholdersEquityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Shareholders' Equity [Table]",
        "label": "Schedule of Shareholders' Equity [Table]",
        "terseLabel": "Schedule of Shareholders' Equity [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareholdersEquityTable",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTComponentsofAccumulatedOtherComprehensiveLossIncomeDetails",
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dgx_ScheduleofLeaseTermandDiscountRateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Lease Term and Discount Rate [Table Text Block]",
        "label": "Schedule of Lease Term and Discount Rate [Table Text Block]",
        "terseLabel": "Schedule of Lease Term and Discount Rate"
       }
      }
     },
     "localname": "ScheduleofLeaseTermandDiscountRateTableTextBlock",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dgx_SdcpIiGradedVestingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SDCP II graded vesting percentage",
        "label": "SDCP II graded vesting percentage",
        "terseLabel": "SDCP II graded vesting percentage"
       }
      }
     },
     "localname": "SdcpIiGradedVestingPercentage",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSSupplementalDeferredCompensationPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dgx_SdcpIiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SDCP II [Member]",
        "label": "Sdcp Ii [Member]",
        "terseLabel": "SDCP II [Member]"
       }
      }
     },
     "localname": "SdcpIiMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSSupplementalDeferredCompensationPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_SeniorunsecuredrevolvingcreditfacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior unsecured revolving credit facility [Member]",
        "label": "Senior unsecured revolving credit facility [Member]",
        "terseLabel": "Senior unsecured revolving credit facility"
       }
      }
     },
     "localname": "SeniorunsecuredrevolvingcreditfacilityMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/DEBTSeniorUnsecuredRevolvingCreditFacilityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_Sharebasedcompensationexcesstaxbenefitamount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation, excess tax benefit, amount",
        "label": "Share-based compensation, excess tax benefit, amount",
        "terseLabel": "Share-based compensation, excess tax benefit, amount"
       }
      }
     },
     "localname": "Sharebasedcompensationexcesstaxbenefitamount",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSActivitiesRelatedtoStockAwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_ShorttermLeaseandVariableLeaseCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term Lease and Variable Lease, Cost",
        "label": "Short-term Lease and Variable Lease, Cost",
        "terseLabel": "Short-term leases and variable lease costs"
       }
      }
     },
     "localname": "ShorttermLeaseandVariableLeaseCost",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_SixPointNineFivePercentSeniorNotesDue2037Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six Point Nine Five Percent Senior Notes Due 2037 [Member]",
        "label": "Six Point Nine Five Percent Senior Notes Due2037 [Member]",
        "terseLabel": "6.95% Senior Notes due July 2037"
       }
      }
     },
     "localname": "SixPointNineFivePercentSeniorNotesDue2037Member",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/DEBTLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_StockAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement - Equity Instruments Other than Options.",
        "label": "Stock Awards [Member]",
        "terseLabel": "Stock Awards"
       }
      }
     },
     "localname": "StockAwardsMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSActivitiesRelatedtoStockAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_StockRepurchaseProgramAdditionalAmountAuthorized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Repurchase Program, Additional Amount Authorized",
        "label": "Stock Repurchase Program, Additional Amount Authorized",
        "terseLabel": "Additional amount authorized"
       }
      }
     },
     "localname": "StockRepurchaseProgramAdditionalAmountAuthorized",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_SubstantialOwnershipInterestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Substantial Ownership Interest",
        "label": "Substantial Ownership Interest [Member]",
        "terseLabel": "Substantial Ownership Interest"
       }
      }
     },
     "localname": "SubstantialOwnershipInterestMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies Line Items",
        "label": "Summary of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dgx_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies [Table]",
        "label": "Summary of Significant Accounting Policies [Table]",
        "terseLabel": "Summary of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dgx_SupplementalDeferredCompensationPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental Deferred Compensation Plan [Member]",
        "label": "Supplemental Deferred Compensation Plan [Member]",
        "terseLabel": "Supplemental Deferred Compensation Plan"
       }
      }
     },
     "localname": "SupplementalDeferredCompensationPlanMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSSupplementalDeferredCompensationPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_SupplementalDeferredCompensationPlanSalaryDeferral": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of salary deferral under the Supplemental Deferred Compensation Plan. This plans is an unfunded, non-qualified plan that provides for certain management and highly compensated employees to defer up to this percentage of their annual salary in excess of their defined contribution plan limits.",
        "label": "Supplemental Deferred Compensation Plan Salary Deferral",
        "terseLabel": "SDCP salary deferral"
       }
      }
     },
     "localname": "SupplementalDeferredCompensationPlanSalaryDeferral",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSSupplementalDeferredCompensationPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dgx_SupplementalDeferredCompensationPlanVariableIncentiveCompensationDeferral": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferral percentage of the variable incentive compensation under the Supplemental Deferred Compensation Plan. The plan is an unfunded, non-qualified plan that provides for certain management and highly compensated eligible employees to defer up to this percentage of their variable incentive compensation.",
        "label": "Supplemental Deferred Compensation Plan Variable Incentive Compensation Deferral",
        "terseLabel": "SDCP variable incentive compensation deferral"
       }
      }
     },
     "localname": "SupplementalDeferredCompensationPlanVariableIncentiveCompensationDeferral",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSSupplementalDeferredCompensationPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dgx_TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity, Noncontrolling interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "label": "Temporary equity, Noncontrolling interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedTerseLabel": "Distributions to noncontrolling interest partners"
       }
      }
     },
     "localname": "TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_TerminationOfInterestRateSwapAgreements": {
     "auth_ref": [],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination Of Interest Rate Swap Agreements",
        "label": "Termination Of Interest Rate Swap Agreements",
        "terseLabel": "Termination of interest rate swap agreements"
       }
      }
     },
     "localname": "TerminationOfInterestRateSwapAgreements",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_ThreePointFiveZeroPercentSeniorNotesdueMarch2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Five Zero Percent Senior Notes due March 2025 [Member]",
        "label": "Three Point Five Zero Percent Senior Notes due March 2025 [Member]",
        "terseLabel": "3.50% Senior Notes due March 2025"
       }
      }
     },
     "localname": "ThreePointFiveZeroPercentSeniorNotesdueMarch2025Member",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/DEBTLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_ThreePointFourFivePercentSeniorNotesdueJune2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Four Five Percent Senior Notes due June 2026 [Member]",
        "label": "Three Point Four Five Percent Senior Notes due June 2026 [Member]",
        "terseLabel": "3.45% Senior Notes due June 2026"
       }
      }
     },
     "localname": "ThreePointFourFivePercentSeniorNotesdueJune2026Member",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/DEBTLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_TotalAmortizingIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Amortizing Intangible Assets [Member]",
        "label": "Total Amortizing Intangible Assets [Member]",
        "terseLabel": "Total Amortizing Intangible Assets"
       }
      }
     },
     "localname": "TotalAmortizingIntangibleAssetsMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_TreasuryStockPurchasedbutNotyetPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Treasury Stock Purchased but Not yet Paid",
        "label": "Treasury Stock Purchased but Not yet Paid",
        "terseLabel": "Accounts payable associated with purchases of treasury stock"
       }
      }
     },
     "localname": "TreasuryStockPurchasedbutNotyetPaid",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dgx_TwoPointEightZeroPercentSeniorNotesDueJune2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Eight Zero Percent Senior Notes due June 2031",
        "label": "Two Point Eight Zero Percent Senior Notes due June 2031 [Member]",
        "terseLabel": "2.80% Senior Notes due June 2031"
       }
      }
     },
     "localname": "TwoPointEightZeroPercentSeniorNotesDueJune2031Member",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/DEBTLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_TwoPointNineFivePercentSeniorNotesdueJune2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Nine Five Percent Senior Notes due June 2030 [Member]",
        "label": "Two Point Nine Five Percent Senior Notes due June 2030 [Member]",
        "terseLabel": "2.95% Senior Notes due June 2030"
       }
      }
     },
     "localname": "TwoPointNineFivePercentSeniorNotesdueJune2030Member",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/DEBTLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_UMassJointVentureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UMass Joint Venture [Member]",
        "label": "UMass Joint Venture [Member]",
        "terseLabel": "UMass Joint Venture"
       }
      }
     },
     "localname": "UMassJointVentureMember",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails",
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dgx_UnrecordedUnconditionalPurchaseObligationDuewithinTwoandThreeYears": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecorded Unconditional Purchase Obligation, Due within Two and Three Years",
        "label": "Unrecorded Unconditional Purchase Obligation, Due within Two and Three Years",
        "terseLabel": "Purchase obligation, 2023 through 2024"
       }
      }
     },
     "localname": "UnrecordedUnconditionalPurchaseObligationDuewithinTwoandThreeYears",
     "nsuri": "http://questdiagnostics.com/20221231",
     "presentation": [
      "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r445",
      "r446",
      "r447",
      "r448",
      "r521",
      "r666",
      "r687",
      "r698",
      "r699",
      "r716",
      "r723",
      "r731",
      "r793",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://questdiagnostics.com/role/DEBTSecuredReceivablesCreditFacilityNarrativeDetails",
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSBusinessAcquisitionDetails",
      "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://questdiagnostics.com/role/LEASESNarrativeDetails",
      "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails",
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails",
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeStockPurchasePlanandDefinedContributionPlansDetails",
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSSupplementalDeferredCompensationPlansDetails",
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSWeightedAverageAssumptionsUsedinValuingOptionsGrantedDetails",
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r445",
      "r446",
      "r447",
      "r448",
      "r521",
      "r666",
      "r687",
      "r698",
      "r699",
      "r716",
      "r723",
      "r731",
      "r793",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails",
      "http://questdiagnostics.com/role/DEBTSecuredReceivablesCreditFacilityNarrativeDetails",
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSBusinessAcquisitionDetails",
      "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://questdiagnostics.com/role/LEASESNarrativeDetails",
      "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails",
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSWeightedAverageAssumptionsUsedinValuingOptionsGrantedDetails",
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails",
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails",
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r385",
      "r668",
      "r717",
      "r730",
      "r788",
      "r789",
      "r796",
      "r825"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails",
      "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r385",
      "r668",
      "r717",
      "r730",
      "r788",
      "r789",
      "r796",
      "r825"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails",
      "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r445",
      "r446",
      "r447",
      "r448",
      "r513",
      "r521",
      "r553",
      "r554",
      "r555",
      "r665",
      "r666",
      "r687",
      "r698",
      "r699",
      "r716",
      "r723",
      "r731",
      "r785",
      "r793",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails",
      "http://questdiagnostics.com/role/DEBTSecuredReceivablesCreditFacilityNarrativeDetails",
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSBusinessAcquisitionDetails",
      "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://questdiagnostics.com/role/LEASESNarrativeDetails",
      "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails",
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails",
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeStockPurchasePlanandDefinedContributionPlansDetails",
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSSupplementalDeferredCompensationPlansDetails",
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSWeightedAverageAssumptionsUsedinValuingOptionsGrantedDetails",
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r445",
      "r446",
      "r447",
      "r448",
      "r513",
      "r521",
      "r553",
      "r554",
      "r555",
      "r665",
      "r666",
      "r687",
      "r698",
      "r699",
      "r716",
      "r723",
      "r731",
      "r785",
      "r793",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails",
      "http://questdiagnostics.com/role/DEBTSecuredReceivablesCreditFacilityNarrativeDetails",
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSBusinessAcquisitionDetails",
      "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://questdiagnostics.com/role/LEASESNarrativeDetails",
      "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails",
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails",
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeStockPurchasePlanandDefinedContributionPlansDetails",
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSSupplementalDeferredCompensationPlansDetails",
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSWeightedAverageAssumptionsUsedinValuingOptionsGrantedDetails",
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r522",
      "r767"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails",
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r331",
      "r522",
      "r743",
      "r767"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails",
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r331",
      "r522",
      "r743",
      "r744",
      "r767"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails",
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AcceleratedShareRepurchasesDateAxis": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by date of execution of accelerated share repurchases.",
        "label": "Accelerated Share Repurchases, Date [Axis]",
        "terseLabel": "Accelerated Share Repurchases, Date [Axis]"
       }
      }
     },
     "localname": "AcceleratedShareRepurchasesDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/EARNINGSLOSSPERSHAREDetails",
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AcceleratedShareRepurchasesDateDomain": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date upon which the accelerated share repurchase agreement was executed.",
        "label": "Accelerated Share Repurchases, Date [Domain]",
        "terseLabel": "Accelerated Share Repurchases, Date [Domain]"
       }
      }
     },
     "localname": "AcceleratedShareRepurchasesDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/EARNINGSLOSSPERSHAREDetails",
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcceleratedShareRepurchasesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accelerated Share Repurchases [Line Items]",
        "terseLabel": "Accelerated Share Repurchases [Line Items]"
       }
      }
     },
     "localname": "AcceleratedShareRepurchasesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AcceleratedShareRepurchasesTable": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table reflecting activity in an accelerated share repurchase (ASR) program.",
        "label": "Accelerated Share Repurchases [Table]",
        "terseLabel": "Accelerated Share Repurchases [Table]"
       }
      }
     },
     "localname": "AcceleratedShareRepurchasesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails",
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities [Abstract]",
        "terseLabel": "Accounts Payable and Accrued Liabilities [Abstract]"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "auth_ref": [
      "r13",
      "r25"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Trade accounts payable"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": {
     "auth_ref": [
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]",
        "terseLabel": "Accounts Receivable, Allowance for Credit Loss"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/REVENUERECOGNITIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r390",
      "r391"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net of allowance for credit losses of $30 and $31 as of December\u00a031, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxes": {
     "auth_ref": [
      "r15",
      "r17",
      "r158",
      "r232",
      "r248"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due. This amount is the total of current and noncurrent accrued income taxes.",
        "label": "Accrued Income Taxes",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r15",
      "r232",
      "r249"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedInsuranceCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Insurance, Current",
        "terseLabel": "Accrued insurance"
       }
      }
     },
     "localname": "AccruedInsuranceCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r107",
      "r269"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENTDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember": {
     "auth_ref": [
      "r42",
      "r46",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges, attributable to the parent.",
        "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]",
        "terseLabel": "Net Deferred Losses on Cash Flow Hedges, net of tax"
       }
      }
     },
     "localname": "AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTComponentsofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r282",
      "r283",
      "r284",
      "r286",
      "r294",
      "r295",
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]",
        "terseLabel": "Net Changes in Available-for-Sale Debt Securities"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTComponentsofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r44",
      "r45",
      "r46",
      "r276",
      "r680",
      "r692",
      "r693"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Accumulated other comprehensive (loss) income",
        "verboseLabel": "Accumulated net loss from designated or qualifying cash flow hedges"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTComponentsofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r43",
      "r46",
      "r192",
      "r658",
      "r688",
      "r689",
      "r748",
      "r749",
      "r750",
      "r764",
      "r765",
      "r766"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "verboseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTComponentsofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r41",
      "r46",
      "r192",
      "r294",
      "r295",
      "r631",
      "r632",
      "r633",
      "r634",
      "r636",
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign Currency Translation Adjustments"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTComponentsofAccumulatedOtherComprehensiveLossIncomeDetails",
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r562",
      "r563",
      "r564",
      "r764",
      "r765",
      "r766",
      "r809"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Shares to cover employee payroll tax withholdings on stock issued under stock-based compensation plans"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r151",
      "r152",
      "r524"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising Costs"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r568"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising cost"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllOtherSegmentsMember": {
     "auth_ref": [
      "r357",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.",
        "label": "Other Segments [Member]",
        "terseLabel": "All other operating segments"
       }
      }
     },
     "localname": "AllOtherSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails",
      "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r277",
      "r392",
      "r399",
      "r400",
      "r403"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r277",
      "r392",
      "r399"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]",
        "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "auth_ref": [
      "r402"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
        "negatedTerseLabel": "Write-offs of accounts receivable, net of recoveries"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r66",
      "r93",
      "r99"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DepreciationDepletionAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets",
        "verboseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Stock options and performance share units not included due to their antidilutive effect"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r66",
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Impairment charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r230",
      "r246",
      "r273",
      "r312",
      "r369",
      "r375",
      "r381",
      "r397",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r607",
      "r612",
      "r629",
      "r729",
      "r791",
      "r792",
      "r816"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r264",
      "r280",
      "r312",
      "r397",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r607",
      "r612",
      "r629",
      "r729",
      "r791",
      "r792",
      "r816"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r217"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r87",
      "r393",
      "r404",
      "r672"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Available-for-sale debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails",
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r528",
      "r529",
      "r530",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSActivitiesRelatedtoStockAwardsDetails",
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeStockPurchasePlanandDefinedContributionPlansDetails",
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeandNonemployeeDirectorsStockOwnershipProgramsDetails",
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTransactionsUnderStockOptionPlansDetails",
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSWeightedAverageAssumptionsUsedinValuingOptionsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSBalanceSheetsDetails",
      "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r203",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSBalanceSheetsDetails",
      "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BankOverdrafts": {
     "auth_ref": [
      "r29",
      "r118"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of payments made in excess of existing cash balances, which will be honored by the bank but reflected as a loan to the entity. Overdrafts generally have a very short time frame for correction or repayment and are therefore more similar to short-term bank financing than trade financing.",
        "label": "Bank Overdrafts",
        "terseLabel": "Overdrafts"
       }
      }
     },
     "localname": "BankOverdrafts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Building and Building Improvements [Member]",
        "terseLabel": "Building and Building Improvements",
        "verboseLabel": "Building and Improvements"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENTDetails",
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r602",
      "r721",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails",
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSBusinessAcquisitionDetails",
      "http://questdiagnostics.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r170",
      "r171",
      "r602",
      "r721",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails",
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSBusinessAcquisitionDetails",
      "http://questdiagnostics.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails",
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSBusinessAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Percentage of voting interests acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": {
     "auth_ref": [
      "r184"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.",
        "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount",
        "terseLabel": "Goodwill deductible for tax purposes"
       }
      }
     },
     "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r179",
      "r180",
      "r182"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Total consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "auth_ref": [
      "r183"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.",
        "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "verboseLabel": "Contingent consideration arrangements, range of outcomes, value, high"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSBusinessAcquisitionDetails",
      "http://questdiagnostics.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r178",
      "r181",
      "r605"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "netLabel": "Contingent consideration, liability",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails",
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails",
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Measurement input"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSBusinessAcquisitionDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r185",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "BUSINESS ACQUISITIONS"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r172",
      "r173"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Finite-lived intangibles"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r172",
      "r173"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r172",
      "r173"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1": {
     "auth_ref": [
      "r168"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value",
        "terseLabel": "Equity interest in acquiree, fair value"
       }
      }
     },
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination.",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage",
        "terseLabel": "Equity interest in acquiree, percentage"
       }
      }
     },
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain": {
     "auth_ref": [
      "r169"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain",
        "terseLabel": "Equity interest in acquiree, remeasurement gain"
       }
      }
     },
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r71",
      "r72",
      "r73"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Accounts payable associated with capital expenditures"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).",
        "label": "Cash Acquired from Acquisition",
        "terseLabel": "Cash acquired from acquisition",
        "verboseLabel": "Less: cash acquired"
       }
      }
     },
     "localname": "CashAcquiredFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails",
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r68",
      "r267",
      "r700"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r62",
      "r68",
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents and restricted cash, end of year",
        "periodStartLabel": "Cash and cash equivalents and restricted cash, beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r62",
      "r225"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Cash Flow, Supplemental Disclosures [Text Block]",
        "terseLabel": "SUPPLEMENTAL CASH FLOW AND OTHER DATA"
       }
      }
     },
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATA"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashSurrenderValueFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of the amount that could be realized under a life insurance contract or contracts owned by the entity, commonly known as corporate-owned life insurance (COLI) or bank-owned life insurance (BOLI).",
        "label": "Cash Surrender Value, Fair Value Disclosure",
        "terseLabel": "Cash surrender value of life insurance policies"
       }
      }
     },
     "localname": "CashSurrenderValueFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails",
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSSupplementalDeferredCompensationPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": {
     "auth_ref": [
      "r214"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge",
        "terseLabel": "Hedged items (Long-term debt)"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSIncomeStatementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r34",
      "r237",
      "r255"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r117",
      "r442",
      "r444",
      "r694",
      "r790"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Dividends per common share"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r764",
      "r765",
      "r809"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]",
        "terseLabel": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r19",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares",
        "terseLabel": "Common stock, shares, outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r19",
      "r729"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, par value $0.01 per share; 600 shares authorized as of both December\u00a031, 2022 and 2021; 162 shares issued as of both December\u00a031, 2022 and 2021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r47",
      "r289",
      "r291",
      "r300",
      "r676",
      "r684"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income attributable to Quest Diagnostics"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r189",
      "r190",
      "r195",
      "r289",
      "r291",
      "r299",
      "r675",
      "r683"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Less: Comprehensive income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r188",
      "r195",
      "r289",
      "r291",
      "r298",
      "r674",
      "r682"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.",
        "label": "Concentration Risk Disclosure [Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in Progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateMember": {
     "auth_ref": [
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component of an entity that usually provides financial, operational and administrative support and is considered an operating segment. Excludes intersegment elimination and reconciling items.",
        "label": "Corporate Segment [Member]",
        "terseLabel": "General corporate income (expenses), Net"
       }
      }
     },
     "localname": "CorporateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r52",
      "r312",
      "r397",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r629",
      "r791"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of services"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Revenue [Abstract]",
        "terseLabel": "Operating costs and expenses and other operating income:"
       }
      }
     },
     "localname": "CostOfRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of Sales"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating costs and expenses, net"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://questdiagnostics.com/role/DEBTSecuredReceivablesCreditFacilityNarrativeDetails",
      "http://questdiagnostics.com/role/DEBTSeniorUnsecuredRevolvingCreditFacilityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://questdiagnostics.com/role/DEBTSecuredReceivablesCreditFacilityNarrativeDetails",
      "http://questdiagnostics.com/role/DEBTSeniorUnsecuredRevolvingCreditFacilityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r763",
      "r804",
      "r806"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Current federal tax expense (benefit)"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r763",
      "r804"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Current foreign income tax expense"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r166",
      "r586",
      "r594",
      "r763"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "terseLabel": "Taxes payable, current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/DISPOSITIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r763",
      "r804",
      "r806"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "Current state and local income tax expense"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer Relationships",
        "verboseLabel": "Customer - related"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails",
      "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r121",
      "r310",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r474",
      "r481",
      "r482",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "DEBT"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/DEBT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r231",
      "r234",
      "r245",
      "r317",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r464",
      "r470",
      "r471",
      "r472",
      "r473",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r640",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://questdiagnostics.com/role/DEBTFinanceLeaseDetails",
      "http://questdiagnostics.com/role/DEBTLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Interest rate in excess of LIBOR",
        "verboseLabel": "Interest rate in excess of LIBOR"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/DEBTSecuredReceivablesCreditFacilityNarrativeDetails",
      "http://questdiagnostics.com/role/DEBTSeniorUnsecuredRevolvingCreditFacilityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r16",
      "r234",
      "r245",
      "r485"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Amount outstanding"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/DEBTSecuredReceivablesCreditFacilityNarrativeDetails",
      "http://questdiagnostics.com/role/DEBTSeniorUnsecuredRevolvingCreditFacilityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r472",
      "r628",
      "r712",
      "r713"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Fair value of debt"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r31",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt instrument, interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/DEBTLongTermDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://questdiagnostics.com/role/DEBTFinanceLeaseDetails",
      "http://questdiagnostics.com/role/DEBTLongTermDebtDetails",
      "http://questdiagnostics.com/role/DEBTSecuredReceivablesCreditFacilityNarrativeDetails",
      "http://questdiagnostics.com/role/DEBTSeniorUnsecuredRevolvingCreditFacilityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r32",
      "r317",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r464",
      "r470",
      "r471",
      "r472",
      "r473",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r640",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://questdiagnostics.com/role/DEBTFinanceLeaseDetails",
      "http://questdiagnostics.com/role/DEBTLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r32",
      "r128",
      "r129",
      "r130",
      "r131",
      "r226",
      "r227",
      "r229",
      "r244",
      "r317",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r464",
      "r470",
      "r471",
      "r472",
      "r473",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r483",
      "r640",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://questdiagnostics.com/role/DEBTFinanceLeaseDetails",
      "http://questdiagnostics.com/role/DEBTLongTermDebtDetails",
      "http://questdiagnostics.com/role/DEBTSecuredReceivablesCreditFacilityNarrativeDetails",
      "http://questdiagnostics.com/role/DEBTSeniorUnsecuredRevolvingCreditFacilityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r226",
      "r229",
      "r794"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/DEBTMaturitiesofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedLabel": "Unamortized discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/DEBTMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instruments [Abstract]",
        "terseLabel": "Debt Instruments [Abstract]"
       }
      }
     },
     "localname": "DebtInstrumentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r156"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "terseLabel": "Significant change in unrecognized tax benefits is reasonably possible, estimated range of change, upper bound"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain": {
     "auth_ref": [
      "r138",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes equity-based compensation plans, defined benefit pension plans and defined benefit other postretirement benefit plans.",
        "label": "Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation [Domain]",
        "terseLabel": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain]"
       }
      }
     },
     "localname": "DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSSupplementalDeferredCompensationPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contributions made by employer into fund established for purposes of making future disbursement to individual in accordance with deferred compensation arrangement.",
        "label": "Deferred Compensation Arrangement with Individual, Contributions by Employer",
        "terseLabel": "Deferred compensation arrangement with individual, employer contribution"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSSupplementalDeferredCompensationPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis": {
     "auth_ref": [
      "r138",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes equity-based compensation plans, defined benefit pension plans and defined benefit other postretirement benefit plans.",
        "label": "Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]",
        "terseLabel": "Deferred Bonus and Profit Sharing Plan, Type of Deferred Compensation [Axis]"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSSupplementalDeferredCompensationPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]",
        "terseLabel": "Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSSupplementalDeferredCompensationPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability": {
     "auth_ref": [
      "r139"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of the liability as of the balance sheet date to an individual under a deferred compensation arrangement. This amount may be the result of periodic accruals made over the period of active employment, or reflect termination benefits resulting contractual terms or a death benefit.",
        "label": "Deferred Compensation Arrangement with Individual, Recorded Liability",
        "terseLabel": "SDCP accrual"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualRecordedLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSSupplementalDeferredCompensationPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1": {
     "auth_ref": [
      "r140",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum period the individual is required to perform services to be fully vested under the deferred compensation arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Deferred Compensation Arrangement with Individual, Requisite Service Period",
        "terseLabel": "SDCP II vesting period"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSSupplementalDeferredCompensationPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).",
        "label": "Deferred Compensation Liability, Classified, Noncurrent",
        "terseLabel": "Deferred compensation liabilities"
       }
      }
     },
     "localname": "DeferredCompensationLiabilityClassifiedNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r763",
      "r805",
      "r806"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Defered federal income tax expense (benefit)"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r166",
      "r763",
      "r805"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Deferred foreign income tax expense (benefit)"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r66",
      "r166",
      "r587",
      "r593",
      "r594",
      "r763"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income tax provision",
        "verboseLabel": "Deferred income tax expense (benefit)"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://questdiagnostics.com/role/DISPOSITIONDetails",
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r763",
      "r805",
      "r806"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "Deferred state and local income tax expense (benefit)"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r163",
      "r803"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r163",
      "r803"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r163",
      "r803"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Liabilities not currently deductible"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r583"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "verboseLabel": "Deferred tax assets, valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r153",
      "r802"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTerseLabel": "Total non-current deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r163",
      "r803"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedTerseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r163",
      "r803"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedTerseLabel": "Non-current deferred tax liability - depreciation and amortization"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r520"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Company's expense for contributions to its defined contribution plans"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeStockPurchasePlanandDefinedContributionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Amended company match percentage of employee contributions"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeStockPurchasePlanandDefinedContributionPlansDetails",
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSSupplementalDeferredCompensationPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r66",
      "r105"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DepreciationDepletionAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r66",
      "r364"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "totalLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails",
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r808"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Derivatives designated as hedging instruments"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSIncomeStatementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r216",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "FINANCIAL INSTRUMENTS"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FINANCIALINSTRUMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r201",
      "r204",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSBalanceSheetsDetails",
      "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSIncomeStatementDetails",
      "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSBalanceSheetsDetails",
      "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSIncomeStatementDetails",
      "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r201",
      "r202",
      "r206",
      "r208",
      "r210",
      "r212",
      "r215",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSBalanceSheetsDetails",
      "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSIncomeStatementDetails",
      "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r197",
      "r198",
      "r201",
      "r202",
      "r211",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r796"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/REVENUERECOGNITIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r527",
      "r558",
      "r559",
      "r561",
      "r566",
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK OWNERSHIP AND COMPENSATION PLANS"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]",
        "terseLabel": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/DISPOSITIONDetails",
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails",
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/DISPOSITIONDetails",
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails",
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r104",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]",
        "terseLabel": "Disposed of by Sale"
       }
      }
     },
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/DISPOSITIONDetails",
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails",
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r11",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "netLabel": "DISPOSITION"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/DISPOSITION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r721",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/DISPOSITIONDetails",
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails",
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r132"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "negatedLabel": "Dividends declared"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPayableCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Dividends Payable, Current",
        "terseLabel": "Dividend payable"
       }
      }
     },
     "localname": "DividendsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r15",
      "r17",
      "r233",
      "r247"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.",
        "label": "Dividends Payable",
        "terseLabel": "Dividend payable"
       }
      }
     },
     "localname": "DividendsPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic Country"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings per share attributable to Quest Diagnostics\u2019 common stockholders:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r301",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r332",
      "r335",
      "r341",
      "r342",
      "r343",
      "r347",
      "r618",
      "r619",
      "r677",
      "r685",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://questdiagnostics.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r301",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r335",
      "r341",
      "r342",
      "r343",
      "r347",
      "r618",
      "r619",
      "r677",
      "r685",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://questdiagnostics.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r77",
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r344",
      "r345",
      "r346",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "EARNINGS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/EARNINGSPERSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r573"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r314",
      "r573",
      "r596"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Tax provision at statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r800",
      "r807"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowances associated with certain net operating losses"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther": {
     "auth_ref": [
      "r800",
      "r807"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other deductions.",
        "label": "Effective Income Tax Rate Reconciliation, Deduction, Other, Percent",
        "negatedTerseLabel": "Excess tax benefits on stock-based compensation arrangements"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeductionsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary": {
     "auth_ref": [
      "r800",
      "r807"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity in earnings (loss) of unconsolidated subsidiaries exempt from income taxes.",
        "label": "Effective Income Tax Rate Reconciliation, Equity in Earnings (Losses) of Unconsolidated Subsidiary, Percent",
        "terseLabel": "Impact of equity earnings"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense": {
     "auth_ref": [
      "r800",
      "r807"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to noncontrolling interest income (loss) exempt from income taxes.",
        "label": "Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Percent",
        "terseLabel": "Impact of noncontrolling interests"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r800",
      "r807"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": {
     "auth_ref": [
      "r800",
      "r807"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.",
        "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent",
        "terseLabel": "Return to provision true-ups"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r800",
      "r807"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State and local income taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued wages and benefits (including incentive compensation)"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r560"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSActivitiesRelatedtoStockAwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized stock-based compensation cost weighted average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSActivitiesRelatedtoStockAwardsDetails",
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTransactionsUnderStockOptionPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r799"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Compensation not yet recognized, stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTransactionsUnderStockOptionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r557"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "terseLabel": "Income tax benefit related to stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSActivitiesRelatedtoStockAwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Employee Separation Costs"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESActivitiesofRestructuringLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeStockPurchasePlanandDefinedContributionPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r127",
      "r258",
      "r293",
      "r294",
      "r295",
      "r318",
      "r319",
      "r320",
      "r322",
      "r328",
      "r330",
      "r350",
      "r398",
      "r500",
      "r562",
      "r563",
      "r564",
      "r589",
      "r590",
      "r617",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r636",
      "r658",
      "r688",
      "r689",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://questdiagnostics.com/role/DISPOSITIONDetails",
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTComponentsofAccumulatedOtherComprehensiveLossIncomeDetails",
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentDividendsOrDistributions": {
     "auth_ref": [
      "r49",
      "r61",
      "r66",
      "r256"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.",
        "label": "Proceeds from Equity Method Investment, Distribution",
        "terseLabel": "Dividends received from equity method investees"
       }
      }
     },
     "localname": "EquityMethodInvestmentDividendsOrDistributions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity method investment, ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal": {
     "auth_ref": [
      "r751",
      "r752",
      "r760"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of an equity method investment.",
        "label": "Equity Method Investment, Realized Gain (Loss) on Disposal",
        "verboseLabel": "Gain on sale of investment, before tax"
       }
      }
     },
     "localname": "EquityMethodInvestmentRealizedGainLossOnDisposal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/DISPOSITIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r88",
      "r370",
      "r746"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Investments in equity method investees",
        "verboseLabel": "Equity method investments carrying value"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r61",
      "r90",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r770"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "terseLabel": "Trading equity securities gain or (loss)"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails",
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r394"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Equity Securities without readily determinable fair value"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FacilityClosingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Closing of a facility associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Facility Closing [Member]",
        "terseLabel": "Facility-Related Costs"
       }
      }
     },
     "localname": "FacilityClosingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESActivitiesofRestructuringLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails",
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r217",
      "r222",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails",
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r472",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r621",
      "r662",
      "r663",
      "r664",
      "r712",
      "r713",
      "r718",
      "r719",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails",
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails",
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSReconciliationofBeginningandEndingBalancesofLiabilitiesUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r220",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails",
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSReconciliationofBeginningandEndingBalancesofLiabilitiesUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r620",
      "r621",
      "r623",
      "r624",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails",
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueHedgingMember": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.",
        "label": "Fair Value Hedging [Member]",
        "terseLabel": "Fair Value Hedging"
       }
      }
     },
     "localname": "FairValueHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSBalanceSheetsDetails",
      "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSIncomeStatementDetails",
      "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r472",
      "r514",
      "r519",
      "r621",
      "r662",
      "r718",
      "r719",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r472",
      "r514",
      "r519",
      "r621",
      "r663",
      "r712",
      "r713",
      "r718",
      "r719",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r472",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r621",
      "r664",
      "r712",
      "r713",
      "r718",
      "r719",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails",
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails",
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSReconciliationofBeginningandEndingBalancesofLiabilitiesUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails",
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSReconciliationofBeginningandEndingBalancesofLiabilitiesUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSReconciliationofBeginningandEndingBalancesofLiabilitiesUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSReconciliationofBeginningandEndingBalancesofLiabilitiesUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r218",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSReconciliationofBeginningandEndingBalancesofLiabilitiesUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r218",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Beginning and Ending Liability Balances Unobservable Inputs"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails",
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r625"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedTerseLabel": "Total fair value adjustments included in earnings - realized/unrealized",
        "terseLabel": "Total (gains)/losses included in earnings - realized/unrealized"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails",
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSReconciliationofBeginningandEndingBalancesofLiabilitiesUnobservableInputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements": {
     "auth_ref": [
      "r219"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases, (sales), issuances and (settlements) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)",
        "terseLabel": "Purchases, additions and issuances"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSReconciliationofBeginningandEndingBalancesofLiabilitiesUnobservableInputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r219"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedTerseLabel": "Settlements"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSReconciliationofBeginningandEndingBalancesofLiabilitiesUnobservableInputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r218"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSReconciliationofBeginningandEndingBalancesofLiabilitiesUnobservableInputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r472",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r662",
      "r663",
      "r664",
      "r712",
      "r713",
      "r718",
      "r719",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails",
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails",
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSReconciliationofBeginningandEndingBalancesofLiabilitiesUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r626",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring Basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails",
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfAssetsAcquired": {
     "auth_ref": [
      "r71",
      "r72",
      "r73"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails": {
       "order": 1.0,
       "parentTag": "dgx_FairValueOfNetAssetsAcquired",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of assets acquired in noncash investing or financing activities.",
        "label": "Fair Value of Assets Acquired",
        "terseLabel": "Fair value of assets acquired"
       }
      }
     },
     "localname": "FairValueOfAssetsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r644",
      "r650",
      "r728"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/LEASESCostsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r646",
      "r651"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease, Interest Payment on Liability",
        "terseLabel": "Operating cash flows from finance leases"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r642",
      "r656"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/LEASESMaturityDetails": {
       "order": 2.0,
       "parentTag": "dgx_OperatingandFinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r642"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/LEASESLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "dgx_LeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Current finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.",
        "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r815"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Finance Lease, Liability, Maturity"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r642"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/LEASESLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "dgx_LeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Noncurrent finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability.",
        "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r656"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/LEASESMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r656"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/LEASESMaturityDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r656"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/LEASESMaturityDetails": {
       "order": 2.0,
       "parentTag": "dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r656"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/LEASESMaturityDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r656"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/LEASESMaturityDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r656"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/LEASESMaturityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r656"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/LEASESMaturityDetails": {
       "order": 2.0,
       "parentTag": "dgx_LesseeOperatingandFinanceLeaseLiabilityPaymentsDueYearTwo",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes finance lease liability.",
        "label": "Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESMaturityDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r656"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/LEASESMaturityDetails": {
       "order": 2.0,
       "parentTag": "dgx_LesseeOperatingandFinanceLeaseLiabilityUndiscountedExcessAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: Interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r645",
      "r651"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "terseLabel": "Financing cash flows from finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r641"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/LEASESLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "dgx_LeaseRightofUseAsset",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Finance lease assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": {
     "auth_ref": [
      "r812",
      "r813"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization",
        "terseLabel": "Right-of-use asset, accumulated amortization"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r644",
      "r650",
      "r728"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/LEASESCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of leased assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.",
        "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r654",
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate, Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESTermandRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r653",
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term,Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESTermandRateDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Finite-lived intangible asset, useful life",
        "verboseLabel": "Weighted average amortization period"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails",
      "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails",
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r271",
      "r423"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated amortization, intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails": {
       "order": 6.0,
       "parentTag": "dgx_FiniteLivedIntangibleAssetsEstimatedAmortizationExpenseTotal",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails": {
       "order": 1.0,
       "parentTag": "dgx_FiniteLivedIntangibleAssetsEstimatedAmortizationExpenseTotal",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails": {
       "order": 5.0,
       "parentTag": "dgx_FiniteLivedIntangibleAssetsEstimatedAmortizationExpenseTotal",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails": {
       "order": 4.0,
       "parentTag": "dgx_FiniteLivedIntangibleAssetsEstimatedAmortizationExpenseTotal",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails": {
       "order": 3.0,
       "parentTag": "dgx_FiniteLivedIntangibleAssetsEstimatedAmortizationExpenseTotal",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails": {
       "order": 2.0,
       "parentTag": "dgx_FiniteLivedIntangibleAssetsEstimatedAmortizationExpenseTotal",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r420",
      "r422",
      "r423",
      "r425",
      "r669",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails",
      "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Future amortization expense"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r94",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails",
      "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign Country"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r270",
      "r408",
      "r671",
      "r710",
      "r729",
      "r774",
      "r781"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, balance at end of year",
        "periodStartLabel": "Goodwill, balance at beginning of year",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails",
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r410",
      "r710"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill acquired during the year"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails",
      "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "GOODWILL AND INTANGIBLE ASSETS"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r418",
      "r419",
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillPeriodIncreaseDecrease": {
     "auth_ref": [
      "r782"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Period Increase (Decrease)",
        "terseLabel": "Adjustments to goodwill"
       }
      }
     },
     "localname": "GoodwillPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease": {
     "auth_ref": [
      "r614"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.",
        "label": "Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)",
        "terseLabel": "Hedge Accounting Basis Adjustment"
       }
      }
     },
     "localname": "HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSBalanceSheetsDetails",
      "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSIncomeStatementDetails",
      "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r313",
      "r595"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Income (loss) from continuing operations - domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r313",
      "r595"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Income (loss) from continuing operations - foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r369",
      "r374",
      "r380",
      "r383",
      "r708"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income taxes and equity in earnings of equity method investees"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails",
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r49",
      "r66",
      "r88",
      "r239",
      "r256",
      "r366"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "terseLabel": "Equity in earnings of equity method investees, net of taxes",
        "verboseLabel": "Share of equity earnings from investments in affiliates"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails",
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r721",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/DISPOSITIONDetails",
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails",
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/DISPOSITIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r109",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/DISPOSITIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r427",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails",
      "http://questdiagnostics.com/role/DISPOSITIONDetails",
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails",
      "http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails",
      "http://questdiagnostics.com/role/DISPOSITIONDetails",
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails",
      "http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r314",
      "r574",
      "r581",
      "r585",
      "r591",
      "r597",
      "r599",
      "r600",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "TAXES ON INCOME"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOME"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r315",
      "r329",
      "r330",
      "r367",
      "r572",
      "r592",
      "r598",
      "r686"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      },
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income tax expense",
        "negatedTotalLabel": "Total",
        "terseLabel": "Income tax (benefit) expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails",
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://questdiagnostics.com/role/DISPOSITIONDetails",
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r292",
      "r570",
      "r571",
      "r581",
      "r582",
      "r584",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Taxes on Income"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r63",
      "r70"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedLabel": "Other assets and liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r336",
      "r337",
      "r338",
      "r343",
      "r526"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/EARNINGSLOSSPERSHAREDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Stock options and performance share units"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r421",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r95",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets Excluding Goodwill"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [
      "r270"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Intangible assets, gross excluding goodwill"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r92",
      "r97"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "verboseLabel": "Total intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestAndDividendIncomeOperating": {
     "auth_ref": [
      "r241"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InterestIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein.",
        "label": "Interest and Dividend Income, Operating",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestAndDividendIncomeOperating",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r228",
      "r243",
      "r296",
      "r363",
      "r639"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InterestIncomeExpenseNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r242"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      },
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Interest expense, net",
        "totalLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r304",
      "r307",
      "r308"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r279",
      "r701",
      "r729"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r266",
      "r278",
      "r349",
      "r405",
      "r406",
      "r407",
      "r667",
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r396",
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r797"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r655",
      "r728"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/LEASESCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Net lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Leases:"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESCostsDetails",
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease, Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r815"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Operating Lease, Liability, Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r656"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/LEASESMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r656"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/LEASESMaturityDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r656"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/LEASESMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r656"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/LEASESMaturityDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r656"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/LEASESMaturityDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r656"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/LEASESMaturityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r656"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/LEASESMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r656"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/LEASESMaturityDetails": {
       "order": 1.0,
       "parentTag": "dgx_LesseeOperatingandFinanceLeaseLiabilityUndiscountedExcessAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://questdiagnostics.com/role/DEBTSecuredReceivablesCreditFacilityNarrativeDetails",
      "http://questdiagnostics.com/role/DEBTSeniorUnsecuredRevolvingCreditFacilityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letters of credit outstanding, amount"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r24",
      "r236",
      "r253",
      "r729",
      "r762",
      "r771",
      "r811"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAssumed1": {
     "auth_ref": [
      "r71",
      "r72",
      "r73"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails": {
       "order": 2.0,
       "parentTag": "dgx_FairValueOfNetAssetsAcquired",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of liabilities assumed in noncash investing or financing activities.",
        "label": "Liabilities Assumed",
        "terseLabel": "Fair value of liabilities assumed"
       }
      }
     },
     "localname": "LiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r30",
      "r265",
      "r312",
      "r397",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r608",
      "r612",
      "r613",
      "r629",
      "r729",
      "r791",
      "r816",
      "r817"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r217"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r27"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Credit facility capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://questdiagnostics.com/role/DEBTSecuredReceivablesCreditFacilityNarrativeDetails",
      "http://questdiagnostics.com/role/DEBTSeniorUnsecuredRevolvingCreditFacilityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationReserve": {
     "auth_ref": [
      "r34",
      "r787"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.",
        "label": "Estimated Litigation Liability",
        "terseLabel": "Litigation reserves"
       }
      }
     },
     "localname": "LitigationReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/DEBTSeniorUnsecuredRevolvingCreditFacilityNarrativeDetails",
      "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r16",
      "r234",
      "r250",
      "r471",
      "r486",
      "r712",
      "r713"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/DEBTLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://questdiagnostics.com/role/DEBTMaturitiesofLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "totalLabel": "Total long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/DEBTLongTermDebtDetails",
      "http://questdiagnostics.com/role/DEBTMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-Term Debt and Lease Obligation",
        "verboseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://questdiagnostics.com/role/DEBTLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "terseLabel": "Less: Current portion of long-term debt",
        "verboseLabel": "Less: current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://questdiagnostics.com/role/DEBTLongTermDebtDetails",
      "http://questdiagnostics.com/role/DEBTMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r119",
      "r317",
      "r795"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/DEBTMaturitiesofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "dgx_LongTermDebtMaturitiesGross",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/DEBTMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r119",
      "r317",
      "r476"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/DEBTMaturitiesofLongTermDebtDetails": {
       "order": 6.0,
       "parentTag": "dgx_LongTermDebtMaturitiesGross",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/DEBTMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r119",
      "r317",
      "r476"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/DEBTMaturitiesofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "dgx_LongTermDebtMaturitiesGross",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/DEBTMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r119",
      "r317",
      "r476"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/DEBTMaturitiesofLongTermDebtDetails": {
       "order": 3.0,
       "parentTag": "dgx_LongTermDebtMaturitiesGross",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/DEBTMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r119",
      "r317",
      "r476"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/DEBTMaturitiesofLongTermDebtDetails": {
       "order": 4.0,
       "parentTag": "dgx_LongTermDebtMaturitiesGross",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/DEBTMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r119",
      "r317",
      "r476"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/DEBTMaturitiesofLongTermDebtDetails": {
       "order": 5.0,
       "parentTag": "dgx_LongTermDebtMaturitiesGross",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/DEBTMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer.",
        "label": "Long-Term Debt [Member]",
        "terseLabel": "Long-term Debt"
       }
      }
     },
     "localname": "LongTermDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSBalanceSheetsDetails",
      "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r275"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/DEBTLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Total long-term debt, net of current portion"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/DEBTLongTermDebtDetails",
      "http://questdiagnostics.com/role/DEBTMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-Term Debt [Text Block]",
        "terseLabel": "Long-term Debt"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/DEBTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://questdiagnostics.com/role/DEBTLongTermDebtDetails",
      "http://questdiagnostics.com/role/DEBTSecuredReceivablesCreditFacilityNarrativeDetails",
      "http://questdiagnostics.com/role/DEBTSeniorUnsecuredRevolvingCreditFacilityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r32",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://questdiagnostics.com/role/DEBTLongTermDebtDetails",
      "http://questdiagnostics.com/role/DEBTSecuredReceivablesCreditFacilityNarrativeDetails",
      "http://questdiagnostics.com/role/DEBTSeniorUnsecuredRevolvingCreditFacilityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MalpracticeLossContingencyAccrualUndiscounted": {
     "auth_ref": [
      "r787"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability) at the end of the accounting period.",
        "label": "Malpractice Loss Contingency, Accrual, Undiscounted",
        "terseLabel": "Self-insurance reserves"
       }
      }
     },
     "localname": "MalpracticeLossContingencyAccrualUndiscounted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSBusinessAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSBusinessAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSBusinessAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r38",
      "r235",
      "r252",
      "r312",
      "r397",
      "r449",
      "r451",
      "r452",
      "r453",
      "r456",
      "r457",
      "r629"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r132"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedLabel": "Distributions to noncontrolling interest partners"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Ownership percentage by noncontrolling owners"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails",
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r351",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "DESCRIPTION OF BUSINESS"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/DESCRIPTIONOFBUSINESS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r306"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r306"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r62",
      "r64",
      "r67"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r50",
      "r67",
      "r240",
      "r257",
      "r263",
      "r287",
      "r290",
      "r295",
      "r312",
      "r321",
      "r323",
      "r324",
      "r325",
      "r326",
      "r329",
      "r330",
      "r339",
      "r369",
      "r374",
      "r380",
      "r383",
      "r397",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r619",
      "r629",
      "r708",
      "r791"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://questdiagnostics.com/role/EARNINGSLOSSPERSHAREDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income attributable to Quest Diagnostics",
        "verboseLabel": "Net income attributable to Quest Diagnostics"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails",
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://questdiagnostics.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r191",
      "r194",
      "r287",
      "r290",
      "r329",
      "r330",
      "r750"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Less: net income attributable to noncontrolling interests",
        "verboseLabel": "Less: Net income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails",
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic": {
     "auth_ref": [
      "r333",
      "r343"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/EARNINGSLOSSPERSHAREDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from continuing operations available to common shareholders.",
        "label": "Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic",
        "totalLabel": "Earnings available to Quest Diagnostics\u2019 common stockholders \u2013 basic and diluted"
       }
      }
     },
     "localname": "NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncompeteAgreementsMember": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.",
        "label": "Noncompete Agreements [Member]",
        "terseLabel": "Non-compete Agreements"
       }
      }
     },
     "localname": "NoncompeteAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r186",
      "r500",
      "r764",
      "r765",
      "r766"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non-controlling Interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Non-operating expenses, net",
        "totalLabel": "Total non-operating (expense) income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails",
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r369",
      "r374",
      "r380",
      "r383",
      "r708"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Total operating income",
        "totalLabel": "Operating income",
        "verboseLabel": "Operating income (loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails",
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r642"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/LEASESMaturityDetails": {
       "order": 1.0,
       "parentTag": "dgx_OperatingandFinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease, liability",
        "verboseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESMaturityDetails",
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r642"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://questdiagnostics.com/role/LEASESLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "dgx_LeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of long-term operating lease liabilities",
        "verboseLabel": "Current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://questdiagnostics.com/role/LEASESLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r642"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      },
      "http://questdiagnostics.com/role/LEASESLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "dgx_LeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities",
        "verboseLabel": "Noncurrent operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://questdiagnostics.com/role/LEASESLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r647",
      "r651"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r641"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://questdiagnostics.com/role/LEASESLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "dgx_LeaseRightofUseAsset",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "netLabel": "Operating lease assets",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://questdiagnostics.com/role/LEASESLiabilitiesDetails",
      "http://questdiagnostics.com/role/LEASESNarrativeDetails",
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r654",
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate, Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESTermandRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r653",
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "verboseLabel": "Weighted-average remaining lease term, Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESTermandRateDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r162"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r12",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Principles of Consolidation and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r272"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r282",
      "r283",
      "r285"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Net change in available-for-sale debt securities, net of taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r46",
      "r48",
      "r294",
      "r630",
      "r632",
      "r636",
      "r748"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "terseLabel": "Other comprehensive (loss) income before reclassifications"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTComponentsofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r281",
      "r285"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "terseLabel": "Net deferred gain on cash flow hedges, net of taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r48",
      "r127",
      "r288",
      "r291",
      "r297",
      "r630",
      "r635",
      "r636",
      "r673",
      "r681",
      "r748",
      "r749"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Net current period other comprehensive income (loss)",
        "totalLabel": "Other comprehensive (loss) income",
        "verboseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTComponentsofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeMember": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other revenue.",
        "label": "Other Income [Member]",
        "terseLabel": "Other Income"
       }
      }
     },
     "localname": "OtherIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/DISPOSITIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "terseLabel": "Other Intangible Assets, Subject To Amortization"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesMember": {
     "auth_ref": [
      "r203",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other liabilities.",
        "label": "Other Liabilities [Member]",
        "terseLabel": "Other Liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLongTermDebt": {
     "auth_ref": [
      "r16",
      "r234",
      "r250"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt classified as other.",
        "label": "Other Long-Term Debt",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/DEBTLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other (expense) income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSIncomeStatementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other operating income (expense).",
        "label": "Other Operating Income (Expense) [Member]",
        "terseLabel": "Other Operating Income (Expense)"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails",
      "http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENTDetails",
      "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "negatedTerseLabel": "Other operating expense (income), net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherRestructuringCosts": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESPreTaxRestructuringchargesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation.",
        "label": "Other Restructuring Costs",
        "terseLabel": "Facility-related costs"
       }
      }
     },
     "localname": "OtherRestructuringCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESPreTaxRestructuringchargesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic": {
     "auth_ref": [
      "r340",
      "r742"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/EARNINGSLOSSPERSHAREDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.",
        "label": "Participating Securities, Distributed and Undistributed Earnings (Loss), Basic",
        "terseLabel": "Less: Earnings allocated to participating securities"
       }
      }
     },
     "localname": "ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r753",
      "r754"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Decrease (increase) in investments and other assets, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Purchases of treasury stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r431",
      "r759"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedTerseLabel": "Cash payments"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESActivitiesofRestructuringLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividendsCommonStock": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.",
        "label": "Payments of Ordinary Dividends, Common Stock",
        "negatedLabel": "Dividends paid"
       }
      }
     },
     "localname": "PaymentsOfDividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividendsMinorityInterest": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends provided by the non-wholly owned subsidiary to noncontrolling interests.",
        "label": "Payments of Ordinary Dividends, Noncontrolling Interest",
        "negatedLabel": "Distributions to noncontrolling interest partners"
       }
      }
     },
     "localname": "PaymentsOfDividendsMinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r303"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedTerseLabel": "Employee payroll tax withholdings on stock issued under stock-based compensation plans"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r57",
      "r604"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "netLabel": "Cash paid for business acquisitions",
        "terseLabel": "Cash consideration"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails",
      "http://questdiagnostics.com/role/SUBSEQUENTEVENTSDetails",
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      },
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Business acquisitions, net of cash acquired",
        "terseLabel": "Business acquisitions, net of cash acquired",
        "totalLabel": "Business acquisitions, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails",
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Capital expenditures",
        "verboseLabel": "Total capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails",
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r747"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidTaxes": {
     "auth_ref": [
      "r703",
      "r709",
      "r773"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Taxes",
        "terseLabel": "Prepaid taxes"
       }
      }
     },
     "localname": "PrepaidTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r755"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from borrowings"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r756",
      "r758"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other financing activities, net"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Proceeds from Sale of Equity Method Investments",
        "terseLabel": "Proceeds from disposition of joint venture"
       }
      }
     },
     "localname": "ProceedsFromSaleOfEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r59",
      "r150"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r263",
      "r287",
      "r290",
      "r305",
      "r312",
      "r321",
      "r329",
      "r330",
      "r369",
      "r374",
      "r380",
      "r383",
      "r397",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r606",
      "r609",
      "r610",
      "r619",
      "r629",
      "r678",
      "r708",
      "r726",
      "r727",
      "r750",
      "r791"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails",
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENTDetails",
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r111",
      "r695",
      "r696",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "PROPERTY, PLANT AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r106",
      "r268"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENTDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r108",
      "r254",
      "r679",
      "r729"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENTDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net",
        "totalLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r108",
      "r695",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENTDetails",
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, plant and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r302",
      "r401"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provision for credit losses"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r46",
      "r48",
      "r294",
      "r630",
      "r634",
      "r636",
      "r748"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "terseLabel": "Amounts reclassified from accumulated other comprehensive loss"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/DISPOSITIONDetails",
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTComponentsofAccumulatedOtherComprehensiveLossIncomeDetails",
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification [Line Items]",
        "terseLabel": "Reclassification [Line Items]"
       }
      }
     },
     "localname": "ReclassificationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationTable": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about reclassification adjustment affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification [Table]",
        "terseLabel": "Reclassification [Table]"
       }
      }
     },
     "localname": "ReclassificationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationTypeAxis": {
     "auth_ref": [
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of reclassification adjustment affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Type [Axis]",
        "terseLabel": "Reclassification, Type [Axis]"
       }
      }
     },
     "localname": "ReclassificationTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESNarrativeDetails",
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationTypeDomain": {
     "auth_ref": [
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of reclassification adjustment affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Type [Domain]",
        "terseLabel": "Reclassification, Type [Domain]"
       }
      }
     },
     "localname": "ReclassificationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/LEASESNarrativeDetails",
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r125"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.",
        "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount",
        "terseLabel": "Redeemable noncontrolling interest"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityFairValue": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r125"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate fair value as of the reporting date of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.",
        "label": "Redeemable Noncontrolling Interest, Equity, Fair Value",
        "terseLabel": "Redeemable noncontrolling interest"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestEquityFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r757"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "negatedTerseLabel": "Repayments of debt"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r429",
      "r431",
      "r434",
      "r440",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "RESTRUCTURING ACTIVITIES"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r66",
      "r435",
      "r437",
      "r786"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESPreTaxRestructuringchargesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Income statement (income) expense",
        "totalLabel": "Total restructuring charges"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESActivitiesofRestructuringLiabilitiesDetails",
      "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESNarrativeDetails",
      "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESPreTaxRestructuringchargesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r430",
      "r431",
      "r437",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESActivitiesofRestructuringLiabilitiesDetails",
      "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESActivitiesofRestructuringLiabilitiesDetails",
      "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESNarrativeDetails",
      "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESPreTaxRestructuringchargesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostsAndAssetImpairmentCharges": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESPreTaxRestructuringchargesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Costs and Asset Impairment Charges",
        "terseLabel": "Asset impairment charges"
       }
      }
     },
     "localname": "RestructuringCostsAndAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESPreTaxRestructuringchargesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESNarrativeDetails",
      "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESPreTaxRestructuringchargesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESNarrativeDetails",
      "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESPreTaxRestructuringchargesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r431",
      "r436"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESActivitiesofRestructuringLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESActivitiesofRestructuringLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r21",
      "r132",
      "r251",
      "r691",
      "r693",
      "r729"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r258",
      "r318",
      "r319",
      "r320",
      "r322",
      "r328",
      "r330",
      "r398",
      "r562",
      "r563",
      "r564",
      "r589",
      "r590",
      "r617",
      "r688",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r360",
      "r361",
      "r373",
      "r378",
      "r379",
      "r385",
      "r386",
      "r388",
      "r509",
      "r510",
      "r668"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Net revenues",
        "verboseLabel": "Total net revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails",
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "REVENUE RECOGNITION"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/REVENUERECOGNITION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r705",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r652",
      "r728"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Leased assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accounts Payable and Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/EARNINGSLOSSPERSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r170",
      "r171",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails",
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSBusinessAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Supplemental Cash Flow and Other Data"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWANDOTHERDATATables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Components of Income Tax Expense"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of components of comprehensive income (loss). Includes, but is not limited to, foreign currency translation adjustments, foreign currency transactions designated as economic hedges of a net investment in foreign entity, gain (loss) and prior service cost (credit) for pension plans and other postretirement benefit plans.",
        "label": "Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Components of Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": {
     "auth_ref": [
      "r138",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.",
        "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]",
        "terseLabel": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]"
       }
      }
     },
     "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSSupplementalDeferredCompensationPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/EARNINGSLOSSPERSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of the Federal Statutory Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r620",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location"
       }
      }
     },
     "localname": "ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r710",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Changes in Goodwill, Net"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Long-term Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/DEBTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested shares.",
        "label": "Schedule of Nonvested Share Activity [Table Text Block]",
        "terseLabel": "Summary of Transactions Under Stock Awards Other than Options"
       }
      }
     },
     "localname": "ScheduleOfNonvestedShareActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule of Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r430",
      "r431",
      "r432",
      "r433",
      "r437",
      "r438",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESActivitiesofRestructuringLiabilitiesDetails",
      "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESNarrativeDetails",
      "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESPreTaxRestructuringchargesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r113",
      "r114",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Schedule of Pre-Tax Restructuring Charges"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r112",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Schedule of Activity of Restructuring Liability"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails",
      "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r523",
      "r525",
      "r528",
      "r529",
      "r530",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSActivitiesRelatedtoStockAwardsDetails",
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeStockPurchasePlanandDefinedContributionPlansDetails",
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeandNonemployeeDirectorsStockOwnershipProgramsDetails",
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTransactionsUnderStockOptionPlansDetails",
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSWeightedAverageAssumptionsUsedinValuingOptionsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r142",
      "r144",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Transactions Under The Company's Stock Option Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Assumptions Used in Valuing The Company's Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Future Amortization Expense Intangible Assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "verboseLabel": "Secured Receivables Credit Facility"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://questdiagnostics.com/role/DEBTSecuredReceivablesCreditFacilityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r357",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r388",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r433",
      "r439",
      "r710",
      "r825"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails",
      "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails",
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r357",
      "r358",
      "r359",
      "r369",
      "r372",
      "r377",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "BUSINESS SEGMENT INFORMATION"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails",
      "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, General and Administrative Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/DEBTLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESPreTaxRestructuringchargesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "verboseLabel": "Employee separation costs"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESPreTaxRestructuringchargesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSActivitiesRelatedtoStockAwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeandNonemployeeDirectorsStockOwnershipProgramsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Shares forfeited and cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSActivitiesRelatedtoStockAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Shares forfeited and cancelled weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSActivitiesRelatedtoStockAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Shares granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSActivitiesRelatedtoStockAwardsDetails",
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeandNonemployeeDirectorsStockOwnershipProgramsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Shares granted weighted average grant date fair value (in dollars per share)",
        "verboseLabel": "Fair value at grant date (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSActivitiesRelatedtoStockAwardsDetails",
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSWeightedAverageAssumptionsUsedinValuingOptionsGrantedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r540",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Shares outstanding, end of year",
        "periodStartLabel": "Shares outstanding, beginning of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSActivitiesRelatedtoStockAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSActivitiesRelatedtoStockAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r540",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Shares outstanding, end of year weighted average grant date fair value",
        "periodStartLabel": "Shares outstanding, beginning of year weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSActivitiesRelatedtoStockAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSActivitiesRelatedtoStockAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Shares vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSActivitiesRelatedtoStockAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r547"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Total fair value of shares vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSActivitiesRelatedtoStockAwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Shares vested weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSActivitiesRelatedtoStockAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSWeightedAverageAssumptionsUsedinValuingOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSWeightedAverageAssumptionsUsedinValuingOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSWeightedAverageAssumptionsUsedinValuingOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSActivitiesRelatedtoStockAwardsDetails",
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeStockPurchasePlanandDefinedContributionPlansDetails",
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeandNonemployeeDirectorsStockOwnershipProgramsDetails",
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTransactionsUnderStockOptionPlansDetails",
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSWeightedAverageAssumptionsUsedinValuingOptionsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Percentage of maximum annual wages witheld for the ESPP"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeStockPurchasePlanandDefinedContributionPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares available for award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeStockPurchasePlanandDefinedContributionPlansDetails",
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeandNonemployeeDirectorsStockOwnershipProgramsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable, end of year shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTransactionsUnderStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable, end of year weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTransactionsUnderStockOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r547"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTransactionsUnderStockOptionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r798"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Options forfeited and cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTransactionsUnderStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r798"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Options forfeited and cancelled weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTransactionsUnderStockOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTransactionsUnderStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Fair value at grant date (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSWeightedAverageAssumptionsUsedinValuingOptionsGrantedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r149"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options outstanding, end of year aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTransactionsUnderStockOptionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r532",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding, end of year",
        "periodStartLabel": "Options outstanding, beginning of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTransactionsUnderStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTransactionsUnderStockOptionPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r532",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding, end of year weighted average exercise price",
        "periodStartLabel": "Options outstanding, beginning of year weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTransactionsUnderStockOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTransactionsUnderStockOptionPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r548"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest, end of year aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTransactionsUnderStockOptionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest, end of year shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTransactionsUnderStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest, end of year weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTransactionsUnderStockOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r528",
      "r529",
      "r530",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSActivitiesRelatedtoStockAwardsDetails",
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeStockPurchasePlanandDefinedContributionPlansDetails",
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeandNonemployeeDirectorsStockOwnershipProgramsDetails",
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTransactionsUnderStockOptionPlansDetails",
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSWeightedAverageAssumptionsUsedinValuingOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTransactionsUnderStockOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, granted weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTransactionsUnderStockOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r531",
      "r550",
      "r551",
      "r552",
      "r553",
      "r556",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected holding period, in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSWeightedAverageAssumptionsUsedinValuingOptionsGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r149"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable, end of year aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTransactionsUnderStockOptionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable, end of year weighted average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTransactionsUnderStockOptionPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options outstanding, end of year weighted average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTransactionsUnderStockOptionPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest, end of year weighted average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTransactionsUnderStockOptionPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r76",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Software and Software Development Costs",
        "verboseLabel": "Computer Software Developed or Obtained for Internal Use"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/PROPERTYPLANTANDEQUIPMENTDetails",
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r261",
      "r357",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r388",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r428",
      "r433",
      "r439",
      "r710",
      "r825"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails",
      "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails",
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r37",
      "r127",
      "r258",
      "r293",
      "r294",
      "r295",
      "r318",
      "r319",
      "r320",
      "r322",
      "r328",
      "r330",
      "r350",
      "r398",
      "r500",
      "r562",
      "r563",
      "r564",
      "r589",
      "r590",
      "r617",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r636",
      "r658",
      "r688",
      "r689",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://questdiagnostics.com/role/DISPOSITIONDetails",
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTComponentsofAccumulatedOtherComprehensiveLossIncomeDetails",
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r318",
      "r319",
      "r320",
      "r350",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r18",
      "r19",
      "r127",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Shares purchased by eligible employees under ESPP"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeStockPurchasePlanandDefinedContributionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r18",
      "r19",
      "r127",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under benefit plans, sharers"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r18",
      "r19",
      "r127",
      "r132",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercise of stock options, shares",
        "terseLabel": "Exercise of stock options, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTransactionsUnderStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued": {
     "auth_ref": [
      "r19",
      "r127",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Shares, Treasury Stock Reissued",
        "terseLabel": "Reissuance of shares for employee benefit plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r18",
      "r19",
      "r132",
      "r145"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under benefit plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r37",
      "r127",
      "r132"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Equity Option"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSEmployeeandNonemployeeDirectorsStockOwnershipProgramsDetails",
      "http://questdiagnostics.com/role/STOCKOWNERSHIPANDCOMPENSATIONPLANSTransactionsUnderStockOptionPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Stock repurchase program, remaining authorized repurchase amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r19",
      "r22",
      "r23",
      "r86",
      "r729",
      "r762",
      "r771",
      "r811"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Quest Diagnostics stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Quest Diagnostics stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r186",
      "r187",
      "r193",
      "r258",
      "r259",
      "r294",
      "r318",
      "r319",
      "r320",
      "r322",
      "r328",
      "r398",
      "r500",
      "r562",
      "r563",
      "r564",
      "r589",
      "r590",
      "r617",
      "r630",
      "r631",
      "r636",
      "r658",
      "r689",
      "r690",
      "r762",
      "r771",
      "r811"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance, value",
        "periodStartLabel": "Balance, value",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r137",
      "r311",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY AND REDEEMABLE NONCONTROLLING INTEREST"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTEREST"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Number of Shares, Par Value and Other Disclosure [Abstract]",
        "terseLabel": "Stockholders' Equity, Number of Shares, Par Value and Other Disclosures [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.",
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "StockholdersEquityPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsegmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business subsegments.",
        "label": "Subsegments [Axis]",
        "terseLabel": "Subsegments [Axis]"
       }
      }
     },
     "localname": "SubsegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails",
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsegmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Subsegments [Domain]",
        "terseLabel": "Subsegments [Domain]"
       }
      }
     },
     "localname": "SubsegmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/REVENUERECOGNITIONDetails",
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r637",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails",
      "http://questdiagnostics.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r637",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r637",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails",
      "http://questdiagnostics.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r637",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails",
      "http://questdiagnostics.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r659",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUBSEQUENTEVENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "auth_ref": [
      "r155",
      "r159",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Summary of Income Tax Contingencies [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Benefits"
       }
      }
     },
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental Cash Flow Elements [Abstract]"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TechnologyBasedIntangibleAssetsMember": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.",
        "label": "Technology-Based Intangible Assets [Member]",
        "terseLabel": "Technology-Based Intangible Assets",
        "verboseLabel": "Technology"
       }
      }
     },
     "localname": "TechnologyBasedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/BUSINESSACQUISITIONSDetails",
      "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": {
     "auth_ref": [
      "r35",
      "r312",
      "r397",
      "r629"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests",
        "periodEndLabel": "Balance, value",
        "periodStartLabel": "Balance, value"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityNetIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of net income or loss attributable to temporary equity interest.",
        "label": "Temporary Equity, Net Income",
        "terseLabel": "Net income"
       }
      }
     },
     "localname": "TemporaryEquityNetIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "verboseLabel": "Intangible Assets Not Subject to Amortization - Tradenames"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradingSecurities": {
     "auth_ref": [
      "r238",
      "r274",
      "r702"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI",
        "terseLabel": "Deferred compensation trading securities"
       }
      }
     },
     "localname": "TradingSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails",
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r36",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock, at Cost"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockRetiredCostMethodAmount": {
     "auth_ref": [
      "r19",
      "r127",
      "r133"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.",
        "label": "Treasury Stock, Retired, Cost Method, Amount",
        "negatedTerseLabel": "Retirement of treasury stock"
       }
      }
     },
     "localname": "TreasuryStockRetiredCostMethodAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r36",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock, shares"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r19",
      "r127",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedTerseLabel": "Purchases of treasury stock, shares",
        "verboseLabel": "Purchases of treasury stock, shares"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesRetired": {
     "auth_ref": [
      "r19",
      "r127",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common and preferred stock retired from treasury during the period.",
        "label": "Treasury Stock, Shares, Retired",
        "terseLabel": "Shares retired (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesRetired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r36",
      "r135",
      "r136"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, at cost; 51 and 43 shares as of December\u00a031, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r127",
      "r132",
      "r135"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedLabel": "Purchases of treasury stock, value",
        "terseLabel": "Treasury stock value acquired cost method"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r430",
      "r431",
      "r437",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESActivitiesofRestructuringLiabilitiesDetails",
      "http://questdiagnostics.com/role/RESTRUCTURINGACTIVITIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "auth_ref": [],
     "calculation": {
      "http://questdiagnostics.com/role/DEBTMaturitiesofLongTermDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.",
        "label": "Unamortized Debt Issuance Expense",
        "negatedTerseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "UnamortizedDebtIssuanceExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/DEBTLongTermDebtDetails",
      "http://questdiagnostics.com/role/DEBTMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnclassifiedIndefinitelivedIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs of contractual or legal rights meeting the criteria for capitalization as intangible assets apart from goodwill, which have indefinite life and that are not otherwise specified in the taxonomy.",
        "label": "Unclassified Indefinite-Lived Intangible Assets [Member]",
        "terseLabel": "Intangible Assets Not Subject to Amortization - Other"
       }
      }
     },
     "localname": "UnclassifiedIndefinitelivedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r569",
      "r575"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Unrecognized tax benefits, ending balance",
        "periodStartLabel": "Unrecognized tax benefits, beginning balance"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r578"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "negatedTerseLabel": "Reductions for settlements"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r577"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions for tax positions of current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r576"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions for tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued": {
     "auth_ref": [
      "r801"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense accrued for an underpayment of income taxes.",
        "label": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued",
        "terseLabel": "Unrecognized tax benefits, interest on income taxes accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense": {
     "auth_ref": [
      "r801"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense for an underpayment of income taxes.",
        "label": "Unrecognized Tax Benefits, Interest on Income Taxes Expense",
        "terseLabel": "Unrecognized tax Benefits, interest on income taxes expense"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r579"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedTerseLabel": "Reductions for expirations of statutes of limitations"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r580"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/TAXESONINCOMEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary": {
     "auth_ref": [
      "r443"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Unrecorded Unconditional Purchase Obligation, to be Paid, Year One",
        "terseLabel": "Purchase obligation, 2022"
       }
      }
     },
     "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount": {
     "auth_ref": [
      "r443"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the unrecorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).",
        "label": "Unrecorded Unconditional Purchase Obligation",
        "terseLabel": "Purchase obligation"
       }
      }
     },
     "localname": "UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r79",
      "r80",
      "r81",
      "r352",
      "r353",
      "r354",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/DEBTSecuredReceivablesCreditFacilityNarrativeDetails",
      "http://questdiagnostics.com/role/DEBTSeniorUnsecuredRevolvingCreditFacilityNarrativeDetails",
      "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/DEBTSecuredReceivablesCreditFacilityNarrativeDetails",
      "http://questdiagnostics.com/role/DEBTSeniorUnsecuredRevolvingCreditFacilityNarrativeDetails",
      "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r334",
      "r343"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/EARNINGSLOSSPERSHAREDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted average common shares outstanding - diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r332",
      "r343"
     ],
     "calculation": {
      "http://questdiagnostics.com/role/EARNINGSLOSSPERSHAREDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Weighted average common shares outstanding - basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://questdiagnostics.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=2122178",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=d3e1243-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(12)(c)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(16)(c)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "14",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "15",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21459-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405686&loc=d3e22802-112653",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=6409961&loc=d3e20487-108367",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613674-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624186-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "https://asc.fasb.org/topic&trid=2229140",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.1-5)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.27(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e526-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "https://asc.fasb.org/topic&trid=2175745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109999712-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r732": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r733": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r734": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r735": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r736": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r737": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r738": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r739": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r741": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2740-109256",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "230",
   "URI": "https://asc.fasb.org/topic&trid=2134446",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(7)(c))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(9)(a))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>119
<FILENAME>0001022079-23-000018-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001022079-23-000018-xbrl.zip
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M=,!F= &P.>ZG[(V#:&W$:L'FDDN@FJS7;"0>!>Z *G<!L/EI&%I0V5D7$Q;
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M6X#LC0#][=;1!3SY[,5;!<B $6H(E$JMAEBYNOQM-+N"V?PZ:\[:B0%"\06
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MUO_7.RUF,U'UI7Q&:]N[%4%)O]J56[%RG4Y50%_)Q]7RT;N5&U/M[.U8N>X
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M<AR"NOM%BBB?J@78DN'^\LLI3:X'LWLDYR+-.:(XUJ/%V?ZE@.=LFU@<'YW
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M@R=\D4V]<91<:N2%%,%"VT1;.(VK#:24@;P_OZ)3]8/.,B$9^V_@5@7,K%0
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M6VR>IQ#^5@.YD] VYEH/Y$I91A:!TT[&<CZ%\;7_;N*2L E2B5C:FH8H89C
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M0&Y@953)XALGBS^(KTGJG4WEC.G@^*#XZ,C,.RLS*GW<WX+T\1;NOL_<TB\
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MTYR),/M)A#U^^=)0TKK 3,SHG57C>9T=T;D,?+&15+U]5YM+%S'&( M\!SU
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MA!$R" J,DTJSL"EV*L#"TCB)Z^H7Q*UI0M*:(Q-(.LE]#OA O)QBL<XH2I*
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MS#?1W2^UJS-\*<G*D66@_3!BX2.6&G_Y)/QSU2ICB9=/"X)CU93S!RM-OD4
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M_KH^;0<%U-]\$*OT_=(Z, .8AOIH5'2@NE+69^+<!+V6THRZJV4)M,2D%'Q
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M#EV #H]%>;NF(+K[ "8=A6V[3D^_*\'V&Q(Q-UUG6)@:?37EV3F71IYE%U1
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MG76_.TQ.P<.]V+12G<:FYT?DO3_1S-]PQYS:G(=!0G5)'2U?PF>;N#V]1=B
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M8[ FM3[X=S<JIP7':WEAJFSZE?M Q;?]Q^E2Q37N5B6C_GV"N%9Q^2!10<J
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M^6$>P<-^=*./N&5;A!JIT-$@FU' X$D4/$W 3)S17_R*EE%'W@O4BU"E-K/
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M0ELI.#I#5>AGBG?'?+$ \DQCX-Y7[-,SZ'22U@M1%\RG,XQQ<0W1FPB.*JP
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MN9J%H6HQ8YD;@YE<V+WG@6'B8&I2$\X-W@IPH#&H,'0D=0P>*TZ 282&YIB
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M'7?]^?*[UVSNOGV^ROJWN;FQVW4BSU=U!7,A0,4L[-MJWA]KWM$3(#B!ZJC
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MM('1OX:'JOBI+CO3R5P.BELJCJY*U''4B*D)99=9C9 F4,C88TBS1(OB^V.
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M+U1Q.P;L*=0KSF^N66'6M9Q8?.2,2HQ.)G<*O?4>+L:&G904(X,X<V6RF5=
M(GAV.F&+.A*"<!JQF>>1(0NYB13NS(!L*;3A@J>S^H&%!U/7O R-967=$M1L
M2!>J7!X1AR-5KT[X&<R&)*R1XN-(/0-T9@B&P8N(#<M'CC_$P<XTEJYE_?*X
MT;0$[FJ:<VSJ=\W.H4FJ-@OL7>?#9=_'%N[7!!WK"Q_[OVF>,:;J,LA#R+O
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M:,%DXQ3KZ09-\I^4/8F$I-RD5(\\D:"&E-.MO?YYW.XR3)?1A_O3W$+.WJ_
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MJ#G79(XBHFP>,44GQNSY;][ "*S,RK,**JM@\G+KU6V6:;WLA>O%A<_&1($
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M+W^C1YOE7KWST#03[[CA^_[D5<9^ +F):=?WFC@1QT'&-H_XG1KQOK\+G6B
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MO5[=WK"LQ0MF*9;%@<3UUV[N8G%@U^[MV7^+NUXO:YB=1LEH/J/?A7"%=X/
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M7=(C%Q_> !#@B^U/7:IF1Q=II":]KU;,S:Y^[9/=:H[XP.HKK?C<2^">G0W
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MUURO'V+WKML.Q7<H#Y(=%<OIK6$4VJY%/:_I*F'W<.U1C+!V_)3. ._VN$4
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M %(!&Q;8?8FU"T'O.X27<'NL/,51SS [2E17,;AA;)FF#BM_"GOX6+P[&MH
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MD;"OCNT1[/:Y[=_8\_C@U_SX,"]0JW<0@HN'7WG$T>C!CL@X[PHGY*%IS],
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M@&U).=79LN <+@9T$FL2^BXV+/3B.!6W_I1D)2K<RJ:=I1& 0,@U8R&N"!;
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M J(=_6KBB9'UYIMP4A),%VBH@55 T7;Z[JT6'O*[&JHAZ*#&_ ^R:,#* ;L
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MD"GO,06WM,QW03UBA6,Q\X$$BN+"860R87PQ*1 >&J"[+=H_ %<3-TBFDQ#
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M)<O@&&Z&'$<,!R"FK&%5?G+'X&3S[1P^:]::@Z[J^+PR3[0.9(+<"E3G5'4
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MK*+^YR._=OT8@!#.H^8(A6A8U-%:2C%3D3+M;,3\GZTOT?]DNGNGYF3T?]=
M7)X%G(_@C3%G3_)SL='W^3_=+P_%QOBI&0YS&Y&<<1S2$Y]6*+U*+/V\P$W/
M"P9X]_71\='KOTX.R5^]0[*%=E__ISH_V#UXAP[?OD)'SU_A[8.MB^VGG\\+
MWNUL^N.CS9.W.\\/Z<[F%MHY_<_Q;KJ6[4_/3@]?=S]L?_KKW>ZF^_CY-9_/
M"UZB'?(L7=\V.GKKT/;;E^3H=9<='KSZM)VNX_!@X]/VZ4NV\ZG[X7\_;<^<
M%WC&/$61@HR8 *-!@37(@_?1**>-- BOK5/,+X\&+A^!6UCY9@+JS/F(?P?'
M%W98"7:@Z7'3)@H5O&<!&6.(HR0ZAHVP1HB*'7!AAR6QP\5U=F#62$0T LDY
M L:B ^VC@+1AFAMN,=)R;5U)<O_LL" %="4N-WT+R'__1%^^1Z]JF/0$=,4^
MRT#;QDU9BM/4^"\9<U6&WV1&]LD@=[K(O_[7$NSXY]J=9X/AYN#<CN/YR>4M
M?"GXF7HP!;%S(?;E>/OI-<2^]\__P_R??YT<D9/W]NW9\<[KEVS[=/O#X:<N
M/7J;KO?URP^'I\^.=TY?XJ.#OXYWR-'I]NMT_R>*[&S\(RRS:4\C:(<B,$XM
M:(,LI#UW7#&F.#%)#J 9O%<*?I['JRE#4!ZO%7F\Z/;+?[QSBGL>@5LJ@!FO
MP"CC %$JD<38"HRRVKSA\?K6S)A)L]:KI5.U,YZZI"0WVHH;->-**Z[&>'P&
M5#MA_!E7DRK/]'$?QT_ZYZ?@!U5@-K]; =V\H*OY:(@8)WC""G61 _/"@N6:
M@4\N&XJ<&A?=VGI5O==V+^VG0U]C9JZ@[[[05_.!(N=61QF >I?0QSA.DL@%
MP($:1E2P2+&,/D;5@_&"E@&JK7YN[#.X.K;GIV6-IFSVY9I>)+(H1# 7$;R:
M#95:[2(-%HB5&)A*9MA8:T$9*05/3A/%-A&!7D(PI!CA>S'"!4X_ J>:7?7<
M$!VX@F@=27#"'#17/GT7M$?8.1Y53EXI5O5'4/(B-W_L3;LQCJ9%W),.MNY:
MTD"QN0W9W.F*=R<+OM'WNWFU)^E()0SU/=QQ.&.*F7)&*4( *\6 F:!!DY#^
M&8UTDG&'H\RF6!13W#*4-66*"\H6@+*:A::(6L=1!&7SZ1_&'FQ@ A01#EEJ
M R(T6>A<$M<R"WV9FYZN*7P=F/?UE_-)BFI-Y*1(K<WJXF PSCTKYA42MV:5
M_OZPR:^Q4/QUFBO1OZ8X\,VLTG!",.(,,.\"L$ X*!PU,*28T2$7N%?1/Z7G
M]%/NAH&EJ9"?%:*-Q>L+1!<&T7J2DA(A&$H@:BN!"<_!R& @<A.]BRH*FLPP
M>239[+GR$B&ZDD&&F\L/7@QSEY;QQ:-J%MFTJ=]_SWMGDSY\_3 NT87&H@N3
MI7Z1%SJY/=W+9:Y"DH5FFJ*9=[-*(!(;-(F)9G)G%88,J*@4\!B"$I(BX2HE
M($6).K0-?<U%'0KZ[@E]]5B$I@P3:8'@2H=C =9S"3A@[G3:289#A3XD6Q>-
M6"53OOMYFMY),-6,QO0[&$3( VW*24&CMOSS6O^=EWHO7\QN?#4*E>]0&&,N
MQNA^R&PQL=F.;;_MXG^((50@F9--0S+8,F#0S@2PSF 4'2%:^+5UKDK27-L
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MV("3MYL($[3A'"CAW"+$B,UM?%2I27SP+F_!VT+P5O-^2<S-'T4 1)3,AHZ
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M/33GP(#[]](G*$(WN.O5OWM]'_KC)Z!G6R<M&59587C'72T*G_KSCSK],&F
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M9M(XW<=GZKA-W+WOWE\\>+79RI(W*25V?OW! DB*HB3;2NQ8:M@/J6U1(+"
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M)?FU9_EDS!D 5$$93CV_8INA7 J*<)YS; 5S(L>>7U>S8G:07[\B)GS*2.?
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M8)/<X3;[.X2C0_Z1@=MFYG>N+1 *EF1] \-N@JP#&!I_S3A;Q#JGLH;I@9I
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MZ1KJX4,#05I#EX;+I@IQC$E,E(FY747X((",0GF7;#-G C(&M)" WJ:0B++
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M2.*"(L_*WQOM"7;M"2X6)_BP3N4-L$_3\/]#^,$?.PD5@%",=W,]!4TK_CF
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M2@)YRA*N90O*SA_E^N8->NN9AKYS&DZ_E!D7]2/3W@K,'?ST03L7,DQU\SL
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M&4VY!'>\0%[>S4;;S -LOT"NK'"BKQU*N],I806O]CSO9&.DD'D5 N2%;IG
M=YPP6L;%:M7SJD*F:P1K5ENAG:H,@4M$R:F'C+786%J&*8/SRKGZI>5YQ=0L
M>@J4YLW/*Z/2TNX?#W[@W%S.=V+]?]!S]CG3_-LK5L55 KKJVEW'#45JPAB
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MIO+:K_%K<NUW/WHLP:^E,?=Z[(^_$TS]\H-5F-[VL4!IF?K_OQ6V,KYN3'/
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M-()MJ=)$[D@.F]UO[8-LYL3&AW[OH&^/GS0#YY9V]'5KFW,?LL=LNV>-]J#
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M=DYQ!P1 M0%S)W#D>)0(*($[+ZF*!(3=3\NZ,83=K<7=8PDQ?#<A1I1A-(3
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M=M*+7UO=TW[[K'$4VV$$IQ=@6_=X@#^.09Q"(TO5(<AX+JDSM,H504CM[C=
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M$T3X] DX8HTT8,0CR<T!A7;(:.T1"4FGZ(DR+JZM<UZ,^)(IX'T]UJ* 3Z2
M$RZK)X(&32TBR6I41Z%Q\@@;YBGQWEJEB@(NH0+>UUM=E (6>KT@Q9S<.W9&
M,L8$4BX!O0Y!(6,B1E1C\')]DF*%SG:^..V\KX];M'/)M'/"^57&<!5A.J.*
M$G$N%'(F"B24$EHP%HQ\RLR.4I9\*<J2+W548>.K;;7S:5L$(('Z@ > 1&[P
M@\,#+P[%%[7]?3'5OW5[>S#1EPB]"3->W)D[XG)S1@EO3@GCWN:^G0GQ9!TR
M'#.$G6"!>T-<CB>0PI>63-,6M0%^>TTKS&A!&C@14"#*$0-KA5*,)->3Q<AB
MGW4Q: FD-4B1BM^RK'JXJ#WPHH>/KH<3\0/,%8\X'TRCU.8:JP(Y'SC"-D02
M!2QN+/&#I=7#1>V1%^;Y8/HVF<3-F*94<61\D(ACI7/?18.$BH0DFHC-2=Q/
MP#Q++& I8@'/ND792RB;_TQKYB\LQE&5T"F9CO<V+=-E@HW3GNMHD.6)(1Z$
M1T99A0+&Q% ADE8$3(LR"ZJ7OX2M.0K +-?#/45HIP#,P@!F(F9CO7. ^A9)
M8P,"US A\#$T0(U6T;-$)0FY_<^<[+4 3 &858I9%8!9&,!,!*-D,#A2X"V$
M<8.XH\!@L',HD$BLCIBQ>(>S&@5?"KZL4BRNX,O"\&4B^(8-D1(+ ="2*- 6
M1I%5DJ% C>1!6ISX_,&WAX67TDSLA?SD2J8,S2Z3/-87L=1*OE>UW/+\Y?F7
M_?E7$KCF*9?<OH2S4B=Y>1[A"38O9F73CXS=V=NV[?=;J15#[DM3'3@?%,H^
M'V4GT[6*.(TT4(>DLPEQ8BVRB2A$DN,Q81)(1=GYG$V 2UW$ A4/N@UQ!Z@H
M*6X+@I");0OL67#6:>1#L@A0PR+#P/^W040<DR(ZE?*J!4:6<K.A,(Z'AXN)
M30BKL#!,8&2(%(@KB9&E)J'@DM(,1V<T*XRC0,6R[1L4QO%T$#*YS^ 4PU@S
M0(]J'S,ZY(3#*!GBM50NLO24AUM*JN]2I/HN-0:_A2M@K  3&:WZK1#K)IGE
ML.^"8DF_GO9A&/T^P+5K=:JYO9SSM^-3?@'B!9CG ^;IRM>8&T*UH,C17$(_
MY\DZ0@6*06KF.,'&@RLHEIW9O3BE6U14YDY*5UC2@I1Q(BYCM(05BQXEE_N*
M>^J18SH@''S"$NNDS.K$95Z<2BXJPE%4\BE5<B+VX6P@FG.*6+(Y5&H,LE)B
MQ'#4DIL@(HM%)9=5)1<522C4]#%4;R)F(*@GP8F$N&0<9><"&1,2,LXF3;PB
M/!_$?P)J6J(%3Q,M6+X!K\J5Y<1U.4^P^M9\48&FL6S<<JC@OH;[W70M.9U/
M)HG $8N9,SO,D?5>HIA4\#S$F*C(^X5ZF8X5E%-+!646&EF["66*Q[X@])GL
M):<86 <<D"2YGI 7#FFJJTS):!.U/"A]1X^](%!!H!4*)!:>LV"DF8@-&DS
M2C""G DX1RDL C,A49!!1Y$9D+M+7E1!F8(R*Q0;+2BS8)29"(,:PI,GX#[9
MW"F0TUP7.&B/:$J&<@MNE#)SAT&?Y1'MQSZY_#)_[PZQ1+),L<39)[3?QQ#C
M<2[XV@ ERD#9Z[;ALL-&"S"S%_N#<M)Q>1[A"8*&EP*R<T4^MH?B43<=NK"
MQ>[-9_>FBS<*9E+T28 $@3//N>5(@VN/J$A!R(13=&EM?=[:C>700<&)!PW[
MS8T3)0ZX(/R8B /R('(5QES:*)\[($8CZZU &-#?4"%5<*O33Z. R-,]PE!$
MBD04B7BZ*$NAGP]M/B:SSW0B-F"*2$P8S =Q0#\-1TJ$) V7RD?Q-/2S<L#_
M-<BRL%[]NJ]2$4^K_$-X)[2^KO]O]<\CZP:]K(<T_>_%A"SG\/:/8B.?$[6=
MLT8WI=CK-SPL@FUU&O'XI-T]BS"& 5S4/3GI]@99X\\:@V[CQ.:5:IW806S
MM39'#]!_3V'=\M'21O_TY*0=CV-G8-N@W[.**9VT;>=UH[%Q>:O.X)_]X<6
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MEJ ;*O^\OC"K>06!W4IH >C!-P>=K0<]4J4QR!^:AOASC;C@P80\32$"L0(
MK^3X4C/Z5T,2</LQK6EE Q9/;"LTXO>LA\.'KQ5\*+=W4'28I[U3P(T9*_;
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M/UT+%36OF4 +BQ7V.&BL;.0D$6V"5MI82YF@1+K9:,$64"RG>6GUM_.S7H
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M$+$D2F$$]=;DC8/I ]H7Z865Z9GGN.M];<_UV:OW$9(7+ >[&P>8!%@-$($
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M+R=HXH#U6( V]E\U.G&0P[ZCD.^P[VSQC.[M&;&[8-[L$VNQ7\!N/K";;C'
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M4U?ZO8(&\&8NVPXR4)F"7/NWX6P[YT$V^D<Q#EXWKL'&E6AK\"/@?%4]>3Z
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M#\8")B$)PZ-C+@1II2<^&JZ,LK/="+6GRA"O<G=/[L$*,41'GD#Y,8NUI+^
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MLI1KI+RTWOE$B,[M+L0516,+&!0P6 @,EDY("QC\'AC,<D_"@& &+Y!UA"&
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M\G]N5@_GCP ;(-[S)V_]4 2_E(3=]J$6>$\P>J=O/JW!\EM=]I;.KUN4N7W
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M2QDWMM@/*T"*YIS]$*+C0FJ)4F(*D"(H9 SC2&CB8,6T)9RMK0M:^R,7ST[
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M%'7-!"P(GRA1,@;F>50JGP/AP1(6!1C*O.28K4C 9G0QCD98X##(YUY[',N
M'',<I<!@;73$+.A<;V\%E7Y_]SS)3TF[50+_TQ1#2H5(1F <D^7)).<8(UPG
MQHUWB8C"5^LFHP=S2M E:YW4! 7)!.(T..1 [R%@0EHXT(+*T+5U\8+@!?GJ
MK>5B93KR&4LNXX$9FV1.S>816VNI9V"O<F*EL\O+#"N2NT3)G=&N.2!D%:4(
MTX015RXB;:Q%8-0R(CWFVI.U=?Y"F04]VO<NN4^+!K\%RONJL>']^'C<K4HI
MA7@RB+FHXGDM,7O<A_&>52\\37;\CQ68#1>F?//"C,/OW9A_ 3S:N##QUV)5
M@:GEP=27^?1Q >N*(T548Y/3QRVR24@D902M0SRS.*VMLQ>,S?/L?Q:*O3(I
M79:)4*2TEE(Z8TPX3I(342&1F$=<.XET!"G5WG@):.U\$EE*L=8/*J5/L^EU
MNS^RW9NMKVD5$CIG@/T>:ZG=5%QW.'9YTU!O2*Z3NZ7U>,K6/P:4W?J6$79B
M#WG>/-HBGZWAQA)!4>"* 6>3'CGJ%+(Z&NX,=9,.UR^4O*Y$\7V+RX.>Y2]8
M5[!N10ZJ@G5+Q[KF9:R37N:"VP8Y8B3B1@#,84:1CY0'AQE/L'@9Z_"" =:5
M8]WE3D%S9;!O41[[NB*SUW0<N77M:+VVOO**JG15%57_[O=#KFH.8K[=&]G>
M00<6J&K&,ZQC3=6#J5B?=%IG&V?[[7\=MNB6:'W: W'=/MOY>X^ N/+]OS^>
M-<^Z<+V][W-U)8^W67.SU6U]VF)[[2]D_^A#MWG4Y/M''T%<#[_LMYMG !=B
M_VCK%$@?W]GXK!D+2LB(3%01<8LU,C: *9)<U-2ZH.A<357CM,1"P?=HY"DH
MK0":A29,6R%5Y+-U)?_>V=G\M/WV;55,=;O5WFC]O?W7VZW&QN[N5GMWV455
M?SVZRT]#>;(Q@!&F*2@9#IN,)<5!CN 79H-XAD58=_UA#.-NW$GG(O2,I42T
M-CXS0@)-3"#E@@'5!0)B(N8H>DEMB*"\XESU56^%#TY*HXCEADGG *YQA!G7
M5%;56B]+2?OPO!M:U?KA8#KS55;\=<V<KJO"6G4YLL-I\=7AJ]^0L8OM!";U
M4+,>G7&HW%RE]9<S\=!56L'Z?(DG%NA=RK0J=1^53X41]U*F]6[%7W\Y6%W*
MM)8RK:5,ZT.4:5V%WZ*ZXE6]':ZI:F:[N6_GBX:+ ,:]W'"HGRJ556JYUN<1
M5N!O.3<@'XMOY6[FY<2W M^A+;C>^]/F61['%FZVM[[#O[2UN4U;9TW:I-E/
M\H6T=F=\*V"2[M$/1_"YL];?3;[7?O\=OLNSCZ9Y!#-PMG>6VYGMM#^2JTJZ
M$DMI!*H&!JG!P-W 2-74&*2TMY($RSD%"U.]P(NF_I2JK@4?KL0'K:ACT=+(
MI.&8)>TQH2:EJJF>8+K"AQL:&Q9\N%=\F#WJGL]">,=14-XB[G-2K\WM<Q*S
M."0=&5%KZ_*%5H^JOFOM,.!\-S>L_]]QYXKNBT\SV6\5[93GG+S3&9^TOWX'
M#](/!3<6PHWY4J^)&,8D-BAB31"G2J+L*T682\($5U@(GSW\U_5BKXU5\>SD
M;&G=J8N<W8><S>IG'%7DTL!:"#.5,V,2PIXH&L#,LC$79:3SN79%.]]>?#9"
M/BY0%8%KC/H_/.Q%)]^73IZ@PW;/#W(EOLTX^;>@Q4)H,5_"-6IM1<A'U'$^
MHI? KK<V9^E2QL#*#[RJ#[V"0[3/42<ODD*_!*4\A >&WXK$W:_$S>AG240@
M)DD4 P/]G' "_AP2(LI9DX3)YC#PYQIGPJ]:,=\UGA![X1>1A)(S6G)&[S<_
MOO@HEX^Q\_5N-674A5R3'I0BXL%*Y+C@B"2-O4TFQ*K>[0NZ:&.9E:>'EE3X
M FLE-/M<8&WV(*5P' <-!B,E''$9+#(^8B1TI((I,/8MOE-H=N6P=JNL]U_E
M%M8KK_;=H-/SG1/;[9XVX,=Y#_M<P-CV3O_O?VA*U)_#G[F9=I@_\LML3/B8
M'0[[^:1S#(UOG=%AHS,:-C:W=QMN/(31#8<O%TO)K->TO;F0HGICANJ+"U-W
M'B'+LW-R<=YG9BI?N/KPL%,A(TSX.^N_-/X[VBZ\_8]AC(U6?Q0;\I\O&XT%
MAF*O=@<V!G%2M0->@RG^^:GSW7 R'OA#8-5YU#[F?=+WDVS7G*K[UKI1](<O
M&B<69*=ZHGY*PSAJN-/\ 9C/7L./!X/8\Z>-T0"6HUM]^UGL +*$'3 \7PA;
M'>4X_ZL_'@VB]8>-[L^N7N?2E3_3C .8\.FNR;)Y^1+3=9O93PL\URVVTXW+
MWZCY$M=]>/=[)*(<()H_&K'UK;GY_G-((6CK"'+).L0U#<@&P1 GD4E+.#=V
M[@118E@))HA,G'(NF,NU7XRPU DI97*S9R-^SOZYQ-Y.\\)=AYUAEKXI2$P.
M1&3+Y^8C$3<>UION1Y[/&IST)Z#TJA+SSM?X\XC!_UF[]*VIH89_?L4Z,,K&
MH^N_<MVIP(>6N3<H1QXOS<^%GX>#GY3V("('*/P%V03#?66[W^SI<.V/R\=(
M.KWSRTOU,D_B[/-?^Y0IW=M33HQ?8#U9=^35&0/:#_*G8$RV-F-I' XRI/W'
MKP]_JK7U=G6J!K;^ZXR&5>\K>_WQGH??;5<?&'W_<6NW#<;QQM^MG=WV]NO=
MQG;K]<Z'=SL?-MI;F]4APMV/?^UNPR<^;&_MUOYY6COMK=U&>Z?Q>J>UN_-V
M>[-ZC#?;K8W6Z^V-MXW=-KS0W&JU=QL5PR!_YD^VMUL?MS9K_W#_Z/0:<-EN
M99>->]W*V *D'7SK@(7<Z06@CX"__WPXZ^':2,/5#W [<^>&\Z:W.S]Z]1FZ
MZT[,_5(_/J(3<X2_%)PM_Q :>6G(74_%/?2).?.24_E(Q@H3RQ[-8!_3Q#ZF
ML3ZV3<!N-]9K3B&:WSR&..A_NZ:6]!1C?^F K?EQSD_5'S%4KJ@-&!D8^I/?
M+Q:RS2],$E :V2RH#JS/94#<98J)>+S'8)=R#/@Q3\!MS@%3OIR#P(L?X+U6
M0!<)G]1\$5[WAZ-;[,)EG:)^0C-WH5;M/-R5&;W#C+;B;;;B\YR;(J=%3NLR
MH[-R>F6V*;DZ<[L^N4;7[);)[LCG,CNS@857*T"G55<F*;<L)5]^E9_V>CR$
MF\/C3\/9"XA)W0#OQ@2\*^/'D0L5G3+"2\^YRL<WF-2.V1AXTI3=(G[\IM/K
MC.+;SM<X6XORXS"F<?=M)\5+B7CP'/Y5& \RBWZDD>5IZMU1:_/P<*>=4^S@
M/K2)=]I[=&=SB^P=[YVVCK9QZPC&?O;EK#E;<?88/OOWEL@I=O!,;._LO6@=
M[?%F^U^=_:-MVCQZ3YM_?V1P[=.K3B\'[P7A6B!O8T+<*8:<)QXE'4C^RRH3
MUM:)NC847*J7/-'J)<XD$RV621'#B5&:*.=H3 %3(I)@MST9,)L54G4YV_KN
MN^,\:<\JP?;AI'SV;%82VD3!$<-1(HX=1I8PAB@+R6@F99!5"7U)5U#;I*#'
M8T&/A<YQ+@D^KC<*AA<8[44R6]!B0;1HS58T$3CH2 TR3 ?$HR+(6!R1%]P:
M%C%1F*^M:T9KW'NLP,2S-C):<72%B5%P83%<F+$B/(TD48D1,#R*.*P9LA2,
MBLB4](8[G*Q:6U>F]I6."C@\"G!0WF">##%@O7(2K,/>:\NE<BGZJ-AM#_$5
M!O+PV+$S8U-(RH6"-41<*< .'\&F<$PAJ9T)RC$2M,X,1.B"'@4]EL) E@4?
MA8'<O[]BMN<?<T1CSBB*B0,%X4PCZSA&A& 7N39*)8 +11^VG$S!B<>"$S6P
M,@H%60HPS#3("T$DG(!T*,QSS^5<*L *B3S!EGI%51)R;5V+%=1P?T*1S%:_
MAWS_^"2.8L,>#&(\GIR,>D[Q3!&D84PQXQEWDN@0G>#4<T4H8=27>&8- &*^
M[B.7F@DJ(V)5E5A#,7)><21IQ%9R'*B(P#/P$N.93Z-&XP(:TQ A&.4\&)$X
M(\F8E*1-A'*7O&)TV9'!HC,7$XD9MQVU-G'!&1).2K"EN4*6VPB_):8,=B81
ML;9>^\#?TQ"S10CLLN2L$-A[E[G9$!H7U(5@'.*D4D.,(Z,%\%<AC$HF64[X
M53)7'_;Z-,2M!EKM:AYXT=><.M]C0&=QT"]RMZC<S>@Z$0,&FQRD+1"%N*2Y
MDEQ@2$<<E(HX"NWS>78-"_EGT7@U$T'O-$W,IUR'EC.IG!%461 _S$FT,BP[
MX%.$;2%AFXWI^!2U3E&AJ&1"W(N(C)06T11MB()+96PQ+&MH6"Y+SHIA>?]D
M;BXRPK Q@45$'0<.1WPN <T88C$9QV3T,K>IJW-JUM.0MQJHM1)A6(J S408
M/!-"4R.05P2T6D@)&5!GR">)26(VNBI3H<07?D-XVM$?]N!>!Z?/*J8 !A-V
M-)$@I.!$<)V$LQ3'&&),*:024Z@!),QW7:!@Y7JA+;)"4L0M5<@()Y!BAA##
M+:$^ 2*($E.XNXZ,SA@1<WTX*3FVU$67.#4)QT0$0&^)*:Q6)&9C"H%3S8A'
M,BB6*_8KI*,+54R!!R\("QQ$@JV@&>-S%+1%R-^R)*V0OWN7NMFH I4"R^0-
M\H& K%GIP#1U8"R [$4L%";2K*U?D4%;R-^34VR%_"U#P&;4F@)[/$;L431:
M(JY P1G))0*%)@A)&@S N+8N5-%J-9,R;R,Q@H5$G.1"8X.EULJ!T&D"*Z-*
MY&"E<C9W&D1*@#^+P6B4"G$:#-)*!20H#91EKJ4<F(^\]F=!GH:@+10[6)*D
M%?/Q_DG;;.P ,Y/+NE"4/!? U4  '2PF2D$EE; (Q@-K4_-=L8O]^.0T6[$?
MER)A,\$#&ISG3CN$=<[[ LL>.9PX,IRZ0!0),C<[D"LP()]0]& G]\YX5H$#
M5O7E$I%0;[GUV@+?]\I*2PUS*I$2.*@!'.S-!PXB"<;QA$12&'%-(G(  ,@I
M%YRQ1"5F  U*W."W&OT* ]2<>8FYI-)%'6**( F&!,W+68052\1L(3+N+)@P
M!($- _K1>8PLQ0HYYZV3.FD=,1 _,F^"%N*W8N*W+$DKQ._>I6XV;A"T\-$(
MC;10"O20YL@QRY . GNJ$Y@7.5J'ZWR:_FD(7 TT6R%^RY"PV=)8C!$<"$$J
MAEPR+S=X=98BQJV1ELNHHEY;+]'PN@F98AX# (J4J.)<)LM-\"%$&WS,KY:X
MP4K%;#9NH#R+Q!N.2(P@9I0Y$#-"D2:&265D4BKG9F)3!*UNYN.R)*V8C_=/
MVF;C!DE*$;CC2,L@$9=2(Q,H0<1I+8P.4I)*[$KBR3-0;<5^7(J(S00..&9.
M!!D04#*>'2,6:2,4 A-?8QR9X):OQ(!<+&Y0W4*]5*+F(81V?V2[SRJ$D 2C
MT7A*J6,\:68]-LPRKL&BHCC:$D*H 3#XN1!"4D)JECBB+FG$O<K%6\  ]D)'
M)SW-:9]+[L]RA::\==.VIZ=&74@8<QY="HD3YJR7V-) )'6> 327-B@U%J89
M+TV,)MD8"!+$4\0)9L@EJI'#8-=2IW):12Y"K-6"BG:1IH:KL76?F@0OU(ID
M22)\%^I9Q'EYXCP;UL!:<QTH!3(J'.**4Z0]UX@(&BC8-P3SJJM1U6#\EL2T
M2/(SU,6%TBY#.F>4;7(A1FYS%2;&\ZG9")9KC"@F+0P#2U9CD2OUS@<=BZI]
MK )J,?5<:$FQCCR"@%+-'8X!!P*K+77IV%%?^9V-M5 FB.+:()MR=2<M C*8
M.Z0$#YXY@25VE;',%DS6*1)<9V-Y62)<XC3W3V]GXS3.<FE5DH@Q*1 /SB+K
M08)A&16L%4F1@4%L\.WKCA99?8;:MIC#2Q'.F0@/(3(F$PV2&DO$*8G(6.WS
MX7TK"38\I0#"R18\\WCO$CH- )W?[WRS\DHP[RB^Y:/EH[_XZ)5Q1Z)_XK[U
M7PX&_7$OH"DTI^J_V3U_ZS!DZ'R=&1#*GW]ESJ_1Z878&[U"IAKD_>H&=:5N
M^ G4#5LA=:/7!Y$?NZ/H1XU1OV$OF%.O?@ &/-FREVJUJE3?2I->#9OE^<OS
M/]OGOZ=#H+6"SFL2/@8VQ,KN'2Z,BX]TL4M^W(WLB5!-B!:8<A.YILP8AGD0
M+'#&DB:\G!Q<(7_:^O9VEC\Q'"7AD@)A2OGH(*/(<NI1%%1);9PV0:^M4[:"
MSG_/4=*F/33*W#Y-%"L^H*5@F+^,88(HQE.T2,7<@ V3A#25@&%$:!NX")*$
M@F&UE#/II?(\.LXBQU3:Z&P@C#@BM0K<EX-B*Y:T+S/>5N\ECM&C)"Q%7&&!
M3% <,28B(*9WVA=KH5@+3V%N:X!BQ5I8"H9MG;V=A'39SN;V]];[ST$[2I.+
M*$BO$4^,(.V#0L99HEF4-'FQ(A0K]<2*/^A)8:/$*A*7; 3+@6/.K4N.89;K
M=$LJ=2C^H%6BX_=Y?Y!.4AJGD)#8($Z"148HBBC0*JVQ$DRJE?1I>HYR5NR[
M)XUAQ;Y;"H+->(-8#%RR*!#7-'NT$UAW"CM$HZ<T8J^]8 7!ZB=E-'*:8*4H
M=9CG'&D1(_/,V\@TYH(67]"*Y6S&%Z288L:FA%R(9G(<Q5$KD/7!6"PTHT84
M.2N6PJ.?VQI@6+$4EH)@<YX@8J3V3G$$.!; 8(@L.X$2DH;9&!.U7-*GU)7V
MNI0B(BX4EZE!6E&N(]/HS.9EWF?JY>Q'+^>!3R80IGLV%?SWSDG4SF?WGS>G
MPR]A&IX.U%,ADA$86*#EN0>Y8XQPG1@W'CB'*!5,:JL)3N>\7L0RPW(&0= Z
MM_ A$AEA&1*"*:>DUER2M77Z8N$2ZDL3G(<QV KJ/4?46^0@Z[)@KU1]634$
M?KP,@1X+1;CS2#'AP12V#NG(-=*$)HEM4#KX.Y9]*>A7T*^^Z%<#F^]J>E_@
M;IEP-Q,ED"SE,AP8$25C;MYAD5$RH8197E-L;*05W)EYN"L67\&\9X-YC(?L
MYI<ZAL CMM92SVCRG%CIK)2E^%"=46\F9L,Y Z8K/;*<5?F["5E!0Z[R1PPL
M+]6,99Z+%2ZH5U#OB:'>@GW9E@)[I6#3 Z!<%=NY&-=1G'M,DT.8,P7HY@RR
M6F$D$PE1>>"RS-VI9%,!N )P]06X&IAUA<H^ -S-AK&585%;C<&LPSKGO4FD
MDV (R"MW.#&G6.6[(XNV2%\YZE5Q\#]&%O;7>C7TO(D[O7&E*<\CP=6/!Y8W
M^O,XP.U_7@Y@UV[8-_9*9UQC7C5,3]Q[X^!7QRSQAA*7(KU%HY-=?QC#N!O[
MZ0:CZ,UX-![$B_;0UO>3V!O&=MX#;1C/7]V^__)(L6+_WX?8'_^K9S^9\<[Q
M-FMNMKJM3UMLK_V%[!]]Z#:/FGS_Z"-O'1U^V6\WSW8^P=B/MJJ#3,W-CY]U
ML#)1"G:-4R#H+O<MR?P- P(0ZK4BBDZ 'F0$S,H,N<SK9+#U)!G#P>1Q!$>F
M'9;PQ<B27FM$0. 36*C18!S7UMN'$5X9 3:#87JI]E4C3I:B,8B5U7JQ-E;.
MTIA+V,BXWXC6'S;ZJ3&"ZR98\L9P['V,&1K@[PS^C=S)9MBPO9 _-(@VC>(
M+I&_M1E]/'9Q,-FAC+QHY.W5Z SS^ZG?[?:_#5]=VZ;E7,[.)6RNT=!$9UX$
ME<G&^N6D 4I6SWP9*$&"N_9D&%^=__)GZ Q/NO;T5:=7R6'UI3^/[>"@TSN'
MU9QX,P."U3@G;__YK1-&AZ\X>6F$R3I^FA4TO?'D7?*R4O\SZ#UY3\&;5%S[
M-GY)KGWOILM2^5*IVUWV41YJNZI6W&1H8+CT!Y-B<.,>K'K^U-KZ'NSAQE:O
MVM;GF[8!^_7IGX![E,M[]=,!MK!;9/4];C;T- G-0R0FS%LE+;A_^UOL?HU-
M&,SA\(FPF?[WUED+[G=PNG^T?]PZVL+ 7+[OY+%F%D,_?ML!MI.ME=;N#)LY
MVF+ @,3.YO\<MX[W:!,8S4X;[GOV\32SF/WV!@>V<]H\.R!@U<QU9A.":,&2
M1$%RBKA,'#F)(TK*@=7)+4V37L0+]K>H<4[NBG".7ZN8GDVR_DH0(]L)[6_]
M A0+ <7V'%!$X:P(@!'1TESX.SBD+5?(::&C$I@PG(_Y7>'B+4"Q$%"( A2K
M XK#08P%*A:"BN8<5%"F@[7*((UU1%R8@(RV##'.*551)1'S246\8*9/@8I9
MJ) %*E8&%6_ZXT%!BH60XOT\4D3+1/9A,ZS J' Z("T\10E6TWIBA7 Y;ES(
MQV\"A2I L3J@@,\6H%@(*#[. 05SB@0:(HJ*A=R&$TP*&0 WJ/3,*BR=\[D-
M9P&*WSD&_",85.!B)7"QD>>^8,:=,&-O#C.X-K!H%I B<(8X5QXYABG"5GME
MX,V8TMHZDPL>,7UXT*ANH2Y4#*@K?N0R O>>$O:H8T$E,V[I4!L.OM\$LUOG
MJ157Y;CD#5MP=B&<]7,X&W!2.G&!O 4FQYD'$J<]1UII@P7%P=#?:)%>\URX
M^==_I)FM_Y<;_'%%;DRUR:)1. HE8'8B%T*#_>J$=SAX'2VVXC,E9.T!,]?F
MTB^JS#7"7JXH>6W#^_ZX-QJ^LZ=Y 39Z 5X9C&-XV[&NT^V,.G&XV1GZ;G\X
M'M0G3ZV]-17A_NE..QPWCS]^;_W]_K3UZ3UN'G6_@-AU6YOO66OSS9<6_=>7
MO783[\WFJ1UMBQ;=.]UO;^']S6VRO_G^=.?3A\.]8[CWIL?-3^_9/OS=//O0
M^?<9B/G&9Q! R3'('<QRR)8.0S#E'&%-.-@^0N.09M/4-+;<2 QHRPT'@TA'
M*:6EPAN3--=R-DUMX_7KG8^M]F[CW<;>QE]OMQH;K<T&O/CAX]9F8^O?[[9:
MNUN[C9LSPZY,_?KE0.J8N5D22\?=N)-N(Z7U2B1=@8 VOWW63GJ>6WA(IA/B
M(6)DF"'(6AZYL30*/R>@"5-FI'%1Z,B=REX.I4!*5* R"!OG!'2Z%HV3R6)4
M^9UVLASGF:3#F[,\\S?R,80\DF%GF%-.SQ-)J\S/K%%_(>(W)7]>*G?&9'6
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ML+=.,1Y0)#(BKF(^CZ$84@ECT!_*F$B>29Y>5S'ZS5R+Y\U7GV<QNZ)RP(
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M<">TN_QTN2A6>_DAD\TF@[?]OR>,J0O[/]X/5TVY:#XWK6NVFOWSKS!2Z^5
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MC>LPD?%C.,SK/TYBNU=Y7>9#C*/I79]$\P% @JS#&3&T0$80APA626MIJ</
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M;&W_N;4!5WS=6-]:^/[4-QOK6T5CL_BP6=_:_+RQ5G;CXT9]M?YA8_5SL=6
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MYA0HJ6FQZLN]P0PH?Y:(M'J)2,5O]O?IG=+;1W^QPKAF=_[/(41O98@N/K3
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M, Z&6!FX-O"/MXQ2AI4+2HBRMH*8*1HU75'4I9Z^(1(#]G\[[=J?"Y_^-2P
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M A''P-O60B/-#$784!F]!;Z@_?039IHV&O.\,?<RB68-9A^,V<WKF%72:N_
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M\SSX#)/1Q0S UN8KS;=H_<%)S@7LYP'8K>SE57E<(1X=CWRF_,J-3QF>Y\D
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M74+;!?"OQ+='R_7GQ6I]!A4Q3RTD%T$U;([1WJ!#,A&T0G(8:"\P,5 -2:-
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M3C%Z8#(>*X6M4<SE08QZ69"% 7!#969#94:CL5XIF?GE>=G,>/@H9SQLE#/
MUTYZ%Z/?JPVXJ^DK(Y47&K(RE;H;;S5!0HJ1B(B84P'(2C!(&RZ1-2%81045
M/L\QGM S;6PSYN75W$*#[S7PE!$N&ZKR)-BM4145"7')<21"Y(B[9)'3X&V
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MG.3+O 9FO3Z>X?#J2/6-6J0S[/8Q2SH]NPF&%\B_LCLP6JX_+U;K,^B("]6
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M&RQ%W)$L?80A:\L5#=X;X3A5P(/4. <::<MW4\G48VO"&IF:>YG:VU?&)R>
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M.73<%0C1[EG7]>*<;+V)FJ]-2OH\,7J/\1A5JM%1JFHI[4S&YX-A&T-[ PO
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M>QB\MOP%,D":H'>JKDD&(AC]5-=BB^W%B679/1W^=%8@JNM@3I\#&>N%K)<
M/QU.YI9PWNZ_'M'4#H6[&?*88,%1!P\5'M. /)=>@DY,@2Y*>MM(M^LD_ER<
MV]^PB?N@Q "$ FR%%KTAH*T_0$)U>]WQ56O86\._[/#-V:D,1BJJ J$F O_Z
M&(C3P,E**5MPPY27:>NITO=GW@U2!<X"M[(HA:?))%4Z[K1F/L$/M:;W34L5
M7XLJ/KX\+:(M ;<EXH)21!B& EUJPDPPW-#2!U[>6&&E8V^H0ML8?XN5X@P[
M/8QA.3M?<)^"@/03V.G^..L_S2&,0AWDY+PH#37*JT#MLNQ'N6@[X^%D-*[\
MLZB6C2J_*+RC^0+K-.!=7U/2(<9]CJ/I]FT>QV4%QF$<XP',<FZ2TSG"%'VU
M0LU$ZWG652G&:.(YWGWV9TOJ:TA=8(415NA M95$!>^) !T,2-VY7$)-VI@\
M#7&S!&!++(]$+)AAXZ*EW!'09(%89*[;0!EA:$1D%'1;+>Y=+E:8]2SV(^PD
M9MG'\6@IA2+?B5?-5;S#CWW/=B^6+_Y' Q4'6"7WNP\= ^H?P H (XQF-HZ9
MY0RN'%Q>#H9CY-BKG.G4\,\X9C"^9+9; Y&'@[.AO5@,I*F.H#B:UV_F8VDB
M/O7NEA6?9%0>Q!;SH'1QZH32FA=*4$,M?--JP%]')NR]Q^>>.J^IP"*<S!8
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M(V):^72V_FC4'PSS-M<>R#=56'NE17] +15Y#G4QG/NP68W'Q,D'MM?X6/Z
M8<ZZNE_M>#\$RG@YMUPMMEK;^GWWY8?36!8\"A6(]-P3(:0GNA""E,PFZ9CS
MGEKLU68V#T:W9'!?9"!."QN9X(4F)6= !LHZT*4*0Z(ME/ Z2,,BD(&\B0SN
M!6"C!6=JC5RL+SPO%J=RJ)):57/E:PZ3JO@UIH-VZP;A5?WCNO8S",O&4ACF
M3JE5G';7;,Q,19_T C'.MKXB<KT>=C/Z9"UX?9CZ\0T#'\=LRGV1ST!@W=VJ
MT"%LP0F\YM?>P+]];'[\N-_P(S^\>'7UZLT.\.'^^\._7]%7%Z_/@;?>')S@
M,_8^'G[<8Z_? #\]6^9'#Y__WCW8?7%Q\&:G>/WF1??UQ?/SP]\./AS"> ].
M#OC!R>L+X'/ZGX_[\*S]4^.%$)8[XGUIB. E ^771)*TB!9$=M)AI9B#EHJ[
M A7B*$34W, 'UAJ90DH4SMTM('5O+]$]-9P ,__Z\GC_<._XN'.\]QLZN#K[
MA\^/7ASLG.P?'2X7G;\#]5^K5GQZ;(MSD:6FA9.IM%0)HY/3MBP#\RXD&1(M
M-]$-LPAL=_>/9R%9W2HB.)>?KQ!?]OV.*OI?#!.!\?4Q?6K>+_#LO!M39^]#
M]),<OW>4\]N'F(LP:!X^IVKDJV<&;CSD<DSXA7T+3_YIZ]G1[L$69A0C-D1X
M.%^C'04JANGXVGM2-7;"<,;AH(YL'@S/;+].&:@1_<)TIU7@YL(<YZ,;Y\NY
M60P_L6%6SWJ:VC"/KYO4R$8KZ5H,UP30?8G6!4RTVSW$#ZI<3*Q:"G_542SX
MI-QZO7IHKC;W[.B:H""<VOO!L!?^@0&CMGKQ]4&;U\UFVC2J:2DU5;%60COA
MH$*"F@L0RJ'[ :8^O"+-NX$V)KFD] !VO0\:&3 DJ?^HMBF\L[GOU8JJEK_%
M^@07,%A8O'/@C;.K6:SI7#W<FR=UW?;6%>QJ/>IL&-&#@4=TO[,6!595Z9:
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M8_DK0.?0'5WV[!6.*=[,H]_RE>TB?%]*U"%H16U:\2,H3'\.!ZD[;G.;[OE
MX2LJDRT$5]25) F&A7>PUZ-4'%L_%C8:(65PZ(JD11NL]/WPZ[WK6RV_/A2_
M+OLEBL1 S=+$@F@E(N%OCC'"32HU0/@@L4\%VZ;ZCH5A6W[=8'Z]=W6MY=>'
MXM<EA2WZI!0<L40:S#W2UA&;N"/&QE 4A:$FJERM8^-B_[XC&/]''(U^[LS
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M+2G_+/*3D \[[^,0=/<1/*'7&[P?_;SAR[$RO&9@%W9XUNUG2EKJ7>(CVM2
M("K3Q")EPGQZ]G(4?VY^^:6):NSV\ZCR3;_43Z_I6*Y6?LOOJ[[^Y7TWC,]_
M-N:)EAR%:&WJJ5]<?5L\R?)UB5VJ[Q1[PHQ:^S5]4JS][J;'%O2)*OAG/?;F
M[R1G[6 +<:O'WM+VM]8"?RLS847Q&V4H1-&SUJ'^8\R_^,'G3Q?F7S-",X[Z
M8IYG_<5K<RM8<8<U_EY>^4UZ'JY737;WCSMN,H+/1^L\"]^/OOF=JHS"!J%U
M*D)R@CJ+'7MI82EE3@6C;].E=U%EG,?*\'LOXB\[_; S!YF_$V7Q\OSUFS-Y
M</**O?[[E03ECKXZV7__ZN]7Q>N35Q\/=G]]>[C[%S_\^&\8[9*R>/'\XFCW
M[8?#-Z][K]_T>J]W7YP?O/D5GO?OWN&;@_<P5U \/8=QL/]\W%_IUAN,$2I2
M1TH&:J*@F/89BH*D0I9>&U[ZTF\]Y73CHQI:*?%-2 FEJ4NE<BEJ)4K%M><\
M,<$2C:DPFM[9?-Y*B8>0$DO]AFD"R>UM))Q:1H0H'+$B%40;D.TR1BE8<7V_
MX59*M%+B[E+"8U%-7T;G7"F$U5J*0D4N1 E'4E#BSN;G5DH\@)18[IC,-(AR
MK20Q.H*4X-Z E"@8;)$6K#1>>8H)3>(1PI._(U5II]?K#,;G<3C7+WD4SW)5
MAA\^R4$I64IAJ%:\$*I,#I2/Z*WAM)14:]$J(8\O. Y6E)""8JLTG4@0/!$1
M2T$<+R-1%)WU,4BERJVG!=MT=/'#L9N7G"M@-MA (4STQGL'0#&6NHPZ6=.B
M^8U@MR4TGP"Z2TTUX=CZ5&A6$,N"(-B[,!G.HE &V.V.6<<MNSU\[)G2)=.F
MU$H;H4 Z2NE >2Y+X#<XY.X>E=&RVP.PVS(L+FD).Y4DT=P'(JBTQ-J2DE)R
MHY4/SFNY];3-7/@2)OHM]@$+]V :P\L!@.+OM ' '61%%-:C"3Y0RD7)E5;*
M62$5BS[QE%IS_ ;(BK]6D+#CMDRZ+$![UB K#)7$&BN!FI1*A5)%,%AC@+5G
M\Z;Q&X^P47 2>^\C/"S8X$SI7 Q!):>2:*'P1O#;$A06FJ9$94E"R)JG9<11
M41)EI+4N4F"YB%!XXPW;/QR_Z8*F8+P0KO2"16IC*I-1!7S A JAQ<*;P&_+
M6%C"7IB !YI(!K!P+(@K R?2<\YI$#K$Q^*WMN!GNPCM(GQFZ=?,<>634FZX
MGG@R&(.6&&Z*PF\3V]M<J<=-;&^1R+TCD;,53;L4BC(O%9 /EE\W@A)3P)]2
M,^ZTI]1XD(6"KW8%V^P4J381M!5NFYSNW@JWAQ!N2V:-4%#'I"Q(00.Z'*(A
M5H62& ;GDM*:1F=!N-$[.AU:X=8*M^])N-U[EGLKW!Y N"W;D+AB47ALM*YD
M)$)020R7G"BN(^<&('906T^Y^@Z2VW$"2+'=_B33SG6?S&5-7Y<F?4-J_%*V
MGD#E_7(PZN)S?Q[&'KS@7?RE28K-O#5W5[U0=':+=; HD_'Z6]:-[VNGHS\G
MV#AP?C7F?YX/9P?+621N&.U;8A,,]V?;>V^O1EO_6LQ5[_:;QZOR"2[B\OS7
MSC*E!YME17P@K- =CKLSZ0/YXE4P)KLQ8^F<#U$4_T\WFI)&64H:3!12:N>\
MD][1X'6TU,K3<NOI24[Y'Z3.,Y3B.=[5KB?KKT]M*\FRF=K^>KEW?-+9W=_Y
M[?#H^&3_V7%G__#9T8L_CU[LG.SM=G8.=SO'+W\]WH<K7NSO'6_\? Z/3O:.
M.R='G6='A\='?^SOYFD\WS_<.7RVO_-'Y_@$/CC8.SPY[OR__Z-!)_@%KSS9
M/WRYM[OQD_NIV^_ 8WM I2. #KTX&E71UN^[H]CI]@.([W$,__QZA37R$W_N
MCF%Q_"TF<+M2&]7/I;.D@B.%U:7"5D*&66&T 64O1! / )*,CBILK;F/QR X
M:(0VJ"24D48$:H%U.1?<AA0_(0H?I?[(,WN)"UL57@G=\6081P]9?>4F:F_K
MF7QC)4*^J<&V]4S:>B9M/9.VGLDFO_([BD=NZYE\^\;!^ZYG\J>]RDF:)X,=
M_]])=QC_'&(&Y_CJSY[MCW?Z 5MM7^(EWXV)\-7' W%X\9*_OGC%7K$]>G02
MSH]V?W_S^N)%[_#-OV%\+S\<['IYL&HB?'/P\8R]/@D7K]^\?O/JY"]YR/;$
MP<7AQ>O?7K+#O_=A#O"NCV^OKJMJH@,F(D=.X"<E0I4E<8XF0HTRD5IJM+=;
M3[G>^+#.5E9\$[+BWJN:M++BX63%DJ]46R]$$24I./94,\$0RTM/8NFYHDQ9
MB[5->+GQ3=5:6?%-R(I[KVW2RHH'DQ4K%4YLXM(F0Y2SBHC"6V*$\J1TO"B2
M5B[Z$F3%8]1!^HZ4I[;"R=>L<-**CP<2'ZMU3JST O>&"*E1+>&<@$+B2/):
MFI@$-9)O/2TV'FG\<$QW[W5.6J9[.*9;PO=6EPR8SA'-HR&")TDL]91XKUGD
MFGI98C>,C3<%_'!,=^_53EJF>S"F6P;*FAF?&.C3LD2FDRH1T'= Q_96,Q^L
MKDH,/4)5X>\()[=%3QZ\Z$DK,AY(9*R6/O%:2*\=)5)X;*^N!;'<1"*89PZ^
M*"G'U/#VF-XPGKOWPB<MSST<SRUAXV@5!?CK2%E@^1-1>F*=X,1)'147A4X^
MMI4 -Y#I[KWZ2<MT#\9T*_DK412E4X$H.-F(@'TC1F,'#D KBJ6RT!H4TLTK
MDKUY-2K:XA_M(K054#ZG HJ_)O"]+7S2IL\^;N&3%H0\$ A9+7]"G56V2"4Q
M*3@B;-+$.5T26PC#L9\/CR56"+BC6?S1DVC;"@&MB-OD\B>MB'LX$;=DW/!1
M!N]5)*94!1%,6>(2C43'%$'?*HV+$D4<;T5<*^)^7!%W[T506A'W8")NV90D
MRM)%1P51!N,1(U=$<\&(\M0R%Q+\H4#$%=]:G:=K2J%\?IF3S4HY/SF/'7MY
M.1Q\  8:QPYP!D["GN7"%OTX[@SCN]B?P$C<5>?"OAD,.S"$=UT?OR0SW8[F
M$],[;6;Z]YSL_4T-MLU,;S/3V\ST-C-]DU_Y'06-O1A,QO!AQ\-7.*;..(YR
MA@5BA2KKHH8;/UJN17^".&HEHDQ0(520HN#"QM+XHF0T4F&T-M&%3]BX6:,<
MA;,//[^H@-WSX> ""YCA /[NCL^?34:P&G&X]\'W)KB:.Z-1A/\/)_;#GQ4Z
MG"I*A'W3FM+@ZM7)/GN]N__Q\+>7'P\^OH7/GW>/3O8^')Z\_?@*QGSX\:^K
MP[]?OSUZMJ0IO?G]_.#-Z[<';P[HZY.#CT<G+\Y?_;TO#T[VBJ.3P_/#CS#^
MW?WB]<5?XKJ,<,4,;))31&&]2$%=(+HTC.@B6J6MMX&CO?OK1H$_!OG_[WV<
MIC^0 '"!!F:3$5+#?[:T#E3MZ)0HT82HBD]8@%L!\%@"8"7-F[.BU)Y(J4MT
M>#'BE&+P)XW2ZR)0GJW!K0!H!<!BJ)TK>8J4IU0*P9)P :N4,F$E+6,ABT_8
M1UL!\$@"8-E62A4UW@5!2D,]$3$%8A3E1"G)8'^I#HZCK?0'$P#?D6KS[.C?
M^[ND,%.5IE5DYO+&16&XB:6BL12E+4QI.=4ZE+ZT4L1/Y8VW8NQ1Q-AJ#GF*
ML&W.!.*2-$1XYHCS7!'K%94T655@"8K'R*QKH<0GH01H$-QRT#<#%4X63I<E
M9Y2+J+30I6]UB0WEP65=(D8O9<E)" ET"68C,<%0XIR$_XE"&RNVGC+5\N#F
M\2#UC'-98(% )LI 02^DE//2LJ Y3[*%\YO)@RMP/JG"L5 2&VW L@Z&F)0<
M\8&Q0&GIG(W @YN71O,M(6K,,"?. NEF]T <#<;P(-_YJ=NO2;MCPSO;]W!!
MZ-JS_@" MQ_]LT7@UT@>'F,4A?,L N!VBEEC(Q=<.NV$M;9%X!LI>583U4U,
M92Q,(L$G="6(1#3L*W$T!2&9*16C6T\Y:T__S>-!6<)A3XTIC11"1_C'NA0"
MUHL #JQ35EH$OGD\N-S@4NE06,8(309XD.N28 @KL*2-BELIA0PM M],'BQM
M]%R:DF$!5)^<D<:FH$74@7J <"T"WTP>7 D^CLJ#_NL)+]"@SD$?UIPJ(K%L
M<D#W"-7 @X]P#GY'"'RG;^'E +DO[?@<WGEVU6+KZV0*PUI/<(Q[Z85)A4M6
M@PPQ"B W-5:WV'H39<K+%6S-M=0A&4&"YI' D>")IB!8"@K"AOL@DN);3]MC
M?0-9L&"6.2$-8UC=+W 3C1#.!:.Q&&#1&K<WE067:T))*POA!%%4 K0.P1!C
MBX(8.,ZYQCQ8*;:>MOZE#61!)K53S"07@\&>%A8.P(*+HBR-83S1%EEO)@LN
M(^M24]"% B>Q0!]O&0)HMT*1,ED+FFTI*=JVV^*I]])DH(7/6UVM&(@)IH'F
M"F$C=X52.G$I>4I,)-["YTT4'*]63=/*NV"#!+R<-%9.U<3">4YDD6+"LCQ>
MLZVG=RQXT)[=7R7.W)9E$A;8STMAHK"!%2X:1;7P(5#5PN<-9<'EJB-)>@FH
MBT3+%!$Z:.*HY\""(&&I$CR$V++@1K)@&:0L61+<<RVDHS9Q44KAHZ*B"*PU
M3&\H"R[#9^NM2X9K$FFD1$26B"V<)1'+-SFC693R45CP^ZPH>3A7L^(68/IA
M*Q%]ZS+H"VLJ[A\^;Z708T@AOX+%HU,V!J,)8/*2B  _8%,]4='IJ$O/A<6^
M0_2.&6>/69OG\;-5OAC$M-+G1B7DR\H=MM+G\:3/DAI"N>3!65#]><1T5QJ)
MC<X09AD3NA!11M-*GU;Z;)+T^<)*A*WT>33ILZR!J8*&PG-*5(H.L(^2Q ;+
M2%GJPFEGL7!"*WT^)U-WL2@BKAZR4+<_L7GYKOED6@%Q37G$BL*C*6E$SU(P
M44BIG?-.>D>#U]%2*T\9UUM?L:CB2C6L7%21%4_6U56L1<WAY")G*'RY4K58
MU/1XXD;QOQ.0#GOO<G%3>/BOO8%_^^@2XFPJ(8Y^>]Z#9_8./X)D^'A&#S[^
M)8[^WB]>G9SQP]]>B5<G+Z]>PWM>71GZ^C_GU%_\NV__-I.C-UZ\^OME\8K!
M.R^>OSG:_>OCX>Z9A/>='^UZD#CGYX<GO[]]=?+O-\#M5P=_G5(3;6+8T)'I
M'*<CB'%<$<I 4L<D2IN*2KH#(<:P,\XD%@4K0RI=*@7GVA:&\](7(!%T67BZ
MU8D@=R]AT<?#2=QZ>OSRU^.]OU[N'9YT]OX-/X\;85'O\;I*GQM5!O3_EOBQ
MX;9/+,7:\J&=W<D0@_^>1S><V.$5EO?DV[DJZ+/!!4SPJF/[_<$DI^2,S^VX
MTQUWSFWHY-)V\%FW/QYT+!R;J0N'<?==[-BS88Q8CK>#WU0E>SNCV(M^W+%P
M,HY'6)D4W]"S#OM,#N"U3?!AQTU&,.E1O@;7[-5@^);\.8PC=X6Y0K:_W7E_
MWO7G^0ZX_G(X>-<%*3W*&467L"C(3C"LZ=W;6*GT?>SU\%]\[<FP2X['6"QU
M9QAMOL_%JT$_/.E@-54XVONCZOAHWM4=Y<XF?HR+,.CXWF 4.Z%:.7SB^!RF
MW+F ?3EOZJC^/NG'#J?;]8(.XX7M]D>=T<2]P87 IV3D@&N.S\-'P<:&+KYW
M].0Z4;RFQ&I-'P+M>I?P(+SZYV'L6=R-7YK*F)EXYNZJ#STZN\4Z.. FX_6W
MK*N3^[5YX#D1<G$U%GZZ0;B"?\['%[VG_S]02P,$%     @ [H555GKOD6N_
M&@  1"8! !    !D9W@M,C R,C$R,S$N>'-D[5U9<^,XDG[O7\'U1NSV1(S*
M1[E<QW;U!*W#I5Y9THAR5?>^3$ D)&&+(M0@Z6-^_28 4J+$ R0EE[%#]T.7
M)1$?@/P20"(S ?[RM\>5:]QCYA/J?3XY?W-V8F#/I@[Q%I]/[J:]UH>3O_WZ
MTT^__%NK]?OU9&!TJ!VNL!<8;891@!WC@01+XYN#_>_&G-&5\8VR[^0>M5J_
MBD)MNGYB9+$,C(NSB[?[O[)/9U<?9Y?H_<<6_G"%6Y?G^*SU\=TE:N'+CQ\^
M7B$'OW]O_W7QZ7+^[OW["_NJA>=7'UJ7E_.KUNS#VZO6_-W9U;L/E^]F>'XA
M0!_]3[Z]Q"MD0,<\_].C__ED&03K3Z>G#P\/;Q[>OJ%L<7IQ=G9^^OOMP!*/
MGD3/NL3[OO/TXXRY\?-O3_G/,^3C^'%G\;AY^L\0^X%#T,*C?D!L_XU-5U#J
MXN+\XNUY7(##D8(*B.<'R+.W%02L%3RML9]=!GX^Y3_S>LY:9^>MBYV:G&!3
M+%G-NU/YXXF!@H"161C@'F6K#IZCT(4BH?=GB%PR)]@!57 Q)WOG@<3/ 6(+
M' S1"OMK9..2TOCU)\/@/)'5FK+ \%+%Y\B?B>;Z+!#%3@S)Z8#:*!"*RI_T
MXYZEGC_%;N#S3RW^Z<VC[YR<EJ\U]%L+A-:5:DZ6D;5'WU1I04)!SS]^_'CZ
MR#4NNP69^B.>;_$_6^<7K;?G%:K-4\3R=<.G5ESN&&W8CK9J;8C+'=B&S,&5
MIPNJDN*S7[(9V8.UI!#B KSW[ZI4Z&/[S8+>GSJ8E%'\_<?Y'QFJCCR/!J(\
M_R;Z;KTFWIS*+^ K3MBGF+4)GL=36&HVSA@:XI]/B-F,NHIQ=+IF=(U90+"?
MG,D%P)+A^><3F,];\23U#Q?-WD!#XB=2^+N:QW\^A2+8'6P[$I?EY'\^\4'^
M+I:BT;C?:X:K]AN*^+!(")K_OW??1F[5[D,1.W3_)7KOX'G5WD,1XI$:G>>E
MI_"[09S/)VT*)N@8+:!Q_/N[2;_8EA!5;PO%R#'VME&_GHG_SHW6UG)M&:*D
MP8O^<KI?8 \J]+$S\GX5?^\K>E0X>J2@X)Z*E"ZW*]S,8M&7L30+9&R&#@GZ
M,/.RE6A)%5&GRBHE?K$K<0%@)! :)/CV:&B-!OV..>UVKLV!.6QWK2_=[M2J
MI.RY($HJWH+\+1 >CK4_ 65$6(8$>V5E:HT1@UXM,<@?N4>A:!=1R==E>;Z,
MGW>P_])0_JPI_/^V.YQ:H]YHW)V8TS[\6I>['#0E;^^*>-N"&J.>L85]9:S7
M'MV.)]TOW:'5_]KM#^%C=S"RCD)?'K22RZOR7.[48<A*C)]Y-:_#$1@PK2^]
MP>C;<>C<@"D)?%^!0$ U!.PK7SUK.FK_]Y?1H-.=6-V_W_6G?QR#N Q4)8,?
MRC.8A/]/0U;0("X[7:L]Z8_Y>C+J7=]9_6&WVO29#:!DZ".W\8EON]0/&>8?
MMCB<EABI0518=[>WYN0/T/C^S;#?Z[?-X=1LMT=WPVE_>#,&_6WWNY6X*8FH
M(NO\;)^L"%B,GRVTL<4V8O &\3?I?NT.[[J3;GL$(N&*7(6KC-)*7L[W>8E
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M\N+L\ITBFZ,FF@:"D/'2,<SQ>#2/M%4XV?I@B8!U$L0'+,6=7%U_O<Z=&^M
MZ3 )QOG077ZP(9N\SB8A^KQ<;G4U+ WTH._=DP6?QG%T+V1Q/W,?UZ K4^&N
M$76,YK&#A_MSK >T-A>P^2L.%Y<NKZD/=N]<N,B%B+9SPG.>F3NQ/3B\O<2Q
M<FKZD>O3PUM;QN2S@%?V=!3K<1]*AQERUS50[&),/*;I5K6'><Y'=)9)L;!G
M/:K!%)=(LY7>A%R'P9!Z8)*QHN.?]<#T#"1&RRU:8#H?XB"RN_/G^MSG=1AV
MF[4FH*,P\,'(M'$4[$:>LSVSU@L]6[8D+W16&4B#H  /5W KBL[O?.DS4\0V
M]A_64T/[GLWD>U_EO\3C)VYY> I6HPZY)P[V^ 6J-BP#V$%^I*&Y?:^-IT$,
M2YZ@NF'(P<Y7F;RZ'9#YJVAQ*1U&+DPE,CV)1Z,W&3H3[, PY&WC$RF_68**
M,1C;F$77OM2"T_70.NP9;(P=O\?H"NP=L!QE-/96'/Y('!*!&OV"R;LBC*;V
M^BUF"U"LY+'C-2+.&CWQQGH%\UZ)DKJJ +]8!705OMHY;ZVZFZ"PD :&68\R
M3!9>6UA)]I.XU=PMT3-U.0TZQ\,<(D$)C ;LTX!'!BI=I5(!0(/NWMTBW_^-
M>W.^PM<A4^P5<A_7H"OESKBJ;YRK"O/"=\^!/>OXW)7#0C_@AZ)D\DM D>NN
M$0N@N6OH@A-MMOGQ.UOZ+5<HL)?</!;I=CZ+[[@/EMCJM,?YAS">KT8]S=GD
M6[*W;[DN7K<+R^CJ-(A=_-,'FNO@C^Z^^E@R6E %2H-)1)P4BDX023-SYY"1
MPC%>KK &W1R@68#MY?8F!%^9T5!81(,N6>11<>.+N./U[7M%E*\JC 9=GU!
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M6N430BF2C#[:D<%E+L#%6"0S)DG?.BA_+Y ^11(:T&#SR6XF]RO6J9B++JF
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M/*T!LT\*LC5WNI9:.WLRSZX-&9/FK&9$F9H)KB3+@&@2),=06B&BL:W-JQL
M&J3F7%K\K#!9\[V@I$*[C\ "/EH!D@QSB=E96JU;"HGMV#9<6\+W9-^L,[O=
M<'6I:U<T5$9K)X(,48&R40#6,C#.QE2<+2:6UI5D5P:YHAKL=@]M1Y9NA=7P
MCMRM35XX2SY,*" 5J]=)4P07R7Y%#![)L4E<MU:!CUM5:QS$G]6;B?\]E_=A
MN9T1/6 R61ZX!NXY(ZFJ"%YS7Y.A@^"2,V&;IZ4\BJA/VG(C/MPYCV\GB*:$
M/RP7]LE )UZ*4P)*(/=,%<\ "W<0/7?:F8""M;\&>@U GVS IJ)??YK;!DP.
M[_7-:Q#'RFBE]0'H_874;2#E'BQI7X%>R6*]QN9>\:.(>A4[;DJ&AI)H5\$@
MSW??7_*(8)W64N_I;#@:3F<5Y)>K((Y4@9<@R L)J;;&"!I\3@B^!%\\6E=4
MZYR=Y9#U*7>C*5DZ$,SS/'[U145K%(T(R<4PJ&E]I R9)<],X"S)UAF#.SM^
M;7D.%'7427H.I=)!)23NU3P_IP*9T"H':5O7+]\H!KXMRZZOW+WC.#61;*<!
M=9W)3;.,O']+YJH*-I'ND1*"BJ5X3F"ZN]CP4+!HM[;C<R'7IM+<62[@J\/?
MWA_M_[K_[OC@]_V#=_3K_MO#XY:)@0^]H>LLP:5&UBAE\)Y2I5=E2LD"U8R3
M\+,69+.0C4(,\ IL89P5+V-N?X_C83@-:A\]].BU"C@YEFEVG"1?W=$BJ==-
M/<<,(1NEBA-2N=:1Q,9#Z-->W(J']Y17VIG46Y;M>F@02X$NCM5^(()0Z@PJ
MIIJ7Y,FG%)X[YG)(JG4R\(:0>Q4"WP$WFXMU&UQ<LYN)5]4S)5NCYN$Y/B^O
M[ "E3:@T<UJUSJGM5(VN&95[LF2X#,%;'L$G%\DDR[(>O'# 2%Z_T=D%UKHN
M9*NB[CW80CIGYKWQO98R;5FKXO+(UFH;3;$1 FD*4):YJKOFR2Q,HT<AF_?<
M6>U ?'MQ_OXP9TWYM#TC>(JYOGBA97*@O;%D!05/'#8>M(Q><>VY=JUK6:RN
MC=J._0WYZL./H\5UN?C]9(*C*<8Y)49I_ML%?=/_/5_XY5>SQ422OC@+)7H$
MQ5P!3$R#Q>)+3@ZQ><Y!-R/ID[9OSM-55/B6R+"51;WW!8>G59W1H([Q-!_G
M>#Y95).\B][:8#6O_=)U37@DAP=0>0V%.1:"<26)UJ'D5MC[M.'LE+R="7PK
M=*UU+MZ<CK_^FM/'_ L.1_,A%=IYCW(\Q>ET6(:+5O=U*58/C<LD73;U&J(A
M*PL9^. =L*2#,:F$X%JG[[3$WZ<:!3NE;:>"WUT4>^_XUS=O#_]H&K>^>F;G
MD>K[T3>*3==2)21TLHB_#.EI/W__,,WI8+0X^:BITK3C?IDKKH%77A&Y2#FY
M6DW?<P1O309KF7$^U=.+UO<=ET>WL<N&W^?G/"?CO?CO\^$D_WP^'8YJEOAB
MU<TK "W^)@U<,CEJ6F\N,;(OC$5R.Y0%SR1J34Z$P.99SBO@Z]7]D(X(=L>E
MZTI^[8("MQ$^6%9QD%V4VL0(V<EJOS*"%J2'3/_1402&N742QO+H>A4VWA6[
MVLBN9< IYISF!]C5W#PL#QYC:YYIN )\KC?H4U#@O2P@7/0^1TMSTSK&N32X
M/IEAVR)6)X)KKK/(B[F.=&Y"WC<5$54I&I%0U6*PJ"4@=QEB#:R1ZXU,-*_#
MNQK$%1,8_U3:JPLIMKQF=-]<7*7.7,/'9- E"@G%AMK62="L2*[):1:H2_"L
M8 ?WY99$U_#LP,?:W@,#D,C(N5(^@%>I7E(TWG@K2VD>".KM9;HNN/'(L< J
M4]]L";S.Y)/'X7Q&Z,^G^<+1OGZA99"24LP(<OAM]*!*,N!%SF 84UQ$EF/S
M#7P97'V*_&V)+LW%U=(<_#*<TNM)X[\>GX=9.3^]K%(Z,"D;XVH.8RD)E,R^
M!L<#6.6CC2HPVSR-]#$\S\#HZT#/M!%/0\U3\F22TT-%E[BQTC$6(=+H0(7B
M &,TH)GV+#FTTK2^C_($I#Y=1-F:OFDGI'87FC[A)/^,-. :4B8X"[7'I&*V
M* \BFMH0RB1PM1>[Y]QXK[7*O/5Q[/U(^M2*8TL\:2"2C>F1/GX;7)X?'(Y>
M#Z>?Q]/AXD+N_QX/1[/?R1\YG]3+%4Q;]!X<JS6M@C?@R/:B/5)D%E%JF6Y5
MT[D3H5_R52LVY-B)X]>*"5W,?O.*8I$FX.9-F^RE$O6<WN3(%H=)6+BJC12C
M$0*E;UX'Y4$P*W;M>-9T:2N9EM<>)[7'R.N\^/^#T:61]!Z_U[/U:FO'.#G/
MZ5I[SD'(127F>2WB'6N1% F>,0;:,"43,9HWOV&]'M)E*.;^7%O3%D3:+?TJ
MLFNWR2Y0#UCV@:L0P&M76_LF#4Z2T<ZD":+NLHJU/A!< =XR1//_'Q"M@?":
M&$8G>7(V'/VH3S)/:#W"63[^BI_W/DYR7H3\>=;*>;+32K2YAIX*N&(M,,V#
MU,;KZ,H2QM&2KULJX,?^'#3I2@H=*I^;U2Q>X>?A#$_G96%#],P9![75'B@N
M!1%96. QD<EO0M:A?7'>9=$M1:I=YR)TKWR:"&\+AM6/%D:#@$5H)1%*1@NJ
MMD'Q)A>P+@ETS"/J]HV3G\:U%*%VG7ZP/;-I38%U?6KWAA3K*-Z< #1*V10=
M"$,J5,5ZJ],34A:S)]>"[#O=.JEE>70M$S .IM-S>GX^+*]SF U<0I**J"?U
MS-:.'1J"X 6\Y;98I91LWH'\833/X%1O4^X\EF*Q@6BZR*DXRI_/)_$3K>C#
M\FI\=C8>'<_&\5\#)Y)Q.=':5::6J,OUT"A9"$X&7[(2F3?OV_4DJN>0]]6<
M.VUEU4V^5X5Q^'E>[F3_6Y[$(4W%(+C$G<H6"MD1H(Q&VFGJJ5*RR(GVS/ .
M"O$^#NH9'/5UJ7PV%U1S'72420 YG8S)(:Z5LC^-3^L]S'IIY?Y#!.-T#&1@
M0");@S :#D'7DP04PD1AK(RM^SVLB_4Y9'IUI:\ZE6MS%M)N/*S3,DK3ZYI5
M&<ZM"P@T(;0>O'?@&$8R;3T/R=BB95>[X/V(5CQ+_%,QJH&,NN3-[;)> ^M+
M4%9:B%(% I8C>.83F.A"(55;^Z!T3Y[;L)[#(>06&+21M#HQHJX9>O-8S7V3
MP#(G#SL'2%$3PW6]ZX8\@,BHA0M:!M?Z8&E%B"L>6OXIV-6A$!MVD_G\8Q%4
MQ],G+84U@B1>:H4K1B.V-&PI<M8VU3.'UM;Y;0PKGC[^*5311G)H5]V)1EK_
M5V]Z?,'3A;TVG4V&D4RV^3VU4;KYP;5OOL^38;T8<C,@>-79AO[P"4<?<SW'
MV"\EQ]F <Z6"%PI*UK5MG'/@0V(0%'*=G;!>MS;9MSO"+=X\2#D*JW0 Z6LV
MKU("G!#$%S1!R:*XE*VK^:Q[\V#'=:+ZR_%[6J9T(?ZN0^SW7=PA+\Z*1*BB
M("6FI,[@$B)M<TXFB\QGV]I"6?>&]HZ+43U[>FXJ_EV< !E>N-/>@V:\)BC3
M#Z>B 2.8%IQ%D9O70EOW!&BWP<GG3\]-Q=]YK9#]O:-W!^]^.:Y%G]_O'QW_
MNG>T_SK/<'@ZO8EAJ2HACSVM57V0I1$WJ@SRQYSI.>U]H8WP8WYW?A;RI#KQ
MI^?TZ3R..#T\GTUG.*J\&C#2,*9X2_OBO-FW3I5 ]*OV3&H6I=>M;RNN"'%3
M5?? Z^Z\YV><#N. %9L4RPFT4N1I8JU-F%@!P0.B-V1'V-97(%8"V"=SL4NN
MW=98W4FQ;8).]5/Q]"+8.@=WLR[FCTC^1=QC;S*IBGV1M:8Y&GHP \FJ+6!$
M[7*F"A!H+24YNHBMO;[-4??)1-PF);<L[VY:@S[4@N.J%-[)^-K@ZHE4GDP7
MBPR++%KJ"%)6OZJ>(G@?/#C-I)..P/O6*3*-H&]^E#&A77[X>>YI_B@2^+HV
MGJJB)_Z-T@=BV-7O^S@9T7>G%?=B]K1CV01BGLZU[954K*HH!<$1Z6I!(]^\
M=V8#V'TK4K5U(M\])]DN%3IJ9LVRUEHD"4D$TGZ9TQ30%@HELHR*<RU$!VE^
M_>Q/U =:K2^=SGVPH_WCDZ,/KT[HV^]^V7MU<O#[P<G!_O'[2;V?,?=OS^.,
MEL'H([FLDX^T%M9VT-9^52OOK<U8&[EV-][W:O&^08C12*T2B%R[I0H>R8!1
M%IS0QF7GN"BMRSO>AV/S#IO58!O%/&\/R0?%J&QC$4 F6+7&Z$_(E 1F)5E,
MSM6"?XV'=0M"GQRMC25_MV_F^M/=]DKQS:%5-(."1<D2$4JMP*)R8!""8)"]
MB(7%D(QKW5SK 2A]VI6:<Z#%]#<\:[^-H]XIK:V_#\X^XW!2W:7+02MOR4]+
M&9STY+-A+C49P  94<;6Q":?6I?"60%>GR+2S3G3E9@Z-UK>[!T<_;[W]L/^
M;_M[QQ^.%E6:CW(<?QP-_SLOAC#%T?7[RSA[0R/Z'4_/\_H63)OWMC)G.IB%
M1K;-XM4_7C6<QM/QM%:[0*.1.R/!>5UKE6L%GKD(R'5AII@85>N [(-@-M5R
M)Q-,-]S$@3+!1%8O$?K:\\*2U^<0.:"RM.F*VNR^=<+C'1!]LG3:\."VVMIL
MWINF$!W/&Z/0G,['=]] 96;2,NU 9V2@%"^ -B=( :UAVJN<N\C\>1)8GXRA
M;FC27CY-"@\L:@O_(.^;W]\=7!T,7Y87NWXOX"[=DV1&2AF!>1EH5E@"9W2
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MG=4FHMMMG3>NP2X]Y]&;S?2O)/!!/6E5=D /_56WW(.E&127;/0TH-TA)BT
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M2A2'S&).SK)6#>_O\_IL*28L>7VVC$8V>CO2!-B/Z[.E5=CXFF05^6^4(&B
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MJT>H5%=M"Q;:"O$V#[:CR7[1"1 ,<QY-RYPGK>0!I9DI23$;PU0(4=;.):H
M^TU2LHX26S $EVY6GJS@03CTKR//I58L(R$:C]^JS+1BXEG_W?7++"R)<5/Q
M"JWQJE6E[$I<PIRA38L1!^43.LA$T5"*2R0481">9 "I/5"N8NWDP 50MG4X
MWZ[Z%ZQAZZBAA75I'JSRY1#N*I\W -C2:?RKX+9S E]%E0WHL;X>MD(8%U,&
M[33Q(3,BI;8DH*F'RS)Z:)%:(:#VR>B6B/+*<?IV>+*,^"MGAW[V\9]_ ]\;
M7QSTT[$/8X@7]R6ME-39$I;0 Y"@%>[0N$TS7$"SR3PK]Z1QXOS.R O?L!/F
M[CJJ&%278PONU%.S^AS_;L+I*%@2%IFLU:2D"$4SS+)$'%4<1#3"Z-H!1HNP
MO ESHHHB6KCIGX?K-D:F ;*6#(G%J+9C0=317@-*K"'Z%FR'%Q *%067FA&/
M:R:1M)2"CB5-)6A#O>0ZITVL'UNT%C;-B64D7ME.>(JJI&'Z85D3)U_U;T[A
M*_2OX>^#4K9J>IPSV?U0AUY+&0C-)0JN-%EUN)$28ZS ;R1W-C2P(E9]_^9M
MC%KZ&VQ8^!LP/28U,Z_[XU,_OJV;JET..942[J(4X:4ID! R)R"]1H/+!BIJ
M']2^CNJ[)TU+"JBXIHR&X\[D F(:O,T,9YDSPI@#Y*E ^QL,DM5%2"YJH6BC
M>W5\Z@,&X'?WVG_TPKVV-U<7;<5*'7<@;FG6 ,8REF033=>?S*^;BVL(_ZGZ
MUI!<&Q-U!D?AOIP%<X0[6NI:"E&0>+1TO-1!0S:NT8*];04N,.WJZV\9@576
MV^\HJ<OKR]N^*0YR4"7G,RF)*[W/)%##"9/:"^\X%<E7T-RCEVYN)UU+[(,:
M,JMH0$V ^&\/@-B8<*?7GJ!G@=LTI$ALJ2ZKM=/9>&VU:A1N\9KR'K[T.U3>
MRC);./,V$R?VR0_+;?C7VC5QGSVWS9BPEP?Q)!(L&9]"]I331"6CR3LT<6A2
M-H40LY;S(\&>O6++-6M=<%$!&G_:E3IHD&6QH]'O1X+Z;"C^MKVR!-NI6?NL
M,.'73]W?<'(?#T:C#K#$N,(=$BQ%*]4Y2DJL)C'"*F^E Z=JAT"\A.<[+/RQ
M#*/FEX>OH)K=B.KJ4# N">'1_!+H_1A*T?MQG$C/HF;"&V\;62SM1G&],9*U
MK<@-Y9G]HSN^^*,_"",8?BVN]C3.O-1,1^'UNI,!W&7TOO.C[NAN.+=3:MH+
M!M)1_X,?]O%CHPYGX$QVEE T+]!>9)*$I"G)+"1K<*R^O3(U;0_NC?%\-TG3
MQOU?MS_ _>+FMCS4R9]]&(XNNE>?81AQT/X+O+MY7$EJ^A$TTZ53W')2VD\0
M*8IWI!5N*3EJ)U#NU-8NW+LRV#?&WLTHM:W2OD>75RB\B50N_/!+J65M+8\E
MUU[9J$H0A2<NXE?9H1N>HY).MU+7]QF2-\:C"NIHI:)O&!_U1^/A]:2RQUTE
M.QD,14N#DH1+*JZD@1+O;"3:ER2C(&V,M5FR ,H;HTD-A;10@[=1+0]O G,)
M1ZN-800A26(5YT1/\M,$LVB=MN;#[T%IP2I&5BT%[4H(?\.Z#"XESBAW!+?9
M0&00B00#EBC&O S!:&5J1_3O0?6=I0BQ6O6=912S]<HH3<#^J+Y34^-KE4A9
M15U;YY@)QE+O#1'6H\7GK276"DZ<IN@G4(A2UCZ+VP%NU:F^LSEJ+:.E#=?.
M<(Y&G9DCS+-RE0JE&C[^DY*,SH-B/M>VS;_CVAE+*7*)VAG+:*'=HH2/FW=,
MYHD%255.BAA>NL.(Y HX1Q";2DHQX+(UBLP#]!:,H#75T&;EP0=M$F9S)IT\
M.5Y]=AC[^"SVZ?!FDZO) -NVE]H:W-9MK'4)M8BJ.\6&-O?.]@;*@P<;&<DT
M&2)EPCW%.4$BH+L.3N24:I=L^4[IWMSL^_[8O@0)*N>0++@FGEDF7FIN931$
MX<:&1K*FQ$=GB;.2>B,<9-XDW?3%EVS1ZML-A0[:T$8+=N)1O]0DNCMT/"Y_
M<)N+;4JO^Q($'TK:@E12DP#H4E%A(T]49JMK>Z(OP-E;&[&6"EJX(UP [=9U
M:@"N)>ON16#;L<RJJ;$9/=;000LVU<L@%551QW*U;7EITN<1KN"2L"AU9-P9
M1FMW6]P"05ZQ9;;#CV5$WP(O3L87,#RYFFQYI2]:@?KA6^DK>AN!SKGG5%!/
M'(^!2%PIB4LV$!RXB3%"$+)V:,NKH#9OO514XJ!-#51.O;@+EIG, @'1@O.!
M4%6"%\O^Z4(VQ*3()<W@96AT/_Q*ZL6CE^Z=5;&>6"N&D#P"<IMBVP!*Q>3$
M)Z_??(+B&HJ8I\XUI%@YX>TI),LL=\F5>!/#2_JL(AZW,1)98L%H%G)HU!!I
M%Q3Z0L)B._I<1GB53PK^^!W]V_\8H#3^CML.^LJW>X+&+84;1X)RZ.OF2<^F
MJ$D2M!3_CNJ9Q3;WC&#!XS>;[[:6N =U9;5P_]Q,]MOC<XY!?@=?NOT2&^W[
MZ4,_3<Y')IO1:) ?G*,\C\2NG#U7'5>;V7?M"O%)]IY+7O$HJ0E<R^"DM38%
MKK@1$:BS;G[V7G6(.W/B?GP7#<==N9MEE-!4RG4$AQ:KL9FH$'3R%#CUK45T
M51S'#MUF'/I>O.Y-<RL&O=['P?!//TP=%M$O4"P3;DH7"'07<'UCEJ10W!'*
MG5.M-6MI:U#?]?GT:G.@Q1N0"L1I,P1BR;RBT8+$HEF@=<Z(FS(B$J#UP!T:
M?2)QPF70TC$K+&RB6^S: _FN9T -PE7*0JO'EMW/Q_Q\/8P7?@2C,]^#T=%H
M=#VQ(<Y@/)Y&=9<[605*LX3&,'-$.NV(M\F6;ZFV4<M$6[OZWM0@?TR=[XEE
M&VK9NL: 'XX,M!!1"TF"0 ]5NEB*T#ET)GE,T;-RXKLKV\OKH_DQ47:2-RU<
M%&\NA]MD'Y4%'!GSI<BW]\1G$TC,C@8K60@;:;V^;XG_;V&^5&)5"VFV[1B?
M-DDCLP(T/@WNDCX!\0S_8<RY$&.0%C:125+95=GJ$<FL6"C*+DB:B1<\E2HK
MF=@,F0ANC=&<.L=A=T]$MI/TNH?''LN3X3M+FO4N"T45PV6C&!5*1&*]B@1,
MMM)QK@QKK8_W;B?-;H4\JR78+J/$K2<_-@'[(\&VIL;7RH)<15U;YUAP!J0&
MG/#)"R+1$"KM(A1)F5$?M<[)M]9;_'M/L-T<M9;1TH83;*T#JH,3)&F&0@A)
M$\M#)@'=;,C:J%P]+OX[3K!=2I%+)-@NHX6-)]@ZKI4..$H/)5<D<D9L1-=+
M4T\#9]G9ZAUJ=SO!=L<,IC55]ETFXS89X(]DW'K)N$L1:N/IB:NPX;M,QH6@
M<C:X1"C'<?_AF1/'O2/1@F=)92I$:Y5BOR^ZKY6,N]ML7X8$&TW&-51'1TL1
M4"$9[F<<K1B#8A/.>,C)&2&>.",_DG&75FCC9-QEM+&Y4-[S@__Z<';RZ>C3
MX<GO'U:/O)W[F$J!LJ]#?!+7FCU0D)"L$;PT0'-4^!"CL318T$9VYCZQ1I+B
MN?]V1X)X<W^H[$RR(A@@3+"2@X=>K0W.DL!-5.BL&,YJ1ZZ\"*A.2F:Y[_J(
M\W/ZANM2??AJQOG1.\B#(=R!@#*WH"BV$V.TBFE/9&G)+(%#6<PUB='%2 -J
MRM:.K5T#[K;2]6HP:7XV9_M::ZV4P%+0/^*WW2^XFL=B'^1 HDBX[O(H"9H2
M&5U[B"QGYFUNI]+ *FC?.-U6T5EEDVK:?N5W&%\,TE'_*[*_'$$]K;S^OCNZ
M*E=J)[G#O%#4X53@R>;2TU&7^AJ6@!&66Z-Q#VK2&W?9]^X#4UJ7=PMG*>\A
MPW!8 CQFTI@E/+^#/NI@W*'69J#.DV3*_7&)F+(*X24T_ICGN84:]Z] V@>F
MM"']%D+5#M'W**73H=C^O>?PE(M"<L8(9:43H6,2N4LY29G[C(N>U[FV[?,*
MI'TB1TWIMQ"(-8,W*<1PT$_'^ ?S0#)ABP.*-I:@1$HMB6=!$.#!LBQ%BE [
M+J(1L#TD2D5-M-#VX);-4Y/H.;S,@W>3/K99E%9PI:6X%HJ4X:-)GK4,M0/%
M7H&TAQ2I(OWGY-"UK)#96K=H.RR[H.4H@<QPV9,Y9&(%-40G%SU$IRS4#D=H
MAFR?J-*"+IXSQM1BS*-%;Q%623.37BFB12HN/S#BN#-$V:!%*.+)M0/AE\&W
MC^RIKI?G'++55IWIJK@(I=%2*.X#$5E&]-XE1TDD2Z+#?R7^#&WQME:=%Y'M
M(V\JZN(Y8UR=<[OGL%BI.J6<+I5UT;;"O90X)H!02D&R:*7BK1V([R\G:DA[
MSG':VJ>W'S*Z5Z7A]QW 4USL'M_%'=SZ;64AO,;GW3SZ<,=P#LY (B!#J83C
MT1IW7)-$&5=9:P:T>E/J]6'O$[LVK<4Y3%P[)*3)&.;OQ##JI*@"32R0S"W.
M)< 1>!X2<=)K1:EB*=;.GUT'[UOC7A6]S2'=VD?&3< _;?7ZJ)AF1X"Q.EA<
ML8TL1Q&1$D<3)T U2TPQD*FVK[\VZ+=&OWH:G,/!E4^F)U<L31;N]#_7TZN7
M\\%D(MW:E_CI!X$V'1TI-Q0XB2'8$HI5@K(4Q6%Y[Z*(P$V3XGT5(>T#S[:I
MI3EL6_NHN\E8WD.ZCI-KX$D9X0X5(G*/"[2)TI0NLT LB$B2<N5XC48ATA;6
MN"<P]X%MF]+2'&:M?2K>!//G87<P_&_PPT=&  \EN4B10"TZP@)$J<P9B4;?
M1\L<F8VU0W57Q?K6.+:VON80;>T3]B; I[$+]Z4>2JP+C$[R'_@G_=&@UTWX
M)^GL.HRZJ>N'-YWD7.:*2T)]=$1:X4BP!I?I)%WT7')M:Q][M#&.MT;05O4\
MA[PK'_8WM2,.+SS*\.-@B". X1@U@!_[/!A-M-C)1GG)>"0T:%O:5N+4HZ"(
M")93)M%N=;:2C?<BD'V@V>8U,H=/:Q_\-Q_!4?^!27J TV0\*L'Z4^NUUQO\
M6>JM=622+#(AB$A"$5DJ;5B1<;H(;?''E.;JE?PJ#V$?N+D+VIW#UK4O'9J,
M9V+-WKM3HTX -&V3M03  4XQ* +TG&@9F8X:I$FU*Q&O@O.M\6XM/<T)_VSI
M+F->='.'H<OM5+8$-WR435"..*\-R3J %38+SFN'<C5'M_]$6ELG<^BS5FCY
ML[43O[C]V>R<\!1*NAJ,?#\=Q#B\]KT1_G=PW9\4-8/N))-MU %J,RVQ:-;(
MTHL>*'ZE)5%",F><L5:^EK%5%= ^D&E[&IK#LVIAZ@U&<O!H),-K2 ^/$BVE
MR3#+2Q4$7LKA:G1E'/HSC%*.0LY6UU[$:F'?!U9N59]SB+EVB'R#@1P.+LM_
MIU9E/\VB&$9G%WX([_P(TL,/' Y&XXX2EFH?/&$1QR/1(2).4X62S=RK& RK
M?KC7QCC>&&';U?,<\JY\K_%D;[C+&K]/6!H]^++;OSL*ZDXVBNGYT>4DQZE[
M_[E.3)%212V) M"6%5(3;W#/\,$R_/\ 3#6Y3*N/;!^(N ,ZFT/!E2] RG ^
MP?BNVV8Y@SSTP^%-'I1:R*/RNSS'&??6<1IHJ8Z5T1#QY>)91B"1<R\4*\:O
M:\"Q%5Z]+R1J6^IS6%(M/^#QO? Q>"3ZEX/AL!SF3/DL<C+:BT"4*OU?J453
M("E#F$\ #!\C1.V4M,;@]H%![6ID#G?6NCQXMFO?,Q^1/BRY\FG0C],<F4Z2
M$ACE0(*6)>E29!*4T"1SZ5.B*02=5_%&&[Q['QBR$;G/(4JU=(#'E/X\'"#V
M\<WGGN^/#Z8;Z55A=D<JX""S)284X0CP*!S#2#:1EI"4D$1;J=$-(>X#G3:A
MG3EL6OO4?D$HD]<B)E"*6!8*R6,@ 9(CV4OK? H)9; 1TNP_-Y:2]9SL^;7/
MUN>969-.'^78'ZS4#$@"@YMB+IE/P442(2KI:<%7^WIF,9I]HD(EF<^AP]K!
M^B]LBL^Q,NX34XEH;1&K,"7&6SO"%2@F8P17O6[R$O#VB3!M:64.@^J?@L^[
MK498N,#YDN%?4E(L$)>E)2IRGRE3SJBV<J3?2'Q!;2W,8<K:Q]*SD_*'$8B(
M!,FK+6%6HB-OI"&.@B,@M U)1TE=;6(\1[%//%A3QG/4OG:@^N<A7/ENFH(Q
M:.=&PRG)J51]SY*2D/$KGQW:/FC^RES;/WGX_GU2]<IRG:/DM6/&GT24Y#_Z
M0_S)EW[W_T[6I-M[AP_?2NNV<AIS.;G._3R-P\,?G \^?/.7*)CR\5,87P_[
MHX=]Z(2W,?%@"->&XS;'/ E&9T*SD=92-*I=;>.T[3'M$QEW2O]S"+[V:>^"
M 7545I1Y&8D6N6RJD$CP$JWX9+-/2DCJ:Y?Q6 !E\W3:+:4/ZBNLA8+Y"V#A
MS!R64\C1*8RN>V5N3@IZ3D\A46#=07H0K(Q6O^<Y.J>)\DRA0:=FYY):,A<\
M8\;'VIE<=9#_8.FVZ=!"P<ZE1C%)19HSAJ0"^JI9$<>CGW4@*.U.8XEFEIX+
M$3>TDBZ%^P>AMTN%BB5&RRW1Z5TR)DIC&I&/X/_C.DT:=W:<-8;:0 FZTK;$
MW>/NH7T@U./\$X;J9KG9+[_E!Z7:4$<+Y487B.D>]".V'_NK$9SD@ZNK7C>6
M$-9I 1?\T7'WLCN>14]S+Z)3@1//?4+[Q)7L7VH(I5((GXQFU?,76QC&#PKO
M%%%:J)VZ8$CO8=Y"?P;C\;0'\JBT$\?/%PU<CR]*.8]R+<8#@%+2E72!23=
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M_Q>&V>>_IR,R-SVO^=]EV>_'U91^I!_ISXI@R0G6?.ST5D"?:-A0D0,8>%N
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MI'<:V6 "B@EK8E(DT@QRCIU:@(/J'Y>0WSZ$E:Y_#$P]U?+52D::C$>4$S@
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MGUY-ZEG75__./W(LSF^__ =02P,$%     @ [H555BO6T-<Z50  IG,  !,
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MVY.NC9:8IE0/FR*O\J=?3W5-$M.9=PG]ONSGHX#M IT0#NP453CH$;DY$+!
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M<@:BE6_E1!MS#MC]#B>EYX!3("+<]KADKV7T<7YMHAZ;34-HC"B%+UVKH<X
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MCO: :?Q7%;8@RU091*]\L2+&%Y^>3VTO.G&&![!GX/634]GR@[)&:NNJ@](
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M+F!A*&"+FP\TSM]^^VA)^K2,K+]&-_+$,QB)Q%]832=J-]03G*E]<4&C7H!
M 8Z!/D36(3F8@5'OTHDF0Q<9FNM?7NCO$MM.D+O1^BY)C+$HB,?S@095=$9/
M9XK&B1XJ(L>4/E61QPSS7&[=IUOA ZI4?A](?V'RD'E>%'!]X6)K34\Z(*P<
M\'JMK;N_W;?X(EN+1>_.(\<A?^YA4W]Q^)06J0%M^+>9\Z1J-N7;BPN,9_C
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M/2FVY:/EX"N'[W$^GMQKA#JY7 MN$>Z' TY56NZ'WD+G,HF4@U^MH12\E"C
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MLNIW>M!BJ)*!4,RQVIX.W#6W"1Q1,MHY9QUYAXE!='?U[WN'TV2[H68^AX@
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MEM:>WK[^@<&A'S\GIZ9G9N?F%Q;AB(W-WUO;.[M[J)/3L_.+2_2?O_^P"P/
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M 9E.42(O4.O>%78BO!(V[_+F#IB*Z??Y,((FNU5;@ER1.'?^]6@N(,U(Y"W
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MYY^1O4;W<C@5)E: SMCNH]$S":FU"G*ZX!;R?>#'"B9[EPI@37&G>BJSI"-
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M\&*I_[NBA]MBR9D2)N,#]+H4-WI5::1H>R>>C2%JP"!;O^.5$[N0E0GC>\[
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M5C?B70!=M6Z7&H.!+X 7M-1X0R\5J('_[TDD1^NTDS4$D(C(%2@UPVLKW[H
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M-X,?XL]6;SI&,G2>\7I@[ \#K4O/2_D3)F]T6&J8[TXY\P!L\5%6,B-X&Q_
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MO4ILK8$;^W>H-06?17O[4>,M[7R94SKZN<IZV#5"3AU_CIV S&KP(C?N$MS
MP15!L^V URTE&+^W[ZH":'.V'V-!DRZ.ALJ\1O1_#8(D 4Y:8(4B2(O8(3'N
MNZ78(T;10CSDQR77=A?XWXW)VC$!4U)REGX6^'M%&[6?5T_=.UGW9D 9@'?N
M)6AC KVO<TJ3J7<VG7P")N)OK+>YKW^/7#5OK!RT8-%Y <A>!>T<789SG0;I
MRS@^>;K.BHO46[7&K[L 0E)8SP&V"Z!Q[CR$%5V&N@"R"%B/3B^3@6*R"&#G
MK^]7.N.KN@#6\(C/<1? 3][@SP&2_5A=YTND=(7\]/P"&']Y =P0 )T <A<
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M(9^DIHV2^1BQP8X-]"OVM)(?J;N;<QRF34G/U3 =IW/L*_:QYQI3$#$,\/@
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MYN]UFDGI@SQ#_YZ7._:KS9GMQ/X*E+3BYA7<.=3-:0JS*^H.#E ?ZMHSJU4
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MYBA[.2M*/7A-$E>.G-]'?K)@DI<U>FD)J[K>8,G:'B/J2\B-/Y4Y.3K"--@
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M-?:#X>3/[I&\X)G @QXUJ;1/;B\EA]):1N@7;%_J<9WU(0. ^EU>;FT1Q_>
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M)FZ8P"M344+7U+,L-LAW*OF].9<E[#0%^83:II=?76\%:#\OG<#?5B5UU\O
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MLS><L^^XZ,I0 IIOK/]_$P!02P,$%     @ [H555CV#B"FHS   U#D! !,
M  !D9W@M,C R,C$R,S%?9S0N:G!G[+P%5%S;UBZX<8= < \22+#@;DFP$"3!
M/3@%P=TMN,,!$B!(@. 0@KM;<(=""PD.56@%J\<YO]S7_[W=A^Y^H_N]\3(9
M:[#VWJOF7%/7-W<Q0,PA5H$'KV059 $D)"0@_NX'0$ (T64\0!8 H*0$/ 4
M !- 11(%D.]FQ'<7K\)  .K='.EN;ICQ^<_? "L /)C9I08P[N[AWEU+W V
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M.DGU\=MW9 I\@[5FN;L6Z!K-W\1NEEF$WA(\E7% NFH0#[\X0Z[W#[>F.@^
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MG?=Y,9D/4_>CGJZ^47PYS<G( ^XJE*/E5+>4T.L]S(NFY2&H\91M\K;/MT(
MZ/SB;GJ%8I*T:?2-]37U*>BA"AR,ZB8PGF^WG&'9CLLMV$9X'DBN-SAO/0]=
ME53U"?:_)NDU-#DL*=)[?K0%[$PG4=J  .:CW@K<><,]39-9[?K&\<Y/!VO?
M[+E/,@YDNXRE!BRPLPE'&9J4R#3K9JO9.'3[Y6LOOC'!L+1LT(P3$N9.#,VA
MOZ1O<B28N5$<2-]1.V&D(H 9DCT7)(@1C8^X9Q'\RXK.V-*7Z6;)O,_*Z-*#
MF.5DC"M(G\+J+RITH?819<VFJP>"AM_;8\\?[ =L#3IV%:RVQW5666 C /(<
M6:3 ,>;%@HQ@A\\E_:<:TSX/UPD(KYDF7^[@-[#6CQ^J;^W7'COR6DZ;:O9=
M@8ZD2)K?#:_11=\BPSA&C]C/.$P4;3 _FBN5$CQ0>.;=',<6?#.1?-38%FY;
MG1[ES8W6<Y[C0I%=6:W!TU@N*#BDH2$KQ=Z-&\^;R/:C]:G. FCE8>N#N;GN
M;PL+1HK$;[A>R@BL$O2K7:NY?IWS&W?H6]MK&L235!M_BR>QB_?<F_]$\^TK
MWNZ]69:BWE>78QC9'LY]C4;A-8,'#_<OTBRJWN5L3=9@3C-C.H:AZ22G)ORH
MW!67D1'LQF')_.7RF45CINQT!U<KU<N'%?9\;Y!U<7>"YX(PE+% M[L>>A3B
M,NQTOM<E"6J"^:2IW[X^*%HT&*!$ZTSAD9]#BPPY5%$.([GKF5M>_3A974ZW
M?[_+R6YH5<$X.I1(H?-]Z1<NP?J!%'D6TID-#>_J2$F1 =-W[;ZB)?E!O*8?
MKVS5+H@?1GO[VHSY,*[%X:WXB-3!T&.(O>3"QIG-=!CDB8AC935%U2&RZEE]
MLY$G*T$R*AUTA/OT<;4KIG1G0UKL1+ V$SVRJN@?":\G]&4E8YE;G:3/1[#.
MB9'VZA  \>EG!C:J89O7T]5+#+<RD2L:C8&DR-KF[IPG3.]BG;9KBDKAX+Y7
M,%Q*M);\GR6EHT@->E2$M&?AU/86">/$EK%ZCXL5URK0/*(ZGNW.7E#:WB;Q
ML)?@M2LXW3SWM!2.IT5>%UXOLUB&)[L21%9 V@CFM77WXD%?;%HTSX%C&2QS
M!F*-1QF;@<+O<BN&)P($7 CH=F@?3;J*IFO;YZ0K?.SP->4HX>_&EPPSL5M:
M07,2DD@>6?!QA>8?? Z93JXM<\0[6*TF(,F$X)""RQXMA> Z!U[$$@SJ9&$R
MR\"#8:2"4RFW+XJDQ(Y5*93[MLE0X'J!-Y/;2ES[8\5MZ&4_"M$J+-FE=ITP
M3HF1%G8->4,G;/I/AQG59_$"%]Q<YM:-<4R9)=P-AI!0B^T8&1G*/;1Z=%6B
M3S%=8Y"W1FOBDT7_*)%=+_Z>^<'_K ^5\E@RA/%Y6ZK!6+-"D;6;!,/W:3O#
MM27^IB;II]4AS3TOD]7/A.DM<\2E)9)6:1@[TSA"<VU7/7#=3,Z:?Y&N*23J
MG)>OE>_/]P$)O=(TTMEX=,0>%8K0V'22Y0K&N&KEE!EH=WI>IN9586Z#!)SV
M+.NKQ^6/BY[@+MW8],+MQN:4N]8A=/F&L1L6FT_+XBK4T3_B(::A$M[*,GE*
M.O;^T*7)0.[-U!EQF#)9 &9V.N/%4#=1D[MCM9UP>Y_N^AF*,^A*WN.UC==T
MRV;_)"=8)I(Y5 B]5P@GL?T!UJ^/4(EJI%FNGBP"A34\19E0/$V#%\HO+>OT
ML% 34[:+*) &.C"8GP<X9VC&!8MYYL.7V2 %TM[F[@5*&\O:*UV;*BC4ZTY!
M<D+B5Y1K?R(@%E$8SFWS?MOI:]>$_'0(C&U=9'NS!S:Y)M IT6H_OV(A?D$)
MG JW/@(=^U:>'K!H3)]>45"R-5VQ$D)B4H\"*+H&ZMI2*B8:).=+;N6'ZV[\
M5!! CF9JNZ^*<@N<*U?.#!9L2=7E2B[61^_&4>\VXN[?7B)X#I*$6=BV[1W[
MWV 'B(Q&[E9 HWJ0II[=#GU<C3XFCO<76?/#6U1:/2+U"(.$YC-^F]RT67JJ
M(+F97Q4O3_>\';:4-='D']E-\,&/=:#O6I$% 8SA.691\UUE$1AM2Q*=>LR7
MG^*$1)ZIK@_7. <1K/7X'^2(%Z)8KJ-.6C?B+I-5N1E5Z^@;K31F$->$"**-
MFAQ[VAPV[;:U/^$H]4.RFE6KUH2Q-J9X:H< .!%.0[[)<BS?BCA0K!$ 0;/>
M.EN>69+!Y):->KQQSG?YC.>M"]\GZ#S%2\+';8_LVDSDHEYK@FX'';I9![BC
M^GC\UP,+42;Y52)%+*(L[8NL&V6K;+_HBQ1;'[T/!:@.JUC]^=4WWOU!(V-K
MD\DYR<=<J8!;5Z>;9%M9]?T-4YTV581TO$#@@,GSP*ECMN!)6PE*^"!D;5<W
MM,13(A'*9JBW#(\]S7M=SVQ Z8-<BBZTCWF@H^N[F1ES)6?E=D$X:)X_"K$Z
MX-,^C")@W50>JI24F#(7%MX98%)%<36P=?4'^[>/#WPU KEKSM0%Z7G/C0G@
M$B6_ZQ^*)A KH94>]@)@EJ'Y\"*Z, 10M2G!0&K7>:A(DVZ,P?PR&H6$16@A
MF8G6)@D6S'7-AP"Z( E-^^X-%%LWK^OSIQ# QD%UW!4I%0*04Y2B&48 T;9E
M9WJ?>14GC\Z:KOBT&H-5M$?CJ9)QCT7H3="?'R[%.JJ?'D6TDDWYD'BN);?8
M^$IT1!IBK;-Q- <$;GYW74H$4(293.K;/O@]JIEL-EUOP]^;Y5ZPX:A0\?KB
MCCW9#<>I$Y?"QL>0ZJSST5@;18.;MC?>YN#'F1>!8/K%!@O@#HK0P\W^'Y6]
M,\;'*2;XXOT]@)4,3%!924VN:KHZ1D]>R38(-"M8V;.IW$>E]821V#0A *+"
MSQ4II@<I8^QII9NH:9'0^ZQ\OOWX\Y/*Q6\-[>S?OP'OGHU,*!.\.KEKK?S!
M-B4^(NGZT^\5!];T6&([>Y]5ODQO/?_)G$6-M_+TY$*.I @&FE$)]\>E%-!2
M*Q/ S@@><D':ID0 D:5BDHZ6('9WLK28*QZPMDZVYU<P3S>R%#:&I@EP5L&1
MKF-@=%X 7;X1.%%JJ)NPC+7QGIO6-Y-O#Y4U,Q?>+95U$OE9T5.$0P#NW*4Q
M;Z[TSLX3T>MWH-K2--.')6J^@'M/7DL-(@ \+0AW\M)-E(2L)P)(J4;:>]VA
M7CD"#+0/7(<X+I/!XD)=R[R[85:ZKCTM/S_":)1-"S[F?>YW:&.E-?U&F%F2
M01@]:VZH"*V[513L4;F\KKK+/HMLO";):"_T LM"I3P0>#F7/V10K^5S>>:H
M* E0]7[T1Z[0X,'& W2;/&A<E$L;E8<3C<T+3TJPIMF3I[8>2\K8W_9E'.B0
M$,#/NSU59NY=OKT=-<O"@6<0.;0^;L(61^\O1!D7D\ON6C-@VG&ODD]1$[I2
M=^16$S--HEV5!C(L:63EO([IHHWP3E4(X/Y*LV)X!7VY'J&S;^I"N^?BV$<.
MKYXGC&7^VNLX,%QR=[<WM>28WA] :V8U5#"S+8X49DH:T^+ F=_3[6D+=RT)
MMSU@1Q'X;",6^95'EG)-2@5?ZY'ZS32+).^#;.JZ'@[I&O_P96PH&_6<M1:'
M9^%+@DOX&EJ* ,U4\OM8..T?/OK-". #;S<M <PO4RS40,%E<)R66,7V:>*;
M,-\F+*,7&LTNC&%K=_D21[4@^2E_9/3=+#U-[H@LX</,P.;>+?!7^+K9+6,K
M5"O$UL\[Z@!D9\@];1Q!\'%K#/@9((HG!YD-JSEPVM* \4?K#AT'4N.X->76
MA@,"#$F!22D<4RFG #X;1"6L#?(07K3^F>!EHA%<SC:FJ@='V#S44JE'6KQ=
MZ*QW\<0PIMPFJ%?^](HEI$;Q#PZBUW/RJ3DIRG[;XHV5J^X,! 0]7^!^0BY1
M!L]%T_<&F!J2!T/3=M6&$K_1B.)",7[D?LO&%8T+SB28<AG\>+8D("ZGVHQ6
M?J:@</6B7XZS5.%)[ \A "E:T[^=N"T*HLYMI*_@C*J5U&?*EM5B5U$C?X?%
M'E4>Q,Z5)^FW11FD;'6=:PW8DEVVR!Z88X\_H>X.N_5Z)I:UBB'^:J8UP3GO
M*0V;3.**Q6=BQX\<_6S(\<^YJ/')"O1-IU11?&36:'@[&_%&JLKUHVS8--#E
MZ),&V@%\!:8 C)9W7;#'':Y+7*]F^&+T9%.U^R<W6V.Y.%=CW8*IXVH:J(74
M^@NNE6$"21 CE$4C&["9;EES8MX3<YZB6!VL'Z&+F !A1KQCG.[J+?W=R2ZW
M[A_&5;Y[[C3ZN(&*.3G#F"%"&:"OY+Q>M>O'N,H5 ]Q%5GH("+9IV:.ZZG8*
M?1NU=<VP+#:U<5<Y'<S89:<QJ5@B#:C6+*+*/:QI3, KJN&C;N>JVL/VM3]U
M4HN?(DNWHR9E %A,[]:39H><_:9:"1+<^MOFJAJ?== P=V!L6TM&:=6FJ70C
M %0C>*)-B2U2RBY8L<2FJ&R(J+%\PBPB.4"(!A:P_ <2>*?M@<O>*"D![JXF
M96A4J0)A&HZM-".=E73&QV5!E_?O8!E_?G.K?L@8\_G[\R#E::9;P,DF4((*
M2DW[=.P,B6,DO\SS ZCB<96SQZY XA#*CZYW^HDJ-*+Q!/Y2U*E!UQJ0-B+K
M9?JH+B^?E#I2K5=I'Q)UHMS23# ','"U;>E3@(EA&/+ 5JL!B\*T:XFOR N2
MS>4L;#'5QN,?@B+5T2W=QN$[,_62=P>+S5VZQ*UCG%L<U=ZTW([657RJ-:B_
M=M23K%K.-_>$VBO5U;J2D7+Q:25L_53 +9VWNP[%@)UGX[;-'[VIK(3+%>T*
M:A$NS'45&[P^D7<KIL=T<AXS:;R16_-+_R*>T7B;4 K2==V/(A;YO(A)O[CB
M[H%O*(8 :J..(F'B3/IU^U5K%"YPL%FP$:A _F/0.'LEKU,!O0.^G!2O8;I$
M.K2KAQ:3LC:WV'!7A"W[CS[W-9QY*>/QU[;<OTYZ%RW%L($=_JR(5KHQ'P-S
MR+#<0=&?KV8&SN6.OQ4/=ST03*JSPB1/H7?/@R* [A:V;EK6!NC1N5]9_FY\
MQ_F'NJD#L=#Z**'E3RR,$O7BOOA""(!(CMJ_VKW+:CWB2XS+U;?*?J=^5*)W
MM"J,N]9]X5A&X-S.CT)+7Q918M<O0@.8H*/='-XZ\(8U)<[UKL9(\,[X@EY9
MM?-"5M4A>R^(EQ7U&^.'92E]U[V)[58.Z$P)C$YCO/I 0KMF4$_#>[#HO4^*
M"RK:VR&4NF54QVCJ8/VX?_T%51[TXOJS7)3D/HX] J@N1$X^BN#7O,E[[^YA
MH^5H#QD0*R$0F!SZ5?#H*\;H?'7(FT'T7WZ'PN7?3PRA;JDP1H5)RSO]D]>4
M-#ZO-=X.:YC;<_U\[(2^7N.6&-*$GQSCM.MO@R-%3B3V6!HXE029QOW(A@??
MX5,4Z.3MBO^I=C:!]+2/(OIGOT;?LL_+)84?F]<M31XTRF6@F^P79L=+#>*N
MK@L)E4",J'<D.+ROO)D;JMLFS8Z/WG.9'O^L$UMW0 W"Q\=D\IY-EY-()CC
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M4;?FI<&B +>>_JY(]/:$C*D%<7]_/=J A8;&  I[N]EZF9G5"N&IK\FZ1I7
M94Q*01XPFV;>4V3S06T\V72IF3I6/3.WDJ1CSUW7/.N PMUF[6IP26)6?2);
M2> GGJPWGX7L^][1A^5.BM2"%'U.O//;F310PV08TJ&+H_AHN/EW>XF?2J^\
MZ^0%69&&$@5XI, $+* ^8 S=O*[/"-MP?LY 1\]Z]L'R,HX43.?P0:5M\03-
MG&J?$)W'ZG7-Q-^WC/5Q\SD:?GAZR:HXAB/:@5,;!-ML5!#YL8K-61<N(FO=
MSW'AI35ZJ?5U2G:'8Z_*'MESOV'6$%>6I]A6497'^)N&<ZY<L.-\&0N:&58B
M&4K)1O,8I]9FL,AN"0)Z7OZ32'Y+"** 08'JBMX(9XG<71:- KVU,I>"#5"A
M:[WEP60,PCR2(OA7?\-3;G=U^RHS! &\,U"\@]!SLPKZ2Q?7R>(XM^V-J;=Q
ME=GXB7_^Y51#T]&OIUYD-X&N7#=TI@;,CJV,,Z=E&&O*@:[EUFY>MDT[(M$V
M')N=G=&]-@S$I/260(8W);!?6&Y_2RH9)+GM=!=DMWAW9]M:(0((B5N-NZ1N
MED0 P?*2\&)@A_5_^65-91YZ,C#<^,$2;:8ZTE_'G&_2GGP9-4A\A-\62(*?
MM=J"H325]"9R1#%]NT/[\.@PORGEF5>(YZ=/_LA/">#:MYAW#>U@%P* \]W5
MH\C<?Y*(HJ4W=KI"N'VRH[N9X5XK"& ]2LKIZ!>F#L+L9TS0O_;']B$DC<"/
M%Y.T.W^V6#;1Q=ATF*"1H$AJHH]F 7#36^;K_=.F)2&F<,;;,"X"!+ Z07#[
M-."I=1N.&&/I[IBU;FB6PZSFW!5O3^%B-T=E-&8R$P[Y^I? 4?Z9WB#6%'[V
MYX6J.E&TX@H;6<[Z1]?L_JC^8YL0!'!-*8T >MX@ !RZ#KI380]_!( >[P]3
M1_+O-B0;]]'+IQ'M]G(1/,^O0_V#NL2K!)=$8C58HYEMU1\/_GA&SQ]GY]D<
M4S<%A:)HJXCY7 J]V>K#7FNZ>]@'Z>(6%7J86R91P?%'[>6'8B*]=+:&,D-S
MFHSNO6;_EK2THPXPS5:H/X3.^W'PJPYT\(0G1Q=*1I"I.1-U1I"#]\\2_\X^
MJ-P-OB$= NC(H[O6H(-67A,B@!>I=] !"L)  "12)._@1A!%>UP%R(*WXMQI
MA)[S?'F)VP/HO-%9\Y-%!<,/J_'RY/*W)/#GXJ0K"@8BJW/@X:V%Y^"804^B
M=S'C28_5BJ[RG)QGRA# WPLC<_'' 5&23-5IDA[S3_4S)N[N_M3[] GCD=B
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MUU4[FW))4W86K=4>]2%,LPEI@#X% >AU^63;D;\WLT0-MKR'-/O06QJX::?
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M!5@&&N#7Y8#\&"<V)ET7R.U+-S9S/CGQB!!NRQ7^_'Z/PH$.5X/,AH@].!Z
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MK> =!3_'8I0DG*HGEF#/4#$LW\90NO:CIF2=L'/WLY8\3)ZU;,KHP..YS(T
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M\7*8[^Y3TJ&_QXL_MEPUB-7P&@@%%.GM1Z4T==;ZVK#&,*0\S?*)8MKO)_I
M-L-P\"I-[T=3I$C/M4?F'#0L3 BD*D0#^G)@H=QQ!X#+GV/21EQ377R:<HM]
M; 2J8V0>=_-[(T'R;"U^7SU4A<HKP8E'SY7DFSGK1BUXJQ$FY;'B)_]6#5,S
M4L7H"[X) ?NCARO.87U+_H(8HQ-F<NC?WKIQZ\KN-TR/K T5\QB2$UA)W NZ
M62/,_&$MY>O26IV2'A4T<V>##I)^)390J82A.P#ZLO]A6:E"#%9TB+;6/'&
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MV5Y8T8^($@D[@"4G=4 2_C("N!;I0[^<1#.A)XA*][U#ZQ"]'[^RI=@7O/X
MII7\\,FFL_\[@=]H=JSWU7:O9ZKNC_5E]<ONNI-%FV0J7NZ6QT]+7I>ZUN,K
M V2RG;L19^WDONZ3*(L/MN@G2+_\E;V++^&\GYHAW$8K?!B?QB1H!BI8VUH;
MIBNV6UN_#CL[/XE78B;ZK:Z!&7A&KXE3C^)2'5%=\_QR5G++.#O</;*EYEXQ
M,-)BKR.J'/"[M!E\]8UP(S.L!+GH:%_H/R)-U1Y88/%9?Y@P^;7D[V@'/>)N
M9,R:"H-RQ4MX;-\V?*Z;(.OA*MAA4;?VVYLOK,G<CQ;85/1T:!Q4-@72WWN,
MR-PC!7U:KPS!&CQD.^1@W?JMH.KW<@;SV/==W\(QHHB!%TI5V23:C7/NW"07
M$E73;LT%01<2HN8Q[C*2'PKP3C)[.#I8XA:I2[-B/ 7VLJHA0>YJ<JB;Q2\O
M<I,\,%U?0B7$4,K8#6G'T:E"EUTU<#JD]*[;#DPYR6)6*>W;>]B7$_Z,;E9S
MIC?!?:LT->W4OJ(U\ BDHA&N(()DWI*VXOM'_B?1GIB/5H3C25C*7649[H#^
MQ7=K]]9E2CJ!DCPQ-)!W2@$;_[!2ON0BXX_73QHK')'8*$-=%QPLKBV_.BAJ
M:$[M\WH3]6#$BH6>>"EUC1LMKN2W1J=!B)SKTFUC-6+(LFQ(/5QGSNZBQ%#Y
MB(,52A<JM^>R2H5RE>9%0AQA/NUXNXA<4L4BD51DQ&NUG\H3'I\[N$,& 7KZ
MF&Q&-5,$C)<F"QNE"9<8XU E4NI.\M"3S01<%O5OZ1RETUI!W78K,[Q/[5_1
M%-01W0RL?7M]((69^)ZD;>JLO*(ODWM<4LNFH#P--MS*N:U1&S/*0:?]..=U
M2M\?OB+N,<WN75G&5<1<]VPFV1RO/W/'3K+G+(YZ?=0G$>B2EZ7=C5P[TR$
M FG< 0GBD!L,512TS1_1WG.SRM0/&_;S7ABIBW6H4G^:_B+9L3^%;3WWB84F
MSM"\F.0V!;3W1M:&#R5Q?Y#<DA3.M\D7\M;Z^RPCS[TS5A1?CGJ;0P/$98 =
M#T//@[RRO=G))4,3VU?R/EY6#M7JE;G-^"$\*2:!L2O42_V9B2,RD2UT&Q "
M)%>':[3I-7I,I[[>1/%H\CFF44LSC;1!QC<["WJK;S@174A/1/$V[+8\)S?_
M:U-%V-&FIRI!<VPF\Y+Y;[S0AT[4=D"F+,W3QF-2Y,KLM?54E_C#]I#229@#
ME,LFU88U107:I[CY<!!:_" J(>8[<"$3*]Z6\P-E M<I3^J;[!O%S5Q^>O7.
M]2^M.>L-.@I%*3SR,>B07MA;^+?*9J6GW,,L/SK?$NHS7P@-@YB8#E%*%OFJ
MZTQ8-M>AM?D,LY?'+IT4,0(KNDOT&Z(?945%UPOO 7_*',%H+^6^BM-5=_&6
M\AW%S9>+= <%OV99^Y+T'"=B/B^ <0:QJEPS=WX,V!A&%D-70*;:"Z)+!0YZ
MTF7C/JGKTL+@>A.D,R)'<4:0(D8"Y,<L#W)\86<_1.FT6T.Z\WDMN,M'[QF"
M?2,7\JAF$2NV>\I&Y-I^H+&Z)?(MF9<#[EZ;YI@ZGR(QB111ANO&G[!(E S(
M8D,#0Q]$E=0NZ&EF!]:6<:W5<\+!Y&2Z!_P"N$8/^@F"MV>,=$]WA6;JG"#:
M5$BD_ME(BRZG"OVC4F7'H_./C6-8<YX%-E"YV\3:?0:>W5HN.E6?5<YU;;I/
MX(4T;QYU*J>A$W4^[[E87TGD'[\U>R/#YN37-6VQ.OSU<9@$.@%]^#_S*=ID
M"^@TLK?%1FY%-D[TP2PZ\';4$V]P9>MI$N[[QOCGL!A9EU(QJ\V$K\-SF-3D
M&#LRU:@*]H/S=7=/2_TC1PH,,7SI$9J.,QI6-%NU?>F[;DB5W\Q1S+I$V5\O
MDCU)Z5\Z-NH/)1QDL4FWU?:!'V]XI*TY/AB#%4H^$UKRC&9-=A4NJ1PX"J0N
M/%&?" $(LXJ*_0F04W< ;GV((XJC".PE-$:\5).IEM>[,OA$B?6; %:W]R9G
M^F:4$X!3@C33;)IN-V]5-]I-M6&I; Z7<.G5^?Z<O0W W'GH6V8Z@G.(^; @
M\$B2VV;-3YQ;7"?^"0XT:YB47X8#P&;'25J.=P'O2#HHDK (_.RCCB=U#;FX
MWX=E@'3Q;<H\;Z>)>T08YKN&9T:B,CMP1+^0.<R^[<NZS&?#SW< P5H]O/^+
MH0S;EG)G8LYWWPZ'9!\O^_G-#7;Z,J_D0+2$-1H#G@O%CEL;3BDK?^:5'[]M
M0'AT\$-E'<#!QP8.]T=<_/&0WZ09D;#:+$*;2Y5\-:9DYWP3,SS"^VS'!,L6
M ^>KQZ:+@(LU9CZ2"K91ZNN9*D/U^M1L=U!JNFJ9X;>#UHS+PIX\OV,A=E-)
M;#@C$YR]CXF6B6(9U%3CG>)CE,&W^S4\Z(C1E'[)=XCEF=)0(U&FN-[C==[H
M1[:,XK\06:$HH=NP"J/*Q\,7Q^)T#1>)7*S^AO'.@0TB<N/II+Q1TD*[_AR-
M:H8R&/.&X!A6 LI[?JKV)VZBI:RXM!NI>K38"WBN5M='E)X?BI@A_0I5!&>)
MZ'_ILVX3VV=MQ@LH =%#3B0(87&]%'"_6@O2#);6CI.61'7=NC\"'NAQJ Y)
M8<9RD0%[#NX'I)3+=Z(Y6^"0J+,[@-1@R^!@ZY2!IFJ;8\"-/=WAK:)7GZM2
M5,L[SPT-:EOQ6^3"L\V\).[%S\JBKW$P136QG5Y&C>.,MU,+CKSL],>$J^7E
MYQ597WMDB:30[=:1+GG5XQ</'3=9PQ=6ED]4=F.<[%#.L%5&_RE&\ED4MY6?
M!4MHZ.4A?ZZE+FD;W:;'V)"3ZX*"J[=C?YQ(P%-X032*PW$=I*]E'F/  \6!
MYN"KX/<[T3L\5)<A\QHC02G73[0],0#'VS\0J9UBL3X[Y!G='HA9%>O3+ZF^
MW6;--(AQ#;SG)HK[/8:_T-,>AOBF ZD&$ZEZM::D2YM''Y:BBS&DL&7[U'TO
M-71J;QOR8N:]^ =?Y,V($AKV-(Z5&V55" 7< 4PUC=*L_1NZ</O^BR@/Q1%S
M]#RCZ5)6&J.B:Y"2L>MDH[W>>K6Q[\?@=>+HG-O0W3<U==7+7OLL6/QUU$\3
M'_+Q!P<G9#H!4ELC"Q [B7/=)T:OZ *D_/^8(S7D*F?N ) CI:DM'GU%_FOV
M^N@^YR?ZT](R"UBW!)C3^)L)%W%5D7W<Z\J2F';)IT:1/E]&?QJJ//(;I^[_
MS-A@G,ZC\:#A)C;R4O<.H/J$V YS6SVX*M?FGDF_E/;^BP^3,.0M!GX!_5K4
M=BW@*7P'/&KA@)%0@"_5$#K]X;6YL^5Y$7N3:M*LRBD&<W_8UC;?!Q!3A9C)
M8L]USZ.8$*HPZ5@8]3F'F\PCZ\8D4GO>9.9D[IL_]%X!V^ST49E*6%?]46B^
M77_VY@2=*121>1XRZ#4NM-I$<+3%W"5_1G,-(TR,I=[<(,[W]82%.%93<@C#
MT1DU<P1!,[?RXC!'9-8*$W<@31^ $:;6%\"%^C#9HI"+4FZ.[3V5=RU4(7S!
M Z,V^C[+3SL8\_LUA ]]X=S'57";?E0;":%=5?J!=%G5 T6:\8#2OD1Q6:;L
M&7/Y':7)#O97E=/UH\6FI9^ ?]F[:L>(&L1]#,6]TL\QAKEXGZBP3V=F<+G"
M1'I3T)0KMF^5<ON+N@O[J<%01X[$KW63="#GTSI%L8W,YY@K@M$B;\(NG!!)
M:?E+M>=EJ;:RJD\_$(;GC27EQC\2O7)1V9!2<S'#:X<1(H/A25,=XHFH5--Z
M*X]++4&!J[>J/%N?$DF4GAC9O!M8S.0C<J5U/,1*8J29/6.'FP3KV\:*Z3]I
MCG\6;4GM[D @[:(NSVM,"/#W+8(7%1(4)FINS;OZ="=F6B(7B>3*'/!L5NSS
MAD3G10*P11Y0AUY5 H)MPM8K;!.2%B#0^G[A.=['JA@NDU=\<DTA!,!8O#HZ
M&XV3OGF228RPS%G+HC#8;Y+GA7)_WQ(97=",$A"IPH&+2BG8^"HA0PI]E1&<
M>TV?\4#T?.'<AW'#N.-D7NPE9.KJV."S\C<!4LU_(= _-J[<S7"1O*],")$_
M$<="D0L\;>-/HPI/O_N&D^*^55<9_/@RB7H&+LG(B$Q$*(YU>51)($6ZZ@0T
MK&R7"*YT)FAM9/=;LSRDL/D$NEJ2U1#9$[Z8A3NTBIGVQ^X&#U;W+'UKOA)_
M?7I(1YZIOWFTR<B'9?H T98'O^G]"DI55J'1[I4D\UM8%UWZ?+&#*Q7.X*V)
M4P62?CR.^@#WZ87^-E3,RMO+I)LY@@7YT&G7DY#;E9(F D0GTN/*H[)B^UF9
MH$E?-83?N1GV"MBJ&RIR(123Y\-]>".UFL4Z>MQ2*/&(<Q,CZG$(II3KUC3&
MF><A;1Q8HM,?'WX<YFIE\7CXA24.U^EK%N@5@WX*@<.HZPA3+7:TY?5]?J6H
MQ3*]=0<H?2\.F.*0[<C<ML&"=+0E;HLP47Y$D 2[59 @C^63C4S8=$"@0E[T
M"%<V]<(3_K8U):PH1ARQS4E$?\]^;'@F9W4[XEDD$>?@&_G\A27<(8Y['%#<
M_"K@<08 SS&A[;9F5^S2C'= !>P.^&G8YH]T+S2T,2-#2?@58=V\H(WB9A'K
MREZ1=D4?KZ"XFI )B&8-9!PLW"UM#'_LTT7%UJ(&93$=Z)!3A"-LBUH* V=)
M[^LXSF1[;=FW8Q#,3PY[WWIEG=)AZ#>+!:I+Y(^9D%[^;A9M11X<@GK:)C+)
MC=+*Y2SN84OYD<G=[DE6*"5!;Y79L%YIWZ(%RV"T;![W?;J%%-YAG3G'\*+'
MF7Y=I4C'4'^TC9,*G-\!"Q#%7V%*"-[P9=)S+L<S<#U&$SFN?MQNPQJD0[HF
MJSJ*"?X=*=,')?DB8FHSU2+ GYXD_2E([;@AJ_6;XIBFUXB77@":"Y2)C5"X
MJ*!6DW-_I?[#D1_*@\=Z-,#$]6!D@&&,XH<CPI*7!"RB [\# @7%W!1F\BP;
MFS+O@$.!GZ31<7&T]H 3WN#F::8L3AEZ5"_!R)<,(;CC2>?3'!9M[*"IT,08
M5N>C#57,\UK/6GBLWXJ@Z-[3XW9TVS(*;OP53RE_!V PFT]A,G#]]F="V4ZU
MX*R!LHB58"H52><91]M^[RPOW' ]"C\?TLENL.^_LY&AJ_%C@46UX01W46D4
MC!%6J;S<QQQA>Z4J_)J:/E/T<"5 0B94!A[F^P:IFH]\ZO?*A,YD<LL&QJ?Z
M9V#RR)(L'YP0/+#'OQAL*(T/]R^4L1Z\ V RJ5-:TX*MM&*E[%KW0>D-]>OZ
MARHR?-V8F5$N$H_7OVPL4VYHC-N?0P@D$W:<<IU,Y_?40,Y/]'A/A?OH7!0!
MC.1T$4F3Z39A9,SI>KJI<)VRO0-SN)&2M<!$FF^\N?G,+Q56Q!C+/<_<S<([
M5VTUNOB&F,G_P64,->%>5\-J%Q#(Z_KY@ 3KX3/_S[-S'7YL4Z^0/Q#LJE,&
MAI.S1\_7"2;()>?5"XYN5[M:\J<V%)*^K!-Y]OA3PPOFA0YM:"P:LS1/US]7
M8WLHHVIO?F/Z_O9B3->&$/J_E(=OW[S=,L'V,W\[8T%F8J):A-O]OHK:C"/&
MY4"%=5NJ$'-&QJK $:EO1CKE/,\[?3A&<VJUE0P+B;!9(4?FK9L(/X).[M%^
MYFM'8-!;OM;:37(][SBCV)8F1&[D(EF,YFJE7G91"0R7+>'E&=0&O :S'AK+
MRGQ9VKQ@]AC,@_'&/$9*]!K^.4K[>74M7"W6D*S:V+QB_O5V_1<69KS&0_'W
MKE%?2=[>?G=7'3Y^  Y:.?%,X2YWI?JN2K'RN7+P,#W=.]YG[C&<Y$;]M%N:
M8]*^ADYDBO<)ET^9R9N)LE\'+ [DEG\],++FBMG\I"W-<)M]T,+B" '!*C#T
MYPU-1-U"'&GJZB4BJXS;7#O6 +Z'5F"ZC50DUYO9FH:69Q;"645+@KL@BN&^
M2@?9J,;W?[Z%T']RS>P',*=:0(X%8S>,?5#?!&,HM-O!WK)):XN"BC.P"B7V
M%LR T?MWG2<J16K[UJGA#IA,JI!N1.[Q^I./K*6UX^FG>6CPL$?LO8YY1M**
MW7E*EDNL>AKCFO!=D@%1"O:$M?8'G5<0R97;_'+$I=W-[FI<TJG,S?J>\%4N
MFWA_K2[,R@:.V=MT)C!"G./*\%O 9*&'-7.%-9RA,"]YZT_:,8]+"YPKK1X1
M%BRI M^70SISS-82#)R+DLUI-M=$8)!)KO&M6S'C+GQS9Q WCV(*RZ(3T@#V
MQ%-,>"9/_YK>>CE<H'03ONYZ!TC"<;6B"-_#<?+,P07]AOZ%)I(L,!\S_&[!
M(*/8:O7)8:X'^ &;1.&X6$\#!# .^##VS6J22OQ@CJ1(<2F\Z,2Z#()A$+G9
MBP^)B<XU3K*:V%+4,5NYM^60K7LGJE^]_6'L48O88WJ\0\F'S.HT]"@JW=U3
MJ\L1/*RBCZ+D.[P*['BF:L^*&?-0$YF#R/55FSP\Y)'DM;&\&#4D2' Y&7XD
MND0>D+,%Q1A@B4GI!!A-3*O+P?OOD'Z(4\U9P?R5]@;5- \9[AY%ZI."\4N<
M*E3)[[.4FD4_13'W$J[(?84_V?5-E ?;]:-:<"GP6$/9'1#.R#6!LBAOJ\C?
MT:-56%I\O0<-:(@.*M2J]:WE=,+V8IG7Q)E$\U7"QWID@!$$DX*=B<&.=U 8
MX/C)1R7NQU?O$FF_QG[L!L> 5.Y2"':+S3H!1)Q;)VE]PJ'L(]F2 JULQ4WM
MBT:[1M&!09WM0%,9&%,X;<5GMPS7-W5W@/*4>S--&0]W1F7Q&(U"HA^-*S*&
MY*-0&R7*>$::>FGY66NN=TP&6%[-ZD6(]'M<PK+@FM/@S@',<4WLT0($3I<(
M$V9:)T9MQAOT"D2ZZ_JH[WG2XRULKD")K\+)QE&W1XE+OI_N@ 0#.-5M=_M9
MQ)L37FKPMLH<2V-8-R/I+_BT7BDMO/OE7Z?O0_'Q@*<.P*$F!K-5GML(8L0!
M3;.+)I]M>69>-)RO^,7&7;*G+YJ6//JWA/]'\K6@><E-UPC@Q/"Z'>96A'.0
M7*SZ@G0IUX,V05 @"8_YP2N=NJ_S4L2XTI_UAK2^D7$D&B2PN)2\CUO"#(X=
MF*O>D6$4-"-!R21WSK;A-Z:IIM+\^#96ALE2VKAZ^@(39TL*R";1A+LG9:R3
M!%YZ9F%O1':+3P]0PC[V_/(:$/A@P[HT_R1F=H#%2=*%:_#OVZ7P&<PW)$?6
MJ6E!9>*SH,IDV20J@J=L^DSK#^=/QZ/.*<904LC\OXL6##S]LG=/1W*6LU7<
M%DLZ1N>9N+Q*J.F"'X^.?H[U;B^^SRO0E*S2PO"*,.(O)4<R=KIMI]G-;_DZ
MORKF/NX<<,@1'1/$6.3MD2%$<JVSQY2U&,F$NW^>.7I6WU29H/:%198F #KB
MY,G3'>!1KH==<_]LL61&R.K.INWN$0<O]B_,"0>+H[,@ ^Q^K>"^2;G]OCO
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MO\?OBHL_9(S=O?P:,+ES#1R:ZIC_0WV&Z@BT/7,-<(SN7;4Z7P/KCXSY_WW
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M%1JM>4,P'M_AR=L\DWF9[CJ[\U0_7KNLJ231''_)/$0$V4:VLTS+?(BWC1?
M@2\H$?-"?ZW"ET6I#&M1GK-QLB/RP^]549HH7KOWFX>MT>  \ J6.>Q65MT'
M9$>01[]C5:'SQV>^(FM">)F*K\>/4OD5_=4+;$02R01^>><F"G-MMFM5)_OE
M9S0<3Y4,67+?LPS1ZHMT5B!YB+]X/^3-1VG%FQ\OT:#Q2:X@UT8N>4QE$^('
M*J6>\-VSEP=AJD=])#P#,GSS&\C*M= C8H9V66N1LR_N8TA]H_R.*7<C\.=Y
MR<,T4LM_+]"+X5<\0VL7<K6'*K&RCZ>&$PY"VRT6EN>59[ 7ZP1)_U':K<8D
MM<]KM_4GGO1/31)$13MO',J.-A;+8_F^H24%G+(,'W_W&8D_X"JEVM_1'ZOD
M&>#$VE=LA59_\Q*D!\ZJP@_X;_L85#7/6*)9JZ:8;OXZCSDZ+%:+?IXL',<%
M5J+3T?ZL"$A\]F\C$B0U55,$+(PVY,N.+UAV)[73E5:,7I1L$KM1$7<4@'G"
M:.#M;I1X R,ZNQ6G=ON_'#1?(?/^.;J@\UB#W_0,G3]>U47CQ'+< ;A6_#7V
M#9/"++&1*([*L0O.8^K$SIDL^.[9S(I62\F]F^9K("&\R1&(\M*E-]KRDUNJ
MMT:@#F;[M=78Z<T4C2]A,5(Q**<3WZT1*2[?W$T(56G]E%U'53H;B\R#US]T
M!1@)NA<)<,.W.BAU^,+0WNK>;_Z$L=+1F/F^68(N%?^@\E(X@/P9OC_TB7[O
M4P4B@IFPK'SBAH1&IA=[(E*H348BQ'YQ+9L2;_.?)8P^C]#&IPR5B//;FG]>
M3OIR'LWVYGU16]GC>XAK0$G8XA_OSM]EFX3]R[_C=UJ@XO]>G9",7)\JU&#D
MN+$W(\7X%6 X,]GW:^#.00H((R;< E73;9H2NH$SSO6,RIDVNDR\C%;:HN0
M@::"+K9&=IKHK1.;'DJ<V=0M0^ ,?AG;D;6#K<WS0S;3H:UU;YL:<VQ%,+3%
M1[23XJM*+:V11%[TP)(/RWEQ-$1\7\O\<:%[VO*/>*H.*%BI"A>\="EG"Y'P
M-FAQ$X3HJUG;U1&IS#[KWFH@3G,F]G*/QR0]'_%Y[M:GKFED>_+./,Y(=6$(
M^ T:0C%WIF%!+:0WH$GMQ 4V^JX?5[JM;PA^46:O?37I+V[[M9"F W4+DSJ9
MSYF;UF7'\[@:A+^IVWN#2(G@'<6V"[C(]5+RQ66&D&N9BAU[DMIG6M/[E"*,
MCB"%L0"CINI%4E+;N@?P)#?+WVWO@0IOB_W?U;]^3;<E;"#S9B^>8'Y+=,#S
MI3Q$D<'?O=GJ&K[W<8W'CY\/@Q XP1E7S3 6<O;1A*GN(-5[EGP*E$2>XM(:
MUDWW1AOHEA<"/Q,K7?'8O0K]YIU#AS^OZ"QN0307[4W",^PJ&^+%'WJAZ5&L
M9[CI#$%1',=40(3"^+RII)V&O>[VUN H%B6+R:Z!#SV93[XW?S71$[@CLS'J
M__1H993_BM5:U92RB75\>;15T5PBMRI:NE_JE,"#*QJO@#^4W@:%D^U*5LIE
MM+T+4;V*L7[Z:?F\/4B\FZ[XQ<05BQ6R^1.O<);WK.26;A#/@X0^A:8G+J7^
MYVW(_#9,EUQEC(X:=5,%?4U'2W6=&?N4O<RN%4&/:Z,&NNW89H3Z$9R67_AA
M8='*:_E[]?[+TF624XI8@V<C0JDLK?'66@9([DTM?ZR)3T>7CFS';/R AX1H
M&PO)>A-5+>;WJSFC#0\0KX.GP!>N\]KSYF#M:R!8=BG,%??!8?!'CL%L[X,0
MR=FJ+XHQ2X:'QC; ;D+@0W/6CX*WI:VM/RLP538XRGT42]?*R1/3DKCK^S_"
M]H%#._\IB[",P/D8[L!8%3QH3!YO&5-\V2T[Z"^N_Q\*T45]K<;$1\;D@IH2
ME0D!:X-N*UWG[(V <Y4.C7[JZ*RN06/[H"/9+5M4$S/40 ]S%'JA7LD5:^1G
MH-E0>L7U_5*L<(@4"GZ!&<B)4*]^ZV.R:I($RRU,_C?BF?;YEB9^N?W1VY>9
MS?T+J.V'^#L=[5I*+S-\I6WAJ9.J,R/NN5)W/\1)%>DK/=9T4?_G2'1&U>HF
M_TF'\FMD)$KA"I=&DOC77[@9NG<?E"=*/II$N1LJ\R@WW#^:C4T&#F)"9/=E
MH>=7K0JGC9K+=L]\P6B-@,6NFKA9C<80@XCF1[U2BSPF!"3*/' 2ZRMBG >:
M]"XN26N"3\J ^0=SKBC"&V],1WIG:-YNS>HW-GP:FQ3 >P&6CKJ@B;.N:_J^
MLL/_T_#+D):2TLKQ ."4K1G_:X%*J)ET(PG\% HSKH[E**M)_?U$K*N_J+WZ
MY<F>[L*M"YXL ]LF_H8R<@4WDQQUXH(X(Y77PD?F@PR;OY(/HRA:P%K0C]+>
M'?0UDY6Z]Y\8=%>UWD8_DQ>34YGO,IP@9 EAZP-C*<,*7@C->Z+T/J1'F$3-
MYI*0LL]2XJW07P2J#'\X2GWZ:OQ(]IY"#M>L<(KU;^I0UUEW2F<\!A46[J.B
M,;3+-YE'/D_=-Y$AFK^Y3W$*.>J+LCC%HHLWHWJSO65Z@C,WGZ#5<;"4D^]G
MZ (H8BFD'$WL\6SB/O9=9=)SDP<U=M)F_=_M30^B2<28<@A&K3(,@QFB-<1E
M_G#V_S,TAULL80V6:5"9VUE8SK3'IE\_1X](?H0M<COA)D,2\G6WD@TEHN.=
MDW3BB]:S-")Y6+J.,2@HWSYR@Z#MJ5+<HUW"R"D0)AQM?!N7#L9YPNX+M$3,
M/ZD&6J^!IP^/6DSDF./1LE3K<+*QR?-VKR!WD>USJCF!GD, WZ8SHG#CZOXH
M>MS5.Z9"7^V$8W_F*>X)Z+"8"M=]#6#B>%!Q]%W/)PIY6:\!>XMX"GSID*'!
M1O8.B-28#TVF]8:;=)[1?)J!:QVB)R9X4 _C'BV!]I>D_X6-B71=N&$E:(-L
M3A[.<OS\P\)T8P<WQ;,(B]3W"'>SO>3&Z<VB])[9TVWO7HT1M$N4Q-L<=@\Q
M;;%W0D0FW*Z!$.3.475H.,X9W6L><II]>7"1<6O?_7+N9%Z.:?#'<HJZ;&L5
M_=ZT Q]KDT!0."715O,/=FF>[.*'M;A/,BP^3S$%H:HUS>=F]YXQ:4P/?P;U
M3XM)8XU@GRZ,9%+R6WY:27@<9Y5*V3T,SMQ?CE(2]VB9_8[M$L(;?V7(&8/E
MM1P^FBWT>)&BT3BLE[@[PS!PP__V]#1#.>)%NB564C="9S@=2QH2UZ8QU6W
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M67K$,PF=X]P,ED_,(IC\KB7)% -U!I<%]5PD;6QG/S>GWQ7#9]N?N.+LF>:
M'Z,<8T770#FSF:KYV-1:A3PB]8VSRAG] 8SD0A*S<YQI)QO48(">33GW?#O"
MEVX5ZR@O6?WSHW0PX+"N3YW LJ. )A0KX)V<7@_?N9N&5!/RY/!>K<R*;EU
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M?F4.A)P@[.[68G7(Y,T0)$<X!^T;10#O,(?A19FOD;!RM4ZC2B3/(XZ$EVN
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MHX58[LSIS6Z)?GRT9VQ&]G!NT _^?4K"CR<#0;@CY6"^=+Z5_R@UJ(2C-#1
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M2G3(G!KLYSG=5: 72+9KF#CVPGC[&H5=/$D*F8Y>9,,Q860$@$P16E:1.H"
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M%,S 1K3L5K1>1O&:M?!AEG^VWAG_^(RJBI[#?.SWWU+5SBD& P",=ZD1< <
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M*_$VC=#]EJ+6M(B1K3'4[_GDFW\4;SB^][9O>9,])%'O];;G>J%\"WOY%4*
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M83 H. +A67;34/'"6FH?Q[''3?(:-7,/^1>S7^CE?F6MUM:C#7ZRX;L^V!]
M;#L#4&EPP1A@R\MR1>&<$4)D4#'+/UG.LX,+SM(QZN-]"@HJE%M-<7<B>J[%
MQEV9O&,P8^T@HWKB\<V1YH2+U\6ED/,;NI^1D/[* )J,9L*0)O%RS#=F+:>
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MRV>T(?MKCG48_^O2CG5F*P^1>QIZR$,$K'O"F:!<*0#"S*MGL\7#BI)@:3V
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M3/^KRT6FI<=8J+(,K2,C@O+VLMT;3KCLSKY]P\I+X%;N>Q$Y/N9(CZ6_[2A
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ML%/<'AZBB3B@R:GF"D.M?3P$'W=/'VSGD+H,G")&J^DTY=>G*_,S!:+[-7-
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M6FG&)/JX^4X]N>/AY_%<ZZ#[A:TT'3>Q6Y]6W__JVD['O,>PX5K/0V@K@]N
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MANN3'-09SD,8MPSQ$+9DMUX,&*"0YX=<'F=,>6?-V4P,9$54[GJPU?/ \N>
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MSSJ1_&XF$U+9?ZRLOR#%XL3R<'"^3JS]JY&:4I5VT::G(+T15NKC]+U\=$?
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M+)&1OJ@H&%\L=PIW#<<L*!]!ELN%/K(*/)1K?[<I? _;_.7T- LVC'3A&E7
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MQ*V<HPF+4NH4]'JC)WST/[#GU[,Y(&7(Z&.F+G&"K\E2(B="1SG+RGG3-TR
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MUC,!6#P*6V7Y:AP+CI3S0BG*6/+\VBR\,;WZB#740YD@)/4]]C7B'%%E*"V
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M'QW\'P?ZRHQF6->J_0[F3(??"41.1S.X_/)_[;QZ,Q7REB:=LSL^7AAK,N;
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MC9)%E9Z,?NW(>)H>$$* QKCP5)(4HK7(/G?N'/W48_NLL285F3#Y/6,)R<6
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M#E!%)JPB(LH $V)AI[?$2X-^R%$X$W0C?>ABW67JH(_JLHGO$3:4VJ3@$%?
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M4O$[ZAICI\C*6)AB$OK/;DSS+W;P7XD=V&F2D?-0%LA-[;1F(0499Q%67PS
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MGMVKE^5G-$MVE,C&*DU>@5WB&*YR!0%<,("N18% 57/H-(8+U9>NU6<[XEP
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M.3M-T,/"2^:$&Q,@9*(M#<&KTBQ>3]E_M0$A4Z!BH")B;3;(ENHZT5F'"]9
MT)+K8<*U+I+O7 .Y.U][>;)^&JSL35<[)+MX&1E([63M4J,J-.4IA[.$;N+"
MB@C2.@,'M%?!F"I2#]>)2((2\^U)RO-/Z.=0/:(YC&-V1P)3>7D)@C9^X?5\
M"]+?8 VB)XG*X@*[T-6(VT@^9DP-'Y+/TD=1[0IK8" 3\L;5S'A9,J >]T@)
MD%>S#V[$'6-U41$-AB=.LMJ_&2Q4TO6:FF=D4&E5+P+/?JVGE0]X,53G772J
M$7/K-_TQQQ@BS!#6&89+)6(?,*E7!7O_ Y>JR,K_O.Y[]F=A_=4[<-N.&X=^
MNF,+=':A6A%<*(Z1K'0!"KG]XX[ZBH%W$>X8 G_T%8&,G5PUKMW.V!YUS;I\
MH?$1\TSX,%FC_Z,+.."-6E_\65YQ]M3 -X>RXUS5PNW*DX&,2A3J]N5]%C.Z
MG__).I7_Z]>:%"9QP'&9)H%AKM^.VSLR[($)NN*0GG)LE2;I6%GWW; N(YK^
MW0@E96'N(RECHY-E8D]L\$D['"QZ$F,F<&)^I[Z)\@40XGS\CA?1JTWP^GKN
MQH5Z/D&^_(F?U2$KT@WU)_FHKSFO'CR];<.++H44!KCH/L@SP&LJCL6S0=?S
MH_@U(+>17(G<C(LE0.8GG0_(<\>7I)((%BH_"COLO/?:6/^0/*J0(/J66W>:
MN'";I"P$]-)\J8_BQMF0*!U)BOE;+5B@8DTUZ:;;1%5HTMB%=W9^CCPKMQ;/
MY>^*^5PUM7R1-L>,0VYM%"MEOD.=!7,8:+CQ1)U37P$/$;PB#%_16:\<TGB&
M#7GJVD 3B8$-OZPM4ZR*O*%R_/:%,+1"B]<*JX0(4%%RK.93#"/;_4&G_>)(
MK?="C"K8$&M76A2'\DN&P&O?!:W=Y]\*I.+&1STD_";(:,;>G/'2.):T7ZL9
M=7?UIV%7T]F @?(/>KZ^OG($'XC=S>R[_F(0O@*9R!7LH&9]$HQBB8T!TX)3
M$S8F9>F9$DCL!,@^!+S'T_2#/4B#P/?#@[HY>+'1.8[Y^'H[&FGQJ'?9'8<G
MPB8JF#.+.!8_&#HO)9!<;,@7=Q"!Y(Q>J0)QQFM*TCL*G"2SH$!7\JO;7TI5
M>PPBHKB]31^'OY]8\M#.BQO*?^ O)U\W'].=>/Y@.P2$]7SH\:]089B3,B -
M7= F=\8$3%,M&N!#<+)$'F5RQ*K_QBD@TC.@Q$HG\V%NS'R[_,9@[7.K[QL[
MF\5PQ19X=#3T2S)#T/42Z$[/_4#(%KGF$8?BZ%Z%B@#K=@0DW%]+YZ2(D#7:
MU26YI/W(XYL'%N\NW[E*F!^[I -/NI% P3;"AEK)R@L<H,FV-LFFHGKL=O0L
M*A7%[4'UK5MUAC^]>K7O=+O(317;T?<ZJZX[VV(M/5.=Q&],K,:Q>&'4D+H*
M(D.L'$2<*?P]-I9^>)+=XQ3NTHWV[KZ<+[&C]AS)BE,?(8^FBB%!S11[,B:,
M=98A0<EI[.3\^@;:J"/ZA7 Z\YB:F&NE=_KQB>CY%Z[9V&/,X)I]?@GCL/E3
M%/MQ=/1MYS4T)T.6LAC^J7'J97E1K]MX(IHK)C2@'2+,&$(: J$DD'= !=;0
MSUARF-8OW9\=RC%<.VEQB2+,]_=EQ5MWL6(8/DX38FP(-W&( 1M0/,V\=Y6[
M%^N1U_8%?^S*P:X@4C05T<2&,(1;:2%@]G.:GR"-+"W>LY-<'IFC^0G,'>%B
MO19EMM:ACF76:9UZ,ZD"Q+]]6]EA-W0Y:!.W^!XE1";R#DSLEOF^/$A,,JI,
MM3T"O?.3Z9;!6KF,&Q2AK7X=8.A-" B@NG0TOO2*7,<E6_5@BZU_A7$;?!$<
M5KAZ#L(?*M*EC<H"XT4>-EZ"IEQ3'NPAD V;FI:&4_"&;@CZ81?CF12)=Q^U
MN\,7:FXA"D9:.+4&-^YD3LX-X-*LZ#(T/]!X,*"4%D+A3*4JX(D'\Z1Z?7AE
M\\_UGKY2YH</63ZS88_?_CG+*_A]E4]3%1SS0!L9BROT?M<R:Y%KOF_CSFQ#
M4XJ/#+="GV>PVUQ;1K'S8A,%O>.!TX'KY'O%3I<K&_>1>/1WVS77#ET03,;[
M6QN:!MHP>P&0='"]V!*'%YF\/$[<C;2D/@TY*M-=)>WA(01]5%49"L; 8Z$%
MA,X6(0LAL0X-^3]G2( /&^@:D/3P:#E5N9[[?@G]U=LBC&^OWR:A-D"9L6>N
M-L5(K%'B*+5A!E%-4^#.ZV)YZC5-V**VU+L+F8E(:7GX)^3)?M6#DH?#^M<T
MTX06/UR'=T4'6F#B_1"I4[3-?+5=2R-[>=B0F7PO9%,CB[]U*<!G:D8/RU0?
M#Q !B8VV%VL7;_[&<Z0\\S5*T.^1S/>;J@9!!B;I)UFMBGT\F$][%^QV3G1N
ME2SF15.M5N@R>%A14'@XJV_$!%]G!^E5*X?5Q:A6]82PYN[6% -G24O@F^ZH
M>D\AS/M23$WB^?R]@&22>?*'EBQ?03CO"9WQR9H< $2[.^\![92 [RZHG<!!
M2HY>,?>^A@R_<X,. 7?&S&S0WURG3TILI_9#G_1@@+ML"&VZGHP'$> WLQI5
M*R@Y&!Q6'"67!5@B<,:AK_1;Z.]"]2!I;XIP4ZH!*+_>5WO< >$.TDKJP4XV
M)#"R.!-=6XV@( 2&+8SC;*B^\U_)K>%>R7W(H(E 7G\A[98Q.QX<)(MNL3"0
M\-N)AVH>Z AN1Y$!9BDHP33^$!M"O+K6YTRDV/&>!0=&'JY:WA&[U)JF3Y=U
MM%&KGI-5-KHA=D>["+,VK?1B.1P^G0UYLD!B.%.(>W,(_HCUC_V(.&F<T#)T
MBY]NE8$SH:)!?HIYAN"NDN8!^2D;$H%5RA<!":K'01BM*\AU&A:&H]AC(YQ
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M=J1&-UY8[#D=FG+%U^FX9<)/B5T@[K5DM>OP(WC\[M@B&C8)3U 2<ZZ?D=K
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MHV^PA)$VE/2$'&RDCU1Y:=]IF==COYR.WMPVM:M^NTAQ ):AL 3(HIF'1)[
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M.B&4&.8?C=J2731CL#TUJG#NXV3E;*VL@0DM5]?_RFVQI%/93LHG+\3<T54
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MM^$X? "W#YCE[]*4';'2"9^RMU=]66#V?+@VB*BU.&P79S6NT[K\]=)7%-P
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MHJ-/U%K.HQ]'$BMG4K6.RMLI7("]+H))GUZ9\N'Z@7BB<#@7S@ZI0 7F('2
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M 0^,0O[,X=;D'V!2I2?:+$[I=E #[K9LBR@EZ#9*IHQ]IM;Z=7\#S5X$"!4
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M[U1!Y\ .5)Y2'WM?4.W(5[3U$#3@-A_EG1'V(@$'?!I"&W#I[>U0I/WM4?+
MZ%M#=.3N_=WHT,IN P7?'1N+0N"[33=PFQ56NA?\(&J&$&2MPX+782J8ITRE
M]CQ[;X#>@=I2;X4"VKO7Y'//4E]46J_HU#]*UXFZ)OCBJ"4UEV%1&:V/.\@/
MSN1^>LJ-R.1>'!EB_L3!5+_@E3^]W5"=Z6SA[<BUG3#_?=_19/_OIVN2-[K4
M8^Y4_"NG5TCWG3FBW8%0H7#T[MW<.>;Z*?J'2[)CX_%OTQX.1F3NY/NMU3K
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MC13_J;$AZJ9.FEJ0)R8AJB2]Q;HGYN.Q_.WX5CNL%P--V\0<6^CEG11V4JP
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M&4KB+T*X^P#_!<)N1CZ4!",/*0FS)]P@]#H+A\K-6K\VZ7%[IEL[G$;O-*K
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M<Q,E9O4X97R^6Q@74DNA)M:BPD+NX\.$0?F@&]MXZ:*/-^^HC=).TQBW!!^
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M)R:/GM/[_-4."S1>02^-_Q=02P,$%     @ [H555J B#+\T@ $ V,</ !0
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M*M$J@\'=!WY&:4>?]>'3)_V8SZAV^ F?NVQ07_G*OW*=\P]J I;'[<X)QGZ
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MVI6;/QK#YOV>IJY\(Z(VP47V38><E."U^D6V!N\(Z^Y2:8BK(2<,P6IL+FA
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M!(=!+ ,K=NL>;FYDUA:,?=3E9YH:3:O\#NI3?;#:-BJOZC:!9:.,=?+OI2E
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M#RT\-%+3.7<@NZP(-$R@Z0O\. 'P9+T>-T_N1^4?Q?HU*>^K,L9<\%=/7]5
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MQ;D"E0YJ@AQV/NJ'G:O&1Y:C3]OWJ!\T1VV/>CZF'R'6YSVW:AFMDK8^Z!=
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M;W7V=5+77J==SY\TV?G6207V3[1.7]#W(/M=MA0?-U5D1,@E"R*UC^!QH@P
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M?1/\<+#K!YU&^=]5MH*N!)B7XC\%*=ZIUW$1!)ABW_-AS%)%2X@(J*B(J-G
M5/"4^I19%7#I)\;<F$J]B['E440_^ W/*$8'=>S#BTH!6&D #LEKKX;JOC97
M0"L"M"8.#S8&(>GJQ*.?$-,>A0P"ZNB,9-C3>EMEE8/S4YWN]WI3%")?+Z@D
M*/*1K[9B40"1%!)BQ"+(HHA3%GAJ7Q99&F(GAID;HUTS5FS4%Y9=<M#;0&EL
M6@T$:'QKJCX::B2\ HV,3JVG#@S<&4RG!IG:1NI0](19U'5U[SC;P[:X;>];
MHS(N2'HRBI,0AHC%$'&I=FJ^Q]7_I8HY8B9C:M6E:* \<V.2#Z(L_W30D;II
M#4X.*KR<.8*U] 4-G4\SEIIPED:FL\YFX;N6X%?3%^1QA+&[<-]!TDP= .P"
MNA,AP4X>.ZSHSKM5(;*[O!Y?#=W8@:]$+F2V7H0)EY(J$XU+W9]68A^JQ^GN
M)9% ..4ACJTL-K-AY\:[V\(PLA:[)=TU^0%$+3GXB=:R&Y:,MYP',R)UC^[(
M?+D%MI&XI4Q=@.=M"^RK2\#VKK9CAI/C0CL7!GV1&CMF0)PKKV-X]\! WF<G
M![I&A. W^6?!E.&J:/$5*;/R:[ZBN@V4YLWW^>-FK?ZL@%!W57O<5T_M,YY>
M+TE9OED]D"Q?)%X:<<R$XCA*(6(8:7ICT$\DXQX+B)=8<=SH$L^-'O?B8^G3
M]FSM"50B@]]KH2VSPL:?=D/_WYPF<VQ7X;!Y[!_J/#:VKL.E1Y/W94*NQX;_
M;-CVZ /;%W-[O<Q$KITBBC?;OC$ACV.>^+IK,H,H"D*88C^!09A*CT0\C&.S
MX,J3CY\;F=<2ZD)MQH':9W#K)MCA:(R]EZ^!J*7KT9_HU)MD7#5M&#(3%4FS
M1,BJ(MIY #H*H)VX:;)Z9^<%WB]OUG%5WWU\D7TCNCU0^6FUS-C3+OHBC+$7
M4)Q"3% *44H$)+Z/H<>%G[*0<R^RW+N?&VIN'+:3%+S+<J*6"[)46\MR752?
MA75YW+,0FV[+70 W^E9\*^05J,4$OS?_'26JY3(JSC;>9P>:>+-]2>'C#?;%
M.R;N<]P6"=]^2E50WY=[DM_4[2[_K!ZQ+M_G=8_FA9<$." ^A<Q# 40D]& J
M?0%%$,94D"#Q$S%)NV-+P>?&:)52);C30HJINA[;3K89&\YQ"D?F5@<]D&OE
M]Q<Q4(<RKY7^X*9MB5Q# +(<U"#,H!ERSVE[Z9[(MF+_?;1&[CD9SCHD]QV_
MWS+W5DK!UMOCM2_DA^Z^7%??V63Y75,.7@V[H#(B(M6N7QV1J7;Z,:1(^A '
MDOO,YUPFTJ:WEOG05DO-!/VSMI)7QUM%5T?UH:";+1CC0#DRY>]0W#O2TG*#
MYPZL*TW4S&G DSU>CKC68N!)V=(>D$.^Z_&$?HSUM=3%<LIU]J">7RXP2F4H
M> J%C-06/O("W3PNAE&"(^Z+"*' *A[J^>/G9N0JZ72 S%8^.]XY@,Z,6_H#
M,C)_'&(QS9[\-!R.Z.'@X9-2P&G%#C_S,U?U^Y1?;<HL%V6I+"2:Y14[G,J1
M"J1/)8XP9&DD(?+U#CED!!)!F>0L"GQAU7C;;-BY??JOOMZ^__CV]A9<O_[W
MK^]OWW]Y?_/1LB*5(=YFO. >Q9'YHA48[$D\?F::'4R.>,1PT$GYQ0Z(0]ZQ
MO'M $^)ZE]4<1P4T9A&/ BB#R(,H5'N>E!(!$Q+'+$126C;3.QIA;BS3.%%J
M$7OT*7V&GJ&W:P@F8^]1]N$8(0_^K.XN^WD^>_[TK3E/J7>RR^;)"P>&Q#5!
M$]J1\I=L?7\4*U$^WVN6ST,KMI$3U;,6ZO/'6' .?>Q%:J^A=AU$U\Z@8:)(
M@HHT%*E]H^I19+7YAB;L6RWNLCS7X?M-0^2>$6].9]63+ D(CZ#'= 0+5YO'
M%,<1Q&I".=?=!W%@V\EZ)G,Z?F-K-<+,IM-LT7GQ"1IYX=H%*EZ!/17K5I+[
M2H):RR.?VU9/4"EZM1?L^%MGJY7^,8YC3(7KN$:G,KY,+.,8,)^-7QQEL+X9
MUTQW3A1O1/W?]WG;<[5)\+S.>9.(O!=UN4 ^\SP41C!.? P132A4-D ,O2"*
M9<1\Q,P*V T38V[[A.-VM3D'I$GC;A)^++V3/>?'C._'1WUD0F\5 #^U*ORL
MS["W\_!I;Q[:='J3 F<]DL6'(.DLF;R7$!,GFP\!ZC@9?=#3>E-F?99SRDWH
MJ;V/3#"'A,8,HD1[9%&(88@2G"9!++!DEL1X=K"YT=^7Z_]X>PMN/H+W'U_?
M_/K6FNC.HVI,9TZP&I^TVH/="4J 78;$'?N<'VIJCKFH] DFN7Q/S^(6A>#9
M^AUAE='69)%%0<SB,)$PI9':7WMI" GS LA9I!Y"4S]!5IU$3@TR-WZH902M
MD#TS_$[":4800T$:F1BL\;&OYM !@*L2#:>&F+;N0H>21\44NJYU4UGTS\6J
M++=5,]NBF8O4\T-$40B#*/4@PG$*:1H+*$*!(QZ&D8^LJOB9#3LW2M@K+$<J
ML:_ G19<[9;:,J-W3LJ,GID%4\/"-;:CFQ@'Q49UA*^&]:?C\JT.ZR/8X312
MS=$S@[YHV=%N("Y5'KUPMWVRJJX')403?);?J=UQG>XD/NA-U-:_U'8B>;/9
M5;],1>!3*@2,)),0A3Z!F! /8AXP1!#%GC[[O1SO.DP,*QJ;(/;5O/CH0/B[
M^6HZ4$?FKUJ)*[!5H_+@-(J 2I,]W_M5F_2@:$[I8U"$U.64F"?G3C,U$R7Q
MCCU%5EF_PY'MR X>\/#)LHB' ["?;>S@:3T3+TBA#\++MGV[/N]@"R]@/DY(
M"A%+D[KK9AJE$I(T\2/$)$*^533SR5'F9AE70H&?LASPU7))BA*HZ0"EEM>R
M5-AI4,TLW\%0C;Q0M/+I;(@Z#>ZJ.IIE#M,BNB!PE0%Q<HQIDQVZU#S*:^B\
MV-X@/1'(J(] [_+LOP5_SQ7)9#(CNP+4[&^;3.W<%3'MN?75W]3"QT\6KB[]
M!2.2^FE (/4"M>'6A6*IQ *F 1($I3(1@5' ]$3RSHV/FGKPRZH>?+83U-S&
MFF*2+]O',YNZD?GQ5'AW%<;2* SV-6X;D[0Z5Q;=?LNC1NTK<*8Y0.G/ZVTP
M-\UG]E9,9,//YNVP,O8GG*N.7<$44DRV?9@0TOU]QI3#SJW@R6^B7&M1ZX3U
M+]I)M8T/6PC,:4@\"3GQU+8'80QIP"DD 4\)#3TO"F=2_J1+C;F9,)5T0.H@
MT&]5M<J5K#=4)?A6J3&7^BB=[X;9QFW^,SZRY3-=[90:D%WM%+4 ;N.,_Q[J
MJ)A,Z.RKJG0J\3^DQHK)1$U7<<5(FAZ%5*OB"'=J1/53F?&F0$*3/.?) $6$
MQE M@P@BQD)(<!A#'W,_]HD?AK%19]Z+(\UM[=H)"YY):U%7M!/8RQMG9W"-
M'45S!JD^I5@[(;.HRNH*NJD*M/:&T*Y6JPDL765;.^^?KH*KB1K/BKD:W= W
M^H@+>;YUWZNG7\E_K8JJYO7UCZQ<T) 2R64 DT"Q*F)A E.L_QFR,!*)YXO$
MZFS%<ORYT>Q._,;3>=RV5]F,E0YM>7NMAF4(H^TDF48IC0;]Z.%*6]1/]QN]
M"'./4*5>8#F+6;(;?>+@I5[0'$<Q]7N,'>^5Q7IQ\SU7U'"?/;:QU1$/L!?Z
MT!<RU-6O!*2QI#!D3$2*W7P4&N5@G'CVW/AJ*YYE,/4IV+I99B 8(S.(!0[&
M5-&A<1<-J-OV*$#]:_?YGWKB))]VARKM9]MUB>4N3F2+M\K"T;M']0V0J@#>
M&[(F;0_:*.0>\=, 8JEK9@9A"BG# 8RXSW'(*?&]V&@3=V&@N7VLM:Q@3UB@
MI;W8NM8.W0L[.8>8C1W;T1,N\SV((18GOO92L#_>K;[]HAY1?^SJA]UW?O'!
MT^Q-#-7;;DU,KQ]8?>;54U,8X_9>B/6?B]7F4>V&ONASGD6<)H&DG$,1L00B
M1!&D"',H,4V2-*8A\?U>/=4Z!IT;3>Q7J5";C49N4 D.6LG![Y7L?;NC=<V!
MV6[#-;(CDXD;4/N7\3! R755CJXA7Z;(A@$(9VMFF-S;\XR7W0N^68H;^:E8
M/8IB_?1)#;2^SBL?^*/VM]4?!N$H"2@3NKBWVE?X.GB,10%,*(EDY'&,8ZN2
MFZ8#SXV@6KGU^6DK^16H9*^"0K;2]R,IX_DP/ D= >61R6H8J/9'BY8(N3H,
M-!UVVN,[2S".#MQL[W=5MV<;KO^:/&9KLKRFY5H;<0OL2Q:D@0>C2'!E4PFU
M\?)\ M,P\E.?8(\3VY(4AD//C;A>W^M3SZK-R6J7ME([&/4WMMQ%%?UI:)F>
ML]-AZLP= ^31_;@GR_'L4H0:T<'OK?!N2UU8(C9:V9VS []PJ9U+@%PNKW/Q
M"3WWAB;I16HWNJ!IF%"><$BI[KGMA1*F@GEJNQ@GL9\0X2=&Y_^V \^-R=1+
MF%AN_4PA-MS^C0#<V%O L[F)ZQ6@ GPB&;]J,A.5Y XW@998N=H(F@X[[6;0
M$HRC#:'M_3V+]I#R7O]/&VW?R%(__+-07)>QM>#Z#\J@>_Z+O2OKD*A#]MQF
M\*L?*D-$]X*I.\0H7O,PC4(?LA@E$,5! -,X(5!*Z7,:I@'&GDT;J6G%MV+'
M"=+Q/XHUJ&74Y@=3VE7F7?6#V.E9_;+8HE#]W;(6T;1OB1DUSW?N1R9XK<H5
MT/\/]C32"2W;*:XOT?-^\,OG=]0H@!/V[!7855!IP:C[<]5P.*S5]"+3Z*H*
MU+3"3UM?ZD4FYJARU<M(,7$:S:_D1_:P>7C[\+A</0EQNZ$E*[(J %D+MV R
M8($4$GH\#B&B/(4X""2D<8)%B!F1J9PD4>:"H'/;/S3- \E=Y<1]J(57O)AO
MU.[\.]%.$ET472PYD"N=\*#X[?;3IXD29"[-NJ'C=P9S.?**YR#)I5$6M-J"
M?76KE6T&.2R&,_+262J7Q/S[R$,Q!-M9IHGI>'WJG*FQ/@L=RZ16M>I?7T3Q
ML$B9\*7P.*2"Z0#!2.VV,%?_E#HL*8@QBXU6C8XQYD;X6PG!LK)HU9@/-N6Q
M3@-Y(=;(#3PC<VCC#MH!5/T"?'$"D$UQL,% 35;YRQXPRVI>G5!TENHZ?>>$
M=;@Z17]>9*O[T@'=^MZ7Y4;P-QO=,J0V]:L0BM,,O: IB>,DQ(H#=;*YCQDD
MD< P9&'"8H_[V+=+-K<686YDJ86O7,7*-F:KAP=E")5:*;#)U4P *G(ALS5X
M5#=9MO/H,3V&QNZHH$]AQI:@%O^J#=,Z:;3NS(DK0*1Z&<"[52%%MMX4+@W5
MWFBZ;%%H)\#T/0Q[ 72RR6&_)_5CR/:L0+TWG\6C>H7OB6[?_+KZSBMI%FD0
M49EB 67,,428>=H^#* 7B#0.E*6(!%[DXDY9IX:M[RX/:O0YXOISW!]Z1!]!
M(V:I:7!=5#VKGFHBM",] \3-2,X1BA,%<37"5@Z4G;@:S%I@<-L)I35IF:/C
MB*0,!IR4E,P!."0ABSO[D<Z'57ZGK;LW@JY_)6JQJH*,U%C-P#I:+,M9]DB6
MUWI5VY[&!Y3[ 0T1#)%06]64)9!&0D*6!(D(691R:I6?VU>0N9EH7^Z%8B0M
MH1T7]9X(,X:: MZQ]\-*!:AU %H)[2"LU'AJ[:T1 B2&HN:(SWJ+,2G+#07K
MD/L&/V]@%[5/JV7&GG:]OGR/)SSQ!0QQ[&GG'%*,AWR( S^AB;+*N+!LC')Z
MH-DQ&OFA3:T<U +W[)YVB*89;;G :&1:VG5-NP*UE.#WYK_C=DX[ XGKKFF'
MP[Q,Q[0SRI[MEG;N^AXEH-5^[U$1S?K/(A?KC)4W3VW-ISA-XX1'T"<Z?IU2
M'Q*J&\P3[">24"*CR+AP\[E1YL8&6T%!*RFX>;*HKGL6S<LN>R<8C<P&)^'I
M4>'I/$X6M8-=X#55Q=]^N-G5Y[V$1U=5W;/W3E<+]Y+XSRK87KRXGW6DNU!6
M5:(V@C<Q]ZN\O,ZY^L/CJB3+*@&RW":5T"#B*(ICR"/MPP_5#C&-%5L2B1&5
M2$CI!S9&D^7X<V//??'!3OXJ\*_5H,[Z+4UR49Q,D9DE-B+P(U.R8\RM#;:>
MR#FRXVQ'G]2\ZPG-H=77]S'VQN VZ_M&?A3KY]6_%T+@)(UE!#G3:=@)DA#S
M-(",AFE,(L+]*#!M0=<UD!6I31#5_NY9X6JUW&Q3%QN!S<V>3GPO6XBN4!N9
MD:8"S-Q4= 7<1-9B?P"M#$835#ILQL[;)S,;3938MQR-KN]G/'X6:Y+E@K==
MFJZ9>ELV2WUD^$;(C&7KA4=3[H6!!PGRL:ZSXT,:$0DC@@(O\J+ -RN19S[D
MW$S$5F(@&I'MK#\#C,T,/K?(C<RH6]"V?==^VI,7- ([["ALCHXC.\Y@P$E-
M-W, #JTUBSOM2V[>,I&3(EM]S<M'P3*9J8?6521IZHL8>QS&H?;6!;K01!1Z
MRCJ+8II&",7,R'W?.<K<R*05M$<5SO-(=O.',WQ&I@QS:*P*<UY4?4")SO//
MGJQ8YT7U]LMV7KYX8,6^7ZO8GRKJKOPLV*;0<5J-GS21'N%)HC.7A80H#7UE
M4]  BC2-4^Q1J?[>JV)?QZ!S^_RWXE6]1RTM"2.4S6P)U]A-L3]K@CUW$+IS
M1O>!Q741OJXA7Z8(GP$(9XOPF=P[<89HTXWF[0]1L*S4E;7^(K*[>V7E7'\3
M!;D3S5_$IR)C8A'(&(4>HMI;I+O <@DQ(3$42/%5''D,42NZFDCNN3'>GMA7
M0.1<^P>>=&#0]T8)0&HM@&C4 (]:CXD22"U?"C-VG>%4CVV[#4\OW79)>_;&
MM/J#!H#VKP)\ZGQ+ILLX[3=G+YV :BGUWT<^:K^I<):>VG/X/MFJ92G$ML(:
MR?FE6D?D680JBWR)?$*A"!,&$?4H3-.4P\0G!'NIEU#/^%QDH"QS.SJQC19V
M,1V7CU$F!'GDA:+6Y&JOTJ,^]3U?<*U5Z0HHI8SCBIU/D4UV[F13-5D6[Q13
M9IGWZP3DSOS@82-,F$?L!(KG^<9N'FG?#.9-\T:_RTI&EM4#U6_*19+&/L$"
M-7V:!/%A*M2N3,0T0LR+>8R,]F(=8\QMW]2*"6HYFR](2VK>_>4<G!<6'#<@
MC;R0],#'JMW+!01Z=7HY]\S)FKQ<4&J_O\NE2_LY;SZ*M2XP]JE8?<NXX*^>
MOI:ZX=N6:ZYU*YDJK60;#1=$491ZD0^CQ",0$2YU,18.2>PCEA*&4FI5=,!>
MA+E10U6%4"Y7WTN@IW>_0OE6=LNJY#WFQ<P5,B[:(W.,K@Y:@=V*KUT8/VD-
M0);_O&<0[;08)6"Q/XB.W P]!)C48] ?H,/-_X G#2]HODV?:TVKA6!25QCP
MU-:<(X@B*2!)E!V41#P4(F2$4*,&>$:CS8WG:F'U]\4.&$\VFX^J0I7M*5HG
MX(;'9ZY@'/O<[/DF;2OJ=H\V3NGRLY",4*_\>*P7*U)^5NVNRN3G;QIX%'\C
M#X)/"?4EB84'*:$<(B_B:A,5))#B,/2II[90V*H"ZMF19L<CSX)3>T7V7D;7
M\MQ]"&:3';9KN)JNVM?.XGB-H7!]P'XTSLN<JI]3]^Q1^MD;[ \.=/:^XA[M
M+[R15>].4:YUZ<S;[^3Q^JX0]8'] D5$I$'HPR1,U)[+0XHJ I[ 5":4D%0D
M*3?SMYB/.3?2V!-;?P99(S@H= 7W4HD.R%9V<S^TZ01</A(8 =:1>64?T1L)
M6IGKFOA::G ](J+F'OP1D)W(4^\$82M'O"56'0YWTR=-YEBW5&W?@6Y[Z^ V
MR=L?_T^F]JD%NW_Z(+XI9'YDY2+ @0P8(C#UDQ0BG$I(8NS!(!*825^(R.]G
M]G4..S<ZWS-JML)6YU@?KW\#OVN)^S=([D+?TBQTANET-J(UG$-:(QN@X[XY
M<M>@+]4>V0"(C@;))G?W[(95=X#?EGUY^T-'T(A7=2'<!5+;3$%I"B-&=;U,
MY.OFH@Q&)(FI'T5A**V*U'4/-S<2J@LW/9*G.K:-U<);-I+J!MB,;]S!-C+/
M-(*"74TGT,@*?FJD=9A#9@:+J\9'W8--VZC(2/&CQD)F=]EO4W_-^/6#*#)&
M7JLKU']TU->JT+.7B?+#A]>_7K_^T.0[T$ RB0,!.0^5>1,%/B0\8!#Q&$=!
M0"(/&V]5+<:=&[4HT4$C.VB%!_O27P$E/_A):W#^BQDT$Y?WK"/A.S('64';
MH[*4#<;FN]B1L)YH)^OF=;;:RO8 K&,[:_.TR;:T/53<W];VN?UE<GQ^4_MM
MP:]SKI<DW=7NRTK_ZF:S+M=JEY+E=YU9'D0;J4B&4%#!=(TL!%./,!C&@OF!
MVC:G8M+4GV'JS&VIJK6I=HNBT4?W5?ZF?CWC#*&!KY297?[W\Z*,O.:ZS"?:
M>]_>[KUOOU7OVQXT?T?)1F[F>28Y2 .5^;M*37(S<:XSEAQ)U2.1J;4?GG3+
MV<<JWG13Y%6/GFL==OY#_U2V!01$F 28"1A*G9'+?0I)JO9[?B#]*$&19,BH
M8(CUR'-;07?"@ZWT5V K?Y.?46M@D2-C-1F7=WNC03SRVF.#;H_MGAW,%HE'
M8\$]59J14]CMTHGZ0->5/&3UO.E2A?JH^2PQJ-<#[)>%V^S'IU66KS]FN= 9
M14T/ZEN19ZOBXVHM=,Y1X(5)\Y&P-.38\Q ,(T0APC2 !"4QI('/1<0BSA-D
MNC!8CCVWI2'^(X[^$=32@DI<P#<"_-MF^02TU.8\93L)EQ>$$:$=>SN2_0"5
MZ$#+7B4R@D;ZYU@W"O18%FSA-E\81H1]HJ7!!GY@AK_5^M 3P?^?O#?=CAW'
MSD1?!6OY7G?F6H$T!Y $7;]TIBS9)X_41\JLY<X?L3!*+(>",AFA3-737X!#
M!$,Q 0R08O5UN],Z$@GL_8'XL 'LX<0*8=OB:&M$3U6[JT3?)NS7B>^"KUFU
M@_F2%Q\?]6ZGO%[^QYH_Z(]R+B1B(DU]2 @+=)H# 4GD^S#E/(R\.(DI16UQ
MQGNSU>%TCT939[<RX_TH2<=:H:L*@ZP6&V1+\/=&<'.:.@/Y^47  8)C93 =
M#35S+G>'WE@NB8\"/!1Y60+RE*\57^<2<,&**G!'@[E>%H+E#\OL'_I8COS9
MUDPN@1)CO:C"ZZJ8GP,#\),;>C<#]02;GVE@-/(V4Z3+U89OV%/SU5(!_I2Q
M9[)ZS!?YPZNB?3V6I2A>,K;9WBHH"4[#"'H!XOJFQ8,T14C]Q$/JA\)/"3:U
MW,VZG)K!WDH--F*#1F[0"F[.,X:HGV=I]U@.S-8&,/8PR@WQ-.=O][B.Q.-.
M\+5B93NH3K"S84.CL;2=8EVVMGRS9T$I(451*,N4_%G'':D?VM\U'EX[MPQ+
MWCA\E8>O(3[FY6J._80JFY]"P4(?(EU*(!640HZQY(KQO9#:59T:0,BIK0Q5
M-6E(J[M-UI'5LOC4$,-I=IO]WH,T\)+3JE)YI=8*SJJ?-W]HE)SM7F'K@^Q6
MT1DX>M.MM758\VK L7!5&&L($<>MGC4@R'LEMH;LJ]_*H2\%5J]W.MMSE2'C
M;YE:IM:K[X+P;/'Z2:SJL"BZ$)OX@ZMJ4S@G*<:ICDHGK"XR$ZMM ",0Q\R/
M>!IY/+(J,M-;DJFM ;4B8*L)^*-61>V.*UW49GJK#)";2'>[1:+_R)FM!*.,
MQ\!T?WPH&C5 5P_035E?Z^*.S"^&TQ%C]Y=C5%J^&*ZWW'MY@SV#J_*GIWQ9
MV845B9<=#YUY%"<\9<JFQDF ((IE K%("(R3%(<AY@1SJU1!ISJ;&DW6LH)2
M"SL#927N#.1;@2UCK$[AS(*8^DGL0;5E46M51!FD'I4P24,F9!CRU/?GSZ+(
M<GZW(L5J7+3?=CP<YA_(0B>Q:>%VB'#HA2F-"8<2QP%$?H+4+DA9 YS[F)&8
MQU%,&X0_+_E[X-MV^\^(KMF*[0JO@1?E9N+?U1/_KIGX-P83WSXXT  15Z&!
MI[H:-S#00.F]L$"3=_HM@#_G.?\C6RSF$<7(]T(.?8]%$"6"01Q('X:(>FD0
M>20FB<UBUS8\M86ME<MN_F]@0B&-_<#W(?(\IE-^*9N I@@RGR*/IY*%I,=:
MU0>L\=:E5KH9H#6' K("5#QD2UW<L TNZ0FH3 -./(&@B+P0(D($Q)X7JY\P
M$<0C41ASVZ6I/YS#+T,'P>S$Z/2$T6P-Z@/,P.O-V?EHO:R\5=+1$K)I=M3E
MXJTR;Y>&O;_W6P9N"_%,,EZE4YBG-.6<<*$P2 E$3$20T"2$+" I"3&AE%N=
M'74;G]IRT,BF_21L;<(=S,SF7U\D!IZ#+0CW)T&PGHB'M'4T&7>:'G5"'E+J
M[:0\^$R_B7E?5&7_7CO&WSPE**4\BF!2%1!GRE[#L?;03GDLE)T6<+L4Q@?Z
MF-HT;47</9"PFZ^'H#2;MA<"-/#LW6"SLV=S-XU/:.]H-A_J8=1)?4+%MW/[
MU*-]UUY=;F#U>JM&=:5#!MM(D ^O]ZK%.N6<YZ5^K&SCA/@)1 AQF,8IAB3Q
M_33!S/-\(Z\NBSZG1@&MR#-0"5U''V_#FK38O=+.F<!ONKH[!75@VOB:+Q_@
MU^RENFY?/F3ZBJ6Z]W2>;<X"%V?FP?D>1[8:C"'8-R;,7[TP[65;B"K3CD]5
MM6%^L]S4&J[J:_^ZS*EVCM)7,=?+9WU%HR%0;U5WWE^SI;A>B:=R[B,1R"#D
M,*)20.1Q E,IF&*LB.L<4HE@5N=)0P@Y-8KKWG!VU 2MGB!?@C?USF>@JRRH
MM 6[ZH+?M<*@TKAO2DZ77X89F;[W> _,ON\YU/W3A0XP%JZ3B[H4\7U2D0X
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MN\_U/L\0"U'H>^XJ']QW\:R^B4==CO5>V\1S%GDI%R2&H><SB!*$88K# (H
MTR0B-$T]HP 4TPZG1D =>>ODA* C,?B]DMGVV/8<YL:;:&=(#K]SO@#$/KME
M(V3<;9%/=S?VOMA(^0.;8;/W^L;VTM4VBNZ;^EB:F Z4BHC$ 851J'/DR)!
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MA2E7NSU*28]4R:=[-9H+XV=,KH0&>2MUZR '?L@J^7^<@:4PS(QDB+Z9^>8
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M4SEG+'M6W;;'Y3H#N#Z@)LO7)[)BC^K1VL.]+,1"T^1*^X_K2Z0Y#A-) A)
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M/.=_9(O%]WRQ^)(7?Y""SWW!.66)@!Z2!"(:<HAQ$D%E<(:>CSTOBE(;J_-
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ME9A[R$O3*"%08IT5,HQ3B"5)H0@B(I*(D9AX)G<:%\HQM>L-]4%&YJ$LEPS
M&8-Q/%@'9JY:BVY<B/8K.YXLH55G!I1"M0E:J33.J)B'#8TT.B,% PT^2E8A
M/@ZP/1&X<TGKHX7C.("@&V3CHKE^^Q*=(*F-YKDG?WX02R&S5=GFY[Q9=FKQ
MMGG'TP@Q%)(8>DC]!Y$PA82+"'J2^IBG:<!3JVU*#QFFMFOIJE =%;=*S#;I
MX77FL9TB[DV27CL;N\]XF9G< X_"P.O8S@#<[PS =6< NF70P><S V!MD5\
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M&&Q]V+8%&TF<"AKZ3&<PBR$*40I3A!'DU(\BP:(@8/T*&1SH;&J4MDW6W_$
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MV(W0Z%62_73+H]5E-U*P6YS=[(613>"Z]QM9FV--(/D_!)_[B&(4A#$, I]
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M'+S4HELXG1G ?^:TS2&:([GQ:03K=-(:R$^[0%9"@]^& -+"9\\MH&-YZCD
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M*9,)](FO6,@3$22QD-!/_!!S2H3ZCXWUO]O\U);^6CI+!^5=P,Q,^OXP#$Q
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M$.5Y 3$I3-U3)F"6D;1@":?<K;BZS:"36^0;F<%S+;.K&]H"9EMGLU_P0IL
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M.=3#^?5YM:;K'W6K[;=TO?YAJDI4R<)W2[YX$?K7^]7:; OW U-,)L9JN=%
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MI3)+U0])R?:R@>T0.7_Y^E)5=WI8TV6YJ#U/XK]>ZNZUS>D4PUIC@6(8B91
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MHEF *7#+.!N(85_:F>LMQ\L]&ZCL7@+:T'M<N0D[>$NR6. LSQ04&980HT)
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M1&E *,QP6NY'F<G_3" /@R25-$.4,Q=>/SC2T*AZU>7VG:@MDY$.PVM'H%Y
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M"&(B,XB2B$/&5 :50"PU_X\RI[P(BS&'Q@@-D2NO&6@(/:JJ)G\W@COF/-O
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M%:*,IFF+(IK#>DWZK\I9O2V;=EJ BO]9UGUT_Q]X:RQ]NX-Z"7KR#J];<8U
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MC5#NKQX>[[]]?OQV?WWS&[CX_'C]C^O'ZZL'-RYI-1UV/-,UR!UST#OQRW/
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MO=\YZRNSWI/4P\JJ]SL5SAGUGH=O67MKE1;PB4Y,L<&'9RD7O\UGRU<];E6
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M6"/@%$^Y5]M6@93OG]1;!.5>!9JAD_LO:)LS_X_91.^-Z;S*ZRW&@8B)*CO
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M,J*W@S'E2<1%F$CAUI[YP$!#(^):3K 6U-G]>Q):.Y[P 5C')-$**_?D_!-
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M"A2EX$ ;PT"N3OZ9G$J5+\J3^Q9DZC9!#B3:&>R]D&<E/:C$!Y7\]7%]H4W
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M6."7? K$;#*A\\)8#]4AZZ]N-'<(6CLB\P!8QU2UDM"<A%:GH"-02^F/AT[
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MD-5U>EQ97.H?"KVI&5.!><0)AR&)%$2<:A)))8&9XK&,TPS%S"GLXPQ9AF:
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MOR40\JXJ%W2--_1E4_WX:;?9?-CEWW'.'@BA*(BC!/J14IO,D ]3'%$8^6&
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M\1N;B;['L<R=6-BQ^,\A7L\0NFC@7HP68QA:):("(PAJIA*!"ZI$X"2QR<;
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M:E )A7]X1X*D@F1)'9-)>YMWRYYJ3$HS"/4X^MD.T_NA?G!9,S\^G"3X_A^
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M+'$8E#%2>#3_>!E^GK,FUN1$4K)6QLBX5[7C:P\(Z+AE1>L8>A.#>Z"I;EM
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M=@.R.B[TJ(&-)]YK96'T6?F<?_Y00E&XC4MGUZTN)9X\HF+EV4O$5:LT"W-
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M6H7W[X?0Y,0C)$V"8);(7!*>O0*"4O#&6K1DA&E+"U1<1[>'?6MX[USD?38
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M3X),GBSSU=$(\80;;Y0,GHE<V[)\2,$N_:3NH;M\YH<?2Z^V%+\]AJRW ;@
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MGMSWV?GSK!S]J-Q):]"%U^!3F2,G) 5'K $?>9 RA!1=[2O6)H_*4V34N$#
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M,OB< M!DA"+4B:1J3W]X@I163VUW4O3#CH(5I-X >-ZY4#S<J]>3V0(%<WT
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MU2NWV"*\-5O48<BBN *9D1EA#%E/&-08UB;!8DA.5X9:)\*&W7N/";KZ>FK
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M]"M-5FN4Y4BX1(FIC"&24*G<A5$/UCE-$B'1A=#?/OH,9</>>AYS*ZVEGI9
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M7<U-M.W?(]'P81PY\LEK:AT'DW,HHS03RK\T00Q9:RJ]#Z)V"%^![&%C_ 8
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MU(6N@>>V]W_25%LW#>!MW;3USU73UMOFKC><?IR_&:/DQKBF5KG+TBB+ I1
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M9&D)%#7%<$6H#)XZ!4S:')WP+JH'IFSK(>^++^H$(_-;P:B^ AHP5S=6MTR
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M;C1TC2;^B>'U8?[W(Z=GF[A(>Q532J8-"PERK@T7DF5PV3.0MHBZN25)'7=
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MR@,W(1IIM>"R]1SU/:OWC]I$-DBQCU?O#Y%R=SBY=GT>2T2A+ 5I4MDZ^ZN
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M8O6BF%-ULI'4(8'R*4,4]779,FX#+RJ;UI<KCQ(U;5?N^.YT3_'WZU%_,C3
M%DN9"X40"IR1C(()IL@61P^6:>.M9D69,7._@XB?ML5W;&,WNCH[L(R/,#[C
MBL?B.()4W%/&1$&OB]7D\[J%(6LF;U>7C(W.B?M]CP>Z0;+OX8KB!P^SR#$Z
M%B445BC/#L%#Y":"U45[%F16Z99-N_]RXL=/G;@QM^6]Q'Z2ZN!&XH$;M6<I
MG7\Y/ZN-X<\NIB1L=3.317 FL>8:SM21WPHB^@*:H20(D\S$F/'Y;E1.W,M[
MG#O/%AKJ_R7Y.?WQP6_(-WY(X]?C^PD<J3DS6,>T9B"=JB/?L("3!"X1LE%2
MH$;3?)QIDW?C:BYOI@Z_S_\F["[RU5*!*LJ9,IDGR3,XR^BTU,EA47.*O:P/
MAB7"L/<[.)O'O]35B_ 0K5[W/XT%VD$(NV6D$OZSF9T%K[-Q(+FI+X,R@S?&
M R_"D$>5AC<OI_^%B*X>:_<!2QOQ=H"/ASSB=3?HM';*B0S)UH:DD MX1H&W
M]39%A8+'T+K/>T?2.C \^P-@0'RRKS8Z ]EV1QS% %=SP;1"1T*RX+.O<_RU
M 9>Y!@KRDJKKEXP8L][D%CD=&*91P'2(U#L T _!S$0)5GLCH.BHZX FA* U
M98@B),N$H<RP^4CEJX]W5?K1Q&L-$N>$&7:-S3Y\)@-(D/JRI3[\#,M^<B,9
M)65H+6B1=7VO$Q"D*ML-R[$8I80O.P2[CW^IJR*0?8/=Q@+M/_F]G)[[_=#\
M]_;/:9P"/TCF.%EP8$9DI"R&G$($E9,$IW,":P1YF.!C:;_48\3JZ6LEZ']<
M3M5^<8X_N$TI,\&L QU9?87(Y 85YT"Y7%V7SK)SK6/9(?1U$-#NAXS=7C8;
M**6+B*2VMMSS=GN-OU_V5B4AG17% F=&U]<*A%@G>'M+H;Q5MFYK:7[4]J-U
M6B".AYX[.U5'5N4)0?9JGQ5W4D3- @B>ZPSP["%&+D$6E8HC1HMKOIIX&(G3
M9FO= 70?Q9T:+K<;K:2)2127H<1(V6L6 IP)%*4ZS:36&5/SY;*#B9PV6>P3
MFX.5=V+HW&ZVLH&S%"225\BA]HPIB(9B)R$\2OJM-K>3T*."<_HE9%UB<[#J
M3@V:=8.0S292/,^AV-H4IBF3CTH8"$&C,9B-:;X%8RB-TW9)] G-H:H[(6C>
MW'#%3 K1A0(BQ3I]'SEX%S-H;HLKV3L1QYG-,Y#0:3LFN@/I_DH\(:3.BDZ&
MJ^TBI+JV1G%;AU44\%G7#:K.BS257Y^VK:([/ Y250=U@P_R]><B7R[EPOSR
M[T3_Z;,OVQ5=44D;E9,0268DR4C.@*D((29OZWQQ:8]ZD70?H=,V:O0!SB9*
M[,!8WL/>S!OI-7,<8A2NYG04G;"B03')L%B;@CY2@]"T31='0UL+173;*G2/
MO*3-&+VF="PI3E:=LC-O$X-LF5#1;RL:CM!M<<"CS;$JV@YYM!E)(1T8KSL[
M2AZZWY?6U>%TB3*MM-W10V8Z%$E,EAP*%CIG1VF>[?:)9BRL[-(*U$IQ)P#,
MJWO]5)(K1AEP%FMC>BQTP"V'DA!Y<LA8\R%@.Y(VK?7K!(;[J.E4T+>]N=<Z
MY1ALA"P,9?89!3AT I)P&G,P7N(D^)O^N:4G! Y6U8E@<'M#C\H+)3&#UK76
M31DRZCH07]ZGI)P/MOE\U5UIF_91I2,$#E;4J0"PWFZ27?=2! .*V .%(4(L
MB0/Q5DPA,^_%%#9P^J>3G@ X5%$G ,";=^S1)!%BR%"R"Z!,'<Q?ZD0%LO3!
MENB2/LJLJ3X?2#J!XOXJ.P$\SCB//JLH #FO42ZQ$I3'NB!",H$L&'9L0SCM
M,T@GJ!NDF X>/^[DY][[<B.CMY3%@[ BDE6WE-EK8< RGH3,SIIP%,/7YV/'
ME!!LHK)>#=^ $4=9^< $95XV) '*UZ+@Z H4$TK@BH)?N=/FPT,1>BISJJ;$
M[$AJ[17%,VL]RA C&"TI,,Y!@LLL@+4,5>+(9#R*SYYX2M64D!ND@XGG5ETR
M$!9YV+MF5LQ:Q^ALH >EHP,7*-R-267.8@["[+)S;[^O=]6CN\\[W)$$/_E(
MM!O5$L3IX$>>P-$4Q@3$4!?M^H 4YX8 J+,5.D:!?+?5CH=2,LT;W+%PLIQ,
M:1/WFP_G]NH!* 9I&,L9K,*Z?(H1DU8ZX,YPC4H[[],HR)ST->XD +F/BDX3
MA]MG()(?LR99D%B##5:?(KE5()E/S"I+&9D>#XG3O<N=#A8'J^DDT;A]$HJ4
M[-.QD\"M1E"2.P@Y%4BF"*^#T4F'T< XW0O=R6!QL)).$XKU,IX$B[:N,S:\
M"C9(">0"'"3+?-1H>?9F/"A.]E9W.E <JJ23@V*X\3ADLW*YQ @ZV#K,VM35
M2YKR1LE2D<:&F,;QTV'Z5[N3 .7^ZCHY9,Z*L=SQ0NQ845V *Q!X#$ 2#98\
M@/&WWU@:@7&:][N3P-\@I9P&Y.Y],'+(N7*4D0E6EZX&1G9?*@DE>W3D#[B)
MJAW^^GK)ZQ>,3=0U,3(?97*FK Q>1 DD0Q*B$QI<+2*R6O@BBM3F]CS^A\=E
MW_>A:=[<)D!76Y$WP\]H,P8_XNH+L?H^;/#0,8-W_*C&DP8?(W:DD?LV<R5X
M!DR46"HK"OCH%+C"<C))HFA>PSOFL,'_Q#JH&?.S;_2GGP@T7\)\<?675<)\
MIKQ%X4("=(Z<MQ&&,AEB6R7OE$PAL=AZB]50&KL:.C@$(0]W1C963G<MDSOP
MQUG(9*X-I(0"E)"1\A0?06;NG&:,9V<:@V\8A5VU3AX"O1$5TT%)R8,'Z\5E
M;%A=R1^X2B3X&84+B<Z4!:DB.?84!80<+3B-J5B6G.2M!Q0,I;&K:H'1K-ZA
MRND ? \<K;NX<SX$K6Q=#J<=9<O)@I=90/$Z1,:,E7G,Q7R-@'>T >+CV+Q#
M%=/S0/'?7[U]]O;YJV>O7[W]\/']GV]>OOWXX6U8U3/X[8# ?Z<?VRP)&,Y$
MHX3@!:[FW[9?>;4@#)YOL\UGB_P?F#^1#7N6Z*^VF6B%T-ER?;[ZF8AZ8;)G
MTD*6.A""*%V, B6(Y'-*SAME6GN5 \@]U.[]_/3'.IE_%I@6,48-R+@&E4T"
M[Y&R<BXP(69F5.L)?K=(F#91.!9R;INY0_30@?N\4VS_H(CT]7*]_NW[I?3>
MX]E6D>O/\Z_/_IZO9YILM:\[IRD\H BU: O!UT7F HE*;AW*UH/R]Z.T%U#N
M 8Y[@3::ICK XQULO%C6#&DFN4YHBP&I5:98Q 6*2S4#:ZU1*NMB0NO+H7N)
MZ055XR%A.89:.L#7[V&^^F<X.\=+CM[@EXBKF=6":8ITZT $5@>C:_ VDVQL
ME)Q<@ SMF[?OI&1:9#52\^U,X'"93XB<]6HS^]$.](%RE;":+[<'B@G&W79%
M5G&4'6E)M"LK@2MON/#6E;S3_1E]X1I@Z'<_P7+OQZ>]&FOAU]K(=6I@7-+]
MYV+]%=.\S#%?'1@OE= E P]9U@-3^VQ1@!2.X,XPZ]TLRF/@N(^ :0Q)(Z4N
M6TNX$YC\OEQA"NO-I064C"66,4+>/G"RS""6D@"STQBE3KSL]/JS(T9N?GU"
M@+11Z1T@.4"^'<0F5UOVZK78]LQXYI)CE)(F5:O)B %P-@AP7%-.6K3DV'JN
MY6T:IKT';YD_'23=SM!Q>5Q<E#F'>DFZG>G*>*H<U/V.P9&9=:7]0I%?J9@V
M8CU,JP] 9 \1=P"2U\M%7BZV.WUC6/SWNT)4X+:,X_6KW]Z]O[2+7DJ9E39D
M#>O*SJ0HF _%@G?,QV($+^WK+'8AK!\H[:/]VV._FZMBXB#F?5A\NCACIDAK
M<ZD]<J74*?H)2#X*G!0&O0PZF=@@;OGQP6G?Q%HE._O)KP>E7V)526MB,+J^
M#&<Z#:4F[)X8,,A2,CI8M].(G5W4/G6,NJ>R;JM[#\E-K/ W\\7\R_F72\*-
M+,SZ),";9"@@UQ&<(3Z\4\H%08*YW4J_E\IO?'1BI>^CLF4+^4VM^/#W-<)1
M.W2*%PJC0AT3ZQT$+2E=CSI'FU+6NTV4?DSQUS\ZS9U6,\7O+;\.XL;?PEDM
MUOCP&7'SNO[75>C;1X.4$PI3(/(<0?%(?*"W-9SF4EI$EG=R]0-"Q?MHF7:*
M:<M4M(FT.T7-9>3,A552> U1:A*/-A37*E% 1N2)ER!":;TAX7YJILTKVFA[
M!PCM(?H.0$1YTJ=:]OH"X]6]'6,&K;4<,J;Z,E1S^$#!ER [7+3-GNGF"ZQ^
MH:(_T.RCWU^3TD.$W0%<?MKAU_,%OMK@E_6,%61.4^HLO;04HDNDZ-QJ,":F
MX(1F'%O/_KR#C&E'&X]3:K*?C#N R;.4SK^<GX4-YG>;S[AZOOQ"I'RN@QMK
MV41:?L%:+?$6-^_*Q_#W3))4.$\9Z'0A*"2#[)3AD 1)C@Y;,J4UA :2V$O-
MR9Z06!Y//PU[<8Y4('S=VJ_;%@G?^:-'+11^G)D.BH4CDX&+X$#S^M(8N017
M9WT9875)PJ%OOC*NHV+A:+2B:,'4O:?D\S.=8:\TDH>003"9K.!I-.Y/O%AX
M"'(>*Q8>HH<.G.J]F8Q%7[Q5"@(/A:PSA1VA[KG*J9@<-;<ZMRZ?.^B6X&@%
MOX,4O.LMP1!I=XJ:JWJ/8)-*GMRXJ_U%PGEP+ N@,T;92)*LN&/@INM;@D':
MWOV68(CH.P#178EK+CI%28FKKNODR2Q#"#:#II!0"&GKC+!_W5N"0?K=X99@
M@+ [@,N>)?+.:J$UY<O><,IH2IUQF$P&H5 +%Q')7A\C*FS3UG*T\M]#O-P1
M--4!'N\OK(^%6Z+7@RZ:PDD1Z9RZ[ "9$I38.J::WUT]K;:604C8N:UEB%HZ
MP-<]+18L")6#0HA.D&Q$,1!8G1*78TZY%C!8WQA<I]76,DC-N[6U#)%Y!\BY
MZV*/H@,K:@TE*R0+A5F#DQ1W"IFS"TQ95EIO*MKW/OUHI<=M?-Q^,NX )A7C
M]-&KV6PWL(_/+ZYR+VYN5W7@PPN\^.=,1JM*PE!M<AWK4,^%U!Z,0R920F54
MZR!]3U)[<7Y[0N0.SS:VODYM#,?%L\*/]J2V]^SW_/!1;]IW8:B#N_:2).:@
M!3!9_:! !0ZC B\+)8]!:U9:UQ!U=->>N?*!E[HHK#[7&TZ,*^7!\BRUU=)*
M.Q[W)W[7/@0YC]VU#]%#!PYWSVR(B$6G1(!B>2+['<B21T%,:^^4BTRYXYRU
M$QO,,0@<;6XPAFBJ SS>GT/5N>.Z6 :)I1JFJ (!6:U'BCDFX@9MZVSA:=U@
M#$+"SC<80]32 ;[NR:858RD;%B%ZLOO*)PW1E Q!)<]<R2A*ZU:UT[K!&*3F
MW6XPALB\ ^3<E3K%+$5Q+$$6-E/@H!5$5<=Z!4_B\I$G,]Y\JF$W&$>[I6_C
MX_:3<0<PV9:9O5TNEE<#42^RIY=_?\4%);Y.2<\L(R,<-0<5BH-@D@0;'>>A
MY!)=ZX+UARGJQ97MJ?#;8VC;2;\#+#W_7!N&7BW^7*PPG,W_+^8K+_]N<7'S
M4B7V:G'SVH7/D%LL.A"'V@M0-D@(P@;0],?!*2N9;?V^N">IO9BN-N@[AKXZ
M@.5/L?UD[^>?O<7-3->E0%S694%8GR2*)"%Z#SQZKP1G),C6(]\?):J7>_XV
M4&NK@YZO6#]\?/?\__N/=Z]?O'S_X>7__O/5Q_]Z]O;%^Y<O7KY\\^RWUR_?
MOGO[_-W;C^_?O7[]ZNT_7KW]^/+]RP\?&XQ";O/=9A>S(XBAT9WMR_\YGV^^
M_]PY;T5(B@"=(ZN-/B&!+TZ L1AC,<XFT[K8[B8%ARQH^I ^8SX_PW?EPV<Z
MUY^79V06UA<__R*\Y2+%*-%#"91 JUPK H*R8!EWA9@E]AY#UDX?FC8N.T"G
MUY<OM15G#S,JMC<I2NLB0RB B5$R''B"$"G/"2C1NBQ,4CO5.S0=3-(<"R,H
M\,XQ)4.DV0,$+J\O(A,)DT^ WE+DYJ.#B-Q#8$E*QZSA8J<KH],:4S)(6?>,
M*1DBN:ZF55CCT3/M01MO09DZZ"^)"%$+E:13VNPV^K_YM(K1QY0,4MF]TRJ&
MR*^#/.?#>5PC162+S<MO],M'^C_;G@%.Z9C;CGW+C(01+;%A) *+CK&ZLTNK
MUI?%]Y R3?H\GF-H*?D^ 715$)@$-ZEVPYMZ]RTI+_,,Z;<B*L:5,CZT3I#O
M)6;:2+.)JA^'SQYR[P] 5T-_;)&&CA89XY1!<1<IQW<9BG+&$H<*3>N7T#L)
MZ0XX^RCY8>CL(?&I9T#?.1;;V.Q4G4Z,3-:Y^E4DR21@QL0<!4].MHA<]I\A
MW_SB;=SLY7 I3PV3>X=CVU2**5925%;+0<G>U@ID^C>=?. ZEKA;(=E3F2@_
M2*D[390?(N%.8')KXGE- - $ =YS!JK44A*A#91L'7<><S0[O6(^F8GR@U3Z
M^$3Y(?+M(4RY.C@7IK4.65DNMO67V[JCF(URLH#&).KF=@LA< $V1W*GEA<2
M7>MPY2&"IAGS>X2DJ9D6.H#4+1XNCYGV&JW3!;RI@[*5$! C%K"*YZQ,RLFW
MCGSO)&3BR+>=HI>MI=X!=#[6%I/SU?</FV7Z[ZMNN:A=8)1-%BGK=.6Z:)AQ
M!).#H51!H6Q>=G,'&3V\Z1RDW&5;24\(EFJ.J].=?UH\/Z?O+M+WCZNP6%\4
M/E[R4HKVRF?RZC(@J$BYG]?.@M:*I.,B^>1;Y7UWOO4]]IUIBV#:P:*Y3#LP
M)M<&R%WCY5G^/^?KS9>?%P0E<V$STX!<1/+;B8$3QD/PWC/%'*+;:<72 /NR
M&V735KVT-SDCZ&/B%.O=7POZ.5=%^@*]3%AK=31)1'FAP&7%(14O$"VS)K58
M]G?CH]-,O![W@F9_J?8"AZLQO+&^CI&IM*GVICFIB71O(!=#::7(:L>"X5T!
M,?4ES &*NTO]>TAQXJCDSS=AO?Y?R_EB\T\2U?GJQQ-LCDI;F2 )N1T(6&\'
M- =,ECDI>71ZE\*C>WY\!PK?1U7+MG+K(.!X,5]_7:[#V3]6R_.OS\^(IWF9
M7YO3%DRB" H-:%]OFEPQ9! %.4\=#2])Z>!%XTCC$9*F&4@]_GU*2TWT#:S+
MDQ=8]M(RBI>83Z $)V-KZDJ2R'7.K(B06@>QCQ(U<7M*2PCL#J\]]-$;P"Y^
M@_E=^>W[AW"&;Y>;VGB_7&SFBW/ZXXO^G.5B?6FE-87^5CD&="CKX&V5(#A/
M47L06+CDVH7F#>4'T-LM+/>!SD/ '%./'6#VUFB3ZX,NGRWRLYSGE;EP]G-H
MQ/JW[S<$M*8?<7:>YXM/=\OEPDXPS8T0&G0PBNR$)H$41X%-<D)1,ARC;ST(
M^SB<[70.[.GY_@YQT<%I&<3@V_#E1T&.Y=$;(2F0=ZKN?HG$85809+1>.V:S
M&#5FW9W4:>UZCZA[R#F,!(&)$_#_+3XLS\ZO.S676&+%9A!)40KID"Q)J:6)
M/,CDHRX2;[4TW9EZ__*#.XHBQE+ELI5<.S!_SU+"LRH0S%N?\QZ_GJ_2Y[#&
M]8NKO>!"N8B<N&'5U2AO"WCO$5)A(1IA*"IJ_="X UD[ <V=GIMNK9'^079Y
M!HV2MD@*LP69<F)*<G#6&Y %(Z.,U-OF'?X[$3:M16L.AV%PVT,W$[NZ^QEZ
M]FF%VR#DRE;++(J6.H&7C(YI<88,?JX&VTLC@XV_K$&XTP?N_L6NH;2/JI>C
MRWUB-#UDZU__F'J@H@W".P&,!5/7D7)BR ?@*+!8"DQ#V:6H8J>/[80A?SI^
M;QPI=^#U_KCZ[K:4:,O8^MGYYO-R5:>HS)23L03%0?)2FX&RA< H6LQ92I>,
MD=FUOC]YF*(^.[+W5/]R-%UTAZP_PNK=:IM@Y^T GC]PM65P%I$ELM<)DM&"
MS*RB=%BG#-:0/8]<AL!;3ZW8C;(^6SS'0%H3W72'N(OS\^Y\L]Z$1<VO9\J@
M$EI2E!!5 A48@UBX .EL]BB\L;KU4\<C)/79H36>-=M7&QV Z_GRRY?EXN'S
M8DUV,:,!=&D[Y8Y2G"SS=F&N%%9QQ5OWI^] 5I]M%VU UEHK?0'MEQ @H$5=
MC -GZFBQVO)$D:P#QA,7T=>U\:WW_3Q 3I_EB\V!=9 6)LX,+T3R!HGV_&KQ
M#2]J=7]4?M$92;4\^,=;\RS['$-".B<\,TJLF0%O*-+4,7@IB;>4;ZTKNS-)
M'/K=/DN9#H/2Z/+OP%B]QW2C"N)WDNT.J]\ONA0VQ/Y\F7_L@,^>E^!] 5%8
M/5<\@Y/UWUA,AE&L0-E/8^O6DOX^G^3;F,/)]-P!QJ^Y@A?S;_.,B[R^"BY>
M5+D023-NC5&H#5A9)\G6@C2'A60=*<)0-FF'(X9^]]+5Y_M3<Q?=1B\3^^K;
MN[KFB[LXO.(LK"^=QTQ*K:R2M192UGLAQB%Z*R%GY$&8H.WMH8AWNNP]/]_G
M3>_AGOL8VICZV:"R\O,%Y(_5\M,J?/E9[?+LR_)\L;D6^ KM-!EJ"9(IK+*D
ME)V(@F0-"RE2EB7*+B\( [^[VYTO.SV,C:J #CSGW?R]Q_J$5U>#_6#LVC/<
MEF4^D]EBU#:"( M.,8)E]>$M 6***B6!OK3>*[D_M;L!]$1?)8ZDQ [@>J.K
M_C+K3R3)&D?0,3,B<0].F7KR5(9(3 #%$FB$#=SDUO'= ^3L!K@3?9QHI8:]
M$?4-5W$Y!J:V]Y)7O#Q?UJE#]6)@AD$GZ80")GWM9J%?HO;T6R>LU-YF?]NO
MM@77/73MAK(3?9YHKIAN*XK6?X3O]=9I5H3A+.9<ZUCJW5).$+%X^K=@M##(
MC-RED?7Q+^T&G!-[<AA!R!WXO"W\7ZW7YYA?G*_(GU_<U5R8W1MGY#W.M__9
M+'FOT#$-PC@2GF,(/F<-N3B=Z0LARM8U(<.IW V")_HX,;+2.H#E'3' >]QL
M0P"33#1U&JR7CA+L4@]8?3?69(N9X 95;/V*?S\UN\'LQ!XN&BNA SB]F2\H
M1]E\?[6@GXGK7QY@PB?\[?O;Y:+V7]"GZ<=\NOA/9LJ[H$U@((I-H++4$#DW
M8$5&0?\;L7G-R-[$[@;&$WV!.(X*.\#J>\Q(R76L+;_7N;EB_'*T4UBMOM?T
M>YMJSQCC&A5+4*OLZT.*A) 3B=<9Y"[QF%/K[I=]Z-P-H2?Z'C&ZXI[<LKB?
M S27Y<'7Q+IF[^)%\<AKY0Z@<-H%=*U$.\ZJ.JP=&U8X8+4 4&5>($2W/6M.
M%N^1PHO&YNJ8J^J"3]HIK<%H21Y'%P>NT!FWY(9L*HZK<&BG17^KZH;H=-BJ
MNB'B[,"!/SPE6).*14)BQJLZ85P(<!2%D,/)Q2 %)OEV2W,'0[DG6G$W2/&#
MAG(/T4('D+I[G">99<L5"DB88F5"@W/HP842-/,JH]IIM\A@*WI"0[D'*7JG
MH=Q#I-X!=':<VRJD=<G4':-.>E U&/42"XDM^: Q.Y]&Z&MN-4?WR*.[!T%@
MOSFZ0_31%\K>XN;G&O:?-:]7V[*OY@2;Z$L)LC9A$G^46T&,A8-G H/R.MK4
MNM9S*(T]3@=OA+SV.NH.@U>\U$K5%[B>?UIL\Y_5_SXGKDO-P)^']>??SY9_
M_0?F3_BCZ]O(+(2H&U\H[E ND8 IKP=K?622:3J3K9]B6]#=X[3Q=E@]@BXG
M?KW=YN6W YBKY:V6BQH)0TJNEK J#5YSBH)MTBFEX-U.RQ >^,0T'6+MT=-2
MDGT9M/L*[*_F.1FNC$$&)*9MM)"!6+%08G(J:Z3TJ?6FIYV)FZ9+["BFJ:%6
M)BU6VOU^W >G4TEU]WBJ2V:(.9]K6IZ%#DHDX;7;P1:UFR$RT8[E?6XFQI'R
M:=BIZKU_]/^P9(.LXRLT<Q94)EM,_-;!\"8B!F%S\WN+@23V>2FV)T"&VZ^]
MM;4W&+]>%+!LPFK3!)(/<?8;EF4MW;K9T?:386>=D-D@1.[M9=%?BB3AY"/Y
M"ZE9:0W/ \CMTTJV@>JQM-B!#6W:8$F>R*".Q+O(=?-&E4+0) 6>D'+Y%'EL
M?9EW]$;:"<N.#X'T9'KN .,[N1LCA/2Z!*##JNH:PPA>R;K:5]B04Y:*M[Z
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M7X8*L9*RJRN*<N8&E$P((0I+SB@;QPU3>;<"T]$G/YU6>?,@7#PZ^6F(DGI
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MKOT-W#J@1%&G$I60K+=7KUUYV^DH^:=\E'H#T+_$P7KX):](&U0NH+'N+*0
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MC^9(&0U3(QH\>FD;=,@GN:RK8;\&,JCW:.?MQ>/-"I?\J]4N\*WZD> E&,]
M$]D7.7.JB,O.D^0#M33+1%GMUED_%:@5XOYQIX[ZOFD!:%O9=Z5G/(BLDW%$
M!5VHQPN+*P97PA4X[QQ-6=8NS'LDP,1KD'J._>&VTKE6GG@O^=7W3/0O8VG'
MY;+:FVD78HOP*5I/O/,) [6R) @<73DGFX*6%'1Z#)Z#N\@GO+*)].8<IW;C
M6[B!V'(UG]^N/\%R/XSV$SH($9311#.! ZF4.EBA$C&"41$R6!IJ7W([+,G$
MT];%\*EHYP;0<MTM<=K&"+P3/S!GO</%6MEB1+ +24) Q#/EA/(,E:"UNS(_
M$6'B7@K5\'&)92=.@MXMN[2)Z]OE+B+V,W&D4E#-*5&T3,?*:A*<8(1Q*8TQ
MF ZR0:=.S^1"A][=2GN-\3=)+K9\&\@II"C[V70_E+*WE&9!M&:2]%W90CG9
MB$D*KA0-,&S^&0:?'P68+JV^W*<_ N1" T]=*]%M</A Q,]FT<_76_*XU4Z?
M?2LE*B2.%$/ J7*YPF3B$LL$/+4LY*A1UR'E$0/>-3DV+G5G-Z)M)\;*]>V'
MUZ^8N]OJ\?ZQ'HKJ7#JRE3Y".(H*WZOGF9$LN3)..]1G" _DS]XQS7)U'&Q4
ML^7$F/@-%A *<Z!?)%AU^-!9/ QTFYR/N+ BG#DHE@K$JFB(H9SA*ETX*N,
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M_B.3 40T0,0 A_BO ![ZO!1"K!'# GY\=MCO=T]P&OJS=])L,1DQ3V@QFF=
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MB1AWBZ+,X[0AD9KB(^OP9+XRK#!#03D>M][B9?C[VDD3].5])-6UAQPRU#I
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MFMLE=SD-]2";.3R)J/2Z.%#:F$/<"2>A7D&V,LR4C/4_O6JYWWNL,@?L<O
MX-RO^N?K;*>>-%[.2?6N:8GUC\]V#TXB^LF&PL%7R;!?.^RM\ZL(0S%?OU=_
M;I$/5K/4]:>$:Q'BZ^=^QV,%ER 545Z ,!AZV+_G=1)01;L];_AN/(;['G)D
M_EX^ZGJDC[9'RIW#+R\._!?_#U!+ P04    " #NA556^$F_6Y@L  "]< $
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M8A'QL(I[7X5GR&2+"NI'285<!66!PGSM*40>&0P>P)QUL$$>[)01*3*Y;MD
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M8<,1>Y/ZQ1XDI/B,YHM+NSDI+YBM#>9X4;!D@3 CJ1!6\%#^O31A=A4I3UC
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MBHJ"U.5[4Q\6)29BOKM.J:,V;RZ9J,BG\]0>G:=^[-G1Y+"4: (Z'5M 4'8
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MGBFTH8^]P>'O#]A' 6B@9W!'?4A^WPD$APL!8K@=71C@?Y!XHGAX^/$YHN9
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MR5W^\?PN&ADE0G9. X64Q,/)<4OP4\&\CM+HW2QMJQ" IWMYY&T*0/LT"MD
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M=V7*D8"Z#1WD+S<UKP .1M9 ;_2[658^=,]TH9>&T@J@U+<#N7@V E/];\7
MI"P?)QRL,_P/);KWIM+#-6R],EVC(2VFKIC5B/HI1)U=/$8I3ZA3GBN,]91(
M*$YH.H.>IQ(Y4Z!3+M2;D@(=6N1&C8V#QJFT^6Q'+;!]>Y5GE9:-<WC;]:!+
M?>T=*CU>D1!<02RTO M.#7#O0N;#'7!CG!DC^'_.PSK@[#!54VQSUJJ&>!SB
MC;[M(<BB+6;$-4"V4$R<!-P(N&<+0:UEDR X6ZOX,HL^4K:OVB XCTO%,PP?
M;@3M=>Y!(JA2<-8B8Y(>7!1#I7I1UF29:%J0I7N9;9WLZEYFDVE5W<LL?+#N
M9:9[F>E>9OGM9:;3)!D[\+>VW_<Z"(WW*8W'CW@RHZQ<&+F9%8B?$146$JI<
MSK?8U]=2KZ[4W_>0D&R/#^+;$@LIM_(NY5GO0CG:_56Y0'.2KI'[S$(/$0&#
M%WNL+!+>>9TG2Z56J;W>SI,)V(ABE)?H\+'C>.B7B=M!\MR1(%(:4*&[SXE@
MO9"RV;H5F3:KV[9@HM#P'=#L,Q&0HV 9^5O ?46RN#EH\)?F%^R&.949OZ!B
M[&7H%UP2!T,">^*5A;)N6F#[LO$IK3Y;Q2UFU%;DJ8R^M[+3Y*5TRL8^>\;4
MQ;&7TJH@7UYJ#C37.D?9DO>'#IV*$*4EZWL<$BZEQ+"D[WBK?<>WM30:LE=+
MS,9(3&SB23C=CSBPA=1@L@/N0X%YO,RSP&1C!#\S!+D(7;LHL4^V1N4\-GZA
M[;8/R:@<:EPE,BD=P8'4YY8+F0BCQ/'MQO<\8W3]2CV-I<KE \9CK%7\VX3I
M"GN]L#M7=^(625>H+C1[PU),:C8C6E_G\#9=1&C4$6<F3]H,^S$\YK"L:8EM
M\N9M<_@.RTXJ[[WLI-BBSD#\<;GOG?P?4$L#!!0    ( .Z%55:^? OA+@8
M -A<   3    9&=X,3(S,3(P,C)E>#(R+FAT;>V<;7/:.!#'W]^G4.GT^@9L
M#"0DA#*30MJFEZ=KZ&7ZZD:V%ZR+D3R2#*&?_E;")+F&I D)I'-1.Y,!VUKM
M_O732C(:M5_UCKO];R=[)-&CE)Q\?7^PWR6EBN^?U;N^W^OWR*?^X0%I>-6
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ML$5G@CCX''RK5?&0*D6C)%>@M2/PL00>L2A!07 ^B-]UKA=-:!R/=P[&Z,5
M2+?%:P4PNE7R4LK^Q<QI= [(1P,I!N3Z'DY'HULJKTVVTPPB1E,]=3\Q_[*#
MM#N"ZBMG*0U)M_B)9?%9<"O4\ 6P^[/\Z=LC:.?7+]V\^PCGZV=D9V)V0GA+
M8DV:C>'&J=E736;;JGI5A(8H+<[4'GK0=O%W=N:W/7V\\R]02P,$%     @
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MT5=X0_)]]&Y)-L#1#'9H03>X>'?.Y3+H'!A9U8:<_ 42DX2GAKL:<B#CY*2
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M<BA ^@*1MTD14B*U>HC-K]+I>DK.1<PM\,K:NP)/M4S7U"B16F&+5K$,[0F
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M?N>8BGN7 E>IQ9K47'7A/O)+81[N\@B6L_'I[CO:FY>G_P502P,$%     @
M[H555G32N&@["   F2D  !0   !D9W@Q,C,Q,C R,F5X,S$R+FAT;>U:VW+;
M.!)]WZ_ R+69I$HW4G)LRXZK'%FNJ#9C9VW-9N=I"R)!"662X!"@9.W7SVF
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M#I3GN0+?'91X&UX==@9[UH4#)YTE.'[I-]9"<5+@2>=<>N^>Z:R-<+ 65^A
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MO76 W:^^#M#U7ZBGK_:?_@=02P,$%     @ [H555N.!7NUH%   &M$  !4
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ME']I2[TO5P^%*XCG 6"AR^,?@Y[BQ8&&-7 =7 <+A*CG.C@XY-\1L]""4Z4
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M<]WS!=XRP."F0!N%WWI3:/.Q8[NVY^@<;LAPF4).H2;8P+)1 G4W!0U+SZ2
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M_6,RSG8<X4I[8J7@O@*@EG/*ZMJ)!(66_8Y26E-*.2U;CA0*G3K47X><+<?
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M &1G>"TR,#(R,3(S,2YX<V102P$"% ,4    " #NA556F0\X7: P   B\0$
M%               @ $RH 0 9&=X+3(P,C(Q,C,Q7V-A;"YX;6Q02P$"% ,4
M    " #NA556G/F#,]BD  "!1P< %               @ $$T00 9&=X+3(P
M,C(Q,C,Q7V1E9BYX;6Q02P$"% ,4    " #NA556*];0USI5  "F<P  $P
M            @ $.=@4 9&=X+3(P,C(Q,C,Q7V<Q+FIP9U!+ 0(4 Q0    (
M .Z%5595(<>I3"4  /9%   3              "  7G+!0!D9W@M,C R,C$R
M,S%?9S(N:G!G4$L! A0#%     @ [H555OVB7ZR$R   $Q(! !,
M     ( !]O % &1G>"TR,#(R,3(S,5]G,RYJ<&=02P$"% ,4    " #NA556
M/8.(*:C,  #4.0$ $P              @ &KN08 9&=X+3(P,C(Q,C,Q7V<T
M+FIP9U!+ 0(4 Q0    ( .Z%55;D7+^_67,! )<% @ 3              "
M 82&!P!D9W@M,C R,C$R,S%?9S4N:G!G4$L! A0#%     @ [H555J B#+\T
M@ $ V,</ !0              ( !#OH( &1G>"TR,#(R,3(S,5]L86(N>&UL
M4$L! A0#%     @ [H555NSI*:_"]@  HQ$+ !0              ( !='H*
M &1G>"TR,#(R,3(S,5]P<F4N>&UL4$L! A0#%     @ [H555M/A6^MK%P
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M,3(S,3(P,C)E>#(Q,2YH=&U02P$"% ,4    " #NA556OGP+X2X&  #87
M$P              @ 'HR0L 9&=X,3(S,3(P,C)E>#(R+FAT;5!+ 0(4 Q0
M   ( .Z%558>OWW9"P0   P-   4              "  4?0"P!D9W@Q,C,Q
M,C R,F5X,C,Q+FAT;5!+ 0(4 Q0    ( .Z%559\ 1Z5.0@  -0I   4
M          "  834"P!D9W@Q,C,Q,C R,F5X,S$Q+FAT;5!+ 0(4 Q0    (
M .Z%559TTKAH.P@  )DI   4              "  >_<"P!D9W@Q,C,Q,C R
M,F5X,S$R+FAT;5!+ 0(4 Q0    ( .Z%559@9.F&J 0  ) 3   4
M      "  5SE"P!D9W@Q,C,Q,C R,F5X,S(Q+FAT;5!+ 0(4 Q0    ( .Z%
M558H4M]HJP0  *L3   4              "  3;J"P!D9W@Q,C,Q,C R,F5X
M,S(R+FAT;5!+ 0(4 Q0    ( .Z%559D 26>/ T  #5    4
M  "  1/O"P!D9W@Q,C,Q,C R,F5X-#,R+FAT;5!+ 0(4 Q0    ( .Z%55;C
M@5[M:!0  !K1   5              "  8'\"P!D9W@Q,C,Q,C R,F5X.3DQ
M,"YH=&U02P$"% ,4    " #NA556;I^L]D 5  ">(0$ %0
M@ $<$0P 9&=X,3(S,3(P,C)E>#DY,3(N:'1M4$L%!@     8 !@ )@8  (\F
$#     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
